PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Tasci, A; Okay, O; Gezici, AR; Ergun, R; Ergungor, F				Tasci, A; Okay, O; Gezici, AR; Ergun, R; Ergungor, F			Prognostic value of interleukin-1 beta levels after acute brain injury	NEUROLOGICAL RESEARCH			English	Article						cytokines; head trauma; inflammation; interleukin-1 beta	RAT-BRAIN; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE; CYTOKINE; EXPRESSION; RELEASE; MENINGITIS; ASTROCYTES; MICROGLIA; ADHESION	Traumatic injury to central nervous system results in the production of inflammatory cytokines via intrinsic mechanisms by neurons, astrocytes and microglia, and extrinsic mechanisms by infiltrating macrophages, lymphocytes and other leukocytes. Interleukin-1 beta is the key mediator of the acute inflammatory host response. While this response is necessary for resolution of the pathologic event, the toxic nature of many of its products can cause significant tissue damage. We analyzed serum interleukin-1 beta levels by enzyme-linked immunosorbent assay in 48 patients with solitary head injury who were transported to our clinic immediately after trauma. We categorized the patients according to their initial Glasgow coma scores in three groups, and compared their serum interleukin-1 beta values both with their Glasgow coma initial and outcome scores. This study helped to provide quantitative data to estimate clinical impressions and prognosis after head injury.	Ankara Numune Hosp, Dept Neurosurg, Ankara, Turkey	Ergun, R (corresponding author), Ozdogukent Sitesi,46,Sokak 15-A-3,B-Block,Keklikp, TR-06450 Ankara, Turkey.	ruchanergun@hotmail.com					BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; Campbell VA, 1998, NEUROBIOL AGING, V19, P575, DOI 10.1016/S0197-4580(98)00097-9; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fassbender K, 1997, J NEUROIMMUNOL, V74, P130, DOI 10.1016/S0165-5728(96)00214-7; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HARTUNG HP, 1989, BRAIN RES, V489, P113, DOI 10.1016/0006-8993(89)90013-9; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; KATABAMI T, 1992, BIOCHEM BIOPH RES CO, V188, P565, DOI 10.1016/0006-291X(92)91093-6; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kohno K, 1998, CLIN IMMUNOL IMMUNOP, V86, P11, DOI 10.1006/clin.1997.4475; Murray CA, 1999, GERONTOLOGY, V45, P136, DOI 10.1159/000022076; PHELPS CP, 1995, BRAIN RES, V688, P193, DOI 10.1016/0006-8993(95)00491-8; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROSTWOROWSKI M, 1997, NEUROSCIENCE, V17, P3663; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; SCHLUTER D, 1995, AM J PATHOL, V146, P999; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xia LN, 1996, NEUROENDOCRINOLOGY, V63, P79, DOI 10.1159/000126938; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yong VW, 1998, MENT RETARD DEV D R, V4, P193, DOI 10.1002/(SICI)1098-2779(1998)4:3<193::AID-MRDD7>3.0.CO;2-P; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6	31	27	28	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	DEC	2003	25	8					871	874		10.1179/016164103771953998			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	756LW	WOS:000187467500016	14669533				2021-06-18	
J	O'Connor, C; Heath, DL; Cernak, I; Nimmo, AJ; Vink, R				O'Connor, C; Heath, DL; Cernak, I; Nimmo, AJ; Vink, R			Effects of daily versus weekly testing and pre-training on the assessment of neurologic impairment following diffuse traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cognitive outcome; deficits; motor outcome; neurotrauma; recovery; stress	CLOSED-HEAD INJURY; AXONAL INJURY; MAGNESIUM THERAPY; IMPACT; MODEL; MOTOR; PERFORMANCE; FORELIMB; RECOVERY; STRESS	A number of test paradigms have been used to determine acute and chronic motor and cognitive deficits after experimental traumatic brain injury (TBI). Some involve daily testing of either trained or untrained animals whereas others utilize periodic testing over extended time periods. Which test paradigm is the most appropriate for the assessment of motor and cognitive deficits is, however, unclear. In the current study, we have used both daily and weekly testing in trained and untrained animals to ascertain which assessment protocol is most suited for the detection of functional deficits after diffuse TBI in rats. Animals were subjected to severe injury using the impact-acceleration model of diffuse TBI. An equal number of animals were also prepared surgically but not subject to injury (shams). The rotarod device and the Barnes Maze were used for motor and cognitive assessment respectively, with half of the animals being pre-trained on each test for 10 days prior to injury. The open field test was used to assess spontaneous exploratory activity (stress). Following injury, animals were assessed for neurologic deficits either on a daily basis (for 10 days) or a weekly basis (for 4 weeks). In trained animals, the greatest differences in neurologic outcome between injured and sham animals were observed early after injury. In contrast, in untrained animals, greatest differences between injured and sham animals were observed at later time points. Pre-injury training did not improve the rate of cognitive recover, or the rate of motor recovery in the weekly test paradigm, but did improve the rate of motor recovery in the daily assessment paradigm. Daily assessment promoted rapid functional recovery whereas weekly assessments did not significantly affect outcome in injured animals over the 4-week assessment period. Spontaneous exploratory activity was decreased after TBI and was not influenced by task exposure. These studies demonstrate that the functional assessment paradigm needs to be considered when quantifying functional deficits following diffuse TBI in rats.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, North Terrace, Adelaide, SA 5005, Australia.		AM, Robert Vink/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X; Nimmo, Alan/0000-0002-0718-7934			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bland ST, 2001, BEHAV BRAIN RES, V126, P33, DOI 10.1016/S0166-4328(01)00243-1; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GIULIAN D, 1975, PHYSIOL BEHAV, V14, P109, DOI 10.1016/0031-9384(75)90150-X; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Vallee M, 1997, J NEUROSCI, V17, P2626; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2	32	27	27	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					985	993		10.1089/089771503770195830			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300007	14588115				2021-06-18	
J	Sauerland, S; Hensler, T; Bouillon, B; Rixen, D; Raum, MR; Andermahr, J; Neugebauer, EAM				Sauerland, S; Hensler, T; Bouillon, B; Rixen, D; Raum, MR; Andermahr, J; Neugebauer, EAM			Plasma levels of procalcitonin and neopterin in multiple trauma patients with or without brain injury	JOURNAL OF NEUROTRAUMA			English	Article						mediators; multiple injuries; neopterin; procalcitonin; traumatic brain injury	CEREBROSPINAL-FLUID; INTENSIVE-CARE; SEPTIC SHOCK; BLUNT TRAUMA; INTERLEUKIN-10; SEVERITY; SERUM; IMMUNODEPRESSION; CYTOKINES; CHILDREN	Clinical and experimental evidence suggests that traumatic brain injury (TBI) leads to a systemic immune response. To examine whether TBI causes a release of procalcitonin (PCT) or neopterin (NT) into the circulation, we compared plasmatic mediator levels among multiple injured patients with or without TBI. In total, 98 trauma patients (24 with TBI only, 39 with extracranial injuries excluding TBI, and 35 with combined injuries) and 35 healthy volunteers were studied. Blood was sampled at 15 predefined time points within 132 h after injury and analysed for NT and PCT. Multivariate statistical comparisons were adjusted for different severity of head, thorax, abdomen and extremity injuries, as quantified by the Abbreviated Injury Scale (AIS). PCT was normal 3 h after trauma, but 24 h after extracranial injuries a massive release (median 3 ng/mL) was observed. Significant positive associations between injury severity and posttraumatic PCT levels were found for abdominal and extremity, but not for cranial or thoracic injuries. Only modest changes of marginal statistical significance were detected for NT. The maximum increase per AIS point was 9% (95% confidence intervals [CI]: 3-16%). The effect of TBI on NT release was significant only at 108 h posttrauma with a 5% (95% CI: 1-10%) increase per AIS point. TBI induces a release of PCT and NT into the plasma, but this effect seems to be smaller for intra- than for extracranial injuries, probably due to more extensive surgery for abdominal and extremity injuries.	Univ Cologne, Dept Surg 2, Biochem & Expt Div, D-51109 Cologne, Germany	Neugebauer, EAM (corresponding author), Univ Cologne, Dept Surg 2, Biochem & Expt Div, Ostmerheimer Str 200, D-51109 Cologne, Germany.			Sauerland, Stefan/0000-0003-1048-796X			ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell MJ, 1997, ACT NEUR S, V70, P96; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Benoist JF, 1998, ANN BIOL CLIN-PARIS, V56, P571; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DANDONA P, 1994, J CLIN ENDOCR METAB, V79, P1605, DOI 10.1210/jc.79.6.1605; FAIST E, 1992, SURGERY, V112, P562; HAGBERG L, 1996, PTERIDINES, V6, P147; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Kretzschmar M, 2001, ACTA ANAESTH SCAND, V45, P1162, DOI 10.1034/j.1399-6576.2001.450918.x; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Monneret G, 1999, INFECTION, V27, P34, DOI 10.1007/BF02565168; NASTKOLB D, 1992, UNFALLCHIRURG, V95, P59; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; Oberhoffer M, 1999, J LAB CLIN MED, V134, P49, DOI 10.1016/S0022-2143(99)90053-7; Pape HC, 2001, J TRAUMA, V50, P989, DOI 10.1097/00005373-200106000-00004; ROGY MA, 1994, J AM COLL SURGEONS, V178, P132; ROUMEN RMH, 1995, CRIT CARE MED, V23, P474, DOI 10.1097/00003246-199503000-00010; Russwurm S, 1999, CLIN CHEM LAB MED, V37, P789, DOI 10.1515/CCLM.1999.119; Schroder J, 1999, LANGENBECK ARCH SURG, V384, P33, DOI 10.1007/s004230050170; Seekamp A, 2002, EUR J TRAUMA, V28, P183; Stiletto RJ, 2001, CRIT CARE MED, V29, P1690, DOI 10.1097/00003246-200109000-00006; STROHMAIER W, 1987, CRIT CARE MED, V15, P757, DOI 10.1097/00003246-198708000-00009; WAYDHAS C, 1993, UNFALLCHIRURG, V96, P62; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Woiciechowsky C, 1999, J MOL MED-JMM, V77, P769, DOI 10.1007/s001099900051	31	27	33	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					953	960		10.1089/089771503770195803			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300004	14588112				2021-06-18	
J	Field, AS; Hasan, K; Jellison, BJ; Arfanakis, K; Alexander, AL				Field, AS; Hasan, K; Jellison, BJ; Arfanakis, K; Alexander, AL			Diffusion tensor imaging in an infant with traumatic brain swelling	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							HEAD-INJURY; CEREBRAL-ISCHEMIA; WATER DIFFUSION; ACUTE STROKE; RAT-BRAIN; ANISOTROPY; CHILDREN; IMAGES; MRI	We present the case of a 14-month-old male infant who underwent diffusion tensor imaging within 24 hours of traumatic brain injury. Although conventional MR findings that included those of diffusion-weighted imaging were unremarkable, full-tensor diffusion imaging revealed striking abnormalities in regions of brain that subsequently developed overt swelling. This case engenders important hypotheses regarding mechanisms of traumatic brain swelling and anisotropic diffusion of water in pathologic tissues.	Univ Wisconsin, Sch Med, Dept Radiol, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Med Phys, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Psychiat, Madison, WI 53792 USA	Field, AS (corresponding author), Univ Wisconsin, Sch Med, Dept Radiol, E3-311 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.		Alexander, Andrew/ABA-2806-2020; Arfanakis, Konstantinos/AAN-3148-2021; Hasan, Khader M./ABB-5767-2020	Arfanakis, Konstantinos/0000-0001-9705-597X; 			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barlow KM, 1999, ACTA PAEDIATR, V88, P734; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 1996, MAGNET RESON MED, V36, P39, DOI 10.1002/mrm.1910360108; Carano RAD, 2000, J MAGN RESON IMAGING, V12, P842, DOI 10.1002/1522-2586(200012)12:6<842::AID-JMRI7>3.0.CO;2-5; Chabrol B, 1999, CHILD ABUSE NEGLECT, V23, P217, DOI 10.1016/S0145-2134(98)00128-8; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Green HAL, 2002, STROKE, V33, P1517, DOI 10.1161/01.STR.0000016973.80180.7B; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; Mukherjee P, 2001, RADIOLOGY, V219, P756, DOI 10.1148/radiology.219.3.r01jn48756; Petitti N, 1998, ACAD RADIOL, V5, P215, DOI 10.1016/S1076-6332(98)80287-0; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; vanderToorn A, 1996, MAGN RESON MED, V36, P52, DOI 10.1002/mrm.1910360110; Woodcock RJ, 2001, SEMIN ULTRASOUND CT, V22, P162, DOI 10.1016/S0887-2171(01)90043-5; Yang Q, 1999, STROKE, V30, P2382, DOI 10.1161/01.STR.30.11.2382	21	27	27	0	2	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	AUG	2003	24	7					1461	1464					4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	713MB	WOS:000184860800038	12917147				2021-06-18	
J	Lacza, Z; Horvath, EM; Komjati, K; Hortobagyi, T; Szabo, C; Busija, DW				Lacza, Z; Horvath, EM; Komjati, K; Hortobagyi, T; Szabo, C; Busija, DW			PARP inhibition improves the effectiveness of neural stem cell transplantation in experimental brain trauma	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						brain trauma; BrDU; cold lesion; neural stem cell transplantation; peroxynitrite; poly (ADP-ribose) polymerase (PARP)	MESENCEPHALIC DOPAMINERGIC-NEURONS; CEREBRAL-ARTERY OCCLUSION; GROWTH-FACTOR PROMOTES; NITRO-L-ARGININE; PARKINSONS-DISEASE; POLY(ADP-RIBOSE) POLYMERASE; NIGRAL TRANSPLANTS; GRAFT-SURVIVAL; RAT MODEL; IN-VITRO	Neural stem cell transplantation is a promising new treatment of ischemic or traumatic brain injury. We have now investigated the involvement of the peroxynitrite - poly(ADP-ribose) polymerase (ONOO- -PARP) activation cascade in brain trauma and neural stem cell transplantation. The forelimb motor cortex of adult male rats was exposed to cold lesion (-60degreesC) and motor function was monitored. Neural stem cells isolated from E14 rat embryos were labeled with brome deoxyuridine (BrDU) and injected into the injured cortex 6 days after the lesion. After another 6 days, the survival and differentiation of the grafted cells were investigated with immunohistochemistry. Increased production of ONOO- revealed by tyrosine nitration was seen in the lesion 2 days after transplantation. Animals treated with the ONOO- decomposition catalyst FP15 or the PARP inhibitor PJ34 had a significantly improved motor score, when compared to vehicle-treated controls. The neurological score further improved following stem cell grafting in the PJ34 treated, but not in the control animals. Six days after transplantation, differentiated BrDU positive cells were found in the cortical penumbra. The majority of these differentiated cells expressed an astrocyte marker and some of the cells expressed oligodendrocyte or neuronal markers. The number of surviving transplanted cells was significantly higher in the PJ34 treated group. Inhibition of the ONOO- - PARP activation cascade significantly improves the effectiveness of neural stem cell transplantation and promotes rapid functional recovery.	Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol Pharmacol, Winston Salem, NC 27157 USA; Semmelweis Univ, Inst Human Physiol & Clin Expt Res, Budapest, Hungary; Inotek Pharmaceut Corp, Beverly, MA USA; Univ Szeged, Dept Pathol, H-6720 Szeged, Hungary	Lacza, Z (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	zlacza@mac.com	Horvath, Eszter/I-9128-2017; Szabo, Csaba/D-1882-2013	Horvath, Eszter/0000-0002-0517-1269; 	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-50557, HL-30260] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL030260] Funding Source: NIH RePORTER		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Bartlett PF, 1998, IMMUNOL CELL BIOL, V76, P414, DOI 10.1046/j.1440-1711.1998.00762.x; Bjorklund L, 1997, EXP NEUROL, V148, P324, DOI 10.1006/exnr.1997.6655; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P79, DOI 10.1016/0149-7634(95)00063-1; Brundin P, 2000, BRAIN, V123, P1380, DOI 10.1093/brain/123.7.1380; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Brundin P, 2001, NAT MED, V7, P512, DOI 10.1038/87796; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Hortobagyi T, 1998, BRAIN RES BULL, V47, P185, DOI 10.1016/S0361-9230(98)00047-1; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Isacson O, 2001, NAT NEUROSCI, V4, P553, DOI 10.1038/88362; Iwai M, 2002, J CEREBR BLOOD F MET, V22, P411, DOI 10.1097/00004647-200204000-00005; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Kanelos SK, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199812000-00003; KOVACH AGB, 1992, J PHYSIOL-LONDON, V449, P183, DOI 10.1113/jphysiol.1992.sp019081; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; MAYER E, 1993, NEUROSCIENCE, V56, P389, DOI 10.1016/0306-4522(93)90340-L; MAYER E, 1993, NEUROSCIENCE, V56, P379, DOI 10.1016/0306-4522(93)90339-H; MOKRY J, 1995, MOL CHEM NEUROPATHOL, V25, P235, DOI 10.1007/BF02960916; Mundt-Petersen U, 2000, EXP NEUROL, V164, P112, DOI 10.1006/exnr.2000.7407; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Rosenblad C, 1999, EUR J NEUROSCI, V11, P1554, DOI 10.1046/j.1460-9568.1999.00566.x; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; SCHNEIDER GH, 1994, ACTA NEUROCHIR, P437; Sinclair SR, 1996, NEUROREPORT, V7, P2547, DOI 10.1097/00001756-199611040-00029; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Szabo C, 2002, MOL MED, V8, P571, DOI 10.1007/BF03402167; TAKAYAMA H, 1995, NAT MED, V1, P53, DOI 10.1038/nm0195-53; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	43	27	27	0	3	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	AUG	2003	12	2					153	159					7	Medicine, Research & Experimental	Research & Experimental Medicine	701AE	WOS:000184142700003	12851710				2021-06-18	
J	Royo, NC; Schouten, JW; Fulp, CT; Stumizu, S; Marklund, N; Graham, DI; McIntosh, TK				Royo, NC; Schouten, JW; Fulp, CT; Stumizu, S; Marklund, N; Graham, DI; McIntosh, TK			From cell death to neuronal regeneration: Building a new brain after traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						apoptosis; cell death; necrosis; neurogenesis; replacement therapy; transplantation; traumatic brain injury	POSTMITOTIC HUMAN NEURONS; EPIDERMAL-GROWTH-FACTOR; CORTICAL IMPACT INJURY; NEUROGENESIS IN-VITRO; STEM-CELLS; SPINAL-CORD; HEAD-INJURY; NEURAL TRANSPLANTATION; MAMMALIAN FOREBRAIN; NEUROTROPHIC FACTOR	During the past decade, there has been accumulating evidence of the involvement of passive and active cell death mechanisms in both the clinical setting and in experimental models of traumatic brain injury (TBI). Traditionally, research for a treatment of TBI consists of strategies to prevent cell death using acute pharmacological therapy. However, to date, encouraging experimental work has not been translated into successful clinical trials. The development of cell replacement therapies may offer an alternative or a complementary strategy for the treatment of TBI. Recent experimental studies have identified a variety of candidate cell lines for transplantation into the injured CNS. Additionally, the characterization of the neurogenic potential of specific regions of the adult mammalian brain and the elucidation of the molecular controls underlying regeneration may allow for the development of neuronal replacement therapies that do not require transplantation of exogenous cells. These novel strategies may represent a new opportunity of great interest for delayed intervention in patients with TBI.	Head Injury Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, TKM, Philadelphia, PA 19104 USA; Univ Glasgow, So Gen Hosp, Dept Neuropathol, Inst Neurol Sci, Glasgow, Lanark, Scotland	McIntosh, TK (corresponding author), Head Injury Ctr, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu		Marklund, Niklas/0000-0002-9797-5626	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS40978, P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Anderson MF, 2002, DEV BRAIN RES, V134, P115; Brezun JM, 2000, HIPPOCAMPUS, V10, P37, DOI 10.1002/(SICI)1098-1063(2000)10:1<37::AID-HIPO4>3.0.CO;2-C; Buki A, 2000, J NEUROSCI, V20, P2825; Cameron HA, 1998, CURR OPIN NEUROBIOL, V8, P677, DOI 10.1016/S0959-4388(98)80099-8; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dergham P, 2002, J NEUROSCI, V22, P6570; Emery DL, 2000, J COMP NEUROL, V424, P521; Fowler J, 2002, CLIN NEUROPATHOL, V21, P156; Fritz JL, 2002, DEV BIOL, V252, P46, DOI 10.1006/dbio.2002.0842; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gould E, 1997, DEV BRAIN RES, V103, P91, DOI 10.1016/S0165-3806(97)00079-5; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507; Gray JA, 1999, PHILOS T R SOC B, V354, P1407, DOI 10.1098/rstb.1999.0488; Grunwald IC, 2002, CURR OPIN NEUROBIOL, V12, P250, DOI 10.1016/S0959-4388(02)00323-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huber AB, 2000, BIOL CHEM, V381, P407, DOI 10.1515/BC.2000.053; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2002, J NEUROSCI, V22, P5365; Katoh-Semba R, 2002, FASEB J, V16, P1328, DOI 10.1096/fj.02-0143fje; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Larsson E, 2002, EXP NEUROL, V177, P1, DOI 10.1006/exnr.2002.7992; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Magavi SS, 2000, NATURE, V405, P951; McKerracher L, 2002, NEURON, V36, P345, DOI 10.1016/S0896-6273(02)01018-8; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakagawa S, 2002, J NEUROSCI, V22, P9868; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Pencea V, 2001, J NEUROSCI, V21, P6706; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Radley JJ, 2002, BRAIN RES, V955, P264, DOI 10.1016/S0006-8993(02)03477-7; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RAGHUPATHI R, 2003, IN PRESS EXP NEUROL; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; RINK A, 1995, AM J PATHOL, V147, P1575; Roy M, 1999, TRENDS NEUROSCI, V22, P419, DOI 10.1016/S0166-2236(99)01435-6; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Trejo JL, 2001, J NEUROSCI, V21, P1628; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wahl F, 1999, ACT NEUR S, V73, P103; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	82	27	32	2	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2003	62	8					801	811		10.1093/jnen/62.8.801			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	717LP	WOS:000185091000001	14503636	Bronze			2021-06-18	
J	Mariak, Z; White, MD; Lyson, T; Lewko, J				Mariak, Z; White, MD; Lyson, T; Lewko, J			Tympanic temperature reflects intracranial temperature changes in humans	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						brain temperature; face fanning; humans; tympanic temperature	SEVERELY HYPERTHERMIC HUMANS; SEVERE HEAD-INJURY; BRAIN TEMPERATURE; BLOOD-FLOW; EXERCISE; HYPOTHERMIA; GRADIENTS; VEINS	The purpose of the study was to identify extracranial locations in which temperature changes in humans reflect those of intracranial temperature in a reliable and repeatable way. This was achieved by subjecting 14 non-anaesthetized patients after neurosurgery to face fanning while intracranial and extracranial temperatures were continuously measured. In all patients the cranium was closed and the group included both febrile and non-febrile as well as hyperthermic and normothermic patients. The patients' faces were fanned for 20-30 min, with a small fan at an air speed of 3.25 m s(-1). This gave intracranial temperature changes measured in the subdural space (T-sd) that were highly and significantly correlated (r = 0.91, P < 0.05, n = 14) with changes in tympanic temperatures (T-ty). A low, statistically insignificant correlation (r = 0.40, P > 0.05, n = 12) was found between T-sd and oesophageal temperatures. In conclusion, intracranial temperature changes, induced by face fanning, were reliably reflected by the changes in T-ty.	Med Univ Bialystok, Dept Neurosurg, PL-15276 Bialystok, Poland; Mem Univ Newfoundland, Sch Human Kinet & Recreat, Lab Exercise & Environm Physiol, St Johns, NF A1C 5S7, Canada	Mariak, Z (corresponding author), Med Univ Bialystok, Dept Neurosurg, Ul M Sklodowskiej Curie 24A, PL-15276 Bialystok, Poland.			Mariak, Zenon/0000-0003-4132-9278			BRENGELMANN GL, 1993, FASEB J, V7, P1148; BRINNEL H, 1989, J THERM BIOL, V14, P47, DOI 10.1016/0306-4565(89)90029-6; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CABANAC M, 1979, J PHYSIOL-LONDON, V286, P255, DOI 10.1113/jphysiol.1979.sp012617; CABANAC M, 1985, EUR J APPL PHYSIOL O, V54, P172, DOI 10.1007/BF02335925; CABANAC M, 1993, PFLUG ARCH EUR J PHY, V424, P367, DOI 10.1007/BF00384366; Cabanac M., 1995, HUMAN SELECTIVE BRAI; CAPUTA M, 1980, J THERM BIOL, V5, P249, DOI 10.1016/0306-4565(80)90029-7; CAPUTA M, 1978, CR ACAD SCI D NAT, V287, P1011; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HIRASHITA M, 1992, EUR J APPL PHYSIOL, V64, P92, DOI 10.1007/BF00376447; JESSEN C, 1992, J APPL PHYSIOL, V72, P664; MARIAK Z, 1994, EUR J APPL PHYSIOL O, V69, P545, DOI 10.1007/BF00239873; Mariak Z, 2000, Neurol Neurochir Pol, V34, P509; Mariak Z, 2002, J THERM BIOL, V27, P219, DOI 10.1016/S0306-4565(01)00087-0; Mariak Z, 1998, ACTA NEUROCHIR, V140, P585, DOI 10.1007/s007010050144; MCCAFFREY TV, 1975, J APPL PHYSIOL, V39, P114; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; NIELSEN B, 1992, PFLUG ARCH EUR J PHY, V422, P168, DOI 10.1007/BF00370416; RASCH W, 1991, J APPL PHYSIOL, V71, P590; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Shibasaki M, 1998, J APPL PHYSIOL, V85, P921; SHIRAKI K, 1988, J APPL PHYSIOL, V65, P482; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004; YASUDA N, 1991, ANESTHESIOLOGY, V74, P489, DOI 10.1097/00000542-199103000-00017	26	27	28	0	7	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0031-6768			PFLUG ARCH EUR J PHY	Pflugers Arch.	MAY	2003	446	2					279	284		10.1007/s00424-003-1021-3			6	Physiology	Physiology	687VX	WOS:000183398600019	12739166				2021-06-18	
J	Mills, WJ; Tejwani, T				Mills, WJ; Tejwani, T			Heterotopic ossification after knee dislocation: The predictive value of the injury severity score	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						knee dislocation; heterotopic ossification; ISS	POSTERIOR CRUCIATE LIGAMENTS; ARTHROPLASTY; RECONSTRUCTION; ANTERIOR	Objective: To determine the relationship of multiple variables, including the Injury Severity Score (ISS), closed head injury (CHI), and timing and type of surgery to formation of motion-limiting heterotopic ossification (HO) following knee dislocation. Design: Longitudinal observational study. Setting: University level 1 trauma center. Patients/Participants: Thirty-five consecutive patients with 36 knee dislocations (OTA fracture and dislocation classification 40-D) admitted over a 26-month period. Main Outcome Measurements: Admission ISS, Glascow Coma scale (GCS) scores, CHI, timing (> or < 3 weeks from injury) and type (open or arthroscopic) of surgery, number of cruciate ligaments reconstructed, medial surgical procedure, and eventual presence or absence of motion-limiting HO. Results: A classification system for HO was developed ranging from none (type 0) to ankylosing (type IV) HO. Twenty-nine patients with type 0-III HO recovered an average range of motion of 126degrees at an average of 14 months (group A). Six patients formed ankylosing type IV HO (group B). The ISS in group A ranged from 9 to 26. ISS in group B ranged from 26 to 50 (P < 0.001). Regarding the formation of type IV HO, the sensitivity of an ISS greater than or equal to26 was 100%, the specificity was 97%, and the positive predictive value was 86%. Patients in group B had a greater incidence of documented CHI (P < 0.025). Timing and type of surgery, number of ligaments reconstructed, and whether or not the patient had a medial surgical procedure had no statistical influence on degree of HO formation. Conclusions: An ISS of 26 seems to be a discrete boundary above which patients with knee dislocation are at extremely high risk for type IV HO formation if undergoing surgical reconstruction and below which patients are likely spared this complication. The presence of a CHI is a significant factor in type IV HO formation, although harder to quantify. None of the remaining independent variables studied were significantly related to ankylosing type IV HO formation.	Univ Washington, Harborview Med Ctr, Dept Orthopaed, Seattle, WA 98104 USA; NYU, Dept Orthopaed, New York, NY USA	Mills, WJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Orthopaed, Box 359798,325 9th Ave, Seattle, WA 98104 USA.			Tejwani, Nirmal/0000-0001-8578-6556			Anglen JO, 1996, J ORTHOP TRAUMA, V10, P258, DOI 10.1097/00005131-199605000-00006; AUSTIN KS, 1995, J ARTHROPLASTY, V10, P695, DOI 10.1016/S0883-5403(05)80219-0; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bellemans J, 1999, Acta Orthop Belg, V65, P98; Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; Chidel MA, 2001, J ARTHROPLASTY, V16, P1, DOI 10.1054/arth.2001.16492; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Dedmond B T, 2001, Am J Knee Surg, V14, P33; FRASSICA FJ, 1991, CLIN ORTHOP RELAT R, P200; Freedman E L, 1996, Am J Orthop (Belle Mead NJ), V25, P559; FURIA JP, 1995, J ARTHROPLASTY, V10, P413, DOI 10.1016/S0883-5403(05)80139-1; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P133; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GHALAMBOR N, 1994, CLIN ORTHOP RELAT R, V305, P96; GREEN NE, 1977, J BONE JOINT SURG AM, V59, P236, DOI 10.2106/00004623-197759020-00017; Harwin S F, 1993, J Arthroplasty, V8, P113, DOI 10.1016/S0883-5403(06)80048-3; HELFET DL, 1993, CLIN ORTHOP RELAT R, V292, P26; Horne LT, 1999, J ORTHOP TRAUMA, V13, P385, DOI 10.1097/00005131-199906000-00013; Ibrahim SA, 1999, J BONE JOINT SURG BR, V81B, P987, DOI 10.1302/0301-620X.81B6.9516; Ilahi OA, 1998, ORTHOPEDICS, V21, P265; IPPOLITO E, 1999, CLIN ORTHOP RELAT R, V43, P130; JOHNSON EE, 1994, CLIN ORTHOP RELAT R, V305, P88; KUNDEL K, 1996, CLIN ORTHOP RELAT R, V41, P200; MAYO KA, 1994, CLIN ORTHOP RELAT R, V332, P31; MEYERS MH, 1971, J BONE JOINT SURG AM, VA 53, P16, DOI 10.2106/00004623-197153010-00002; Noyes FR, 1997, AM J SPORT MED, V25, P769, DOI 10.1177/036354659702500608; Patton WC, 2000, AM J SPORT MED, V28, P398, DOI 10.1177/03635465000280032001; Rader GP, 1997, ACTA ORTHOP SCAND, V68, P46, DOI 10.3109/17453679709003974; Roman P D, 1987, Orthop Rev, V16, P917; ROUTT MLC, 1990, J BONE JOINT SURG AM, V72A, P897, DOI 10.2106/00004623-199072060-00016; SHAPIRO MS, 1995, AM J SPORT MED, V23, P580, DOI 10.1177/036354659502300511; SILISKI JM, 1998, MASTER TECHNIQUES OR, P347; TAYLOR A R, 1972, Journal of Bone and Joint Surgery British Volume, V54, P96; Tomaino M, 2000, KNEE SURG SPORT TR A, V8, P163, DOI 10.1007/s001670050208; Twaddle BC, 1996, J BONE JOINT SURG BR, V78B, P573; VARNELL RM, 1989, AM SURGEON, V55, P699; WALKER DN, 1994, J TRAUMA, V36, P898, DOI 10.1097/00005373-199406000-00027; Wascher DC, 1997, J ORTHOP TRAUMA, V11, P525, DOI 10.1097/00005131-199710000-00011; Wascher DC, 2000, CLIN SPORT MED, V19, P457, DOI 10.1016/S0278-5919(05)70218-0; Yeh WL, 1999, J TRAUMA, V46, P693, DOI 10.1097/00005373-199904000-00023	41	27	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	MAY	2003	17	5					338	345		10.1097/00005131-200305000-00004			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	675AJ	WOS:000182670600004	12759638				2021-06-18	
J	Turkstra, L; Ciccia, A; Seaton, C				Turkstra, L; Ciccia, A; Seaton, C			Interactive behaviors in adolescent conversation dyads	LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS			English	Article						pragmatics; social communication; gaze; adolescent	TRAUMATIC BRAIN-INJURY; LANGUAGE-SKILLS; DISCOURSE; COMMUNICATION; CLINICIAN; COHESION; STUDENTS	Purpose: Verbal and nonverbal conversational behaviors often are the target of intervention for adolescents with social communication disorders. There are, however, few sources of data on the interactive conversational behaviors of typically developing-adolescents that can be used as guidelines when working with clinical populations. The purpose of this study was to collect behavioral data from conversations of adolescents so as to provide comparison data for adolescents with communication disorders. Method: Conversational behaviors were measured in 50 typically developing African American and Caucasian adolescents (24 females, 26 males) from the Midwest United States who engaged in extemporaneous, 3-minute conversations in dyads with peers. The effects of age, race, and sex of the participant were assessed. Results: Behaviors occurring at relatively high frequencies included directing gaze at the partner, particularly during listening; nodding and showing neutral and positive facial expressions; using back-channel responses; and giving contingent responses. Participants rarely showed negative emotions, turned away from each other, asked for clarification, or failed to answer questions. Overall, there were few effects of race and sex of the speaker and greater variability within than between groups. Clinical Implications: The data may serve as a source of information for clinicians serving individuals with communication disorders, with the caveat that the conversations included here represent a subset of typical adolescent interactive conversational behaviors.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA	Turkstra, L (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.	ls2@po.cwru.edu	Ciccia, Angela/J-5967-2019				ASHER SR, 1986, SOCIAL WORK ED, V8, P205; Body R, 1998, BRAIN INJURY, V12, P963, DOI 10.1080/026990598122016; Brice A, 1996, LANG SPEECH HEAR SER, V27, P68, DOI 10.1044/0161-1461.2701.68; BUCHNER A, 1997, GASTERISKPOWER PRIOR; CAPPELLA JN, 1994, HDB INTERPERSONAL CO, P380; CHAMBERS Jack, 1995, SOCIOLINGUISTIC THEO; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Cherney L.R., 1998, ANAL DISCOURSE COMMU; CHERULNIK PD, 1978, J SOC PSYCHOL, V104, P263, DOI 10.1080/00224545.1978.9924068; CIECIA A, 2002, ADV SPEECH LANGUAGE, V4, P1; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Csikszentmihalyi M., 1984, BEING ADOLESCENT CON; DAVIS AD, 1991, J COMMUN DISORD, V24, P251, DOI 10.1016/0021-9924(91)90001-Y; Duck, 1991, STUDYING INTERPERSON, P197; DUNCAN S, 1972, J PERS SOC PSYCHOL, V23, P283, DOI 10.1037/h0033031; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FLAVELL JH, 1968, DEV ROLE TAKING COMM; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hendry LB, 2000, J ADOLESCENCE, V23, P705, DOI 10.1006/jado.2000.0354; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HUGHES J, 1990, HDB PSYCHOL ED ASSES, P423; Hux K, 1997, J COMMUN DISORD, V30, P133, DOI 10.1016/S0021-9924(96)00060-3; KENDON A, 1967, ACTA PSYCHOL, V26, P22, DOI 10.1016/0001-6918(67)90005-4; LAFRANCE M, 1976, J PERS SOC PSYCHOL, V33, P547, DOI 10.1037/0022-3514.33.5.547; Lagomarsino J, 1998, PSYCHOL REC, V48, P317, DOI 10.1007/BF03395272; LAPADAT JC, 1991, J LEARN DISABIL-US, V24, P147, DOI 10.1177/002221949102400303; Larson RW, 1996, DEV PSYCHOL, V32, P744, DOI 10.1037/0012-1649.32.4.744; LARSON RW, 1983, J MARRIAGE FAM, V45, P739, DOI 10.2307/351787; MARCELLE YM, 1976, THESIS KANSAS STATE; McBride CK, 1997, ADOLESCENCE, V32, P515; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Mundy P, 1997, MENT RETARD DEV D R, V3, P343; Muuss R.E., 1996, THEORIES ADOLESCENCE, V6th ed.; Myers P.S., 1999, RIGHT HEMISPHERE DAM; *NOLD CORP, 2000, OBS VERS 3 0; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; Penn C, 1999, BRAIN LANG, V68, P535, DOI 10.1006/brln.1999.2127; PLACE KS, 1991, DISCOURSE PROCESS, V14, P227, DOI 10.1080/01638539109544783; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RAFFAELLI M, 1989, J YOUTH ADOLESCENCE, V18, P567, DOI 10.1007/BF02139074; Readdick CA, 1997, ADOLESCENCE, V32, P313; Smith TE, 1997, ADOLESCENCE, V32, P483; Snow PC, 2000, BRAIN INJURY, V14, P397; SPENCE SH, 1981, J APPL BEHAV ANAL, V14, P159, DOI 10.1901/jaba.1981.14-159; *STATA, 1999, STATA STAT SOFTW VER; Steinberg L., 1999, ADOLESCENCE; Stephens J., 1986, J LANG SOC PSYCHOL, V5, P119, DOI [10.1177/0261927X8652003, DOI 10.1177/0261927X8652003]; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; Stevens J.P., 1990, INTERMEDIATE STAT MO; *SYST SOFTW, 1998, SYSTAT VERS 8 0; Turkstra LS, 2001, J COMMUN DISORD, V34, P151, DOI 10.1016/S0021-9924(00)00046-0; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WERTZ RT, 1998, APPROACHES TREATMENT, P11; WIEMANN JM, 1981, HUM COMMUN RES, V7, P302, DOI 10.1111/j.1468-2958.1981.tb00577.x; WINT G, 1965, 3 KILLER MEDIATIONS	60	27	28	0	7	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	0161-1461	1558-9129		LANG SPEECH HEAR SER	Lang. Speech Hear. Serv. Sch.	APR	2003	34	2					117	127		10.1044/0161-1461(2003/010)			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	668AU	WOS:000182268800003	27764492				2021-06-18	
J	Duperier, T; Mosenthal, A; Swan, KG; Kaul, S				Duperier, T; Mosenthal, A; Swan, KG; Kaul, S			Acute complications associated with Greenfield filter insertion in high-risk trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Greenfield filter; complications; pulmonary embolism; arteriovenous fistula; deep venous thrombosis	VENA-CAVA FILTERS; DEEP VENOUS THROMBOSIS; TERM FOLLOW-UP; PULMONARY-EMBOLISM; PERCUTANEOUS INSERTION; INTERMITTENT COMPRESSION; PLACEMENT; FIBRINOLYSIS; PROPHYLAXIS; EXPERIENCE	Background: Use of Greenfield filters (GFs) to prevent fatal pulmonary embolism (PE) in trauma patients is generally well accepted. Nonetheless, a surprisingly small number of trauma surgeons insert filters in their patients. Among the reasons cited is fear of complications. Methods: We observed three femoral arteriovenous fistulae (AVF) in trauma patients who had inferior vena caval placement of filters for PE prophylaxis in one 12-month period (academic year 1999). In an effort to document the magnitude of this problem, we evaluated trauma patients who had a GF inserted in academic year 2000. Results: During that year, 133 consecutive patients (8.6% of trauma admissions) received 133 GFs through a percutaneous approach. The most common isolated indications for GF insertion included closed head injuries (n = 28), multiple long bone fractures (n = 27), pelvic and acetabular fractures (n 6), spinal cord injuries (n = 16), and vertebral fractures (n = 3). Five patients had documented deep venous thrombosis (DVT) diagnosed by duplex ultrasonography before GF placement, and 11 patients had other indications requiring a filter. There were 37 patients with more than one indication requiring filter placement. Most patients (57%) underwent preinsertion duplex scanning of their lower extremity veins; 77% of patients underwent postinsertion scanning. Filters were inserted an average of 6.8 +/- 0.6 (SE) days after trauma. No AVF were suspected clinically or detected ultrasonographically. No operative or postoperative complications occurred. DVT was observed in 30% of patients despite 92% prophylaxis; there was a 26% incidence of de novo thrombi detected. None of the patients evidenced DVT clinically. Conclusion: Our data indicate that complications of GF insertion for prophylaxis against PE from DVT complicating trauma patients continue to be negligible. In addition, the incidence of insertion-site thrombosis may be lower than expected. Moreover, femoral AVF is a rare complication of this procedure.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA	Swan, KG (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave,Room G-592, Newark, NJ 07103 USA.						ALLENBY F, 1973, LANCET, V2, P1412; Aswad MA, 1996, J VASC SURG, V24, P809, DOI 10.1016/S0741-5214(96)70017-4; BECKER DM, 1992, ARCH INTERN MED, V152, P1985, DOI 10.1001/archinte.152.10.1985; Blebea J, 1999, J VASC SURG, V30, P821, DOI 10.1016/S0741-5214(99)70006-6; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; DORFMAN GS, 1989, RADIOLOGY, V173, P159, DOI 10.1148/radiology.173.1.2675182; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; Gosin JS, 1997, ANN VASC SURG, V11, P100, DOI 10.1007/s100169900017; GRASSI CJ, 1988, AM J ROENTGENOL, V151, P681, DOI 10.2214/ajr.151.4.681; Greenfield LJ, 2000, J VASC SURG, V32, P490, DOI 10.1067/mva.2000.108636; GREENFIELD LJ, 1977, ANN SURG, V185, P692, DOI 10.1097/00000658-197706000-00012; HIRSCH SB, 1987, J VASC SURG, V6, P609, DOI 10.1067/mva.1987.avs0060609; KANTOR A, 1987, AM J ROENTGENOL, V149, P1065, DOI 10.2214/ajr.149.5.1065; KAPSCH DN, 1984, SURGERY, V95, P473; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; KNIGHT MTN, 1976, LANCET, V2, P1265; Langan EM, 1999, J VASC SURG, V30, P484, DOI 10.1016/S0741-5214(99)70075-3; LEACH TA, 1994, AM SURGEON, V60, P292; MASTROBATTISTA JM, 1995, GYNECOL ONCOL, V56, P399, DOI 10.1006/gyno.1995.1070; McMurtry AL, 1999, J AM COLL SURGEONS, V189, P314, DOI 10.1016/S1072-7515(99)00137-4; Meissner M H, 1998, Semin Vasc Surg, V11, P274; MEWISSEN MW, 1989, RADIOLOGY, V173, P159; PAIS SO, 1988, J VASC SURG, V8, P460; Patton JH, 1996, J TRAUMA, V41, P231, DOI 10.1097/00005373-199608000-00006; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; Rogers FB, 1998, ARCH SURG-CHICAGO, V133, P406, DOI 10.1001/archsurg.133.4.406; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; Snedecor G.W., 1980, STAT METHODS, V7th; Trousseau A, 1865, CLIN MED HOTEL DIEU, P94; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021; Wojcik R, 2000, J TRAUMA, V49, P839, DOI 10.1097/00005373-200011000-00008	33	27	29	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2003	54	3					545	549		10.1097/00005373-200303000-00018			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	660EA	WOS:000181819800018	12634536				2021-06-18	
J	Tate, RL				Tate, RL			Impact of pre-injury factors on outcome after severe traumatic brain injury: Does post-traumatic personality change represent an exacerbation of premorbid traits?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEVERE HEAD-INJURY; SUBSTANCE-ABUSE; REHABILITATION OUTCOMES; PSYCHOSOCIAL ADJUSTMENT; FOLLOW-UP; PREDICTION; IMPAIRMENT; DYSFUNCTION; DISABILITY; COMMUNITY	Although personality change is a frequent and disabling consequence of severe degrees of traumatic brain injury (TBI), little information is available beyond descriptive statements. The present paper presents a brief overview of the literature on the effects of pre-injury variables on post-trauma psychosocial functioning, and makes specific examination of the effect of premorbid personality structure on the post-trauma personality in people with TBI. A close relative of 28 people undergoing rehabilitation after TBI completed the Eysenck Personality Questionnaire-Revised (EPQ-R) and Current Behaviour Scale (CBS) regarding the injured person's personality and character. Data were collected on three occasions: Ratings about premorbid status were taken as soon as feasible after admission, and follow-up ratings regarding current status were made at 6 and 12 months post-trauma. As a group, premorbid ratings indicated an unremarkable profile on the EPQ-R. Significant changes had occurred by 6 months post-trauma, which were sustained at 12 months post-trauma for both the EPQ-R and CBS. Yet none of the specific hypotheses regarding premorbid personality structure on the EPQ-R and post-trauma characterological deficits on the two CBS factors, Loss of Emotional Control (LEC) and Loss of Motivation (LM), was supported: There were no significant differences between subgroups with high or low premorbid levels of Extraversion, Neuroticism, Psychoticism, Addiction and Criminality and post-trauma CBS factors, LEC, and LM. These findings suggest that although personality changes occur as a result of traumatic brain injury, they are largely independent of the premorbid personality structure.	Univ Sydney, Royal Rehabil Ctr Sydney, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia	Tate, RL (corresponding author), Univ Sydney, Royal Rehabil Ctr Sydney, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.						ALBERTS MS, 1991, COGNITIVE REHABILITA, P95; Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bond M. R., 1990, REHABILITATION ADULT, P179; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P746; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DODWELL D, 1988, PSYCHOL MED, V18, P495, DOI 10.1017/S0033291700008035; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; ELSASS L, 1991, THESIS LA TROBE U AU; Elsass L, 1989, P 14 ANN BRAIN IMP C, P124; Eysenck H. J., 1991, MANUAL EYSENCK PERSO; Eysenck H.J., 1981, MODEL PERSONALITY; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; Fleming J, 1999, BRAIN INJURY, V13, P417; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; GASS CS, 1995, CLIN PERSONALITY ASS, P192; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JAMIESON KG, 1966, 13 NAT HLTH MED RES; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KAY T, 1992, REHABILITATION POST, P109; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; Lazarus R.S., 1984, STRESS APPRAISAL COP; Ley P., 1972, QUANTITATIVE ASPECTS; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1998, ORGANIC PSYCHIAT PSY; LONDON PS, 1967, ANN ROY COLL SURG, V41, P607; Luria A. R, 1973, WORKING BRAIN; Luria A. R., 1969, HDB CLINICAL NEUROLO, V2, P725; MACMILLAN M, 1996, BRAIN DAM B, P243; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; SELECKI BR, 1967, MED J AUSTR     0715, P113; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Tate PS, 1999, BRAIN INJURY, V13, P767; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	75	27	27	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		43	64		10.1080/09602010244000372			22	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500004	21854327				2021-06-18	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO; Minich, NM			Parent-adolescent interactions after traumatic brain injury - Their relationship to family adaptation and adolescent adjustment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; child adjustment; conflict; criticism; family adaptation; parent-adolescent interaction; pediatric	EXPRESSED EMOTION; CHILDREN; RELIABILITY; PREDICTORS; VALIDITY; SEVERITY; BURDEN	To examine changes in parent-adolescent interactions after traumatic brain injury (17131) and their relationship to parent and adolescent adjustment. Design: Concurrent cohort, cross-sectional study. Analysis of variance was used to examine group differences and regression analysis to assess associations between interactional measures and concurrent adjustment. Setting: Four hospitals in north-central Ohio. Participants: Adolescents with severe TBI (25), moderate TBI (22), and orthopedic injuries (35) and their parents. Main outcome measures: Observer ratings of parent-adolescent interactions, Conflict Behavior Questionnaire (CBQ), Family Burden of Injury Interview (FBII), Brief Symptom Inventory (BSI), Family Assessment Device (FAD), Child Behavior Checklist, Vineland Adaptive Behavior Scale, and Children's Depression Inventory. Results: No group differences were found on ratings of parent-adolescent interaction or the parent or child CBQ. However, observed criticism/coldness and self-rated conflict had stronger associations with the FBII, BSI, and FAD in the severe TBI group than in the orthopedic injury group, suggesting that conflict is more disruptive after TBI. Ratings of criticism/coldness and parent and adolescent CBQ scores were also associated with parent and adolescent adjustment. Conclusions: Results support the utility of observational measures in assessing dyadic interactions after TBI.	Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Metrohlth Med Ctr, Cleveland, OH USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 380611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; AIKEN IS, 1991, MULTIPLE REGRESSION; Borduin C. M., 1985, CHILD FAMILY BEHAV T, V7, P51, DOI DOI 10.1300/J019V07N02_04; Borduln CM, 1987, J APPL DEV PSYCHOL, V8, P273; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Derogatis L., 1982, BRIEF SYMPTOM INVENT; DISHION TJ, 1985, AM J DRUG ALCOHOL AB, V11, P11, DOI 10.3109/00952998509016846; DOSSETOR DR, 1994, J INTELL DISABIL RES, V38, P487; FLANNERY DJ, 1993, J SOC PERS RELAT, V10, P495, DOI 10.1177/0265407593104002; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Henggeler S.W., 1987, J APPL DEV PSYCHOL, V8, P97, DOI [10.1016/0193-3973(87)90023-2, DOI 10.1016/0193-3973(87)90023-2]; Hodes M, 1999, J CHILD PSYCHOL PSYC, V40, P1083, DOI 10.1111/1469-7610.00526; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KOVACS M, 1981, ACTA PAEDOPSYCHIATR, V46, P305; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Patterson G. R., 1982, COERCIVE FAMILY PROC; PATTERSON GR, 1983, COPING DEV CHILDREN, P235; PETERSEN AC, 1988, J YOUTH ADOLESCENCE, V17, P117, DOI 10.1007/BF01537962; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; ROBIN AL, 1989, NEGOTIATING PARENT A; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Singer G. H. S., 1996, CHILDREN ACQUIRED BR, P23; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wamboldt MZ, 2000, J AM ACAD CHILD PSY, V39, P1212, DOI 10.1097/00004583-200010000-00006; WEBSTERSTRATTON C, 1990, J CLIN CHILD PSYCHOL, V19, P302, DOI 10.1207/s15374424jccp1904_2; WILLIAMS J, 1991, HEAD INJURY FAMILY M; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	36	27	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					164	176		10.1097/00001199-200303000-00007			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600007	12802225				2021-06-18	
J	Seidberg, NA; Clark, RSB; Zhang, XP; Lai, YC; Chen, MZ; Graham, SH; Kochanek, PM; Watkins, SC; Marion, DW				Seidberg, NA; Clark, RSB; Zhang, XP; Lai, YC; Chen, MZ; Graham, SH; Kochanek, PM; Watkins, SC; Marion, DW			Alterations in inducible 72-kDa heat shock protein and the chaperone cofactor BAG-1 in human brain after head injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; Bcl-2; head injury; Hsc70; Hsp70; trauma	OXIDE SYNTHASE EXPRESSION; CULTURED NEURONS; STRESS-RESPONSE; RAT-BRAIN; INDUCTION; HSP70; HEAT-SHOCK-PROTEIN-70; CELLS; FLUID; GENE	The stress response in injured brain is well characterized after experimental ischemic and traumatic brain injury (TBI); however, the induction and regulation of the stress response in humans after TBI remains largely undefined. Accordingly, we examined injured brain tissue from adult patients (n=8) that underwent emergent surgical decompression after TBI, for alterations in the inducible 72-kDa heat shock protein (Hsp70), the constitutive 73-kDa heat shock protein (Hsc70), and isoforms of the chaperone cofactor BAG-1. Control samples (n=6) were obtained postmortem from patients dying of causes unrelated to CNS trauma. Western blot analysis showed that Hsp70, but not Hsc70, was increased in patients after TBI versus controls. Both Hsp70 and Hsc70 coimmunoprecipitated with the cofactor BAG-1. The 33 and 46, but not the 50-kDa BAG-1 isoforms were increased in patients after TBI versus controls. The ratio of the 46/33-kDa isoforms was increased in TBI versus controls, suggesting negative modulation of Hsp70/Hsc70 protein refolding activity in injured brain. These data implicate induction of the stress response and its modulation by the chaperone cofactor and Bcl-2 family member BAG-1, after TBI in humans.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Anesthesiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Clark, RSB (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506; watkins, simon/0000-0003-4092-1552	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318, KO8 NS01946] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620, K08NS001946] Funding Source: NIH RePORTER		Bechtold DA, 2000, J NEUROCHEM, V74, P641, DOI 10.1046/j.1471-4159.2000.740641.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; BURDON RH, 1993, MOL ASPECTS MED, V14, P83, DOI 10.1016/0098-2997(93)90020-E; Champagne MJ, 1999, HYPERTENSION, V33, P906, DOI 10.1161/01.HYP.33.3.906; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; CHEN Q, 1993, J CEREBR BLOOD F MET, V13, P389, DOI 10.1038/jcbfm.1993.52; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; deVera ME, 1996, HEPATOLOGY, V24, P1238; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Dutcher SA, 1998, J NEUROTRAUM, V15, P421, DOI 10.1089/neu.1998.15.421; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gotohda Takako, 2000, Journal of Medical Investigation, V47, P76; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KATO M, 1992, ACTA NEUROPATHOL, V83, P420, DOI 10.1007/BF00713535; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LI Y, 1992, ACTA NEUROPATHOL, V84, P94, DOI 10.1007/BF00427221; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LING J, 1998, GENE DEV, V12, P3236; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Matz PG, 1996, J NEUROSURG, V85, P138, DOI 10.3171/jns.1996.85.1.0138; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MORRISONBOGORAD M, 1995, J NEUROCHEM, V64, P235; Papadopoulos MC, 1996, NEUROREPORT, V7, P429, DOI 10.1097/00001756-199601310-00013; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; PUARUD S, 1994, CELL MOL NEUROBIOL, V14, P341; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Schett G, 1999, FASEB J, V13, P833; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; SIMON RP, 1991, J NEUROSCI, V11, P881; Someren JS, 1999, BIOCHEM BIOPH RES CO, V260, P619, DOI 10.1006/bbrc.1999.0800; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; Tytell M, 1998, MOL CHEM NEUROPATHOL, V35, P97, DOI 10.1007/BF02815118; VASS K, 1989, NEUROSCI LETT, V100, P259, DOI 10.1016/0304-3940(89)90695-2; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403	52	27	28	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2003	84	3					514	521		10.1046/j.1471-4159.2003.01547.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	635UF	WOS:000180417200011	12558971	Bronze			2021-06-18	
J	Murai, T; Fujimoto, S				Murai, T; Fujimoto, S			Rapid cycling bipolar disorder after left temporal polar damage	BRAIN INJURY			English	Article							BRAIN INJURY; HEAD-INJURY; RESPONSES; VALPROATE; ANGER	The case of a 48-year-old woman with rapid cycling bipolar disorder subsequent to a traumatic brain injury is reported. Both depressive and manic episodes had an average duration of similar to1 month, alternating without stable euthymic periods. Neuroradiological examinations revealed a circumscribed lesion in the left temporal pole. After 1 year without treatment, psychiatric intervention and pharmacotherapy was initiated. Her mood swings were successfully treated with the co-administration of valproate and lithium. Case reports of rapid cycling bipolar disorder after traumatic brain injury are very rare and this case supports the idea that temporal polar dysfunction is a candidate for the neurobiological basis of rapid cycling bipolar disorder.	Kyoto Univ, Fac Med, Dept Psychiat, Kyoto 6068507, Japan	Murai, T (corresponding author), Kyoto Univ, Fac Med, Dept Psychiat, Shogoin Kawaharacho 54, Kyoto 6068507, Japan.		anand, amit/A-7222-2009				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARNOLD SE, 1994, ARCH NEUROL-CHICAGO, V51, P145, DOI 10.1001/archneur.1994.00540140051014; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; Dolan RS, 2000, NEUROIMAGE, V11, P203, DOI 10.1006/nimg.2000.0538; Dougherty DD, 1999, BIOL PSYCHIAT, V46, P466, DOI 10.1016/S0006-3223(99)00063-3; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; MESULAM MM, 1985, PRINCIPLES BEHAVIORA, P1; Monji A, 1999, PSYCHOSOMATICS, V40, P448, DOI 10.1016/S0033-3182(99)71215-6; MORAN MA, 1987, J COMP NEUROL, V256, P88, DOI 10.1002/cne.902560108; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; Royet JP, 2000, J NEUROSCI, V20, P7752; ZWIL AS, 1993, BRAIN INJURY, V7, P147, DOI 10.3109/02699059309008168	12	27	28	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	4					355	358		10.1080/0269905031000070170			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	660MP	WOS:000181837200008	12637187				2021-06-18	
J	Rush, AJ				Rush, AJ			Toward an understanding of bipolar disorder and its origin	JOURNAL OF CLINICAL PSYCHIATRY			English	Article; Proceedings Paper	Roundtable Discussion on Bipolar Disorder - From Clinical Research to Therapeutic Intervention	JUN 30, 2001	BERLIN, GERMANY				TRAUMATIC BRAIN INJURY; LIFE EVENTS; PERINATAL COMPLICATIONS; PSYCHIATRIC-DISORDERS; SUBSTANCE-ABUSE; SECONDARY MANIA; MOOD DISORDERS; SOCIAL-CLASS; DRUG-ABUSE; SCHIZOPHRENIA	Bipolar disorder, a disease with significant morbidity and mortality, continues to present diagnostic and clinical challenges. Lifetime prevalence of bipolar I disorder has been estimated at 1.3%, with an equal distribution between males and females. Recognition of the illness may take years, but most patients are diagnosed before the age of 30. The role of genetic influences in bipolar disease is supported by family studies and high concordance rates among monozygotic twins. Current speculation proposes a likely interaction between genetic predisposition and environmental influences, including stressful life events. Diagnostic work-up should exclude mania secondary to drug use or general medical causes, particularly in patients whose symptoms begin after age 30 and in those with no family history of bipolar or unipolar disease. Patients with cyclothymia or thyroid dysfunction or postpartum women are at particular risk for bipolar disease. Substance abuse, which is extremely common among patients with bipolar disorder, interferes with diagnosis and can worsen the course of the disease. Alcohol dependence has been reported in approximately one third of those with bipolar I and one fifth of those with bipolar 11 disorder. To facilitate early diagnosis and effective management, clinicians should be aware of the risk factors, possible causes, and comorbidities of bipolar disease.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA	Rush, AJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	john.rush@UTSouthwestern.edu		Rush, Augustus/0000-0003-2004-2382			AKISKAL HS, 1977, AM J PSYCHIAT, V134, P1227; Alda M, 1997, CAN J PSYCHIAT, V42, P378, DOI 10.1177/070674379704200404; BAUER MS, 1990, ARCH GEN PSYCHIAT, V47, P427; BEBBINGTON P, 1995, SOC PSYCH PSYCH EPID, V30, P279, DOI 10.1007/BF00805795; Begley CE, 2001, PHARMACOECONOMICS, V19, P483, DOI 10.2165/00019053-200119050-00004; Berrettini WH, 1997, ARCH GEN PSYCHIAT, V54, P27; BRADY KT, 1992, J CLIN PSYCHOPHARM, V12, pS17, DOI 10.1097/00004714-199202001-00004; Brady KT, 2000, J CLIN PSYCHIAT, V61, P32; BRADY KT, 1995, J CLIN PSYCHIAT, V56, P19; Buka SL, 1999, SCHIZOPHR RES, V39, P113, DOI 10.1016/S0920-9964(99)00109-7; CADORET RJ, 1978, AM J PSYCHIAT, V135, P463; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; Cassidy F, 2001, BIPOLAR DISORD, V3, P181, DOI 10.1034/j.1399-5618.2001.030403.x; CORYELL W, 1989, AM J PSYCHIAT, V146, P983; Craddock N, 1999, J MED GENET, V36, P585, DOI 10.1136/jmg.36.8.585; EGELAND JA, 1987, NATURE, V325, P783, DOI 10.1038/325783a0; ELLICOTT A, 1990, AM J PSYCHIAT, V147, P1194; Evans DL, 2000, J CLIN PSYCHIAT, V61, P26; Griswold KS, 2000, AM FAM PHYSICIAN, V62, P1343; HAGGERTY JJ, 1990, BIOL PSYCHIAT, V27, P51, DOI 10.1016/0006-3223(90)90019-X; Hendrick V, 2000, J CLIN PSYCHIAT, V61, P393, DOI 10.4088/JCP.v61n0514; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HIRSCHFELD RMA, 2002, 155 ANN M AM PSYCH A; Hultman CM, 1999, BRIT MED J, V318, P421, DOI 10.1136/bmj.318.7181.421; HUNT N, 1992, J AFFECT DISORDERS, V25, P13, DOI 10.1016/0165-0327(92)90088-N; Johnson SL, 2000, J ABNORM PSYCHOL, V109, P721, DOI 10.1037/0021-843X.109.4.721; Johnson SL, 1997, J ABNORM PSYCHOL, V106, P449, DOI 10.1037/0021-843X.106.3.449; Johnson SL, 1999, J ABNORM PSYCHOL, V108, P558, DOI 10.1037/0021-843X.108.4.558; JONES BE, 1986, HOSP COMMUNITY PSYCH, V37, P61; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kinney DK, 1998, J AFFECT DISORDERS, V50, P117; KINNEY DK, 1993, PSYCHIAT RES, V48, P47, DOI 10.1016/0165-1781(93)90112-T; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; Leibenluft E, 1996, AM J PSYCHIAT, V153, P163; LENZI A, 1993, SOC PSYCH PSYCH EPID, V28, P56, DOI 10.1007/BF00802092; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; LISH JD, 1994, J AFFECT DISORDERS, V31, P281, DOI 10.1016/0165-0327(94)90104-X; Maier W, 1996, BRIT J PSYCHIAT, V168, P93, DOI 10.1192/S0007125000298462; Moller HJ, 2003, J CLIN PSYCHIAT, V64, P23; MUKHERJEE S, 1983, AM J PSYCHIAT, V140, P1571; Oomen HAPC, 1996, CLIN ENDOCRINOL, V45, P215, DOI 10.1046/j.1365-2265.1996.d01-1558.x; Potash JB, 2000, AM J PSYCHIAT, V157, P2048, DOI 10.1176/appi.ajp.157.12.2048; Preisig M, 2001, COMPR PSYCHIAT, V42, P87, DOI 10.1053/comp.2001.21221; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; SCHWARZKOPF SB, 1989, PSYCHIAT RES, V27, P233, DOI 10.1016/0165-1781(89)90139-X; SHULMAN K, 1980, BRIT J PSYCHIAT, V136, P26, DOI 10.1192/bjp.136.1.26; STINE OC, 1995, AM J HUM GENET, V57, P1384; Strakowski SM, 2000, CLIN PSYCHOL REV, V20, P191, DOI 10.1016/S0272-7358(99)00025-2; STRAKOWSKI SM, 1994, INT J PSYCHIAT MED, V24, P305, DOI 10.2190/CM8E-46R5-9AJL-03FN; VERDOUX H, 1995, J AFFECT DISORDERS, V33, P181, DOI 10.1016/0165-0327(94)00087-P; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Winokur G, 1998, J AFFECT DISORDERS, V50, P81, DOI 10.1016/S0165-0327(98)00108-6; Winokur G, 1996, AM J MED GENET, V67, P197, DOI 10.1002/(SICI)1096-8628(19960409)67:2<197::AID-AJMG10>3.0.CO;2-E; Woods SW, 2000, J CLIN PSYCHIAT, V61, P38; YASSA R, 1988, J AFFECT DISORDERS, V14, P197, DOI 10.1016/0165-0327(88)90035-3	56	27	28	0	11	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry		2003	64			6			4	8					5	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	677UU	WOS:000182827000002	12720474				2021-06-18	
J	Parker, MW; Chen, Y; Hallenbeck, JM; Ford, BD				Parker, MW; Chen, Y; Hallenbeck, JM; Ford, BD			Neuregulin expression after focal stroke in the rat	NEUROSCIENCE LETTERS			English	Article						stroke; glial growth factor; heregulin; acetylcholine receptor inducing activity; focal cerebral ischemia	NERVOUS-SYSTEM; BRAIN; CELLS; RECEPTOR; ISOFORMS; ISCHEMIA; INJURY; DEATH; ARIA	Upregulation of neuregulin has been demonstrated in traumatic brain injury, but a role for neuregulin in ischemic brain injury has not been investigated. Therefore, we used a rat permanent middle cerebral artery occlusion model to examine the distribution of neuregulin after the onset of ischemic stroke. We found an increase in immunohistochemical staining for neuregulin in the penumbral regions of the cortex. The increase in neuregulin appeared to be neuronal. There was no neuregulin co-localization with astrocytes or macrophages. These results demonstrate that neuregulin is induced in neurons following ischemic stroke and may be involved in neuroprotection and repair. (C) 2002 Published by Elsevier Science Ireland Ltd.	Morehouse Sch Med, Inst Neurosci, Dept Anat & Neurobiol, Atlanta, GA 30310 USA; Johns Hopkins Sch Med, Baltimore, MD USA; NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA	Ford, BD (corresponding author), Morehouse Sch Med, Inst Neurosci, Dept Anat & Neurobiol, 720 Westview Dr,Sw,MRC 223, Atlanta, GA 30310 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34194] Funding Source: Medline		Abe K, 2000, J CEREBR BLOOD F MET, V20, P1393, DOI 10.1097/00004647-200010000-00001; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; Erlich S, 2001, NEUROSCIENCE, V107, P353, DOI 10.1016/S0306-4522(01)00350-5; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Furuya K, 2001, J CEREBR BLOOD F MET, V21, P226, DOI 10.1097/00004647-200103000-00006; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Mattson MP, 1997, NEUROSCI BIOBEHAV R, V21, P193, DOI 10.1016/S0149-7634(96)00010-3; MCAULEY MA, 1995, CEREBROVAS BRAIN MET, V7, P153; ter Laak MP, 2000, J NEUROSCI RES, V60, P237, DOI 10.1002/(SICI)1097-4547(20000415)60:2<237::AID-JNR13>3.0.CO;2-5; Tokita Y, 2001, J NEUROSCI, V21, P1257; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200	18	27	29	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	DEC 16	2002	334	3					169	172	PII S0304-3940(02)01126-6	10.1016/S0304-3940(02)01126-6			4	Neurosciences	Neurosciences & Neurology	624MK	WOS:000179763300007	12453622				2021-06-18	
J	Santaniello, JM; Miller, PR; Croce, MA; Bruce, L; Bee, TK; Malhotra, AK; Fabian, TC				Santaniello, JM; Miller, PR; Croce, MA; Bruce, L; Bee, TK; Malhotra, AK; Fabian, TC			Blunt aortic injury with concomitant intra-abdominal solid organ injury: Treatment priorities revisited	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blunt aortic injury; liver and spleen; nonoperative management; heparin	TRAUMATIC RUPTURE; HEPATIC-TRAUMA; MANAGEMENT; ASSOCIATION; SURGERY; ISTHMUS	Background: Patients with blunt aortic injury (BAI) often have concomitant liver or spleen (L/S) injuries. With increasing use of cardiopulmonary bypass with heparinization in repair of BAI, many advocate operative management of the US injury before aortic repair to eliminate risk of hemorrhage. We evaluated the safety of nonoperative management (NOM) of blunt L/S injuries in patients undergoing acute BAI repair with bypass. Methods: All patients admitted over a 6-year period with BAI were identified from the registry of our Level I trauma center. Patients with isolated L/S injuries without BAI admitted over the same period served as controls. Groups were compared with regard to demographics, injury characteristics, hospital course, and mortality. Results. Eighty-four patients were diagnosed with BAI from 1994 to 2000; 28 (33%) also had blunt abdominal trauma. Three patients with severe brain injury did not undergo BAI repair, and five required laparotomy before BAI repair for other intra-abdominal injuries (two for hemodynamic instability with splenic injury, and three for concomitant bowel injury). Therefore, 20 of 28 (71.4%) BAI patients with grade I or II US injury (Aorta L/S group) underwent planned NOM. All BAIs were repaired using partial bypass with full heparinization. These 20 patients are compared with 894 patients with grade I or II L/S injuries with no BAI (L/S group) over the same time period. There was no difference in the nonoperative failure rate of the Aorta L/S group versus the L/S group (0% vs. 1.7%). Both groups had similar complication rates. The Aorta L/S group was also compared with 56 BAIs without solid organ injury (Aorta group). Although the Aorta L/S group was more severely injured than the Aorta group (Injury Severity Score of 35.3 vs. 26.8, p < 0.0001), transfusion rates (5.7 U of packed red blood cells vs. 8.0 U of packed red blood cells, p = NS), hospital days (17.9 vs. 19.1, p = NS) and mortality (10% vs. 9%, p = NS) were similar. Conclusion: NOM of patients with grade I or II L/S injury who undergo systemic anticoagulation with heparin for repair of BAI is safe and associated with transfusion rates similar to BAI alone. Patients with low-grade liver or spleen injuries do not require laparotomy before BAI repair using partial bypass.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA; Univ Tennessee, Dept Surg, Memphis, TN 38104 USA; Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Richmond, VA 23298 USA	Santaniello, JM (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Surg, 2160 S 1st Ave,Bldg 110,Room 4234, Maywood, IL 60153 USA.	jsantan@lumc.edu					Attar S, 1999, ANN THORAC SURG, V67, P959, DOI 10.1016/S0003-4975(99)00174-5; BORMAN KR, 1982, AM J SURG, V144, P728, DOI 10.1016/0002-9610(82)90559-1; CROCE MA, 1995, ANN SURG, V221, P744, DOI 10.1097/00000658-199506000-00013; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Fisher PJ, 2000, SOUTH MED J, V93, P865; Frick EJ, 1997, J TRAUMA, V43, P844, DOI 10.1097/00005373-199711000-00018; Hunt JP, 1996, J TRAUMA, V40, P547, DOI 10.1097/00005373-199604000-00005; LEE RB, 1992, AM SURGEON, V58, P37; MATTOX KL, 1985, ANN THORAC SURG, V40, P456, DOI 10.1016/S0003-4975(10)60100-2; Morgan PB, 2000, SOUTHERN MED J, V93, P173; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Pierangeli A, 2000, CARDIOVASC SURG, V8, P280, DOI 10.1016/S0967-2109(00)00015-6; Richardson JD, 2000, ANN SURG, V232, P324, DOI 10.1097/00000658-200009000-00004; Sweeney MS, 1997, ANN THORAC SURG, V64, P384, DOI 10.1016/S0003-4975(97)00561-4; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; Wahl WL, 1999, J TRAUMA, V47, P254, DOI 10.1097/00005373-199908000-00006	20	27	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2002	53	3					442	445		10.1097/00005373-200209000-00008			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	599GA	WOS:000178324700010	12352478				2021-06-18	
J	Woertgen, C; Rothoerl, RD; Brawanski, A				Woertgen, C; Rothoerl, RD; Brawanski, A			Early S-100B serum level correlates to quality of life in patients after severe head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; GLASGOW-OUTCOME-SCALE; PROTEIN MEASUREMENTS; FOLLOW-UP; OF-LIFE; INDIVIDUALS; DAMAGE; CONSEQUENCES; PREDICTORS	Purpose: S-100B protein is a new possible indicator of brain damage after severe head injury. In outcome assessment there is an increasing focus on measures of health outcome incorporating the person's own perspective. Therefore, the aim of the study was to investigate the correlation of early S-100B serum level to the quality of life. Method: Fifty-one patients with severe head injury were included in a prospective study. Blood samples were taken on admission (mean 2.5 hours). The outcome was assessed at follow-up using the Glasgow Outcome Scale and a questionnaire according to Blau to assess the quality of life. Results: High serum concentrations of S-100B on admission correlate to unfavourable outcome according to the GOS (4.9 mug/l vs 1.6 mug/l, mean, p<0.0008). In addition, the S-100B serum concentrations on admission correlate to quality of life in the survivor group. Patients with S-100B serum levels &LE; 0.5 &mu;g/l scored 71.4 points (mean) on the QoL index compared to patients with elevated S-100B concentrations, who scored 55.4 points (mean, p<0.05). Conclusion: S-100B seems to be able to assess the extent of primary brain damage after trauma.	Univ Regensburg, Dept Neurosurg, D-93042 Regensburg, Germany	Woertgen, C (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.						BLAU TH, 1977, PROFESSIONAL PSY NOV, P464; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bullock MR, 1999, NEUROSURGERY, V45, P483; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; JENNETT B, 1975, LANCET, V1, P480; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MISSLER U, 1995, EUR J CLIN CHEM CLIN, V33, P743; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; TEASDALE G, 1974, LANCET, V2, P81; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woischneck D, 1998, ACT NEUR S, V71, P138	24	27	32	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2002	16	9					807	816		10.1080/02699050210128933			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	585PD	WOS:000177532800006	12217206				2021-06-18	
J	Teplicky, R; Law, M; Russell, D				Teplicky, R; Law, M; Russell, D			The effectiveness of casts, orthoses, and splints for children with neurological disorders	INFANTS & YOUNG CHILDREN			English	Article						brain injury; casting; cerebral palsy; lower extremity; orthosis; upper extremity	ANKLE-FOOT ORTHOSES; CEREBRAL-PALSY; NEURODEVELOPMENTAL THERAPY; GAIT; MANAGEMENT; IMPROVEMENT; WALKING; GRASP	Casts. orthoses. and splints are often used for children with neurological conditions to improve limb positioning and increase functional movement. This article reports the results of a critical review of the literature examining the effectiveness of casts. orthoses, and splints for the upper and lower extremity when used for children with cerebral palsy or brain injury. Results indicate that for children with cerebral palsy, hands splints improve grasp, and upper extremity casts lead to increased range of motion and decreased muscle tone. The effects on upper extremity function need to he studied further. For lower extremity casts. orthoses, and splints, there is evidence to support their effectiveness for children with cerebral palsy in improving range of motion At the ankle, leading to changes in the quality of walking. For children with traumatic brain injury, there is less information on the effects of casts, orthoses, and splints for both the upper and lower extremity. Further research in this area is needed.	McMaster Univ, Inst Appl Hlth Sci, Canchild Ctr Childhood Disabil Res, Hamilton, ON L8S 4L8, Canada	Teplicky, R (corresponding author), McMaster Univ, Inst Appl Hlth Sci, Canchild Ctr Childhood Disabil Res, Hamilton, ON L8S 4L8, Canada.						BERTOTI DB, 1986, PHYS THER, V66, P1522, DOI 10.1093/ptj/66.10.1522; BLAIR E, 1995, DEV MED CHILD NEUROL, V37, P544; Brouwer B, 1998, DEV MED CHILD NEUROL, V40, P168; Brouwer B, 2000, J PEDIATR ORTHOPED, V20, P221, DOI 10.1097/00004694-200003000-00017; Buckon CE, 2001, DEV MED CHILD NEUROL, V43, P371, DOI 10.1017/S0012162201000706; Cameron ME, 1998, NZ J PHYS THER, V26, P28; Carlson WE, 1997, AM J PHYS MED REHAB, V76, P219, DOI 10.1097/00002060-199705000-00012; COPLEY J, 1999, MANAGEMENT LIMB HYPE; Corry IS, 1998, J PEDIATR ORTHOPED, V18, P304, DOI 10.1097/00004694-199805000-00006; Cottalorda J, 2000, J BONE JOINT SURG BR, V82B, P541, DOI 10.1302/0301-620X.82B4.10188; Crenshaw S, 2000, J PEDIATR ORTHOPED, V20, P210, DOI 10.1097/00004694-200003000-00015; Dent K., 1996, AUST OCCUP THER J, V43, P39; Evans C, 1994, DEV MED CHILD NE S70, V36, P26; EXNER CE, 1983, OCCUP THER J RES, V3, P75, DOI 10.1177/153944928300300202; FEHLINGS DL, 1998, KEEPING CURRENT; FLEGLE JH, 1988, RES DEV DISABIL, V9, P145, DOI 10.1016/0891-4222(88)90048-0; Flett PJ, 1999, J PAEDIATR CHILD H, V35, P71, DOI 10.1046/j.1440-1754.1999.00330.x; Hainsworth F, 1997, DEV MED CHILD NEUROL, V39, P243; HILL J, 1994, AM J OCCUP THER, V48, P219, DOI 10.5014/ajot.48.3.219; HINDERER KA, 1988, DEV MED CHILD NEUROL, V30, P370; Katz K, 2000, FOOT ANKLE INT, V21, P1011, DOI 10.1177/107110070002101205; LAW M, 1991, DEV MED CHILD NEUROL, V33, P379; Law M, 1997, DEV MED CHILD NEUROL, V39, P664; Law M., 1998, GUIDELINES CRITICAL; MACKAY S, 1996, AUSTR OCCUPATIONAL T, V43, P51; Maltais D, 2001, MED SCI SPORT EXER, V33, P320; MILLS VM, 1984, PHYS THER, V64, P190, DOI 10.1093/ptj/64.2.190; MOSSBERG KA, 1990, ARCH PHYS MED REHAB, V71, P490; OTIS JC, 1985, J PEDIATR ORTHOPED, V5, P682, DOI 10.1097/01241398-198511000-00010; Radtka SA, 1997, PHYS THER, V77, P395, DOI 10.1093/ptj/77.4.395; Reid D T, 1992, Int J Rehabil Res, V15, P15, DOI 10.1097/00004356-199203000-00002; Rethlefsen S, 1999, J PEDIATR ORTHOPED, V19, P470, DOI 10.1097/00004694-199907000-00009; STANGER M, 1997, ORTHOTICS FUNCTIONAL, P246; TARDIEU G, 1982, ARCH PHYS MED REHAB, V63, P103; WATT J, 1986, DEV MED CHILD NEUROL, V28, P480; Wilson H, 1997, J PEDIATR ORTHOPED, V17, P370	36	27	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0896-3746	1550-5081		INFANT YOUNG CHILD	Infants Young Child.	JUL	2002	15	1					42	50		10.1097/00001163-200207000-00007			9	Education, Special; Psychology, Developmental; Rehabilitation	Education & Educational Research; Psychology; Rehabilitation	566NP	WOS:000176435100007					2021-06-18	
J	White, H; Baker, A				White, H; Baker, A			Continuous jugular venous oximetry in the neurointensive care unit - a brief review	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SEVERE HEAD-INJURY; BULB OXYHEMOGLOBIN SATURATION; OXYGEN-SATURATION; CEREBRAL OXYGENATION; COMATOSE PATIENTS; CARDIAC-SURGERY; INTENSIVE-CARE; BRAIN INJURY; MANAGEMENT; ACCURACY	Purpose: To describe the technique of continuous jugular venous oxygen saturation (SjVO2) monitoring and review its applications in the neurointensive care unit (NICU), with special reference to the management of raised intracranial pressure (ICP) following severe acute brain injury. Source: This narrative review is based on a selection of current literature on SjVO2 monitoring in conjunction with local experience using this technique. Principal findings: Despite limitations, the use of SjVO2 monitoring has the potential to impact on patient care in the NICU. The placement of the catheter is relatively simple. Studies have confirmed that abnormalities in cerebral venous oxygen saturation are associated with adverse outcome following traumatic brain injury. There is evidence that SjVO2 may be a useful adjunct to ICP monitoring of patients with intracranial hypertension. Furthermore, managing cerebral extraction of oxygen in conjunction with cerebral perfusion pressure may result in an improved outcome. Further research in this area is needed. Other indications for SjVO2 monitoring include subarachnoid hemorrhage, cardiopulmonary/bypass and following ischemic stroke. Conclusion: In the past, the management of severe acute brain injury was targeted at ICP and perfusion pressure with little consideration for the metabolic requirements of the injured brain. SjVO2 monitoring is another tool the intensivist can use to obtain information about the global oxygen requirements of the injured brain on a continuous basis. Whether this will impact on care in the long term remains to be seen.	St Michaels Hosp, Dept Anaesthesia, Trauma & Neurosurg Intens Care Unit, Toronto, ON M5B 1W8, Canada	Baker, A (corresponding author), St Michaels Hosp, Dept Anaesthesia, Trauma & Neurosurg Intens Care Unit, 30 Bond St, Toronto, ON M5B 1W8, Canada.						Anastasiou E, 1999, J CARDIOTHOR VASC AN, V13, P276, DOI 10.1016/S1053-0770(99)90263-X; Artru F, 1998, NEUROL RES, V20, pS48; BANKIER AA, 1995, AM J ROENTGENOL, V16, P437; Bardt TF, 1998, ACTA NEUROCHIR, V140, P357, DOI 10.1007/s007010050109; Basso A, 2001, WORLD J SURG, V25, P1174; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Buunk G, 1999, RESUSCITATION, V41, P257, DOI 10.1016/S0300-9572(99)00060-X; Cheng CSA, 1996, J ACCOUNTING RES, V34, P173, DOI 10.2307/2491338; Citerio G, 1998, ACT NEUR S, V71, P316; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; CROUGHWELL ND, 1994, ANN THORAC SURG, V58, P1702, DOI 10.1016/0003-4975(94)91666-7; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; De Deyne C, 1996, Eur J Emerg Med, V3, P69, DOI 10.1097/00063110-199606000-00002; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; HATIBOGLU MT, 1992, J ANAT, V180, P191; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Komiyama M, 1999, NEUROSURGERY, V45, P1469, DOI 10.1097/00006123-199912000-00040; Lam JMK, 1996, BRIT J NEUROSURG, V10, P357; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; Manno EM, 1997, CRIT CARE CLIN, V13, P79, DOI 10.1016/S0749-0704(05)70297-9; Matta BF, 1997, ANESTHESIOLOGY, V86, P806, DOI 10.1097/00000542-199704000-00010; Metz C, 1998, ACT NEUR S, V71, P324; Mutch WAC, 2000, ANN THORAC SURG, V69, P491, DOI 10.1016/S0003-4975(99)01077-2; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Schaffranietz L, 1998, NEUROL RES, V20, pS66; Schell RM, 2000, ANESTH ANALG, V90, P559, DOI 10.1097/00000539-200003000-00012; SCHNEIDER GH, 1995, ACTA NEUROCHIR, V134, P71, DOI 10.1007/BF01428507; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Souter MJ, 1998, BRIT J ANAESTH, V81, P239; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Trubiano P, 1996, ANESTH ANALG, V82, P964, DOI 10.1097/00000539-199605000-00013; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; van den Brink WA, 1998, ACT NEUR S, V71, P190; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878	44	27	32	1	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUN-JUL	2002	49	6		S			623	629		10.1007/BF03017393			7	Anesthesiology	Anesthesiology	573NB	WOS:000176835400020	12067878	Bronze			2021-06-18	
J	Beaulieu, CL				Beaulieu, CL			Rehabilitation and outcome following pediatric traumatic brain injury	SURGICAL CLINICS OF NORTH AMERICA			English	Article							HEAD-INJURY; CHILDREN; PLASTICITY; SEVERITY; RECOVERY; CORTEX; TBI; AGE; ADOLESCENTS	Mounting evidence indicates that children are more vulnerable than adults to the consequences of traumatic brain injuries. The long-term outcome following traumatic brain injuries sustained in childhood must be viewed in the context of development and maturation. The ultimate outcome is determined by the impact on the child's ability to achieve developmental milestones following injury. Although neuronal plasticity provides a potential for neuronal reorganization, neuronal reorganization is generally incomplete and comes at a cost to long-term development. Pediatric rehabilitation is the setting that not only provides the behavioral and environmental demands necessary to stimulate neuronal reorganization, but also sets the stage for meeting the child's long-term recovery and developmental needs.	Brooks Rehabil Hosp, Neuropsychol Serv, Jacksonville, FL 32216 USA	Beaulieu, CL (corresponding author), Brooks Rehabil Hosp, Neuropsychol Serv, 3599 Univ Blvd S, Jacksonville, FL 32216 USA.	cynthia.beaulieu@brookshealth.org					ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2000, SCI PRACT NEUROPSYCH, P117; Bakker K, 1999, Pediatr Rehabil, V3, P149; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Beaulieu CL, 1997, ARCH CLIN NEUROPSYCH, V12, P285, DOI 10.1093/arclin/12.4.285a; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Braverman SE, 1999, BRAIN INJURY, V13, P405; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; *COMM ACCR REH FAC, 2001, MED REH STAND MAN JU; Conway TW, 1998, J INT NEUROPSYCH SOC, V4, P608, DOI 10.1017/S1355617798466104; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; Dennis M., 1988, MASTER LECT SERIES, V7, P85; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P685; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Fraser R, 1998, TRAUMATIC BRAIN INJU, P417; GREENOUGH WT, 1979, BEHAV NEURAL BIOL, V26, P287, DOI 10.1016/S0163-1047(79)91278-0; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Indredavik B, 1999, STROKE, V30, P1524, DOI 10.1161/01.STR.30.8.1524; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; James HE, 1999, ACT NEUR S, V73, P85; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; JURASKA JM, 1980, BEHAV NEURAL BIOL, V29, P157, DOI 10.1016/S0163-1047(80)90482-3; Kelly T P, 1999, Pediatr Rehabil, V3, P187; Kilgard MP, 1998, NAT NEUROSCI, V1, P727, DOI 10.1038/3729; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Ludlow L H, 2000, J Outcome Meas, V4, P482; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Osberg J S, 1997, Pediatr Rehabil, V1, P131; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Pittler MH, 1997, ARCH PHYS MED REHAB, V78, P1281, DOI 10.1016/S0003-9993(97)90346-4; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; ROTHI LJG, 2000, 20 ANN M NAT AC NEUR; ROTHI LJG, 1998, APPROACHES TREATMENT, P179; RUSSELL ML, 1998, TRAUMATIC BRAIN INJU, P61; Satz P., 1994, NEUROPSYCHOLOGY, V8, P255, DOI DOI 10.1037/0894-4105.8.2.255; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Szekeres SF, 1998, TRAUMATIC BRAIN INJU, P389; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEUBER H, 1962, Dev Med Child Neurol, V4, P3; Unsworth C A, 1997, Pediatr Rehabil, V1, P207; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WAALAND PK, 1998, TRAUMATIC BRAIN INJU, P345; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; YEATES KO, 2000, PEDIAT NEUROPSYCHOLO, V8, P85; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P429; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P125; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303	67	27	29	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	APR	2002	82	2					393	+	PII S0039-6109(02)00009-9	10.1016/S0039-6109(02)00009-9			17	Surgery	Surgery	567XZ	WOS:000176513500011	12113374				2021-06-18	
J	Szelies, B; Sobesky, J; Pawlik, G; Mielke, R; Bauer, B; Herholz, K; Heiss, WD				Szelies, B; Sobesky, J; Pawlik, G; Mielke, R; Bauer, B; Herholz, K; Heiss, WD			Impaired benzodiazepine receptor binding in peri-lesional cortex of patients with symptomatic epilepsies studied by [C-11]-flumazenil PET	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						flumazenil positron; emission tomography; lesional epilepsy; peri-lesional FMZ binding; positron emission tomography/magnetic resonance imaging coregistration	TEMPORAL-LOBE EPILEPSY; C-11 FLUMAZENIL-PET; POSITRON-EMISSION-TOMOGRAPHY; INTRAOPERATIVE ELECTROCORTICOGRAPHY; FLUORODEOXYGLUCOSE-PET; INTRACTABLE EPILEPSY; MRI; BRAIN; SURGERY; INVIVO	Individual benzodiazepine receptor (BZR) binding of peri-lesional cortex was investigated in symptomatic epilepsies. Eleven patients aged 19-44 years were studied whose diagnosis was established by medical history, clinical, electroencephalographic, and magnetic resonance imaging (MRI) findings. Three-dimensional [C-11]-flumazenil (FMZ) positron emission tomography and MRI scans were obtained and coregistered. Lesions (five low-grade brain tumours, one AV malformation, one cavernoma, one cystic lesion of unknown aetiology, one traumatic brain injury, one post-operative and one post-haemorrhagic defect) were outlined on individual MRI scans. Adjacent to those lesions, and in homologous contralateral structures, FMZ binding was analysed in four pairs of cortical 9 x 9-mm regions of interest (ROIs) placed on transaxial and coronal slices, respectively, as well as in the lesion volume and its mirror region. Percentage asymmetry ratios were calculated and those at or outside the 90-110% range were operationally defined significant. Peri-lesional FMZ binding asymmetries ranged from 70 to 125%, lesional asymmetries from 38 to 82%. Only one patient showed no significant change, whilst nine exhibited significant reductions of FMZ binding in at least one ROI (3 x 1, 4 x 2, 1 x 3, 1 x 4), and significant increases were observed in two ROIs of another patient. Therefore, peri-lesional disturbances of BZR binding are common but variable in location. Because a close correlation between regional decreases in FMZ binding and spiking activity was recently demonstrated in neocortical epilepsies, abnormal peri-lesional FMZ binding may bear some relation to the mechanisms of epileptogenesis in symptomatic epilepsies.	Neurol Univ Klin, D-50931 Cologne, Germany; Max Planck Inst Neurol Res, D-50931 Cologne, Germany	Szelies, B (corresponding author), Neurol Univ Klin, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.						Arnold S, 2000, EPILEPSIA, V41, P818, DOI 10.1111/j.1528-1157.2000.tb00248.x; AWAD IA, 1991, EPILEPSIA, V32, P179, DOI 10.1111/j.1528-1157.1991.tb05242.x; BURDETTE DE, 1995, NEUROLOGY, V45, P934, DOI 10.1212/WNL.45.5.934; ENGEL J, 1993, J CLIN NEUROPHYSIOL, V10, P90, DOI 10.1097/00004691-199301000-00010; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; FREY KA, 1991, ANN NEUROL, V30, P663, DOI 10.1002/ana.410300506; HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209; HENRY TR, 1993, NEUROLOGY, V43, P1998, DOI 10.1212/WNL.43.10.1998; Juhasz C, 2000, NEUROLOGY, V55, P825, DOI 10.1212/WNL.55.6.825; Juhasz C, 2000, J CLIN NEUROPHYSIOL, V17, P29; Koepp MJ, 1997, NEUROLOGY, V49, P764, DOI 10.1212/WNL.49.3.764; Koepp MJ, 2000, NEUROLOGY, V54, P332, DOI 10.1212/WNL.54.2.332; Koepp MJ, 1998, ANN NEUROL, V43, P618, DOI 10.1002/ana.410430510; Lamusuo S, 2000, NEUROLOGY, V54, P2252, DOI 10.1212/WNL.54.12.2252; Madar I, 1997, ANN NEUROL, V41, P358, DOI 10.1002/ana.410410311; MAZIERE M, 1984, INT J APPL RADIAT IS, V35, P973, DOI 10.1016/0020-708X(84)90215-1; Muzik O, 2000, NEUROLOGY, V54, P171, DOI 10.1212/WNL.54.1.171; Muzik O, 1998, Comput Aided Surg, V3, P74, DOI 10.3109/10929089809148132; Nagy F, 1999, J CEREBR BLOOD F MET, V19, P939, DOI 10.1097/00004647-199909000-00001; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; PIETRZYK U, 1994, J NUCL MED, V35, P2011; PILCHER WH, 1993, J NEUROSURG, V78, P891, DOI 10.3171/jns.1993.78.6.0891; Richardson MP, 1998, NEUROLOGY, V51, P485, DOI 10.1212/WNL.51.2.485; Richardson MP, 1996, ANN NEUROL, V40, P188, DOI 10.1002/ana.410400210; Ryvlin P, 1999, NEUROLOGY, V53, P1882, DOI 10.1212/WNL.53.8.1882; Ryvlin P, 1998, BRAIN, V121, P2067, DOI 10.1093/brain/121.11.2067; SAVIC I, 1993, J NEUROL NEUROSUR PS, V56, P615, DOI 10.1136/jnnp.56.6.615; SAVIC I, 1988, LANCET, V2, P863, DOI 10.1016/S0140-6736(88)92468-3; Spencer SS, 1996, EPILEPSIA, V37, P807, DOI 10.1111/j.1528-1157.1996.tb00032.x; Szelies B, 2000, EUR J NEUROL, V7, P393, DOI 10.1046/j.1468-1331.2000.00077.x; Szelies B, 1996, NEUROIMAGE, V3, P109, DOI 10.1006/nimg.1996.0013; Tran TA, 1997, EPILEPSIA, V38, P1132, DOI 10.1111/j.1528-1157.1997.tb01203.x; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; Wolf HK, 1996, ACTA NEUROPATHOL, V91, P376, DOI 10.1007/s004010050439; Wyllie E, 1998, ANN NEUROL, V44, P740, DOI 10.1002/ana.410440507; Zentner J, 1997, NEUROSURGERY, V41, P378, DOI 10.1097/00006123-199708000-00008	36	27	27	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAR	2002	9	2					137	142		10.1046/j.1468-1331.2002.00338.x			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	529QW	WOS:000174310900003	11882054				2021-06-18	
J	Edwards, L; Nashmi, R; Jones, O; Backx, P; Ackerley, C; Becker, L; Fehlings, MG				Edwards, L; Nashmi, R; Jones, O; Backx, P; Ackerley, C; Becker, L; Fehlings, MG			Upregulation of Kv 1.4 protein and gene expression after chronic spinal cord injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						neurotrauma; voltage-gated potassium channels; glia; axons; rat	ION CHANNEL EXPRESSION; WHITE MATTER GLIA; OLIGODENDROCYTE PROGENITOR CELLS; HETEROMULTIMERIC K+ CHANNELS; GATED POTASSIUM CHANNELS; MYELIN BASIC-PROTEIN; DM20 TRANSGENIC MICE; IN-VIVO; PRECURSOR CELLS; MULTIPLE-SCLEROSIS	After spinal cord injury (SCI), white matter tracts are characterized by demyelination and increased sensitivity to the K+ channel blocker 4-aminopyridine (4-AP). These effects appear to contribute to neurological impairment after SCI, although the molecular changes in K+ channel subunit expression remain poorly understood. We examined changes in gene expression of the 4-AP-sensitive voltage-gated K+ channel Kv 1.4 after chronic SCI in the rat. Quantitative immunoblotting showed that Kv 1.4 protein was significantly increased at 6 weeks, but not at 1 week, after SCI in spinal cord white matter. Kv 1.4 was localized to astrocytes, oligodendrocytes, and oligodendrocyte progenitor cells but not to axons in both the normal and the injured spinal cord white matter. Because glial cells proliferate after SCI, we used immunogold electron microscopy to quantify Kv 1.4 protein in individual glial cells and found a sixfold increase of Kv 1.4 in cells of the oligodendrocyte lineage after chronic injury. Finally, quantitative in situ hybridization showed that Kv 1.4 mRNA was significantly upregulated in spinal cord white matter, but not gray matter, after SCI. In summary, we show that Kv 1.4 is expressed in glial cells and not in axons in the rat spinal cord white matter and that its expression is markedly increased in cells of the oligodendrocyte lineage after chronic SCI. Given that K+ channels play a role in glial cell proliferation, cells exhibiting changes in Kv 1.4 expression may represent proliferating oligodendroglia in the chronically injured spinal cord. (C) 2002. 9 2002 Wiley-Liss, Inc.	Univ Toronto, Div Neurosurg, Toronto Western Res Inst, Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Div Cellular & Mol Biol, Toronto Western Res Inst, Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto Gen Res Inst, Hlth Network, Toronto, ON M5G 2C4, Canada; Hosp Sick Children, Div Pathol, Toronto, ON M5G 1X8, Canada	Fehlings, MG (corresponding author), MCL 12-407,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Fehlings, Michael/0000-0002-5722-6364; Nashmi, Raad/0000-0001-6596-2620			Amat JA, 1998, GLIA, V22, P64, DOI 10.1002/(SICI)1098-1136(199801)22:1<64::AID-GLIA6>3.0.CO;2-8; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; Attali B, 1997, J NEUROSCI, V17, P8234; BALENTINE JD, 1978, LAB INVEST, V39, P254; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; BARRES BA, 1988, GLIA, V1, P10, DOI 10.1002/glia.440010104; BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; BLIGHT AR, 1987, J NEUROL SCI, V82, P145, DOI 10.1016/0022-510X(87)90014-1; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; CHITTAJALLU R, 2000, SOC NEUR ABSTR, V26, P1890; CHVATAL A, 1995, EUR J NEUROSCI, V7, P129, DOI 10.1111/j.1460-9568.1995.tb01027.x; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; HANSEBOUT RR, 1993, J NEUROTRAUM, V10, P1, DOI 10.1089/neu.1993.10.1; HAYES KC, 1994, J NEUROTRAUM, V11, P433, DOI 10.1089/neu.1994.11.433; Horner PJ, 2000, J NEUROSCI, V20, P2218; Jou I, 1998, GLIA, V24, P408, DOI 10.1002/(SICI)1098-1136(199812)24:4<408::AID-GLIA6>3.3.CO;2-4; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Knutson P, 1997, J NEUROSCI, V17, P2669, DOI 10.1523/jneurosci.17-08-02669.1997; Kotecha SA, 1999, J NEUROSCI, V19, P10680; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 1999, EXP NEUROL, V160, P333, DOI 10.1006/exnr.1999.7224; LUDWIN SK, 1985, LAB INVEST, V52, P20; LUDWIN SK, 1988, J NEUROSCI, V8, P1239; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; Mastronardi FG, 1996, J CLIN INVEST, V97, P349, DOI 10.1172/JCI118422; Mastronardi FG, 1996, J NEUROSCI RES, V44, P301, DOI 10.1002/(SICI)1097-4547(19960515)44:4<301::AID-JNR1>3.0.CO;2-G; MatusLeibovitch N, 1996, MOL BRAIN RES, V40, P261, DOI 10.1016/0169-328X(96)00054-X; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; MIDHA R, 1987, BRAIN RES, V410, P299, DOI 10.1016/0006-8993(87)90328-3; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Qiao J, 1997, J NEUROTRAUM, V14, P135, DOI 10.1089/neu.1997.14.135; Rasband M, 1998, J NEUROSCI, V18, P36; Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Roy ML, 1996, GLIA, V18, P177, DOI 10.1002/(SICI)1098-1136(199611)18:3<177::AID-GLIA2>3.3.CO;2-8; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; Schmidt K, 1999, BRAIN RES, V843, P145, DOI 10.1016/S0006-8993(99)01938-1; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Shi JY, 1998, J NEUROSCI, V18, P4627; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Smart SL, 1997, GLIA, V20, P127, DOI 10.1002/(SICI)1098-1136(199706)20:2<127::AID-GLIA4>3.0.CO;2-6; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P985; SONTHEIMER H, 1989, NEURON, V2, P1135, DOI 10.1016/0896-6273(89)90180-3; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; Wickenden AD, 1997, J PHYSIOL-LONDON, V504, P271, DOI 10.1111/j.1469-7793.1997.271be.x; Wrathall JR, 1998, J NEUROSCI, V18, P8780; Yuan XQ, 1998, DEVELOPMENT, V125, P2901	69	27	27	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	FEB 4	2002	443	2					154	167		10.1002/cne.10115			14	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	508PM	WOS:000173097700004	11793353				2021-06-18	
J	Gaviria, M; Haton, H; Sandillon, F; Privat, A				Gaviria, M; Haton, H; Sandillon, F; Privat, A			A mouse model of acute ischemic spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						C57BL/6 mice; functional outcome; histopathology; immunocytochemistry; photochemical lesion; spinal cord injury; wound healing response	CENTRAL-NERVOUS-SYSTEM; ADULT-RATS; REACTIVE GLIOSIS; GENE-THERAPY; TRAUMA; ANTAGONIST; CONTUSION; SECONDARY; LESION; TRANSPLANTATION	Mice models of spinal cord injury (SCI) should improve our knowledge of the mechanisms of injury and repair of the nervous tissue. They represent a powerful tool for the development of therapeutic strategies in the fields of pharmacological, cellular, and genetic approaches of neurotrauma. We demonstrate here that the photochemical graded ischemic spinal cord injury model, described in rats, can be successfully adapted in mice, in a reliable and reproducible manner. Following the intravenous injection of Rose Bengal, the translucent dorsal surface of the T9 vertebral laminae of C57BL/6 female mice was irradiated with a 560-nm wavelength-light (3-8 min depending on the experimental group). Animals were sacrificed at 1 day or 7 days after injury. Functional tests were performed daily for motor, sensory, autonomic, and reflex responses. Lesion histopathology was assessed for lesion length, percentage of residual white matter, and astrocytic reactivity. Experimental groups demonstrated a functional deficit, which was correlated to the increase of the irradiation time and, therefore, to the severity of the injury. Histopathological and immunocytochemical data were reliable morphological measurements characterizing the degree of injury, which were strongly correlated to the severity of the functional impairment. Despite differences in the mechanism of injury, the wound healing response described in other traumatic SCI mice models was confirmed (no cavitation and, conversely, the formation of a dense connective tissue matrix). In this context, the precise understanding of the mechanisms of healing response after SCI in mice and of neurochemical kinetics appear to be crucial in the development of therapeutic strategies of CNS repair. Thus, the possible use of an increasing collection of transgenic mice offers a new dimension for experimental research in this area. The ischemic photochemical model of SCI in mice represents a relevant model that can play a key role in this new era of neurotrauma research.	Ctr Propara, Lab Neurochirurg Expt, F-34195 Montpellier 5, France; Ctr Propara, Clin Neurophysiol Lab, Montpellier, France; INSERM, U336, Montpellier, France; Fac Med, Lab Physiopathol Malad Neuromusculaires, Montpellier, France	Gaviria, M (corresponding author), Ctr Propara, Lab Neurochirurg Expt, Parc Euromed, F-34195 Montpellier 5, France.	gaviria@univ-montp2.fr	Gaviria, Manuel/AAH-4403-2019	Gaviria, Manuel/0000-0001-6106-6538			Audouy S, 1999, GLIA, V25, P293, DOI 10.1002/(SICI)1098-1136(19990201)25:3<293::AID-GLIA9>3.0.CO;2-G; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; CAMERON T, 1990, EXP NEUROL, V109, P214, DOI 10.1016/0014-4886(90)90076-5; Cauquil-Caubere I, 1999, J NEUROSCI RES, V56, P160, DOI 10.1002/(SICI)1097-4547(19990415)56:2<160::AID-JNR5>3.0.CO;2-C; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; Guth L, 1999, ANN NY ACAD SCI, V890, P366, DOI 10.1111/j.1749-6632.1999.tb08017.x; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Olby NJ, 1996, J NEUROCYTOL, V25, P481, DOI 10.1007/BF02284817; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Pikov V, 2001, J NEUROSCI, V21, P559, DOI 10.1523/JNEUROSCI.21-02-00559.2001; PRADO R, 1987, J NEUROSURG, V67, P745, DOI 10.3171/jns.1987.67.5.0745; PRIVAT A, 1994, B ACAD NAT MED PARIS, V178, P445; RATABOUL P, 1988, J NEUROSCI RES, V20, P165, DOI 10.1002/jnr.490200204; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Ribotta MGY, 1998, CURR OPIN NEUROL, V11, P647, DOI 10.1097/00019052-199812000-00007; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Ribotta MGY, 1997, J NEUROSCI RES, V48, P281; RIDET JL, 1995, J NEUROSCI RES, V42, P287, DOI 10.1002/jnr.490420302; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; SAMPATH D, 1995, INT J DEV NEUROSCI, V13, P645, DOI 10.1016/0736-5748(95)00033-D; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VANREEMPTS J, 1994, HISTOL HISTOPATHOL, V9, P185; WATSON BD, 1986, BRAIN RES, V367, P296, DOI 10.1016/0006-8993(86)91606-9; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; Zhang ZY, 1996, J COMP NEUROL, V371, P485	43	27	30	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2002	19	2					205	221		10.1089/08977150252806965			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	526ER	WOS:000174117100003	11893023				2021-06-18	
J	Polo, MD; Newton, P; Rogers, D; Escera, C; Butler, S				Polo, MD; Newton, P; Rogers, D; Escera, C; Butler, S			ERPs and behavioural indices of long-term preattentive and attentive deficits after closed head injury	NEUROPSYCHOLOGIA			English	Article						MMN; P1; N165; P3b; RT; TBI	EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY MMN; TRAUMATIC BRAIN INJURY; AUDITORY ODDBALL TASK; ELECTROPHYSIOLOGICAL EVIDENCE; INVOLUNTARY ATTENTION; PERFORMANCE; DISTRACTIBILITY; GENERATORS; HUMANS	Attentional deficits are often reported even years after sustaining a closed head injury (CHI). Disturbance of cognitive attentional functions following CHI has been documented in both behavioural and event-related brain potential (ERP) studies. Recently, the possibility that the sequelae of CHI extend to preattentive processes of attention has been pointed out. We used a paradigm that makes it possible to assess simultaneously the processing of relevant information and involuntary mechanisms of attention to gain further insight in this matter. Eleven patients with CHI greater than I year post-trauma and 14 age-matched control subjects were engaged in the performance of a continuous visual reaction time (RT) discrimination task while ignoring streams of auditory task-irrelevant stimuli. The main characteristic in the paradigm was that all visual stimuli were shortly preceded by an auditory stimulus, which could be a repeated (90%) or a different (deviant) tone. We measured performance on the discrimination task, and ERP indices of preattentive (mismatch negativity MMN) and attentive information processing (P1, N165, P3b). In relation to control subjects, CHI patients showed an attenuation of the MMN evoked by the deviant-tone. In response to the visual stimuli, CHI patients showed a delay of P1, and a reduction of the N165 and P3b components. Moreover, they had slower RT and missed more responses in a visual discrimination task. These results indicate both preattentive and attentive deficits, which is consistent with the typical diffuse axonal injury (DAI) resulting after CHI. (C) 2002 Elsevier Science Ltd. All rights reserved.	Frenchay Hosp, Burden Neurol Inst, Bristol BS16 1JB, Avon, England; Univ Barcelona, Dept Psychiat & Psychobiol, Neurodynam Lab, Barcelona 08035, Catalonia, Spain	Polo, MD (corresponding author), Frenchay Hosp, Burden Neurol Inst, Bristol BS16 1JB, Avon, England.	dolorespolo@hotmail.com	Escera, Carles/A-8658-2010	Escera, Carles/0000-0001-8203-2951			Alain C, 1998, BRAIN RES, V812, P23, DOI 10.1016/S0006-8993(98)00851-8; ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; Alho K, 1997, NEUROREPORT, V8, P3233, DOI 10.1097/00001756-199710200-00010; ALHO K, 1994, ELECTROEN CLIN NEURO, V91, P353, DOI 10.1016/0013-4694(94)00173-1; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Barcelo F, 2000, NAT NEUROSCI, V3, P399; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; Deacon-Elliott D., 1987, COGNITIVE REHABILITA, V5, P12; Deouell LY, 1998, PSYCHOPHYSIOLOGY, V35, P355, DOI 10.1017/S0048577298970287; Escera C, 2000, AUDIOL NEURO-OTOL, V5, P151, DOI 10.1159/000013877; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; FernandezDuque D, 1997, NEUROPSYCHOLOGIA, V35, P477, DOI 10.1016/S0028-3932(96)00103-0; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; JENNETT B, 1975, LANCET, V1, P480; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kaipio ML, 2001, NEUROREPORT, V12, P1517, DOI 10.1097/00001756-200105250-00043; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; LEVIN HS, 1982, NEUROBEHAVIOURAL CON, P3; LEVIN HS, 1987, HEAD INJURY; MANGUN GR, 1988, ELECTROEN CLIN NEURO, V70, P417, DOI 10.1016/0013-4694(88)90019-3; Martinez A, 1999, NAT NEUROSCI, V2, P364; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Naatanen R., 1992, ATTENTION BRAIN FUNC; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; VANZOMEREN AH, 1984, ATTENTIONAL DEFICITS, P74; Vogenthaler D R, 1987, Brain Inj, V1, P113; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	38	27	27	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	13					2350	2359	PII S0028-3932(02)00127-6	10.1016/S0028-3932(02)00127-6			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	623RH	WOS:000179716300014	12417464				2021-06-18	
J	Soustiel, JF; Shik, V; Feinsod, M				Soustiel, JF; Shik, V; Feinsod, M			Basilar vasospasm following spontaneous and traumatic subarachnoid haemorrhage: Clinical implications	ACTA NEUROCHIRURGICA			English	Article						basilar artery; vasospasm; subarachnoid haemorrhage; transcranial Doppler	TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL ARTERIAL SPASM; FLOW VELOCITIES; HEAD-INJURY; VERTEBROBASILAR VASOSPASM; BLOOD-FLOW; HEMORRHAGE; ULTRASONOGRAPHY; HYPEREMIA	Background. Cerebral vasospasm has been commonly described following subarachnoid haemorrhage (SAH) though its impact on neurological outcome, especially in head trauma, has not been yet elucidated. The purpose of this study was to monitor and correlate neurological condition and flow velocities (FVs) in the arteries of the brain after SAH and more particularly to investigate the influence of basilar artery (BA) vasospasm on neurological outcome. Methods. Daily transcranial Doppler (TCD) evaluations were conducted in 116 consecutive patients with subarachnoid haemorrhage. SAH was of traumatic origin (tSAH) in 59 patients an spontaneous (sSAH) in 57 patients. Vasospasm in the MCA and ACA was defined by a mean FV exceeding 120 cm/s and three times the mean FV of the ipsilateral ICA. Basilar artery (BA) vasospasm was defined as moderate whenever the FV was higher than 60 cm/s and severe above 85 cm/s. Findings. Sixty-two patients (53.4%) had elevated FVs in the BA, among these 34 (29.3%) had FVs above 85 cm/s. Basilar vasospasm was significantly more common in tSAH (59.7%) than in sSAH (40.3%, P = 0.041). In patients with moderate and severe BA vasospasm, FVs in the BA increased on the third day after admission and remained elevated for a week before returning to normal value by them end of the second week. This elevation in BA FVs in patients with BA vasospasm. was followed by a significant and progressive worsening in the neurological condition at the end of the first week. Permanent neurological deficit was associated with elevated BA FVs consistent with moderate BA vasospasm whereas patients who remained in persistent vegetative state, had FVs consistent with severe BA vasospasm (P = 0.00019). Interpretation. The present results further support that BA vasospasm may act as an independent factor of ischaemic brain damage following SAH, especially in head trauma.	Technion Israel Inst Technol, Rambam Med Ctr, Dept Neurosurg, Brain Injury Appl Res Ctr, IL-31096 Haifa, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Dept Neurosurg, Brain Injury Appl Res Ctr, POB 9602, IL-31096 Haifa, Israel.						AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fujioka KA., 1992, TRANSCRANIAL DOPPLER, P9; JENNETT B, 1975, LANCET, V1, P480; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SLOAN MA, 1994, STROKE, V25, P2187, DOI 10.1161/01.STR.25.11.2187; Soustiel JF, 1998, NEUROSURGERY, V43, P282, DOI 10.1097/00006123-199808000-00061; Soustiel JF, 2001, STROKE, V32, P629, DOI 10.1161/01.STR.32.3.629; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	19	27	28	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2002	144	2					137	144		10.1007/s007010200016			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	525VQ	WOS:000174095100006	11862513				2021-06-18	
J	Zurita, M; Vaquero, J; Oya, S; Morales, C				Zurita, M; Vaquero, J; Oya, S; Morales, C			Effects of dexamethasone on apoptosis-related cell death after spinal cord injury	JOURNAL OF NEUROSURGERY			English	Article						spinal cord injury; apoptosis; Apostain; dexamethasone; rat	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; HEMORRHAGIC NECROSIS; CEREBRAL-ISCHEMIA; MALIGNANT GLIOMA; NEURONAL DEATH; T-LYMPHOCYTES; GENE-TRANSFER; BRAIN INJURY; ADULT-RAT	Object. The purpose of this study was to analyze the expression of F7-26 (Apostain) in injured spinal cord tissue, and the modifying effects of dexamethasone administration. Methods. A total of 56 adult female Wistar rats were subjected to traumatic spinal cord injury (SCI) to induce complete paraplegia. These rats were divided into two groups according to whether they received dexamethasone (doses of 1 mg/kg daily) post-SCI. Injured spinal cord tissue was studied by means of conventional histological techniques, and Apostain expression was determined by immunohistochemical analysis at 1, 4, 8, 24, and 72 hours, and at 1 and 2 weeks after SCI in all the animals. Apostain-positive cells, mainly neurons and glial cells, were detected 1 hour after injury, peaking at 8 hours, after which the number decreased. One week after injury, apoptosis was limited to a few glial cells, mainly oligodendrocytes, and 2 weeks after injury there was no evidence of Apostain-positive cells. In the group of paraplegic rats receiving post-SCI intraperitoneal dexamethasone, there was a significant decrease in the number of Apostain-positive cells. Conclusions. Analysis of the results indicated that apoptosis plays a role in the early period after SCI and that administration of dexamethasone decreases apoptosis-related cell death in the injured spinal cord tissue.	Univ Autonoma Madrid, Puerta de Hierro Clin, Neurosurg Serv, Madrid 28035, Spain; Mapfre Med Fdn, Neurosci Res Unit, Madrid, Spain	Vaquero, J (corresponding author), Univ Autonoma Madrid, Puerta de Hierro Clin, Neurosurg Serv, San Martin de Porres 4, Madrid 28035, Spain.						Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; ANDERSON TE, 1992, J NEUROTRAUMA S1, V9, P135; BALENTINE JD, 1978, LAB INVEST, V39, P236; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; BLIGHT AR, 1992, J NEUROTRAUM, V9, P147, DOI 10.1089/neu.1992.9.147; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Crowe M. J., 1995, Society for Neuroscience Abstracts, V21, P232; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; DAWSON VL, 1993, J NEUROSCI, V13, P2651; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Ferlini C, 1997, J IMMUNOL METHODS, V205, P95, DOI 10.1016/S0022-1759(97)00054-9; Frankfurt OS, 1996, EXP CELL RES, V226, P387, DOI 10.1006/excr.1996.0240; Gonzalez SL, 1999, CELL MOL NEUROBIOL, V19, P597, DOI 10.1023/A:1006980301382; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; Katoh K, 1996, NEUROSCI LETT, V216, P9; Katoh O, 1998, CANCER RES, V58, P5565; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KIWERSKI JE, 1993, INJURY, V24, P457, DOI 10.1016/0020-1383(93)90149-Z; KOBRINE AI, 1975, J NEUROSURG, V42, P144, DOI 10.3171/jns.1975.42.2.0144; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1995, AM J PATHOL, V146, P1045; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; Namura S, 1998, J NEUROSCI, V18, P3659; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Olby N, 1999, J VET INTERN MED, V13, P399, DOI 10.1892/0891-6640(1999)013&lt;0399:CCITMO&gt;2.3.CO;2; Oneda K, 1999, Arerugi, V48, P13; OSTERHOLM JL, 1972, J NEUROSURG, V36, P386, DOI 10.3171/jns.1972.36.4.0386; OSTERHOLM JL, 1972, J NEUROSURG, V36, P395, DOI 10.3171/jns.1972.36.4.0395; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Rieger J, 1998, ONCOGENE, V17, P2323, DOI 10.1038/sj.onc.1202154; RINK A, 1995, AM J PATHOL, V147, P1575; Schmidt M, 1999, J IMMUNOL, V163, P3484; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Tacconi MT, 1998, NEUROCHEM RES, V23, P759, DOI 10.1023/A:1022463527474; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TSAI YH, 1975, BIOCHEMISTRY-US, V14, P1257, DOI 10.1021/bi00677a026; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WELLER M, 1995, CANCER RES, V55, P2936; WEN LP, 1997, AM J PHYSIOL, V273, P921; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yick LW, 1999, EXP NEUROL, V159, P131, DOI 10.1006/exnr.1999.7134; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; YOUNG W, 1994, HORMONAL RESTRUCTURI, P241; YOUNG W, 1992, SPINAL CORD TRAUMA H, V17, P399; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zunino SJ, 1996, AM J PATHOL, V149, P653; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257; ZURITA M, 1994, POLYTRAUMATIZED, P343	70	27	33	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2002	96	1		S			83	89		10.3171/spi.2002.96.1.0083			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	509PA	WOS:000173155100014	11795719				2021-06-18	
J	Carlotti, APCP; Bohn, D; Rutka, JT; Singh, S; Berry, D; Sharman, A; Cusimano, M; Halperin, ML				Carlotti, APCP; Bohn, D; Rutka, JT; Singh, S; Berry, D; Sharman, A; Cusimano, M; Halperin, ML			A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting	JOURNAL OF NEUROSURGERY			English	Article						chloride; hyponatremia; neurosurgery; syndrome of inappropriate antidiuretic hormone secretion; traumatic brain injury	ANTI-DIURETIC HORMONE; TOTAL-BODY WATER; INAPPROPRIATE SECRETION; ACUTE HYPONATREMIA; FLUID VOLUME; SALINE	Object. Two major criteria are necessary to diagnose cerebral salt wasting (CSW): a cerebral lesion and a large urinary excretion of Na+ and Cl- at a time when the extracellular fluid (ECF) volume is contracted. Nevertheless, it is difficult for the physician to confirm from bedside observation that a patient has a contracted ECF volume. Hyponatremia, although frequently present, should not be a criterion for a diagnosis of salt wasting. A contracted ECF volume is unlikely if there are positive balances of Na+ and Cl-. The goal of this study was to assess the accuracy of calculating balances for Na+ plus K+ and of Cl- over 1 to 10 days in an intensive care unit (ICU) setting. Methods. A prospective comparison of measured and estimated quantities of Na+ plus K+ and of Cl- excreted over 1 to 10 days in 10 children and 12 adults who had recently received a traumatic brain injury or undergone recent neurosurgery. Plasma concentrations of electrolytes were recorded at the beginning and end of the study period. The total volumes infused and excreted and the concentrations of Na+, K+, and Cl- in the infusate were obtained from each patient's ICU chart. The electrolytes in the patients' urine were measured and calculated. Correlations between measured and calculated values for excretions of Cl- and of Na+ plus K+ were excellent. Conclusions. Mass balances for Na+ plus K+ and for Cl- can be accurately estimated. These data provide information to support or refute a clinical diagnosis of CSW. The danger of relying on balances for these electrolytes measured within a single day to diagnose CSW is illustrated.	St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1A6, Canada; Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	Halperin, ML (corresponding author), St Michaels Hosp, Div Nephrol, 38 Shuter St, Toronto, ON M5B 1A6, Canada.	mitchell.halperin@utoronto.ca	Cusimano, Michael/X-4059-2019; Carlotti, Ana PCP/G-4893-2012	Carlotti, Ana PCP/0000-0003-2760-8801; Cusimano, Michael/0000-0002-9989-0650			BURCH GE, 1945, AM J MED SCI, V209, P226, DOI 10.1097/00000441-194502000-00014; CHUNG HM, 1987, AM J MED, V83, P905, DOI 10.1016/0002-9343(87)90649-8; de Wardener HE., 1998, SALT DIET HLTH NEPTU; DECAUX G, 1980, AM J MED, V69, P99, DOI 10.1016/0002-9343(80)90506-9; DECAUX G, 1981, NEW ENGL J MED, V304, P329, DOI 10.1056/NEJM198102053040605; Gowrishankar M, 1998, CLIN NEPHROL, V50, P352; Gowrishankar M, 1996, KIDNEY INT, V50, P1490, DOI 10.1038/ki.1996.463; HALPERIN ML, 1985, AM J PHYSIOL, V248, pF607; HALPERIN ML, 1993, CLIN DETECTIVE STORI, P273; Halperin ML., 1999, FLUID ELECTROLYTE AC, V3; HANTMAN D, 1973, ANN INTERN MED, V78, P870, DOI 10.7326/0003-4819-78-6-870; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; Kamel KS, 1998, KIDNEY INT, V53, P531, DOI 10.1046/j.1523-1755.1998.00803.x; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; Laredo S, 1996, J AM SOC NEPHROL, V7, P2527; Mallie JP, 1997, CLIN INVEST MED, V20, P16; McCance RA, 1936, LANCET, V1, P823; MOOREEDE MC, 1977, AM J PHYSIOL, V232, pF128; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Porzio P, 2000, CRIT CARE MED, V28, P1905, DOI 10.1097/00003246-200006000-00037; QUINTON PM, 1987, KIDNEY INT, V32, pS102; ROBERTSON GL, 2000, KIDNEY PHYSL PATHOPH, V2, P1133; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3; Schmidt-Nielsen K., 1997, 'Animal Physiology: Adaptation and Environment; SPITAL A, 1989, ARCH INTERN MED, V149, P1255, DOI 10.1001/archinte.149.6.1255; Steele A, 1997, ANN INTERN MED, V126, P20, DOI 10.7326/0003-4819-126-1-199701010-00003; Sterns Richard H., 1993, P225; Taubes C, 1998, SCIENCE, V281, P898, DOI 10.1126/science.281.5379.898; WATSON PE, 1980, AM J CLIN NUTR, V33, P27; WIJDICKS EFM, 1985, ANN NEUROL, V17, P137, DOI 10.1002/ana.410170206	30	27	28	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2001	95	3					420	424		10.3171/jns.2001.95.3.0420			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	470WP	WOS:000170894600008	11565862				2021-06-18	
J	Kahveci, FS; Kahveci, N; Alkan, T; Goren, B; Korfali, E; Ozluk, K				Kahveci, FS; Kahveci, N; Alkan, T; Goren, B; Korfali, E; Ozluk, K			Propofol versus isoflurane anesthesia under hypothermic conditions: Effects on intracranial pressure and local cerebral blood flow after diffuse traumatic brain injury in the rat	SURGICAL NEUROLOGY			English	Article						propofol; isoflurane; hypothermia; head injury; rat; LCBF	GLUCOSE-UTILIZATION; MILD HYPOTHERMIA; HEAD-INJURY; HIPPOCAMPAL GLUTAMATE; MODERATE HYPOTHERMIA; ELECTRICAL-ACTIVITY; ISCHEMIA; METABOLISM; HALOTHANE; ANTIOXIDANT	BACKGROUND The aim of this study was to compare the cerebral protective effects of two known protective anesthetics, isoflurane and propofol, when these were used in combination with moderate hypothermia (33-34 degreesC) after diffuse traumatic brain injury (TBI) in the rat. We assessed cerebral protection by measuring local cerebral blood flow (LCBF), mean arterial blood pressure (MABP), cerebral perfusion pressure (CPP) and intracranial pressure (ICP). METHODS Sixteen female Wistar rats weighing 275 to 350 g were anesthetized and subjected to an accelerated-impact weight-drop model of diffuse TBI. Hypothermia (33-34 degreesC) was induced 45 minutes after TBI (baseline), and was maintained for 180 minutes. The isoflurane group (n = 8) received 70% N2O in O-2, and isoflurane at 0.9 +/- 0.04%. The propofol group (n = 8) received 70% N2O in O-2 and a propofol infusion (12 mg/kg/hr). LCBF was measured by laser Doppler flowmeter. MABP, ICP, and brain and rectal temperatures were measured every 15 minutes from baseline through 180 minutes. Blood gas and hematocrit testing was also done at baseline and every 60 minutes thereafter to assess the animals' physiological state. RESULTS In the isoflurane group, MABP and CPP decreased significantly from baseline to 180 minutes (p <0.05 and p <0.01, respectively), and MABP was significantly lower than the pressure in the propofol group from 45 minutes through 180 minutes (p <0.05, p <0.01). ICP and LCBF remained unchanged in this group. In the propofol group, from baseline to 180 minutes, CPP increased to maximum 120 +/- 8 mmHg at 75 minutes from 98 +/- 5 mmHg (p <0.05) and ICP fell from 18 +/- 2 mmHg to 7 +/- 1 mmHg (p <0.01); and the latter was significantly lower than ICP in the isoflurane group (P <0.05, p <0.01, p <0.001). LCBF in this group was significantly higher than LCBF in the isoflurane group in the last 30 minutes of the experiment (p <0.05). The propofol group showed no change in MABP over the course of the experiment. CONCLUSION In the clinical setting, propofol anesthesia may be better for use in combination with hypothermia in cases of traumatic brain injury, as it reduces ICP and increases CPP under these conditions. (C) 2001 by Elsevier Science Inc.	Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey; Uludag Univ, Sch Med, Dept Anesthesiol, Gorukle, Bursa, Turkey; Uludag Univ, Sch Med, Intens Care Unit, Gorukle, Bursa, Turkey; Uludag Univ, Sch Med, Dept Physiol, Gorukle, Bursa, Turkey	Korfali, E (corresponding author), Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey.		Alkan, Tulin/AAH-1792-2021; Kahveci, Ferda/AAG-9356-2021; Kahveci, Nevzat/AAG-7070-2021; Goren, Bulent/AAH-1718-2021	Kahveci, Nevzat/0000-0003-0841-8201; Kahveci, Ferda Sohret/0000-0003-4820-2288			AARTS L, 1995, FEBS LETT, V357, P83, DOI 10.1016/0014-5793(94)01337-Z; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; ARCHER DP, 1987, ANESTHESIOLOGY, V67, P642, DOI 10.1097/00000542-198711000-00005; BERNARD JM, 1990, ANESTHESIOLOGY, V72, P659, DOI 10.1097/00000542-199004000-00014; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN Q, 1993, J CEREBR BLOOD F MET, V13, P389, DOI 10.1038/jcbfm.1993.52; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CRAWFORD MW, 1992, ANESTH ANALG, V75, P1000; DAM M, 1990, ANESTHESIOLOGY, V73, P499, DOI 10.1097/00000542-199009000-00021; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; FARLING PA, 1989, ANAESTHESIA, V44, P222, DOI 10.1111/j.1365-2044.1989.tb11228.x; GELB AW, 1989, ANESTHESIOLOGY, V70, P678, DOI 10.1097/00000542-198904000-00023; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hans P, 1997, J NEUROSURG ANESTH, V9, P234, DOI 10.1097/00008506-199707000-00006; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; Herregods L, 1988, Anaesthesia, V43 Suppl, P107, DOI 10.1111/j.1365-2044.1988.tb09089.x; HINDMAN BJ, 1991, ANESTHESIOLOGY, V75, P662, DOI 10.1097/00000542-199110000-00017; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; Hudspith MJ, 1997, BRIT J ANAESTH, V78, P731, DOI 10.1093/bja/78.6.731; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P571, DOI 10.1097/00000542-198910000-00016; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; KIM HK, 1888, J NEUROSURG ANESTHES, V6, P260; KOCHS E, 1992, ANESTHESIOLOGY, V76, P245, DOI 10.1097/00000542-199202000-00014; Krafft P, 2000, STROKE, V31, P1393, DOI 10.1161/01.STR.31.6.1393; LAPTOOK AR, 1995, PEDIATR RES, V38, P919, DOI 10.1203/00006450-199512000-00015; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; LUMB WV, 1973, VET ANESTHESIA, P285; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MCCULLOCH J, 1982, J NEUROCHEM, V39, P255, DOI 10.1111/j.1471-4159.1982.tb04729.x; MERGAERT C, 1991, EUR J ANAESTH, V8, P324; MOSS E, 1990, BRIT J ANAESTH, V65, P823, DOI 10.1093/bja/65.6.823; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; NEWBERG LA, 1983, ANESTHESIOLOGY, V59, P23, DOI 10.1097/00000542-198307000-00005; Niwa K, 1998, BRAIN RES, V789, P68, DOI 10.1016/S0006-8993(98)00013-4; ORSER BA, 1995, BRIT J PHARMACOL, V116, P1761, DOI 10.1111/j.1476-5381.1995.tb16660.x; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; PINAUD M, 1990, ANESTHESIOLOGY, V73, P404, DOI 10.1097/00000542-199009000-00007; RAMANI R, 1992, J NEUROSURG ANESTH, V4, P110, DOI 10.1097/00008506-199204000-00006; RAMANI R, 2000, ANESTHESIOLOGY, V73, pA703; SAKABE T, 1994, ANESTHESIA NEUROSURG, P149; Sarraf-Yazdi S, 1998, ANESTH ANALG, V87, P72, DOI 10.1097/00000539-199807000-00016; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P51, DOI 10.1097/00008506-199701000-00012; Shuaib A, 1996, NEUROSCI LETT, V204, P1, DOI 10.1016/0304-3940(96)12336-3; SMITH AL, 1976, ANESTHESIOLOGY, V45, P64, DOI 10.1097/00000542-197607000-00012; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; VANHEMELRIJCK J, 1990, ANESTH ANALG, V71, P49; VITEZ TS, 1974, ANESTHESIOLOGY, V41, P80, DOI 10.1097/00000542-197407000-00020; Weir D L, 1989, J Neurosurg Anesthesiol, V1, P284, DOI 10.1097/00008506-198909000-00014; WHITE PF, 1974, ANESTHESIOLOGY, V40, P52, DOI 10.1097/00000542-197401000-00012; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; YANG J, 1991, ANN NY ACAD SCI, V625, P287, DOI 10.1111/j.1749-6632.1991.tb33851.x; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x; ZAPP M, 1992, NEUROCHEM RES, V17, P301, DOI 10.1007/BF00974569	63	27	30	0	9	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0090-3019			SURG NEUROL	Surg. Neurol.	SEP	2001	56	3					206	214		10.1016/S0090-3019(01)00555-9			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	480NX	WOS:000171468800026	11597656				2021-06-18	
J	Schopp, LH; Shigaki, CL; Johnstone, B; Kirkpatrick, HA				Schopp, LH; Shigaki, CL; Johnstone, B; Kirkpatrick, HA			Gender differences in cognitive and emotional adjustment to traumatic brain injury	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS			English	Article						depression; emotion; traumatic brain injury; neuropsychological testing; gender	SEX-DIFFERENCES; HEAD; INTELLIGENCE; PROGESTERONE	This study examined gender differences in cognitive and emotional status after traumatic brain injury (TBI) among 262 men and 140 women with TBI referred for neuropsychological evaluations. In this cross-sectional study, cognition was measured in terms of both absolute level of functioning (i.e., raw/standard scores) and estimated decline from premorbid levels expressed as z-deficit scores in the following domains: intelligence [Wechsler Adult Intelligence Scale-Revised (WAIS-R)], memory and attention [Wechsler Memory Scale-Revised (WMS-R)], processing speed (Trails A), and cognitive flexibility (Trails B). Emotional functioning was measured in terms of depression (Beck Depression Inventory) and general emotional distress (Brief Symptom Inventory). Kruskal-Wallis nonparametric one-way ANOVAs indicated that women and men differed significantly on 2 of 8 raw/standard cognitive scores [men demonstrated lower WMS-R General Memory (p < .05) and Trails B scores (p < .0001) and 4 of 8 relative decline scores [women demonstrated more estimated change in VIQ (Verbal IQ) [p < .0001], FSIQ (Full Scale IQ) [p < .01], and Attention (p < .01)]; men demonstrated greater estimated z-decline scores on Trails B (p < .01)]. Women reported significantly higher levels of depression (p < .01), but men endorsed significantly greater general psychological distress (p < .05). Research and assessment recommendations are suggested.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65212 USA	Schopp, LH (corresponding author), Univ Missouri, Sch Med, Dept Phys Med & Rehabil, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.	schoppl@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; ANDREASEN NC, 1993, AM J PSYCHIAT, V150, P130; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEROGATIS LR, 1993, ADMINISTRATION SCORI; FARACE E, 2000, DO WOMEN FARE WORSE; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HAYES ZL, 1994, CAN J BEHAV SCI, V26, P421, DOI 10.1037/0008-400X.26.3.421; INGLIS J, 1982, CAN J PSYCHOL, V36, P670, DOI 10.1037/h0080670; JASTAK S, 1984, WRAT R WIDE RANGE AC; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; JOHNSTONE BJ, 1999, J HEAD TRAUMA REHAB, V14, P10; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Levy J., 1992, SEXUAL DIFFERENTIATI, V11; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Millis Scott R., 1993, Brain Injury, V7, P53, DOI 10.3109/02699059309008156; *NAT CTR INJ PREV, 2000, EP TRAUM BRAIN INJ U; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Reitan R, 1986, TRAIL MAKING TEST MA; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; STEIN DG, 1995, RESTOR NEUROL NEUROS, V8, P105, DOI 10.3233/RNN-1995-81226; *TBI MOD SYST NAT, 1998, TBI FACTS FIG; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Turkheimer E., 1992, PSYCHOL ASSESSMENT, V4, P498; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1987, MANUAL WECHSLER MEMO; WEISSMAN MM, 1993, J AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F; Wilkinson G, 1993, WRAT3 WIDE RANGE ACH; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	40	27	27	0	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9583	1573-3572		J CLIN PSYCHOL MED S	J. Clin. Psychol. Med. Settings	SEP	2001	8	3					181	188		10.1023/A:1011369620254			8	Psychology, Clinical	Psychology	471FN	WOS:000170918000006					2021-06-18	
J	Tooth, L; McKenna, K; Strong, J; Ottenbacher, K; Connell, J; Cleary, M				Tooth, L; McKenna, K; Strong, J; Ottenbacher, K; Connell, J; Cleary, M			Rehabilitation outcomes for brain injured patients in Australia: functional status, length of stay and discharge destination	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; MEDICAL REHABILITATION; INDEPENDENCE; RECOVERY; RELIABILITY; PREDICTION; COMMUNITY; SYSTEM; TRAUMA	This study describes the rehabilitation length of stay (LOS), discharge destination and discharge functional status of 149 patients admitted with traumatic brain injury (TBI) to an Australian hospital over a 5-year period. Hospital charts of patients admitted between 1993-1998 were reviewed. Average LOS over the 5-year time period was 61.8 days and only decreased nominally over this time. Longer LOS was predicted by lower admission motor FIM scores and presence of comorbidities. Mean admission and discharge motor FIM scores were 58 and 79, which represented a gain of 21 points. Higher discharge motor FIM scores were predicted by higher admission motor FIM scores and younger age. FIM gain was predicted by cognitive status and age. Most patients, 88%, were discharged back to the community, with 30% changing their living setting or situation. Changing living status was predicted by living alone and having poorer functional status on admission.	Univ Queensland, Dept Social & Prevent Med, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia	Tooth, L (corresponding author), Univ Queensland, Dept Social & Prevent Med, Brisbane, Qld 4072, Australia.		Strong, Jenny/F-1211-2010; Tooth, Leigh/F-2769-2010	Strong, Jenny/0000-0002-9367-8755; Ottenbacher, Kenneth/0000-0001-5990-3982; Tooth, Leigh/0000-0002-1569-934X			BARRY P, 1989, ARCH PHYS MED REHAB, V70, P902; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; Davis CH, 1997, AM J PHYS MED REHAB, V76, P213, DOI 10.1097/00002060-199705000-00011; EAGER K, 1997, AUSTR NATL SUBACUTE; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fiedler RC, 1998, AM J PHYS MED REHAB, V77, P444, DOI 10.1097/00002060-199809000-00019; Fleming J, 1999, BRAIN INJURY, V13, P417; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; FORTUNE N, 1999, 15 AIHW DIS; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Jong CN, 1999, BRAIN INJURY, V13, P1017; KAPLAN CP, 1994, ARCH PHYS MED REHAB, V75, P643, DOI 10.1016/0003-9993(94)90186-4; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McPherson KM, 1997, INT J REHABIL RES, V20, P1, DOI 10.1097/00004356-199703000-00001; Nyein K, 1999, CLIN REHABIL, V13, P56, DOI 10.1191/026921599701532135; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Torenbeek M, 1998, BRAIN INJURY, V12, P307, DOI 10.1080/026990598122610; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Zafonte R, 1999, BRAIN INJURY, V13, P31, DOI 10.1080/026990599121854; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	34	27	27	0	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2001	15	7					613	631		10.1080/02699050010013923			19	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	444PD	WOS:000169407900006	11429090				2021-06-18	
J	Woertgen, C; Rothoerl, RD; Brawanski, A				Woertgen, C; Rothoerl, RD; Brawanski, A			Neuron-specific enolase serum levels after controlled cortical impact injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						neuron-specific enolase; rat; traumatic brain injury	MINOR HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; S-100 PROTEIN; BRAIN-DAMAGE; CEREBROSPINAL-FLUID; COMPUTED-TOMOGRAPHY; ISCHEMIC STROKE; SERIAL S-100; BLOOD; INDICATORS	The aim of this study was to investigate the time course and the correlation of neuron-specific enolase (NSE) serum levels to the severity of traumatic brain injury in rats, Sixty-five male Wistar rats were subjected to severe cortical impact injury (100 PSI, 2 mm deformation). Blood samples were drawn directly after trauma and after 1, 6, 12, 24, and 48 h in the trauma group. In the sham operated levels animals samples were drawn directly after craniotomy and after 6 and 48 h, Additionally, NSE serum levels after controlled cortical impact at different levels of severity samples (45 PSI, 75 PSI; 2 mm deformity) were compared to sham-operated animals, The severity of the injury was not validated histopathologically, NSE serum levels were estimated with a commercially available enzyme immunoassay (LIA mat Sangtec(R)), The control animals showed a NSE serum level of 8.82 mug/L (mean, n = 10) and the injured animals demonstrated a time-dependent release of NSE into the serum. The highest NSE serum values were detected 6 h after trauma (31.5 mug/L mean, n = 10), In addition, we found a close relationship between NSE serum levels and the severity of traumatic brain injury in the cortical impact model. NSE serum levels reflect in a time-dependent manner the severity of brain trauma induced by cortical impact model in rat.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany	Woertgen, C (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.						DIXON CE, 1991, J NEUROSCI METH, V39, P253; FAGNART OC, 1988, CLIN CHEM, V34, P1387; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	19	27	46	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					569	573		10.1089/089771501300227378			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000010	11393260				2021-06-18	
J	McCracken, E; Dewar, D; Hunter, AJ				McCracken, E; Dewar, D; Hunter, AJ			White matter damage following systemic injection of the mitochondrial inhibitor 3-nitropropionic acid in rat	BRAIN RESEARCH			English	Article						ischemia; oxidative stress; axon	TRAUMATIC BRAIN INJURY; METHYL-D-ASPARTATE; SUCCINATE-DEHYDROGENASE; FREE-RADICALS; CALPAIN ACTIVATION; OXIDATIVE STRESS; GLOBAL-ISCHEMIA; TOXIN; NEURODEGENERATION; NEUROTOXICITY	Oxidative stress has been implicated as a pathogenic mediator of neuronal perikarya cell death. Axons and oligodendrocytes. components of white matter, could also be vulnerable to oxidative damage. An experimental model of oxidative stress was induced by systemic injection of 3-nitropropionic acid (3-NPA). Animals received an i.p. injection of 10, 15, 20 or 30 mg/kg 3-NPA or vehicle and were killed 24 h later. 3-NPA produced a concentration-dependent increase in axonal pathology within the striatum reflected by the amount of beta -APP and SNAP-25 accumulation. Axonal damage was anatomically coincident with the neuronal lesion. There was no neuronal or axonal damage in the subcortical white matter or cerebral cortex in any of the animals treated with 3-NPA. Manganese superoxide dismutase (Mn-SOD) immunoreactivity was present in the vehicle and all 3-NPA treated groups. The amount of Mn-SOD cellular staining was concentration-dependently increased within the striatum supporting a role for oxidative stress in the mechanism of 3-NPA neurotoxicity. Oligodendrocyte-like cells within the subcortical white matter were immunopositive for calpain-mediated spectrin breakdown products and increased in a concentration-dependent manner. Therefore in this experimental modal, mitochondrial inhibition may lead to the initiation of oxidative stress and calpain activation, which could mediate cytoskeletal breakdown in axons and oligodendrocytes suggesting an interaction between at least two pathogenic mechanisms. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Glasgow, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England	McCracken, E (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	emc27m@udcf.gla.ac.uk	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763			Alexi T, 1998, NEUROREPORT, V9, pR57, DOI 10.1097/00001756-199808030-00001; ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BEAL MF, 1995, J NEUROCHEM, V65, P919; BEAL MF, 1993, J NEUROSCI, V13, P4181; Binienda Z, 1998, NEUROSCI LETT, V251, P173, DOI 10.1016/S0304-3940(98)00539-4; BORLONGAN CV, 1995, BRAIN RES BULL, V36, P549, DOI 10.1016/0361-9230(94)00242-S; Brouillet E, 1998, J NEUROCHEM, V70, P794; BROUILLET E, 1993, J NEUROCHEM, V60, P356, DOI 10.1111/j.1471-4159.1993.tb05859.x; CHAN PH, 1994, BRAIN PATHOL, V4, P59; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; COLES CJ, 1979, J BIOL CHEM, V254, P5161; Deshpande SB, 1997, EXP NEUROL, V145, P38, DOI 10.1006/exnr.1997.6457; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; FITZPATRICK MO, 1997, J CEREB BLOOD FLO S1, V17, pS415; FLAMM ES, 1978, BRAIN RES, V624, P445; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; FU YT, 1995, TOXICON, V33, P327, DOI 10.1016/0041-0101(94)00173-6; Geddes JW, 1996, MOL CHEM NEUROPATHOL, V28, P65, DOI 10.1007/BF02815206; GEDDES JW, 1994, NEUROBIOL AGING S, V25; Greene JG, 1998, NEUROSCIENCE, V84, P503, DOI 10.1016/S0306-4522(97)00389-8; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Love S, 1999, BRAIN PATHOL, V9, P119; LUDOLPH AC, 1991, CAN J NEUROL SCI, V18, P492, DOI 10.1017/S0317167100032212; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Miller PJ, 1997, EXP NEUROL, V146, P212, DOI 10.1006/exnr.1997.6522; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nishino H, 1996, J CHEM NEUROANAT, V10, P209, DOI 10.1016/0891-0618(96)00134-2; Pang Z, 1997, J NEUROSCI, V17, P3064; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; RAICHLE ME, 1983, ANN NEUROL, V13, P2, DOI 10.1002/ana.410130103; RIEPE MW, 1995, NEUROSCIENCE, V64, P91, DOI 10.1016/0306-4522(94)00332-Y; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHRAUFSTATTER IU, 1985, J CLIN INVEST, V76, P1131, DOI 10.1172/JCI112068; Schulz JB, 1996, NEUROCHEM INT, V29, P167, DOI 10.1016/0197-0186(95)00122-0; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SILVER IA, 1990, J GEN PHYSIOL, V95, P837, DOI 10.1085/jgp.95.5.837; SUSSMAN MS, 1990, METHOD ENZYMOL, V186, P711; Takamatsu H, 1998, EUR J PHARMACOL, V352, P165, DOI 10.1016/S0014-2999(98)00353-7; Tsai MJ, 1997, NEUROSCIENCE, V79, P819, DOI 10.1016/S0306-4522(97)00015-8; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; WULLNER U, 1994, J NEUROCHEM, V63, P1772	51	27	28	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 23	2001	892	2					329	335		10.1016/S0006-8993(00)03266-2			7	Neurosciences	Neurosciences & Neurology	403BJ	WOS:000167022400012	11172780				2021-06-18	
J	Abraham, KE; McGinty, JF; Brewer, KL				Abraham, KE; McGinty, JF; Brewer, KL			The role of kainic acid/AMPA and metabotropic glutamate receptors in the regulation of opioid mRNA expression and the onset of pain-related behavior following excitotoxic spinal cord injury	NEUROSCIENCE			English	Article						dynorphin; enkephalin; pain; spinal cord injury; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline; (RS)-1-aminoindan-1,5-dicarboxylic acid	RADIOIMMUNOASSAY TECHNIQUE; TRAUMATIC INJURY; QUISQUALIC ACID; RAT STRIATUM; NMDA; IMMUNOREACTIVITY; AMPHETAMINE; ANTAGONISTS; ALLODYNIA; DYNORPHIN	Intraspinal injection of quisqualic acid. a mixed kainic acid/2-amino-3(3-hydroxy-5-methylisonazol-4-yl) pionic acid and metabotropic glutamate receptor agonist, produces an excitotoxic injury that leads to the onset of both spontaneous and evoked pain behavior as well as changes in spinal and cortical expression of opioid peptide mRNA, preprodynorphin and preproenkephalin. What characteristics of the quisqualic acid-induced injury are attributable to activation of each receptor subtype is unknown. This study attempted to define the role of activation of the kainic acid/2-amino-3(3-hydroxy-5-methylisoxazol-4-yl) acid (AMPA) and metabotropic glutamate receptor subtypes in the regulation of opioid peptide expression and the onset of spontaneous and evoked pain-related behavior following excitotoxic spinal cord injury by comparing quisqualic acid-induced changes with those created by co-injection of quisqualic acid and the kainic acid/AMPA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline, (NBQX) or the metabotropic antagonist, IRS)-1-aminoindan-1,5-dicarboxylic acid (AIDA). Therefore, 42 male Long Evans adult rats were divided into seven treatment groups and received intraspinal microinjections of saline (sham). 0.5% dimethylsulphoxide (sham), quisqualic acid (1.2 mul, 125 mM), NBQX (1.2 mul. 60 muM). AIDA (1.2 mul. 250 muM), quisqualic acid/ NBQX (1.2 mul. 125 mM/60 muM), or quisqualic acid/AIDA (1.2 mul, 125 mM/250 muM) directed at spinal levels thoracic 12-lumbar 2. Behavioral observations of spontaneous and evoked pain responses were completed following surgery. After a 10-day survival period, animals were killed and brain and spinal cord tissues were removed and processed for histologic analysis and in situ hybridization. Both AIDA and NBQX affected the quisqualic acid-induced total lesion volume but only AIDA caused a decrease in the percent tissue damage at the lesion epicenter. Preprodynorphin and preproenkephalin expression is increased in both spinal and cortical areas in quisqualic acid-injected animals versus sham-, NBQX or AIDA-injected animals. NBQX did not affect quisqualic acid-induced spinal or cortical expression of preprodynorphin or preproenkephalin except for a significant decrease in preproenkephalin expression in the spinal cord. In contrast, AIDA significantly decreases quisqualic acid-induced preprodynorphin and preproenkephalin expression within the spinal cord and cortex. AIDA. but not NBQX, significantly reduced the frequency of, and delayed the onset of, quisqualic acid-induced spontaneous pain-related behavior. From these data we suggest that both the kainic acid/AMPA and metabotropic glutamate receptor subtypes are involved in the induction of the excitotoxic cascade responsible for quisqualic acid-induced neuronal damage and changes in opioid peptide mRNA expression, while metabotropic glutamate receptors may play a more significant role in the onset of post-injury pain-related behavior. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Greenville, NC 27858 USA; Shenandoah Univ, Div Phys Therapy, Winchester, VA 22601 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Brewer, KL (corresponding author), E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Physicians Quadrangle Bldg M, Greenville, NC 27858 USA.	brewerk@mail.ecu.edu					Abraham KE, 2001, PAIN, V90, P181, DOI 10.1016/S0304-3959(00)00402-4; Abraham KE, 2000, NEUROSCIENCE, V99, P189, DOI 10.1016/S0306-4522(00)00150-0; Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; BREWER KL, 1997, SOC NEUR ABSTR, V23, P437; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; EIMERL S, 1994, J NEUROCHEM, V62, P1223; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GOMEZPINELLA F, EXP NEUROL, V104, P118; HAO JX, 1991, PAIN, V45, P175, DOI 10.1016/0304-3959(91)90186-2; HAO JX, 1992, EXP NEUROL, V118, P143, DOI 10.1016/0014-4886(92)90031-K; Hao JX, 1998, EXP BRAIN RES, V118, P259, DOI 10.1007/s002210050280; HELTON TE, 1993, MOL CELL NEUROSCI, V4, P319, DOI 10.1006/mcne.1993.1042; KOSTERLITZ HW, 1985, PROC R SOC SER B-BIO, V225, P27, DOI 10.1098/rspb.1985.0048; LEES GJ, 1993, BRAIN RES, V628, P1, DOI 10.1016/0006-8993(93)90930-L; LENZ FA, 1991, SYMP PAIN R, P171; LEVITT M, 1985, BRAIN RES REV, V10, P247, DOI 10.1016/0165-0173(85)90027-X; LITTMAN L, 1995, NEUROPHARMACOLOGY, V34, P829, DOI 10.1016/0028-3908(95)00070-M; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; MARTINEZARIZALA A, 1990, EXP NEUROL, V108, P232, DOI 10.1016/0014-4886(90)90128-F; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; Morrow TJ, 2000, EXP NEUROL, V161, P220, DOI 10.1006/exnr.1999.7246; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PORTER RHP, 1992, BRIT J PHARMACOL, V106, P509, DOI 10.1111/j.1476-5381.1992.tb14366.x; PRZEWLOCKI R, 1988, MOL BRAIN RES, V4, P37, DOI 10.1016/0169-328X(88)90016-2; Ruda MA, 1995, PROG BRAIN RES, V104, P349; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; SHARMA HS, 1992, NEUROSCI RES, V14, P195; SIDDALL P, 1995, NEUROREPORT, V6, P1241, DOI 10.1097/00001756-199506090-00003; SMITH AJW, 1994, MOL BRAIN RES, V21, P359, DOI 10.1016/0169-328X(94)90268-2; Tachibana T, 1998, J NEUROTRAUM, V15, P485, DOI 10.1089/neu.1998.15.485; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VIERCK CJ, 1991, SYMP PAIN R, P129; WANG JQ, 1995, J PHARMACOL EXP THER, V273, P909; WANG JQ, 1994, SYNAPSE, V18, P343, DOI 10.1002/syn.890180410; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, BRAIN RES, V573, P324; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; ZELTSER R, 1994, PROG PAIN RES MANAG, V3, P295	51	27	27	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	104	3					863	874		10.1016/S0306-4522(01)00134-8			12	Neurosciences	Neurosciences & Neurology	453TT	WOS:000169933100024	11440816				2021-06-18	
J	Adams, J; Frumiento, C; Shatney-Leach, L; Vane, DW				Adams, J; Frumiento, C; Shatney-Leach, L; Vane, DW			Mandatory admission after isolated mild closed head injury in children: Is it necessary?	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	31st Annual Meeting of the American-Pediatric-Surgical-Association	MAY 25-29, 2000	ORLANDO, FLORIDA	Amer Pediat Surg Assoc		concussion; closed head injury; minor head injury	UTILITY; TRAUMA	Background/Purpose: Children with closed head injuries diagnosed as concussion alone or concussion with brief loss of consciousness are admitted routinely for observation despite a normal central nervous system finding, negative computed tomography (CT) scan, and a Glasgow Coma Score (GCS) of 15. Recent studies have questioned the necessity of such an admission. The purpose of this study was to review a large pediatric database and study the length of stay as well as any required procedures or complications in these children. The hypothesis was that routine admission is unnecessary in this population. Methods: The National Pediatric Trauma Registry-Phase II was reviewed for the period from October 1988 to January 1996, Entry criteria included age less than 18 and an isolated closed head injury after blunt trauma with an admission GCS of 15, Variables studied included age, gender, mechanism of injury, length of stay, procedures, and outcome. Results: A total of 1,033 children met criteria for this study. The average age was 8.3 years. Males predominated at 61.9%. Falls, sports, and motor vehicle crashes were the most common mechanisms of injury. The average length of stay was 1.19 days, and 60 children were not admitted. A total of 583 children had no procedures performed, whereas 386 received a CT scan, and 148 had x-rays. None required neurosurgical intervention, and all were discharged alive. Conclusion: These findings indicate that routine admission may not be necessary for children with isolated mild closed head injuries with a negative CT scan and a normal neurologic finding and allows for a prospective randomized trial to confirm this. J Pediatr Surg 36:119-121. Copyright (C) 2001 by W.B. Saunders Company.	Univ Vermont, Coll Med, Div Pediat Surg, Burlington, VT 05401 USA	Vane, DW (corresponding author), Univ Vermont, Coll Med, Div Pediat Surg, 111 Colchester Ave,Fletcher 4,MCHV Campus, Burlington, VT 05401 USA.						Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; KRAUS JF, 1987, PEDIATRICS, V79, P501; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009	7	27	27	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	JAN	2001	36	1					119	121		10.1053/jpsu.2001.20026			3	Pediatrics; Surgery	Pediatrics; Surgery	388KW	WOS:000166180500021	11150449				2021-06-18	
J	Bianchini, KJ; Mathias, CW; Greve, KW; Houston, RJ; Crouch, JA				Bianchini, KJ; Mathias, CW; Greve, KW; Houston, RJ; Crouch, JA			Classification accuracy of the Portland digit recognition test in traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							MEMORY; DEFICITS	This study examined the classification accuracy of the Portland Digit Recognition Test (PDRT) in traumatic brain injury (TBI). It differs from past studies in assigning patients to malingering and control groups on the basis of compensation-seeking status and the presence of external markers for malingering. Sensitivity and Specificity were .77 and 1.00, respectively. Past research comparing compensation-seekers to noncompensation-seekers reported Sensitivities of .33 or lower (Specificity is always high). This study demonstrates that past research has seriously underestimated the Sensitivity of the PDRT and raises questions about the true Sensitivity of other malingering techniques as well.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA; Inst Living, Hartford, CT USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.			Mathias, Charles/0000-0003-1902-673X			BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; Denney RL, 1996, ARCH CLIN NEUROPSYCH, V11, P589, DOI 10.1016/0887-6177(95)00042-9; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; FELDBAUM C, 1998, GUIDE REHABILITATION, P1; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Hennekens CH, 1987, EPIDEMIOLOGY MED; Heubrock D, 1998, EUR J PSYCHOL ASSESS, V14, P211, DOI 10.1027/1015-5759.14.3.211; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Pankratz L., 1988, CLIN ASSESSMENT MALI, P169; Rey A, 1964, EXAMEN CLIN PSYCHOL; REYNOLDS C, 1998, DETECTION MALINGERIN; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; TEASDALE G, 1974, LANCET, V2, P81; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; WASYLIW OE, 1985, BEHAV SCI LAW, V3, P149, DOI DOI 10.1002/BSL.2370030204; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WECHSLER ADULT INTEL; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	29	27	27	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2001	15	4					461	470		10.1076/clin.15.4.461.1890			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QR	WOS:000174656100004	11935447				2021-06-18	
J	Martins, RN; Taddei, K; Kendall, C; Evin, G; Bates, KA; Harvey, AR				Martins, RN; Taddei, K; Kendall, C; Evin, G; Bates, KA; Harvey, AR			Altered expression of apolipoprotein E, amyloid precursor protein and presenilin-1 is associated with chronic reactive gliosis in rat cortical tissue	NEUROSCIENCE			English	Article						Alzheimer's disease; astrocytes; amyloid; cerebral cortex; inflammation; foetal transplants	TRAUMATIC BRAIN-INJURY; CHONDROITIN SULFATE PROTEOGLYCANS; SPORADIC ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; SENILE PLAQUES; MESSENGER-RNA; BETA-PEPTIDE; MICROGLIAL PHAGOCYTOSIS; MISSENSE MUTATIONS; GLIAL RESPONSES	A major characteristic feature of Alzheimer's disease is the formation of compact, extracellular deposits of beta -amyloid (senile plaques). These deposits are surrounded by reactive astrocytes, microglia and dystrophic neurites. Mutations in three genes have been implicated in early-onset familial Alzheimer's disease, However, inflammatory changes and astrogliosis are also believed to play a role in Alzheimer's pathology. What is unclear is the extent to which these factors initiate or contribute to the disease progression. Previous rat studies demonstrated that heterotopic transplantation of foetal cortical tissue onto the midbrain of neonatal hosts resulted in sustained glial reactivity for many months. Similar changes were not seen in cortex-to-cortex grafts. Using this model of chronic cortical gliosis, we have now measured reactive changes in the levels of the key Alzheimer's disease proteins. namely the amyloid precursor protein, apolipoprotein E and presenilin-1. These changes were visualised immunohistochemically and were quantified by western blot analysis. We report here that chronic cortical gliosis in the rat results in a sustained increase in the levels ci apolipoprotein E and total amyloid precursor protein. Reactive astrocytes in heterotopic cortical grafts were immunopositive for both of these proteins. Using a panel of amyloid precursor protein antibodies we demonstrate that chronic reactive gliosis is associated with alternative cleavage of the peptide. No significant changes in apolipoprotein E or amyloid precursor protein expression were seen in non-gliotic cortex-to-cortex transplants. Compared to host cortex, the levels of both N-terminal and C-terminal fragments of presenilin-1 were significantly lower in gliotic heterotopic grafts, The changes described here largely mirror those seen in the cerebral cortex of humans with Alzheimer's disease and are consistent with the proposal that astrogliosis may be an important factor in the pathogenesis of this disease. (C) 2001 IBRO. Published by Elsevier Science Ltd, All rights reserved.	Univ Western Australia, Sir James McCusker Alzheimer Res Unit, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia; Hollywood Private Hosp, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Anat & Human Biol, Perth, WA 6009, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic 3050, Australia	Martins, RN (corresponding author), Univ Western Australia, Sir James McCusker Alzheimer Res Unit, Monash Ave, Nedlands, WA 6009, Australia.		Bates, Kristyn/C-4245-2011; Evin, Genevieve M/E-5891-2013	Martins, Ralph/0000-0002-4828-9363			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Baskin F, 1997, J NEUROL SCI, V148, P15, DOI 10.1016/S0022-510X(96)05335-X; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Casadei VM, 1999, NEUROLOGY, V53, P1888, DOI 10.1212/WNL.53.8.1888; CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189; Chauvet N, 1997, J COMP NEUROL, V377, P550; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; CHUI DH, 1994, AM J PATHOL, V145, P771; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; DEWITT DA, 1994, BRAIN RES, V656, P205, DOI 10.1016/0006-8993(94)91386-2; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P454, DOI 10.1001/archneur.57.4.454; Evans RM, 2000, NEUROLOGY, V54, P240, DOI 10.1212/WNL.54.1.240; Frautschy SA, 1998, J NEUROSCI, V18, P8311; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Harvey AR, 1997, NEUROSCI LETT, V228, P58, DOI 10.1016/S0304-3940(97)00341-8; HOKE A, 1994, EXP NEUROL, V130, P56, DOI 10.1006/exnr.1994.1185; Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8; JAEGER CB, 1980, J COMP NEUROL, V194, P571, DOI 10.1002/cne.901940307; JENKINSON ML, 1989, BRIT J RHEUMATOL, V28, P86; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Licastro F, 1999, NEUROSCI LETT, V270, P129, DOI 10.1016/S0304-3940(99)00468-1; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; LUCCA U, 1994, BIOL PSYCHIAT, V36, P854, DOI 10.1016/0006-3223(94)90598-3; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; McMillan PJ, 2000, MOL BRAIN RES, V78, P138, DOI 10.1016/S0169-328X(00)00086-3; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; Mouchel Y, 1995, NEUROREPORT, V7, P205; MYLLYKANGASLUOSUJARVI R, 1994, BRIT J RHEUMATOL, V33, P501; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Niquet J, 1996, GLIA, V16, P359, DOI 10.1002/(SICI)1098-1136(199604)16:4<359::AID-GLIA8>3.0.CO;2-V; PANGALOS MN, 1995, J NEUROCHEM, V65, P762; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; REBECK GW, 1993, NEURON, V11, P575; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Roitbak T, 1999, GLIA, V28, P40, DOI 10.1002/(SICI)1098-1136(199910)28:1<40::AID-GLIA5>3.0.CO;2-6; ROTHWELL N, 1995, CYTOKINES NEURODEGEN, P77; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schubert P, 2000, ANN NY ACAD SCI, V903, P24, DOI 10.1111/j.1749-6632.2000.tb06346.x; Schwab SG, 1999, DEMENT GERIATR COGN, V10, P469, DOI 10.1159/000017191; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Sykova E, 1999, NEUROSCIENCE, V91, P783, DOI 10.1016/S0306-4522(98)00603-4; Takami K, 1997, BRAIN RES, V748, P122, DOI 10.1016/S0006-8993(96)01274-7; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Veerhuis R, 1999, EXP NEUROL, V160, P289, DOI 10.1006/exnr.1999.7199; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Vincent B, 2000, BIOCHEM BIOPH RES CO, V271, P82, DOI 10.1006/bbrc.2000.2581; Weldon DT, 1998, J NEUROSCI, V18, P2161; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949; Young MJ, 1999, BRAIN RES BULL, V50, P27, DOI 10.1016/S0361-9230(99)00084-2; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	86	27	28	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	106	3					557	569		10.1016/S0306-4522(01)00289-5			13	Neurosciences	Neurosciences & Neurology	483NH	WOS:000171640800007	11591456				2021-06-18	
J	McMillan, TM				McMillan, TM			Errors in diagnosing post-traumatic stress disorder after traumatic brain injury	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY; FOLLOW-UP; EVENT; EPIDEMIOLOGY; DISASTER; SYMPTOMS; VICTIMS; AMNESIA; IMPACT	Evidence to support the view that post-traumatic stress disorder (PTSD) can occur after traumatic brain injury (TBI) continues to grow. However, the reported incidence of cases with both diagnoses ranges widely, from less than 1% to more than 50%. Given that the incidence of TBI is high, a more precise incidence has to be established if screening and treatment resources are to be considered. Are cases being missed or are they over-diagnosed? The single case report presented here does not definitively answer this question, but illustrates the potential shortcomings of diagnosing PTSD using questionnaire measures alone (Impact of Events Scale, Post-traumatic Stress Diagnostic Scale and General Health Questionnaire) and indicates a need for a conjoint interview which takes into account the common effects of TBI and the symptom overlap between PTSD and TBI.	Univ Glasgow, Dept Psychol Med, Glasgow G12 8QQ, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Dept Psychol Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P424; BADDELEY A, 1991, SPEED CAPACITY LANGU; Beck AT., 1990, BECK ANXIETY INVENTO; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; BURGES C, IN PRESS BRIT J CLIN; COUGHLAN AT, 1985, ASSESSMENT MEMORY IN; DAVIDSON JRT, 1933, POST TRAUMATIC STRES; Edgeworth JA, 1998, BALLOONS TEST TEST V; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FIELD HJ, 1976, EPIDEMIOLOGY HEAD IN; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JOSEPH S, 1993, BRIT J CLIN PSYCHOL, V32, P327, DOI 10.1111/j.2044-8260.1993.tb01063.x; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Koren D, 1999, AM J PSYCHIAT, V156, P367; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; MALT U, 1988, BRIT J PSYCHIAT, V159, P431; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Middelboe T., 1992, European Psychiatry, V7, P183; MILLER JD, 1985, LANCET, V1, P1141; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Shallice, 1997, HAYLING BRIXTON TEST; Silver JM, 1997, NEUROCASE, V3, P151, DOI 10.1093/neucas/3.2.151; THOMPSON J, 1994, BRIT J CLIN PSYCHOL, V33, P75, DOI 10.1111/j.2044-8260.1994.tb01096.x; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson, 1991, NATL ADULT READING T; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x	47	27	29	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2001	15	1					39	46		10.1080/02699050150209110			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	384UF	WOS:000165963600004	11201313				2021-06-18	
J	Radensky, PW; Archer, JW; Dournaux, SF; O'Brien, CF				Radensky, PW; Archer, JW; Dournaux, SF; O'Brien, CF			The estimated cost of managing focal spasticity: A physician practice patterns survey	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						spasticity; stroke; traumatic brain injury; botulinum toxin type A; baclofen	UPPER EXTREMITY SPASTICITY; BOTULINUM TOXIN; PERCEPTIONS; PATIENT; TRIAL	The purpose of this study was to estimate the overall cost of managing focal spasticity after stroke (CVA) and traumatic brain injury (TBI) and the cost impact of individual treatments. Sixty physicians described management strategies over six treatment visits for four focal spasticity case studies (one upper and one lower extremity case for CVA and TBI). Mean and median per-case costs were determined across physicians; median per,case costs of physicians who did or did not report use of specific treatments were compared. Mean per-case costs of managing spasticity are as follows: CVA upper, $5,131; CVA tower, $5,384; TBI upper, $14,615; and TBI lower, $13,966. Median per,case costs for strategies including botulinum toxin type A (BTX-A) were less than those without BTX-A in CVA upper; median costs for strategies including oral baclofen were more than those without baclofen in CVA lower. Fewer total treatments were reported with BTX-A than without; more total treatments were reported with baclofen than without. No individual treatment had a significant impact on median treatment costs in TBI. Physician,reported spasticity management costs are substantial. Despite higher drug costs for BTX-A compared with oral therapies like baclofen, strategies for managing spasticity in CVA that include BTX-A may cost less than those without BTX-A.	McDermott Will & Emery, Miami, FL 33131 USA; Colorado Neurol Inst, Englewood, CO USA	Radensky, PW (corresponding author), McDermott Will & Emery, 201 S Biscayne Blvd,Suite 2200, Miami, FL 33131 USA.						Barnes MP, 1997, EUR J NEUROL, V4, pS33; BRIN MF, 1997, MUSCLE NERVE       S, V6, P146; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; Gracies JM, 1997, MUSCLE NERVE, pS92; Hirth RA, 2000, INT J TECHNOL ASSESS, V16, P35, DOI 10.1017/S0266462300016147; KLAINMAN MD, 1997, TRAUMA, V39, P33; Mayer N, 1996, MED REHABILITATION T, P411; MAYER NH, 1997, MUSCLE NERVE       S, V6, P21; Meschia JF, 1998, CNS DRUGS, V9, P357, DOI 10.2165/00023210-199809050-00003; *NAT CTR HLTH STAT, 1994, NAT HOSP DISCH SURV; *NAT STROK ASS, 2000, BRAIN ATT STAT; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; PEDERSEN E, 1974, ACTA NEUROL SCAND, V50, P665; Pierson SH, 1996, ARCH PHYS MED REHAB, V77, P717, DOI 10.1016/S0003-9993(96)90015-5; Ryan M, 1996, PHARMACOECONOMICS, V9, P321, DOI 10.2165/00019053-199609040-00005; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Taylor TN, 1997, DRUGS, V54, P51, DOI 10.2165/00003495-199700543-00008; Viriyavejakul Adulya, 1998, Journal of the Medical Association of Thailand, V81, P413; Wallesch CW, 1997, EUR J NEUROL, V4, pS53; Wennberg DE, 1997, J GEN INTERN MED, V12, P172; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	21	27	29	0	0	DEMOS MEDICAL PUBLISHING	NEW YORK	386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA	0888-4390			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair		2001	15	1					57	68		10.1177/154596830101500108			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	466BH	WOS:000170624100008	11527280				2021-06-18	
J	Price, EA; Rush, LR; Perper, JA; Bell, MD				Price, EA; Rush, LR; Perper, JA; Bell, MD			Cardiopulmonary resuscitation-related injuries and homicidal blunt abdominal trauma in children	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						cardiopulmonary resuscitation; homicidal blunt abdominal trauma; child abuse	COMPLICATIONS	Defendants accused of inflicting fatal abdominal injuries to children occasionally raise the defense that the injuries were caused by cardiopulmonary resuscitation (CPR). The purpose of this study is to answer the question: Does closed chest CPR result in fatal blunt abdominal injuries that can be mistaken for homicidal assault? To that end, a retrospective study was conducted of all homicidal blunt abdominal injuries in children 10 years and younger from the Dade, Broward, and Palm Beach Medical Examiner's Offices from 1981 through 1997. These were compared to cases of children who died of natural causes during the same time period in Broward County who had CPR (control group 1) and to children who died of nonvehicular accidental blunt abdominal trauma (control group 2). Children with life-threatening head injuries were excluded. Medical examiner records, autopsy reports, documenting photographs, and clinical records were reviewed. The data analyzed included subject demographics, whether CPR was performed and by whom, and autopsy findings. Thirty-three child homicides with fatal abdominal injuries were reviewed. Twenty-four (73%) of the homicides received CPR. There was no difference in the nature and severity of injuries between the 24 children who received CPR and the 9 who did not. Three hundred and twenty-four cases of pediatric natural deaths were reviewed, all of which had CPR. No traumatic abdominal injuries were found in any of the children who died of natural causes. Only four children who died of natural causes had evidence of extraabdominal trauma related to CPR. No cases of nonvehicular accidental blunt abdominal trauma were identified during the 17-year period, although there were nonvehicular accidental fatalities due to extraabdominal. injuries. The likelihood of CPR-related primary abdominal trauma in child homicides is very low.	Broward Cty Med Examiners Off, Ft Lauderdale, FL 33312 USA	Price, EA (corresponding author), Broward Cty Med Examiners Off, 5301 SW 31 Ave, Ft Lauderdale, FL 33312 USA.						BARRY RC, 1994, CHID MALTREATMENT CL, P57; BEDELL SE, 1986, ARCH INTERN MED, V146, P1725, DOI 10.1001/archinte.146.9.1725; Bush CM, 1996, ANN EMERG MED, V28, P40, DOI 10.1016/S0196-0644(96)70137-3; Custer J R, 1987, Pediatr Emerg Care, V3, P24, DOI 10.1097/00006565-198703000-00007; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287; POWNER DJ, 1984, CRIT CARE MED, V12, P54, DOI 10.1097/00003246-198401000-00015; THALER MM, 1962, NEW ENGL J MED, V207, P500; WALDMAN PJ, 1984, AM J EMERG MED, V2, P510, DOI 10.1016/0735-6757(84)90076-7	9	27	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2000	21	4					307	310		10.1097/00000433-200012000-00001			4	Medicine, Legal; Pathology	Legal Medicine; Pathology	375CW	WOS:000165382800001	11111786				2021-06-18	
J	Solbakk, AK; Reinvang, I; Nielsen, CS				Solbakk, AK; Reinvang, I; Nielsen, CS			ERP indices of resource allocation difficulties in mild head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							EVENT-RELATED POTENTIALS; PREFRONTAL LESIONS; MENTAL CHRONOMETRY; BRAIN POTENTIALS; ATTENTION; P300; TASK; DEFICITS; LATENCY; DISTRACTIBILITY	This study examined the hypothesis that distractibility is a characteristic sequela of mild closed head injury (MHI). The Minnesota Multiphasic Personality Inventory (MMPI-2) was used to study whether comorbid stress-related symptoms are associated with behavioral and electrophysiological indexes of attention. Event-related potentials (ERPs) and performance (reaction time, accuracy) were studied in patients with MHI (n = 20), patients with frontal lesions (n = 14), and healthy controls (n = 20) during a three-tone oddball task. Participants were instructed to detect rare target (2000 Hz) tones, and to withhold responding to equally rare distracter (500 Hz) tones and frequently occurring standard (1000 Hz) tones. All groups distinguished the two classes of deviants as indicated by the larger P3 amplitude to target relative to distracter tones. This indicates that the group with MHI was capable of differential allocation of attentional resources to target and non-target events. However, impaired performance and attenuated ERP amplitudes to both classes of deviants relative to patients with frontal lesions and controls, suggest limited availability, or expenditure of the resources needed for adequate task performance. In the group with MHI, both P3 amplitude acid reaction time (RT) were significantly related to subjectively reported distress. The difference in RT disappeared, whereas the P3 amplitude differences between the patient groups remained when adjusting for level of distress.	Univ Oslo, Inst Psychol, Blindern, Norway; Univ Oslo, Natl Hosp, Dept Psychosomat & Behav Med, Oslo, Norway	Solbakk, AK (corresponding author), Univ Oslo, Inst Psychol, PB 1094, Blindern, Norway.	a.k.solbakk@psykologi.uio.no					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boller F, 1995, ANN NY ACAD SCI, V769, P23, DOI 10.1111/j.1749-6632.1995.tb38129.x; Butcher JN., 1989, MMPI 2 MINNESOTA MUL; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; Cripe L I, 1996, Appl Neuropsychol, V3, P97, DOI 10.1207/s15324826an0303&4_1; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Gentilini M., 1989, MILD HEAD INJURY; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; JOHNSON R, 1995, HDB NEUROPSYCHOLOGY, P241; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Katayama J, 1998, PSYCHOPHYSIOLOGY, V35, P23, DOI 10.1017/S0048577298961479; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KNIGHT RT, 1981, ELECTROEN CLIN NEURO, V52, P571, DOI 10.1016/0013-4694(81)91431-0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V504, P338, DOI 10.1016/0006-8993(89)91381-4; KNIGHT RT, 1991, FRONTAL LOBE FUNCTIO; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI; Naatanen R., 1992, ATTENTION BRAIN FUNC; NIELSEN CS, 1997, READPEAK DATA PROGRA; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Reinvang I, 1998, J CLIN EXP NEUROPSYC, V20, P885, DOI 10.1076/jcen.20.6.885.1106; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; Schroger E, 1998, COGNITIVE BRAIN RES, V7, P71, DOI 10.1016/S0926-6410(98)00013-5; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; SQUIRES KC, 1973, PERCEPT PSYCHOPHYS, V14, P265, DOI 10.3758/BF03212388; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STUSS DT, 1991, SELF : INTERDISCIPLINARY APPROACHES, P255; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Vilkki J, 1995, Appl Neuropsychol, V2, P93, DOI 10.1207/s15324826an0203&4_1; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212	48	27	27	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2000	22	6					743	760		10.1076/jcen.22.6.743.953			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	403QT	WOS:000167054500004	11320433				2021-06-18	
J	Yu, WR; Westergren, H; Farooque, M; Holtz, A; Olsson, Y				Yu, WR; Westergren, H; Farooque, M; Holtz, A; Olsson, Y			Systemic hypothermia following spinal cord compression injury in the rat: an immunohistochemical study on MAP 2 with special reference to dendrite changes	ACTA NEUROPATHOLOGICA			English	Article						hypothermia; immunohistochemistry; microtubule-associated protein 2 (MAP2); rat; spinal cord injury	MICROTUBULE-ASSOCIATED PROTEIN-2; TRAUMATIC BRAIN INJURY; SENSITIVE MARKER; NERVOUS-SYSTEM; BLOOD-FLOW; PEROXIDASE; TEMPERATURE; ISCHEMIA	Systemic hypothermia has been shown to exert neuroprotective effects in experimental ischemic CNS models caused by vascular occlusions. The present study addresses the question as to whether systemic hypothermia has similar neuroprotective qualities following severe spinal cord compression trauma using microtubule-associated protein 2 (MAP2) immunohistochemistry combined with the avidin-biotin-peroxidase complex method as marker to identify neuronal and dendritic lesions. Fifteen rats were randomized into three equally sized groups. One group sustained thoracic laminectomy. the others severe spinal cord compression trauma of the T8-9 segment. The control roup contained laminectomized animals submitted to a hypothermic procedure in which the esophageal temperature was reduced from 38 degrees C to 30 degrees C. The two trauma groups were either submitted to the same hypothermic procedure or kept normothermic during the corresponding time. All animals were sacrificed 24 h following the surgical procedure. The MAP2 immunostaining in the normothermic trauma group indicated marked reductions in MAP2 antigen in the cranial and caudal peri-injury zones (T7 and T10, respectively). This reduction was much less pronounced in the hypothermic trauma group. In fact, the MAP2 antigen was present in almost equally sized areas in both the hypothermic groups independent of previous laminectomy alone or the addition of trauma. Our study thus indicates that hypothermia has a neuroprotective effect on dendrites of rat spinal cords subjected to compression trauma.	Univ Uppsala Hosp, Dept Genet & Pathol, Neuropathol Lab, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Neurosci, Neurosurg Unit, Uppsala, Sweden	Yu, WR (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Neuropathol Lab, S-75185 Uppsala, Sweden.			Westergren, Hans/0000-0002-4052-9692			BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BRACKEN MB, 1997, JAMA-J AM MED ASSOC, V277, P1591; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; CACERES A, 1988, MOL BRAIN RES, V3, P233, DOI 10.1016/0169-328X(88)90046-0; CLIFTON GL, 1995, J NEUROSURG ANESTH, V7, P152, DOI 10.1097/00008506-199504000-00023; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Eguchi Y, 1997, J NEUROTRAUM, V14, P109, DOI 10.1089/neu.1997.14.109; GEISLER FH, 1996, PRINCIPLES SPINAL SU, P769; HANCOCK MB, 1984, J HISTOCHEM CYTOCHEM, V32, P311, DOI 10.1177/32.3.6198359; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; HOLTZ A, 1993, J NEUROTRAUM, V7, P115; Holtz Anders, 1995, Upsala Journal of Medical Sciences, V100, P93; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MAUNEY MC, 1995, ANN THORAC SURG, V59, P245, DOI 10.1016/0003-4975(94)00815-O; MIYAWAKI A, 1993, TASK VEG SC, V30, P5; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; WILBERGER JE, 1996, PRINCIPLES SPINAL SU, P753; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x	32	27	28	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2000	100	5					546	552		10.1007/s004010000206			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	352GK	WOS:000089206800013	11045677				2021-06-18	
J	Franulic, A; Horta, E; Maturana, R; Scherpenisse, J; Carbonell, C				Franulic, A; Horta, E; Maturana, R; Scherpenisse, J; Carbonell, C			Organic personality disorder after traumatic brain injury: cognitive, anatomic and psychosocial factors. A 6 month follow-up	BRAIN INJURY			English	Article							HEAD-INJURY; INDIVIDUALS; SEQUELAE	Objective: The purpose of the study is to describe psychosocial adjustment in patients who present Organic Personality Disorder (OPD) after TBI in relation to patients with TBI without OPD. Method: The group included patients who were admitted as inpatients in the Neurology Service. Exclusion criteria were: previous personality disorders; previous alcohol and drugs addiction, history of head injury and other neurological diseases. For this purpose, a semi-structured interview based on the ICD-10 was applied to the patient or significant other during the 1st or 2nd week after the accident. Selected patients were evaluated with psychological and psychosocial tests and questionnaires 6 months after head injury, among them: WAIS, Benton Test, Rey Osterrieth Test, Wisconsin Cards, Psychosocial Scale and Neurobehavioural Rating Scale (NRS-27). Results: No significant differences were observed in relation to demographic characteristics, type of head injury, GCS, or psychometric results. Significant differences were found in the answers to neurobehavioural and psychosocial questionnaires, showing more impairment in patients with OPD. Conclusions: The results show that, in this group, patients with OPD after TBI present more psychosocial adjustment and emotional problems than patients with TBI without OPD diagnosis. The difference found is independent of cognitive impairments.	Hosp Trabajador Santiago, Mental Hlth Serv, Santiago, Chile; Hosp Trabajador Santiago, Serv Neurol, Santiago, Chile	Franulic, A (corresponding author), Hosp Trabajador Santiago, Mental Hlth Serv, Vicuna Mackenna 200, Santiago, Chile.	ghtrae@gw.achs.cl		Carbonell, Carmen Gloria/0000-0001-9279-1847			[Anonymous], 1994, DIAGNOSTIC STAT MANU, V4th; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BAMRAH JS, 1991, BRIT J PSYCHIAT, V158, P117, DOI 10.1192/bjp.158.1.117; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BOND M, 1984, PSICHIATRY CLOSED HE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1984, CLOSED HEAD INJURY P; *CIE 10, 1995, CLAS EST INT ENF PRO; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P260; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Labbate L A, 1997, Ann Clin Psychiatry, V9, P27, DOI 10.1023/A:1026278224598; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LISHMAN WD, 1987, ORGANIC PSICHIATRY P; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Munoz Cespedes JM., 1997, MAPFRE MED, V8, P41; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; YUDOFSKY SC, 1992, CURRENT OPINION PSYC, V5, P103	24	27	28	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2000	14	5					431	439					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	316MQ	WOS:000087171500004	10834338				2021-06-18	
J	Butler, PV				Butler, PV			Reverse Othello syndrome subsequent to traumatic brain injury	PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES			English	Article							DELUSIONAL MISIDENTIFICATION; EROTOMANIA; SELF; DISORDER	Delusional syndromes that occur following head injury are frequently ascribed directly to the consequences of organic insult and seen as empty of psychological significance. The presence of an organic factor, however, does not necessarily indicate that delusional ideation is a direct product of that factor. In this article a detailed report is given of Reverse Othello syndrome (a delusional belief in the fidelity of a romantic partner) appearing in a 49-year-old male following extremely severe traumatic brain injury. This case report highlights the interaction and interpenetration of a complex array of biological, psychological, and social factors in the crystallization of a delusion system. It is argued, following Jaspers, that the emergence of erotically themed delusions following trauma may represent an active attempt to regain intrapsychic coherence and to confer meaning on otherwise catastrophic loss or emptiness.	Royal Rehabil Ctr, Psychol Serv, Ryde, NSW 2112, Australia	Butler, PV (corresponding author), Royal Rehabil Ctr, Psychol Serv, Ryde, NSW 2112, Australia.	butlerp@doh.health.nsw.gov.au					Bowins B, 1998, CAN J PSYCHIAT, V43, P154, DOI 10.1177/070674379804300204; Burgess P. W., 1996, METHOD MADNESS CASE, P51, DOI [10.1006/ccog.1995.1002, DOI 10.1006/CC0G.1995.1002]; COLERIDGE ST, 1997, ST COLERIDGE SELECTE, P155; Crichton P, 1996, J FORENSIC PSYCHIATR, V7, P161, DOI 10.1080/09585189608409924; Enoch M., 1991, UNCOMMON PSYCHIAT SY, V3; EVANS DL, 1982, B MENNINGER CLIN, V46, P507; FLEMINGER S, 1994, PSYCHOPATHOLOGY, V27, P161, DOI 10.1159/000284865; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; FREUD S, 1979, PELICAN FREUD LIB, V10, P209; GELDER M, 1990, OXFORD TXB PSYCHIAT; GILLETT T, 1990, ACTA PSYCHIAT SCAND, V82, P65, DOI 10.1111/j.1600-0447.1990.tb01357.x; Halligan P. W., 1996, METHOD MADNESS CASE; Jaspers K., 1963, GEN PSYCHOPATHOLOGY; John S, 1996, J INTELL DISABIL RES, V40, P279, DOI 10.1046/j.1365-2788.1996.765765.x; LABAW WL, 1997, INJURED BRAINS MED M, P298; LEONG GB, 1994, J FORENSIC SCI, V39, P1445; Lo Y, 1997, ACTA PSYCHIAT SCAND, V95, P161, DOI 10.1111/j.1600-0447.1997.tb00390.x; LYON HM, 1994, BRIT J PSYCHIAT, V164, P637, DOI 10.1192/bjp.164.5.637; Maher B.A., 1984, COMPREHENSIVE HDB PS, P383; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P455; Marshall J.C., 1996, METHOD MADNESS CASE, P3; MILLER L, 1994, J COGNITIVE REHABILI, V12, P12; MORSE JM, 1995, J ADV NURS, V21, P886, DOI 10.1046/j.1365-2648.1995.21050886.x; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; PRIGATANO GP, 1995, J HEAD TRAUMA REHAB, V10, P87; ROBERTS G, 1991, BRIT J PSYCHIAT, V159, P19, DOI 10.1192/S0007125000296438; Sacks O., 1986, MAN WHO MISTOOK HIS; SEGAL JH, 1989, AM J PSYCHIAT, V146, P1261; SIGNER SF, 1987, BRIT J PSYCHIAT, V151, P402, DOI 10.1192/bjp.151.3.402; TODD J, 1959, J NERV MENT DIS, V122, P367; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WEINSTEIN E, 1996, METHOD MADNESS, P13; Werblowsky R, 1997, OXFORD DICT JEWISH R; YOUNG AW, 1996, METHOD MADNESS CASE, P147	35	27	27	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0033-2747	1943-281X		PSYCHIATRY	Psychiatry-Interpers. Biol. Process.	SPR	2000	63	1					85	92		10.1080/00332747.2000.11024897			8	Psychiatry	Psychiatry	318BW	WOS:000087264900011	10855763				2021-06-18	
J	Currens, JAB; Coats, TJ				Currens, JAB; Coats, TJ			The timing of disability measurements following injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; MULTIPLE INJURIES; OUTCOME MEASURES; REHABILITATION; CARE; RELIABILITY; IMPAIRMENT; AGREEMENT	Disability following trauma has profound personal, social and economic costs. Currently, measurement of disability is not standardised and no agreed time interval between injury and disability measurement exists. This study was designed to define the best time at which to measure disability following trauma. The functional independence measurement (FIM) and Glasgow outcome scale (GOS) were assessed at 3, 6, 12 and more than 24 months after injury for 201 trauma patients. The best time to measure was defined as the point at which a steady state was reached, i.e. when further functional improvement ceased. Motor FIM showed significant change between 3 and 6 month assessments (p < 0.002) and 6 and 12 months (p < 0.002). No statistically significant change occurred beyond 12 months (p > 0.2). For Cognitive FIM, there was significant change between 3 and 6 months (p = 0.02), but not beyond 6 months (p > 0.2). For GOS there was significant change between 3 and 6 months (p < 0.002) and 6 and 12 months (p < 0.002) but not beyond 12 months (p > 0.2). Disability measurements should be performed 12 months after injury, when patients have reached a steady state. This time of measurement should be adopted as the standard for trauma databases and outcome studies. (C) 2000 Elsevier Science Ltd. All rights reserved.	St Bartholomews & Royal London Sch Med & Dent, Acad Unit Accident & Emergency, London, England	Currens, JAB (corresponding author), Univ E London, Dept Hlth Sci, Stratford Campus,Romford Rd, London E15 4LZ, England.			Coats, Timothy/0000-0003-2736-2784			ARMITAGE P, 1994, STAT METHODS MED RES, P125; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BLAND M, 1995, INTRO MED STAT, P146; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; CURRENS JAB, UNPUB EVALUATION DIS; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; DITUNNO JF, 1992, J NEUROTRAUM, V9, pS301; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; EARLAM R, 1989, ANN R COLL SURG ENG, V71, pS60; EMHOFF TA, 1991, J TRAUMA, V31, P1227, DOI 10.1097/00005373-199109000-00005; FRUTIGER A, 1991, J TRAUMA, V31, P1216, DOI 10.1097/00005373-199109000-00004; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HETHERINGTON H, 1995, INJURY, V26, P97, DOI 10.1016/0020-1383(95)92185-D; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MARSHALL IF, 1992, J NEUROSURG, V75, pS28; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pollak N, 1996, ARCH PHYS MED REHAB, V77, P1056, DOI 10.1016/S0003-9993(96)90068-4; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; Seekamp A, 1996, INJURY, V27, P133, DOI 10.1016/0020-1383(95)00178-6; TATE DG, 1994, AM J PHYS MED REHAB, V73, P89, DOI 10.1097/00002060-199404000-00004; TurnerStokes L, 1997, CLIN REHABIL, V11, P306, DOI 10.1177/026921559701100407; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; World Health Organization, 1980, INT CLASS IMP DIS HA; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090	35	27	27	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAR	2000	31	2					93	98		10.1016/S0020-1383(99)00244-2			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	287DW	WOS:000085490700006	10748811				2021-06-18	
J	Gauggel, S; Peleska, B; Bode, RK				Gauggel, S; Peleska, B; Bode, RK			Relationship between cognitive impairments and rated activity restrictions in stroke patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						competency rating; disability; neuropsychological tests; stroke	TRAUMATIC BRAIN INJURY; BARTHEL ADL INDEX; FUNCTIONAL INDEPENDENCE; BEHAVIORAL LIMITATIONS; DISABILITY; LIFE; AWARENESS; RELATIVES; QUALITY; PEOPLE	Objective: To investigate the relationship between cognitive impairments and rated activity restrictions. Design: Comparison of neuropsychological tests and activity questionnaires. Activity ratings were made by staff and stroke patients. Setting: Two neurological rehabilitation hospitals. Participants: Eighty-seven stroke patients. Results: Moderately high correlations were found between cognitive test scores and activity ratings made by staff members. In contrast, correlations between ratings made by patients and cognitive rests were much lower. There was also little agreement between the staffs' ratings and the patients' own ratings. Multiple regression analyses indicate that cognitive impairments account for 28.9% of the variance in the activin rating made by the staff members. The coefficient of determination was slightly higher when age, time since onset of illness, and depression scores were included as predictors. Conclusions: These findings provide partial support fur a hierarchical structure of the "International Classification of Impairment, Activities and Participation" model of the World Health Organization.	Univ Marburg, Dept Psychol, D-35032 Marburg, Germany; Northwestern Univ, Sch Med, Rehabil Inst Chicago, Rehabil Serv Evaluat Unit, Chicago, IL 60611 USA	Gauggel, S (corresponding author), Univ Marburg, Dept Psychol, Gutenbergstr 18, D-35032 Marburg, Germany.			Gauggel, Siegfried/0000-0002-2742-4917			Baker KA, 1998, REHABIL PSYCHOL, V43, P30, DOI 10.1037/0090-5550.43.1.30; Beck R, 1996, AGRO FOOD IND HI TEC, V7, P3; BENDALL MJ, 1989, AGE AGEING, V18, P327, DOI 10.1093/ageing/18.5.327; BOHANNON RW, 1990, ARCH PHYS MED REHAB, V71, P330; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; DEHAAN R, 1993, STROKE, V24, P1178, DOI 10.1161/01.STR.24.8.1178; DITTMAR SS, 1997, FUNCTIONAL ASSESSMEN; FUGLMEYER AR, 1980, SCAND J REHABIL MED, P140; GAUGGEL S, 1999, UNPUB MARBURGER KOMP; GRESHAM GE, 1995, POST STROKE REHABILI, V16; Hajek VE, 1997, ARCH PHYS MED REHAB, V78, P1331, DOI 10.1016/S0003-9993(97)90306-3; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Horn W, 1983, LEISTUNGSPRUFSYSTEM; KAPLAN CP, 1994, ARCH PHYS MED REHAB, V75, P643, DOI 10.1016/0003-9993(94)90186-4; Lai SM, 1998, STROKE, V29, P1838, DOI 10.1161/01.STR.29.9.1838; LAWRENCE L, 1979, AGE AGEING, V8, P167, DOI 10.1093/ageing/8.3.167; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Pohjasvaara T, 1997, STROKE, V28, P729, DOI 10.1161/01.STR.28.4.729; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RANHOFF AH, 1993, AGE AGEING, V22, P171, DOI 10.1093/ageing/22.3.171; ROBINSON RG, 1985, ARCH PHYS MED REHAB, V66, P496; Roth EJ, 1998, ARCH PHYS MED REHAB, V79, P329, DOI 10.1016/S0003-9993(98)90015-6; SEGAL ME, 1994, STROKE, V25, P2391, DOI 10.1161/01.STR.25.12.2391; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; SQUIRE LR, 1988, J CLIN EXP NEUROPSYC, V10, P727, DOI 10.1080/01688638808402810; Sturm W, 1983, DIAGNOSTICA, V29, P346; Wade DT, 1992, MEASUREMENT NEUROLOG; *WHO, 1997, ICIDH 2 INT CLASS IM; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; WRIGHT BD, 1997, BIGSTEPS RASCH COMPU; WYLLER TB, 1995, AGE AGEING, V24, P398, DOI 10.1093/ageing/24.5.398; Wyller TB, 1996, DISABIL REHABIL, V18, P454, DOI 10.3109/09638289609165909	37	27	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2000	15	1					710	723		10.1097/00001199-200002000-00009			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	287MX	WOS:000085510800010	10745186				2021-06-18	
J	Marlowe, WB				Marlowe, WB			An intervention for children with disorders of executive functions	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; CLOSED-HEAD-INJURY; LEARNING-DISABILITIES; CHILDHOOD; ATTENTION; CONSEQUENCES; PERFORMANCE; ADOLESCENTS; DISCOURSE; DEFICITS	This article describes a cognitive-behavioral approach to teaching metacognitive executive thinking strategies to children with disorders of executive function. The intervention is based on the notion that some children with disorders of executive function have disorders of higher level language, which predispose them to the executive impairments. It is proposed that teaching and reinforcing metacognitive thinking strategies may help advance verbal mediation of complex tasks and self-regulation of behavior. Despite the growing literature on developmental executive disorders, little has been written about interventions that may enable the children to acquire some of the requisite adaptive skills. The ideas expressed herein should be considered an invitation for the initiation of empirical studies of intervention and outcome effects.		Marlowe, WB (corresponding author), Cabrini Towers,901 Boren Ave,Suite 610, Seattle, WA 98104 USA.						ACKERLY SS, 1947, RES PUBL ASSOC RES N, V27, P479; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; APPELLOF ES, 1985, J CLIN EXP NEUROPSYC, V7, P604; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BECKER MG, 1987, DEV NEUROPSYCHOL, V3, P275, DOI 10.1080/87565648709540381; Bell N, 1986, VISUALIZING VERBALIZ; BERNSTEIN J, 1990, NEUROMETHODS NEUROPS, P311, DOI DOI 10.1385/0-89603-133-0:311; BERNSTEIN JH, 1996, LEARNING LEARN SKILL; BROUWERS P, 1990, AM J PEDIAT HEMATOL, V12, P174; BRUNER JS, 1973, CHILD DEV, V44, P1; CAMP BW, 1981, THINK ALOUD INCREASI; Chance P., 1986, THINKING CLASSROOM S; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHELUNE GJ, 1987, DEV NEUROPSYCHOL, V3, P81, DOI 10.1080/87565648709540365; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; Connor PD, 2000, DEV NEUROPSYCHOL, V18, P331, DOI 10.1207/S1532694204Connor; Denckla MB., 1989, INT PEDIAT, V4, P155; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; ENGLEMANN S, 1969, CONCEPTUAL LEARNING; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P53, DOI 10.1080/87565649609540640; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; KIRK U, 1985, J CLIN EXP NEUROPSYC, V7, P604; LANDRY HS, 1994, ADV CHILD NEUROPSYCH, V1, P85; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Luria A. R., 1961, ROLE SPEECH REGULATI; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Montessori M., 1967, THE ABSORBENT MIND; Montessori M., 1912, MONTESSORI METHOD; NEEDLEMAN HL, 1982, PSYCHOL MED, V12, P461, DOI 10.1017/S0033291700055550; Nelson K., 1996, LANGUAGE COGNITIVE D; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Rieber R. W., 1987, COLLECTED WORKS LS V, V1; Sperber D., 1986, RELEVANCE COMMUNICAT; STORES G, 1978, DEV MED CHILD NEUROL, V20, P502; STREISSGUTH AP, 1994, ALCOHOL CLIN EXP RES, V18, P202, DOI 10.1111/j.1530-0277.1994.tb00904.x; STUSS DT, 1999, FUNCTIONS FRONTAL LO; Taylor HG, 1996, DEV NEUROPSYCHOL, V12, P35, DOI 10.1080/87565649609540639; TAYLOR HG, 1995, J PEDIATR PSYCHOL, V20, P703, DOI 10.1093/jpepsy/20.6.703; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; TAYLOR HG, 1993, J CLIN CHILD PSYCHOL, V22, P196, DOI 10.1207/s15374424jccp2202_6; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, V9; Vygotsky L. S., 1962, THOUGHT LANGUAGE; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WELSH MC, 1990, CHILD DEV, V61, P1697, DOI 10.1111/j.1467-8624.1990.tb03560.x; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X	58	27	27	0	22	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2000	18	3					445	454		10.1207/S1532694209Marlowe			10	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	432UW	WOS:000168714900009	11385834				2021-06-18	
J	Zubkov, AY; Pilkington, AS; Bernanke, DH; Parent, AD; Zhang, J				Zubkov, AY; Pilkington, AS; Bernanke, DH; Parent, AD; Zhang, J			Posttraumatic cerebral vasospasm: Clinical and morphological presentations	JOURNAL OF NEUROTRAUMA			English	Article						head injury; cerebral vasospasm; posttraumatic vasospasm; computed tomographic angiography; morphology	TRANSCRANIAL DOPPLER ULTRASOUND; BLOOD-FLOW VELOCITY; SEVERE HEAD-INJURY; ARTERIAL SPASM; SUBARACHNOID HEMORRHAGE; ANGIOGRAPHIC FINDINGS; ULTRASONOGRAPHY; TCD	Head injury is one of the leading causes of morbidity and mortality in the young population. Many factors complicate head injury and worsen an outcome. One of these factors is posttraumatic cerebral vasospasm. We studied 75 patients admitted to the University of Mississippi Medical Center with head injury. Their ages ranged from 14 to 67 years (mean 30 years, SD 11.63). Eighty percent of the patients were men, and 20 % were women. Of these patients, 53 (70.6 %) suffered severe blunt trauma, and 4 patients suffered gunshot wounds to the head. Four patients had mild head injury, and 14 had moderate head injury. Posttraumatic vasospasm was detected in 24 (32 %) patients. Among these patients, 19 (79.2 %) had severe closed head injury, 3 patients had moderate head injury, and 2 suffered gunshot wounds. The severity of the patient's respective condition was correlated with the development of posttraumatic cerebral vasospasm: 50 % of the patients with Glasgow Coma Scale (GCS) 3-4 developed PTV, and only 30 % with GCS 9-11, and none of the patients with GCS >12 developed PTV. Overall, posttraumatic vasospasm started earlier and had a shorter course than did aneurysmal vasospasm. Morphologically, posttraumatic vasospasm resembled the features of aneurysmal vasospasm. We found increased corrugation of the internal elastic lamina and increased amounts of connective tissue in the subendothelial layer. These findings show that posttraumatic vasospasm, although clinically more mild, demonstrates the same morphological changes as aneurysmal vasospasm.	Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Surg Intens Care Unit, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Anat, Jackson, MS 39216 USA	Zubkov, AY (corresponding author), Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1 S10 RR11321-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR011321] Funding Source: NIH RePORTER		ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; BACKMUND H, 1972, NEURORADIOLOGY, V4, P46, DOI 10.1007/BF00344809; BASS A, 1993, STROKE, V24, P520; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1992, NEUROSURGERY, V30, P697; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; ECHLIN FA, 1980, CEREBRAL ARTERIAL SP, P251; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FRENIDENFELT H, 1963, ACTA RADIOL, V1, P278; GARDNER D, 1986, NURS CLIN N AM, V21, P555; GROLIMUND P, 1988, LANCET, V1, P1173; HAMER J, 1976, NEUROCHIRURGIA, V19, P185; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LEWIN W, 1968, BRIT J SURG, V55, P321, DOI 10.1002/bjs.1800550502; Lindegaard K F, 1986, Acta Radiol Suppl, V369, P96; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Rozsa L, 1989, Radiol Diagn (Berl), V30, P151; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; WILLIAMS AR, 1993, STROKE, V24, P520; Zhang J, 1998, ANAT REC, V253, P58, DOI 10.1002/(SICI)1097-0185(199804)253:2<58::AID-AR9>3.0.CO;2-A; Zubkov AY, 1999, SURG NEUROL, V51, P399, DOI 10.1016/S0090-3019(98)00133-5; ZUBKOV AY, 1998, J NEUROVASC DIS, V3, P257; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X	35	27	30	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					763	770		10.1089/neu.1999.16.763			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700002	10521136				2021-06-18	
J	Tirassa, M				Tirassa, M			Communicative competence and the architecture of the mind/brain	BRAIN AND LANGUAGE			English	Article							CLOSED-HEAD-INJURY; DISCOURSE; COMPREHENSION; REQUESTS; ABILITY; ADULTS	Cognitive pragmatics is concerned with the mental processes involved in intentional communication. I discuss a few issues that may help clarify the relationship between this area and the broader cognitive science and the contribution that they give, or might give, to each other. Rather than dwelling on the many technicalities of the various theories of communication that have been advanced, I focus on the different conceptions of the nature and the architecture of the mind/brain that underlie them. My aims are, first, to introduce and defend mentalist views of communication in general; second, to defend one such view, namely that communication is a cognitive competence, that is, a faculty, and the underlying idea that the architecture of the mind/brain is domain-specific; and, third, to review the (scarce) neuropsychological evidence that bears on these issues. (C) 1999 Academic Press.	Univ Turin, Ctr Cognit Sci, I-10123 Turin, Italy	Tirassa, M (corresponding author), Univ Turin, Ctr Cognit Sci, Via Lagrange 3, I-10123 Turin, Italy.						AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; AIRENTI G, 1998, P 6 C INT ASS DIAL A; Austin J. L., 1975, DO THINGS WORDS; Bara BG, 1999, BRAIN LANG, V68, P507, DOI 10.1006/brln.1999.2125; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Barkow J. H., 1992, ADAPTED MIND EVOLUTI; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BOSCO FM, 1998, P 20 ANN C COGN SCI; Bratman M.E., 1987, INTENTIONS PLANS PRA; BURLING R, 1993, CURR ANTHROPOL, V34, P25, DOI 10.1086/204132; Caplan D., 1992, LANGUAGE STRUCTURE P; Chomsky N., 1980, RULES REPRESENTATION; Churchland P.M., 1984, MATTER CONSCIOUSNESS; Churchland P.S., 1986, NEUROPHILOSOPHY UNIF; CHURCHLAND PM, 1988, BEHAV BRAIN SCI, V11, P507, DOI 10.1017/S0140525X00058647; Clark H. H., 1996, USING LANGUAGE; Clark Herbert H., 1981, ELEMENTS DISCOURSE U; CLEMENTS WA, 1994, COGNITIVE DEV, V9, P377, DOI 10.1016/0885-2014(94)90012-4; Cohen P. R., 1990, INTENTIONS COMMUNICA; COHEN PR, 1990, ARTIF INTELL, V42, P213, DOI 10.1016/0004-3702(90)90055-5; COSMIDES L, 1994, COGNITION, V50, P41, DOI 10.1016/0010-0277(94)90020-5; Cosmides L., 1994, MAPPING MIND DOMAIN; Davis A. G, 1985, ADULT APHASIA REHABI; DAVIS AG, 1981, LANGUAGE INTERVENTIO; DEBLESER R, 1986, PRAGMATICS ED; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; FEYEREISEN P, 1982, BRAIN LANG, V16, P191, DOI 10.1016/0093-934X(82)90083-9; Fodor J., 1975, LANGUAGE THOUGHT; Fodor J, 1983, MODULARITY MIND ESSA; FODOR JA, 1988, COGNITION, V28, P3, DOI 10.1016/0010-0277(88)90031-5; Foldi N.S., 1983, LANGUAGE FUNCTIONS B; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Grice H.P, 1989, STUDIES WAY WORDS; GRICE HP, 1957, PHILOS REV, V66, P377, DOI 10.2307/2182440; GRICE HP, 1982, MUTUAL KNOWLEDGE; GUILFORD AM, 1982, J COMMUN DISORD, V15, P337, DOI 10.1016/0021-9924(82)90001-6; Hirschfeld L, 1994, MAPPING MIND DOMAIN; HOLLAND AL, 1982, J SPEECH HEAR DISORD, V47, P50, DOI 10.1044/jshd.4701.50; Howard D., 1987, APHASIA THERAPY HIST; James W., 1890, PRINCIPLES PSYCHOL; JOANETTE Y, 1986, BRAIN LANG, V29, P81, DOI 10.1016/0093-934X(86)90035-0; JOANETTE Y, 1991, DISCOURSE ABILITY BR; Johnson-Laird P. N., 1983, MENTAL MODELS COGNIT; Karmiloff-Smith A, 1992, MODULARITY DEV PERSP; KASHER A, 1991, J PRAGMATICS, V16, P381, DOI 10.1016/0378-2166(91)90132-H; Kasher A., 1976, LANGUAGE FOCUS FDN M; KASHER A, 1991, CHOMSKYAN TURN; KASHER A, 1991, PRAGMATICS READER; Leslie A. M, 1994, MAPPING MIND DOMAIN; Marr D., 1982, VISION COMPUTATIONAL; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Minsky M., 1985, SOC MIND; Newell A., 1990, UNIFIED THEORIES COG; Newell A, 1972, HUMAN PROBLEM SOLVIN, V104; PENN C, 1988, BRAIN INJURY, V1, P3; Penn C., 1987, APHASIOLOGY, V1, P235, DOI [10.1080/02687038708248840, DOI 10.1080/02687038708248840]; Perner J, 1991, UNDERSTANDING REPRES; Pinker S., 1997, MIND WORKS; PLUM F, 1988, LANGUAGE COMMUNICATI; POLLACK ME, 1990, INTENTIONS COMMUNICA; PREMACK D, 1990, COGNITION, V36, P1, DOI 10.1016/0010-0277(90)90051-K; Premack D., 1986, GAVAGAI FUTURE HIST; RAO A, 1992, P KR 92 3 INT C KNOW; Schiffer S., 1972, MEANING; Searle J., 1992, REDISCOVERY MIND; Searle J., 1979, EXPRESSION MEANING; Searle J. R., 1969, SPEECH ACTS ESSAY PH, V626; Searle John, 1983, INTENTIONALITY ESSAY; SHERRATT SM, 1990, APHASIOLOGY, V4, P539, DOI 10.1080/02687039008248506; SPELKE E, 1994, COGNITION, V50, P431, DOI 10.1016/0010-0277(94)90039-6; STEMMER B, 1994, BRAIN LANG, V46, P565, DOI 10.1006/brln.1994.1031; Stich S.P., 1983, FOLK PSYCHOL COGNITI; STRAWSON PF, 1964, PHILOS REV, V73, P439, DOI 10.2307/2183301; TIRASSA M, 1999, BEHAV BRAIN SCI; TIRASSA M, 1997, P 2 EUR C COGN SCI M; TIRASSA M, IN PRESS SPATIAL COG; TIRASSA M, 1994, PSYCOLOQUY, V5; Trevarthen C., 1978, ACTION GESTURE SYMBO; Wellman H. M., 1990, CHILDS THEORY MIND; WEYLMAN ST, 1989, BRAIN LANG, V36, P362; WILCOX MJ, 1978, BRAIN LANG, V6, P362, DOI 10.1016/0093-934X(78)90069-X; Wilson D., 1995, RELEVANCE COMMUNICAT; WILSON D, 1991, PRAGMATICS READER; Winner E., 1977, BRAIN, V100, P719; WYCKOFF LH, 1984, THESIS U FLORIDA	87	27	29	0	0	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					419	441		10.1006/brln.1999.2121			23	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100004	10441187	Green Published			2021-06-18	
J	Zentner, J; Wolf, HK; Helmstaedter, C; Grunwald, T; Aliashkevich, AF; Wiestler, OD; Elger, CE; Schramm, J				Zentner, J; Wolf, HK; Helmstaedter, C; Grunwald, T; Aliashkevich, AF; Wiestler, OD; Elger, CE; Schramm, J			Clinical relevance of amygdala sclerosis in temporal lobe epilepsy	JOURNAL OF NEUROSURGERY			English	Article						corpus amygdaloideum; sclerosis; epilepsy; temporal lobe seizure	STATUS EPILEPTICUS; MEMORY IMPAIRMENT; EMOTIONAL MEMORY; VERBAL MEMORY; NEURON LOSS; HIPPOCAMPUS; LOBECTOMY; CONVULSIONS; RESECTION; DEFICITS	Object. The goal of this study was to define the incidence and clinical significance of amygdala sclerosis (AS) in patients with temporal lobe epilepsy (TLE). Methods. Surgical specimens of the lateral amygdaloid nucleus and the hippocampus excised from 71 patients who were treated for medically intractable TLE were quantitatively evaluated using a computer-assisted image-analysis system and compared with 10 normal autopsy specimens. Densities of neurons and reactive astrocytes in the patients with TLE were correlated with clinical, neuropsychological, and depth-electroencephalography data. The neuron counts of the lateral amygdaloid nucleus did not correlate with various presumed etiological factors of TLE including hereditary seizures, birth complications, febrile convulsions, traumatic brain injury, infections, seizure semiology, and epileptological outcome. However, patient age at surgery was significantly higher (mean difference 10 years) when AS was present, as compared with patients without AS (p < 0.01). Seizure origin, as determined by using amygdalohippocampal depth electrodes, did not correlate with the presence or absence of AS. Neuropsychologically, there was a significant correlation between the neuronal densities of the lateral amygdaloid nucleus and both preoperative visual recognition and postoperative deterioration of short-term verbal memory performance (p < 0.05). Conclusions. Except for the relatively long history of epilepsy, the presence of AS is not associated with specific clinical or electrocorticographic features of mesial TLE. However, patients without AS are particularly at risk for deterioration of short-term verbal memory following amygdalohippocampectomy.	Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany; Univ Bonn, Dept Epileptol, D-5300 Bonn, Germany; Univ Bonn, Dept Neuropathol, D-5300 Bonn, Germany	Zentner, J (corresponding author), Univ Freiburg Klinikum, Dept Neurosurg, Breisacherstr 64, D-79106 Freiburg, Germany.						AICARDI J, 1970, EPILEPSIA, V11, P187, DOI 10.1111/j.1528-1157.1970.tb03880.x; ANDERSEN R, 1978, NEUROPSYCHOLOGIA, V16, P439, DOI 10.1016/0028-3932(78)90067-2; BEHRENS E, 1994, ACTA NEUROCHIR, V128, P84, DOI 10.1007/BF01400656; BLUME WT, 1993, ANN NEUROL, V33, P105, DOI 10.1002/ana.410330118; Brockhaus H, 1940, J PSYCHOL NEUROL, V49, P1; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; CAHILL L, 1995, NATURE, V377, P295, DOI 10.1038/377295a0; CAVANAGH JB, 1958, TEMPORAL LOBE EPILEP, P140; CENDES F, 1994, BRAIN, V117, P739, DOI 10.1093/brain/117.4.739; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; DAM AM, 1980, EPILEPSIA, V21, P617, DOI 10.1111/j.1528-1157.1980.tb04315.x; EARLE KM, 1953, AMA ARCH NEUROL PSY, V69, P27, DOI 10.1001/archneurpsyc.1953.02320250033003; Elger CE, 1997, NEUROPSYCHOLOGIA, V35, P657, DOI 10.1016/S0028-3932(96)00110-8; Engel Jerome Jr., 1993, P609; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FEINDEL W, 1991, CAN J NEUROL SCI, V18, P603; GASTAUT H, 1959, EPILEPSIA, V1, P56, DOI 10.1111/j.1528-1157.1959.tb04249.x; GLOOR P, 1992, P505; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOLDRING S, 1992, J NEUROSURG, V77, P185, DOI 10.3171/jns.1992.77.2.0185; Helmstaedter C, 1990, Schweiz Arch Neurol Psychiatr (1985), V141, P21; HELMSTAEDTER C, 1991, CORTEX, V27, P547, DOI 10.1016/S0010-9452(13)80004-4; HOSOKAWA J, 1995, EPILEPSY RES, V20, P11, DOI 10.1016/0920-1211(94)00058-5; HUDSON LP, 1993, ANN NEUROL, V33, P622, DOI 10.1002/ana.410330611; JOOMA R, 1995, ACTA NEUROCHIR, V133, P44, DOI 10.1007/BF01404946; KESNER R P, 1992, P379; KIM HI, 1992, STEREOT FUNCT NEUROS, V58, P162, DOI 10.1159/000098990; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; LEE K, 1981, ACTA NEUROL SCAND, V63, P231; LEONARD G, 1991, CAN J NEUROL SCI, V18, P593, DOI 10.1017/S0317167100032777; MALAMUD N, 1958, TEMPORAL LOBE EPILEP, P149; MALDONADO HM, 1988, EPILEPSIA, V29, P420, DOI 10.1111/j.1528-1157.1988.tb03741.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MCINTYRE DC, 1982, BRAIN RES, V250, P53, DOI 10.1016/0006-8993(82)90952-0; MEENCKE HJ, 1992, EPILEPSY SURGERY, P705; MEYER A, 1955, J NEUROL NEUROSUR PS, V18, P24, DOI 10.1136/jnnp.18.1.24; MILLER LA, 1994, J NEUROL NEUROSUR PS, V57, P1099, DOI 10.1136/jnnp.57.9.1099; MORRELL F, 1987, SURGICAL TREATMENT E, P701; MURRAY EA, 1984, J NEUROSCI, V4, P2565; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NORMAN RM, 1958, TEMPORAL LOBE EPILEP, P20; OROURKE DM, 1993, NEUROSURGERY, V32, P574, DOI 10.1227/00006123-199304000-00013; Ounsted C., 1966, CLIN DEV MED, V22; PEINADOMANZANO MA, 1990, BEHAV BRAIN RES, V38, P117, DOI 10.1016/0166-4328(90)90010-C; Penfield W, 1954, EPILEPSY FUNCTIONAL; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; SANO K, 1953, AMA ARCH NEUROL PSY, V70, P40, DOI 10.1001/archneurpsyc.1953.02320310046003; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SAUNDERS RC, 1984, NEUROPSYCHOLOGIA, V22, P785, DOI 10.1016/0028-3932(84)90103-9; SOININEN HS, 1994, NEUROLOGY, V44, P1660, DOI 10.1212/WNL.44.9.1660; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; TRANEL D, 1990, ARCH NEUROL-CHICAGO, V47, P349, DOI 10.1001/archneur.1990.00530030131029; VanRoost D, 1995, STEREOT FUNCT NEUROS, V64, P101, DOI 10.1159/000098739; WIESER HG, 1988, EPILEPSIA S2, V29, P100; WIESER HG, 1983, ELECTROCLINICAL FEAT; WOLF HK, 1993, J NEUROPATH EXP NEUR, V52, P499, DOI 10.1097/00005072-199309000-00008; Wolf HK, 1997, ACTA NEUROPATHOL, V93, P606, DOI 10.1007/s004010050658; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15; ZENTNER J, 1995, J NEUROL NEUROSUR PS, V58, P666, DOI 10.1136/jnnp.58.6.666; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P1922	61	27	27	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1999	91	1					59	67		10.3171/jns.1999.91.1.0059			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	209PM	WOS:000081057000009	10389881				2021-06-18	
J	Bagley, LJ; Grossman, RI; Galetta, SL; Sinson, GP; Kotapka, M; McGowan, JC				Bagley, LJ; Grossman, RI; Galetta, SL; Sinson, GP; Kotapka, M; McGowan, JC			Characterization of white matter lesions in multiple sclerosis and traumatic brain injury as revealed by magnetization transfer contour plots	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							HEAD-INJURY; MICROSCOPIC DISEASE; TRANSFER CONTRAST; AXONAL INJURY; MR; IMAGES; BURDEN; MILD; MS	BACKGROUND AND PURPOSE: Magnetization transfer imaging provides information about the structural integrity of macromolecular substances, such as myelin, Our objective was to use this imaging technique and contour plotting to characterize and to define the extent of white matter lesions in multiple sclerosis and traumatic brain injury. METHODS: Magnetization transfer imaging was performed of 30 multiple sclerosis plaques and 10 traumatic white matter lesions. Magnetization transfer ratios (MTRs) were calculated for the lesions, for the normal- or abnormal-appearing surrounding white matter, and for remote normal-appearing white matter, MTR contour plots were constructed about these lesions. RESULTS: The contour plot appearance of MS plaques differed from that of traumatic white matter lesions, There was a gradual increase in MTR values at points at increasing distances from the center of the MS plaques; this was true for those lesions with and without surrounding T2 signal abnormality (halos), In contrast, there was an abrupt transition in MTR values between traumatic lesions and normal-appearing surrounding white matter, Additionally, the size of the MTR abnormality exceeded the size of the T2 signal abnormality for the MS plaques. CONCLUSION: MTR contour plots permit characterization and border definition of white matter lesions, Analysis of the contour plots suggests that MS is a centrifugal process with the lowest MTR within the center of the lesion. In contrast, traumatic white matter injuries are discrete lesions with abrupt transitions between the abnormal lesion and normal brain.	Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA	Bagley, LJ (corresponding author), Univ Penn, Med Ctr, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS34353] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS034353, R55NS034353, P50NS008803, P01NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALLEN IV, 1979, J NEUROL SCI, V41, P81, DOI 10.1016/0022-510X(79)90142-4; Allen IV, 1991, MCALPINES MULTIPLE S, P341; ANDERSON DW, 1992, ANN NEUROL, V31, P333, DOI 10.1002/ana.410310317; BAGLEY LJ, 1997, INT SOC MAGN RES MED; BAUMHEFNER RW, 1990, ARCH NEUROL-CHICAGO, V47, P19, DOI 10.1001/archneur.1990.00530010027014; BOORSTEIN JM, 1994, RADIOLOGY, V191, P799, DOI 10.1148/radiology.191.3.8184068; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FARBER M, 1994, SPORTS ILLUSTRATED, V81, P39; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; HUBER SJ, 1988, J NEUROL SCI, V86, P1, DOI 10.1016/0022-510X(88)90002-0; Kasner SE, 1997, NEUROLOGY, V48, P534, DOI 10.1212/WNL.48.2.534; Kato Y, 1997, AM J NEURORADIOL, V18, P1541; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; LOEVNER LA, 1995, AM J NEURORADIOL, V16, P1473; MCGOWAN JC, 1994, JMRI-J MAGN RESON IM, V4, P79; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; THOMPSON AJ, 1990, BMJ-BRIT MED J, V600, P631; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TRUYEN L, 1990, J NEUROL SCI, V96, P173, DOI 10.1016/0022-510X(90)90130-F; van Buchem MA, 1998, NEUROLOGY, V50, P1609, DOI 10.1212/WNL.50.6.1609; vanBuchem MA, 1997, AM J NEURORADIOL, V18, P1287; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	34	27	27	0	0	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JUN-JUL	1999	20	6					977	981					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	224WC	WOS:000081922100007	10445432				2021-06-18	
J	Bombardier, CH; Rimmele, CT				Bombardier, CH; Rimmele, CT			Motivational interviewing to prevent alcohol abuse after traumatic brain injury: A case series	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; DRINKERS; ISSUES	Objective: Our goal was to test motivational interviewing as a means of preventing return to alcohol abuse after traumatic brain injury.: Participants: Twelve of 15 inpatients (80%) who screened positive for alcoholism were approached about the study. Historical controls were 20 similar but untreated patients with follow-up data. Results: One-year outcome data were obtained on 9 participants (75%). Seventy-six percent were male and an average of 35 years old. Eighty-nine percent of participants and 55% of controls reported drinking no alcohol during atypical week at 1 year after discharge. Conclusion: Motivational interviewing is feasible during inpatient rehabilitation and may reduce drinking after traumatic brain injury. Controlled studies are needed.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Seattle Vet Affairs Med Ctr, Seattle, WA USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359740, Seattle, WA 98104 USA.	chb@u.washington.edu					Allen JP, 1997, J STUD ALCOHOL, V58, P7; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANTTIPOIKA I, 1988, ALCOHOL ALCOHOLISM, V23, P115; BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; BEIN T, 1992, ADDICTIONS, V88, P315; BOMBARDIER C, 1997, ARCH PHYSICAL MED RE, V7, P592; Bombardier CH, 1997, REHABIL PSYCHOL, V42, P259; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CHICK J, 1985, BRIT MED J, V290, P965, DOI 10.1136/bmj.290.6473.965; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FREEDLAND E, 1993, EMERGENCY MED CLIN N, V11, P255; HEATHER N, 1993, 19 U NEW S WAL NAT D; HUNT WA, 1971, J CLIN PSYCHOL, V27, P355; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; MCLELLAN AT, 1994, J CONSULT CLIN PSYCH, V62, P1141, DOI 10.1037/0022-006X.62.6.1141; Miller W., 1995, DRINKER INVENTORY CO; Miller W, 1992, PROJECT MATCH MONOGR; Miller W.R., 1984, MANUAL COMPREHENSIVE; MILLER WR, 1992, J STUD ALCOHOL, V53, P249, DOI 10.15288/jsa.1992.53.249; MILLER WR, 1991, BRIT J ADDICT, V86, P43; Miller WR, 1987, BRIEF DRINKER PROFIL; Miller WR, 1991, MOTIVATIONAL INTERVI; *NAT HEAD INJ FDN, 1988, SUBST AB TASK FORC W; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; SOBELL L, 1996, AM J PUBLIC HEALTH, V84, P966; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020	40	27	27	0	12	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FEB	1999	44	1					52	67		10.1037/0090-5550.44.1.52			16	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	178VP	WOS:000079290100005					2021-06-18	
J	Farmer, JE; Haut, JS; Williams, J; Kapila, C; Johnstone, B; Kirk, KS				Farmer, JE; Haut, JS; Williams, J; Kapila, C; Johnstone, B; Kirk, KS			Comprehensive assessment of memory functioning following traumatic brain injury in children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	103rd Annual Meeting of the American-Psychological-Association	AUG 11-15, 1995	NEW YORK, NEW YORK	Amer Psychol Assoc			CLOSED-HEAD-INJURY; ADOLESCENTS; SEQUELAE; COHORT	This study examined specific memory functions in 52 children with mild-moderate or severe traumatic brain injury (TBI) and 29 noninjured controls using the Wide Range Assessment of Memory and Learning (WRAML). Children's recall varied as a function of injury severity and task demands. The participants with severe brain injuries performed worse than controls on global measures of visual memory, learning, and general memory functioning, as well as on specific subtests measuring recall of contextual verbal information. Children with mild-moderate brain injuries performed similarly to controls except for poorer performance on 2 subtests measuring sound-symbol learning and recall of geometric designs. Results suggest that the WRAML provides clinically useful information and that specific aspects of memory processing need to be evaluated following childhood TBI.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65211 USA; W Virginia Univ, Hlth Sci Ctr, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA; Univ Arkansas Med Sci, Dept Pediat Psychol, Little Rock, AR 72205 USA	Farmer, JE (corresponding author), Rusk Rehabil Ctr, 501, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			ADAMS W, 1991, 11 ANN M NAT AC NEUR; AYLWARD GP, 1995, J PSYCHOEDUC ASSESS, V13, P132, DOI 10.1177/073428299501300203; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BEGALI V, 1992, HEAD INJURY CHILDREN; CALLAHAN TSA, 1993, 101ST ANN M AM PSYCH; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; Daniel WW, 1990, APPL NONPARAMETRIC S; Delis D, 1994, MANUAL CALIFORNIA VE; DENCKLA MB, 1994, ATYPICAL COGNITIVE D, P283; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1996, 24 ANN M INT NEUR SO; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; GIOIA G, 1991, 19 ANN M INT NEUR SO; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; HAUT JS, 1992, 12 ANN M NAT AC NEUR; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; Sheslow D., 1990, MANUAL WIDE RANGE AS; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS J, 1995, DEV NEUROPSYCHOL, V11, P201, DOI 10.1080/87565649509540613; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	40	27	28	0	1	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		1999	15	2					269	289		10.1080/87565649909540749			21	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	182YJ	WOS:000079525500006					2021-06-18	
J	Grady, MS; Cody, RF; Maris, DO; McCall, TD; Seckin, H; Sharar, SR; Winn, HR				Grady, MS; Cody, RF; Maris, DO; McCall, TD; Seckin, H; Sharar, SR; Winn, HR			P-selectin blockade following fluid-percussion injury: Behavioral and immunochemical sequelae	JOURNAL OF NEUROTRAUMA			English	Article						cell adhesion molecule; fluid-percussion injury; Morris water maze; neuroprotection; neutrophil migration; P-selectin; rats	TRAUMATIC BRAIN INJURY; ENDOTHELIAL ADHESION MOLECULES; CONTROLLED CORTICAL IMPACT; CLOSED HEAD-INJURY; NEUTROPHIL ACCUMULATION; REPERFUSION INJURY; CHOLINE-ACETYLTRANSFERASE; ISCHEMIA-REPERFUSION; RAT; DAMAGE	Traumatic brain injury (TBI) can cause polymorphonuclear leukocyte (PMN) migration into brain parenchyma, mediating various cytodestructive mechanisms. We examined the effect of blocking leukocyte/endothelial cell adhesion molecules (CAMs) on the anatomic and behavioral sequelae in lateral fluid-percussion injury in rats. Monoclonal antibodies (MAb) directed against a functional (PB1.3) or nonfunctional (PNB1.6) epitope on endothelial P-selectin were used as treatments. Subjects were tested in the Morris water maze (MWM) at 7 and 14 days postinjury then immunohistochemistry was performed using antibodies that recognize ChAT, GFAP and OX-42. A second set of animals underwent myeloperoxidase (MPO) assay in the brain parenchyma and a third set was used to examine neutrophil migration using the MAb RP-3. Time in quadrant, but not escape latency or proximity improved with PB1.3 (p < 0.05). Similarly, PB1.3 reduced MPO levels after injury (p < 0.05), in the ipsilateral cortex. No significant difference occurred in neutrophil counts in cortex, corpus callosum, hippocampus, and thalamus between injured only rats and injured rats treated with PB1.3. Quantitative analysis of cholinergic cells in the medial septum showed a protective effect by PB1.3. Densitometry readings of GFAP and OX-42 immunolabeling revealed no discernible differences between the treated and untreated injured rats. Qualitatively, there was no difference in microglia or astrocyte response to treatment. Treatment with P-selectin blockade in brain-injured rats may reduce PMN migration into brain, help preserve cholinergic immunolabeling of medial septal nucleus neurons, and may alleviate mnemonic deficits.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Anesthesia, Seattle, WA 98104 USA	Grady, MS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, 325 9th Ave,Box 359766, Seattle, WA 98104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 33107, P50 NS30305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305, R01NS033107] Funding Source: NIH RePORTER		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ALBELDA SM, 1994, FASEB J, V8, P504; ARSENIONUNES ML, 1973, ACTA NEUROPATHOL, V26, P329, DOI 10.1007/BF00688080; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHIANG J, 1968, AM J PATHOL, V52, P455; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cody R. F., 1995, Society for Neuroscience Abstracts, V21, P1731; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVENPECK KL, 1994, AM J PHYSIOL, V267, pH622; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Gibbs SAL, 1996, SURGERY, V119, P652, DOI 10.1016/S0039-6060(96)80189-9; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GRAMMAS P, 1993, FREE RADICAL BIO MED, V14, P553, DOI 10.1016/0891-5849(93)90113-9; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kochanek P M, 1993, Crit Care Med, V21, pS333, DOI 10.1097/00003246-199309001-00016; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; POBER JS, 1990, PHYSIOL REV, V70, P427; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SEEKAMP A, 1994, AM J PATHOL, V144, P592; SHARAR SR, 1993, J IMMUNOL, V151, P4982; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Soares HD, 1995, J NEUROSCI, V15, P8223; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Weiser MR, 1996, SHOCK, V5, P402, DOI 10.1097/00024382-199606000-00003; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WHALEN MJ, 1997, J CEREB BLOOD FLOW M, V17, pS77; WINN RK, 1994, AM J PHYSIOL-HEART C, V267, pH2391; WINN RK, 1993, J CLIN INVEST, V92, P2042, DOI 10.1172/JCI116799; ZIMMERMAN J, 1986, CRITICAL CARE STATE, P281	59	27	33	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	1999	16	1					13	25		10.1089/neu.1999.16.13			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	162BL	WOS:000078325300002	9989463				2021-06-18	
J	Nowell, SA; Leakey, JEA; Warren, JF; Lang, NP; Frame, LT				Nowell, SA; Leakey, JEA; Warren, JF; Lang, NP; Frame, LT			Identification of enzymes responsible for the metabolism of heme in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN INJURY; HUMAN-LIVER; RAT-BRAIN; UDP-GLUCURONOSYLTRANSFERASE; BILIVERDIN REDUCTASE; GILBERTS-SYNDROME; OXYGENASE-1 HO-1; CARBON-MONOXIDE; IN-VIVO; EXPRESSION	The major enzymes involved in the degradation of heme were identified in human platelets. It was determined that heme oxygenase activity levels in umbilical cord blood platelets were higher, whereas biliverdin reductase activity levels were comparable with that found in platelets from adults. In membranes prepared from adenosine diphosphate-activated platelets, UDP-glucuronic acid-dependent bilirubin conjugation was detected, whereas activity was negligible in unactivated platelets and undetected in serum and heat-inactivated platelets, and in platelets prepared from umbilical cord blood. Platelet fractions were analyzed by Western blot and shown to express heme oxygenase, biliverdin reductase, and UDP-glucuronosyltransferases, and there was concordance with known developmental profiles found in other tissues. Heme oxygenase expression was higher, whereas UGT expression was lower, in neonatal compared with adult platelets. These data suggest that platelets are involved in multiple steps of heme and bilirubin metabolism and that developmental regulation of these enzymes may be similar to that in other human tissues.	John L McClellan Mem Vet Affairs Med Ctr, Surg Serv 112LR, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Surg Oncol, Little Rock, AR 72205 USA; Natl Ctr Toxicol Res, Div Microbiol & Chem HFT230, Jefferson, AR 72079 USA; Reece Ctr, Inst Environm & Human Hlth, Lubbock, TX 79416 USA	Lang, NP (corresponding author), John L McClellan Mem Vet Affairs Med Ctr, Surg Serv 112LR, 4300 W 7th St, Little Rock, AR 72205 USA.				NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 55751, CA 58697] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 15722] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA055751, R01CA058697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG015722] Funding Source: NIH RePORTER		BISSELL DM, 1972, BLOOD-J HEMATOL, V40, P812, DOI 10.1182/blood.V40.6.812.812; Brown A. L., 1982, TOPICS LEARNING LEAR, V2, P1; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; CASTELLANI R, 1995, BRAIN RES, V696, P268, DOI 10.1016/0006-8993(95)00535-X; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; COUGHTRIE MWH, 1986, ANAL BIOCHEM, V159, P198, DOI 10.1016/0003-2697(86)90328-3; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; Hume R, 1996, BLOOD, V87, P762, DOI 10.1182/blood.V87.2.762.bloodjournal872762; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; LANDAW SA, 1970, J CLIN INVEST, V49, P914, DOI 10.1172/JCI106311; LIN JHC, 1989, ARCH BIOCHEM BIOPHYS, V270, P623, DOI 10.1016/0003-9861(89)90545-6; LINCOLN BC, 1988, ANAL BIOCHEM, V170, P485, DOI 10.1016/0003-2697(88)90662-8; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1992, CLIN APPL FUNCTIONS; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MILLS DCB, 1968, J PHYSIOL-LONDON, V195, P715, DOI 10.1113/jphysiol.1968.sp008484; MORI H, 1991, JPN J CANCER RES, V82, P755, DOI 10.1111/j.1349-7006.1991.tb02698.x; NEUZIL J, 1993, FEBS LETT, V331, P281, DOI 10.1016/0014-5793(93)80353-V; NOWELL S, 1997, 8 N AM ISSX M HILT H, P92; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; PIMSTONE NR, 1971, J CLIN INVEST, V50, P1264; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; RITTER JK, 1991, J BIOL CHEM, V266, P1043; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; Tiribelli C, 1996, HEPATOLOGY, V24, P1296; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vallis KA, 1996, CARCINOGENESIS, V17, P649, DOI 10.1093/carcin/17.4.649; VANROY FP, 1971, CLIN CHIM ACTA, V31, P109, DOI 10.1016/0009-8981(71)90367-6; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WALTERS MI, 1970, MICROCHEM J, V15, P231, DOI 10.1016/0026-265X(70)90045-7; WEBER CM, 1994, J NEUROCHEM, V63, P953; WILLIAMS M, 1994, BBA-LIPID LIPID MET, V1211, P310, DOI 10.1016/0005-2760(94)90155-4; WISHART GJ, 1978, BIOCHEM J, V174, P485, DOI 10.1042/bj1740485; Wu TW, 1994, LIFE SCI, V54, pP477	44	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33342	33346		10.1074/jbc.273.50.33342			5	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	146YY	WOS:000077462500038	9837908	Other Gold			2021-06-18	
J	Schreiber, S; Klag, E; Gross, Y; Segman, RH; Pick, CG				Schreiber, S; Klag, E; Gross, Y; Segman, RH; Pick, CG			Beneficial effect of risperidone on sleep disturbance and psychosis following traumatic brain injury	INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY			English	Article						psychosis; risperidone; sleep disturbances; traumatic brain injury		Severe disturbances of sleep architecture and circadian rhythms are common in traumatic brain injured patients; however, complete absence of the rapid eye movement sleep stage is very rare. We describe a brain injured patient with cognitive disturbances who developed severe alterations of sleep architecture, accompanied by paranoid and jealousy delusions. Following several trials with conventional antipsychotics his psychotic state stabilized but he continued to complain of insomnia and daytime fatigue. When treated with risperidone 2 mg/day, both his sleep and the delusional thoughts improved markedly and his daytime alertness increased. Severe deterioration of his support system brought about discontinuation of treatment with re-emergence of all symptoms. Int Clin Psychopharmacol 13:273-275 (C) 1998 Lippincott Williams & Wilkins.	Chaim Sheba Med Ctr, Dept Psychiat C, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; Neuropsychol Unit Treatment & Rehabil, Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; Hadassah Hebrew Univ Med Ctr, Dept Psychiat, Jerusalem, Israel	Schreiber, S (corresponding author), Chaim Sheba Med Ctr, Dept Psychiat C, IL-52621 Tel Hashomer, Israel.		Schreiber, Shaul/E-5821-2010; Pick, Chaim/D-4789-2009; Sanguansri, Luz/B-6630-2011	Schreiber, Shaul/0000-0002-2189-0693; Sanguansri, Luz/0000-0003-1908-7604			ALDRICH MS, 1993, J PSYCHOSOM RES, V37, P3, DOI 10.1016/0022-3999(93)90022-8; CRICK F, 1983, NATURE, V304, P111, DOI 10.1038/304111a0; FADDA P, 1993, PROG NEURO-PSYCHOPH, V17, P269, DOI 10.1016/0278-5846(93)90047-V; JACOBSEN FM, 1995, J CLIN PSYCHIAT, V56, P423; JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685; LAVIE P, 1984, NEUROLOGY, V34, P118, DOI 10.1212/WNL.34.1.118; Mahowald Mark W., 1996, P285; Schreiber S, 1997, NEUROSCI LETT, V228, P25, DOI 10.1016/S0304-3940(97)00345-5; SCHREIBER S, 1997, J NEUROPSYCHIAT, V9, P640; Staedt J, 1996, EUR ARCH PSY CLIN N, V246, P305, DOI 10.1007/BF02189023; WAUQUIER A, 1985, SLEEP NEUROTRANSMITT	11	27	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0268-1315			INT CLIN PSYCHOPHARM	Int. Clin. Psychopharmacol.	NOV	1998	13	6					273	275		10.1097/00004850-199811000-00006			3	Pharmacology & Pharmacy; Psychiatry	Pharmacology & Pharmacy; Psychiatry	146HW	WOS:000077424100006	9861578				2021-06-18	
J	Nagurney, JT; Borczuk, P; Thomas, SH				Nagurney, JT; Borczuk, P; Thomas, SH			Elder patients with closed head trauma: A comparison with nonelder patients	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 19-22, 1997	WASHINGTON, D.C.	Soc Acad Emergency Med		geriatrics; aged; accidents; neurosurgery; head injuries, closed; trauma	COMPUTED-TOMOGRAPHY; BRAIN INJURY	Objective: Little is known about the circumstances surrounding closed head trauma (CHT) in elders, and how they differ from nonelders. The study objective was to compare the 2 populations for outcome (positive cranial CT scan depicting traumatic injury, or the need for neurosurgery), mechanism of injury, and the value of the neurologic examination to predict a CT scan positive for traumatic injury or the need for neurosurgical intervention. Methods: A retrospective study was conducted by collecting a case series of patients with blunt head trauma who underwent CT scanning, and comparing elder (aged greater than or equal to 60 years) with nonelder patients. The setting was the ED of a university-affiliated Level-1 trauma center. Results: Twenty percent of the elders and 13% of the nonelders had CT scans positive for traumatic injury, which conferred a risk ratio of 1.58 (95% CI 1.21-2.05). Older women were more at risk for the need for neurosurgery than were younger ones (3.1 vs 0.3%, RR 10.66, 95% CI 1.26-90.46). Among the elders, falls were the dominant mechanism of closed head trauma, followed by motor vehicle collisions (MVCs), then being struck as a pedestrian. In the nonelders, MVCs, falls, and assaults were the most important mechanisms of injury. A focally abnormal neurologic examination imparted an increased risk for both a CT scan positive for traumatic injury (elder 4.39, 95% CI 2.91-6.62; nonelder 7.75, 95% CI 5.53-10.72) and the need for neurosurgery (elder 35.68, 95% CI 4.58-275.89; nonelder 142.58, 95% CI 19.11-1064.22) in both age groups. Conclusions: Significant differences exist between elder and nonelder victims of CHT with respect to mechanisms of trauma and outcomes (CT scan positive for traumatic injury, or the need for neurosurgery).	Massachusetts Gen Hosp, Clin 117, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Nagurney, JT (corresponding author), Massachusetts Gen Hosp, Clin 117, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA.	nagurney.john@mgh.harvard.edu					Baker SP, 1992, THE INJURY FACT BOOK; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOSENTHAL AC, 1995, J TRAUMA, V38, P753, DOI 10.1097/00005373-199505000-00013; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SPAITE DW, 1990, ANN EMERG MED, V19, P1418, DOI 10.1016/S0196-0644(05)82611-3; WEST JG, 1988, TRAUMA	17	27	27	0	1	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUL	1998	5	7					678	684		10.1111/j.1553-2712.1998.tb02485.x			7	Emergency Medicine	Emergency Medicine	100KJ	WOS:000074815100006	9678391				2021-06-18	
J	Stahel, PF; Kossmann, T; Joller, H; Trentz, O; Morganti-Kossmann, MC				Stahel, PF; Kossmann, T; Joller, H; Trentz, O; Morganti-Kossmann, MC			Increased interleukin-12 levels in human cerebrospinal fluid following severe head trauma	NEUROSCIENCE LETTERS			English	Article						cytokines; interleukin-12; traumatic brain injury; blood-brain barrier	CYTOKINE; THERAPY; DISEASE	An overwhelming intracranial inflammatory response occurs as a consequence of severe head trauma, leading to cerebral edema and secondary brain injury. Cytokines are important mediators of post-traumatic cerebral inflammation. In the present study, levels of interleukin-12 (IL-12), a pro-inflammatory cytokine which activates cellular immune response mechanisms, were measured by ELISA in 140 matched serum and ventricular cerebrospinal fluid (CSF) samples from ten patients with severe traumatic brain injury. The mean IL-12 CSF levels were significantly elevated in all patients in the course of 14 days after trauma, compared to CSF samples from 15 control patients. Assessment of the IL-12 CSF/serum ratio and of the blood-brain barrier function, using the CSF/serum albumin ratio, suggest that elevated IL-12 CSF levels might be in part derived from intracerebral cytokine synthesis. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.	Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med, Clin Immunol Sect, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland	Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			Aloisi F, 1997, J IMMUNOL, V159, P1604; Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; CLEMONS KV, 1994, ANTIMICROB AGENTS CH, V38, P460, DOI 10.1128/AAC.38.3.460; Constantinescu CS, 1996, ANN NY ACAD SCI, V795, P328, DOI 10.1111/j.1749-6632.1996.tb52684.x; Drulovic J, 1997, J NEUROL SCI, V147, P145, DOI 10.1016/S0022-510X(96)05320-8; Guery JC, 1997, EUR J IMMUNOL, V27, P1632, DOI 10.1002/eji.1830270707; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KOCHANEK PM, 1997, BRAIN DAMAGE 2 HEMOR, P197; Kornelisse RF, 1997, INFECT IMMUN, V65, P877, DOI 10.1128/IAI.65.3.877-881.1997; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Leonard JP, 1997, CRIT REV IMMUNOL, V17, P545; Mastroianni CM, 1997, CLIN IMMUNOL IMMUNOP, V84, P171, DOI 10.1006/clin.1997.4367; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Park JH, 1996, BIOCHEM BIOPH RES CO, V224, P391, DOI 10.1006/bbrc.1996.1038; Reiss CS, 1996, ANN NY ACAD SCI, V795, P257, DOI 10.1111/j.1749-6632.1996.tb52675.x; Stalder AK, 1997, J IMMUNOL, V159, P1344; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; WINDHAGEN A, 1995, J EXP MED, V182, P1986	20	27	30	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 19	1998	249	2-3					123	126		10.1016/S0304-3940(98)00410-8			4	Neurosciences	Neurosciences & Neurology	ZZ591	WOS:000074745500014	9682832				2021-06-18	
J	Hogg, S; Sanger, DJ; Moser, PC				Hogg, S; Sanger, DJ; Moser, PC			Mild traumatic lesion of the right parietal cortex in the rat: Characterisation of a conditioned freezing deficit and its reversal by dizocilpine	BEHAVIOURAL BRAIN RESEARCH			English	Article						cerebral trauma; context; conditioned emotional response; dizocilpine; MK-801	CLOSED-HEAD-INJURY; PERCUSSION BRAIN INJURY; CONTEXTUAL FEAR; BILATERAL LESIONS; HIPPOCAMPUS; INFORMATION; IMPAIRMENT; ATTENTION; AMYGDALA; MEMORY	We have previously demonstrated that traumatic injury of the lateral aspect of the right parietal cortex results in reduced acquisition of the passive avoidance task but enhanced learning in an active avoidance procedure. In order to try to explain the apparent dichotomy between these findings a series of experiments examined the effect of fluid percussion-induced traumatic brain injury (FP-TBI) on the conditioned freezing response to a context previously paired with an aversive stimulus. Rats subjected to FP-TBI displayed less conditioned freezing than the sham-operated controls. This effect was particularly marked when the delay between context exposure and footshock was short (less than or equal to 30 s) and was no longer significant when this delay was 3 min, indicating that the injured animals did not have an impaired freezing response per se. This phenomenon was enduring such that it could still be observed 2 months following the surgery. There was no significant freezing deficit after FP-TBI of the motor cortex, demonstrating that the site of injury is important and that the freezing deficit is not a general response to CNS trauma. The NMDA receptor antagonist dizocilpine (MK-801: 1 mg/kg i.v.) significantly reduced the trauma-induced freezing deficit when administered as a single bolus 15 min prior to the surgery, or as three repeated treatments (3 x 0.33 mg/kg) 15 min, and 6 and 24 h following lesion. The trauma-induced deficit in conditioned freezing can explain the differences in active and passive avoidance behaviours and appears to be specific to lesion of the lateral parietal cortex. In addition, the behavioural deficit can be attenuated using the neuroprotective agent dizocilpine, suggesting that it may prove useful as a sensitive and specific measure of cortical damage following traumatic injury. (C) 1998 Elsevier Science B.V. All rights reserved.	Synthelabo Rech, F-92500 Rueil Malmaison, France; Synthelabo Rech, F-92220 Bagneux, France	Moser, PC (corresponding author), Synthelabo Rech, 10 Rue Carrieres, F-92500 Rueil Malmaison, France.			Moser, Paul/0000-0002-6887-3508			BEVINS RA, 1995, ANIM LEARN BEHAV, V23, P400, DOI 10.3758/BF03198940; BLANCHARD RJ, 1976, B PSYCHONOMIC SOC, V8, P129, DOI 10.3758/BF03335103; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; CORODIMAS KP, 1995, BEHAV NEUROSCI, V109, P613, DOI 10.1037/0735-7044.109.4.613; CROWNE DP, 1987, BEHAV NEUROSCI, V101, P134, DOI 10.1037/0735-7044.101.1.134; CROWNE DP, 1992, BEHAV NEUROSCI, V106, P808, DOI 10.1037/0735-7044.106.5.808; CROWNE DP, 1986, BEHAV BRAIN RES, V22, P227, DOI 10.1016/0166-4328(86)90067-7; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DRISCOLL P, 1983, GENETICS BRAIN, P95; FANSELOW MS, 1990, ANIM LEARN BEHAV, V18, P264, DOI 10.3758/BF03205285; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853; Frysztak RJ, 1991, CEREB CORTEX, V1, P418, DOI 10.1093/cercor/1.5.418; GOOD M, 1991, BEHAV NEUROSCI, V105, P499, DOI 10.1037/0735-7044.105.4.499; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HIRAKAWA M, 1994, STROKE, V25, P2471, DOI 10.1161/01.STR.25.12.2471; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; HOGG S, 1997, BEHAV BRAIN RES; Holm Soren, 1993, Acta Neurobiologiae Experimentalis (Warsaw), V53, P569; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KIERNAN MJ, 1993, Q J EXP PSYCHOL-B, V46, P271, DOI 10.1080/14640749308401089; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KING VR, 1992, BEHAV BRAIN RES, V50, P53; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; LANDEIRAFERNANDEZ J, 1995, ANIM LEARN BEHAV, V23, P335, DOI 10.3758/BF03198930; LEDOUX JE, 1988, J NEUROSCI, V8, P2517; LORENZINI CA, 1991, PHYSIOL BEHAV, V49, P765, DOI 10.1016/0031-9384(91)90316-G; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MAIER SE, 1993, BEHAV BRAIN RES, V56, P31, DOI 10.1016/0166-4328(93)90020-Q; McINTOSH T., 1988, NEUROL NEUR, P653; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Miller E, 1970, Cortex, V6, P121; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PETERSEN SE, 1989, EXP BRAIN RES, V76, P267; PHILLIPS RG, 1994, LEARN MEMORY, V1, P34; PHILLIPS RG, 1995, J NEUROSCI, V15, P5308; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; POLSTER MR, 1994, CORTEX, V30, P487, DOI 10.1016/S0010-9452(13)80344-9; POSNER MI, 1984, J NEUROSCI, V4, P1863; RAPCSAK SZ, 1994, CORTEX, V30, P565, DOI 10.1016/S0010-9452(13)80236-5; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STOEHR JD, 1995, PSYCHOBIOLOGY, V23, P173; Tortella FC, 1996, NEUROPHARMACOLOGY, V35, P441, DOI 10.1016/0028-3908(95)00190-5; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; UEKI A, 1994, J NEUROL SCI, V125, P14, DOI 10.1016/0022-510X(94)90236-4; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; WILSON A, 1995, BEHAV NEUROSCI, V109, P828, DOI 10.1037/0735-7044.109.5.828; Yamaguchi T, 1996, NEUROPHARMACOLOGY, V35, P329, DOI 10.1016/0028-3908(95)00171-9	56	27	31	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN	1998	93	1-2					157	165		10.1016/S0166-4328(97)00145-9			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	ZX806	WOS:000074557300017	9659997				2021-06-18	
J	Li, XS; Williams, M; Bartlett, WP				Li, XS; Williams, M; Bartlett, WP			Induction of IGF-1 mRNA expression following traumatic injury to the postnatal brain	MOLECULAR BRAIN RESEARCH			English	Article						brain injury; IGF-1; mRNA; astrogliosis	GROWTH-FACTOR-I; MESSENGER RIBONUCLEIC-ACID; CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; SKELETAL-MUSCLE; RAT-BRAIN; RNA; ASTROCYTES; HIPPOCAMPUS; PROTEIN	A variety of adult, non-neural tissues respond to injury by increasing expression of the gene which encodes for insulin-like growth factor-1 (IGF-1). This response is thought to be a key component in the regenerative capacity of these tissues. In contrast, the central nervous system (CNS) has relatively little regenerative capacity following injury. interestingly, compared to many non-neuronal tissues, little IGF-1 mRNA can be detected in the adult CNS, raising the possibility that its lack of regenerative capacity is related its relative lack of IGF-1 expression. However, in the 2-week-old adolescent CNS IGF-1 mRNA can be detected in numerous brain regions. Therefore, the purpose of this study was to determine the responsiveness of the IGF-1 gene to injury in adolescent CNS tissue, a period in which expression of this gene is relatively abundant. Expression of IGF-1 mRNA was measured by means of a sensitive solution hybridization/RNase protection assay in the parieto-occipital lobes of 2-week-old and adult mice following penetrating injury. Levels of IGF-1 transcript in the injured brains were significantly increased above those of controls in both 2-week-old and adult brains 3-day post injury and remained elevated for 1 week after injury. These observations demonstrate that the adult CNS, like other tissues, can respond to injury by increasing expression of IGF-1 mRNA. (C) 1998 Elsevier Science B.V. All rights reserved.	Texas Womans Univ, Sch Phys Therapy, Houston, TX 77030 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Anat & Neurosci, Hershey, PA 17033 USA	Bartlett, WP (corresponding author), Texas Womans Univ, Sch Phys Therapy, 1130 MD Anderson Blvd, Houston, TX 77030 USA.						AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; BACH M A, 1991, Molecular Brain Research, V10, P43, DOI 10.1016/0169-328X(91)90054-2; BARONVANEVERCOO.A, 1991, J NEUROL RES, V28, P24; BARTLETT WP, 1992, MOL BRAIN RES, V12, P285, DOI 10.1016/0169-328X(92)90131-T; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; BONDY CA, 1991, J NEUROSCI, V11, P3442; Breese CR, 1996, J COMP NEUROL, V369, P388; BURGESS SK, 1987, J BIOL CHEM, V262, P1618; CHEN H, 1993, J NEUROL SCI, V118, P109, DOI 10.1016/0022-510X(93)90099-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1992, PATHOPHYSIOL MECH; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Del Rio-Hortega P, 1927, B JOHNS HOPKINS HOSP, V41, P278; EDWALL D, 1989, ENDOCRINOLOGY, V124, P820, DOI 10.1210/endo-124-2-820; Eng LF, 1987, PROG BRAIN RES <D>, V71, P439; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HAN VKM, 1987, J NEUROSCI, V7, P501; HANSSON HA, 1986, ACTA PHYSIOL SCAND, V126, P609, DOI 10.1111/j.1748-1716.1986.tb07862.x; HANSSON HA, 1987, CELL TISSUE RES, V250, P499; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V129, P9, DOI 10.1111/j.1748-1716.1987.tb08034.x; KANJE M, 1989, BRAIN RES, V486, P36; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LENOIR D, 1983, DEV BRAIN RES, V7, P205, DOI 10.1016/0165-3806(83)90177-3; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LINDSAY RM, 1986, ASTROCYTES, V2, P226; LUDWIN SK, 1985, LAB INVEST, V52, P20; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PHILIPPS AF, 1988, PEDIATR RES, V23, P298, DOI 10.1203/00006450-198803000-00014; RUSSELL WE, 1985, AM J PHYSIOL, V248, P618; SHEMER J, 1987, J BIOL CHEM, V262, P7698; SJOBERG J, 1989, BRAIN RES, V485, P102, DOI 10.1016/0006-8993(89)90671-9; SMITH FE, 1991, P NATL ACAD SCI USA, V88, P6152, DOI 10.1073/pnas.88.14.6152; SUMI SM, 1968, ACTA NEUROPATHOL, V10, P324, DOI 10.1007/BF00690707; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; YAMAGUCHI F, 1991, NEUROSCI LETT, V128, P273, DOI 10.1016/0304-3940(91)90278-2	40	27	27	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUN 1	1998	57	1					92	96		10.1016/S0169-328X(98)00075-8			5	Neurosciences	Neurosciences & Neurology	ZW068	WOS:000074370700011	9630538				2021-06-18	
J	Snow, P; Douglas, J; Ponsford, J				Snow, P; Douglas, J; Ponsford, J			Procedural discourse following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; AMNESIA; ABILITY; ADULTS	Procedural discourse is a monologue discourse task concerned with explaining to a listener how a particular activity is carried out. The study reported here is part of a series of investigations into discourse abilities following severe traumatic brain injury (TBI). The aim of this study was to compare the procedural discourse skills of a group of 26 TBI speakers, with those of two demographically distinct control groups. The first control group comprised 26 non-TBI orthopaedic patients, and the second control group comprised 26 university students. These control groups were selected because of the hypothesis that premorbid demographic factors could influence sociolinguistic skills, and hence performance on a procedural discourse task. The TBI group was systematically compared with the control groups on content, productivity, and pragmatic measures. They were not significantly different from orthopaedic patients on measures relating to content and productivity; however, they did differ significantly from the university students on these measures. The TBI group differed significantly from both control groups with respect to the production of pragmatic errors, and these were predominantly concerned with information transfer. The results are discussed in relation to issues in selecting control groups for discourse research following TBI, together with the clinical implications of the findings.	LA TROBE UNIV,MELBOURNE,VIC,AUSTRALIA; BETHESDA HOSP,MELBOURNE,VIC,AUSTRALIA			Douglas, Jacinta M/C-2380-2009	Snow, Pamela/0000-0002-2426-8349; Douglas, Jacinta/0000-0003-0940-6624			ANDERSON DW, 1980, J NEUROSURGERY S, V53; BAYLES C, 1994, LANGUAGE INTERVENTIO, P535; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CANNITO M P, 1988, Seminars in Speech and Language, V9, P117, DOI 10.1055/s-0028-1082459; COEHLO CA, 1994, DISCOURSE ANAL APPL, P95; COEHLO CA, 1991, ARCH PHYSICAL MED RE, V72, P465; COEHLO CA, 1991, BRAIN INJURY, V5, P381; COEHLO CA, 1996, J SPEECH HEARING S 1, V39, pS5; COEHLO CA, 1995, APHASIOLOGY, V9, P409; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Damico JS, 1985, COMMUNICATION SKILLS, P165; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HAGEN C, 1981, TOPICS LANGUAGE  SEP, P73; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HUDSON RA, 1980, SOCIOLINGUISTICS; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V18, P69; KEPPELL G, 1991, DESIGN ANAL RES HDB; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LINSCOTT RJ, 1996, BRAIN INJURY, V10, P3987; Loban W., 1963, 1 NCTE; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Patry R., 1990, DISCOURSE ABILITY BR, P3, DOI 10.1007/978-1-4612-3262-9_1; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Rimel RW, 1990, REHABILITATION ADULT, P8; Ruff R, 1991, COGNITIVE REHABILITA, P23; Shadden B.B., 1991, CLIN APHASIOLOGY, V20, P327; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1997, BRAIN INJURY, V11, P409; SNOW P, 1995, TRAUMATIC BRAIN INJU, P137; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; ULATOWSKA H, 1981, CLIN APHASIOLOGY C P, V17, P75; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; ULATOWSKA HK, 1983, BRAIN LANG, V18, P315, DOI 10.1016/0093-934X(83)90023-8; ULATOWSKA HK, 1988, NEUROPSYCHOLOGICAL S, P108	45	27	27	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	OCT	1997	11	10					947	967		10.1080/02687039708249421			21	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	XY420	WOS:A1997XY42000002					2021-06-18	
J	Ashley, MJ; Persel, CS; Clark, MC; Krych, DK				Ashley, MJ; Persel, CS; Clark, MC; Krych, DK			Long-term follow-up of post-acute traumatic brain injury rehabilitation: A statistical analysis to test for stability and predictability of outcome	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; RECOVERY; TELEPHONE; IMPACT; RETURN; WORK; AGE	A high percentage of the estimated 500 000 traumatic brain injuries (TBI) in the US every year occur with young people who will face many years of neurobehavioral and economic consequences. This study examined the long-term stability of outcome after post-acute TBI rehabilitation and possible predictors of long-term outcome based on a 127-item survey of 332 clients up to 14 years post-discharge. Correlational, factor, and multiple regression analysis indicated positive long-term outcome stability following rehabilitation with the exception of vocational status, which decreased over the same time period. A number of possible explanations for this occupational anomaly are suggested. Rating scale scores and latency-to-rehabilitation proved to be better predictors of long-term outcome than demographic data.	CTR NEUROSKILLS,DEPT RES & DEV,BAKERSFIELD,CA 93306; KERN REG CTR DEV DISABLED,BAKERSFIELD,CA; CTR NEUROSKILLS,IRVING,TX							Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Arokiasamy C V, 1994, NeuroRehabilitation, V4, P45, DOI 10.3233/NRE-1994-4107; Ashley M. J., 1993, J HEAD TRAUMA REHAB, V8, P30; BELLINI J, 1995, REHABIL COUNS BULL, V39, P151; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; CRISP R, 1992, J REHABIL, V58, P27; DELEEUW E, 1988, TELEPHONE SURVERY ME; DEVANEY CW, 1991, J HEAD TRAUMA REHAB, V6, P59; EISENBERG H, 1991, J NEUROSURG, V75, pS1; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KORNERBITENSKY N, 1994, ARCH PHYS MED REHAB, V75, P1287; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NARINS P, 1995, KEYWORDS, V56, P6; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Sale P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, 10.1097/00001199-199109000-00004.]; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SIEMIATYCKI J, 1979, AM J PUBLIC HEALTH, V69, P238, DOI 10.2105/AJPH.69.3.238; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Webb C, 1996, BRAIN INJURY, V10, P303, DOI 10.1080/026990596124476	32	27	30	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					677	690					14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600006	9376835				2021-06-18	
J	Isaksson, J; Lewen, A; Hillered, L; Olsson, Y				Isaksson, J; Lewen, A; Hillered, L; Olsson, Y			Up-regulation of intercellular adhesion molecule 1 in cerebral microvessels after cortical contusion trauma in a rat model	ACTA NEUROPATHOLOGICA			English	Article						intercellular adhesion molecule 1; immunohistochemistry; rat; brain; trauma	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; BRAIN INJURY; LEUKOCYTE ADHESION; ARTERY OCCLUSION; ISCHEMIC-INJURY; CELL-ADHESION; BLOOD-FLOW; EXPRESSION; ICAM-1	A study was made on the expression of the intercellular adhesion molecule 1 (ICAM-1) in cerebral microvessels after cortical contusion trauma of the rat brain. The trauma was produced by a free-falling weight on the exposed dura of one fronto-parietal lobe. Immunohistochemistry was done on cryostat sections using a monoclonal antibody and the reaction product was visualized using the avidin-biotin-peroxidase complex method. Control and sham-operated rats showed immunostaining of some penetrating arteries of the cerebral cortex, the epithelial cells of the choroid plexus and occasional microvessels of the brain parenchyma. The same pattern of immunostaining was seen in rats that were subjected to trauma and killed after 30 min. All rats with contusion trauma that were allowed to survive for 6-72 h showed a substantial increase in the number of immunostained capillaries throughout the site of the lesion. The ipsilateral hippocampus showed a mild to moderate increase in the number of immunostained microvascular profiles. This phenomenon was also present in the lateral thalamus of some rats. The staining was seen as an uninterrupted line at the position of the endothelial cells, indicating an upregulation of this adhesion molecule after brain trauma. Up-regulation of ICAM-1 is a well-known phenomenon in inflammatory and ischemic lesions of the brain but has not previously been described in detail in traumatic brain injury. ICAM-1 may be involved in the production of several post-traumatic events such as leukocyte adhesion, microcirculatory disturbances and edema formation.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN	Isaksson, J (corresponding author), UNIV UPPSALA HOSP,NEUROPATHOL LAB,S-75185 UPPSALA,SWEDEN.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Carlos T. M., 1995, Journal of Neurotrauma, V12, P458; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; DECKERTSCHLUTER M, 1994, J NEUROPATH EXP NEUR, V53, P457, DOI 10.1097/00005072-199409000-00005; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1995, BRAIN PATHOL, V5, P395; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; KUROSE I, 1994, CIRC RES, V74, P336, DOI 10.1161/01.RES.74.2.336; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LINDSBERG PJ, 1995, J CEREB BLOOD FLOW M, V15, pS681; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOBEL RA, 1990, AM J PATHOL, V136, P1309; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; WASHINGTON R, 1994, ANN NEUROL, V35, P89, DOI 10.1002/ana.410350114; WILCOX CE, 1990, J NEUROIMMUNOL, V30, P43, DOI 10.1016/0165-5728(90)90051-N; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	34	27	31	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JUL	1997	94	1					16	20		10.1007/s004010050666			5	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	XG013	WOS:A1997XG01300003	9224525				2021-06-18	
J	VanderSchaaf, PJ; Kriel, RL; Krach, LE; Luxenberg, MG				VanderSchaaf, PJ; Kriel, RL; Krach, LE; Luxenberg, MG			Late improvements in mobility after acquired brain injuries in children	PEDIATRIC NEUROLOGY			English	Article							PROLONGED UNCONSCIOUSNESS; COHORT	The purpose of this investigation was to describe the late improvements in functional mobility in children who have sustained severe acquired anoxic or traumatic brain injuries, Ninety-eight children from a consecutive series of 199 with acquired brain injuries met inclusion criteria, As expected, children with traumatic injuries had better mobility at time of discharge from rehabilitation than did children with anoxic injury, In addition, children with traumatic injuries improved more in mobility status during the first 2 years after injury than did children with anoxic injury, The children who continued to improve in mobility after discharge were unconscious for a shorter time, Children who became community ambulators during the first year after discharge had higher mobility ratings at discharge, Although children who eventually achieved more functional mobility were admitted to rehabilitation service sooner after injury, discriminant analysis revealed that the duration of unconsciousness, and therefore severity of injury, was more closely correlated with the final mobility status. (C) 1997 by Elsevier Science Inc. All rights reserved.	HENNEPIN CTY MED CTR 867B,MINNEAPOLIS,MN 55415; GILLETTE CHILDRENS SPECIALTY HEALTHCARE,DEPT REHABIL,ST PAUL,MN; GILLETTE CHILDRENS SPECIALTY HEALTHCARE,DEPT NEUROL,ST PAUL,MN; GILLETTE CHILDRENS SPECIALTY HEALTHCARE,DEPT PEDIAT,ST PAUL,MN; HENNEPIN CTY MED CTR,ST PAUL,MN							BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1993, PEDIATR NEUROL, V9, P362, DOI 10.1016/0887-8994(93)90104-K; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; KRIEL RL, 1994, PEDIATR NEUROL, V10, P207, DOI 10.1016/0887-8994(94)90024-8; Kriel RL, 1995, J NEUROL REHABIL, V9, P145; KRIEL RL, 1989, PEDIATR NEUROL, V25, P296; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201	12	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	MAY	1997	16	4					306	310		10.1016/S0887-8994(97)00025-8			5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	XP128	WOS:A1997XP12800005	9258963				2021-06-18	
J	Blostein, PA; Jones, SJ; Buechler, CM; Vandongen, S				Blostein, PA; Jones, SJ; Buechler, CM; Vandongen, S			Cognitive screening in mild traumatic brain injuries: Analysis of the neurobehavioral cognitive status examination when utilized during initial trauma hospitalization	JOURNAL OF NEUROTRAUMA			English	Article						cognitive screen; mild traumatic brain injury; neurobehavioral cognitive status exam; Glasgow Coma Scale	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; CONCUSSION; SYMPTOMS; SEQUELAE; RECOVERY; CAPACITY; MEMORY	Cognitive screening following mild traumatic brain injury (MTBI) remains variable with method of diagnosis, indications for testing, and utilization of results differing between institutions. The Neurobehavioral Cognitive Status Examination (NCSE) was originally developed for use in organic brain dysfunction and central nervous system (CNS) lesions. When attention is given to both the objective cognitive area scores and the ''process features'' component of the exam, it is an effective tool for identifying cognitive deficits associated with MTBI. One hundred seven MTBI patients underwent cognitive screening in the acute care setting. Memory was the function most frequently affected in patients with positive cognitive screens. Several of the NCSE deficits also correlated significantly with each other but not with memory. Age, length of stay, injury severity score (ISS), and cranial computed tomography scan were not associated with cognitive screen results. An admission Glasgow Coma Scale (GCS) of 13 or 14 was significantly associated with a positive cognitive screen, but a GCS of 15 did not predict a negative cognitive screen. All patients with MTBI require cognitive screening to identify deficits, ensure patient and family education, and when necessary facilitate treatment.		Blostein, PA (corresponding author), BRONSON METHODIST HOSP,TRAUMA SURG SERV,252 E LOVELL ST,KALAMAZOO,MI 49007, USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BOHNEN N, 1992, NEUROSURGERY, V30, P692; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Marshall LF, 1989, MILD HEAD INJURY, P276; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; NELSON A, 1986, J NERV MENT DIS, V174, P73, DOI 10.1097/00005053-198602000-00002; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Ruff RM, 1986, J HEAD TRAUMA REHAB, V1, P43; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHWAMM LH, 1987, ANN INTERN MED, V107, P486, DOI 10.7326/0003-4819-107-4-486; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; VanDongen S, 1993, Rehabil Nurs, V18, P76; Veltman R H, 1993, J Neurosci Nurs, V25, P367; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	31	27	29	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1997	14	3					171	177		10.1089/neu.1997.14.171			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WT814	WOS:A1997WT81400005	9104934				2021-06-18	
J	Craig, SC; Morgan, J				Craig, SC; Morgan, J			Parachuting injury surveillance, Fort Bragg, North Carolina, May 1993 to December 1994	MILITARY MEDICINE			English	Article								Surveillance for parachute-related injuries was conducted at Fort Bragg, North Carolina, between May 1993 and December 1994, During this 20-month period, lower-extremity injuries (27% of all injuries), axial skeletal (back and neck) strains and sprains (19.3%), and closed head injuries (18.4%) were the leading causes of injury, The incidence of injuries requiring emergency care was 8/1,000 jumps, This rate is well within the jump injury planning estimate, suggesting that airborne training and operations are conducted in a safe and effective manner at Fort Bragg.		Craig, SC (corresponding author), USA,EPIDEMIOL PROGRAM BRANCH,CTR HLTH PROMOT WELLNESS & PREVENT MED,ABERDEEN PROVING GROUND,MD 21045, USA.						*USA, 1994, T951 US ARM RES I EN	1	27	31	0	1	ASSN MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814	0026-4075			MIL MED	Milit. Med.	MAR	1997	162	3					162	164					3	Medicine, General & Internal	General & Internal Medicine	WP113	WOS:A1997WP11300006	9121659				2021-06-18	
J	Lam, CH; Montes, J; Farmer, JP; OGorman, AM; MeagherVillemure, K				Lam, CH; Montes, J; Farmer, JP; OGorman, AM; MeagherVillemure, K			Traumatic aneurysm from shaken baby syndrome: Case report	NEUROSURGERY			English	Article						porencephaly; shaken baby syndrome; traumatic aneurysm	INTRACRANIAL ANEURYSMS; ARTERIES; INJURY; BRAIN	OBJECTIVE AND IMPORTANCE: We present a 6-week-old infant who developed a traumatic aneurysm from clearly documented shaken baby syndrome. Despite the theoretical similarity in the mechanism of such injuries, this is the first aneurysm reported that resulted from such a cause. The infant is also the youngest reported patient to have suffered from a traumatic aneurysm. CLINICAL PRESENTATION: Police records documented shaking of the child as well as direct impact on the child's head. Three weeks later, the patient developed an intracerebral hemorrhage, which was revealed by angiography to have resulted from a pericallosal artery aneurysm. TECHNIQUE: The aneurysm was totally resected through a porencephalic cyst, which had developed secondary to ischemic injury to the brain. CONCLUSION: The temporal course, as well as the location of this traumatic aneurysm, is similar to that in older patients.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,DIV NEUROSURG,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,DEPT RADIOL,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,DEPT PATHOL,MONTREAL,PQ H3H 1P3,CANADA							ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; Birrell R G, 1968, Med J Aust, V2, P1023; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; CAFFEY J, 1974, PEDIATRICS, V54, P396; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; NEWTON RW, 1989, ARCH DIS CHILD, V64, P188, DOI 10.1136/adc.64.2.188; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; SMITH DR, 1970, J NEUROSURG, V32, P357, DOI 10.3171/jns.1970.32.3.0357; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; SMITH SM, 1974, BMJ-BRIT MED J, V3, P666, DOI 10.1136/bmj.3.5932.666; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; YAZBAK PA, 1995, PEDIATR NEUROSURG, V22, P15, DOI 10.1159/000121294	16	27	27	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1996	39	6					1252	1255		10.1097/00006123-199612000-00041			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VT943	WOS:A1996VT94300093	8938784				2021-06-18	
J	Tayag, EC; Nair, SN; Wahhab, S; Katsetos, CD; Lighthall, JW; Lehmann, JC				Tayag, EC; Nair, SN; Wahhab, S; Katsetos, CD; Lighthall, JW; Lehmann, JC			Cerebral uric acid increases following experimental traumatic brain injury in rat	BRAIN RESEARCH			English	Article						uric acid; thalamus; cortex; rat; traumatic brain injury; microdialysis	CORTICAL IMPACT INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; XANTHINE-OXIDASE; FOCAL ISCHEMIA; INTENSIVE-CARE; MICRODIALYSIS; HYPOXANTHINE; RADICALS; STROKE	Following traumatic brain injury (TBI), cortical and thalamic areas were analyzed histologically and by high-performance liquid chromatography with electrochemical detection for uric acid at various survival times. Following TBI, cortical uric acid was elevated by ten-fold at 24 and 48 h, but not at 1 h post-TBI. Histological evidence of neurodegeneration was found not only in cortex but also in the anteroventral thalamus. These data suggest that as in stroke, uric acid measurements may be a convenient and sensitive method for measuring peroxidative status in TBI.	MED COLL PENN & HAHNEMANN UNIV, DEPT NEUROSURG, PHILADELPHIA, PA 19102 USA; MED COLL PENN & HAHNEMANN UNIV, DEPT PATHOL, PHILADELPHIA, PA 19102 USA; GM CORP, RES LABS, DEPT BIOMED SCI, WARREN, MI 48090 USA							BETZ AL, 1985, J NEUROCHEM, V44, P574, DOI 10.1111/j.1471-4159.1985.tb05451.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENGERSON TD, 1987, J CLIN INVEST, V79, P1564, DOI 10.1172/JCI112990; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; KANEMITSU H, 1989, BRAIN RES, V499, P367, DOI 10.1016/0006-8993(89)90786-5; KANEMITSU H, 1988, J NEUROCHEM, V51, P1882, DOI 10.1111/j.1471-4159.1988.tb01172.x; KINUTA Y, 1989, J NEUROSURG, V71, P417, DOI 10.3171/jns.1989.71.3.0417; KINUTA Y, 1989, J NEUROSURG, V71, P421, DOI 10.3171/jns.1989.71.3.0421; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LEHMANN JC, 1993, DRUG NEWS PERSPECT, V6, P692; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NIHEI H, 1989, NEUROSURGERY, V25, P613, DOI 10.1227/00006123-198910000-00016; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; UEMURA Y, 1991, STROKE, V22, P1548, DOI 10.1161/01.STR.22.12.1548; YOSHIURA M, 1986, J LIQ CHROMATOGR, V9, P177, DOI 10.1080/01483918608076630	25	27	31	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 16	1996	733	2					287	291		10.1016/0006-8993(96)00669-5			5	Neurosciences	Neurosciences & Neurology	VK400	WOS:A1996VK40000016	8891312				2021-06-18	
J	Levin, HS; Fletcher, JM; Kusnerik, L; Kufera, JA; Lilly, MA; Duffy, FF; Chapman, S; Mendelsohn, D; Bruce, D				Levin, HS; Fletcher, JM; Kusnerik, L; Kufera, JA; Lilly, MA; Duffy, FF; Chapman, S; Mendelsohn, D; Bruce, D			Semantic memory following pediatric head injury: Relationship to age, severity of injury, and MRI	CORTEX			English	Article							CHILDREN; ADOLESCENTS; AMNESIA; DISTINCTION; ABILITY	The effects of closed head injury (CHI) severity (mild vs. severe) and age at injury were analyzed in a longitudinal study (3, 12 months postinjury) of semantic memory which used magnetic resonance imaging (MRI) to characterize focal brain lesions. Semantic memory was evaluated by word and category fluency, semantic verification, semantic clustering in word list recall, and vocabulary. Episodic memory was assessed by word list recall. Comparison of normal control (n = 104) data with the patients' data (n = 77) at 3 months postinjury disclosed semantic and episodic memory deficits in the severe CHI patients. Analysis of the longitudinal data revealed significant effects of age at injury for all of the semantic memory measures. The effects of injury severity were confined to the latency of verifying correct statements. Volume of left frontal and extrafrontal lesions was predictive of performance on several semantic memory measures, but less robust for right hemisphere lesions.	UNIV MARYLAND,MED SYST,DIV NEUROSURG,BALTIMORE,MD 21201; UNIV TEXAS,MED BRANCH,DEPT SURG,GALVESTON,TX 77550; UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX; UNIV TEXAS,CALLIER CTR COMMUN DISORDERS,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235			Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Baddeley A.D, 1976, PSYCHOL MEMORY; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1993, MANUAL MULTILINGUAL; CERMAK LS, 1983, NEUROPSYCHOLOGIA, V21, P213, DOI 10.1016/0028-3932(83)90039-8; Cohen N.J., 1984, NEUROPSYCHOLOGY MEMO, P83; COLLINS AM, 1975, PSYCHOL REV, V82, P407, DOI 10.1037/0033-295X.82.6.407; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DAMASIO H, 1991, FRONTAL LOBE FUNCTIO, P99; DELIS DC, 1986, CALIFORNIA VERBAL LE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; GABRIELI JDE, 1988, BRAIN COGNITION, V7, P157, DOI 10.1016/0278-2626(88)90027-9; GATHERCOLE SE, 1993, MEMORY LANGUAGE; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P1871; MCKOON G, 1986, J EXP PSYCHOL LEARN, V12, P295, DOI 10.1037/0278-7393.12.2.295; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; PATTERSON K, 1995, HDB MEMORY DISORDERS, P167; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; TULVING E, 1986, J EXP PSYCHOL LEARN, V12, P307, DOI 10.1037/0278-7393.12.2.307; Wechsler D., 1974, MANUAL WECHSLER INTE	29	27	27	0	7	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	SEP	1996	32	3					461	478		10.1016/S0010-9452(96)80004-9			18	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	VH618	WOS:A1996VH61800004	8886522				2021-06-18	
J	Carnevale, GJ				Carnevale, GJ			Natural-setting behavior management for individuals with traumatic brain injury: Results of a three-year caregiver training program	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior management; community reentry; family training; traumatic brain injury	HEAD	The Natural-Setting Behavior Management Program (NSBM) is a mobile ream approach that is designed to teach persons with traumatic brain injury (TBI) and their caregivers how to implement and sustain home-based behavior management programs. Of 35 families assessed over a 3-year period, 17 were referred for NSBM training and 11 completed the program, including a 1-year follow-up. This group demonstrated an 82% improvement in target behaviors over the course of training, with the greatest improvement occurring during the education phase. These initial results promote the value of family training programs to support community stabilization of persons with TBI who experience behavioral challenges.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103	Carnevale, GJ (corresponding author), KESSLER INST REHABIL,DEPT PSYCHOL NEUROPSYCHOL,240 CENT AVE,E ORANGE,NJ 07018, USA.						Brooks N., 1984, CLOSED HEAD INJURY P; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; JACOBS H, 1991, HEAD INJURY FAMILY M; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T; JACOBS HE, 1990, NEUROPSYCHOLOGY EVER; JACOBS HE, 1993, BEHAVIOR ANAL GUIDEL; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MUIR CA, 1987, 6TH ANN NAT S SAN DI; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Siegel S., 1956, NONPARAMETRIC STAT B; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1974, SCANDINAVIAN J REHAB, V6, P180	15	27	27	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1996	11	1					27	38		10.1097/00001199-199602000-00005			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TU021	WOS:A1996TU02100005					2021-06-18	
J	Holmin; Mathiesen, T				Holmin; Mathiesen, T			Dexamethasone and colchicine reduce inflammation and delayed oedema following experimental brain contusion	ACTA NEUROCHIRURGICA			English	Article						CNS trauma; experimental contusion; inflammation; brain oedema	CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HIGH-DOSE DEXAMETHASONE; MONONUCLEAR PHAGOCYTES; CEREBRAL EDEMA; TRAUMATIC INJURY; RAT; MACROPHAGES; ANTIGENS	The effect of anti-inflammatory treatment on monocyte/macrophage infiltration, major histocompatibility complex molecules (MHC) class II expression and delayed oedema following experimental brain contusion was studied by immunohistochemistry and tissue-specific gravity measurement in 44 rats. Colchicine, chloroquine and dexamethasone administered once daily for five days after the trauma reduced inflammation and oedema. The difference was statistically significant with colchicine and dexamethasone. The findings comprise further evidence of a pathogenetically important inflammation after experimental contusion. It is probable that anti-inflammatory agents may prevent secondary neurological damage due to elevated intracranial pressure and cell to cell- or cytokine-mediated neuronal degeneration and demyelination.	KAROLINSKA HOSP, DEPT CLIN NEUROSCI, NEUROSURG SECT, S-17176 STOCKHOLM, SWEDEN				Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; BARCLAY AN, 1981, IMMUNOLOGY, V42, P593; BAUER J, 1993, J NEUROIMMUNOL, V48, P13, DOI 10.1016/0165-5728(93)90053-2; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1989, P 7 INT S INTR PRESS; DAMOISEAUX JGMC, 1989, J LEUKOCYTE BIOL, V46, P246; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DUPLESSIS JJ, 1992, BRIT J NEUROSURG, V6, P145, DOI 10.3109/02688699209002917; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Gobiet W, 1976, INTRACRANIAL PRESSUR, P231; GORDON CR, 1990, ACT NEUR S, V51, P268; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kobrine A I, 1973, Surg Neurol, V1, P38; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; MCLAURIN RL, 1965, J NEUROSURG, V296; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; POLMAN CH, 1986, J NEUROIMMUNOL, V11, P215, DOI 10.1016/0165-5728(86)90005-6; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SMINIA T, 1987, IMMUNOBIOLOGY, V174, P43, DOI 10.1016/S0171-2985(87)80083-9; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STEIN SC, 1993, NEUROSURGERY, V32, P30; TODD NV, 1990, ACT NEUR S, V51, P296; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; UNTERBERG A, 1993, NEUROSURGERY, V32, P23; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WOODROOFE MN, 1993, CYTOKINE, V5, P583, DOI 10.1016/S1043-4666(05)80008-0	44	27	27	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1996	138	4					418	424		10.1007/BF01420304			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	UG867	WOS:A1996UG86700018	8738392				2021-06-18	
J	NILSSON, F; BJORKMAN, S; ROSEN, I; MESSETER, K; NORDSTROM, CH				NILSSON, F; BJORKMAN, S; ROSEN, I; MESSETER, K; NORDSTROM, CH			CEREBRAL VASOCONSTRICTION BY INDOMETHACIN IN INTRACRANIAL HYPERTENSION - AN EXPERIMENTAL INVESTIGATION IN PIGS	ANESTHESIOLOGY			English	Article							SEVERE HEAD-INJURY; TRAUMATIC BRAIN-LESIONS; BLOOD-FLOW; PROSTAGLANDIN SYNTHESIS; PERFUSION-PRESSURE; AUTO-REGULATION; CARBON-DIOXIDE; DIHYDROERGOTAMINE; HYPERVENTILATION; INHIBITION	Background: Uncontrolled increase in intracranial pressure is the most significant cause of mortality in patients with severe traumatic brain lesions, and the efficacy of common nonsurgical treatments has been questioned. Pharmacologically induced cerebral vasoconstriction aiming at a decrease of cerebral blood volume and brain edema has recently been suggested as an alternative. Limited clinical experience with indomethacin as a cerebral vasoconstrictor has been reported but dose- or concentration-effect relationships were not investigated. In particular, there is a lack of data showing whether a therapeutic window exists in which risk of cerebral ischemia is minimized. Methods: In a porcine model of intracranial hypertension induced with two epidural balloons to a level of 26-28 mmHg, 18 animals were randomized into three groups receiving 0.1, 0.3, and 3.0 mg . kg(-1). h(-1) indomethacin, respectively, as an infusion during 80 min. Intracranial pressure, mean arterial blood pressure, and electrocortical activity were recorded continuously and measurements of cerebral blood now, arteriovenous difference in oxygen content and cerebral venous pH were performed at 5, 20, 40, 60, and 75 min during and 10 min after the indomethacin infusion. Baseline measurements, performed before the indomethacin infusion, were used as an internal control. The infusions were pharmacokinetically designed to mimic the reported clinical conditions. Results: An 11% mean decrease in intracranial pressure during the infusion, but no effects on cerebral blood flow, arteriovenous difference in oxygen content, venous pH, and electrocortical activity were observed in the group of animals receiving 0.1 mg . kg(-1). h(-1). When the rate of infusion was 0.3 and 3.0 mg . kg(-1). h(-1), the decrease in intracranial pressure was 20 and 25%, respectively, but this was accompanied by a decrease in cerebral blood flow and venous pH, an increase in arteriovenous difference in oxygen content, and a slowing of the electrocortical activity. All changes were statistically significant. Conclusions: Indomethacin, which is known to constrict precapillary resistance vessels, caused a decrease in intracranial pressure during experimental intracranial hypertension. This was accompanied by signs of cerebral ischemia when Indomethacin was used in a dose that has previously been suggested for the treatment of increased intracranial pressure in patients.								AKESON J, 1992, ACTA ANAESTH SCAND, V36, P419, DOI 10.1111/j.1399-6576.1992.tb03491.x; ALBRECHT RF, 1987, STROKE, V18, P649, DOI 10.1161/01.STR.18.3.649; ALVAN G, 1975, CLIN PHARMACOL THER, V18, P364; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P922, DOI 10.1111/j.1399-6576.1995.tb04199.x; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P354; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; INGVAR M, 1981, ACTA PHYSIOL SCAND, V111, P205, DOI 10.1111/j.1748-1716.1981.tb06726.x; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; JONKMAN EJ, 1986, HDB EL CLIN NEUROPHY, P205; KAGSTROM E, 1983, ACTA PHYSIOL SCAND, V118, P193, DOI 10.1111/j.1748-1716.1983.tb07262.x; KAUFMAN AM, 1992, J NEUROSURG, V77, P854; KRAAIER V, 1992, ELECTROEN CLIN NEURO, V82, P208, DOI 10.1016/0013-4694(92)90169-I; LUNDBERG N, 1959, ACTA PSYCHIAT SCAND, V34, P139; MCCARTHY BG, 1989, HEADACHE, V29, P420, DOI 10.1111/j.1526-4610.1989.hed2907420.x; MELLANDER S, 1970, CLIN SCI, V39, P183, DOI 10.1042/cs0390183; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MULLER H, 1988, PHARMACOLOGY, V37, P248, DOI 10.1159/000138473; NAGATA K, 1986, TOPOGRAPHIC MAPPING, P357; NILSSON B, 1981, ACTA PHYSIOL SCAND, V111, P455, DOI 10.1111/j.1748-1716.1981.tb06763.x; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P827, DOI 10.1111/j.1399-6576.1995.tb04179.x; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P916, DOI 10.1111/j.1399-6576.1995.tb04198.x; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; PICKARD JD, 1977, CIRC RES, V40, P198, DOI 10.1161/01.RES.40.2.198; PICKARD JD, 1973, NATURE-NEW BIOL, V245, P187; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAKABE T, 1979, ACTA PHYSIOL SCAND, V107, P283, DOI 10.1111/j.1748-1716.1979.tb06476.x; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SEVERINGHAUS JW, 1967, CIRC RES, V20, P272, DOI 10.1161/01.RES.20.2.272; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; THOMAS RM, 1989, B LOND MATH SOC, V21, P463, DOI 10.1112/blms/21.5.463; VANHUFFELEN AC, 1984, PROG BRAIN RES, V62, P3; WAHLINBOLL E, 1981, EUR J CLIN PHARMACOL, V20, P375, DOI 10.1007/BF00615408; WENNMALM A, 1981, CLIN PHYSIOL, V1, P227, DOI 10.1111/j.1475-097X.1981.tb00891.x	44	27	27	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQUARE, PHILADELPHIA, PA 19106	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	1995	83	6					1283	1292		10.1097/00000542-199512000-00019			10	Anesthesiology	Anesthesiology	TJ329	WOS:A1995TJ32900019	8533921				2021-06-18	
J	FABIANO, RJ; CREWE, N				FABIANO, RJ; CREWE, N			VARIABLES ASSOCIATED WITH EMPLOYMENT FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	REHABILITATION PSYCHOLOGY			English	Article							SEVERE HEAD-INJURY	The results of a survey of employment outcome and their relationship to psychometric indices indicated that competitive employment following severe traumatic brain injury is an ambitious endeavor. While 98% of the subjects sampled were either employed or in school premorbidly, 43% of the subjects were unemployed post-injury. Psychometric variables were most highly related to employment outcome which suggested a useful role of neuropsychological testing in assisting in vocational rehabilitation planning. Furthermore, the psychometric test results indicated that many subjects who were unemployed may be capable of part-time employment. Future studies are needed to further examine those neuropsychological abilities which subsequently affect employability following severe traumatic brain injury.	MICHIGAN STATE UNIV,E LANSING,MI 48824							BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DENNYBROWN D, 1942, NEW ENGL J MED, V227, P813; FAHY TJ, 1967, LANCET, V2, P475; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; HEATON RK, 1978, J NERV MENT DIS, V116, P408; KAY T, 1988, HEAD TRAUMA RES PROJ; KAY T, 1988, EXPT DESIGN PROCEDUR, V3, P65; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIMEL RW, 1983, REHABILITATION HEAD; ROWBOTHAM GF, 1954, BRIT MED J, V1, P726, DOI 10.1136/bmj.1.4864.726; SACHS PR, 1993, REHABIL PSYCHOL, V38, P87, DOI 10.1037/h0080294; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; *US DEP LAB EMPL T, 1981, SEL CHAR OCC DEF DIC; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEHMAN P, 1990, VOCATIONAL REHABILIT	22	27	27	0	0	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	FAL	1995	40	3					223	231		10.1037/0090-5550.40.3.223			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	TH449	WOS:A1995TH44900006					2021-06-18	
J	MARSH, NV; SMITH, MD				MARSH, NV; SMITH, MD			POST-CONCUSSION SYNDROME AND THE COPING HYPOTHESIS	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; MILD CONCUSSION; RECOVERY; SYMPTOMS; SEQUELAE; MEMORY	Neuropsychological functioning and level of subjective symptomatology was assessed in 15 adults at 2 weeks, 1 month, and 3 months post-concussion. Performance by the concussion subjects was compared to the results obtained by a matched group of normal controls. At 2 weeks post-injury the concussion subjects had deficits in intellectual, attentional, memory, and language abilities. Visuospatial constructional abilities were relatively preserved. Concussed subjects also reported high levels of disturbance in affective, cognitive, and social functioning. By 3 months post-injury the concussed subjects were still displaying deficits in attentional and language functioning. The level of subjective symptoms reported by the concussed subjects was not significantly different fi om that reported by controls. Results provide some support for the 'coping hypothesis' explanation of post-concussion syndrome.		MARSH, NV (corresponding author), UNIV WAIKATO,DEPT PSYCHOL,PRIVATE BAG 3105,HAMILTON,NEW ZEALAND.		Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Beck A.T., 1987, BECK DEPRESSION INVE; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROOKER BH, 1986, J CLIN PSYCHOL, V42, P982, DOI 10.1002/1097-4679(198611)42:6<982::AID-JCLP2270420624>3.0.CO;2-G; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JOHNSTON R, 1983, REVISION SOCIOECONOM; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; Nelson H., 1982, NATIONAL ADULT READI; OSHAUGHNESSY EJ, 1984, J FAMILY PRACTICE, V18, P394; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SMITH MD, 1993, THESIS U WAIKATO HAM; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Spreen O., 1991, COMPENDIUM NEUROPSYC; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111	32	27	27	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1995	9	6					553	562		10.3109/02699059509008214			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RU016	WOS:A1995RU01600002	7581351				2021-06-18	
J	ROBERTS, MA; MANSHADI, FF; BUSHNELL, DL; HINES, ME				ROBERTS, MA; MANSHADI, FF; BUSHNELL, DL; HINES, ME			NEUROBEHAVIORAL DYSFUNCTION FOLLOWING MILD TRAUMATIC BRAIN INJURY IN CHILDHOOD - A CASE-REPORT WITH POSITIVE FINDINGS ON POSITRON EMISSION TOMOGRAPHY (PET)	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; SEQUELAE; CHILDREN; EEG; ANTIDEPRESSANTS; PHENOMENOLOGY; SYMPTOMS; EPILEPSY; SEIZURES; CT	The present case study describes the neurobehavioural, neurodiagnostic, and positron emission tomography (PET) scan findings in a child who sustained a whiplash-type injury in a motor vehicle accident. Although neck and back pain were reported immediately, neurobehavioural symptoms, such as staring spells, gradually increased in frequency over a 2-year period following the accident. At 4 years after the accident the patient's symptoms persisted, as reported by teachers and parents, and more extensive diagnostic work-up was initiated. Standard EEG was normal while two ambulatory EEGs were abnormal and interpreted as epileptiform. A PET scan showed evidence of marked hypometabolism in both temporal lobes. Neuropsychological findings were consistent with PET findings and reflected verbal and visual memory deficits in the context of high average intelligence. Treatment with carbamazepine, verapamil, and fluoxetine greatly improved the patient's symptoms. The present case illustrates an example of a poor outcome in a paediatric case of mild traumatic brain injury, the importance of PET in demonstrating definitive evidence of brain dysfunction, and the child's positive response to anticonvulsant medication.	PHYS MED & REHABIL ASSOCIATES,WATERLOO,IA; UNIV IOWA,COLL MED,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT VET AFFAIRS MED CTR,COLL MED,DEPT PEDIAT,NUCL MED SERV,IOWA CITY,IA; OTTUMWA REG MED CTR,OTTUMWA,IA 52501				Bushnell, David/0000-0002-2768-396X			ABOUKHALIL BW, 1987, ANN NEUROL, V22, P480, DOI 10.1002/ana.410220407; ADAMEC RE, 1990, BIOL PSYCHIAT, V27, P249, DOI 10.1016/0006-3223(90)90001-I; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARNHILL LJ, 1989, NEUROPSY NEUROPSY BE, V2, P211; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BIJUR PE, 1990, PEDIATRICS, V86, P337; Engel J, 1991, KINDLING SYNAPTIC PL, P195; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; GORMAN LL, 1990, J CLIN EXP NEUROPSYC, V12, P76; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS DC, 1986, BRAIN, V109, P251, DOI 10.1093/brain/109.2.251; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LIGUORI G, 1989, CHILD NERV SYST, V5, P160, DOI 10.1007/BF00272119; Lindgren S.D., 1987, ADV BEHAVIORAL ASSES, V3, P57; LIU YK, 1984, SPINE, V9, P329, DOI 10.1097/00007632-198405000-00001; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; ROBERTS MA, PEDIATRIC INVENTORY; ROBERTS RJ, 1992, EPILEPSY RES, V13, P167, DOI 10.1016/0920-1211(92)90073-3; ROBERTS RJ, 1991, DICHOTIC WORD LISTEN; ROBERTS RJ, 1992, NEUROPSYCHOLOGY, V4, P65; ROSENSTEIN DL, 1993, J CLIN PSYCHIAT, V54, P289; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1986, J HEAD TRAUMA REHAB, V1, P43; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; THEODORE WH, 1990, NEUROLOGY, V40, P797, DOI 10.1212/WNL.40.5.797; TORRES F, 1961, ARCH NEUROL-CHICAGO, V5, P28, DOI 10.1001/archneur.1961.00450130030005; TUCKER GJ, 1986, J NERV MENT DIS, V174, P348, DOI 10.1097/00005053-198606000-00007; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; Wechsler D., 1974, MANUAL WECHSLER INTE; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	40	27	27	0	4	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1995	9	5					427	436		10.3109/02699059509008202			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RJ331	WOS:A1995RJ33100001	7550214				2021-06-18	
J	MUIR, JK; TYNAN, M; CALDWELL, R; ELLIS, EF				MUIR, JK; TYNAN, M; CALDWELL, R; ELLIS, EF			SUPEROXIDE-DISMUTASE IMPROVES POSTTRAUMATIC CORTICAL BLOOD-FLOW IN RATS	JOURNAL OF NEUROTRAUMA			English	Article						BRAIN INJURY; SUPEROXIDE; OXYGEN RADICAL; CEREBRAL BLOOD FLOW; LASER-DOPPLER FLOWMETRY; RAT	EXPERIMENTAL BRAIN INJURY; LASER-DOPPLER ASSESSMENT; FLUID-PERCUSSION MODEL; SEVERE HEAD-INJURY; CEREBRAL-ISCHEMIA; OXYGEN RADICALS; EDEMA; CATS; MICROCIRCULATION; PERMEABILITY	Oxygen free radicals, such as the superoxide anion, are known to mediate damage to the; cerebral microcirculation following traumatic brain injury. The purpose of this study was to determine if superoxide dismutase (SOD), a scavenger of superoxide anion, could alter posttraumatic cortical blood flow, Following barbiturate anesthesia, rats were surgically prepared for moderate fluid percussion brain injury, Cortical blood flow contralateral to the site of injury was measured using laser-Doppler flowmetry, Laser-Doppler flowmetry assesses flow by measuring Cell volume and velocity, which are multiplied electronically to give flow, Starting 10 min before injury, animals received either superoxide dismutase (24,000 U/kg bolus, followed by continuous infusion of 1600 U/kg/min) or an equal volume of saline, Blood pressure, heart rate, and cortical blood flow were measured up to 1 h posttrauma, Rats receiving superoxide dismutase had significantly higher cortical blood flow posttrauma (F = 6.91, p < 0.02), One hour posttrauma, the blood flow in SOD-treated rats was 89 +/- 8% of preinjury baseline, whereas this value was only 66 +/- 6% of control in saline-treated rats, SOD caused not only greater blood velocity but also less reduction in cortical blood volume after injury, There were no significant differences between the groups with respect to blood pressure or heart rate, This study further supports the role of oxygen radical-mediated cerebrovascular dysfunction following traumatic brain injury and is the first to show the beneficial effect of SOD on cortical blood flow following fluid percussion brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [07027, 27214] Funding Source: Medline		BERNE RM, 1972, CARDIOVASCULAR PHYSL, P1; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ELLIS EF, 1995, FASEB J, V9, pA591; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255; HE YY, 1993, AM J PHYSIOL, V265, pH252; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KIRSCH JR, 1993, PEDIATR RES, V34, P530, DOI 10.1203/00006450-199310000-00030; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MUIR JK, 1992, J NEUROTRAUM, V9, P394; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356; PFISTER HW, 1992, J INFECT DIS, V166, P1442, DOI 10.1093/infdis/166.6.1442; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; SCHLEIEN CL, 1994, STROKE, V25, P1830, DOI 10.1161/01.STR.25.9.1830; TRUELOVE D, 1994, FREE RADICAL BIO MED, V17, P445, DOI 10.1016/0891-5849(94)90171-6; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YOSHIDA K, 1992, J NEUROTRAUM, V9, P85, DOI 10.1089/neu.1992.9.85; YOSHIDA K, 1992, STROKE, V23, P865, DOI 10.1161/01.STR.23.6.865; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHANG XM, 1991, STROKE, V22, P489, DOI 10.1161/01.STR.22.4.489; ZHANG XM, 1990, AM J PHYSIOL, V259, pH497	44	27	27	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1995	12	2					179	188		10.1089/neu.1995.12.179			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QZ508	WOS:A1995QZ50800004	7629864				2021-06-18	
J	DUNNMEYNELL, AA; LEVIN, BE				DUNNMEYNELL, AA; LEVIN, BE			LATERALIZED EFFECT OF UNILATERAL SOMATOSENSORY CORTEX CONTUSION ON BEHAVIOR AND CORTICAL REORGANIZATION	BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; RECOVERY OF FUNCTION; PLASTICITY; BARREL RECEPTOR FIELD; VIBRISSA; MULTIMODALITY; OCCIPITAL CORTEX; VICARIATION	CEREBRAL GLUCOSE-UTILIZATION; RAT BARREL CORTEX; C-14 2-DEOXYGLUCOSE UPTAKE; MOTOR RECOVERY; FUNCTIONAL REORGANIZATION; VIBRISSAL STIMULATION; THROMBOTIC INFARCTION; FACILITATE RECOVERY; LOCUS COERULEUS; LEFT-HEMISPHERE	Previous studies have shown that rats recover function after unilateral somatosensory cortex lesions, possibly by transfer of information processing to other brain areas not normally involved in those functions. In the present study, adult rats underwent unilateral contusions of the somatosensory cortex with ablation of the barrel receptor field. Behavioral testing with modified beam-walking and sensory neglect tasks demonstrated persistent somatosensory deficits in rats with left contusions but no apparent deficits in right injured animals. After 2 months, the [C-14]2-deoxyglucose (2-DG) method was used to show the metabolic activity produced by unilateral stimulation of the facial vibrissae. In left injured animals, cortical metabolic activity rostral and caudal to the injury site was depressed both under basal conditions and during right vibrissal stimulation. On the other hand, comparison of the pattern of [C-14]2-DG uptake in the intact, right cortex revealed changes in the pattern of glucose utilization associated with left injury combined with right vibrissal stimulation. Pattern changes were quantified by measuring the area in which glucose utilization was within the highest 25% of this range (high activity area; HAA). Right vibrissal stimulation in left injured rats caused an expansion of this HAA in the intact occipital/temporal cortex. Also, in the intact somatosensory cortex of left injured rats, there was an enlarged HAA whether or not vibrissal stimulation was performed. Thus, a combination of depressed peri-injury metabolic activity and aberrant activity in remote brain areas occurs following unilateral somatosensory cortex injury. It remains to be shown whether these factors ameliorate or contribute to persistent behavioral deficits.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT NEUROSCI,NEWARK,NJ 07103	DUNNMEYNELL, AA (corresponding author), DEPT VET AFFAIRS MED CTR,NEUROL SERV 127,E ORANGE,NJ 07018, USA.						ADAMS FS, 1992, BRAIN RES, V597, P114, DOI 10.1016/0006-8993(92)91512-D; AFONSO D, 1993, BRAIN RES BULL, V32, P11, DOI 10.1016/0361-9230(93)90312-Y; BARNEOUD P, 1991, BEHAV BRAIN RES, V44, P87, DOI 10.1016/S0166-4328(05)80242-6; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1993, PHARMACOL BIOCHEM BE, V44, P297, DOI 10.1016/0091-3057(93)90465-6; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, PHARMACOL BIOCHEM BE, V43, P771, DOI 10.1016/0091-3057(92)90407-7; BOYESON MG, 1991, RESTOR NEUROL NEUROS, V3, P227, DOI 10.3233/RNN-1991-3501; Boyeson MG, 1991, J NEUROTRAUM, V8, P205, DOI 10.1089/neu.1991.8.205; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; CIRICILLO SP, 1994, NEUROSCIENCE, V59, P975, DOI 10.1016/0306-4522(94)90300-X; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CRAIK R L, 1988, Society for Neuroscience Abstracts, V14, P843; CRAIK RL, 1987, BRAIN RES BULL, V19, P495, DOI 10.1016/0361-9230(87)90154-7; DELACOUR J, 1987, NEUROSCIENCE, V23, P63, DOI 10.1016/0306-4522(87)90271-5; DELACOUR J, 1990, NEUROSCIENCE, V37, P237, DOI 10.1016/0306-4522(90)90209-M; DENENBERG VH, 1978, SCIENCE, V201, P1150, DOI 10.1126/science.684436; Dietrich W. D., 1987, CEREBROVASC DIS, P285; Duvdevani R., 1992, Society for Neuroscience Abstracts, V18, P178; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FUKUSHIMA T, 1979, J COMP NEUROL, V183, P169, DOI 10.1002/cne.901830112; GINSBERG MD, 1992, J CEREB BLOOD FLOW M, V9, P329; GLASSMAN RB, 1994, EXP NEUROL, V125, P125, DOI 10.1006/exnr.1994.1016; GLICK SD, 1981, BRAIN RES, V205, P222, DOI 10.1016/0006-8993(81)90737-X; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; GONZALEZ MF, 1985, J COMP NEUROL, V231, P457, DOI 10.1002/cne.902310405; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRABOWSKI M, 1991, BRAIN RES, V547, P249, DOI 10.1016/0006-8993(91)90968-2; GRABOWSKI M, 1993, ANN NEUROL, V34, P362, DOI 10.1002/ana.410340310; GUICROBLES E, 1992, BEHAV BRAIN RES, V48, P145, DOI 10.1016/S0166-4328(05)80150-0; HOVDA DA, 1990, BEHAV BRAIN RES, V37, P119, DOI 10.1016/0166-4328(90)90087-U; Hovda David A., 1992, Brain Dysfunction, V5, P3; HURWITZ BE, 1990, BRAIN RES, V512, P210, DOI 10.1016/0006-8993(90)90628-O; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; HUSTON JP, 1986, EXP NEUROL, V93, P380, DOI 10.1016/0014-4886(86)90198-6; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; KAAS JH, 1983, ANN REV NEUROSCI, V6, P125; KOLB B, 1992, ADV EXP MED BIOL, V325, P169; KOLB B, 1989, PROG NEUROBIOL, V32, P235, DOI 10.1016/0301-0082(89)90023-3; KORALEK KA, 1990, J COMP NEUROL, V299, P133, DOI 10.1002/cne.902990202; KOSSUT M, 1988, J NEUROPHYSIOL, V60, P829; LEVIN BE, 1988, BRAIN RES, V443, P261, DOI 10.1016/0006-8993(88)91620-4; LEVIN BE, 1993, MOL BRAIN RES, V18, P59, DOI 10.1016/0169-328X(93)90173-M; LEVIN BE, 1991, EXP NEUROL, V113, P237, DOI 10.1016/0014-4886(91)90180-K; LEVIN BE, 1993, BRAIN RES; LU SM, 1993, SOMATOSENS MOT RES, V10, P1, DOI 10.3109/08990229309028819; MIKLYAEVA EI, 1993, BEHAV BRAIN RES, V56, P145, DOI 10.1016/0166-4328(93)90032-L; MILLER MW, 1993, J COMP NEUROL, V335, P283, DOI 10.1002/cne.903350211; MITCHELL IJ, 1984, BRAIN RES, V298, P191, DOI 10.1016/0006-8993(84)91168-5; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PAPPIUS HM, 1982, ANN NEUROL, V12, P157, DOI 10.1002/ana.410120205; PESCHANSKI M, 1984, NEUROSCIENCE, V12, P465, DOI 10.1016/0306-4522(84)90066-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Ramachandran R., 1993, Society for Neuroscience Abstracts, V19, P1447; ROBINSON RG, 1994, SCIENCE, V205, P707; RODRIGUEZ M, 1993, PHYSIOL BEHAV, V54, P91, DOI 10.1016/0031-9384(93)90048-K; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; SCHALLERT T, 1984, BEHAV NEUROSCI, V3, P518; SCHWARTING RKW, 1990, PHARMACOL BIOCHEM BE, V35, P989, DOI 10.1016/0091-3057(90)90389-Y; SHARP FR, 1984, NEUROLOGY, V34, P1305, DOI 10.1212/WNL.34.10.1305; SHARP JW, 1988, BRAIN RES, V438, P357, DOI 10.1016/0006-8993(88)91363-7; SHERMAN GF, 1980, BRAIN RES, V192, P61, DOI 10.1016/0006-8993(80)91008-2; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V23, P897; STEINER H, 1989, EXP BRAIN RES, V77, P421, DOI 10.1007/BF00275000; SULLIVAN RM, 1994, BRAIN RES, V637, P114, DOI 10.1016/0006-8993(94)91223-8; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TOLDI J, 1994, NEUROSCI LETT, V167, P1, DOI 10.1016/0304-3940(94)91014-6; TOLDI J, 1990, NEUROSCIENCE, V37, P675, DOI 10.1016/0306-4522(90)90098-O; TRACEY DJ, 1985, RAT NERVOUS SYSTEM, P136; TRUGMAN JM, 1986, BRAIN RES, V379, P264, DOI 10.1016/0006-8993(86)90780-8; VOLGYI B, 1993, NEUROREPORT, V4, P827; Von Monakow C, 1969, BRAIN BEHAVIOR, P27; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; WELKER C, 1971, J COMP NEUROL, V166, P173; WELKER E, 1992, J NEUROSCI, V12, P153; WISE SP, 1976, J COMP NEUROL, V168, P313, DOI 10.1002/cne.901680302; WOLFF JR, 1992, J COMP NEUROL, V317, P187, DOI 10.1002/cne.903170207; Zilles K., 1985, RAT NERVOUS SYSTEM, P375	92	27	27	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 27	1995	675	1-2					143	156		10.1016/0006-8993(95)00050-Z			14	Neurosciences	Neurosciences & Neurology	QQ322	WOS:A1995QQ32200019	7796123				2021-06-18	
J	MCINTOSH, TK; FERNYAK, S; YAMAKAMI, I; FADEN, AI				MCINTOSH, TK; FERNYAK, S; YAMAKAMI, I; FADEN, AI			CENTRAL AND SYSTEMIC KAPPA-OPIOID AGONISTS EXACERBATE NEUROBEHAVIORAL RESPONSE TO BRAIN INJURY IN RATS	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						ENDOGENOUS OPIOIDS; FLUID-PERCUSSION	SPINAL-CORD INJURY; DYNORPHIN-RELATED PEPTIDES; EXCITATORY AMINO-ACIDS; GUINEA-PIG BRAIN; RECEPTOR AGONIST; INTRATHECAL INJECTION; NONOPIOID MECHANISMS; HINDLIMB PARALYSIS; ENDOGENOUS OPIOIDS; MOTOR DYSFUNCTION	The endogenous opioid peptide dynorphin has been implicated in the pathophysiology of secondary tissue injury after central nervous system (CNS) trauma. The detrimental effects of dynorphin appear to be mediated through both opioid receptors (probably kappa-receptors) and nonopioid mechanisms. However, both kappa-opioid agonists and antagonists have been reported to improve outcome in models of CNS trauma. To attempt to clarify this controversy, we examined the effects of centrally or systemically administered kappa-opioid agonists on neurological recovery after experimental fluid-percussion brain injury in the rat. Agonists included dynorphin-A-(1-17) [Dyn A-(1-17)], which has actions at both kappa(1)- and kappa(2)-sites, and the selective kappa(1)-agonlsts U-50,488H and U-69,593. des-Tyr-dynorphin A-(2-17) [Dyn A-(2-17)], which is inactive at opioid receptors, was also used. Microinjection of Dyn A-(1-17), but not Dyn A-(2-17) or U-50,488H, into the lateral ventricle 15 min before brain injury significantly worsened motor deficits over a 2-wk period. However, systemic administration of high doses of the kappa-agonists U-50;488H and U-69,593 also significantly worsened neurologi cal outcome. These results fail to demonstrate any protective actions of kappa(1)-agonists in this model of experimental traumatic brain injury and suggest that the opioid-related pathophysiological actions of dynorphin may be mediated by kappa(2)-opioid receptors.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; CHIBA UNIV,DEPT NEUROSURG,CHIBA 28913,JAPAN; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007	MCINTOSH, TK (corresponding author), UNIV PENN,DEPT SURG,DIV NEUROSURG,105 HAYDEN HALL,240 S 33RD ST,PHILADELPHIA,PA 19104, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-26818, R01 NS-27849] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849, R01NS026818] Funding Source: NIH RePORTER		ALZHEIMER C, 1990, J PHARMACOL EXP THER, V255, P900; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793; BIRCH PJ, 1991, BRIT J PHARMACOL, V103, P1819, DOI 10.1111/j.1476-5381.1991.tb09869.x; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; CONTRERAS PC, 1991, BRAIN RES, V546, P79, DOI 10.1016/0006-8993(91)91161-S; DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; DEVLIN T, 1990, J PHARMACOL EXP THER, V253, P749; Faden A I, 1987, Cent Nerv Syst Trauma, V4, P227; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1985, PEPTIDES, V6, P15, DOI 10.1016/0196-9781(85)90006-3; FADEN AI, 1993, HDB EXPT PHARM, P325; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GANNON RL, 1991, BRAIN RES, V548, P242, DOI 10.1016/0006-8993(91)91127-M; HALL E, 1987, BRAIN RES, V436, P174; HALL E, 1990, STROKE, V21, P327; HAN JS, 1982, LIFE SCI, V31, P1781, DOI 10.1016/0024-3205(82)90209-0; HAYES AG, 1988, J PHARM PHARMACOL, V40, P718, DOI 10.1111/j.2042-7158.1988.tb07002.x; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; HUNTER JC, 1990, BRIT J PHARMACOL, V101, P183, DOI 10.1111/j.1476-5381.1990.tb12110.x; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; KRUMINS SA, 1985, BIOCHEM BIOPH RES CO, V127, P120, DOI 10.1016/S0006-291X(85)80134-0; KUSUMOTO K, 1992, BRAIN RES, V576, P147, DOI 10.1016/0006-8993(92)90621-F; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LASON W, 1989, BRAIN RES, V482, P333, DOI 10.1016/0006-8993(89)91196-7; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; MCFADZEAN I, 1987, NEUROSCIENCE, V20, P231, DOI 10.1016/0306-4522(87)90015-7; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1993, J CEREB BLOOD FLOW S, V11, pS7334; MOISES HC, 1985, EUR J PHARMACOL, V108, P85, DOI 10.1016/0014-2999(85)90286-9; PAXINOS G, 1990, STEREOTAXIC ATLAS RA; PINNOCK RD, 1992, NEUROSCIENCE, V47, P87; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; ROTHMAN RB, 1990, PEPTIDES, V11, P311, DOI 10.1016/0196-9781(90)90088-M; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; SPAMPINATO S, 1985, EUR J PHARMACOL, V110, P21, DOI 10.1016/0014-2999(85)90024-X; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1990, J NEUROSCI, V10, P3524; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	57	27	28	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0002-9513			AM J PHYSIOL	Am. J. Physiol.	SEP	1994	267	3	2				R665	R672					8	Physiology	Physiology	PH383	WOS:A1994PH38300054	7916537				2021-06-18	
J	OKIYAMA, K; ROSENKRANTZ, TS; SMITH, DH; GENNARELLI, TA; MCINTOSH, TK				OKIYAMA, K; ROSENKRANTZ, TS; SMITH, DH; GENNARELLI, TA; MCINTOSH, TK			(S)-EMOPAMIL ATTENUATES ACUTE REDUCTION IN REGIONAL CEREBRAL BLOOD-FLOW FOLLOWING EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							CALCIUM-CHANNEL BLOCKER; ACUTE HEAD-INJURY; ISCHEMIC BRAIN; ARTERY OCCLUSION; ENERGY-METABOLISM; GLUCOSE-UTILIZATION; CONSCIOUS RATS; MICROSPHERES; ANTAGONIST; NIMODIPINE	We examined the effects of (S)-emopamil, a phenylalkylamine calcium channel blocker with serotonin receptor antagonist properties, on regional cerebral blood flow (rCBF) following experimental brain injury in the rat. Animals were subjected to fluid percussion brain injury of moderate severity (2.1 atm), and received (S)-emopamil (20 mg/kg, i.p., n = 10) or saline (n = 10) at 20 minutes postinjury and 2.5 hours after the first injection of the drug. Consecutive rCBF measurements were performed: (1) prior to injury, (2) 15 minutes, (3) 90 minutes, and (4) 4 hours postinjury, using the radiolabeled microsphere technique. Brain injury produced an acute and significant reduction of rCBF at 15 minutes postinjury in all the regions examined (p < 0.05). At 90 minutes postinjury, rCBF remained significantly de-pressed in the forebrain regions. All brain regions showed a recovery of rCBF to normal by 4 hours following injury in saline-treated animals, with the exception of injured left parietal cortex and bilateral hippocampi, where rCBF remained significantly depressed. A significant attenuation of the trauma-induced reduction in rCBF was observed at 70 minutes after the first administration of (S)-emopamil in the forebrain regions and cerebellum (p < 0.05). Following the second (S)-emopamil injection, the significant improvement in rCBF observed in left injured cortex was maintained. These results suggest that (S)-emopamil may be efficacious in reversing post-traumatic alterations in rCBF, which may contribute to the post-traumatic pathophysiologic sequelae.	UNIV PENN, DIV NEUROSURG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA			smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818, R55NS026818, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818, NS08803] Funding Source: Medline		ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; BAER RW, 1984, AM J PHYSIOL, V246, pH418; BIELENBERG GW, 1987, J CEREBR BLOOD F MET, V7, P480, DOI 10.1038/jcbfm.1987.91; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BUCKBERG GD, 1971, J APPL PHYSIOL, V31, P598; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEFEUDIS FV, 1989, TRENDS PHARMACOL SCI, V10, P215, DOI 10.1016/0165-6147(89)90262-9; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARRIS RJ, 1982, STROKE, V13, P759, DOI 10.1161/01.STR.13.6.759; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEISS WD, 1976, ARCH NEUROL-CHICAGO, V33, P813, DOI 10.1001/archneur.1976.00500120017003; HOFFMAN WE, 1981, LIFE SCI, V28, P2167, DOI 10.1016/0024-3205(81)90624-X; HOFMANN HP, 1989, ARZNEIMITTEL-FORSCH, V39-1, P304; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JACEWICZ M, 1986, J CEREBR BLOOD F MET, V6, P263, DOI 10.1038/jcbfm.1986.48; JACEWICZ M, 1992, J CEREBR BLOOD F MET, V12, P359, DOI 10.1038/jcbfm.1992.53; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; KUSCHINSKY W, 1978, PHYSIOL REV, V58, P656; LIN BW, 1990, STROKE, V21, P1734, DOI 10.1161/01.STR.21.12.1734; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYDIC R, 1991, J COMP NEUROL, V304, P517, DOI 10.1002/cne.903040402; MADSEN PL, 1991, J CEREBR BLOOD F MET, V11, P502, DOI 10.1038/jcbfm.1991.94; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; MEMEZAWA H, 1992, EXP BRAIN RES, V89, P67; MENDELOW AD, 1984, STROKE, V15, P704, DOI 10.1161/01.STR.15.4.704; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MOHAMED AA, 1984, J CEREBR BLOOD F MET, V4, P206, DOI 10.1038/jcbfm.1984.29; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PENFIELD W, 1937, RES PUBL ASS NERV ME, V18, P605; PLUM F, 1968, ARCH NEUROL-CHICAGO, V18, P1; RUBANYI GM, 1991, J CELL BIOCHEM, V46, P27, DOI 10.1002/jcb.240460106; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SIESJO BK, 1991, THROMBOLYTIC THERAPY, P60; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOKOLOFF L, 1981, FED PROC, V40, P2311; STANEK KA, 1983, AM J PHYSIOL, V245, pH920; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1985, BRIT J ANAESTH, V57, P34, DOI 10.1093/bja/57.1.34; SYMON L, 1974, STROKE, V5, P355, DOI 10.1161/01.STR.5.3.355; SZABO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P309; SZABO L, 1989, ARZNEIMITTELFORSCH, V39-1, P314; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; TSUCHIYA M, 1977, AM J PHYSIOL, V233, pH617; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; VORSTRUP S, 1986, J CEREBR BLOOD F MET, V6, P222, DOI 10.1038/jcbfm.1986.35; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	76	27	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1994	11	1					83	95		10.1089/neu.1994.11.83			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	NC365	WOS:A1994NC36500005	8201628				2021-06-18	
J	HOVDA, DA; FU, K; BADIE, H; SAMII, A; PINANONG, P; BECKER, DP				HOVDA, DA; FU, K; BADIE, H; SAMII, A; PINANONG, P; BECKER, DP			ADMINISTRATION OF AN OMEGA-CONOPEPTIDE ONE-HOUR FOLLOWING TRAUMATIC BRAIN INJURY REDUCES CA-45 ACCUMULATION	ACTA NEUROCHIRURGICA			English	Article						CALCIUM; BRAIN INJURY; CONCUSSION	CEREBRAL BLOOD-FLOW	The omega-conopeptide, SNX-111 (NEUREX Corporation) was administered to rats 1 hour following a lateral fluid percussion brain injury to determine if the drug could reduced the extent and duration of trauma-induced calcium accumulation. Administration at doses of 3 or 5 mg/kg (i.v.) markedly reduced the extent of calcium accumulation as determined using calcium-45 autoradiography primarily within the cerebral cortex and hippocampus. The reduction of calcium accumulation was particularly event within the parietal cortex beginning as early as 6 hours and lasting out to 48 hours following injury. Although not as effective as in the cerebral cortex, SNX-111 did exhibit a reduction of calcium accumulation within the dorsal hippocampus especially at 24 and 48 hours after the insult. These preliminary results demonstrate that SNX-111 can reduce the injury-induced accumulation of calcium even when administered 1 hour after the insult and offers this compound as a potential therapeutic treatment for traumatic brain injury.	UNIV CALIF LOS ANGELES, SCH MED, INST BRAIN RES, LOS ANGELES, CA 90024 USA	HOVDA, DA (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, 74-140 CHS, LOS ANGELES, CA 90024 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		FINEMAN I, 1993, IN PRESS BRAIN RES; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	5	27	27	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			521	523					3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600143	7976637				2021-06-18	
J	CRUZ, J; GENNARELLI, TA; ALVES, WM				CRUZ, J; GENNARELLI, TA; ALVES, WM			CONTINUOUS MONITORING OF CEREBRAL HEMODYNAMIC RESERVE IN ACUTE BRAIN INJURY - RELATIONSHIP TO CHANGES IN BRAIN-SWELLING	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	51ST ANNUAL SESSION OF THE AMERICAN ASSOC FOR THE SURGERY OF TRAUMA	SEP 11-14, 1991	PHILADELPHIA, PA	AMER ASSOC SURG TRAUMA			BLOOD-FLOW; COMATOSE PATIENTS	A new concept of cerebral hemodynamic and metabolic physiology, cerebral hemodynamic reserve (CHR), was evaluated in 20 comatose adults with acute traumatic brain swelling who were undergoing continuous monitoring of the arteriojugular difference in oxyhemoglobin saturation, along with cerebral perfusion pressure and expired PCO2. The CHR was measured as the ratio of relative (percent) changes in cerebral oxygen extraction to relative changes in cerebral perfusion pressure during spontaneous increases in intracranial pressure. In patients with initially severe brain swelling, the CHR was more frequently abnormal (compromised) on the first day, and tended to improve on the second day. In patients with initially moderate brain swelling, the CHR was more frequently normal (preserved) on the first day, but tended to become compromised on the second day if the brain swelling exacerbated. It is concluded that cerebral hemodynamic reserve abnormalities very closely associate with signs of increased intracranial "tightness" on computed tomographic scans of the head. Cerebral hemodynamic reserve could therefore become an important guide in the functional evaluation and management of acute brain swelling (focusing on cerebral oxygenation and perfusion pressure) in a variety of predominantly diffuse acute intracranial disorders.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HEAD INJURY CTR,PHILADELPHIA,PA 19104					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803-19] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303687-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER		BAELE PL, 1982, ANESTH ANALG, V61, P513; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1992, J TRAUMA, V32, P401, DOI 10.1097/00005373-199203000-00020; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1984, Society for Neuroscience Abstracts, V10, P542; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; CRUZ J, 1984, 52ND ANN M AM ASS NE; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385; GUILLAUME J, 1951, REV NEUROL, V84, P131; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Lundberg N, 1960, ACTA PSYCHIAT NEUR S, V36, P149; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; TEASDALE G, 1974, LANCET, V2, P81	18	27	27	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1992	32	5					629	635		10.1097/00005373-199205000-00015			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	HW811	WOS:A1992HW81100015	1588652				2021-06-18	
J	MCGUIRT, WF; STOOL, SE				MCGUIRT, WF; STOOL, SE			TEMPORAL BONE-FRACTURES IN CHILDREN - A REVIEW WITH EMPHASIS ON LONG-TERM SEQUELAE	CLINICAL PEDIATRICS			English	Article							HEAD-INJURY; FACIAL PARALYSIS	A 10-year retrospective study of pediatric basilar skull fractures identified 102 patients with temporal bone fractures, of which 92 had otolaryngologic and audiologic evaluations. The otologic data provide documentation of the nature, common physical findings, complications, and management of these fractures. The prognosis of hearing impairment in children caused by temporal bone fractures is elucidated, as 76 of the 92 patients were available for long-term follow-up. Close interaction between involved services evaluating and treating pediatric trauma cases is mandatory for optimal patient outcome. A literature review of the presentation, complications, and management of pediatric temporal bone fractures is presented.	CHILDRENS HOSP,PEDIAT & OTOLARYNGOL,PITTSBURGH,PA 15213	MCGUIRT, WF (corresponding author), UNIV PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213, USA.						AQUILAR EA, 1987, HEAD NECK SURG, V9, P162; BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; BRAWLEY BW, 1967, J NEUROSURG, V26, P56; CALDICOTT WJ, 1973, J NEUROSURG, V38, P1, DOI 10.3171/jns.1973.38.1.0001; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; EAVEY RD, 1989, ARCH OTOLARYNGOL, V115, P600; FISCH U, 1974, LARYNGOSCOPE, V84, P2141, DOI 10.1288/00005537-197412000-00005; FISCH U, 1984, AM J OTOL, V5, P494; GOODWIN WJ, 1983, OTOLARYNG CLIN N AM, V16, P651; GRIFFIN JE, 1979, LARYNGOSCOPE, V89, P1432, DOI 10.1002/lary.5540890908; GRIFFITH MV, 1979, J LARYNGOL OTOL, V93, P252; GROVE WE, 1939, LARYNGOSCOPE, V45, P678; HARKER LA, 1974, OTOLARYNG CLIN N AM, V7, P425; HASSO AN, 1988, OTOLARYNG CLIN N AM, V21, P295; Hendrick E B, 1964, Clin Neurosurg, V11, P46; Hicks G W, 1980, Laryngoscope, V90, P1, DOI 10.1288/00005537-198011001-00001; HOUGH JVD, 1969, ANN OTO RHINOL LARYN, V78, P210, DOI 10.1177/000348946907800202; Klastersky J, 1976, Surg Neurol, V6, P111; LEECH PJ, 1973, LANCET, V1, P1013; LINDSAY JR, 1976, ANN OTO RHINOL LARYN, V86, P699; LIUSHINDO M, 1989, INT J PEDIATR OTORHI, V17, P109, DOI 10.1016/0165-5876(89)90086-4; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MAKASHIMA K, 1975, ARCH OTOLARYNGOL, V101, P426; MAY M, 1979, LARYNGOSCOPE, V89, P906; MAY M, 1982, DISORDERS FACIAL NER, P413; MEALEY J, 1982, PEDIAT NEUROSURGERY, P292; Muller D, 1965, HNO, V13, P161; PODOSHIN L, 1975, ARCH OTOLARYNGOL, V101, P15; SCHUBIGER O, 1986, NEURORADIOLOGY, V28, P93, DOI 10.1007/BF00327878; SCHUKNECHT JF, 1969, ANN OTO RHINOL LARYN, V78, P253; Tos M, 1971, J Laryngol Otol, V85, P1147, DOI 10.1017/S0022215100074569; TOS M, 1973, ACTA OTO-LARYNGOL, V75, P353, DOI 10.3109/00016487309139745; VARTIAINEN E, 1985, ACTA OTO-LARYNGOL, V99, P529, DOI 10.3109/00016488509182257; WIET RJ, 1985, AM J OTOL, V6, P207	34	27	27	0	1	WESTMINSTER PUBL INC	GLEN HEAD	708 GLEN COVE AVE, GLEN HEAD, NY 11545	0009-9228			CLIN PEDIATR	Clin. Pediatr.	JAN	1992	31	1					12	18		10.1177/000992289203100103			7	Pediatrics	Pediatrics	HE454	WOS:A1992HE45400003	1737413				2021-06-18	
J	HARTLEY, LL; LEVIN, HS				HARTLEY, LL; LEVIN, HS			LINGUISTIC DEFICITS AFTER CLOSED HEAD-INJURY - A CURRENT APPRAISAL	APHASIOLOGY			English	Article										HARTLEY, LL (corresponding author), GALVESTON INST HUMAN COMMUN,TRANSIT LEARNING COMMUNITY,1528 PO,GALVESTON,TX 77550, USA.							0	27	28	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	JUL-AUG	1990	4	4					353	370		10.1080/02687039008249088			18	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	DT690	WOS:A1990DT69000005					2021-06-18	
J	CRAGOE, EJ				CRAGOE, EJ			DRUGS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY	MEDICINAL RESEARCH REVIEWS			English	Article										CRAGOE, EJ (corresponding author), MERCK SHARP & DOHME RES LABS, W POINT, PA 19486 USA.						AUEN EL, 1979, ACTA NEUROPATHOL, V47, P175, DOI 10.1007/BF00690544; Avezaat C J, 1979, Acta Neurochir Suppl (Wien), V28, P26; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; BARRON KD, 1986, ANN NEUROL, V20, P144; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; BELOPAVLOVIC M, 1980, ANAESTHESIA, V35, P235, DOI 10.1111/j.1365-2044.1980.tb05090.x; BLACK KL, 1979, CLIN RES, V27, pA714; BOURKE RS, 1976, BRAIN RES, V105, P309, DOI 10.1016/0006-8993(76)90427-3; BOURKE RS, 1978, BRAIN RES, V154, P196, DOI 10.1016/0006-8993(78)91072-7; BOURKE RS, 1969, EXP BRAIN RES, V8, P232; BOURKE RS, 1983, NEUROCHEM RES, V8, P5, DOI 10.1007/BF00965650; BOURKE RS, 1981, J NEUROSURG, V55, P364, DOI 10.3171/jns.1981.55.3.0364; BOURKE RS, 1979, STUDIES FORMATION AS, P108; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; BURG M, 1973, KIDNEY INT, V4, P301, DOI 10.1038/ki.1973.121; CANDIA OA, 1981, AM J PHYSIOL, V240, pF25; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CASTANER J, 1978, Drugs of the Future, V3, P229; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; COTTRELL JE, 1977, ANESTHESIOLOGY, V47, P28, DOI 10.1097/00000542-197707000-00006; CRAGOE EJ, 1986, J MED CHEM, V29, P825, DOI 10.1021/jm00155a038; CRAGOE EJ, 1982, J MED CHEM, V25, P567, DOI 10.1021/jm00347a017; CRAGOE EJ, 1986, Patent No. 4579869; CRAGOE EJ, 1903, Patent No. 741068; CRAGOE EJ, 1986, Patent No. 4604396; CRAGOE EJ, 1857, Patent No. 17403; CRAGOE EJ, 1983, DIURETICS CHEM BIOL, P212; CRAGOE EJ, 1982, Patent No. 4316043; CRAGOE EJ, 1984, DIURETICS CHEM PHARM, P12; CROSS PE, 1978, J MED CHEM, V21, P845, DOI 10.1021/jm00207a001; DAVISON C, 1961, J PHARMACOL EXP THER, V133, P161; DODSON RF, 1977, J NEUROL SCI, V33, P161, DOI 10.1016/0022-510X(77)90190-3; Ehrenreich DL, 1961, ARCH NEUROL-CHICAGO, V5, P125; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GAAB M, 1979, J NEUROL, V220, P185, DOI 10.1007/BF00705536; GARAY RP, 1986, N-S ARCH PHARMACOL, V334, P202, DOI 10.1007/BF00505823; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; GRONWALL D, 1974, LANCET, V2, P605; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JANE JA, 1982, HEAD INJURY BASIC CL, P229; JENNETT B, 1980, TRENDS NEUROSCI, V3, pR1, DOI 10.1016/S0166-2236(80)80059-2; JENNETT B, 1981, MANAGEMENT HEAD INJU, P317; KIMELBERG H K, 1986, Society for Neuroscience Abstracts, V12, P86; Kimelberg H.K., 1982, HEAD INJURY BASIC CL, P31; KIMELBERG HK, 1986, BIOCHEM PHARMACOL, V35, P2273, DOI 10.1016/0006-2952(86)90451-X; KIMELBERG HK, 1983, CELL MOL NEUROBIOL, V3, P1, DOI 10.1007/BF00734994; KIMELBERG HK, 1979, BRAIN RES, V173, P111; KIMELBERG HK, 1981, BIOCHIM BIOPHYS ACTA, V646, P179, DOI 10.1016/0005-2736(81)90285-6; KIMELBERG HK, 1979, NEURAL TRAUMA, P137; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; KIMELBERG HK, IN PRESS CENTRAL NER; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kraus J F, 1978, Adv Neurol, V19, P261; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LONG DM, 1976, HDB CLIN NEUROLOGY 2, V24, P627; LORBER J, 1973, J NEUROSURG, V39, P702, DOI 10.3171/jns.1973.39.6.0702; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MARSHALL LF, 1977, CEREBRAL FUNCTION ME, P156; MARSHALL LF, 1979, SEMINARS NEUROLOGICA, P347; Meinig G, 1980, Adv Neurol, V28, P471; METZEL E, 1981, NEUROCHIRURGIA, V24, P15; MUYAZAKI Y, 1969, ARZNEI-FORSCHUNG, V19, P1961; NELSON LR, 1979, SEMINARS NEUROLOGICA, P297; NELSON LR, 1981, HEAD INJURY BASIC CL, P117; NELSON LR, 1979, SOC NEUR ABSTR, V5, P516; PARDRIDGE WM, 1986, FASEB J, V45, P2047; PIETRUSZKIEWICZ AM, 1857, Patent No. 17379; POPE A, 1978, DYNAMIC PROPERTIES G, P13; RANDALL WC, 1983, COMMUNICATION; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; ROTIN D, 1987, CANCER RES, V47, P1497; SCHWAM H, 1984, INVEST OPHTHALMOL  S, V25, P181; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TOCCO DJ, 1984, COMMUNICATION; TOTTEN J, 1979, LANCET, V1, P369; WARREN SE, 1981, ARCH INTERN MED, V141, P493, DOI 10.1001/archinte.141.4.493; WILKINSON HA, 1971, J NEUROSURG, V34, P203, DOI 10.3171/jns.1971.34.2part1.0203; WISE BL, 1961, ARCH NEUROL-CHICAGO, V4, P200, DOI 10.1001/archneur.1961.00450080082009; WOLTERSDORF OW, 1977, J MED CHEM, V20, P1400, DOI 10.1021/jm00221a010; WOLTERSDORF OW, 1983, Patent No. 4394385; WOLTERSDORF OW, 1978, ACS SYM SER, V83, P190; YEN JK, 1978, J NEUROL NEUROSUR PS, V41, P1125, DOI 10.1136/jnnp.41.12.1125; YEN JK, 1979, SEMINARS NEUROLOGICA, P329; ZIMMERMAN RA, 1979, SEMINARS NEUROLOGICA, P253; DHEW PSH791120 PUBL; 1981, MED WORLD NEWS, P56; 1979, UNPUB MORTALITY STAT	92	27	27	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0198-6325	1098-1128		MED RES REV	Med. Res. Rev.	JUL-SEP	1987	7	3					271	305		10.1002/med.2610070302			35	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	J0934	WOS:A1987J093400001	3306216				2021-06-18	
J	BENNETTLEVY, JM				BENNETTLEVY, JM			LONG-TERM EFFECTS OF SEVERE CLOSED HEAD-INJURY ON MEMORY - EVIDENCE FROM A CONSECUTIVE SERIES OF YOUNG-ADULTS	ACTA NEUROLOGICA SCANDINAVICA			English	Article									RADCLIFFE INFIRM, NEUROPSYCHOL UNIT, OXFORD OX2 6HE, ENGLAND				Bennett-Levy, James/0000-0003-0998-116X			ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENNETTLEVY J, 1984, BRIT J CLIN PSYCHOL, V23, P109, DOI 10.1111/j.2044-8260.1984.tb00634.x; BENNETTLEVY J, 1980, CORTEX, V16, P543, DOI 10.1016/S0010-9452(80)80002-5; BLAKEMORE CB, 1967, J NEUROL NEUROSUR PS, V30, P364, DOI 10.1136/jnnp.30.4.364; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Conkey RC, 1938, ARCH PSYCHOL, P5; DYE OA, 1981, J CLIN PSYCHOL, V37, P472, DOI 10.1002/1097-4679(198107)37:3<472::AID-JCLP2270370304>3.0.CO;2-Q; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; JENNETT B, 1975, LANCET, V1, P480; LAWLER KA, 1981, THESIS OXFORD U; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Miller E, 1970, Cortex, V6, P121; MOONEY CM, 1956, CAN J PSYCHOLOGY, V10, P191, DOI 10.1037/h0083671; NELSON HE, 1975, BRIT J SOC CLIN PSYC, V14, P259, DOI 10.1111/j.2044-8260.1975.tb00178.x; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Newcombe F., 1969, MISSILE WOUNDS BRAIN; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Russell W Ritchie, 1934, Edinb Med J, V41, P129; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SMITH E, 1974, J NEUROL NEUROSUR PS, V37, P719, DOI 10.1136/jnnp.37.6.719; STEVENS M, 1979, BRIT PSYCHOL SOC C N; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; YNTEMA DB, 1963, HUM FACTORS, V5, P7, DOI 10.1177/001872086300500102	37	27	28	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.		1984	70	4					285	298					14	Clinical Neurology	Neurosciences & Neurology	TP933	WOS:A1984TP93300004	6507038				2021-06-18	
J	PARSONS, LC; BEEK, DV				PARSONS, LC; BEEK, DV			SLEEP-AWAKE PATTERNS FOLLOWING CEREBRAL CONCUSSION	NURSING RESEARCH			English	Article									UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22903; GREENVILLE GEN HOSP,GREENVILLE,SC	PARSONS, LC (corresponding author), UNIV VIRGINIA,SCH NURSING,CHARLOTTESVILLE,VA 22903, USA.						ADEY WR, 1968, ARCH NEUROL-CHICAGO, V19, P377, DOI 10.1001/archneur.1968.00480040043003; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; BERGAMASCO B, 1968, ACTA NEUROL SCAND, V44, P495, DOI 10.1111/j.1600-0404.1968.tb05588.x; COURJON J, 1972, CLIN EEG 4, V14, P47; COURJON J, 1962, CAH MED LYON, V38, P315; Duensing F, 1948, NERVENARZT, V19, P544; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; Foulkes D, 1970, Int Psychiatry Clin, V7, P147; GRONWALL, 1974, LANCET, V2, P605; HARTMANN E, 1970, INT PSYCHIATRY CLIN, V7, P64; LADURNER G, 1970, ELECTROENCEPHALOGER, V28, pP326; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LORENZONI E, 1963, WIEN MED WSCHR, V42, P787; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; MONROE LJ, 1965, J PERS SOC PSYCHOL, V2, P456, DOI 10.1037/h0022218; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARSONS LC, 1981, NEUROSCI LETT, V24, P199, DOI 10.1016/0304-3940(81)90248-2; PARSONS LC, 1967, PHYSIOLOGIST, V10, P273; PARSONS LC, 1980, NEUR ABST, V8, P12; PARSONS LC, 1968, THESIS U TEXAS MED B; PETERSON PJ, 1981, THESIS U VIRGINIA SC; RICHARDSON JC, 1951, CAN MED ASSOC J, V64, P414; STRICH SJ, 1961, LANCET, V2, P443; TAUB JM, 1973, PSYCHOPHYSIOLOGY, V10, P559, DOI 10.1111/j.1469-8986.1973.tb00805.x; TEASDALE G, 1974, LANCET, V2, P81	27	27	27	0	2	AMER J NURSING CO	NEW YORK	555 W 57TH ST, NEW YORK, NY 10019-2961	0029-6562			NURS RES	Nurs. Res.		1982	31	5					260	264					5	Nursing	Nursing	PG320	WOS:A1982PG32000002	6922465				2021-06-18	
J	CRAMER, F; PASTER, S; STEPHENSON, C				CRAMER, F; PASTER, S; STEPHENSON, C			CEREBRAL INJURIES DUE TO EXPLOSION WAVES - CEREBRAL BLAST CONCUSSION - A PATHOLOGIC, CLINICAL AND ELECTROENCEPHALOGRAPHIC STUDY	ARCHIVES OF NEUROLOGY AND PSYCHIATRY			English	Article																Abbott WD, 1943, J AMER MED ASSOC, V121, P739, DOI 10.1001/jama.1943.02840100025007; Abbott WD, 1943, J AMER MED ASSOC, V121, P664, DOI 10.1001/jama.1943.02840090034010; AITA J A, 1946, Bull U S Army Med Dep, V6, P411; Ascroft PB, 1943, LANCET, V1, P234; Barrow DW, 1944, J AMER MED ASSOC, V125, P900, DOI 10.1001/jama.1944.02850310020006; Bell R C, 1944, Br Med J, V2, P689; Bernal JD, 1941, NATURE, V147, P594, DOI 10.1038/147594a0; BETTINGTON RHB, 1945, MED J AUSTRALIA, V2, P210; Bollinger O, 1891, INT BEITRAGE WEISSEN, P457; Brazier MAB, 1944, J CLIN INVEST, V23, P303, DOI 10.1172/JCI101495; BRUBAKER RE, 1945, B US ARMY M DEP, V87, P110; COHEN H, 1946, ARCH PATHOL, V42, P12; COREY E L, 1946, U S Nav Med Bull, V46, P623; Davis PA, 1941, J NEUROPHYSIOL, V4, P92; DAVISON C, 1946, ARCH NEURO PSYCHIATR, V55, P111, DOI 10.1001/archneurpsyc.1946.02300130037002; DAVISON C, 1946, ARCH NEURO PSYCHIATR, V55, P126, DOI 10.1001/archneurpsyc.1946.02300130052003; DAVISON C, 1946, ARCH NEURO PSYCHIATR, V55, P364, DOI 10.1001/archneurpsyc.1946.02300150068005; DENNYBROWN D, 1943, T AM NEUROL ASSOC, V69, P98; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; FEARNLEY GR, 1945, BMJ-BRIT MED J, V1, P474, DOI 10.1136/bmj.1.4396.474; Fulton J. F., 1942, NEW ENGL J MED, V226, P1; GANADO W, 1943, BMJ-BRIT MED J, V2, P118; GARAI O, 1944, LANCET, V1, P788; Gibbs FA, 1943, ARCH NEURO PSYCHIATR, V50, P111, DOI 10.1001/archneurpsyc.1943.02290200011001; Grinker Roy R, 1943, WAR NEUROSES N AFRIC; GRINKER RR, COMMUNICATION; Groat RA, 1944, AM J PHYSIOL, V141, P0117; GRUNNAGLE JF, TRAUMATIC INTRACEREB; GUTMAN PE, 1944, AM J SURG, V45, P408; Hamlin H., 1943, U S NAVAL MED BULL, V41, P26; HASSIN GB, 1940, INJURIES SKULL BRAIN, P13; JASPER H, 1945, ASS RES NERV MENT DI, V24, P388; Jefferson G, 1944, BRIT MED J, V1944, P1; JEFFERSON G, 1943, T AM NEUROL A, V69, P13; POLLOCK LJ, 1943, ILLINOIS M J, V83, P165; ROBINSON CS, 1944, EXPLOSIONS THEIR ANA; ROGERS L, 1945, MED J AUSTRALIA, V2, P209; Rowbotham G. F., 1945, ACUTE INJURIES HEAD; STALLARD HB, 1944, BMJ-BRIT MED J, V2, P330; Stewart OW, 1941, LANCET, V1, P172; Sutherland GA, 1940, LANCET, V2, P641; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; TUNBRIDGE RE, 1945, WAR MED, V7, P3; TURNER EA, 1945, BRAIN, V68, P98, DOI 10.1093/brain/68.2.98; VONSTORCH TJC, 1945, STUDY CEREBRAL CONCU; WAKELEY CPG, 1945, LANCET, V248, P715; WILLIAMS D, 1945, BRAIN, V68, P123, DOI 10.1093/brain/68.2.123; Wilson JV, 1943, BMJ-BRIT MED J, V1943, P470; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WOOD H, 1946, U S Nav Med Bull, V46, P51; ZUCKERMAN S, 1941, LANCET, V1, P110; 1945, B US ARMY M DEP, V4, P360; 1946, DIGEST NEUROL PSYCHI, V14, P145	54	27	27	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0096-6754			ARCH NEURO PSYCHIATR			1949	61	1					1	20					20	Psychiatry	Psychiatry	UF291	WOS:A1949UF29100001	18108324				2021-06-18	
J	Khan, M; Tisdall, M; James, G; Tahir, MZ				Khan, Mehdi; Tisdall, Martin; James, Greg; Tahir, Muhammad Zubair			Resistant Pseudomeningocele following Craniotomy for Non-Traumatic Acute Intracranial Haematoma in Very Young Children: Report of Four Cases	PEDIATRIC NEUROSURGERY			English	Article						Decompressive craniectomy; Traumatic brain injury; Intracranial haemorrhage; Leptomeningeal cyst	DECOMPRESSIVE CRANIECTOMY; HEMORRHAGE; REPAIR	Background: The incidence of non-traumatic intracranial haemorrhage among neonates is less than among adults. However, the outcomes are generally poor, with high rates of morbidity and mortality. Non-traumatic intracranial haemorrhage can cause a sudden increase in intracranial pressure, requiring emergency craniotomy for evacuation. Methods: We report 4 cases following craniotomy for non-traumatic acute intracranial haematoma in very young children. The surgical technique and postoperative course are discussed, with emphasis on dural repair to avoid resistant pseudomeningocele. Results: Despite successful management of the acutely raised intracranial pressure, all patients afterwards developed tense pseudomeningoceles and required formal dural repair. This led to a change in institutional practice and modifications to the surgical technique. Conclusion: The authors highlight the postoperative occurrence of resistant pseudomeningoceles in young children after clot evacuations and leaving the dura open. They describe the surgical procedures to avoid these pseudomeningoceles.	[Khan, Mehdi; Tisdall, Martin; James, Greg; Tahir, Muhammad Zubair] Children NHS Fdn Trust, Great Ormond St Hosp, London, England; [Tisdall, Martin; James, Greg; Tahir, Muhammad Zubair] UCL, Great Ormond St Inst Child Hlth, London, England	Tahir, MZ (corresponding author), Great Ormond St Hosp Sick Children, Dept Neurosurg, Great Ormond St, London WC1N 3JH, England.	zubair.tahir@gosh.nhs.uk		Tisdall, Martin/0000-0001-8880-8386			Aquilina K, 2012, J NEUROSURG-PEDIATR, V10, P529, DOI 10.3171/2012.8.PEDS11386; Aryan HE, 2004, NEUROSURGERY, V55, P235, DOI 10.1227/01.NEU.0000126951.74653.A6; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Lo WD, 2008, ARCH NEUROL-CHICAGO, V65, P1629, DOI 10.1001/archneurol.2008.502; Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028; Riyaz M, 2015, CHILD NERV SYST, V31, P2117, DOI 10.1007/s00381-015-2808-1; Vieira E, 2018, J NEUROSURG, V129, P1017, DOI 10.3171/2017.4.JNS152954	10	26	26	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	OCT	2019	54	5					319	323		10.1159/000502360			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	JF4GF	WOS:000491345100004	31533115				2021-06-18	
J	Cross, MJ; Tucker, R; Raftery, M; Hester, B; Williams, S; Stokes, KA; Ranson, C; Mathema, P; Kemp, S				Cross, Matthew J.; Tucker, Ross; Raftery, Martin; Hester, Ben; Williams, Sean; Stokes, Keith A.; Ranson, Craig; Mathema, Pray; Kemp, Simon			Tackling concussion in professional rugby union: a case-control study of tackle-based risk factors and recommendations for primary prevention	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INJURY; EVENTS	Background/aim Concussion, the most common injury in professional rugby union, occurs most commonly during the tackle. Thus, we investigated the association between tackle characteristics and concussion. Methods 182 video clips of tackles leading to clinically diagnosed concussion and 4619 tackles that did not were coded across three professional rugby union competitions. A variable selection process was undertaken to identify the most important variables for interpretation. A multivariate generalised linear model was used to model the association between retained variables and concussion risk. Magnitude-based inferences provided an interpretation of the real-world relevance of the outcomes. Results The four retained variables were: accelerating player, tackler speed, head contact type and tackle type. Overall, 70% of concussions occurred to the tackler and 30% to the ball carrier. There was a higher risk of concussion if the tackler accelerated into the tackle (OR: 2.49, 95% CI 1.70 to 3.64) or the tackler was moving at high speed (OR: 2.64, 95% CI 1.92 to 3.63). Head contact with the opposing player's head (OR: 39.9, 95% CI 22.2 to 71.1) resulted in a substantially greater risk of concussion compared with all other head contact locations. Conclusions Interventions that reduce the speed and acceleration of the tackler and reduce exposure to headto- head contact would likely reduce concussion risk in professional rugby union.	[Cross, Matthew J.; Kemp, Simon] Rugby Football Union, Prof Rugby Dept, London, England; [Cross, Matthew J.; Williams, Sean; Stokes, Keith A.] Univ Bath, Dept Hlth, Bath, Avon, England; [Tucker, Ross; Raftery, Martin; Hester, Ben] World Rugby, Dublin, Ireland; [Ranson, Craig] Cardiff Metropolitan Univ, Sports Injury Res Grp, Cardiff, S Glam, Wales; [Ranson, Craig; Mathema, Pray] Welsh Rugby Union, Cardiff, S Glam, Wales	Cross, MJ (corresponding author), Rugby Football Union, Prof Rugby Dept, Twickenham TW2 7BA, England.	m.cross@bath.ac.uk	Ranson, Craig/AAQ-5452-2020; Stokes, Keith/C-2605-2009	Ranson, Craig/0000-0002-3783-0505; Williams, Sean/0000-0003-1460-0085; Kemp, Simon/0000-0002-3250-2713; Stokes, Keith/0000-0002-5049-2838			Batten J, 2016, BRIT J SPORT MED, V50, P1293, DOI 10.1136/bjsports-2015-095949; Batterham AM, 2006, INTJ SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, CLIN J SPORT MED, V17, P182, DOI 10.1097/JSM.0b013e31805930b0; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Genuer R, 2010, PATTERN RECOGN LETT, V31, P2225, DOI 10.1016/j.patrec.2010.03.014; Greenland S, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1981; Hagel B, 2004, RISK COMPENSATION SI; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hopkins W., 2010, SPORTSCIENCE, V14, P49; Hopkins WG, 2007, SPORTSCIENCE, V11, P16; Kemp S, 2016, BR J SPORTS MED, V50; Lachance J, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-57; Li, 2004, APPL LINEAR REGRESSI; Li HJ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-291; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; Preatoni E, 2016, SCAND J MED SCI SPOR, V26, P1398, DOI 10.1111/sms.12592; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Raftery M, 2016, BRIT J SPORT MED, V50, P642, DOI 10.1136/bjsports-2016-095959; Rugby Football Union, 2017, PROF RUGB INJ SURV P; Seminati E, 2017, BRIT J SPORT MED, V51; Tierney GJ, 2016, BRAIN INJURY, V30, P1350, DOI 10.1080/02699052.2016.1193630; Tucker R, 2016, BRIT J SPORT MED, V50, P921, DOI 10.1136/bjsports-2016-096322; World Rugby, 2017, NEW TACKL LAWS LIM C	28	26	26	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2019	53	16					1021	+		10.1136/bjsports-2017-097912			6	Sport Sciences	Sport Sciences	IT0BD	WOS:000482510800010	29021244				2021-06-18	
J	Mayhew, LJ; Bergin, C				Mayhew, Laura J.; Bergin, Colleen			Impact of e-scooter injuries on Emergency Department imaging	JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY			English	Article						electric scooter; emergency; e-scooter; imaging; radiology		Introduction Since the introduction of a shared e-scooter service to Auckland in October there have been multiple media reports of associated injuries, but no quantitation of the number or severity of these injuries, or the impact on hospital emergency department services in Auckland. Methods We performed a retrospective chart review on all patients referred to Auckland hospital ED radiology with the indication containing 'e-scooter' between 15 August 2018 and 15 December 2018. All requests were screened to ensure that the injury was caused by an e-scooter. Recorded data included patient demographics, type of imaging utilised, injury type, and whether admission or surgery was required. Results Sixty-four patients met the inclusion criteria, only one of these was prior to introduction of shared e-scooters on 15 October 2018. Of these, there were 27 limb fractures, 3 dislocations, a fractured spine, 12 patients with concussion, 1 extra-dural bleed, 9 facial/skull fractures and multiple soft tissue injuries. Almost 40% of the patients required admission to a specialty service following imaging, and 25.4% required surgery. A total of 221 plain films and 47 CT scans were performed for e-scooter injuries in the 2-month period after their introduction. Conclusion Introduction of shared e-scooters has resulted in a large number of serious related injuries that have required urgent radiology imaging. Many of these patients required further specialist consultation or surgery, and place an increased burden on overstretched emergency department services.	[Mayhew, Laura J.] Auckland City Hosp, Dept Radiol, 2 Pk Rd, Auckland 1023, New Zealand; [Bergin, Colleen] Univ Auckland, FMHS, Auckland, New Zealand	Mayhew, LJ (corresponding author), Auckland City Hosp, Dept Radiol, 2 Pk Rd, Auckland 1023, New Zealand.	lmay023@aucklanduni.ac.nz					[Anonymous], 2019, LOW POW VEH; Azad A., 2018, CNN; Holley P, 2018, WASHINGTON POST; Leahy B., 2018, NZ HERALD; Marshall A, 2018, WIRED           0417; Olivier J, 2017, INT J EPIDEMIOL, V46, P278, DOI 10.1093/ije/dyw153; Orsman B, 2019, NZ HERALD; Pritchard C, 2018, AUSTIN MONITOR  0430	8	26	26	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1754-9477	1754-9485		J MED IMAG RADIAT ON	J. Med. Imag. Radiat. Oncol.	AUG	2019	63	4					461	466		10.1111/1754-9485.12889			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	IN8PV	WOS:000478942900005	30972936	Bronze			2021-06-18	
J	Jahns, FP; Miroz, JP; Messerer, M; Daniel, RT; Taccone, FS; Eckert, P; Oddo, M				Jahns, Fritz-Patrick; Miroz, John Paul; Messerer, Mahmoud; Daniel, Roy T.; Taccone, Fabio Silvio; Eckert, Philippe; Oddo, Mauro			Quantitative pupillometry for the monitoring of intracranial hypertension in patients with severe traumatic brain injury	CRITICAL CARE			English	Article						Traumatic brain injury; Pupillometry; Pupillary reactivity; Neurological Pupil index; Intracranial pressure; Intracranial hypertension; Outcome; Prognosis	PORTABLE INFRARED PUPILLOMETRY; MODELS; INDEX	Background: Elevated intracranial pressure (ICP) is frequent after traumatic brain injury (TBI) and may cause abnormal pupillary reactivity, which in turn is associated with a worse prognosis. Using automated infrared pupillometry, we examined the relationship between the Neurological Pupil index (NPi) and invasive ICP in patients with severe TBI. Methods: This was an observational cohort of consecutive subjects with severe TBI (Glasgow Coma Scale [GCS] <9 with abnormal lesions on head CT) who underwent parenchymal ICP monitoring and repeated NPi assessment with the NPi-200 (R) pupillometer. We examined NPi trends over time (four consecutive measurements over intervals of 6h) prior to sustained elevated ICP >20mmHg. We further analyzed the relationship of cumulative abnormal NPi burden (%NPi values <3 during total ICP monitoring time) with intracranial hypertension (ICHT)categorized as refractory (ICHT-r; requiring surgical decompression) vs. non-refractory (ICHT-nr; responsive to medical therapy)and with the 6-month Glasgow Outcome Score (GOS). Results: A total of 54 patients were studied (mean age 54 +/- 21years, 74% with focal injuries on CT), of whom 32 (59%) had ICHT. Among subjects with ICHT, episodes of sustained elevated ICP (n=43, 172 matched ICP-NPi samples; baseline ICP [T-6h] 14 +/- 5mmHg vs. ICPmax [T-0h] 30 +/- 9mmHg) were associated with a concomitant decrease of the NPi (baseline 4.2 +/- 0.5 vs. 2.8 +/- 1.6, p<0.0001 ANOVA for repeated measures). Abnormal NPi values were more frequent in patients with ICHT-r (n=17; 38 [3-96]% of monitored time vs. 1 [0-9]% in patients with ICHT-nr [n=15] and 0.5 [0-10]% in those without ICHT [n=22]; p=0.007) and were associated with an unfavorable 6-month outcome (15 [1-80]% in GOS 1-3 vs. 0 [0-7]% in GOS 4-5 patients; p=0.002). Conclusions: In a selected cohort of severe TBI patients with abnormal head CT lesions and predominantly focal cerebral injury, elevated ICP episodes correlated with a concomitant decrease of NPi. Sustained abnormal NPi was in turn associated with a more complicated ICP course and worse outcome.	[Jahns, Fritz-Patrick; Eckert, Philippe; Oddo, Mauro] Univ Lausanne, CHUV, Dept Intens Care Med, Fac Biol & Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland; [Miroz, John Paul; Oddo, Mauro] Univ Lausanne, CHUV, Crit Care Clin Res Unit, Fac Biol & Med, CH-1011 Lausanne, Switzerland; [Messerer, Mahmoud; Daniel, Roy T.] Lausanne Univ Hosp, CHUV, Fac Biol & Med, Dept Clin Neurosci,Neurosurg Serv, CH-1011 Lausanne, Switzerland; [Taccone, Fabio Silvio] Erasme Univ Hosp, Dept Intens Care Med, Brussels, Belgium	Oddo, M (corresponding author), Univ Lausanne, CHUV, Dept Intens Care Med, Fac Biol & Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.; Oddo, M (corresponding author), Univ Lausanne, CHUV, Crit Care Clin Res Unit, Fac Biol & Med, CH-1011 Lausanne, Switzerland.	Mauro.Oddo@chuv.ch	Messerer, Mahmoud/AAZ-3527-2020; MIROZ, John-Paul/AAR-7445-2020		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission	Mauro Oddo is supported by research grants from the Swiss National Science Foundation.	Alali AS, 2019, J NEUROSURG, V9, P1; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen JW, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-548; Chesnut RM, 2018, J NEUROTRAUM, V35, P54, DOI 10.1089/neu.2016.4472; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Couret D, 2019, NEUROCRIT CARE, V30, P492, DOI 10.1007/s12028-018-0664-z; Couret D, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1239-z; Delfino AE, 2009, BRIT J ANAESTH, V103, P255, DOI 10.1093/bja/aep138; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Hall CA, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8010019; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Hoshi Takuo, 2017, Masui, V66, P174; Kesmarky K, 2017, J NEUROTRAUM, V34, P2235, DOI 10.1089/neu.2016.4606; Larson MD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1349-7; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Larson MD, 2012, ANESTHESIOLOGY, V116, P980, DOI 10.1097/ALN.0b013e318251d21b; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Olson DM, 2016, NEUROCRIT CARE, V24, P251, DOI 10.1007/s12028-015-0182-1; Ong C, 2019, NEUROCRIT CARE, V30, P307, DOI 10.1007/s12028-018-0620-y; Ong C, 2019, NEUROCRIT CARE, V30, P316, DOI 10.1007/s12028-018-0607-8; Robba C, 2018, INTENS CARE MED, V44, P1284, DOI 10.1007/s00134-018-5305-7; Rollins MD, 2014, ANESTHESIOLOGY, V121, P1037, DOI 10.1097/ALN.0000000000000384; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Sharshar T, 2014, INTENS CARE MED, V40, P484, DOI 10.1007/s00134-014-3214-y; Shirozu K, 2017, J CLIN MONIT COMPUT, V31, P291, DOI 10.1007/s10877-016-9839-3; Shoyombo I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25477-7; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Volpi PC, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0197-y	32	26	26	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	MAY 2	2019	23								155	10.1186/s13054-019-2436-3			9	Critical Care Medicine	General & Internal Medicine	HW9LB	WOS:000467011200001	31046817	DOAJ Gold, Green Published			2021-06-18	
J	Galea, MD				Galea, Marinella DeFre			Telemedicine in Rehabilitation	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Telerehabilitation; Telehealth; Telemedicine	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; LOW-BACK-PAIN; HEART-FAILURE; HOME VISITS; TOTAL HIP; TELEREHABILITATION; CARE; TELEHEALTH; THERAPY	Telerehabilitation refers to the virtual delivery of rehabilitation services into the patient's home. This methodology has shown to be advantageous when used to enhance or replace conventional therapy to overcome geographic, physical, and cognitive barriers. The exponential growth of technology has led to the development of new applications that enable health care providers to monitor, educate, treat, and support patients in their own environment. Best practices and well-designed Telerehabilitation studies are needed to build and sustain a strong Telerehabilitation system that is integrated in the current health care structure and is cost-effective.	[Galea, Marinella DeFre] James J Peters VAMC, Multiple Sclerosis Reg Ctr, Amyotroph Lateral Sclerosis Program, Dept Spinal Cord Injury & Disorder,SCI D Unit, 130 West Kingsbridge Rd, Bronx, NY 10468 USA	Galea, MD (corresponding author), James J Peters VAMC, Multiple Sclerosis Reg Ctr, Amyotroph Lateral Sclerosis Program, Dept Spinal Cord Injury & Disorder,SCI D Unit, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.	Marinella.galea@va.gov	Galea, Marinella/Y-4010-2019	Galea, Marinella/0000-0002-4211-6170			Adamse C, 2018, J TELEMED TELECARE, V24, P511, DOI 10.1177/1357633X17716576; Bennell KL, 2017, ANN INTERN MED, V166, P453, DOI 10.7326/M16-1714; Brouwers RWM, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0477-6; Capistrant G, 2017, STATE TELEMEDICINE G; Charvet LE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177177; Conroy SS, 2018, J TELEMED TELECARE, V24, P410, DOI 10.1177/1357633X17702757; Cottrell MA, 2017, CLIN REHABIL, V31, P625, DOI 10.1177/0269215516645148; Cranen K, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5951; Cumming RG, 1999, J AM GERIATR SOC, V47, P1397, DOI 10.1111/j.1532-5415.1999.tb01556.x; Doiron-Cadrin P, 2016, CONT CLIN TRIAL COMM, V4, P192, DOI 10.1016/j.conctc.2016.10.001; English C, 2015, INT J STROKE, V10, P465, DOI 10.1111/ijs.12474; Frederix I, 2017, ACTA CARDIOLO, V73, P222; Frederix I, 2017, EUR J PREV CARDIOL, V24, P1708, DOI 10.1177/2047487317732274; Hailey D, 2011, J TELEMED TELECARE, V17, P281, DOI 10.1258/jtt.2011.101208; Herbert MS, 2017, J PAIN, V18, P200, DOI 10.1016/j.jpain.2016.10.014; Hwang R, 2017, J PHYSIOTHER, V63, P101, DOI 10.1016/j.jphys.2017.02.017; Irgens I, 2018, SPINAL CORD, V56, P643, DOI 10.1038/s41393-017-0033-3; Jhaveri MM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017340; Kairy D, 2009, DISABIL REHABIL, V31, P427, DOI 10.1080/09638280802062553; Khan F, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010508.pub2; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lai Byron, 2016, JMIR Rehabil Assist Technol, V3, pe8, DOI 10.2196/rehab.5524; Lichtman JH, 2013, STROKE, V44, P3429, DOI 10.1161/STROKEAHA.113.003165; Linder SM, 2015, AM J OCCUP THER, V69, DOI 10.5014/ajot.2015.015636; Martinez RN, 2017, TELEMED E-HEALTH, V23, P567, DOI 10.1089/tmj.2016.0200; Marzano G, 2017, OPEN PUBLIC HLTH J, V1, P1; Moffet H, 2017, TELEMED E-HEALTH, V23, P80, DOI 10.1089/tmj.2016.0060; Mohr DC, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1602; Nelson M, 2017, JMIR RES PROTOC, V6, P3, DOI 10.2196/resprot.7083; Nix J, 2017, INT J TELEREHABILITA, V9, P47, DOI 10.5195/ijt.2017.6218; Nouryan CN, 2018, TELEMED J E HLTH; Office of the National Coordinator for Health Information Technology, 2016, BREACH UNS PROT HLTH; Ownsworth T, 2018, J HEAD TRAUMA REHAB, V33, pE33, DOI 10.1097/HTR.0000000000000350; Pani D, 2017, J TELEMED TELECARE, V23, P292, DOI 10.1177/1357633X16632950; Pastora-Bernal Jose Manuel, 2017, J Med Internet Res, V19, pe142, DOI 10.2196/jmir.6836; Peterson C, 2014, INT J TELEREHABILITA, V6, P75, DOI [10.5195/IJT.2014.6161, 10.5195/ijt.2014.6161]; Peterson S, 2018, PHYSIOTHER THEOR PR, V34, P393, DOI 10.1080/09593985.2017.1401190; Phillips VL, 2001, PUBLIC HEALTH REP, V116, P94, DOI 10.1093/phr/116.S1.94; Piga M, 2017, SEMIN ARTHRITIS RHEU, V47, P121, DOI 10.1016/j.semarthrit.2017.03.014; Piotrowicz E, 2015, EUR J PREV CARDIOL, V22, P1368, DOI 10.1177/2047487314551537; Piotrowicz E, 2010, EUR J HEART FAIL, V12, P164, DOI 10.1093/eurjhf/hfp181; QYR Pharma & Healthcare Research Center, 2017, GLOB US TEL SYST MAR; Remy C, 2018, ANN PHYS REHABIL MED, V61, pe99; Richmond T, 2017, INT J TELEREHABILITA, V9, P63, DOI 10.5195/ijt.2017.6232; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rietdijk R, 2012, J REHABIL MED, V44, P913, DOI 10.2340/16501977-1058; Rimmer JH, 2018, CONTEMP CLIN TRIALS, V71, P186, DOI 10.1016/j.cct.2018.05.016; Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013; Schwamm LH, 2005, CIRCULATION, V111, P1078, DOI 10.1161/01.CIR.0000154252.62394.1E; Shem K, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00058; Tsavourelou A, 2016, INT J TELEREHABILITA, V8, P61, DOI 10.5195/ijt.2016.6205; Van Straaten MG, 2014, ARCH PHYS MED REHAB, V95, P1810, DOI 10.1016/j.apmr.2014.05.004; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vloothius J, 2017, BMC NEUROL, V15, P193; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Wang S, 2016, ARCH PHYS MED REHAB, V97, P1403, DOI 10.1016/j.apmr.2016.04.002; Wechsler LR, 2013, NEUROLOGY, V80, P670, DOI 10.1212/WNL.0b013e3182823361; Woo C, 2016, J SPINAL CORD MED, V39, P3, DOI 10.1179/2045772314Y.0000000202; World Federation Occupational The, 2014, INT J TELEREHABILITA, V6, P37, DOI [10.5195/ijt.2014.6153, 10.5195/IJT.2014.6153]; Wulsin L, 2012, J PSYCHOSOM RES, V72, P175, DOI 10.1016/j.jpsychores.2011.11.015	61	26	30	8	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2019	30	2					473	+		10.1016/j.pmr.2018.12.002			12	Rehabilitation	Rehabilitation	HW6VZ	WOS:000466830100014	30954160				2021-06-18	
J	Carlozzi, NE; Kallen, MA; Hanks, R; Hahn, EA; Brickell, TA; Lange, RT; French, LM; Kratz, AL; Tulsky, DS; Cella, D; Miner, JA; Ianni, PA; Sander, AM				Carlozzi, Noelle E.; Kallen, Michael A.; Hanks, Robin; Hahn, Elizabeth A.; Brickell, Tracey A.; Lange, Rael T.; French, Louis M.; Kratz, Anna L.; Tulsky, David S.; Cella, David; Miner, Jennifer A.; Ianni, Phillip A.; Sander, Angelle M.			The TBI-CareQOL Measurement System: Development and Preliminary Validation of Health-Related Quality of Life Measures for Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Caregivers; Health care; Military personnel; Quality of life; Rehabilitation; Traumatic brain injuries; Veterans	PORTLAND ADAPTABILITY INVENTORY; ITEM RESPONSE THEORY; HEAD-INJURY; FAMILY; OUTCOMES; INDIVIDUALS; BURDEN; REHABILITATION; PROGRAM; PREVALENCE	Objective: To develop a new measurement system, the Traumatic Brain Injury Caregiver Quality of Life (TBI-CareQOL), that can evaluate both general and caregiving-specific aspects of health-related quality of life (HRQOL) in caregivers of persons with traumatic brain injury (TBI). Design: New item pools were developed and refined using literature reviews, qualitative data from focus groups, and cognitive debriefing with caregivers of civilians and service members/veterans with TBI, as well as expert review, reading level assessment, and translatability review; existing item banks and new item pools were assessed using an online data capture system. Exploratory and confirmatory factor analysis, item response theory, and differential item functioning analyses were utilized to develop new caregiver-specific item banks. Known-groups validity was examined using a series of independent samples t tests comparing caregivers of low-functioning vs high-functioning persons with TBI for each of the new measures, as well as for 10 existing Patient-Reported Outcomes Measurement Information System (PROMIS) measures. Setting: Three TBI Model Systems rehabilitation hospitals, an academic medical center, and a military medical treatment facility. Participants: Caregivers (N=560) of civilians (n=344) or service members/veterans with TBI (n=216). INTERVENTIONS: Not applicable. Main outcome measures: The TBI-CareQOL measurement system (including 5 new measures and 10 existing PROMIS measures). Results: Exploratory and confirmatory factor analysis, item response theory, and differential item functioning analyses supported the development of 5 new item banks for Feelings of Loss-Self, Feelings of Loss-Person with TBI, Caregiver-Specific Anxiety, Feeling Trapped, and Caregiver Strain. In support of validity, individuals who were caring for low-functioning persons with TBI had significantly worse HRQOL than caregivers that were caring for high-functioning persons with TBI for both the new caregiver-specific HRQOL measures, and for the 10 existing PROMIS measures. Conclusions: The TBI-CareQOL includes both validated PROMIS measures and newly developed caregiver-specific measures. Together, these generic and specific measures provide a comprehensive assessment of HRQOL for caregivers of civilians and service members/veterans with TBI. (C) 2018 by the American Congress of Rehabilitation Medicine	[Carlozzi, Noelle E.; Kratz, Anna L.; Miner, Jennifer A.; Ianni, Phillip A.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Kallen, Michael A.; Hahn, Elizabeth A.; Cella, David] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Hanks, Robin] Rehabil Inst Michigan, Dept Psychol & Neuropsychol, Detroit, MI USA; [Hanks, Robin] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada; [Tulsky, David S.] Univ Delaware, Ctr Assessment Res & Translat, Dept Psychol & Brain Sci, Newark, DE USA; [Sander, Angelle M.] Baylor Coll Med, H Ben Taub Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] Harris Hlth Syst, Houston, TX USA; [Sander, Angelle M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	Tulsky, David/0000-0002-4335-4509; french, louis/0000-0002-9451-0604	National Institutes of Health National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR013658]; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	Supported by the National Institutes of Health National Institute of Nursing Research (grant no. R01 NR013658), the National Center for Advancing Translational Sciences (grant no. UL1TR000433), and the Defense and Veterans Brain Injury Center.	Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Anastasi A, 1997, PSYCHOL TESTING, V7th; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Brouwer WBF, 2006, QUAL LIFE RES, V15, P1005, DOI 10.1007/s11136-005-5994-6; Bryant F.B., 1995, READING UNDERSTANDIN, P99, DOI DOI 10.3109/07420528.2010.540363; Cappelleri JC, 2014, CLIN THER, V36, P648, DOI 10.1016/j.clinthera.2014.04.006; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS110, DOI 10.1016/j.apmr.2018.06.026; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS43, DOI 10.1016/j.apmr.2018.06.025; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS13, DOI 10.1016/j.apmr.2018.05.033; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS85, DOI 10.1016/j.apmr.2018.05.034; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS31, DOI 10.1016/j.apmr.2018.05.026; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS22, DOI 10.1016/j.apmr.2018.05.027; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS94, DOI 10.1016/j.apmr.2018.05.021; Carlozzi NE, 2019, ARCH PHYS MED REHAB, V100, pS102, DOI 10.1016/j.apmr.2018.05.020; Carlozzi NE, 2018, J HEAD TRAUMA REHAB, V33, P342, DOI 10.1097/HTR.0000000000000373; Carlozzi NE, 2016, J REHABIL RES DEV, V53, P669, DOI 10.1682/JRRD.2015.07.0136; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; CDC, 2000, MEAS HLTH DAYS POP A; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Choi SW, 2011, J STAT SOFTW, V39, P1; Choi SW, 2009, APPL PSYCH MEAS, V33, P644, DOI 10.1177/0146621608329892; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; CLAUSER BE, 1994, J EDUC MEAS, V31, P88; Cook KF, 2009, QUAL LIFE RES, V18, P447, DOI 10.1007/s11136-009-9464-4; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; EVERITT BS, 1975, BRIT J PSYCHIAT, V126, P237, DOI 10.1192/bjp.126.3.237; Ferrans CE., 2005, OUTCOMES ASSESSMENT, P14; Fisher RA, 1914, BIOMETRIKA, V10, P507; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Fortune DG, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01368; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; Gorsuch R. L., 1983, FACTOR ANAL; Griffin JM, 2017, AM J ORTHOPSYCHIAT, V87, P139, DOI 10.1037/ort0000207; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanauer DA, 2015, J BIOMED INFORM, V55, P290, DOI 10.1016/j.jbi.2015.05.003; Heaton RK, 2004, REVISED COMPREHENSIV; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kean J, 2011, J NEUROTRAUM, V28, P745, DOI 10.1089/neu.2010.1573; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Krauss Joachim K, 2015, Handb Clin Neurol, V128, P475, DOI 10.1016/B978-0-444-63521-1.00030-3; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Lai JS, 2011, ARCH PHYS MED REHAB, V92, pS20, DOI 10.1016/j.apmr.2010.08.033; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Malec JF, 2012, ARCH PHYS MED REHAB, V93, P2271, DOI 10.1016/j.apmr.2012.06.013; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, MAYO PORTLAND ADAPTA; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McDonald R. P., 1999, TEST THEORY UNIFIED; McLaughlin Anne Marie, 1993, Brain Injury, V7, P45, DOI 10.3109/02699059309008155; MetaMetrics, 1995, LEXILE FRAM READ; MONTGOMERY RJV, 1985, FAM RELAT, V34, P19, DOI 10.2307/583753; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Osborn AJ, 2016, NEUROPSYCHOLOGY, V30, P247, DOI 10.1037/neu0000221; Osborn AJ, 2014, NEUROSCI BIOBEHAV R, V47, P1, DOI 10.1016/j.neubiorev.2014.07.007; Paap MCS, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0500-0; Panting A., 1972, REHABILITATION, V38, P33; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pilkonis PA, 2011, ASSESSMENT, V18, P263, DOI 10.1177/1073191111411667; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Reise SP, 2007, QUAL LIFE RES, V16, P19, DOI 10.1007/s11136-007-9183-7; Saban KL, 2016, J REHABIL RES DEV, V53, P681, DOI 10.1682/JRRD.2015.07.0143; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Samejima F., 1969, PSYCHOMETRIC MONOGRA, V17; Samejima F, 1996, HDB MODERN ITEM RESP, P85, DOI DOI 10.1007/978-1-4757-2691-6_5; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P842, DOI 10.1016/j.apmr.2011.11.031; Simpson GK, 2013, J HEAD TRAUMA REHAB, V28, P202, DOI 10.1097/HTR.0b013e31828dc5ae; Smith A M, 1998, Rehabil Nurs, V23, P252; Tourangeau R., 1984, COGNITIVE ASPECTS SU, P73; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Zaider TI, 2003, PSYCHOL MED, V33, P611, DOI 10.1017/S0033291703007414; Zarit S., 1985, HIDDEN VICTIMS ALZHE	85	26	26	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2019	100	4		1			S1	S12		10.1016/j.apmr.2018.08.175			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HR2FV	WOS:000462951900001	30195987	Green Accepted			2021-06-18	
J	Sosa, MAG; De Gasperi, R; Garcia, GSP; Perez, GM; Searcy, C; Vargas, D; Spencer, A; Janssen, PL; Tschiffely, AE; McCarron, RM; Ache, B; Manoharan, R; Janssen, WG; Tappan, SJ; Hanson, RW; Gandy, S; Hof, PR; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Garcia, Georgina S. Perez; Perez, Gissel M.; Searcy, Courtney; Vargas, Danielle; Spencer, Alicia; Janssen, Pierce L.; Tschiffely, Anna E.; McCarron, Richard M.; Ache, Benjamin; Manoharan, Rajaram; Janssen, William G.; Tappan, Susan J.; Hanson, Russell W.; Gandy, Sam; Hof, Patrick R.; Ahlers, Stephen T.; Elder, Gregory A.			Low-level blast exposure disrupts gliovascular and neurovascular connections and induces a chronic vascular pathology in rat brain	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Animal model; Blast; Brain; Chronic; Gliovascular; Neurovascular; Rat; Vascular pathology	DISORDER-RELATED TRAITS; BLOOD-VESSELS; INJURY MODEL; STRESS; PRESSURE; WAVE; INFLAMMATION; MEMBRANES; BIOMARKER; DISEASE	Much concern exists over the role of blast-induced traumatic brain injury (TBI) in the chronic cognitive and mental health problems that develop in veterans and active duty military personnel. The brain vasculature is particularly sensitive to blast injury. The aim of this study was to characterize the evolving molecular and histologic alterations in the neurovascular unit induced by three repetitive low-energy blast exposures (3x74.5kPa) in a rat model mimicking human mild TBI or subclinical blast exposure. High-resolution two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry of purified brain vascular fractions from blast-exposed animals 6weeks post-exposure showed decreased levels of vascular-associated glial fibrillary acidic protein (GFAP) and several neuronal intermediate filament proteins (-internexin and the low, middle, and high molecular weight neurofilament subunits). Loss of these proteins suggested that blast exposure disrupts gliovascular and neurovascular interactions. Electron microscopy confirmed blast-induced effects on perivascular astrocytes including swelling and degeneration of astrocytic endfeet in the brain cortical vasculature. Because the astrocyte is a major sensor of neuronal activity and regulator of cerebral blood flow, structural disruption of gliovascular integrity within the neurovascular unit should impair cerebral autoregulation. Disrupted neurovascular connections to pial and parenchymal blood vessels might also affect brain circulation. Blast exposures also induced structural and functional alterations in the arterial smooth muscle layer. Interestingly, by 8months after blast exposure, GFAP and neuronal intermediate filament expression had recovered to control levels in isolated brain vascular fractions. However, despite this recovery, a widespread vascular pathology was still apparent at 10months after blast exposure histologically and on micro-computed tomography scanning. Thus, low-level blast exposure disrupts gliovascular and neurovascular connections while inducing a chronic vascular pathology.	[Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Searcy, Courtney; Vargas, Danielle; Spencer, Alicia; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Garcia, Georgina S. Perez; Janssen, Pierce L.; Janssen, William G.; Gandy, Sam; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [De Gasperi, Rita; Garcia, Georgina S. Perez; Perez, Gissel M.; Searcy, Courtney; Vargas, Danielle; Spencer, Alicia; Gandy, Sam] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Garcia, Georgina S. Perez; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA; [Janssen, Pierce L.; Janssen, William G.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Tschiffely, Anna E.; McCarron, Richard M.; Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [McCarron, Richard M.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20914 USA; [Ache, Benjamin; Manoharan, Rajaram] Micro Photon Inc, 1550 Pond Rd, Allentown, PA 18104 USA; [Tappan, Susan J.] MBF Biosci, 185 Allen Brook Lane, Williston, VT 05495 USA; [Hanson, Russell W.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Gandy, Sam; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Gandy, Sam; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA	Sosa, MAG (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Sosa, MAG (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA.; Sosa, MAG (corresponding author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.	miguel.gama-sosa@mssm.edu		Vargas, Danielle/0000-0003-4409-9391	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardsUS Department of Veterans Affairs [1 I01RX000996, 1 I01RX000684, 1 I21 RX002069-01, 1 I21 RX002876-01]; Department of DefenseUnited States Department of Defense [0000B999.0000.000.A1503]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG005138]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH099721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000684, I01RX002660, I01RX000996, I21RX002876, I21RX002069] Funding Source: NIH RePORTER	We thank Dr. Virginia Lee for generously providing the rat anti-GFAP antibody. We thank Timothy Tetreault for assistance with automatic quantification of vasculature. Work described in this paper was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1 I01RX000996, 1 I01RX000684, 1 I21 RX002069-01 and 1 I21 RX002876-01; by Department of Defense work unit number 0000B999.0000.000.A1503 and by NIH grant P50 AG005138. PLJ was a Carolyn L. Kuckein Student Research Fellow of the Alpha Omega Alpha Honor Medical Society. MAGS, RDG, GMP, GE, AET, SG and STA are employees of the U.S. government. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, Department of Veterans Affairs, nor the U.S. Government.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Balaban C, 2016, J NEUROSCI METH, V272, P56, DOI 10.1016/j.jneumeth.2016.02.001; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bir C, 2012, MAGN RESON IMAGING, V30, P527, DOI 10.1016/j.mri.2011.12.003; Boulay AC, 2015, JOVE-J VIS EXP, DOI 10.3791/53208; BUSIJA DW, 1984, REV PHYSIOL BIOCH P, V101, P161, DOI 10.1007/BFb0027696; CAMPAGNE MV, 1991, J HISTOCHEM CYTOCHEM, V39, P1267, DOI 10.1177/39.9.1833448; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen HJ, 2015, CHIN J TRAUMATOL, V18, P267, DOI 10.1016/j.cjtee.2015.11.006; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Chun HB, 2011, J CEREBR BLOOD F MET, V31, P2267, DOI 10.1038/jcbfm.2011.104; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; dela Paz NG, 2009, CELL TISSUE RES, V335, P5, DOI 10.1007/s00441-008-0706-5; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Franciosi S, 2007, J NEUROSCI METH, V163, P76, DOI 10.1016/j.jneumeth.2007.02.020; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Hald ES, 2014, TRANSL STROKE RES, V5, P385, DOI 10.1007/s12975-013-0300-3; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Iadecola C, 2017, NEURON, V96, P17, DOI 10.1016/j.neuron.2017.07.030; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Li BC, 2014, NEUROL RES, V36, P974, DOI 10.1179/1743132813Y.0000000314; Logsdon AF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29341-6; Logsdon AF, 2017, ARCH NEUROSCI, V4, DOI 10.5812/archneurosci.44254; Logsdon AF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00421; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Ma Y, 2014, NEUROCHEM RES, V39, P1809, DOI 10.1007/s11064-014-1395-y; Mackie AR, 2011, TEX HEART I J, V38, P474; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Pasquinelli G, 2007, STEM CELLS, V25, P1627, DOI 10.1634/stemcells.2006-0731; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Perez-Garcia G, 2019, NEUROPHARMACOLOGY, V145, P220, DOI 10.1016/j.neuropharm.2018.09.023; Perez-Garcia G, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0357-17.2018; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Rajkowska G, 2013, BIOL PSYCHIAT, V73, P613, DOI 10.1016/j.biopsych.2012.09.024; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Rodriguez UA, 2018, J NEUROTRAUM, V35, P375, DOI 10.1089/neu.2017.5256; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sajja Venkata Siva Sai S, 2012, Biomed Sci Instrum, V48, P374; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Searcy JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089970; Sharrock AE, 2019, INJURY, V50, P125, DOI 10.1016/j.injury.2018.06.037; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sosa MAG, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0483-z; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Stenmark KR, 2013, ANNU REV PHYSIOL, V75, P23, DOI 10.1146/annurev-physiol-030212-183802; Stokum JA, 2017, BEHAV BRAIN RES, V333, P43, DOI 10.1016/j.bbr.2017.06.038; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tchantchou F, 2018, J NEUROTRAUM, V35, P1192, DOI 10.1089/neu.2017.5401; Toklu HZ, 2015, J CEREBR BLOOD F MET, V35, P1950, DOI 10.1038/jcbfm.2015.151; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Wang JM, 2016, CHIN J TRAUMATOL, V19, P125, DOI 10.1016/j.cjtee.2016.03.001; Wang Y, 2017, J NEUROTRAUM, V34, P952, DOI 10.1089/neu.2016.4465; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Zhang YM, 2014, NEUROCHEM RES, V39, P950, DOI 10.1007/s11064-014-1292-4	93	26	26	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.	JAN 9	2019	7								6	10.1186/s40478-018-0647-5			20	Neurosciences	Neurosciences & Neurology	HG9II	WOS:000455320300002	30626447	DOAJ Gold, Green Published			2021-06-18	
J	Ponsford, J; Nguyen, S; Downing, M; Bosch, M; McKenzie, JE; Turner, S; Chau, M; Mortimer, D; Gruen, RL; Knott, J; Green, S				Ponsford, Jennie; Nguyen, Sylvia; Downing, Marina; Bosch, Marije; McKenzie, Joanne E.; Turner, Simon; Chau, Marisa; Mortimer, Duncan; Gruen, Russell L.; Knott, Jonathan; Green, Sally			FACTORS ASSOCIATED WITH PERSISTENT POST-CONCUSSION SYMPTOMS FOLLOWING MILD TRAUMATIC BRAIN INJURY IN ADULTS	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; post-concussion symptoms; anxiety; quality of life	HEAD-INJURY; EARLY PREDICTORS; OUTCOMES; POPULATION; DEPRESSION; VALIDITY; ANXIETY; SCALES; RISK	Objectives: Debate regarding factors associated with persistent symptoms following mild traumatic brain injury continues. Nested within a trial aiming to change practice in emergency department management of mild traumatic brain injury, this study investigated the nature of persistent symptoms, work/ study outcomes, anxiety and quality of life and factors associated with persistent symptoms following injury, including the impact of receiving information about mild traumatic brain injuries in the emergency department. Methods: A total of 343 individuals with mild traumatic brain injury completed the Rivermead Post-Concussion Symptom Questionnaire, Hospital Anxiety Depression Scale - Anxiety Scale, and Quality of Life - Short Form an average 7 months post-injury. Results: Overall, 18.7% of participants reported 3 or more post-concussional symptoms, most commonly fatigue (17.2%) and forgetfulness (14.6%). Clinically significant anxiety was reported by 12.8%, and was significantly associated with symptom reporting, as were mental and physical quality of life scores. Significant predictors of post-concussional symptoms at follow-up were pre-injury psychological issues, experiencing loss of consciousness, and having no recall of receiving information about brain injury in the emergency department. Conclusion: This study confirms that loss of consciousness and pre-injury psychological issues are associated with persistent symptom reporting. Not receiving injury information in the emergency department may also negatively influence symptom reporting.	[Ponsford, Jennie; Nguyen, Sylvia; Downing, Marina] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie; Nguyen, Sylvia; Downing, Marina] Monash Univ, Sch Psychol Sci, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Bosch, Marije; Chau, Marisa] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic, Australia; [Bosch, Marije; Chau, Marisa] Alfred & Monash Univ, Natl Trauma Res Inst, Melbourne, Vic, Australia; [McKenzie, Joanne E.; Turner, Simon; Green, Sally] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Mortimer, Duncan] Monash Univ, Ctr Hlth Econ, Monash Business Sch, Melbourne, Vic, Australia; [Gruen, Russell L.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Gruen, Russell L.] Alfred Hosp, Dept Trauma, Melbourne, Vic, Australia; [Gruen, Russell L.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Knott, Jonathan] Univ Melbourne, Melbourne Med Sch, Melbourne, Vic, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Dept Emergency Med, Melbourne, Vic, Australia; [Bosch, Marije] Univ Groningen, Fac Econ & Business, Groningen, Netherlands	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020; McKenzie, Joanne/I-2925-2014	Downing, Marina/0000-0002-3126-6632; Mortimer, Duncan Stuart/0000-0002-7211-6454; McKenzie, Joanne/0000-0003-3534-1641; Turner, Simon/0000-0001-9163-4524	Victorian Transport Accident Commission (TAC), Australia	The authors would like to thank all the hospital emergency departments (ED) involved in this study, in particular the ED staff who recruited patients for this study. We would like to also thank all MERRC staff who conducted the follow-up interviews. This study is part of a 5-year grant (the Neurotrauma Evidence Translation (NET) Program), funded by the Victorian Transport Accident Commission (TAC), Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews G, 2002, AUST NZ J PUBL HEAL, V26, P508, DOI 10.1111/j.1467-842X.2002.tb00357.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bosch M, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-281; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chiang CC, 2016, QUAL LIFE RES, V25, P2009, DOI 10.1007/s11136-015-1215-0; Cnossen MC, 2018, J NEUROTRAUM, V35, P2691, DOI 10.1089/neu.2017.5486; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Hadanny A, 2016, EXPERT REV NEUROTHER, V16, P875, DOI 10.1080/14737175.2016.1205487; Hardin J. W., 2012, GEN ESTIMATING EQUAT; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kumar RG, 2014, AM J PHYS MED REHAB, V93, P687, DOI 10.1097/PHM.0000000000000077; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TURNERSTOKES L, 2015, COCHRANE DATABASE SY; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wojcik SM, 2014, BRAIN INJURY, V28, P422, DOI 10.3109/02699052.2014.884241; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	26	27	0	10	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JAN	2019	51	1					32	39		10.2340/16501977-2492			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HF1LG	WOS:000453927200006	30426138	DOAJ Gold, Green Published			2021-06-18	
J	Lessley, DJ; Kent, RW; Funk, JR; Sherwood, CP; Cormier, JM; Crandall, JR; Arbogast, KB; Myers, BS				Lessley, David J.; Kent, Richard W.; Funk, James R.; Sherwood, Christopher P.; Cormier, Joseph M.; Crandall, Jeff R.; Arbogast, Kristy B.; Myers, Barry S.			Video Analysis of Reported Concussion Events in the National Football League During the 2015-2016 and 2016-2017 Seasons	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries/concussion; general sports trauma; medical aspects of sports; American football; biomechanics; general; epidemiology	PROFESSIONAL FOOTBALL; IMPACT PERFORMANCE; BRAIN-INJURY; LOCATION	Background: Concussions in American football remain a high priority of sports injury prevention programs. Detailed video review provides important information on causation, the outcomes of rule changes, and guidance on future injury prevention strategies. Purpose: Documentation of concussions sustained in National Football League games played during the 2015-2016 and 2016-2017 seasons, including consideration of video views unavailable to the public. Study Design: Descriptive epidemiology study. Methods: All reported concussions were reviewed with all available video footage. Standardized terminology and associated definitions were developed to describe and categorize the details of each concussion. Results: Cornerbacks sustained the most concussions, followed by wide receivers, then linebackers and offensive linemen. Half (50%) of concussions occurred during a passing play, 28% during a rushing play, and 21% on a punt or kickoff. Tackling was found to be the most common activity of concussed players, with the side of the helmet the most common helmet impact location. The distribution of helmet impact source-the object that contacted the concussed player's helmet-differed from studies of earlier seasons, with a higher proportion of helmet-to-body impacts (particularly shoulder) and helmet-to-ground impacts and with a lower proportion of helmet-to-helmet impacts. Helmet-to-ground concussive impacts were notable for the high prevalence of impacts to the back of the helmet and their frequency during passing plays. Conclusion: Concussion causation scenarios in the National Football League have changed over time. Clinical Relevance: The results of this study suggest the need for expanded evaluation of concussion countermeasures beyond solely helmet-to-helmet test systems, including consideration of impacts with the ground and with the body of the opposing player. It also suggests the possibility of position-specific countermeasures as part of an ongoing effort to improve safety.	[Lessley, David J.; Kent, Richard W.; Funk, James R.; Sherwood, Christopher P.; Cormier, Joseph M.; Crandall, Jeff R.; Arbogast, Kristy B.; Myers, Barry S.] Biomech Consulting & Res BioCore LLC, 1621 Quail Run, Charlottesville, VA 22911 USA; [Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Myers, Barry S.] Duke Univ, Biomed Engn, Durham, NC USA	Lessley, DJ (corresponding author), Biomech Consulting & Res BioCore LLC, 1621 Quail Run, Charlottesville, VA 22911 USA.	dlessley@biocorellc.com		Arbogast, Kristy/0000-0002-1694-4562			Alshareef A, 2017, P 2017 INT IRCOBI C; ASTM International, 2010, F35510 ASTM INT; Beusenberg M, 2001, P 2001 INT IRCOBI C; British Standards Institution Motorcyclists' protective clothing against mechanical impact, 2003, 162122003 BS EN; Clark MD, 2017, AM J SPORT MED, V45, P929, DOI 10.1177/0363546516677793; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Davis G, 2016, J SCI MED SPORT, V19, P898, DOI 10.1016/j.jsams.2016.02.005; Funk J., 2017, NFL LINEAR IMPACTOR; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; HeadHealthTECH Challenge V NFL Play Smart Play Safe website, HEADHEALTHTECH CHALL; Health and safety related changes for the, 2017, HLTH SAF REL CHANG 2; Helmet laboratory testing performance results, HELM LAB TEST PERF R; Hutchison M. G., 2011, THESIS; Kerr ZY, 2017, J ATHL TRAINING, V52, P167, DOI 10.4085/1062-6050-51.6.05; Kerr ZY, 2014, PEDIATRICS, V134, P489, DOI 10.1542/peds.2014-0770; Kerrigan JR, 2008, STAPP CAR C, V52, P527; Nathanson JT, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967115622621; National Operating Committee on Standards for Athletic Equipment, 2017, ND00217M17A NOCSAE; National Operating Committee on Standards for Athletic Equipment, 2015, ND00213M15 NOCSAE; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; NFL Head Neck and Spine Committee's Concussion Diagnosis Management Protocol, 2017, NFL HEAD NECK SPIN C; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Prange M T, 2000, Stapp Car Crash J, V44, P205; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Smith TA, 2015, SPORTS ENG, V18, P165, DOI 10.1007/s12283-015-0175-5; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019	37	26	26	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2018	46	14					3502	3510		10.1177/0363546518804498			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	HD2BH	WOS:000452315600023	30398897				2021-06-18	
J	Chen, XR; Pan, ZG; Fang, ZN; Lin, WB; Wu, SK; Yang, FX; Li, YS; Fu, HD; Gao, HZ; Li, S				Chen, Xiangrong; Pan, Zhigang; Fang, Zhongning; Lin, Weibin; Wu, Shukai; Yang, Fuxing; Li, Yasong; Fu, Huangde; Gao, Hongzhi; Li, Shun			Omega-3 polyunsaturated fatty acid attenuates traumatic brain injury-induced neuronal apoptosis by inducing autophagy through the upregulation of SIRT1-mediated deacetylation of Beclin-1	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Omega-3 polyunsaturated fatty acid; Apoptosis; Autophagy	NF-KAPPA-B; INDUCED INFLAMMATION; NUCLEAR TRANSLOCATION; MELATONIN; DISEASE; STRESS; OMEGA-3-FATTY-ACIDS; INVOLVEMENT; ACTIVATION; MECHANISMS	BackgroundEnhancing autophagy after traumatic brain injury (TBI) may decrease the expression of neuronal apoptosis-related molecules. Autophagy-mediated neuronal survival is regulated by the sirtuin family of proteins (SIRT). Omega-3 polyunsaturated fatty acids (-3 PUFA) are known to have antioxidative and anti-inflammatory effects. We previously demonstrated that -3 PUFA supplementation attenuated neuronal apoptosis by modulating the neuroinflammatory response through SIRT1-mediated deacetylation of the HMGB1/NF-B pathway, leading to neuroprotective effects following experimental traumatic brain injury (TBI). However, no studies have elucidated if the neuroprotective effects of -3 PUFAs against TBI-induced neuronal apoptosis are modulated by SIRT1-mediated deacetylation of the autophagy pathway.MethodsThe Feeney DM TBI model was adopted to induce TBI rats. Modified neurological severity scores, the rotarod test, brain water content, and Nissl staining were employed to determine the neuroprotective effects of -3 PUFA supplementation. Immunofluorescent staining and western blot analysis were used to detect Beclin-1 nuclear translocation and autophagy pathway activation. The impact of SIRT1 deacetylase activity on Beclin-1 acetylation and the interaction between cytoplasmic Beclin-1 and Bcl-2 were assessed to evaluate the neuroprotective effects of -3 PUFAs and to determine if these effects were dependent on SIRT1-mediated deacetylation of the autophagy pathway in order to gain further insight into the mechanisms underlying the development of neuroprotection after TBI.Results-3 PUFA supplementation protected neurons against TBI-induced neuronal apoptosis via enhancement of the autophagy pathway. We also found that treatment with -3 PUFA significantly increased the NAD+/NADH ratio and SIRT1 activity following TBI. In addition, -3 PUFA supplementation increased Beclin-1 deacetylation and its nuclear export and induced direct interactions between cytoplasmic Beclin-1 and Bcl-2 by increasing SIRT1 activity following TBI. These events led to the inhibition of neuronal apoptosis and to neuroprotective effects through enhancing autophagy after TBI, possibly due to elevated SIRT1.Conclusions-3 PUFA supplementation attenuated TBI-induced neuronal apoptosis by inducing the autophagy pathway through the upregulation of SIRT1-mediated deacetylation of Beclin-1.	[Fu, Huangde] YouJiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China; [Chen, Xiangrong; Pan, Zhigang; Fang, Zhongning; Lin, Weibin; Wu, Shukai; Yang, Fuxing; Li, Yasong; Gao, Hongzhi] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China; [Li, Shun] North Sichuan Med Coll, Affiliated Hosp, Dept Neurosurg, Nanchong 637000, Sichuan, Peoples R China	Fu, HD (corresponding author), YouJiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China.; Gao, HZ (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China.; Li, S (corresponding author), North Sichuan Med Coll, Affiliated Hosp, Dept Neurosurg, Nanchong 637000, Sichuan, Peoples R China.	rong281@163.com; 13265040480@163.com; hongzhi_gao@hotmail.com; morelee@163.com	zhang, chuengji/AAD-4591-2020		Fujian Province Scientific Foundation [2015J01443]; Fujian Province Science and technology innovation Foundation [2017Y9201]; Sichuan Provincial Department of Education [18ZA0205]; Health and Family Planning Commission of Sichuan Province [17PJ174]	This work was supported by grants from the funds for Fujian Province Scientific Foundation (no. 2015J01443) and Fujian Province Science and technology innovation Foundation (no. 2017Y9201) from Dr. Xiangrong Chen; Sichuan Provincial Department of Education (no. 18ZA0205) and the Health and Family Planning Commission of Sichuan Province (no. 17PJ174) from Dr. Shun Li.	Balan M, 2014, J BIOL CHEM, V289, P3126, DOI 10.1074/jbc.M113.508044; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Chen XR, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00117; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60; Contreras AU, 2013, J CELL BIOL, V201, P427, DOI 10.1083/jcb.201205064; Delattre AM, 2017, MOL NEUROBIOL, V54, P2090, DOI 10.1007/s12035-016-9803-8; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Dupont N, 2017, INT REV CEL MOL BIO, V328, P1, DOI 10.1016/bs.ircmb.2016.08.001; Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Frudd K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02352-z; Gao Y, 2017, AM J TRANSL RES, V135, P886; Grishchuk Y, 2011, AUTOPHAGY, V7, P1115, DOI 10.4161/auto.7.10.16608; Gwon DH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102081; Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; He RN, 2015, AUTOPHAGY, V11, P740, DOI 10.1080/15548627.2015.1034404; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013; Inoue T, 2017, BBA-MOL CELL BIOL L, V1862, P552, DOI 10.1016/j.bbalip.2017.02.010; Jin SH, 2016, EMBO J, V35, P866, DOI 10.15252/embj.201593596; Kurtys E, 2016, NEUROCHEM INT, V99, P206, DOI 10.1016/j.neuint.2016.07.008; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Ma YX, 2015, CURR MED CHEM, V22, P1239, DOI 10.2174/0929867322666150209154420; Marquez RT, 2012, AM J CANCER RES, V2, P214; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Pant K, 2017, CHEM-BIOL INTERACT, V273, P99, DOI 10.1016/j.cbi.2017.06.001; Park SE, 2016, ONCOTARGET, V7, P39796, DOI 10.18632/oncotarget.9290; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Qiu GL, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/6869415; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x; Serini S, 2016, CURR ALZHEIMER RES, V13, P123, DOI 10.2174/1567205012666150921101147; Shen LL, 2017, J LIPID RES, V58, P1808, DOI 10.1194/jlr.M075879; Sinha SP, 2017, BRAIN BEHAV IMMUN, V61, P353, DOI 10.1016/j.bbi.2017.01.006; Sun TJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10159; Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133; Tang CH, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2923182; Vlahakis A, 2017, AUTOPHAGY, V13, P1256, DOI 10.1080/15548627.2017.1299314; Wang B, 2016, WORLD J GASTROENTERO, V22, P9784, DOI 10.3748/wjg.v22.i44.9784; Wang TJ, 2017, FISH SHELLFISH IMMUN, V71, P76, DOI 10.1016/j.fsi.2017.09.064; Xie XQ, 2017, MOL NEUROBIOL, V54, P7251, DOI 10.1007/s12035-016-0173-z; Yang XY, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00131; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292	49	26	27	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	NOV 8	2018	15								310	10.1186/s12974-018-1345-8			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	HA0GQ	WOS:000449886400001	30409173	DOAJ Gold, Green Published			2021-06-18	
J	George, MJ; Prabhakara, K; Toledano-Furman, NE; Wang, YW; Gill, BS; Wade, CE; Olson, SD; Cox, CS				George, Mitchell J.; Prabhakara, Karthik; Toledano-Furman, Naama E.; Wang, Yao-Wei; Gill, Brijesh S.; Wade, Charles E.; Olson, Scott D.; Cox, Charles S., Jr.			Clinical Cellular Therapeutics Accelerate Clot Formation	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Tissue factor; Coagulation; Clinical cellular therapeutics	MESENCHYMAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; BONE-MARROW; PROCOAGULANT ACTIVITY; PROGENITOR CELLS; ANTICOAGULANT; THERAPY; THROMBELASTOGRAPHY; DELIVERY; BLOOD	Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion.	[George, Mitchell J.; Wang, Yao-Wei; Gill, Brijesh S.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, McGovern Med Sch, Houston, TX 77030 USA; [George, Mitchell J.; Prabhakara, Karthik; Toledano-Furman, Naama E.; Olson, Scott D.; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, McGovern Med Sch, 6431 Fannin St,MSB 5-246, Houston, TX 77030 USA	Cox, CS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, McGovern Med Sch, 6431 Fannin St,MSB 5-246, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Olson, Scott/0000-0001-8032-3755	Glassell Family Stem Cell Research Program; NIH T32United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM008792-14]; Cellvation Inc.; Athersys Inc.; Hope Biosciences; CBR Inc.; Biostage Inc.; Athersys; Hope Bio; GenzymeSanofi-AventisGenzyme Corporation; Biostage; CBR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This study was supported by the Glassell Family Stem Cell Research Program. M.G. was supported by the NIH T32 grant GM008792-14. C.S.C. has sponsored research and scientific advisory board positions with Cellvation Inc., Athersys Inc., Hope Biosciences, CBR Inc., and Biostage Inc. Dr S.D.O. has sponsored research with Athersys, Hope Bio, and Biostage Inc. B.S.G. discloses consulting relationship with Cellvation, Inc. S.D.O. discloses research funding through sponsored research agreements with Hope Bio, CBR, and Athersys with recent funding from Genzyme and Biostage. All other authors declare no potential financial conflict.	Aranda P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007809; Baygan A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00795; Boozer Sherry, 2009, J Stem Cells, V4, P17, DOI jsc.2009.4.1.17; Burrows GG, 2013, STEM CELL TRANSL MED, V2, P745, DOI 10.5966/sctm.2013-0031; Christy BA, 2017, J TRAUMA ACUTE CARE, V83, pS164, DOI 10.1097/TA.0000000000001485; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Elliott A, 2015, INT J STROKE, V10, P194, DOI 10.1111/j.1747-4949.2012.00919.x; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gleeson BM, 2015, STEM CELLS, V33, P2726, DOI 10.1002/stem.2050; Hincker A, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0549-2; Hogan NM, 2013, BIOCHEM BIOPH RES CO, V435, P574, DOI 10.1016/j.bbrc.2013.05.013; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Katori N, 2005, ANESTH ANALG, V100, P1781, DOI 10.1213/01.ANE.0000149902.73689.64; Kota DJ, 2017, STEM CELLS, V35, P1416, DOI 10.1002/stem.2603; Levi M, 1997, EUR J CLIN INVEST, V27, P3, DOI 10.1046/j.1365-2362.1997.570614.x; Liao L, 2017, THERANOSTICS, V7, P106, DOI 10.7150/thno.16911; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Moll G, 2015, STEM CELLS DEV, V24, P2269, DOI 10.1089/scd.2015.0120; Moll G, 2014, STEM CELLS, V32, P2430, DOI 10.1002/stem.1729; Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111; Moll G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021703; Park MS, 2017, J TRAUMA ACUTE CARE, V83, P381, DOI 10.1097/TA.0000000000001466; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; Roobrouck VD, 2011, STEM CELLS, V29, P871, DOI 10.1002/stem.633; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; Stephenne X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042819; Taylor F B Jr, 1994, Prog Clin Biol Res, V388, P175; Van Haren RM, 2013, J TRAUMA ACUTE CARE, V75, P37, DOI 10.1097/TA.0b013e3182984911; Van PY, 2009, J TRAUMA, V66, P1509, DOI 10.1097/TA.0b013e3181a51e33; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Weiss Daniel J, 2011, Proc Am Thorac Soc, V8, P223, DOI 10.1513/pats.201012-071DW	32	26	27	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	OCT	2018	7	10					731	739		10.1002/sctm.18-0015			9	Cell & Tissue Engineering	Cell Biology	GW8MF	WOS:000447232200006	30070065	DOAJ Gold, Green Published			2021-06-18	
J	Schafer, MKE; Tegeder, I				Schaefer, Michael K. E.; Tegeder, Irmgard			NG2/CSPG4 and progranulin in the posttraumatic glial scar	MATRIX BIOLOGY			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; CHONDROITIN-SULFATE PROTEOGLYCAN; PROTEIN-TYROSINE-PHOSPHATASE; CENTRAL-NERVOUS-SYSTEM; LONG-TERM POTENTIATION; MEMBRANE-SPANNING PROTEOGLYCAN; PROMOTES FUNCTIONAL RECOVERY; ANTIGEN-RELATED PHOSPHATASE; GROWTH-FACTOR PROGRANULIN	Traumatic injury of the central nervous system is one of the leading causes of death and disability in young adults. Failure of regeneration is caused by autonomous neuronal obstacles and by formation of the glial scar, which is essential to seal the injury but also constitutes a barrier for regrowing axons. The scar center is highly inflammatory and populated by NG2+ glia, whereas astrocytes form the sealing border and trap regrowing axons, suggesting that the non-permissive environment of activated astrocytes and extracellular matrix components is one of the reasons for the regenerative failure. Particularly, secreted chondroitin-sulfate proteoglycans, CSPGs, of the lectican family hinder axonal regrowth. In contrast, the transmembrane CSPG, NG2/CSPG4, appears to be functionally closer related to axon growth permissive heparan sulfate proteoglycans, HSPGs, and synaptic adhesion molecules, which all regulate synaptic signaling and plasticity upon alpha-secretase mediated shedding. Consequently, knockout of NG2/CSPG4 aggravates tissue loss, inflammation and neurologic deficits after brain injury, a phenotype partly mimicked by deletion of HSPG-binding proteins such as the HSPG2/perlecan-interacting protein, progranulin that is also a functional ligand of Notch and Eph2a. Indeed, structural features or progranulin's targets and NG2 may point to direct reciprocal regulations that may act in concert to overcome injury -evoked inflammation and neuronal dystrophy. This review provides an overview of the pathophysiology of the glial scar after brain injury, with a specific focus on NG2/CSPG4, its functions before and after shedding and putative reciprocal influences with the glycoprotein progranulin. (C) 2017 Elsevier B.V. All rights reserved.	[Schaefer, Michael K. E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anesthesiol, Mainz, Germany; [Tegeder, Irmgard] Goethe Univ Hosp, Inst Clin Pharmacol, Frankfurt, Germany	Tegeder, I (corresponding author), Goethe Univ Hosp, Inst Clin Pharmacol ZAFES, Frankfurt, Germany.	tegeder@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2246-2020; Schaefer, Michael K.E./S-1715-2019	Tegeder, Irmgard/0000-0001-7524-8025; Schaefer, Michael K.E./0000-0001-6055-6244	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC1080]	We acknowledge the financial support of the Deutsche Forschungsgemeinschaft (CRC1080, A03 to IT).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Altmann C, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0132-1; Altmann C, 2016, NEUROBIOL DIS, V96, P294, DOI 10.1016/j.nbd.2016.09.010; Anderegg U, 2009, J INVEST DERMATOL, V129, P1471, DOI 10.1038/jid.2008.323; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Asher RA, 2005, MOL CELL NEUROSCI, V29, P82, DOI 10.1016/j.mcn.2005.02.001; Assinck P., 2017, J NEUROSCI; Babayan AH, 2012, J NEUROSCI, V32, P12854, DOI 10.1523/JNEUROSCI.2024-12.2012; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Beller JA, 2014, NEURAL REGEN RES, V9, P343, DOI 10.4103/1673-5374.128235; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Birbrair A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt512; Bonfanti E, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.256; Bozkulak EC, 2009, MOL CELL BIOL, V29, P5679, DOI 10.1128/MCB.00406-09; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brakebusch C, 2002, MOL CELL BIOL, V22, P7417, DOI 10.1128/MCB.22.21.7417-7427.2002; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Chan CS, 2007, LEARN MEMORY, V14, P606, DOI 10.1101/lm.648607; Chan CS, 2006, J NEUROSCI, V26, P223, DOI 10.1523/JNEUROSCI.4110-05.2006; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen ZY, 2005, J NEUROSCI, V25, P6156, DOI 10.1523/JNEUROSCI.1017-05.2005; Coles CH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6209; Coles CH, 2011, SCIENCE, V332, P484, DOI 10.1126/science.1200840; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Davies SJA, 1997, NATURE, V390, P680; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; De Biase LM, 2010, J NEUROSCI, V30, P3600, DOI 10.1523/JNEUROSCI.6000-09.2010; Deguchi Y, 2002, J NEUROCHEM, V83, P381, DOI 10.1046/j.1471-4159.2002.01129.x; DOU CL, 1994, J NEUROSCI, V14, P7616; Dyck SM, 2015, STEM CELLS, V33, P2550, DOI 10.1002/stem.1979; Egashira Y, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-105; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Faux C, 2007, BBA-MOL CELL RES, V1773, P1689, DOI 10.1016/j.bbamcr.2007.06.008; Fawcett JW, 2015, PROG BRAIN RES, V218, P213, DOI 10.1016/bs.pbr.2015.02.001; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Filous AR, 2014, J NEUROSCI, V34, P16369, DOI 10.1523/JNEUROSCI.1309-14.2014; Fisher D, 2011, J NEUROSCI, V31, P14051, DOI 10.1523/JNEUROSCI.1737-11.2011; Fox AN, 2005, CURR BIOL, V15, P1701, DOI 10.1016/j.cub.2005.08.035; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Gao K, 2013, GLIA, V61, P2063, DOI 10.1002/glia.22577; Gaudet AD, 2014, EXP NEUROL, V258, P24, DOI 10.1016/j.expneurol.2013.11.020; Gherardini L, 2015, CEREB CORTEX, V25, P202, DOI 10.1093/cercor/bht217; Gokce O, 2013, J NEUROSCI, V33, P14617, DOI 10.1523/JNEUROSCI.1232-13.2013; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; Grako KA, 1999, J CELL SCI, V112, P905; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Grimpe B, 2004, J NEUROSCI, V24, P1393, DOI 10.1523/JNEUROSCI.4986-03.2004; Gubbiotti MA, 2017, MATRIX BIOL, V57-58, P285, DOI 10.1016/j.matbio.2016.09.003; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Hackett AR, 2016, NEUROBIOL DIS, V89, P10, DOI 10.1016/j.nbd.2016.01.017; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; He ZH, 2002, CANCER RES, V62, P5590; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Heinrich C, 2014, STEM CELL REP, V3, P1000, DOI 10.1016/j.stemcr.2014.10.007; Hering TM, 2015, MATRIX BIOL, V41, P8, DOI 10.1016/j.matbio.2014.11.006; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Honsa P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036816; Hossain-Ibrahim MK, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-80; Hsieh T. H., 2016, CEREB CORTEX; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Huang CS, 2016, GLIA, V64, P507, DOI 10.1002/glia.22944; Huang WH, 2014, GLIA, V62, P896, DOI 10.1002/glia.22648; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Johnson KG, 2006, NEURON, V49, P517, DOI 10.1016/j.neuron.2006.01.026; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Joo NE, 2014, DNA CELL BIOL, V33, P854, DOI 10.1089/dna.2014.2399; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Karus M, 2016, GLIA, V64, P270, DOI 10.1002/glia.22928; Kattenstroth G, 2004, P NATL ACAD SCI USA, V101, P2607, DOI 10.1073/pnas.0308626100; Kerever A, 2014, STEM CELL RES, V12, P492, DOI 10.1016/j.scr.2013.12.009; Kim SY, 2016, J NEUROSCI RES, V94, P794, DOI 10.1002/jnr.23758; Komitova M, 2011, GLIA, V59, P800, DOI 10.1002/glia.21152; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kramar EA, 2006, P NATL ACAD SCI USA, V103, P5579, DOI 10.1073/pnas.0601354103; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Kucharova K, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-158; Kuhn PH, 2016, ELIFE, V5, DOI 10.7554/eLife.12748; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurihara D, 2012, J BIOL CHEM, V287, P13822, DOI 10.1074/jbc.M111.314070; Kwon SK, 2010, J BIOL CHEM, V285, P13966, DOI 10.1074/jbc.M109.061127; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lang BT, 2015, NATURE, V518, P404, DOI 10.1038/nature13974; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Leadbeater WE, 2006, J NEUROCHEM, V96, P1189, DOI 10.1111/j.1471-4159.2005.03632.x; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lin B, 2003, J NEUROPHYSIOL, V89, P2874, DOI 10.1152/jn.00783.2002; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Lin RY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014557; Liu HQ, 2011, EXP NEUROL, V231, P236, DOI 10.1016/j.expneurol.2011.06.015; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Losada-Perez M, 2017, NEURAL REGEN RES, V12, P31, DOI 10.4103/1673-5374.198969; Losada-Perez M, 2016, J CELL BIOL, V214, P587, DOI 10.1083/jcb.201603054; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lukovic D, 2014, STEM CELLS, V32, P594, DOI 10.1002/stem.1562; Mangin JM, 2012, NAT NEUROSCI, V15, P1192, DOI 10.1038/nn.3190; Matusica D, 2008, J NEUROSCI RES, V86, P553, DOI 10.1002/jnr.21507; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; McRae PA, 2007, J NEUROSCI, V27, P5405, DOI 10.1523/JNEUROSCI.5425-06.2007; Menzel L., 2016, GLIA; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Neill T, 2016, J CELL BIOL, V215, P687, DOI 10.1083/jcb.201603079; Nishihara T, 2015, J BIOL CHEM, V290, P3693, DOI 10.1074/jbc.M114.603431; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nowicka D, 2009, EUR J NEUROSCI, V30, P2053, DOI 10.1111/j.1460-9568.2009.06996.x; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Orduz D, 2015, ELIFE, V4, DOI 10.7554/eLife.06953; Orlando C, 2015, BRAIN STRUCT FUNCT, V220, P1077, DOI 10.1007/s00429-013-0701-9; Passlick S, 2013, J NEUROSCI, V33, P12030, DOI 10.1523/JNEUROSCI.5562-12.2013; Perez-Moreno JJ, 2017, J CELL SCI, V130, P950, DOI 10.1242/jcs.197459; Pickford F, 2011, AM J PATHOL, V178, P284, DOI 10.1016/j.ajpath.2010.11.002; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Poluzzi C, 2014, J BIOL CHEM, V289, P16114, DOI 10.1074/jbc.M114.556530; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Pottker B., 2017, BRAIN STRUCT FUNCT; Rademakers R, 2012, NAT REV NEUROL, V8, P423, DOI 10.1038/nrneurol.2012.117; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Raposo C, 2014, GLIA, V62, P1895, DOI 10.1002/glia.22676; Rauch U, 2005, BIOCHEM BIOPH RES CO, V328, P608, DOI 10.1016/j.bbrc.2005.01.026; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Robins SC, 2013, GLIA, V61, P1735, DOI 10.1002/glia.22554; Rogers CJ, 2011, P NATL ACAD SCI USA, V108, P9747, DOI 10.1073/pnas.1102962108; Rolls A, 2008, PLOS MED, V5, P1262, DOI 10.1371/journal.pmed.0050171; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Saftig P, 2015, PROG NEUROBIOL, V135, P1, DOI 10.1016/j.pneurobio.2015.10.003; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Sakry D, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001993; Sarhan AR, 2016, J CELL SCI, V129, P2962, DOI 10.1242/jcs.191379; Sarrazin S., 2011, COLD SPRING HARB PER, V3; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Schultz N, 2014, J NEUROPATH EXP NEUR, V73, P684, DOI 10.1097/NEN.0000000000000084; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Shinozaki Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep04329; Shuo T, 2007, J NEUROCHEM, V102, P1561, DOI 10.1111/j.1471-4159.2007.04658.x; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sirko S, 2007, DEVELOPMENT, V134, P2727, DOI 10.1242/dev.02871; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sirko S, 2010, STEM CELLS, V28, P775, DOI 10.1002/stem.309; Smith PD, 2015, EXP NEUROL, V274, P100, DOI 10.1016/j.expneurol.2015.08.004; SMITHTHOMAS LC, 1995, J CELL SCI, V108, P1307; Soderblom C, 2013, J NEUROSCI, V33, P13882, DOI 10.1523/JNEUROSCI.2524-13.2013; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Soleman S, 2013, NEUROSCIENCE, V253, P194, DOI 10.1016/j.neuroscience.2013.08.050; Sprinzak D, 2010, NATURE, V465, P86, DOI 10.1038/nature08959; Stegmuller J, 2003, J BIOL CHEM, V278, P3590, DOI 10.1074/jbc.M210010200; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Takahashi H, 2013, TRENDS NEUROSCI, V36, P522, DOI 10.1016/j.tins.2013.06.002; Takahashi H, 2011, NEURON, V69, P287, DOI 10.1016/j.neuron.2010.12.024; Tan AM, 2006, J NEUROSCI, V26, P4729, DOI 10.1523/JNEUROSCI.3900-05.2006; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Tangkeangsirisin W, 2004, CARCINOGENESIS, V25, P1587, DOI 10.1093/carcin/bgh171; Tanimoto R., 2017, MATRIX BIOL; Thallmair M, 2006, EXP NEUROL, V202, P167, DOI 10.1016/j.expneurol.2006.05.025; Tillet E, 1997, J BIOL CHEM, V272, P10769; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Troeberg L, 2014, CHEM BIOL, V21, P1300, DOI 10.1016/j.chembiol.2014.07.014; Uetani N, 2000, EMBO J, V19, P2775, DOI 10.1093/emboj/19.12.2775; Ughrin YM, 2003, J NEUROSCI, V23, P175; Um JW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6423; Um JW, 2013, TRENDS CELL BIOL, V23, P465, DOI 10.1016/j.tcb.2013.07.004; Vadivelu S, 2015, STEM CELL TRANSL MED, V4, P401, DOI 10.5966/sctm.2014-0107; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Velez-Fort M, 2010, J NEUROSCI, V30, P6921, DOI 10.1523/JNEUROSCI.0238-10.2010; Vigano F, 2016, GLIA, V64, P287, DOI 10.1002/glia.22929; Vischer P, 1997, EUR J CELL BIOL, V73, P332; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson MT, 2000, J COMP NEUROL, V424, P532, DOI 10.1002/1096-9861(20000828)424:3<532::AID-CNE10>3.0.CO;2-Z; Woo J, 2009, NAT NEUROSCI, V12, P428, DOI 10.1038/nn.2279; Xie YM, 2001, J NEUROSCI, V21, P5130, DOI 10.1523/JNEUROSCI.21-14-05130.2001; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yaron A, 2012, TRENDS NEUROSCI, V35, P230, DOI 10.1016/j.tins.2011.12.003; Ye Q, 2013, MATRIX BIOL, V32, P352, DOI 10.1016/j.matbio.2013.04.001; Yim YS, 2013, P NATL ACAD SCI USA, V110, P4057, DOI 10.1073/pnas.1209881110; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; You WK, 2014, ANGIOGENESIS, V17, P61, DOI 10.1007/s10456-013-9378-1; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhou XH, 2001, MOL CELL BIOL, V21, P5970, DOI 10.1128/MCB.21.17.5970-5978.2001; Zhu Y, 2015, NEUROBIOL DIS, V74, P114, DOI 10.1016/j.nbd.2014.10.024; Zimmer G, 2010, CEREB CORTEX, V20, P2411, DOI 10.1093/cercor/bhp309; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	216	26	30	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0945-053X	1569-1802		MATRIX BIOL	Matrix Biol.	AUG	2018	68-69				SI		571	588		10.1016/j.matbio.2017.10.002			18	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	GM8LO	WOS:000438480300036	29054751				2021-06-18	
J	Song, HL; Konan, LM; Cui, JK; Johnson, CE; Langenderfer, M; Grant, D; Ndam, T; Simonyi, A; White, T; Demirci, U; Mott, DR; Schwer, D; Hubler, GK; Cernak, I; DePalma, RG; Gu, ZZ				Song, Hailong; Konan, Landry M.; Cui, Jiankun; Johnson, Catherine E.; Langenderfer, Martin; Grant, DeAna; Ndam, Tina; Simonyi, Agnes; White, Tommi; Demirci, Utkan; Mott, David R.; Schwer, Doug; Hubler, Graham K.; Cernak, Ibolja; DePalma, Ralph G.; Gu, Zezong			Ultrastructural brain abnormalities and associated behavioral changes in mice after low-intensity blast exposure	BEHAVIOURAL BRAIN RESEARCH			English	Article						Blast-induced TBI; Blast wave; Behavior; Neuropathology; Ultrastructural abnormalities	INJURY; MODEL; STRESS; MATTER; WHITE; AXONS	Explosive blast-induced mild traumatic brain injury (mTBI), a "signature wound" of recent military conflicts, commonly affects service members. While past blast injury studies have provided insights into TBI with moderate- to high-intensity explosions, the impact of primary low-intensity blast (LIB)-mediated pathobiology on neurological deficits requires further investigation. Our prior considerations of blast physics predicted ultrastructural injuries at nanoscale levels. Here, we provide quantitative data using a primary LIB injury murine model exposed to open field detonation of 350 g of high-energy explosive C4. We quantified ultrastructural and behavioral changes up to 30 days post blast injury (DPI). The use of an open-field experimental blast generated a primary blast wave with a peak overpressure of 6.76 PSI (46.6 kPa) at a 3-m distance from the center of the explosion, a positive phase duration of approximate 3.0 milliseconds (ms), a maximal impulse of 8.7 PSI x ms and a sharp rising time of 9 x 10(-3) ms, with no apparent impact/acceleration in exposed animals. Neuropathologically, myelinated axonal damage was observed in blast-exposed groups at 7 DPI. Using transmission electron microscopy, we observed and quantified myelin sheath defects and mitochondrial abnormalities at 7 and 30 DPI. Inverse correlations between blast intensities and neurobehavioral outcomes including motor activities, anxiety levels, nesting behavior, spatial learning and memory occurred. These observations uncover unique ultrastructural brain abnormalities and associated behavioral changes due to primary blast injury and provide key insights into its pathogenesis and potential treatment.	[Song, Hailong; Konan, Landry M.; Cui, Jiankun; Ndam, Tina; Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA; [Johnson, Catherine E.; Langenderfer, Martin] Missouri Univ Sci & Technol, Dept Min & Nucl Engn, Rolla, MO 65409 USA; [Grant, DeAna; White, Tommi] Univ Missouri, Electron Microscopy Core Facil, Columbia, MO 65211 USA; [Simonyi, Agnes] Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65212 USA; [Demirci, Utkan] Stanford Univ, Dept Radiol, Sch Med, Dept Elect Engn, Stanford, CA 94305 USA; [Mott, David R.; Schwer, Doug] US Naval Res Lab, Washington, DC 20375 USA; [Hubler, Graham K.] Univ Missouri, Dept Phys & Astron, Sidney Kimmel Inst Nucl Renaissance, Columbia, MO 65211 USA; [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Canadian Mil & Vet Clin Rehabil, Edmonton, AB T6G 2G4, Canada; [DePalma, Ralph G.] Off Res & Dev, Dept Vet Affairs, Washington, DC 20420 USA; [Cui, Jiankun; Gu, Zezong] Truman VA Hosp Res Serv, Columbia, MO 65201 USA	Gu, ZZ (corresponding author), Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA.	guze@health.missouri.edu	Song, Hailong/I-9418-2018; DePalma, Ralph/P-1733-2019	Song, Hailong/0000-0002-4204-6459; Ibolja, Cernak/0000-0003-3214-698X	DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA) [AZ140109]; University of Missouri	The authors thank the technical support of Drs. Shanyan Chen and Zhe Qu for the initial blast studies. This publication was made possible by funding from the DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA; AZ140109) and the research funds of the University of Missouri (ZG). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the United States government, the DoD, the United States Army or the Department of Veterans Affairs.	Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; [Anonymous], 2017, DVBIC DOD WORLDWIDE; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Beamer M, 2016, EXP NEUROL, V283, P16, DOI 10.1016/j.expneurol.2016.05.025; Bowen I. G., 1968, ESTIMATE MANS TOLERA, P37; Castejon OJ, 2004, BRAIN INJURY, V18, P1107, DOI 10.1080/02699050410001672332; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I., 2015, BRAIN NEUROTRAUMA MO; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2017, BRAIN INJURY, V31, P1168, DOI 10.1080/02699052.2016.1274779; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chandra N., 2015, BRAIN NEUROTRAUMA MO; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CLEMEDSON C, 1961, J APPL PHYSIOL, V16, P426; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DePalma R, 2011, P NATO RTO MP HFM 20, P1; DePalma R. G., 2015, COMBAT TBI HIST EPID; DePalma RG, 2018, BEHAV BRAIN RES, V340, P102, DOI 10.1016/j.bbr.2016.08.036; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Feng K, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00179; Fievisohn E., 2018, J BIOMECH ENG, V140, DOI [10.1-115/1.4038710, DOI 10.1-115/1.4038710]; Gao J, 2014, EPILEPSY RES, V108, P162, DOI 10.1016/j.eplepsyres.2013.11.016; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; JOHNSON ES, 1981, ACTA NEUROPATHOL, V53, P93, DOI 10.1007/BF00689988; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kucherov Y, 2012, J APPL PHYS, V112, DOI 10.1063/1.4765727; Kucherov Y, 2012, J APPL PHYS, V111, DOI 10.1063/1.3675274; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Perez-Garcia G, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0357-17.2018; Proud W. G., 2016, FUNDAMENTALS BLAST P, P3; Przekwas A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00002; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Song HL, 2018, BEHAV BRAIN RES, V340, P147, DOI 10.1016/j.bbr.2016.08.037; Sosa MAG, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0483-z; Stewart C., 2006, EMERGENCY MED PRACTI, V8, P1; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024	58	26	27	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUL 16	2018	347						148	157		10.1016/j.bbr.2018.03.007			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	GL2BA	WOS:000436916800018	29526786	Bronze			2021-06-18	
J	Jiang, HS; Wang, YZ; Liang, X; Xing, XF; Xu, XZ; Zhou, CF				Jiang, Hongsheng; Wang, Yanzhou; Liang, Xin; Xing, Xiaofeng; Xu, Xiuzhen; Zhou, Caifeng			Toll-Like Receptor 4 Knockdown Attenuates Brain Damage and Neuroinflammation After Traumatic Brain Injury via Inhibiting Neuronal Autophagy and Astrocyte Activation	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Toll-like receptor 4; Neuroinflammation; Autophagy; Astrocyte; Hippocampus	INTERLEUKIN-1 RECEPTOR; WHITE-MATTER; TLR4; ASTROGLIOSIS; INFLAMMATION; EXPRESSION; ISCHEMIA; STROKE; RAT	Toll-like receptor 4 (TLR4) has been linked to various pathophysiological conditions, such as traumatic brain injury (TBI). It is reported that posttraumatic neuroinflammation is an essential event in the progression of brain injury after TBI. Recent evidences indicate that TLR4 mediates glial phagocytic activity and inflammatory cytokines production. Thus, TLR4 may be an important therapeutic target for neuroinflammatory injury post-TBI. This study was designed to explore potential effects and underlying mechanisms of TLR4 in rats suffered from TBI. TBI model was induced using a controlled cortical impact in rats, and application of TLR4 shRNA silenced TLR4 expression in brain prior to TBI induction. Elevated TLR4 was specifically observed in the hippocampal astrocytes and neurons posttrauma. Interestingly, TLR4 shRNA decreased the concentrations of interleukin (IL)-1 beta, IL-6, and tissue necrosis factor-alpha; alleviated hippocampal neuronal damage; reduced brain edema formation; and improved neurological deficits after TBI. Meanwhile, to further explore underlying molecular mechanisms of this neuroprotective effects of TLR4 knockdown, our results showed that TLR4 knockdown significantly inhibited the upregulation of autophagy-associated proteins caused by TBI. More importantly, an autophagy inducer, rapamycin pretreated, could partially abolish neuroprotective effects of TLR4 knockdown on TBI rats. Furthermore, TLR4 silencing markedly suppressed GFAP upregulation and improved cell hypertrophy to attenuate TBI-induced astrocyte activation. Taken together, these findings suggested that TLR4 knockdown ameliorated neuroinflammatory response and brain injury after TBI through suppressing autophagy induction and astrocyte activation.	[Jiang, Hongsheng; Wang, Yanzhou; Liang, Xin; Xing, Xiaofeng; Xu, Xiuzhen] Cangzhou Cent Hosp, Dept Neurosurg, Cangzhou 061001, Hebei, Peoples R China; [Zhou, Caifeng] Cangzhou Cent Hosp, Dept Teaching, Cangzhou 061001, Hebei, Peoples R China	Zhou, CF (corresponding author), Cangzhou Cent Hosp, Dept Teaching, Cangzhou 061001, Hebei, Peoples R China.	kaixinhuniu@163.com					Bellot-Saez A, 2017, NEUROSCI BIOBEHAV R, V77, P87, DOI 10.1016/j.neubiorev.2017.03.002; Carpenter S, 2009, J IMMUNOL, V183, P3989, DOI 10.4049/jimmunol.0901518; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Chang CP, 2013, CELL DEATH DIFFER, V20, P515, DOI 10.1038/cdd.2012.146; Copeland CS, 2017, NEUROPHARMACOLOGY, V121, P100, DOI 10.1016/j.neuropharm.2017.04.019; de Lima NMR, 2017, BEHAV PHARMACOL, V28, P223, DOI 10.1097/FBP.0000000000000265; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dooves S, 2016, J CLIN INVEST, V126, P1512, DOI 10.1172/JCI83908; Fellner L, 2013, GLIA, V61, P349, DOI 10.1002/glia.22437; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; Hang Z, 2017, MOL NEUROBIOL, DOI [10.1007/s12035-017-0552-0, DOI 10.1007/S12035-017-0552-0]; Huang F, 2013, J NEUROINFLAMM, V10, P794; Hyakkoku K, 2010, NEUROSCIENCE, V171, P258, DOI 10.1016/j.neuroscience.2010.08.054; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Li D, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0841-6; Lin S, 2012, J NEUROINFLAMM, V9, P1; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Morizawa YM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00037-1; Nakano Y, 2015, J NEUROIMMUNOL, V278, P144, DOI 10.1016/j.jneuroim.2014.12.013; Rannikko EH, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0192-0; Rosciszewski G, 2018, MOL NEUROBIOL, V55, P3875, DOI 10.1007/s12035-017-0618-z; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Semple BD, 2017, J NEUROSCI, V37, P7864, DOI 10.1523/JNEUROSCI.0982-17.2017; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008; Woodward NC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0858-x; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771	33	26	28	1	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2018	38	5					1009	1019		10.1007/s10571-017-0570-5			11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	GH6AQ	WOS:000433521700004	29222622				2021-06-18	
J	Kuo, C; Wu, L; Loza, J; Senif, D; Anderson, SC; Camarillo, DB				Kuo, Calvin; Wu, Lyndia; Loza, Jesus; Senif, Daniel; Anderson, Scott C.; Camarillo, David B.			Comparison of video-based and sensor-based head impact exposure	PLOS ONE			English	Article							SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; IN-VIVO; MOUTHGUARD; MANAGEMENT; KINEMATICS; DEVICE; SYSTEM	Previous research has sought to quantify head impact exposure using wearable kinematic sensors. However, many sensors suffer from poor accuracy in estimating impact kinematics and count, motivating the need for additional independent impact exposure quantification for comparison. Here, we equipped seven collegiate American football players with instrumented mouthguards, and video recorded practices and games to compare video-based and sensor-based exposure rates and impact location distributions. Over 50 player-hours, we identified 271 helmet contact periods in video, while the instrumented mouthguard sensor recorded 2,032 discrete head impacts. Matching video and mouthguard real-time stamps yielded 193 video-identified helmet contact periods and 217 sensor-recorded impacts. To compare impact locations, we binned matched impacts into frontal, rear, side, oblique, and top locations based on video observations and sensor kinematics. While both video-based and sensor-based methods found similar location distributions, our best method utilizing integrated linear and angular position only correctly predicted 81 of 217 impacts. Finally, based on the activity timeline from video assessment, we also developed a new exposure metric unique to American football quantifying number of cross-verified sensor impacts per player-play. We found significantly higher exposure during games (0.35, 95% CI: 0.29 - 0.42) than practices (0.20, 95% CI: 0.17 - 0.23) (p<0.05). In the traditional impacts per player-hour metric, we observed higher exposure during practices (4.7) than games (3.7) due to increased player activity in practices. Thus, our exposure metric accounts for variability in on-field participation. While both video-based and sensor-based exposure datasets have limitations, they can complement one another to provide more confidence in exposure statistics.	[Kuo, Calvin; Loza, Jesus; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Wu, Lyndia; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Senif, Daniel; Anderson, Scott C.] Stanford Univ, Stanford Sports Med, Stanford, CA 94305 USA	Kuo, C (corresponding author), Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA.	calvink@stanford.edu	Wu, Lyndia/AAQ-1106-2020; Kuo, Calvin/AAH-1933-2019	Wu, Lyndia/0000-0002-8236-032X; Kuo, Calvin/0000-0001-8401-9136	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; Stanford Child Health Research Institute Transdisciplinary Initiatives Program; Stanford Bio-X Graduate Research Fellowship Program	This study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, the Stanford Child Health Research Institute Transdisciplinary Initiatives Program, and the Stanford Bio-X Graduate Research Fellowship Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barris S, 2008, SPORTS MED, V38, P1025, DOI 10.2165/00007256-200838120-00006; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Group BD and TCW, 2018, TRAUM BRAIN INJ COMM; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Kindschi K, 2015, CLIN J SPORT MED, V25, P201; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Kuo C, 2016, J BIOMECH; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Li BX, 2001, IEEE WORKSHOP ON CONTENT-BASED ACCESS OF IMAGE AND VIDEO LIBRARIES, PROCEEDINGS, P132, DOI 10.1109/IVL.2001.990867; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2014, AM SOC TEST MATER, V1552, P41, DOI 10.1520/STP155220120108; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Society of Automotive Engineers (SAE), 1995, J2111 SAE; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wu LC, 2018, SCI REP, V8, P1, DOI [10.1038/s41598-017-17765-5, DOI 10.1038/S41598-017-17765-5]; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; Xing JL, 2011, IEEE T IMAGE PROCESS, V20, P1652, DOI 10.1109/TIP.2010.2102045	44	26	26	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2018	13	6							e0199238	10.1371/journal.pone.0199238			19	Multidisciplinary Sciences	Science & Technology - Other Topics	GJ7CA	WOS:000435541300028	29920559	DOAJ Gold, Green Published			2021-06-18	
J	Kerr, NA; Vaccari, JPD; Abbassi, S; Kaur, H; Zambrano, R; Wu, S; Dietrich, WD; Keane, RW				Kerr, Nadine A.; Vaccari, Juan Pablo de Rivero; Abbassi, Sam; Kaur, Harmanpreet; Zambrano, Ronald; Wu, Shu; Dietrich, W. Dalton; Keane, Robert W.			Traumatic Brain Injury-Induced Acute Lung Injury: Evidence for Activation and Inhibition of a Neural-Respiratory-Inflammasome Axis	JOURNAL OF NEUROTRAUMA			English	Article						acute lung injury; extracellular vesicles; inflammasome; innate immune response; traumatic brain injury	MOLECULAR-WEIGHT HEPARIN; DISTRESS-SYNDROME; EXTRACELLULAR VESICLES; IMPACT; HMGB1	Approximately 20-25% of traumatic brain injury (TBI) subjects develop acute lung injury (ALI), but the pathomechanisms of TBI-induced ALI remain poorly defined. Our previous work has shown that the inflammasome plays a critical role in TBI-induced secondary pathophysiology and that inflammasome proteins are released in extracellular vesicles (EV) after TBI. Here we investigated whether EV-mediated inflammasome signaling contributed to the etiology of TBI-induced ALI. C57/BL6 male mice were subjected to controlled cortical impact (CCI), and the brains and lungs were examined for inflammasome activation and ALI at 4 and 24 h after TBI. We show that TBI releases EV containing inflammasome proteins into serum that target the lung to cause ALI, supporting activation of a neural-respiratory-inflammasome axis. Administration of a low-molecular-weight heparin (enoxaparin, a blocker of EV uptake) or treatment with a monoclonal antibody against apoptosis speck-like staining protein containing a caspase recruitment domain (anti-ASC) after adoptive transfer of EV isolated from TBI-injured mice significantly inhibited inflammasome activation in the lungs of recipient mice resulting in improved ALI scores.This axis constitutes an important arm of the innate inflammatory response in lung pathology after TBI and targeting this axis represents a novel therapeutic treatment for TBI-induced ALI.	[Kerr, Nadine A.; Vaccari, Juan Pablo de Rivero; Kaur, Harmanpreet; Dietrich, W. Dalton; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Kerr, Nadine A.; Vaccari, Juan Pablo de Rivero; Abbassi, Sam; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave,RMSB 5058, Miami, FL 33136 USA; [Zambrano, Ronald; Wu, Shu] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave,RMSB 5058, Miami, FL 33136 USA.	rwkeane@med.miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R42NS086274, HL132425, R01 NS042133, NS089443]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133] Funding Source: NIH RePORTER	We thank Dr. Tahir Ahmed for scientific discussions and for critically reading the manuscript and Ofelia E. Furones-Alonso for help with blood gas determinations. This project was supported in part with NIH grant R42NS086274 to RWK, NIH grant HL132425 to NK, and R01 NS042133 and NS089443 to WDD.	Andersson U, 2011, J INTERN MED, V270, P296, DOI 10.1111/j.1365-2796.2011.02430.x; Assis-Nascimento P, 2016, J NEUROSCI METH, V263, P57, DOI 10.1016/j.jneumeth.2016.01.025; Atai NA, 2013, J NEURO-ONCOL, V115, P343, DOI 10.1007/s11060-013-1235-y; Atkins CM, 2013, NEUROSCI LETT, V532, P1, DOI 10.1016/j.neulet.2012.10.019; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Buzas EI, 2014, NAT REV RHEUMATOL, V10, P356, DOI 10.1038/nrrheum.2014.19; Campo C, 1999, J APPL PHYSIOL, V86, P549; Campolo M, 2018, METHODS MOL BIOL, V1727, P385, DOI 10.1007/978-1-4939-7571-6_30; Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030; Cross LJM, 2011, CRIT CARE CLIN, V27, P355, DOI 10.1016/j.ccc.2010.12.005; Feldman P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-180; Fernandes-Alnemri T, 2008, METHOD ENZYMOL, V442, P251, DOI [10.1016/S0076-6S79(08)01413-4, 10.1016/S0076-6879(08)01413-4]; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Hendrickson CM, 2016, J TRAUMA ACUTE CARE, V80, P989, DOI 10.1097/TA.0000000000000982; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kokiko-Cochran ON, 2018, J NEUROTRAUM, V35, P73, DOI 10.1089/neu.2017.5203; Liu LY, 2014, BIOCHEM BIOPH RES CO, V450, P851, DOI 10.1016/j.bbrc.2014.06.074; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290; Luan ZG, 2014, INFLAMMATION, V37, P924, DOI 10.1007/s10753-014-9812-6; Luh Shi-Ping, 2007, Journal of Zhejiang University-Science B, V8, P60, DOI 10.1631/jzus.2007.B0060; Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Mrozek S, 2014, CRIT CARE, V18, DOI 10.1186/cc13841; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Newton K, 2012, COLD SPRING HARB PER, V4; Nicolls MR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010259; Ning FY, 2015, GENE, V557, P88, DOI 10.1016/j.gene.2014.12.018; Peltz ED, 2009, SHOCK, V32, P17, DOI 10.1097/SHK.0b013e3181997173; Qu Y, 2007, J IMMUNOL, V179, P1913, DOI 10.4049/jimmunol.179.3.1913; Ragaller Maximillian, 2010, J Emerg Trauma Shock, V3, P43, DOI 10.4103/0974-2700.58663; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Shomer E, 2016, THROMB RES, V137, P141, DOI 10.1016/j.thromres.2015.11.026; Spector R, 2015, EXP NEUROL, V273, P57, DOI 10.1016/j.expneurol.2015.07.027; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sun Q, 2017, HEPATOLOGY, V65, P253, DOI 10.1002/hep.28893; Sustar V, 2009, BLOOD CELL MOL DIS, V42, P223, DOI 10.1016/j.bcmd.2009.01.012; Tyrrell DJ, 1999, ADV PHARMACOL, V46, P151, DOI 10.1016/S1054-3589(08)60471-8; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Weber DJ, 2014, SCI TRANSL MED, V6, P252; Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316; Wu S, 2010, AM J RESP CELL MOL, V42, P552, DOI 10.1165/rcmb.2009-0068OC; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yadav H, 2016, CRIT CARE MED, V44, P1082, DOI 10.1097/CCM.0000000000001617; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	51	26	28	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2067	2076		10.1089/neu.2017.5430		JUN 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000434937100001	29648974	Green Published			2021-06-18	
J	Howell, DR; O'Brien, MJ; Raghuram, A; Shah, AS; Meehan, WP				Howell, David R.; O'Brien, Michael J.; Raghuram, Aparna; Shah, Ankoor S.; Meehan, William P., III			Near Point of Convergence and Gait Deficits in Adolescents After Sport-Related Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						cerebral concussion; eye convergence; gait; dual-task; visual flow	TRAUMATIC BRAIN-INJURY; BALANCE CONTROL; MANAGEMENT; STABILITY; STATEMENT; ATTENTION; SYMPTOMS; RECOVERY	Objective: To prospectively examine gait characteristics of participants acutely after concussion with and without receded near point of convergence (NPC), compared with healthy controls. Design: Cross-sectional study. Setting: Sports-medicine clinic. Participants: Patients examined after concussion (n = 33; mean +/- SD = 7.2 +/- 3.1 days) and a group of uninjured athletes (n = 31) completed a Postconcussion Symptom Scale, underwent NPC testing, and single/dual-task gait assessments. Independent Variables: Near point of convergence was defined as the patient-reported diplopia distance when a fixation target moved toward the nose. Receded NPC was defined as a distance >5 cm from the tip of the nose. Main Outcome Measures: Spatiotemporal gait characteristics in single-task and dual-task conditions were evaluated with analysis of variance; correlations were calculated between NPC and gait measures. Results: Eighteen of 33 (55%) patients with concussion presented with receded NPC. Those with receded NPC exhibited slower gait speed (single-task = 1.06 +/- 0.14 m/s vs 1.19 +/- 0.15 m/s; dual-task = 0.80 +/- 0.13 m/s vs 0.94 +/- 0.13 m/s; P = 0.003) and shorter stride lengths (single-task = 1.11 +/- 0.10 m vs 1.24 +/- 0.11 m; dual-task = 0.97 +/- 0.11 m vs 1.09 +/- 0.11 m; P = 0.001) than healthy controls. Near point of convergence was moderately correlated with dual-task average walking speed for the normal NPC group (rho = -0.56; P = 0.05). Postconcussion Symptom Scale scores did not significantly differ between groups (27 +/- 18 vs 28 +/- 16). Conclusions: After concussion, adolescents with receded NPC exhibited significant gait-related deficits compared with healthy controls, whereas those with normal NPC did not. Vergence and gross motor system dysfunction may be associated after concussion. Gait and vergence measures may contribute useful information to postconcussion evaluations.	[Howell, David R.; O'Brien, Michael J.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.; O'Brien, Michael J.; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Howell, David R.; O'Brien, Michael J.; Raghuram, Aparna; Shah, Ankoor S.; Meehan, William P., III] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [O'Brien, Michael J.; Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA; [Raghuram, Aparna; Shah, Ankoor S.] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA USA; [Raghuram, Aparna; Shah, Ankoor S.] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA	Howell, DR (corresponding author), Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, 9 Hope Ave, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu		Raghuram, Aparna/0000-0002-2913-6046	National Hockey League Alumni Association; Football Players Health Study at Harvard University; NFL Players Association	W. P. Meehan receives royalties from (1) ABC-Clio publishing for the sale of his books, Kids, Sports, and Concussion: A guide for coaches and parents, and Concussions; (2) Springer International for the book Head and Neck Injuries in Young Athlete; and (3) Wolters Kluwer for working as an author for UpToDate. His research is funded, in part, by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament and by a grant from the Football Players Health Study at Harvard University, which is funded by the NFL Players Association. M. J. O'Brien receives royalties from Wolters Kluwer for working as an author for UpToDate and from Springer International publishing for the book, Head and Neck Injuries in Young Athletes. The remaining authors report no conflicts of interest.	Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P417, DOI 10.1016/j.jshs.2015.03.010; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gibson JJ, 1950, PERCEPTION VISUAL WO; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2017, CLIN J SPORT MED, V27, P444, DOI 10.1097/JSM.0000000000000374; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Howell DR, 2016, J APPL BIOMECH, V33, P1; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Mancini Martina, 2011, J Bioeng Biomed Sci, VSuppl 1, P007; Mancini M, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-59; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meagher J, 2015, WORLD J PSYCHIATR, V5, P305, DOI 10.5498/wjp.v5.i3.305; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Patla AE, 1997, GAIT POSTURE, V5, P54, DOI 10.1016/S0966-6362(96)01109-5; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Poltavski DV, 2014, BRAIN INJURY, V28, P475, DOI 10.3109/02699052.2014.888771; Scheiman M, 2003, OPTOMETRY VISION SCI, V80, P214, DOI 10.1097/00006324-200303000-00011; Scheiman MM, 2017, OPTOMETRY VISION SCI, V94, P74, DOI 10.1097/OPX.0000000000000936; Smith AT, 2006, EUR J NEUROSCI, V23, P561, DOI 10.1111/j.1460-9568.2005.04526.x; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Wright JM, 2014, WILD ENVIRON MED, V25, P319, DOI 10.1016/j.wem.2014.01.004; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zhu WM, 2012, J SPORT HEALTH SCI, V1, P9, DOI 10.1016/j.jshs.2012.02.002	36	26	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2018	28	3					262	267		10.1097/JSM.0000000000000439			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GP1HS	WOS:000440566600004	28742610				2021-06-18	
J	Wang, Q; Zhang, S; Liu, TT; Wang, HH; Liu, KL; Wang, QJ; Zeng, WW				Wang, Qi; Zhang, Shan; Liu, Tingting; Wang, Huanhuan; Liu, Kaili; Wang, Qiujun; Zeng, Wenwen			Sarm1/Myd88-5 Regulates Neuronal Intrinsic Immune Response to Traumatic Axonal Injuries	CELL REPORTS			English	Article							CENTRAL-NERVOUS-SYSTEM; WALLERIAN DEGENERATION; DEATH PATHWAY; BRAIN-INJURY; ACTIVATION; SARM1; PAIN; INFECTION; CNS	Traumatic injuries can trigger inflammatory reactions, leading to profound neuropathological consequences. However, the immune capacity of neurons, distinct from that of immune cells or glial cells, in response to traumatic insults remains to be fully characterized. In this study, we demonstrate that neurons can detect, cell autonomously, distant axonal damage, resulting in rapid production of a specific collection of cytokines and chemokines. This neuronal immune response appears spatially and temporally separated from injury-induced axon degeneration. We then identify through the genetic screen that this immune response is regulated by TIR-domain adaptor Sarm1/Myd88-5. We further show that Sarm1 functions through the downstream Jnk-c-Jun signal, and blockage of this Sarm1-Jnk-c-Jun pathway effectively abolishes the recruitment of immune cells to injury-afflicted neural tissues. We therefore uncover the key function of the Sarm1 signaling pathway, independent of its known role in axon degeneration, in the neuronal intrinsic immune response to traumatic axonal injuries.	[Wang, Qi; Liu, Tingting; Liu, Kaili; Zeng, Wenwen] Tsinghua Univ, Ctr Life Sci, Beijing 100084, Peoples R China; [Zhang, Shan; Zeng, Wenwen] Tsinghua Univ, Inst Immunol, Beijing 100084, Peoples R China; [Zhang, Shan; Zeng, Wenwen] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China; [Zeng, Wenwen] Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China; [Wang, Qiujun] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Wang, Qi; Liu, Tingting] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China; [Wang, Huanhuan] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China	Zeng, WW (corresponding author), Tsinghua Univ, Ctr Life Sci, Beijing 100084, Peoples R China.; Zeng, WW (corresponding author), Tsinghua Univ, Inst Immunol, Beijing 100084, Peoples R China.; Zeng, WW (corresponding author), Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.; Zeng, WW (corresponding author), Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.	wenwenzeng@tsinghua.edu.cn	Zeng, Wenwen/D-7276-2017	Zeng, Wenwen/0000-0001-8544-3318; Wang, Qi/0000-0002-9239-1998	National Key R&D Program of China [2017YFA0505800]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31770936, 91742106]; Beijing Natural Science FoundationBeijing Natural Science Foundation [5172016]; Thousand-Talent Young Investigator Program; Center for Life Sciences; Institute for Immunology; School of Medicine at Tsinghua University; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H01188] Funding Source: KAKEN	This work was supported by the National Key R&D Program of China (2017YFA0505800), the National Natural Science Foundation of China (31770936 and 91742106 to W.Z.), the Beijing Natural Science Foundation (5172016 to W.Z.), and the Thousand-Talent Young Investigator Program (to W.Z.). The Zeng laboratory was also supported by the Center for Life Sciences, the Institute for Immunology, and the School of Medicine at Tsinghua University.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Belle M, 2014, CELL REP, V9, P1191, DOI 10.1016/j.celrep.2014.10.037; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Essuman K, 2017, NEURON, V93, P1334, DOI 10.1016/j.neuron.2017.02.022; Gerdts J, 2013, J NEUROSCI, V33, P13569, DOI 10.1523/JNEUROSCI.1197-13.2013; Ghosh AS, 2011, J CELL BIOL, V194, P751, DOI 10.1083/jcb.201103153; Grace PM, 2014, NAT REV IMMUNOL, V14, P217, DOI 10.1038/nri3621; Guan ZH, 2016, NAT NEUROSCI, V19, P94, DOI 10.1038/nn.4189; Hou YJ, 2013, J IMMUNOL, V191, P875, DOI 10.4049/jimmunol.1300374; Kim YH, 2007, J EXP MED, V204, P2063, DOI 10.1084/jem.20070868; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lewis AE, 2013, DEV BIOL, V379, P229, DOI 10.1016/j.ydbio.2013.04.026; Limatola C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00229; Lin CW, 2014, INNATE IMMUN-LONDON, V20, P161, DOI 10.1177/1753425913485877; Mukherjee P, 2013, IMMUNITY, V38, P705, DOI 10.1016/j.immuni.2013.02.013; MURPHY PG, 1995, J NEUROSCI, V15, P5130; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Old EA, 2012, CURR OPIN PHARMACOL, V12, P67, DOI 10.1016/j.coph.2011.10.015; Osterloh JM, 2012, SCIENCE, V337, P481, DOI 10.1126/science.1223899; Panneerselvam P, 2015, INT REV IMMUNOL, V34, P432, DOI 10.3109/08830185.2015.1065826; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Renier N, 2016, CELL, V165, P1789, DOI 10.1016/j.cell.2016.05.007; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Schreiber RC, 2001, NEUROREPORT, V12, P601, DOI 10.1097/00001756-200103050-00034; SMITH ML, 1972, ANAT REC, V172, P581, DOI 10.1002/ar.1091720311; Szretter KJ, 2009, J VIROL, V83, P9329, DOI 10.1128/JVI.00836-09; Walker LJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22540; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053	33	26	26	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	APR 17	2018	23	3					716	724		10.1016/j.celrep.2018.03.071			9	Cell Biology	Cell Biology	GD3EC	WOS:000430384900007	29669278	DOAJ Gold			2021-06-18	
J	Zhao, W; Choate, B; Ji, SB				Zhao, Wei; Choate, Bryan; Ji, Songbai			Material properties of the brain in injury-relevant conditions - Experiments and computational modeling	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Traumatic brain injury; Concussion; Material properties; Head injury model; Hyperelasticity; Viscoelasticity	MECHANICAL CHARACTERIZATION; IN-VIVO; HEAD; TISSUE; STRAIN; DEFORMATION; BEHAVIOR; CONCUSSIONS; VALIDATION; IMPACT	Material properties of the brain have been extensively studied but remain poorly characterized. The vast variations in constitutive models and material constants are well documented. However, no study exists to translate the variations into disparities in impact-induced brain strains most relevant to brain injury. Here, we reviewed a subset of injury-relevant brain material properties either characterized in experiments or adopted in recent head injury models. To highlight how variations in measured brain material properties manifested in simulated brain strains, we selected six experiments that have provided a complete set of brain material model and constants to implement a common head injury model. Responses resulting from two extreme events representing a high-rate cadaveric head impact and a low-rate in vivo head rotation, respectively, varied substantially. We hypothesized, and further confirmed, that the time-varying shear moduli at the appropriate time scales (e.g., similar to 5 ms and similar to 40 ms corresponding to the impulse durations of the major acceleration peaks for the two impacts, respectively), rather than the initial or long-term shear moduli, were the most indicative of impact-induced brain strains. These results underscored the need to implement measured brain material properties into an actual head injury model for evaluation. They may also provide guidelines to better characterize brain material properties in future experiments and head injury models. Finally, our finding provided a practical solution to satisfy head injury model validation requirements at both ends of the impact severity spectrum. This would improve the confidence in model simulation performance across a range of time scales relevant to concussion and sub concussion in the real-world.	[Zhao, Wei; Choate, Bryan; Ji, Songbai] Worcester Polytech Inst, Dept Biomed Engn, 60 Prescott St, Worcester, MA 01605 USA; [Ji, Songbai] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA	Ji, SB (corresponding author), Worcester Polytech Inst, Dept Biomed Engn, 60 Prescott St, Worcester, MA 01605 USA.	sji@wpi.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS092853, R21 NS088781]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092853, R21NS088781] Funding Source: NIH RePORTER	Funding is provided by the NIH Grants R01 NS092853 and R21 NS088781.	Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bayly PV, 2012, ANNU REV BIOMED ENG, V14, P369, DOI [10.1146/annurev-bioeng-071811-150032, 10.1146/annurev.bioeng-071811-150032]; Bigler ED, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00055; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Budday S, 2017, J MECH BEHAV BIOMED, V74, P463, DOI 10.1016/j.jmbbm.2017.07.014; Budday S, 2017, ACTA BIOMATER, V60, P315, DOI 10.1016/j.actbio.2017.06.024; Budday S, 2017, ACTA BIOMATER, V48, P319, DOI 10.1016/j.actbio.2016.10.036; Chatelin Simon, 2013, Journal of Biorheology, V27, P26, DOI 10.1007/s12573-012-0055-6; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Coats B, 2007, STAPP CAR CRASH JO, V51, P1; Daneshvar D.H., 2011, CLIN SPORTS MED; de Rooij R, 2016, APPL MECH REV, V68, DOI 10.1115/1.4032436; Di Ieva A, 2010, NEUROSURG REV, V33, P137, DOI 10.1007/s10143-010-0249-6; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Feng Y, 2017, J MECH BEHAV BIOMED, V65, P490, DOI 10.1016/j.jmbbm.2016.09.020; Finan JD, 2017, ACTA BIOMATER, V55, P333, DOI 10.1016/j.actbio.2017.03.037; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Ganpule S, 2017, J NEUROTRAUM, V34, P2154, DOI 10.1089/neu.2016.4744; Garimella HT, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2823; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Goriely A, 2015, ADV APPL MECH, V48, P79, DOI 10.1016/bs.aams.2015.10.002; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hrapko M., 2008, OURNAL BIOMECH ENG, V130; Ji S., 2015, ANN BIOMED ENG, V43; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lytton W.W., 2017, BRAIN INFORM; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Meaney DF, 2003, BIOMECH MODEL MECHAN, V1, P279, DOI 10.1007/s10237-002-0020-1; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Mihalik JP, 2017, MED SCI SPORT EXER, V49, P247, DOI 10.1249/MSS.0000000000001089; Miller LE, 2017, COMPUT METHOD BIOMEC, V20, P1273, DOI 10.1080/10255842.2017.1340462; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Peden M., 2004, WORLD REPORT ROAD TR; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shigeta K., 2009, P 21 INT TECHN C ENH, P1; Shuck L.Z., 1972, J BASIC ENG; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tamura A., 2008, J BIOMECH SCI ENG, V3; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; van Dommelen J. A. W., 2009, V2, P249; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang King H, 2006, Stapp Car Crash J, V50, P429; Zhao W, 2017, ANN BIOMED ENG, V45, P2437, DOI 10.1007/s10439-017-1888-3; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P1709, DOI 10.1007/s10237-017-0915-5; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P449, DOI 10.1007/s10237-016-0829-7; Zhao W, 2016, J NEUROTRAUM, V33, P1834, DOI 10.1089/neu.2015.4239; Zhao W, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0091	75	26	26	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	APR	2018	80						222	234		10.1016/j.jmbbm.2018.02.005			13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	GA7AK	WOS:000428486800028	29453025	Green Accepted			2021-06-18	
J	Dekmak, A; Mantash, S; Shaito, A; Toutonji, A; Ramadan, N; Ghazale, H; Kassem, N; Darwish, H; Zibara, K				Dekmak, AmiraSan; Mantash, Sarah; Shaito, Abdullah; Toutonji, Amer; Ramadan, Naify; Ghazale, Hussein; Kassem, Nouhad; Darwish, Hala; Zibara, Kazem			Stem cells and combination therapy for the treatment of traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Stem cells; Combination therapy; Traumatic brain injury; Pathophysiology; Treatment; Growth factors; ROCK inhibitors	INDUCED PLURIPOTENT STEM; MARROW STROMAL CELLS; HYPERBARIC-OXYGEN THERAPY; NEUROTROPHIC FACTOR GDNF; NEURAL PROGENITOR CELLS; RHO-KINASE INHIBITOR; GROWTH-FACTOR; LONG-TERM; DECOMPRESSIVE CRANIECTOMY; NEURONAL DIFFERENTIATION	TBI is a nondegenerative, noncongenital insult to the brain from an external mechanical force; for instance a violent blow in a car accident. It is a complex injury with a broad spectrum of symptoms and has become a major cause of death and disability in addition to being a burden on public health and societies worldwide. As such, finding a therapy for TBI has become a major health concern for many countries, which has led to the emergence of many monotherapies that have shown promising effects in animal models of TBI, but have not yet proven any significant efficacy in clinical trials. In this paper, we will review existing and novel TBI treatment options. We will first shed light on the complex pathophysiology and molecular mechanisms of this disorder, understanding of which is a necessity for launching any treatment option. We will then review most of the currently available treatments for TBI including the recent approaches in the field of stem cell therapy as an optimal solution to treat TBI. Therapy using endogenous stem cells will be reviewed, followed by therapies utilizing exogenous stem cells from embryonic, induced pluripotent, mesenchymal, and neural origin. Combination therapy is also discussed as an emergent novel approach to treat TBI. Two approaches are highlighted, an approach concerning growth factors and another using ROCK inhibitors. These approaches are highlighted with regard to their benefits in minimizing the outcomes of TBI. Finally, we focus on the consequent improvements in motor and cognitive functions after stem cell therapy. Overall, this review will cover existing treatment options and recent advancements in TBI therapy, with a focus on the potential application of these strategies as a solution to improve the functional outcomes of TBI. (C) 2017 Elsevier B.V. All rights reserved.	[Dekmak, AmiraSan; Mantash, Sarah; Ramadan, Naify; Kassem, Nouhad; Zibara, Kazem] Lebanese Univ, PRASE, DSST, ER045,Lab Stem Cells,Fac Sci, Beirut, Lebanon; [Mantash, Sarah; Toutonji, Amer; Ramadan, Naify; Ghazale, Hussein] Amer Univ Beirut, Dept Biochem & Mol Genet, Beirut, Lebanon; [Shaito, Abdullah] Lebanese Int Univ, Dept Biol & Chem Sci, Beirut, Lebanon; [Darwish, Hala] Amer Univ Beirut, Hariri Sch Nursing, Fac Med, Beirut, Lebanon; [Zibara, Kazem] Lebanese Univ, Fac Sci 1, Biol Dept, Lab Cardiovasc Dis & Stem Cells, Beirut, Lebanon	Zibara, K (corresponding author), Lebanese Univ, Fac Sci 1, Biol Dept, Lab Stem Cells ER045, Rafic Hariri Campus, Beirut, Lebanon.	kzibara@ul.edu.lb	SHAITO, ABDALLAH/AAJ-4034-2020; mantash, sarah/N-1204-2016	SHAITO, ABDALLAH/0000-0003-3524-7962; Darwish, Hala/0000-0001-5744-6466; Zibara, Kazem/0000-0002-9887-072X; mantash, sarah/0000-0002-1599-316X; Ramadan, Naify/0000-0001-7339-0263			Agostoe DV, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00047; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Aminmansour Bahram, 2014, Adv Biomed Res, V3, P35, DOI 10.4103/2277-9175.125031; An MC, 2012, CELL STEM CELL, V11, P253, DOI 10.1016/j.stem.2012.04.026; Anbari F, 2014, NEURAL REGEN RES, V9, P919, DOI 10.4103/1673-5374.133133; Atri A, 2008, ALZ DIS ASSOC DIS, V22, P209, DOI 10.1097/WAD.0b013e31816653bc; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74; Barkho BZ, 2011, CURR STEM CELL RES T, V6, P327; Bergstrom T, 2012, UPSALA J MED SCI, V117, P132, DOI 10.3109/03009734.2012.665096; Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Busch H. J., 2003, J CEREB BLOOD FLOW M, V23; Cary WA, 2015, WORLD NEUROSURG, V84, P1256, DOI 10.1016/j.wneu.2015.05.076; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Chen S, 2015, CELL PHYSIOL BIOCHEM, V36, P531, DOI 10.1159/000430118; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chua JY, 2011, J CEREBR BLOOD F MET, V31, P1263, DOI 10.1038/jcbfm.2010.213; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Colombel J. F., 2010, N ENGL J MED, V362; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Dadwal P, 2015, STEM CELL REP, V5, P166, DOI 10.1016/j.stemcr.2015.06.011; Dardiotis E, 2012, BRAIN INJURY PATHOGE, P23; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; del Zoppo Gregory J., 2009, V25, P34, DOI 10.1159/000209471; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ding J, 2010, MOL CELL NEUROSCI, V43, P201, DOI 10.1016/j.mcn.2009.11.001; Ding J, 2009, BRAIN BEHAV IMMUN, V23, P1083, DOI 10.1016/j.bbi.2009.05.002; Dobrowolski S. a. G. L, 2013, AM J NEUROSCIENCE, P13, DOI DOI 10.3844/AMJNSP.2013.13.24; Donega M, 2014, JOVE-J VIS EXP, DOI 10.3791/51154; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Duan H., 2014, FASEB J S618, V28; Dunkerson J, 2014, RESTOR NEUROL NEUROS, V32, P675, DOI 10.3233/RNN-140408; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Gascon S, 2016, CELL STEM CELL, V18, P396, DOI 10.1016/j.stem.2015.12.003; Goodus MT, 2015, DEV NEUROSCI-BASEL, V37, P29, DOI 10.1159/000367784; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Gutierrez-Fernandez M, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt159; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hatton J., J NEUROSURG, V105; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hosseini SM, 2015, INT J STEM CELLS, V8, P99, DOI 10.15283/ijsc.2015.8.1.99; Hou Y, 2012, NEUROSCIENCE, V200, P120, DOI 10.1016/j.neuroscience.2011.10.030; Huang YH, 2013, J NEUROSURG, V118, P1329, DOI 10.3171/2013.1.JNS121775; Huat TJ, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-91; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Ichikawa H, 2012, CRYOBIOLOGY, V64, P12, DOI 10.1016/j.cryobiol.2011.11.005; Isaksson J., ACTA NEUROPATHOL, V102; Iudice A, 2000, DRUGS, V59, P1091, DOI 10.2165/00003495-200059050-00005; Jalloh I, 2015, METAB BRAIN DIS, V30, P615, DOI 10.1007/s11011-014-9628-y; Kazanis I, 2003, BRAIN RES, V991, P34, DOI 10.1016/S0006-8993(03)03525-X; Kobayashi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052787; Kobeissy F.H, 2015, BRAIN NEUROTRAUMA MO; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Kouchi Z, 2011, J BIOL CHEM, V286, P8459, DOI 10.1074/jbc.M110.171223; Kubo T., CURR PHARM DES, V13; Lam PK, 2013, J CLIN NEUROSCI, V20, P300, DOI 10.1016/j.jocn.2012.03.028; Lee HS, 2015, J CELL BIOCHEM, V116, P310, DOI 10.1002/jcb.24969; Li LA, 2011, J NEUROTRAUM, V28, P535, DOI 10.1089/neu.2010.1619; Li Q, 2011, CELL MOL NEUROBIOL, V31, P243, DOI 10.1007/s10571-010-9614-9; Li XS, 1998, MOL BRAIN RES, V57, P92, DOI 10.1016/S0169-328X(98)00075-8; Liao DK, 2007, J CARDIOVASC PHARM, V50, P17; Lim HS, 2013, BIOMOL THER, V21, P447, DOI 10.4062/biomolther.2013.041; Llorens-Bobadilla E., CELL STEM CELL, V17; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Martinez-Monedero R, 2007, HEARING RES, V227, P48, DOI 10.1016/j.heares.2006.12.015; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; May MT, 2006, LANCET, V368, P451; McDonagh M, 2004, ARCH PHYS MED REHAB, V85, P1198, DOI 10.1016/j.apmr.2003.12.026; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mert T, 2015, INFLAMMATION, V38, P1302, DOI 10.1007/s10753-014-0101-1; Minnich JE, 2010, RESTOR NEUROL NEUROS, V28, P293, DOI 10.3233/RNN-2010-0528; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Motawea HK, 2014, J CYTOL MOL BIOL, V1; Mouhieddine TH, 2014, NEURAL REGEN RES, V9, P901, DOI 10.4103/1673-5374.133129; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PECHADRE JC, 1991, PRESSE MED, V20, P841; Perez-Pinzon Miguel A, 1996, CNS Drug Rev, V2, P257; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Prakash A, 2012, J PEDIATR NEUROSCI, V7, P4, DOI 10.4103/1817-1745.97610; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; REILLY PL, 1975, LANCET, V2, P375; Reitz M, 2012, STEM CELL TRANSL MED, V1, P866, DOI 10.5966/sctm.2012-0045; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Rizvanov AA, 2011, EXP BIOL MED, V236, P91, DOI 10.1258/ebm.2010.010172; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Rostami E, 2016, METHODS MOL BIOL, V1462, P47, DOI 10.1007/978-1-4939-3816-2_4; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salzwedel K, 2007, AIDS REV, V9, P162; Scafidi J, 2014, NATURE, V506, P230, DOI 10.1038/nature12880; Scalfani MT, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.008; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Song J, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.134; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sun D., 2011, J NEUROTRAUMA, V28; Sun D, 2014, NEURAL REGEN RES, V9, P688, DOI 10.4103/1673-5374.131567; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TANG H, 2015, BRAIN INJURY, P1; Tieves Kelly S, 2005, WMJ, V104, P22; Tomkins Oren, 2011, Cardiovasc Psychiatry Neurol, V2011, P765923, DOI 10.1155/2011/765923; Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52; Utsunomiya T, 2001, BRIT J PHARMACOL, V134, P1724, DOI 10.1038/sj.bjp.0704410; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Wallenquist U, 2009, RESTOR NEUROL NEUROS, V27, P323, DOI 10.3233/RNN-2009-0481; Wang Y, 2014, MED GAS RES, V4, DOI 10.1186/2045-9912-4-18; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Wennersten A., J NEUROSURG, V100; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Wiesenhofer B, 2000, ACTA NEUROPATHOL, V99, P131, DOI 10.1007/PL00007416; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Wu JH, 2012, CELL MOL NEUROBIOL, V32, P1187, DOI 10.1007/s10571-012-9845-z; Xie ZY, 2016, STEM CELLS, V34, P627, DOI 10.1002/stem.2238; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu X, 2010, BIOTECHNOL PROGR, V26, P781, DOI 10.1002/btpr.358; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Yan J, 2007, PLOS MED, V4, P318, DOI 10.1371/journal.pmed.0040039; Zhang AM, 2012, MOL MED REP, V6, P1315, DOI 10.3892/mmr.2012.1069; Zhang Z, 2006, CELL MOL BIOL LETT, V11, P12, DOI 10.2478/s11658-006-0002-x; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; ZHOU YL, 1995, PHYSIOL BEHAV, V57, P1107, DOI 10.1016/0031-9384(95)00019-F; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007	164	26	27	0	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		49	62		10.1016/j.bbr.2016.12.039			14	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400006	28043902				2021-06-18	
J	Gill, J; Mustapic, M; Diaz-Arrastia, R; Lange, R; Gulyani, S; Diehl, T; Motamedi, V; Osier, N; Stern, RA; Kapogiannis, D				Gill, Jessica; Mustapic, Maja; Diaz-Arrastia, Ramon; Lange, Rael; Gulyani, Seema; Diehl, Tom; Motamedi, Vida; Osier, Nicole; Stern, Robert A.; Kapogiannis, Dimitrios			Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel	BRAIN INJURY			English	Article						Exosomes; post-traumatic stress disorder; tau; traumatic brain injury (TBI); inflammation	TRAUMATIC BRAIN-INJURY; PRECLINICAL ALZHEIMERS-DISEASE; POSTTRAUMATIC-STRESS-DISORDER; EXTRACELLULAR VESICLES; BLOOD EXOSOMES; IN-VIVO; ENCEPHALOPATHY; PTSD; PROTEINS; INVENTORY	Objective: Identify biomarkers in peripheral blood that relate to chronic post-concussive and behavioural symptoms following traumatic brain injuries (TBIs) to ultimately improve clinical management.Research design: We compared military personnel with mild TBIs (mTBIs) (n=42) to those without TBIs (n=22) in concentrations of tau, amyloid-beta (A42) and cytokines (tumour necrosis factor alpha (TNF, interleukin (IL)-6 and -10) in neuronal-derived exosomes from the peripheral blood. We utilized nanosight technology coupled with ultra-sensitivity immunoassay methods. We also examined the impact of post-concussive and behavioural symptoms including depression and post-traumatic stress disorder (PTSD) on these neuronal-derived markers.Results: We report that concentrations of exosomal tau (F-1,F-62=10.50), A42 (F-1,F-61=5.32) and IL-10 (F-1,F-59=4.32) were elevated in the mTBI group compared to the controls. Within the mTBI group, regression models show that post-concussive symptoms were most related to exosomal tau elevations, whereas exosomal IL-10 levels were related to PTSD symptoms.Conclusions: These findings suggest that chronic post-concussive symptoms following an mTBI relate to altered exosomal activity, and that greater tau pathology may underlie chronic post-concussive symptoms that develop following mTBIs. It also suggests that central inflammatory activity contributes to PTSD symptoms following an mTBI, providing necessary insights into the role of inflammation in chronic PTSD symptoms.	[Gill, Jessica; Motamedi, Vida; Osier, Nicole] NINR, Tissue Injury Branch, NIH, Bethesda, MD 20892 USA; [Mustapic, Maja; Gulyani, Seema; Diehl, Tom; Kapogiannis, Dimitrios] NIA, Aging, NIH, Baltimore, MD 21224 USA; [Diaz-Arrastia, Ramon] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Lange, Rael] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Stern, Robert A.] Boston Univ, Alzheimers Dis & CTE Ctr, Neurosurg & Anat & Neurobiol, Boston, MA 02215 USA	Gill, J (corresponding author), NIH, Intramural Res Program, Bldg 10, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Osier, Nicole/Q-7913-2017; Kapogiannis, Dimitrios/AAW-4934-2020; Gill, Gill M/Q-2020-2017; , Bob/ABA-8507-2020; Mustapic, Maja/AAV-3212-2020	Osier, Nicole/0000-0002-2903-6774; Kapogiannis, Dimitrios/0000-0003-2181-3118; 	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institute of Nursing Research, Intramural Research Program; National Institute on Aging, Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000975] Funding Source: NIH RePORTER	This work was supported by the The Center for Neuroscience and Regenerative Medicine; National Institute of Nursing Research, Intramural Research Program; and National Institute on Aging, Intramural Research Program.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Armstrong RA, 2016, NEUROPATHOL APPL NEU, V2, P185; Baker S, 2016, J ALZHEIMERS DIS, V54, P1207, DOI 10.3233/JAD-160371; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bersani FS, 2016, BRAIN BEHAV IMMUN, V52, P153, DOI 10.1016/j.bbi.2015.10.015; Bogoslovsky T, 2016, J NEUROTRAUM, V5, P70; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Devoto C, 2017, CELL TRANSPLANT, V26, P1169, DOI 10.1177/0963689717714098; Dinkins MB, 2014, NEUROBIOL AGING, V35, P1792, DOI 10.1016/j.neurobiolaging.2014.02.012; Ebenezer PJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160923; Falker C, 2016, J NEUROCHEM, V137, P88, DOI 10.1111/jnc.13514; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gatson JW, 2016, J NEUROSURG, V124, P1646, DOI 10.3171/2015.6.JNS15639; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Hamlett ED, 2018, FREE RADICAL BIO MED, V114, P110, DOI 10.1016/j.freeradbiomed.2017.08.028; Hoge EA, 2009, DEPRESS ANXIETY, V26, P447, DOI 10.1002/da.20564; Jin Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2783-2; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Korkut C, 2009, CELL, V139, P393, DOI 10.1016/j.cell.2009.07.051; Lai CPK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00228; Lejbman N, 2016, BRAIN INJURY, V30, P1436, DOI 10.1080/02699052.2016.1219054; Lindqvist D, 2014, BRAIN BEHAV IMMUN, V42, P81, DOI 10.1016/j.bbi.2014.06.003; Mac Donald CL, 2016, J NEUROTRAUM, V22, P23; Mac Donald CL, 2016, J NEUROTRAUM, V4, P12; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mittelbrunn M, 2012, NAT REV MOL CELL BIO, V13, P328, DOI 10.1038/nrm3335; Nie H, 2014, PROG NEURO-PSYCHOPH, V51, P16, DOI 10.1016/j.pnpbp.2014.01.002; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Rajendrana L, 2007, NEURODEGENER DIS, V4, P164, DOI 10.1159/000101841; Rissin DM, 2011, ANAL CHEM, V83, P2279, DOI 10.1021/ac103161b; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Saenz-Cuesta M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00050; Saman S, 2014, J ALZHEIMERS DIS, V40, pS47, DOI 10.3233/JAD-132135; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sokolova V, 2011, COLLOID SURFACE B, V87, P146, DOI 10.1016/j.colsurfb.2011.05.013; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Tucker Phebe, 2010, Am J Disaster Med, V5, P113; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Yuyama K, 2012, J BIOL CHEM, V287, P10977, DOI 10.1074/jbc.M111.324616; Zhou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092828	60	26	27	2	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	10			SI		1277	1284		10.1080/02699052.2018.1471738			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	GS6YO	WOS:000443846200014	29913077	Green Accepted			2021-06-18	
J	Glushakova, OY; Glushakov, AO; Borlongan, CV; Valadka, AB; Hayes, RL; Glushakov, AV				Glushakova, Olena Y.; Glushakov, Andriy O.; Borlongan, Cesar V.; Valadka, Alex B.; Hayes, Ronald L.; Glushakov, Alexander V.			yy Role of Caspase-3-Mediated Apoptosis in Chronic Caspase-3-Cleaved Tau Accumulation and Blood-Brain Barrier Damage in the Corpus Callosum after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						BBB; caspase-3-cleaved tau; chronic TBI; cleaved-caspase-3; GFAP	CORTICAL IMPACT INJURY; WHITE-MATTER; CEREBROSPINAL-FLUID; ALZHEIMER-DISEASE; CASPASE-CLEAVAGE; AMYLOID-BETA; NEURODEGENERATIVE DISEASE; NEURONAL APOPTOSIS; TEMPORAL PROFILE; PATHOLOGICAL TAU	Traumatic brain injury (TBI) may be a significant risk factor for development of neurodegenerative disorders such as chronic traumatic encephalopathy (CTE), post-traumatic epilepsy (PTE), and Alzheimer's (AD) and Parkinson's (PD) diseases. Chronic TBI is associated with several pathological features that are also characteristic of neurodegenerative diseases, including tau pathologies, caspase-3-mediated apoptosis, neuroinflammation, and microvascular alterations. The goal of this study was to evaluate changes following TBI in cleaved-caspase-3 and caspase-3-cleaved tau truncated at Asp421, and their relationships to cellular markers potentially associated with inflammation and blood-brain (BBB) barrier damage. We studied astrocytes (glial fibrillary acidic protein [GFAP]), microglia (ionized calcium-binding adapter molecule 1 [Iba1]), BBB (endothelial barrier antigen [EBA]), and activated microglia/macrophages (cluster of differentiation 68 [CD68]). We employed immunohistochemistry at different time points from 24h to 3 months after controlled cortical impact (CCI) injury in rats, with particular interest in white matter. The study demonstrated that CCI caused chronic upregulation of cleaved-caspase-3 in the white matter of the corpus callosum. Increases in cleaved-caspase-3 in the corpus callosum were accompanied by accumulation of caspase-3-cleaved tau, with increasing perivascular aggregation 3 months after CCI. Immunofluorescence experiments further showed cellular co-localization of cleaved-caspase-3 with GFAP and CD68 and its adjacent localization with EBA, suggesting involvement of apoptosis and neuroinflammation in mechanisms of delayed BBB and microvascular damage that could contribute to white matter changes. This study also provides the first evidence that evolving upregulation of cleaved-caspase-3 is associated with accumulation of caspase-3-cleaved tau following experimental TBI, thus providing new insights into potential common mechanisms mediated by caspase-3 and underlying chronic TBI pathologies and neurodegenerative diseases.	[Glushakova, Olena Y.; Valadka, Alex B.; Hayes, Ronald L.] Virginia Commonwealth Univ, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA; [Glushakov, Andriy O.; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Glushakov, Alexander V.] Single Breath Inc, Gainesville, FL USA	Glushakova, OY (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA.; Glushakov, AV (corresponding author), Single Breath Inc, POB 1074, Midlothian, VA 23113 USA.	olenaglushakova@gmail.com; glushakov@single-breath.com	Glushakov, Alexander V/B-5452-2008	Glushakov, Alexander V/0000-0003-2872-8960			Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Albayram O, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0124-4; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Bolos M, 2016, J ALZHEIMERS DIS, V50, P77, DOI 10.3233/JAD-150704; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cai Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037599; Cartagena CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158576; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Cotman CW, 2005, J NEUROPATH EXP NEUR, V64, P104, DOI 10.1093/jnen/64.2.104; Dams-O'Connor K, 2016, NEURODEGENER DIS MAN, V6, P417, DOI 10.2217/nmt-2016-0017; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Day RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132637; Edwards G, 2017, BIOCHEM BIOPH RES CO, V483, P1137, DOI 10.1016/j.bbrc.2016.07.123; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gendron TF, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-13; Glushakov AV, 2016, METHODS MOL BIOL, V1462, P481, DOI 10.1007/978-1-4939-3816-2_27; Glushakov AV, 2016, FRONT MOL BIOSCI, V3, DOI 10.3389/fmolb.2016.00034; Glushakov AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113689; Glushakov AV, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-132; Glushakov AV, 2015, J TRAUMA CARE, V1, P1007; Glushakova O.Y., 2017, BRAIN CIRC IN PRESS; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Henriksen K, 2015, J ALZHEIMERS DIS, V43, P1331, DOI 10.3233/JAD-140984; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLNESS CL, 1993, BLOOD, V81, P1607; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Huh JW, 2011, J NEUROTRAUM, V28, P245, DOI 10.1089/neu.2010.1639; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Ji W, 2017, CELL MOL NEUROBIOL, V37, P683, DOI 10.1007/s10571-016-0404-x; Johnson EA, 2005, EXP BRAIN RES, V167, P17, DOI 10.1007/s00221-005-2362-2; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Laskowitz D., 2016, TRANSLATIONAL RES TR; Lingor P, 2012, CELL TISSUE RES, V349, P289, DOI 10.1007/s00441-012-1362-3; LoBue C, 2017, CLIN NEUROPSYCHOL, V31, P85, DOI 10.1080/13854046.2016.1257069; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Lorente L, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0485-z; Lorente L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121739; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Love S, 2000, NEUROREPORT, V11, P2495, DOI 10.1097/00001756-200008030-00030; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; Luo WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11161; Lyck L, 2008, J HISTOCHEM CYTOCHEM, V56, P201, DOI 10.1369/jhc.7A7187.2007; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; Majerova P, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0161-z; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Osier ND, 2015, J NEUROTRAUM, V32, P1861, DOI 10.1089/neu.2014.3680; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Pozueta J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2927; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reyes-Haro D, 2013, BIOL RES, V46, P27, DOI 10.4067/S0716-97602013000100004; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Rodhe J, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0365-9; Rohn Troy T, 2015, Int J Neurol Neurother, V2, P014; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Taylor KM, 2016, PARKINSONISM RELAT D, V23, P57, DOI 10.1016/j.parkreldis.2015.12.005; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Woertgen C, 2002, ACT NEUR S, V81, P205; Yang Xinyu, 2002, Chin J Traumatol, V5, P250; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhao XH, 2016, NAT MED, V22, P1268, DOI 10.1038/nm.4199; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	103	26	30	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					157	173		10.1089/neu.2017.4999			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700018	28637381				2021-06-18	
J	Bramley, H; Henson, A; Lewis, MM; Kong, L; Stetter, C; Silvis, M				Bramley, Harry; Henson, Alyssa; Lewis, Mechelle M.; Kong, Lan; Stetter, Christy; Silvis, Matthew			Sleep Disturbance Following Concussion Is a Risk Factor for a Prolonged Recovery	CLINICAL PEDIATRICS			English	Article						concussion; mild traumatic brain injury; treatment; pediatric; sleep disturbance; melatonin	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; MINOR HEAD-INJURY; WAKE DISTURBANCES; SEX-DIFFERENCES; HIGH-SCHOOL; DISORDERS; SYMPTOMS; ADOLESCENTS; MELATONIN	Sleep disturbance is a common problem following concussion. A retrospective chart review was conducted at a regional concussion clinic on patients 13 to 18 years of age between 2005 and 2011. Statistical analysis evaluated sleep disturbance and duration of concussion, as well as the use and effectiveness of melatonin. A total of 417 patients met inclusion criteria. One hundred twenty-three (34%) reported disturbance in sleep. There was no difference in sleep disturbance based on age, gender, or past number of concussions. Sleep disturbance was associated with a 3- to 4-fold increase in recovery time. Non-sport-related concussions were more likely to be associated with sleep disturbance compared to sport-related concussions (45% vs 29%, P = .01). Melatonin improved sleep disturbance in 67% of the patients. Evaluating sleep disorders following concussion is an important part of the assessment. These findings will help clinicians provide anticipatory guidance and treatment for adolescents recovering from concussion.	[Bramley, Harry; Henson, Alyssa; Lewis, Mechelle M.; Kong, Lan; Stetter, Christy; Silvis, Matthew] Penn State Milton S Hershey Med Ctr, Hershey, PA USA	Bramley, H (corresponding author), Penn State Milton S Hershey Med Ctr, Dept Pediat, Mail Code H085,500 Univ Dr, Hershey, PA 17033 USA.	hbramley@hmc.psu.edu			National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000127, TR002014]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Kong is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR000127 and TR002014. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Barlow KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-271; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bramley H, 2015, PEDIATR NEUROL, V52, P493, DOI 10.1016/j.pediatrneurol.2015.01.008; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Halstead ME, 2016, SPORTS HEALTH, V8, P50, DOI 10.1177/1941738115622158; Halstead ME, 2010, PEDIATR ANN, V39, P275, DOI 10.3928/00904481-20100422-07; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kim Eui-Joong, 2007, Behav Sleep Med, V5, P256; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pace-Schott EF, 2015, BIOL MOOD ANXIETY DI, V5, DOI 10.1186/s13587-015-0018-9; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Shay N, 2014, J NEUROTRAUM, V31, P1305, DOI 10.1089/neu.2013.3275; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Singh K, 2016, PEDIATR NEUROL, V60, P30, DOI 10.1016/j.pediatrneurol.2016.02.013; Stallard P, 1998, BRIT MED J, V317, P1619, DOI 10.1136/bmj.317.7173.1619; Tham SW, 2015, J NEUROTRAUM, V32, P847, DOI 10.1089/neu.2014.3559; Vandekerckhove M, 2010, SLEEP MED REV, V14, P219, DOI 10.1016/j.smrv.2010.01.002; Rios ERV, 2010, INT J NEUROSCI, V120, P583, DOI 10.3109/00207454.2010.492921; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249	42	26	26	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	DEC	2017	56	14					1280	1285		10.1177/0009922816681603			6	Pediatrics	Pediatrics	FL0NK	WOS:000413907900002	29073787				2021-06-18	
J	Feng, Y; Cui, CM; Liu, X; Wu, Q; Hu, FG; Zhang, HF; Ma, ZZ; Wang, LQ				Feng, Yan; Cui, Changmeng; Liu, Xin; Wu, Qiang; Hu, Fuguang; Zhang, Haofeng; Ma, Zhizhao; Wang, Liqun			Protective Role of Apocynin via Suppression of Neuronal Autophagy and TLR4/NF-kappa B Signaling Pathway in a Rat Model of Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Apocynin; Traumatic brain injury; Autophagy; Toll-like receptor 4; Nuclear factor-kappa B	NADPH OXIDASE INHIBITOR; ACTIVATION; RESPONSES; DEFICITS; EDEMA; DEATH	Neuronal autophagy and inflammatory responses are important in the pathogenesis of traumatic brain injury (TBI), and toll-like receptor 4 (TLR4) may play an important role in the related molecular cascade. The present study investigated the protective effect of apocynin, an inhibitor of NADPH oxidase, in a TBI rat model and further examined neuronal autophagy and the TLR4-mediated pathway. Adult male Sprague-Dawley rats were subjected to controlled cortical impact injury and intraperitoneally injected with apocynin (50 mg/kg) immediately after the trauma. In addition to motor and behavioral studies, brain water content and histology analyses were performed. Expression of autophagy-related proteins as well as TLR4/NF-kappa B signaling and inflammatory mediators was analyzed. The apocynin treatment significantly attenuated TBI-induced motor and behavioral impairment, brain edema and neuronal damage in rats. Immunohistochemical and Western blot analyses revealed that apocynin treatment significantly reduced the expression of NOX2, LC3 and Beclin1 in the hippocampus at 12-48 h after injury. Double immunolabeling demonstrated that apocynin decreased the co-localization of LC3 or TLR4-positive cells with hippocampal neurons at 24 h following TBI. In addition, CD11b (microglial marker) and GFAP (astrocyte marker)-immunopositive cells were also clearly decreased in hippocampal tissues. Meanwhile, protein levels of TLR4, NF-kappa B p65, TNF-alpha and IL-1 beta were found to be significantly downregulated by Western blot analysis. In conclusion, our findings indicate that the protective effects of apocynin may be related to modulation of neuronal autophagy and the TLR4/NF-kappa B signaling pathway.	[Feng, Yan; Liu, Xin; Wu, Qiang; Hu, Fuguang; Zhang, Haofeng; Ma, Zhizhao; Wang, Liqun] Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Cui, Changmeng] Jining Med Univ, Affiliated Hosp, Dept Neurosurg, Jining, Shandong, Peoples R China	Wang, LQ (corresponding author), Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China.	lqwangdr@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	This work was supported by the Natural Science Foundation of Hebei Province (Grant No. H2014105079).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ano Y, 2010, NEUROSCI LETT, V469, P39, DOI 10.1016/j.neulet.2009.11.040; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Carty M, 2011, BIOCHEM PHARMACOL, V81, P825, DOI 10.1016/j.bcp.2011.01.003; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Haar CV, 2012, RESTOR NEUROL NEUROS, V30, P291, DOI 10.3233/RNN-2012-110196; Hayashi T, 2005, DIABETES OBES METAB, V7, P334, DOI 10.1111/j.1463-1326.2004.00393.x; Hoffmann O, 2007, J IMMUNOL, V178, P6476, DOI 10.4049/jimmunol.178.10.6476; Huang J, 2009, AUTOPHAGY, V5, P887, DOI 10.4161/auto.9125; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jinnouchi Y, 2007, BRAIN RES, V1167, P92, DOI 10.1016/j.brainres.2007.04.088; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lu Q, 2015, REDOX BIOL, V6, P516, DOI 10.1016/j.redox.2015.06.016; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Teng RJ, 2012, AM J PHYSIOL-LUNG C, V302, P1651, DOI 10.1152/ajplung.00177.2011; Tu XK, 2010, NEUROCHEM RES, V35, P1147, DOI 10.1007/s11064-010-0167-6; Uysal A, 2015, PERFUSION-UK, V30, P472, DOI 10.1177/0267659114559260; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	39	26	26	2	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2017	42	11					3296	3309		10.1007/s11064-017-2372-z			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FK4IR	WOS:000413457000026	28786047				2021-06-18	
J	Lynall, RC; Mauntel, TC; Pohlig, RT; Kerr, ZY; Dompier, TP; Hall, EE; Buckley, TA				Lynall, Robert C.; Mauntel, Timothy C.; Pohlig, Ryan T.; Kerr, Zachary Y.; Dompier, Thomas P.; Hall, Eric E.; Buckley, Thomas A.			Lower Extremity Musculoskeletal Injury Risk After Concussion Recovery in High School Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; adolescents; functional movement; dynamic balance	GENERALIZED ESTIMATING EQUATIONS; LONGITUDINAL DATA-ANALYSIS; GAIT BALANCE CONTROL; FOOTBALL PLAYERS; CONTROL DEFICITS; COLLEGIATE; ASSOCIATION; ADOLESCENTS; INCREASES; STATEMENT	Context: Although an association between concussion and musculoskeletal injury has been described in collegiate and professional athletes, no researchers have investigated an association in younger athletes. Objective: To determine if concussion in high school athletes increased the risk for lower extremity musculoskeletal injury after return to activity. Design: Observational cohort study. Setting: One hundred ninety-six high schools across 26 states. Patients or Other Participants: We used data from the National Athletic Treatment, Injury and Outcomes Network surveillance system. Athletic trainers provided information about sport-related concussions and musculoskeletal injuries in athletes in 27 sports, along with missed activity time due to these injuries. Main Outcome Measure(s): Three general estimating equations were modeled to predict the odds of sustaining (1) any lower extremity injury, (2) a time-loss lower extremity injury, or (3) a non-time-loss lower extremity injury after concussion. Predictors were the total number of previous injuries, number of previous concussions, number of previous lower extremity injuries, number of previous upper extremity injuries, and sport contact classification. Results: The initial dataset contained data from 18 216 athletes (females = 39%, n = 6887) and 46 217 injuries. Lower extremity injuries accounted for most injuries (56.3%), and concussions for 4.3% of total injuries. For every previous concussion, the odds of sustaining a subsequent time-loss lower extremity injury increased 34% (odds ratio [OR] = 1.34; 95% confidence interval [CI] = 1.13, 1.60). The number of previous concussions had no effect on the odds of sustaining any subsequent lower extremity injury (OR = 0.97; 95% CI = 0.89, 1.05) or a non-time-loss injury (OR = 1.01; 95% CI = 0.92, 1.10). Conclusions: Among high school athletes, concussion increased the odds of sustaining subsequent time-loss lower extremity injuries but not non-time-loss injuries. By definition, time-loss injuries may be considered more severe than non-time-loss injuries. The exact mechanism underlying the increased risk of lower extremity injury after concussion remains elusive and should be further explored in future research.	[Lynall, Robert C.] Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA; [Mauntel, Timothy C.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed, Bethesda, MD USA; [Pohlig, Ryan T.] Univ Delaware, Biostat Core Facil, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE 19716 USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN USA; [Hall, Eric E.] Elon Univ, Dept Exercise Sci, Elon, NC USA	Lynall, RC (corresponding author), Univ Georgia, Dept Kinesiol, 330 River Rd, Athens, GA 30602 USA.	rlynall@uga.edu	Buckley, Thomas A/B-7525-2016; Lynall, Robert/M-2888-2014	Buckley, Thomas A/0000-0002-0515-0150; Lynall, Robert/0000-0002-0785-6640	National Athletic Trainers' Association Research & Education Foundation; Bio Crossroads in partnership; Central Indiana Corporate Partnership Foundation	Funding for this study was provided by the National Athletic Trainers' Association Research & Education Foundation and BioCrossroads in partnership with the Central Indiana Corporate Partnership Foundation. The funding organizations had no role in the design and conduct of this study; the collection, management, analysis, or data interpretation; the preparation, review, or manuscript approval; or the decision to submit the manuscript for publication. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the study sponsors. We thank the many athletic trainers who have volunteered their time and efforts to submit data to the NATION. Their efforts are greatly appreciated and have had a tremendously positive effect on the safety of high school student- athletes.	[Anonymous], 1988, PEDIATRICS, V81, P737; Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Dubose DF, 2017, MED SCI SPORT EXER, V49, P167, DOI 10.1249/MSS.0000000000001067; Ghisletta P, 2004, J EDUC BEHAV STAT, V29, P421, DOI 10.3102/10769986029004421; Gilbert FC, 2016, SPORTS HEALTH, V8, P661, DOI 10.1177/1941738116666509; Grier TL, 2011, MIL MED, V176, P1292, DOI 10.7205/MILMED-D-11-00215; Hauret KG, 2010, AM J PREV MED, V38, pS61, DOI 10.1016/j.amepre.2009.10.021; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kucera KL, 2016, MED SCI SPORT EXER, V48, P1053, DOI 10.1249/MSS.0000000000000872; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lynall RC, 2016, BRIT J SPORT MED, V50, P1211, DOI 10.1136/bjsports-2015-095360; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Federation of State High School Associations, 2015, PART STAT; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Oldham JR, 2017, SPORTS HEALTH, V9, P305, DOI 10.1177/1941738116680999; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Talarico MK, 2017, J SPORT SCI, V35, P1118, DOI 10.1080/02640414.2016.1211307; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	31	26	26	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV	2017	52	11					1028	1034		10.4085/1062-6050-52.11.22			7	Sport Sciences	Sport Sciences	FR0MQ	WOS:000418756400005	29140128	Bronze, Green Published			2021-06-18	
J	Rohlwink, UK; Meuff, K; Wilkinson, KA; Enslin, N; Wegoye, E; Wilkinson, RJ; Figajil, AA				Rohlwink, Ursula K.; Meuff, Katya; Wilkinson, Katalin A.; Enslin, Nico; Wegoye, Emmanuel; Wilkinson, Robert J.; Figajil, Anthony A.			Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis	CLINICAL INFECTIOUS DISEASES			English	Article						pediatric tuberculous meningitis; biomarkers; S100B; NSE; GFAP	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM TUBERCULOSIS; CEREBROSPINAL-FLUID; PERIPHERAL-BLOOD; DIAGNOSTIC-VALUE; CHILDREN; SERUM; HYDROCEPHALUS	Background. Tuberculous meningitis (TBM) leads to death or disability in half the affected individuals. Tools to assess severity and predict outcome are lacking. Neurospecific biomarkers could serve as markers of the severity and evolution of brain injury, but have not been widely explored in TBM. We examined biomarkers of neurological injury (neuromarkers) and inflammation in pediatric TBM and their association with outcome. Methods. Blood and cerebrospinal fluid (CSF) of children with TBM and hydrocephalus taken on admission and over 3 weeks were analyzed for the neuromarkers S100B, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), in addition to multiple inflammatory markers. Results were compared with 2 control groups: patients with (1) a fatty filum (abnormal filum terminale of the spinal cord); and (2) pulmonary tuberculosis (PTB). Imaging was conducted on admission and at 3 weeks. Outcome was assessed at 6 months. Results. Data were collected from 44 patients with TBM (cases; median age, 3.3 [min-max 0.3-13.1] years), 11 fatty filum controls (median age, 2.8 [min-max 0.8-8] years) and 9 PTB controls (median age, 3.7 [min-max 1.3-11.8] years). Seven cases (16%) died and 16 (36%) had disabilities. Neuromarkers and inflammatory markers were elevated in CSF on admission and for up to 3 weeks, but not in serum. Initial and highest concentrations in week 1 of S100B and NSE were associated with poor outcome, as were highest concentration overall and an increasing profile over time in S100B, NSE, and GFAP. Combined neuromarker concentrations increased over time in patients who died, whereas inflammatory markers decreased. Cerebral infarcts were associated with highest overall neuromarker concentrations and an increasing profile over time. Tuberculomas were associated with elevated interleukin (IL) 12p40, interferon-inducible protein 10, and monocyte chemoattractant protein 1 concentrations, whereas infarcts were associated with elevated tumor necrosis factor a, macrophage inflammatory protein 1 alpha, IL-6, and IL-8. Conclusions. CSF neuromarkers are promising biomarkers of injury severity and are predictive of mortality. An increasing trend suggested ongoing brain injury, even though markers of inflammation declined with treatment. These findings could offer novel insight into the pathophysiology of TBM.	[Rohlwink, Ursula K.; Enslin, Nico; Wegoye, Emmanuel; Figajil, Anthony A.] Univ Cape Town, Div Neurosurg, Cape Town, South Africa; [Rohlwink, Ursula K.; Wilkinson, Katalin A.; Wilkinson, Robert J.] Univ Cape Town, Wellcome Ctr Infect Dis Res Africa, Inst Infect Dis & Mol Med, Dept Med, Cape Town, South Africa; [Meuff, Katya] Univ Cape Town, Dept Stat Sci, Cape Town, South Africa; [Wilkinson, Katalin A.; Wilkinson, Robert J.] Imperial Coll London, Francis Crick Inst, London, England; [Wilkinson, Robert J.] Imperial Coll London, Dept Med, London, England	Rohlwink, UK (corresponding author), Red Cross War Mem Childrens Hosp, Sixth Floor,ICH Bldg,Klipfontein Rd, ZA-7700 Cape Town, South Africa.	ursulakarin@gmail.com	Wilkinson, Katalin/AAQ-7713-2021; Rohlwink, Ursula Karin/U-8917-2019; Rohlwink, Ursula/AAE-2513-2020; Wilkinson, Katalin/AAF-6805-2020	Wilkinson, Katalin/0000-0002-9796-2040; Enslin, Johannes/0000-0002-6384-7781; Figaji, Anthony/0000-0002-3357-6490; Wilkinson, Robert/0000-0002-2753-1800	Wellcome TrustWellcome TrustEuropean Commission [084323]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U117588499] Funding Source: researchfish; Wellcome TrustWellcome TrustEuropean Commission [104803/Z/14/Z] Funding Source: researchfish; The Francis Crick Institute [10218] Funding Source: researchfish	This work was supported by the Wellcome Trust (grant number 084323 to U. K. R.).	Babu GN, 2008, NEUROSCI LETT, V436, P48, DOI 10.1016/j.neulet.2008.02.060; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; DONALD PR, 1995, CLIN INFECT DIS, V21, P924, DOI 10.1093/clinids/21.4.924; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Figaji AA, 2010, TUBERCULOSIS, V90, P393, DOI 10.1016/j.tube.2010.09.005; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Kashyap RS, 2010, NEUROIMMUNOMODULAT, V17, P333, DOI 10.1159/000292023; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Marais S, 2010, LANCET INFECT DIS, V10, P803, DOI 10.1016/S1473-3099(10)70138-9; MASTROIANNI CM, 1994, PEDIATR INFECT DIS J, V13, P1008; Mastroianni CM, 1997, CLIN IMMUNOL IMMUNOP, V84, P171, DOI 10.1006/clin.1997.4367; Misra UK, 2010, NEUROSCI LETT, V483, P6, DOI 10.1016/j.neulet.2010.07.029; Ramzan A, 2013, PEDIATR NEUROL, V48, P30, DOI 10.1016/j.pediatrneurol.2012.09.004; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; Rich AR, 1933, B JOHNS HOPKINS HOSP, V52, P5; Rohlwink UK, 2016, PEDIATR INFECT DIS J, V35, pE301, DOI 10.1097/INF.0000000000001236; Rohlwink UK, 2016, DEV MED CHILD NEUROL, V58, P461, DOI 10.1111/dmcn.13054; Rohlwink UK, 2014, CLIN CHEM, V60, P823, DOI 10.1373/clinchem.2013.212472; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Simmons CP, 2006, J IMMUNOL, V176, P2007, DOI 10.4049/jimmunol.176.3.2007; Song F, 2014, IRISH J MED SCI, V183, P85, DOI 10.1007/s11845-013-0980-4; Stewart A, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.02.049; Tarnaris A, 2011, NEUROCHEM RES, V36, P528, DOI 10.1007/s11064-010-0374-1; van Toorn R, 2014, PEDIATR INFECT DIS J, V33, P248, DOI 10.1097/INF.0000000000000065; van Well Gijs T J, 2009, Pediatrics, V123, pe1, DOI 10.1542/peds.2008-1353; Yaramis A, 2001, PEDIATRICS, V107, P1236, DOI 10.1542/peds.107.5.1236; Yaramis A, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e49; Zhang CX, 2016, EUR REV MED PHARMACO, V20, P1474	32	26	28	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1058-4838	1537-6591		CLIN INFECT DIS	Clin. Infect. Dis.	OCT 15	2017	65	8					1298	1307		10.1093/cid/cix540			10	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	FI5KR	WOS:000412022500007	28605426	Other Gold, Green Published			2021-06-18	
J	Ganetsky, M; Lopez, G; Coreanu, T; Novack, V; Horng, S; Shapiro, NI; Bauer, KA				Ganetsky, Michael; Lopez, Gregory; Coreanu, Tara; Novack, Victor; Horng, Steven; Shapiro, Nathan I.; Bauer, Kenneth A.			Risk of Intracranial Hemorrhage in Ground-level Fall With Antiplatelet or Anticoagulant Agents	ACADEMIC EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; VITAMIN-K ANTAGONISTS; NET CLINICAL BENEFIT; PREINJURY WARFARIN; HEAD-INJURY; MORTALITY; DABIGATRAN; COMPLICATIONS	Objectives: Anticoagulant and antiplatelet medications are known to increase the risk and severity of traumatic intracranial hemorrhage (tICH), even with minor head trauma. Most studies on bleeding propensity with head trauma are retrospective, are based on trauma registries, or include heterogeneous mechanisms of injury. The goal of this study was to determine the rate of tICH from only a common low-acuity mechanism of injury, that of a ground-level fall, in patients taking one or more of the following antiplatelet or anticoagulant medications: aspirin, warfarin, prasugrel, ticagrelor, dabigatran, rivaroxaban, apixaban, or enoxaparin. Methods: This was a prospective cohort study conducted at a Level I tertiary care trauma center of consecutive patients meeting the inclusion criteria of a ground-level fall with head trauma as affirmed by the treating clinician, a computed tomography (CT) head obtained, and taking and one of the above antiplatelet or anticoagulants. Patients were identified prospectively through electronic screening with confirmatory chart review. Emergency department charts were abstracted without subsequent knowledge of the hospital course. Patients transferred with a known abnormal CT head were excluded. Primary outcome was rate of tICH on initial CT head. Rates with 95% confidence intervals (CIs) were compared. Results: Over 30 months, we enrolled 939 subjects. The mean +/- SD age was 78.3 +/- 11.9 years and 44.6% were male. There were a total of 33 patients with tICH (3.5%, 95% CI = 2.5%-4.9%). Antiplatelets had a rate of tICH of 4.3% (95% CI = 3.0%-6.2%) compared to anticoagulants with a rate of 1.7% (95% CI = 0.4%-4.5%). Aspirin without other agents had an tICH rate of 4.6% (95% CI = 3.2%-6.6%); of these, 81.5% were taking lowdose 81 mg aspirin. Two patients received a craniotomy (one taking aspirin, one taking warfarin). There were four deaths (three taking aspirin, one taking warfarin). Most (72.7%) subjects with tICH were discharged home or to a rehabilitation facility. There were no tICH in 31 subjects taking a direct oral anticoagulant. CIs were overlapping for the groups. Conclusion: There is a low incidence of clinically significant tICH with a ground-level fall in head trauma in patients taking an anticoagulant or antiplatelet medication. There was no statistical difference in rate of tICH between antiplatelet and anticoagulants, which is unanticipated and counterintuitive as most literature and teaching suggests a higher rate with anticoagulants. A larger data set is needed to determine if small differences between the groups exist.	[Ganetsky, Michael; Lopez, Gregory; Horng, Steven; Shapiro, Nathan I.] Harvard Med Sch, Dept Emergency Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Bauer, Kenneth A.] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Coreanu, Tara; Novack, Victor] Soroka Univ, Med Ctr, Clin Res Ctr, Negev, Israel; [Coreanu, Tara; Novack, Victor] Ben Gurion Univ Negev, Negev, Israel	Ganetsky, M (corresponding author), Harvard Med Sch, Dept Emergency Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.	mganetsk@bidmc.harvard.edu			Boehringer IngelheimBoehringer Ingelheim; Philips Healthcare; JanssenJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc	MG reports having received grant money to BIDMC to conduct research conceived and sponsored by Boehringer Ingelheim; SH reports grant support from Philips Healthcare; and KB has received funding personally from Janssen, Boehringer Ingelheim, and Instrumentation Laboratory for consulting.	Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1; Alrajhi KN, 2015, J EMERG MED, V48, P137, DOI 10.1016/j.jemermed.2014.08.016; Beynon C, 2015, CLIN NEUROL NEUROSUR, V136, P73, DOI 10.1016/j.clineuro.2015.05.035; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; Connolly BJ, 2014, STROKE, V45, P1672, DOI 10.1161/STROKEAHA.114.005430; Connolly SJ, 2011, ANN INTERN MED, V155, P579, DOI 10.7326/0003-4819-155-9-201111010-00004; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gaetani P, 2012, J NEUROSURG SCI, V56, P231; Ganetsky M, 2015, J EMERG MED, V49, P693, DOI 10.1016/j.jemermed.2015.04.028; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hamden K, 2014, AM J EMERG MED, V32, P890, DOI 10.1016/j.ajem.2014.04.051; Harper P, 2012, NEW ENGL J MED, V366, P864, DOI 10.1056/NEJMc1112874; Karni A, 2001, AM SURGEON, V67, P1098; Major J, 2009, EMERG MED J, V26, P871, DOI 10.1136/emj.2008.068643; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Singer DE, 2009, ANN INTERN MED, V151, P297, DOI 10.7326/0003-4819-151-5-200909010-00003; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6	26	26	26	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	OCT	2017	24	10					1258	1266		10.1111/acem.13217			9	Emergency Medicine	Emergency Medicine	FK2YM	WOS:000413349800008	28475282	Bronze			2021-06-18	
J	Gill, J; Motamedi, V; Osier, N; Dell, K; Arcurio, L; Carr, W; Walker, P; Ahlers, S; LoPresti, M; Yarnell, A				Gill, Jessica; Motamedi, Vida; Osier, Nicole; Dell, Kristine; Arcurio, Lindsay; Carr, Walter; Walker, Peter; Ahlers, Stephen; LoPresti, Mathew; Yarnell, Angela			Moderate blast exposure results in increased IL-6 and TNF alpha in peripheral blood	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Blast; Traumatic brain injury (TBI); Military; Inflammation; Cytokines	TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; INTERLEUKIN-6; STRESS; NEUROINFLAMMATION; CSF; ASSOCIATIONS; ASTROCYTES; PROFILES; RHYTHMS	A unique cohort of military personnel exposed to isolated blast was studied to explore acute peripheral cytokine levels, with the aim of identifying blast-specific biomarkers. Several cytokines, including interleukin (IL) 6, IL-10 and tumor necrosis factor alpha (TNF alpha) have been linked to pre-clinical blast exposure, but remained unstudied in clinical blast exposure. To address this gap, blood samples from 62 military personnel were obtained at baseline, and daily, during a 10-day blast-related training program; changes in the peripheral concentrations of IL-6, IL-10 and TNF alpha were evaluated using an ultrasensitive assay. Two groups of trainees were matched on age, duration of military service, and previous history of blast exposure(s), resulting in moderate blast cases and no/low blast controls. Blast exposures were measured using helmet sensors that determined the average peak pressure in pounds per square inch (psi). Moderate blast cases had significantly elevated concentrations of IL-6 (F-1,F-60 = 18.81, p < 0.01) and TNF alpha (F-1,F-60 = 12.03, p < 0.01) compared to no/low blast controls; levels rebounded to baseline levels the day after blast. On the day of the moderate blast exposure, the extent of the overpressure (psi) in those exposed correlated with IL-6 (r = 0.46, p < 0.05) concentrations. These findings indicate that moderate primary blast exposure results in changes, specifically acute and transient increases in peripheral inflammatory markers which may have implications for neuronal health. Published by Elsevier Inc.	[Gill, Jessica; Motamedi, Vida; Osier, Nicole; Arcurio, Lindsay] NINR, NIH, 1 Cloisters Dr, Bethesda, MD 20892 USA; [Dell, Kristine; Walker, Peter; Ahlers, Stephen; LoPresti, Mathew; Yarnell, Angela] Walter Reed Army Inst Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Carr, Walter] USARMY MEDCOM USAMRMC, Ft Detrick, MD USA; [Dell, Kristine] 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Walker, Peter; Ahlers, Stephen] Natl Res Med Ctr, 503 Robert Grant Ave, Silver Spring, MD 20910 USA	Gill, J (corresponding author), NINR, NIH, 1 Cloisters Dr, Bethesda, MD 20892 USA.	gillj@mail.nih.gov; Vida.Motamedi@nih.gov; Nicole.Osier@nih.gov; kristine.dell@nih.gov; larcurio@mail.nih.gov; walter.s.carr.mil@mail.mil; Peter.b.walker.mil@mail.mil; stephen.tahlers.civ@mail.mil; matthew.l.lopresti.mil@mail.mil; angela.m.yarnell.mil@mail.mil	Osier, Nicole/Q-7913-2017; Gill, Gill M/Q-2020-2017	Osier, Nicole/0000-0002-2903-6774; 	National Institute of Nursing Research, Intramural Program; Walter Reed Army Institute of Research; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000034] Funding Source: NIH RePORTER	This study was funded by the National Institute of Nursing Research, Intramural Program, and by the Walter Reed Army Institute of Research. We would like to thank the service members who participated in this study.	Altara R, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0477-1; Black PH, 2002, BRAIN BEHAV IMMUN, V16, P622, DOI 10.1016/S0889-1591(02)00021-1; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Carr W, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00049; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; CHANDRA N, 2015, BRAIN NEUROTRAUMA MO; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Devoto C., 2016, CELL TRANSPLANT; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Hansel A, 2010, NEUROSCI BIOBEHAV R, V35, P115, DOI 10.1016/j.neubiorev.2009.12.012; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Kumar RG, 2016, BRAIN BEHAV IMMUN, V53, P183, DOI 10.1016/j.bbi.2015.12.008; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Mac Donald CL, 2016, J NEUROTRAUMA; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Manners J.L., 2016, J NEUROTRAUMA; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; Petrovsky N, 1998, CYTOKINE, V10, P307, DOI 10.1006/cyto.1997.0289; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Scheff JD, 2010, J THEOR BIOL, V264, P1068, DOI 10.1016/j.jtbi.2010.03.026; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vgontzas AN, 2005, NEUROIMMUNOMODULAT, V12, P131, DOI 10.1159/000084844; Wallach D, 2014, NAT REV IMMUNOL, V14, P51, DOI 10.1038/nri3561; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	36	26	28	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2017	65						90	94		10.1016/j.bbi.2017.02.015			5	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FC6YD	WOS:000406986700009	28232173	Green Accepted			2021-06-18	
J	Manley, GT; Mac Donald, CL; Markowitz, AJ; Stephenson, D; Robbins, A; Gardner, RC; Winkler, E; Bodien, YG; Taylor, SR; Yue, JK; Kannan, L; Kumar, A; McCrea, MA; Wang, KK				Manley, Geoffrey T.; Mac Donald, Christine L.; Markowitz, Amy J.; Stephenson, Diane; Robbins, Ann; Gardner, Raquel C.; Winkler, Ethan; Bodien, Yelena G.; Taylor, Sabrina R.; Yue, John K.; Kannan, Lakshmi; Kumar, Allison; McCrea, Michael A.; Wang, Kevin K.		TED Investigators	The Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration To Accelerate Diagnosis and Treatment of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; clinical outcome measures; CT; FDA; MRI; traumatic brain injury	COMMON DATA ELEMENTS; ALZHEIMERS-DISEASE; BIOMARKER QUALIFICATION; OUTCOME PREDICTION; UNITED-STATES; TRACK-TBI; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; DRUG DEVELOPMENT; MILD	The Traumatic Brain Injury Endpoints Development (TED) Initiative is a 5-year, Department of Defense-funded project that is working toward the ultimate goal of developing better designed clinical trials, leading to more precise diagnosis, and effective treatments for traumatic brain injury (TBI). TED is comprised of leading academic clinician-scientists, along with innovative industry leaders in biotechnology and imaging technology, patient advocacy organizations, and philanthropists, working collaboratively with regulatory authorities, specifically the U.S. Food and Drug Administration (FDA). The goals of the TED Initiative are to gain consensus and validation of TBI clinical outcome assessment measures and biomarkers for endorsement by global regulatory agencies for use in drug and device development processes. This article summarizes the Initiative's Stage I progress over the first 18 months, including intensive engagement with a number of FDA divisions responsible for review and validation of biomarkers and clinical outcome assessments, progression into the prequalification phase of the FDA's Medical Device Development Tool program for a candidate set of neuroimaging biomarkers, and receipt of the FDA's Recognition of Research Importance Letter and a Letter of Support regarding TBI. Other signal achievements relate to the creation of the TED Metadataset, harmonizing study measures across eight major TBI studies, and the leadership role played by TED investigators in the conversion of the NINDS TBI Common Data Elements to Clinical Data Interchange Standards Consortium standards. This article frames both the near-term expectations and the Initiative's long-term vision to accelerate approval of treatments for patients affected by TBI in urgent need of effective therapies.	[Manley, Geoffrey T.; Markowitz, Amy J.; Taylor, Sabrina R.; Yue, John K.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA; [Manley, Geoffrey T.; Markowitz, Amy J.; Taylor, Sabrina R.; Yue, John K.] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA 94143 USA; [Manley, Geoffrey T.; Markowitz, Amy J.; Taylor, Sabrina R.; Yue, John K.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Mac Donald, Christine L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Stephenson, Diane; Robbins, Ann] Crit Path Inst, Tucson, AZ USA; [Gardner, Raquel C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Winkler, Ethan] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Bodien, Yelena G.] Harvard Med Sch, Dept Phys Med & Rehabil, Charlestown, MA USA; [Kannan, Lakshmi] US FDA, Ctr Devices & Radiol Hlth, Emergency Preparedness Operat & Med Countermeasur, Silver Spring, MD USA; [Kumar, Allison] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Wang, Kevin K.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL USA	Manley, GT (corresponding author), Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA.; Manley, GT (corresponding author), Trauma Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Markowitz, Amy/0000-0001-9314-2814; Gardner, Raquel C./0000-0003-4028-440X; Bodien, Yelena/0000-0003-4858-2903; Wang, Kevin/0000-0002-9343-6473	DoDUnited States Department of Defense [W81XWH-14-2-0176]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, K23NS095755] Funding Source: NIH RePORTER	The TED team recognizes the contribution of Brian Fabian as rapporteur for TED Consensus Conference 1 and the editorial assistance of Amy Porter, Critical Path Institute. This study was supported by the following grants: DoD W81XWH-14-2-0176 and One Mind.	Amur S, 2015, CLIN PHARMACOL THER, V98, P34, DOI 10.1002/cpt.136; Amur SG, 2015, BIOMARK MED, V9, P1095, DOI 10.2217/bmm.15.90; Bahcall O, 2015, NATURE, V526, P335, DOI 10.1038/526335a; Butlen-Ducuing F, 2016, NAT REV DRUG DISCOV, V15, P813, DOI 10.1038/nrd.2016.237; Center for Drug Evaluation and Research (CDER) Food and Drug Administration, 2014, QUAL PROC DRUG DEV T; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Clinical Data Interchange Standards Consortium (CDISC), 2016, TRAUM BRAIN INJ THER; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Department of Defense, 2013, NAT RES ACT PLAN RES; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; EMA, 2009, QUAL NOV METH DRUG D; Faster_Cures, 2015, CONS PED; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; FDA, 2015, MAN POL PROC; FDA, 2015, PRECISIONFDA; FDA, 2015, TARG DRUG DEV WHY AR; FDA, 2016, BIOM QUAL PROGR; FDA, 2015, CRIT PATH IN; FDA, 2015, DRUG DEV TOOLS DDT; Fehnel S, 2013, EXPERT REV PHARM OUT, V13, P441, DOI 10.1586/14737167.2013.814957; Furger R.E., 2016, FREQUENCY FACTORS CO; Garber K, 2007, NAT BIOTECHNOL, V25, P837, DOI 10.1038/nbt0807-838; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Haas M, 2015, NAT REV DRUG DISCOV, V14, P221, DOI 10.1038/nrd4585; Hill DLG, 2014, ALZHEIMERS DEMENT, V10, P421, DOI 10.1016/j.jalz.2013.07.003; Isaac M, 2015, EUR NEUROPSYCHOPHARM, V25, P1003, DOI 10.1016/j.euroneuro.2015.03.013; Kozauer N, 2013, NEW ENGL J MED, V368, P1169, DOI 10.1056/NEJMp1302513; Lavezzari G, 2016, CLIN PHARMACOL THER, V99, P208, DOI 10.1002/cpt.264; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Manley G.T., 2016, CLIN OUTCOME ASSESSM; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; McMurry-Heath M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3005269; Muhkerjee P., 2015, TRACK TBI TED TEAM R; O'Callaghan K., 2013, MED DEVICE DEV TOOLS; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Research! America, 2013, INV RES SAV LIV MON; Romero K, 2015, CLIN PHARMACOL THER, V97, P210, DOI 10.1002/cpt.16; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Snyder HM, 2014, ALZHEIMERS DEMENT, V10, P109, DOI 10.1016/j.jalz.2013.10.007; Stephenson D, 2015, J PARKINSON DIS, V5, P581, DOI 10.3233/JPD-150570; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; TRACK_TBI_Investigators, 2015, TED MET; Wang K.K., 2015, TRACK TBI TED TEAM R; Weiner MW, 2015, ALZHEIMERS DEMENT, V11, P865, DOI 10.1016/j.jalz.2015.04.005; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P231, DOI 10.1080/87565641003689549; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woodcock Janet, 2011, Expert Opin Med Diagn, V5, P369, DOI 10.1517/17530059.2011.588947; Woodcock J, 2011, NEW ENGL J MED, V364, P985, DOI 10.1056/NEJMp1101548; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	60	26	27	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2017	34	19					2721	2730		10.1089/neu.2016.4729			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FI1DZ	WOS:000411672700007	28363253	Green Published			2021-06-18	
J	Zhao, W; Cai, YL; Li, ZG; Ji, SB				Zhao, Wei; Cai, Yunliang; Li, Zhigang; Ji, Songbai			Injury prediction and vulnerability assessment using strain and susceptibility measures of the deep white matter	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Concussion; Deep white matter; Fiber strain; Injury susceptibility; Tractography	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; FINITE-ELEMENT-ANALYSIS; TENSOR IMAGING FINDINGS; PROFESSIONAL FOOTBALL; CONTACT SPORTS; AXONAL DAMAGE; HEAD IMPACTS; MODEL; VALIDATION	Reliable prediction and diagnosis of concussion is important for its effective clinical management. Previous model-based studies largely employ peak responses from a single element in a pre-selected anatomical region of interest (ROI) and utilize a single training dataset for injury prediction. A more systematic and rigorous approach is necessary to scrutinize the entire white matter (WM) ROIs as well as ROI-constrained neural tracts. To this end, we evaluated injury prediction performances of the 50 deep WM regions using predictor variables based on strains obtained from simulating the 58 reconstructed American National Football League head impacts. To objectively evaluate performance, repeated random subsampling was employed to split the impacts into independent training and testing datasets (39 and 19 cases, respectively, with 100 trials). Univariate logistic regressions were conducted based on training datasets to compute the area under the receiver operating characteristic curve (AUC), while accuracy, sensitivity, and specificity were reported based on testing datasets. Two tract-wise injury susceptibilities were identified as the best overall via pair-wise permutation test. They had comparable AUC, accuracy, and sensitivity, with the highest values occurring in superior longitudinal fasciculus (SLF; 0.867-0.879, 84.4-85.2, and 84.1-84.6%, respectively). Using metrics based on WM fiber strain, the most vulnerable ROIs included genu of corpus callosum, cerebral peduncle, and uncinate fasciculus, while genu and main body of corpus callosum, and SLF were among the most vulnerable tracts. Even for one un-concussed athlete, injury susceptibility of the cingulum (hippocampus) right was elevated. These findings highlight the unique injury discriminatory potentials of computational models and may provide important insight into how best to incorporate WM structural anisotropy for investigation of brain injury.	[Zhao, Wei; Cai, Yunliang; Ji, Songbai] Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA; [Li, Zhigang] Dartmouth Coll, Geisel Sch Med, Dept Biomed Data Sci, Lebanon, NH 03766 USA; [Ji, Songbai] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA; [Ji, Songbai] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Ji, SB (corresponding author), Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.; Ji, SB (corresponding author), Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA.; Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.	sji@wpi.edu	Cai, Yunliang/AAF-2375-2019		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS092853, R21 NS088781]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092853, R21NS088781] Funding Source: NIH RePORTER	Funding is provided by the NIH Grants R01 NS092853 and R21 NS088781. The authors are grateful to the National Football League (NFL) Committee on Mild Traumatic Brain Injury (MTBI) and Biokinetics and Associates Ltd. for providing the reconstructed head impact kinematics. The authors thank Dr. Thomas W. McAllister at Indiana University for providing neuroimaging data, Dr. James C. Ford and Dr. Laura A. Flashman at Dartmouth College, and Dr. Richard M. Greenwald and Mr. Jonathan Beckwith at Simbex, LLC, for their help. In addition, they thank Dr. Qiang Liu at Dartmouth College, and Ms. Chiara Giordano at Royal Institute of Technology (KTH) for helpful discussions.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Anderson Andrew E., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P171, DOI 10.1080/10255840601160484; Andersson J, 2007, TR07JA2 OXF U OXF CT; Arlot S, 2010, STAT SURV, V4, P40, DOI 10.1214/09-SS054; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bandak F.A, 1994, STAPP CAR CRASH C SO, P145; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Centers for Disease Control and Prevention(CDC), 2015, REP C TRAUM BRAIN IN; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Donnelly BR, 1983, STAPP CAR CRASH J, V27, P299; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Fahlstedt M, 2015, J BIOMECH, V48, P1331, DOI 10.1016/j.jbiomech.2015.02.057; Fijalkowski RJ, 2009, STAPP CAR CRASH JO, V53, P193; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Garimella HT, 2017, INT J NUMER METH BIO, V33, DOI 10.1002/cnm.2823; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Ji SB, 2015, ANN BIOMED ENG, V43, P1877, DOI 10.1007/s10439-014-1193-3; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miller LE, 2016, BIOMECH MODEL MECHAN, V15, P1201, DOI 10.1007/s10237-015-0754-1; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; National Research Council (NRC) and Institute of Medicine (IOM), 2014, SPORTS REL CONC YOUT; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Rice J, 2006, MATH STAT DATA ANAL, V3; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sahoo D, 2016, ACCIDENT ANAL PREV, V92, P53, DOI 10.1016/j.aap.2016.03.013; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Xiong KL, 2014, BRAIN RES, V1591, P86, DOI 10.1016/j.brainres.2014.10.030; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049; Zhao W, 2015, IRCOBI C LYON FRANC, P208; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P449, DOI 10.1007/s10237-016-0829-7; Zhao W, 2016, J NEUROTRAUM, V33, P1834, DOI 10.1089/neu.2015.4239	72	26	27	1	10	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	OCT	2017	16	5					1709	1727		10.1007/s10237-017-0915-5			19	Biophysics; Engineering, Biomedical	Biophysics; Engineering	FG9KH	WOS:000410757300015	28500358	Green Accepted			2021-06-18	
J	Reith, FCM; Lingsma, HF; Gabbe, BJ; Lecky, FE; Roberts, I; Maas, AIR				Reith, Florence C. M.; Lingsma, Hester F.; Gabbe, Belinda J.; Lecky, Fiona E.; Roberts, Ian; Maas, Andrew I. R.			Differential effects of the Glasgow Coma Scale Score and its Components: An analysis of 54,069 patients with traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Components; Floor and ceiling effects; Glasgow Coma Scale Score; GCS; Prognosis; TBI	SEVERE HEAD-INJURY; PROGNOSTIC VALUE; MOTOR SCORE; CLASSIFICATION; CONSCIOUSNESS; PREDICTION; GUIDELINES; MORTALITY; CHILDREN; LEVEL	Introduction: The Glasgow Coma Scale (GCS) is widely used in the assessment of clinical severity and prediction of outcome after traumatic brain injury (TBI). The sum score is frequently applied, but the differential influence of the components infrequently addressed. We aimed to investigate the contribution of the GCS components to the sum score, floor and ceiling effects of the components, and their prognostic effects. Methods: Data on adult TBI patients were gathered from three data repositories: TARN (n = 50,064), VSTR (n = 14,062), and CRASH (n = 9,941). Data on initial hospital GCS-assessment and discharge mortality were extracted. A descriptive analysis was performed to identify floor and ceiling effects. The relation between GCS and outcome was studied by comparing case fatality rates (CFR) between different component-profiles adding up to identical sum scores using Chi2-tests, and by quantifying the prognostic value of each component and sum score with Nagelkerke's R-2 derived from logistic regression analyses across TBI severities. Results: In the range 3-7, the sum score is primarily determined by the motor component, as the verbal and eye components show floor-effects at sum scores 7 and 8, respectively. In the range 8-12, the effect of the motor component attenuates and the verbal and eye components become more relevant. The motor, eye and verbal scores reach their ceiling-effects at sum 13, 14 and 15, respectively. Significant variations were exposed in CFR between different component-profiles despite identical sum scores, except in sum scores 6 and 7. Regression analysis showed that the motor score had highest R2 values in severe TBI patients, whereas the other components were more relevant at higher sum scores. The prognostic value of the three components combined was consistently higher than that of the sum score alone. Conclusion: The GCS-components contribute differentially across the spectrum of consciousness to the sum score, each having floor and ceiling effects. The specific component-profile is related to outcome and the three components combined contain higher prognostic value than the sum score across different TBI severities. We, therefore, recommend a multidimensional use of the three-component GCS both in clinical practice, and in prognostic studies. (C) 2017 Elsevier Ltd. All rights reserved.	[Reith, Florence C. M.; Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium; [Reith, Florence C. M.; Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Lingsma, Hester F.] Erasmus Univ, Dept Publ Hlth, Med Ctr, Rotterdam, Netherlands; [Gabbe, Belinda J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Gabbe, Belinda J.] Swansea Univ, Farr Inst CIPHER, Singleton Pk, Swansea, W Glam, Wales; [Lecky, Fiona E.] Univ Sheffield, Emergency Med Res Sheffield EMRiS Grp, Hlth Serv Res Sch Hlth & Related Res SCHaRR, Sheffield, S Yorkshire, England; [Lecky, Fiona E.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp,Fac Biol Med & Hlth, Trauma Audit & Res Network,Ctr Epidemiol,Inst Pop, Salford, Lancs, England; [Roberts, Ian] London Sch Hyg & Trop Med, Clin Trials Unit, London, England	Reith, FCM (corresponding author), Antwerp Univ Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	florence.reith@uza.be	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264	European UnionEuropean Commission [602150-2]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [GNT1048731]; Transport Accident Commission (TAC)	This work was in part supported by the Framework 7 program of the European Union in the context of CENTER-TBI (grant number 602150-2); Belinda Gabbe was supported by a Career Development Fellowship from the National Health and Medical Research Council of Australia (GNT1048731).; The Victorian State Trauma Registry is a Department of Health and Human Services, State Government of Victoria and Transport Accident Commission (TAC) funded project.	Akaike H., 1974, SELECTED PAPERS HIRO, P215; Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; BHATTY GB, 1993, ACTA NEUROCHIR, V120, P132, DOI 10.1007/BF02112031; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Christensen MC, 2008, CRIT CARE, V12, DOI 10.1186/cc6797; Fortune PM, 2010, PEDIATR CRIT CARE ME, V11, P339, DOI 10.1097/PCC.0b013e3181c014ab; Gabbe BJ, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0047-z; Gennarelli T.A., 2008, ABBREVIATED INJURY S; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hirai S, 1996, NEUROSURGERY, V39, P441, DOI 10.1097/00006123-199609000-00002; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B., 2002, TRAUMA, V4, P91, DOI DOI 10.1191/1460408602TA2330A; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; Lesko MM, 2013, J NEUROTRAUM, V30, P17, DOI 10.1089/neu.2012.2438; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Moore L, 2006, J TRAUMA, V60, P1238, DOI 10.1097/01.ta.0000195593.60245.80; Morris S, 2008, ANAESTHESIA, V63, P499, DOI 10.1111/j.1365-2044.2007.05432.x; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Osler T, 2016, INJURY, V47, P1879, DOI 10.1016/j.injury.2016.04.016; Peters MJ, 2010, PEDIATR CRIT CARE ME, V11, P423, DOI 10.1097/PCC.0b013e3181d4fcb1; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1; SUGIURA K, 1983, NEUROSURGERY, V12, P411, DOI 10.1227/00006123-198304000-00007; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	38	26	27	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2017	48	9					1932	1943		10.1016/j.injury.2017.05.038			12	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	FE2LA	WOS:000408046600014	28602178	Green Accepted			2021-06-18	
J	Sandel, N; Reynolds, E; Cohen, PE; Gillie, BL; Kontos, AP				Sandel, Natalie; Reynolds, Erin; Cohen, Paul E.; Gillie, Brandon L.; Kontos, Anthony P.			Anxiety and Mood Clinical Profile Following Sport-Related Concussion: From Risk Factors to Treatment	SPORT EXERCISE AND PERFORMANCE PSYCHOLOGY			English	Article						concussion; anxiety; mood; sport	TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL THERAPY; 4TH INTERNATIONAL-CONFERENCE; CHRONIC SUBJECTIVE DIZZINESS; POSTCONCUSSION-LIKE SYMPTOMS; RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSIVE DISORDER; MILITARY SERVICE MEMBERS; SCHOOL FOOTBALL PLAYERS; MOTOR SCREENING VOMS	Conceptual models for assessing and treating sport-related concussion (SRC) have evolved from a homogenous approach to include different clinical profiles that reflect the heterogeneous nature of this injury and its effects. There are six identified clinical profiles, or subtypes, from SRC, and one such clinical profile is the anxiety and mood profile. Athletes with this profile experience predominant emotional disturbance and anxiety following SRC. The purpose of this targeted review was to present an overview of the empirical evidence to support factors contributing to the anxiety and mood profile, along with methods of evaluation and treatment of this clinical profile following SRC. We discuss the potential underlying mechanisms and risk factors for this clinical profile, describe comprehensive assessments to evaluate concussed athletes with an anxiety and mood clinical profile, and explore behavioral and other interventions for treating these athletes. Although there is limited, but growing, empirical evidence for the anxiety and mood clinical profile following SRC, understanding this clinical profile is germane for clinicians who are treating athletes with emotional sequelae after SRC.	[Sandel, Natalie; Reynolds, Erin; Cohen, Paul E.; Gillie, Brandon L.; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr Sports Concuss Program, Dept Orthopaed Surg, 3200 South Water St, Pittsburgh, PA 15203 USA; [Reynolds, Erin; Kontos, Anthony P.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA	Sandel, N (corresponding author), Univ Pittsburgh, Med Ctr Sports Concuss Program, Dept Orthopaed Surg, 3200 South Water St, Pittsburgh, PA 15203 USA.	sandelnk@upmc.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Anthony P. Kontos.	Alsalaheen BA, 2013, PHYSIOTHER RES INT, V18, P100, DOI 10.1002/pri.1532; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alvaro PK, 2017, J AFFECT DISORDERS, V207, P167, DOI 10.1016/j.jad.2016.08.032; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Anzalone AJ, 2017, AM J SPORT MED, V45, P474, DOI 10.1177/0363546516668624; Armistead-Jehle P, 2016, APPL NEUROPSYCH-ADUL, V23, P264, DOI 10.1080/23279095.2015.1055564; Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Balaban CD, 1998, J VESTIBUL RES-EQUIL, V8, P7; Balabann CD, 2011, EXPERT REV NEUROTHER, V11, P379, DOI 10.1586/ERN.11.19; Balasundaram AP, 2016, ARCH CLIN NEUROPSYCH, V31, P197, DOI 10.1093/arclin/acw001; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck AT, 2010, BIB, V1988, P54; Beck J.S., 2011, COGNITIVE BEHAV THER; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Briere J., 1996, TRAUMA SYMPTOM INVEN; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Butcher J. N., 2003, MMPI 2 MINNESOTA MUL; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carroll LJ, 2006, PAIN, V124, P18, DOI 10.1016/j.pain.2006.03.012; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Centers for Disease Control and Prevention, 2011, BURD MENT ILLN; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Clement D, 2013, J ATHL TRAINING, V48, P512, DOI 10.4085/1062-6050-48.3.21; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Conn VS, 2010, NURS RES, V59, P224, DOI 10.1097/NNR.0b013e3181dbb2f8; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2014, J ATHL TRAINING, V49, P462, DOI 10.4085/1062-6059-49.2.03; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Edelman S, 2012, AM J OTOLARYNG, V33, P395, DOI 10.1016/j.amjoto.2011.10.009; Edmed S, 2012, PSYCHIAT RES, V200, P41, DOI 10.1016/j.psychres.2012.05.022; Elbin RJ, 2016, APPL NEUROPSYCH-CHIL, V5, P294, DOI 10.1080/21622965.2015.1077334; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Erikson E. H., 1993, CHILDHOOD SOC; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldberg J. M., 2012, VESTIBULAR SYSTEM 6; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hou R., 2011, J NEUROL NEUROSUR PS, V83, P217; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jacob RG, 2001, CURR OPIN NEUROL, V14, P41, DOI 10.1097/00019052-200102000-00007; Jayakody K, 2014, BRIT J SPORT MED, V48, P187, DOI 10.1136/bjsports-2012-091287; Jensen MP, 2001, J CONSULT CLIN PSYCH, V69, P655, DOI 10.1037/0022-006X.69.4.655; Jones RM, 2014, PERS RELATIONSHIP, V21, P51, DOI 10.1111/pere.12017; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kemper K. J., 2017, J EVIDENCE BASED COM; Kontos AP, 2016, BRIT J SPORT MED, V50, P139, DOI 10.1136/bjsports-2015-095564; Kontos AP, 2013, RES SPORTS MED, V21, P367, DOI 10.1080/15438627.2013.825801; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Lu W, 2016, NEUROREHABILITATION, V38, P59, DOI 10.3233/NRE-151296; MacPherson E, 2016, PSYCHOL SPORT EXERC, V23, P73, DOI 10.1016/j.psychsport.2015.10.002; Maestas KL, 2014, J HEAD TRAUMA REHAB, V29, P407, DOI 10.1097/HTR.0b013e31828654b4; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Merritt VC, 2015, BRAIN INJURY, V29, P1325, DOI 10.3109/02699052.2015.1043948; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Morey L. C., 1991, PERSONALITY ASSESSME; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; National Institute of Neurological Disorders and Stroke, 2017, SPORT REL CONC COMM; O'Brien LM, 2009, CHILD ADOL PSYCH CL, V18, P813, DOI 10.1016/j.chc.2009.04.008; O'Leary K, 2017, COGNITION EMOTION, V31, P435, DOI 10.1080/02699931.2015.1126554; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Parks A. C., 2016, APPL NEUROPSYCHOLOGY; Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581; Martinez MP, 2014, J BEHAV MED, V37, P683, DOI 10.1007/s10865-013-9520-y; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Reynolds Erin, 2014, Neurosurgery, V75 Suppl 4, pS71, DOI 10.1227/NEU.0000000000000471; Ritterband LM, 2017, JAMA PSYCHIAT, V74, P68, DOI 10.1001/jamapsychiatry.2016.3249; Roesch SC, 2001, J PSYCHOSOM RES, V50, P205, DOI 10.1016/S0022-3999(01)00188-X; Ruckenstein MJ, 2009, OTOLARYNG CLIN N AM, V42, P71, DOI 10.1016/j.otc.2008.09.011; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Silverberg ND, 2016, JAMA PEDIATR, V170, P946, DOI 10.1001/jamapediatrics.2016.1187; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Stubbs B, 2017, J AFFECT DISORDERS, V208, P545, DOI 10.1016/j.jad.2016.10.028; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Tracey J, 2003, J APPL SPORT PSYCHOL, V15, P279, DOI 10.1080/714044197; Tsai MC, 2014, J PEDIATR-US, V164, P136, DOI 10.1016/j.jpeds.2013.08.042; van Veldhoven LM, 2011, J NEUROL NEUROSUR PS, V82, P782, DOI 10.1136/jnnp.2010.228254; Vargas G, 2015, J ATHL TRAINING, V50, P250, DOI 10.4085/1062-6050-50.3.02; Venzala E, 2013, EUR NEUROPSYCHOPHARM, V23, P697, DOI 10.1016/j.euroneuro.2012.05.010; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Wojcik SM, 2014, BRAIN INJURY, V28, P422, DOI 10.3109/02699052.2014.884241; WOLPE J, 1964, BEHAV RES THER, V2, P27, DOI 10.1016/0005-7967(64)90051-8; Womble Melissa N, 2016, Am J Orthop (Belle Mead NJ), V45, P352; Wood RL, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/HTR.0b013e31827eabba; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	137	26	27	0	30	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	2157-3905	2157-3913		SPORT EXERC PERFORM	Sport Exerc. Perform. Psychol.	AUG	2017	6	3					304	323		10.1037/spy0000098			20	Hospitality, Leisure, Sport & Tourism; Psychology, Applied	Social Sciences - Other Topics; Psychology	FD8RW	WOS:000407792800009	29130023	Green Accepted, Bronze			2021-06-18	
J	Jalloh, I; Helmy, A; Howe, DJ; Shannon, RJ; Grice, P; Mason, A; Gallagher, CN; Stovell, MG; van der Heide, S; Murphy, MP; Pickard, JD; Menon, DK; Carpenter, TA; Hutchinson, PJ; Carpenter, KLH				Jalloh, Ibrahim; Helmy, Adel; Howe, Duncan J.; Shannon, Richard J.; Grice, Peter; Mason, Andrew; Gallagher, Clare N.; Stovell, Matthew G.; van der Heide, Susan; Murphy, Michael P.; Pickard, John D.; Menon, David K.; Carpenter, T. Adrian; Hutchinson, Peter J.; Carpenter, Keri L. H.			Focally perfused succinate potentiates brain metabolism in head injury patients	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Traumatic brain injury (human); microdialysis; nuclear magnetic resonance spectroscopy; cerebral metabolism; succinate	ACID DIMETHYL ESTER; CEREBRAL MICRODIALYSIS; RAT-BRAIN; C-13-LABELED MICRODIALYSIS; SLC13 FAMILY; C-13 NMR; LACTATE; GLUCOSE; TRANSPORTERS; GLYCEROL	Following traumatic brain injury, complex cerebral energy perturbations occur. Correlating with unfavourable outcome, high brain extracellular lactate/pyruvate ratio suggests hypoxic metabolism and/or mitochondrial dysfunction. We investigated whether focal administration of succinate, a tricarboxylic acid cycle intermediate interacting directly with the mitochondrial electron transport chain, could improve cerebral metabolism. Microdialysis perfused disodium 2,3-C-13(2) succinate (12mmol/L) for 24h into nine sedated traumatic brain injury patients' brains, with simultaneous microdialysate collection for ISCUS analysis of energy metabolism biomarkers (nine patients) and nuclear magnetic resonance of C-13-labelled metabolites (six patients). Metabolites 2,3-C-13(2) malate and 2,3-C-13(2) glutamine indicated tricarboxylic acid cycle metabolism, and 2,3-C-13(2) lactate suggested tricarboxylic acid cycle spinout of pyruvate (by malic enzyme or phosphoenolpyruvate carboxykinase and pyruvate kinase), then lactate dehydrogenase-mediated conversion to lactate. Versus baseline, succinate perfusion significantly decreased lactate/pyruvate ratio (p=0.015), mean difference -12%, due to increased pyruvate concentration (+17%); lactate changed little (-3%); concentrations decreased for glutamate (-43%) (p=0.018) and glucose (-15%) (p=0.038). Lower lactate/pyruvate ratio suggests better redox status: cytosolic NADH recycled to NAD(+) by mitochondrial shuttles (malate-aspartate and/or glycerol 3-phosphate), diminishing lactate dehydrogenase-mediated pyruvate-to-lactate conversion, and lowering glutamate. Glucose decrease suggests improved utilisation. Direct tricarboxylic acid cycle supplementation with 2,3-C-13(2) succinate improved human traumatic brain injury brain chemistry, indicated by biomarkers and C-13-labelling patterns in metabolites.	[Jalloh, Ibrahim; Helmy, Adel; Shannon, Richard J.; Gallagher, Clare N.; Stovell, Matthew G.; van der Heide, Susan; Pickard, John D.; Hutchinson, Peter J.; Carpenter, Keri L. H.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England; [Howe, Duncan J.; Grice, Peter; Mason, Andrew] Univ Cambridge, Dept Chem, Cambridge, England; [Pickard, John D.; Menon, David K.; Carpenter, T. Adrian; Hutchinson, Peter J.; Carpenter, Keri L. H.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge, England; [Gallagher, Clare N.] Univ Calgary, Dept Clin Neurosci, Div Neurosurg, Calgary, AB, Canada; [Murphy, Michael P.] MRC Mitochondrial Biol Unit, Cambridge, England; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge, England	Jalloh, I; Carpenter, KLH (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Box 167,Cambridge Biomed Campus, Cambridge CB2 0QQ, England.	ibrahim.jalloh@cantab.net; klc1000@wbic.cam.ac.uk	Helmy, Adel/AAS-3084-2020; Murphy, Michael/C-2120-2009	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727; Murphy, Michael/0000-0003-1115-9618	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986 ID79068, G1002277 ID98489]; National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802251]; Raymond and Beverly Sackler Fellowship; National Institute for Health Research Senior Investigator Awards; National Institute for Health Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105663142, G1002277, G0001237, G9439390, G1000183B, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013, NF-SI-0508-10327] Funding Source: researchfish	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical Research Council (Grant Nos. G0600986 ID79068 and G1002277 ID98489) and National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). Authors' support: IJ - Medical Research Council (Grant no. G1002277 ID 98489) and National Institute for Health Research Biomedical Research Centre, Cambridge; KLHC - National Institute for Health Research Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); CG - the Canadian Institute of Health Research; AH - Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship (Grant no. G0802251) and Raymond and Beverly Sackler Fellowship; DKM and JDP - National Institute for Health Research Senior Investigator Awards; PJH - National Institute for Health Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and the National Institute for Health Research Biomedical Research Centre, Cambridge.	ALDRIDGE WN, 1959, BIOCHEM J, V73, P270, DOI 10.1042/bj0730270; Bergeron MJ, 2013, MOL ASPECTS MED, V34, P299, DOI 10.1016/j.mam.2012.12.001; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; CERDAN S, 1990, J BIOL CHEM, V265, P12916; Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909; Clausen F, 2011, ACTA NEUROCHIR, V153, P653, DOI 10.1007/s00701-010-0871-7; Cruz F, 1998, J NEUROCHEM, V70, P2613; Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.3.CO;2-5; ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529; Ferreira FL, 2000, HORM METAB RES, V32, P335, DOI 10.1055/s-2007-978647; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gonzalez SV, 2005, J NEUROCHEM, V95, P284, DOI 10.1111/j.1471-4159.2005.03365.x; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; Kerby D. S., 2014, COMPREHENSIVE PSYCHO, V3, DOI [10.2466/11.IT.3.1, DOI 10.2466/11.IT.3.1]; Lamp J, 2011, J BIOL CHEM, V286, P17777, DOI 10.1074/jbc.M111.232744; Lin AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046585; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; Malaisse WJ, 1997, NUTRITION, V13, P330; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Murugan M, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00019; Nelson DW, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-21; Nguyen NHT, 2007, J NEUROCHEM, V101, P1694, DOI 10.1111/j.1471-4159.2006.04433.x; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; Pajor AM, 2014, PFLUG ARCH EUR J PHY, V466, P119, DOI 10.1007/s00424-013-1369-y; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Patet C, 2015, J NEUROTRAUM, V32, P1560, DOI 10.1089/neu.2014.3781; Protti A, 2006, CRIT CARE, V10, DOI 10.1186/cc5014; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rich PR, 2010, ESSAYS BIOCHEM, V47, P1, DOI [10.1042/BSE0470001, 10.1042/bse0470001]; Sanganahalli BG, 2013, J CEREBR BLOOD F MET, V33, P1115, DOI 10.1038/jcbfm.2013.61; Schlessinger A, 2014, J BIOL CHEM, V289, P16998, DOI 10.1074/jbc.M114.554790; Shannon RJ, 2014, BRIT J CLIN PHARMACO, V78, P981, DOI 10.1111/bcp.12414; Sonnewald U, 2014, J NEUROCHEM, V131, P399, DOI 10.1111/jnc.12812; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606	45	26	26	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2017	37	7					2626	2638		10.1177/0271678X16672665			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EY3XE	WOS:000403907700026	27798266	Green Published, Other Gold			2021-06-18	
J	Rachmany, L; Tweedie, D; Rubovitch, V; Li, YZ; Holloway, HW; Kim, DS; Ratliff, WA; Saykally, JN; Citron, BA; Hoffer, BJ; Greig, NH; Pick, CG				Rachmany, Lital; Tweedie, David; Rubovitch, Vardit; Li, Yazhou; Holloway, Harold W.; Kim, Dong Seok; Ratliff, Whitney A.; Saykally, Jessica N.; Citron, Bruce A.; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration	SCIENTIFIC REPORTS			English	Article							GLUCAGON-LIKE PEPTIDE-1; REVERSES BEHAVIORAL IMPAIRMENTS; BRIGADE COMBAT TEAM; OBJECT RECOGNITION; AUTOMATED QUANTIFICATION; RODENT HIPPOCAMPUS; RECEPTOR AGONIST; GENE-EXPRESSION; ANIMAL-MODELS; MICE	Mild blast traumatic brain injury (B-TBI) induced lasting cognitive impairments in novel object recognition and less severe deficits in Y-maze behaviors. B-TBI significantly reduced the levels of synaptophysin (SYP) protein staining in cortical (CTX) and hippocampal (HIPP) tissues. Treatment with exendin-4 (Ex-4) delivered by subcutaneous micro-osmotic pumps 48 hours prior to or 2 hours immediately after B-TBI prevented the induction of both cognitive deficits and B-TBI induced changes in SYP staining. The effects of a series of biaxial stretch injuries (BSI) on a neuronal derived cell line, HT22 cells, were assessed in an in vitro model of TBI. Biaxial stretch damage induced shrunken neurites and cell death. Treatment of HT22 cultures with Ex-4 (25 to 100 nM), prior to injury, attenuated the cytotoxic effects of BSI and preserved neurite length similar to sham treated cells. These data imply that treatment with Ex-4 may represent a viable option for the management of secondary events triggered by blast-induced, mild traumatic brain injury that is commonly observed in militarized zones.	[Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Dr Miriam & Sheldon G Adelson Chair, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Ctr Biol Addict Dis, IL-69978 Tel Aviv, Israel; [Tweedie, David; Li, Yazhou; Holloway, Harold W.; Kim, Dong Seok; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Kim, Dong Seok] Peptron Inc, 37-24,Yuseong Daero 1628 Beon Gil, Daejeon 305811, South Korea; [Ratliff, Whitney A.; Saykally, Jessica N.; Citron, Bruce A.] Bay Pines VA Healthcare Syst, Lab Mol Biol, Res & Dev 151, Bay Pines, FL 33744 USA; [Ratliff, Whitney A.; Saykally, Jessica N.; Citron, Bruce A.] USF Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA	Tweedie, D (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov	Ratliff, Whitney/L-3556-2016	Ratliff, Whitney/0000-0002-5461-7802	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Sackler School of Medicine, Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; Joseph Sagol fellowships; Ari and Regine Aprijaskis Fund, Tel-Aviv University, Tel-Aviv, Israel; Depts. of Defense and Veterans Affairs; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001520] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (D.T., Y.L., H.W.H., DS.K., N.H.G.), (ii) the Sackler School of Medicine, Tel-Aviv University (C.G.P., V.R., L.R.), (iii) a grant from the Israel Science Foundation, grant number 108/09 (C.G.P., V.R., L.R.), (iv) and the Joseph Sagol fellowships (C.G.P., V.R., L.R.), (v) the Ari and Regine Aprijaskis Fund, Tel-Aviv University, Tel-Aviv 69978, Israel (C.G.P., V.R., L.R.), (vi) the Depts. of Defense and Veterans Affairs (B.A.C., W.A.R., J.N.S.). This work was performed in partial fulfillment of the requirements for a Ph.D. degree of L.R., Sackler Faculty of Medicine, Tel Aviv University, Israel.	[Anonymous], 2006, J NEUROL SCI, V249, P63; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Beaudet G, 2016, ALCOHOL CLIN EXP RES, V40, P2591, DOI 10.1111/acer.13256; Belmont Philip J, 2010, J Surg Orthop Adv, V19, P2; Belmont PJ, 2010, J TRAUMA, V68, P204, DOI 10.1097/TA.0b013e3181bdcf95; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; CHOI DW, 1987, J NEUROSCI, V7, P357; Cohen SJ, 2013, CURR BIOL, V23, P1685, DOI 10.1016/j.cub.2013.07.002; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Courtney E, 2014, DEF TECHNOL, V10, P245, DOI 10.1016/j.dt.2014.04.003; Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Du JF, 2016, AM J PHYSIOL-CELL PH, V310, pC270, DOI 10.1152/ajpcell.00194.2015; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fischer H., 2015, RS22452 CRS; Gardner AJ, 2016, HAND CLINIC, V138, P207, DOI 10.1016/B978-0-12-802973-2.00012-4; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gu YL, 2014, NEUROSCI LETT, V570, P86, DOI 10.1016/j.neulet.2014.04.004; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Kane MJ, 2011, BRAIN RES, V1425, P123, DOI 10.1016/j.brainres.2011.09.047; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Leea AS, 2008, P NATL ACAD SCI USA, V105, P17163, DOI 10.1073/pnas.0807749105; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Linnebjerg H, 2007, BRIT J CLIN PHARMACO, V64, P317, DOI 10.1111/j.1365-2125.2007.02890.x; Liu J, 2009, PROCEEDINGS OF THE 2009 INTERNATIONAL CONFERENCE ON COMPUTER AND COMMUNICATIONS SECURITY, P84, DOI 10.1109/ICCCS.2009.21; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Ning YL, 2015, CHIN J TRAUMATOL, V18, P187, DOI 10.1016/j.cjtee.2015.04.005; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Pool M, 2008, J NEUROSCI METH, V168, P134, DOI 10.1016/j.jneumeth.2007.08.029; Popivanov G, 2014, J ROY ARMY MED CORPS, V160, P52, DOI 10.1136/jramc-2013-000132; Preston AR, 2013, CURR BIOL, V23, pR764, DOI 10.1016/j.cub.2013.05.041; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Sannino S, 2012, LEARN MEMORY, V19, P211, DOI 10.1101/lm.025213.111; Schatzle P, 2012, J NEUROSCI METH, V204, P144, DOI 10.1016/j.jneumeth.2011.11.010; Shi S, 2012, ARZNEIMITTEL-FORSCH, V62, P75, DOI 10.1055/s-0031-1295484; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Smith M, 2016, EXP NEUROL, V286, P107, DOI 10.1016/j.expneurol.2016.10.002; Sun LD, 2016, BIOCHEM PHARMACOL, V110, P80, DOI 10.1016/j.bcp.2016.04.016; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Vogel EW, 2017, J NEUROTRAUM, V34, P1063, DOI 10.1089/neu.2016.4578; Vogel EW, 2016, J NEUROTRAUM, V33, P652, DOI 10.1089/neu.2015.4045; Wang DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160159; Wang SL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151397; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang JL, 2016, THERANOSTICS, V6, P2015, DOI 10.7150/thno.15993; Yi JH, 2016, BEHAV BRAIN RES, V297, P141, DOI 10.1016/j.bbr.2015.10.018; Yusta B, 2006, CELL METAB, V4, P391, DOI 10.1016/j.cmet.2006.10.001; Zhang HN, 2016, AAPS J, V18, P385, DOI 10.1208/s12248-015-9854-1; Zhang HN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148827	77	26	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 16	2017	7								3735	10.1038/s41598-017-03792-9			13	Multidisciplinary Sciences	Science & Technology - Other Topics	EX7FN	WOS:000403413700097	28623327	DOAJ Gold, Green Published			2021-06-18	
J	Kelley, ME; Urban, JE; Miller, LE; Jones, DA; Espeland, MA; Davenport, EM; Whitlow, CT; Maldjian, JA; Stitzel, JD				Kelley, Mireille E.; Urban, Jillian E.; Miller, Logan E.; Jones, Derek A.; Espeland, Mark A.; Davenport, Elizabeth M.; Whitlow, Christopher T.; Maldjian, Joseph A.; Stitzel, Joel D.			Head Impact Exposure in Youth Football: Comparing Age- and Weight-Based Levels of Play	JOURNAL OF NEUROTRAUMA			English	Article						biomechanics; football; impact frequency; impact magnitude; mild traumatic brain injury; pediatric	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; STATES HIGH-SCHOOL; LEAGUE PLAYERS; CONCUSSION; ENCEPHALOPATHY; EPIDEMIOLOGY; KINEMATICS; SPORTS	Approximately 5,000,000 athletes play organized football in the United States, and youth athletes constitute the largest proportion with similar to 3,500,000 participants. Investigations of head impact exposure (HIE) in youth football have been limited in size and duration. The objective of this study was to evaluate HIE of athletes participating in three age-and weight-based levels of play within a single youth football organization over four seasons. Head impact data were collected using the Head Impact Telemetry (HIT) System. Mixed effects linear models were fitted, and Wald tests were used to assess differences in head accelerations and number of impacts among levels and session type (competitions vs. practices). The three levels studied were levels A (n = 39, age = 10.8 +/- 0.7 years, weight = 97.5 +/- 11.8 lb), B (n = 48, age = 11.9 +/- 0.5 years, weight = 106.1 +/- 13.8 lb), and C (n = 32, age = 13.0 +/- 0.5 years, weight = 126.5 +/- 18.6 lb). A total of 40,538 head impacts were measured. The median/95th percentile linear head acceleration for levels A, B, and C was 19.8/49.4g, 20.6/51.0g, and 22.0/57.9g, respectively. Level C had significantly greater mean linear acceleration than both levels A (p = 0.005) and B (p = 0.02). There were a significantly greater number of impacts per player in a competition than in a practice session for all levels (A, p = 0.0005, B, p = 0.0019, and C, p < 0.0001). Athletes at lower levels experienced a greater percentage of their high magnitude impacts (>= 80g) in practice, whereas those at the highest level experienced a greater percentage of their high magnitude impacts in competition. These data improve our understanding of HIE within youth football and are an important step in making evidence-based decisions to reduce HIE.	[Kelley, Mireille E.; Urban, Jillian E.; Miller, Logan E.; Jones, Derek A.; Stitzel, Joel D.] Wake Forest Sch Med, Dept Biomed Engn, Winston Salem, NC USA; [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Dept Radiol Neuroradiol, Winston Salem, NC USA; [Whitlow, Christopher T.] Wake Forest Sch Med, Clin & Translat Sci Inst, Winston Salem, NC USA; [Kelley, Mireille E.; Urban, Jillian E.; Miller, Logan E.; Jones, Derek A.; Whitlow, Christopher T.; Stitzel, Joel D.] Virginia Tech, Wake Forest Sch Biomed Engn & Sci, Winston Salem, NC USA; [Maldjian, Joseph A.] Univ Texas Southwestern, Dept Radiol, Dallas, TX USA	Stitzel, JD (corresponding author), Wake Forest Sch Med, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA.	jstitzel@wakehealth.edu	Stitzel, Joel/B-4045-2012	Stitzel, Joel/0000-0001-9762-3033; Maldjian, Joseph/0000-0002-6384-1072	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094410, R01NS082453]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001421]; Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001421] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers R01NS094410 and R01NS082453. The National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR001421 supported Dr. Jillian E. Urban. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors give special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center for providing support for this study. The authors also thank the youth football league's coordinators, coaches, parents, athletes, and athletic trainer whose support made this study possible. The authors also thank Amanda Dunn, Matt Bennett, Eliza Szuch, Danielle Rocheleau, Joeline Kane, Katie Fabian, Ana Katsafanas, Megan Anderson, and Leslie Hoyt for their valuable assistance in data collection.	Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Herman-Giddens ME, 2012, PEDIATRICS, V130, pE1058, DOI 10.1542/peds.2011-3291; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2015, BRAIN PATHOL, V25, P304, DOI 10.1111/bpa.12250; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tarnutzer AA, 2017, BRIT J SPORT MED, V51, P1592, DOI 10.1136/bjsports-2016-096593; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	41	26	26	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1939	1947		10.1089/neu.2016.4812			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500004	28274184	Green Published			2021-06-18	
J	Pekic, S; Popovic, V				Pekic, Sandra; Popovic, Vera			DIAGNOSIS OF ENDOCRINE DISEASE Expanding the cause of hypopituitarism	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; LANGERHANS CELL HISTIOCYTOSIS; CENTRAL-NERVOUS-SYSTEM; PITUITARY DYSFUNCTION; GROWTH-HORMONE; SHEEHANS-SYNDROME; SUBARACHNOID HEMORRHAGE; SELLAR GLOMANGIOMA; EXCESS MORTALITY; CASE SERIES	Hypopituitarism is defined as one or more pituitary hormone deficits due to a lesion in the hypothalamic-pituitary region. By far, the most common cause of hypopituitarism associated with a sellar mass is a pituitary adenoma. A high index of suspicion is required for diagnosing hypopituitarism in several other conditions such as other massess in the sellar and parasellar region, brain damage caused by radiation and by traumatic brain injury, vascular lesions, infiltrative/immunological/inflammatory diseases (lymphocytic hypophysitis, sarcoidosis and hemochromatosis), infectious diseases and genetic disorders. Hypopituitarism may be permanent and progressive with sequential pattern of hormone deficiencies (radiation-induced hypopituitarism) or transient after traumatic brain injury with possible recovery occurring years from the initial event. In recent years, there is increased reporting of less common and less reported causes of hypopituitarism with its delayed diagnosis. The aim of this review is to summarize the published data and to allow earlier identification of populations at risk of hypopituitarism as optimal hormonal replacement may significantly improve their quality of life and life expectancy.	[Pekic, Sandra] Univ Belgrade, Sch Med, Internal Med, Belgrade, Serbia; [Popovic, Vera] Univ Belgrade, Sch Med, Belgrade, Serbia; [Pekic, Sandra] Univ Clin Ctr Belgrade, Clin Endocrinol Diabet & Metab Dis, Belgrade, Serbia	Popovic, V (corresponding author), Univ Belgrade, Sch Med, Belgrade, Serbia.	popver@gmail.com	Pekic, Sandra/S-7175-2016		Ministry of Science of Republic of SerbiaMinistry of Science, Serbia [175033]	This study was supported by a grant from the Ministry of Science of Republic of Serbia (Project 175033).	Abele TA, 2012, CLIN RADIOL, V67, P821, DOI 10.1016/j.crad.2012.01.001; Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Al-Aridi R, 2014, PITUITARY, V17, P575, DOI 10.1007/s11102-013-0542-9; Anthony J, 2016, PITUITARY, V19, P19, DOI 10.1007/s11102-015-0678-x; ASA SL, 1984, ULTRASTRUCT PATHOL, V7, P49, DOI 10.3109/01913128409141853; Badalian-Very G, 2010, BLOOD, V116, P1919, DOI 10.1182/blood-2010-04-279083; Bando H, 2015, PEDIATR ENDOCR REV P, V12, P290; Beatrice Anne M, 2013, Indian J Endocrinol Metab, V17, pS608, DOI 10.4103/2230-8210.123546; Berkmann S, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.05.029; Bricaire L, 2015, J CLIN ENDOCR METAB, V100, P2837, DOI 10.1210/jc.2015-2049; Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042; Carmichael JD, 2012, CURR OPIN ENDOCRINOL, V19, P314, DOI 10.1097/MED.0b013e32835430ed; Caturegli P, 2016, AM J PATHOL, V186, P3225, DOI 10.1016/j.ajpath.2016.08.020; Chemaitilly W, 2015, J CLIN ONCOL, V33, P492, DOI 10.1200/JCO.2014.56.7933; Cheung C. C., 2013, J CLIN ENDOCRINOLOGY, V86, P1048, DOI [DOI 10.1210/JCEM.86.3.7265, 10.1210/jcem.86.3.7265]; Cives M, 2015, CRIT REV ONCOL HEMAT, V95, P1, DOI 10.1016/j.critrevonc.2015.02.004; Courtillot C, 2016, J CLIN ENDOCR METAB, V101, P304, DOI 10.1210/jc.2015-3357; De Parisot A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000748; Dhanwal DK, 2010, PITUITARY, V13, P304, DOI 10.1007/s11102-010-0234-7; Diri H, 2016, ENDOCRINE, V51, P22, DOI 10.1007/s12020-015-0726-3; Diri H, 2014, EUR J ENDOCRINOL, V171, P311, DOI 10.1530/EJE-14-0244; Ebinu JO, 2011, ENDOCR PATHOL, V22, P218, DOI 10.1007/s12022-011-9179-2; Faje A, 2016, PITUITARY, V19, P82, DOI 10.1007/s11102-015-0671-4; Fleseriu M, 2016, J CLIN ENDOCR METAB, V101, P3888, DOI 10.1210/jc.2016-2118; Golay V, 2014, PITUITARY, V17, P125, DOI 10.1007/s11102-013-0477-1; Hall J, 2015, BRIT J NEUROSURG, V29, P303, DOI 10.3109/02688697.2014.969681; Hamdeh S, 2015, AM J EMERG MED, V33, DOI 10.1016/j.ajem.2015.04.071; Haroche J, 2013, BLOOD, V121, P1495, DOI 10.1182/blood-2012-07-446286; Hautala T, 2002, CLIN INFECT DIS, V35, P96, DOI 10.1086/340859; He WZ, 2015, PITUITARY, V18, P159, DOI 10.1007/s11102-014-0552-2; Heshmati HM, 2001, MAYO CLIN PROC, V76, P789; Higham CE, 2016, LANCET, V388, P2403, DOI 10.1016/S0140-6736(16)30053-8; Iannuzzi MC, 2007, NEW ENGL J MED, V357, P2153, DOI 10.1056/NEJMra071714; Imashuku S, 2011, INT J HEMATOL, V94, P556, DOI 10.1007/s12185-011-0955-z; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; Joukhadar R, 2012, PITUITARY, V15, P146, DOI 10.1007/s11102-011-0352-x; Kapoor E, 2014, J CLIN ENDOCR METAB, V99, P3988, DOI 10.1210/jc.2014-1962; Kara O, 2013, J PEDIATR ENDOCR MET, V26, P959, DOI 10.1515/jpem-2013-0033; Karaca Z, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.92; Karaca Z, 2016, MINERVA ENDOCRINOL, V41, P390; Karaca Z, 2016, PROG MOL BIOL TRANSL, V138, P167, DOI 10.1016/bs.pmbts.2015.10.010; Karaca Z, 2009, ENDOCR RES, V34, P10, DOI 10.1080/07435800902841306; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Khajeh L, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0205-0; Klose M, 2015, J CLIN MED, V4, P1480, DOI 10.3390/jcm4071480; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Kreitschmann-Andermahr Ilonka, 2005, Pituitary, V8, P219, DOI 10.1007/s11102-006-6044-2; Langrand C, 2012, QJM-INT J MED, V105, P981, DOI 10.1093/qjmed/hcs121; Lasolle H, 2016, LANCET DIABETES ENDO, V4, P374, DOI 10.1016/S2213-8587(15)00458-1; Lury Kenneth M, 2005, Top Magn Reson Imaging, V16, P301, DOI 10.1097/01.rmr.0000224686.21748.ea; Miljic D, 2003, J ENDOCRINOL INVEST, V26, P450, DOI 10.1007/BF03345201; Noblett J, 2015, BMJ CASE REPORTS, V25, P2015; Olsson DS, 2017, EUR J ENDOCRINOL, V176, P67, DOI 10.1530/EJE-16-0450; Olsson DS, 2015, J CLIN ENDOCR METAB, V100, P2651, DOI 10.1210/jc.2015-1475; Pappachan JM, 2015, J CLIN ENDOCR METAB, V100, P1405, DOI 10.1210/jc.2014-3787; Partanen T, 2016, CLIN ENDOCRINOL, V84, P85, DOI 10.1111/cen.12863; Patterson BC, 2014, J CLIN ENDOCR METAB, V99, P2030, DOI 10.1210/jc.2013-4159; Pekic S, 2005, ENDOCRINE, V26, P79, DOI 10.1385/ENDO:26:2:079; Pekic S, 2014, HAND CLINIC, V124, P271, DOI 10.1016/B978-0-444-59602-4.00018-6; Pekic S, 2010, LANCET, V375, P432, DOI 10.1016/S0140-6736(09)61835-3; Pekic S, 2008, ENDOCRINE, V34, P11, DOI 10.1007/s12020-008-9109-3; Pepene CE, 2010, PITUITARY, V13, P385, DOI 10.1007/s11102-008-0150-2; Phillips M, 2009, PEDIATR BLOOD CANCER, V52, P97, DOI 10.1002/pbc.21782; Rajagopala S, 2015, QJM-INT J MED, V108, P719, DOI 10.1093/qjmed/hcv011; Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x; Ramiandrasoa C, 2013, EUR J ENDOCRINOL, V169, P431, DOI 10.1530/EJE-13-0279; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Robba C, 2016, PITUITARY, V19, P522, DOI 10.1007/s11102-016-0733-2; Sanchez JE, 2000, REV NEUROLOGIA, V30, P939, DOI 10.33588/rn.3010.99409; Schaefer S, 2008, EUR J ENDOCRINOL, V158, P3, DOI 10.1530/EJE-07-0484; Shalet SM, 1997, J ROY SOC MED, V90, P192, DOI 10.1177/014107689709000404; Sharma MC, 2000, CLIN NEUROL NEUROSUR, V102, P72, DOI 10.1016/S0303-8467(00)00063-9; Spinner CD, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-481; Stojanovic M, 2008, J CLIN ENDOCR METAB, V93, P2722, DOI 10.1210/jc.2008-0311; Tanimoto K, 2015, INTERNAL MED, V54, P1247, DOI 10.2169/internalmedicine.54.3435; Tanriverdi F, 2014, ENDOCRINE, V47, P198, DOI 10.1007/s12020-013-0127-4; Tanriverdi F, 2015, ENDOCR REV, V36, P305, DOI 10.1210/er.2014-1065; Tarabay A, 2016, J NEURO-ONCOL, V130, P383, DOI 10.1007/s11060-016-2249-z; Torino F, 2013, EUR J ENDOCRINOL, V169, pR153, DOI 10.1530/EJE-13-0434; Treip C S, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P178; Tsiakalos A, 2010, J CLIN ENDOCR METAB, V95, P3277, DOI 10.1210/jc.2010-0144; Vates GE, 2001, J NEUROSURG, V95, P233, DOI 10.3171/jns.2001.95.2.0233; Yamamoto M, 2011, J CLIN INVEST, V121, P113, DOI 10.1172/JCI44073; Young J, 2007, PRESSE MED, V36, P1319, DOI 10.1016/j.lpm.2007.01.041; Zhang X, 2002, J CLIN PATHOL, V55, P965, DOI 10.1136/jcp.55.12.965	85	26	29	0	6	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JUN	2017	176	6					R269	R282		10.1530/EJE-16-1065			14	Endocrinology & Metabolism	Endocrinology & Metabolism	EW4OP	WOS:000402481100002	28258131	Bronze			2021-06-18	
J	Zhang, MK; Cui, ZW; Cui, H; Wang, Y; Zhong, CL				Zhang, Mingkun; Cui, Zhenwen; Cui, Hua; Wang, Yong; Zhong, Chunlong			Astaxanthin protects astrocytes against trauma-induced apoptosis through inhibition of NKCC1 expression via the NF-kappa B signaling pathway	BMC NEUROSCIENCE			English	Article						Astaxanthin; Traumatic brain injury; Apoptosis; Astrocyte; Na+-K+-2Cl(-) co-transporter-1; NF-kappa B	INDUCED BRAIN EDEMA; CULTURED ASTROCYTES; CL-COTRANSPORTER; OXIDATIVE STRESS; ACTIVATION; INJURY; NEUROPROTECTION; GENE; NA+; INFLAMMATION	Background: Astaxanthin (ATX) is a carotenoid pigment with pleiotropic pharmacological properties that is seen as a possible drug for treating cerebral ischemic injury and subarachnoid hemorrhage. Na+-K+-2Cl(-) co-transporter-1 (NKCC1), an intrinsic membrane protein expressed by many cell types, is activated by various insults, leading to the formation of cell swelling and brain edema. We previously established that ATX attenuated brain edema and improved neurological outcomes by modulating NKCC1 expression after traumatic brain injury in mice. This paper explored the molecular mechanism of ATX-mediated inhibition of NKCC1 utilizing an in vitro astrocyte stretch injury model. Results: Stretch injury in cultured astrocytes lowered cell viability time-dependently, which was substantially reducing by pretreating with ATX (50 mu mol/L). Stretch injury increased Bax level and cleaved caspase-3 activity, and decreased Bcl-2 level and pro-caspase 3 activity, resulting in the apoptosis of astrocytes. Additionally, stretch injury substantially raised the gene and protein expressions of interleukin (IL)-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha and prompted the expression and nuclear translocation of NF-kappa B. Pretreatment with ATX remarkably prevented the trauma-induced initiation of NF-kappa B, expressions of pro-inflammatory cytokines, and cell apoptosis. Moreover, stretch injury markedly elevated the gene and protein expression of NKCC1, which was partly blocked by co-treatment with ATX (50 mu mol/L) or an NF-kappa B inhibitor (PDTC, 10 mu mol/L). Cleaved caspase-3 activity was partially reduced by PDTC (10 mu mol/L) or an NKCC1 inhibitor (bumetanide, 50 mu mol/L). Conclusions: ATX attenuates apoptosis after stretch injury in cultured astrocytes by inhibiting NKCC1 expression, and it acts by reducing the expression of NF-kappa B-mediated pro-inflammatory factors.	[Zhang, Mingkun; Cui, Hua; Wang, Yong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Zhang, Mingkun; Cui, Zhenwen; Zhong, Chunlong] Tongji Univ, Sch Med, East Hosp, Dept Neurosurg, 150 Jimo Rd, Shanghai 200120, Peoples R China; [Cui, Zhenwen] Qingdao Univ, Dept Neurosurg, Affiliated Hosp, Qingdao 266005, Peoples R China	Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China.; Zhong, CL (corresponding author), Tongji Univ, Sch Med, East Hosp, Dept Neurosurg, 150 Jimo Rd, Shanghai 200120, Peoples R China.	wangyong68@163.com; drchunlongzhong@126.com		Zhong, Chunlong/0000-0002-0605-7273	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571184, 81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [15140902100, 10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	We received funds from the National Natural Science Foundation of China (Nos. 81571184, 81070990, 30670719, 30500525) and the Shanghai Science and Technology Commission (Nos. 15140902100, 10QH1401700) in the process of study design, experiment implementation and data collection. Data interpretation and article writing were supported by the grants from the Shanghai Science and Technology Commission (No. 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20).	Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Chan KC, 2009, J FOOD SCI, V74, pH225, DOI 10.1111/j.1750-3841.2009.01274.x; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Conti L, 2011, EPILEPSIA, V52, P1635, DOI 10.1111/j.1528-1167.2011.03111.x; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Cui ZW, 2015, ACTA PHARMACOL SIN, V36, P1426, DOI 10.1038/aps.2015.90; Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Franceschelli S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088359; Haas BR, 2010, CANCER RES, V70, P5597, DOI 10.1158/0008-5472.CAN-09-4666; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jayakumar AR, 2010, METAB BRAIN DIS, V25, P31, DOI 10.1007/s11011-010-9180-3; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Khan SK, 2010, THROMB RES, V126, P299, DOI 10.1016/j.thromres.2010.07.003; Kim JA, 2001, BIOCHEM BIOPH RES CO, V281, P511, DOI 10.1006/bbrc.2001.4371; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lee SJ, 2003, MOL CELLS, V16, P97; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Marmarou A, 2003, ACT NEUR S, V86, P7; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Sathish V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023662; Sehnert B, 2013, P NATL ACAD SCI USA, V110, P16556, DOI 10.1073/pnas.1218219110; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Sirabella R, 2009, STROKE, V40, P922, DOI 10.1161/STROKEAHA.108.531962; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Valsecchi V, 2013, ADV EXP MED BIOL, V961, P137, DOI 10.1007/978-1-4614-4756-6_12; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Xing B, 2007, J NEUROIMMUNOL, V192, P89, DOI 10.1016/j.jneuroim.2007.09.029; Yan YP, 2001, J CEREBR BLOOD F MET, V21, P711, DOI 10.1097/00004647-200106000-00009; Youdim MBH, 1999, ANN NY ACAD SCI, V890, P7, DOI 10.1111/j.1749-6632.1999.tb07977.x; Yu Y, 2009, CIRCULATION, V119, P2313, DOI 10.1161/CIRCULATIONAHA.108.782458; Zhang MA, 2016, ENERGY STORAGE MATER, V4, P1, DOI 10.1016/j.ensm.2016.02.001; Zhang XS, 2014, J SURG RES, V192, P206, DOI 10.1016/j.jss.2014.05.029; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730	47	26	29	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	MAY 10	2017	18								42	10.1186/s12868-017-0358-z			12	Neurosciences	Neurosciences & Neurology	EV4LP	WOS:000401731800001	28490320	DOAJ Gold, Green Published			2021-06-18	
J	Keselman, P; Yu, EY; Zhou, XYY; Goodwill, PW; Chandrasekharan, P; Ferguson, RM; Khandhar, AP; Kemp, SJ; Krishnan, KM; Zheng, B; Conolly, SM				Keselman, Paul; Yu, Elaine Y.; Zhou, Xinyi Y.; Goodwill, Patrick W.; Chandrasekharan, Prashant; Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.; Zheng, Bo; Conolly, Steven M.			Tracking short-term biodistribution and long-term clearance of SPIO tracers in magnetic particle imaging	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						SPIO biodistribuition; SPIO tracking; SPIO clearance	CELLS IN-VIVO; DRUG-DELIVERY; NANOPARTICLES; TOXICITY; CONTRAST; THERAPY; MPI; MR	Magnetic particle imaging ( MPI) is an emerging tracer-based medical imaging modality that images non-radioactive, kidney-safe superparamagnetic iron oxide (SPIO) tracers. MPI offers quantitative, high-contrast and high-SNR images, so MPI has exceptional promise for applications such as cell tracking, angiography, brain perfusion, cancer detection, traumatic brain injury and pulmonary imaging. In assessing MPI's utility for applications mentioned above, it is important to be able to assess tracer short-term biodistribution as well as long-term clearance from the body. Here, we describe the biodistribution and clearance for two commonly used tracers in MPI: Ferucarbotran (Meito Sangyo Co., Japan) and LS-oo8 (LodeSpin Labs, Seattle, WA). We successfully demonstrate that 3D MPI is able to quantitatively assess short-term biodistribution, as well as long-term tracking and clearance of these tracers in vivo.	[Keselman, Paul; Yu, Elaine Y.; Zhou, Xinyi Y.; Chandrasekharan, Prashant; Zheng, Bo; Conolly, Steven M.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Conolly, Steven M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA; [Goodwill, Patrick W.] Magnet Insight Inc, Newark, CA 94560 USA; [Ferguson, R. Matthew; Khandhar, Amit P.; Kemp, Scott J.; Krishnan, Kannan M.] LodeSpin Labs, POB 95632, Seattle, WA 98145 USA; [Krishnan, Kannan M.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA	Keselman, P (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.	pkeselma@berkeley.edu	Chandrasekharan, Prashant/I-2196-2019; Chandrasekharan, Prashant/C-5174-2011	Chandrasekharan, Prashant/0000-0002-6139-1979; Khandhar, Amit/0000-0003-4049-1855; Goodwill, Patrick/0000-0003-4240-1956	Keck FoundationW.M. Keck Foundation [009323]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01EB019458, 1R24MH106053, 2R42EB013520-02A1]; UC DiscoveryUniversity of California System; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R42EB013520, R01EB019458, R01EB013689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R24MH106053] Funding Source: NIH RePORTER	We are grateful for funding support from the Keck Foundation Grant 009323, NIH 1R01EB019458, NIH 1R24MH106053, NIH 2R42EB013520-02A1, and the UC Discovery Grant.	Abdollah MRA, 2014, FARADAY DISCUSS, V175, P41, DOI 10.1039/c4fd00114a; Ahrens ET, 2013, NAT REV IMMUNOL, V13, P755, DOI 10.1038/nri3531; Antonelli A, 2016, NANOMEDICINE, V11, P0216; Antonelli A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078542; Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330; Chehade M, 2016, TOMOGRAPHY, V2, P158, DOI 10.18383/j.tom.2016.00160; Dutz S, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/45/452001; Ferguson RM, 2015, IEEE T MED IMAGING, V34, P1077, DOI 10.1109/TMI.2014.2375065; Ferguson RM, 2011, MED PHYS, V38, P1619, DOI 10.1118/1.3554646; Ferguson RM, 2013, BIOMED ENG-BIOMED TE, V58, P493, DOI 10.1515/bmt-2012-0058; Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808; Goodwill P W, 2015, 5 INT WORKSH MAGN PA, P1; Goodwill PW, 2011, IEEE T MED IMAGING, V30, P1581, DOI 10.1109/TMI.2011.2125982; Goodwill PW, 2010, IEEE T MED IMAGING, V29, P1851, DOI 10.1109/TMI.2010.2052284; Goodwill PW, 2012, ADV MATER, V24, P3870, DOI 10.1002/adma.201200221; Gu L, 2012, ACS NANO, V6, P4947, DOI 10.1021/nn300456z; Hensley D, 2015, 5 INT WORKSH MAGN PA, P1; Hergt R, 2006, J PHYS-CONDENS MAT, V18, pS2919, DOI 10.1088/0953-8984/18/38/S26; Janib SM, 2010, ADV DRUG DELIVER REV, V62, P1052, DOI 10.1016/j.addr.2010.08.004; Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/nnm.11.19, 10.2217/NNM.11.19]; Kemp SJ, 2016, RSC ADV, V6, P77452, DOI 10.1039/c6ra12072e; Konkle J J, 2014, 2014 4 INT WORKSH MA, P1; Lawaczeck R, 1997, ACTA RADIOL, V38, P584, DOI 10.1080/02841859709174391; Li SH, 2012, BIOCONJUGATE CHEM, V23, P1322, DOI 10.1021/bc300175d; Lu K, 2015, 2015 5 INT WORKSH MA, P1; Lu K, 2013, IEEE T MED IMAGING, V32, P1565, DOI 10.1109/TMI.2013.2257177; Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002; Mahmoudi M, 2012, CHEM REV, V112, P2323, DOI 10.1021/cr2002596; Nguyen PK, 2014, CELL STEM CELL, V14, P431, DOI 10.1016/j.stem.2014.03.009; OCallaghan C, 1997, THORAX, V52, pS31, DOI 10.1136/thx.52.2008.S31; Orendorff R, 2016, PHYS MED BIOL; Park K., 2013, CANC TARGETED DRUG D; Rahmer J, 2015, PHYS MED BIOL, V60, P1775, DOI 10.1088/0031-9155/60/5/1775; Rahmer J, 2013, PHYS MED BIOL, V58, P3965, DOI 10.1088/0031-9155/58/12/3965; Ruangwattanapaisarn N, 2015, PEDIATR RADIOL, V45, P831, DOI 10.1007/s00247-014-3226-3; Saritas EU, 2013, J MAGN RESON, V229, P116, DOI 10.1016/j.jmr.2012.11.029; Shinkai M, 2002, PHYS MED BI IN PRESS; Wang Q, 2015, SCI REP-UK, V5, DOI 10.1038/srep07774; Wang YXJ, 2011, QUANT IMAGING MED SU, V1, P35, DOI 10.3978/j.issn.2223-4292.2011.08.03; Yu E, 2016, NANOLETT IN PRESS; Zheng B, 2016, THERANOSTICS, V6, P291, DOI 10.7150/thno.13728; Zheng B, 2015, SCI REP-UK, V5, DOI 10.1038/srep14055; Zhou X, 2016, PHYS MED BI IN PRESS	43	26	28	0	20	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	MAY 7	2017	62	9					3440	3453		10.1088/1361-6560/aa5f48			14	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	ES0JL	WOS:000399212500003	28177301	Green Accepted			2021-06-18	
J	Santos, VV; Stark, R; Rial, D; Silva, HB; Bayliss, JA; Lemus, MB; Davies, JS; Cunha, RA; Prediger, RD; Andrews, ZB				Santos, V. V.; Stark, R.; Rial, D.; Silva, H. B.; Bayliss, J. A.; Lemus, M. B.; Davies, J. S.; Cunha, R. A.; Prediger, R. D.; Andrews, Z. B.			Acyl ghrelin improves cognition, synaptic plasticity deficits and neuroinflammation following amyloid beta (A beta 1-40) administration in mice	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						Acyl ghrelin; Alzheimer's disease; amyloid beta; Y-maze; novel object recognition; olfactory discrimination; ghrelin knockout	OREXIGENIC HORMONE GHRELIN; DECREASE FOOD-INTAKE; ALZHEIMERS-DISEASE; MOUSE MODEL; HIPPOCAMPAL NEUROGENESIS; PARKINSONS-DISEASE; RECOGNITION MEMORY; OLFACTORY-BULB; ADULT MICE; SPATIAL MEMORY	Ghrelin is a metabolic hormone that has neuroprotective actions in a number of neurological conditions, including Parkinson's disease (PD), stroke and traumatic brain injury. Acyl ghrelin treatment in vivo and in vitro also shows protective capacity in Alzheimer's disease (AD). In the present study, we used ghrelin knockout (KO) and their wild-type littermates to test whether or not endogenous ghrelin is protective in a mouse model of AD, in which human amyloid beta peptide 1-40 (A beta 1-40) was injected into the lateral ventricles i.c.v. Recognition memory, using the novel object recognition task, was significantly impaired in ghrelin KO mice and after i.c.v. A beta 1-40 treatment. These deficits could be prevented by acyl ghrelin injections for 7 days. Spatial orientation, as assessed by the Y-maze task, was also significantly impaired in ghrelin KO mice and after i.c.v. A beta 1-40 treatment. These deficits could be prevented by acyl ghrelin injections for 7 days. Ghrelin KO mice had deficits in olfactory discrimination; however, neither i.c.v. A beta 1-40 treatment, nor acyl ghrelin injections affected olfactory discrimination. We used stereology to show that ghrelin KO and A beta 1-40 increased the total number of glial fibrillary acidic protein expressing astrocytes and ionised calcium-binding adapter expressing microglial in the rostral hippocampus. Finally, A beta 1-40 blocked long-term potentiation induced by high-frequency stimulation and this effect could be acutely blocked with co-administration of acyl ghrelin. Collectively, our studies demonstrate that ghrelin deletion affects memory performance and also that acyl ghrelin treatment may delay the onset of early events of AD. This supports the idea that acyl ghrelin treatment may be therapeutically beneficial with respect to restricting disease progression in AD.	[Santos, V. V.; Stark, R.; Bayliss, J. A.; Lemus, M. B.; Andrews, Z. B.] Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic, Australia; [Santos, V. V.; Stark, R.; Bayliss, J. A.; Lemus, M. B.; Andrews, Z. B.] Monash Univ, Dept Physiol, Clayton, Vic, Australia; [Davies, J. S.] Swansea Univ, Inst Life Sci, Mol Neurobiol, Swansea, W Glam, Wales; [Rial, D.; Prediger, R. D.] Univ Fed Santa Catarina, Ctr Biol Sci, Dept Pharmacol, Florianopolis, SC, Brazil; [Rial, D.; Silva, H. B.; Cunha, R. A.] Univ Coimbra, Ctr Neurosci & Cell Biol, CNC, Coimbra, Portugal; [Cunha, R. A.] Univ Coimbra, Fac Med, Coimbra, Portugal	Andrews, ZB (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic, Australia.; Andrews, ZB (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic, Australia.	zane.andrews@monash.edu	Rial, Daniel/D-3219-2009; Prediger, Rui Daniel/AAV-3419-2020; da silva, Henrique Bernardo/AAY-4358-2020; Davies, Jeffrey S/K-1400-2019; Santos, Vanessa/AAP-4130-2020; Cunha, Rodrigo A/E-7475-2015; Prediger, Rui D/C-4036-2013; Rial, Daniel/C-3595-2013	Prediger, Rui Daniel/0000-0002-7547-6463; da silva, Henrique Bernardo/0000-0002-7234-3411; Davies, Jeffrey S/0000-0002-4234-0033; Cunha, Rodrigo A/0000-0003-2550-6422; Prediger, Rui D/0000-0002-7547-6463; Andrews, Zane B./0000-0002-9097-7944; Rial, Daniel/0000-0002-2079-7331; Stark, Romana/0000-0002-4264-0060	Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [546131, 1084344]; Australian Research CouncilAustralian Research Council [FT100100966]; Santa Casa da Misericordia; QREN; CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; National Health and Medical Research Council, Grant/Award Number: 546131 and 1084344; Australian Research Council, Grant/Award Number: FT100100966; Santa Casa da Misericordia and QREN; Brazilian Funding Agency CNPq	Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Andrews ZB, 2009, J NEUROSCI, V29, P14057, DOI 10.1523/JNEUROSCI.3890-09.2009; Attems J, 2014, ACTA NEUROPATHOL, V127, P459, DOI 10.1007/s00401-014-1261-7; Bayliss JA, 2016, J NEUROCHEM, V137, P460, DOI 10.1111/jnc.13576; Bayliss JA, 2016, J NEUROSCI, V36, P3049, DOI 10.1523/JNEUROSCI.4373-15.2016; Bayliss JA, 2013, THER ADV ENDOCRINOL, V4, P25, DOI 10.1177/2042018813479645; Beheshti S, 2015, NEUROPEPTIDES, V52, P97, DOI 10.1016/j.npep.2015.05.003; Briggs DI, 2011, NEUROENDOCRINOLOGY, V93, P48, DOI 10.1159/000322589; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Brown MW, 2010, HIPPOCAMPUS, V20, P1228, DOI 10.1002/hipo.20858; Cahill SP, 2014, BEHAV BRAIN RES, V264, P105, DOI 10.1016/j.bbr.2014.02.004; Canas PM, 2014, NEUROPHARMACOLOGY, V76, P51, DOI 10.1016/j.neuropharm.2013.08.026; Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Davis JF, 2011, PHYSIOL BEHAV, V103, P39, DOI 10.1016/j.physbeh.2010.10.017; Dhurandhar EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060437; Diano S, 2006, NAT NEUROSCI, V9, P381, DOI 10.1038/nn1656; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; dos Santos VV, 2013, BEHAV BRAIN RES, V244, P107, DOI 10.1016/j.bbr.2013.01.039; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Gomes S, 2014, J NEUROENDOCRINOL, V26, P176, DOI 10.1111/jne.12138; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Harmatz E.S., 2016, BIOL PSYCHIAT; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hornsby AKE, 2016, PSYCHONEUROENDOCRINO, V63, P198, DOI 10.1016/j.psyneuen.2015.09.023; Hsu TM, 2015, ELIFE, V4, DOI 10.7554/eLife.11190; Kang S, 2015, PEPTIDES, V71, P84, DOI 10.1016/j.peptides.2015.07.005; Kanoski SE, 2017, BIOL PSYCHIAT, V81, P748, DOI 10.1016/j.biopsych.2015.09.011; Kaster MP, 2015, P NATL ACAD SCI USA, V112, P7833, DOI 10.1073/pnas.1423088112; Kent BA, 2015, PSYCHONEUROENDOCRINO, V51, P431, DOI 10.1016/j.psyneuen.2014.10.015; Kunath N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11452; Li E, 2014, EXP NEUROL, V252, P75, DOI 10.1016/j.expneurol.2013.11.021; Loch D, 2015, CHEM SENSES, V40, P469, DOI 10.1093/chemse/bjv028; Lutter M, 2008, NAT NEUROSCI, V11, P752, DOI 10.1038/nn.2139; Mani BK, 2014, J COMP NEUROL, V522, P3644, DOI 10.1002/cne.23627; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Martins I, 2013, NEUROSCIENCE, V241, P41, DOI 10.1016/j.neuroscience.2013.02.062; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McFarlane MR, 2014, CELL METAB, V20, P54, DOI 10.1016/j.cmet.2014.04.007; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Moon M, 2014, J ALZHEIMERS DIS, V41, P233, DOI 10.3233/JAD-132417; Moon M, 2011, J ALZHEIMERS DIS, V23, P147, DOI 10.3233/JAD-2010-101263; Moon M, 2009, ENDOCR J, V56, P525, DOI 10.1507/endocrj.K09E-089; Moreno MM, 2009, P NATL ACAD SCI USA, V106, P17980, DOI 10.1073/pnas.0907063106; Muller TD, 2015, MOL METAB, V4, P437, DOI 10.1016/j.molmet.2015.03.005; Ondrejcak T, 2010, NEUROMOL MED, V12, P13, DOI 10.1007/s12017-009-8091-0; Prediger RDS, 2007, BEHAV BRAIN RES, V177, P205, DOI 10.1016/j.bbr.2006.11.032; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shibata N, 2011, DEMENT GERIATR COGN, V32, P178, DOI 10.1159/000333075; Sultan S, 2010, FASEB J, V24, P2355, DOI 10.1096/fj.09-151456; Takeda S, 2009, BRAIN RES, V1280, P137, DOI 10.1016/j.brainres.2009.05.035; Theodoropoulou A, 2012, J NUTR HEALTH AGING, V16, P472, DOI 10.1007/s12603-012-0058-4; Tong J, 2011, J NEUROSCI, V31, P5841, DOI 10.1523/JNEUROSCI.5680-10.2011; Van Dam D, 2011, NEUROMETHODS, V48, P35, DOI 10.1007/978-1-60761-898-0_3; Vann SD, 2011, CURR OPIN NEUROBIOL, V21, P440, DOI 10.1016/j.conb.2011.02.002; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wortley KE, 2005, J CLIN INVEST, V115, P3573, DOI 10.1172/JCI26003; Yi JH, 2016, BEHAV BRAIN RES, V297, P141, DOI 10.1016/j.bbr.2015.10.018; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107; Zigman JM, 2016, TRENDS ENDOCRIN MET, V27, P348, DOI 10.1016/j.tem.2016.02.007; Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823	66	26	27	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	MAY	2017	29	5								10.1111/jne.12476			11	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	EX1LY	WOS:000402986000008	28380673	Bronze, Green Published			2021-06-18	
J	Berkowitz, CD				Berkowitz, Carol D.			Physical Abuse of Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SHAKEN BABY SYNDROME; HEAD TRAUMA; YOUNG-CHILDREN; INFANTS; FRACTURES; RISK; LESS-THAN-1; PATTERNS; TODDLERS	A 4-month-old male infant is brought to the emergency department by paramedics. His mother had dialed 911 because the infant appeared to be limp when she lifted him from his crib after she returned from work; she had left him with her boyfriend while she was at work. On arrival in the emergency department, the infant's temperature is 37 degrees C, heart rate 114 beats per minute, blood pressure 90/68 mm Hg, and respiratory rate 28 breaths per minute. The physical examination is normal except for decreased muscle tone, and there is a 1-cm bruise on his left cheek. How should this case be evaluated and managed?	[Berkowitz, Carol D.] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Torrance, CA USA	Berkowitz, CD (corresponding author), Harbor UCLA Med Ctr, Dept Pediat, 1000 W Carson St, Torrance, CA 90509 USA.	cberkowitz52@gmail.com					Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2017, YOUTH FAM CHILDR BUR; Barr RG, 2012, P NATL ACAD SCI USA, V109, P17294, DOI 10.1073/pnas.1121267109; Barsness KA, 2003, J TRAUMA, V54, P1107, DOI 10.1097/01.TA.0000068992.01030.A8; Bell E, 2011, CHILD ABUSE NEGLECT, V35, P74, DOI 10.1016/j.chiabu.2010.11.001; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; Cheung MS, 2008, REV ENDOCR METAB DIS, V9, P153, DOI 10.1007/s11154-008-9074-4; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Dias MS, 2017, JAMA PEDIATR, V171, P223, DOI 10.1001/jamapediatrics.2016.4218; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Gaines BA, 2004, J PEDIATR SURG, V39, P600, DOI 10.1016/j.jpedsurg.2003.12.010; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Greiner MV, 2013, J PEDIATR-US, V163, P527, DOI 10.1016/j.jpeds.2013.01.063; Hymel KP, 2013, PEDIATR CRIT CARE ME, V14, P210, DOI 10.1097/PCC.0b013e3182712b09; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Jenny C, 2006, PEDIATRICS, V118, P1299, DOI 10.1542/peds.2006-1795; Jones R, 2008, PEDIATRICS, V122, P259, DOI 10.1542/peds.2007-2312; Kairys SW, 2001, PEDIATRICS, V108, P206; Kemp AM, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1518; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Kleinman PK, 2008, PEDIATR RADIOL, V38, pS388, DOI 10.1007/s00247-008-0845-6; Lane WG, 2009, PEDIATRICS, V124, P1595, DOI 10.1542/peds.2009-0904; Leaman LA, 2016, J CHILD ORTHOP, V10, P467, DOI 10.1007/s11832-016-0764-2; Levey EJ, 2017, CHILD ABUSE NEGLECT, V65, P48, DOI 10.1016/j.chiabu.2017.01.004; Levin AV, 2010, PEDIATRICS, V126, P376, DOI 10.1542/peds.2010-1397; Lindberg DM, 2013, PEDIATRICS, V131, P268, DOI 10.1542/peds.2012-1952; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Maguire S, 2005, ARCH DIS CHILD, V90, P182, DOI 10.1136/adc.2003.044065; Maguire S, 2005, ARCH DIS CHILD, V90, P187, DOI 10.1136/adc.2003.044073; Maguire S, 2007, ARCH DIS CHILD, V92, P1113, DOI 10.1136/adc.2006.113001; Maguire SA, 2011, PEDIATRICS, V128, pE550, DOI 10.1542/peds.2010-2949; Matschke J, 2009, PEDIATRICS, V124, P1587, DOI 10.1542/peds.2008-3734; Matshes EW, 2011, ACAD FOR PATHOL, V1, P82; Mehta H, 2016, AM J NEURORADIOL, V37, P11, DOI 10.3174/ajnr.A4464; Perez-Rossello JM, 2012, RADIOLOGY, V262, P234, DOI 10.1148/radiol.11110358; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Schilling S, 2011, PEDIATRICS, V127, P835, DOI 10.1542/peds.2010-0533; Sheets LK, 2013, PEDIATRICS, V131, P701, DOI 10.1542/peds.2012-2780; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spies EL, 2016, MMWR-MORBID MORTAL W, V65, P505, DOI 10.15585/mmwr.mm6520a1; Sugar NF, 1999, ARCH PEDIAT ADOL MED, V153, P399, DOI 10.1001/archpedi.153.4.399; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; Trokel M, 2006, PEDIATR EMERG CARE, V22, P700, DOI 10.1097/01.pec.0000238734.76413.d0; van Rijn RR, 2011, MAGN RESON IMAGING C, V19, P791, DOI 10.1016/j.mric.2011.08.006	48	26	26	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2017	376	17					1659	1666		10.1056/NEJMcp1701446			8	Medicine, General & Internal	General & Internal Medicine	ET2AY	WOS:000400071900009	28445667				2021-06-18	
J	Kulbe, JR; Hill, RL; Singh, IN; Wang, JA; Hall, ED				Kulbe, Jacqueline R.; Hill, Rachel L.; Singh, Indrapal N.; Wang, Juan A.; Hall, Edward D.			Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria after Traumatic Brain Injury and Are Protected by Cyclosporine A	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporine A; mitochondria; neuroprotection; synaptic and non-synaptic; traumatic brain injury	NERVOUS-SYSTEM TOXICITY; MEDIATED CYTOSKELETAL DEGRADATION; SKELETAL-MUSCLE MITOCHONDRIA; PERMEABILITY TRANSITION PORE; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; CORTICAL CONTUSION; CYCLOPHILIN-D; SPINAL-CORD; NEUROLOGIC COMPLICATIONS	Currently, there are no Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of those with traumatic brain injury (TBI). As central mediators of the secondary injury cascade, mitochondria are promising therapeutic targets for prevention of cellular death and dysfunction after TBI. One of the most promising and extensively studied mitochondrial targeted TBI therapies is inhibition of the mitochondrial permeability transition pore (mPTP) by the FDA-approved drug, cyclosporine A (CsA). A number of studies have evaluated the effects of CsA on total brain mitochondria after TBI; however, no study has investigated the effects of CsA on isolated synaptic and non-synaptic mitochondria. Synaptic mitochondria are considered essential for proper neurotransmission and synaptic plasticity, and their dysfunction has been implicated in neurodegeneration. Synaptic and non-synaptic mitochondria have heterogeneous characteristics, but their heterogeneity can be masked in total mitochondrial (synaptic and non-synaptic) preparations. Therefore, it is essential that mitochondria targeted pharmacotherapies, such as CsA, be evaluated in both populations. This is the first study to examine the effects of CsA on isolated synaptic and non-synaptic mitochondria after experimental TBI. We conclude that synaptic mitochondria sustain more damage than non-synaptic mitochondria 24 h after severe controlled cortical impact injury (CCI), and that intraperitoneal administration of CsA (20 mg/kg) 15 min after injury improves synaptic and non-synaptic respiration, with a significant improvement being seen in the more severely impaired synaptic population. As such, CsA remains a promising neuroprotective candidate for the treatment of those with TBI.	[Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, BBSRB Room 477,741 South Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013	Kulbe, Jacqueline/0000-0002-7070-9264	Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT) [5R01 NS083405, 5R01 NS084857, 5P30 NS051220, 1F30 NS096876]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS096876, R01NS083405, T32NS077889] Funding Source: NIH RePORTER	This work was supported by 5R01 NS083405, 5R01 NS084857, 5P30 NS051220, 1F30 NS096876, and funding from the Kentucky Spinal Cord & Head Injury Research Trust (KSCHIRT).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BERDEN JHM, 1985, LANCET, V1, P219; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cheng AW, 2010, ASN NEURO, V2, P243, DOI 10.1042/AN20100019; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; Coronado VG, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P84; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Gilmer LK, 2010, MECH AGEING DEV, V131, P133, DOI 10.1016/j.mad.2009.12.011; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Greco T, 2016, J CEREBR BLOOD F MET, V36, P1603, DOI 10.1177/0271678X15610584; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2016, J BIOENERG BIOMEMBR, V48, P169, DOI 10.1007/s10863-015-9600-5; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Hazelton JL, 2009, J NEUROSCI RES, V87, P1250, DOI 10.1002/jnr.21921; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kristian T, 2006, J NEUROSCI METH, V152, P136, DOI 10.1016/j.jneumeth.2005.08.018; LAI JCK, 1976, BIOCHEM J, V154, P423, DOI 10.1042/bj1540423; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu YX, 2013, OXID MED CELL LONGEV, V2013, DOI [10.1155/2013/146860, 10.1155/2013/329183]; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacAskill AF, 2010, EUR J NEUROSCI, V32, P231, DOI 10.1111/j.1460-9568.2010.07345.x; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Mustafa AG, 2011, J NEUROCHEM, V117, P579, DOI 10.1111/j.1471-4159.2011.07228.x; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; NASSBERGER L, 1990, PHARMACOL TOXICOL, V67, P147; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x; Pocernich CB, 2003, NEUROTOX RES, V5, P515, DOI 10.1007/BF03033161; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sanchez H, 2001, BRIT J PHARMACOL, V133, P781, DOI 10.1038/sj.bjp.0704129; Sanchez H, 2000, J MOL CELL CARDIOL, V32, P323, DOI 10.1006/jmcc.1999.1078; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156; Shi RY, 2011, MOL NUTR FOOD RES, V55, P1320, DOI 10.1002/mnfr.201100217; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	106	26	26	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1291	1301		10.1089/neu.2016.4628			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600001	27596283	Green Published			2021-06-18	
J	Crichton, AJ; Babl, F; Oakley, E; Greenham, M; Hearps, S; Delzoppo, C; Hutchison, J; Beauchamp, M; Anderson, VA				Crichton, Alison J.; Babl, Franz; Oakley, Ed; Greenham, Mardee; Hearps, Stephen; Delzoppo, Carmel; Hutchison, Jamie; Beauchamp, Miriam; Anderson, Vicki A.			Prediction of Multidimensional Fatigue After Childhood Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; depression; fatigue; sleep-wake disturbance; traumatic brain injury	QUALITY-OF-LIFE; PEDIATRIC MULTIPLE-SCLEROSIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENERIC CORE SCALES; SICKLE-CELL-DISEASE; MINOR HEAD-INJURY; PSYCHOMETRIC PROPERTIES; CEREBRAL-PALSY; FOLLOW-UP; CHILDREN	Objectives: To determine (1) the presence of fatigue symptoms and predictors of fatigue after childhood brain injury and examine (2) the feasibility, reliability, and validity of a multidimensional fatigue measure (PedsQL Multidimensional Fatigue Scale [ MFS]) obtained from parent and child perspectives. Setting: Emergency and intensive care units of a hospital in Melbourne, Australia. Participants: Thirty-five families (34 parent-proxies and 32 children) aged 8 to 18 years (mean child age = 13.29 years) with traumatic brain injury (TBI) of all severities (27 mild, 5 moderate, and 3 severe) admitted to the Royal Children's Hospital. Design: Longitudinal prospective study. Fatigue data collected at 6-week follow-up (mean = 6.9 weeks). Main Outcome Measures: Postinjury child-and parent-rated fatigue (PedsQL MFS), mood, sleep, and pain based on questionnaire report: TBI severity (mild vs moderate/severe TBI). Results: A score greater than 2 standard deviations below healthy control data indicated the presence of abnormal fatigue, rates of which were higher compared with normative data for both parent and child reports (47% and 29%). Fatigue was predicted by postinjury depression and sleep disturbance for parent, but not child ratings. Fatigue, as rated by children, was not significantly predicted by TBI severity or other symptoms. The PedsQL MFS demonstrated acceptable measurement properties in child TBI participants, evidenced by good feasibility and reliability (Cronbach alpha values >0.90). Interrater reliability between parent and child reports was poor to moderate. Conclusions: Results underscore the need to assess fatigue and associated sleep-wake disturbance and depression after child TBI from both parent and child perspectives.	[Crichton, Alison J.; Babl, Franz; Greenham, Mardee; Hearps, Stephen; Delzoppo, Carmel; Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Crichton, Alison J.] Monash Childrens, Victorian Pediat Rehabil Serv, Melbourne, Vic, Australia; [Crichton, Alison J.; Babl, Franz; Oakley, Ed; Greenham, Mardee; Anderson, Vicki A.] Univ Melbourne, Melbourne, Vic, Australia; [Babl, Franz; Oakley, Ed; Delzoppo, Carmel; Anderson, Vicki A.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Hutchison, Jamie] Hosp Sick Children, Res Inst, Toronto, ON, Canada; [Beauchamp, Miriam] Univ Montreal, Montreal, PQ, Canada	Crichton, AJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Crit Care & Neurosci Theme, Flemington Rd, Parkville, Vic 3052, Australia.	ali.crichton@mcri.edu.au	Hearps, Stephen/L-6853-2016; Greenham, Mardee/AAR-1711-2020		Ontario Neurotrauma Foundation, Toronto, Canada; Victorian Neurotrauma Initiative, Melbourne, Australia; Moving Ahead Seed Grant; National Health and Medical Research Council Postgraduate Scholarship, Canberra, Australia; Neurosciences Victoria Brain and Mind Scholarship, Melbourne, Australia; Victorian Government's Infrastructure Support Program, Melbourne, Australia; National Health and Medical Research Council Centre for Research Excellence Grant in Paediatric Emergency Medicine, Canberra, Australia; Royal Children's Hospital Foundation grant	This work is supported by a jointly awarded grant from the Ontario Neurotrauma Foundation, Toronto, Canada, and the Victorian Neurotrauma Initiative, Melbourne, Australia; a Moving Ahead Seed Grant; a National Health and Medical Research Council Postgraduate Scholarship (Alison Crichton, awarded 2014), Canberra, Australia; a Neurosciences Victoria Brain and Mind Scholarship, Melbourne, Australia (Alison Crichton, awarded 2012); the Victorian Government's Infrastructure Support Program, Melbourne, Australia, and in part funded by a National Health and Medical Research Council Centre for Research Excellence Grant in Paediatric Emergency Medicine, Canberra, Australia. Franz Babl was in part funded by a Royal Children's Hospital Foundation grant.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chambers CT, 1996, PAIN, V68, P307, DOI 10.1016/S0304-3959(96)03209-5; Christodoulou C, 2005, ISS CLIN COGN NEUROP, P19; Crichton A, 2015, PEDIATRICS, V135, pE1015, DOI 10.1542/peds.2014-2440; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dampier C, 2010, PEDIATR BLOOD CANCER, V55, P485, DOI 10.1002/pbc.22497; De Los Reyes A, 2015, PSYCHOL BULL, V141, P858, DOI 10.1037/a0038498; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Dieruf K, 2009, PEDIATR PHYS THER, V21, P45, DOI 10.1097/PEP.0b013e31818ec835; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Ewing-Cobbs L, 2014, J PEDIATR PSYCHOL, V39, P653, DOI 10.1093/jpepsy/jsu018; Falk AC, 2013, SCAND J CARING SCI, V27, P51, DOI 10.1111/j.1471-6712.2012.00999.x; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Gold JI, 2009, CLIN J PAIN, V25, P407, DOI 10.1097/AJP.0b013e318192bfb1; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Gordijn MS, 2013, PEDIATR BLOOD CANCER, V60, P479, DOI 10.1002/pbc.24261; Goretti B, 2012, MULT SCLER J, V18, P329, DOI 10.1177/1352458511420846; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hilger T, 2009, ADV CLIN EXP MED, V18, P169; Hockenberry Marilyn J, 2010, Oncol Nurs Forum, V37, pE16, DOI 10.1188/10.ONF.E16-E27; Holland AA, 2014, CHILD NEUROPSYCHOL, V20, P71, DOI 10.1080/09297049.2012.748888; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Jonsson CCA, 2014, INT J REHABIL RES, V37, P317, DOI 10.1097/MRR.0000000000000073; Ketelslegers IA, 2010, EUR J PAEDIATR NEURO, V14, P320, DOI 10.1016/j.ejpn.2009.09.004; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Kovacs M., 2011, CHILDRENS DEPRESSION; Levine J, 2009, PHYS MED REH CLIN N, V20, P347, DOI 10.1016/j.pmr.2008.12.006; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; MacAllister WS, 2009, MULT SCLER J, V15, P1502, DOI 10.1177/1352458509345902; Marcus SB, 2009, CLIN GASTROENTEROL H, V7, P554, DOI 10.1016/j.cgh.2009.01.022; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; Meeske K, 2004, CANCER, V101, P2116, DOI 10.1002/cncr.20609; Mort S, 2011, ONCOL NURS FORUM, V38, pE445, DOI 10.1188/11.ONF.E445-E454; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Nauta MH, 2004, BEHAV RES THER, V42, P813, DOI 10.1016/S0005-7967(03)00200-6; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Nunnally J.C., 1967, PSYCHOMETRIC THEORY, V226; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2000, ARCH PEDIAT ADOL MED, V154, P549, DOI 10.1001/archpedi.154.6.549; Panepinto JA, 2014, PEDIATR BLOOD CANCER, V61, P171, DOI 10.1002/pbc.24776; Perdikaris P, 2008, INT NURS REV, V55, P412, DOI 10.1111/j.1466-7657.2008.00644.x; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2015, J HEAD TRAUMA REHAB, V30, P277, DOI 10.1097/HTR.0000000000000049; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schonberger M, 2014, J HEAD TRAUMA REHAB, V29, P427, DOI 10.1097/HTR.0b013e31829ddd08; SCOTT PJ, 1977, ANN RHEUM DIS, V36, P186, DOI 10.1136/ard.36.2.186; Selewski DT, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-29; Spence SH, 1998, BEHAV RES THER, V36, P545, DOI 10.1016/S0005-7967(98)00034-5; Spence SH, 1997, J ABNORM PSYCHOL, V106, P280, DOI 10.1037/0021-843X.106.2.280; StataCorp, 2013, STATA STAT SOFTW REL; TEASDALE G, 1974, LANCET, V2, P81; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2015, QUAL LIFE RES, V24, P1921, DOI 10.1007/s11136-014-0914-2; Varni JW, 2013, QUAL LIFE RES, V22, P2581, DOI 10.1007/s11136-013-0370-4; Varni JW, 2010, INT J PEDIATR OBES, V5, P34, DOI 10.3109/17477160903111706; Varni JW, 2009, PEDIATR DIABETES, V10, P321, DOI 10.1111/j.1399-5448.2008.00482.x; Varni JW, 2006, DEV MED CHILD NEUROL, V48, P442, DOI 10.1017/S001216220600096X; Varni JW, 2004, J RHEUMATOL, V31, P2494; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Whitsett SF, 2008, J PEDIATR ONCOL NURS, V25, P86, DOI 10.1177/1043454208315546; Wong D L, 1988, Pediatr Nurs, V14, P9; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	70	26	26	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2017	32	2					107	116		10.1097/HTR.0000000000000248			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EN3YU	WOS:000395944700011	27455435				2021-06-18	
J	Sandel, NK; Schatz, P; Goldberg, KB; Lazar, M				Sandel, Natalie K.; Schatz, Philip; Goldberg, Kenneth B.; Lazar, Mary			Sex-Based Differences in Cognitive Deficits and Symptom Reporting Among Acutely Concussed Adolescent Lacrosse and Soccer Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						lacrosse; soccer; head injury; female athletes	SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; PREDICT PROTRACTED RECOVERY; SCHOOL FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; LINE TEST-PERFORMANCE; NEUROCOGNITIVE PERFORMANCE; GENDER-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE	Background: Research on the acute effects of a concussion among lacrosse players is limited, and postconcussion patterns between male and female athletes have yet to be clearly established. Differences in the style of play and protective gear worn among male and female lacrosse players potentially confound a direct comparison of sex-based differences in this population. Purpose: To explore sex-based differences in postconcussive neurocognitive functioning and symptom reporting outcomes in concussed adolescent male and female lacrosse players compared with a group of soccer players. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 224 adolescent lacrosse players (112 male, 112 female) aged 13 to 17 years (mean [SD] age, 15.43 1.09 years) were included in this study. A comparison group of soccer players was added and matched to lacrosse players based on age and sex to address confounding sport differences in male and female versions of lacrosse. All athletes underwent baseline and postinjury testing within 3 days of an injury using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) tool. Data were analyzed at baseline using a multivariate analysis of variance (MANOVA) with sport and sex as between-participant factors. A 2 x 2 x 2 mixed-factorial MANOVA was also conducted for sex and sport comparisons at baseline versus after a concussion. Ancillary analyses evaluated sex-based differences in exceeded reliable change indices (RCIs) using an independent-samples t test and established postinjury cutoff scores reflective of a protracted recovery using chi-square tests. Results: All athletes had a significantly worse cognitive profile and greater endorsement of symptoms after an injury (F-5,F-216 = 30.30, P < .001, (2) = .41). Sport yielded a significant main effect (F-5,F-216 = 2.36, P = .04, (2) = .05), but subsequent univariate analyses were nonsignificant (P > .05) across all neurocognitive and symptom outcome variables. Likewise, there were no significant interaction effects for sport x time (F-5,F-216 = 1.46, P = .21, (2) = .03) or sport x sex x time (F-5,F-216 = 2.09, P = .07, (2) = .05), indicating that lacrosse and soccer players respond similarly on neurocognitive testing and symptom reporting after sustaining a concussion. Regarding sex-based differences, female athletes had a significantly greater neurocognitive decline and increased symptoms after a concussion relative to male athletes, regardless of the sport type (sex x time interaction effect: F-5,F-216 = 3.86, P = .002, (2) = .08), with the relationship between concussions and sex demonstrating a medium- to large-sized effect. Female athletes demonstrated a significantly greater number of exceeded RCIs (t(216.16) = -3.732, P < .001), with 59% of male and 74% of female athletes with at least 1 RCI decline. Approximately 13% of male athletes, compared with 30% of female athletes, demonstrated scores indicative of protracted recovery at a 75% sensitivity ((2) (1, N = 224) = 9.43, P = .002). Conclusion: Athletes performed more poorly on computerized cognitive screening tools and reported greater symptoms after an acute concussion relative to their baseline performance. Female sex may be a modifier of an acute concussion outcome, given that female athletes in this study performed significantly worse than male athletes across all neurocognitive measures and reported greater symptoms relative to their baseline testing compared with male athletes, regardless of the sport played. Female athletes were also more likely than male athletes to demonstrate scores on neurocognitive testing that exceeded reliable change cutoffs and were predictive of a protracted recovery. The practical significance of these findings should be further verified by prospective longitudinal research given the medium- to large-sized effect demonstrated for the overall relationship between sex and concussions.	[Sandel, Natalie K.; Goldberg, Kenneth B.; Lazar, Mary] Widener Univ, Inst Grad Clin Psychol, One Univ Pl, Chester, PA 19013 USA; [Schatz, Philip] St Josephs Univ, Philadelphia, PA 19131 USA	Sandel, NK (corresponding author), Widener Univ, Inst Grad Clin Psychol, One Univ Pl, Chester, PA 19013 USA.	nksandel@gmail.com			ImPACT Applications Inc	One or more of the authors has declared the following potential conflict of interest or source of funding: N.K.S. and P.S. have received financial compensation as consultants to ImPACT Applications Inc for projects unrelated to the current study. No compensation was received for any aspect of the current study.	Alsalaheen B, 2016, SPORTS MED, V46, P1487, DOI 10.1007/s40279-016-0532-y; Alsalaheen B, 2016, J HEAD TRAUMA REHAB, V31, P242, DOI 10.1097/HTR.0000000000000175; Barth JT., 1989, MILD HEAD INJURY, P257; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1969, STAT POWER ANAL BEHA; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cosgrove KP, 2007, BIOL PSYCHIAT, V62, P847, DOI 10.1016/j.biopsych.2007.03.001; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Esposito G, 1996, J NUCL MED, V37, P559; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Granito VJ., 2002, J SPORT BEHAV, V25, P243; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Henry LC, 2015, APPL NEUROPSYCH-CHIL, V4, P266, DOI 10.1080/21622965.2014.911094; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; ImPACT Applications Inc, TECHN MAN ONL VERS 2; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kinnaman KA, 2013, ACTA PAEDIATR, V102, pE424, DOI 10.1111/apa.12315; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; National Federation of State High School Associations, HIGH SCH ATHL PART S; National Federation of State High School Associations, HIGH SCH PART INCR 2; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Richardson JTE, 2011, EDUC RES REV-NETH, V6, P135, DOI 10.1016/j.edurev.2010.12.001; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sandel NK, 2013, APPL NEUROPSYCH-CHIL, V2, P64, DOI 10.1080/21622965.2012.670580; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; US Lacrosse, 2013, US LACR PART SURV; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	59	26	26	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2017	45	4					937	944		10.1177/0363546516677246			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EP6MD	WOS:000397492700024	27940807				2021-06-18	
J	Venkataraman, A; Kalk, N; Sewell, G; Ritchie, CW; Lingford-Hughes, A				Venkataraman, Ashwin; Kalk, Nicola; Sewell, Gavin; Ritchie, Craig W.; Lingford-Hughes, Anne			Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?	ALCOHOL AND ALCOHOLISM			English	Article							TOLL-LIKE RECEPTORS; INNATE IMMUNE ACTIVATION; BINGE ETHANOL EXPOSURE; COGNITIVE DEFICITS; BRAIN-DAMAGE; MOUSE MODEL; BENZODIAZEPINE RECEPTORS; MICROGLIAL ACTIVATION; CONSUMPTION; INFLAMMATION	Aims: To investigate the underlying neurobiology between alcohol use, misuse and dependence and cognitive impairment, particularly Alzheimer's disease (AD). Methods: Review of the literature using searches of Medline, Pubmed, EMBASE, PsycInfo, and meeting abstracts and presentations. Results: The role of alcohol as a risk factor and contributor for cognitive decline associated with AD has received little attention. This is despite the high prevalence of alcohol use, the potential reversibility of a degree of cognitive impairment and the global burden of AD. Until now the focus has largely been on the toxic effects of alcohol, neuronal loss and the role of thiamine. Conclusion: We propose alcohol adds to the cognitive burden seen in dementia through additional mechanisms to neurodegenerative processes or may contribute at various mechanistic points in the genesis and sustenance of AD pathology via neuroinflammation. We describe the common underlying neurobiology in alcohol and AD, and examine ways alcohol likely contributes to neuroinflammation directly via stimulation of Toll-like receptors and indirectly from small bowel changes, hepatic changes, withdrawal and traumatic brain injury to the pathogenesis of AD. Short Summary: Alcohol use, misuse and dependence cause cognitive impairment. We propose alcohol adds to the cognitive burden seen in dementia through additional mechanisms to neurodegenerative processes or may contribute at various mechanistic points in the genesis and sustenance of AD pathology via neuroinflammation.	[Venkataraman, Ashwin; Kalk, Nicola; Lingford-Hughes, Anne] Imperial Coll London, Div Brain Sci, Neuropsychopharmacol Unit, Ctr Psychiat, 5th Floor Burlington Danes Bldg,160 Du Cane Rd, London W12 0NN, England; [Sewell, Gavin] Charing Cross Hosp, Dept Oncol, Fulham Palace Rd, London W6 8RF, England; [Ritchie, Craig W.] Univ Edinburgh, Ctr Clin Brain Sci, Chancellors Bldg,49 Chancellors Bldg, Edinburgh EH16 4SB, Midlothian, Scotland	Venkataraman, A (corresponding author), Imperial Coll London, Div Brain Sci, Neuropsychopharmacol Unit, Ctr Psychiat, 5th Floor Burlington Danes Bldg,160 Du Cane Rd, London W12 0NN, England.	a.venkataraman@imperial.ac.uk		Kalk, Nicola/0000-0002-3820-9243	GSKGlaxoSmithKline; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ARUK-PCRF2016A-2] Funding Source: researchfish	Dr Venkataraman reports grants from Alzheimer's Research UK, NIHR and BRC, outside the submitted work. He is working on a GSK funded study and receives no financial or other support from them. He receives non-financial support from Eli-Lilly. Dr Kalk reports previous support from Wellcome Trust, from GSK, other from the NIHR, during the past 36 months. Dr Sewell has nothing to declare. Prof. Ritchie has nothing to declare. Prof. Lingford-Hughes reports other from Wellcome Trust, other from GSK, non-financial support from Imanova, during the conduct of the study; grants, personal fees and non-financial support from Lundbeck, non-financial support from GSK, grants from NIHR RfPB & HTA, grants from MRC, grants from Imanova, outside the submitted work.	Agartz I, 1999, ARCH GEN PSYCHIAT, V56, P356, DOI 10.1001/archpsyc.56.4.356; Aho L, 2009, J NEUROSCI RES, V87, P2786, DOI 10.1002/jnr.22091; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alfonso-Loeches S, 2010, J NEUROSCI, V30, P8285, DOI 10.1523/JNEUROSCI.0976-10.2010; Cagnin A, 2006, GUT, V55, P547, DOI 10.1136/gut.2005.075051; Combs CK, 2001, J NEUROSCI, V21, P1179; Cunningham C, 2009, BIOL PSYCHIAT, V65, P304, DOI 10.1016/j.biopsych.2008.07.024; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Fernandez-Lizarbe S, 2008, MOL IMMUNOL, V45, P2007, DOI 10.1016/j.molimm.2007.10.025; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Gambuzza ME, 2014, CNS NEUROL DISORD-DR, V13, P1542, DOI 10.2174/1871527313666140806124850; Gonzalez-Quintela A, 2000, CYTOKINE, V12, P1437, DOI 10.1006/cyto.2000.0715; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Harwood DG, 2010, INT J GERIATR PSYCH, V25, P511, DOI 10.1002/gps.2372; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hommer D, 1996, ARCH NEUROL-CHICAGO, V53, P359, DOI 10.1001/archneur.1996.00550040099019; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Jana M, 2008, J IMMUNOL, V181, P7254, DOI 10.4049/jimmunol.181.10.7254; Laso FJ, 2007, ALCOHOL CLIN EXP RES, V31, P846, DOI 10.1111/j.1530-0277.2007.00377.x; Jin JJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-23; Kapaki E, 2005, INT J GERIATR PSYCH, V20, P722, DOI 10.1002/gps.1351; Karuppagounder SS, 2009, NEUROBIOL AGING, V30, P1587, DOI 10.1016/j.neurobiolaging.2007.12.013; Keogh B, 2011, TRENDS PHARMACOL SCI, V32, P435, DOI 10.1016/j.tips.2011.03.008; Khaw KT, 2008, PLOS MED, V5, P39, DOI 10.1371/journal.pmed.0050012; Kim SR, 2011, BMB REP, V44, P135, DOI 10.5483/BMBRep.2011.44.2.135; Kril JJ, 2012, NEUROPSYCHOL REV, V22, P72, DOI 10.1007/s11065-012-9195-0; Kuno R, 2005, J NEUROIMMUNOL, V162, P89, DOI 10.1016/j.jneuroim.2005.01.015; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Landreth GE, 2009, CURR TOP MICROBIOL, V336, P137, DOI 10.1007/978-3-642-00549-7_8; Li XW, 2015, FASEB J, V29, P1754, DOI 10.1096/fj.14-262683; Lingford-Hughes AR, 2000, ALCOHOL CLIN EXP RES, V24, P1449, DOI 10.1111/j.1530-0277.2000.tb02116.x; Liu SR, 2012, J IMMUNOL, V188, P1098, DOI 10.4049/jimmunol.1101121; Lotz M, 2005, J NEUROCHEM, V94, P289, DOI 10.1111/j.1471-4159.2005.03188.x; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Marshall SA, 2013, NEUROBIOL DIS, V54, P239, DOI 10.1016/j.nbd.2012.12.016; Marshall SA, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6020016; McClain CJ, 1999, SEMIN LIVER DIS, V19, P205, DOI 10.1055/s-2007-1007110; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; Minoretti P, 2006, NEUROSCI LETT, V391, P147, DOI 10.1016/j.neulet.2005.08.047; Moos RH, 2009, ADDICTION, V104, P1293, DOI 10.1111/j.1360-0443.2009.02604.x; Myint PK, 2011, AGE AGEING, V40, P589, DOI 10.1093/ageing/afr058; National Institute for Health and Care Excellence, 2006, NICE GUID CG42; National Institute for Health and Care Excellence, 2015, NICE GUID; NIXON SJ, 1994, ALCOHOL HEALTH RES W, V18, P228; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Pascual M, 2007, EUR J NEUROSCI, V25, P541, DOI 10.1111/j.1460-9568.2006.05298.x; Pascual M, 2015, NEUROPHARMACOLOGY, V89, P352, DOI 10.1016/j.neuropharm.2014.10.014; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; PFEFFERBAUM A, 1992, ALCOHOL CLIN EXP RES, V16, P1078, DOI 10.1111/j.1530-0277.1992.tb00702.x; Prince M, 2014, ALZHEIMERS DIS INT, V1, P104; Qin LY, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-10; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Rehm J, 2003, EUR ADDICT RES, V9, P147, DOI 10.1159/000072221; Rehm J, 2010, ADDICTION, V105, P817, DOI 10.1111/j.1360-0443.2010.02899.x; Richard KL, 2008, J NEUROSCI, V28, P5784, DOI 10.1523/JNEUROSCI.1146-08.2008; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Royal College of Psychiatrists, 2014, CR185 ROY COLL PSYCH, V1, P25; Rubio-Araiz A, 2016, ADDICT BIOL, P1; Sharp D, 2014, NEUROLOGY, V82; Sheng JG, 2003, NEUROBIOL DIS, V14, P133, DOI 10.1016/S0969-9961(03)00069-X; Song M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-92; SYAPIN PJ, 1988, EUR J PHARMACOL, V147, P101, DOI 10.1016/0014-2999(88)90638-3; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Todd KG, 1999, GLIA, V25, P190, DOI 10.1002/(SICI)1098-1136(19990115)25:2<190::AID-GLIA9>3.0.CO;2-B; Tsukahara M, 2005, J CEREBRAL BLOOD FLO, V25, pS370; Udan MLD, 2008, J NEUROCHEM, V104, P524, DOI 10.1111/j.1471-4159.2007.05001.x; URBANOMARQUEZ A, 1995, JAMA-J AM MED ASSOC, V274, P149, DOI 10.1001/jama.274.2.149; Valles SL, 2004, BRAIN PATHOL, V14, P365; Walter S, 2007, CELL PHYSIOL BIOCHEM, V20, P947, DOI 10.1159/000110455; Wang DM, 2010, BIOCHEM BIOPH RES CO, V402, P123, DOI 10.1016/j.bbrc.2010.09.128; Ward RJ, 2009, ALCOHOL ALCOHOLISM, V44, P128, DOI 10.1093/alcalc/agn100; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; WHO (World Health Organization), 2015, GLOB STAT REP ROAD S; Wilsnack SC, 2013, ALCOHOL RES-CURR REV, V35, P219; Wilson K, 2012, ALCOHOL ALCOHOLISM, V47, P304, DOI 10.1093/alcalc/agr167; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yaghmoor F., 2014, J ALZHEIMERS DIS PAR, V4, P1; Zilkens RR, 2014, CURR ALZHEIMER RES, V11, P681, DOI 10.2174/1567205011666140812115004	81	26	26	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0735-0414	1464-3502		ALCOHOL ALCOHOLISM	Alcohol Alcohol.	MAR	2017	52	2					151	158		10.1093/alcalc/agw092			8	Substance Abuse	Substance Abuse	EQ4CZ	WOS:000398022700004	27915236	Bronze			2021-06-18	
J	Chien, CY; Chen, YH; Han, ST; Blaney, GN; Huang, TS; Chen, KF				Chien, Chih-Ying; Chen, Yu-Hsien; Han, Shih-Tsung; Blaney, Gerald N.; Huang, Ting-Shuo; Chen, Kuan-Fu			The number of displaced rib fractures is more predictive for complications in chest trauma patients	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Rib Fractures; Displaced Rib Fractures; Complications; Chest Trauma; Prognosis; Sensitivity and Specificity; Hospitalization	ACUTE PAIN MANAGEMENT; SEVERITY SCORE; THORACIC TRAUMA; MORTALITY; MORBIDITY; INJURY	Background: Traumatic rib fractures can cause chest complications that need further treatment and hospitalization. We hypothesized that an increase in the number of displaced rib fractures will be accompanied by an increase in chest complications. Methods: We retrospectively reviewed the trauma registry between January 2013 and May 2015 in a teaching hospital in northeastern Taiwan. Patients admitted with chest trauma and rib fractures without concomitant severe brain, splenic, pelvic or liver injuries were included. The demographic data, such as gender, age, the index of coexistence disease, alcohol consumption, trauma mechanisms were analyzed as potential predictors of pulmonary complications. Pulmonary complications were defined as pneumothorax, hemothorax, flail chest, pulmonary contusion, and pneumonia. Results: In the 29 months of the study period, a total of 3151 trauma patients were admitted to our hospital. Among them, 174 patients were enrolled for final analysis. The most common trauma mechanism was road traffic accidents (58.6%), mainly motorbike accidents (n = 70, 40.2%). Three or more displaced rib fractures had higher specificity for predicting complications, compared to three or more total rib fractures (95.5% vs 59.1%). Adjusting the severity of chest trauma using TTSS and Ribscore by multivariable logistic regression analysis, we found that three or more rib fractures or any displaced rib fracture was the most significant predictor for developing pulmonary complication (aOR: 5.49 95% CI: 1.82-16.55). Furthermore, there were 18/57 (31.6%) patients with fewer than three ribs fractures developed pulmonary complications. In these 18 patients, only five patients had delayed onset complications and four of them had at least one displaced rib fracture. Discussion: In this retrospective cohort study, we found that the number of displaced or total rib fractures, bilateral rib fractures, and rib fractures in more than two areas were associated with the more chest complications. Furthermore, three or more rib fracture or any displacement were found to be the most sensitive risk factor for chest complications, independent of other risk factors or severity index. Conclusion: The number of displaced rib fractures could be a strong predictor for developing pulmonary complications. For patients with fewer than three rib fractures without rib displacement and initial lung or other organ injuries, outpatient management could be safe and efficient.	[Chien, Chih-Ying; Chen, Yu-Hsien; Blaney, Gerald N.; Huang, Ting-Shuo] Chang Gung Mem Hosp, Dept Gen Surg, Keelung, Taiwan; [Han, Shih-Tsung] Chang Gung Mem Hosp, Dept Emergency Med, Linkou, Taiwan; [Chen, Kuan-Fu] Chang Gung Mem Hosp, Dept Emergency Med, Keelung, Taiwan; [Chen, Kuan-Fu] Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan; [Chen, Kuan-Fu] Chang Gung Mem Hosp, Community Med Res Ctr, Keelung, Taiwan	Chen, KF (corresponding author), Chang Gung Mem Hosp, Dept Emergency Med, Keelung, Taiwan.; Chen, KF (corresponding author), Chang Gung Univ, Clin Informat & Med Stat Res Ctr, Taoyuan, Taiwan.; Chen, KF (corresponding author), Chang Gung Mem Hosp, Community Med Res Ctr, Keelung, Taiwan.	kfchen@cgmh.org.tw		Clark, Andrea/0000-0002-4269-5547; Huang, Ting-Shuo/0000-0002-2932-6878	National Science Council and Chang Gung Memorial Hospital in Taiwan [100-2314-B-182A-038-MY3, CMRPG2C0201, CMRPG2B0123, CMRPG2B0273, CIRPG2E0022, CMRPG2B0373]	The study was supported by the National Science Council and Chang Gung Memorial Hospital in Taiwan (100-2314-B-182A-038-MY3, CMRPG2C0201, CMRPG2B0123, CMRPG2B0273, CIRPG2E0022 and CMRPG2B0373). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aukema TS, 2011, OPEN ACCESS EMERG M, V3, P49, DOI 10.2147/OAEM.S22802; Martinez RJA, 2013, ARCH BRONCONEUMOL, V49, P177, DOI 10.1016/j.arbres.2012.12.005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Battle CE, 2012, INJURY, V43, P8, DOI 10.1016/j.injury.2011.01.004; Ceran S, 2002, EUR J CARDIO-THORAC, V21, P57, DOI 10.1016/S1010-7940(01)01056-9; Chapman BC, 2016, J TRAUMA ACUTE CARE, V80, P95, DOI 10.1097/TA.0000000000000867; Daurat A, 2016, INJURY, V47, P147, DOI 10.1016/j.injury.2015.08.031; Dreizin D, 2012, RADIOGRAPHICS, V32, P609, DOI 10.1148/rg.323115099; Ho AMH, 2011, CURR OPIN CRIT CARE, V17, P323, DOI 10.1097/MCC.0b013e328348bf6f; JORGENSEN K, 1981, ACTA ORTHOP SCAND, V52, P273, DOI 10.3109/17453678109050103; Karmakar MK, 2003, J TRAUMA, V54, P615, DOI 10.1097/01.TA.0000053197.40145.62; Liman ST, 2003, EUR J CARDIO-THORAC, V23, P374, DOI 10.1016/S1010-7940(02)00813-8; Livingston DH, 2008, J TRAUMA, V64, P905, DOI 10.1097/TA.0b013e3181668ad7; Miskulin DC, 2001, KIDNEY INT, V60, P1498, DOI 10.1046/j.1523-1755.2001.00954.x; Pape HC, 2000, J TRAUMA, V49, P496, DOI 10.1097/00005373-200009000-00018; POOLE GV, 1981, ANN SURG, V193, P70, DOI 10.1097/00000658-198101000-00012; Simon BJ, 1998, J TRAUMA, V45, P673, DOI 10.1097/00005373-199810000-00005; Sirmali M, 2003, EUR J CARDIO-THORAC, V24, P133, DOI 10.1016/S1010-7940(03)00256-2; Subcommittee A, 2013, J TRAUMA ACUTE CARE, V74, P1363; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; WILSON RF, 1977, SURG CLIN N AM, V57, P17; ZIEGLER DW, 1994, J TRAUMA, V37, P975, DOI 10.1097/00005373-199412000-00018	22	26	28	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	FEB 28	2017	25								19	10.1186/s13049-017-0368-y			10	Emergency Medicine	Emergency Medicine	EM5GY	WOS:000395341200001	28241883	DOAJ Gold, Green Published			2021-06-18	
J	Burger, N; Lambert, MI; Viljoen, W; Brown, JC; Readhead, C; den Hollander, S; Hendricks, S				Burger, Nicholas; Lambert, Mike Ian; Viljoen, Wayne; Brown, James Craig; Readhead, Clint; den Hollander, Steve; Hendricks, Sharief			Mechanisms and Factors Associated With Tackle-Related Injuries in South African Youth Rugby Union Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						tackle; rugby injuries; youth rugby; etiology	CERVICAL-SPINE INJURIES; HIGH-SCHOOL; CONSENSUS STATEMENT; AMERICAN FOOTBALL; INCIDENT ANALYSIS; VIDEO ANALYSIS; EPIDEMIOLOGY; HEAD; CONCUSSIONS; CONTACT	Background: The majority of injuries in rugby union occur during tackle events. The mechanisms and causes of these injuries are well established in senior rugby union. Purpose: To use information from an injury database and assess video footage of tackle-related injuries in youth rugby union matches to identify environmental factors and mechanisms that are potentially confounding to these injuries. Study Design: Descriptive epidemiological study. Methods: Injury surveillance was conducted at the under-18 Craven Week rugby tournament. Tackle-related injury information was used to identify injury events in match video footage (role-matched noninjury tackle events were identified for the cohort of injured players). Events were coded using match situational variables (precontact, contact, and postcontact). Relative risk ratio (RRR; ratio of probability of an injury or noninjury outcome occurring when a characteristic was observed) was reported by use of logistic regression. Results: In comparison with the first quarter, injury risk was greater in the third (RRR = 9.75 [95% CI, 1.71-55.64]; P = .010) and fourth quarters (RRR = 6.97 [95% CI, 1.09-44.57]; P = .040) for ball carriers and in the fourth quarter (RRR = 9.63 [95% CI, 1.94-47.79]; P = .006) for tacklers. Ball carriers were less likely to be injured when they were aware of impending contact (RRR = 0.14 [95% CI, 0.03-0.66]; P = .012) or when they executed a moderate fend (hand-off) (RRR = 0.22 [95% CI, 0.06-0.84]; P = .026). Tacklers were less likely to be injured when performing shoulder tackles (same side as leading leg) in comparison to an arm-only tackle (RRR = 0.02 [95% CI, 0.001-0.79]; P = .037). Ball carriers (RRR = 0.09 [95% CI, 0.01-0.89]; P = .040) and tacklers (RRR = 0.02 [95% CI, 0.001-0.32]; P =.006) were less likely to be injured when initial contact was made with the tackler's shoulder/arm instead of his head/neck. Conclusion: The relative risk of tackle-related injury was higher toward the end of matches. Incorrect technique may contribute to increased injury risk. Implementing recovery strategies between matches, training safe and effective techniques, and improving levels of conditioning may counter the negative effects of fatigue. These findings may assist stakeholders in youth rugby to formulate injury prevention strategies and may improve the preparation of field-side medical staff for managing tackle-related injuries at these or similar tournaments.	[Burger, Nicholas; Lambert, Mike Ian; Viljoen, Wayne; Brown, James Craig; Readhead, Clint; den Hollander, Steve; Hendricks, Sharief] Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, Boundary Rd, ZA-7725 Cape Town, WP, South Africa; [Viljoen, Wayne; Readhead, Clint] South African Rugby Union SA Rugby, Cape Town, South Africa; [Lambert, Mike Ian; Brown, James Craig] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Lambert, Mike Ian; Brown, James Craig] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Hendricks, Sharief] Leeds Beckett Univ, Ctr Sport Performance, Inst Sport Phys Act & Leisure, Sch Sport, Fairfax Hall,Headingley Campus, Leeds, W Yorkshire, England	Burger, N (corresponding author), Univ Cape Town, Div Exercise Sci & Sports Med, Dept Human Biol, Fac Hlth Sci, Boundary Rd, ZA-7725 Cape Town, WP, South Africa.	nicholas.burger@uct.ac.za	Hendricks, Sharief/U-3278-2019; Brown, James Craig/H-7637-2019	Hendricks, Sharief/0000-0002-3416-6266; Brown, James Craig/0000-0002-7778-7783; Viljoen, Wayne/0000-0002-9432-6153; den Hollander, Steve/0000-0002-6064-038X	National Research Foundation (Scarce Skills Development Fund Doctoral Scholarship)	One or more of the authors has declared the following potential conflict of interest or source of funding: Funding for N.B. was provided by the National Research Foundation (Scarce Skills Development Fund Doctoral Scholarship). The injury data and video footage used in this study were provided by SA Rugby and the BokSmart National Rugby Safety Programme. C.R. is the senior medical manager and W.V. is the senior rugby safety manager at SA Rugby. No payment was received from SA Rugby for formulating this manuscript.	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Balague N, 2013, J SYST SCI COMPLEX, V26, P4, DOI 10.1007/s11424-013-2285-0; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Brown JC, 2012, S AFR J SPORTS MED, V24, P49; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Burger N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005556; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; COUNCIL SPORTS MED FITNESS, 2015, PEDIATRICS, V136, pE1419, DOI 10.1542/peds.2015-3282; Emery CA, 2010, BRIT J SPORT MED, V44, P555, DOI 10.1136/bjsm.2010.074377; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gabbett TJ, 2011, J STRENGTH COND RES, V25, P72, DOI 10.1519/JSC.0b013e3181ff506f; Gabbett TJ, 2009, J STRENGTH COND RES, V23, P540, DOI 10.1519/JSC.0b013e31818efe8b; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Heck JF, 2004, J ATHL TRAINING, V39, P101; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2013, PERCEPT MOTOR SKILL, V117, P65, DOI 10.2466/30.25.PMS.117x17z6; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Institute for Digital Research and Education University of California Los Angeles, STAT ANN OUTP MULT L; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; King D, 2012, RES SPORTS MED, V20, P86, DOI 10.1080/15438627.2012.660824; Knowles SB, 2009, EPIDEMIOLOGY, V20, P302, DOI 10.1097/EDE.0b013e318193107c; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGuine TA, 2014, AM J SPORT MED, V42, P2470, DOI 10.1177/0363546514541926; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McKay CD, 2014, BRIT J SPORT MED, V48, P57, DOI 10.1136/bjsports-2013-092860; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Nicol A, 2011, J PUBLIC HEALTH-UK, V33, P256, DOI 10.1093/pubmed/fdq047; O'Donoghue P., 2010, RES METHODS PERFORMA; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; Orchard J, 2002, BRIT J SPORT MED, V36, P270, DOI 10.1136/bjsm.36.4.270; Palmer-Green DS, 2013, AM J SPORT MED, V41, P749, DOI 10.1177/0363546512473818; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; Roberts SP, 2015, BRIT J SPORT MED, V49, P536, DOI 10.1136/bjsports-2013-092988; Salces JN, 2014, J SPORT SCI, V32, P1263, DOI 10.1080/02640414.2014.884720; Sparks J P, 1985, Br J Sports Med, V19, P71; Torg JS, 2002, J BONE JOINT SURG AM, V84A, P112, DOI 10.2106/00004623-200201000-00017; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278; Viljoen W, 2012, SA RUGBY BOKSMART SA; Wheeler K, 2009, INT J SPORTS SCI COA, V4, P535, DOI 10.1260/174795409790291420; Wheeler KW, 2010, J SPORT SCI MED, V9, P445; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1; Willigenburg NW, 2016, AM J SPORT MED, V44, P753, DOI 10.1177/0363546515622389; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9; World Rugby Training and Education, RUGB READ COLL RESP	62	26	26	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2017	45	2					278	285		10.1177/0363546516677548			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	EL7BU	WOS:000394776900002	28125898				2021-06-18	
J	Ding, H; Wang, HD; Zhu, L; Wei, WT				Ding, Hui; Wang, Handong; Zhu, Lin; Wei, Wuting			Ursolic Acid Ameliorates Early Brain Injury After Experimental Traumatic Brain Injury in Mice by Activating the Nrf2 Pathway	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Nrf2; Ursolic acid; Neuroprotection	OXIDATIVE STRESS; SUBARACHNOID HEMORRHAGE; ANTIOXIDANT ENZYMES; DAMAGE; MODEL; NEUROPROTECTION; EXPRESSION; APOPTOSIS; PROTECTS; FIBROSIS	Previous studies have indicated oxidative stress and inflammatory injury as significant contributors to the secondary damage associated with traumatic brain injury (TBI). Ursolic acid (UA) has been demonstrated to exert anti-oxidative and anti-inflammatory effects on cerebral ischemia by activating the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway. However, the effects of UA on TBI remain unclear. The aim of this study is to evaluate the potential roles of UA in the activation of the Nrf2 pathway using an experimental TBI model and the underlying mechanism. Wild-type (WT) and Nrf2((-/-)) mice were divided into eight groups: (1) sham; (2) TBI; (3) TBI + vehicle; (4) TBI + 50 mg/kg UA; (5) TBI + 100 mg/kg UA; (6) TBI + 150 mg/kg UA; (7) TBI + Nrf2((-/-)) + vehicle; (8) TBI + Nrf2((-/-)) + UA. All mice underwent the TBI with the exception of the sham group. The neurologic outcomes of the mice were evaluated at 24 h after TBI, as well as the expression of Nrf2, NQO1, HO1,SOD, GPx, and MDA. Treatment of UA significantly ameliorated brain edema and the neurological insufficiencies after TBI. In addition, UA treatment markedly strengthened the nuclear translocation of Nrf2 protein and increased the expression of NQO1 and HO1. Moreover, UA significantly increased the expression of AKT, an Nrf2 upstream factor, suggesting that UA play a neuroprotective role through the activation of the Nrf2-ARE signal pathway. On the contrary, UA showed no neuroprotective effect on the Nrf2((-/-)) mice. These data indicated that UA increases the activity of antioxidant enzymes and attenuated brain injury via Nrf2 factor.	[Ding, Hui; Wang, Handong; Zhu, Lin; Wei, Wuting] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81371357]	This study was grant-supported by the National Natural Science Fund of China (Grant No. 81371357).	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Baskaran R, 2016, BIOMED PHARMACOTHER, V83, P1407, DOI 10.1016/j.biopha.2016.08.063; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cui T, 2006, J AGR FOOD CHEM, V54, P4574, DOI 10.1021/jf060310m; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Kandhare AD, 2015, CHEM-BIOL INTERACT, V237, P151, DOI 10.1016/j.cbi.2015.06.019; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Lee J, 2014, INDIAN J EXP BIOL, V52, P683; Lee YJ, 2012, FOOD CHEM TOXICOL, V50, P116, DOI 10.1016/j.fct.2011.10.035; Li LT, 2013, BRAIN RES, V1497, P32, DOI 10.1016/j.brainres.2012.12.032; Liu D., 2016, ONCOTARGET; Liu WB, 2012, MOLECULES, V17, P9104, DOI 10.3390/molecules17089104; Ma JQ, 2015, CLIN RES HEPATOL GAS, V39, P188, DOI 10.1016/j.clinre.2014.09.007; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang XM, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/419343; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072528; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang Y, 2014, J MOL CELL CARDIOL, V67, P103, DOI 10.1016/j.yjmcc.2013.12.018; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang TT, 2014, INT IMMUNOPHARMACOL, V23, P585, DOI 10.1016/j.intimp.2014.10.009	35	26	28	0	10	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	FEB	2017	42	2					337	346		10.1007/s11064-016-2077-8			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EM9GY	WOS:000395621100002	27734181				2021-06-18	
J	Jokar, A; Ahmadi, K; Salehi, T; Sharif-Alhoseini, M; Rahimi-Movaghar, V				Jokar, Abolfazl; Ahmadi, Koorosh; Salehi, Tayyebeh; Sharif-Alhoseini, Mahdi; Rahimi-Movaghar, Vafa			The effect of tranexamic acid in traumatic brain injury: A randomized controlled trial	CHINESE JOURNAL OF TRAUMATOLOGY			English	Article						Traumatic brain injuries; Intracranial hemorrhage; Traumatic; Tranexamic acid	HEMORRHAGE; CRASH-2	Purpose: Traumatic brain injury (TBI) is a leading cause of death and disability. Intracranial hemorrhage (ICH) secondary to TBI is associated with a high risk of coagulopathy which leads to increasing risk of hemorrhage growth and higher mortality rate. Therefore, antifibrinolytic agents such as tranexamic acid (TA) might reduce traumatic ICH. The aim of the present study was to investigate the extent of ICH growth after TA administration in TBI patients. Methods: This single-blind randomized controlled trial was conducted on patients with traumatic ICH (with less than 30 ml) referring to the emergency department of Vali-Asr Hospital, Arak, Iran in 2014. Patients, based on the inclusion and exclusion criteria, were divided into intervention and control groups (40 patients each). All patients received a conservative treatment for ICH, as well as either intravenous TA or placebo. The extent of ICH growth as the primary outcome was measured by brain CT scan after 48 h. Results: Although brain CT scan showed a significant increase in hemorrhage volume in both groups after 48 h, it was significantly less in the TA group than in the control group (p = 0.04). The mean total hemorrhage expansion was (1.7 +/- 9.7) ml and (4.3 +/- 12.9) ml in TA and placebo groups, respectively (p < 0.001). Conclusion: It has been established that TA, as an effective hospital-based treatment for acute TBI, could reduce ICH growth. Larger studies are needed to compare the effectiveness of different doses. (c) 2017 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Production and hosting by Elsevier B.V.	[Jokar, Abolfazl; Salehi, Tayyebeh] Arak Univ Med Sci, Dept Emergency Med, Arak, Iran; [Ahmadi, Koorosh] Alborz Univ Med Sci, Dept Emergency Med, Karaj, Iran; [Sharif-Alhoseini, Mahdi; Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran; [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Shariati Hosp, Dept Neurosurg, Tehran, Iran	Rahimi-Movaghar, V (corresponding author), Sina Hosp, Sina Trauma & Surg Res Ctr, Hassan Abad Sq,Imam Khomeini Ave, Tehran, Iran.	v_rahimi@sina.tums.ac.ir	Rahimi-Movaghar, Vafa/L-6339-2019; Ahmadi, Koorosh/AAF-7559-2020		Arak University of Medical Sciences [806]	This study was supported by Arak University of Medical Sciences (Grant No. 806).	[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Epstein DS, 2015, BRIT J NEUROSURG, V29, P118, DOI 10.3109/02688697.2014.950632; French KF, 2012, NEUROCRIT CARE, V17, P107, DOI 10.1007/s12028-012-9681-5; Gruen RL, 2011, LANCET, V377, P1052, DOI 10.1016/S0140-6736(11)60396-6; Harvey V, 2014, ANN EMERG MED, V63, P460, DOI 10.1016/j.annemergmed.2013.08.028; Lipsky AM, 2014, INJURY, V45, P66, DOI 10.1016/j.injury.2013.08.025; Liu Lin-tao, 2006, Chin J Traumatol, V9, P249; Meretoja A, 2014, INT J STROKE, V9, P519, DOI 10.1111/ijs.12132; Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Rahimi-Movaghar V, 2011, AM SURGEON, V77, pE112; Roberts I, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5839; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Specogna AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096743; Valle EJ, 2014, J TRAUMA ACUTE CARE, V76, P1373, DOI 10.1097/TA.0000000000000242; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2015, AM J EMERG MED, V33, P458, DOI 10.1016/j.ajem.2014.11.009; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023	20	26	26	0	2	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	1008-1275			CHIN J TRAUMATOL	Chin. J. Traumatol.	FEB	2017	20	1					49	51		10.1016/j.cjtee.2016.02.005			3	Orthopedics	Orthopedics	GQ9PH	WOS:000442113000011	28209450	DOAJ Gold, Green Published			2021-06-18	
J	Liu, ZY; Pouli, D; Sood, D; Sundarakrishnan, A; Mingalone, CKH; Arendt, LM; Alonzo, C; Quinn, KP; Kuperwasser, C; Zeng, L; Schnelldorfer, T; Kaplan, DL; Georgakoudi, I				Liu, Zhiyi; Pouli, Dimitra; Sood, Disha; Sundarakrishnan, Aswin; Mingalone, Carrie K. Hui; Arendt, Lisa M.; Alonzo, Carlo; Quinn, Kyle P.; Kuperwasser, Charlotte; Zeng, Li; Schnelldorfer, Thomas; Kaplan, David L.; Georgakoudi, Irene			Automated quantification of three-dimensional organization of fiber-like structures in biological tissues	BIOMATERIALS			English	Article						Three-dimensional organization; Collagen fiber; Neuronal axon; Cancer; Traumatic brain injury; Multi-photon microscopy	VIVO MULTIPHOTON MICROSCOPY; TRAUMATIC BRAIN-INJURY; 2ND-HARMONIC GENERATION; EXTRACELLULAR-MATRIX; IMAGING MICROSCOPY; PANCREATIC-CANCER; STEM-CELLS; COLLAGEN; PROGRESSION; FIBROBLASTS	Fiber-like structures are prevalent in biological tissues, yet quantitative approaches to assess their three-dimensional (3D) organization are lacking. We develop 3D directional variance, as a quantitative biomarker of truly 3D fibrillar organization by extending the directional statistics formalism developed for describing circular data distributions (i.e. when 0 degrees and 360 degrees are equivalent) to axial ones (i.e. when 0 degrees and 180 degrees are equivalent). Significant advantages of this analysis include its time efficiency, sensitivity and ability to provide quantitative readouts of organization over different size scales of a given data set. We establish a broad range of applications for this method by characterizing collagen fibers, neuronal axons and fibroblasts in the context of cancer diagnostics, traumatic brain injury and cell-matrix interactions in developing engineered tissues. This method opens possibilities for unraveling in a sensitive, and quantitative manner the organization of essential fiber-like structures in tissues and ultimately its impact on tissue function. (C) 2016 Elsevier Ltd. All rights reserved.	[Liu, Zhiyi; Pouli, Dimitra; Sood, Disha; Sundarakrishnan, Aswin; Alonzo, Carlo; Quinn, Kyle P.; Kaplan, David L.; Georgakoudi, Irene] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Mingalone, Carrie K. Hui; Arendt, Lisa M.; Kuperwasser, Charlotte; Zeng, Li] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA; [Schnelldorfer, Thomas] Lahey Hosp & Med Ctr, Burlington, MA 01805 USA; [Quinn, Kyle P.] Univ Arkansas, Dept Biomed Engn, Fayetteville, AR 72701 USA		Irene.Georgakoudi@tufts.edu		Arendt, Lisa/0000-0002-7954-3635; Sundarakrishnan, Aswin/0000-0002-2672-7780	American Cancer SocietyAmerican Cancer Society [RSG-09-174-01-CCE]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH/NIBIB P41EB002520, NIH R01NS092847, NIH/NIBIB R00EB017723, NIH/NCI CA170851, NIH F31AR067638-01A1]; Tufts University; Raymond & Beverly Sackler Convergence Lab; Breast Cancer Research Foundation; Alexander S. Onassis Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA170851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [F31AR067638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520, R00EB017723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092847] Funding Source: NIH RePORTER	This study was supported by the American Cancer Society (RSG-09-174-01-CCE to I.G.), the National Institutes of Health (NIH/NIBIB P41EB002520 to D.L.K., NIH R01NS092847 to D.L.K., NIH/NIBIB R00EB017723 to K.P.Q., NIH/NCI CA170851 to C.K. and NIH F31AR067638-01A1 to C.K.H.M.), Tufts University (Tufts Collaborates awards to T.S., L.Z. and I.G.), Raymond & Beverly Sackler Convergence Lab, the Breast Cancer Research Foundation and the Alexander S. Onassis Foundation. We acknowledge valuable help and support from Dr. Michael Whalen from the Massachusetts General Hospital in establishing the in vitro brain TBI model.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Altendorf H, 2012, J MICROSC-OXFORD, V247, P161, DOI 10.1111/j.1365-2818.2012.03629.x; Ambekar R, 2012, BIOMED OPT EXPRESS, V3, P2021, DOI 10.1364/BOE.3.002021; Balu M, 2015, JAMA DERMATOL, V151, P1068, DOI 10.1001/jamadermatol.2015.0453; Balu M, 2014, CANCER RES, V74, P2688, DOI 10.1158/0008-5472.CAN-13-2582; Barnes C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093325; Bayan C, 2009, J APPL PHYS, V105, DOI 10.1063/1.3116626; Birk JW, 2014, DIGEST DIS SCI, V59, P1529, DOI 10.1007/s10620-014-3121-7; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894; Choi SH, 2014, NATURE, V515, P274, DOI 10.1038/nature13800; Chwalek K, 2015, NAT PROTOC, V10, P1362, DOI 10.1038/nprot.2015.091; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; Dedinaite A, 2012, SOFT MATTER, V8, P273, DOI 10.1039/c1sm06335a; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Hanley CJ, 2016, ONCOTARGET, V7, P6159, DOI 10.18632/oncotarget.6740; Hirokawa N, 2010, NEURON, V68, P610, DOI 10.1016/j.neuron.2010.09.039; HOLBROOK KA, 1982, J INVEST DERMATOL, V79, pS7, DOI 10.1111/1523-1747.ep12544609; Hughes L C, 2005, Eur Cell Mater, V9, P68; Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di; Ingber DE, 2008, SEMIN CANCER BIOL, V18, P356, DOI 10.1016/j.semcancer.2008.03.016; Lau TY, 2012, OPT EXPRESS, V20, P21821, DOI 10.1364/OE.20.021821; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li MY, 2005, BIOMATERIALS, V26, P5999, DOI 10.1016/j.biomaterials.2005.03.030; Liu ZY, 2015, BIOMED OPT EXPRESS, V6, P2294, DOI 10.1364/BOE.6.002294; Mardia KV., 2000, DIRECTIONAL STAT; Nadiarnykh O, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-94; Napadow VJ, 2001, BIOPHYS J, V80, P2968, DOI 10.1016/S0006-3495(01)76262-5; Nieminen MT, 2001, MAGN RESON MED, V46, P487, DOI 10.1002/mrm.1218; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Perentes JY, 2009, NAT METHODS, V6, P143, DOI [10.1038/NMETH.1295, 10.1038/nmeth.1295]; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Quinn KP, 2015, EXP DERMATOL, V24, P78, DOI 10.1111/exd.12553; Quinn KP, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.4.046003; Robertson C, 2013, BIOMATERIALS, V34, P6127, DOI 10.1016/j.biomaterials.2013.04.019; Roy P, 2002, NAT CELL BIOL, V4, pE91, DOI 10.1038/ncb0402-e91; Schnelldorfer T, 2008, ANN SURG, V247, P456, DOI 10.1097/SLA.0b013e3181613142; Schriefl AJ, 2012, J R SOC INTERFACE, V9, P1275, DOI 10.1098/rsif.2011.0727; Tang-Schomer MD, 2014, P NATL ACAD SCI USA, V111, P13811, DOI 10.1073/pnas.1324214111; TINGSTROM A, 1992, J CELL SCI, V102, P315; Whatcott CJ, 2015, CLIN CANCER RES, V21, P3561, DOI 10.1158/1078-0432.CCR-14-1051; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zamir E, 2000, NAT CELL BIOL, V2, P191; Zemel A, 2010, NAT PHYS, V6, P468, DOI 10.1038/NPHYS1613; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	54	26	28	0	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	FEB	2017	116						34	47		10.1016/j.biomaterials.2016.11.041			14	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	EI7MC	WOS:000392681100004	27914265	Green Accepted			2021-06-18	
J	Michailidou, I; Naessens, DMP; Hametner, S; Guldenaar, W; Kooi, EJ; Geurts, JJG; Baas, F; Lassmann, H; Ramaglia, V				Michailidou, Iliana; Naessens, Daphne M. P.; Hametner, Simon; Guldenaar, Willemijn; Kooi, Evert-Jan; Geurts, Jeroen J. G.; Baas, Frank; Lassmann, Hans; Ramaglia, Valeria			Complement C3 on Microglial Clusters in Multiple Sclerosis Occur in Chronic but Not Acute Disease: Implication for Disease Pathogenesis	GLIA			English	Article						microglia; pathology; lesions	TRAUMATIC BRAIN-INJURY; WHITE-MATTER; SYSTEMIC INFLAMMATION; LESIONS; ACTIVATION; HETEROGENEITY; EXPRESSION; ANTIBODIES; RECOVERY; ABILITY	Microglial clusters with C3d deposits are observed in the periplaque of multiple sclerosis (MS) brains and were proposed as early stage of lesion formation. As such they should appear in the brain of MS donors with acute disease but thus far this has not been shown. Using postmortem brain tissue from acute (n=10) and chronic (n=15) MS cases we investigated whether C3d+ microglial clusters are part of an acute attack against myelinated axons, which could have implications for disease pathogenesis. The specificity of our findings to MS was tested in ischemic stroke cases (n=8) with initial or advanced lesions and further analyzed in experimental traumatic brain injury (TBI, n=26), as both conditions are primarily nondemyelinating but share essential features of neurodegeneration with MS lesions. C3d+ microglial clusters were found in chronic but not acute MS. They were not associated with antibody deposits or terminal complement activation. They were linked to slowly expanding lesions, localized on axons with impaired transport and associated with neuronal C3 production. C3d+ microglial clusters were not specific to MS as they were also found in stroke and experimental TBI. We conclude that C3d+ microglial clusters in MS are not part of an acute attack against myelinated axons. As such it is unlikely that they drive formation of new lesions but could represent a physiological mechanism to remove irreversibly damaged axons in chronic disease.	[Michailidou, Iliana; Naessens, Daphne M. P.; Baas, Frank; Ramaglia, Valeria] Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 Amsterdam, Netherlands; [Hametner, Simon; Lassmann, Hans] Med Univ Vienna, Dept Neuroimmunol, Ctr Brain Res, Spitalgasse 4, A-1090 Vienna, Austria; [Guldenaar, Willemijn; Kooi, Evert-Jan; Geurts, Jeroen J. G.] Vrije Univ Amsterdam Med Ctr, Dept Anat & Neurosci, De Boelelaan 1118, NL-1081 Amsterdam, Netherlands	Ramaglia, V (corresponding author), Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 Amsterdam, Netherlands.	v.ramaglia@amc.uva.nl	Lassmann, Hans/Z-2269-2019; Baas, Frank/F-9574-2010	Lassmann, Hans/0000-0001-8617-5052; Baas, Frank/0000-0003-3912-5428; Naessens, Daphne/0000-0001-7898-2559	Boehringer Ingelheim FondsBoehringer Ingelheim; Stichting MS Research travel grant [ES63]; National Multiple Sclerosis Society grantNational Multiple Sclerosis Society [RG 4775A1/1]; Brain Foundation of the Netherlands Fellowship [F2010(1)-05]	This work was funded by the Boehringer Ingelheim Fonds travel grant to I.M.; the Stichting MS Research travel grant no. ES63 to I.M.; the National Multiple Sclerosis Society grant no. RG 4775A1/1 to F.B. and V.R.; the Brain Foundation of the Netherlands Fellowship F2010(1)-05 to V.R.	Barnett MH, 2009, ANN NEUROL, V65, P32, DOI 10.1002/ana.21524; Budde BS, 2008, NAT GENET, V40, P1113, DOI 10.1038/ng.204; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Groot CJA, 2001, BRAIN, V124, P1635, DOI 10.1093/brain/124.8.1635; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Frischer JM, 2015, ANN NEUROL, V78, P710, DOI 10.1002/ana.24497; Frischer JM, 2009, BRAIN, V132, P1175, DOI 10.1093/brain/awp070; Geurts JJG, 2012, LANCET NEUROL, V11, P1082, DOI 10.1016/S1474-4422(12)70230-2; Geurts JJG, 2003, BRAIN, V126, P1755, DOI 10.1093/brain/awg179; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Hendriks JJA, 2005, BRAIN RES REV, V48, P185, DOI 10.1016/j.brainresrev.2004.12.008; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; King G, 1997, J PATHOL, V183, P237, DOI 10.1002/(SICI)1096-9896(199710)183:2<237::AID-PATH893>3.0.CO;2-0; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Lassmann H, 2015, NEUROINFLAMMATION: NEW INSIGHTS INTO BENEFICIAL AND DETRIMENTAL FUNCTIONS, P3; Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903; Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018; Liu GJ, 2009, EUR J NEUROSCI, V29, P1108, DOI 10.1111/j.1460-9568.2009.06659.x; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Marburg O., 1906, JB PSYCHIAT, V27, P211; Mena H, 2004, ACTA NEUROPATHOL, V108, P524, DOI 10.1007/s00401-004-0918-z; Metz I, 2014, ANN NEUROL, V75, P728, DOI 10.1002/ana.24163; Michailidou I, 2015, ANN NEUROL, V77, P1007, DOI 10.1002/ana.24398; Misu T, 2013, ACTA NEUROPATHOL, V125, P815, DOI 10.1007/s00401-013-1116-7; Moreno B, 2011, ANN NEUROL, V70, P932, DOI 10.1002/ana.22550; Nakajima K, 2001, NEUROSCI LETT, V307, P171, DOI 10.1016/S0304-3940(01)01943-7; Nijland PG, 2014, GLIA, V62, P1125, DOI 10.1002/glia.22667; Palin K, 2008, NEUROBIOL DIS, V30, P19, DOI 10.1016/j.nbd.2007.11.012; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; PIDDLESDEN SJ, 1993, AM J PATHOL, V143, P555; Prineas JW, 2001, ANN NEUROL, V50, P646, DOI 10.1002/ana.1255; Ramaglia V, 2012, P NATL ACAD SCI USA, V109, P965, DOI 10.1073/pnas.1111924109; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Ruseva MM, 2015, P NATL ACAD SCI USA, V112, P14319, DOI 10.1073/pnas.1513698112; Saper CB, 2003, J COMP NEUROL, V465, P161, DOI 10.1002/cne.10858; Singh S, 2013, ACTA NEUROPATHOL, V125, P595, DOI 10.1007/s00401-013-1082-0; Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; van der Valk P, 2009, CURR OPIN NEUROL, V22, P207, DOI 10.1097/WCO.0b013e32832b4c76; van Horssen J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-156; van Noort JM, 2010, J NEUROPATH EXP NEUR, V69, P694, DOI 10.1097/NEN.0b013e3181e4939c; VANGURI P, 1982, P NATL ACAD SCI-BIOL, V79, P3290, DOI 10.1073/pnas.79.10.3290	50	26	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2017	65	2					264	277		10.1002/glia.23090			14	Neurosciences	Neurosciences & Neurology	EK1ER	WOS:000393669100004	27778395	Green Published, Other Gold			2021-06-18	
J	Tamargo, IA; Bader, M; Li, YZ; Yu, SJ; Wang, Y; Talbot, K; DiMarchi, RD; Pick, CG; Greig, NH				Tamargo, Ian A.; Bader, Miaad; Li, Yazhou; Yu, Seong-Jin; Wang, Yun; Talbot, Konrad; DiMarchi, Richard D.; Pick, Chaim G.; Greig, Nigel H.			Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neurodegeneration; Incretin mimetic; Incretin; Glucagon-like peptide-1; Glucose-dependent insulinotropic peptide	GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; REVERSES BEHAVIORAL IMPAIRMENTS; SECONDARY NEURONAL DAMAGE; FOCAL CEREBRAL-ISCHEMIA; RECEPTOR AGONIST; PARKINSONS-DISEASE; MOUSE MODEL; GENE-EXPRESSION; HEAD-INJURY	Several single incretin receptor agonists that are approved for the treatment of type 2 diabetes mellitus (T2DM) have been shown to be neuroprotective in cell and animal models of neurodegeneration. Recently, a synthetic dual incretin receptor agonist, nicknamed "twincretin," was shown to improve upon the metabolic benefits of single receptor agonists in mouse and monkey models of T2DM. In the current study, the neuroprotective effects of twincretin are probed in cell and mouse models of mild traumatic brain injury (mTBI), a prevalent cause of neurodegeneration in toddlers, teenagers and the elderly. Twincretin is herein shown to have activity at two different receptors, dose-dependently increase levels of intermediates in the neurotrophic CREB pathway and enhance viability of human neuroblastoma cells exposed to toxic concentrations of glutamate and hydrogen peroxide, insults mimicking the inflammatory conditions in the brain post-mTBI. Additionally, twincretin is shown to improve upon the neurotrophic effects of single incretin receptor agonists in these same cells. Finally, a clinically translatable dose of twincretin, when administered post-mTBI, is shown to fully restore the visual and spatial memory deficits induced by mTBI, as evaluated in a mouse model of weight drop close head injury. These results establish twincretin as a novel neuroprotective agent and suggest that it may improve upon the effects of the single incretin receptor agonists via dual agonism. Published by Elsevier Inc.	[Tamargo, Ian A.; Li, Yazhou; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Bader, Miaad; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, Tel Aviv, Israel; [Yu, Seong-Jin; Wang, Yun] Natl Hlth Res Inst, Ctr Neuropsychiat Res, Miaoli, Taiwan; [Talbot, Konrad] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA USA; [DiMarchi, Richard D.] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel	Tamargo, IA; Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, NIH, 251 Bayview Blvd, Baltimore, MD 21224 USA.	iatamargo@gmail.com; Greign@mail.nih.gov		Talbot, Konrad/0000-0003-4549-0835	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG000333]; Ari and Regine Aprijaskis Fund at Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, grant number AG000333 (2016), (ii) the Ari and Regine Aprijaskis Fund at Tel-Aviv University, and (iii) a grant from the Israel Science Foundation, grant number 108/09.	Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Al-Sabah S, 2014, EUR J PHARMACOL, V741, P311, DOI 10.1016/j.ejphar.2014.08.019; Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Alvarez E, 2005, J NEUROCHEM, V92, P798, DOI 10.1111/j.1471-4159.2004.02914.x; Anderberg RH, 2016, PSYCHONEUROENDOCRINO, V65, P54, DOI 10.1016/j.psyneuen.2015.11.021; Athauda D, 2016, DRUG DISCOV TODAY, V21, P802, DOI 10.1016/j.drudis.2016.01.013; Bales James W, 2010, Open Drug Discov J, V2, P119; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barkhoudarian G., 2011, SPORTS MED, V30, pvii; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bassil F, 2014, PROG NEUROBIOL, V118, P1, DOI 10.1016/j.pneurobio.2014.02.005; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Briyal S, 2012, BRAIN RES, V1427, P23, DOI 10.1016/j.brainres.2011.10.026; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Cao L, 2016, NEUROREPORT; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; CICCARONE V, 1989, CANCER RES, V49, P219; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dachir S, 2014, BRAIN RES, V1555, P78, DOI 10.1016/j.brainres.2014.01.044; De Toro-Martin J, 2014, ENDOCRINOLOGY, V155, P3769, DOI 10.1210/en.2013-2043; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Deselms H., 2016, J NEUROSCI METHODS; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Doulames VM, 2015, FRONT BEHAV NEUROSCI, V9, DOI [10.3389/fnbeh.2015.00369, 10.3389/fnbeh.2015.00275]; Duarte AI, 2013, BBA-MOL BASIS DIS, V1832, P527, DOI 10.1016/j.bbadis.2013.01.008; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Faul M., 2010, CONTROL; Finan B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007218; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gault VA, 2003, DIABETOLOGIA, V46, P222, DOI 10.1007/s00125-002-1028-x; Gault VA, 2002, BIOCHEM BIOPH RES CO, V290, P1420, DOI 10.1006/bbrc.2002.6364; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han L, 2016, NEUROREPORT, V27, P23, DOI 10.1097/WNR.0000000000000490; Hansen HH, 2015, J ALZHEIMERS DIS, V46, P877, DOI 10.3233/JAD-143090; Harkavyi A, 2010, BRIT J PHARMACOL, V159, P495, DOI 10.1111/j.1476-5381.2009.00486.x; Holscher C, 2014, J ENDOCRINOL, V221, pT31, DOI 10.1530/JOE-13-0221; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Impellizzeri D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00458; Isacson R, 2011, EUR J PHARMACOL, V650, P249, DOI 10.1016/j.ejphar.2010.10.008; Ji CH, 2016, BRAIN RES, V1634, P1, DOI 10.1016/j.brainres.2015.09.035; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; Kim SJ, 2008, MOL CELL BIOL, V28, P1644, DOI 10.1128/MCB.00325-07; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Li YZ, 2015, J NEUROCHEM, V135, P1203, DOI 10.1111/jnc.13169; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Liu W, 2015, NEUROSCIENCE, V303, P42, DOI 10.1016/j.neuroscience.2015.06.054; Liu WZ, 2015, REV NEUROSCIENCE, V26, P371, DOI 10.1515/revneuro-2015-0005; Lotharius J, 1999, J NEUROSCI, V19, P1284; Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799; McClean PL, 2010, REGUL PEPTIDES, V164, P40, DOI 10.1016/j.regpep.2010.07.102; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; Melo A, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/467180; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nyberg J, 2007, J NEUROSCI RES, V85, P2099, DOI 10.1002/jnr.21349; Orman J. A. L., 2011, EPIDEMIOLOGY TXB TRA, P3; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Schiehser DM, 2016, PARKINSONISM RELAT D, V30, P58, DOI 10.1016/j.parkreldis.2016.05.024; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; Shao WJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE1263, DOI 10.1152/ajpendo.00600.2012; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Sparre-Ulrich AH, 2016, BRIT J PHARMACOL, V173, P27, DOI 10.1111/bph.13323; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2016, ALZHEIMERS DEMENT, V12, P34, DOI 10.1016/j.jalz.2015.07.489; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wu TZ, 2016, HANDB EXP PHARMACOL, V233, P137, DOI 10.1007/164_2015_9; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	90	26	26	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2017	288						176	186		10.1016/j.expneurol.2016.11.005			11	Neurosciences	Neurosciences & Neurology	EI4JY	WOS:000392461100017	27845037	Green Accepted			2021-06-18	
J	Mayeux, J; Katz, P; Edwards, S; Middleton, JW; Molina, PE				Mayeux, Jacques; Katz, Paige; Edwards, Scott; Middleton, Jason W.; Molina, Patricia E.			Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability	JOURNAL OF NEUROTRAUMA			English	Article						endocannabinoids; MAGL; neuroinflammation; TBI; 2-AG	DEPOLARIZATION-INDUCED SUPPRESSION; LONG-TERM POTENTIATION; DIFFUSE AXONAL INJURY; AMYLOID-BETA; ALZHEIMERS-DISEASE; ENDOGENOUS CANNABINOIDS; MICROGLIAL ACTIVATION; HIPPOCAMPAL SYNAPSES; PROTECTS NEURONS; HEAD-INJURY	Traumatic brain injury (TBI) is an increasingly prevalent condition affecting soldiers, athletes, and motor vehicle accident victims. Unfortunately, it currently lacks effective therapeutic interventions. TBI is defined as a primary mechanical insult followed by a secondary cascade involving inflammation, apoptosis, release of reactive oxygen species, and excitotoxicity, all of which can cause synaptic changes, altered neuronal signaling, and, ultimately, behavioral changes. Previously we showed that preventing degradation of the endocannabinoid (EC) 2-acylglycerol (2-AG) with JZL184 after mild TBI attenuated neuroinflammation and improved recovery of neurobehavioral function during the early 24 h post-TBI period. The aim of this study was to extend the timeline of observations to 2 weeks post-injury and to investigate JZL184's impact on synaptic transmission, which we view as a potential mechanism for TBI-induced cellular and behavioral pathology. Adult male rats underwent mild TBI (mTBI) followed by a single intraperitoneal injection of JZL184 or vehicle 30min postinjury. JZL184 administered-TBI animals showed improved neurobehavioral recovery compared with vehicle-injected TBI animals beginning 24 h post-injury and persisting for 2 weeks. JZL184-treated animals had significantly diminished gray and white matter astrocyte activation when compared with vehicle-treated animals at day 7 post-TBI. JZL184 administration significantly attenuated the increased pGluR1 S845/GluR1 and pERK 1/2/ERK and the increases in miniature excitatory postsynaptic potential (mEPSC) frequency and amplitude observed in layer 5 pyramidal neurons at 10 days post-TBI. These results suggest a neuroprotective role for ECs in ameliorating the TBI-induced neurobehavioral, neuroinflammatory, and glutamate dyshomeostasis from mTBI. Further studies elucidating the cellular mechanisms involved are warranted.	[Mayeux, Jacques; Katz, Paige; Edwards, Scott; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7212, New Orleans, LA 70112 USA; [Middleton, Jason W.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Cell Biol & Anat, New Orleans, LA USA	Molina, PE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7212, New Orleans, LA 70112 USA.	pmolin@lsuhsc.edu	Molina, Patricia E./AAK-9814-2021	Molina, Patricia E./0000-0002-3598-384X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AA007577, AA020839];  [DOD-W81XWH-11-2-0011]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R00AA020839, T32AA007577] Funding Source: NIH RePORTER	This work was supported by NIH training (AA007577, JM, PK) and research grants AA020839 (SE), and DOD-W81XWH-11-2-0011 (PM). The authors would like to thank Dr. Nicholas Gilpin for scientific discussions during the preparation of this article and Kylie Mills for assistance with animal behavior and surgery experiments. Paige Katz was a post-doctoral fellow at LSUHSC during the completion of these studies but has since completed her fellowship.	Abraham WC, 1996, BRAIN RES, V722, P217, DOI 10.1016/0006-8993(96)00130-8; Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Alger BE, 2002, PROG NEUROBIOL, V68, P247; BARNES CA, 1995, NEURON, V15, P751, DOI 10.1016/0896-6273(95)90166-3; Bisogno T, 2010, CNS NEUROL DISORD-DR, V9, P564, DOI 10.2174/187152710793361568; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brettschneider J, 2012, ACTA NEUROPATHOL, V123, P395, DOI 10.1007/s00401-011-0932-x; Chen X, 2011, NEUROSCIENCE, V178, P159, DOI 10.1016/j.neuroscience.2011.01.024; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Diana MA, 2004, BRIT J PHARMACOL, V142, P9, DOI 10.1038/sj.bjp.0705726; Dinh TP, 2002, P NATL ACAD SCI USA, V99, P10819, DOI 10.1073/pnas.152334899; Du HZ, 2011, BRIT J PHARMACOL, V163, P1533, DOI 10.1111/j.1476-5381.2011.01444.x; Edwards S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.70; Eikelenboom P, 2010, NEURODEGENER DIS, V7, P38, DOI 10.1159/000283480; Eljaschewitsch E, 2006, NEURON, V49, P67, DOI 10.1016/j.neuron.2005.11.027; Fuzik J, 2013, NEUROSCIENCE, V228, P371, DOI 10.1016/j.neuroscience.2012.10.042; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; HAWKINS RD, 1984, PSYCHOL REV, V91, P375, DOI 10.1037/0033-295X.91.3.375; ISAACSON JS, 1995, NEURON, V15, P875, DOI 10.1016/0896-6273(95)90178-7; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kano M, 2009, PHYSIOL REV, V89, P309, DOI 10.1152/physrev.00019.2008; Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508; Kimura A, 2000, J NEUROPHYSIOL, V84, P1894; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kreitzer AC, 2001, J NEUROSCI, V21, part. no.; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129; Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McIntosh TK, 1996, LAB INVEST, V74, P315; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Ohno-Shosaku T, 2002, J NEUROSCI, V22, P3864, DOI 10.1523/JNEUROSCI.22-10-03864.2002; Oliet SHR, 1996, SCIENCE, V271, P1294, DOI 10.1126/science.271.5253.1294; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Prow NA, 2008, J NEUROCHEM, V105, P1276, DOI 10.1111/j.1471-4159.2008.05230.x; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Sarne Y, 2005, CNS NEUROL DISORD-DR, V4, P677, DOI 10.2174/156800705774933005; Shors TJ, 1997, BEHAV BRAIN SCI, V20, P597, DOI 10.1017/S0140525X97001593; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Stella N, 2009, NEUROPHARMACOLOGY, V56, P244, DOI 10.1016/j.neuropharm.2008.07.037; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; van der Stelt M, 2005, NEUROMOL MED, V7, P37, DOI 10.1385/NMM:7:1-2:037; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Xu JY, 2015, NEUROSCIENTIST, V21, P152, DOI 10.1177/1073858414524632; Xu JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010306; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhang JC, 2005, BRAIN RES, V1050, P110, DOI 10.1016/j.brainres.2005.05.032; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200	65	26	26	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					436	443		10.1089/neu.2016.4452			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800019	27189876	Green Published			2021-06-18	
J	Treble-Barna, A; Zang, HY; Zhang, NH; Taylor, HG; Yeates, KO; Wade, S				Treble-Barna, Amery; Zang, Huaiyu; Zhang, Nanhua; Taylor, H. Gerry; Yeates, Keith Owen; Wade, Shari			Long-Term Neuropsychological Profiles and Their Role as Mediators of Adaptive Functioning after Traumatic Brain Injury in Early Childhood	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; neuropsychology; outcome measures; pediatric brain injury	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; EVERYDAY EXECUTIVE FUNCTION; TEMPORAL-LOBE EPILEPSY; CLOSED-HEAD INJURY; RECOVERY 10 YEARS; YOUNG-CHILDREN; ACADEMIC-ACHIEVEMENT; DEVELOPMENTAL DISORDERS; COGNITIVE PREDICTORS; ORTHOPEDIC INJURY	The objectives of the study were to characterize long-term neuropsychological outcomes following traumatic brain injury (TBI) sustained during early childhood, and determine whether identified neuropsychological impairments mediated the effect of TBI on long-term adaptive functioning. Participants included 16 children with severe TBI, 42 children with moderate TBI, and 72 children with orthopedic injuries (OI) sustained between ages 3 and 7 years. Children completed neuropsychological tests and caregivers completed a structured interview of child adaptive functioning at 6.9 (+/- 1.10) years post-injury. Profile analysis and multiple mediator modeling were employed. Children with severe TBI demonstrated poorer fluid reasoning and inhibitory control than both children with moderate TBI and OI, as well as slower processing speed than the OI group. Both fluid reasoning and processing speed were significant independent mediators of the effect of severe TBI on adaptive functioning. No neuropsychological measure significantly mediated the effect of moderate TBI on adaptive functioning. Children sustaining early severe TBI demonstrate persisting neuropsychological impairments into adolescence and young adulthood. The impact of severe TBI on children's long-term adaptive functioning is mediated in part by its effects on fluid reasoning and processing speed.	[Treble-Barna, Amery; Wade, Shari] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Zang, Huaiyu; Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Treble-Barna, Amery] Univ Cincinnati, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Rainbow Child Dev Ctr, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Alberta Childrens Hosp, Dept Psychol,Res Inst, Calgary, AB, Canada	Treble-Barna, A (corresponding author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Treble-Barna, A (corresponding author), Univ Cincinnati, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Amery.Treble-Barna@cchmc.org	Yeates, Keith/AAJ-4223-2020	Zhang, Nanhua/0000-0001-5796-3404; Yeates, Keith/0000-0001-7680-2892	Institutional Clinical and Translational Science Award, NIH/NCRR [1UL1RR026314]; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; Trauma Research grants from the State of Ohio Emergency Medical Services; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER	This publication was supported by an Institutional Clinical and Translational Science Award, NIH/NCRR Grant Number 1UL1RR026314. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH). Additional support provided to Dr. Wade included grant R01 HD42729 from National Institute of Child Health and Human Development (NICHD) and Trauma Research grants from the State of Ohio Emergency Medical Services.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Ashford JM, 2014, J NEURO-ONCOL, V118, P193, DOI 10.1007/s11060-014-1420-7; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Beauchamp MH, 2013, HAND CLINIC, V112, P913, DOI 10.1016/B978-0-444-52910-7.00013-1; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Campbell LK, 2009, J PEDIATR PSYCHOL, V34, P317, DOI 10.1093/jpepsy/jsn080; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Carpentieri S, 1996, J AUTISM DEV DISORD, V26, P611, DOI 10.1007/BF02172350; Carrow-Woolfolk E., 1999, COMPREHENSIVE ASSESS; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Clark CAC, 2013, DEV PSYCHOL, V49, P1481, DOI 10.1037/a0030578; Collette F, 2006, NEUROSCIENCE, V139, P209, DOI 10.1016/j.neuroscience.2005.05.035; Constantinidis C, 2002, NAT NEUROSCI, V5, P175, DOI 10.1038/nn799; Crowe LM, 2014, J HEAD TRAUMA REHAB, V29, P217, DOI 10.1097/HTR.0b013e31829babfd; Crowe LM, 2013, CHILD NEUROPSYCHOL, V19, P113, DOI 10.1080/09297049.2011.651079; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Culbertson WC, 1998, ARCH CLIN NEUROPSYCH, V13, P285, DOI 10.1016/S0887-6177(97)00033-4; Culhane-Shelburne K, 2002, J INT NEUROPSYCH SOC, V8, P623, DOI 10.1017/S1355617702801308; Davis BE, 2006, DEV MED CHILD NEUROL, V48, P253, DOI 10.1017/S0012162206000569; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dennis M., 1988, LANGUAGE YOUNG DAMAG, V7; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fulton JB, 2012, NEUROPSYCHOLOGY, V26, P314, DOI 10.1037/a0027973; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Gonzalez LM, 2007, EPILEPSIA, V48, P124, DOI 10.1111/j.1528-1167.2006.00907.x; Harris R.J., 1985, PRIMER MULTIVARIATE, V2nd ed.; Hedvall A, 2013, SCI WORLD J, DOI 10.1155/2013/158263; Hodges K, 1998, J BEHAV HEALTH SER R, V25, P325, DOI 10.1007/BF02287471; Hodges K, 1997, J MENT HEALTH ADMIN, V24, P278, DOI 10.1007/BF02832662; Hodges K., 1994, CHILD ADOLESCENT FUN; Hodges K., 1996, J CHILD FAM STUD, V5, P445, DOI [10.1007/BF02233865, DOI 10.1007/BF02233865]; Hodges K., 2005, CAFAS MANUAL TRAININ, V3; Jacobson LA, 2011, CHILD NEUROPSYCHOL, V17, P255, DOI 10.1080/09297049.2010.535654; Kassam I, 2016, J NEUROL NEUROSUR PS, V87, P433, DOI 10.1136/jnnp-2015-310500; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kurowski B. G., 2015, J HEAD TRAUMA REHABI; Kurowski B, 2012, J PEDIATR REHAB MED, V5, P217, DOI 10.3233/PRM-2012-0214; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Liss M, 2001, J AUTISM DEV DISORD, V31, P219, DOI 10.1023/A:1010707417274; LOVELAND KA, 1991, AM J MENT RETARD, V96, P13; Luria A. R., 1966, HIGHER CORTICAL FUNC; Manly T., 1999, TEA CH TEST EVERYDAY; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Molfese VJ, 2010, CONTEMP EDUC PSYCHOL, V35, P116, DOI 10.1016/j.cedpsych.2010.03.004; Murray A, 2014, J INTELL DISABIL RES, V58, P777, DOI 10.1111/jir.12092; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nowrangi MA, 2014, J NEUROPSYCH CLIN N, V26, P114, DOI 10.1176/appi.neuropsych.12070176; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Papazoglou A, 2013, J INT NEUROPSYCH SOC, V19, P189, DOI 10.1017/S1355617712001191; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Raghubar KP, 2013, J INT NEUROPSYCH SOC, V19, P254, DOI 10.1017/S1355617712001312; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Roberts RJ, 1996, DEV NEUROPSYCHOL, V12, P105, DOI 10.1080/87565649609540642; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Robinson KE, 2014, J PEDIATR PSYCHOL, V39, P846, DOI 10.1093/jpepsy/jsu031; ROSZKOWSKI MJ, 1980, PSYCHOL SCHOOLS, V17, P452, DOI 10.1002/1520-6807(198010)17:4<452::AID-PITS2310170406>3.0.CO;2-F; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; SCHATZ J, 1995, J AUTISM DEV DISORD, V25, P51, DOI 10.1007/BF02178167; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1985, DEV NEUROPSYCHOLOGY; Stahl L, 2005, CHILD NEUROPSYCHOL, V11, P175, DOI 10.1080/092970490911315; Stuss D.T., 1986, FRONTAL LOBES; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; TEASDALE G, 1974, LANCET, V2, P81; van Aken L, 2016, ACTA NEUROPSYCHIATR, V28, P31, DOI 10.1017/neu.2015.46; Verger K, 2000, BRAIN INJURY, V14, P495; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Walsh KS, 2015, CHILD NEUROPSYCHOL, V21, P78, DOI 10.1080/09297049.2013.876491; Ware AL, 2012, ALCOHOL CLIN EXP RES, V36, P1431, DOI 10.1111/j.1530-0277.2011.01718.x; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2004, WECHSLER INTELLIGENC; Willoughby MT, 2012, CHILD NEUROPSYCHOL, V18, P79, DOI 10.1080/09297049.2011.578572; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Zelazo PD, 1998, DEV PSYCHOL, V34, P203, DOI 10.1037/0012-1649.34.2.203	109	26	27	0	31	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					353	362		10.1089/neu.2016.4476			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800010	27080734	Green Published			2021-06-18	
J	Kislin, M; Sword, J; Fomitcheva, IV; Croom, D; Pryazhnikov, E; Lihavainen, E; Toptunov, D; Rauvala, H; Ribeiro, AS; Khiroug, L; Kirov, SA				Kislin, Mikhail; Sword, Jeremy; Fomitcheva, Ioulia V.; Croom, Deborah; Pryazhnikov, Evgeny; Lihavainen, Eero; Toptunov, Dmytro; Rauvala, Heikki; Ribeiro, Andre S.; Khiroug, Leonard; Kirov, Sergei A.			Reversible Disruption of Neuronal Mitochondria by Ischemic and Traumatic Injury Revealed by Quantitative Two-Photon Imaging in the Neocortex of Anesthetized Mice	JOURNAL OF NEUROSCIENCE			English	Article						brain trauma; dendrite; mitochondria; stroke; structural dynamics; two-photon in vivo imaging	PERMEABILITY TRANSITION; FLUORESCENT PROTEIN; CEREBRAL-ISCHEMIA; DENDRITIC SPINES; TRANSGENIC MICE; CELL-DEATH; FUSION; TRANSIENT; CALCIUM; FISSION	Mitochondria play a variety of functional roles in cortical neurons, from metabolic support and neuroprotection to the release of cytokines that trigger apoptosis. In dendrites, mitochondrial structure is closely linked to their function, and fragmentation (fission) of the normally elongated mitochondria indicates loss of their function under pathological conditions, such as stroke and brain trauma. Using in vivo two-photon microscopy in mouse brain, we quantified mitochondrial fragmentation in a full spectrum of cortical injuries, ranging from severe to mild. Severe global ischemic injury was induced by bilateral common carotid artery occlusion, whereas severe focal stroke injury was induced by Rose Bengal photosensitization. The moderate and mild traumatic injury was inflicted by focal laser lesion and by mild photo-damage, respectively. Dendritic and mitochondrial structural changes were tracked longitudinally using transgenic mice expressing fluorescent proteins localized either in cytosol or in mitochondrial matrix. In response to severe injury, mitochondrial fragmentation developed in parallel with dendritic damage signified by dendritic beading. Reconstruction from serial section electron microscopy confirmed mitochondrial fragmentation. Unlike dendritic beading, fragmentation spread beyond the injury core in focal stroke and focal laser lesion models. In moderate and mild injury, mitochondrial fragmentation was reversible with full recovery of structural integrity after 1-2 weeks. The transient fragmentation observed in the mild photo-damage model was associated with changes in dendritic spine density without any signs of dendritic damage. Our findings indicate that alterations in neuronal mitochondria structure are very sensitive to the tissue damage and can be reversible in ischemic and traumatic injuries.	[Kislin, Mikhail; Pryazhnikov, Evgeny; Rauvala, Heikki; Khiroug, Leonard] Univ Helsinki, Neurosci Ctr, FI-00014 Helsinki, Finland; [Pryazhnikov, Evgeny; Toptunov, Dmytro; Khiroug, Leonard] Neurotar Ltd, FI-00790 Helsinki, Finland; [Lihavainen, Eero; Ribeiro, Andre S.] Tampere Univ Technol, Dept Signal Proc, Lab Biosyst Dynam, FI-33101 Tampere, Finland; [Sword, Jeremy; Croom, Deborah; Kirov, Sergei A.] Augusta Univ, Brain & Behav Discovery Inst, Med Coll Georgia, 1120 15th St,CB 3706, Augusta, GA 30912 USA; [Fomitcheva, Ioulia V.; Kirov, Sergei A.] Augusta Univ, Dept Neurosurg, Med Coll Georgia, Augusta, GA 30912 USA	Kirov, SA (corresponding author), Augusta Univ, Brain & Behav Discovery Inst, Med Coll Georgia, 1120 15th St,CB 3706, Augusta, GA 30912 USA.; Khiroug, L (corresponding author), Univ Helsinki, In Vivo Microscopy Unit, Neurosci Ctr, POB 56,Viikinkaari 4, FI-00014 Helsinki, Finland.; Kirov, SA (corresponding author), Augusta Univ, Med Coll Georgia, Multiphoton Imaging Lab, Dept Neurosurg, 1120 15th St,CB 3706, Augusta, GA 30912 USA.	leonard.khirug@helsinki.fi; skirov13@gmail.com	Ribeiro, Andre S/G-4294-2014	Ribeiro, Andre S/0000-0002-7255-5211; Kislin, Mikhail/0000-0002-5447-8881	Academy of FinlandAcademy of FinlandEuropean Commission [SA-126321, 295027, 305342]; FGSN; CIMO; University of Helsinki; Emil Aaltonen Foundation; Jane and Aatos Erkko Foundation [610536]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS083858]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS083858, R01NS083858] Funding Source: NIH RePORTER	This work was supported by the Academy of Finland Grant SA-126321, FGSN, CIMO, and University of Helsinki to L.K., Emil Aaltonen Foundation to E.L., Academy of Finland Grants 295027 and 305342, and Jane and Aatos Erkko Foundation Grant 610536 to A.S.R., and by National Institutes of Health Grant NS083858 to S.A.K. We thank Libby Perry and Brendan Marshall (Electron Microscopy Core at the Medical College of Georgia) for assistance with electron microscopy; and Julia Kolikova (Neurotar Ltd) and Marina Tibeykina (In Vivo Microscopy Unit at the University of Helsinki) for assistance with animal surgeries.	Abramov AY, 2008, BBA-BIOENERGETICS, V1777, P953, DOI 10.1016/j.bbabio.2008.04.017; Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky T, 2009, CELL CALCIUM, V46, P18, DOI 10.1016/j.ceca.2009.03.017; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chandrasekaran K, 2006, J NEUROSCI, V26, P13123, DOI 10.1523/JNEUROSCI.4191-06.2006; Chang DTW, 2006, J NEUROSCI, V26, P7035, DOI 10.1523/JNEUROSCI.1012-06.2006; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen SB, 2011, J NEUROSCI METH, V195, P222, DOI 10.1016/j.jneumeth.2010.12.018; Dirnagl U, 2012, ANN NY ACAD SCI, V1268, P21, DOI 10.1111/j.1749-6632.2012.06691.x; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Holtmaat A, 2009, NAT PROTOC, V4, P1128, DOI 10.1038/nprot.2009.89; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; Hossmann KA, 2006, CELL MOL NEUROBIOL, V26, P1057, DOI 10.1007/s10571-006-9008-1; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Kasischke KA, 2011, J CEREBR BLOOD F MET, V31, P68, DOI 10.1038/jcbfm.2010.158; Kirov AS, 2014, PATHOLOGICAL POTENTI, P127; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Kremneva E, 2013, CELL CALCIUM, V53, P85, DOI 10.1016/j.ceca.2012.10.003; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Labat-gest V, 2013, JOVE-J VIS EXP, V2013, P76, DOI DOI 10.3791/50370; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Lihavainen E, 2015, J MICROSC-OXFORD, V260, P338, DOI 10.1111/jmi.12301; Lihavainen E, 2012, BIOINFORMATICS, V28, P1050, DOI 10.1093/bioinformatics/bts073; Liot G, 2009, CELL DEATH DIFFER, V16, P899, DOI 10.1038/cdd.2009.22; Liu RR, 2009, J BIOL CHEM, V284, P36109, DOI 10.1074/jbc.M109.055301; Liu WT, 2012, J NEUROSCI RES, V90, P1183, DOI 10.1002/jnr.23016; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mattson MP, 2008, NEURON, V60, P748, DOI 10.1016/j.neuron.2008.10.010; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Misgeld T, 2007, NAT METHODS, V4, P559, DOI 10.1038/NMETH1055; Mouli PK, 2009, BIOPHYS J, V96, P3509, DOI 10.1016/j.bpj.2008.12.3959; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Otera H, 2013, BBA-MOL CELL RES, V1833, P1256, DOI 10.1016/j.bbamcr.2013.02.002; Owens K, 2015, J BIOENERG BIOMEMBR, V47, P13, DOI 10.1007/s10863-014-9575-7; Parone PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003257; Paveliev M, 2014, JOVE-J VIS EXP, V2014, P86; Peng JY, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002212; Peron S, 2015, CURR OPIN NEUROBIOL, V32, P115, DOI 10.1016/j.conb.2015.03.016; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; Popov V, 2005, J COMP NEUROL, V492, P50, DOI 10.1002/cne.20682; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Rodriguez A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001997; Rugarli EI, 2012, EMBO J, V31, P1336, DOI 10.1038/emboj.2012.38; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shitara H, 2001, FEBS LETT, V500, P7, DOI 10.1016/S0014-5793(01)02574-1; Sigler A, 2008, J NEUROSCI METH, V170, P35, DOI 10.1016/j.jneumeth.2007.12.015; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Steffensen AB, 2015, J NEUROSCI, V35, P12172, DOI 10.1523/JNEUROSCI.0400-15.2015; Stetler RA, 2013, J CEREBR BLOOD F MET, V33, P22, DOI 10.1038/jcbfm.2012.158; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Sword J, 2017, J CEREBR BLOOD F MET, V37, P1626, DOI 10.1177/0271678X16639328; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; TOMIMOTO H, 1992, BRAIN RES, V598, P87, DOI 10.1016/0006-8993(92)90171-5; TOMIMOTO H, 1994, NEUROSCIENCE, V63, P957, DOI 10.1016/0306-4522(94)90564-9; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wappler EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063206; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Yang O, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3528610; Yin W, 2008, STROKE, V39, P3057, DOI 10.1161/STROKEAHA.108.520114; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zhang SX, 2007, PLOS BIOL, V5, P1152, DOI 10.1371/journal.pbio.0050119; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005	79	26	26	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 11	2017	37	2					333	348		10.1523/JNEUROSCI.1510-16.2017			16	Neurosciences	Neurosciences & Neurology	EJ9CZ	WOS:000393525500012	28077713	Bronze			2021-06-18	
J	Chrisman, SPD; Whitlock, KB; Somers, E; Burton, MS; Herring, SA; Rowhani-Rahbar, A; Rivara, FP				Chrisman, Sara P. D.; Whitlock, Kathryn B.; Somers, Elissa; Burton, Monique S.; Herring, Stanley A.; Rowhani-Rahbar, Ali; Rivara, Frederick P.			Pilot study of the Sub-Symptom Threshold Exercise Program (SSTEP) for persistent concussion symptoms in youth	NEUROREHABILITATION			English	Article						Brain concussion; sport; child; adolescent; traumatic brain injury; exercise; treatment; prolonged concussion syndrome	TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; VOLUNTARY EXERCISE; CHILDREN; RECOVERY; PREDICTORS; REST; REHABILITATION; TRIAL	BACKGROUND: Prior studies suggest potential benefit using monitored aerobic exercise to treat youth with persistent concussion symptoms, but these studies have been small. OBJECTIVES: To explore the safety and potential benefits of a rehabilitative exercise intervention, the Sub-symptom Threshold Exercise Program (SSTEP), for treating youth with persistent concussion symptoms >1 month. METHODS: We conducted a retrospective cohort study of 83 youth who participated inSSTEP, completing trajectory analysis of concussion symptoms using the symptom subscale of the Sport Concussion Assessment Tool, version 2 (SCAT-2). RESULTS: The average age of patients was 14.9+/-2.3 years and 54% were female. Most concussions (76%) were due to sports, the majority from football and girls' soccer, and 55% had a previous concussion. Comorbidity was not uncommon: 14% had history of ADHD and 16% history of depression and/or anxiety. Most patients improved following the intervention, and none reported worsening. Symptoms decreased exponentially following initiation of SSTEP, and trajectory did not differ by duration of symptoms at presentation (< 6 weeks, 6-12 weeks, >12 weeks). CONCLUSIONS: Monitored exercise programs appear to be safe and potentially beneficial for youth with persistent concussive symptoms. Large-scale controlled studies are needed to examine efficacy, ideal timing and duration.	[Chrisman, Sara P. D.; Whitlock, Kathryn B.; Rivara, Frederick P.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Chrisman, Sara P. D.] Univ Washington, Adolescent Med, Seattle, WA 98195 USA; [Chrisman, Sara P. D.; Rivara, Frederick P.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Somers, Elissa] Seattle Childrens Hosp, Dept Phys Therapy Seattle, Seattle, WA USA; [Burton, Monique S.] Seattle Childrens Hosp, Dept Orthoped & Sports Med, Dept Pediat, Seattle, WA USA; [Herring, Stanley A.] Univ Washington, Sports Spine & Orthoped Hlth, Seattle, WA 98195 USA; [Rowhani-Rahbar, Ali] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Chrisman, SPD (corresponding author), POB 5371,Mailstop CW8-6, Seattle, WA 98145 USA.	sara.chrisman@seattlechildrens.org		Chrisman, Sara/0000-0001-5373-7223	Satterberg Foundation, Seattle Pediatric Concussion Research Collaborative	This study was funded by the Satterberg Foundation, Seattle Pediatric Concussion Research Collaborative. Dr. Stan Herring has multiple affiliations within in the Sports Medicine arena, including acting as Chair of the Medical Advisory Committee for USA Football and participating as a member of the Board of Directors USA Football, the Pop Warner Medical Advisory Board and the NCAA Concussion Task Force, as well as a former member of the NFL Head, Neck and Spine Committee. The authors have no financial interests to disclose.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667; Steiner Emanuel, 2016, J Trauma Manag Outcomes, V10, P5, DOI 10.1186/s13032-016-0035-8; Szabo Z, 2010, BRAIN RES, V1341, P25, DOI 10.1016/j.brainres.2009.01.035; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Winkelman C, 2009, AACN ADV CRIT CARE, V20, P254, DOI 10.1097/NCI.0b013e3181ac838d; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	35	26	26	2	14	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2017	40	4					493	499		10.3233/NRE-161436			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EX7SC	WOS:000403447500004	28222566				2021-06-18	
J	Karhade, AV; Cote, DJ; Larsen, AMG; Smith, TR				Karhade, Aditya V.; Cote, David J.; Larsen, Alexandra M. G.; Smith, Timothy R.			Neurosurgical Infection Rates and Risk Factors: A National Surgical Quality Improvement Program Analysis of 132,000 Patients, 2006e-2014	WORLD NEUROSURGERY			English	Article						Complications; Infection; Neurosurgery; NSQIP; Quality improvement; Organ space infections; Surgical site infections; Urinary tract infections	TRAUMATIC BRAIN-INJURY; SITE INFECTIONS; AMERICAN-COLLEGE; SURGERY; CRANIOTOMY; PREDICTORS; CARE; REOPERATION; READMISSION; MORTALITY	BACKGROUND: The existing body of literature on postoperative neurosurgical infections lacks large multi-center reports on postoperative neurosurgical infections. This is the largest study to date of postoperative neurosurgical infections rates, time to event, and risk factors. METHODS: Demographics, medical history, and post-operative infections were assessed for all adult patients in the large, randomized, multicenter American College of Surgeonse-National Surgical Quality Improvement Program (ACS-NSQIP) database undergoing an operation with a surgeon whose primary specialty was neurological surgery from 2006 to 2014. RESULTS: Of 3,723,797 cases from 517 institutions in the NSQIP from 2006 to 2014, 132,063 neurosurgery cases were identified. Within these patients, the 30-day rate of postoperative infections was 5.3%. Postoperatively, 1.8% of patients developed surgical site infections (SSI), and 3.9% developed other infections including pneumonia and urinary tract infections. Superficial SSI had a cumulative incidence of 0.8% at a median of 16 (interquartile range [IQR], 11-22) days. Pneumonia had a cumulative incidence of 1.4% at a median of 5 days (IQR, 2-10 days). Systemic inflammatory response syndrome had a cumulative incidence of 1.6% at a median of 3 days (IQR, 8-16 days). Predictors of post-operative infections on multivariable analysis included female sex, older age, obesity, functionally dependent status before surgery, ventilator dependence, preoperative steroid use, bleeding disorders, hyponatremia, lymphocytosis, anemia, thrombocytosis, emergent case status, wound class II-IV, American Society of Anesthesiologists class 3-5, and longer operative times. CONCLUSION: The overall ACS- NSQIP reported rate of postoperative infections was 5.3% from 2006 to 2014. Multivariable analysis demonstrated several predictive factors for postoperative infections.	[Smith, Timothy R.] Brigham & Womens Hosp, Cushing Neurosurg Outcomes Ctr, Harvard Med Sch, Dept Neurosurg, Boston, MA 02115 USA	Smith, TR (corresponding author), Brigham & Womens Hosp, Cushing Neurosurg Outcomes Ctr, Harvard Med Sch, Dept Neurosurg, Boston, MA 02115 USA.	trsmith@partners.org		Giantini Larsen, Alexandra/0000-0002-9545-8502			Abu Hamdeh S, 2014, BRIT J NEUROSURG, V28, P270, DOI 10.3109/02688697.2013.835376; Algattas H, 2016, WORLD NEUROSURG, V87, P531, DOI 10.1016/j.wneu.2015.09.020; Algattas H, 2015, WORLD NEUROSURG, V84, P1372, DOI 10.1016/j.wneu.2015.06.033; ARUNODAYA GR, 2001, NEUROL INDIA S1, V49, P51; Beiner JM, 2003, NEUROSURG FOCUS, V15, P1, DOI [http://dx.doi.org/10.3171/foc.2003.153.14, DOI 10.3171/F0C.2003.15.3.14]; Birkmeyer JD, 2008, J AM COLL SURGEONS, V207, P777, DOI 10.1016/j.jamcollsurg.2008.07.018; BLOMSTEDT GC, 1985, ACTA NEUROCHIR, V78, P81, DOI 10.1007/BF01808684; Braxton EE, 2005, NEUROSURG REV, V28, P249, DOI 10.1007/s10143-005-0403-8; Cassir N, 2015, AM J INFECT CONTROL, V43, P1288, DOI 10.1016/j.ajic.2015.07.005; Chaichana KL, 2015, NEUROL RES, V37, P717, DOI 10.1179/1743132815Y.0000000042; Chiang HY, 2014, J NEUROSURG, V120, P509, DOI 10.3171/2013.9.JNS13843; Dasenbrock HH, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.10.FOCUS15386; Dettenkofer M, 1999, ACTA NEUROCHIR, V141, P1303, DOI 10.1007/s007010050434; Erman T, 2005, SURG NEUROL, V63, P107, DOI 10.1016/j.surneu.2004.04.024; Gupta H, 2013, CHEST, V143, P1599, DOI 10.1378/chest.12-1499; Hover AR, 2014, AM J MED QUAL, V29, P517, DOI 10.1177/1062860613505680; Karhade AV, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16168; Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(01)00938-3; Khuri SF, 2008, ANN SURG, V248, P329, DOI 10.1097/SLA.0b013e3181823485; Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kourbeti IS, 2011, BRIT J NEUROSURG, V25, P9, DOI 10.3109/02688697.2010.500411; Lieber B, 2016, WORLD NEUROSURG, V89, P517, DOI 10.1016/j.wneu.2015.12.085; Lieber BA, 2016, J NEUROSURG, V125, P187, DOI 10.3171/2015.4.JNS142719; Longo WE, 2005, AM J SURG, V190, P662, DOI 10.1016/j.amjsurg.2005.07.001; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721; McClelland S, 2008, AM J INFECT CONTROL, V36, P570, DOI 10.1016/j.ajic.2007.07.015; Oz BS, 2013, CARDIOVASC J AFR, V24, P184, DOI 10.5830/CVJA-2013-034; PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786; Raval MV, 2011, J AM COLL SURGEONS, V212, P1, DOI 10.1016/j.jamcollsurg.2010.08.013; Rolston JD, 2014, J NEUROSURG, V120, P736, DOI 10.3171/2013.10.JNS122419; Seicean A, 2015, J NEUROSURG, V123, P91, DOI 10.3171/2014.10.JNS14551; Sherrod BA, 2016, J NEUROSURG-PEDIATR, V18, P350, DOI 10.3171/2016.2.PEDS15604; Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031; Valentini LG, 2008, NEUROSURGERY, V62, P88, DOI 10.1227/01.NEU.0000311065.95496.C5; 김영희, 2014, [The Journal of Fundamentals of Nursing, 기본간호학회지], V21, P151, DOI 10.7739/jkafn.2014.21.2.151; Zhan R, 2014, EUR J CLIN MICROBIOL, V33, P861, DOI 10.1007/s10096-013-2026-2	40	26	32	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2017	97						205	212		10.1016/j.wneu.2016.09.056			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EO1HO	WOS:000396449400027	27671880				2021-06-18	
J	Hirai, K; Ishii, H; Shimoshikiryo, T; Shimomura, T; Tsuji, D; Inoue, K; Kadoiri, T; Itoh, K				Hirai, Keita; Ishii, Hidetoshi; Shimoshikiryo, Takayuki; Shimomura, Tatsuki; Tsuji, Daiki; Inoue, Kazuyuki; Kadoiri, Toshihiko; Itoh, Kunihiko			Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin	THERAPEUTIC DRUG MONITORING			English	Article						augmented renal clearance; vancomycin; febrile neutropenia	CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; CREATININE CLEARANCE; PHARMACODYNAMICS; INFECTIONS; GUIDELINES; OUTCOMES	Background: Augmented renal clearance (ARC) has frequently been observed in critically ill patients. The risk factors for ARC in patients, including those in the general ward, and their influences on vancomycin (VCM) treatment remain unclear. The aims of this study were to investigate the risk factors for ARC and to evaluate the influence of ARC on the pharmacokinetic parameters of VCM. Methods: This study included a total of 292 patients with VCM treatment who had normal serum creatinine concentrations. ARC was defined by an estimated creatinine clearance >= 130 mL.min(-1).1.73 m(-2). The risk factors for ARC were determined with stepwise logistic regression analysis. The pharmacokinetic parameters of VCM were estimated through the Bayesian method using a 2-compartment model. Results: ARC was observed in 48 patients (16.4%). Age <= 65 years [odds ratio (OR): 5.77; 95% CI: 2.89-11.97; P < 0.0001], brain injury (OR: 5.11; 95% CI: 1.49-17.57; P = 0.0086), febrile neutropenia (OR: 2.76; 95% CI: 1.11-6.67; P = 0.0254), and a mean volume of infusion fluid >= 1500 mL/d (OR: 2.53; 95% CI: 1.27-5.16; P = 0.0091) were independent risk factors for the occurrence of ARC. The patients with ARC exhibited higher VCM clearance values than the non-ARC patients. The median trough serum concentrations of VCM were 7.4 (interquartile range: 5.2-11.6) mcg/mL in the ARC patients and 12.2 (8.9-16.3) mcg/mL in the non-ARC patients (P < 0.0001). Subtherapeutic trough concentrations of VCM (<10.0 mcg/mL) were found in 68.8% of the ARC patients and in 32.8% of the non-ARC patients (P < 0.0001). Conclusions: This observational study investigated the influence of febrile neutropenia on the emergency of ARC for the first time. ARC was strongly associated with VCM pharmacokinetics, and twothirds of the ARC patients had subtherapeutic VCM concentrations. In patients with ARC, individualized dosing regimens are required to achieve the target trough concentration.	[Hirai, Keita; Ishii, Hidetoshi; Shimoshikiryo, Takayuki; Shimomura, Tatsuki; Tsuji, Daiki; Inoue, Kazuyuki; Itoh, Kunihiko] Univ Shizuoka, Sch Pharmaceut Sci, Dept Clin Pharmacol & Genet, Shizuoka, Japan; [Hirai, Keita; Tsuji, Daiki; Inoue, Kazuyuki; Itoh, Kunihiko] Shizuoka Prefectural Gen Hosp, Lab Clin Pharmacogen, Shizuoka, Japan; [Ishii, Hidetoshi; Kadoiri, Toshihiko] Shizuoka Prefectural Gen Hosp, Dept Pharm, Shizuoka, Japan	Itoh, K (corresponding author), Univ Shizuoka, Dept Clin Pharmacol & Genet, Sch Pharmaceut Sci, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	itohk@u-shizuoka-ken.ac.jp	Hirai, Keita/K-6290-2014	Hirai, Keita/0000-0001-8027-3508			Baptista JP, 2012, INT J ANTIMICROB AG, V39, P420, DOI 10.1016/j.ijantimicag.2011.12.011; Baptista JP, 2011, CRIT CARE, V15, DOI 10.1186/cc10262; BROWN R, 1980, CRIT CARE MED, V8, P68, DOI 10.1097/00003246-198002000-00004; Carlier M, 2013, CRIT CARE, V17, DOI 10.1186/cc12705; Conil JM, 2007, BRIT J CLIN PHARMACO, V63, P583, DOI 10.1111/j.1365-2125.2006.02807.x; Cook AM, 2013, NEUROCRIT CARE, V19, P210, DOI 10.1007/s12028-013-9837-y; Fuster-Lluch O, 2008, ANAESTH INTENS CARE, V36, P674, DOI 10.1177/0310057X0803600507; Grootaert V, 2012, ANN PHARMACOTHER, V46, P952, DOI 10.1345/aph.1Q708; Haeseker MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112008; Hirai K, 2016, THER DRUG MONIT, V38, P393, DOI 10.1097/FTD.0000000000000270; Hobbs ALV, 2015, PHARMACOTHERAPY, V35, P1063, DOI 10.1002/phar.1653; Huttner A, 2015, INT J ANTIMICROB AG, V45, P385, DOI 10.1016/j.ijantimicag.2014.12.017; Kullar R, 2011, CLIN INFECT DIS, V52, P975, DOI 10.1093/cid/cir124; Lortholary O, 2008, LANCET INFECT DIS, V8, P612, DOI 10.1016/S1473-3099(08)70228-7; Martin JH, 2011, INTERN MED J, V41, P537, DOI 10.1111/j.1445-5994.2009.02160.x; Matsumoto K, 2013, J INFECT CHEMOTHER, V19, P365, DOI 10.1007/s10156-013-0599-4; May CC, 2015, NEUROCRIT CARE, V23, P374, DOI 10.1007/s12028-015-0127-8; Minkute R, 2013, J CLIN PHARM THER, V38, P462, DOI 10.1111/jcpt.12088; Minville V, 2011, CRIT CARE, V15, DOI 10.1186/cc10013; Moise-Broder PA, 2004, CLIN PHARMACOKINET, V43, P925, DOI 10.2165/00003088-200443130-00005; Ruiz S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0090-8; Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI 10.2146/ajhp080434; Shimamoto Y, 2013, INTENS CARE MED, V39, P1247, DOI 10.1007/s00134-013-2909-9; Udy A, 2010, ANESTH ANALG, V111, P1505, DOI 10.1213/ANE.0b013e3181f7107d; Udy AA, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0750-y; Udy AA, 2015, INT J ANTIMICROB AG, V45, P331, DOI 10.1016/j.ijantimicag.2014.12.020; Udy AA, 2013, CRIT CARE, V17, DOI 10.1186/cc12544; Udy AA, 2012, CHEST, V142, P30, DOI 10.1378/chest.11-1671; Udy AA, 2010, INT J ANTIMICROB AG, V35, P606, DOI 10.1016/j.ijantimicag.2010.02.013; Udy AA, 2010, CLIN PHARMACOKINET, V49, P1, DOI 10.2165/11318140-000000000-00000; Yamamoto M, 2009, J CLIN PHARM THER, V34, P473, DOI 10.1111/j.1365-2710.2008.01016.x	31	26	28	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	DEC	2016	38	6					706	710		10.1097/FTD.0000000000000346			5	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	ED5LY	WOS:000388894900009	27681114				2021-06-18	
J	Spiegelberg, A; Preuss, M; Kurtcuoglu, V				Spiegelberg, Andreas; Preuss, Matthias; Kurtcuoglu, Vartan			B-waves revisited	INTERDISCIPLINARY NEUROSURGERY-ADVANCED TECHNIQUES AND CASE MANAGEMENT			English	Article						Intracranial pressure; B-waves; Slow waves; Vasogenic waves; Waveform analysis	BLOOD-FLOW-VELOCITY; INTRACRANIAL-PRESSURE OSCILLATIONS; RHYTHMIC OSCILLATIONS; HYDROCEPHALUS; DIAGNOSIS; HEALTHY	Reduced intracranial compliance is a key manifestation common to a number of pathological conditions of the brain. It is encountered in, but not limited to, traumatic brain injury, cerebral edema, and hydrocephalus. There are no clinically accepted methods to measure intracranial compliance available to date. Intracranial pressure (ICP) waveform analysis is seeing a revival driven by advances in our understanding of cerebrospinal fluid and pressure dynamics. Its translation to widespread clinical use is dependent on the possibility to derive relevant metrics such as intracranial compliance reliably and non-invasively. The B-wave is one of the features of the ICP waveform, reflecting vasogenic activity of cerebral autoregulation. Bwaves were originally defined to occupy the 0.5 to 2 cycles per minute frequency range. Recently renamed and redefined as slow waves with an extended range of 0.33 to 3 cycles per minute, specific changes in their pattern of occurrence are considered to be indicative of reduced intracranial compliance. With the still unmet need for a clinically acceptable method for acquiring intracranial compliance, and the revival of ICP waveform analysis, B-waves are moving back into the research focus. Herein we provide a concise review of the literature on B-waves, including a critical assessment of non-invasive methods for obtaining B-wave surrogates. (C) 2016 The Authors. Published by Elsevier B.V.	[Spiegelberg, Andreas; Kurtcuoglu, Vartan] Univ Zurich, Inst Physiol, Interface Grp, Zurich, Switzerland; [Kurtcuoglu, Vartan] Univ Zurich, Neurosci Ctr Zurich, Zurich, Switzerland; [Kurtcuoglu, Vartan] Univ Zurich, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Preuss, Matthias] Universitatsklinikum Leipzig AoR, Klin & Poliklin Neurochirurg, Leipzig, Germany	Kurtcuoglu, V (corresponding author), Univ Zurich, Inst Physiol, Interface Grp, Zurich, Switzerland.	vartan.kurtcuoglu@uzh.ch	Kurtcuoglu, Vartan/A-8940-2008	Kurtcuoglu, Vartan/0000-0003-2665-0995	Swiss National Science Foundation (NCCR Kidney.CH) through NCCR Kidney.CH	We gratefully acknowledge the financial support of the Swiss National Science Foundation (NCCR Kidney.CH) through NCCR Kidney.CH.	Aaslid R., 1986, INTRACRANIAL PRESSUR, P226; Agren-Wilsson A., 2005, THESIS; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BORGESEN SE, 1982, BRAIN, V105, P65, DOI 10.1093/brain/105.1.65; Brinker T, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-10; BROCK M, 1977, RADIOLOGE, V17, P460; Brock M., 1978, HEAD INJURIES TUMORS, P188; Cushing H., 1901, DEFINITE REGULATORY; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 2004, PHYSIOL MEAS, V25, pR51, DOI 10.1088/0967-3334/25/5/R01; Czosnyka M., 2015, COMMUNICATIONS; Czosnyka Z., 2014, HYDROCEPH, P78; De Rougemont J., 1972, INTRACRANIAL PRESSUR, P232; Diehl R. R., 2013, FUNKTIONELLE DOPPLER; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; DROSTE DW, 1993, SLEEP, V16, P603; DROSTE DW, 1993, J NEUROL NEUROSUR PS, V56, P75, DOI 10.1136/jnnp.56.1.75; Droste DW, 1999, NEUROL RES, V21, P627, DOI 10.1080/01616412.1999.11740987; DROSTE DW, 1994, ACTA NEUROL SCAND, V90, P99; Einhaupl K. M., 1986, INTRACRANIAL PRESSUR, VVI, P290, DOI 10.1007/978-3-642-70971-5_55; Eklund A, 2001, J NEUROSURG, V94, P392, DOI 10.3171/jns.2001.94.3.0392; Gaab M. R., 1981, THESIS; Greitz D, 2004, NEUROSURG REV, V27, P145, DOI 10.1007/s10143-004-0326-9; Hashimoto M., 1989, INTRACRANIAL PRESSUR, P217; Higashi S., 1989, INTRACRANIAL PRESSUR, P220; Huber P, 1967, Invest Radiol, V2, P17, DOI 10.1097/00004424-196701000-00016; Kasprowicz M, 2010, J NEUROSCI METH, V190, P310, DOI 10.1016/j.jneumeth.2010.05.015; Kiefer M, 2002, UNFALLCHIRURG, V105, P578, DOI 10.1007/s00113-002-0469-5; KRAUSS JK, 1994, NEUROL RES, V16, P398; KRAUSS JK, 1995, ACTA NEUROCHIR, V136, P195, DOI 10.1007/BF01410626; Lang EW, 1999, NEUROL RES, V21, P665, DOI 10.1080/01616412.1999.11740995; Lenfeldt N, 2004, J NEUROSURG, V101, P944, DOI 10.3171/jns.2004.101.6.0944; Lundberg N., 1959, ACTA PSYCHIAT SCAND, V36, P1; Maldonado E. R., 2013, THESIS; MARTIN G, 1978, SURG NEUROL, V9, P347; MAUTNER-HUPPERT D, 1989, Neurological Research, V11, P194; Minns R. A., 1991, HYDROCEPHALUS PATHOG, P270; Momjian S, 2004, BRIT J NEUROSURG, V18, P56, DOI 10.1080/02688690410001660481; Mueller JU, 2000, ZENTRALBL NEUROCH S1, V61, P14; Muller J. - U., 2000, FEEDBACK, P4; Muller J. U., 1998, ZENTRALBL NEUROCHI S; Nasi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025415; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; NILSSON C, 1992, AM J PHYSIOL, V262, pR20; Pfisterer WK, 2007, ACTA NEUROCHIR, V149, P983, DOI 10.1007/s00701-007-1240-z; Pickard J.D., 1980, INTRACRANIAL PRESSUR, P498; PIERREKAHN A, 1976, CHILD BRAIN, V2, P156; Poca M. A., 2013, INT ICP S 2013, P42; Raftopoulos Christian, 1992, Neurological Research, V14, P389; Rosner M., 1986, INTRACRANIAL PRESSUR, P137, DOI [10.1007/978-3-642-70971-5_25, DOI 10.1007/978-3-642-70971-5_25]; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Sorensen S. C., 1980, INTRACRANIAL PRESSUR, P123; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Stephensen H, 2005, J NEUROL NEUROSUR PS, V76, P965, DOI 10.1136/jnnp.2004.039834; Symon L, 1977, Clin Neurosurg, V24, P285; SYMON L, 1972, LANCET, V2, P1291; Tamaki N, 1983, No To Shinkei, V35, P131; VENES JL, 1979, CHILD BRAIN, V5, P352; Virtanen J., 2011, EUR C BIOM OPT; Weerakkody Ruwan Alwis, 2012, Acta Neurochir Suppl, V114, P181, DOI 10.1007/978-3-7091-0956-4_35; Williams MA, 1998, ACT NEUR S, V71, P328; Woodworth GF, 2009, NEUROSURGERY, V64, P919, DOI 10.1227/01.NEU.0000341902.44760.10; Yamamoto S., 1983, INTRACRANIAL PRESSUR, P333; Zunker P., 1997, NEW TRENDS CEREBRAL, P718	66	26	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2214-7519			INTERDISCIP NEUROSUR	Interdiscip. Neurosurg.	DEC	2016	6						13	17		10.1016/j.inat.2016.03.004			5	Clinical Neurology	Neurosciences & Neurology	ER8OG	WOS:000399078500004		DOAJ Gold, Green Accepted			2021-06-18	
J	Li, ZM; Xiao, YL; Zhu, JX; Geng, FY; Guo, CJ; Chong, ZL; Wang, LX				Li, Zhong-min; Xiao, Yi-lei; Zhu, Jian-xin; Geng, Feng-yang; Guo, Chuan-jun; Chong, Zong-lei; Wang, Le-xin			Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: A randomized, double blind and controlled clinical trial	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Erythropoietin; Severe traumatic brain injury; Neurological function; Thromboembolic events; Neuron specific enolase	PROGNOSTIC VALUE; RATS; NEUROPROTECTION; SAFETY; MRI	Objective: To investigate the short-term effect of recombinant human erythropoietin (EPO) on patients with severe traumatic brain injury. Methods: One hundred and fifty-nine patients with severe traumatic brain injury were randomly divided into EPO (n=79) and control group (n=80). EPO group was treated with subcutaneous injection of EPO (100 units/kg) on day 1, 3, 6, 9 and 12 following the brain injury. Glasgow outcome scores (GOS) were used to evaluate the outcomes three months after the treatment. Serum neuron specific enolase (NSE) and S-100 beta protein were measured within the first three months after treatment. Results: In the end, 146 patients (75 of the EPO group and 71 of the control group) completed the trial. Three months after the treatment, Good recovery was found in 33.3% of the EPO and 12.6% of the control group patients (p < 0.05). Serum NSE and S-100 beta protein were decreased gradually in both groups after treatment, but their levels in the EPO group were lower than that of control group (p < 0.05). There was no statistically significant difference in blood pressure, hemoglobin levels, pneumonia, sepsis or thromboembolic events between the two groups three months after the treatment (p >0.05). Conclusion: Treatment with five doses of recombinant human erythropoietin is associated with an improved functional recovery in patients with severe traumatic brain injury. This treatment does not seem to increase the risk of thromboembolic events or severe infections. (C) 2016 Elsevier B.V. All rights reserved.	[Li, Zhong-min; Xiao, Yi-lei; Zhu, Jian-xin; Geng, Feng-yang; Guo, Chuan-jun; Chong, Zong-lei] Taishan Med Univ, Dept Neurosurg, Liaocheng Peoples Hosp, Liaocheng 252000, Shandong, Peoples R China; [Wang, Le-xin] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia	Wang, LX (corresponding author), Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia.	lwang@csu.edu.au		Wang, Lexin/0000-0002-9760-7436			Bohlius J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003407.pub4; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Fauchere JC, 2015, J PEDIATR-US, V167, P52, DOI 10.1016/j.jpeds.2015.02.052; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Juul S, 2012, J MATERN-FETAL NEO M, V25, P105, DOI 10.3109/14767058.2012.715025; Kumral A, 2011, BRAIN DEV-JPN, V33, P632, DOI 10.1016/j.braindev.2010.10.014; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Ponce Lucido L, 2013, Pathophysiology, V20, P31, DOI 10.1016/j.pathophys.2012.02.005; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Talving P, 2010, ANN SURG, V251, P1, DOI 10.1097/SLA.0b013e3181b844fa; Tonia T, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD003407.PUB5; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2015, TRANSL STROKE RES, V6, P50, DOI 10.1007/s12975-014-0362-x; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844	21	26	28	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	NOV	2016	150						80	83		10.1016/j.clineuro.2016.09.001			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EA5EN	WOS:000386642300014	27611985				2021-06-18	
J	Zhao, W; Ford, JC; Flashman, LA; McAllister, TW; Ji, SB				Zhao, Wei; Ford, James C.; Flashman, Laura A.; McAllister, Thomas W.; Ji, Songbai			White Matter Injury Susceptibility via Fiber Strain Evaluation Using Whole-Brain Tractography	JOURNAL OF NEUROTRAUMA			English	Article						Dartmouth Head Injury Model; fiber strain; neural pathway; tractography; traumatic brain injury; white matter injury	MAXIMUM PRINCIPAL STRAIN; IN-VITRO MODELS; HEAD IMPACT; AXONAL DAMAGE; RESPONSES; KINEMATICS; FOOTBALL; SPORTS; ATLAS; ACCELERATIONS	Microscale brain injury studies suggest axonal elongation as a potential mechanism for diffuse axonal injury (DAI). Recent studies have begun to incorporate white matter (WM) structural anisotropy in injury analysis, with initial evidence suggesting improved injury prediction performance. In this study, we further develop a tractography-based approach to analyze fiber strains along the entire lengths of fibers from voxel- or anatomically constrained whole-brain tractography. This technique potentially extends previous element- or voxel-based methods that instead utilize WM fiber orientations averaged from typically coarse elements or voxels. Perhaps more importantly, incorporating tractography-based axonal structural information enables assessment of the overall injury risks to functionally important neural pathways and the anatomical regions they connect, which is not possible with previous methods. A DAI susceptibility index was also established to quantify voxel-wise WM local structural integrity and tract-wise damage of individual neural pathways. This graded injury susceptibility potentially extends the commonly employed treatment of injury as a simple binary condition. As an illustration, we evaluate the DAI susceptibilities of WM voxels and transcallosal fiber tracts in three idealized head impacts. Findings suggest the potential importance of the tractography-based approach for injury prediction. These efforts may enable future studies to correlate WM mechanical responses with neuroimaging, cognitive alteration, and concussion, and to reveal the relative vulnerabilities of neural pathways and identify the most vulnerable ones in real-world head impacts.	[Zhao, Wei; Ji, Songbai] Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Lebanon, NH 03766 USA; [Ford, James C.; Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg & Orthopaed Surg, Lebanon, NH USA	Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Lebanon, NH 03766 USA.	Songbai.Ji@Dartmouth.edu	Ford, James/AAF-7039-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092853, R21NS078607, R21NS088781] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS092853, R21 NS078607, R21 NS088781] Funding Source: Medline		Abaqus, 2012, ABAQUS, V6, P12; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Carlsen RW, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00028; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Debanne D, 2011, PHYSIOL REV, V91, P555, DOI 10.1152/physrev.00048.2009; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Feigl GC, 2014, WORLD NEUROSURG, V81, P144, DOI 10.1016/j.wneu.2013.01.004; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gennarelli TA, 1987, DIRECTIONAL DEPENDEN; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, ANN BIOMED ENG, V43, P1877, DOI 10.1007/s10439-014-1193-3; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leemans A., 2009, 17 ANN M INT SOC MAG; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morrison B, 2011, STUD MECHANOBIOL TIS, V3, P247, DOI 10.1007/8415_2011_79; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nahum A. M., 1977, 770922 SAE; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J A, 2000, Stapp Car Crash J, V44, P215; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Prasad G, 2014, NEUROIMAGE, V97, P284, DOI 10.1016/j.neuroimage.2014.04.033; Roossien DH, 2014, J CELL SCI, V127, P3593, DOI 10.1242/jcs.152611; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; The CDC NI H DoD and VA Leadership Panel, 2013, REP C TRAUM BRAIN IN; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Versace J, 1971, 15 STAPP CAR CRASH C; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049; Zhao W, 2015, IRCOBI C LYON FRANC, P208; Zhao W, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0091; Zhao W, 2015, BIOMECH MODEL MECHAN, V14, P753, DOI 10.1007/s10237-014-0634-0	76	26	26	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1834	1847		10.1089/neu.2015.4239			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300004	26782139	Green Published			2021-06-18	
J	Wang, Y; Zhang, CH; Peng, WJ; Xia, ZA; Gan, PP; Huang, W; Shi, YF; Fan, R				Wang, Yang; Zhang, Chunhu; Peng, Weijun; Xia, Zian; Gan, Pingping; Huang, Wei; Shi, Yafei; Fan, Rong			Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						hydroxysafflor yellow A; traumatic brain injury; oxidative stress; neuroprotective effect; ultra performance liquid chromatography-tandem mass spectrometry	OXIDATIVE STRESS; ISCHEMIA; MICE; NEURODEGENERATION; NEUROPROTECTION; OVEREXPRESSION; EPIDEMIOLOGY; PEROXIDATION; PERMEABILITY; CONTRIBUTES	Free radical-induced oxidative damage occurs rapidly and is of primary importance during the secondary pathophysiological cascades of traumatic brain injury (TBI). Hydroxysafflor yellow A (HSYA) is a constituent of the flower petals of Carthamus tinctorius (safflower) and may represent a potential therapeutic strategy to improve outcomes following TBI. The present study aimed to identify HSYA in the brain tissues of rats exposed to TBI to determine its absorption and to investigate the underlying effects of HSYA on antioxidant enzymes in the brain tissues of TBI rats. To determine the absorption of HSYA for the investigation of the underlying antioxidant effects of HSYA in TBI, the presence of HSYA in the brain tissues of the TBI rats was identified using an ultra performance liquid chromatography-tandem mass spectrometry method. Subsequently, the state of oxidative stress in the TBI rat model following the administration of HSYA was investigated by determining the levels of antioxidant enzymes, including superoxide dismutase (SOD), malondialdehyde (MDA) and catalase (CAT), and the ratio of glutathione (GSH)/glutathione disulfide (GSSG). The data obtained demonstrated that HSYA was absorbed in the brain tissues of the TBI rats. HSYA increased the activities of SOD and CAT, the level of GSH and the GSH/GSSG ratio. However, HSYA concomitantly decreased the levels of MDA and GSSG. These preliminary data suggest that HSYA has the potential to be utilized as a neuroprotective drug in cases of TBI.	[Wang, Yang; Zhang, Chunhu; Peng, Weijun; Xia, Zian; Gan, Pingping; Huang, Wei; Fan, Rong] Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Shi, Yafei] Guangzhou Univ Tradit Chinese Med, Coll Basic Med, Guangzhou 510006, Guangdong, Peoples R China	Fan, R (corresponding author), Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	fanrong819@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074, 81403259, 81202781, 81303098]; Administration of Traditional Chinese Medicine of Hunan Province, China [201455]	This study was supported by the National Natural Science Foundation of China (grant nos. 81303074, 81403259, 81202781 and 81303098) and the Administration of Traditional Chinese Medicine of Hunan Province, China (grant no. 201455).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Alexi T, 2000, PROG NEUROBIOL, V60, P409, DOI 10.1016/S0301-0082(99)00032-5; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bar-Or D, 2015, REDOX BIOL, V4, P340, DOI 10.1016/j.redox.2015.01.006; Bie XD, 2010, J ASIAN NAT PROD RES, V12, P239, DOI 10.1080/10286020903510636; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Ehsaei M, 2015, ACTA NEUROL BELG, V115, P69, DOI 10.1007/s13760-014-0300-4; Fan LH, 2011, CELL MOL NEUROBIOL, V31, P1187, DOI 10.1007/s10571-011-9720-3; Freire MAM, 2012, W INDIAN MED J, V61, P751; Gan L, 2015, BIOMED ENVIRON SCI, V28, P148, DOI 10.3967/bes2015.019; Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7; Guo Y, 2014, BIOMED CHROMATOGR, V28, P1090, DOI 10.1002/bmc.3124; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kim JY, 2013, J NEUROTRAUM, V30, P1170, DOI 10.1089/neu.2012.2691; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Lau WKW, 2012, NEUROTOX RES, V22, P170, DOI 10.1007/s12640-011-9301-8; Lei J, 2013, J NEUROTRAUM, V30, P529, DOI 10.1089/neu.2012.2548; Li J, 2013, BIOMED REP, V1, P925, DOI 10.3892/br.2013.162; Li J, 2013, NEUROSCI LETT, V535, P51, DOI 10.1016/j.neulet.2012.12.056; Lv LZ, 2013, INT J NANOMED, V8, P2709, DOI 10.2147/IJN.S47400; Mojtahedzadeh M, 2014, J RES MED SCI, V19, P867; Pharmacopoeia Commission of PRC, 2010, PHARMACOPOEIA PEOPLE, P141; Qi JP, 2011, INT J NANOMED, V6, P985, DOI 10.2147/IJN.S18821; Qi ZF, 2014, TRANSL STROKE RES, V5, P501, DOI 10.1007/s12975-014-0346-x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; SHARMA SK, 1980, J BIOCHEM BIOPH METH, V2, P247, DOI 10.1016/0165-022X(80)90039-1; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sun L, 2012, BRAIN RES, V1473, P227, DOI 10.1016/j.brainres.2012.07.047; Tuominen R, 2012, BRAIN INJURY, V26, P1697, DOI 10.3109/02699052.2012.722256; Wang CY, 2013, PHYTOMEDICINE, V20, P592, DOI 10.1016/j.phymed.2013.02.001; Wang D, 2012, MOLECULES, V17, P9803, DOI 10.3390/molecules17089803; Wang Y, 2012, CHIN J INTEGR MED, V18, P690, DOI 10.1007/s11655-012-1053-7; Wei XB, 2005, NEUROSCI LETT, V386, P58, DOI 10.1016/j.neulet.2005.05.069; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xie ZY, 2012, BRAIN RES, V1472, P113, DOI 10.1016/j.brainres.2012.06.053; Xue T, 2012, TOXICOL APPL PHARM, V261, P280, DOI 10.1016/j.taap.2012.04.010; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhao H, 2009, HIGH ALT MED BIOL, V10, P283, DOI 10.1089/ham.2008.1087; Zhu HB, 2003, PLANTA MED, V69, P429, DOI 10.1055/s-2003-39714	46	26	27	0	15	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	OCT	2016	14	4					3690	3696		10.3892/mmr.2016.5720			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	DZ1ED	WOS:000385580800106	27599591	Other Gold, Green Published			2021-06-18	
J	Kimbrel, NA; DeBeer, BB; Meyer, EC; Gulliver, SB; Morissette, SB				Kimbrel, Nathan A.; DeBeer, Bryann B.; Meyer, Eric C.; Gulliver, Suzy B.; Morissette, Sandra B.			Nonsuicidal self-injury and suicide attempts in Iraq/Afghanistan war veterans	PSYCHIATRY RESEARCH			English	Article						Nonsuicidal self-injury; Suicide; Suicide attempts; Suicidal ideation; PTSD; Depression; Veterans	POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; ACQUIRED CAPABILITY; WARZONE EXPERIENCES; MILITARY PERSONNEL; ERA VETERANS; RISK-FACTORS; IDEATION; PTSD; COMBAT	The present study examined the association between history of nonsuicidal self-injury (NSSI) and history of suicide attempts (SA) among 292 Iraq/Afghanistan veterans, half of whom carried a lifetime diagnosis of posttraumatic stress disorder (PTSD). Consistent with hypotheses, veterans who reported a history of NSSI were significantly more likely to report a history of SA than veterans without a history of NSSI. In addition, logistic regression demonstrated that NSSI remained a significant predictor of SA even after a wide range of covariates (i.e., combat exposure, traumatic brain injury, PTSD, depression, alcohol dependence) were considered. Taken together, these findings suggest that clinicians working with veterans should include NSSI history as part of their standard risk assessment battery. Published by Elsevier Ireland Ltd.	[Kimbrel, Nathan A.] Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA; [Kimbrel, Nathan A.] VA Midatlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA; [Kimbrel, Nathan A.] Duke Univ, Med Ctr, Durham, NC USA; [DeBeer, Bryann B.; Meyer, Eric C.] VISN 17 Ctr Excellence Res Returning War Vet, Waco, TX USA; [DeBeer, Bryann B.; Meyer, Eric C.] Cent Texas Vet Hlth Care Syst, Temple, DC USA; [DeBeer, Bryann B.; Meyer, Eric C.] Texas A&M Univ, Hlth Sci Ctr, College Stn, TX USA; [Gulliver, Suzy B.] Baylor Scott & White Healthcare Syst, Warriors Res Inst, Waco, DC USA; [Morissette, Sandra B.] Univ Texas San Antonio, San Antonio, TX USA	Kimbrel, NA (corresponding author), Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.	Nathan.Kimbrel@va.gov	Kimbrel, Nathan/P-3109-2016; Gulliver, Suzy/X-9776-2019	Kimbrel, Nathan/0000-0001-7218-1005; Gulliver, Suzy Bird/0000-0002-6476-9447	Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) Office of Research and Development (ORD) [I01RX000304]; VA VISN 17 Center of Excellence for Research on Returning War Veterans; Central Texas Veterans Health Care System; VA Mid-Atlantic Mental Illness Research, Education, and Clinical Center; Research & Development and Mental Health Services of the Durham VA Medical Center; Clinical Science Research and Development Service of the VA ORD [IK2 CX000525]; Veterans AffairsUS Department of Veterans Affairs [I01RX000304, IK2CX000525] Funding Source: NIH RePORTER	This work was supported by a Merit Award (I01RX000304) to Dr. Morissette from the Rehabilitation Research and Development Service of the Department of Veterans Affairs (VA) Office of Research and Development (ORD), the VA VISN 17 Center of Excellence for Research on Returning War Veterans, the Central Texas Veterans Health Care System, the VA Mid-Atlantic Mental Illness Research, Education, and Clinical Center, and the Research & Development and Mental Health Services of the Durham VA Medical Center. Dr. Kimbrel was supported by a Career Development Award (IK2 CX000525) from the Clinical Science Research and Development Service of the VA ORD. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	Asarnow JR, 2011, J AM ACAD CHILD PSY, V50, P772, DOI 10.1016/j.jaac.2011.04.003; Bentley KH, 2015, CLIN PSYCHOL REV, V37, P72, DOI 10.1016/j.cpr.2015.02.006; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blosnich JR, 2012, AM J PUBLIC HEALTH, V102, pS44, DOI 10.2105/AJPH.2011.300565; Briere J, 1998, AM J ORTHOPSYCHIAT, V68, P609, DOI 10.1037/h0080369; Bryan C., 2014, J CLIN PSYCHOL, P1; Bryan CJ, 2015, COMPR PSYCHIAT, V59, P1, DOI 10.1016/j.comppsych.2014.07.009; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Bryan CJ, 2011, SUICIDE LIFE-THREAT, V41, P126, DOI 10.1111/j.1943-278X.2011.00023.x; Bryan CJ, 2010, J CLIN PSYCHOL, V66, P1044, DOI 10.1002/jclp.20703; BULLMAN TA, 1994, J NERV MENT DIS, V182, P604, DOI 10.1097/00005053-199411000-00002; Chapman AL, 2006, BEHAV RES THER, V44, P371, DOI 10.1016/j.brat.2005.03.005; Crosby AE., 2011, SELF DIRECTED VIOLEN; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI 10.1016/j.psychres.2014.02.010; First MB, 1994, COMMUNICATION; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gratz KL, 2014, PSYCHOL MED, V44, P2099, DOI 10.1017/S0033291713002134; Hamza CA, 2012, CLIN PSYCHOL REV, V32, P482, DOI 10.1016/j.cpr.2012.05.003; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kimbrel NA, 2015, PSYCHIAT RES, V227, P360, DOI 10.1016/j.psychres.2015.03.026; Kimbrel NA, 2015, PSYCHIAT RES, V226, P78, DOI 10.1016/j.psychres.2014.12.007; Kimbrel NA, 2014, PSYCHIAT RES, V220, P1118, DOI 10.1016/j.psychres.2014.08.053; Kimbrel NA, 2014, PSYCHIAT RES, V220, P397, DOI 10.1016/j.psychres.2014.07.064; Kimbrel NA, 2014, J TRAUMA STRESS, V27, P474, DOI 10.1002/jts.21932; Klonsky ED, 2011, PSYCHOL MED, V41, P1981, DOI 10.1017/S0033291710002497; Klonsky ED, 2013, J ABNORM PSYCHOL, V122, P231, DOI 10.1037/a0030278; Linehan MM., 1993, COGNITIVE BEHAV TREA; Maguen S, 2012, DEPRESS ANXIETY, V29, P918, DOI 10.1002/da.21954; Miller D., 1994, WOMEN WHO HURT THEMS; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29; Nock MK, 2006, PSYCHIAT RES, V144, P65, DOI 10.1016/j.psychres.2006.05.010; Nock MK, 2006, J ABNORM PSYCHOL, V115, P616, DOI 10.1037/0021-843X.115.3.616; Pinder RJ, 2012, INT J SOC PSYCHIATR, V58, P433, DOI 10.1177/0020764011408534; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Remafedi G, 1998, AM J PUBLIC HEALTH, V88, P57, DOI 10.2105/AJPH.88.1.57; Sacks MB, 2008, J PSYCHIATR RES, V42, P487, DOI 10.1016/j.jpsychires.2007.05.001; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Silverman MM, 2007, SUICIDE LIFE-THREAT, V37, P248, DOI 10.1521/suli.2007.37.3.248; Suyemoto KL, 1998, CLIN PSYCHOL REV, V18, P531, DOI 10.1016/S0272-7358(97)00105-0; US Department of Veterans Affairs, 2013, SUICIDE DATA REPORT; Vasterling J.J., 2008, COMMUNICATION	45	26	26	1	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	SEP 30	2016	243						232	237		10.1016/j.psychres.2016.06.039			6	Psychiatry	Psychiatry	DW7EA	WOS:000383812800038	27419652	Green Accepted, Bronze			2021-06-18	
J	Cashion, AK; Gill, J; Hawes, R; Henderson, WA; Saligan, L				Cashion, Ann K.; Gill, Jessica; Hawes, Rebecca; Henderson, Wendy A.; Saligan, Leorey			National Institutes of Health Symptom Science Model sheds light on patient symptoms	NURSING OUTLOOK			English	Article						Biomarkers; Genotype; Model; Phenotype; Research; Symptom science	TRAUMATIC BRAIN-INJURY; MILITARY PERSONNEL; RADIATION-THERAPY; DIFFERENTIAL EXPRESSION; SLEEP DISTURBANCE; FATIGUE; ASSOCIATION; DEPRESSION; INSOMNIA; GENES	Since the establishment of the nursing profession, identifying and alleviating the subjective symptoms experienced by patients has been at the core of nursing practice. In supporting the scientific foundation for clinical practice, nursing science has maintained a consistent commitment to prevent, manage, and eliminate symptoms. Scientists from the intramural research program at the National Institute of Nursing Research (NINR), a component of the National Institutes of Health, developed a National Institutes of Health Symptom Science Model (NIH-SSM) to guide symptom science research programs engaged in the use of emerging "omic" methods such as the genotyping of symptom phenotypes. The NIH-SSM was developed based on the NINR intramural research program's success in designing and implementing methods for examining identified symptoms or symptom clusters. The NIH-SSM identifies the research process of characterizing symptom phenotypes, identifying and testing biomarkers, and ultimately developing clinical interventions in cancer-related fatigue, gastrointestinal disorders, and traumatic brain injuries. The purpose of this article was to demonstrate how scientists can apply the NIH-SSM, leading the broader scientific community in advancing personalized and precise clinical interventions.	[Cashion, Ann K.; Gill, Jessica; Henderson, Wendy A.; Saligan, Leorey] NINR, Div Intramural Res, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; [Hawes, Rebecca] NINR, Div Sci Policy & Publ Liaison, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA	Cashion, AK (corresponding author), Natl Inst Nursing, Dept Hlth & Human Serv, 3 Ctr Dr,Rm 5E26, Bethesda, MD 20892 USA.	Ann.cashion@nih.gov	Henderson, Wendy/F-1171-2018; Gill, Gill M/Q-2020-2017; Saligan, Leorey/M-7101-2015	Henderson, Wendy/0000-0003-3924-7118; Saligan, Leorey/0000-0001-9481-7836	Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health [s ZIA-NR000018, ZIA-NR000019, ZIA-NR000027, ZIA-NR000030]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000030, ZIANR000018, ZIANR000019, ZIANR000027] Funding Source: NIH RePORTER	Drs. A.K.C., J.G., W.A.H., and L.S. gratefully acknowledge the scientific contributions of the individuals in their labs and members of their research teams. This research was supported by the Division of Intramural Research, National Institute of Nursing Research, National Institutes of Health (Grant #s ZIA-NR000018, ZIA-NR000019, ZIA-NR000027, ZIA-NR000030).	Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889; Alosco M. L., 2015, J HEAD TRAUMA REHABI; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bower JE, 2009, CLIN CANCER RES, V15, P5534, DOI 10.1158/1078-0432.CCR-08-2584; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Cashion AK, 2015, NURS OUTLOOK, V63, P484, DOI 10.1016/j.outlook.2015.03.001; Corwin EJ, 2014, NURS OUTLOOK, V62, P346, DOI 10.1016/j.outlook.2014.06.006; Dodd M, 2001, J ADV NURS, V33, P668, DOI 10.1046/j.1365-2648.2001.01697.x; Drossman DA, 2006, ROME 3 FUNCTIONAL GA; FERRER CF, 1995, AVIAT SPACE ENVIR MD, V66, P571; Fourie NH, 2014, EXP MOL PATHOL, V96, P422, DOI 10.1016/j.yexmp.2014.04.009; Gill J, 2014, PSYCHIAT RES, V216, P116, DOI 10.1016/j.psychres.2014.01.046; Gill JM, 2015, BIOL RES NURS, V17, P384, DOI 10.1177/1099800415575343; Grundmann O, 2010, J GASTROEN HEPATOL, V25, P691, DOI 10.1111/j.1440-1746.2009.06120.x; Guardado P, 2016, J ANXIETY DISORD, V38, P9, DOI 10.1016/j.janxdis.2015.12.004; Heinzelmann M, 2014, SLEEP MED, V15, P1565, DOI 10.1016/j.sleep.2014.08.004; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Henderson W. A., 2015, GASTROENTEROLOGY NUR; Henderson WA, 2012, TRANSL BEHAV MED, V2, P1, DOI 10.1007/s13142-012-0116-9; Henderson Wendy A, 2012, World J Gastrointest Pathophysiol, V3, P102, DOI 10.4291/wjgp.v3.i6.102; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hsiao CP, 2013, INT J MOL SCI, V14, P16943, DOI 10.3390/ijms140816943; Hsiao CP, 2013, CANCER NURS, V36, P189, DOI 10.1097/NCC.0b013e318263f514; Kurz K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036956; Livingston WS, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00059; Lukkahatai N, 2014, J PAIN SYMPTOM MANAG, V47, P748, DOI 10.1016/j.jpainsymman.2013.05.016; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Miller NL, 2010, SLEEP, V33, P1623, DOI 10.1093/sleep/33.12.1623; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Patel KV, 2015, ANN PHARMACOTHER, V49, P477, DOI 10.1177/1060028015570467; Pertl MM, 2014, J HEALTH PSYCHOL, V19, P699, DOI 10.1177/1359105313477675; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Rutledge D.M., 2004, CANC SYMPTOM MANAGEM, P3; Ryan JL, 2007, ONCOLOGIST, V12, P22, DOI 10.1634/theoncologist.12-S1-22; Saligan LN, 2013, BRAIN BEHAV IMMUN, V27, P63, DOI 10.1016/j.bbi.2012.09.009; Saligan LN, 2012, BRAIN BEHAV IMMUN, V26, P830, DOI 10.1016/j.bbi.2012.05.004; Saligan L. N., 2015, WORLD J BIOL PSYCHIA, V27, P1; Saligan LN, 2014, CANCER INFORM, V13, P141, DOI 10.4137/CIN.S19745; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Seugnet L, 2009, J NEUROSCI, V29, P7148, DOI 10.1523/JNEUROSCI.5629-08.2009; U. S. Army Medical Command, 2011, JOINT MENT HLTH ADV; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845; Xiao CH, 2010, EUR J ONCOL NURS, V14, P417, DOI 10.1016/j.ejon.2010.05.011; Yellen SB, 1997, J PAIN SYMPTOM MANAG, V13, P63, DOI 10.1016/S0885-3924(96)00274-6; Yost KJ, 2011, J CLIN EPIDEMIOL, V64, P507, DOI 10.1016/j.jclinepi.2010.11.018	45	26	26	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0029-6554	1528-3968		NURS OUTLOOK	Nurs. Outlook	SEP-OCT	2016	64	5			SI		499	506		10.1016/j.outlook.2016.05.008			8	Nursing	Nursing	DW6CE	WOS:000383733200013	27349632	Green Accepted			2021-06-18	
J	Guo, L; Zhang, HY; Hou, YL; Wei, TS; Liu, J				Guo, Ling; Zhang, Hongyan; Hou, Yinglong; Wei, Tianshu; Liu, Ju			Plasmalemma vesicle-associated protein: A crucial component of vascular homeostasis	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						plasmalemma vesicle-associated protein-1; endothelial cell; diaphragms; permeability; homeostasis	FAMILIAL EXUDATIVE VITREORETINOPATHY; SPINAL-CORD-INJURY; FENESTRAL DIAPHRAGMS; GENE-EXPRESSION; PHENOTYPIC HETEROGENEITY; DIABETIC-RETINOPATHY; ENDOTHELIAL-CELLS; LYMPH-NODES; VEGF-A; PAL-E	Endothelial subcellular structures, including caveolae, fenestrae and transendothelial channels, are crucial for regulating microvascular function. Plasmalemma vesicle-associated protein (PLVAP) is an endothelial cell-specific protein that forms the stomatal and fenestral diaphragms of blood vessels and regulates basal permeability, leukocyte migration and angiogenesis. Loss of PLVAP in mice leads to premature mortality due to disrupted homeostasis. Evidence from previous studies suggested that PLVAP is involved in cancer, traumatic spinal cord injury, acute ischemic brain disease, transplant glomerulopathy, Norrie disease and diabetic retinopathy. Specifically, PLVAP expression has been demonstrated to be upregulated in these diseases, accompanied by pro-angiogenic or pro-inflammatory responses. Therefore, PLVAP is considered a novel therapeutic target, in addition to an endothelial cell marker. The present review summarizes the structure and functions of PLVAP, and its roles in pathophysiological processes.	[Guo, Ling; Liu, Ju] Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Lab Microvasc Med, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China; [Zhang, Hongyan] Taishan Med Univ, Dept Cardiovasc Med, Xintai City Peoples Hosp, Xintai 271200, Shandong, Peoples R China; [Hou, Yinglong] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Cardiol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China; [Wei, Tianshu] Univ Melbourne, Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia	Liu, J (corresponding author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Med Res Ctr, Lab Microvasc Med, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.; Hou, YL (corresponding author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Cardiol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.	houyinglong2013@hotmail.com; ju.liu@sdu.edu.cn	Liu, Ju/Q-6319-2016	Liu, Ju/0000-0001-9932-2613	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81370269]; Shandong Taishan Scholarship	The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81370269). We are grateful for the support from the Shandong Taishan Scholarship, which was awarded to Dr Ju Liu.	Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; BEARER EL, 1985, J CELL BIOL, V100, P418, DOI 10.1083/jcb.100.2.418; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Black GCM, 1999, HUM MOL GENET, V8, P2031, DOI 10.1093/hmg/8.11.2031; Carson-Walter EB, 2005, CLIN CANCER RES, V11, P7643, DOI 10.1158/1078-0432.CCR-05-1099; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; CHEN ZY, 1993, NAT GENET, V5, P180, DOI 10.1038/ng1093-180; Deharvengt SJ, 2012, J CELL MOL MED, V16, P2690, DOI 10.1111/j.1582-4934.2012.01587.x; Germain RN, 2012, SCIENCE, V336, P1676, DOI 10.1126/science.1221063; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; HALLMANN R, 1995, DEV DYNAM, V202, P325, DOI 10.1002/aja.1002020402; Herrnberger L, 2012, HISTOCHEM CELL BIOL, V138, P709, DOI 10.1007/s00418-012-0987-3; Hisatsune H, 2005, BLOOD, V105, P4657, DOI 10.1182/blood-2004-09-3554; Hnasko R, 2002, J ENDOCRINOL, V175, P649, DOI 10.1677/joe.0.1750649; Hnasko R, 2006, CELL CYCLE, V5, P2012, DOI 10.4161/cc.5.17.3216; Hofman P, 2001, OPHTHALMIC RES, V33, P156, DOI 10.1159/000055663; Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637; Ichimura K, 2008, J AM SOC NEPHROL, V19, P1463, DOI 10.1681/ASN.2007101138; Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103; Joosten SA, 2005, KIDNEY INT, V68, P1, DOI 10.1111/j.1523-1755.2005.00376.x; Keuschnigg J, 2009, BLOOD, V114, P478, DOI 10.1182/blood-2008-11-188763; Klaassen I, 2009, EXP EYE RES, V89, P4, DOI 10.1016/j.exer.2009.01.006; Liu Y, 2010, J NEURO-ONCOL, V99, P13, DOI 10.1007/s11060-009-0105-0; Luhmann UFO, 2005, INVEST OPHTH VIS SCI, V46, P3372, DOI 10.1167/iovs.05-0174; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; MILICI AJ, 1985, CIRC RES, V56, P709, DOI 10.1161/01.RES.56.5.709; Minshall R. D., 2006, V176, P107; Mozer AB, 2010, CURR NEUROVASC RES, V7, P238; Niemela H, 2005, BLOOD, V106, P3405, DOI 10.1182/blood-2005-01-0254; Rantakari P, 2015, NAT IMMUNOL, V16, P386, DOI 10.1038/ni.3101; Rostgaard J, 1997, MICROVASC RES, V53, P1, DOI 10.1006/mvre.1996.1987; Schafer NF, 2009, INVEST OPHTH VIS SCI, V50, P906, DOI 10.1167/iovs.08-1731; Shastry BS, 1997, HUM MUTAT, V9, P396, DOI 10.1002/(SICI)1098-1004(1997)9:5<396::AID-HUMU3>3.0.CO;2-2; Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29; SIMIONESCU M, 1981, J CELL BIOL, V90, P614, DOI 10.1083/jcb.90.3.614; Stan RV, 2007, J CELL MOL MED, V11, P621, DOI 10.1111/j.1582-4934.2007.00075.x; Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003; Stan RV, 1999, J CELL BIOL, V145, P1189, DOI 10.1083/jcb.145.6.1189; Stan RV, 2004, MOL BIOL CELL, V15, P3615, DOI 10.1091/mbc.E03-08-0593; Stan RV, 2004, AM J PHYSIOL-HEART C, V286, pH1347, DOI 10.1152/ajpheart.00909.2003; Stan RV, 2001, GENOMICS, V72, P304, DOI 10.1006/geno.2000.6489; Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203; Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008; Strickland LA, 2005, J PATHOL, V206, P466, DOI 10.1002/path.1805; Tichauer KM, 2014, MOL IMAGING BIOL, V16, P372, DOI 10.1007/s11307-013-0692-1; Tse D, 2010, SEMIN THROMB HEMOST, V36, P236, DOI 10.1055/s-0030-1253447; Wang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-815; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; WILLIAMSON J, 1961, AM J PATHOL, V39, P239; Wisniewska-Kruk J, 2014, EXP EYE RES, V122, P123, DOI 10.1016/j.exer.2014.03.005; Wisniewska-Kruk J, 2012, EXP EYE RES, V96, P181, DOI 10.1016/j.exer.2011.12.003; Yamamoto I, 2007, AM J TRANSPLANT, V7, P1954, DOI 10.1111/j.1600-6143.2007.01876.x	53	26	26	2	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	SEP	2016	12	3					1639	1644		10.3892/etm.2016.3557			6	Medicine, Research & Experimental	Research & Experimental Medicine	DU8EL	WOS:000382446000062	27602081	Green Published, Other Gold			2021-06-18	
J	Meehan, WP; O'Brien, MJ; Geminiani, E; Mannix, R				Meehan, William P., III; O'Brien, Michael J.; Geminiani, Ellen; Mannix, Rebekah			Initial symptom burden predicts duration of symptoms after concussion	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Mild traumatic brain injury; Sports; Head trauma; Sports injury	SPORT-RELATED CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; PROTRACTED RECOVERY; PROLONGED RECOVERY; AGE; MANAGEMENT; MIGRAINE; HEAD	Objectives: To determine which variables predict prolonged (>28 days) duration of symptoms after a concussion. Design: We conducted a prospective cohort study of adult (>18yo) patients cared for in a specialty concussion clinic. Methods: Symptoms were assessed using the Post-Concussion Symptom Scale (PCSS) developed at the 3rd International Conference on Concussion in Sports. Possible predictors including age, sex, loss of consciousness, amnesia, history of prior concussion, prior treatment for headaches, history of migraines, and family history of concussions, were measured by self-report. We recorded a PCSS score at each clinical visit and defined time to symptom resolution as the number of days between the date of injury and date of last symptoms. Results: Of 64 adult patients included in the study, 53.3% were male; 20.3% reported experiencing a loss of consciousness at the time of injury while 23.4% reported amnesia. Patients ranged in age from 18 to 27 years (mean 21 2 years). Most concussions (92.2%) occurred during sports. The mean initial PCSS score for those suffering symptoms for longer than 28 days was significantly higher than those who symptoms resolved within 28 days (42.5 vs. 19.2, p<0.01). Of all potential predictor variables, only the initial PCSS score was independently associated with the odds of symptoms lasting longer than 28 days (aOR 1.037; 95% CI 1.011, 1.063). Conclusions: Among adult patients with concussions, those with a higher symptom burden after injury have an increased odds of suffering from prolonged symptoms. Other potential predictor variables are not associated with the risk of prolonged recovery. (C) 2015 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Meehan, William P., III; O'Brien, Michael J.; Geminiani, Ellen; Mannix, Rebekah] Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA; [Meehan, William P., III; O'Brien, Michael J.; Geminiani, Ellen] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA USA; [Meehan, William P., III; O'Brien, Michael J.; Mannix, Rebekah] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Meehan, William P., III; Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA	Meehan, WP (corresponding author), Micheli Ctr Sports Injury Prevent, Waltham, MA 02453 USA.; Meehan, WP (corresponding author), Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA USA.; Meehan, WP (corresponding author), Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA.; Meehan, WP (corresponding author), Boston Childrens Hosp, Div Emergency Med, Boston, MA USA.	William.meehan@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A]; NFL Players Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health (NIH) T32 HD040128-06A (Meehan) and the NFL Players Association (Meehan).	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; BERNEY J, 1994, CHILD NERV SYST, V10, P517, DOI 10.1007/BF00335074; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Sperandei S, 2013, BIOCHEM MEDICA, V24, P12; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x	25	26	26	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	SEP	2016	19	9					722	725		10.1016/j.jsams.2015.12.002			4	Sport Sciences	Sport Sciences	DV3DJ	WOS:000382800900007	26718812	Green Accepted			2021-06-18	
J	Ballester, BR; Maier, M; Mozo, RMSS; Castaneda, V; Duff, A; Verschure, PFMJ				Rubio Ballester, Belen; Maier, Martina; Segundo Mozo, Rosa Maria San; Castaneda, Victoria; Duff, Armin; Verschure, Paul F. M. J.			Counteracting learned non-use in chronic stroke patients with reinforcement-induced movement therapy	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Stroke; Rehabilitation; Deductive medicine; Learned non-use; Virtual reality	TRAUMATIC BRAIN-INJURY; VIRTUAL-REALITY; FUNCTIONAL RECOVERY; UPPER-LIMB; REHABILITATION; ARM; NEUROREHABILITATION; RELIABILITY; INTEGRATION; ADJUSTMENT	Background: After stroke, patients who suffer from hemiparesis tend to suppress the use of the affected extremity, a condition called learned non-use. Consequently, the lack of training may lead to the progressive deterioration of motor function. Although Constraint-Induced Movement Therapies (CIMT) have shown to be effective in treating this condition, the method presents several limitations, and the high intensity of its protocols severely compromises its adherence. We propose a novel rehabilitation approach called Reinforcement-Induced Movement Therapy (RIMT), which proposes to restore motor function through maximizing arm use. This is achieved by exposing the patient to amplified goal-oriented movements in VR that match the intended actions of the patient. We hypothesize that through this method we can increase the patients self-efficacy, reverse learned non-use, and induce long-term motor improvements. Methods: We conducted a randomized, double-blind, longitudinal clinical study with 18 chronic stroke patients. Patients performed 30 minutes of daily VR-based training during six weeks. During training, the experimental group experienced goal-oriented movement amplification in VR. The control group followed the same training protocol but without movement amplification. Evaluators blinded to group designation performed clinical measurements at the beginning, at the end of the training and at 12-weeks follow-up. We used the Fugl-Meyer Assessment for the upper extremities (UE-FM) (Sanford et al., Phys Ther 73:447-454, 1993) as a primary outcome measurement of motor recovery. Secondary outcome measurements included the Chedoke Arm and Hand Activity Inventory (CAHAI-7) (Barreca et al., Arch Phys Med Rehabil 6:1616-1622, 2005) for measuring functional motor gains in the performance of Activities of Daily Living (ADLs), the Barthel Index (BI) for the evaluation of the patient's perceived independence (Collin et al., Int Disabil Stud 10:61-63, 1988), and the Hamilton scale (Knesevich et al., Br J Psychiatr J Mental Sci 131:49-52, 1977) for the identification of improvements in mood disorders that could be induced by the reinforcement-based intervention. In order to study and predict the effects of this intervention we implemented a computational model of recovery after stroke. Results: While both groups showed significant motor gains at 6-weeks post-treatment, only the experimental group continued to exhibit further gains in UE-FM at 12-weeks follow-up (p < .05). This improvement was accompanied by a significant increase in arm-use during training in the experimental group. Conclusions: Implicitly reinforcing arm-use by augmenting visuomotor feedback as proposed by RIMT seems beneficial for inducing significant improvement in chronic stroke patients. By challenging the patients' self-limiting believe system and perceived low self-efficacy this approach might counteract learned non-use.	[Rubio Ballester, Belen; Maier, Martina; Duff, Armin; Verschure, Paul F. M. J.] Univ Pompeu Fabra, Lab Synthet Percept Emot & Cognit Syst, Roc Boronat 138, Barcelona, Spain; [Verschure, Paul F. M. J.] ICREA, Barcelona, Spain; [Segundo Mozo, Rosa Maria San; Castaneda, Victoria] Hosp Univ Joan XXIII Tarragona, Serv Med Fis & Rehabil, Tarragona, Spain	Verschure, PFMJ (corresponding author), Univ Pompeu Fabra, Lab Synthet Percept Emot & Cognit Syst, Roc Boronat 138, Barcelona, Spain.; Verschure, PFMJ (corresponding author), ICREA, Barcelona, Spain.	paul.verschure@upf.edu		Rubio Ballester, Belen/0000-0003-3496-5356; Maier, Martina/0000-0001-8898-5657	ERCEuropean Research Council (ERC)European Commission [FP7-IDEAS-ERC 341196]; ECEuropean CommissionEuropean Commission Joint Research Centre [H2020-EU.1.2.2. 641321]; MINECO; ICREAICREA Funding Source: Custom	This project was supported through ERC project cDAC (FP7-IDEAS-ERC 341196), EC H2020 project socSMCs (H2020-EU.1.2.2. 641321) and MINECO project SANAR (Gobierno de Espana).	Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; ANDREWS K, 1979, RHEUMATOL REHABIL, V18, P43, DOI 10.1093/rheumatology/18.1.43; Arbib MA, 2008, MIND SOC, V7, P43, DOI DOI 10.1007/S11299-007-0041-7; Ballester BR, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0039-z; Ballester BR, 2015, INT C VIRT REH ICVR; Ballester BR, 2015, IEEE INT C REH ROB I; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barreca SR, 2005, ARCH PHYS MED REHAB, V86, P1616, DOI 10.1016/j.apmr.2005.03.017; Bonaiuto J, 2010, BIOL CYBERN, V102, P341, DOI 10.1007/s00422-010-0371-0; Cameirao MS, 2012, STROKE, V43, P2720, DOI 10.1161/STROKEAHA.112.653196; Cameirao MS, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-48; Collin C, 1988, Int Disabil Stud, V10, P61; Daw ND, 2002, NEURAL NETWORKS, V15, P603, DOI 10.1016/S0893-6080(02)00052-7; Dettmers C, 2005, ARCH PHYS MED REHAB, V86, P204, DOI 10.1016/j.apmr.2004.05.007; DONNELLAN KS, 1968, PHILOS REV, V77, P203, DOI 10.2307/2183321; FOLKMAN S, 1988, SOC SCI MED, V26, P309, DOI 10.1016/0277-9536(88)90395-4; Han CE, 2013, NEUROREHAB NEURAL RE, V27, P439, DOI 10.1177/1545968312471904; Han CE, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000133; Herzfeld DJ, 2014, SCIENCE, V345, P1349, DOI 10.1126/science.1253138; ILLERT M, 1976, EXP BRAIN RES, V26, P509; Jones F, 2006, DISABIL REHABIL, V28, P841, DOI 10.1080/09638280500534952; KNESEVICH JW, 1977, BRIT J PSYCHIAT, V131, P49, DOI 10.1192/bjp.131.1.49; Kwakkel G, 2015, LANCET NEUROL, V14, P224, DOI 10.1016/S1474-4422(14)70160-7; Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; Lucca LF, 2009, J REHABIL MED, V41, P1003, DOI 10.2340/16501977-0405; Marcos E, 2013, BMC NEUROSCI, V14, P408, DOI [10.1186/1471-2202-14-S1-P408, DOI 10.1186/1471-2202-14-S1-P408]; Marcos E, 2013, NEURON, V78, P249, DOI 10.1016/j.neuron.2013.02.006; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Nirme J, 2011, IEEE ENG MED BIO, P6749, DOI 10.1109/IEMBS.2011.6091665; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Page SJ, 2002, CLIN REHABIL, V16, P55, DOI 10.1191/0269215502cr473oa; Page SJ, 2005, NEUROREHAB NEURAL RE, V19, P27, DOI 10.1177/1545968304272701; Prochnow D, 2013, EUR J NEUROSCI, V37, P1441, DOI 10.1111/ejn.12157; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; SANFORD J, 1993, PHYS THER, V73, P447, DOI 10.1093/ptj/73.7.447; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Schweighofer N, 2009, PHYS THER, V89, P1327, DOI 10.2522/ptj.20080402; Shelton FDAP, 2001, NEUROREHAB NEURAL RE, V15, P229, DOI 10.1177/154596830101500311; Smania N, 2012, NEUROREHAB NEURAL RE, V26, P1035, DOI 10.1177/1545968312446003; Sterr A, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00204; Stins JF, 2001, LATERALITY, V6, P347; Sutton R.S., 1998, IEEE T NEURAL NETWOR, DOI [DOI 10.1109/TNN.1998.712192, 10.1109/tnn.1998.712192]; Taub E, 2006, Eura Medicophys, V42, P241; Taub E, 2003, J REHABIL MED, V35, P34, DOI 10.1080/16501960310010124; Timmermans AAA, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-1; Verschure PFMJ, 2012, BIOL INSPIR COGN ARC, V1, P55, DOI 10.1016/j.bica.2012.04.005; Verschure PFMJ, 2003, NATURE, V425, P620, DOI 10.1038/nature02024; Viana R, 2012, TOP STROKE REHABIL, V19, P104, DOI 10.1310/tsr1902-104; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408	51	26	27	0	36	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1743-0003		J NEUROENG REHABIL	J. NeuroEng. Rehabil.	AUG 9	2016	13								74	10.1186/s12984-016-0178-x			15	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	DT2UT	WOS:000381338000001	27506203	DOAJ Gold, Green Published			2021-06-18	
J	Barateiro, A; Afonso, V; Santos, G; Cerqueira, JJ; Brites, D; van Horssen, J; Fernandes, A				Barateiro, Andreia; Afonso, Vera; Santos, Gisela; Cerqueira, Joo Jos; Brites, Dora; van Horssen, Jack; Fernandes, Adelaide			S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis	MOLECULAR NEUROBIOLOGY			English	Article						Cerebellar organotypic slice cultures; Demyelination; Glial inflammatory response; Human samples; Multiple sclerosis; S100B	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; END-PRODUCTS; NEUROBIOCHEMICAL MARKERS; S-100 PROTEIN; IN-VITRO; DEMYELINATION; RECEPTOR	Multiple sclerosis (MS) pathology is characterized by neuroinflammation and demyelination. Recently, the inflammatory molecule S100B was identified in cerebrospinal fluid (CSF) and serum of MS patients. Although seen as an astrogliosis marker, lower/physiological levels of S100B are involved in oligodendrocyte differentiation/maturation. Nevertheless, increased S100B levels released upon injury may induce glial reactivity and oligodendrocyte demise, exacerbating tissue damage during an MS episode or delaying the following remyelination. Here, we aimed to unravel the functional role of S100B in the pathogenesis of MS. Elevated S100B levels were detected in the CSF of relapsing-remitting MS patients at diagnosis. Active demyelinating MS lesions showed increased expression of S100B and its receptor, the receptor for advanced glycation end products (RAGE), in the lesion area, while chronic active lesions displayed increased S100B in demyelinated areas with lower expression of RAGE in the rim. Interestingly, reactive astrocytes were identified as the predominant cellular source of S100B, whereas RAGE was expressed by activated microglia/macrophages. Using an ex vivo demyelinating model, cerebral organotypic slice cultures treated with lysophosphatidylcholine (LPC), we observed a marked elevation of S100B upon demyelination, which co-localized mostly with astrocytes. Inhibition of S100B action using a directed antibody reduced LPC-induced demyelination, prevented astrocyte reactivity and abrogated the expression of inflammatory and inflammasome-related molecules. Overall, high S100B expression in MS patient samples suggests its usefulness as a diagnostic biomarker for MS, while the beneficial outcome of its inhibition in our demyelinating model indicates S100B as an emerging therapeutic target in MS.	[Barateiro, Andreia; Afonso, Vera; Santos, Gisela; Brites, Dora; Fernandes, Adelaide] Univ Lisbon, Res Inst Med iMed ULisboa, Fac Pharm, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal; [Cerqueira, Joo Jos] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Campus Gualtar, P-4710057 Braga, Portugal; [Cerqueira, Joo Jos] ICVS 3Bs PT Govt Associate Lab, Braga Guimaraes, Portugal; [Brites, Dora; Fernandes, Adelaide] Univ Lisbon, Dept Biochem & Human Biol, Fac Pharm, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal; [van Horssen, Jack] Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol & Immunol, Neurosci Campus Amsterdam,POB 7057, NL-1007 MB Amsterdam, Netherlands	Fernandes, A (corresponding author), Univ Lisbon, Res Inst Med iMed ULisboa, Fac Pharm, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal.	amaf@ff.ulisboa.pt	Santos, Gisela/AAG-1929-2019; Barateiro, Andreia/AAE-1711-2021; Fernandes, Adelaide/AAX-4091-2020; Brites, Dora/M-8293-2013; Fernandes, Adelaide/A-4787-2011; Cerqueira, Joao J/B-4579-2008; iMed.ULisboa, NeuronGliaBiol/B-5403-2014; Barateiro, Andreia/I-5746-2014	Fernandes, Adelaide/0000-0002-2782-9519; Brites, Dora/0000-0002-3024-9777; Fernandes, Adelaide/0000-0002-2782-9519; Cerqueira, Joao J/0000-0003-3155-2775; Barateiro, Andreia/0000-0002-0378-4854; Santos, Gisela/0000-0002-7264-9162	Medal of Honor L'Oreal for Women in Science (FCT, UNESCO, L'Oreal); Ordem dos Farmaceuticos; Fundacao para a Ciencia e TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission [FCT-SFRH/BPD/96794/2013]; DuPre Grant from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS);  [FCT-Pest-OE/SAU/UI4013]	This work was supported by Medal of Honor L'Oreal for Women in Science (FCT, UNESCO, L'Oreal) and innovation grant (Ordem dos Farmaceuticos) to AF, a post-doctoral grant from Fundacao para a Ciencia e Tecnologia (FCT-SFRH/BPD/96794/2013) and a DuPre Grant from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) to AB, and by FCT-Pest-OE/SAU/UI4013 to iMed.ULisboa.	Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; Astrand Ramona, 2013, Methods Mol Biol, V963, P373, DOI 10.1007/978-1-62703-230-8_23; Bartosik-Psujek H, 2011, ACTA NEUROL SCAND, V123, P252, DOI 10.1111/j.1600-0404.2010.01393.x; Bianchi R, 2011, J BIOL CHEM, V286, P7214, DOI 10.1074/jbc.M110.169342; Bianchi R, 2010, NEUROBIOL AGING, V31, P665, DOI 10.1016/j.neurobiolaging.2008.05.017; Birgbauer E, 2004, J NEUROSCI RES, V78, P157, DOI 10.1002/jnr.20248; Blakemore WF, 2003, EXP NEUROL, V184, P955, DOI 10.1016/S0014-4886(03)00347-9; Brozzi F, 2009, J BIOL CHEM, V284, P8788, DOI 10.1074/jbc.M805897200; Cammer W, 1999, J NEUROIMMUNOL, V97, P37, DOI 10.1016/S0165-5728(99)00045-4; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Chen YC, 2012, J NEUROIMMUNOL, V243, P56, DOI 10.1016/j.jneuroim.2011.12.008; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Deloulme JC, 2004, MOL CELL NEUROSCI, V27, P453, DOI 10.1016/j.mcn.2004.07.008; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Dyer JK, 2005, SPINAL CORD, V43, P417, DOI 10.1038/sj.sc.3101737; Falcao AS, 2014, NEUROTOX RES, V26, P1, DOI 10.1007/s12640-013-9427-y; Farooq SM, 2014, BRAIN BEHAV IMMUN, V42, P118, DOI 10.1016/j.bbi.2014.06.010; Ortiz GG, 2014, ARCH MED RES, V45, P687, DOI 10.1016/j.arcmed.2014.11.013; Gerlach R, 2006, NEUROSCIENCE, V141, P1697, DOI 10.1016/j.neuroscience.2006.05.008; Goncalves DS, 2000, NEUROREPORT, V11, P807, DOI 10.1097/00001756-200003200-00030; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Hachem S, 2005, GLIA, V51, P81, DOI 10.1002/glia.20184; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Inoue M, 2013, AUTOIMMUN DIS, V2013, DOI 10.1155/2013/859145; Inoue M, 2012, P NATL ACAD SCI USA, V109, P10480, DOI 10.1073/pnas.1201836109; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Kooi EJ, 2011, ACTA NEUROPATHOL, V122, P313, DOI 10.1007/s00401-011-0849-4; Kotter MR, 2001, GLIA, V35, P204, DOI 10.1002/glia.1085; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Lu B, 2013, PROTEIN CELL, V4, P163, DOI 10.1007/s13238-012-2118-2; MICHETTI F, 1979, NEUROSCI LETT, V11, P171, DOI 10.1016/0304-3940(79)90122-8; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Miron VE, 2010, AM J PATHOL, V176, P2682, DOI 10.2353/ajpath.2010.091234; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Napoli I, 2010, EXP NEUROL, V225, P24, DOI 10.1016/j.expneurol.2009.04.024; NEEPER M, 1992, J BIOL CHEM, V267, P14998; O'Connell KE, 2014, AUTOIMMUNITY, V47, P505, DOI 10.3109/08916934.2014.930734; Ondruschka B, 2013, J NEUROTRAUM, V30, P1862, DOI 10.1089/neu.2013.2895; Ostendorp T, 2007, EMBO J, V26, P3868, DOI 10.1038/sj.emboj.7601805; Pan WH, 2010, METHODS MOL BIOL, V629, P367, DOI [10.1007/978-1-60761-657-3_24, 10.3791/2039]; Park JW, 2013, YONSEI MED J, V54, P567, DOI 10.3349/ymj.2013.54.3.567; Petzold A, 2002, BRAIN, V125, P1462, DOI 10.1093/brain/awf165; Reali C, 2005, J NEUROSCI RES, V81, P677, DOI 10.1002/jnr.20584; Rejdak K, 2008, MULT SCLER J, V14, P59, DOI 10.1177/1352458507082061; Rejdak K, 2007, J NEURAL TRANSM, V114, P1011, DOI 10.1007/s00702-007-0667-y; Robinson AP, 2013, J AUTOIMMUN, V43, P32, DOI 10.1016/j.jaut.2013.02.005; Rossi S, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-32; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Sheridan GK, 2012, GLIA, V60, P382, DOI 10.1002/glia.22272; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sorci Guglielmo, 2010, Cardiovasc Psychiatry Neurol, V2010, DOI 10.1155/2010/656481; Steiner J, 2008, NEUROSCIENCE, V154, P496, DOI 10.1016/j.neuroscience.2008.03.060; Steinhoff BJ, 1999, EPILEPSY RES, V36, P75, DOI 10.1016/S0920-1211(99)00026-1; Su ZD, 2011, J NEUROTRAUM, V28, P1089, DOI 10.1089/neu.2010.1597; TAKAHASHI K, 1984, VIRCHOWS ARCH B, V45, P385, DOI 10.1007/BF02889881; Turco F, 2014, GUT, V63, P105, DOI 10.1136/gutjnl-2012-302090; van der Valk P, 2000, NEUROPATH APPL NEURO, V26, P2, DOI 10.1046/j.1365-2990.2000.00217.x; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; Villarreal A, 2014, J NEUROCHEM, V131, P190, DOI 10.1111/jnc.12790; Villarreal A, 2011, J NEUROCHEM, V117, P321, DOI 10.1111/j.1471-4159.2011.07207.x; Witte ME, 2009, J PATHOL, V219, P193, DOI 10.1002/path.2582; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Xie JJ, 2008, J BIOL CHEM, V283, P27255, DOI 10.1074/jbc.M801622200; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831; Zhang LY, 2011, GLIA, V59, P486, DOI 10.1002/glia.21118	71	26	27	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2016	53	6					3976	3991		10.1007/s12035-015-9336-6			16	Neurosciences	Neurosciences & Neurology	DR2AO	WOS:000379707600040	26184632				2021-06-18	
J	LoBue, C; Wilmoth, K; Cullum, CM; Rossetti, HC; Lacritz, LH; Hynan, LS; Hart, J; Womack, KB				LoBue, Christian; Wilmoth, Kristin; Cullum, C. Munro; Rossetti, Heidi C.; Lacritz, Laura H.; Hynan, Linda S.; Hart, John, Jr.; Womack, Kyle B.			Traumatic brain injury history is associated with earlier age of onset of frontotemporal dementia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ENVIRONMENTAL RISK-FACTORS; HEAD-INJURY; ALZHEIMERS-DISEASE; POPULATION; ENCEPHALOPATHY; DEGENERATION; TDP-43	Objective We retrospectively examined whether a history of traumatic brain injury (TBI) is associated with an earlier age of symptom onset and diagnosis in a large sample of patients with behavioural variant frontotemporal dementia (bvFTD). Methods Data on patients with bvFTD (n=678) were obtained from the National Alzheimer's Coordinating Center Uniform Data Set. TBI was categorised based on reported lifetime history of TBI with loss of consciousness (LOC) but no chronic deficits occurring more than 1 year prior to diagnosis of bvFTD. Analysis of covariance (ANCOVA) was used to determine if clinician-estimated age of symptom onset and age at diagnosis of bvFTD differed between those who reported a history of TBI with LOC (TBI+) and those who did not (TBI-). Results Controlling for sex, the TBI+ bvFTD group had an age of symptom onset and age of diagnosis that was on average 2.8 and 3.2 years earlier (p<0.01) than the TBI-bvFTD group. Conclusions TBI history with LOC occurring more than 1 year prior to diagnosis is associated with an earlier age of symptom onset and diagnosis in patients with bvFTD. TBI may be related to the underlying neurodegenerative processes in bvFTD, but the implications of age at time of injury, severity and repetitive injuries remain unclear.	[LoBue, Christian; Wilmoth, Kristin; Cullum, C. Munro; Rossetti, Heidi C.; Lacritz, Laura H.; Hynan, Linda S.; Hart, John, Jr.; Womack, Kyle B.] Univ Texas Southwestern Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; [Cullum, C. Munro; Lacritz, Laura H.; Hart, John, Jr.; Womack, Kyle B.] Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas Southwestern Med Ctr, Dept Clin Sci, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.] Univ Texas Dallas, Ctr BrainHlth, Sch Behav & Brain Sci, Dallas, TX 75230 USA	Womack, KB (corresponding author), Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	kyle.womack@utsouthwestern.edu	Hynan, Linda S/P-6473-2016; Womack, Kyle/O-5422-2018; Cullum, C. Munro/AAC-2496-2019; Wilmoth, Kristin/ABB-4014-2020	Womack, Kyle/0000-0002-6060-9075; Cullum, C. Munro/0000-0001-9706-5465; Wilmoth, Kristin/0000-0003-4192-8756; Hynan, Linda/0000-0002-4642-7769	NIH/NIA Alzheimer's Disease Center grant [P30 AG012300]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017]; National Institute of AgeingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501]; (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG012300, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P50 AG005136, P50 AG033514, P50 AG005681, P50 AG000000, U01 AG032984]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG003991, P30AG010133, P30AG010124, P50AG005138, P30AG013846, P50AG016570, P30AG013854, P30AG019610, U01AG016976, P50AG016573, P50AG005133, P30AG028383, P30AG012300, P50AG005131, P50AG005136, P50AG025688, U01AG032984, P50AG005142, P50AG033514, P50AG008702, P50AG005134, P30AG010161, P50AG005681, P30AG035982, P50AG016574, P50AG005146, P30AG008051, P50AG023501, P30AG010129, P30AG008017] Funding Source: NIH RePORTER	This study was provided funding in part by the NIH/NIA P30 AG012300 Alzheimer's Disease Center grant. The NACC database is funded by NIA/NIH grant U01 AG016976. NACC data are contributed by the NIA funded: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD), P50 AG000000 (PI Bruce Wayne and Co-PI Richard Grayson, Gotham City Concussion Study). The Alzheimer's Disease Genetic Consortium (ADGC) is funded by NIA grant U01 AG032984.	Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; Barker WW, 2002, ALZ DIS ASSOC DIS, V16, P203, DOI 10.1097/00002093-200210000-00001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Boot BP, 2013, NEUROLOGY, V81, P833, DOI 10.1212/WNL.0b013e3182a2cbd1; Brunnstrom H, 2009, ARCH GERONTOL GERIAT, V49, P146, DOI 10.1016/j.archger.2008.06.005; Chapman J, 2001, NEUROLOGY, V57, P1482, DOI 10.1212/WNL.57.8.1482; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Deutsch MB, 2015, DEMENT GERIATR COGN, V39, P143, DOI 10.1159/000369787; Faul M, 2010, TRAUMATIC BRAIN INJU, V2, P1; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kalkonde YV, 2012, ALZHEIMERS DEMENT, V8, P204, DOI 10.1016/j.jalz.2011.03.011; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ng ASL, 2015, ANN NY ACAD SCI, V1338, P71, DOI 10.1111/nyas.12638; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pupillo E, 2012, EUR J NEUROL, V19, P1509, DOI 10.1111/j.1468-1331.2012.03723.x; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Schoenberg MR, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P357, DOI 10.1007/978-0-387-76978-3_14; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	40	26	26	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2016	87	8					817	820		10.1136/jnnp-2015-311438			4	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	DS1VP	WOS:000380392200004	26359171	Green Accepted			2021-06-18	
J	Shahan, CP; Magnotti, LJ; McBeth, PB; Weinberg, JA; Croce, MA; Fabian, TC				Shahan, Charles P.; Magnotti, Louis J.; McBeth, Paul B.; Weinberg, Jordan A.; Croce, Martin A.; Fabian, Timothy C.			Early antithrombotic therapy is safe and effective in patients with blunt cerebrovascular injury and solid organ injury or traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	29th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		Blunt cerebrovascular injury; antithrombotic therapy; traumatic brain injury; solid organ injury; bleeding complications	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CAROTID INJURIES; FOLLOW-UP; OUTCOMES; ANTICOAGULATION; ACCURACY; DIAGNOSIS	BACKGROUND: Early antithrombotic therapy (AT) is the mainstay of treatment in the management of blunt cerebrovascular injury (BCVI). Despite this, optimal timing of initiation of AT in patients with BCVI in the presence of concomitant traumatic brain injury (TBI) or solid organ injury (SOI) remains controversial. The purpose of this study was to evaluate the impact of early initiation of AT on outcomes in patients with BCVI and TBI and/or SOI. METHODS: Patients with BCVI and concomitant TBI and/or SOI over 6 years were identified. Aspirin and/or clopidogrel or low-intensity heparin infusion (AT) was instituted in all patients immediately upon diagnosis of BCVI. Cessation of AT, worsening TBI, the need for delayed operative intervention, ischemic stroke, and mortality were reviewed and compared. Worsening of TBI or delayed operative intervention for SOI were compared with those of patients without BCVI treated at the same institution during the study period. RESULTS: A total of 119 patients (74 with TBI, 26 with SOI, and 19 with both) were identified. Seventy-one percent were treated with heparin infusion (goal activated partial thromboplastin time, 45-60 seconds), and 29% received antiplatelet therapy alone. When compared with patients without BCVI, there was no difference in worsening of TBI (9% vs. 10% with no BCVI, p = 0.75) or need for delayed operative intervention for SOI (7% vs. 5% with no BCVI, p = 0.61). No patients required cessation of AT. A total of 11 patients (9%) experienced a BCVI-related stroke. CONCLUSION: Initiation of early AT for patients with BCVI and concomitant TBI or SOI does not increase risk of worsening TBI or SOI above baseline. Close monitoring is required, but our results suggest that appropriate antiplatelet or heparin therapy should not be withheld in patients with BCVI and concomitant TBI or SOI. In fact, prompt treatment with either antiplatelet or heparin therapy remains the mainstay for prevention of stroke-related morbidity and mortality in these patients. (J Trauma Acute Care Surg. 2016; 81: 173-177. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)	[Shahan, Charles P.; Magnotti, Louis J.; McBeth, Paul B.; Weinberg, Jordan A.; Croce, Martin A.; Fabian, Timothy C.] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA	Magnotti, LJ (corresponding author), Dept Surg, 910 Madison Ave,Suite 220, Memphis, TN 38163 USA.	lmagnotti@uthsc.edu					Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Byrnes MC, 2012, WORLD J EMERG SURG, V7, DOI 10.1186/1749-7922-7-25; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; DiCocco JM, 2013, J TRAUMA ACUTE CARE, V74, P955, DOI 10.1097/TA.0b013e318287800f; DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035; Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Kitagawa RS, 2013, J NEUROSURG, V119, P324, DOI 10.3171/2013.5.JNS1397; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Mutze S, 2005, RADIOLOGY, V237, P884, DOI 10.1148/radiol.2373042189; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Schneidereit NP, 2006, J TRAUMA, V60, P209, DOI 10.1097/01.ta.0000195651.60080.2c; Sliker CW, 2008, AM J ROENTGENOL, V190, P790, DOI 10.2214/AJR.07.2378; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146	17	26	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2016	81	1					173	177		10.1097/TA.0000000000001058			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DS5BV	WOS:000380796400027	27027559				2021-06-18	
J	Xu, JL; Ypma, M; Chiarelli, PA; Park, J; Ellenbogen, RG; Stayton, PS; Mourad, PD; Lee, D; Convertine, AJ; Kievit, FM				Xu, Julia; Ypma, Menko; Chiarelli, Peter A.; Park, Joshua; Ellenbogen, Richard G.; Stayton, Patrick S.; Mourad, Pierre D.; Lee, Donghoon; Convertine, Anthony J.; Kievit, Forrest M.			Theranostic Oxygen Reactive Polymers for Treatment of Traumatic Brain Injury	ADVANCED FUNCTIONAL MATERIALS			English	Article							RADICAL POLYMERIZATION; SUPEROXIDE-DISMUTASE; TARGETED DELIVERY; OXIDATIVE STRESS; HUMAN NEURONS; NANOPARTICLES; PROGESTERONE; ACID; NANOTHERANOSTICS; PEROXIDATION	Traumatic brain injury (TBI) is the leading cause of disability and death in children and adults under 45, with approximately ten million new cases per year worldwide. Significant progress has been made in understanding the complex pathophysiological response to TBI; however, reducing the damage associated with the reactive oxygen species (ROS)-dependent secondary phase of the injury remains a substantial challenge. The development of an image-guided, Gd-conjugated, oxygen reactive polymer (ORP) to reduce ROS levels in damaged brain tissue is reported. ORP effectively sequesters ROS while remaining biocompatible even at elevated concentrations. ORP is retained in damaged brains of controlled cortical impact (CCI) mouse models of TBI for over 24 h when injected intravenously immediately and up to 3 h post-CCI. The polymer reduces neurodegeneration tenfold and gliosis twofold in these mouse models. ORP shows initial promise as an effective therapy for TBI and helps provide a better understanding of nanomaterial interaction with damaged brain.	[Xu, Julia] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA; [Ypma, Menko; Stayton, Patrick S.; Convertine, Anthony J.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Chiarelli, Peter A.; Ellenbogen, Richard G.; Mourad, Pierre D.; Kievit, Forrest M.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Park, Joshua; Lee, Donghoon] Univ Washington, Dept Radiol, Seattle, WA 98109 USA; [Stayton, Patrick S.; Convertine, Anthony J.] Univ Washington, Dept Mol Engn, Seattle, WA 98195 USA; [Mourad, Pierre D.] Univ Washington, Div Engn & Math, Bothell, WA 98011 USA	Convertine, AJ (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.; Kievit, FM (corresponding author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.; Convertine, AJ (corresponding author), Univ Washington, Dept Mol Engn, Seattle, WA 98195 USA.	aconv@uw.edu; fmkemt@neurosurgery.washington.edu	Stayton, Patrick/C-1975-2018	Stayton, Patrick/0000-0001-6939-6371			Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Astete CE, 2011, ACS NANO, V5, P9313, DOI 10.1021/nn102845t; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Berguig GY, 2015, MOL THER, V23, P907, DOI 10.1038/mt.2015.22; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Boyd BJ, 2015, J DRUG TARGET, V23, P847, DOI 10.3109/1061186X.2015.1034280; Boyer C, 2009, CHEM REV, V109, P5402, DOI 10.1021/cr9001403; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Chu DSH, 2012, ACCOUNTS CHEM RES, V45, P1089, DOI 10.1021/ar200242z; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Driessen MD, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0108-2; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kievit FM, 2011, ADV MATER, V23, pH217, DOI 10.1002/adma.201102313; Lane DD, 2015, POLYM CHEM-UK, V6, P1286, DOI 10.1039/c4py01250j; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Miyamoto K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/379206; Moad G, 2012, AUST J CHEM, V65, P985, DOI 10.1071/CH12295; Muthu MS, 2014, THERANOSTICS, V4, P660, DOI 10.7150/thno.8698; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Roy D, 2014, POLYM CHEM-UK, V5, P1791, DOI 10.1039/c3py01404e; Singhal A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.362; Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Wan AJ, 2013, J AGR FOOD CHEM, V61, P6921, DOI 10.1021/jf402242e; Wei J, 2013, ACTA PHARMACOL SIN, V34, P1485, DOI 10.1038/aps.2013.160; Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009	41	26	26	2	54	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1616-301X	1616-3028		ADV FUNCT MATER	Adv. Funct. Mater.	JUN 20	2016	26	23					4124	4133		10.1002/adfm.201504416			10	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	DR2JT	WOS:000379731500009					2021-06-18	
J	Tweedie, D; Fukui, K; Li, YZ; Yu, QS; Barak, S; Tamargo, IA; Rubovitch, V; Holloway, HW; Lehrmann, E; Wood, WH; Zhang, YQ; Becker, KG; Perez, E; Van Praag, H; Luo, Y; Hoffer, BJ; Becker, RE; Pick, CG; Greig, NH				Tweedie, David; Fukui, Koji; Li, Yazhou; Yu, Qian-sheng; Barak, Shani; Tamargo, Ian A.; Rubovitch, Vardit; Holloway, Harold W.; Lehrmann, Elin; Wood, William H., III; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Van Praag, Henriette; Luo, Yu; Hoffer, Barry J.; Becker, Robert E.; Pick, Chaim G.; Greig, Nigel H.			Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms	PLOS ONE			English	Article							OBJECT RECOGNITION MEMORY; FLUID-PERCUSSION INJURY; HEAD-INJURY; ALZHEIMERS-DISEASE; CHOLINESTERASE-INHIBITORS; OXIDATIVE STRESS; ACETYLCHOLINESTERASE INHIBITION; GENE-EXPRESSION; RISK-FACTOR; CELL-DEATH	Traumatic brain injury (TBI), often caused by a concussive impact to the head, affects an estimated 1.7 million Americans annually. With no approved drugs, its pharmacological treatment represents a significant and currently unmet medical need. In our prior development of the anti-cholinesterase compound phenserine for the treatment of neurodegenerative disorders, we recognized that it also possesses non-cholinergic actions with clinical potential. Here, we demonstrate neuroprotective actions of phenserine in neuronal cultures challenged with oxidative stress and glutamate excitotoxicity, two insults of relevance to TBI. These actions translated into amelioration of spatial and visual memory impairments in a mouse model of closed head mild TBI (mTBI) two days following cessation of clinically translatable dosing with phenserine (2.5 and 5.0 mg/kg BID x 5 days initiated post mTBI) in the absence of anti-cholinesterase activity. mTBI elevated levels of thiobarbituric acid reactive substances (TBARS), a marker of oxidative stress. Phenserine counteracted this by augmenting homeostatic mechanisms to mitigate oxidative stress, including superoxide dismutase [SOD] 1 and 2, and glutathione peroxidase [GPx], the activity and protein levels of which were measured by specific assays. Microarray analysis of hippocampal gene expression established that large numbers of genes were exclusively regulated by each individual treatment with a substantial number of them co-regulated between groups. Molecular pathways associated with lipid peroxidation were found to be regulated by mTBI, and treatment of mTBI animals with phenserine effectively reversed injury-induced regulations in the 'Blalock Alzheimer's Disease Up' pathway. Together these data suggest that multiple phenserine-associated actions underpin this compound's ability to ameliorate cognitive deficits caused by mTBI, and support the further evaluation of the compound as a therapeutic for TBI.	[Tweedie, David; Fukui, Koji; Li, Yazhou; Yu, Qian-sheng; Tamargo, Ian A.; Holloway, Harold W.; Becker, Robert E.; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Fukui, Koji] Shibaura Inst Technol, Div Biosci & Engn, Saitama 3378570, Japan; [Barak, Shani; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Lehrmann, Elin; Wood, William H., III; Zhang, Yongqing; Becker, Kevin G.] NIA, Lab Genet & Genom, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Behav Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Van Praag, Henriette] NIA, Neurosci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Luo, Yu; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Becker, Robert E.] 7123 Pinebrook Rd, Park City, UT 84098 USA; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Greig, NH (corresponding author), NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.	greign@mail.nih.gov	Fukui, Koji/I-7067-2019	Fukui, Koji/0000-0003-2748-3228; Luo, Yu/0000-0002-7939-5505; van Praag, Henriette/0000-0002-5727-434X; Lehrmann, Elin/0000-0002-9869-9475; Holloway, Courtney Jean/0000-0003-3661-1957	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Ari and Regine Aprijaskis Fund, at Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZICAG000616, ZIAAG000311, ZIAAG000328] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (ii) the Ari and Regine Aprijaskis Fund, at Tel-Aviv University, and (iii) a grant from the Israel Science Foundation, grant number 108/09. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (ii) the Ari and Regine Aprijaskis Fund, at Tel-Aviv University, and (iii) a grant from the Israel Science Foundation, grant number 108/09.	AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2; Allen TGJ, 2006, J NEUROSCI, V26, P1588, DOI 10.1523/JNEUROSCI.3979-05.2006; [Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Araujo JA, 2011, J ALZHEIMERS DIS, V26, P143, DOI 10.3233/JAD-2011-110005; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Ballesteros J, 2008, J HEAD TRAUMA REHAB, V23, P171, DOI 10.1097/01.HTR.0000319935.99837.96; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barger SW, 2004, FRONT BIOSCI-LANDMRK, V9, P3286, DOI 10.2741/1481; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; Boyajyan A, 2015, RECENT ADV DNA GENE; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Campbell N, 2009, CLIN INTERV AGING, V4, P225; Chen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099818; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cox CD, 2008, J NEUROTRAUM, V25, P1355, DOI 10.1089/neu.2008.0671; Crepaldi L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003699; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Dixon CE, 1979, EXP NEUROL, V146, P479; Djordjevic J, 2016, CURR ALZHEIMER RES; Donat CK, 2008, BRAIN RES, V1246, P167, DOI 10.1016/j.brainres.2008.09.059; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; Dumas JA, 2011, PHARMACOL BIOCHEM BE, V99, P254, DOI 10.1016/j.pbb.2011.02.022; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Greig NH, 2000, ACTA NEUROL SCAND, V102, P74, DOI 10.1034/j.1600-0404.2000.00311.x; Greig Nigel H., 2005, Current Alzheimer Research, V2, P483, DOI 10.2174/156720505774330564; Hendrickx A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099467; HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holschneider DP, 2011, J NEUROTRAUM, V28, P1909, DOI 10.1089/neu.2011.1978; IKARI H, 1995, NEUROREPORT, V6, P481, DOI 10.1097/00001756-199502000-00019; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jenkner FL, 1954, NERVENARZT, V25, P77; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Kadir A, 2008, ANN NEUROL, V63, P621, DOI 10.1002/ana.21345; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Klein BD, 2004, EPILEPSY RES, V62, P13, DOI 10.1016/j.eplepsyres.2004.06.007; Lahiri DK, 2003, J ALZHEIMERS DIS, V5, P81, DOI 10.3233/JAD-2003-5203; Lahiri DK, 2007, J PHARMACOL EXP THER, V320, P386, DOI 10.1124/jpet.106.112102; LECHNER H, 1963, Wien Klin Wochenschr, V75, ppassim; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Lilja AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058752; Lilja AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054887; Lusardi TA, 2009, CURR NEUROPHARMACOL, V7, P228, DOI 10.2174/157015909789152137; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marutle A, 2007, P NATL ACAD SCI USA, V104, P12506, DOI 10.1073/pnas.0705346104; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; Mikkilineni S, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/142372; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Ostberg A, 2011, NEUROLOGY, V76, P1046, DOI 10.1212/WNL.0b013e318211c1c4; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Parsons CG, 2013, NEUROTOX RES, V24, P358, DOI 10.1007/s12640-013-9398-z; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pike BR, 1997, J NEUROTRAUM, V14, P897, DOI 10.1089/neu.1997.14.897; Pilipovic K, 2011, NEUROCHEM RES, V36, P913, DOI 10.1007/s11064-011-0424-3; Poole NA, 2008, BRAIN INJURY, V22, P519, DOI 10.1080/02699050802132495; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reale M, 2014, CURR ALZHEIMER RES, V11, P608, DOI 10.2174/1567205010666131212113218; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; Ruszkiewicz J, 2015, NEUROCHEM INT, V88, P66, DOI 10.1016/j.neuint.2014.12.012; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Saso L, 2014, CURR DRUG TARGETS, V15, P1177, DOI 10.2174/1389450115666141024113925; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Scarr E, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00055; Schliebs R, 2006, J NEURAL TRANSM, V113, P1625, DOI 10.1007/s00702-006-0579-2; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Scremin OU, 2012, J NEUROTRAUM, V29, P2457, DOI 10.1089/neu.2012.2465; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Shaw KTY, 2001, P NATL ACAD SCI USA, V98, P7605, DOI 10.1073/pnas.131152998; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Wang XD, 1999, NEUROSCI LETT, V272, P21, DOI 10.1016/S0304-3940(99)00567-4; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Winblad B, 2010, J ALZHEIMERS DIS, V22, P1201, DOI 10.3233/JAD-2010-101311; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yu QS, 2001, J MED CHEM, V44, P4062, DOI 10.1021/jm010080x; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	127	26	26	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2016	11	6							e0156493	10.1371/journal.pone.0156493			26	Multidisciplinary Sciences	Science & Technology - Other Topics	DN6XB	WOS:000377218700033	27254111	DOAJ Gold, Green Published			2021-06-18	
J	Trefan, L; Houston, R; Pearson, G; Edwards, R; Hyde, P; Maconochie, I; Parslow, RC; Kemp, A				Trefan, L.; Houston, R.; Pearson, G.; Edwards, R.; Hyde, P.; Maconochie, I.; Parslow, R. C.; Kemp, A.			Epidemiology of children with head injury: a national overview	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							TRAUMATIC BRAIN-INJURY; REGION	Background The National Confidential Enquiry describes the epidemiology of children admitted to hospital with head injury. Method Children (< 15 years old) who died or were admitted for > 4 h with head injury were identified from 216 UK hospitals (1 September 2009 to 28 February 2010). Data were collected using standard proformas and entered on to a database. A descriptive analysis of the causal mechanisms, child demographics, neurological impairment, CT findings, and outcome at 72 h are provided. Results Details of 5700 children, median age 4 years (range 0-14.9 years), were analysed; 1093 (19.2%) were < 1 year old, 3500 (61.4%) were boys. There was a significant association of head injury with social deprivation 39.7/100 000 (95% CI 37.0 to 42.6) in the least deprived first quintile vs. 55.1 (95% CI 52.1 to 58.2) in the most deprived fifth quintile (p< 0.01). Twenty-four children died (0.4%). Most children were admitted for one night or less; 4522 (79%) had a Glasgow Coma Scale score of 15 or were Alert (on AVPU (Alert, Voice, Pain, Unresponsive)). The most common causes of head injury were falls (3537 (62.1%); children < 5 years), sports-related incidents (783 (13.7%); median age 12.4 years), or motor vehicle accidents (MVAs) (401 (7.1%); primary-school-aged children). CT scans were performed in 1734 (30.4%) children; 536 (30.9%) were abnormal (skull fracture and/or intracranial injury or abnormality): 269 (7.6%) were falls, 82 (10.5%) sports related and 100 (25%). A total of 357 (6.2%) children were referred to social care because of child protection concerns (median age 9 months (range 0-14.9 years)). Conclusions The data described highlight priorities for targeted age-specific head injury prevention and have the potential to provide a baseline to evaluate the effects of regional trauma networks (2012) and National Institute of Health and Care Excellence (NICE) head injury guidelines (2014), which were revised after the study was completed.	[Trefan, L.; Kemp, A.] Cardiff Univ, Sch Med, Coll Biomed & Life Sci, Cardiff CF14 4XY, S Glam, Wales; [Houston, R.] Kids Co, London, England; [Pearson, G.] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Edwards, R.] Bristol Hosp Children, Dept Neurosurg, Bristol, Avon, England; [Hyde, P.] Southampton Childrens Hosp, Paediat Intens Care Unit, Southampton, Hants, England; [Maconochie, I.] Imperial Coll NHS Healthcare Trust, London, England; [Parslow, R. C.] Univ Leeds, Sch Med, Leeds Inst Cardiovasc & Metab Med, Leeds LS2 9JT, W Yorkshire, England	Kemp, A (corresponding author), Cardiff Univ, Sch Med, Coll Biomed & Life Sci, Cardiff CF14 4XY, S Glam, Wales.	KempAM@cf.ac.uk	Parslow, Roger/AAV-1477-2020	Edwards, Richard/0000-0001-8415-2180; Parslow, Roger/0000-0002-3945-5294; Maconochie, Ian/0000-0001-6319-8550	Health Quality Improvement Partnership [504835]	Health Quality Improvement Partnership, grant number 504835.	Advanced Life Support Group, 1997, ADV PED LIF SUPP PRA; Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arbogast KB, 2013, PEDIAT INJURY BIOMEC, P33; Burrows P, 2015, ARCH DIS CHILD, V100, P1032, DOI 10.1136/archdischild-2014-307119; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Crandall JR, 2013, PEDIAT INJURY BIOMEC, P33; Department for Transport, 2012, REP ROAD CAS GREAT B; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hawley C, 2013, INJURY, V44, P1855, DOI 10.1016/j.injury.2013.07.021; Houston R, 2012, EMERG MED J, V29, P309, DOI 10.1136/emj.2011.112110; IBM Corp, 2011, IBM SPSS Statistics for Windows, Version 20.0; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kendrick D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005014.pub2; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Laflamme L, 2010, INT J PEDIAT, V2010, DOI 10.1155/2010/819687; Mackay CA, 2000, PREHOSPITAL IMMEDIAT, V4, P17; McNarry AF, 2004, ANAESTHESIA, V59, P34, DOI 10.1111/j.1365-2044.2004.03526.x; National Health Service, 2012, MAJ TRAUM CTR; NICE, 2014, HEAD INJ TRIAG ASS I; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Public Health England, 2014, RED UN INJ HOM CHILD; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	32	26	26	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	JUN	2016	101	6					527	532		10.1136/archdischild-2015-308424			6	Pediatrics	Pediatrics	DN3BJ	WOS:000376936900007	26998632	Green Published, Other Gold			2021-06-18	
J	Fishbein, D; Dariotis, JK; Ferguson, PL; Pickelsimer, EE				Fishbein, Diana; Dariotis, Jacinda K.; Ferguson, Pamela L.; Pickelsimer, E. Elisabeth			Relationships Between Traumatic Brain Injury and Illicit Drug Use and Their Association With Aggression in Inmates	INTERNATIONAL JOURNAL OF OFFENDER THERAPY AND COMPARATIVE CRIMINOLOGY			English	Article						traumatic brain injury; drug use; aggression; inmates; dysregulation	HEAD-INJURIES; SUBSTANCE USE; RISK; PREVALENCE; DISORDERS; BEHAVIOR; TBI; CHILDHOOD; OUTCOMES; ABUSE	Extensive interviews of correctional inmates in South Carolina (2009-2010) were conducted under a Center for Disease Control and Prevention (CDC) grant. We evaluated the extent to which early traumatic brain injury (TBI) and subsequent illicit drug abuse may conjointly influence development of aggression, controlling for alcohol use, and whether cognitive or emotional dysregulation mediated this relationship. Early TBI predicted greater severity and earlier onset of drug use, and an earlier age at first use predicted greater aggression regardless of the age of TBI. Emotional dysregulation mediated effects of TBI on aggression. The potential to design more targeted treatments for this susceptible population are discussed.	[Fishbein, Diana] Univ Maryland, Sch Med, 5900 Waterloo Rd,2nd Floor, Ellicott City, MD 21045 USA; [Dariotis, Jacinda K.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Ferguson, Pamela L.; Pickelsimer, E. Elisabeth] Med Univ S Carolina, Charleston, SC USA	Fishbein, D (corresponding author), Univ Maryland, Sch Med, 5900 Waterloo Rd,2nd Floor, Ellicott City, MD 21045 USA.	dfishbei@psych.umaryland.edu		fishbein, diana/0000-0003-1644-2762	Division of Injury Response (DIR), National Center for Injury Prevention and Control (NCIPC); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001318]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the Division of Injury Response (DIR), National Center for Injury Prevention and Control (NCIPC), and Centers for Disease Control and Prevention (CDC); Cooperative Agreement No. U49CE001318).	Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; Blanchard R, 2003, ARCH SEX BEHAV, V32, P573, DOI 10.1023/A:1026093612434; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bradley B, 2011, J CLIN PSYCHIAT, V72, P685, DOI 10.4088/JCP.10m06409blu; Bradshaw CP, 2010, J YOUTH ADOLESCENCE, V39, P953, DOI 10.1007/s10964-009-9442-8; Brewer-Smyth Kathleen, 2004, Health Care Women Int, V25, P835, DOI 10.1080/07399330490517118; Brophy M, 2002, INFANT CHILD DEV, V11, P125, DOI 10.1002/icd.301; Bryant FB, 2001, J RES PERS, V35, P138, DOI 10.1006/jrpe.2000.2302; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Calkins SD, 2002, DEV PSYCHOPATHOL, V14, P477, DOI 10.1017/S095457940200305X; CARLSSON GS, 1983, J NEUROL NEUROSUR PS, V46, P818, DOI 10.1136/jnnp.46.9.818; CASPI Y, 2001, ALCOHOL TREAT Q, V19, P49, DOI DOI 10.1300/J020V19N04_; Chandler RK, 2009, JAMA-J AM MED ASSOC, V301, P183, DOI 10.1001/jama.2008.976; Cicchetti D, 1994, HDB DEPRESSION CHILD, P123, DOI DOI 10.1007/978-1-4899-1510-8_7; Cohen R A, 1999, Violence Vict, V14, P397; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Deckel AW, 1996, ALCOHOL CLIN EXP RES, V20, P1173, DOI 10.1111/j.1530-0277.1996.tb01107.x; Diamond PM, 2005, CRIM JUSTICE BEHAV, V32, P546, DOI 10.1177/0093854805278416; DURKIN MS, 1994, AM J PUBLIC HEALTH, V84, P587, DOI 10.2105/AJPH.84.4.587; Eshel N, 2007, NEUROPSYCHOLOGIA, V45, P1270, DOI 10.1016/j.neuropsychologia.2006.10.004; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Fein G, 2010, ALCOHOL CLIN EXP RES, V34, P1045, DOI 10.1111/j.1530-0277.2010.01179.x; Ferguson P. L., 2011, SCORING SCALES STATE; Ferguson P. L., 2012, J HEAD TRAUMA REHAB, V27, pE1; Fishbein D, 2000, CRIM JUSTICE BEHAV, V27, P139, DOI 10.1177/0093854800027002001; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Giancola PR, 1999, PSYCHOL SCI, V10, P203, DOI 10.1111/1467-9280.00135; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hayatbakhsh MR, 2009, AM J DRUG ALCOHOL AB, V35, P399, DOI 10.3109/00952990903353415; Hayes A. F., 2013, STAT MEDIATION ANAL; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hill J, 2002, J CHILD PSYCHOL PSYC, V43, P133, DOI 10.1111/1469-7610.00007; HINSHAW SP, 1992, PSYCHOL BULL, V111, P127, DOI 10.1037/0033-2909.111.1.127; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Jane-Llopis E, 2006, DRUG ALCOHOL REV, V25, P515, DOI 10.1080/09595230600944461; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Lo CC, 2000, AM J DRUG ALCOHOL AB, V26, P229, DOI 10.1081/ADA-100100602; Lynam DR, 2001, CA CH AD PS, P235; Mezzich AC, 2001, J CHILD ADOLES SUBST, V10, P35, DOI 10.1300/J029v10n04_04; MOELLER FG, 1994, PROG NEURO-PSYCHOPH, V18, P1027, DOI 10.1016/0278-5846(94)90128-7; Moffitt T. E., 1989, DEV PSYCHOPATHOL, V1, P105, DOI DOI 10.1017/S0954579400000298; Moffitt T. E., 1989, NEUROPSYCHOLOGY AGGR, P131; MOSS HB, 1993, AM J ADDICTION, V2, P149, DOI DOI 10.1111/J.1521-0391.1993.TB00215.X; Pardini DA, 2003, J AM ACAD CHILD PSY, V42, P364, DOI 10.1097/00004583-200303000-00018; Pihet S, 2012, PSYCHIAT PSYCHOL LAW, V19, P427, DOI 10.1080/13218719.2011.598634; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SPELLACY F, 1977, J CLIN PSYCHOL, V33, P966, DOI 10.1002/1097-4679(197710)33:4<966::AID-JCLP2270330409>3.0.CO;2-4; Sugden SG, 2006, J NEUROPSYCH CLIN N, V18, P302, DOI 10.1176/appi.neuropsych.18.3.302; Taylor J, 1999, PSYCHOPHYSIOLOGY, V36, P193, DOI 10.1111/1469-8986.3620193; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; WHITE JL, 1994, J ABNORM PSYCHOL, V103, P192, DOI 10.1037/0021-843X.103.2.192	59	26	26	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0306-624X	1552-6933		INT J OFFENDER THER	Int. J. Offender Ther. Comp. Criminol.	APR	2016	60	5					575	597		10.1177/0306624X14554778			23	Criminology & Penology; Psychology, Applied	Criminology & Penology; Psychology	DI6US	WOS:000373636300005	25326469				2021-06-18	
J	Dixon, CE; Bramlett, HM; Dietrich, WD; Shear, DA; Yan, HQ; Deng-Bryant, Y; Mondello, S; Wang, KKW; Hayes, RL; Empey, PE; Povlishock, JT; Tortella, FC; Kochanek, PM				Dixon, C. Edward; Bramlett, Helen M.; Dietrich, W. Dalton; Shear, Deborah A.; Yan, Hong Q.; Deng-Bryant, Ying; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Empey, Philip E.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						therapy; rat; biomarker; fluid percussion; calcineurin; neuroprotection; controlled cortical impact; penetrating ballistic-like brain injury; phosphatase	MITOCHONDRIAL PERMEABILITY TRANSITION; DOSE-RESPONSE; AXONAL INJURY; DAMAGE; MODEL; NIM811; MOTOR	Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.	[Dixon, C. Edward; Yan, Hong Q.] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Shear, Deborah A.; Deng-Bryant, Ying; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Ctr Pharmaceut Sci, Pittsburgh, PA 15260 USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Empey, Philip/L-9604-2019; Mondello, Stefania/A-1813-2012	Empey, Philip/0000-0001-7474-2339; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Aminmansour Bahram, 2014, Adv Biomed Res, V3, P35, DOI 10.4103/2277-9175.125031; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Friberg H, 1998, J NEUROSCI, V18, P5151; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Lemaire M, 1996, CANCER CHEMOTH PHARM, V38, P481, DOI 10.1007/s002800050515; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Tanaka C, 1999, J PHARMACOKINET BIOP, V27, P597, DOI 10.1023/A:1020978509566; Van den Heuvel C, 2004, J NEUROTRAUM, V21, P1562, DOI 10.1089/0897715042441783; WINDEBANK AJ, 1994, J PHARMACOL EXP THER, V268, P1051; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	38	26	27	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					553	566		10.1089/neu.2015.4122			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800005	26671075				2021-06-18	
J	Wang, D; Li, T; Wei, HJ; Wang, Y; Yang, GL; Tian, Y; Zhao, ZL; Wang, L; Yu, SP; Zhang, YQ; Chen, JL; Jiang, RC; Zhang, JN				Wang, Dong; Li, Tuo; Wei, Huijie; Wang, Yi; Yang, Guili; Tian, Ye; Zhao, Zilong; Wang, Liang; Yu, Shengping; Zhang, Yongqiang; Chen, Jieli; Jiang, Rongcai; Zhang, Jian Ning			Atorvastatin enhances angiogenesis to reduce subdural hematoma in a rat model	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Subdural hematoma; Atorvastatin; Angiogenesis; Rat model	ENDOTHELIAL PROGENITOR CELLS; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR; ANGIOPOIETIN-1 AND-2; STATINS; LEAKAGE; VEGF; NEUROGENESIS; INHIBITORS; PERICYTES	Background and purpose: Statins are active in reducing plasma lipids, suppressing inflammation and promoting angiogenesis. Because angiogenesis is critical for the absorbance of subdural hematoma (SDH), we hypothesize that atorvastatin promotes angiogenesis to enhance hematoma absorption. Methods: SDH was induced in adult Wistar rats and treated with 3 mg/kg, 8 mg/kg of atorvastatin, or vehicle saline daily for 7 days. The treated rats were examined for the level of CD34+/CD133+ endothelial progenitor cells (EPCs) in the circulation by flow cytometry, hematoma volumes by magnetic resonance imaging (MRI), and changes in cognitive functions. We also examined angiogenesis in the hematoma wall by transmission electronic microscopy and immunohistochemistry for the expression of vascular endothelial growth factor (VEGF), matrix metalloprotease 9 (MMP 9) and angiopoietin. Results: SDH volume was significantly reduced and neurological deficits improved in rats receiving the low dose atorvastatin compared to those receiving either the high dose of atorvastatin or saline. Consistent with these outcome measures, the low dose atorvastatin increased the expression of angiopoient-1 and VEGF and reduced MMP9 expression in the connective tissue of the SDH wall, resulting in an increased vascular density and enhanced vascular maturation. Conclusions: The low-dose atorvastatin is effective in reducing SDH and improving neurological deficits in a rat model, primarily by promoting angiogenesis and vascular maturation. (C) 2016 Published by Elsevier B.V.	[Wang, Dong; Li, Tuo; Wei, Huijie; Wang, Yi; Tian, Ye; Zhao, Zilong; Zhang, Jian Ning] Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg,Tianjin Neurol Inst, Tianjin, Peoples R China; [Yang, Guili; Yu, Shengping; Zhang, Yongqiang; Jiang, Rongcai] Tianjin Neurol Inst, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg, Tianjin, Peoples R China; [Wang, Liang] Tianjin 5th Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Chen, Jieli] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg,Tianjin Neurol Inst, Tianjin, Peoples R China.; Jiang, RC (corresponding author), Tianjin Neurol Inst, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Dept Neurosurg, Tianjin, Peoples R China.	54454241@qq.com; lt19880619@sina.com; huijiewei@126.com; sinuosiwo@sina.com; yangguili1985@163.com; yetian1986@gmail.com; ZilongZ@BloodWorksNW.org; 757171007@qq.com; yshpvip@sina.com; friskyzyq@163.com; jieli@neuro.hfh.edu; jiang116216@163.com; jianningzhang@hotmail.com	Zhao, Zilong/AAZ-2196-2020		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100920, 81200907, 81501069, 81271359, 81502171]; science and technology grant of Tianjin Health Bureau [2014KZ020]; Tianjin Research Program of Application Foundation and Advanced Technology [14ZCZDSY00179]	We are grateful to Fanglian Chen, Weiyun Cui, Lei Zhou and Liu Li from the Tianjin Neurological Institute for their assistance with the experiments and data analyses. This work was supported by the National Natural Science Foundation of China (grant 81100920, 81200907, 81501069, 81271359 and 81502171), the science and technology grant of Tianjin Health Bureau (2014KZ020) and the Tianjin Research Program of Application Foundation and Advanced Technology (grant 14ZCZDSY00179).	Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Ahmad SA, 2001, CANCER RES, V61, P1255; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH107, DOI 10.1152/ajpheart.00542.2005; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Brudno Y, 2013, BIOMATERIALS, V34, P9201, DOI 10.1016/j.biomaterials.2013.08.007; Chauvet S, 2013, CELL MOL LIFE SCI, V70, P1685, DOI 10.1007/s00018-013-1278-4; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Dulak J, 2005, ENDOTHELIUM-J ENDOTH, V12, P233, DOI 10.1080/10623320500476559; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hohenstein A, 2005, J NEUROTRAUM, V22, P518, DOI 10.1089/neu.2005.22.518; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Karabiyikoglu M, 2005, NEUROSURGERY, V57, P565, DOI 10.1227/01.NEU.0000170435.47739.AE; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lam CF, 2008, ANESTH ANALG, V107, P686, DOI 10.1213/ane.0b013e31817e6719; Lara-Hernandez R, 2010, ANN VASC SURG, V24, P287, DOI 10.1016/j.avsg.2009.10.012; Li T, 2014, J NEUROL SCI, V341, P88, DOI 10.1016/j.jns.2014.04.009; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI13131; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298; Naduk-Kik J, 2008, POSTEP HIG MED DOSW, V62, P442; Nagy JA, 2002, COLD SPRING HARB SYM, V67, P227, DOI 10.1101/sqb.2002.67.227; Qin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061831; Ribatti D, 2011, INT J DEV BIOL, V55, P261, DOI 10.1387/ijdb.103167dr; Sata M, 2002, CIRCULATION, V106, pE47, DOI 10.1161/01.CIR.0000030081.54465.2D; Sun TFD, 2005, BRIT J NEUROSURG, V19, P327, DOI 10.1080/02688690500305332; Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x; Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015; Wang D, 2014, J NEUROL SCI, V336, P237, DOI 10.1016/j.jns.2013.11.005; Wang D, 2010, J NEUROTRAUM, V27, P1489, DOI 10.1089/neu.2009.1057; WATANABE S, 1972, J NEUROSURG, V37, P552, DOI 10.3171/jns.1972.37.5.0552; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Xu Y, 2011, NEUROSCIENCE, V181, P292, DOI 10.1016/j.neuroscience.2011.02.051; Yan T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067949; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6	40	26	33	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAR 15	2016	362						91	99		10.1016/j.jns.2016.01.017			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DH1PW	WOS:000372558400017	26944125				2021-06-18	
J	Young, AMH; Donnelly, J; Czosnyka, M; Jalloh, I; Liu, XY; Aries, MJ; Fernandes, HM; Garnett, MR; Smielewski, P; Hutchinson, PJ; Agrawal, S				Young, Adam M. H.; Donnelly, Joseph; Czosnyka, Marek; Jalloh, Ibrahim; Liu, Xiuyun; Aries, Marcel J.; Fernandes, Helen M.; Garnett, Matthew R.; Smielewski, Peter; Hutchinson, Peter J.; Agrawal, Shruti			Continuous Multimodality Monitoring in Children after Traumatic Brain Injury-Preliminary Experience	PLOS ONE			English	Article							CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; REACTIVITY	Introduction Multimodality monitoring is regularly employed in adult traumatic brain injury (TBI) patients where it provides physiologic and therapeutic insight into this heterogeneous condition. Pediatric studies are less frequent. Methods An analysis of data collected prospectively from 12 pediatric TBI patients admitted to Addenbrooke's Hospital, Pediatric Intensive Care Unit (PICU) between August 2012 and December 2014 was performed. Patients' intracranial pressure (ICP), mean arterial pressure (MAP), and cerebral perfusion pressure (CPP) were monitored continuously using brain monitoring software ICM+(R)) Pressure reactivity index (PRx) and 'Optimal CPP' (CPPopt) were calculated. Patient outcome was dichotomized into survivors and non-survivors. Results At 6 months 8/12 (66%) of the cohort survived the TBI. The median (+/- IQR) ICP was significantly lower in survivors 13.1 +/- 3.2 mm Hg compared to non-survivors 21.6 +/- 42.9 mm Hg (p = 0.003). The median time spent with ICP over 20 mm Hg was lower in survivors (9.7+ 9.8% vs 60.5 + 67.4% in non-survivors; p = 0.003). Although there was no evidence that CPP was different between survival groups, the time spent with a CPP close (within 10 mm Hg) to the optimal CPP was significantly longer in survivors (90.7 +/- 12.6%) compared with non-survivors (70.6 +/- 21.8%; p = 0.02). PRx provided significant outcome separation with median PRx in survivors being 0.02 +/- 0.19 compared to 0.39 +/- 0.62 in non-survivors (p = 0.02). Conclusion Our observations provide evidence that multi-modality monitoring may be useful in pediatric TBI with ICP, deviation of CPP from CPPopt, and PRx correlating with patient outcome.	[Young, Adam M. H.; Donnelly, Joseph; Czosnyka, Marek; Jalloh, Ibrahim; Liu, Xiuyun; Aries, Marcel J.; Fernandes, Helen M.; Garnett, Matthew R.; Smielewski, Peter; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Acad Neurosurg, Cambridge CB2 2QQ, England; [Agrawal, Shruti] Univ Cambridge, Addenbrookes Hosp, Dept Pediat Intens Care, Cambridge CB2 2QQ, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Aries, Marcel J.] Univ Groningen, Univ Med Ctr Groningen, Dept Intens Care, NL-9700 AB Groningen, Netherlands	Young, AMH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Acad Neurosurg, Cambridge CB2 2QQ, England.	ay276@cam.ac.uk	Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018	Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Smielewski, Peter/0000-0001-5096-3938	Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986 ID79068, G1002277 ID98489]; National Institute for Health Research Biomedical Research Centre (NIHR BRC) Cambridge; Peter J Hutchinson NIHR Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; NIHR Cambridge BRC; Woolf Fisher Scholarship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2014-14-005, 12/35/57, NIHR-RP-R3-12-013] Funding Source: researchfish	The authors gratefully acknowledge financial support as follows: Research support: the Medical Research Council (MRC, Grant Nos. G0600986 ID79068 and G1002277 ID98489) and the National Institute for Health Research Biomedical Research Centre (NIHR BRC) Cambridge (Neuroscience Theme; Brain Injury and Repair Theme). Authors' support: Peter J Hutchinson NIHR Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and NIHR Cambridge BRC. Joseph Donnelly is supported by a Woolf Fisher Scholarship. MC-NIHR BRC. PS and MC have a financial interest in a part of the licensing fee for ICM+, a software licensed by Cambridge Enterprise Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Carlson JN, 2015, PEDIAT CRIT CARE MED; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GUILLAUME J, 1951, REV NEUROL, V84, P131; Haubrich C, 2015, MED ENG PHYS, V37, P175, DOI 10.1016/j.medengphy.2014.11.009; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Lang E W, 1995, New Horiz, V3, P400; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lewis PM, 2015, PEDIATR CRIT CARE ME, V16, P739, DOI 10.1097/PCC.0000000000000471; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; MRC CRASH Trial Collaborators, 2008, BMJ-BRIT MED J, P336; Nordstrom C-H, 2013, CRIT CARE MED, V41, pe3; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Paulson O. B., 1990, BRAIN METAB REV, V2, P161; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Roux P Le, 2015, NEUROCRIT CARE; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Weersink CSA, 2015, CRIT CARE MED, V43, P1952, DOI 10.1097/CCM.0000000000001165	24	26	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2016	11	3							e0148817	10.1371/journal.pone.0148817			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DH1VK	WOS:000372572800013	26978532	DOAJ Gold, Green Published			2021-06-18	
J	Soltani, Z; Khaksari, M; Shahrokhi, N; Mohammadi, G; Mofid, B; Vaziri, A; Amiresmaili, S				Soltani, Zahra; Khaksari, Mohammad; Shahrokhi, Nader; Mohammadi, Gholamabbas; Mofid, Behshad; Vaziri, Ali; Amiresmaili, Sedigheh			Effect of estrogen and/or progesterone administration on traumatic brain injury-caused brain edema: the changes of aquaporin-4 and interleukin-6	JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Interleukin-6; Aquaporin-4; Traumatic brain injury; Estrogen; Progesterone	SEX STEROID-HORMONES; REACTIVE ASTROCYTES; BARRIER DISRUPTION; ISCHEMIC BRAIN; MESSENGER-RNA; RAT-BRAIN; EXPRESSION; STROKE; TNF; MATRIX-METALLOPROTEINASE-9	The role of aquaporin-4 (AQP4) and interleukin-6 (IL-6) in the development of brain edema post-traumatic brain injury (TBI) has been indicated. The present study was designed to investigate the effect(s) of administration of progesterone (P) and/or estrogen (E) on brain water content, AQP4 expression, and IL-6 levels post-TBI. The ovariectomized rats were divided into 11 groups: sham, one vehicle, two vehicles, E1, E2, P1, P2, E1 + P1, E1 + P2, E2 + P1, and E2 + P2. The brain AQP4 expression, IL-6 levels, and water content were evaluated 24 h after TBI induced by Marmarou's method. The low (E1 and P1) and high (E2 and P2) doses of estrogen and progesterone were administered 30 min post-TBI. The results showed that brain water content and AQP4 expression decreased in the E1, E2, P1, and P2-treated groups. The administration of E1 decreased IL-6 levels. Addition of progesterone decreased the inhibitory effect of E1 and E2 on the accumulation of water in the brain. Administration of E1 + P1 and E1 + P2 decreased the inhibitory effect of E1 on the IL-6 levels and AQP4 protein expression. Our findings suggest that estrogen or progesterone by itself has more effective roles in decrease of brain edema than combination of both. Possible mechanism may be mediated by the alteration of AQP4 and IL-6 expression. However, further studies are required to verify the exact mechanism.	[Soltani, Zahra; Shahrokhi, Nader] Kerman Univ Med Sci, Physiol Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Ctr Res Neurosci, Inst Neuropharmacol, Kerman, Iran; [Mohammadi, Gholamabbas; Vaziri, Ali] Kerman Univ Med Sci, Med Sch Afzalipour, Dept Biochem, Kerman, Iran; [Mofid, Behshad] Shahid Bahonar Hosp Kerman, Dept Neurosurg, Kerman, Iran; [Amiresmaili, Sedigheh] Bam Univ Med Sci, Kerman, Iran	Khaksari, M (corresponding author), Kerman Univ Med Sci, Ctr Res Neurosci, Inst Neuropharmacol, Kerman, Iran.	mkhaksari@kmu.ac.ir	Shahrokhi, Nader/AAV-3747-2020; Haddad, Mohammad Khaksari/AAB-9025-2019; Soltani, Zahra/AAC-1350-2019	Shahrokhi, Nader/0000-0002-0149-7819; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Soltani, Zahra/0000-0002-8423-6189; Mohammadi, Gholamabbas/0000-0002-2621-0810	neuroscience research center of Kerman University of Medical Sciences; physiology research center of Kerman University of Medical Sciences	The present study was supported by neuroscience and physiology research centers of Kerman University of Medical Sciences.	Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Jain SK, 2004, CYTOKINE, V26, P102, DOI 10.1016/j.cyto.2004.01.002; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI 10.1139/y10-103; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P151, DOI 10.1007/s00701-012-1558-z; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leonardo CC, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-13; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P981, DOI 10.1016/0002-9378(95)90246-5; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shi WZ, 2012, NEUROSCI LETT, V520, P121, DOI 10.1016/j.neulet.2012.05.052; Shi WZ, 2012, NEUROSCI BULL, V28, P61, DOI 10.1007/s12264-012-1063-7; Shin JA, 2011, BBA-MOL BASIS DIS, V1812, P1154, DOI 10.1016/j.bbadis.2011.05.004; Simpkins J. W., 1997, AM J MED, V103, p19S, DOI 10.1016/s0002-9343(97)00260-x; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Teede HJ, 2003, BEST PRACT RES CL EN, V17, P73, DOI 10.1016/S1521-690X(02)00083-0; Tomas-Camardiel M, 2005, J NEUROSCI RES, V80, P235, DOI 10.1002/jnr.20443; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang XY, 2013, EXP THER MED, V6, P263, DOI 10.3892/etm.2013.1116; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207	42	26	27	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1138-7548	1877-8755		J PHYSIOL BIOCHEM	J. Physiol. Biochem.	MAR	2016	72	1					33	44		10.1007/s13105-015-0453-5			12	Biochemistry & Molecular Biology; Physiology	Biochemistry & Molecular Biology; Physiology	DF5PG	WOS:000371403500004	26638215	Green Accepted			2021-06-18	
J	Zimmerman, DL; Ownsworth, T; O'Donovan, A; Roberts, J; Gullo, MJ				Zimmerman, David L.; Ownsworth, Tamara; O'Donovan, Analise; Roberts, Jacqueline; Gullo, Matthew J.			Independence of Hot and Cold Executive Function Deficits in High-Functioning Adults with Autism Spectrum Disorder	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						autism spectrum disorder; adults; executive functions; social cognition; neuropsychological assessment	TRAUMATIC BRAIN-INJURY; PERVASIVE DEVELOPMENTAL DISORDERS; COGNITIVE ENHANCEMENT THERAPY; ASSESSING SOCIAL-PERCEPTION; SPATIAL WORKING-MEMORY; ASPERGER-SYNDROME; INFERENCE TEST; EYES TEST; MIND; SCHIZOPHRENIA	Individuals with autistic spectrum disorder (ASD) display diverse deficits in social, cognitive and behavioral functioning. To date, there has been mixed findings on the profile of executive function deficits for high-functioning adults (IQ 70) with ASD. A conceptual distinction is commonly made between "cold" and -hot" executive functions. Cold executive functions refer to mechanistic higher-order cognitive operations (e.g., working memory), whereas hot executive functions entail cognitive abilities supported by emotional awareness and social perception (e.g., social cognition). This study aimed to determine the independence of deficits in hot and cold executive functions for high-functioning adults with ASD. Forty-two adults with ASD (64% male, aged 18-66 years) and 40 age and gender matched controls were administered The Awareness of Social Inference Test (TASIT; emotion recognition and social inference), Letter Number Sequencing (working memory) and Hayling Sentence Completion Test (response initiation and suppression). Between-group analyses identified that the ASD group performed significantly worse than matched controls on all measures of cold and hot executive functions (d = 0.54 - 1.5). Hierarchical multiple regression analyses revealed that the ASD sample performed more poorly on emotion recognition and social inference tasks than matched controls after controlling for cold executive functions and employment status. The findings also indicated that the ability to recognize emotions and make social inferences was supported by working memory and response initiation and suppression processes. Overall, this study supports the distinction between hot and cold executive function impairments for adults with ASD. Moreover, it advances understanding of higher-order impairments underlying social interaction difficulties for this population which, in turn, may assist with diagnosis and inform intervention programs.	[Zimmerman, David L.; Ownsworth, Tamara; O'Donovan, Analise] Griffith Univ, Sch Appl Psychol, Behav Basis Hlth, Mt Gravatt, Qld 4122, Australia; [Zimmerman, David L.; Ownsworth, Tamara; O'Donovan, Analise] Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld 4122, Australia; [Roberts, Jacqueline] Griffith Univ, Sch Educ & Profess Studies, Mt Gravatt, Qld 4122, Australia; [Gullo, Matthew J.] Univ Queensland, Ctr Youth Substance Abuse Res, St Lucia, Qld, Australia	Zimmerman, DL (corresponding author), Griffith Univ, Sch Appl Psychol, Behav Basis Hlth, Mt Gravatt, Qld 4122, Australia.; Zimmerman, DL (corresponding author), Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld 4122, Australia.	david.zimmerman@griffithuni.edu.au	Gullo, Matthew/C-3850-2008	Gullo, Matthew/0000-0003-3657-5191; Ownsworth, Tamara/0000-0003-1835-7094	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP1036365]	No specific funding was utilized in conducting this study or preparing this manuscript, which was produced in partial fulfillment PhD requirements for the first author. MG is supported by a National Health and Medical Research Council of Australia Early Career Fellowship (APP1036365).	Abell F, 2005, AUTISM, V9, P515, DOI 10.1177/1362361305057857; Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2010, NEURON, V65, P752, DOI 10.1016/j.neuron.2010.03.006; Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashwin C, 2007, NEUROPSYCHOLOGIA, V45, P2, DOI 10.1016/j.neuropsychologia.2006.04.014; Auyeung B, 2009, J AUTISM DEV DISORD, V39, P1509, DOI 10.1007/s10803-009-0772-x; Baez S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00270; Baez S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00302; Baron-Cohen S, 2003, PHILOS T ROY SOC B, V358, P361, DOI 10.1098/rstb.2002.1206; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 2000, DEV PSYCHOPATHOL, V12, P489, DOI 10.1017/S0954579400003126; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bauman M.L., 2005, NEUROBIOLOGY AUTISM, P121; Bauman ML, 1996, J AUTISM DEV DISORD, V26, P199, DOI 10.1007/BF02172012; Bennetto L, 1996, CHILD DEV, V67, P1816, DOI 10.1111/j.1467-8624.1996.tb01830.x; Bishop-Fitzpatrick L, 2013, J AUTISM DEV DISORD, V43, P687, DOI 10.1007/s10803-012-1615-8; Boucher Jill, 2005, Cogn Neuropsychiatry, V10, P165, DOI 10.1080/13546800444000038; Burgess P. W., 1997, HAYLING BRIXTONS TES; Castelli F, 2002, BRAIN, V125, P1839, DOI 10.1093/brain/awf189; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chung YS, 2011, SCHIZOPHRENIA BULL, V37, P1048, DOI 10.1093/schbul/sbq012; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Couture SM, 2010, PSYCHOL MED, V40, P569, DOI 10.1017/S003329170999078X; D'Elia L., 1996, COLOR TRAILS TEST PR; Diamond A, 2005, PSYCHOL SCI, V16, P291, DOI 10.1111/j.0956-7976.2005.01530.x; Eack SM, 2013, J AUTISM DEV DISORD, V43, P2866, DOI 10.1007/s10803-013-1834-7; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Flanagan S, 2002, AWARENESS SOCIAL INF; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Goldenfeld N, 2005, CLIN NEUROPSYCHIATR, V2, P338; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Happe F, 2006, NAT NEUROSCI, V9, P1218, DOI 10.1038/nn1770; Hill EL, 2004, TRENDS COGN SCI, V8, P26, DOI 10.1016/j.tics.2003.11.003; Hill EL, 2006, NEUROPSYCHOLOGIA, V44, P2822, DOI 10.1016/j.neuropsychologia.2006.06.007; Hogarty GE, 1999, SCHIZOPHRENIA BULL, V25, P693, DOI 10.1093/oxfordjournals.schbul.a033411; HOLLAND BS, 1988, PSYCHOL BULL, V104, P145, DOI 10.1037/0033-2909.104.1.145; HOLM S, 1979, SCAND J STAT, V6, P65; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Jarrold C, 2000, DEV PSYCHOL, V36, P126, DOI 10.1037/0012-1649.36.1.126; Johnston K, 2011, J AUTISM DEV DISORD, V41, P903, DOI 10.1007/s10803-010-1113-9; Johnston L, 2008, AUST J PSYCHOL, V60, P135, DOI 10.1080/00049530701449521; Kern RS, 2009, PSYCHOL MED, V39, P645, DOI 10.1017/S0033291708003966; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; Kleinhans N, 2005, DEV NEUROPSYCHOL, V27, P379, DOI 10.1207/s15326942dn2703_5; Koshino H, 2005, NEUROIMAGE, V24, P810, DOI 10.1016/j.neuroimage.2004.09.028; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; LOTTER V, 1978, AUTISM REAPPRAISAL C, P475; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Mathersul D, 2013, J CLIN EXP NEUROPSYC, V35, P655, DOI 10.1080/13803395.2013.809700; McAlonan GM, 2005, BRAIN, V128, P268, DOI 10.1093/brain/awh332; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDonald S, 2012, AUST PSYCHOL, V47, P39, DOI 10.1111/j.1742-9544.2011.00054.x; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P991, DOI 10.1038/nn1494; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; Ozonoff S, 2004, J AUTISM DEV DISORD, V34, P139, DOI 10.1023/B:JADD.0000022605.81989.cc; Ozonoff S, 2001, J AUTISM DEV DISORD, V31, P257, DOI 10.1023/A:1010794902139; Pallant J., 2013, SPSS SURVIVAL MANUAL; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.1111/j.1467-8624.1989.tb02749.x; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Rajendran G, 2005, J AUTISM DEV DISORD, V35, P429, DOI 10.1007/s10803-005-5033-z; Rajendran G, 2007, DEV REV, V27, P224, DOI 10.1016/j.dr.2007.02.001; Ritvo RA, 2008, J AUTISM DEV DISORD, V38, P213, DOI 10.1007/s10803-007-0380-6; Ritvo RA, 2011, J AUTISM DEV DISORD, V41, P1076, DOI 10.1007/s10803-010-1133-5; Schmitz C, 2015, LIMESURVEY OPEN SOUR; SHUM D, 2006, PSYCHOL TESTING ASSE; Sparks A, 2010, SCHIZOPHR RES, V122, P172, DOI 10.1016/j.schres.2010.06.011; Steele SD, 2007, J AUTISM DEV DISORD, V37, P605, DOI 10.1007/s10803-006-0202-2; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tabachnick BG, 2007, USING MULTIVARIATE S; Uljarevic M, 2013, J AUTISM DEV DISORD, V43, P1517, DOI 10.1007/s10803-012-1695-5; Vermeulen P, 2015, FOCUS AUTISM DEV DIS, V30, P182, DOI 10.1177/1088357614528799; Wechsler D., 2009, WECHSLER INDIVIDUAL; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Williams DL, 2005, J AUTISM DEV DISORD, V35, P747, DOI 10.1007/s10803-005-0021-x	84	26	27	2	68	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	FEB 5	2016	10								24	10.3389/fnhum.2016.00024			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	DC7QY	WOS:000369416500001	26903836	DOAJ Gold, Green Published			2021-06-18	
J	Kontos, AP; Elbin, RJ; Sufrinko, A; Dakan, S; Bookwalter, K; Price, A; Meehan, WP; Collins, MW				Kontos, Anthony P.; Elbin, R. J.; Sufrinko, Alicia; Dakan, Scott; Bookwalter, Kylie; Price, Ali; Meehan, William P., III; Collins, Michael W.			Incidence of Concussion in Youth Ice Hockey Players	PEDIATRICS			English	Article							STATES HIGH-SCHOOL; INJURY; EPIDEMIOLOGY; SPORTS; RATES; RISK	BACKGROUND: Ice hockey is a fast-paced collision sport that entails both intentional (ie, body checking) and incidental contact that may involve the head. The objective of this study was to determine the incidence of concussions in relation to games/practices and age among competition-level youth ice hockey players (ages 12-18 years). METHODS: Participants included 397 youth ice hockey players from Western Pennsylvania; Boston, Massachusetts; and Birmingham, Alabama, during the 2012-2013 and 2013-2014 youth ice hockey seasons. Incidence rates (IRs) and incidence rate ratios (IRRs) of concussion were calculated for games/practices and age groups. RESULTS: A total of 23 369 (12 784 practice/10 585 game) athletic exposures (AEs) involving 37 medically diagnosed concussions occurred. More than 40% of concussions involved illegal contact. The combined IR for games and practices was 1.58 concussions per 1000 AEs. The IRR was 2.86 times (95% confidence interval 0.68-4.42) higher during games (2.49 per 1000 AEs) than practices (1.04 per 1000 AEs). CONCLUSIONS: The overall IR for concussion in youth ice hockey was comparable to those reported in other youth collision sports. The game-to-practice IRR was lower than previously reported in ice hockey and other youth sports, although more concussions per exposure occurred in games compared with practices. Younger players had a higher rate of concussions than older players.	[Kontos, Anthony P.; Sufrinko, Alicia; Dakan, Scott; Bookwalter, Kylie; Price, Ali; Collins, Michael W.] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, Fayetteville, AR 72701 USA; [Dakan, Scott] Lake Erie Coll Osteopath Med, Coll Med, Erie, PA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA	Kontos, AP (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; University of PittsburghUniversity of Pittsburgh; Bauer Performance Sports, Ltd.; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	Supported in part by a grant to the University of Pittsburgh through the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos, and through a research contract between the University of Pittsburgh and Bauer Performance Sports, Ltd. with Dr Kontos and Dr Collins. Funded by the National Institutes of Health (NIH).	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Blake Tracy, 2012, Clin J Sport Med, V22, P377, DOI 10.1097/JSM.0b013e31826038e0; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Brenner JS, 2014, PEDIATRICS, V133, P1151, DOI 10.1542/peds.2014-0692; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2011, BRIT J SPORT MED, V45, P1289, DOI 10.1136/bjsports-2011-090538; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gwin J. T., 2009, J ASTM INT, V6, P1; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Katzmarzyk PT, 2004, PEDIATRICS, V114, P198; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Council of Youth Sports, REP TRENDS PART ORG; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091	21	26	26	0	16	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2016	137	2							e20151633	10.1542/peds.2015-1633			6	Pediatrics	Pediatrics	DF5LA	WOS:000371392000014	26746405	Bronze, Green Published			2021-06-18	
J	Leung, A; Shukla, S; Fallah, A; Song, D; Lin, LS; Golshan, S; Tsai, A; Jak, A; Polston, G; Lee, R				Leung, Albert; Shukla, Shivshil; Fallah, Amir; Song, David; Lin, Lisa; Golshan, Shahrokh; Tsai, Alice; Jak, Amy; Polston, Greg; Lee, Roland			Repetitive Transcranial Magnetic Stimulation in Managing Mild Traumatic Brain Injury-Related Headaches	NEUROMODULATION			English	Article						Chronic posttraumatic headaches; mild traumatic brain injury-related headache; MTBI-HA; pain; repetitive transcranial magnetic stimulation; rTMS; traumatic brain injury	MAJOR DEPRESSION; PREFRONTAL CORTEX; YOUNG-PATIENTS; RTMS TREATMENT; PREVALENCE; VETERANS; MIGRAINE; SAFETY; PAIN	ObjectiveHeadache is one of the most common debilitating chronic pain conditions in either active or retired military personnel with mild traumatic brain injury (MTBI). This study assessed the effect of repetitive transcranial magnetic stimulation (rTMS) in alleviating MTBI-related headache (MTBI-HA). Materials and MethodVeterans with MTBI-HA were randomized to receive either real rTMS (REAL group) at 10 hz for a total of 2000 pulses divided into 20 trains with one-sec inter-train interval or sham rTMS (SHAM group) at the left motor cortex (LMC) with brain magnetic resonance imaging neuronavigation guidance. Pretreatment, posttreatment one-week and four-week headache and neuropsychological assessments were conducted. ResultThirty veterans were screened and twenty four (21 men and 3 women with average year-old SD at 14.3 +/- 12.6) subjects' data were analyzed. A two-factor (visit x treatment) repeated measures analysis of variance (RM-ANOVA) indicated a close to significant (p = 0.06) trend of interaction between pretreatment and posttreatment one-week assessment with the intensity of the persistent daily headache decreasing from 5.7 +/- 1.9 to 2.2 +/- 2.7 and 4.6 +/- 1.3 to 3.5 +/- 2.0 for the REAL and SHAM groups, respectively. Subsequent analyses indicated REAL group demonstrated a significantly (p = 0.041) higher % of reduction in persistent headache intensity than the SHAM group (56.3 +/- 48.2% vs.15.4 +/- 43.6%) at the posttreatment one-week assessment and the trend continued to the four-week assessment. Overall, a significantly (p = 0.035) higher percentage of the subjects in the REAL group (58.3%) demonstrated at least a 50% headache intensity reduction at posttreatment one-week assessment compared with the SHAM group (16.6%). The overall composite score of functionally debilitating headache exacerbation is significantly (p = 0.017) reduced in REAL group at the posttreatment four-week assessment in comparison with the SHAM group. No major sustained change in neuropsychological assessments was noted. ConclusionThe studied rTMS protocol appears to be a clinically feasible and effective treatment option in managing MTBI-HA.	[Leung, Albert; Shukla, Shivshil; Fallah, Amir; Song, David; Lin, Lisa; Golshan, Shahrokh; Tsai, Alice; Jak, Amy; Polston, Greg; Lee, Roland] Vet Adm San Diego Healthcare Syst, La Jolla, CA USA; [Golshan, Shahrokh] Vet Med Res Fdn, Biostat Core, San Diego, CA USA	Leung, A (corresponding author), Univ Calif San Diego, Dept Anesthesiol, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.; Leung, A (corresponding author), Vet Adm San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ayleung@ucsd.edu	Brighina, Filippo/K-9864-2016	Brighina, Filippo/0000-0001-5875-3126	VA Rehabilitation and Research Development Award	VA Rehabilitation and Research Development Award	Bakker N, 2015, BRAIN STIMUL, V8, P208, DOI 10.1016/j.brs.2014.11.002; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brighina F, 2004, J NEUROL SCI, V227, P67, DOI 10.1016/j.jns.2004.08.008; Brunelin J, 2007, ENCEPHALE, V33, P126; Caeyenberghs K, 2015, BRAIN CONNECT, V5, P423, DOI 10.1089/brain.2014.0293; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; Joubert Jacques, 2005, Aust Fam Physician, V34, P621; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Leung A, 2014, HEADACHE, V54, P57; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton RB, 2010, NEUROTHERAPEUTICS, V7, P204, DOI 10.1016/j.nurt.2010.03.002; Ljubisavljevic M, 1996, ELECTROMYOGR MOTOR C, V101, P281, DOI 10.1016/0924-980X(96)95627-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Misra UK, 2013, J NEUROL, V260, P2793, DOI 10.1007/s00415-013-7072-2; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Ohn SH, 2012, NEUROREHAB NEURAL RE, V26, P344, DOI 10.1177/1545968311423110; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Peng HJ, 2012, J AFFECT DISORDERS, V136, P249, DOI 10.1016/j.jad.2011.12.006; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wu E, 2015, J HEAD TRAUMA REHABI	35	26	27	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	FEB	2016	19	2					133	141		10.1111/ner.12364			9	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	DF1KF	WOS:000371097600002	26555886				2021-06-18	
J	Taylor, KM; Saint-Hilaire, MH; Sudarsky, L; Simon, DK; Hersh, B; Sparrow, D; Hu, H; Weisskopf, MG				Taylor, Kathryn M.; Saint-Hilaire, Marie-Helene; Sudarsky, Lewis; Simon, David K.; Hersh, Bonnie; Sparrow, David; Hu, Howard; Weisskopf, Marc G.			Head injury at early ages is associated with risk of Parkinson's disease	PARKINSONISM & RELATED DISORDERS			English	Article						Head injury; Parkinson's disease; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MICROGLIAL ACTIVATION; INFLAMMATION; EXPOSURE	Introduction: The literature on the effect of head injuries on the risk of PD is inconclusive. Some researchers have hypothesized that studies that have seen an effect are simply capturing injury related to pre-clinical PD. However in animal models brain inflammation, which can be initiated by head trauma, has been shown to produce PD-like effects. Furthermore, animal studies have found that early life inflammation in particular is of relevance for PD pathology. Methods: We conducted an unmatched case control study of 379 neurologist confirmed PD patients and 230 controls from the greater Boston, Massachusetts area with questionnaire data on history of head injury and other covariates. We used multivariable logistic regression to estimate adjusted odds ratios (OR) and their corresponding 95% confidence intervals (CI) for PD. Results: When we excluded injuries that occurred less than 10 years prior to the diagnosis of PD (in order to avoid reverse causation), we found an increased risk of PD associated with a head injury that resulted in a loss of consciousness, but it did not reach statistical significance (OR = 1.57; 95% CI = 0.89-2.80). We found a significant (p = 0.04) effect of age at first head injury. For every 5 year earlier age at first head injury with loss of consciousness the OR for PD was 1.37 (95% CI: 1.01-1.86). Conclusion: Our results suggest that head injury in early life increases the risk of PD. (C) 2015 Published by Elsevier Ltd.	[Taylor, Kathryn M.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 401 Pk Dr,Landmark Bldg,3rd Floor, Boston, MA 02215 USA; [Saint-Hilaire, Marie-Helene] Boston Univ, Dept Neurol, Med Ctr, 72 East Concord St,C3, Boston, MA 02118 USA; [Sudarsky, Lewis] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA; [Simon, David K.] Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA; [Simon, David K.] Harvard Univ, Sch Med, Dept Neurol, 330 Brookline Ave, Boston, MA 02215 USA; [Hersh, Bonnie] Harvard Vanguard Med Associates, 133 Brookline Ave, Boston, MA 02215 USA; [Sparrow, David] VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA; [Sparrow, David] Boston Univ, Sch Publ Hlth, 715 Albany St, Boston, MA 02118 USA; [Sparrow, David] Boston Univ, Sch Med, 715 Albany St, Boston, MA 02118 USA; [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Epidemiol, 6th Floor,155 Coll St, Toronto, ON, Canada; [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Global Hlth, 6th Floor,155 Coll St, Toronto, ON, Canada; [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Environm Hlth, 6th Floor,155 Coll St, Toronto, ON, Canada; [Weisskopf, Marc G.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol & Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA	Taylor, KM (corresponding author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 401 Pk Dr,Landmark Bldg,3rd Floor, Boston, MA 02215 USA.	kmt691@mail.harvard.edu; neuromsh@bu.edu; lsudarsky@partners.com; dsimon1@bidmc.harvard.edu; bonnie_hersh@vmed.org; david.sparrow@va.gov; howard.hu@utoronto.ca; mweissko@hsph.harvard.edu		Hu, Howard/0000-0002-3676-2707	National Institute of Health, National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01-ES010798, P01-ES000002]; National Institute of Health: IMSD Academic Training grant [R25 GM055353]; National Institute for Occupational Safety and Health: ERC training grant [T42 OH008416]; VA Research Career Scientist award; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [T42OH008416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES000002, R01ES010798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM055353] Funding Source: NIH RePORTER	This work was supported by the National Institute of Health, National Institute of Environmental Health Sciences (R01-ES010798 and P01-ES000002 (M W.)), National Institute of Health: IMSD Academic Training grant (R25 GM055353 (K.T.)), the National Institute for Occupational Safety and Health: ERC training grant (T42 OH008416 (K T.)) and VA Research Career Scientist award (D.S.)	Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cai ZW, 2013, DEV NEUROSCI-BASEL, V35, P155, DOI 10.1159/000346156; Cory-Slechta DA, 2005, BIRTH DEFECTS RES A, V73, P136, DOI 10.1002/bdra.20118; Ezcurra ALD, 2010, NEUROBIOL DIS, V37, P630, DOI 10.1016/j.nbd.2009.11.018; Fang F, 2012, MOVEMENT DISORD, V27, P1632, DOI 10.1002/mds.25143; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gao JJ, 2015, PARKINSONISM RELAT D, V21, P292, DOI 10.1016/j.parkreldis.2014.12.033; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Harris MA, 2013, OCCUP ENVIRON MED, V70, P839, DOI 10.1136/oemed-2013-101444; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Ling ZD, 2006, EXP NEUROL, V199, P499, DOI 10.1016/j.expneurol.2006.01.010; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; R.C. Team, 2013, R LANG ENV STAT COMP; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; S.I. Inc, 2012, SAS ONL DOC; Tanner CM, 2003, ADV NEUROL, V91, P133	26	26	26	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1353-8020	1873-5126		PARKINSONISM RELAT D	Parkinsonism Relat. Disord.	FEB	2016	23						57	61		10.1016/j.parkreldis.2015.12.005			5	Clinical Neurology	Neurosciences & Neurology	DE8KW	WOS:000370885900009	26725141	Green Accepted			2021-06-18	
J	Paget, A; Mallewa, M; Chinguo, D; Mahebere-Chirambo, C; Gladstone, M				Paget, Amelia; Mallewa, Macpherson; Chinguo, Dorothy; Mahebere-Chirambo, Chawanangwa; Gladstone, Melissa			"It means you are grounded" - caregivers' perspectives on the rehabilitation of children with neurodisability in Malawi	DISABILITY AND REHABILITATION			English	Article						Africa; carers; child; developing countries; disability; qualitative; rehabilitation	TRAUMATIC BRAIN-INJURY; QUALITATIVE RESEARCH; DISABLED-CHILDREN; RISK-FACTORS; DISABILITY; HEALTH; MOTHERS; CARERS; KENYA; INTERVENTION	Purpose: Rates of childhood disability are estimated to be high in African settings; however, services to provide information and support are limited. This study aims to explore perspectives and experiences of caregivers of children with disabilities (CWD) from acquired brain injury to inform the development of training packages for health-workers (HW) in hospital settings. Methods: The study was conducted in a tertiary hospital using qualitative methods. Fourteen in-depth interviews (IDIs) were conducted with parents/carers (PC), and 10 IDIs and 4 focus-group discussions (FGDs) with HW. Data were audio-recorded, transcribed, translated and analysed using thematic approaches. Results: HWs and PCs held varying perspectives on aetiology and prognosis for CWD. HWs raised concerns about impact on families, risks of neglect and abuse. Barriers to care and support included prioritisation of acute illness, lack of HW knowledge and confidence, stigma, poor communication, focus on physical disability, and poor availability of services. Among ideas for improvement, good communication and counselling was seen as a priority but not often achieved. Conclusion: A range of family, health service and wider contextual factors affect care for CWD. Training for HW should emphasise disability rights, access to services, a range of disabilities and specific training on counselling.Implications for RehabilitationTo create good training programmes for workers who manage children with neurodisability, workers' views on their training needs, as well parents' views of what feel they need to know most, must be taken into account.The need for training regarding communication skills is a priority for health-workers (HW), who manage children with neurodisability in Malawi and confidence in this area is likely to be vital in providing support for these families.Disability rights and inclusion should be imperative in any training programme for managing children with neurodisability in hospital settings.Even in low-resource settings such as Malawi, it is vital that the links between hospital management and the limited resources in the community are updated and maintained.	[Paget, Amelia] Univ Bristol, Sch Social & Community Med, Ctr Child & Adolescent Hlth, Bristol, Avon, England; [Mallewa, Macpherson] Univ Malawi, Coll Med, Blantyre, Malawi; [Mallewa, Macpherson] Univ Liverpool, Inst Infect & Global Hlth, Brain Infect Grp, Liverpool L69 3BX, Merseyside, England; [Chinguo, Dorothy] Queen Elizabeth Cent Hosp, Blantyre, Malawi; [Mahebere-Chirambo, Chawanangwa] Malawi Liverpool Wellcome Trust, Blantyre, Malawi; [Gladstone, Melissa] Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool L69 3BX, Merseyside, England	Gladstone, M (corresponding author), Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool L69 3BX, Merseyside, England.	M.J.Gladstone@liverpool.ac.uk	Gladstone, Melissa J./L-6535-2018	Gladstone, Melissa J./0000-0002-2579-9301; Paget, Amelia/0000-0002-3371-1891	Sir Halley Stewart Charitable Trust; University of Liverpool; Wellcome TrustWellcome TrustEuropean Commission; British Heart FoundationBritish Heart Foundation; Arthritis Research UKVersus Arthritis [/2011Dec/round6]; WellcomeTrust Biosciences fellowship [/Z/11/Z]; Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-SGCL6-Gladstone] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2009-07-003] Funding Source: researchfish	This research was funded by the Sir Halley Stewart Charitable Trust and the University of Liverpool. M.G. gratefully acknowledges the Academy of Medical Sciences "Clinical Lecturer Starter Grant" supported by the Wellcome Trust, British Heart Foundation and Arthritis Research UK (/2011Dec/round6) as well as a WellcomeTrust Biosciences fellowship (/Z/11/Z). This provided the support for Dr. Gladstone whilst supervising and conducting this research in Malawi. The authors declare no conflicts of interests.	African Child Policy Forum, 2014, AFR REP CHILDR DIS P; Alavi Y, 2012, DISABIL REHABIL, V34, P1736, DOI 10.3109/09638288.2012.662260; [Anonymous], 2012, DEV NAT COMM BAS REH; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; Brown FL, 2013, BRAIN INJURY, V27, P1570, DOI 10.3109/02699052.2013.841996; Danesco E., 1997, INT J DISABIL DEV ED, V44, P41, DOI DOI 10.1080/0156655970440104; Davidson LL, 2003, DEV MED CHILD NEUROL, V45, P18; Disability ICfEi, 2014, MAL KEY INF CHILD DI; ELLIS M, 2010, CONS COMM NETW C CCN, P1, DOI DOI 10.1111/J.1365-2214.2010.01139.X; Foster GM, 1976, AM ANTHROPOL, V78, P9; Geere JL, 2013, CHILD CARE HLTH DEV, V39, P381, DOI 10.1111/j.1365-2214.2012.01398.x; Gladstone M, 2014, SEMIN PEDIATR NEUROL, V21, P50, DOI 10.1016/j.spen.2014.01.002; Gona JK, 2014, CHILD CARE HLTH DEV, V40, P29, DOI 10.1111/cch.12031; Gona JK, 2011, CHILD CARE HLTH DEV, V37, P175, DOI 10.1111/j.1365-2214.2010.01124.x; Gupta Ashum., 2004, ASIA PACIFIC DISABIL, V15, P22; Hartley S, 2005, CHILD CARE HLTH DEV, V31, P167, DOI 10.1111/j.1365-2214.2004.00464.x; Hartley S, 2008, CBR POLICY DEV IMPLE; Hartley Sally, 2004, Community Eye Health, V17, P38; John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709; Jordan J, 2013, BRAIN INJURY, V27, P1063, DOI 10.3109/02699052.2013.794962; KELLEHER KJ, 1993, PEDIATRICS, V91, P941; Kerac M, 2014, SEMIN PEDIATR NEUROL, V21, P42, DOI 10.1016/j.spen.2014.01.003; Kielmann K., 2011, INTRO QUALITATIVE RE; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Kuper A, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a288; Lakhan R, 2014, INDIAN J PSYCHIAT, V56, P39, DOI 10.4103/0019-5545.124712; Loeb M., 2004, LIVING CONDITIONS PE; Maloni PK, 2010, DISABIL REHABIL, V32, P845, DOI 10.3109/09638280903326063; Maulik PK, 2007, PEDIATRICS, V120, pS1, DOI 10.1542/peds.2007-0043B; McConachie H, 2000, J PEDIATR-US, V137, P769, DOI 10.1067/mpd.2000.110135; McConkey R, 2000, INT J DISABIL DEV ED, V47, P311, DOI DOI 10.1080/713671113; McNally A, 2013, AFR J DISABIL, V2, DOI 10.4102/ajod.v2i1.21; Mung'ala-Odera V, 2006, INT J EPIDEMIOL, V35, P683, DOI 10.1093/ije/dyl023; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Prost A, 2013, LANCET, V381, P1736, DOI 10.1016/S0140-6736(13)60685-6; Ramakrishnan M, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-47; Russell PSS, 1999, BRIT J PSYCHIAT, V174, P254, DOI 10.1192/bjp.174.3.254; UNCF, 2005, STAT WORLDS CHILDR; UNICEF, 2013, STAT WORLDS CHILDR 2; UNICEF, 2015, COUNTR STAT MAL; United Nations, 2006, CONVENTION RIGHTS PE; WHO, 2011, WORLD REPORT ON DISABILITY, P1; Wisconsin UNCFUUO, 2008, MON CHILD DIS DEV CO; World Health Organization, 2010, MHGAP INT GUID MENT; World Health Organization, 2001, INT CLASS FUNCT DIS; Yousafzai AK, 2011, DISABIL REHABIL, V33, P989, DOI 10.3109/09638288.2010.520811	48	26	26	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	JAN 30	2016	38	3					223	234		10.3109/09638288.2015.1035458			12	Rehabilitation	Rehabilitation	CZ3OE	WOS:000367013100004	25879468	Bronze, Green Published			2021-06-18	
J	Delouche, A; Attye, A; Heck, O; Grand, S; Kastler, A; Lamalle, L; Renard, F; Krainik, A				Delouche, Aurelie; Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Lamalle, Laurent; Renard, Felix; Krainik, Alexandre			Diffusion MRI: Pitfalls, literature review and future directions of research in mild traumatic brain injury	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Brain injury; Diffusion tractography; Post concussion syndrome; Magnetic resonance imaging	CONSTRAINED SPHERICAL DECONVOLUTION; AXONAL INJURY; MATTER ABNORMALITIES; SPATIAL STATISTICS; ENDURING FREEDOM; CORPUS-CALLOSUM; GRAY-MATTER; KURTOSIS; DTI; TRACTOGRAPHY	Mild traumatic brain injury (mTBI) is a leading cause of disability in adults, many of whom report a distressing combination of physical, emotional and cognitive symptoms, collectively known as post-concussion syndrome, that persist after the injury. Significant developments in magnetic resonance diffusion imaging, involving voxel-based quantitative analysis through the measurement of fractional anisotropy or mean diffusivity, have enhanced our knowledge on the different stages of mTBI pathophysiology. Other diffusion imaging-derived techniques, including diffusion kurtosis imaging with multi-shell diffusion and high-order tractography models, have recently demonstrated their usefulness in mTBI. Our review starts by briefly outlining the physical basis of diffusion tensor imaging including the pitfalls for use in brain trauma, before discussing findings from diagnostic trials testing its usefulness in assessing brain structural changes in patients with mTBI. Use of different post-processing techniques for the diffusion imaging data, identified the corpus callosum as the most frequently injured structure in mTBI, particularly at sub-acute and chronic stages, and a crucial location for evaluating functional outcome. However, structural changes appear too subtle for identification using traditional diffusion biomarkers, thus disallowing expansion of these techniques into clinical practice. In this regard, more advanced diffusion techniques are promising in the assessment of this complex disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Delouche, Aurelie; Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Renard, Felix; Krainik, Alexandre] Grenoble Univ Hosp, SFR RMN Neurosci, Dept Neuroradiol & MRI, F-38043 Grenoble 9, France; [Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Lamalle, Laurent; Krainik, Alexandre] Univ Grenoble Alpes, IRMaGe, F-38000 Grenoble, France; [Attye, Arnaud; Heck, Olivier; Grand, Sylvie; Kastler, Adrian; Lamalle, Laurent; Renard, Felix; Krainik, Alexandre] UMS IRMaGe, Grenoble, France	Attye, A (corresponding author), Grenoble Univ Hosp, Neuroradiol & MR Unit, CS 10217, F-38043 Grenoble 9, France.	aattye@chu-grenoble.fr	Attye, Arnaud/AAM-7762-2020; KRAINIK, Alexandre/L-5874-2014	Attye, Arnaud/0000-0002-0233-0367; Lamalle, Laurent/0000-0002-8930-7337			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2005, NEUROIMAGE, V27, P48, DOI 10.1016/j.neuroimage.2005.03.042; Attye A, 2015, EUR RADIOL; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beaulieu C, 1999, ANN NEUROL, V46, P568, DOI 10.1002/1531-8249(199910)46:4<568::AID-ANA4>3.0.CO;2-R; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Calamante F, 2013, HUM BRAIN MAPP, V34, P2538, DOI 10.1002/hbm.22083; Calamante F, 2012, NEUROIMAGE, V59, P286, DOI 10.1016/j.neuroimage.2011.07.014; de Groot M, 2013, NEUROIMAGE, V76, P400, DOI 10.1016/j.neuroimage.2013.03.015; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Fukunaga I, 2013, RADIOL PHYS TECHNOL, V6, P343, DOI 10.1007/s12194-013-0206-5; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Hui ES, 2008, IEEE ENG MED BIO, P3941, DOI 10.1109/IEMBS.2008.4650072; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Kim S, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001900; Kristo G, 2013, MAGN RESON MED, V70, P1544, DOI 10.1002/mrm.24602; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurki T, 2014, NEURORADIOLOGY, V56, P833, DOI 10.1007/s00234-014-1410-7; Latt J, 2013, J MAGN RESON IMAGING, V37, P610, DOI 10.1002/jmri.23857; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Maier SE, 2008, MAGN RESON IMAGING, V26, P897, DOI 10.1016/j.mri.2008.01.042; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Paydar A, 2014, NEURAL REGEN RES, V9, P1108, DOI 10.4103/1673-5374.135309; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Szczepankiewicz F, 2013, NEUROIMAGE, V76, P145, DOI 10.1016/j.neuroimage.2013.02.078; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Veraart J, 2011, MAGN RESON MED, V65, P138, DOI 10.1002/mrm.22603; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	62	26	26	1	17	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	JAN	2016	85	1					25	30		10.1016/j.ejrad.2015.11.004			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CZ8OA	WOS:000367357800004	26724645				2021-06-18	
J	Fisher, LB; Pedrelli, P; Iverson, GL; Bergquist, TF; Bombardier, CH; Hammond, FM; Hart, T; Ketchum, JM; Giacino, J; Zafonte, R				Fisher, Lauren B.; Pedrelli, Paola; Iverson, Grant L.; Bergquist, Thomas F.; Bombardier, Charles H.; Hammond, Flora M.; Hart, Tessa; Ketchum, Jessica M.; Giacino, Joseph; Zafonte, Ross			Prevalence of suicidal behaviour following traumatic brain injury: Longitudinal follow-up data from the NIDRR Traumatic Brain Injury Model Systems	BRAIN INJURY			English	Article						Traumatic brain injury; depression; suicide; suicidal ideation; suicide attempt; prevalence	MAJOR DEPRESSIVE DISORDER; MINOR DEPRESSION; UNITED-STATES; RISK-FACTORS; REHABILITATION; IDEATION; HEALTH; RATES; EPIDEMIOLOGY; POPULATION	Objective: This study utilized the Traumatic Brain Injury Model Systems (TBIMS) National Database to examine the prevalence of depression and suicidal behaviour in a large cohort of patients who sustained moderate-to-severe TBI.Method: Participants presented to a TBIMS acute care hospital within 72 hours of injury and received acute care and comprehensive rehabilitation in a TBIMS designated brain injury inpatient rehabilitation programme. Depression and suicidal ideation were measured with the Patient Health Questionnaire (PHQ-9). Self-reported suicide attempts during the past year were recorded at each follow-up examination, at 1, 2, 3, 10, 15 and 20 years post-injury.Results: Throughout the 20 years of follow-up, rates of depression ranged from 24.8-28.1%, suicidal ideation ranged from 7.0-10.1% and suicide attempts (past year) ranged from 0.8-1.7%. Participants who endorsed depression and/or suicidal behaviour at year 1 demonstrated consistently elevated rates of depression and suicidal behaviour 5 years after TBI.Conclusion: Compared to the general population, individuals with TBI are at greater risk for depression and suicidal behaviour many years after TBI. The significant psychiatric symptoms evidenced by individuals with TBI highlight the need for routine screening and mental health treatment in this population.	[Fisher, Lauren B.; Pedrelli, Paola; Giacino, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Fisher, Lauren B.; Pedrelli, Paola] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Iverson, Grant L.; Giacino, Joseph; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.; Giacino, Joseph; Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med Rochester, Dept Psychol, Rochester, MN USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med Rochester, Dept Psychiat, Rochester, MN USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med Rochester, Dept Phys Med & Rehabil, Rochester, MN USA; [Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Div Clin & Neuropsychol, Seattle, WA 98195 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Hammond, Flora M.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Ketchum, Jessica M.] Georgia Regents Univ, Dept Biostat & Epidemiol, Augusta, GA USA; [Zafonte, Ross] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Zafonte, Ross] Brigham & Womens Hosp, Dept Phys Med & Rehabil, 75 Francis St, Boston, MA 02115 USA	Fisher, LB (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA.	lbfisher@mgh.harvard.edu	Giacino, Joseph/AAF-1952-2021; Ketchum, Jessica/AAE-8200-2020	Giacino, Joseph/0000-0002-7916-9698; Iverson, Grant/0000-0001-7348-9570	Department of Health and Human Services, National Institute on Disability, Independent Living and Rehabilitation Research [H133A120085, H133A 120026, H133A120028, H133A120035, H133A120037, H133A120031]; Harvard Medical School; Avanir; INTRuST Post-traumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Programme [X81XWH-07-CC-CSDoD]	The contents of this manuscript were developed under a grant from the Department of Health and Human Services, National Institute on Disability, Independent Living and Rehabilitation Research grant numbers H133A120085, H133A 120026, H133A120028, H133A120035, H133A120037 and H133A120031. However, those contents do not necessarily represent the policy of the Department of Education and you should not assume endorsement by the Federal Government. Lauren B. Fisher, PhD received a fellowship grant from Harvard Medical School to support the current work. Flora Hammond, MD, has received personal fees from Avanir for participation on the PRISM II Steering Committee and stock ownership [Stock ownership in health care companies include: ABBVIE INC SHS ($34 247 market value), ELI LILLY & CO ($14 535), GLAXOSMITHKLINE PLC ADR ($23 794), Exchange Traded Funds ($84 545) and Mutual Funds ($47 095)]. Joseph Giacino, PhD, is a member of the Advisory Board of the TBIMS National Data and Statistical Center. Dr. Zafonte and Dr. Iverson acknowledge additional support from the INTRuST Post-traumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Programme (X81XWH-07-CC-CSDoD). Grant Iverson, PhD, has been reimbursed by the government, professional scientific bodies and commercial organizations for discussing or presenting research relating to MTBI and sport-related concussion atmeetings, scientific conferences and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs. He has received honorariums for serving on research panels that provide scientific peer review of programmes. He is a co-investigator, collaborator or consultant on grants relating to mild TBI funded by several organizations. For the remaining authors, no conflicts were declared.	Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; First MB., 2002, STRUCTURED CLIN INTE; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097; Hoffman JM, 2011, ARCH PHYS MED REHAB, V92, P411, DOI 10.1016/j.apmr.2010.10.036; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Linsley KR, 2001, BRIT J PSYCHIAT, V178, P465, DOI 10.1192/bjp.178.5.465; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, pE100, DOI 10.2105/AJPH.2013.301794; Moller HJ, 2003, ACTA PSYCHIAT SCAND, V108, P73, DOI 10.1034/j.1600-0447.108.s418.15.x; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; PHILLIPS DP, 1993, SUICIDE LIFE-THREAT, V23, P307; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; Uebelacker Lisa A, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10m01027; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	33	26	26	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	11					1311	1318		10.1080/02699052.2016.1195517			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DZ8TP	WOS:000386144900004	27541868				2021-06-18	
J	Mehta, H; Acharya, J; Mohan, AL; Tobias, ME; LeCompte, L; Jeevan, D				Mehta, H.; Acharya, J.; Mohan, A. L.; Tobias, M. E.; LeCompte, L.; Jeevan, D.			Minimizing Radiation Exposure in Evaluation of Pediatric Head Trauma: Use of Rapid MR Imaging	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							BRAIN-INJURY; COMPUTED-TOMOGRAPHY; DECISION-ANALYSIS; CLINICAL ARTICLE; UNITED-STATES; CT; MILD; CHILDREN; HYDROCEPHALUS; MANAGEMENT	This study is a retrospective review of 103 pediatric patients who underwent initial head CT and subsequent follow-up rapid MR imaging between January 2010 and July 2013. Patients had minor head injuries that required imaging. There was almost perfect agreement in the ability to detect extra-axial hemorrhage on rapid MR imaging and CT (kappa = 0.84). Evaluation of hemorrhagic contusion/hemorrhage demonstrated a moderate level of agreement between MR imaging and CT (kappa = 0.61). The authors conclude that rapid MRI is an adequate imaging technique for the follow-up of pediatric patients with minor head trauma. BACKGROUND AND PURPOSE: With >473,000 annual emergency department visits for children with traumatic brain injuries in the United States, the risk of ionizing radiation exposure during CT examinations is a real concern. The purpose of this study was to assess the validity of rapid MR imaging to replace CT in the follow-up imaging of patients with head trauma. MATERIALS AND METHODS: A retrospective review of 103 pediatric patients who underwent initial head CT and subsequent follow-up rapid MR imaging between January 2010 and July 2013 was performed. Patients had minor head injuries (Glasgow Coma Scale, >13) that required imaging. Initial head CT was performed, with follow-up rapid MR imaging completed within 48 hours. A board-certified neuroradiologist, blinded to patient information and scan parameters, then independently interpreted the randomized cases. RESULTS: There was almost perfect agreement in the ability to detect extra-axial hemorrhage on rapid MR imaging and CT ( = 0.84, P < .001). Evaluation of hemorrhagic contusion/intraparenchymal hemorrhage demonstrated a moderate level of agreement between MR imaging and CT ( = 0.61, P < .001). The ability of MR imaging to detect a skull fracture also showed a substantial level of agreement with CT ( = 0.71, P < .001). Detection of diffuse axonal injury demonstrated a slight level of agreement between MR imaging and CT ( = 0.154, P = .04). However, the overall predictive agreement for the detection of an axonal injury was 91%. CONCLUSIONS: Rapid MR imaging is a valid technique for detecting traumatic cranial injuries and an adequate examination for follow-up imaging in lieu of repeat CT.	[Mehta, H.; Acharya, J.; LeCompte, L.] New York Med Coll, Dept Radiol, Valhalla, NY 10595 USA; [Mohan, A. L.; Tobias, M. E.; Jeevan, D.] New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA	Mehta, H (corresponding author), New York Med Coll, Dept Radiol, 100 Woods Rd, Valhalla, NY 10595 USA.	MehtaH@wcmc.com					af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; Ashley WW, 2005, J NEUROSURG, V103, P124, DOI 10.3171/ped.2005.103.2.0124; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Cote CJ, 2000, PEDIATRICS, V106, P633, DOI 10.1542/peds.106.4.633; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Ikeda K, 2000, J PERINAT MED, V28, P151, DOI 10.1515/JPM.2000.021; JENKINS A, 1986, LANCET, V2, P445; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Klig JE, 2006, CURR OPIN PEDIATR, V18, P231, DOI 10.1097/01.mop.0000193319.06322.76; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Linton OW, 2003, AM J ROENTGENOL, V181, P321, DOI 10.2214/ajr.181.2.1810321; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Malviya S, 2000, BRIT J ANAESTH, V84, P743; Missios S, 2008, J NEUROS-PEDIATR, V2, P438, DOI 10.3171/PED.2008.2.12.438; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morrison J, 2013, PEDIATR EMERG CARE, V29, P1189, DOI 10.1097/PEC.0b013e3182a9f7c1; O'Neill BR, 2013, WORLD NEUROSURG, V80, pE307, DOI 10.1016/j.wneu.2012.10.066; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Partovi S, 1999, NEUROIMAG CLIN N AM, V9, P553; Roguski M, 2015, J NEUROSURG-PEDIATR, V15, P529, DOI 10.3171/2014.10.PEDS14128; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Sarsfield MJ, 2013, PEDIATR EMERG CARE, V29, P884, DOI 10.1097/PEC.0b013e31829ec0d9; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Thompson EM, 2014, J NEUROSURG-PEDIATR, V13, P636, DOI 10.3171/2014.2.PEDS13567; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; White KS, 1996, PEDIATR RADIOL, V26, P5, DOI 10.1007/BF01403695; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	35	26	26	0	2	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2016	37	1					11	18		10.3174/ajnr.A4464			8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DA0DI	WOS:000367466500007	26381555	Other Gold, Green Published			2021-06-18	
J	Reith, FCM; Brennan, PM; Maas, AIR; Teasdale, GM				Reith, Florence C. M.; Brennan, Paul M.; Maas, Andrew I. R.; Teasdale, Graham M.			Lack of Standardization in the Use of the Glasgow Coma Scale: Results of International Surveys	JOURNAL OF NEUROTRAUMA			English	Article						consciousness; Glasgow Coma Scale; humans; questionnaires; reproducibility of results	INJURY	The Glasgow Coma Scale (GCS) was introduced 40 years ago and has received world-wide acceptance. The GCS rates eye, motor, and verbal responses to assess the level of consciousness. Concerns have been expressed with regard to reliability and consistency of assessments. We considered that lack of standardization in application techniques and reporting of the GCS may have contributed to these concerns, and aimed to assess current procedures in its use. Questionnaire-based assessments were conducted by an online survey and during neurosurgical training courses. Overall, 616 participants were recruited, representing 48 countries and including physicians and nurses from different disciplines. Use of the GCS was reported by nearly all participants for assessment of patients with traumatic brain injury, but not for all patients with a reduced level of consciousness from other causes (78%). Major differences were found regarding the type of stimulus applied when patients do not obey commands: Nail bed pressure, supraorbital pressure, trapezius or pectoralis pinch, and sternal rub were all frequently used, whereas 25% of responders reported to never use a peripheral stimulus. Strategies for reporting the GCS varied greatly, and 35% of participants limited the reporting to a summary score. Moreover, different approaches were used when one of the components could not be assessed. Overall, the surveys have identified a general lack of standardization in assessment and reporting of the GCS. The results illustrate the need for continued education to improve reliability of assessments through guidance to a standard approach.	[Reith, Florence C. M.; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Reith, Florence C. M.; Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Brennan, Paul M.] Western Gen Hosp, Dept Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland; [Teasdale, Graham M.] Univ Glasgow, Neurosurg, Glasgow, Lanark, Scotland	Reith, FCM (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	florence.reith@uza.be					Baker M, 2008, J NEUROSCI NURS, V4, P342; Edwards S L, 2001, Br J Nurs, V10, P92; Fielding K, 1990, Aust J Adv Nurs, V7, P13; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Heron R, 2001, Aust Crit Care, V14, P100, DOI 10.1016/S1036-7314(01)80026-6; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Koch D, 2000, INT MED J, V7, P51; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Mattar I, 2013, J NEUROSCI NURS, V45, P272, DOI 10.1097/JNN.0b013e31829db970; Middleton PM, 2012, AUSTRALAS EMERG NURS, V15, P170, DOI 10.1016/j.aenj.2012.06.002; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Shoqirat N, 2006, Nurs Stand, V20, P41; Teasdale, 2014, NURS TIMES, V110, P12; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1975, Nurs Times, V71, P914; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	23	26	27	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					89	94		10.1089/neu.2014.3843			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200011	25951090	Green Accepted			2021-06-18	
J	Kabadi, SV; Stoica, BA; Zimmer, DB; Afanador, L; Duffy, KB; Loane, DJ; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Zimmer, Danna B.; Afanador, Lauriaselle; Duffy, Kara B.; Loane, David J.; Faden, Alan I.			S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						AGER; behavior (rodent); brain trauma; microglia; neurodegeneration; neuroprotection; S100B	FLUID-PERCUSSION INJURY; GLYCATION END-PRODUCTS; NEURONAL SURVIVAL; TRANSGENIC MICE; PROTEIN S100B; RAGE; RECEPTOR; ACTIVATION; S100-BETA; EXPRESSION	Neuroinflammation following traumatic brain injury (TBI) is increasingly recognized to contribute to chronic tissue loss and neurologic dysfunction. Circulating levels of S100B increase after TBI and have been used as a biomarker. S100B is produced by activated astrocytes and can promote microglial activation; signaling by S100B through interaction with the multiligand advanced glycation end product-specific receptor (AGER) has been implicated in brain injury and microglial activation during chronic neurodegeneration. We examined the effects of S100B inhibition in a controlled cortical impact model, using S100B knockout mice or administration of neutralizing S100B antibody. Both interventions significantly reduced TBI-induced lesion volume, improved retention memory function, and attenuated microglial activation. The neutralizing antibody also significantly reduced sensorimotor deficits and improved neuronal survival in the cortex. However, S100B did not alter microglial activation in BV2 cells or primary microglial cultures stimulated by lipopolysaccharide or interferon gamma. Further, proximity ligation assays did not support direct interaction in the brain between S100B and AGER following TBI. Future studies are needed to elucidate specific pathways underlying S100B-mediated neuroinflammatory actions after TBI. Our results strongly implicate S100B in TBI-induced neuroinflammation, cell loss, and neurologic dysfunction, thereby indicating that it is a potential therapeutic target for TBI.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Zimmer, Danna B.; Afanador, Lauriaselle; Duffy, Kara B.] Univ Maryland, Sch Med, Ctr Biomol Therapeut, Baltimore, MD 21201 USA; [Zimmer, Danna B.; Afanador, Lauriaselle; Duffy, Kara B.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, HSFII, S247 20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348; Loane, David/0000-0003-0393-3503	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052568, R01NS037313]; Center for Biomolecular Therapeutics (University of Maryland School of Medicine); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568, R01NS037313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	These studies were supported by grants from the National Institutes of Health (R01NS052568 and R01NS037313) to Dr Alan I Faden and by the Center for Biomolecular Therapeutics (University of Maryland School of Medicine).	Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Afanador L, 2014, CELL CALCIUM, V56, P68, DOI 10.1016/j.ceca.2014.05.002; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bianchi R, 2007, J LEUKOCYTE BIOL, V81, P108, DOI 10.1189/jlb.0306198; Bianchi R, 2010, NEUROBIOL AGING, V31, P665, DOI 10.1016/j.neurobiolaging.2008.05.017; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Bouvier D, 2012, CLIN CHEM, V58, P1116, DOI 10.1373/clinchem.2011.180828; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Gazzolo D, 2010, CARDIOVASC PSYCHIAT, V2010, P1; GERLAI R, 1995, LEARN MEMORY, V2, P26, DOI 10.1101/lm.2.1.26; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Roltsch E, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-78; Schmidt A, 2007, J NEURAL TRANSM, V114, P1413, DOI 10.1007/s00702-007-0770-0; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Tsoporis JN, 2010, CIRC RES, V106, P93, DOI 10.1161/CIRCRESAHA.109.195834; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Villarreal A, 2014, J NEUROCHEM, V131, P190, DOI 10.1111/jnc.12790; Villarreal A, 2011, J NEUROCHEM, V117, P321, DOI 10.1111/j.1471-4159.2011.07207.x; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Winocur G, 2001, NEUROBIOL LEARN MEM, V75, P230, DOI 10.1006/nlme.2000.3961; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	40	26	29	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2015	35	12					2010	2020		10.1038/jcbfm.2015.165			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CX7OI	WOS:000365891300013	26154869	Green Published, Bronze			2021-06-18	
J	Mayer, AR; Ling, JM; Dodd, AB; Gasparovic, C; Klimaj, SD; Meier, TB				Mayer, Andrew R.; Ling, Josef M.; Dodd, Andrew B.; Gasparovic, Charles; Klimaj, Stefan D.; Meier, Timothy B.			A Longitudinal Assessment of Structural and Chemical Alterations in Mixed Martial Arts Fighters	JOURNAL OF NEUROTRAUMA			English	Article						concussion; longitudinal; repetitive injury; spectroscopy; volumetrics	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; COLLEGIATE FOOTBALL PLAYERS; PROTON MR SPECTROSCOPY; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FIGHTERS; N-ACETYLASPARTATE; NCAA CONCUSSION; HEAD TRAUMA; SYMPTOMS	Growing evidence suggests that temporally proximal acute concussions and repetitive subconcussive head injuries may lead to long-term neurological deficits. However, the underlying mechanisms of injury and their relative time-scales are not well documented in human injury models. The current study therefore investigated whether biomarkers of brain chemistry (magnetic resonance [MR] spectroscopy: N-acetylaspartate [NAA], combined glutamate and glutamine [Glx], total creatine [Cre], choline compounds [Cho], and myo-inositol [mI]) and structure (cortical thickness, white matter [WM]/subcortical volume) differed between mixed martial artists (MMA; n=13) and matched healthy controls (HC) without a history of contact sport participation (HC; n=14). A subset of participants (MMA=9; HC=10) returned for follow-up visits, with MMA (n=3) with clinician-documented acute concussions also scanned serially. As expected, MMA self-reported a higher incidence of previous concussions and significantly more cognitive symptoms during prior concussion recovery. Fighters also exhibited reduced memory and processing speed relative to controls on neuropsychological testing coupled with cortical thinning in the left posterior cingulate gyrus and right occipital cortex at baseline assessment. Over a 1-year follow-up period, MMA experienced a significant decrease in both WM volume and NAA concentration, as well as relative thinning in the left middle and superior frontal gyri. These longitudinal changes did not correlate with self-reported metrics of injury (i.e., fight diary). In contrast, HC did not exhibit significant longitudinal changes over a 4-month follow-up period (p>0.05). Collectively, current results provide preliminary evidence of progressive changes in brain chemistry and structure over a relatively short time period in individuals with high exposure to repetitive head hits. These findings require replication in independent samples.	[Mayer, Andrew R.; Ling, Josef M.; Dodd, Andrew B.; Gasparovic, Charles; Klimaj, Stefan D.; Meier, Timothy B.] Mind Res Network, Lovelace Biomed & Environm Res Inst, Albuquerque, NM 87106 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Mayer, AR (corresponding author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020				Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Banks SJ, 2014, J NEUROPSYCH CLIN N, V26, P44, DOI 10.1176/appi.neuropsych.12070185; Bartsch AJ, 2012, J NEUROSURG, V116, P1070, DOI 10.3171/2011.12.JNS111478; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Gasparovic C, 2001, NEUROSCI LETT, V301, P87, DOI 10.1016/S0304-3940(01)01616-0; Gasparovic C, 2006, MAGN RESON MED, V55, P1219, DOI 10.1002/mrm.20901; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heath CJ, 2013, RES SPORTS MED, V21, P195, DOI 10.1080/15438627.2013.792082; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hutchison MG, 2014, AM J SPORT MED, V42, P1352, DOI 10.1177/0363546514526151; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Schlaffke L, 2014, NEUROSCIENCE, V259, P35, DOI 10.1016/j.neuroscience.2013.11.046; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sivak S, 2014, BRAIN INJURY, V28, P341, DOI 10.3109/02699052.2013.865270; Sobell L.C., 1996, TIMELINE FOLLOWBACK; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wright MJ, 2013, BRAIN IMAGING BEHAV, V7, P307, DOI 10.1007/s11682-013-9231-6; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	61	26	26	1	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1759	1767		10.1089/neu.2014.3833			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500006	26096140				2021-06-18	
J	Michael, AP; Stout, J; Roskos, PT; Bolzenius, J; Gfeller, J; Mogul, D; Bucholz, R				Michael, Alex P.; Stout, Jeffrey; Roskos, P. Tyler; Bolzenius, Jacob; Gfeller, Jeffrey; Mogul, David; Bucholz, Richard			Evaluation of Cortical Thickness after Traumatic Brain Injury in Military Veterans	JOURNAL OF NEUROTRAUMA			English	Article						cortical thickness; magnetic resonance imaging; military veterans; traumatic brain injury	WHITE-MATTER INTEGRITY; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; SERVICE MEMBERS; IMAGING APPROACH; MILD; BLAST; SEGMENTATION; MODERATE; DIFFUSE	Military service members frequently sustain traumatic brain injuries (TBI) while on active duty, a majority of which are related to explosive blasts and are mild in severity. Studies evaluating the cortical gray matter in persons with injuries of this nature remain scarce. The purpose of this study was to assess cortical thickness in a sample of military veterans with chronic blast-related TBI. Thirty-eight veterans with mild TBI and 17 veterans with moderate TBI were compared with 58 demographically matched healthy civilians. All veterans with TBI sustained injuries related to a blast and were between 5 and 120 months post-injury (M=62.08). Measures of post-traumatic stress disorder (PTSD) and depression were administered, along with a battery of neuropsychological tests to assess cognition. The Freesurfer software package was used to calculate cortical thickness of the participants. Results demonstrated significant clusters of cortical thinning in the right hemispheric insula and inferior portions of the temporal and frontal lobe in both mild and moderate TBI participants. The TBI sample from this study demonstrated a high incidence of comorbid PTSD and depression symptoms, which is consistent with the previous literature. Cortical thickness values correlated with measures of PTSD, depression, and post-concussive symptoms. This study provides evidence of cortical thinning in the context of chronic blast-related mild and moderate TBI in military veterans who have comorbid psychiatric symptoms. Our findings provide important insight into the natural progression of long-term cortical change in this population and may have implications for future clinical evaluation and treatment.	[Michael, Alex P.] So Illinois Univ, Sch Med, Div Neurosurg, Springfield, IL 62702 USA; [Stout, Jeffrey; Mogul, David] IIT, Dept Biomed Engn, Chicago, IL 60616 USA; [Roskos, P. Tyler] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Dearborn, MI USA; [Bolzenius, Jacob] Univ Missouri, St Louis, MO 63121 USA; [Gfeller, Jeffrey] St Louis Univ, Dept Psychol, Sch Med, St Louis, MO 63103 USA; [Bucholz, Richard] St Louis Univ, Sch Med, Dept Neurosurg, St Louis, MO USA	Michael, AP (corresponding author), So Illinois Univ, Sch Med, Div Neurosurg, 421 N 9th St, Springfield, IL 62702 USA.	amichael@siumed.edu	Mogul, David/L-2765-2019; Stout, Jeffrey R/F-5805-2014	Stout, Jeffrey R/0000-0001-6114-1649	Department of Defense: Evidence-Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress DisorderUnited States Department of Defense [W81XWH-08-2-0191]	We would first like to thank the participants for taking part in this study. We would also like to thank D. Whitson, S. Taylor, and L. McDurmont for their work in recruitment and collection of data. This research was supported by the following grant from the Department of Defense: Evidence-Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder. Contract Number W81XWH-08-2-0191, Richard Bucholz, Principal Investigator.	Army Individual Test Battery, 1944, MAN DIR SCOR; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Christopoulos GI, 2009, J NEUROSCI, V29, P12574, DOI 10.1523/JNEUROSCI.2614-09.2009; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Corbo V, 2014, PSYCHIAT RES-NEUROIM, V223, P53, DOI 10.1016/j.pscychresns.2014.04.013; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dickerson BC, 2008, NEUROIMAGE, V39, P10, DOI 10.1016/j.neuroimage.2007.08.042; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Liberzon I, 2006, ANN NY ACAD SCI, V1071, P87, DOI 10.1196/annals.1364.009; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Weathers F.W., 1993, ANN CONV INT SOC TRA, V141; Weschsler D., 1997, WAIS 3 ADM SCORING M; White SF, 2015, NEUROIMAGE-CLIN, V7, P19, DOI 10.1016/j.nicl.2014.11.012; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160	56	26	28	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1751	1758		10.1089/neu.2015.3918			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500005	26131617				2021-06-18	
J	Matsushima, K; Inaba, K; Siboni, S; Skiada, D; Strumwasser, AM; Magee, GA; Sung, GY; Benjaminm, ER; Lam, L; Demetriades, D				Matsushima, Kazuhide; Inaba, Kenji; Siboni, Stefano; Skiada, Dimitra; Strumwasser, Aaron M.; Magee, Gregory A.; Sung, Gene Y.; Benjaminm, Elizabeth R.; Lam, Lydia; Demetriades, Demetrios			Emergent operation for isolated severe traumatic brain injury: Does time matter?	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; emergency operation; time; prognosis	ACUTE SUBDURAL-HEMATOMA; COMATOSE PATIENTS; TO-TREATMENT; MORTALITY; GUIDELINES; MANAGEMENT; HOSPITALS; SURGERY; STROKE	BACKGROUND It remains unclear whether the timing of neurosurgical intervention impacts the outcome of patients with isolated severe traumatic brain injury (TBI). We hypothesized that a shorter time between emergency department (ED) admission to neurosurgical intervention would be associated with a significantly higher rate of patient survival. METHODS Our institutional trauma registry was queried for patients (2003-2013) who required an emergent neurosurgical intervention (craniotomy, craniectomy) for TBI within 300 minutes after the ED admission. We included patients with altered mental status upon presentation in the ED (Glasgow Coma Scale [GCS] score < 9). Patients with associated severe injuries (Abbreviated Injury Scale [AIS] score 2) in other body regions were excluded. In-hospital mortality of patients who underwent surgery in less than 200 minutes (early group) was compared with those who underwent surgery in 200 minutes or longer (late group) using univariate and multivariate analyses. RESULTS A total of 161 patients were identified during the study time frame. Head computed tomographic scan demonstrated subdural hematoma in 85.8%, subarachnoid hemorrhage in 55.5%, and equal numbers of epidural hematoma and intraparenchymal hemorrhage in 22.6%. Median time between ED admission and neurosurgical intervention was 133 minutes. In univariate analysis, a significantly lower in-hospital mortality rate was identified in the early group (34.5% vs. 59.1%, p = 0.03). After adjusting for clinically important covariates in a logistic regression model, early neurosurgical intervention was significantly associated with a higher odds of patient survival (odds ratio, 7.41; 95% confidence interval, 1.66-32.98; p = 0.009). CONCLUSION Our data suggest that the survival rate of isolated severe TBI patients who required an emergent neurosurgical intervention could be time dependent. These patients might benefit from expedited process (computed tomographic scan, neurosurgical consultation, etc.) to shorten the time to surgical intervention. LEVEL OF EVIDENCE Prognostic study, level IV.	[Matsushima, Kazuhide; Inaba, Kenji; Siboni, Stefano; Skiada, Dimitra; Strumwasser, Aaron M.; Magee, Gregory A.; Benjaminm, Elizabeth R.; Lam, Lydia; Demetriades, Demetrios] Univ So Calif, Div Acute Care Surg, Los Angeles, CA USA; [Sung, Gene Y.] Univ So Calif, Div Neurocrit Care & Stroke, Los Angeles, CA USA	Matsushima, K (corresponding author), 1200 N State St,Inpatient Tower C,Rm C5L100, Los Angeles, CA 90033 USA.	mkazu45@gmail.com	Siboni, Stefano/AAF-5456-2019; INABA, KENJI/AAC-8532-2020	Siboni, Stefano/0000-0003-0532-3135; 			American College of Surgeons, NAT TRAUM DAT STAND; American College of Surgeons, 2014, RESOURCES OPTIMAL CA; American College of Surgeons, 2012, ADV TRAUM LIF SUPP S; Bradley EH, 2005, J AM COLL CARDIOL, V46, P1236, DOI 10.1016/j.jacc.2005.07.009; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 2006, NEUROSURGERY, V58, pS16; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fung Kon Jin PH, 2009, EUR J RADIOL, V72, P134; Hartings JA, 2014, J NEUROSURG, V120, P434, DOI 10.3171/2013.9.JNS13581; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P965, DOI 10.1097/TA.0000000000000161; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Rasouli MR, 2013, ANN SURG, V257, pE8, DOI 10.1097/SLA.0b013e318289f0c9; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Tien HCN, 2011, ANN SURG, V253, P1178, DOI 10.1097/SLA.0b013e318217e339; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Xian Y, 2014, STROKE, V45, P1387, DOI 10.1161/STROKEAHA.113.003898	23	26	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2015	79	5					838	842		10.1097/TA.0000000000000719			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CV3XX	WOS:000364201100021	26317818				2021-06-18	
J	Zhang, CC; Chen, JQ; Lu, H				Zhang, Chengcheng; Chen, Jianqiang; Lu, Hong			Expression of aquaporin-4 and pathological characteristics of brain injury in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						traumatic brain injury; cerebral edema; histopathology; aquaporin 4; contralateral non-damaged side; vasogenic edema	EDEMA; ASTROCYTES; TISSUE	Aquaporin 4 (AQP4) is a widely distributed membrane protein, which is found in glial cells, ependymocytes and capillary endothelial cells in the brain, and particularly in the choroid plexus. AQP4 is a key regulator of water metabolism, and changes in its expression following brain injury are associated with pathological changes in the damaged side of the brain; however, the effects of brain injury on AQP4 and injury-induced pathological changes in the contralateral non-damaged side of the brain remain to be fully elucidated. In the present study, male Sprague-Dawley rats were subjected to traumatic brain injury (TBI) and changes in brain water content, the expression of AQP4 expression and pathological characteristics in the damaged and contralateral non-damaged sides of the brain were examined. In the damaged side of the brain, vasogenic edema appeared first, followed by cellular edema. The aggravated cellular edema in the damaged side of the brain resulted in two periods of peak edema severity. Pathological changes in the contralateral non-damaged side of the brain occurred later than those in the damaged side; cellular edema appeared first, followed by vasogenic edema, which was alleviated earlier than the cellular edema. AQP4 was downregulated during vasogenic edema, and upregulated during cellular edema. Taken together, these results suggested that the downregulation of AQP4 was a result of vasogenic edema and that the upregulation of AQP4 may have induced cellular edema.	[Zhang, Chengcheng; Chen, Jianqiang; Lu, Hong] Cent S Univ, Affiliated Haikou Hosp, Xiangya Sch Med, Dept Radiol, Haikou 570208, Hainan, Peoples R China	Lu, H (corresponding author), Cent S Univ, Affiliated Haikou Hosp, Xiangya Sch Med, Dept Radiol, 43 Renmin Rd, Haikou 570208, Hainan, Peoples R China.	471739847@qq.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81160181]; Hainan Provincial International Corporation Project of China [2012-GH016]	This study was supported by the National Natural Science Foundation of China (grant. no.81160181) and the Hainan Provincial International Corporation Project of China (grant. no. 2012-GH016).	Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Ding Z, 2013, CHINESE J DIFFICULT, V12, P950; Easton AS, 2013, ADV EXP MED BIOL, V763, P1; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hu H, 2012, NEURAL REGEN RES, V7, P1659, DOI 10.3969/j.issn.1673-5374.2012.21.009; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Kim JY, 2015, J KOREAN MED SCI, V30, P943, DOI 10.3346/jkms.2015.30.7.943; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; [刘辉 Liu Hui], 2009, [解剖学杂志, Chinese Journal of Anatomy], V32, P68; Lo Pizzo M, 2013, NEUROL SCI, V34, P1309, DOI 10.1007/s10072-012-1233-4; Lu H, 2011, CHINESE J ANATOMY, V34, P47; Lu H, 2013, CHINESE MED J-PEKING, V126, P4316, DOI 10.3760/cma.j.issn.0366-6999.20131139; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Sabre L, 2013, SPINAL CORD, V51, P623, DOI 10.1038/sc.2013.41; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Yang J, 2013, LIFE SCI, V93, P1033, DOI 10.1016/j.lfs.2013.10.015; Yao XM, 2008, J NEUROSCI, V28, P5460, DOI 10.1523/JNEUROSCI.0257-08.2008; Zhang L, 2008, SHOUDU YIKE DAXUE XU, V29, P732	24	26	27	0	4	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2015	12	5	B				7351	7357		10.3892/mmr.2015.4372			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CW3JR	WOS:000364889100020	26459070	Green Published, Other Gold			2021-06-18	
J	Su, EJ; Fredriksson, L; Kanzawa, M; Moore, S; Folestad, E; Stevenson, TK; Nilsson, I; Sashindranath, M; Schielke, GP; Warnock, M; Ragsdale, M; Mann, K; Lawrence, ALE; Medcalf, RL; Eriksson, U; Murphy, GG; Lawrence, DA				Su, Enming J.; Fredriksson, Linda; Kanzawa, Mia; Moore, Shannon; Folestad, Erika; Stevenson, Tamara K.; Nilsson, Ingrid; Sashindranath, Maithili; Schielke, Gerald P.; Warnock, Mark; Ragsdale, Margaret; Mann, Kris; Lawrence, Anna-Lisa E.; Medcalf, Robert L.; Eriksson, Ulf; Murphy, Geoffrey G.; Lawrence, Daniel A.			Imatinib treatment reduces brain injury in a murine model of traumatic brain injury	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						traumatic brain injury; TBI outcome; blood brain barrier; platelet derived growth factor-CC; platelet derived growth factor receptor alpha; Imatinib; cerebral edema; Morris water maze	TISSUE-PLASMINOGEN ACTIVATOR; CEREBRAL-BLOOD-FLOW; MORRIS WATER MAZE; GROWTH-FACTOR-CC; UNITED-STATES; HEAD-INJURY; ISCHEMIC-STROKE; CLINICAL-TRIAL; PDGF-CC; MICE	Current therapies for Traumatic brain injury (TBI) focus on stabilizing individuals and on preventing further damage from the secondary consequences of TBI. A major complication of TBI is cerebral edema, which can be caused by the loss of blood brain barrier (BBB) integrity. Recent studies in several CNS pathologies have shown that activation of latent platelet derived growth factor-CC (PDGF-CC) within the brain can promote BBB permeability through PDGF receptor alpha (PDGFR alpha) signaling, and that blocking this pathway improves outcomes. In this study we examine the efficacy for the treatment of TBI of an FDA approved antagonist of the PDGFR alpha, Imatinib. Using a murine model we show that Imatinib treatment, begun 45 min after TBI and given twice daily for 5 days, significantly reduces BBB dysfunction. This is associated with significantly reduced lesion size 24 h, 7 days, and 21 days after TBI, reduced cerebral edema, determined from apparent diffusion co-efficient (ADC) measurements, and with the preservation of cognitive function. Finally, analysis of cerebrospinal fluid (CSF) from human TBI patients suggests a possible correlation between high PDGF-CC levels and increased injury severity. Thus, our data suggests a novel strategy for the treatment of TBI with an existing FDA approved antagonist of the PDGFR alpha.	[Su, Enming J.; Fredriksson, Linda; Kanzawa, Mia; Schielke, Gerald P.; Warnock, Mark; Ragsdale, Margaret; Mann, Kris; Lawrence, Anna-Lisa E.; Lawrence, Daniel A.] Univ Michigan, Dept Internal Med, Sch Med, Div Cardiovasc Med, Ann Arbor, MI 48109 USA; [Fredriksson, Linda; Folestad, Erika; Nilsson, Ingrid; Eriksson, Ulf] Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, Stockholm, Sweden; [Moore, Shannon; Murphy, Geoffrey G.] Univ Michigan, Mol & Behav Neurosci Inst, Sch Med, Ann Arbor, MI 48109 USA; [Stevenson, Tamara K.; Murphy, Geoffrey G.; Lawrence, Daniel A.] Univ Michigan, Dept Mol & Integrat Physiol, Sch Med, Ann Arbor, MI 48109 USA; [Sashindranath, Maithili; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Mol Neurotrauma & Haemostasis, Melbourne, Vic 3004, Australia	Lawrence, DA (corresponding author), Univ Michigan, Dept Internal Med, Sch Med, Div Cardiovasc Med, 7301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dlawrenc@umich.edu	Sashindranath, Maithili/AAI-7408-2021; Medcalf, Robert L/E-9632-2011	Sashindranath, Maithili/0000-0002-9712-4784; Moore, Shannon/0000-0002-5874-6572; Fredriksson, Linda/0000-0003-4952-2742; Lawrence, Daniel/0000-0003-3126-1935	Massey Foundation TBI Innovation Fund at the University of Michigan; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL055374, NS079639, AG028488]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024986]; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433]; Swedish Governmental Agency for Innovation SystemsVinnova [201103503]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2012-1853]; Karolinska InstitutetKarolinska Institutet; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024986] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL055374, T32HL125242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG028488] Funding Source: NIH RePORTER	We wish to acknowledge Dr Amanda Au (Monash) for providing the positive control (platelet releasate) for the human CSF western blot data. We also wish to acknowledge Prof Richard MacDonnell, Dr Marion Simpson and Ms Jennifer Horvath (Austin Hospital, Heidelberg, Victoria, Australia) for providing control CSF samples. This research was supported by The Massey Foundation TBI Innovation Fund at the University of Michigan, by NIH Grants HL055374 (DAL), NS079639 (DAL) AG028488 (GGM), by the National Center for Research Resources, Grant UL1RR024986, and is now at the National Center for Advancing Translational Sciences, Grant UL1TR000433, and by the Swedish Governmental Agency for Innovation Systems, Grant 201103503 (LF), the Swedish Research Council, Grant 2012-1853 (LF) and Karolinska Institutet (LF).	Abrams MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038760; Adzemovic MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056586; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Finnie JW, 2014, VET RES COMMUN, V38, P297, DOI 10.1007/s11259-014-9616-z; Fredriksson L, 2005, J BIOL CHEM, V280, P26856, DOI 10.1074/jbc.M503388200; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Fredriksson L, 2015, ANN CLIN TRANSL NEUR, V2, P722, DOI 10.1002/acn3.209; Fridgeirsdottir GA, 2014, UPSALA J MED SCI, V119, P1, DOI 10.3109/03009734.2013.847511; Frieden T.R., 2014, C TRAUM BRAIN INJ US; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Gilmer LK, 2008, J NEUROTRAUM, V25, P593, DOI 10.1089/neu.2007.0477; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hemphill J. C., 2013, TRAUMATIC BRAIN INJU; Hemphill J. C., 2013, MANAGEMENT ACUTE SEV; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Liu NK, 2013, BRAIN RES, V1499, P121, DOI 10.1016/j.brainres.2012.12.031; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu J, 2010, J NEUROTRAUM, V27, P843, DOI 10.1089/neu.2010.1293; Ma QY, 2011, ANN NEUROL, V70, P920, DOI 10.1002/ana.22549; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Maei HR, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.004.2009; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney BC, 2008, GENES BRAIN BEHAV, V7, P629, DOI 10.1111/j.1601-183X.2008.00399.x; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Perkowski JJ, 2011, J NEUROSCI, V31, P46, DOI 10.1523/JNEUROSCI.2634-10.2011; Rau PR, 2006, LIFE SCI, V78, P1175, DOI 10.1016/j.lfs.2005.06.032; Rodriguez-Gonzalez R, 2013, ATHEROSCLEROSIS, V226, P165, DOI 10.1016/j.atherosclerosis.2012.10.072; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Shipton OA, 2014, P NATL ACAD SCI USA, V111, P15238, DOI 10.1073/pnas.1405648111; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; White JA, 2008, LEARN MEMORY, V15, P1, DOI 10.1101/lm.773208; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Yepes M, 2000, BLOOD, V96, P569; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zauner A, 1996, ACT NEUR S, V67, P40	60	26	26	0	10	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	OCT 7	2015	9								385	10.3389/fncel.2015.00385			12	Neurosciences	Neurosciences & Neurology	CT1CG	WOS:000362534300001	26500491	DOAJ Gold, Green Published			2021-06-18	
J	Dawes, AJ; Sacks, GD; Cryer, HG; Gruen, JP; Preston, C; Gorospe, D; Cohen, M; McArthur, DL; Russell, MM; Maggard-Gibbons, M; Ko, CY				Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Gruen, J. Peter; Preston, Christy; Gorospe, Deidre; Cohen, Marilyn; McArthur, David L.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.		Los Angeles Cty Trauma Consortium	Compliance With Evidence-Based Guidelines and Interhospital Variation in Mortality for Patients With Severe Traumatic Brain Injury	JAMA SURGERY			English	Article							BLOOD-STREAM INFECTIONS; CARE QUALITY MEASURES; INTRACRANIAL-PRESSURE; UNITED-STATES; SURGICAL OUTCOMES; ASSOCIATION; IMPROVEMENT; HOSPITALS; SURVEILLANCE; ADJUSTMENT	IMPORTANCE Compliance with evidence-based guidelines in traumatic brain injury (TBI) has been proposed as a marker of hospital quality. However, the association between hospital-level compliance rates and risk-adjusted clinical outcomes for patients with TBI remains poorly understood. OBJECTIVE To examine whether hospital-level compliance with the Brain Trauma Foundation guidelines for intracranial pressure monitoring and craniotomy is associated with risk-adjusted mortality rates for patients with severe TBI. DESIGN, SETTING, AND PARTICIPANTS All adult patients (N = 734) who presented to a regional consortium of 14 hospitals from January 1, 2009, through December 31, 2010, with severe TBI (ie, blunt head trauma, Glasgow Coma Scale score of < 9, and abnormal intracranial findings from computed tomography of the head). Data analysis took place from December 2013 through January 2015. We used hierarchical mixed-effects models to assess the association between hospital-level compliance with Brain Trauma Foundation guidelines and mortality rates after adjusting for patient-level demographics, severity of trauma (eg, mechanism of injury and Injury Severity Score), and TBI-specific variables (eg, cranial nerve reflexes and findings from computed tomography of the head). MAIN OUTCOMES AND MEASURES Hospital-level risk-adjusted inpatient mortality rate and hospital-level compliance with Brain Trauma Foundation guidelines for intracranial pressure monitoring and craniotomy. RESULTS Unadjusted mortality rates varied by site from 20.0% to 50.0% (median, 42.6; interquartile range, 35.5-46.2); risk-adjusted rates varied from 24.3% to 56.7% (median, 41.1; interquartile range, 36.4-47.8). Overall, only 338 of 734 patients (46.1%) with an appropriate indication underwent placement of an intracranial pressure monitor and only 134 of 335 (45.6%) underwent craniotomy. Hospital-level compliance ranged from 9.6% to 65.2% for intracranial pressure monitoring and 6.7% to 76.2% for craniotomy. Despite widespread variation in compliance across hospitals, we found no association between hospital-level compliance rates and risk-adjusted patient outcomes (Spearman. = 0.030 [P = .92] for ICP monitoring and Spearman. = -0.066 [P = .83] for craniotomy). CONCLUSIONS AND RELEVANCE Hospital-level compliance with evidence-based guidelines has minimal association with risk-adjusted outcomes in patients with severe TBI. Our results suggest that caution should be taken before using compliance with these measures as independent quality metrics. Given the complexity of TBI care, outcomes-based metrics, including functional recovery, may be more accurate than current process measures at determining hospital quality.	[Dawes, Aaron J.; Sacks, Greg D.; Cryer, H. Gill; Cohen, Marilyn; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; [Dawes, Aaron J.; Sacks, Greg D.] Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA; [Dawes, Aaron J.; Russell, Marcia M.; Maggard-Gibbons, Melinda; Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA; [Gruen, J. Peter] Univ So Calif, Dept Neurosurg, Los Angeles, CA USA; [Preston, Christy; Gorospe, Deidre] Cty Los Angeles Dept Hlth Serv, Emergency Med Serv Agcy, Los Angeles, CA USA; [McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	Dawes, AJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Dept Surg, 757 Westwood Plaza,Room B7-11, Los Angeles, CA 90095 USA.	adawes@mednet.ucla.edu	Dawes, Aaron/I-1680-2019	Dawes, Aaron/0000-0003-4574-6765	Veterans Affairs Robert Wood Johnson Clinical Scholars Program; Veterans Affairs Office of Academic Affiliations	This study was supported by the Veterans Affairs Robert Wood Johnson Clinical Scholars Program (Drs Dawes and Sacks) and the Veterans Affairs Office of Academic Affiliations (Dr Dawes).	Adams J, 2009, RELIABILITY PROVIDER; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Arabi YM, 2010, J CRIT CARE, V25, P190, DOI 10.1016/j.jcrc.2009.05.004; Ayanian JZ, 2002, MILBANK Q, V80, P569, DOI 10.1111/1468-0009.00023; Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F; Berwick DM, 2015, JAMA-J AM MED ASSOC, V313, P469, DOI 10.1001/jama.2015.4; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Bilimoria KY, 2013, JAMA-J AM MED ASSOC, V310, P1482, DOI 10.1001/jama.2013.280048; Birkmeyer JD, 2004, J AM COLL SURGEONS, V198, P626, DOI 10.1016/j.jamcollsurg.2003.11.017; Bratton S. L., 2007, J NEUROTRAUMA S1, V24, pS37; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cohen ME, 2013, J AM COLL SURGEONS, V217, P336, DOI 10.1016/j.jamcollsurg.2013.02.027; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dawes AJ, 2015, J TRAUMA ACUTE CARE, V78, P492, DOI 10.1097/TA.0000000000000559; Dimick JB, 2012, ANN SURG, V255, P703, DOI 10.1097/SLA.0b013e31824b46ff; Dimick JB, 2010, HEALTH SERV RES, V45, P1614, DOI 10.1111/j.1475-6773.2010.01158.x; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P1170, DOI 10.1001/archsurg.2011.247; Hawn MT, 2008, J AM COLL SURGEONS, V206, P814, DOI 10.1016/j.jamcollsurg.2007.12.013; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Howell EA, 2014, JAMA-J AM MED ASSOC, V312, P1531, DOI 10.1001/jama.2014.13381; Karamanos E, 2014, AM J SURG, V208, P363, DOI 10.1016/j.amjsurg.2013.10.026; Kernisan LP, 2009, JAMA-J AM MED ASSOC, V301, P1341, DOI 10.1001/jama.2009.422; Khuri SF, 2001, ANN SURG, V234, P370, DOI 10.1097/00000658-200109000-00011; Morse RB, 2011, JAMA-J AM MED ASSOC, V306, P1454, DOI 10.1001/jama.2011.1385; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Qian F, 2011, MED CARE, V49, P1082, DOI 10.1097/MLR.0b013e318238f26b; Ryan AM, 2009, INQUIRY-J HEALTH CAR, V46, P274, DOI 10.5034/inquiryjrnl_46.03.274; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2014, J AM COLL SURGEONS, V219, P189, DOI 10.1016/j.jamcollsurg.2014.04.005; Stulberg JJ, 2010, JAMA-J AM MED ASSOC, V303, P2479, DOI 10.1001/jama.2010.841; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tang A, 2015, J SURG RES, V194, P565, DOI 10.1016/j.jss.2014.11.017; Urbach DR, 2014, NEW ENGL J MED, V370, P1029, DOI 10.1056/NEJMsa1308261; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694	45	26	27	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	OCT	2015	150	10					965	972		10.1001/jamasurg.2015.1678			8	Surgery	Surgery	DA1WB	WOS:000367585200010	26200744	Bronze			2021-06-18	
J	Fulkerson, DH; White, IK; Rees, JM; Baumanis, MM; Smith, JL; Ackerman, LL; Boaz, JC; Luerssen, TG				Fulkerson, Daniel H.; White, Ian K.; Rees, Jacqueline M.; Baumanis, Maraya M.; Smith, Jodi L.; Ackerman, Laurie L.; Boaz, Joel C.; Luerssen, Thomas G.			Analysis of long-term (median 10.5 years) outcomes in children presenting with traumatic brain injury and an initial Glasgow Coma Scale score of 3 or 4	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						traumatic brain injury; pediatric; Glasgow Coma Scale; Glasgow Outcome Scale; trauma	SEVERE HEAD-INJURY; FUNCTIONAL OUTCOMES; PROGNOSTIC VALUE; PREDICTORS; HYPOTHERMIA; DISABILITY; ADMISSION; DISCHARGE; REHABILITATION; ADOLESCENTS	OBJECT Patients with traumatic brain injury (TBI) with low presenting Glasgow Coma Scale (GCS) scores have very high morbidity and mortality rates. Neurosurgeons may be faced with difficult decisions in managing the most severely injured (GCS scores of 3 or 4) patients. The situation may be considered hopeless, with little chance of a functional recovery. Long-term data are limited regarding the clinical outcome of children with severe head injury. The authors evaluate predictor variables and the clinical outcomes at discharge, 1 year, and long term (median 10.5 years) in a cohort of children with TBI presenting with postresuscitation GCS scores of 3 and 4. METHODS A review of a prospectively collected trauma database was performed. Patients treated at Riley Hospital for Children (Indianapolis, Indiana) from 1988 to 2004 were reviewed. All children with initial GCS (modified for pediatric patients) scores of 3 or 4 were identified. Patients with a GCS score of 3 were compared with those with a GCS score of 4. The outcomes of all patients at the time of death or discharge and at 1-year and long-term follow-up were measured with a modified Glasgow Outcome Scale (GOS) that included a "normal" outcome. Long-term outcomes were evaluated by contacting surviving patients. Statistical "classification trees" were formed for survival and outcome, based on predictor variables. RESULTS Sixty-seven patients with a GCS score of 3 or 4 were identified in a database of 1636 patients (4.1%). Three of the presenting factors differed between the GCS 3 patients (n = 44) and the GCS 4 patients (n = 23): presence of hypoxia, single seizure, and open basilar cisterns on CT scan. The clinical outcomes were statistically similar between the 2 groups. In total, 48 (71.6%) of 67 patients died, remained vegetative, or were severely disabled by 1 year. Eight patients (11.9%) were normal at 1 year. Ten of the 22 patients with long-term follow-up were either normal or had a GOS score of 5. Multiple clinical, historical, and radiological factors were analyzed for correlation with survival and clinical outcome. Classification trees were formed to stratify predictive factors. The pupillary response was the factor most predictive of both survival and outcome. Other factors that either positively or negatively correlated with survival included hypothermia, mechanism of injury (abuse), hypotension, major concurrent symptoms, and midline shift on CT scan. Other factors that either positively or negatively predicted long-term outcome included hypothermia, mechanism of injury, and the assessment of the fontanelle. CONCLUSIONS In this cohort of 67 TBI patients with a presenting GCS score of 3 or 4, 56.6% died within 1 year. However, approximately 15% of patients had a good outcome at 10 or more years. Factors that correlated with survival and outcome included the pupillary response, hypothermia, and mechanism. The authors discuss factors that may help surgeons make critical decisions regarding their most serious pediatric trauma patients.	[Fulkerson, Daniel H.; Smith, Jodi L.; Ackerman, Laurie L.; Boaz, Joel C.] Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Dept Neurol Surg, Div Pediat Neurosurg, Indianapolis, IN 46202 USA; [White, Ian K.; Rees, Jacqueline M.; Baumanis, Maraya M.] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Luerssen, Thomas G.] Texas Childrens Hosp, Baylor Coll Med, Dept Neurol Surg, Pediat Neurosurg, Houston, TX 77030 USA	Fulkerson, DH (corresponding author), Indiana Univ Sch Med, Goodman Campbell Brain & Spine, James Whitcomb Riley Hosp Children, 702 Barnhill Dr 1134, Indianapolis, IN 46202 USA.	dfulkers@iupui.edu			Goodman Campbell Foundation	Funding for the statistical analysis was provided by the Goodman Campbell Foundation.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Chung CY, 2006, PEDIATR NEUROL, V34, P379, DOI 10.1016/j.pediatrneurol.2005.10.012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cuff S, 2007, J TRAUMA, V63, P172, DOI 10.1097/TA.0b013e31805c14b1; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Haider AH, 2011, J PEDIATR SURG, V46, P1557, DOI 10.1016/j.jpedsurg.2011.04.055; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jeon IC, 2008, J KOREAN NEUROSURG S, V44, P295, DOI 10.3340/jkns.2008.44.5.295; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kirkham FJ, 2008, DEV MED CHILD NEUROL, V50, P267, DOI 10.1111/j.1469-8749.2008.02042.x; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Kouloulas EJ, 2013, INT J REHABIL RES, V36, P260, DOI 10.1097/MRR.0b013e32835fd99a; Leitgeb J, 2013, EUR J TRAUMA EMERG S, V39, P285, DOI 10.1007/s00068-013-0269-3; Luerssen TG, 1998, PEDIAT SURG; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Olshen RA, 1984, CLASSIFICATION REGRE; Pineda JA, 2013, LANCET NEUROL, V12, P45, DOI 10.1016/S1474-4422(12)70269-7; Ramaiah VK, 2013, CHILD NERV SYST, V29, P629, DOI 10.1007/s00381-012-1984-5; Rivara FP, 2012, AM J PUBLIC HEALTH, V102, P2074, DOI 10.2105/AJPH.2012.300696; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Thais MERD, 2014, J NEUROPSYCHOL, V8, P125, DOI 10.1111/jnp.12000; Saadat S, 2012, ULUS TRAVMA ACIL CER, V18, P219, DOI [10.5505/tjtes.2012.03453, 10.5505/tjtes.2012. 03453]; Sandhaug M, 2010, BRAIN INJURY, V24, P740, DOI 10.3109/02699051003652849; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; SIMPSON D, 1982, LANCET, V2, P450; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Suskauer SJ, 2009, J PEDIATR REHAB MED, V2, P297, DOI 10.3233/PRM-2009-0092; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tepas JJ, 2009, J PEDIATR SURG, V44, P368, DOI 10.1016/j.jpedsurg.2008.10.089; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109	53	26	27	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2015	16	4					410	419		10.3171/2015.3.PEDS14679			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CS1XS	WOS:000361862800009	26140392	Bronze			2021-06-18	
J	O'Brien, NF; Maa, T; Reuter-Rice, K				O'Brien, Nicole F.; Maa, Tensing; Reuter-Rice, Karin			Noninvasive screening for intracranial hypertension in children with acute, severe traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						intracranial pressure; traumatic brain injury; transcranial Doppler ultrasound; pulsatility index; end diastolic flow velocity; intracranial hypertension; pediatrics; trauma	DOPPLER PULSATILITY INDEX; BLOOD-FLOW-VELOCITY; SEVERE HEAD-INJURY; TRANSCRANIAL DOPPLER; CEREBROVASCULAR RESPONSE; PRESSURE; AUTOREGULATION; METABOLISM; ULTRASOUND; HYPEREMIA	OBJECT The aim of this study was to determine the relationship between transcranial Doppler (TCD) derived pulsatility index (PI), end diastolic flow velocity (Vd), and intracranial pressure (ICP). The subjects in this study were 36 children admitted after severe traumatic brain injury (TBI) (postresuscitation Glasgow Coma Scale <= 8) undergoing invasive ICP monitoring., METHODS Subjects underwent a total of 148 TCD studies. TCD measurements of systolic flow velocity (Vs), Vd, and mean flow velocity (Vm) were performed on the middle cerebral artery (MCA) ipsilateral to the ICP monitor. The PI was calculated by the TCD software (Vs-Vd/Vm). ICP registrations were made in parallel with TCD measurements. RESULTS Using a PI threshold of 1.3, postinjury Day 0-1 PI had 100% sensitivity and 82% specificity at predicting an ICP >= 20 mm Hg (n = 8). During this time frame, a moderately strong relationship was observed between the MCA PI and actual ICP (r = 0.611, p = 0.01). When using a threshold of < 25 cm/sec, postinjury Day 0-1 Vd had a 56% sensitivity to predict an ICP 20 mm Hg. Beyond the initial 24 hours from injury, the sensitivity of an MCA PI of 1.3 to detect an ICP >= 20 mm Hg was 47%, and a weak relationship between actual ICP values and MCA PI (r = 0.376, p = 0.01) and MCA Vd (r = 0.284, p = 0.01) was found. CONCLUSIONS Postinjury Day 0-1 MCA PI > 1.3 has good sensitivity and specificity at predicting an ICP >= 20 mm Hg. In those children with TBI who initially do not meet clear criteria for invasive ICP monitoring but who are at risk for development of intracranial hypertension, TCD may be used as a noninvasive tool to screen for the development of elevated ICP in the first 24 hours following injury.	[O'Brien, Nicole F.; Maa, Tensing] Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Dept Pediat, Columbus, OH 43205 USA; [Reuter-Rice, Karin] Duke Univ, Dept Pediat, Sch Nursing, Sch Med, Durham, NC 27706 USA	O'Brien, NF (corresponding author), Ohio State Univ, Nationwide Childrens Hosp, Div Crit Care Med, Dept Pediat, 700 Childrens Dr,ED-350, Columbus, OH 43205 USA.	nicole.obrien@nationwidechildrens.org	Maa, Tensing/J-9791-2012	Maa, Tensing/0000-0001-6104-8401; Reuter-Rice, Karin/0000-0003-1501-8994	Intramural Funding Program Nationwide Children's Hospital	This work was supported by the Intramural Funding Program Nationwide Children's Hospital.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Behrens A, 2010, NEUROSURGERY, V66, P1050, DOI 10.1227/01.NEU.0000369519.35932.F2; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; de Riva N, 2012, NEUROCRIT CARE, V17, P58, DOI 10.1007/s12028-012-9672-6; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; Goutorbe PV, 2001, ANN FR ANESTH S, V20, pR451; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Moreno J A, 2000, Neurosurg Focus, V8, pe8; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Nagai H, 1997, STROKE, V28, P603, DOI 10.1161/01.STR.28.3.603; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Melo JRT, 2011, CHILD NERV SYST, V27, P979, DOI 10.1007/s00381-010-1367-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Zierski J, 1987, Acta Neurochir Suppl (Wien), V40, P95; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	32	26	26	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2015	16	4					420	425		10.3171/2015.3.PEDS14521			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CS1XS	WOS:000361862800010	26140576	Bronze			2021-06-18	
J	Kummer, TT; Magnoni, S; MacDonald, CL; Dikranian, K; Milner, E; Sorrell, J; Conte, V; Benetatos, JJ; Zipfel, GJ; Brody, DL				Kummer, Terrance T.; Magnoni, Sandra; MacDonald, Christine L.; Dikranian, Krikor; Milner, Eric; Sorrell, James; Conte, Valeria; Benetatos, Joey J.; Zipfel, Gregory J.; Brody, David L.			Experimental subarachnoid haemorrhage results in multifocal axonal injury	BRAIN			English	Article						subarachnoid haemorrhage; traumatic brain injury; axonal injury; diffusion tensor imaging; brain haemorrhage	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; WHITE-MATTER INJURY; MOUSE MODEL; EPIDEMIOLOGY; VASOSPASM; IMMUNOREACTIVITY; PERMEABILITY; DYSFUNCTION; TRANSPORT	Mechanisms of brain injury after haemorrhagic stroke are poorly understood. Kummer et al. provide experimental evidence in a mouse model that subarachnoid haemorrhage causes widespread axonal injury similar to that seen after traumatic brain injury, suggesting that these disease entities share common underlying mechanisms.Mechanisms of brain injury after haemorrhagic stroke are poorly understood. Kummer et al. provide experimental evidence in a mouse model that subarachnoid haemorrhage causes widespread axonal injury similar to that seen after traumatic brain injury, suggesting that these disease entities share common underlying mechanisms.The great majority of acute brain injury results from trauma or from disorders of the cerebrovasculature, i.e. ischaemic stroke or haemorrhage. These injuries are characterized by an initial insult that triggers a cascade of injurious cellular processes. The nature of these processes in spontaneous intracranial haemorrhage is poorly understood. Subarachnoid haemorrhage, a particularly deadly form of intracranial haemorrhage, shares key pathophysiological features with traumatic brain injury including exposure to a sudden pressure pulse. Here we provide evidence that axonal injury, a signature characteristic of traumatic brain injury, is also a prominent feature of experimental subarachnoid haemorrhage. Using histological markers of membrane disruption and cytoskeletal injury validated in analyses of traumatic brain injury, we show that axonal injury also occurs following subarachnoid haemorrhage in an animal model. Consistent with the higher prevalence of global as opposed to focal deficits after subarachnoid haemorrhage and traumatic brain injury in humans, axonal injury in this model is observed in a multifocal pattern not limited to the immediate vicinity of the ruptured artery. Ultrastructural analysis further reveals characteristic axonal membrane and cytoskeletal changes similar to those associated with traumatic axonal injury. Diffusion tensor imaging, a translational imaging technique previously validated in traumatic axonal injury, from these same specimens demonstrates decrements in anisotropy that correlate with histological axonal injury and functional outcomes. These radiological indicators identify a fibre orientation-dependent gradient of axonal injury consistent with a barotraumatic mechanism. Although traumatic and haemorrhagic acute brain injury are generally considered separately, these data suggest that a signature pathology of traumatic brain injury-axonal injury-is also a functionally significant feature of subarachnoid haemorrhage, raising the prospect of common diagnostic, prognostic, and therapeutic approaches to these conditions.	[Kummer, Terrance T.; MacDonald, Christine L.; Sorrell, James; Benetatos, Joey J.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Magnoni, Sandra; Conte, Valeria] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anaesthesiol & Intens Care, I-20122 Milan, Italy; [Dikranian, Krikor] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Milner, Eric; Zipfel, Gregory J.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA	Kummer, TT (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA.	kummert@neuro.wustl.edu			Hope Center for Neurological Diseases; American Heart AssociationAmerican Heart Association; US National Institutes of Health K12 grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ICTS UL1 TR000448]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065069, NS071011]; National Institutes of Health Shared Instrumentation GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10 RR0227552]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000448, KL2TR000450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071011, R01NS065069] Funding Source: NIH RePORTER	This study was supported by a grant from the Hope Center for Neurological Diseases (to T.T.K.), an American Heart Association Scientist Development Grant (to T.T.K.), a US National Institutes of Health K12 grant (ICTS UL1 TR000448; to T.T.K.), a National Institutes of Health R01 grant (NS065069; to D.L.B.), a National Institutes of Health R01 grant (NS071011; to G.J.Z.), an American Heart Association Grant-in-Aid (to G.J.Z.), and a National Institutes of Health Shared Instrumentation Grant (S10 RR0227552).	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendel P, 2009, NEURORADIOLOGY, V51, P711, DOI 10.1007/s00234-009-0552-5; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cai JY, 2013, CLIN CHIM ACTA, V424, P182, DOI 10.1016/j.cca.2013.06.019; CARPENTER DA, 1991, J CEREBR BLOOD F MET, V11, P837, DOI 10.1038/jcbfm.1991.143; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Egashira Y, 2014, STROKE, V45, P2141, DOI 10.1161/STROKEAHA.114.005307; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Frattalone AR, 2013, NEUROSURG CLIN N AM, V24, P309, DOI 10.1016/j.nec.2013.03.006; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Helbok R, 2015, J NEUROL NEUROSUR PS, V86, P79, DOI 10.1136/jnnp-2013-307326; Hu HT, 2012, CLIN BIOCHEM, V45, P1320, DOI 10.1016/j.clinbiochem.2012.06.003; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston SC, 1998, NEUROLOGY, V50, P1413, DOI 10.1212/WNL.50.5.1413; Kim-Han JS, 2006, STROKE, V37, P2457, DOI 10.1161/01.STR.0000240674.99945.4e; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Milner E, 2014, J CEREBR BLOOD F MET, V34, P1571, DOI 10.1038/jcbfm.2014.108; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; Parra A, 2002, NEUROL RES, V24, P510, DOI 10.1179/016164102101200276; Passier PECA, 2011, J STROKE CEREBROVASC, V20, P324, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.001; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Powers WJ, 2010, STROKE, V41, pS107, DOI 10.1161/STROKEAHA.110.595058; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Venkatasubramanian C, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000090; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yu CS, 2009, NEUROIMAGE, V47, P451, DOI 10.1016/j.neuroimage.2009.04.066; Zanier ER, 2013, BRIT J ANAESTH, V111, P424, DOI 10.1093/bja/aet149; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	60	26	29	0	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP 1	2015	138		9				2608	2618		10.1093/brain/awv180			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CR5PS	WOS:000361396200022	26115676	Green Published, Bronze			2021-06-18	
J	Mahler, B; Carlsson, S; Andersson, T; Adelow, C; Ahlbom, A; Tomson, T				Mahler, Benno; Carlsson, Sofia; Andersson, Tomas; Adelow, Cecilia; Ahlbom, Anders; Tomson, Torbjorn			Unprovoked seizures after traumatic brain injury: A population-based case-control study	EPILEPSIA			English	Article						Epidemiology; Seizure; Epilepsy; Traumatic brain injury; Case-control; Population-based	LATE POSTTRAUMATIC SEIZURES; RISK-FACTORS; HEAD-INJURY; EPILEPSY; HOSPITALIZATION; EPIDEMIOLOGY; IMPACT	ObjectiveTo quantify the risk of unprovoked seizures after traumatic brain injury (TBI) MethodsWe used the Stockholm Incidence Registry on Epilepsy to carry out a population-based case-control study, including 1,885 cases with incident unprovoked seizures from September 1, 2000 through August 31, 2008, together with 15,080 matched controls. Information of prior hospitalizations for TBI was obtained through record linkage with the Swedish National Inpatient Registry for the period 1980-2008. Relative risks (RRs) for unprovoked seizures were estimated after various TBI diagnoses, and influences of TBI severity and time since trauma were studied in detail. ResultsAfter hospitalization for mild TBI, the RR was 2.0 (95% confidence interval [CI] 1.5-2.7). The RR was higher after brain contusion (5.9, 95% CI 2.4-15.0) or intracranial hemorrhage (ICH) (4.5, 95% CI 2.2-9.0), whereas a combination of both diagnoses led to a further sevenfold increase in RR (42.6, 95% CI 12.2-148.5). The risk was greatest during the first 6months after severe TBI (RR 48.9, 95% CI 10.9-218.9) or mild TBI (RR 8.1, 95% CI 3.1-21.7), but was still elevated >10years after any TBI. SignificanceHerein we present a large population-based case-control study on TBI as a risk factor for unprovoked epileptic seizures, including cases of all ages with individually validated seizure diagnoses. The risk for epileptic seizures was substantially increased after TBI, especially during the first 6months after the injury and in patients with a combination of ICH and brain contusion.	[Mahler, Benno; Adelow, Cecilia; Tomson, Torbjorn] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Carlsson, Sofia; Ahlbom, Anders] Karolinska Inst, Inst Environm Med, Epidemiol Unit, S-10401 Stockholm, Sweden; [Andersson, Tomas] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden	Mahler, B (corresponding author), Karolinska Univ, Sjukhuset Huddinge, S-14186 Huddinge, Sweden.	benno.mahler@karolinska.se		carlsson, sofia/0000-0002-9497-2331	Stockholm County Council (ALF)Stockholm County Council; AFA Insurance	This study was supported by a grant from the Stockholm County Council (ALF) and AFA Insurance.	Adelow C, 2012, NEUROLOGY, V78, P396, DOI 10.1212/WNL.0b013e318245f461; Adelow C, 2009, EPILEPSIA, V50, P1094, DOI 10.1111/j.1528-1167.2008.01726.x; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1986, KLASS SJUKD 1968 SYS; [Anonymous], 1996, KLASS SJUKD HOLS 199; [Anonymous], 1986, KLASS SJUKD 1987 SYS; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Banerjee PN, 2008, EPILEPSY COMPREHENSI, V1, P45; Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003; Bharucha NE, 1997, EPILEPSIA, V38, P614; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DASILVA AM, 1990, ACT NEUR S, V50, P48; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; JENNETT B, 1973, LANCET, V2, P652; JENNETT B, 1978, SCOT MED J, V23, P102, DOI 10.1177/003693307802300145; Kessing LV, 1998, EUR PSYCHIAT, V13, P392, DOI 10.1016/S0924-9338(99)80685-3; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; Roe C, 2013, J REHABIL MED, V45, P734, DOI 10.2340/16501977-1198; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Salazar A, 1999, POSTTRAUMATIC EPILEP; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Samokhvalov AV, 2010, EPILEPSIA, V51, P1177, DOI 10.1111/j.1528-1167.2009.02426.x; Smedby B, 2006, HLTH CLASSIFICATIONS; Vandenbroucke JP, 2012, INT J EPIDEMIOL, V41, P1480, DOI 10.1093/ije/dys147; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	42	26	26	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2015	56	9					1438	1444		10.1111/epi.13096			7	Clinical Neurology	Neurosciences & Neurology	CQ7PF	WOS:000360795400020	26332184	Bronze			2021-06-18	
J	Mirabelli, MH; Devine, MJ; Singh, J; Mendoza, M				Mirabelli, Mark H.; Devine, Mathew J.; Singh, Jaskaran; Mendoza, Michael			The Preparticipation Sports Evaluation	AMERICAN FAMILY PHYSICIAN			English	Article							HEART-ASSOCIATION COUNCIL; CONSENSUS STATEMENT; ELECTROCARDIOGRAPHIC INTERPRETATION; INTERNATIONAL-CONFERENCE; SCIENTIFIC STATEMENT; PHYSICAL-ACTIVITY; AMERICAN-COLLEGE; ATHLETE; PARTICIPATION; DEATH	The preparticipation physical evaluation is a commonly requested medical visit for amateur and professional athletes of all ages. The overarching goal is to maximize the health of athletes and their safe participation in sports. Although studies have not found that the preparticipation physical evaluation prevents morbidity and mortality associated with sports, it may detect conditions that predispose the athlete to injury or illness and can provide strategies to prevent injuries. Clearance depends on the outcome of the evaluation and the type of sport (and sometimes position or event) in which the athlete participates. All persons undergoing a preparticipation physical evaluation should be questioned about exertional symptoms, presence Of a heart murmur, symptoms of Marfan syndrome, and family history of premature serious cardiac conditions or sudden death. The physical examination should focus on the cardiovascular and musculoskeletal systems. U.S. medical and athletic organizations discourage screening electrocardiography and blood and urine testing in asymptomatic patients. Further evaluation should be considered for persons with heart or lung disease, bleeding disorders, musculoskeletal problems, history of concussion, or other neurologic disorders. Copyright (C) 2015 American Academy of Family Physicians.	[Mirabelli, Mark H.] Univ Rochester, Med Ctr, Dept Orthoped, Rochester, NY 14642 USA; [Mirabelli, Mark H.; Devine, Mathew J.; Singh, Jaskaran; Mendoza, Michael] Univ Rochester, Med Ctr, Dept Family Med, Rochester, NY 14642 USA; [Mirabelli, Mark H.] Univ Rochester, Med Ctr, Dept Phys Med & Rehabil, Rochester, NY 14642 USA	Mirabelli, MH (corresponding author), Univ Rochester, 601 Elmwood Ave,Box 665, Rochester, NY 14642 USA.	mark_mirabelli@urmc.rochester.edu					Bernhardt DT, 2010, PPE PREPARTICIPATION; Bille K, 2006, EUR J CARDIOV PREV R, V13, P859, DOI 10.1097/01.hjr.0000238397.50341.4a; Canadian Hemophilia Society, PASSP WELL BEING EMP; Carek PJ, 1999, ARCH FAM MED, V8, P307, DOI 10.1001/archfami.8.4.307; Chaitman BR, 2007, CIRCULATION, V116, P2610, DOI 10.1161/CIRCULATIONAHA.107.711465; Clem KL, 2007, CLIN SPORT MED, V26, P413, DOI 10.1016/j.csm.2007.04.012; Corrado D, 2006, JAMA-J AM MED ASSOC, V296, P1593, DOI 10.1001/jama.296.13.1593; De Souza MJ, 2014, CLIN J SPORT MED, V24, P96, DOI 10.1097/JSM.0000000000000085; Diokno E, 2010, PEDIATR CLIN N AM, V57, P839, DOI 10.1016/j.pcl.2010.03.005; Drezner JA, 2013, BRIT J SPORT MED, V47, P122, DOI 10.1136/bjsports-2012-092067; Fudge J, 2014, BRIT J SPORT MED, V48, P1172, DOI 10.1136/bjsports-2014-093840; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Harmon KG, 2012, BRIT J SPORT MED, V46, P325, DOI 10.1136/bjsports-2011-090896; Harris KM, 2006, ANN INTERN MED, V145, P507, DOI 10.7326/0003-4819-145-7-200610030-00008; Hong G, 2005, CLIN REV ALLERG IMMU, V29, P97, DOI 10.1385/CRIAI:29:2:097; Howard Gregory M, 2004, Curr Sports Med Rep, V3, P15; Klossner D, 2013 14 NCAA SPORTS; Kurowski K, 2000, AM FAM PHYSICIAN, V61, P2683; Ljungqvist A, 2009, BRIT J SPORT MED, V43, P631, DOI 10.1136/bjsm.2009.064394; Lombardo J A, 2001, Clin Cornerstone, V3, P10, DOI 10.1016/S1098-3597(01)90066-3; Maron BJ, 2007, CIRCULATION, V115, P1643, DOI 10.1161/CIRCULATIONAHA.107.181423; Maron BJ, 2014, J AM COLL CARDIOL, V64, P1479, DOI 10.1016/j.jacc.2014.05.006; Maron BJ, 2005, J AM COLL CARDIOL, V45, P1318, DOI 10.1016/j.jacc.2005.02.006; Mayer F, 2012, BRIT J SPORT MED, V46, P524, DOI 10.1136/bjsports-2011-090966; McCambridge Teri M, 2010, Pediatrics, V125, P1287, DOI 10.1542/peds.2010-0658; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Mercer KW, 2005, CLIN SPORT MED, V24, P599, DOI 10.1016/j.csm.2005.03.006; Mick TM, 2004, CLEV CLIN J MED, V71, P587, DOI 10.3949/ccjm.71.7.587; Mitchell JH, 2005, J AM COLL CARDIOL, V45, P1364, DOI 10.1016/j.jacc.2005.02.015; Myerburg RJ, 2007, CIRCULATION, V116, P2616, DOI 10.1161/CIRCULATIONAHA.107.733519; National Hemophilia Foundation, PLAYING IT SAF BLEED; Patel DR, 2010, PEDIATR CLIN N AM, V57, P795, DOI 10.1016/j.pcl.2010.03.002; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Riding NR, 2015, HEART, V101, P384, DOI 10.1136/heartjnl-2014-306437; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Sharma S, 2015, JAMA INTERN MED, V175, P125, DOI 10.1001/jamainternmed.2014.6023; Thompson PD, 2007, CIRCULATION, V115, P2358, DOI 10.1161/CIRCULATIONAHA.107.181485	38	26	26	0	11	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	SEP 1	2015	92	5					371	376					6	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	CQ7KM	WOS:000360783000008	26371570				2021-06-18	
J	Wang, HK; Lee, YC; Huang, CY; Liliang, PC; Lu, K; Chen, HJ; Li, YC; Tsai, KJ				Wang, H. -K.; Lee, Y. -C.; Huang, C. -Y.; Liliang, P. -C.; Lu, K.; Chen, H. -J.; Li, Y. -C.; Tsai, K. -J.			TRAUMATIC BRAIN INJURY CAUSES FRONTOTEMPORAL DEMENTIA AND TDP-43 PROTEOLYSIS	NEUROSCIENCE			English	Article						traumatic brain injury; frontotemporal dementia; TAR-DNA binding protein 43	AMYOTROPHIC-LATERAL-SCLEROSIS; ENVIRONMENTAL RISK-FACTORS; LOBAR DEGENERATION; ALZHEIMERS-DISEASE; MOUSE MODEL; RATS; DIAGNOSIS; AGGREGATION; PROGRANULIN; POPULATION	Traumatic brain injury (TBI) is a major risk factor for dementia. Recently, TBI has also been suggested as a risk factor for frontotemporal dementia (FTD), and plasma immunoreactivity to the TAR-DNA binding protein 43 (TDP-43) has been observed in both patients with acute TBI and long-term survivors of this condition. We used a population-based study to estimate and compare the risk of FTD in individuals with and without TBI. Furthermore, we used a rat model of TBI to show that increased TDP-43 proteolysis following TBI produces FTD-like impairments, including abnormal limb-clasping, and impaired performances in the Morris water maze. We recruited 24,585 patients who received ambulatory or hospital care for TBI and 122,925 patients without TBI for this study. Each individual was investigated for 4 years to evaluate FTD development, and data were analyzed by Cox proportional hazard regression. In the TBI rat model, behavior and TDP-43 inclusions were assessed following intracranial administration of a caspase-3 inhibitor or vehicle. FTD was more likely to occur in the TBI group than in the group without TBI (adjusted hazard ratio, 4.43; 95% confidence interval, 3.85-5.10; P<0.001). Rats developed behavioral impairments similar to those in patients with FTD after TBI. Further, the behavioral impairments were likely associated with TDP-43 short fragment mislocalization and accumulation. Our findings suggest that in humans, TBI is associated with a greater occurrence of FTD. Moreover, clinical FTD manifestations may be associated with TDP-43 proteolysis, since impaired behaviors in TBI rats were reminiscent of those in humans with FTD. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wang, H. -K.; Lee, Y. -C.; Huang, C. -Y.; Tsai, K. -J.] Natl Cheng Kung Univ, Inst Clin Med, Tainan 701, Taiwan; [Wang, H. -K.; Liliang, P. -C.; Lu, K.; Chen, H. -J.] I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Lee, Y. -C.] I Shou Univ, E Da Hosp, Dept Nephrol, Kaohsiung, Taiwan; [Huang, C. -Y.] Natl Cheng Kung Univ Hosp, Dept Surg, Neurosurg Serv, Tainan 70428, Taiwan; [Lu, K.; Chen, H. -J.; Li, Y. -C.] Natl Sun Yat Sen Univ, Inst Hlth Care Management, Kaohsiung 80424, Taiwan	Tsai, KJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Tainan 701, Taiwan.	kjtsai@mail.ncku.edu.tw	Tsai, Kuen-Jer/B-9393-2009	Tsai, Kuen-Jer/0000-0002-2170-9735	E-Da Hospital, Kaohsiung, Taiwan [EDAHP-101026, EDAHP-103012, NCKUEDA10303]	This study was supported in part by grants from the E-Da Hospital, Kaohsiung, Taiwan (EDAHP-101026, EDAHP-103012, and NCKUEDA10303). This study was based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, Taiwan, and managed by the National Health Research Institutes. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, the Department of Health, or the National Health Research Institutes.	Barmada SJ, 2010, J NEUROSCI, V30, P639, DOI 10.1523/JNEUROSCI.4988-09.2010; Che MX, 2011, FASEB J, V25, P2344, DOI 10.1096/fj.10-174482; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Ito D, 2011, NEUROLOGY, V77, P1636, DOI 10.1212/WNL.0b013e3182343365; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Kalkonde YV, 2012, ALZHEIMERS DEMENT, V8, P204, DOI 10.1016/j.jalz.2011.03.011; Kanazawa M, 2011, J NEUROCHEM, V116, P957, DOI 10.1111/j.1471-4159.2010.06860.x; Kleinberger G, 2010, J NEUROCHEM, V115, P735, DOI 10.1111/j.1471-4159.2010.06961.x; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mackenzie IRA, 2010, LANCET NEUROL, V9, P995, DOI 10.1016/S1474-4422(10)70195-2; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Rossor MN, 2010, LANCET NEUROL, V9, P793, DOI 10.1016/S1474-4422(10)70159-9; Seelaar H, 2011, J NEUROL NEUROSUR PS, V82, P476, DOI 10.1136/jnnp.2010.212225; Sieben A, 2012, ACTA NEUROPATHOL, V124, P353, DOI 10.1007/s00401-012-1029-x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsai KJ, 2002, P NATL ACAD SCI USA, V99, P3990, DOI 10.1073/pnas.062405399; Tsai KJ, 2010, J EXP MED, V207, P1661, DOI 10.1084/jem.20092164; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang IF, 2012, P NATL ACAD SCI USA, V109, P15024, DOI 10.1073/pnas.1206362109; World Health Organization, 2012, DEM PUBL HLTH PRIOR, P19; Xu ZS, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-27; Yang Z, 2014, J CEREB BLOOD FLOW M, V34, P1444; Zhang YJ, 2009, P NATL ACAD SCI USA, V106, P7607, DOI 10.1073/pnas.0900688106	40	26	26	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	AUG 6	2015	300						94	103		10.1016/j.neuroscience.2015.05.013			10	Neurosciences	Neurosciences & Neurology	CL2IQ	WOS:000356767400010	25982564				2021-06-18	
J	Albayrak, S; Atci, IB; Kalayci, M; Yilmaz, M; Kuloglu, T; Aydin, S; Kom, M; Ayden, O; Aydin, S				Albayrak, Serdal; Atci, Ibrahim Burak; Kalayci, Mehmet; Yilmaz, Musa; Kuloglu, Tuncay; Aydin, Suna; Kom, Mustafa; Ayden, Omer; Aydin, Suleyman			Effect of carnosine, methylprednisolone and their combined application on irisin levels in the plasma and brain of rats with acute spinal cord injury	NEUROPEPTIDES			English	Article						Carnosine; Methylprednisolone; Irisin; Spinal cord injury	METABOLIC SYNDROME; MOTOR FUNCTION; COMPRESSION; EXPRESSION; RECOVERY; IMPROVES; TISSUES; ISCHEMIA; GHRELIN; ALPHA	Spinal cord injury (SCI) might occur to anybody at any time and any age. In its treatment, methylprednisolone (MP) is a first choice worldwide, but there is still no significant breakthrough in truly beneficial treatment due to SCI's complex pathophysiology. We investigated the effect of camosine, methylprednisolone (MP) and its combination on irisin levels in the plasma, brain and medulla spinalis tissues in SCI using a rat model. The rats were divided into 6 groups: I (Control, saline); II (sham animals with laminectomy without cross-clamping); III (SCI); IV (SCI treated with 150 mg/kg carnosine); V (SCI treated with 30 mg/kg methylprednisolone); and VI (SCI treated with a combination of carnosine and MP). The animals were given traumatic SCI after laminectomy, using 70-g closing force aneurysm clips (Yasargil FE 721). Irisin concentration was measured by ELISA. The distribution of irisin in brain and spinal cord tissues was examined by immunochemistry. Irisin was mainly expressed in the astrocytes and microglia of brain tissues, and multipolar neurones of the anterior horn of spinal cord tissue in rats of all groups, indicating that irisin is physiologically indispensable. MP and camosine and the combination of the two, significantly increased irisin in plasma and were accompanied by a significant rise in irisin immunoreactivity of brain and spinal cord tissues of the injured rats compared with control and sham. This finding raises the possibility that methylprednisolone and camosine regulate the brain and spinal cord tissues in SCI by inducing irisin expression, and may therefore offer a better neurological prognosis. (C) 2015 Elsevier Ltd. All rights reserved.	[Albayrak, Serdal; Atci, Ibrahim Burak; Ayden, Omer] Elazig Educ & Res Hosp, Dept Neurosurg, TR-23100 Elazig, Turkey; [Kalayci, Mehmet] Elazig Educ & Res Hosp, Med Biochem Lab, TR-23100 Elazig, Turkey; [Yilmaz, Musa; Aydin, Suleyman] Firat Univ, Sch Med, Dept Med Biochem, First Hormones Res Grp, TR-23119 Elazig, Turkey; [Kuloglu, Tuncay] Firat Univ, Sch Med, Dept Histol & Embryol, TR-23119 Elazig, Turkey; [Aydin, Suna] Elazig Educ & Res Hosp, Cardiovasc Surg Anat, TR-23100 Elazig, Turkey; [Kom, Mustafa] Firat Univ, Vet Med, Dept Surg, TR-23119 Elazig, Turkey	Aydin, S (corresponding author), Firat Univ, Sch Med, Dept Med Biochem, First Hormones Res Grp, TR-23119 Elazig, Turkey.	saydinl@hotmail.com	kuloglu, tuncay/W-2310-2018	KALAYCI, Mehmet/0000-0001-9122-9289			Aydin S, 2014, BIOTECH HISTOCHEM, V89, P98, DOI 10.3109/10520295.2013.821167; Aydin S., 2014, BIOTECH HISTOCHEM, P1; Aydin S, 2007, J BIOCHEM MOL BIOL, V40, P29; Aydin S, 2014, PEPTIDES, V61, P130, DOI 10.1016/j.peptides.2014.09.014; Aydin S, 2014, PEPTIDES, V56, P94, DOI 10.1016/j.peptides.2014.03.021; Aydin S, 2015, PEPTIDES, V64, P14, DOI 10.1016/j.peptides.2014.11.008; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Boldyrev AA, 2012, BIOCHEMISTRY-MOSCOW+, V77, P313, DOI 10.1134/S0006297912040013; Boldyrev AA, 2013, PHYSIOL REV, V93, P1803, DOI 10.1152/physrev.00039.2012; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Cassano M, 2009, J MUSCLE RES CELL M, V30, P243, DOI 10.1007/s10974-010-9204-y; Catak Z, 2014, NEUROPEPTIDES, V48, P167, DOI 10.1016/j.npep.2014.04.002; Coban Jale, 2013, Curr Aging Sci, V6, P199; Di Paola R, 2011, BIOCHEM PHARMACOL, V82, P1478, DOI 10.1016/j.bcp.2011.07.074; Dun SL, 2013, NEUROSCIENCE, V240, P155, DOI 10.1016/j.neuroscience.2013.02.050; Farooque M, 1996, J NEUROCHEM, V66, P1125; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; Gravholt CH, 2002, OBES RES, V10, P774, DOI 10.1038/oby.2002.105; Holmes FE, 2005, NEUROPEPTIDES, V39, P191, DOI 10.1016/j.npep.2005.01.001; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jing YH, 2012, ACTA NEUROBIOL EXP, V72, P240; Kumamaru H, 2012, J CELL PHYSIOL, V227, P1335, DOI 10.1002/jcp.22845; Li XL, 2007, NEUROPEPTIDES, V41, P135, DOI 10.1016/j.npep.2007.02.001; Meng B, 2011, J INT MED RES, V39, P805, DOI 10.1177/147323001103900313; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Nasirinezhad F, 2015, MOL PAIN, V11, DOI 10.1186/1744-8069-11-2; Pereira RMR, 2011, JOINT BONE SPINE, V78, P41, DOI 10.1016/j.jbspin.2010.02.025; Shaw PJ, 1997, J NEUROL SCI, V147, P115, DOI 10.1016/S0022-510X(96)05316-6; Shi E, 2005, J THORAC CARDIOV SUR, V129, P364, DOI 10.1016/j.jtcvs.2004.05.006; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; Taylor JA, 2011, PM&R, V3, P817, DOI 10.1016/j.pmrj.2011.03.020; Vaquero J, 2006, HISTOL HISTOPATHOL, V21, P1091, DOI 10.14670/HH-21.1091; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245; Young W, 1992, J NEUROTRAUMA S1, V9, P9	36	26	29	0	15	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179	1532-2785		NEUROPEPTIDES	Neuropeptides	AUG	2015	52						47	54		10.1016/j.npep.2015.06.004			8	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	CQ2FT	WOS:000360416100005	26142757				2021-06-18	
J	Cole, MA; Muir, JJ; Gans, JJ; Shin, LM; D'Esposito, M; Harel, BT; Schembri, A				Cole, Michael A.; Muir, James J.; Gans, Jennifer J.; Shin, Lisa M.; D'Esposito, Mark; Harel, Brian T.; Schembri, Adrian			Simultaneous Treatment of Neurocognitive and Psychiatric Symptoms in Veterans with Post-Traumatic Stress Disorder and History of Mild Traumatic Brain Injury: A Pilot Study of Mindfulness-Based Stress Reduction	MILITARY MEDICINE			English	Article							PERSISTENT POSTCONCUSSIVE SYMPTOMS; COGNITIVE IMPAIRMENT; CHRONIC PAIN; MEDITATION; MECHANISMS; BATTERY; PROGRAM; PARTICIPATION; SCHIZOPHRENIA; INTERVENTION	Treating patient populations with significant psychiatric and neurocognitive symptomatology can present a unique clinical dilemma: progress in psychotherapy can be significantly fettered by cognitive deficits, whereas neurocognitive rehabilitation efforts can be ineffective because of psychiatric overlay. Application of mindfulness-based interventions to address either cognitive or psychiatric symptoms in isolation appears efficacious in many contexts; however, it remains unclear whether this type of intervention might help address simultaneous neurocognitive and psychiatric symptomatology. In a pre-post mixed methods design pilot study, nine Veterans with post-traumatic stress disorder (PTSD) and a history of mild traumatic brain injury with chronic cognitive complaints participated in Mindfulness-Based Stress Reduction (MBSR). Clinical interview, questionnaires, and attention and PTSD measures were administered immediately before, immediately after, and 3 months after MBSR completion. Qualitative and quantitative findings suggest high levels of safety, feasibility, and acceptability. Measurement of attention revealed significant improvement immediately following MBSR (p < 0.05, d = 0.57) and largely sustained improvement 3 months after completion of MBSR (p < 0.10, d = 0.48). Significant reduction in PTSD symptoms was found immediately after MBSR (p < 0.05, d = -1.56), and was sustained 3 months following MBSR completion (p < 0.05, d = -0.93). These results warrant a randomized controlled trial follow-up. Potential mechanisms for the broad effects observed will be explored.	[Cole, Michael A.; Muir, James J.; Gans, Jennifer J.; D'Esposito, Mark] Vet Affairs Northern Calif Hlth Care Syst, Martinez, CA 94553 USA; [Cole, Michael A.] Univ Calif Davis, Dept Neurol, Davis, CA 95817 USA; [Cole, Michael A.; D'Esposito, Mark] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; [Gans, Jennifer J.] Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94115 USA; [Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA; [Harel, Brian T.; Schembri, Adrian] Cogstate Inc, New Haven, CT 06510 USA; [Harel, Brian T.] Yale Univ, Yale Child Study Ctr, New Haven, CT 06519 USA; [Schembri, Adrian] RMIT Univ, Sch Hlth Sci, Div Psychol, Melbourne, Vic 3000, Australia	Cole, MA (corresponding author), Vet Affairs Northern Calif Hlth Care Syst, 150 Muir Rd, Martinez, CA 94553 USA.				VA Research and Development Career Development Award (Cole); CogState	Support for this work was provided by a VA Research and Development Career Development Award (Cole). Authors BTH and AS are employed by CogState. CogState provided support in the form of salaries for authors BTH and AS and use of CogState tests, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Heather G. Cole, MSW, for her helpful feedback on earlier drafts of this manuscript.	Azulay J, 2013, J HEAD TRAUMA REHAB, V28, P323, DOI 10.1097/HTR.0b013e318250ebda; Barnes V, 2013, MIL MED, V178, P836; Bedard Michel, 2012, Adv Mind Body Med, V26, P14; Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077; Boden MT, 2012, PSYCHIAT RES, V200, P609, DOI 10.1016/j.psychres.2012.07.011; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bryant R, 2006, COGN BEHAV PRACT, V160, P585; Carlson K, ASSESSMENT TREATMENT; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carmody J, 2009, J CLIN PSYCHOL, V65, P613, DOI 10.1002/jclp.20579; Chambers R, 2009, CLIN PSYCHOL REV, V29, P560, DOI 10.1016/j.cpr.2009.06.005; Chiesa A, 2010, PSYCHOL MED, V40, P1239, DOI 10.1017/S0033291709991747; Chiesa A, 2014, HOLIST NURS PRACT, V28, P124, DOI 10.1097/HNP.0000000000000017; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; Chiesa A, 2010, J ALTERN COMPLEM MED, V16, P37, DOI 10.1089/acm.2009.0362; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cole M, 2011, J INT NEUROPSYCH SOC, V17, P118; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Follette V., 2006, J RATIONAL EMOTIVE C, V24, P45, DOI [https://doi.org/10.1007/s10942-006-0025-2, DOI 10.1007/S10942-006-0025-2]; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; Gabbard Glen O., 2007, OXFORD TXB PSYCHOTHE; Goldin P, 2013, SOC COGN AFFECT NEUR, V8, P65, DOI 10.1093/scan/nss054; Hammers D, 2011, AM J ALZHEIMERS DIS, V26, P326, DOI 10.1177/1533317511411907; Holzel BK, 2011, PERSPECT PSYCHOL SCI, V6, P537, DOI 10.1177/1745691611419671; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kabat-Zinn J., 1990, USING WISDOM YOUR BO; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kearney DJ, 2013, J CLIN PSYCHOL, V69, P14, DOI 10.1002/jclp.21911; Kearney DJ, 2012, J CLIN PSYCHOL, V68, P101, DOI 10.1002/jclp.20853; Kimbrough E, 2010, J CLIN PSYCHOL, V66, P17, DOI 10.1002/jclp.20624; King AP, 2013, DEPRESS ANXIETY, V30, P638, DOI 10.1002/da.22104; Kinney A., 2001, J CONTEMP PSYCHOTHER, V31, P89, DOI DOI 10.1023/A:1010261422373; Lang AJ, 2012, BEHAV MODIF, V36, P759, DOI 10.1177/0145445512441200; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Marchand WR, 2012, J PSYCHIATR PRACT, V18, P233, DOI 10.1097/01.pra.0000416014.53215.86; Maruff Paul, 2013, BMC Psychol, V1, P30, DOI 10.1186/2050-7283-1-30; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Monson CM, 2008, PSYCHOL ASSESSMENT, V20, P131, DOI 10.1037/1040-3590.20.2.131; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Pietrzak RH, 2009, J CLIN EXP NEUROPSYC, V31, P848, DOI 10.1080/13803390802592458; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rosenthal JZ, 2011, MIL MED, V176, P626, DOI 10.7205/MILMED-D-10-00254; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schmied EA, 2013, MIL MED, V178, P1051, DOI 10.7205/MILMED-D-13-00135; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; Tang YY, 2012, CHILD DEV PERSPECT, V6, P361, DOI 10.1111/j.1750-8606.2012.00250.x; Tang YY, 2012, P NATL ACAD SCI USA, V109, P10570, DOI 10.1073/pnas.1207817109; Thompson BL, 2010, J ANXIETY DISORD, V24, P409, DOI 10.1016/j.janxdis.2010.02.005; Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P82; Vita A, 2013, SCHIZOPHR RES, V150, P51, DOI 10.1016/j.schres.2013.08.011; Vujanovic AA, 2009, J ANXIETY DISORD, V23, P297, DOI 10.1016/j.janxdis.2008.08.005; Weathers F. W., 1993, 9 ANN M INT SOC TRAU	62	26	26	1	38	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2015	180	9					956	963		10.7205/MILMED-D-14-00581			8	Medicine, General & Internal	General & Internal Medicine	CQ3TL	WOS:000360525600007	26327547	Bronze			2021-06-18	
J	Corrigan, JD; Horn, SD; Barrett, RS; Smout, RJ; Bogner, J; Hammond, FM; Brandstater, ME; Majercik, S				Corrigan, John D.; Horn, Susan D.; Barrett, Ryan S.; Smout, Randall J.; Bogner, Jennifer; Hammond, Flora M.; Brandstater, Murray E.; Majercik, Sarah			Effects of Patient Preinjury and Injury Characteristics on Acute Rehabilitation Outcomes for Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Craniocerebral trauma; Outcome assessment (health care); Rehabilitation	FUNCTIONAL RECOVERY; IMPACT; PREDICTION; DISABILITY; SEVERITY; TIME; AGE	Objective: To examine associations of patient and injury characteristics with outcomes at inpatient rehabilitation discharge and 9 months postdischarge for patients with traumatic brain injury (TBI). Design: Prospective, longitudinal observational study. Setting: Inpatient rehabilitation centers. Participants: Consecutive patients (N=2130) enrolled between 2008 and 2011, admitted for inpatient rehabilitation after index TBI, and divided into 5 subgroups based on rehabilitation admission FIM cognitive score. Interventions: Not applicable. Main Outcome Measures: Rehabilitation length of stay, discharge to home, and FIM at discharge and 9 months postdischarge. Results: Severity indices increased explained variation in outcomes beyond that accounted for by patient characteristics. FIM motor scores were generally the most predictable. Higher functioning subgroups had more predictable outcomes then subgroups with lower cognitive function at admission. Age at injury, time from injury to rehabilitation admission, and functional independence at rehabilitation admission were the most consistent predictors across all outcomes and subgroups. Conclusions: Findings from previous studies of the relations among patient and injury characteristics and rehabilitation outcomes were largely replicated. Discharge outcomes were most strongly associated with injury severity characteristics, whereas predictors of functional independence at 9 months postdischarge included both patient and injury characteristics. (C) 2015 by the American Congress of Rehabilitation Medicine	[Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Horn, Susan D.; Barrett, Ryan S.; Smout, Randall J.] Int Sever Informat Syst, Inst Clin Outcomes Res, Salt Lake City, UT USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Brandstater, Murray E.] Loma Linda Univ, Med Ctr, Loma Linda, CA USA; [Majercik, Sarah] Intermt Med Ctr, Div Trauma & Surg Crit Care, Salt Lake City, UT USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu			National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01HD050439-01]; National Institute on Disability and Rehabilitation Research [H133A080023]; Ontario Neurotrauma Foundation [2007-ABI-ISIS-525]; American Congress of Rehabilitation Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	Supported by the National Institutes of Health, National Center for Medical Rehabilitation Research (grant no. 1R01HD050439-01); National Institute on Disability and Rehabilitation Research (grant no. H133A080023); and Ontario Neurotrauma Foundation (grant no. 2007-ABI-ISIS-525).; Publication of this article was supported by the American Congress of Rehabilitation Medicine.	Avesani R, 2012, EUR J PHYS REHAB MED, V48, P433; Barker MD, 2014, J HEAD TRAUMA REHAB, V29, P400, DOI 10.1097/HTR.0b013e31828a0a45; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coronado V, MORTALITY M IN PRESS; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1315; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Gardizi E, 2014, ARCH PHYS MED REHAB, V95, P2396, DOI 10.1016/j.apmr.2014.06.004; Godbolt AK, 2015, J HEAD TRAUMA REHAB, V30, pE41, DOI 10.1097/HTR.0000000000000050; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hart T, 2014, ARCH PHYS MED REHAB, V95, P2103, DOI 10.1016/j.apmr.2014.07.001; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Horn SD, 2015, ARCH PHYS MED REHAB, V96, pS178, DOI 10.1016/j.apmr.2014.09.042; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Leon-Carrion J, 2013, BRAIN INJURY, V27, P1119, DOI 10.3109/02699052.2013.804204; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Pedersen AR, 2015, NEUROREHAB NEURAL RE, V29, P299, DOI 10.1177/1545968314545171; Perrin PB, 2015, J HEAD TRAUMA REHAB, V30, P136, DOI 10.1097/HTR.0000000000000026; Ponsford J, 2013, NEUROREHABILITATION, V32, P803, DOI 10.3233/NRE-130904; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023	27	26	28	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2015	96	8		3			S209	S221		10.1016/j.apmr.2015.03.026			13	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CO3CV	WOS:000359035100004	26212398	Green Accepted, Bronze			2021-06-18	
J	Wilcox, BJ; Beckwith, JG; Greenwald, RM; Raukar, NP; Chu, JJ; McAllister, TW; Flashman, LA; Maerlender, AC; Duhaime, AC; Crisco, JJ				Wilcox, Bethany J.; Beckwith, Jonathan G.; Greenwald, Richard M.; Raukar, Neha P.; Chu, Jeffrey J.; McAllister, Thomas W.; Flashman, Laura A.; Maerlender, Arthur C.; Duhaime, Ann-Christine; Crisco, Joseph J.			Biomechanics of head impacts associated with diagnosed concussion in female collegiate ice hockey players	JOURNAL OF BIOMECHANICS			English	Article						Impact biomechanics; Concussion; Female; Hockey	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; ACCELERATION; SYMPTOMS; EXPOSURE; GENDER; GAME; SEX	Epidemiological evidence suggests that female athletes may be at a greater risk of concussion than their male counterparts. The purpose of this study was to examine the biomechanics of head impacts associated with diagnosed concussions in a cohort of female collegiate ice hockey players. Instrumented helmets were worn by 58 female ice hockey players from 2 NCAA programs over a three year period. Kinematic measures of single impacts associated with diagnosed concussion and head impact exposure on days with and without diagnosed concussion were evaluated. Nine concussions were diagnosed. Head impact exposure was greater in frequency and magnitude on days of diagnosed concussions than on days without diagnosed concussion for individual athletes. Peak linear accelerations of head impacts associated with diagnosed concussion in this study are substantially lower than those previously reported in male athletes, while peak rotational accelerations are comparable. Further research is warranted to determine the extent to which female athletes' biomechanical tolerance to concussion injuries differs from males. (C) 2015 Elsevier Ltd. All rights reserved.	[Wilcox, Bethany J.; Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Bioengn Lab, Dept Orthopaed, Providence, RI 02903 USA; [Wilcox, Bethany J.; Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Raukar, Neha P.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Maerlender, Arthur C.] Univ Nebraska, Ctr Brain Biol & Behav, Lincoln, NE USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Pediat Neurosurg, Boston, MA 02114 USA	Wilcox, BJ (corresponding author), Brown Univ, Alpert Med Sch, Bioengn Lab, Dept Orthopaed, CORO West,Suite 404,1 Hoppin St, Providence, RI 02903 USA.	Bethany_Wilcox@brown.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute of General Medical Sciences at the National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01HD048638, RO1NS055020, R25GM083270, R25GM083270-S1]; National Operating Committee on Standards for Athletic Equipment (NOCSAE); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937, R25GM083270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Child Health and Human Development, the National Institute of Neurological Disorders and Stroke, and the National Institute of General Medical Sciences at the National Institute of Health under award numbers R01HD048638, RO1NS055020, R25GM083270 and R25GM083270-S1 and the National Operating Committee on Standards for Athletic Equipment (NOCSAE). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or NOCSAE. We gratefully acknowledge and thank the engineering team at Simbex for all of their technical support. We would like to thank Lindley Brainard and Wendy Chamberlin at Simbex for their role in data collection and clinical coordination. We would also like to thank Russell Fiore, M.Ed., A.T.C, Emily Burmeister M.S., A.T.C, and Brian Daigneault, MS, A.T.C at Brown University; Jeff Frechette, A.T.C., and Tracey Poro, A.T.C.at Dartmouth College Sports Medicine and Mary Hynes, R.N., M.P.H. at Dartmouth Medical School for their support on this project.	Agel J, 2010, CAN J SURG, V53, P319; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Dick R.W., 2009, BR J SPORTS MED S1, V43, pSi46; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004	29	26	26	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL 16	2015	48	10					2201	2204		10.1016/j.jbiomech.2015.04.005			4	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CN5HG	WOS:000358459800073	25913243	Green Published, Green Accepted			2021-06-18	
J	Laksari, K; Wu, LC; Kurt, M; Kuo, C; Camarillo, DC				Laksari, Kaveh; Wu, Lyndia C.; Kurt, Mehmet; Kuo, Calvin; Camarillo, David C.			Resonance of human brain under head acceleration	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						mild traumatic brain injury; resonance frequency; rigid body motion; repetitive head exposure; tagged MRI; injury risk criterion	IN-VIVO; INJURY; DISPLACEMENT; DEFORMATION; CONCUSSION; MOTION	Although safety standards have reduced fatal head trauma due to single severe head impacts, mild trauma from repeated head exposures may carry risks of long-term chronic changes in the brain's function and structure. To study the physical sensitivities of the brain to mild head impacts, we developed the first dynamic model of the skull brain based on in vivo MRI data. We showed that the motion of the brain can be described by a rigid-body with constrained kinematics. We further demonstrated that skull brain dynamics can be approximated by an under-damped system with a low-frequency resonance at around 15 Hz. Furthermore, from our previous field measurements, we found that head motions in a variety of activities, including contact sports, show a primary frequency of less than 20 Hz. This implies that typical head exposures may drive the brain dangerously close to its mechanical resonance and lead to amplified brain skull relative motions. Our results suggest a possible cause for mild brain trauma, which could occur due to repetitive low-acceleration head oscillations in a variety of recreational and occupational activities.	[Laksari, Kaveh; Wu, Lyndia C.; Kurt, Mehmet; Camarillo, David C.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Kuo, Calvin; Camarillo, David C.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Camarillo, DC (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.	dcamarillo@stanford.edu	Wu, Lyndia/AAQ-1106-2020; Kuo, Calvin/AAH-1933-2019	Wu, Lyndia/0000-0002-8236-032X; Kuo, Calvin/0000-0001-8401-9136; Kurt, Mehmet/0000-0002-5618-0296	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; David and Lucile Packard FoundationThe David & Lucile Packard Foundation [38454]; Child Health Research Institute-Transdisciplinary Initiatives Programme; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000093]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001085, UL1TR000093] Funding Source: NIH RePORTER	The study was supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, David and Lucile Packard Foundation 38454, Child Health Research Institute-Transdisciplinary Initiatives Programme, and NIH UL1 TR000093 for biostatistics consultation.	Abney TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022063; Alem NM, 1974, 741192 SAE, DOI [10.4271/741192, DOI 10.4271/741192]; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Garrick JG, 2005, CLIN J SPORT MED, V15, P385, DOI 10.1097/01.jsm.0000181438.48892.1b; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gennarelli TA, 2014, PROG NEUROL SURG, V28, P243, DOI 10.1159/000358788; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosch H, SURG FORUM, V20, P425; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; HAKANSSON B, 1994, J ACOUST SOC AM, V95, P1474, DOI 10.1121/1.408535; Hardy WN, 2011, STAPP CAR CRASH J, V45, P337; Hernandez F., 2014, ANN BIOMED ENG, V43, P1; Hirsch A, 1968, 2876 DEP NAV NAV SHI; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Low T, 1987, INT RES COUNCIL BIOK, V15, P203; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Nahum AM, 2001, ACCIDENTAL INJURY BI, V119; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; SHATSKY SA, 1974, J NEUROSURG, V41, P523, DOI 10.3171/jns.1974.41.5.0523; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stalnaker R.L., 1977, SAE TECHNICAL PAPER, DOI [10.4271/770921, DOI 10.4271/770921]; STALNAKER RL, 1971, J BIOMECH, V4, P127, DOI 10.1016/0021-9290(71)90023-6; Sullivan S, 2014, BIOMECH MODEL MECHAN, P1; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Wu L, 2014, IEEE T BIOMED ENG, V9294, P1; Zou H, 2008, INT J CRASHWORTHINES, V13, P337, DOI 10.1080/13588260801943047; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024; Zou H, 2007, J BIOMECH, V40, P1183, DOI 10.1016/j.jbiomech.2006.06.018	48	26	26	0	14	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	JUL 6	2015	12	108							20150331	10.1098/rsif.2015.0331			9	Multidisciplinary Sciences	Science & Technology - Other Topics	CO0FD	WOS:000358824600021	26063824	Green Published, Bronze			2021-06-18	
J	Gao, Y; Xu, SY; Cui, ZW; Zhang, MK; Lin, YY; Cai, L; Wang, ZG; Luo, XG; Zheng, Y; Wang, Y; Luo, QZ; Jiang, JY; Neale, JH; Zhong, CL				Gao, Yang; Xu, Siyi; Cui, Zhenwen; Zhang, Mingkun; Lin, Yingying; Cai, Lei; Wang, Zhugang; Luo, Xingguang; Zheng, Yan; Wang, Yong; Luo, Qizhong; Jiang, Jiyao; Neale, Joseph H.; Zhong, Chunlong			Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						behavior; gene knockout; Glutamate carboxypep-tidase II; histopathology; N-acetylaspartylglutamate; traumatic brain injury	NAAG PEPTIDASE INHIBITOR; N-ACETYLASPARTYLGLUTAMATE NAAG; MEMBRANE ANTIGEN; NEUROPATHIC PAIN; GCP-II; MODEL; NAALADASE; ENZYME; NEUROTRANSMITTER; ASTROCYTES	Glutamate carboxypeptidase II (GCPII) is a transmembrane zinc metallopeptidase found mainly in the nervous system, prostate and small intestine. In the nervous system, glia-bound GCPII mediates the hydrolysis of the neurotransmitter N-acetylaspartylglutamate (NAAG) into glutamate and N-acetylaspartate. Inhibition of GCPII has been shown to attenuate excitotoxicity associated with enhanced glutamate transmission under pathological conditions. However, different strains of mice lacking the GCPII gene are reported to exhibit striking phenotypic differences. In this study, a GCPII gene knockout (KO) strategy involved removing exons 3-5 of GCPII. This generated a new GCPII KO mice line with no overt differences in standard neurological behavior compared to their wild-type (WT) littermates. However, GCPII KO mice were significantly less susceptible to moderate traumatic brain injury (TBI). GCPII gene KO significantly lessened neuronal degeneration and astrocyte damage in the CA2 and CA3 regions of the hippocampus 24h after moderate TBI. In addition, GCPII gene KO reduced TBI-induced deficits in long-term spatial learning/memory tested in the Morris water maze and motor balance tested via beam walking. Knockout of the GCPII gene is not embryonic lethal and affords histopathological protection with improved long-term behavioral outcomes after TBI, a result that further validates GCPII as a target for drug development consistent with results from studies using GCPII peptidase inhibitors.	[Gao, Yang; Xu, Siyi; Cui, Zhenwen; Zhang, Mingkun; Lin, Yingying; Zheng, Yan; Wang, Yong; Luo, Qizhong; Jiang, Jiyao; Zhong, Chunlong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Cai, Lei; Wang, Zhugang] Shanghai Res Ctr Model Organisms, Shanghai, Peoples R China; [Luo, Xingguang] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Neale, Joseph H.] Georgetown Univ, Dept Biol, Washington, DC 20057 USA	Zhong, CL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	drchunlongzhong@126.com			basic research program of project 973 by the Ministry of Science and Technology of China [2011CB013304]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	The authors report no conflicts of interest. This research was supported in part by a basic research program of project 973 by the Ministry of Science and Technology of China (2011CB013304), and by grants from the National Natural Science Foundation of China (No. 81070990, 30670719, 30500525), the Shanghai Science and Technology Commission (No. 10QH1401700, 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20). JN supported by an endowment and generous gifts from Nancy and Daniel Paduano.	Bacich DJ, 2005, J NEUROCHEM, V95, P314, DOI 10.1111/j.1471-4159.2005.03361.x; Bacich DJ, 2002, J NEUROCHEM, V83, P20, DOI 10.1046/j.1471-4159.2002.01117.x; Bacich DJ, 2001, MAMM GENOME, V12, P117, DOI 10.1007/s003350010240; Barinka C, 2012, CURR MED CHEM, V19, P856, DOI 10.2174/092986712799034888; Berger UV, 1999, J COMP NEUROL, V415, P52, DOI 10.1002/(SICI)1096-9861(19991206)415:1<52::AID-CNE4>3.0.CO;2-K; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; Cao P, 2013, CNS NEUROSCI THER, V19, P337, DOI 10.1111/cns.12082; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CASSIDY M, 1993, NEUROPEPTIDES, V24, P271, DOI 10.1016/0143-4179(93)90015-3; Chang SS, 1999, CLIN CANCER RES, V5, P2674; Chopra M, 2009, J PHARMACOL EXP THER, V330, P212, DOI 10.1124/jpet.109.152553; Crawley JN, 2008, NEURON, V57, P809, DOI 10.1016/j.neuron.2008.03.001; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dvela-Levitt M, 2014, J NEUROTRAUM, V31, P1942, DOI 10.1089/neu.2014.3544; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Feng JF, 2012, BRAIN RES, V1469, P144, DOI 10.1016/j.brainres.2012.06.021; Feng JF, 2011, BRAIN RES, V1395, P62, DOI 10.1016/j.brainres.2011.04.022; Fricker AC, 2009, NEUROPHARMACOLOGY, V56, P1060, DOI 10.1016/j.neuropharm.2009.03.002; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gurkoff GG, 2013, BRAIN RES, V1515, P98, DOI 10.1016/j.brainres.2013.03.043; Han LQ, 2009, SYNAPSE, V63, P625, DOI 10.1002/syn.20649; Hlouchova K, 2007, J NEUROCHEM, V101, P682, DOI 10.1111/j.1471-4159.2006.04341.x; ISRAELI RS, 1993, CANCER RES, V53, P227; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; Janczura KJ, 2013, EUR J PHARMACOL, V701, P27, DOI 10.1016/j.ejphar.2012.11.027; Kozikowski AP, 2004, J MED CHEM, V47, P1729, DOI 10.1021/jm0306226; Kunkler PE, 1997, J CEREBR BLOOD F MET, V17, P26, DOI 10.1097/00004647-199701000-00005; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Marmiroli P, 2012, CURR MED CHEM, V19, P1277, DOI 10.2174/092986712799462568; McKinzie DL, 2000, ADDICT BIOL, V5, P411, DOI 10.1111/j.1369-1600.2000.tb00209.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nagel J, 2006, NEUROPHARMACOLOGY, V51, P1163, DOI 10.1016/j.neuropharm.2006.07.018; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Neale JH, 2011, J NEUROCHEM, V119, P891, DOI 10.1111/j.1471-4159.2011.07380.x; Neale JH, 2011, J NEUROCHEM, V118, P490, DOI 10.1111/j.1471-4159.2011.07338.x; Olszewski RT, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.68; Olszewski RT, 2008, BIOL PSYCHIAT, V63, P86, DOI 10.1016/j.biopsych.2007.04.016; Olszewski RT, 2012, SCHIZOPHR RES, V136, P160, DOI 10.1016/j.schres.2012.01.007; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Popik P, 2003, NEUROPSYCHOPHARMACOL, V28, P457, DOI 10.1038/sj.npp.1300048; Rahn KA, 2012, P NATL ACAD SCI USA, V109, P20101, DOI 10.1073/pnas.1209934109; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; Romei C, 2013, NEUROPHARMACOLOGY, V66, P311, DOI 10.1016/j.neuropharm.2012.05.030; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Slusher BS, 2001, SYNAPSE, V41, P22, DOI 10.1002/syn.1056; Thomas AG, 2001, EUR J PHARMACOL, V426, P35, DOI 10.1016/S0014-2999(01)01198-0; Thomas AG, 2001, EUR J PHARMACOL, V430, P33, DOI 10.1016/S0014-2999(01)01239-0; Tsai G, 2003, SYNAPSE, V50, P285, DOI 10.1002/syn.10263; Vornov JJ, 2013, J PHARMACOL EXP THER, V346, P406, DOI 10.1124/jpet.113.205039; Wolfer DP, 1998, NEWS PHYSIOL SCI, V13, P118; Wozniak KM, 2012, CURR MED CHEM, V19, P1323, DOI 10.2174/092986712799462630; Wozniak KM, 2012, J PHARMACOL EXP THER, V343, P746, DOI 10.1124/jpet.112.197665; Yamada T, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-67; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Yamamoto T, 2001, NEUROSCIENCE, V102, P473, DOI 10.1016/S0306-4522(00)00502-9; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x; Zhong CL, 2014, INT J NEUROSCI, V124, P867, DOI 10.3109/00207454.2014.890935; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903; Zuo DY, 2012, J BIOL CHEM, V287, P21773, DOI 10.1074/jbc.M112.363226; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	66	26	26	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2015	134	2					340	353		10.1111/jnc.13123			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CM3QK	WOS:000357598000014	25872793	Bronze			2021-06-18	
J	Schiehser, DM; Twamley, EW; Liu, L; Matevosyan, A; Filoteo, JV; Jak, AJ; Orff, HJ; Hanson, KL; Sorg, SF; Delano-Wood, L				Schiehser, Dawn M.; Twamley, Elizabeth W.; Liu, Lin; Matevosyan, Adelina; Filoteo, J. Vincent; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Sorg, Scott F.; Delano-Wood, Lisa			The Relationship Between Postconcussive Symptoms and Quality of Life in Veterans With Mild to Moderate Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; FATIGUE; COMPLAINTS; INSOMNIA; WHOQOL	Objective: To assess the relationship between postconcussive symptoms and quality of life (QOL) in Veterans with mild to moderate traumatic brain injury (TBI). Methods: Sixty-one Operation Enduring Freedom/Operation Iraqi Freedom/Persian Gulf War Veterans with a history of mild or moderate TBI, more than 6 months postinjury, and 21 demographically matched Veteran controls were administered self-report measures of QOL (World Health Organization Quality of Life-BREF) and postconcussive symptom severity (Neurobehavioral Symptom Inventory). Results: Perceived QOL was significantly worse in Veterans with mild-moderate TBI than in controls. In the TBI group, QOL was predominantly associated with affective symptoms, and moderate to strong correlations with fatigue and depression were evident across all QOL areas. Multivariate analyses revealed depression and fatigue to be the best predictors of Psychological, Social, and Environmental QOL, whereas sleep difficulty best predicted Physical QOL in mild-moderate TBI. Conclusion: Veterans with post-acute mild-moderate TBI evidence worse QOL than demographically matched Veteran controls. Affective symptoms, and specifically those of fatigue, depression, and sleep difficulty, appear to be the most relevant postconcussive symptoms predicting QOL in this population. These findings underscore the importance of examining specific symptoms as they relate to post-acute TBI QOL and provide guidance for treatment and intervention studies.	[Schiehser, Dawn M.; Twamley, Elizabeth W.; Matevosyan, Adelina; Filoteo, J. Vincent; Jak, Amy J.; Hanson, Karen L.; Delano-Wood, Lisa] VA San Diego Healthcare Syst, San Diego, CA USA; [Schiehser, Dawn M.; Twamley, Elizabeth W.; Filoteo, J. Vincent; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Delano-Wood, Lisa] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA; [Liu, Lin] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Twamley, Elizabeth W.; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Delano-Wood, Lisa] VASDHS, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Sorg, Scott F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA	Schiehser, DM (corresponding author), VA San Diego Healthcare Syst 151B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	dschiehser@ucsd.edu			VA Career Development award; Department of Defense awardUnited States Department of Defense	This study was supported by VA Career Development (D.M.S. and L.D-W.) and Department of Defense (L.D-W.) awards. The authors thank Russell Kim, Elisa Lanni, and Norman Luc for their help with data collection and compilation. They also thank the patients, staff, and volunteers associated with the VA San Diego Healthcare System for their involvement in this study.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; [Anonymous], 2014, DOD WORLDWIDE NUMBER; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Den Oudsten BL, 2007, MOVEMENT DISORD, V22, P1528, DOI 10.1002/mds.21567; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gross T, 2012, ACTA ANAESTH SCAND, V56, P1163, DOI 10.1111/j.1399-6576.2012.02724.x; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Schiehser DM, 2015, J HEAD TRAUMA REHAB, V30, P116, DOI 10.1097/HTR.0000000000000019; Tanielian T, 2008, INVISIBLE WOUNDS WAR; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Williamson MLC, 2013, BRAIN INJURY, V27, P992, DOI 10.3109/02699052.2013.801512	31	26	26	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2015	30	4					E21	E28		10.1097/HTR.0000000000000065			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CM8JB	WOS:000357944800003	24922041				2021-06-18	
J	Villacampa, N; Almolda, B; Vilella, A; Campbell, IL; Gonzalez, B; Castellano, B				Villacampa, Nadia; Almolda, Beatriz; Vilella, Antonietta; Campbell, Iain L.; Gonzalez, Berta; Castellano, Bernardo			Astrocyte-Targeted Production of IL-10 Induces Changes in Microglial Reactivity and Reduces Motor Neuron Death After Facial Nerve Axotomy	GLIA			English	Article						microglia; transgenic animal; neuronal survival; lymphocytes; nerve injury; neurodegeneration; cytokines; IL-10R; CD18; CD16; 32; MHC-II; CD39; arginase-1; Ym-1; CD150	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INTERLEUKIN-10 RECEPTOR; T-CELLS; LYMPHOCYTE RECRUITMENT; CELLULAR-LOCALIZATION; MOLECULAR-MECHANISMS; IMMUNE SURVEILLANCE; PROMOTES SURVIVAL; CEREBRAL-CORTEX	Interleukin-10 (IL-10) is a cytokine that plays a crucial role in regulating the inflammatory response and immune reactions. In the central nervous system (CNS), IL-10 is mainly produced by astrocytes and microglia and it is upregulated after various insults, such as experimental autoimmune encephalomyelitis, middle cerebral artery occlusion, excitotoxicity and traumatic brain injury. To better understand the effects of IL-10 in the normal and injured CNS, we generated transgenic mice (termed GFAP-IL-10Tg) that expressed the murine IL-10 gene under the transcriptional control of the glial fibrillary acidic protein (GFAP) promoter. Previous studies demonstrated marked changes in the microglial phenotype in these mice under basal conditions. The objective of the present study was to investigate the effects of local astrocyte-targeted IL-10 production on glial activation, neuronal degeneration and leukocyte recruitment after axotomy. GFAP-IL-10Tg mice had marked changes in the phenotype of activated microglial cells, as well as in the number of microglial clusters and in microglial cell density. These microglial changes are accompanied by a twofold increase in lymphocyte infiltration in GFAP-IL-10Tg mice and around twofold decrease in neuronal cell death at 21 dpi. Altogether, our findings suggested that astrocyte-targeted production of IL-10 impacted the microglial response and lymphocyte recruitment and culminated in a beneficial effect on neuronal survival. GLIA 2015;63:1166-1184	[Villacampa, Nadia; Almolda, Beatriz; Gonzalez, Berta; Castellano, Bernardo] Univ Autonoma Barcelona, Inst Neurosci, Dept Cell Biol Physiol & Immunol, E-08193 Barcelona, Spain; [Vilella, Antonietta] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Campbell, Iain L.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia	Villacampa, N (corresponding author), Univ Autonoma Barcelona, Fac Med, Unitat Histol, Torre M5, E-08193 Barcelona, Spain.	nadia.villacampa@uab.cat	Castellano, Bernardo/G-1428-2010; Vilella, Antonietta/AAF-2084-2019; Villacampa, Dr Nadia/K-5304-2014; Almolda, Beatriz/L-6920-2014; Gonzalez, Berta/G-1428-2010	Castellano, Bernardo/0000-0003-1976-971X; Villacampa, Dr Nadia/0000-0001-6513-0250; Almolda, Beatriz/0000-0001-6631-4385; Vilella, Antonietta/0000-0003-3820-0115; Gonzalez, Berta/0000-0002-1860-3980	Spanish Ministry of Science and InnovationSpanish Government [BFU2011-27400]; NHMRCNational Health and Medical Research Council of Australia [632754]	Grant sponsor: Spanish Ministry of Science and Innovation; Grant number: BFU2011-27400 (to BCL); Grant sponsor: NHMRC; Grant number: 632754 (to ILC)	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Aldskogius Hakan, 2011, Front Biosci (Schol Ed), V3, P857; Almolda B, 2015, BRAIN BEHAV IMMUN, V45, P80, DOI 10.1016/j.bbi.2014.10.015; Almolda B, 2014, GLIA, V62, P1142, DOI 10.1002/glia.22668; Almolda B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027473; Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Atkins S, 2007, J PERIPHER NERV SYST, V12, P269, DOI 10.1111/j.1529-8027.2007.00148.x; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Bohatschek M, 2004, J NEUROIMMUNOL, V156, P132, DOI 10.1016/j.jneuroim.2004.07.018; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Bulavina L, 2013, PURINERG SIGNAL, V9, P199, DOI 10.1007/s11302-012-9339-y; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Conde JR, 2006, NEUROBIOL AGING, V27, P1451, DOI 10.1016/j.neurobiolaging.2005.07.012; Csoka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934; Dwyer KM, 2007, PURINERG SIGNAL, V3, P171, DOI 10.1007/s11302-006-9050-y; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Ferri CC, 1998, J NEUROBIOL, V34, P1; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; Gonzalez P, 2009, J NEUROPATH EXP NEUR, V68, P391, DOI 10.1097/NEN.0b013e31819dca30; GRAEBER MB, 1993, ACTA NEUROPATHOL, V86, P179, DOI 10.1007/BF00334886; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; Groux H, 1997, NATURE, V389, P737; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Hao HP, 2007, J NEUROSCI RES, V85, P2196, DOI 10.1002/jnr.21357; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; Hulshof S, 2002, GLIA, V38, P24, DOI 10.1002/glia.10050; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Jinno S, 2011, NEURON GLIA BIOL, V7, P55, DOI 10.1017/S1740925X11000135; Jones KJ, 2005, BRAIN BEHAV IMMUN, V19, P12, DOI 10.1016/j.bbi.2004.05.004; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; Jones LL, 1997, EUR J NEUROSCI, V9, P1854, DOI 10.1111/j.1460-9568.1997.tb00752.x; Jovanova-Nesic Katica, 2012, Curr Aging Sci, V5, P209; Kalla R, 2001, J COMP NEUROL, V436, P182; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Ledeboer A, 2002, EUR J NEUROSCI, V16, P1175, DOI 10.1046/j.1460-9568.2002.02200.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makwana M, 2005, FEBS J, V272, P2628, DOI 10.1111/j.1742-4658.2005.04699.x; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; MIZUNO T, 1994, BIOCHEM BIOPH RES CO, V205, P1907, DOI 10.1006/bbrc.1994.2893; Molina-Holgado F, 2001, GLIA, V33, P97, DOI 10.1002/1098-1136(200102)33:2<97::AID-GLIA1009>3.0.CO;2-N; Moller JC, 1996, GLIA, V17, P121; MONETA ME, 1993, J NEUROIMMUNOL, V45, P203, DOI 10.1016/0165-5728(93)90181-W; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moran LB, 2004, BRAIN RES REV, V44, P154, DOI 10.1016/j.brainresrev.2003.11.004; MOSMANN TR, 1991, ANN NY ACAD SCI, V628, P337, DOI 10.1111/j.1749-6632.1991.tb17266.x; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Park KW, 2007, EXP MOL MED, V39, P812, DOI 10.1038/emm.2007.88; Perry VH, 2010, ASN NEURO, V2, P281, DOI 10.1042/AN20100024; Petitto JN, 2003, J NEUROIMMUNOL, V134, P95, DOI 10.1016/S0165-5728(02)00422-8; Pousset F, 2001, J NEUROCHEM, V79, P726, DOI 10.1046/j.1471-4159.2001.00569.x; Raivich G, 1998, J NEUROSCI, V18, P5804; Raivich G, 2003, J NEUROSCI RES, V72, P726, DOI 10.1002/jnr.10621; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RINAMAN L, 1991, NEUROSCIENCE, V44, P765, DOI 10.1016/0306-4522(91)90096-7; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P315, DOI 10.1016/j.cytogfr.2010.11.001; Samoilova EB, 1998, CELL IMMUNOL, V188, P118, DOI 10.1006/cimm.1998.1365; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; SCHOEN SW, 1992, GLIA, V6, P314, DOI 10.1002/glia.440060410; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 2003, BRAIN BEHAV IMMUN, V17, P393, DOI 10.1016/S0889-1591(03)00028-X; Serpe CJ, 1999, J NEUROSCI, V19; Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096; Spera PA, 1998, NEUROSCI LETT, V251, P189, DOI 10.1016/S0304-3940(98)00537-0; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Strle K, 2002, J NEUROIMMUNOL, V122, P9, DOI 10.1016/S0165-5728(01)00444-1; SVENSSON M, 1994, NEUROPATH APPL NEURO, V20, P185; Trinchieri G, 2007, J EXP MED, V204, P239, DOI 10.1084/jem.20070104; van Horssen J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-156; Walter L, 2009, SEMIN IMMUNOPATHOL, V31, P513, DOI 10.1007/s00281-009-0180-5; Werner A, 1998, J NEUROCYTOL, V27, P219, DOI 10.1023/A:1006928830251; Xin JP, 2008, BRAIN BEHAV IMMUN, V22, P528, DOI 10.1016/j.bbi.2007.10.006; Xin JP, 2011, BRAIN BEHAV IMMUN, V25, P820, DOI 10.1016/j.bbi.2010.08.004; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018	86	26	30	0	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2015	63	7					1166	1184		10.1002/glia.22807			19	Neurosciences	Neurosciences & Neurology	CG6IC	WOS:000353402100005	25691003				2021-06-18	
J	Lapchak, PA; Boitano, PD; Butte, PV; Fisher, DJ; Holscher, T; Ley, EJ; Nuno, M; Voie, AH; Rajput, PS				Lapchak, Paul A.; Boitano, Paul D.; Butte, Pramod V.; Fisher, David J.; Hoelscher, Thilo; Ley, Eric J.; Nuno, Miriam; Voie, Arne H.; Rajput, Padmesh S.			Transcranial Near-Infrared Laser Transmission (NILT) Profiles (800 nm): Systematic Comparison in Four Common Research Species	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; TERM NEUROLOGICAL DEFICITS; ACUTE ISCHEMIC-STROKE; LIGHT THERAPY; NEUROTHERA EFFECTIVENESS; EMBOLIC STROKES; RAT-BRAIN; IRRADIATION; SAFETY; RABBITS	Background and Purpose Transcranial near-infrared laser therapy (TLT) is a promising and novel method to promote neuroprotection and clinical improvement in both acute and chronic neurodegenerative diseases such as acute ischemic stroke (AIS), traumatic brain injury (TBI), and Alzheimer's disease (AD) patients based upon efficacy in translational animal models. However, there is limited information in the peer-reviewed literature pertaining to transcranial near-infrared laser transmission (NILT) profiles in various species. Thus, in the present study we systematically evaluated NILT characteristics through the skull of 4 different species: mouse, rat, rabbit and human. Results Using dehydrated skulls from 3 animal species, using a wavelength of 800nm and a surface power density of 700 mW/cm(2), NILT decreased from 40.10% (mouse) to 21.24% (rat) to 11.36% (rabbit) as skull thickness measured at bregma increased from 0.44 mm in mouse to 0.83 mm in rat and then 2.11 mm in rabbit. NILT also significantly increased (p<0.05) when animal skulls were hydrated (i.e. compared to dehydrated); but there was no measurable change in thickness due to hydration. In human calvaria, where mean thickness ranged from 7.19 mm at bregma to 5.91 mm in the parietal skull, only 4.18% and 4.24% of applied near-infrared light was transmitted through the skull. There was a slight (9.2-13.4%), but insignificant effect of hydration state on NILT transmission of human skulls, but there was a significant positive correlation between NILT and thickness at bregma and parietal skull, in both hydrated and dehydrated states. Conclusion This is the first systematic study to demonstrate differential NILT through the skulls of 4 different species; with an inverse relationship between NILT and skull thickness. With animal skulls, transmission profiles are dependent upon the hydration state of the skull, with significantly greater penetration through hydrated skulls compared to dehydrated skulls. Using human skulls, we demonstrate a significant correlation between thickness and penetration, but there was no correlation with skull density. The results suggest that TLT should be optimized in animals using novel approaches incorporating human skull characteristics, because of significant variance of NILT profiles directly related to skull thickness.	[Lapchak, Paul A.; Boitano, Paul D.] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA; [Lapchak, Paul A.; Butte, Pramod V.; Nuno, Miriam; Rajput, Padmesh S.] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA; [Fisher, David J.; Hoelscher, Thilo; Voie, Arne H.] BURL Concepts Inc, San Diego, CA USA; [Ley, Eric J.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA	Lapchak, PA (corresponding author), Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA.	Paul.Lapchak@cshs.org	Lapchak, Paul/P-1845-2019	Lapchak, Paul/0000-0003-4413-7554	U01 Translational research grant [NS060685]; R01 research grant [HL091043]; BURL Concepts Inc.	Dr. Lapchak serves as Editor-in-Chief of the Journal of Neurology & Neurophysiology and Associate Editor of Translational Stroke Research. The scientific content of this work was not directly supported by NIH or any other funding source external to Cedars-Sinai Medical Center. PAL was supported in part by a U01 Translational research grant NS060685. Dr. Hoelscher is employed by Burl Concepts Inc. TH was supported by an R01 research grant HL091043. This study utilized a K-Laser USA LLC model K-1200 device, but K-Laser USA LLC did not have an editorial influence on the study design or scientific content of this article. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The scientific content of this work was not directly supported by NIH or any other funding source external to Cedars-Sinai Medical Center. PAL was supported in part by a U01 Translational research grant NS060685. TH was supported by an R01 research grant HL091043. This study utilized a K-Laser USA LLC model K-1200 device, but K-Laser USA LLC did not have an editorial influence on the study design or scientific content of this article. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-authors David J. Fisher, Thilo Hoelscher and Arne H. Voie are employed by BURL Concepts Inc. BURL Concepts Inc. provided support in the form of salaries for authors DJF, TH and AHV, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Farfara D, 2015, J MOL NEUROSCI, V55, P430, DOI 10.1007/s12031-014-0354-z; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086; Hacke W, 2014, STROKE, V45, P3187, DOI 10.1161/STROKEAHA.114.005795; Haeussinger FB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026377; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Kasner SE, 2013, STROKE, V44, P2025, DOI 10.1161/STROKEAHA.113.000870; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2013, TRANSL STROKE RES, V4, P279, DOI 10.1007/s12975-012-0209-2; Lapchak PA, 2012, EXPERT REV MED DEVIC, V9, P71, DOI 10.1586/ERD.11.64; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lychagov VV, 2006, PROC SPIE, V6085, DOI 10.1117/12.650116; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Oron U, 2001, CIRCULATION, V103, P296; Schellinger PD, 2012, NERVENARZT, V83, P966, DOI 10.1007/s00115-012-3567-9; Trimmer PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-26; Voie A, 2014, COMPUT MED IMAG GRAP, V38, P675, DOI 10.1016/j.compmedimag.2014.06.022; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	38	26	26	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2015	10	6							e0127580	10.1371/journal.pone.0127580			17	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ7ST	WOS:000355700700067	26039354	DOAJ Gold, Green Published			2021-06-18	
J	Zuckerman, SL; Morgan, CD; Burks, S; Forbes, JA; Chambless, LB; Solomon, GS; Sills, AK				Zuckerman, Scott L.; Morgan, Clinton D.; Burks, Stephen; Forbes, Jonathan A.; Chambless, Lola B.; Solomon, Gary S.; Sills, Allen K.			Functional and Structural Traumatic Brain Injury in Equestrian Sports: A Review of the Literature	WORLD NEUROSURGERY			English	Article						Brain concussion; Head protective devices; Intracranial epidural hematoma; Recreation; Sports; Subdural hematoma; TBI (traumatic brain injury)	HORSE-RELATED INJURIES; STATES HIGH-SCHOOL; UNITED-STATES; PROFESSIONAL JOCKEYS; CONCUSSIONS; HEAD; PATTERNS; ACCIDENTS; SEVERITY; CHILDREN	OBJECTIVE: Sports-related concussions and traumatic brain injury (TBI) represent a growing public health concern. We reviewed the literature regarding equestrian-related brain injury, ranging from concussion to severe TBI. METHODS: A literature review was performed to address the epidemiology of sports-related concussion and TBI in equestrian-related sports. MEDLINE and PUBMED databases were searched to identify all studies pertaining to brain injury in equestrian-related sports. We included two broad types of brain injury using a distinction established in the literature: 1) TBI with functional impairment, including concussion, or mild TBI, with negative imaging findings; and 2) TBI with structural impairment, with positive imaging and at least one of the following pathologies identified: subdural hemorrhage, epidural hemorrhage, subarachnoid hemorrhage, intraparenchymal hemorrhage, cerebral contusions, and skull fractures. RESULTS: Our literature search yielded 199 results. We found 26 studies describing functional TBI and 25 mentioning structural TBI, and 8 including both. Of all modern sporting activities, equestrian sports were found to cause some of the highest rates of total bodily injury, severe brain injury, and mortality. Concussions comprise 9.7%-15% of all equestrian-related injuries brought to hospitals for evaluation. Structural TBI was rare, and documentation of these injuries was poor. Although demographic risk factors like age and sex are minimally discussed in the literature, two studies identified a protective effect of increasing rider experience on all forms of bodily injury. However, it remains unclear whether increasing rider experience protects specifically against head injury. Finally, rates of helmet use in horseback riding remain dismally low-ranging from 9%-25%, depending on the activity. These low rates have persisted over time, despite evidence in this literature that helmets lead to an absolute risk reduction for head injury of 40%-50% in equestrian sports. CONCLUSIONS: Equestrian-related functional and structural TBI represent a significant public health burden. Rider and horse characteristics make the sport uniquely dangerous, as the athlete has limited control over an animal weighing a thousand pounds. Helmet use rates remain very low despite clear evidence of risk reduction. Health care providers are strongly urged to lobby professional and governmental organizations for mandatory helmet use in all equestrian sports.	[Zuckerman, Scott L.; Morgan, Clinton D.; Chambless, Lola B.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37235 USA; [Burks, Stephen] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Forbes, Jonathan A.] Travis Air Force Base, David Grant Med Ctr, Dept Neurol Surg, Fairfield, CA USA	Zuckerman, SL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37235 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019	Morgan, Clinton/0000-0002-7511-0488			Abu-Kishk Ibrahim, 2013, Isr Med Assoc J, V15, P169; Abu-Zidan FM, 2003, INJURY, V34, P897, DOI 10.1016/S0020-1383(03)00054-8; Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; ARONSON H, 1993, AM J FOREN MED PATH, V14, P28, DOI 10.1097/00000433-199303000-00006; ASTM, 2013, STAND SPEC PROT HEAD; Balendra G, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.038950; Ball CG, 2007, AM J SURG, V193, P636, DOI 10.1016/j.amjsurg.2007.01.016; Ball Jill E, 2009, J Trauma Manag Outcomes, V3, P2, DOI 10.1186/1752-2897-3-2; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; Bixby-Hammett Doris M, 2006, N C Med J, V67, P161; Bleetman D, 2012, INJURY, V43, P2023, DOI 10.1016/j.injury.2011.09.026; BOND GR, 1995, PEDIATRICS, V95, P487; British Standards Institution, 2005, SPEC HELM EQ ACT; BUCKLEY SM, 1993, AUST J PUBLIC HEALTH, V17, P269; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P209; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; Costa-Paz M, 1999, BRIT J SPORT MED, V33, P329, DOI 10.1136/bjsm.33.5.329; Cripps RA, 2000, AUSTR INJURY PREV B, V24; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Cuenca AG, 2009, J PEDIATR SURG, V44, P148, DOI 10.1016/j.jpedsurg.2008.10.025; Deignan Patrick J, 2012, MD Advis, V5, P41; Dohman T, 2005, J EMERG NURS, V31, P456, DOI 10.1016/j.jen.2005.08.008; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Dunn IF, 2009, NEUROSURGERY, V65, P383, DOI 10.1227/01.NEU.0000347474.69080.A1; Eckert V, 2011, CLIN J SPORT MED, V21, P353, DOI 10.1097/JSM.0b013e318221840f; Edmiston J, 2012, TRAUMATIC BRAIN INJU, V25, P70; Edmiston Julie, 2012, JAAPA, V25, P67; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Fleming PRI, 2001, CLIN EXP OPHTHALMOL, V29, P208, DOI 10.1046/j.1442-9071.2001.00430.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Griffen M, 2002, SOUTHERN MED J, V95, P441, DOI 10.1097/00007611-200204000-00013; Guyton K, 2013, AM SURGEON, V79, P76; Harrison TI MN, 1996, JOCKEYS INJURIES SKU; Hasler Rebecca M, 2011, J Trauma Manag Outcomes, V5, P4, DOI 10.1186/1752-2897-5-4; Hendricks K J, 2001, Inj Prev, V7, P307, DOI 10.1136/ip.7.4.307; Jagodzinski Tanya, 2005, WMJ, V104, P50; Johns E, 2004, INJURY, V35, P1234, DOI 10.1016/j.injury.2003.11.003; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lim J, 2003, ANZ J SURG, V73, P567, DOI 10.1046/j.1445-2197.2003.02707.x; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Loder RT, 2008, J TRAUMA, V65, P447, DOI 10.1097/TA.0b013e31817dac43; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mayberry JC, 2007, J TRAUMA, V62, P735, DOI 10.1097/ta.0b013e318031b5d4; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McCrory P, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.006338; McCrory P, 2005, MED SPORT SCI, V48, P8, DOI 10.1159/000084280; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moss PS, 2002, EMERG MED J, V19, P412, DOI 10.1136/emj.19.5.412; Fontan MM, 2009, AN PEDIATR, V70, P434, DOI 10.1016/j.anpedi.2008.12.005; Nanda Anil, 2012, J La State Med Soc, V164, P246; National Electronic Injury Surveillance System, 2002, NAT EL INJ SURV SYST; Newton AM, 2005, J EMERG NURS, V31, P442, DOI 10.1016/j.jen.2005.08.009; Norwood S, 2000, J TRAUMA, V48, P740, DOI 10.1097/00005373-200004000-00025; OGAWA Y, 1994, NEUROSURG REV, V17, P217, DOI 10.1007/BF00418437; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; Petridou E, 2004, J TRAUMA, V56, P643, DOI 10.1097/01.TA.0000053470.38129.F4; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Ross DS, 2010, CURR SPORT MED REP, V9, P342, DOI 10.1249/JSR.0b013e3181fc7357; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Saigal R, 2014, WORLD NEUROSURG, V82, P485, DOI 10.1016/j.wneu.2014.06.043; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; Temes RT, 1997, J TRAUMA, V43, P492, DOI 10.1097/00005373-199709000-00017; Thomas KE, 2006, BRIT J SPORT MED, V40, P619, DOI 10.1136/bjsm.2006.025858; Thompson JM, 1996, CAN FAM PHYSICIAN, V42, P1103; Trojian Thomas H, 2012, Conn Med, V76, P495; Turner M, 2008, BRIT J SPORT MED, V42, P763, DOI 10.1136/bjsm.2007.040337; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Worley GH, 2009, J EMERG NURS, V35, P230, DOI 10.1016/j.jen.2008.08.012; Yim VWT, 2007, INJURY, V38, P98, DOI 10.1016/j.injury.2006.08.026; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257	77	26	26	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2015	83	6					1098	1113		10.1016/j.wneu.2014.12.030			16	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CK3TN	WOS:000356138800048	25535066				2021-06-18	
J	Miao, W; Bao, TH; Han, JH; Yin, M; Yan, Y; Wang, WW; Zhu, YH				Miao, W.; Bao, T. H.; Han, J. H.; Yin, M.; Yan, Y.; Wang, W. W.; Zhu, Y. H.			Voluntary exercise prior to traumatic brain injury alters miRNA expression in the injured mouse cerebral cortex	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH			English	Article						Voluntary exercise; Running wheel; miRNA; Traumatic brain injury	SPINAL-CORD-INJURY; MICRORNAS; RECOVERY; RATS; MODEL	MicroRNAs (miRNAs) may be important mediators of the profound molecular and cellular changes that occur after traumatic brain injury (TBI). However, the changes and possible roles of miRNAs induced by voluntary exercise prior to TBI are still not known. In this report, the microarray method was used to demonstrate alterations in miRNA expression levels in the cerebral cortex of TBI mice that were pretrained on a running wheel (RW). Voluntary RW exercise prior to TBI: i) significantly decreased the mortality rate and improved the recovery of the righting reflex in TBI mice, and ii) differentially changed the levels of several miRNAs, upregulating some and downregulating others. Furthermore, we revealed global upregulation of miR-21, miR-92a, and miR-874 and downregulation of miR-138, let-7c, andmiR-124 expression among the sham-non-runner, TBI-non-runner, and TBI-runner groups. Quantitative reverse transcription polymerase chain reaction data (RT-qPCR) indicated good consistency with the microarray results. Our microarray-based analysis of miRNA expression in mice cerebral cortex after TBI revealed that some miRNAs such as miR-21, miR-92a, miR-874, miR-138, let-7c, and miR-124 could be involved in the prevention and protection afforded by voluntary exercise in a TBI model.	[Miao, W.; Bao, T. H.; Han, J. H.; Yin, M.; Yan, Y.; Zhu, Y. H.] Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming, Peoples R China; [Bao, T. H.] Psychiat Hosp Yunnan Prov, Kunming, Peoples R China; [Wang, W. W.] Kunming Med Univ, Affiliated Hosp 2, Dept Cardiol, Kunming, Peoples R China	Zhu, YH (corresponding author), Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming, Peoples R China.	yuhong_lilin@aliyun.com					Banzet S, 2013, J APPL PHYSIOL, V115, P1237, DOI 10.1152/japplphysiol.00075.2013; Bao TH, 2014, J MOL NEUROSCI, V54, P622, DOI 10.1007/s12031-014-0344-1; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Denham J, 2014, SPORTS MED, V44, P189, DOI 10.1007/s40279-013-0114-1; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Gu X, 2014, J MOL NEUROSCI, V52, P156, DOI 10.1007/s12031-013-0190-6; Hou WH, 2012, BBA-GENE REGUL MECH, V1819, P1113, DOI 10.1016/j.bbagrm.2012.06.001; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Koo HM, 2013, J PHYS THER SCI, V25, P1103, DOI 10.1589/jpts.25.1103; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li J, 2014, NUCLEIC ACIDS RES, V42, P458, DOI 10.1093/nar/gkt839; Ouchi Y, 2013, J NEUROSCI, V33, P9408, DOI 10.1523/JNEUROSCI.2700-12.2013; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pasiakos SM, 2013, ADV NUTR, V4, P412, DOI 10.3945/an.113.003699; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rosi S, 2012, HIPPOCAMPUS, V22, P544, DOI 10.1002/hipo.20920; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Truettner JS, 2013, BRAIN RES, V1533, P122, DOI 10.1016/j.brainres.2013.08.011; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057	27	26	27	0	7	ASSOC BRAS DIVULG CIENTIFICA	SAO PAULO	FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL	0100-879X	1678-4510		BRAZ J MED BIOL RES	Brazilian J. Med. Biol. Res.	MAY	2015	48	5					433	439		10.1590/1414-431X20144012			7	Biology; Medicine, Research & Experimental	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine	CH6ZU	WOS:000354186100009	25760028	DOAJ Gold, Green Published			2021-06-18	
J	Schnakers, C; Giacino, JT; Lovstad, M; Habbal, D; Boly, M; Di, HB; Majerus, S; Laureys, S				Schnakers, Caroline; Giacino, Joseph T.; Lovstad, Marianne; Habbal, Dina; Boly, Melanie; Di, Haibo; Majerus, Steve; Laureys, Steven			Preserved Covert Cognition in Noncommunicative Patients With Severe Brain Injury?	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						vegetative state; minimally conscious state; consciousness; attention; event-related potentials	MINIMALLY CONSCIOUS STATE; EVENT-RELATED POTENTIALS; VEGETATIVE STATE; ATTENTIONAL NETWORKS; OWN NAME; DISORDERS; STIMULUS; P300; AWARENESS; COMA	Background. Despite recent evidence suggesting that some severely brain-injured patients retain some capacity for top-down processing (covert cognition), the degree of sparing is unknown. Objective. Top-down attentional processing was assessed in patients in minimally conscious (MCS) and vegetative states (VS) using an active event-related potential (ERP) paradigm. Methods. A total of 26 patients were included (38 +/- 12 years old, 9 traumatic, 21 patients >1 year postonset): 8 MCS+, 8 MCS-, and 10 VS patients. There were 14 healthy controls (30 +/- 8 years old). The ERP paradigm included (1) a passive condition and (2) an active condition, wherein the participant was instructed to voluntarily focus attention on his/her own name. In each condition, the participant's own name was presented 100 times (ie, 4 blocks of 25 stimuli). Results. In 5 MCS+ patients as well as in 3 MCS- patients and 1 VS patient, an enhanced P3 amplitude was observed in the active versus passive condition. Relative to controls, patients showed a response that was (1) widely distributed over frontoparietal areas and (2) not present in all blocks (3 of 4). In patients with covert cognition, the amplitude of the response was lower in frontocentral electrodes compared with controls but did not differ from that in the MCS+ group. Conclusion. The results indicate that volitional top-down attention is impaired in patients with covert cognition. Further investigation is crucially needed to better understand top-down cognitive functioning in this population because this may help refine brain-computer interface-based communication strategies.	[Schnakers, Caroline; Habbal, Dina; Boly, Melanie; Laureys, Steven] Univ Hosp Liege, B-4000 Liege, Belgium; [Schnakers, Caroline; Habbal, Dina; Boly, Melanie; Majerus, Steve; Laureys, Steven] Univ Liege, B-4000 Liege, Belgium; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Boston, MA USA; [Giacino, Joseph T.] Harvard Univ, Sch Med, Boston, MA USA; [Giacino, Joseph T.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Lovstad, Marianne] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Lovstad, Marianne] Univ Oslo, Oslo, Norway; [Di, Haibo] Hangzhou Normal Univ, Hangzhou, Zhejiang, Peoples R China	Schnakers, C (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B30, B-4000 Liege, Belgium.	c.schnakers@gmail.com	Laureys, Steven/AAN-2097-2021; Giacino, Joseph/AAF-1952-2021; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Giacino, Joseph/0000-0002-7916-9698; Majerus, Steve/0000-0002-8206-8097; Boly, Melanie/0000-0001-9584-0907	National Funds for Scientific Research (MCF/DM) [A 4/5]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30870861]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Funds for Scientific Research (A 4/5, MCF/DM) and the National Natural Science Foundation of China (30870861).	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baluchi F, 2011, TRENDS NEUROSCI, V34, P210, DOI 10.1016/j.tins.2011.02.003; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Cass M, 1997, BIOL PSYCHOL, V46, P51, DOI 10.1016/S0301-0511(96)05233-7; Chennu S, 2013, NEUROIMAGE-CLIN, V3, P450, DOI 10.1016/j.nicl.2013.10.008; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Croft RJ, 2003, PSYCHOPHYSIOLOGY, V40, P322, DOI 10.1111/1469-8986.00036; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Duncan CC, 2009, CLIN NEUROPHYSIOL, V120, P1883, DOI 10.1016/j.clinph.2009.07.045; Eichenlaub JB, 2012, BRAIN RES, V1447, P65, DOI 10.1016/j.brainres.2012.01.072; Fan J, 2009, BRAIN COGNITION, V70, P209, DOI 10.1016/j.bandc.2009.02.002; Faugeras F, 2011, NEUROLOGY, V77, P264, DOI 10.1212/WNL.0b013e3182217ee8; Folmer RL, 1997, BRAIN LANG, V56, P306, DOI 10.1006/brln.1997.1828; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Herrmann CS, 2001, NEUROSCI BIOBEHAV R, V25, P465, DOI 10.1016/S0149-7634(01)00027-6; Katayama J, 1998, PSYCHOPHYSIOLOGY, V35, P23, DOI 10.1017/S0048577298961479; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KNIGHT RT, 1980, ELECTROEN CLIN NEURO, V50, P112, DOI 10.1016/0013-4694(80)90328-4; Kuebler A, 2007, CURR OPIN NEUROL, V20, P643, DOI 10.1097/WCO.0b013e3282f14782; La Porta F, 2013, ARCH PHYS MED REHAB, V94, P527, DOI 10.1016/j.apmr.2012.09.035; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Lechinger J, 2013, CLIN NEUROPHYSIOL, V124, P27, DOI 10.1016/j.clinph.2012.05.016; Lehembre R, 2012, FUNCT NEUROL, V27, P41; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; Lule D, 2013, CLIN NEUROPHYSIOL, V124, P101, DOI 10.1016/j.clinph.2012.04.030; Mertens R, 1997, EVOKED POTENTIAL, V104, P488, DOI 10.1016/S0168-5597(97)00041-5; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nachev P, 2010, PROG NEUROBIOL, V91, P68, DOI 10.1016/j.pneurobio.2010.01.009; Naci L, 2012, ANN NEUROL, V72, P312, DOI 10.1002/ana.23656; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Perrin F, 1999, CLIN NEUROPHYSIOL, V110, P2153, DOI 10.1016/S1388-2457(99)00177-7; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Polich J, 1997, INT J PSYCHOPHYSIOL, V25, P169, DOI 10.1016/S0167-8760(96)00742-8; POLICH J, 1994, ELECTROEN CLIN NEURO, V92, P253, DOI 10.1016/0168-5597(94)90068-X; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Posner MI, 2006, NEURAL NETWORKS, V19, P1422, DOI 10.1016/j.neunet.2006.08.004; Posner MI, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00064; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schupp HT, 2006, PROG BRAIN RES, V156, P31, DOI 10.1016/S0079-6123(06)56002-9; Sorger B, 2012, CURR BIOL, V22, P1333, DOI 10.1016/j.cub.2012.05.022; WOOD N, 1995, J EXP PSYCHOL LEARN, V21, P255, DOI 10.1037/0278-7393.21.1.255; Yeomans JS, 1995, BRAIN RES REV, V21, P301, DOI 10.1016/0165-0173(96)00004-5	51	26	28	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2015	29	4					308	317		10.1177/1545968314547767			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CE8DL	WOS:000352071400002	25160566				2021-06-18	
J	Wasserman, EB; Abar, B; Shah, MN; Wasserman, D; Bazarian, JJ				Wasserman, Erin B.; Abar, Beau; Shah, Manish N.; Wasserman, Daniel; Bazarian, Jeffrey J.			Concussions Are Associated With Decreased Batting Performance Among Major League Baseball Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussion; baseball; softball; epidemiology; proprioception; balance	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; CLOSED-HEAD INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; CLINICAL MANAGEMENT; REACTION-TIME; RECOVERY; SYMPTOMS; FOOTBALL	Background: Concussions impair balance, visual acuity, and reaction timeall of which are required for high-level batting performancebut the effects of concussion on batting performance have not been reported. The authors examined this relationship between concussion and batting performance among Major League Baseball (MLB) players. Hypothesis: Batting performance among concussed MLB players will be worse upon return to play than batting performance among players missing time for noninjury reasons. Study Design: Cohort study; Level of evidence, 3. Methods: The authors identified MLB players who sustained a concussion between 2007 and 2013 through league disabled-list records and a Baseball Prospectus database. For a comparison group, they identified players who went on paternity or bereavement leave during the same period. Using repeated-measures generalized linear models, the authors compared 7 batting metrics between the 2 groups for the 2 weeks upon return, as well as 4 to 6 weeks after return, controlling for pre-leave batting metrics, number of days missed, and position. Results: The authors identified 66 concussions and 68 episodes of bereavement/paternity leave to include in the analysis. In the 2 weeks after return, batting average (.235 vs .266), on-base percentage (.294 vs .326), slugging percentage (.361 vs .423), and on-base plus slugging (.650 vs .749) were significantly lower among concussed players relative to the bereavement/paternity leave players (time x group interaction, P < .05). In weeks 4 to 6 after leave, these metrics were slightly lower in concussed players but not statistically significantly so. Conclusion: Although concussed players may be asymptomatic upon return to play, the residual effects of concussion on the skills required for batting may still be present. Further work is needed to clarify the mechanism through which batting performance after concussion is adversely affected and to identify better measures to use for return-to-play decisions.	[Wasserman, Erin B.; Abar, Beau; Shah, Manish N.; Wasserman, Daniel; Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA	Wasserman, EB (corresponding author), Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, 265 Crittenden Blvd,Box 644, Rochester, NY 14642 USA.	erin_wasserman@urmc.rochester.edu		Shah, Manish/0000-0001-6331-1074; Wasserman, Erin/0000-0001-5957-5878; Abar, Beau/0000-0003-1536-220X			Ahmad CS, 2014, AM J SPORT MED, V42, P1464, DOI 10.1177/0363546514529083; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Athiviraham A, 2012, AM J SPORT MED, V40, P2808, DOI 10.1177/0363546512461754; Bell S., 2011, ANAL MLBS CONCUSSION; Beyer JA, 2012, ANN BIOMED ENG, V40, P150, DOI 10.1007/s10439-011-0412-4; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Castaneda B, 2007, J SPORT EXERCISE PSY, V29, P60, DOI 10.1123/jsep.29.1.60; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Clark JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029109; Classe J G, 1997, J Am Optom Assoc, V68, P43; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Dawkins C, 2011, CONCUSSION DISCUSSIO; Dutton C, 2008, BATTERS AND BABIP; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fast M, 2011, DOES QUALITY CONTACT; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fortenbaugh D, 2011, SPORT BIOMECH, V10, P270, DOI 10.1080/14763141.2011.629205; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gray R, 2004, J EXP PSYCHOL-APPL, V10, P42, DOI 10.1037/1076-898X.10.1.42; Green W, 2010, OPTOMETRY, V81, P129, DOI 10.1016/j.optm.2009.07.015; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Heitger MH, 2005, BRAIN INJURY, V19, P109, DOI 10.1080/02699050410001720095; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kida N, 2005, COGNITIVE BRAIN RES, V22, P257, DOI 10.1016/j.cogbrainres.2004.09.003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kumar NS, 2014, AM J SPORT MED, V42, P2050, DOI 10.1177/0363546514539449; Laby DM, 1996, AM J OPHTHALMOL, V122, P476, DOI 10.1016/S0002-9394(14)72106-3; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Major League Baseball, 2011, MAJ LEAG BAS MAJ LEA; Major League Baseball, MLB PLAY T; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; Muraskin J., 2013, 7 ANN MIT SLOAN SPOR; Nakamoto H, 2008, PERCEPT MOTOR SKILL, V106, P163, DOI 10.2466/PMS.106.1.163-170; Nakamoto H, 2013, EXP BRAIN RES, V228, P193, DOI 10.1007/s00221-013-3547-8; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Radlo SJ, 2001, RES Q EXERCISE SPORT, V72, P22, DOI 10.1080/02701367.2001.10608928; Regan D, 1997, J SPORT SCI, V15, P533, DOI 10.1080/026404197366985; Schwarz A, 2011, NY TIMES; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Slowinski S, 2010, BABIP WHAT DO WE KNO; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Taliep MS, 2008, PERCEPTION, V37, P96, DOI 10.1068/p5620; WELCH CM, 1995, J ORTHOP SPORT PHYS, V22, P193, DOI 10.2519/jospt.1995.22.5.193; Yamashiro K, 2013, EXP BRAIN RES, V225, P197, DOI 10.1007/s00221-012-3361-8; Zhang J, 2005, PERCEPT MOTOR SKILL, V100, P1127, DOI 10.2466/PMS.100.4.1127-1136	58	26	26	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2015	43	5					1127	1133		10.1177/0363546515576130			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CH4CV	WOS:000353980000018	25784627				2021-06-18	
J	Jak, AJ; Gregory, A; Orff, HJ; Colon, C; Steele, N; Schiehser, DM; Delano-Wood, L; Jurick, SM; Twamley, EW				Jak, Amy J.; Gregory, Amber; Orff, Henry J.; Colon, Candice; Steele, Norma; Schiehser, Dawn M.; Delano-Wood, Lisa; Jurick, Sarah M.; Twamley, Elizabeth W.			Neuropsychological performance in treatment-seeking Operation Enduring Freedom/Operation Iraqi Freedom Veterans with a history of mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Veterans; Validity; Concussion; Neuropsychology	POSTCONCUSSION SYNDROME; SYMPTOM COMPLAINTS; OUTCOMES; CONTEXT; BLAST; TBI	Introduction: Clinical neuropsychological presentation of treatment-seeking Veterans with a remote history of mild traumatic brain injury (mTBI) is widely variable. This manuscript seeks to better characterize cognitive concerns in the post-acute phase following mTBI and to identify the neuropsychological profiles of a large sample of clinically referred Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) Veterans with a history of mTBI and current cognitive complaints. We hypothesized that a minority of cases would exhibit valid and widespread neuropsychological deficits. Method: Retrospective chart reviews of neuropsychological testing and mental health symptoms and diagnoses were conducted on 411 clinically referred OEF/OIF/OND Veterans with a history of mTBI. Groups were created based on scores on performance validity measures and based on overall neuropsychological performance. Results: A total of 29.9% of the sample performed below normative expectations on at least one performance validity test (PVT). Of those Veterans performing adequately on PVTs, 60% performed within normal limits on virtually all neuropsychological measures administered, leaving only 40% performing below expectations on two or more measures. Mood and neurobehavioral symptoms were significantly elevated in Veterans performing below cutoff on PVTs compared to Veterans who performed within normative expectations or those with valid deficits. Neurobehavioral symptoms were significantly correlated with mental health symptom reports but not with injury variables. Conclusions: In summary, in a large sample of clinically referred Veterans with persistent cognitive complaints after mild TBI, a third demonstrated invalid clinical neuropsychological testing, and, of those performing at or above cutoff on PVTs, over half performed within normative expectations across most neuropsychological tests administered. Results highlight the importance of objective assessment of cognitive functioning in this population as subjective reports do not correspond to objective assessment in the majority of cases.	[Jak, Amy J.; Steele, Norma] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA; [Jak, Amy J.; Orff, Henry J.; Schiehser, Dawn M.; Delano-Wood, Lisa; Twamley, Elizabeth W.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Jak, Amy J.; Orff, Henry J.; Schiehser, Dawn M.; Delano-Wood, Lisa; Twamley, Elizabeth W.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Gregory, Amber] Univ Alabama Birmingham, Birmingham, AL USA; [Colon, Candice; Schiehser, Dawn M.; Delano-Wood, Lisa] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Jurick, Sarah M.] San Diego State Univ Univ Calif San Diego Joint D, San Diego, CA USA	Jak, AJ (corresponding author), 3350 La Jolla Village Dr,151B, San Diego, CA USA.	ajak@ucsd.edu			Office of Research & Development, Veterans Health Administration	Salary support for D. M. Schiehser was provided by a Career Development Award from the Office of Research & Development, Veterans Health Administration.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Beck A.T., 1993; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Cooper DB, 2014, J REHABIL RES DEV, V51, P1023, DOI [10.1682/JRRD.2013.05.0104, 10.1682/JRRD.2013.05.0140]; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Department of Veterans Affairs/ Department of Defense ( VA/ DoD), 2009, VA DOD CLIN PRACT GU; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Grant DA, 2000, WISCONSIN CARD SORTI; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GRONWALL D, 1974, LANCET, V2, P605; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; King PR, 2014, J NERV MENT DIS, V202, P231, DOI 10.1097/NMD.0000000000000103; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Tombaugh TN, 1996, TEST MEMORY MALINGER; US Dept of Veterans Affairs, 2013, ANN BEN REP FISC YEA; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; World Health Organization, 1992, INT STAT CLASS DIS R, V10	43	26	26	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR 21	2015	37	4					379	388		10.1080/13803395.2015.1020769			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CI7GP	WOS:000354931400004	25850338				2021-06-18	
J	Bachstetter, AD; Webster, SJ; Goulding, DS; Morton, JE; Watterson, DM; Van Eldik, LJ				Bachstetter, Adam D.; Webster, Scott J.; Goulding, Danielle S.; Morton, Jonathan E.; Watterson, D. Martin; Van Eldik, Linda J.			Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic	JOURNAL OF NEUROINFLAMMATION			English	Article						Cytokines; Glia; Interleukin; Neuroinflammation; Drug discovery; Microglia; Astrocytes; Traumatic brain injury; Closed head injury; Cognitive dysfunction	PROINFLAMMATORY CYTOKINE; ALZHEIMERS-DISEASE; UP-REGULATION; MOUSE MODEL; MICROGLIAL ACTIVATION; SYNAPTIC DYSFUNCTION; BEHAVIORAL DEFICITS; GLIAL ACTIVATION; NEUROINFLAMMATION; DRUG	Background: Evidence from clinical studies and preclinical animal models suggests that proinflammatory cytokine overproduction is a potential driving force for pathology progression in traumatic brain injury (TBI). This raises the possibility that selective targeting of the overactive cytokine response, a component of the neuroinflammation that contributes to neuronal dysfunction, may be a useful therapeutic approach. MW151 is a CNS-penetrant, small molecule experimental therapeutic that selectively restores injury-or disease-induced overproduction of proinflammatory cytokines towards homeostasis. We previously reported that MW151 administered post-injury (p.i.) is efficacious in a closed head injury (CHI) model of diffuse TBI in mice. Here we test dose dependence of MW151 to suppress the target mechanism (proinflammatory cytokine up-regulation), and explore the therapeutic window for MW151 efficacy. Methods: We examined suppression of the acute cytokine surge when MW151 was administered at different times post-injury and the dose-dependence of cytokine suppression. We also tested a more prolonged treatment with MW151 over the first 7 days post-injury and measured the effects on cognitive impairment and glial activation. Results: MW151 administered up to 6 h post-injury suppressed the acute cytokine surge, in a dose-dependent manner. Administration of MW151 over the first 7 days post-injury rescues the CHI-induced cognitive impairment and reduces glial activation in the focus area of the CHI. Conclusions: Our results identify a clinically relevant time window post-CHI during which MW151 effectively restores cytokine production back towards normal, with a resultant attenuation of downstream cognitive impairment.	[Bachstetter, Adam D.; Webster, Scott J.; Goulding, Danielle S.; Morton, Jonathan E.; Van Eldik, Linda J.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA; [Watterson, D. Martin] Northwestern Univ, Dept Pharmacol, Chicago, IL 60611 USA; [Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Van Eldik, LJ (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone St, Lexington, KY 40506 USA.	linda.vaneldik@uky.edu		Bachstetter, Adam/0000-0003-4646-6757; Watterson, Daniel/0000-0001-7605-5866	NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K99AG044445]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS084605]; Kentucky Spinal Cord and Head Injury Research Trust [12-20A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS084605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K99AG044445] Funding Source: NIH RePORTER	We thank Edgardo Dimayuga for his assistance with various aspects of this work. This research was supported in part by NIH/NIA (K99AG044445 to ADB), NIH/NINDS (F32 NS084605 to SJW), and the Kentucky Spinal Cord and Head Injury Research Trust (12-20A to LVE).	Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Craft JM, 2006, GLIA, V53, P484, DOI 10.1002/glia.20306; Craft JM, 2004, NEUROBIOL AGING, V25, P1283, DOI 10.1016/j.neurobiolaging.2004.01.006; Craft JM, 2004, J MOL NEUROSCI, V24, P115, DOI 10.1385/JMN:24:1:115; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; James ML, 2012, ANESTHESIOLOGY, V116, P1299, DOI 10.1097/ALN.0b013e318253a02a; Jenrow KA, 2013, RADIAT RES, V179, P549, DOI 10.1667/RR3026.1; Jordan Barry D, 2014, Continuum (Minneap Minn), V20, P1588, DOI 10.1212/01.CON.0000458972.94013.e1; Karpus WJ, 2008, J NEUROIMMUNOL, V203, P73, DOI 10.1016/j.jneuroim.2008.06.039; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Macauley SL, 2014, J NEUROSCI, V34, P13077, DOI 10.1523/JNEUROSCI.2518-14.2014; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Shineman DW, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt90; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Somera-Molina KC, 2009, BRAIN RES, V1282, P162, DOI 10.1016/j.brainres.2009.05.073; Webster SJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt182; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	27	26	26	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 10	2015	12								69	10.1186/s12974-015-0289-5			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CF7XG	WOS:000352769100001	25886256	DOAJ Gold, Green Published			2021-06-18	
J	Fuller, GW; Kemp, SPT; Decq, P				Fuller, Gordon Ward; Kemp, Simon P. T.; Decq, Philippe			The International Rugby Board (IRB) Pitch Side Concussion Assessment trial: a pilot test accuracy study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Head Injuries; Injury Prevention; Rugby	SENSITIVITY; INJURIES; SPORT; SPECIFICITY; STATEMENT; FRACTURES; RISK	Background On the field and on the run' assessments of head impact events in professional rugby have resulted in a high proportion of players subsequently diagnosed with confirmed concussion not leaving the field of play at the time of injury. The International Rugby Board (IRB) consequently developed a process to support team doctors in the recognition and management of players at risk of concussion, including development of a multimodal assessment instrumentthe Pitch Side Concussion Assessment (PSCA) tool. Methods This was a pilot cohort study designed to determine the feasibility of assessing the accuracy of the IRB PSCA tool in elite male rugby. The study population comprised consecutive players identified with a head impact event with the potential to result in concussion during eight international/national competitions. Players were assessed off field by match-day or team doctors, following a temporary substitution. The accuracy of the PSCA tool was measured against a reference standard of postmatch confirmed concussion, based on clinical judgement aided by an established concussion support instrument. Results A total of 165 head injury events with the potential to cause concussion were included in the study. The PSCA tool demonstrated a sensitivity of 84.6% (95% CI 73.5% to 92.4%) and a specificity of 74% (95% CI 64.3% to 82.3%) to identify players subsequently diagnosed with confirmed concussion. The negative predictive value was 88.1% (95% CI 79.2% to 94.1%); the positive predictive value was 67.9% (95% CI 56.6% to 77.8%). There were no major barriers identified that would prevent the evaluation of the PSCA process or tool in a future large-scale study. Conclusions This pilot study has provided the first preliminary estimates for the performance of the PSCA tool, suggesting a potentially favourable balance between positive and negative predictive values. The study has also offered a strong basis to conduct a further larger trial, providing information for sample size calculations and highlighting areas for methodological development.	[Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Emergency Med Res Sheffield Grp, Sheffield S1 4DA, S Yorkshire, England; [Kemp, Simon P. T.] Rugby Football Union, Twickenham, Middx, England; [Decq, Philippe] Hop Beaujon, Assistance Publ Hop Paris, French Federat Rugby, Dept Neurosurg,Med Sch Rene Diderot Paris 7, Paris, France	Fuller, GW (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Emergency Med Res Sheffield Grp, 30 Regent St, Sheffield S1 4DA, S Yorkshire, England.	g.fuller@sheffield.ac.uk		Fuller, Gordon Ward/0000-0001-8532-3500; Kemp, Simon/0000-0002-3250-2713			Anderson L, 2011, BRIT J SPORT MED, V45, P948, DOI 10.1136/bjsm.2011.083881; Bachmann LM, 2004, ANN INTERN MED, V140, P121, DOI 10.7326/0003-4819-140-5-200403020-00013; Bachmann LM, 2003, BMJ-BRIT MED J, V326, P417, DOI 10.1136/bmj.326.7386.417; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2010, CLIN J SPORT MED, V20, P179, DOI 10.1097/JSM.0b013e3181df1eea; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Genders TSS, 2012, RADIOLOGY, V265, P910, DOI 10.1148/radiol.12120509; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Helmy A, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5748; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Rutjes AWS, 2005, CLIN CHEM, V51, P1335, DOI 10.1373/clinchem.2005.048595; Spirduso WW, 2005, PHYS DIMENSIONS AGIN, P144; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1	25	26	27	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					529	535		10.1136/bjsports-2014-093498			7	Sport Sciences	Sport Sciences	CF4OI	WOS:000352529000009	24997205				2021-06-18	
J	Weber, ML; Welch, CE; Parsons, JT; McLeod, TCV				Weber, Michelle L.; Welch, Cailee E.; Parsons, John T.; McLeod, Tamara C. Valovich			School Nurses' Familiarity and Perceptions of Academic Accommodations for Student-Athletes Following Sport-Related Concussion	JOURNAL OF SCHOOL NURSING			English	Article						concussion management; IEPs; 504 plans	STATES HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; EPIDEMIOLOGY; MANAGEMENT; CHILDREN; ZURICH	The purpose of this study was to evaluate school nurses' familiarity and perceptions regarding academic accommodations for student-athletes following sport-related concussion. School nurses (N = 1,246) accessed the survey School Nurses' Beliefs, Attitudes and Knowledge of Pediatric Athletes with Concussions (BAKPAC-SN). The BAKPAC-SN contained several questions pertaining to concussion management and academic accommodations. There were significant differences regarding personal experience as well as familiarity of academic accommodations (p < .001) between school nurses who work at a school that employs an athletic trainer and school nurses who work at a school that does not employ an athletic trainer. There were significant weak positive relationships between years of experience and familiarity with academic accommodations (r = .210, p < .001), 504 plans (r = .243, p < .001), and individualized education plans (r = .205, p < .001). School nurses employed at a single school were significantly more familiar with academic accommodations (p = .027) and 504 plans (p = .001) than school nurses employed at multiple schools. Health care professionals should collaborate to effectively manage a concussed patient and should consider academic accommodations to ensure whole-person health care.	[Weber, Michelle L.] AT Still Univ, Postprofess Athlet Training Program, Mesa, AZ 85206 USA; [Welch, Cailee E.] AT Still Univ, Dept Interdisciplinary Hlth Sci, Athlet Training, Mesa, AZ 85206 USA; [McLeod, Tamara C. Valovich] AT Still Univ, Postprofess Athlet Training Program, Dept Interdisciplinary Hlth Sci, Mesa, AZ 85206 USA; [Parsons, John T.] Natl Collegiate Athlet Assoc, Sports Sci Inst, Indianapolis, IN USA	Welch, CE (corresponding author), AT Still Univ, Dept Interdisciplinary Hlth Sci, 5850 E Still Circle, Mesa, AZ 85206 USA.	cwmccarty@atsu.edu	McLeod, Tamara/AAU-9435-2020		National Association of School Nurses (NASN)	The authors acknowledge the National Association of School Nurses (NASN) for their support and cooperation in obtaining the mailing lists for this study.	[Anonymous], 2013, PROTECTING STUDENTS; [Anonymous], 2010, ALL ABOUT THE IEP; [Anonymous], 2013, DEFINING ATHLETIC TR; [Anonymous], 2006, INDIVIDUALIZED ED PR; Board C., 2011, ROLE SCH NURSE POSIT; Borich M., 2013, J NEUROL PHYS THER, V37, P7; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Diaz Anne L, 2013, NASN Sch Nurse, V28, P110; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kay M. C., 2014, MES INT RES COMM RES; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee Michael A, 2009, Conn Med, V73, P171; Lowe R, 2009, MANDATING ATHLETIC T; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall Cameron M, 2012, J Can Chiropr Assoc, V56, P299; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Mayfield R., J ATHLETIC IN PRESS; Mayfield R., SPORTS HLTH IN PRESS; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N., 2010, J ATHL TRAINING, V45, P8; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Rains C., 2010, NASN SCH NURSE, V25, P5, DOI DOI 10.1177/1942602X10376672; Saffary R., 2012, AM J LIFESTYLE MED, V2, P8	31	26	26	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1059-8405	1546-8364		J SCH NURS	J. Sch. Nurs.	APR	2015	31	2					146	154		10.1177/1059840514540939			9	Nursing	Nursing	CE0CZ	WOS:000351473300009	25015367				2021-06-18	
J	Hakon, J; Ruscher, K; Romner, B; Tomasevic, G				Hakon, Jakob; Ruscher, Karsten; Romner, Bertil; Tomasevic, Gregor			Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; INTERCELLULAR-ADHESION MOLECULE-1; PEPTIDE-1 RECEPTOR AGONIST; ENDOTHELIAL-CELLS; GENE-EXPRESSION; EDEMA FORMATION; RATS; IMPACT; MICE; HYPERGLYCEMIA	Cerebral edema is a common complication following moderate and severe traumatic brain injury (TBI), and a significant risk factor for development of neuronal death and deterioration of neurological outcome. To this date, medical approaches that effectively alleviate cerebral edema and neuronal death after TBI are not available. Glucagon-like peptide-1 (GLP-1) has anti-inflammatory properties on cerebral endothelium and exerts neuroprotective effects. Here, we investigated the effects of GLP-1 on secondary injury after moderate and severe TBI. Male Sprague Dawley rats were subjected either to TBI by Controlled Cortical Impact (CCI) or sham surgery. After surgery, vehicle or a GLP-1 analogue, Liraglutide, were administered subcutaneously twice daily for two days. Treatment with Liraglutide (200 mu g/kg) significantly reduced cerebral edema in pericontusional regions and improved sensorimotor function 48 hours after CCI. The integrity of the blood-brain barrier was markedly preserved in Liraglutide treated animals, as determined by cerebral extravasation of Evans blue conjugated albumin. Furthermore, Liraglutide reduced cortical tissue loss, but did not affect tissue loss and delayed neuronal death in the thalamus on day 7 post injury. Together, our data suggest that the GLP-1 pathway might be a promising target in the therapy of cerebral edema and cortical neuronal injury after moderate and severe TBI.	[Hakon, Jakob; Ruscher, Karsten; Tomasevic, Gregor] Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, Lund, Sweden; [Hakon, Jakob; Romner, Bertil] Copenhagen Univ Hosp, Risgshosp, Dept Neurosurg, Copenhagen, Denmark; [Romner, Bertil; Tomasevic, Gregor] Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden	Hakon, J (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, Lund, Sweden.	jakobhakon@gmail.com		Hakon, Jakob/0000-0003-1079-0141			Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Astrup A, 2009, LANCET, V374, P1606, DOI 10.1016/S0140-6736(09)61375-1; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Briyal S, 2012, BRAIN RES, V1427, P23, DOI 10.1016/j.brainres.2011.10.026; Ceriello A, 2013, DIABETES CARE, P1; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Collard CD, 2002, J BIOL CHEM, V277, P14801, DOI 10.1074/jbc.M110557200; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings BP, 2010, DIABETES, V59, P2653, DOI 10.2337/db09-1564; Darsalia V, 2012, CLIN SCI, V122, P473, DOI 10.1042/CS20110374; DeFronzo R, 2014, EFFECTS LIRAGLUTIDE; DellaValle B, 2014, ANN CLIN TRANSL NEUR, V1, P721, DOI 10.1002/acn3.99; DERYCK M, 1992, BRAIN RES, V573, P44; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Eakins James, 2009, J Diabetes Sci Technol, V3, P1373; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Fischer S, 2005, EUR J CELL BIOL, V84, P687, DOI 10.1016/j.ejcb.2005.03.002; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; Gejl Michael, 2013, Front Neuroenergetics, V5, P2, DOI 10.3389/fnene.2013.00002; Gejl M, 2012, J CEREBR BLOOD F MET, V32, P2146, DOI 10.1038/jcbfm.2012.118; Godoy DA, 2010, NEUROCRIT CARE, V13, P425, DOI 10.1007/s12028-010-9404-8; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Hou J, 2012, J INEQUAL APPL, P1, DOI 10.1186/1029-242X-2012-60; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Hunter K, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-33; Iwai T, 2006, NEUROSCI RES, V55, P352, DOI 10.1016/j.neures.2006.04.008; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Krasner NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097554; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Lee CH, 2011, J NEUROSCI RES, V89, P1103, DOI 10.1002/jnr.22596; Li PA, 2000, STROKE, V31, P183, DOI 10.1161/01.STR.31.1.183; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Madinier A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093121; McClean PL, 2014, NEUROPHARMACOLOGY, V76, P57, DOI 10.1016/j.neuropharm.2013.08.005; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nauck MA, 2002, J CLIN ENDOCR METAB, V87, P1239, DOI 10.1210/jc.87.3.1239; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Rachmany L, 2012, AGE; Raun K, 2007, DIABETES, V56, P8, DOI 10.2337/db06-0565; Sato K, 2013, INT J MOL SCI, V14, P21513, DOI 10.3390/ijms141121513; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwarzkopf TM, 2013, EXP BIOL MED, V238, P84, DOI 10.1258/ebm.2012.012261; Secher A, 2014, J CLIN INVEST, V124, P4473, DOI 10.1172/JCI75276; [Services USDoHaH Food and Drug Adminstration CfDEaR], 2005, GUID IND EST MAX SAF; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shiraki A, 2012, ATHEROSCLEROSIS, V221, P375, DOI 10.1016/j.atherosclerosis.2011.12.039; Sturis J, 2003, BRIT J PHARMACOL, V140, P123, DOI 10.1038/sj.bjp.0705397; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; SZTRIHA L, 1986, ACTA NEUROPATHOL, V70, P169, DOI 10.1007/BF00691435; Teramoto S, 2011, J CEREBR BLOOD F MET, V31, P1696, DOI 10.1038/jcbfm.2011.51; Tomlinson DR, 2008, NAT REV NEUROSCI, V9, P36, DOI 10.1038/nrn2294; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yrjanheikki J, 2005, BRAIN RES, V1052, P174, DOI 10.1016/j.brainres.2005.06.004; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0	76	26	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2015	10	3							e0120074	10.1371/journal.pone.0120074			17	Multidisciplinary Sciences	Science & Technology - Other Topics	CE9AD	WOS:000352134700054	25822252	DOAJ Gold, Green Published			2021-06-18	
J	Xie, CC; Cong, DM; Wang, XJ; Wang, YH; Liang, HS; Zhang, XT; Huang, Q				Xie, Chuncheng; Cong, Damin; Wang, Xiujuan; Wang, Yuehua; Liang, Hongsheng; Zhang, Xiangtong; Huang, Qi			The effect of simvastatin treatment on proliferation and differentiation of neural stem cells after traumatic brain injury	BRAIN RESEARCH			English	Article						Simvastatin; Neural stem cells; Notch signaling; Traumatic brain injury	DENTATE GYRUS; NEURONS; NEUROGENESIS; ACTIVATION; FOREBRAIN; INCREASE; THERAPY; DEATH; RAT	Objective: To study the effect of simvastatin on neurological functional recovery after traumatic brain injuries (TBI) and the possible molecular mechanisms, we evaluated simvastatin-induced proliferation and differentiation of neural stem cells (NSCs) in vitro and in vivo and possible involvement of Notch-1 signaling in this process. Methods: Adult Wistar rats were randomly divided into three groups (n=28 for each): sham group, saline-treated group and simvastatin-treated group. Simvastatin was given orally at a dose of 1 mg/kg/day starting at day 1 after TBI. At 1, 3, 7, 14, 21, 28, and 35 days after simvastatin treatment, functional outcome was measured using modified neurological severity scores (mNSS). Immunofluorescence of nestin was used to identify neurogenesis of NSCs in injured area of TBI rats. Western blot was applied to detect the expression level of Notch-1 protein in TBI rats with simvastatin. Results: Immunostaining showed a significant increase in the number of nestin-positive cells in injured area of the simvastatin-treated group compared to that of the salinetreated group (p < 0.05). In in vitro experiment, simvastatin induced enhanced proliferation and neurogenesis of cultured NSCs and elevated Notch-1 protein expression. Coincubation of y-secretase inhibitor, an inhibitor of Notch-1 pathway, with simvastatin abolished its neurorestoration effect. Most importantly, the simvastatin-treated group had significantly decreased mNSS at day 35 after TBI compared with the saline-treated group (p < 0.05). Conclusion: Simvastatin treatment enhanced neurological functional recovery after TBI possibly via activation of Notch signaling and increasing neurogenesis in the injured area. (C) 2014 Elsevier B.V. All rights reserved.	[Xie, Chuncheng; Wang, Yuehua; Liang, Hongsheng; Zhang, Xiangtong] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin 150001, Heilongjiang, Peoples R China; [Cong, Damin] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150001, Heilongjiang, Peoples R China; [Wang, Xiujuan] Heilongjiang Prov Hosp, Dept Pediat, Harbin, Heilongjiang, Peoples R China; [Huang, Qi] Harbin Med Univ, Dept Pathol, Harbin 150001, Heilongjiang, Peoples R China	Zhang, XT (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, 23 Youzheng St, Harbin 150001, Heilongjiang, Peoples R China.	zgxgtg@sina.com			Science Foundation of Heilongjiang Province [D200922/C160802]; Director Foundation of Science Department [81041082]	This work was supported by the Science Foundation of Heilongjiang Province (D200922/C160802) and Director Foundation of Science Department(81041082). The founders did not participate in study design, data collection and analysis, and writing the manuscript.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Arumugam TV, 2011, MOL PHARMACOL, V80, P23, DOI 10.1124/mol.111.071076; Baliko F, 2007, AM J PATHOL, V170, P1686, DOI 10.2353/ajpath.2007.060971; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Devaraj S, 2006, J CLIN ENDOCR METAB, V91, P4489, DOI 10.1210/jc.2006-0299; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Keilani S, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-69; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Shimada IS, 2011, STROKE, V42, P3231, DOI 10.1161/STROKEAHA.111.623280; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2011, NEUROSURGERY, V68, P1363, DOI 10.1227/NEU.0b013e31820c06b9; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Xu J, 2009, AM J PHYSIOL-CELL PH, V296, pC535, DOI 10.1152/ajpcell.00310.2008; Zacharek A, 2009, STROKE, V40, P254, DOI 10.1161/STROKEAHA.108.524116	25	26	26	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 30	2015	1602						1	8		10.1016/j.brainres.2014.03.021			8	Neurosciences	Neurosciences & Neurology	CG2CK	WOS:000353082300001	25445996				2021-06-18	
J	Barrus, MM; Hosking, JG; Zeeb, FD; Tremblay, M; Winstanley, CA				Barrus, Michael M.; Hosking, Jay G.; Zeeb, Fiona D.; Tremblay, Melanie; Winstanley, Catharine A.			Disadvantageous decision-making on a rodent gambling task is associated with increased motor impulsivity in a population of male rats	JOURNAL OF PSYCHIATRY & NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; REACTION-TIME-TASK; DOPAMINERGIC MODULATION; ORBITOFRONTAL CORTEX; FUNCTIONAL NEUROCHEMISTRY; REFLECTION-IMPULSIVITY; PSYCHIATRIC-DISORDERS; BASOLATERAL AMYGDALA; PREFRONTAL CORTEX; NEGATIVE URGENCY	Background: Impulsivity is understood as a range of behaviours, but the association between these behaviours is not well understood. Although high motor impulsivity is a key symptom of disorders like pathological gambling and addiction, in which decision-making on laboratory tasks is compromised, there have been no clear demonstrations that choice and motor impulsivity are associated in the general population. We examined this association in a large population of rodents. Methods: We performed a meta-analysis on behavioural data from 211 manipulation-naive male animals that performed a rodent gambling task in our laboratory between 2008 and 2012. The task measures an aspect of both impulsive decision-making and impulsive action, making it possible to evaluate whether these 2 forms of maladaptive behaviour are related. Results: Our meta-analysis revealed that motor impulsivity was positively correlated with poor decision-making under risk. Highly motor impulsive rats were slower to adopt an advantageous choice strategy and quicker to make a choice on individual trials. Limitations: The data analyzed were limited to that produced by our laboratory and did not include data of other researchers who have used the task. Conclusion: This work may represent the first demonstration of a clear association between choice and motor impulsivity in a nonclinical population. This lends support to the common practice of studying impulsivity in nonclinical populations to gain insight into impulse control disorders and suggests that differences in impulsive behaviours between clinical and nonclinical populations may be ones of magnitude rather than ones of quality.	[Barrus, Michael M.; Hosking, Jay G.; Zeeb, Fiona D.; Tremblay, Melanie; Winstanley, Catharine A.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada; [Zeeb, Fiona D.] Ctr Addict & Mental Hlth, Toronto, ON, Canada	Barrus, MM (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	michaelbarrus@psych.ubc.ca	Winstanley, Catharine/K-5003-2015	Winstanley, Catharine/0000-0001-7032-4471	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); National Sciences and Engineering Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); Michael Smith Foundation for Health Research (MSFHR)Michael Smith Foundation for Health Research; Parkinson Society Canada; National Council for Responsible Gambling; Canadian Foundation for InnovationCanada Foundation for Innovation; MSFHRMichael Smith Foundation for Health Research; CIHRCanadian Institutes of Health Research (CIHR)	This work was supported by operating grant funding to C.A. Winstanley from the Canadian Institutes of Health Research (CIHR), The National Sciences and Engineering Council of Canada, the Michael Smith Foundation for Health Research (MSFHR), Parkinson Society Canada, the Institute for Research into Pathological Gambling and Related Disorders (now the National Council for Responsible Gambling) and the Canadian Foundation for Innovation. C.A. Winstanley also receives salary support through the MSFHR and CIHR New Investigator Award program.	Adams ZW, 2012, ADDICT BEHAV, V37, P848, DOI 10.1016/j.addbeh.2012.03.016; AINSLIE G, 1975, PSYCHOL BULL, V82, P463, DOI 10.1037/h0076860; Baarendse PJJ, 2013, PSYCHOPHARMACOLOGY, V225, P719, DOI 10.1007/s00213-012-2857-z; Bari A, 2013, PSYCHOPHARMACOLOGY, V230, P89, DOI 10.1007/s00213-013-3141-6; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Clark L, 2006, BIOL PSYCHIAT, V60, P515, DOI 10.1016/j.biopsych.2005.11.007; Crean J, 2002, BEHAV BRAIN RES, V136, P349, DOI 10.1016/S0166-4328(02)00132-8; Crean JP, 2000, EXP CLIN PSYCHOPHARM, V8, P155, DOI 10.1037/1064-1297.8.2.155; Cunningham KA, 2014, NEUROPHARMACOLOGY, V76, P460, DOI 10.1016/j.neuropharm.2013.06.030; Cyders MA, 2008, PSYCHOL BULL, V134, P807, DOI 10.1037/a0013341; Dalley JW, 2008, PHARMACOL BIOCHEM BE, V90, P250, DOI 10.1016/j.pbb.2007.12.021; de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x; Dickman SJ, 1993, IMPULSIVE CLIENT THE, P151, DOI [10.1037/10500-010, DOI 10.1037/10500-010]; Dougherty DM, 2003, J CHILD PSYCHOL PSYC, V44, P1145, DOI 10.1111/1469-7610.00197; Eagle DM, 2010, NEUROSCI BIOBEHAV R, V34, P50, DOI 10.1016/j.neubiorev.2009.07.003; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P422, DOI 10.1007/PL00005487; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Flagel SB, 2010, NEUROPSYCHOPHARMACOL, V35, P388, DOI 10.1038/npp.2009.142; Flagel SB, 2009, NEUROPHARMACOLOGY, V56, P139, DOI 10.1016/j.neuropharm.2008.06.027; Fletcher PJ, 2011, NEUROPHARMACOLOGY, V61, P468, DOI 10.1016/j.neuropharm.2011.02.025; Frank MJ, 2006, NEURAL NETWORKS, V19, P1120, DOI 10.1016/j.neunet.2006.03.006; Hajcak G, 2007, PSYCHOPHYSIOLOGY, V44, P91, DOI 10.1111/j.1469-8986.2006.00487.x; Howell D. C., 1997, STAT METHODS PSYCHOL; Hulka LM, 2014, PSYCHOL MED, V44, P1015, DOI 10.1017/S0033291713001839; Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Mendez IA, 2012, PSYCHOPHARMACOLOGY, V224, P489, DOI 10.1007/s00213-012-2777-y; Mendez M F, 2000, Curr Psychiatry Rep, V2, P440, DOI 10.1007/s11920-000-0030-6; Mitchell JM, 2005, ALCOHOL CLIN EXP RES, V29, P2158, DOI 10.1097/01.alc.0000191755.63639.4a; Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI 10.1176/appi.ajp.158.11.1783; Monterosso J, 2001, ADDICTION, V96, P1825, DOI 10.1046/j.1360-0443.2001.9612182512.x; Murphy ER, 2012, PSYCHOPHARMACOLOGY, V219, P401, DOI 10.1007/s00213-011-2572-1; Pattij T, 2008, TRENDS PHARMACOL SCI, V29, P192, DOI 10.1016/j.tips.2008.01.002; Pattij T, 2007, PSYCHOPHARMACOLOGY, V193, P85, DOI 10.1007/s00213-007-0773-4; Pattij T, 2013, CURR OPIN NEUROBIOL, V23, P700, DOI 10.1016/j.conb.2013.01.023; Perales JC, 2009, J CLIN EXP NEUROPSYC, V31, P927, DOI 10.1080/13803390902758793; Reynolds B, 2006, PHARMACOL BIOCHEM BE, V83, P194, DOI 10.1016/j.pbb.2006.01.007; Robbins TW, 2002, PSYCHOPHARMACOLOGY, V163, P362, DOI 10.1007/s00213-002-1154-7; Robinson ESJ, 2009, BEHAV BRAIN RES, V196, P310, DOI 10.1016/j.bbr.2008.09.021; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Specker S M, 1995, Ann Clin Psychiatry, V7, P175, DOI 10.3109/10401239509149623; STEIN DJ, 1993, J NEUROPSYCH CLIN N, V5, P9; Sun HS, 2012, PSYCHOPHARMACOLOGY, V219, P285, DOI 10.1007/s00213-011-2419-9; Tomie A, 1998, PSYCHOPHARMACOLOGY, V139, P376, DOI 10.1007/s002130050728; Tomie A, 2008, BRAIN RES REV, V58, P121, DOI 10.1016/j.brainresrev.2007.12.003; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003; Voon V, 2014, BIOL PSYCHIAT, V75, P148, DOI 10.1016/j.biopsych.2013.05.013; Winstanley CA, 2004, NEUROPSYCHOPHARMACOL, V29, P1331, DOI 10.1038/sj.npp.1300434; Winstanley CA, 2006, CLIN PSYCHOL REV, V26, P379, DOI 10.1016/j.cpr.2006.01.001; Winstanley CA, 2011, BRIT J PHARMACOL, V164, P1301, DOI 10.1111/j.1476-5381.2011.01323.x; Winstanley CA, 2010, ALCOHOL CLIN EXP RES, V34, P1306, DOI 10.1111/j.1530-0277.2010.01215.x; Winstanley CA, 2010, BEHAV BRAIN RES, V210, P263, DOI 10.1016/j.bbr.2010.02.044; Zeeb FD, 2013, J NEUROSCI, V33, P6434, DOI 10.1523/JNEUROSCI.3971-12.2013; Zeeb FD, 2013, PSYCHOPHARMACOLOGY, V225, P381, DOI 10.1007/s00213-012-2822-x; Zeeb FD, 2011, J NEUROSCI, V31, P2197, DOI 10.1523/JNEUROSCI.5597-10.2011; Zeeb FD, 2009, NEUROPSYCHOPHARMACOL, V34, P2329, DOI 10.1038/npp.2009.62	63	26	26	0	8	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	1180-4882	1488-2434		J PSYCHIATR NEUROSCI	J. Psychiatry Neurosci.	MAR	2015	40	2					108	117		10.1503/jpn.140045			10	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CD6NU	WOS:000351206800006	25703645	Green Published			2021-06-18	
J	Sierra, A; Laitinen, T; Grohn, O; Pitkanen, A				Sierra, Alejandra; Laitinen, Teemu; Grohn, Olli; Pitkanen, Asla			Diffusion tensor imaging of hippocampal network plasticity	BRAIN STRUCTURE & FUNCTION			English	Article						Diffusion tensor imaging; Epilepsy; Epileptogenesis; Hippocampus; Magnetic resonance imaging; Mossy fiber sprouting; Myelin; Status epilepticus; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; SYNAPTIC REORGANIZATION; STATUS EPILEPTICUS; WATER DIFFUSION; RAT; MRI; EPILEPSY; TRACTOGRAPHY; ANISOTROPY; SCHEMES	Diffusion tensor imaging (DTI) has become a valuable tool to investigate white matter integrity in the brain. DTI also gives contrast in gray matter, which has been relatively little explored in studies assessing post-injury structural abnormalities. The present study was designed to compare white and gray matter reorganization in the rat hippocampus after two epileptogenic brain injuries, status epilepticus (SE) and traumatic brain injury (TBI), using ex vivo high-resolution DTI. Imaging was performed at 6-12 months post-injury and findings were compared to histological analyses of Nissl, myelin, and Timm-stained preparations from the same animals. In agreement with the severity of histological damage, fractional anisotropy (FA), axial (D (||)) and radial (D (aSyen)) diffusivities, and mean diffusivity (MD) measurements were altered in the order SE > TBI ipsilaterally > TBI contralaterally. After SE, the most severe abnormalities were found in the dentate gyrus and CA3b-c subfields, in which the mean FA was increased to 125 % (p < 0.001) and 143 % (p < 0.001) of that in controls, respectively. In both subfields, the change in FA was associated with an increase in D (||) (p < 0.01). In the stratum radiatum of the CA1, FA was decreased to 81 % of that in controls (p < 0.05) which was associated with an increase in D (aSyen) (p < 0.01). After TBI, DTI did not reveal any major abnormalities in the dentate gyrus. In the ipsilateral CA3b-c, however, FA was increased to 126 % of that in controls (p < 0.01) and associated with a mild decrease in D (aSyen) (p < 0.05). In the stratum radiatum of the ipsilateral CA1, FA was decreased to 88 % of that in controls (p < 0.05). Our data demonstrate that DTI reveals subfield-specific abnormalities in the hippocampus with remarkable qualitative and quantitative differences between the two epileptogenic etiologies, suggesting that DTI could be a valuable tool for follow-up of focal circuitry reorganization during the post-injury aftermath.	[Sierra, Alejandra; Laitinen, Teemu; Grohn, Olli; Pitkanen, Asla] Univ Eastern Finland, Dept Neurobiol, AI Virtanen Inst Mol Sci, Kuopio 70211, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, Kuopio 70211, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, Dept Neurobiol, AI Virtanen Inst Mol Sci, POB 1627, Kuopio 70211, Finland.	asla.pitkanen@uef.fi		Sierra Lopez, Alejandra/0000-0001-5399-2056	Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; University of Eastern Finland	This study was supported by the Academy of Finland (A.S., O.G., A.P.), Sigrid Juselius Foundation (A.P.), and UEF-Brain strategic funding from the University of Eastern Finland. We thank Ms. Maarit Pulkkinen for assistance in histology, Dr. Jari Nissinen and Dr. Tamuna Bolkvadze for technical assistance, MSc Juha-Pekka Niskanen for drawing the diffusion ellipsoids, and Dr. Nick Hayward for revising the language of the manuscript.	Amaral D.G., 1990, HUMAN NERVOUS SYSTEM, P711; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baulac M, 2008, EPILEPSIA; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Buckmaster PS., 2012, JASPERS BASIC MECH E; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chan KC, 2012, NEUROIMAGE, V59, P2274, DOI 10.1016/j.neuroimage.2011.09.055; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Cross DJ, 2007, EPILEPSY RES, V73, P156, DOI 10.1016/j.eplepsyres.2006.09.004; Dauguet J, 2007, NEUROIMAGE, V37, P530, DOI 10.1016/j.neuroimage.2007.04.067; deLanerolle N. C., 2012, JASPERS BASIC MECH E; Dityatev A, 2008, NEURON GLIA BIOL, V4, P235, DOI 10.1017/S1740925X09000118; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Hauser W.A., 1997, EPILEPSY COMPREHENSI, P47, DOI 10.1007/978-88~470~2903~3_81; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Heidemann RM, 2012, NEUROIMAGE, V60, P967, DOI 10.1016/j.neuroimage.2011.12.081; Horsfield MA, 2002, NMR BIOMED, V15, P570, DOI 10.1002/nbm.787; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Kaufman JA, 2005, ANAT REC PART A, V287A, P1026, DOI 10.1002/ar.a.20264; Kelley Melinda S, 2009, Epilepsia, V50, P579, DOI 10.1111/j.1528-1167.2008.01813.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kuo LW, 2008, NEUROIMAGE, V41, P789, DOI 10.1016/j.neuroimage.2008.03.013; Laitinen T, 2010, NEUROIMAGE, V51, P521, DOI 10.1016/j.neuroimage.2010.02.077; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; Leergaard TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008595; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Nairismagi J, 2006, NEUROIMAGE, V30, P130, DOI 10.1016/j.neuroimage.2005.09.007; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Ni H, 2006, AM J NEURORADIOL, V27, P1776; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Oechslin MS, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.076.2009; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Parekh MB, 2010, EXP NEUROL, V224, P258, DOI 10.1016/j.expneurol.2010.03.031; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rangel CD, 2011, MAGN RESON IMAGING C, V19, P23, DOI 10.1016/j.mric.2010.10.006; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Savander V, 1996, J COMP NEUROL, V374, P291, DOI 10.1002/(SICI)1096-9861(19961014)374:2<291::AID-CNE10>3.0.CO;2-Y; Shepherd TM, 2006, NEUROIMAGE, V32, P1499, DOI 10.1016/j.neuroimage.2006.04.210; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sierra A, 2011, BRAIN STRUCT FUNCT, V216, P123, DOI 10.1007/s00429-010-0299-0; Sigal T, 2012, J NEUROIMAGING, V22, P33, DOI 10.1111/j.1552-6569.2010.00556.x; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Wong M, 2005, EPILEPSY BEHAV, V7, P569, DOI 10.1016/j.yebeh.2005.08.007; Yassa MA, 2010, P NATL ACAD SCI USA, V107, P12687, DOI 10.1073/pnas.1002113107; Zalesky A, 2011, BIOL PSYCHIAT, V69, P80, DOI 10.1016/j.biopsych.2010.08.022; Zhang JY, 2007, MAGN RESON MED, V58, P454, DOI 10.1002/mrm.21371; Zhang JY, 2002, NEUROIMAGE, V15, P892, DOI 10.1006/nimg.2001.1012; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	63	26	26	0	16	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAR	2015	220	2					781	801		10.1007/s00429-013-0683-7			21	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	CC4UU	WOS:000350350300011	24363120				2021-06-18	
J	Wijdicks, EFM; Kramer, AA; Rohs, T; Hanna, S; Sadaka, F; O'Brien, J; Bible, S; Dickess, SM; Foss, M				Wijdicks, Eelco F. M.; Kramer, Andrew A.; Rohs, Thomas, Jr.; Hanna, Susan; Sadaka, Farid; O'Brien, Jacklyn; Bible, Shonna; Dickess, Stacy M.; Foss, Michelle			Comparison of the Full Outline of UnResponsiveness Score and the Glasgow Coma Scale in Predicting Mortality in Critically III Patients	CRITICAL CARE MEDICINE			English	Article						brainstem reflexes; coma; critical illness; intensive care unit; prognosis; scales	TRAUMATIC BRAIN-INJURY; VALIDATION; VERSION	Objective: Impaired consciousness has been incorporated in prediction models that are used in the ICU. The Glasgow Coma Scale has value but is incomplete and cannot be assessed in intubated patients accurately. The Full Outline of UnResponsiveness score may be a better predictor of mortality in critically ill patients. Setting: Thirteen ICUs at five U.S. hospitals. Subjects: One thousand six hundred ninety-five consecutive unselected ICU admissions during a six-month period in 2012. Design: Glasgow Coma Scale and Full Outline of UnResponsiveness score were recorded within 1 hour of admission. Baseline characteristics and physiologic components of the Acute Physiology and Chronic Health Evaluation system, as well as mortality were linked to Glasgow Coma Scale/Full Outline of UnResponsiveness score information. Interventions: None. Measurements and Results: We recruited 1,695 critically ill patients, of which 1,645 with complete data could be linked to data in the Acute Physiology and Chronic Health Evaluation system. The area under the receiver operating characteristic curve of predicting ICU mortality using the Glasgow Coma Scale was 0.715 (95% Cl, 0.663-0.768) and using the Full Outline of UnResponsiveness score was 0.742 (95% Cl, 0.694-0.790), statistically different (p = 0.001). A similar but nonsignificant difference was found for predicting hospital mortality (p = 0.078). The respiratory and brainstem reflex components of the Full Outline of UnResponsiveness score showed a much wider range of mortality than the verbal component of Glasgow Coma Scale. In multivariable models, the Full Outline of UnResponsiveness score was more useful than the Glasgow Coma Scale for predicting mortality. Conclusions: The Full Outline of UnResponsiveness score might be a better prognostic tool of ICU mortality than the Glasgow Coma Scale in critically ill patients, most likely a result of incorporating brainstem reflexes and respiration into the Full Outline of UnResponsiveness score.	[Wijdicks, Eelco F. M.] Mayo Clin, Div Crit Care Neurol, Dept Neurol, Rochester, MN 55905 USA; [Kramer, Andrew A.] Cerner Corp, Vienna, VA USA; [Rohs, Thomas, Jr.] Borgess Med Ctr, Dept Trauma & Emergency Surg, Kalamazoo, MI USA; [Hanna, Susan] Borgess Med Ctr, Dept Crit Care, Kalamazoo, MI USA; [Sadaka, Farid; O'Brien, Jacklyn] Mercy Hosp, Dept Crit Care Med, St Louis, MO USA; [Bible, Shonna] Spartanburg Reg Med Ctr, Project Management Qual, Spartanburg, SC USA; [Dickess, Stacy M.] St Marys Hosp, Performance Improvement Dept, Huntington, WV USA; [Foss, Michelle] Shawnee Mission Med Ctr, Intens Care Unit, Shawnee Mission, KS USA	Wijdicks, EFM (corresponding author), Mayo Clin, Div Crit Care Neurol, Dept Neurol, Rochester, MN 55905 USA.	wijde@mayo.edu	Kramer, Andrew/AAI-9086-2020	Kramer, Andrew/0000-0002-5681-5781			Akavipat P, 2009, NEUROL MED-CHIR, V49, P565, DOI 10.2176/nmc.49.565; Breslow MJ, 2012, CHEST, V141, P245, DOI 10.1378/chest.11-0330; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Kevric J, 2011, EMERG MED J, V28, P486, DOI 10.1136/emj.2009.085845; Knox DB, 2013, C104 CRITICAL ILLNES, pA5073; Kramer AA, 2013, CRIT CARE MED, V41, P24, DOI 10.1097/CCM.0b013e3182657b8a; Kramer AA, 2012, CRIT CARE MED, V40, P2671, DOI 10.1097/CCM.0b013e318258fd88; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marcati E, 2012, INTERN EMERG MED, V7, P145, DOI 10.1007/s11739-011-0583-x; Pepe MS, 2013, STAT MED, V32, P1467, DOI 10.1002/sim.5727; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prasad V, 2011, ARCH INTERN MED, V171, P1675, DOI 10.1001/archinternmed.2011.295; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; TEASDALE G, 1974, LANCET, V2, P81; Weiss N, 2009, REV NEUROL-FRANCE, V165, P796, DOI 10.1016/j.neurol.2009.01.045; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	23	26	29	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					439	444		10.1097/CCM.0000000000000707			6	Critical Care Medicine	General & Internal Medicine	AZ2YX	WOS:000348096200021	25393699				2021-06-18	
J	Gautam, A; Arpa, PD; Donohue, DE; Muhie, S; Chakraborty, N; Luke, BT; Grapov, D; Carroll, EE; Meyerhoff, JL; Hammamleh, R; Jett, M				Gautam, Aartl; Arpa, Peter D'; Donohue, Duncan E.; Muhie, Seid; Chakraborty, Nabarun; Luke, Brian T.; Grapov, Dmitry; Carroll, Erica E.; Meyerhoff, James L.; Hammamleh, Rasha; Jett, Marti			Acute and Chronic Plasma Metabolomic and Liver Transcriptomic Stress Effects in a Mouse Model with Features of Post-Traumatic Stress Disorder	PLOS ONE			English	Article							GUT MICROBIOTA; PSYCHOSOCIAL STRESS; ACID-METABOLISM; INJURY; PHASE; PTSD; MATRIX-METALLOPROTEINASE-9; MYELOPEROXIDASE; COMORBIDITY; COMPLEMENT	Acute responses to intense stressors can give rise to post-traumatic stress disorder (PTSD). PTSD diagnostic criteria include trauma exposure history and self-reported symptoms. Individuals who meet PTSD diagnostic criteria often meet criteria for additional psychiatric diagnoses. Biomarkers promise to contribute to reliable phenotypes of PTSD and comorbidities by linking biological system alterations to behavioral symptoms. Here we have analyzed unbiased plasma metabolomics and other stress effects in a mouse model with behavioral features of PTSD. In this model, C57BL/6 mice are repeatedly exposed to a trained aggressor mouse (albino SJL) using a modified, resident-intruder, social defeat paradigm. Our recent studies using this model found that aggressor-exposed mice exhibited acute stress effects including changed behaviors, body weight gain, increased body temperature, as well as inflammatory and fibrotic histopathologies and transcriptomic changes of heart tissue. Some of these acute stress effects persisted, reminiscent of PTSD. Here we report elevated proteins in plasma that function in inflammation and responses to oxidative stress and damaged tissue at 24 hrs post-stressor. Additionally at this acute time point, transcriptomic analysis indicated liver inflammation. The unbiased metabolomics analysis showed altered metabolites in plasma at 24 hrs that only partially normalized toward control levels after stress-withdrawal for 1.5 or 4 wks. In particular, gut-derived metabolites were altered at 24 hrs post-stressor and remained altered up to 4 wks after stress-withdrawal. Also at the 4 wk time point, hyperlipidemia and suppressed metabolites of amino acids and carbohydrates in plasma coincided with transcriptomic indicators of altered liver metabolism (activated xenobiotic and lipid metabolism). Collectively, these system-wide sequelae to repeated intense stress suggest that the simultaneous perturbed functioning of multiple organ systems (e.g., brain, heart, intestine and liver) can interact to produce injuries that lead to chronic metabolic changes and disorders that have been associated with PTSD.	[Gautam, Aartl; Arpa, Peter D'; Donohue, Duncan E.; Chakraborty, Nabarun; Meyerhoff, James L.; Hammamleh, Rasha; Jett, Marti] US Army Ctr Environm Hlth Res, Ft Detrick, MD 21702 USA; [Gautam, Aartl; Arpa, Peter D'; Donohue, Duncan E.; Chakraborty, Nabarun; Meyerhoff, James L.] Geneva Fdn, Tacoma, WA 98402 USA; [Muhie, Seid; Luke, Brian T.] Adv Biomed Comp Ctr, Frederick Natl Lab Canc Res, Frederick, MD USA; [Grapov, Dmitry] Univ Calif Davis, NIH, West Coast Metabol Ctr, Davis, CA USA; [Carroll, Erica E.] Army Inst Publ Hlth, Aberdeen Proving Ground, MD 21010 USA	Jett, M (corresponding author), US Army Ctr Environm Hlth Res, Ft Detrick, Ft Detrick, MD 21702 USA.	marti.jett-tilton.civ@mail.mil		Donohue, Duncan/0000-0002-3137-8773; Grapov, Dmitry/0000-0002-7204-3128; D'Arpa, Peter/0000-0002-0562-0263	Office of the Assistant Secretary of Defense for Health Affairs; Military Operational Medicine Research Program (MOMRP); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 U24 DK097154];  [09284002]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U24DK097154] Funding Source: NIH RePORTER	This project is supported by the Office of the Assistant Secretary of Defense for Health Affairs and the Military Operational Medicine Research Program (MOMRP), and the support of grant #USAMRMC NO: 09284002 is highly acknowledged. DG was supported by NIH 1 U24 DK097154. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055766; ARAGOZZINI F, 1979, APPL ENVIRON MICROB, V38, P544, DOI 10.1128/AEM.38.3.544-546.1979; Association AP, 2013, DIAGN STAT MAN MENT, DOI [10.1016/j.amsu.2013.12.001, DOI 10.1016/J.AMSU.2013.12.001]; Atkinson C, 2005, EXP BIOL MED, V230, P155, DOI 10.1177/153537020523000302; Bailey MT, 2011, BRAIN BEHAV IMMUN, V25, P397, DOI 10.1016/j.bbi.2010.10.023; Bailey MT, 2006, J NEUROIMMUNOL, V171, P29, DOI 10.1016/j.jneuroim.2005.09.008; Balmer ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008618; Bartoli F, 2013, METAB SYNDR RELAT D, V11, P301, DOI 10.1089/met.2013.0010; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger JA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-194; Bessede A, 2014, NATURE; Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12; Calabrese JR, 2011, J CLIN PSYCHIAT, V72, P1072, DOI 10.4088/JCP.11m06956; Camprecios G, 2009, GROWTH FACTORS, V27, P300, DOI 10.1080/08977190903137736; Cho JH, 2014, P NATL ACAD SCI USA, V111, P3188, DOI 10.1073/pnas.1400113111; Choudhary SP, 2011, CURR MED CHEM, V18, P4557; Chuang JC, 2010, J LIPID RES, V51, P1344, DOI 10.1194/jlr.M002196; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Conover WJ, 1971, PRACTICAL NONPARAMET; Coughlin SS, 2011, OPEN CARDIOVASC MED, V5, P164, DOI 10.2174/1874192401105010164; CRISPENS CG, 1973, LAB ANIM SCI, V23, P408; Czech B, 2013, INT J CLIN EXP PATHO, V6, P1585; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Eckel-Mahan KL, 2012, P NATL ACAD SCI USA, V109, P5541, DOI 10.1073/pnas.1118726109; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Freidman MJ, 2007, PTSD HIST OVERVIEW, DOI [10.1093/jxb/erm028, DOI 10.1093/JXB/ERM028]; Fury Wen, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5531; Gall WE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010883; Galley JD, 2014, GUT MICROBES, V5, DOI [10.4161/19490976.2014.973349, DOI 10.4161/19490976.2014.973349]; Gareau MG, 2008, CURR MOL MED, V8, P274, DOI 10.2174/156652408784533760; Garvin P, 2009, PSYCHOSOM MED, V71, P292, DOI 10.1097/PSY.0b013e3181960e7f; GOODWIN BL, 1994, BIOCHEM PHARMACOL, V47, P2294, DOI 10.1016/0006-2952(94)90268-2; Green BT, 2012, FOOD CHEM TOXICOL, V50, P2049, DOI 10.1016/j.fct.2012.03.049; Gupta MA, 2013, INT REV PSYCHIATR, V25, P86, DOI 10.3109/09540261.2012.736367; Hall JE, 2011, GUYTON HALL TXB MED, DOI [10.3390/jpm1010005, DOI 10.3390/JPM1010005]; Hammamieh R, 2012, BEHAV BRAIN RES, V235, P55, DOI 10.1016/j.bbr.2012.07.022; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016185; Health NIoM, 2008, NAT I MENT HLTH STRA; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Heslop CL, 2010, J AM COLL CARDIOL, V55, P1102, DOI 10.1016/j.jacc.2009.11.050; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P15; Jennewein C, 2011, MOL MED, V17, P568, DOI 10.2119/molmed.2010.00146; Jensen KJ, 2013, COMPR PHYSIOL, V3, P655, DOI 10.1002/cphy.c120018; JOYCE PR, 1992, BIOL PSYCHIAT, V32, P1035, DOI 10.1016/0006-3223(92)90065-8; KEANE TM, 1987, J CLIN PSYCHOL, V43, P32, DOI 10.1002/1097-4679(198701)43:1<32::AID-JCLP2270430106>3.0.CO;2-X; Keeney A, 2006, J NEUROENDOCRINOL, V18, P330, DOI 10.1111/j.1365-2826.2006.01422.x; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kramer A, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-253; Lee CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076817; Li X, 2009, ANAL CHIM ACTA, V633, P257, DOI 10.1016/j.aca.2008.11.058; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lord RS, 2008, ALTERN MED REV, V13, P292; Lu K, 2012, J PROTEOME RES, V11, P4916, DOI 10.1021/pr300429x; Lyte M, 2011, CELL TISSUE RES, V343, P23, DOI 10.1007/s00441-010-1050-0; Ma BW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047416; MACFARLANE GT, 1991, LARGE INTESTINE PHYS, P51; Marcobal A, 2013, ISME J, V7, P1933, DOI 10.1038/ismej.2013.89; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Murray LA, 2011, INT J BIOCHEM CELL B, V43, P154, DOI 10.1016/j.biocel.2010.10.013; Nakamura MT, 2014, PROG LIPID RES, V53, P124, DOI 10.1016/j.plipres.2013.12.001; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Pacella ML, 2013, J ANXIETY DISORD, V27, P33, DOI 10.1016/j.janxdis.2012.08.004; Peckett AJ, 2011, METABOLISM, V60, P1500, DOI 10.1016/j.metabol.2011.06.012; Phipson B, 2010, STAT APPL GENET MOL, V9, DOI 10.2202/1544-6115.1585; R Core Team, 2020, R LANG ENV STAT COMP; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Sanchez O, 2002, CELL STRESS CHAPERON, V7, P36, DOI 10.1379/1466-1268(2002)007<0036:ASITII>2.0.CO;2; Sanchez O, 2007, AM J PHYSIOL-REG I, V293, pR1908, DOI 10.1152/ajpregu.00113.2007; Sanghez V, 2013, PSYCHONEUROENDOCRINO, V38, P2933, DOI 10.1016/j.psyneuen.2013.07.022; Saura-Calixto F, 2010, MOL NUTR FOOD RES, V54, P939, DOI 10.1002/mnfr.200900276; Savignac HM, 2011, BEHAV BRAIN RES, V216, P576, DOI 10.1016/j.bbr.2010.08.049; Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Smith EA, 1997, ANAEROBE, V3, P327, DOI 10.1006/anae.1997.0121; SONG C, 1994, J AFFECT DISORDERS, V30, P283, DOI 10.1016/0165-0327(94)90135-X; Stengel A, 2009, ANNU REV PHYSIOL, V71, P219, DOI 10.1146/annurev.physiol.010908.163221; Sundstrom J, 2006, CURR OPIN LIPIDOL, V17, P45, DOI 10.1097/01.mol.0000203891.34890.b5; Uschold-Schmidt N, 2013, J ENDOCRINOL, V218, P193, DOI 10.1530/JOE-13-0027; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Wilson EB, J AM STAT ASS, V22, P209; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040; Zhao Y, 2013, J PROTEOME RES, V12, P2987, DOI 10.1021/pr400263n	88	26	26	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2015	10	1							e0117092	10.1371/journal.pone.0117092			24	Multidisciplinary Sciences	Science & Technology - Other Topics	CA2IM	WOS:000348732100063	25629821	DOAJ Gold, Green Published			2021-06-18	
J	Alexander, DG; Shuttleworth-Edwards, AB; Kidd, M; Malcolm, CM				Alexander, D. G.; Shuttleworth-Edwards, A. B.; Kidd, M.; Malcolm, C. M.			Mild traumatic brain injuries in early adolescent rugby players: Long-term neurocognitive and academic outcomes	BRAIN INJURY			English	Article						Academic performance; adolescence; concussion; mild traumatic brain injury; MTBI; neurocognitive; rugby	REPORTED CONCUSSIONS; EXECUTIVE FUNCTIONS; DIGIT SYMBOL; HEAD-INJURY; CHILDREN; SCHOOL; VULNERABILITY; PERFORMANCE; MANAGEMENT; SPEED	Background: Information is scant concerning enduring brain injury effects of participation in the contact sport of Rugby Union (hereafter rugby) on early adolescents. Objective: The objective was prospectively to investigate differences between young adolescent male rugby players and non-contact sports controls on neurocognitive test performance over 3 years and academic achievement over 6 years. Method: A sample of boys from the same school and grade was divided into three groups: rugby with seasonal concussions (n = 45), rugby no seasonal concussions (n = 21) and non-contact sports controls (n = 30). Baseline neurocognitive testing was conducted pre-season in Grade 7 and post-season in Grades 8 and 9. Year-end academic grades were documented for Grades 6-9 and 12 (pre-high school to year of school leaving). A mixed model repeated measures ANOVA was conducted to investigate comparative neurocognitive and academic outcomes between the three sub-groups. Results: Compared with controls, both rugby groups were significantly lower on the WISC-III Coding Immediate Recall sub-test. There was a significant interaction effect on the academic measure, with improved scores over time for controls, that was not in evidence for either rugby group. Conclusions: Tentatively, the outcome suggests cognitive vulnerability in association with school level participation in rugby.	[Alexander, D. G.] Univ Stellenbosch, Dept Psychiat, ZA-7600 Stellenbosch, South Africa; [Alexander, D. G.; Malcolm, C. M.] Univ Western Cape, Dept Psychol, Cape Town, South Africa; [Shuttleworth-Edwards, A. B.] Rhodes Univ, Dept Psychol, ZA-6140 Grahamstown, South Africa; [Kidd, M.] Univ Stellenbosch, Ctr Stat Consultat, ZA-7600 Stellenbosch, South Africa	Alexander, DG (corresponding author), Univ Stellenbosch, Fac Med & Hlth Sci, Dept Psychiat, POB 19063, ZA-7505 Tygerberg, South Africa.	debalex@sun.ac.za	Meijer, Anna/K-5118-2016				Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Bagiella E, 2000, PSYCHOPHYSIOLOGY, V37, P13, DOI 10.1111/1469-8986.3710013; Baker JH, 1967, DETROIT TEST LEARNIN; Baker Robert J., 2000, Indian Journal of Pediatrics, V67, P317, DOI 10.1007/BF02820676; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Barth JT., 1989, MILD HEAD INJURY, P257; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BIJUR PE, 1990, PEDIATRICS, V86, P337; Blakemore SJ, 2012, NEUROIMAGE, V61, P397, DOI 10.1016/j.neuroimage.2011.11.080; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy T., 2004, UNDERSTANDING SPORTS; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farace E, 2003, J INT NEUROPSYCH SOC, V9, P207; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Golden CJ., 2000, NEUROPSYCHOLOGICAL I; HART RP, 1987, J CONSULT CLIN PSYCH, V55, P236; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Horton AM, 2010, APPL NEUROPSYCHOL, V17, P99, DOI 10.1080/09084281003708944; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kolb B., 2003, FUNDAMENTALS HUMAN N; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Macleod DAD, 1993, SOFT TISSUES TRAUMA, P371; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mira M. P., 1992, TRAUMATIC BRAIN INJU; Mitrushina M., 1999, HDB NORMATIVE DATA N; NATHAN M, 1983, S AFR MED J, V64, P132; Newman BM, 2005, DEV LIFE PSYCHOL APP; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pettersen JA, 2000, PSYCHOBIOLOGY, V28, P81; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Psychological Corporation, 1992, WECHSL IND ACH TEST; Sattler JM, 2001, COGNITIVE APPL; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shuttleworth-Edwards A, 2004, STUD NEUROPSYCHOL DE, P149; Shuttleworth-Edwards A, 2013, ARCH CLIN NEUROPSYCH, V129, P86; Shuttleworth-Edwards A.B., 2013, PSYCHOL ASSESSMENT S, P33, DOI [10.18772/22013015782.8, DOI 10.18772/22013015782.8]; Shuttleworth-Edwards AB, 2004, J CLIN EXP NEUROPSYC, V26, P903, DOI 10.1080/13803390490510824; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Shuttleworth-Edwards AB, 2008, CLIN J SPORT MED, V18, P403, DOI 10.1097/JSM.0b013e3181895910; Shuttleworth-Edwards AB, 2014, PROG NEUROL SURG, V28, P213, DOI 10.1159/000358785; Shuttleworth-Edwards Ann B, 2009, Phys Sportsmed, V37, P45, DOI 10.3810/psm.2009.12.1741; Shuttleworth-Jordan AB, 1993, P 5 NAT NEUR C S AFR, P38; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; SHUTTLEWORTHJORDAN AB, 1995, J CLIN EXP NEUROPSYC, V17, P439, DOI 10.1080/01688639508405135; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 1991, MANUAL WECHSLER INTE	69	26	26	2	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	9					1113	1125		10.3109/02699052.2015.1031699			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CR1UG	WOS:000361110000012	26004752				2021-06-18	
J	An, F; Qu, YY; Liu, XM; Zhong, RT; Luo, Y				An, Fan; Qu, Yueyang; Liu, Xianming; Zhong, Runtao; Luo, Yong			Organ-on-a-Chip: New Platform for Biological Analysis	ANALYTICAL CHEMISTRY INSIGHTS			English	Article						organ-on-a-chip; tissue engineering; microenvironment; drug screening	TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; RAT HEPATOCYTES; CULTURE; LIVER; DIFFERENTIATION; SPHEROIDS; CONFIGURATION; NEUROGENESIS; STIMULATION	Direct detection and analysis of biomolecules and cells in physiological microenvironment is urgently needed for fast evaluation of biology and pharmacy. The past several years have witnessed remarkable development opportunities in vitro organs and tissues models with multiple functions based on microfluidic devices, termed as "organ-on-a-chip". Briefly speaking, it is a promising technology in rebuilding physiological functions of tissues and organs, featuring mammalian cell co-culture and artificial microenvironment created by microchannel networks. In this review, we summarized the advances in studies of heart-, vessel-, liver-, neuron-, kidney- and Multi-organs-on-a-chip, and discussed some noteworthy potential on-chip detection schemes.	[An, Fan; Qu, Yueyang; Luo, Yong] Dalian Univ Technol, Sch Pharmaceut Sci & Technol, Dalian, Peoples R China; [An, Fan; Qu, Yueyang; Luo, Yong] Dalian Univ Technol, Dept Chem Engn, State Key Lab Fine Chem, Dalian, Peoples R China; [Liu, Xianming; Zhong, Runtao] Chinese Acad Sci, Dalian Inst Chem Phys, Dalian, Peoples R China	Zhong, RT (corresponding author), Chinese Acad Sci, Dalian Inst Chem Phys, Dalian, Peoples R China.	rintozh@dicp.ac.cn; yluo@dlut.edu.cn	Zhong, Runtao/AAA-2687-2021				Abaci HE, 2015, INTEGR BIOL-UK, V7, P383, DOI 10.1039/c4ib00292j; [Anonymous], 2014, J SPINAL CORD MED, V37, P243; Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989; Chen AA, 2011, P NATL ACAD SCI USA, V108, P11842, DOI 10.1073/pnas.1101791108; Chen HY, 2013, LAB CHIP, V13, P2999, DOI 10.1039/c3lc50123j; DUNN JCY, 1991, BIOTECHNOL PROGR, V7, P237, DOI 10.1021/bp00009a007; Dvir-Ginzberg M, 2004, TISSUE ENG, V10, P1806, DOI 10.1089/ten.2004.10.1806; Ferrell N, 2012, BIOTECHNOL BIOENG, V109, P797, DOI 10.1002/bit.24339; Fraczek J, 2013, ARCH TOXICOL, V87, P577, DOI 10.1007/s00204-012-0983-3; Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2; Hald ES, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/4/045005; Hamilton G, 2001, IN VITRO CELL DEV-AN, V37, P656; Jagasia R, 2006, TRENDS MOL MED, V12, P400, DOI 10.1016/j.molmed.2006.07.006; Jang KJ, 2013, INTEGR BIOL-UK, V5, P1119, DOI 10.1039/c3ib40049b; Jang KJ, 2010, LAB CHIP, V10, P36, DOI 10.1039/b907515a; Kaufmann PM, 1997, CELL TRANSPLANT, V6, P463, DOI 10.1016/S0963-6897(97)00052-3; Kim S, 2013, LAB CHIP, V13, P1489, DOI 10.1039/c3lc41320a; LeCluyse EL, 2001, EUR J PHARM SCI, V13, P343, DOI 10.1016/S0928-0987(01)00135-X; Lei KF, 2014, LANGMUIR, V30, P14241, DOI 10.1021/la5039238; Li CY, 2014, TISSUE ENG PT A, V20, P2200, DOI [10.1089/ten.tea.2013.0667, 10.1089/ten.TEA.2013.0667]; Nguyen MD, 2015, ANAL CHEM, V87, P2107, DOI 10.1021/ac503716z; Maschmeyer I, 2015, LAB CHIP, V15, P2688, DOI 10.1039/c5lc00392j; Maton A, 1993, HUMAN BIOL HLTH; Michalopoulos GK, 2010, AM J PATHOL, V176, P2, DOI 10.2353/ajpath.2010.090675; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nait-Oumesmar B, 2008, J NEUROL SCI, V265, P26, DOI 10.1016/j.jns.2007.09.032; Nerya FC, 2015, J NEUROSCI METH, V239, P80, DOI 10.1016/j.jneumeth.2014.09.028; Nishikawa Y, 1996, EXP CELL RES, V223, P357, DOI 10.1006/excr.1996.0091; REINECKE M, 1985, PROG HISTOCHEM CYTOC, V16, P1; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richert L, 2002, TOXICOL IN VITRO, V16, P89, DOI 10.1016/S0887-2333(01)00099-6; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Shamloo A, 2015, INTEGR BIOL-UK, V7, P335, DOI 10.1039/c4ib00144c; Sherafat MA, 2012, J MOL NEUROSCI, V48, P144, DOI 10.1007/s12031-012-9791-8; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Theberge AB, 2015, ANAL CHEM, V87, P3239, DOI 10.1021/ac503700f; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; TONG JZ, 1990, EXP CELL RES, V189, P87, DOI 10.1016/0014-4827(90)90260-H; Underhill GH, 2007, BIOMATERIALS, V28, P256, DOI 10.1016/j.biomaterials.2006.08.043; Vinci B, 2011, BIOTECHNOL J, V6, P554, DOI 10.1002/biot.201000326; World Health Organization, CARD DIS CVDS; Xiao Y, 2014, LAB CHIP, V14, P869, DOI 10.1039/c3lc51123e; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yuan B, 2012, ADV MATER, V24, P890, DOI 10.1002/adma.201104589	44	26	27	0	65	LIBERTAS ACAD	AUCKLAND	PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND	1177-3901			ANAL CHEM INSIGHTS	Anal. Chem. Insights		2015	10						39	45		10.4137/ACICI.S28905			7	Chemistry, Analytical	Chemistry	CZ7NS	WOS:000367286700001	26640364				2021-06-18	
J	Babcock, L; Yuan, WH; Leach, J; Nash, T; Wade, S				Babcock, Lynn; Yuan, Weihong; Leach, James; Nash, Tiffany; Wade, Shari			White matter alterations in youth with acute mild traumatic brain injury	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Mild traumatic brain injury; child; diffusion tensor imaging; acute		PURPOSE: To examine acute alterations in white matter (WM) diffusion based on diffusion tensor imaging (DTI) in youth with mild traumatic brain injury (mTBI) relative to orthopedic injury (OI) controls. METHODS: A prospective cohort study of 23 patients with mTBI and 20 OI controls ages 11- 16 years were recruited from the emergency department (ED). DTI was performed within 96 hours. Voxel based analysis quantified group differences for DTI indices: fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). The Post Concussion Symptom Scale assessed symptom burden. RESULTS: Youth with mTBI had significantly higher symptom burdens in the ED and at scanning than controls. The mTBI group had significantly higher levels of FA and AD in several WM regions including the middle temporal gyrus WM, superior temporal gyrus WM, anterior corona radiata, and superior longitudinal fasciculus. The mTBI group had significantly lower levels of MD and/or RD in a fewWM regions including the middle frontal gyrus WM and anterior corona radiata. Diffusion alterations correlated poorly with acute symptom burden. CONCLUSIONS: Alterations of diffusivity were detected in spatially heterogeneous WM regions shortly after mTBI in youth. The pattern of alterations may reflect restrictive water diffusion inWM early post- injury.	[Babcock, Lynn] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Div Pediat Emergency Med, Cincinnati, OH USA; [Yuan, Weihong; Leach, James; Nash, Tiffany] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Radiol, Cincinnati, OH USA; [Wade, Shari] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH USA	Babcock, L (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, 3333 Burnet Ave,ML 2008, Cincinnati, OH 45229 USA.	lynn.babcock@cchmc.org		Babcock, Lynn/0000-0002-2658-6893	National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR000078, KL2 RR026315]; Cincinnati Children's Hospital Medical Center Division of Emergency Medicine; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425, KL2TR000078] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR026315] Funding Source: NIH RePORTER	This study was funded in part by (1) National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR000078 (KL2 RR026315); and (2) Cincinnati Children's Hospital Medical Center Division of Emergency Medicine.	Achenbach TM, 1983, MANUAL CHILD BEHAV C; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Eierud C, 2013, 19 ANN M ORG HUM BRA; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kaiser D, 2015, BRAIN IMAGING BEHAV, V9, P32, DOI 10.1007/s11682-014-9327-7; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Ledberg A, 1998, NEUROIMAGE, V8, P113, DOI 10.1006/nimg.1998.0336; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mori S., 2007, INTRO DIFFUSION TENS; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Schmithorst VJ, 2011, EAR HEARING, V32, P156, DOI 10.1097/AUD.0b013e3181f7a481; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yan P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037837	51	26	26	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2015	8	4					285	296		10.3233/PRM-150347			12	Pediatrics	Pediatrics	VG7LK	WOS:000448290900003	26684069	Green Accepted			2021-06-18	
J	Chase, RP; Nevin, RL				Chase, Rachel P.; Nevin, Remington L.			Population Estimates of Undocumented Incident Traumatic Brain Injuries Among Combat-Deployed US Military Personnel	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Afghan war; Iraq war; late diagnosis; military; traumatic brain injury	IRAQ	Objective: To estimate the number of undocumented incident traumatic brain injuries (TBIs) among active component US military personnel serving in Iraq and Afghanistan prior to policy changes implemented in late 2006 and 2010 that improved TBI documentation. Methods: Negative binomial regression was used to model monthly incident TBI counts between December 2010 and June 2012 (N = 19) and then estimate expected monthly counts of incident TBIs during 2 periods: January 2003-October 2006 and November 2006-November 2010. Monthly amputation counts from Department of Defense surveillance data were used as a proxy for changing injury rates. Monthly active component deployment estimates derived from the Congressional Research Service, Brookings Institution, and Defense Manpower Data Center were used to estimate the size of the at-risk population each month. The difference between expected monthly incident TBI counts and reported counts is presented as the estimated number of undocumented incident TBIs. Results: The full model estimates that 21 257 active component military personnel experienced undocumented incident TBIs while deployed in Iraq or Afghanistan between January 2003 and October 2006, more than 4 times the 5272 incident TBIs documented during that period. Conclusions: A sizeable majority of Iraq and Afghanistan combat veterans who experienced incident TBI while deployed prior to November 2006 are likely to have had their injuries undocumented, creating challenges for clinical care, disability evaluation, and future research.	[Chase, Rachel P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Nevin, Remington L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA	Chase, RP (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	rachel.chase@jhu.edu		Nevin, Remington/0000-0002-0534-1889; Chase, Rachel/0000-0002-1503-4954			Ader Melissa, 2012, CASTING TROOPS ASIDE; *ARM FORC HLTH SUR, 2009, MED SURVEILLANCE MON, V16, P2; Armed Forces Health Surveillance Center, 2007, MED SURVEILL MON REP, V14, P30; Armed Forces Health Surveillance Center, 2010, MED SURVEILL MON REP, V17, P21; Armed Forces Health Surveillance Center, 2012, MED SURVEILL MON REP, V19, P24; Army Medical Surveillance Activity, 2005, MED SURVEILL MON REP, V11, P22; Auerbach D., 2013, HLTH CARE SPENDING E; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belasco A., 2011, COST IRAQ AFGHANISTA; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cameron KL, 2012, J NEUROTRAUM, V29, P1313, DOI 10.1089/neu.2011.2168; Casscells W, 2007, 0730 ASS SECR DEF HL; Center AFHS, 2010, MSMR, V17, P18; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Defense and Veterans Brain Injury Center, 2013, DOD WORLDW NUMB TRAU; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Edgar E., 2012, LOOK INSIDE CENTCOM; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Hampton T, 2011, JAMA-J AM MED ASSOC, V306, P477, DOI 10.1001/jama.2011.1092; Hicks MHR, 2011, AM J PSYCHIAT, V168, P341, DOI 10.1176/appi.ajp.2011.11010074; Kors J, 2007, NATION; Lechner R, 2010, UNFALLCHIRURG, V113, P106, DOI 10.1007/s00113-009-1732-9; Livingston IS, 2012, AFGHANISTAN INDEX AL; Lynn WJ, 2010, 0933 DEP SECR DEF; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Miller T.C., 2010, MILITARY STILL FAILI; Miller TC, 2010, SOLIDERS BRAIN TRAUM; Nevin RL, 2011, PSYCHIAT SERV, V62, P805, DOI 10.1176/ps.62.7.pss6207_0805a; O'Hanlon ME, 2011, IRAQ INDEX TRACKING; O'Neil C., 2012, CHANGING GUARD LOOK; Panangala SV, 2011, VETERANS AFFAIRS PRE; Rauh MJ, 2013, J REHABIL RES DEV, V50, P161, DOI 10.1682/JRRD.2011.11.0212; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rooney JA, 2012, OFFICE SECRETARY DEF; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1; Snethen B, 2010, ARMY HOSP SAVES TIME; United States Central Command (USCENTCOM), 2010, AMPL MIN STAND FITN; US Department of Veterans Affairs, 2009, VET BEN TIM INF VET; US Department of Veterans Affairs, 2013, FED REGISTER, V78, P76196; *US GOV ACC OFF, 2008, GAO08615; *US GOV ACC OFF, 2008, GAO08276; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wallace D, 2009, AUSTRALAS PSYCHIATRY, V17, P218, DOI 10.1080/10398560902878679; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wojcik BE, 2010, J DEF MODEL SIMUL-AP, V7, P157, DOI 10.1177/1548512910371083; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	47	26	26	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					E57	E64		10.1097/HTR.0000000000000061			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400007	24810487				2021-06-18	
J	Echemendia, RJ; Giza, CC; Kutcher, JS				Echemendia, Ruben J.; Giza, Christopher C.; Kutcher, Jeffrey S.			Developing guidelines for return to play: Consensus and evidence-based approaches	BRAIN INJURY			English	Article						Guidelines; mild traumatic brain injury; sports concussion	ASSOCIATION POSITION STATEMENT; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; CONCUSSION; SPORT; MANAGEMENT; SYMPTOMS; CONSCIOUSNESS	Background: Sports-related concussions are commonplace at all levels of play and across all age groups. The dynamic, evolving nature of this injury coupled with a lack of objective biomarkers creates a challenging management issue for the sports medicine team. Athletes who return to play following a concussion are known to be at higher risk for an additional brain injury, which necessitates a careful, informed return to play (RTP) process. Aim: The goal of this paper is to outline historical attempts at developing RTP guidelines and trace their evolution over time, culminating in a discussion of the process and outcomes of the most recent consensus statements/guidelines published by the international Concussion In Sport Group (CISG), the American Academy of Neurology (AAN), the National Athletic Trainers' Association, and the 2013 Team Physician Consensus Statement Update. Method: An evaluation of the pros and cons of these guidelines is presented along with suggestions for future directions. In addition, the Institute of Medicine recently conducted a comprehensive report outlining the current state of evidence regarding youth concussions, which provides specific recommendations for future research. Conclusions: The different methodologies utilized in the development of consensus statements have distinct advantages and disadvantages, and both approaches add value to the everyday management of sports concussions. Importantly, the overall approach for management of sports concussion is remarkably similar using either consensus-based or formal evidence-based methods, which adds confidence to the current guidelines and allows practitioners to focus on accepted standards of clinical care. Moving forward, careful study designs need to be utilized to avoid bias in selection of research subjects, collection of data, and interpretation of results. Although useful, clinicians must venture beyond consensus statements to examine reviews of the literature that are published in much greater frequency than consensus statements	[Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA 16801 USA; [Echemendia, Ruben J.] Univ Missouri, Univ Orthoped Comprehens Concuss Care, Kansas City, MO 64110 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Kutcher, Jeffrey S.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA	Echemendia, RJ (corresponding author), Psychol & Neurobehav Associates Inc, 204 East Calder Way,Ste 205, State Coll, PA 16801 USA.	echemendia@panba.com	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NCAA; DODUnited States Department of Defense; Joseph Drown Foundation; ElMindA, Ltd.	The authors report no conflicts of interest. Dr Echemendia serves as a consultant to the NHL, MLS and US Soccer Federation. He is on the Medical Advisory Board for BrainScope, but does not receive financial compensation. He is also a member of the NCAA Concussion Task Force and a member of the US Lacrosse Sports Science Safety Committee. He is involved in Medicolegal cases, primarily regarding brain injury. He was a member of the scientific organizing committee for CISG-IV. Dr Giza serves as a consultant NHL/NHLPA and NFL NCP. He is a member of the MLS Concussion Program Committee, NCAA Concussion Task Force and California State Athletic Commission. He receives research support from NINDS, NCAA, DOD and the Joseph Drown Foundation. He is involved in 1-2 Medicolegal cases annually. Dr Kutcher is the Director of NBA Concussion Program and serves as a consultant to the NHLPA and NFLPA. He is a member of the NCAA Concussion Task Force and receives research support from ElMindA, Ltd.	[Anonymous], 2013, MED SCI SPORT EXER, V45, P1618, DOI 10.1249/MSS.0b013e31829ba437; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], 2011, CLIN PRACTICE GUIDEL; [Anonymous], 2004, CLIN PRACTICE GUIDEL; Aubry M., 2002, BRIT J SPORT MED, V36, P3, DOI [DOI 10.1136/BJSM.36.1.6, 10.1136/bjsm.36.1.6]; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brown BB, 1968, DELPHI PROCESS, P1; Brown CN, 2003, J ATHL TRAINING, V38, pS; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Denny-Brown D, 1940, J PHYSL, V99, P2250; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2011, CLIN NEUROPSYCHOL, V25, P1289, DOI 10.1080/13854046.2011.618466; Erlanger D, 2001, J ATHL TRAINING, V36, P280; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Giza CC, 2013, NEUROLOGY, P1; Graham R., 2014, SPORTS RELATED CONCU; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011; Herring Stanley A, 2012, Med Sci Sports Exerc, V44, P2446, DOI 10.1249/MSS.0b013e3182750534; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS, 1982, NEUROBEHAVIORAL CONS, P221; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Report of the Sports Medicine Committee, 1990, GUID MAN CONC SPORTS; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SCIARRA D, 1984, MERRITTS TXB NEUROLO, P277; SMITH A, 1961, DIS NERV SYST, V22, P69; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X	48	26	27	0	37	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					185	194		10.3109/02699052.2014.965212			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500008	25587745				2021-06-18	
J	Gioia, GA				Gioia, Gerard A.			Multimodal evaluation and management of children with concussion: Using our heads and available evidence	BRAIN INJURY			English	Article						Assessment; concussion; children; mild traumatic brain injury; rehabilitation	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; COMPUTER-BASED ASSESSMENT; HIGH-SCHOOL; AGE SUBGROUPS; RECOMMENDATIONS; RECOVERY; SPECIFICITY; VALIDATION	Background: Significant attention has been focused on concussions in children, but a dearth of research evidence exists supporting clinical evaluation and management. Aim: The primary objective of this review paper is to describe a multimodal, developmentally adapted, standardized concussion assessment and active rehabilitation approach for children as young as 5 years old. Methods: This study reviews the CDC-funded research programme, including the development of tools for post-concussion symptom assessment involving the child and parent, measurement of specific neurocognitive functions and assessment of dynamic cognitive exertional effects. Results: A clinical approach to active, individualized, moderated concussion rehabilitation management is presented, including a 10-step guide to symptom management, with a specific focus on the school challenges faced by the recovering student. Conclusion: To better inform concussion practice across the developmental age spectrum, a significant need exists for further research evidence to refine clinical assessment methods and develop effective treatment approaches.	[Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Div Pediat Neuropsychol Childrens Natl Hlth Syst, Rockville, MD 20852 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat & Behav Med, Rockville, MD USA	Gioia, GA (corresponding author), George Washington Univ, Sch Med, Dept Pediat, Div Pediat Neuropsychol Childrens Natl Hlth Syst, Rockville, MD 20852 USA.	ggioia@childrensnational.org	Meijer, Anna/K-5118-2016		CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5-MOI-RR-020359-02]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	I declare that I am a co-author of the Acute Concussion Evaluation (ACE), Post-Concussion Symptom Inventories (PCSI), Multimodal Assessment of Cognition & Symptoms for Children (MACS), and Exertion Effects Rating Scale (EERS). The work reported in this paper was supported in part by grants from CDC no. U17/CCU323352-01 and NIH no. 5-MOI-RR-020359-02. I have received no financial remuneration for the development of the above tools.	Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; (CDC). National Center for Injury Prevention and Control, 2007, HEADS SCH KNOW YOUR; Chelune GJ, 2010, CLIN NEUROPSYCHOL, V24, P454, DOI 10.1080/13854040802360574; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Echemendia RJ, 2011, CLIN NEUROPSYCHOL, V25, P1289, DOI 10.1080/13854046.2011.618466; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fritz GK, 1996, J PEDIATR PSYCHOL, V21, P153, DOI 10.1093/jpepsy/21.2.153; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia G, 2011, J INT NEUROPSYCH SOC, V17, P134; Gioia G, 2006, J INT NEUROPSYCHO S1, V12, P39; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2012, PEDIATR ANN, V41, P198, DOI 10.3928/00904481-20120426-10; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Institute of Medicine's Committee on Sports-Related Concussions in Youth, 2013, SPORTS REL CONC YOUT; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Iverson GL, 2012, HDB SPORT NEUROPSYCH, P131; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Newman JB, 2013, CLIN NEUROPSYCHOL, V27, P779, DOI 10.1080/13854046.2013.789552; Ransom D, ACAD EFFECTS C UNPUB; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Riccio CA, 2001, ANN NY ACAD SCI, V931, P113; Riccio CA, 2001, J NEUROPSYCH CLIN N, V13, P326, DOI 10.1176/appi.neuropsych.13.3.326; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sady MD, 2013, J INT NEUROPSYCH SOC, V19, P194, DOI DOI 10.1017/S1355617713000362; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Wodka EL, 2008, CLIN NEUROPSYCHOL, V22, P826, DOI 10.1080/13854040701563583; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Youngwirth SD, 2007, CHILD NEUROPSYCHOL, V13, P422, DOI 10.1080/13825580601025890	57	26	26	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					195	206		10.3109/02699052.2014.965210			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500009	25356518	Green Accepted			2021-06-18	
J	Porro, C; Cianciulli, A; Calvello, R; Panaro, MA				Porro, Chiara; Cianciulli, Antonia; Calvello, Rosa; Panaro, Maria Antonietta			Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities	CURRENT PHARMACEUTICAL DESIGN			English	Article						Microglial cells; neuroinflammation; resveratrol	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; GROWTH-FACTOR-BETA; NIGRAL DOPAMINERGIC-NEURONS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE	Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a natural phytoalexin found in grape-skin, exerts multiple biological activities, including anti-inflammatory, antiproliferative and antioxidant effects. In the past few years, mounting evidence has suggested that resveratrol is neuroprotective against a number of neurological diseases. An important contributor to the pathogenesis of neurological disorders is neuroinflammation, of which microglial activation is an important hallmark. It is possible that M1/M2 polarization of microglia may play an important role in controlling the balance between promoting and resolving neuroinflammation in the CNS. Immunomodulatory strategies capable of redirecting the microglial response toward the neuroprotective M2 phenotype could offer attractive options for neurodegenerative diseases with inflammatory components. The neuroprotective actions of resveratrol seem to be attributable to its anti-inflammatory properties, due not only to its direct scavenger effects versus toxic molecules but also to a capacity to upregulate natural anti-inflammatory defences, thus counteracting excessive responses of classically activated M1 microglia. The goal of this review is to summarize recent insights into the therapeutic potential of resveratrol as a natural modulator of microglia-mediated neurotoxicity.	[Porro, Chiara] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy; [Cianciulli, Antonia; Calvello, Rosa; Panaro, Maria Antonietta] Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Via Orabona 4, I-70125 Bari, Italy	Panaro, MA (corresponding author), Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Via Orabona 4, I-70125 Bari, Italy.	mariaantonietta.panaro@uniba.it	Porro, Chiara/G-7849-2018	Porro, Chiara/0000-0002-7526-6968			Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amiot MJ, 2013, BIOCHIMIE, V95, P1233, DOI 10.1016/j.biochi.2013.01.008; Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025; Augustin MA, 2013, ANN NY ACAD SCI, V1290, P107, DOI 10.1111/nyas.12130; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Barton BE, 1996, INFECT IMMUN, V64, P714, DOI 10.1128/IAI.64.3.714-718.1996; Bayer C, 2013, J VIROL, V87, P67, DOI 10.1128/JVI.01585-12; Behrens MM, 2008, J NEUROSCI, V28, P13957, DOI 10.1523/JNEUROSCI.4457-08.2008; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bi XL, 2005, INT IMMUNOPHARMACOL, V5, P185, DOI 10.1016/j.intimp.2004.08.008; Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Bureau G, 2008, J NEUROSCI RES, V86, P403, DOI 10.1002/jnr.21503; Burkon A, 2008, MOL NUTR FOOD RES, V52, P549, DOI 10.1002/mnfr.200700290; Burton MD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-54; Candelario-Jalil E, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-25; Capiralla H, 2012, J NEUROCHEM, V120, P461, DOI 10.1111/j.1471-4159.2011.07594.x; Cardozo LFMF, 2013, BIOCHIMIE, V95, P1525, DOI 10.1016/j.biochi.2013.04.012; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Choi SH, 2003, J NEUROSCI, V23, P5877; Chung YC, 2010, BMB REP, V43, P225, DOI 10.5483/BMBRep.2010.43.4.225; Cianciulli A, 2015, INT IMMUNOPHARMACOL, V24, P369, DOI 10.1016/j.intimp.2014.12.035; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Constant JP, 2012, NEUROSCIENCE, V222, P333, DOI 10.1016/j.neuroscience.2012.06.067; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Dawn B, 2007, J MOL CELL CARDIOL, V42, P484, DOI 10.1016/j.yjmcc.2006.11.014; de Bilbao F, 2009, J NEUROCHEM, V110, P12, DOI 10.1111/j.1471-4159.2009.06098.x; De Simone R, 2004, MOL NEUROBIOL, V29, P197, DOI 10.1385/MN:29:2:197; Delmas D, 2011, ANN NY ACAD SCI, V1215, P48, DOI 10.1111/j.1749-6632.2010.05871.x; Doi Y, 2009, AM J PATHOL, V175, P2121, DOI 10.2353/ajpath.2009.090418; Dragone T, 2014, TOXICOL IN VITRO, V28, P1126, DOI 10.1016/j.tiv.2014.05.005; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Estrela JM, 2013, CRIT REV CL LAB SCI, V50, P65, DOI 10.3109/10408363.2013.805182; Farber K, 2006, GLIA, V54, P656, DOI 10.1002/glia.20412; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Gomez-Nicola D, 2010, GLIA, V58, P264, DOI 10.1002/glia.20920; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x; Griffiths MR, 2009, J NEUROPATH EXP NEUR, V68, P217, DOI 10.1097/NEN.0b013e3181996688; Guo Y, 2013, NEUROSCIENCE, V238, P1, DOI 10.1016/j.neuroscience.2013.01.047; Gutteridge J M, 1989, Baillieres Clin Haematol, V2, P195, DOI 10.1016/S0950-3536(89)80017-4; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; Haupt C, 2007, MOL CELL NEUROSCI, V35, P89, DOI 10.1016/j.mcn.2007.02.005; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hoffmann A, 2003, J NEUROSCI, V23, P4410; Hoozemans JJM, 2006, INT J DEV NEUROSCI, V24, P157, DOI 10.1016/j.ijdevneu.2005.11.001; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Huang TC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029102; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Hwang J, 2010, NEUROPHARMACOLOGY, V58, P1122, DOI 10.1016/j.neuropharm.2010.02.003; Izzi V, 2012, FRONT BIOSCI-LANDMRK, V17, P2396, DOI 10.2741/4061; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Juhasz B, 2010, CURR PHARM BIOTECHNO, V11, P810, DOI 10.2174/138920110793262079; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Karuppagounder SS, 2009, NEUROCHEM INT, V54, P111, DOI 10.1016/j.neuint.2008.10.008; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kesherwani V, 2013, NEUROSCIENCE, V241, P80, DOI 10.1016/j.neuroscience.2013.03.015; Kim SR, 2010, J NEUROSCI RES, V88, P1537, DOI 10.1002/jnr.22318; Kiyota T, 2012, GENE THER, V19, P724, DOI 10.1038/gt.2011.126; Kiyota T, 2010, FASEB J, V24, P3093, DOI 10.1096/fj.10-155317; Krakauer Teresa, 2004, Current Drug Targets - Inflammation and Allergy, V3, P317; Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lee CH, 2011, J NEUROL SCI, V300, P120, DOI 10.1016/j.jns.2010.09.005; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lim JY, 2010, EUR J PHARMACOL, V642, P10, DOI 10.1016/j.ejphar.2010.05.047; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lofrumento DD, 2014, INNATE IMMUN-LONDON, V20, P249, DOI 10.1177/1753425913488429; Lu JY, 2013, KIDNEY INT, V84, P745, DOI 10.1038/ki.2013.135; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Lu XF, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-46; Lund S, 2006, J NEUROIMMUNOL, V180, P71, DOI 10.1016/j.jneuroim.2006.07.007; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; Maher FO, 2005, NEUROBIOL AGING, V26, P717, DOI 10.1016/j.neurobiolaging.2004.07.002; Mandel S, 2003, TRENDS PHARMACOL SCI, V24, P184, DOI 10.1016/S0165-6147(03)00067-1; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Markus MA, 2008, CLIN INTERV AGING, V3, P331; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; MATTIVI F, 1993, Z LEBENSM UNTERS FOR, V196, P522, DOI 10.1007/BF01201331; McGeer PL, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00077; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Minghetti L, 2005, BRAIN RES REV, V48, P251, DOI 10.1016/j.brainresrev.2004.12.015; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Munoz L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-21; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Neves AR, 2013, INT J NANOMED, V8, P177, DOI 10.2147/IJN.S37840; Nimmagadda VK, 2013, J IMMUNOL, V190, P4595, DOI 10.4049/jimmunol.1202584; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; Nolan Y, 2005, J BIOL CHEM, V280, P9354, DOI 10.1074/jbc.M412170200; Nomura Y, 2001, LIFE SCI, V68, P1695, DOI 10.1016/S0024-3205(01)00967-5; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Orsu P, 2013, J NEURAL TRANSM, V120, P1217, DOI 10.1007/s00702-013-0982-4; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Panaro MA, 2012, CURR PHARM DESIGN, V18, P200; Park EJ, 2015, BBA-MOL BASIS DIS, V1852, P1071, DOI 10.1016/j.bbadis.2015.01.014; Park KW, 2007, EXP MOL MED, V39, P812, DOI 10.1038/emm.2007.88; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Pfister HW, 1997, CURR OPIN NEUROL, V10, P254, DOI 10.1097/00019052-199706000-00015; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Piotrowska H, 2012, MUTAT RES-REV MUTAT, V750, P60, DOI 10.1016/j.mrrev.2011.11.001; Pizzolato G, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00002; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Pratico D, 2004, J ALZHEIMERS DIS, V6, P171; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Qin HW, 2006, J IMMUNOL, V177, P7761, DOI 10.4049/jimmunol.177.11.7761; Rahman Arshad, 2011, Proc Am Thorac Soc, V8, P497, DOI 10.1513/pats.201101-009MW; Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004; Raivich G, 1999, ACTA NEUROCHIR SUPPL, V73, P21; Rajendrasozhan S, 2008, AM J RESP CRIT CARE, V177, P861, DOI 10.1164/rccm.200708-1269OC; Ramanan S, 2008, FREE RADICAL BIO MED, V45, P1695, DOI 10.1016/j.freeradbiomed.2008.09.002; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Richard KL, 2008, J NEUROSCI, V28, P5784, DOI 10.1523/JNEUROSCI.1146-08.2008; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Rubartelli A, 2007, TRENDS IMMUNOL, V28, P429, DOI 10.1016/j.it.2007.08.004; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Samavati L, 2008, J BIOL CHEM, V283, P21134, DOI 10.1074/jbc.M801954200; Scholtzova H, 2009, J NEUROSCI, V29, P1846, DOI 10.1523/JNEUROSCI.5715-08.2009; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Shastri A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/342931; Sheu JN, 2013, COMP IMMUNOL MICROB, V36, P137, DOI 10.1016/j.cimid.2012.11.002; Silva SL, 2012, NEUROPHARMACOLOGY, V62, P2398, DOI 10.1016/j.neuropharm.2012.02.002; Song J, 2014, INT J MOL SCI, V15, P15512, DOI 10.3390/ijms150915512; Souto Eliana B, 2013, Methods Mol Biol, V1028, P37, DOI 10.1007/978-1-62703-475-3_3; Spasic MR, 2009, NEUROSCIENTIST, V15, P309, DOI 10.1177/1073858408327805; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Stone DK, 2009, ANTIOXID REDOX SIGN, V11, P2151, DOI [10.1089/ars.2009.2460, 10.1089/ARS.2009.2460]; Strle K, 2001, CRIT REV IMMUNOL, V21, P427; Szczepanik AM, 2001, J NEUROIMMUNOL, V113, P49, DOI 10.1016/S0165-5728(00)00404-5; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tansey MG, 2008, FRONT BIOSCI-LANDMRK, V13, P709, DOI 10.2741/2713; Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325; Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004; Tsuda Y, 2011, EUR J PHARMACOL, V666, P189, DOI 10.1016/j.ejphar.2011.05.019; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vingtdeux V, 2011, FASEB J, V25, P219, DOI 10.1096/fj.10-167361; Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061; Vitrac X, 2003, LIFE SCI, V72, P2219, DOI 10.1016/S0024-3205(03)00096-1; Vivien D, 2006, CYTOKINE GROWTH F R, V17, P121, DOI 10.1016/j.cytogfr.2005.09.011; Vogel DYS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-35; Waddell SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009753; Walle T, 2011, ANN NY ACAD SCI, V1215, P9, DOI 10.1111/j.1749-6632.2010.05842.x; Wang J, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00042; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Weisser Shelley B, 2013, Methods Mol Biol, V946, P225, DOI 10.1007/978-1-62703-128-8_14; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; Williams LM, 2007, J BIOL CHEM, V282, P6965, DOI 10.1074/jbc.M609101200; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Xu XY, 2000, LIFE SCI, V67, P3221, DOI 10.1016/S0024-3205(00)00902-4; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yasuda S., 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P45; Ye JM, 2013, NEUROSCI LETT, V553, P72, DOI 10.1016/j.neulet.2013.08.020; Ye YX, 2012, INT IMMUNOPHARMACOL, V12, P384, DOI 10.1016/j.intimp.2011.12.011; Yet SF, 2003, FASEB J, V17, P1759, DOI 10.1096/fj.03-0187fje; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yoshizaki T, 2009, MOL CELL BIOL, V29, P1363, DOI 10.1128/MCB.00705-08; Zhang F, 2013, PHYTOTHER RES, V27, P344, DOI 10.1002/ptr.4734; Zhong LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032195; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	216	26	27	0	10	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2015	21	36					5277	5291		10.2174/1381612821666150928155612			15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CV8FW	WOS:000364517500011	26416082				2021-06-18	
J	Tal, S; Hadanny, A; Berkovitz, N; Sasson, E; Ben-Jacob, E; Efrati, S				Tal, Sigal; Hadanny, Amir; Berkovitz, Nadav; Sasson, Efrat; Ben-Jacob, Eshel; Efrati, Shai			Hyperbaric oxygen may induce angiogenesis in patients suffering from prolonged post-concussion syndrome due to traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Hyperbaric oxygen; angiogenesis; MRI; perfusion; cognitive; TBI; post concussion	HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES; MINOR HEAD-INJURY; STROKE; DAMAGE; RATS; NETWORKS; LANGUAGE; THERAPY; TRIAL	Purpose: Recent clinical studies present convincing evidence that hyperbaric oxygen therapy (HBOT) may be the coveted neurotherapeutic method for brain repair. One of the most interesting ways in which HBOT can induce neuroplasticity is angiogenesis. The objective in this study was to assess the neurotherapeutic effect of HBOT in post TBI patients using brain perfusion imaging and clinical cognitive functions. Methods: Retrospective analysis of patients suffering from chronic neuro-cognitive impairment from TBI treated with HBOT. The HBOT protocol included 60 daily HBOT sessions, 5 days per week. All patients had pre and post HBOT objective computerized cognitive tests (NeuroTrax) and brain perfusion MRI. Results: Ten post-TBI patients were treated with HBOT with mean of 10.3 +/- 3.2 years after their injury. After HBOT, whole-brain perfusion analysis showed significantly increased cerebral blood flow and cerebral blood volume. Clinically, HBOT induced significant improvement in the global cognitive scores (p = 0.007). The most prominent improvements were seen in information processing speed, visual spatial processing and motor skills indices. Conclusion: HBOT may induce cerebral angiogenesis, which improves perfusion to the chronic damage brain tissue even months to years after the injury.	[Hadanny, Amir; Efrati, Shai] Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-7030 Zerifin, Israel; [Tal, Sigal; Hadanny, Amir; Berkovitz, Nadav; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Tal, Sigal; Berkovitz, Nadav] Assaf Harofeh Med Ctr, Dept Radiol, IL-7030 Zerifin, Israel; [Sasson, Efrat] WiseImage, Hod Hasharon, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-7030 Zerifin, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Ben-Jacob, Eshel] Tel Aviv Univ, Sch Phys & Astron, Raymond & Beverly Sackler Fac Exact Sci, IL-69978 Tel Aviv, Israel	Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-7030 Zerifin, Israel.	efratishai@013.net					Achiron A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071058; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boussi-Gross R, 2015, NEUROPSYCHOLOGY, V29, P610, DOI 10.1037/neu0000149; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen ZQ, 2010, J MAGN RESON IMAGING, V31, P1054, DOI 10.1002/jmri.22142; Doniger GM, 2014, GUIDE NORMATIVE DATA; Duan SS, 2015, INT J NEUROSCI, V125, P625, DOI 10.3109/00207454.2014.956101; Dwolatzky Tzvi, 2003, BMC Geriatr, V3, P4, DOI 10.1186/1471-2318-3-4; Efrati S, 2014, UNDERSEA HYPERBAR M, V41, P71; Efrati S, 2014, EXPERT REV NEUROTHER, V14, P233, DOI 10.1586/14737175.2014.884928; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hadanny A. G. H., 2015, RESTORATIVE IN PRESS; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kim JS, 2005, NEUROLOGY, V64, P1438, DOI 10.1212/01.WNL.0000158656.09335.E7; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; KOCHANEK PM, 2007, BRAIN INJURY MED PRI, P81; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Melton J.L., 2005, PSYCHOMETRIC EVALUAT; Neubauer RA, 1998, NEUROL RES, V20, pS33; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; Peleg RK, 2013, DIVING HYPERB MED, V43, P218; Peng ZR, 2014, J NEUROL SCI, V342, P114, DOI 10.1016/j.jns.2014.04.037; Purves D., 2012, NEUROSCIENCE; Schweiger A., 2003, ACTA NEUROPSYCHOLOGI, V1, P407, DOI DOI 10.5604/17307503/9168; Simon O, 2004, NEUROIMAGE, V23, P1192, DOI 10.1016/j.neuroimage.2004.09.023; Simon O, 2002, NEURON, V33, P475, DOI 10.1016/S0896-6273(02)00575-5; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Thaler A, 2012, NEUROLOGY, V79, P1027, DOI 10.1212/WNL.0b013e3182684646; Timmann D, 2010, CORTEX, V46, P845, DOI 10.1016/j.cortex.2009.06.009; Urbanski M, 2008, J NEUROL NEUROSUR PS, V79, P598, DOI 10.1136/jnnp.2007.126276; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wolf EG, 2012, UNDERSEA HYPERBAR M, V39, P1075; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zur D, 2015, J NEURO-OPHTHALMOL, V35, P26, DOI 10.1097/WNO.0000000000000199	50	26	28	0	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2015	33	6					943	951		10.3233/RNN-150585			9	Neurosciences	Neurosciences & Neurology	DA1MU	WOS:000367560700012	26484702				2021-06-18	
J	Titus, DJ; Furones, C; Atkins, CM; Dietrich, WD				Titus, David J.; Furones, Concepcion; Atkins, Coleen M.; Dietrich, W. Dalton			Emergence of cognitive deficits after mild traumatic brain injury due to hyperthermia	EXPERIMENTAL NEUROLOGY			English	Article						Cognition; Concussion; Hyperthermia; Memory; Temperature; Traumatic brain injury	SPORT-RELATED CONCUSSION; WORKING-MEMORY DYSFUNCTION; FLUID PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; INTENSIVE-CARE-UNIT; SPINAL-CORD-INJURY; POSTTRAUMATIC HYPERTHERMIA; EXERCISE PERFORMANCE; FOOTBALL PLAYERS; COOLING METHODS	Mild elevations in core temperature can occur in individuals involved in strenuous activities that are risky for potentially sustaining a mild traumatic brain injury (mTBI) or concussion. Recently, we have discovered that mild elevations in brain temperature can significantly aggravate the histopathological consequences of mTBI. However, whether this exacerbation of brain pathology translates into behavioral deficits is unknown. Therefore, we investigated the behavioral consequences of elevating brain temperature to mildly hyperthermic levels prior to mTBI. Adult male Sprague Dawley rats underwent mild fluid-percussion brain injury or sham surgery while normothermic (37 degrees C) or hyperthermic (39 degrees C) and were allowed to recover for 7 days. Animals were then assessed for cognition using the water maze and cue and contextual fear conditioning. We found that mTBI alone at normothermia had no effect on long-term cognitive measures whereas mTBI animals that were hyperthermic for 15 min prior to and for 4 h after brain injury were significantly impaired on long-term retention for both the water maze and fear conditioning. In contrast, hyperthermic mTBI animals cooled within 15 min to normothermia demonstrated no significant long-term cognitive deficits. Mild TBI irrespective of temperature manipulations resulted in significant short-term working memory deficits. Cortical atrophy and contusions were detected in all mTBI treatment groups and contusion volume was significantly less in hyperthermic mTBI animals that were cooled as compared to hyperthermic mTBI animals that remained hyperthermic. These results indicate that brain temperature is an important variable for mTBI outcome and that mildly elevated temperatures at the time of injury result in persistent cognitive deficits. Importantly, cooling to normothermia after mTBI prevents the development of long-term cognitive deficits caused by hyperthermia. Reducing temperature to normothermic levels soon after mTBI represents a rational approach to potentially mitigate the long-term consequences of mTBI. (C) 2014 Elsevier Inc. All rights reserved.	[Titus, David J.; Furones, Concepcion; Atkins, Coleen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14 Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	National Football League Medical Charities; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [PT110767]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133] Funding Source: NIH RePORTER	This work was supported by the National Football League Medical Charities, US Army Medical Research and Materiel Command PT110767, and The Miami Project to Cure Paralysis. We thank Melissa Carballosa, Jonathan Mendoza, and Rosmery Santos for technical assistance.	Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090956; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Cadarette BS, 2001, AVIAT SPACE ENVIR MD, V72, P32; Campos F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078429; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cornelussen RNM, 2001, AM J PHYSIOL-HEART C, V280, pH1736; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; DeMartini JK, 2011, J STRENGTH COND RES, V25, P2065, DOI 10.1519/JSC.0b013e3182259b1d; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Goosey-Tolfrey V, 2008, J APPL PHYSIOL, V105, P37, DOI 10.1152/japplphysiol.01084.2007; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hermstad Erik, 2010, J Emerg Trauma Shock, V3, P66, DOI 10.4103/0974-2700.58660; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P1; Lin DW, 2011, NEUROPHARMACOLOGY, V61, P1354, DOI 10.1016/j.neuropharm.2011.08.011; Lingsma H., 2014, J NEUROTRAU IN PRESS; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Nybo L, 2008, J APPL PHYSIOL, V104, P871, DOI 10.1152/japplphysiol.00910.2007; Nybo L, 2012, EXP PHYSIOL, V97, P333, DOI 10.1113/expphysiol.2011.062273; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Sakurai A, 2012, J NEUROTRAUM, V29, P313, DOI 10.1089/neu.2011.2152; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Siegel R, 2012, SPORTS MED, V42, P89, DOI 10.2165/11596870-000000000-00000; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tomkins Oren, 2011, Cardiovasc Psychiatry Neurol, V2011, P765923, DOI 10.1155/2011/765923; Tyler C.J., 2013, BR J SPORTS MED; U.S. Army, 2003, DEP ARM AIR FORC TEC, P48; Uchimoto K, 2014, ANESTHESIOLOGY, V121, P302, DOI 10.1097/ALN.0000000000000269; Urdzikova L, 2006, SPINAL CORD, V44, P113, DOI 10.1038/sj.sc.3101792; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang CX, 2009, INT J STROKE, V4, P274, DOI 10.1111/j.1747-4949.2009.00317.x; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171	76	26	26	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2015	263						254	262		10.1016/j.expneurol.2014.10.020			9	Neurosciences	Neurosciences & Neurology	AX0EM	WOS:000346626100026	25447938	Green Accepted			2021-06-18	
J	Wells, TS; Seelig, AD; Ryan, MAK; Jones, JM; Hooper, TI; Jacobson, IG; Boyko, EJ				Wells, Timothy S.; Seelig, Amber D.; Ryan, Margaret A. K.; Jones, Jason M.; Hooper, Tomoko I.; Jacobson, Isabel G.; Boyko, Edward J.			Hearing loss associated with US military combat deployment	NOISE & HEALTH			English	Article						Combat disorders; hearing loss; military personnel	TRAUMATIC BRAIN-INJURY; MILLENNIUM COHORT; SERVICE MEMBERS; NATIONAL-HEALTH; IMPULSE NOISE; ADULTS; PERSONNEL; RISK; POPULATION; IMPAIRMENT	The objective of this study was to define the risk of hearing loss among US military members in relation to their deployment experiences. Data were drawn from the Millennium Cohort Study. Self-reported data and objective military service data were used to assess exposures and outcomes. Among all 48,540 participants, 7.5% self-reported new-onset hearing loss. Self-reported hearing loss showed moderate to substantial agreement (k = 0.57-0.69) with objective audiometric measures. New-onset hearing loss was associated with combat deployment (adjusted odds ratio [AOR] = 1.63, 95% confidence interval [CI] = 1.49-1.77), as well as male sex and older age. Among deployers, new-onset hearing loss was also associated with proximity to improvised explosive devices (AOR = 2.10, 95% CI = 1.62-2.73) and with experiencing a combat-related head injury (AOR = 6.88, 95% CI = 3.77-12.54). These findings have implications for health care and disability planning, as well as for prevention programs.	[Wells, Timothy S.] Adv Analyt Optum, Ann Arbor, MI USA; [Wells, Timothy S.] Adv Analyt Optum, San Diego, CA USA; [Seelig, Amber D.; Jacobson, Isabel G.] Naval Hlth Res Ctr, San Diego, CA USA; [Ryan, Margaret A. K.; Jones, Jason M.] Naval Hosp Camp Pendleton, San Diego, CA USA; [Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Seelig, Amber D.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA; [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA	Wells, TS (corresponding author), 1839 Waverly Rd, Holt, MI USA.	tmlbwells@wowway.com	Boyko, Edward J/G-2484-2017	Boyko, Edward J/0000-0002-3695-192X			Abel SM, 2008, AVIAT SPACE ENVIR MD, V79, P591, DOI 10.3357/ASEM.2262.2008; Agrawal Y, 2009, OTOL NEUROTOL, V30, P139, DOI 10.1097/MAO.0b013e318192483c; Boyko EJ, 2010, DIABETES CARE, V33, P1771, DOI 10.2337/dc10-0296; Casali JG, 2009, NOISE HEALTH, V11, P69, DOI 10.4103/1463-1741.48564; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Ferrite S, 2011, REV SAUDE PUBL, V45, P824, DOI 10.1590/S0034-89102011005000050; Geckle L., 2004, FORC HLTH PROT C ALB; Gray GC, 2002, MIL MED, V167, P483; Groenewold Matthew R., 2011, Morbidity and Mortality Weekly Report, V60, P955; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); Helfer TM, 2010, AM J PREV MED, V38, pS71, DOI 10.1016/j.amepre.2009.10.025; HENDERSON D, 1986, J ACOUST SOC AM, V80, P569, DOI 10.1121/1.394052; Hong OS, 2011, NURS RES, V60, P326, DOI 10.1097/NNR.0b013e3182281ca0; Humes LE, 2005, NOISE MILITARY SERVI; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LeardMann CA, 2007, HUM VACCINES, V3, P245, DOI 10.4161/hv.4589; Lee DJ, 1996, EPIDEMIOLOGY, V7, P443, DOI 10.1097/00001648-199607000-00019; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lin FR, 2012, JARO-J ASSOC RES OTO, V13, P109, DOI 10.1007/s10162-011-0298-8; Littman AJ, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-99; Mac Crawford J, 2008, J OCCUP ENVIRON MED, V50, P817, DOI 10.1097/JOM.0b013e31816a8caf; Mahboubi H, 2013, EUR ARCH OTO-RHINO-L, V270, P461, DOI 10.1007/s00405-012-1979-6; Mcllwain DS, 2008, AM J PUBLIC HEALTH, V98, P2167, DOI 10.2105/AJPH.2007.128504; Muhr P, 2006, INT J AUDIOL, V45, P247, DOI 10.1080/14992020500190052; Murphy WJ, 2012, INT J AUDIOL, V51, pS31, DOI 10.3109/14992027.2011.630330; Niebuhr DW, 2007, MIL MED, V172, P63, DOI 10.7205/MILMED.172.1.63; Nondahl DM, 1998, AUDIOLOGY, V37, P295; Paakkonen R, 2005, Noise Health, V7, P11; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Rovig GW, 2004, MIL MED, V169, P429, DOI 10.7205/MILMED.169.6.429; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Saunders GH, 2009, NOISE HEALTH, V11, P14, DOI 10.4103/1463-1741.45308; Sindhusake D, 2001, INT J EPIDEMIOL, V30, P1371, DOI 10.1093/ije/30.6.1371; Smith B, 2007, ANN EPIDEMIOL, V17, P976, DOI 10.1016/j.annepidem.2007.07.102; Smith B, 2007, AM J EPIDEMIOL, V166, P1345, DOI 10.1093/aje/kwm212; Smith B, 2007, AM J PREV MED, V32, P347, DOI 10.1016/j.amepre.2006.12.015; Smith TC, 2007, INT J ENVIRON HEAL R, V17, P271, DOI 10.1080/09603120701372243; Smith TC, 2007, ANN EPIDEMIOL, V17, P525, DOI 10.1016/j.annepidem.2006.12.002; Smith TC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-69; Starck J, 2003, Noise Health, V5, P63; Trost RP, 2007, MIL MED, V172, P426, DOI 10.7205/MILMED.172.4.426; US Government Accountability Office, 2011, HEAR LOSS PREV IMPR; VOIGT P, 1980, SCAND AUDIOL, P319; Vyskocil A, 2012, TOXICOL IND HEALTH, V28, P796, DOI 10.1177/0748233711425067; Wells TS, 2008, EUR J EPIDEMIOL, V23, P79, DOI 10.1007/s10654-007-9216-0	48	26	26	0	10	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1463-1741	1998-4030		NOISE HEALTH	Noise Health	JAN-FEB	2015	17	74					34	42		10.4103/1463-1741.149574			9	Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health	Audiology & Speech-Language Pathology; Public, Environmental & Occupational Health	AZ7EH	WOS:000348381200005	25599756	DOAJ Gold, Green Published			2021-06-18	
J	Chen, CC; Hung, TH; Lee, CY; Wang, LF; Wu, CH; Ke, CH; Chen, SF				Chen, Chien-Cheng; Hung, Tai-Ho; Lee, Chao Yu; Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu			Berberine Protects against Neuronal Damage via Suppression of Glia-Mediated Inflammation in Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; COPTIDIS-RHIZOMA EXTRACT; CEREBRAL-ISCHEMIA; INTESTINAL INJURY; TYROSINE KINASE; NERVOUS-SYSTEM; NITRIC-OXIDE; IN-VITRO; MICROGLIA; MICE	Traumatic brain injury (TBI) triggers a series of neuroinflammatory processes that contribute to evolution of neuronal injury. The present study investigated the neuroprotective effects and anti-inflammatory actions of berberine, an isoquinoline alkaloid, in both in vitro and in vivo TBI models. Mice subjected to controlled cortical impact injury were injected with berberine (10 mg.kg(-1)) or vehicle 10 min after injury. In addition to behavioral studies and histology analysis, blood-brain barrier (BBB) permeability and brain water content were determined. Expression of PI3K/Akt and Erk signaling and inflammatory mediators were also analyzed. The protective effect of berberine was also investigated in cultured neurons either subjected to stretch injury or exposed to conditioned media with activated microglia. Berberine significantly attenuated functional deficits and brain damage associated with TBI up to day 28 post-injury. Berberine also reduced neuronal death, apoptosis, BBB permeability, and brain edema at day 1 post-injury. These changes coincided with a marked reduction in leukocyte infiltration, microglial activation, matrix metalloproteinase-9 activity, and expression of inflammatory mediators. Berberine had no effect on Akt or Erk 1/2 phosphorylation. In mixed glial cultures, berberine reduced TLR4/MyD88/NF-kappa B signaling. Berberine also attenuated neuronal death induced by microglial conditioned media; however, it did not directly protect cultured neurons subjected to stretch injury. Moreover, administration of berberine at 3 h post-injury also reduced TBI-induced neuronal damage, apoptosis and inflammation in vivo. Berberine reduces TBI-induced brain damage by limiting the production of inflammatory mediators by glial cells, rather than by a direct neuroprotective effect.	[Chen, Chien-Cheng; Lee, Chao Yu; Ke, Chia-Hua; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Wang, Liang-Fei; Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan; [Wang, Liang-Fei; Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Chen, SF (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/ABD-1800-2020; Hung, Tai-Ho/C-7584-2011; WU, CHUN-HU/P-3958-2018	Hung, Tai-Ho/0000-0003-2354-7060; WU, CHUN-HU/0000-0001-6851-7936	National Science Council of Taiwan, R.O.C. (NSC)Ministry of Science and Technology, Taiwan [101-2314-B-350-001-MY3]; Cheng Hsin General Hospital	This work was supported by 1. SFC: Grants from the National Science Council of Taiwan, R.O.C. (NSC 101-2314-B-350-001-MY3); 2. SFC and CCC: Cheng Hsin General Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Amasheh M, 2010, J CELL SCI, V123, P4145, DOI 10.1242/jcs.070896; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Chai YS, 2013, EUR J PHARMACOL, V708, P44, DOI 10.1016/j.ejphar.2013.02.041; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Durairajan SSK, 2012, NEUROBIOL AGING, V33, P2903, DOI 10.1016/j.neurobiolaging.2012.02.016; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hu J, 2012, EUR J PHARMACOL, V674, P132, DOI 10.1016/j.ejphar.2011.11.014; Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x; Jia LY, 2012, J PHARM PHARMACOL, V64, P1510, DOI 10.1111/j.2042-7158.2012.01529.x; Jiang-Shieh YF, 2005, J NEUROSCI RES, V82, P515, DOI 10.1002/jnr.20663; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Kulkarni SK, 2010, PHYTOTHER RES, V24, P317, DOI 10.1002/ptr.2968; Li HM, 2011, ACTA PHARMACOL SIN, V32, P1364, DOI 10.1038/aps.2011.102; Liao YJ, 2013, NEW ENGL J MED, V368, P2014, DOI 10.1056/NEJMicm1205007; Lu DY, 2010, J CELL BIOCHEM, V110, P697, DOI 10.1002/jcb.22580; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Ma YY, 2004, NAT IMMUNOL, V5, P380, DOI 10.1038/ni1054; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Song B, 2012, CELL IMMUNOL, V276, P91, DOI 10.1016/j.cellimm.2012.04.006; Tan XS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077969; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Wang XL, 2005, AM J CHINESE MED, V33, P935, DOI 10.1142/S0192415X05003557; Wang XL, 2005, LIFE SCI, V77, P3058, DOI 10.1016/j.lfs.2005.02.033; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang YQ, 2009, CARDIOVASC RES, V82, P484, DOI 10.1093/cvr/cvp078; Zhang QA, 2011, FOOD CHEM TOXICOL, V49, P61, DOI 10.1016/j.fct.2010.09.032; Zhang XL, 2012, BRAIN RES, V1459, P61, DOI 10.1016/j.brainres.2012.03.065; Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008; Zhou XQ, 2008, NEUROSCI LETT, V447, P31, DOI 10.1016/j.neulet.2008.09.064; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	54	26	32	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2014	9	12							e115694	10.1371/journal.pone.0115694			30	Multidisciplinary Sciences	Science & Technology - Other Topics	AX7UN	WOS:000347120200055	25546475	DOAJ Gold, Green Published			2021-06-18	
J	Dekker, SE; Bambakidis, T; Sillesen, M; Liu, BL; Johnson, CN; Jin, G; Li, YQ; Alam, HB				Dekker, Simone E.; Bambakidis, Ted; Sillesen, Martin; Liu, Baoling; Johnson, Craig N.; Jin, Guang; Li, Yongqing; Alam, Hasan B.			Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	44th Annual Meeting of the Western-Trauma-Association	MAR 02-07, 2014	Steamboat Springs, CO	Western Trauma Assoc		Injury; brain; genes; apoptosis; hemorrhage; pigs	VALPROIC ACID; PRO-SURVIVAL; INFLAMMATION; APOPTOSIS; CELLS; IDENTIFICATION; ACETYLATION; ACTIVATION; INHIBITOR; PHENOTYPE	BACKGROUND: We have previously shown that addition of valproic acid (VPA; a histone deacetylase inhibitor) to hetastarch (Hextend [HEX]) resuscitation significantly decreases lesion size in a swine model of traumatic brain injury (TBI) and hemorrhagic shock (HS). However, the precise mechanisms have not been well defined. As VPA is a transcriptional modulator, the aim of this study was to investigate its effect on brain gene expression profiles. METHODS: Swine were subjected to controlled TBI and HS (40% blood volume), kept in shock for 2 hours, and resuscitated with HEX or HEX + VPA (n = 5 per group). Following 6 hours of observation, brain RNA was isolated, and gene expression profiles were measured using a Porcine Gene ST 1.1 microarray (Affymetrix, Santa Clara, CA). Pathway analysis was done using network analysis tools Gene Ontology, Ingenuity Pathway Analysis, and Parametric Gene Set Enrichment Analysis. Real-time polymerase chain reaction was used to verify the key microarray findings. RESULTS: A total of 1,668 probe sets mapping to 370 known genes were differentially expressed between the HEX and HEX + VPA groups. Expression of apoptotic genes differed between groups, and biologic function analysis predicted a significant downregulation of apoptosis (p = 1.29 x 10(-12)), cell death (p = 8.46 x 10(-12)), and necrosis (p = 9.07 x 10(-11)). Pathway analysis indicated a significant modulation of pathways involved in cell signaling, dendritic cell response, and the complement system. CONCLUSION: This is the first high-throughput analysis of cerebral gene profiling following TBI + HS. It shows that treatment with VPA significantly alters early transcription of pathways related to cell survival, which may explain its neuroprotective effects. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Dekker, Simone E.; Bambakidis, Ted; Liu, Baoling; Jin, Guang; Li, Yongqing; Alam, Hasan B.] Univ Michigan Hosp, Dept Surg, Ann Arbor, MI 48109 USA; [Dekker, Simone E.] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Inst Cardiovasc Res, Amsterdam, Netherlands; [Sillesen, Martin] Harvard Univ, Sch Med, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care,Massac, Boston, MA 02115 USA; [Sillesen, Martin] Copenhagen Univ Hosp, Dept Surg, Hillerod, Denmark; [Johnson, Craig N.] Univ Michigan, Biomed Res Core Facil, DNA Sequencing Core Lab, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Dept Surg, 2920 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Sillesen, Martin/0000-0001-9494-5475; Johnson, Craig/0000-0003-3955-7394			Affymetrix, 2008, GENECHIP 3 IVT EXPR; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Finkelstein RA, 2010, J SURG RES, V163, P146, DOI 10.1016/j.jss.2010.04.024; Gene Ontology, NEUR LIGHT POL ASS S; Gene Ontology, SIN OC HOM HOM 4 ASS; Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531; Holt SV, 2012, BRIT J CANCER, V106, P858, DOI 10.1038/bjc.2012.8; Ichiba T, 2003, BLOOD, V102, P763, DOI 10.1182/blood-2002-09-2748; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jin G, 2012, J TRAUMA ACUTE CARE, V73, P1461, DOI 10.1097/TA.0b013e3182782641; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Klintman D, 2005, ANN SURG, V242, P830, DOI 10.1097/01.sla.0000189132.86878.f7; Kochanek AR, 2012, J SURG RES, V176, P185, DOI 10.1016/j.jss.2011.06.007; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Li P, 2010, SCIENCE, V329, P85, DOI 10.1126/science.1188063; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Li YQ, 2012, SURGERY, V152, P455, DOI 10.1016/j.surg.2012.06.036; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Liu HL, 2014, BIOMED PHARMACOTHER, V68, P267, DOI 10.1016/j.biopha.2013.12.003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manson J, 2012, BRIT J SURG, V99, P12, DOI 10.1002/bjs.7717; McLachlan JL, 2005, BBA-MOL BASIS DIS, V1741, P271, DOI 10.1016/j.bbadis.2005.03.007; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Ritchie ME, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-261; Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P1, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Suganuma T, 2012, J MOL CELL BIOL, V4, P348, DOI 10.1093/jmcb/mjs043; Wang ZW, 2012, ONCOTARGET, V3, P1294; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	36	26	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2014	77	6					906	912		10.1097/TA.0000000000000345			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AU8EE	WOS:000345828500027	25051383				2021-06-18	
J	Joseph, B; Aziz, H; Pandit, V; Kulvatunyou, N; Sadoun, M; Tang, A; O'Keeffe, T; Gries, L; Green, DJ; Friese, RS; Lemole, MG; Rhee, P				Joseph, Bellal; Aziz, Hassan; Pandit, Viraj; Kulvatunyou, Narong; Sadoun, Moutamn; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Lemole, Michael G., Jr.; Rhee, Peter			Prospective validation of the brain injury guidelines: Managing traumatic brain injury without neurosurgical consultation	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	44th Annual Meeting of the Western-Trauma-Association	MAR 02-07, 2014	Steamboat Springs, CO	Western Trauma Assoc		Management of traumatic brain injury; neurosurgical consultation; brain injury guidelines; neurosurgical intervention; acute care surgeons	HEAD COMPUTED-TOMOGRAPHY; MANAGEMENT; MILD; CARE; COAGULOPATHY; UTILITY	BACKGROUND: To optimize neurosurgical resources, guidelines were developed at our institution, allowing the acute care surgeons to independently manage traumatic intracranial hemorrhage less than or equal to 4 mm. The aim of our study was to evaluate our established Brain Injury Guidelines (BIG 1 category) for managing patients with traumatic brain injury (TBI) without neurosurgical consultation. METHODS: We formulated the BIG based on a 4-year retrospective chart review of all TBI patients presenting at our Level 1 trauma center. We then prospectively implemented our BIG 1 category to identify TBI patients that were to be managed without neurosurgical consultation (No-NC). Propensity scoring matched patients with No-NC to a similar cohort of patients managed with NC before the implementation of our BIG in a 1:1 ratio for demographics, severity of injury, and type and size of intracranial hemorrhage. Primary outcome measure was need for neurosurgical intervention and 30-day readmission rates. RESULTS: A total of 254 TBI patients (127 of NC and 127 of No-NC patients) were included in the analysis. The mean (SD) age was 40.8 (22.7) years, 63.4% (n = 161) were male, median Glasgow Coma Scale (GCS) score was 15 (range, 13-15), and median head Abbreviated Injury Scale (AIS) score was 2 (range, 2-3). There was no neurosurgical intervention or 30-day readmission in both the groups. In the No-NC group, 3.9% of the patients had postdischarge emergency department visits compared with 4.7% of the NC group (p = 0.5). All patients were discharged home from the emergency department. CONCLUSION: We validated our BIG and demonstrated that acute care surgeons can effectively care for minimally injured TBI patients with good outcomes. Anational multi-institutional prospective evaluation is warranted. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Aziz, Hassan; Pandit, Viraj; Kulvatunyou, Narong; Sadoun, Moutamn; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Lemole, Michael G., Jr.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Emergency Surg Crit Care & Burns, Med Ctr, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Aziz H, 2013, J TRAUMA ACUTE CARE, V75, P550, DOI 10.1097/TA.0b013e3182a53a77; Barker DE, 2006, AM SURGEON, V72, P1166; Borczuk P, 2013, J TRAUMA ACUTE CARE, V74, P1504, DOI 10.1097/TA.0b013e31829215cf; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Huynh T, 2006, AM SURGEON, V72, P1162; Injury Prevention and Control, INJ PREV CONTR TRAUM; Joseph B, 2014, J AM COLL SURGEONS, V219, P45, DOI 10.1016/j.jamcollsurg.2013.12.062; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P965, DOI 10.1097/TA.0000000000000161; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P121, DOI 10.1097/TA.0b013e3182a9cc95; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; Rhodes M, 1993, J TRAUMA, V35, P979; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e	16	26	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2014	77	6					984	988		10.1097/TA.0000000000000428			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AU8EE	WOS:000345828500043	25423541				2021-06-18	
J	Lu, HZ; Liu, PY; Yezhuvath, U; Cheng, YM; Marshall, O; Ge, YL				Lu, Hanzhang; Liu, Peiying; Yezhuvath, Uma; Cheng, Yamei; Marshall, Olga; Ge, Yulin			MRI Mapping of Cerebrovascular Reactivity via Gas Inhalation Challenges	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Medicine; Issue 94; Cerebrovascular reactivity; cerebrovascular diseases; MRI-compatible gas delivery systems; hypercapnia; hyperoxia; CO2; O-2	CEREBRAL-BLOOD-FLOW; LEVEL-DEPENDENT MRI; CARBON-DIOXIDE; OXYGEN; HYPERCAPNIA; RESPONSES; DISEASE; CO2	The brain is a spatially heterogeneous and temporally dynamic organ, with different regions requiring different amount of blood supply at different time. Therefore, the ability of the blood vessels to dilate or constrict, known as Cerebral-Vascular-Reactivity (CVR), represents an important domain of vascular function. An imaging marker representing this dynamic property will provide new information of cerebral vessels under normal and diseased conditions such as stroke, dementia, atherosclerosis, small vessel diseases, brain tumor, traumatic brain injury, and multiple sclerosis. In order to perform this type of measurement in humans, it is necessary to deliver a vasoactive stimulus such as CO2 and/or O-2 gas mixture while quantitative brain magnetic resonance images (MRI) are being collected. In this work, we presented a MR compatible gas-delivery system and the associated protocol that allow the delivery of special gas mixtures (e.g., O-2, CO2, N-2, and their combinations) while the subject is lying inside the MRI scanner. This system is relatively simple, economical, and easy to use, and the experimental protocol allows accurate mapping of CVR in both healthy volunteers and patients with neurological disorders. This approach has the potential to be used in broad clinical applications and in better understanding of brain vascular pathophysiology. In the video, we demonstrate how to set up the system inside an MRI suite and how to perform a complete experiment on a human participant.	[Lu, Hanzhang; Liu, Peiying; Yezhuvath, Uma; Cheng, Yamei] Univ Texas Southwestern Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Marshall, Olga; Ge, Yulin] NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, New York, NY 10003 USA	Lu, HZ (corresponding author), Univ Texas Southwestern Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75390 USA.	hanzhang.lu@utsouthwestern.edu	Ge, Yulin/L-7052-2019; Liu, Peiying/D-7512-2017; Ge, Yulin/D-9060-2019	Liu, Peiying/0000-0003-0830-5960; Ge, Yulin/0000-0002-2320-6031	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH084021, R01 NS067015, R01 AG042753, NS076588, NS029029-20S1, R21 NS078656]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4707A2]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076588, R01NS067015, R37NS029029, R21NS078656, R01NS029029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042753] Funding Source: NIH RePORTER	This work was partly supported by grants from the National Institutes of Health (NIH), under grant numbers R01 MH084021, R01 NS067015, R01 AG042753, NS076588, NS029029-20S1, R21 NS078656; and from National Multiple Sclerosis Society, under grant number of RG4707A2.	Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Bright MG, 2011, J CEREBR BLOOD F MET, V31, P426, DOI 10.1038/jcbfm.2010.187; ELLINGSEN I, 1987, ACTA PHYSIOL SCAND, V129, P157, DOI 10.1111/j.1748-1716.1987.tb08054.x; GREENBERG SM, 2006, NEW ENGL J MED, V354, P1451, DOI DOI 10.1056/NEJMP068043; Han JS, 2008, NAT CLIN PRACT NEURO, V4, P628, DOI 10.1038/ncpneuro0918; Hsu YY, 2004, J MAGN RESON IMAGING, V19, P160, DOI 10.1002/jmri.10447; Ide Kojiro, 2003, Journal of Applied Physiology, V95, P129; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Krainik A, 2005, STROKE, V36, P1146, DOI 10.1161/01.STR.0000166178.40973.a7; Liu PY, 2013, HUM BRAIN MAPP, V34, P2078, DOI 10.1002/hbm.22053; Liu PY, 2013, NEUROIMAGE, V78, P415, DOI 10.1016/j.neuroimage.2013.04.053; Lu H, 2003, MAGNET RESON MED, V50, P263, DOI 10.1002/mrm.10519; Lu HZ, 2011, CEREB CORTEX, V21, P1426, DOI 10.1093/cercor/bhq224; Mandell DM, 2008, STROKE, V39, P2021, DOI 10.1161/STROKEAHA.107.506709; Marshall O., 2014, JAMA NEUROL IN PRESS; Mikulis DJ, 2005, J NEUROSURG, V103, P347, DOI 10.3171/jns.2005.103.2.0347; Rostrup E, 2000, NEUROIMAGE, V11, P87, DOI 10.1006/nimg.1999.0526; Slessarev M, 2007, J PHYSIOL-LONDON, V581, P1207, DOI 10.1113/jphysiol.2007.129395; Thesen T, 2012, HUM BRAIN MAPP, V33, P715, DOI 10.1002/hbm.21242; Thomas BP, 2013, J MAGN RESON IMAGING, V38, P1177, DOI 10.1002/jmri.24090; van der Zande FHR, 2005, NEURORADIOLOGY, V47, P114, DOI 10.1007/s00234-004-1274-3; Wise RG, 2007, J CEREBR BLOOD F MET, V27, P1521, DOI 10.1038/sj.jcbfm.9600465; Xie AL, 2005, AM J RESP CRIT CARE, V172, P371, DOI 10.1164/rccm.200406-807OC; Xu F, 2011, J CEREBR BLOOD F MET, V31, P58, DOI 10.1038/jcbfm.2010.153; Yezhuvath US, 2012, NEUROBIOL AGING, V33, P75, DOI 10.1016/j.neurobiolaging.2010.02.005; Yezhuvath US, 2009, NMR BIOMED, V22, P779, DOI 10.1002/nbm.1392; Zappe AC, 2008, CEREB CORTEX, V18, P2666, DOI 10.1093/cercor/bhn023	28	26	26	0	4	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	DEC	2014		94							e52306	10.3791/52306			9	Multidisciplinary Sciences	Science & Technology - Other Topics	CB1AE	WOS:000349358000064	25549106	Green Published, Bronze			2021-06-18	
J	Majdan, M; Lingsma, HF; Nieboer, D; Mauritz, W; Rusnak, M; Steyerberg, EW				Majdan, Marek; Lingsma, Hester F.; Nieboer, Daan; Mauritz, Walter; Rusnak, Martin; Steyerberg, Ewout W.			Performance of IMPACT, CRASH and Nijmegen models in predicting six month outcome of patients with severe or moderate TBI: an external validation study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Prognostic model; External validation; Traumatic brain injury; Outcome prediction	TRAUMATIC BRAIN-INJURY; PROGNOSTIC MODELS; INTERNATIONAL MISSION; EPIDEMIOLOGY; PROGRESS	Background: External validation on different TBI populations is important in order to assess the generalizability of prognostic models to different settings. We aimed to externally validate recently developed models for prediction of six month unfavourable outcome and six month mortality. Methods: The International Neurotrauma Research Organization - Prehospital dataset (INRO-PH) was collected within an observational study between 2009-2012 in Austria and includes 778 patients with TBI of GCS < = 12. Three sets of prognostic models were externally validated: the IMPACT core and extended models, CRASH basic models and the Nijmegen models developed by Jacobs et al - all for prediction of six month unfavourable outcome and six month mortality. The external validity of the models was assessed by discrimination (Area Under the receiver operating characteristic Curve, AUC) and calibration (calibration statistics and plots). Results: Median age in the validation cohort was 50 years and 44% had an admission GSC motor score of 1-3. Six-month mortality was 27%. Mortality could better be predicted (AUCs around 0.85) than unfavourable outcome (AUCs around 0.80). Calibration plots showed that the observed outcomes were systematically better than was predicted for all models considered. The best performance was noted for the original Nijmegen model, but refitting led to similar performance for the IMPACT Extended, CRASH Basic, and Nijmegen models. Conclusions: In conclusion, all the prognostic models we validated in this study possess good discriminative ability for prediction of six month outcome in patients with moderate or severe TBI but outcomes were systemically better than predicted. After adjustment for this under prediction in locally adapted models, these may well be used for recent TBI patients.	[Majdan, Marek; Rusnak, Martin] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava 91701, Slovakia; [Majdan, Marek; Mauritz, Walter; Rusnak, Martin] INRO, A-1080 Vienna, Austria; [Lingsma, Hester F.; Nieboer, Daan; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3015 CE Rotterdam, Netherlands	Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.	mmajdan@igeh.org	Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042	Austrian Ministry of Health; Austrian Worker's Compensation Board (AUVA) [FK 11/2008, FK 11/2010]; AUVA [FK 09/13]; Trnava University [12/TU/13]; European Union Seventh Framework Programme (FP7) [602150]	The project was funded jointly by the Austrian Ministry of Health (Contract Oct. 15, 2008) and by the Austrian Worker's Compensation Board (AUVA; FK 11/2008 and FK 11/2010). Data analysis was supported by a grant from AUVA (FK 09/13). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources. The work of Marek Majdan on this paper was supported by an institutional grant from the Trnava University, No. 12/TU/13. The validation study and the preparation of this paper has been partly done within the CENTER-TBI project that has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602150.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Franschman G, 2012, INJURY, V43, P1838, DOI 10.1016/j.injury.2012.05.020; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; LINGSMA H, 2013, TRAUMA ACUTE CARE SU, V74, P639; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165	19	26	26	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	NOV 19	2014	22								68	10.1186/s13049-014-0068-9			10	Emergency Medicine	Emergency Medicine	AX3YF	WOS:000346870900001	25406964	DOAJ Gold, Green Published			2021-06-18	
J	Johnstone, VPA; Shultz, SR; Yan, EB; O'Brien, TJ; Rajan, R				Johnstone, Victoria P. A.; Shultz, Sandy R.; Yan, Edwin B.; O'Brien, Terence J.; Rajan, Ramesh			The Acute Phase of Mild Traumatic Brain Injury Is Characterized by a Distance-Dependent Neuronal Hypoactivity	JOURNAL OF NEUROTRAUMA			English	Article						barrel cortex; electrophysiology; hypoexcitability; mild TBI; neuronal encoding; sensory cortex	LATERAL FLUID-PERCUSSION; RAT BARREL CORTEX; CONTROLLED CORTICAL IMPACT; SPREADING DEPRESSION; POSTTRAUMATIC EPILEPSY; WHISKER VIBRATION; HIPPOCAMPAL CA1; AXONAL INJURY; ANIMAL-MODEL; NEUROINFLAMMATION	The consequences of mild traumatic brain injury (TBI) on neuronal functionality are only now being elucidated. We have now examined the changes in sensory encoding in the whisker-recipient barrel cortex and the brain tissue damage in the acute phase (24 h) after induction of TBI (n = 9), with sham controls receiving surgery only (n = 5). Injury was induced using the lateral fluid percussion injury method, which causes a mixture of focal and diffuse brain injury. Both population and single cell neuronal responses evoked by both simple and complex whisker stimuli revealed a suppression of activity that decreased with distance from the locus of injury both within a hemisphere and across hemispheres, with a greater extent of hypoactivity in ipsilateral barrel cortex compared with contralateral cortex. This was coupled with an increase in spontaneous output in Layer 5a, but only ipsilateral to the injury site. There was also disruption of axonal integrity in various regions in the ipsilateral but not contralateral hemisphere. These results complement our previous findings after mild diffuse-only TBI induced by the weight-drop impact acceleration method where, in the same acute post-injury phase, we found a similar depth-dependent hypoactivity in sensory cortex. This suggests a common sequelae of events in both diffuse TBI and mixed focal/diffuse TBI in the immediate post-injury period that then evolve over time to produce different long-term functional outcomes.	[Johnstone, Victoria P. A.; Yan, Edwin B.; Rajan, Ramesh] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Shultz, Sandy R.; O'Brien, Terence J.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne Brain Ctr, Parkville, Vic 3052, Australia	Rajan, R (corresponding author), Monash Univ, Dept Physiol, Wellington Rd, Melbourne, Vic 3800, Australia.	ramesh.rajan@monash.edu	rajan, ramesh/L-4842-2019; Johnstone, Victoria/B-5083-2015	Johnstone, Victoria/0000-0001-9885-3607; Shultz, Sandy/0000-0002-2525-8775; Rajan, Ramesh/0000-0001-9862-0520; O'Brien, Terence/0000-0002-7198-8621	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP1029311, APP1006077]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This work was supported by the National Health and Medical Research Council of Australia (grant numbers APP1029311, APP1006077) and a research fellowship from the Canadian Institutes of Health Research.	Aitken PG, 1998, J NEUROPHYSIOL, V80, P1514; Akasu T, 2002, NEUROSCI LETT, V329, P305, DOI 10.1016/S0304-3940(02)00707-3; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Alwis DS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00124; Alwis DS, 2013, CLIN EXP PHARMACOL P, V40, P473, DOI 10.1111/1440-1681.12100; Alwis DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052169; Arabzadeh E, 2004, J NEUROSCI, V24, P6011, DOI 10.1523/JNEUROSCI.1389-04.2004; Arabzadeh E, 2003, J NEUROSCI, V23, P9146; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Brands D.W.A., 2002, THESIS TU EINDHOVEN; Brecht M, 2002, J PHYSIOL-LONDON, V543, P49, DOI 10.1113/jphysiol.2002.018465; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hartmann MJ, 2003, J NEUROSCI, V23, P6510; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRERAS O, 1993, BRAIN RES, V610, P276, DOI 10.1016/0006-8993(93)91411-K; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Johnstone VPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063454; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kao T, 2011, J NEUROPHYSIOL, V106, P2662, DOI 10.1152/jn.01017.2010; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KORALEK KA, 1988, BRAIN RES, V463, P346, DOI 10.1016/0006-8993(88)90408-8; Lamy M, 2013, MED BIOL ENG COMPUT, V51, P353, DOI 10.1007/s11517-012-1004-7; Leblanc Kim Edward, 1999, Comprehensive Therapy, V25, P39, DOI 10.1007/BF02889833; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Lubke J, 2003, CEREB CORTEX, V13, P1051, DOI 10.1093/cercor/13.10.1051; Mao HJ, 2011, J MECH MED BIOL, V11, P1199, DOI 10.1142/S021951941100423X; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer HS, 2011, P NATL ACAD SCI USA, V108, P16807, DOI 10.1073/pnas.1113648108; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Mulders WHAM, 2009, NEUROSCIENCE, V164, P733, DOI 10.1016/j.neuroscience.2009.08.036; Murray CJL., 1996, GLOBAL HLTH STAT COM; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; Petersen C. C., 2009, ENCY NEUROSCIENCE, V10, P41; Pinto DJ, 2000, J NEUROPHYSIOL, V83, P1158; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rajan R, 2007, EUR J NEUROSCI, V25, P2383, DOI 10.1111/j.1460-9568.2007.05481.x; Rajan R, 2006, J NEUROSCI METH, V157, P103, DOI 10.1016/j.jneumeth.2006.04.008; Ritt JT, 2008, NEURON, V57, P599, DOI 10.1016/j.neuron.2007.12.024; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Theriot JJ, 2012, J NEUROSCI, V32, P15252, DOI 10.1523/JNEUROSCI.2092-12.2012; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; WEISS JH, 1990, NEUROLOGY, V40, P1288, DOI 10.1212/WNL.40.8.1288; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yan EB, 2013, NEUROSCIENCE, V248, P17, DOI 10.1016/j.neuroscience.2013.05.045; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	85	26	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1881	1895		10.1089/neu.2014.3343			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400007	24927383	Green Published			2021-06-18	
J	Lv, QS; Lan, WY; Sun, WS; Ye, RD; Fan, XB; Ma, MM; Yin, Q; Jiang, YJ; Xu, GL; Dai, JW; Guo, RB; Liu, XF				Lv, Qiushi; Lan, Wenya; Sun, Wenshan; Ye, Ruidong; Fan, Xiaobing; Ma, Minmin; Yin, Qin; Jiang, Yongjun; Xu, Gelin; Dai, Jianwu; Guo, Ruibing; Liu, Xinfeng			Intranasal nerve growth factor attenuates tau phosphorylation in brain after traumatic brain injury in rats	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Nerve growth factor; Tau; Intranasal; GSK-3 beta; IL-1 beta	NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; A-BETA; MICE; NEURODEGENERATION; PATHOLOGY; ACCUMULATION; DELIVERY; NEURONS; IMPACT	Traumatic brain injury (TBI) is a considerable cause of mild cognitive impairment and dementia. Intranasal administration of nerve growth factor (NGF) has previously been found to improve cognitive function after TBI, but the mechanism remains unclear. This study aimed to investigate the effects of intranasal NGF on the tau hyperphosphorylation following TBI. A modified Feeney's weight-drop model was used to induce TBI. Rats were randomly divided into control group, TBI group, TBI + NGF group, TBI + PDTC group and TBI + IL-1ra group. Rats in TBI + NGF group were administered with NGF (5 mu g/d) for 3 d before surgery. Hyperphosphorylated tau protein was remarkable in the peri-contusional cortex area with TBI. Both western blotting and immunostaining results displayed intranasal pretreatment of NGF significantly reduced tau phosphorylation. To evaluate the underlying mechanism, the levels of glycogen synthase kinase 3 beta (GSK-3 beta), interleukin-1 beta (IL-1 beta), and the DNA binding activity of nuclear factor-kappa B (NF-kappa B) were assayed. NGF markedly inhibited GSK-3 beta. NGF also reduced TBI-induced elevation of IL-1 beta and NF-kappa B DNA binding activity. Furthermore, PDTC and IL-1ra were injected to prove a potential signaling pathway among NF-kappa B, IL-1 beta and GSK-3 beta. Taken together, these findings demonstrated that intranasal NGF could effectively attenuate the hyperphosphorylation of tau after TBI, which might involve an integrated signaling pathway related to NF-kappa B. (C) 2014 Published by Elsevier B.V.	[Lv, Qiushi; Lan, Wenya; Sun, Wenshan; Ye, Ruidong; Fan, Xiaobing; Ma, Minmin; Yin, Qin; Jiang, Yongjun; Xu, Gelin; Guo, Ruibing; Liu, Xinfeng] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China; [Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China	Guo, RB (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China.	grb1995@163.com; xfliu2@viop.163.com		Xu, Gelin/0000-0002-6194-0341	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31171016, 31100784, 31200817]; Jinling Hospital Foundation [2012005]	This work was supported by the grant from National Natural Science Foundation of China (#31171016, 31100784 and 31200817) and Jinling Hospital Foundation (#2012005).	Albeck D, 2003, BRAIN RES, V967, P306, DOI 10.1016/S0006-8993(03)02272-8; Calissano P, 2010, DEV NEUROBIOL, V70, P372, DOI 10.1002/dneu.20759; Capsoni S, 2002, P NATL ACAD SCI USA, V99, P12432, DOI 10.1073/pnas.192442999; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; DEGARCINI EM, 1986, BIOCHEM BIOPH RES CO, V141, P790, DOI 10.1016/S0006-291X(86)80242-X; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Fan Xin-ying, 2012, Zhonghua Yi Xue Za Zhi, V92, P2366; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Guo R, 2012, J MED POSTGRAD, V5, P471; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jiang Y, 2011, NEUROSCIENCE, V172, P398, DOI 10.1016/j.neuroscience.2010.10.054; Jiang YJ, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/372423; Jiang YJ, 2011, EXPERT OPIN DRUG DEL, V8, P623, DOI 10.1517/17425247.2011.566267; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li YK, 2003, J NEUROSCI, V23, P1605; Liu XF, 2001, J NEUROL SCI, V187, P91, DOI 10.1016/S0022-510X(01)00532-9; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Lv QS, 2013, BRAIN RES, V1493, P80, DOI 10.1016/j.brainres.2012.11.028; Mandelkow E, 2007, BRAIN PATHOL, V17, P83, DOI 10.1111/j.1750-3639.2007.00053.x; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medeiros R, 2011, CNS NEUROSCI THER, V17, P514, DOI 10.1111/j.1755-5949.2010.00177.x; Metcalfe MJ, 2010, MT SINAI J MED, V77, P50, DOI 10.1002/msj.20163; Obulesu M, 2011, NEUROCHEM RES, V36, P1329, DOI 10.1007/s11064-011-0475-5; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Vossel KA, 2010, SCIENCE, V330, P198, DOI 10.1126/science.1194653; Williams BJ, 2006, PROG NEUROBIOL, V80, P114, DOI 10.1016/j.pneurobio.2006.09.001; Yamaguchi H, 1996, ACTA NEUROPATHOL, V92, P232, DOI 10.1007/s004010050513; Ye R, 2011, NEUROSCIENCE, V178, P169, DOI 10.1016/j.neuroscience.2011.01.007; Ye RD, 2012, CRIT CARE MED, V40, P2685, DOI 10.1097/CCM.0b013e318258fb90; Ye X, 2011, NEUROSCIENCE, V190, P339, DOI 10.1016/j.neuroscience.2011.06.004; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Zhu J, 2012, NEUROSCIENCE, V202, P342, DOI 10.1016/j.neuroscience.2011.11.070	44	26	27	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2014	345	1-2					48	55		10.1016/j.jns.2014.06.037			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AR6JJ	WOS:000343689600007	25128470				2021-06-18	
J	Stratton, KJ; Clark, SL; Hawn, SE; Amstadter, AB; Cifu, DX; Walker, WC				Stratton, Kelcey J.; Clark, Shaunna L.; Hawn, Sage E.; Amstadter, Ananda B.; Cifu, David X.; Walker, William C.			Longitudinal Interactions of Pain and Posttraumatic Stress Disorder Symptoms in US Military Service Members Following Blast Exposure	JOURNAL OF PAIN			English	Article						Chronic pain; stress disorders; posttraumatic; military personnel; blast injuries; longitudinal studies	TRAUMATIC BRAIN-INJURY; PREVALENCE; VETERANS; COMORBIDITY; AFGHANISTAN; IRAQ; DEPRESSION; PTSD; RESILIENCE; GENDER	Military personnel returning from conflicts in Iraq and Afghanistan often endorse pain and posttraumatic stress disorder (PTSD) symptoms, either separately or concurrently. Associations between pain and PTSD symptoms may be further complicated by blast exposure from explosive munitions. Although many studies have reported on the prevalence and disability associated with polytraumatic injuries following combat, less is known about symptom maintenance over time. Accordingly, this study examined longitudinal interactive models of co-occurring pain and PTSD symptoms in a sample of 209 military personnel (mean age = 27.4 years, standard deviation = 7.6) who experienced combat-related blast exposure. Autoregressive cross-lagged analysis examined longitudinal associations between self-reported pain and PTSD symptoms over a 1-year period. The best-fitting covariate model indicated that pain and PTSD were significantly associated with one another across all assessment periods, chi(2) (3) = 3.66, P =.30, Tucker-Lewis index =.98, comparative fit index = 1.00, root mean squared error of approximation =.03. PTSD symptoms had a particularly strong influence on subsequent pain symptoms. The relationship between pain and PTSD symptoms is related to older age, race, and traumatic brain injury characteristics. Results further the understanding of complex injuries among military personnel and highlight the need for comprehensive assessment and rehabilitation efforts addressing the interdependence of pain and co-occurring mental health conditions. Perspective: This longitudinal study demonstrates that pain and PTSD symptoms strongly influence one another and interact across time. These findings have the potential to inform the integrative assessment and treatment of military personnel with polytrauma injuries and who are at risk for persistent deployment-related disorders. (C) Published by Elsevier Inc. on behalf of the American Pain Society	[Stratton, Kelcey J.; Cifu, David X.; Walker, William C.] Hunter Holmes McGuire VA Med Ctr, Richmond, VA 23249 USA; [Stratton, Kelcey J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Cifu, David X.; Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Stratton, Kelcey J.; Hawn, Sage E.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA; [Clark, Shaunna L.] Virginia Commonwealth Univ, Sch Pharm, Ctr Biomarker Res & Personalized Med, Richmond, VA USA	Stratton, KJ (corresponding author), Hunter Holmes McGuire VA Med Ctr, 1201 Broad Rock Blvd 116-B, Richmond, VA 23249 USA.	Kelcey.Stratton@va.gov		Cifu, David/0000-0003-1600-9387	Office of Academic AffiliationsUS Department of Veterans Affairs; Advanced Fellowship Program in Mental Illness Research and Treatment; Department of Veterans Affairs, United States GovernmentUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; U.S. Army Medical Research and Material Command, Congressionally Directed Medical Research Program [W191ZSQ8118N6200001]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K02AA023239, K01AA021266, R01AA020179] Funding Source: NIH RePORTER	Writing of this manuscript was supported in part by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs, United States Government (K.J.S.), the Defense and Veterans Brain Injury Center, and by a grant by the U.S. Army Medical Research and Material Command, Congressionally Directed Medical Research Program (grant no. W191ZSQ8118N6200001; W.C.W.).	ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; [Anonymous], 2012, NAT CTR PTSD US PTSD; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Curran PJ, 2001, DECADE BEHAV, P107, DOI 10.1037/10409-004; Gatchel RJ, 2004, AM PSYCHOL, V59, P795, DOI 10.1037/0003-066X.59.8.795; Gibson CA, 2012, J REHABIL RES DEV, V49, P753, DOI 10.1682/JRRD.2011.09.0158; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Green CR, 2003, PAIN MED, V4, P277, DOI 10.1046/j.1526-4637.2003.03034.x; Gureje O, 2001, PAIN, V92, P195, DOI 10.1016/S0304-3959(00)00483-8; Hardt J, 2008, PAIN MED, V9, P803, DOI 10.1111/j.1526-4637.2008.00425.x; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jenewein J, 2009, J TRAUMA STRESS, V22, P540, DOI 10.1002/jts.20453; Keogh E, 2006, EUR J PAIN, V10, P413, DOI 10.1016/j.ejpain.2005.05.007; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koenen KC, 2003, J CONSULT CLIN PSYCH, V71, P980, DOI 10.1037/0022-006X.71.6.980; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moeller-Bertram T, 2014, PSYCHOSOMATICS, V55, P172, DOI 10.1016/j.psym.2013.01.011; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Outcalt SD, 2013, PAIN MED; Palyo SA, 2005, PAIN, V117, P121, DOI 10.1016/j.pain.2005.05.028; Perilla JL, 2002, J SOC CLIN PSYCHOL, V21, P20, DOI 10.1521/jscp.21.1.20.22404; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010; Rahim-Williams FB, 2007, PAIN, V129, P177, DOI 10.1016/j.pain.2006.12.016; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; RICHARDS JS, 1980, PAIN, V8, P355, DOI 10.1016/0304-3959(80)90079-2; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Sledjeski EM, 2008, J BEHAV MED, V31, P341, DOI 10.1007/s10865-008-9158-3; Sterling M, 2005, PAIN, V114, P141, DOI 10.1016/j.pain.2004.12.005; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Ullrich PM, 2013, REHABIL PSYCHOL, V58, P158, DOI 10.1037/a0032047; Villano CL, 2007, J REHABIL RES DEV, V44, P167, DOI 10.1682/JRRD.2006.05.0052; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weathers F.W., 1993, P 9 ANN M INT SOC TR	45	26	26	0	14	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	OCT	2014	15	10					1023	1032		10.1016/j.jpain.2014.07.002			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AQ2XQ	WOS:000342653700006	25038401	Green Accepted			2021-06-18	
J	Kesinger, MR; Nagy, LR; Sequeira, DJ; Charry, JD; Puyana, JC; Rubiano, AM				Kesinger, Matthew R.; Nagy, Lisa R.; Sequeira, Denisse J.; Charry, Jose D.; Puyana, Juan C.; Rubiano, Andres M.			A standardized trauma care protocol decreased in-hospital mortality of patients with severe traumatic brain injury at a teaching hospital in a middle-income country	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Quality improvement in LMIC; Trauma; Severe TBI; Outcomes	LIFE-SUPPORT PROGRAM; HEALTH-ORGANIZATIONS GUIDELINES; DAMAGE CONTROL RESUSCITATION; WORLD; CAPABILITIES; QUALITY	Introduction: Standardized trauma protocols (STP) have reduced morbidity and in-hospital mortality in mature trauma systems. Most hospitals in low-and middle-income countries (LMICs) have not implemented STPs, often because of financial and logistic limitations. We report the impact of an STP designed for the care of trauma patients in the emergency department (ED) at an LMIC hospital on patients with severe traumatic brain injury (STBI). Methods: We developed an STP based on generally accepted best practices and damage control resuscitation for a level I trauma centre in Colombia. Without a pre-existing trauma registry, we adapted an administrative electronic database to capture clinical information of adult patients with TBI, a head abbreviated injury score (AIS) >3, and who presented <12 h from injury. Demographics, mechanisms of injury, and injury severity were compared. Primary outcome was in-hospital mortality. Secondary outcomes were Glasgow Coma Score (GCS), length of hospital and ICU stay, and prevalence of ED interventions recommended in the STP. Logistic regression was used to control for potential confounders. Results: The pre-STP group was hospitalized between August 2010 and August 2011, the post-STP group between September 2011 and June 2012. There were 108 patients meeting inclusion criteria, 68 pre-STP implementation and 40 post-STP. The pre- and post-STP groups were similar in age (mean 37.1 vs. 38.6, p = 0.644), head AIS (median 4.5 vs. 4.0, p = 0.857), Injury Severity Scale (median 25 vs. 25, p = 0.757), and initial GCS (median 7 vs. 7, p = 0.384). Post-STP in-hospital mortality decreased (38% vs. 18%, p = 0.024), and discharge GCS increased (median 10 vs. 14, p = 0.034). After controlling for potential confounders, odds of in-hospital mortality post-STP compared to pre-STP were 0.248 (95% CI: 0.074-0.838, p = 0.025). Hospital and ICU stay did not significantly change. The use of many ED interventions increased post-STP, including bladder catheterization (49% vs. 73%, p = 0.015), hypertonic saline (38% vs. 63%, p = 0.014), arterial blood gas draws (25% vs. 43%, p = 0.059), and blood transfusions (3% vs. 18%, p = 0.008). Conclusions: An STP in an LMIC decreased in-hospital mortality, increased discharge GCS, and increased use of vital ED interventions for patients with STBI. An STP in an LMIC can be implemented and measured without a pre-existing trauma registry. (C) 2014 Elsevier Ltd. All rights reserved.	[Kesinger, Matthew R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; [Nagy, Lisa R.; Puyana, Juan C.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA; [Sequeira, Denisse J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Charry, Jose D.; Rubiano, Andres M.] Univ Surcolombiana, La Plata, Huila, Colombia	Kesinger, MR (corresponding author), Univ Pittsburgh, Dept Surg, 200 Lothrop St,Suite F1263-3, Pittsburgh, PA 15213 USA.	kesingermr2@upmc.edu; lisarnagy7@gmail.com; Des103@pitt.edu; danielcharry06@hotmail.com; puyajc@upmc.edu; rubianoam@gmail.com	RUBIANO, ANDRES M/K-6704-2012	RUBIANO, ANDRES M/0000-0001-8931-3254; Charry, Jose D./0000-0002-8789-7281	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R21 TW009332] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R21TW009332] Funding Source: NIH RePORTER		Aboutanos MB, 2007, J TRAUMA, V62, P714, DOI 10.1097/TA.0b013e318031b56d; Aboutanos MB, 2010, WORLD J SURG, V34, P2735, DOI 10.1007/s00268-010-0716-9; ALI J, 1994, J TRAUMA, V36, P391, DOI 10.1097/00005373-199403000-00020; ALI J, 1993, J TRAUMA, V34, P890, DOI 10.1097/00005373-199306000-00022; ALI J, 1993, CAN J SURG, V36, P181; ALI J, 1993, J TRAUMA, V34, P8; *AM COLL SURG, 2004, ADV TRAUM LIF SUPP S; Arreola-Risa C, 2006, REV PANAM SALUD PUBL, V19, P94, DOI 10.1590/S1020-49892006000200004; Gerhardt RT, 2013, TRANSFUSION, V53, p9S, DOI 10.1111/trf.12030; Gosselin RA, 2009, B WORLD HEALTH ORGAN, V87, P246, DOI 10.2471/BLT.08.052290; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Hanche-Olsen TP, 2012, WORLD J SURG, V36, P2371, DOI 10.1007/s00268-012-1659-0; Hashmi ZG, 2013, J TRAUMA ACUTE CARE, V75, P60, DOI 10.1097/TA.0b013e31829880a0; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Joshipura MK, 2003, INJURY, V34, P686, DOI 10.1016/S0020-1383(03)00163-3; Kesinger MR, 2014, WORLD J SURG, V38, P1869, DOI 10.1007/s00268-014-2534-y; Krug E.G., 2002, WORLD REPORT VIOLENC; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Mock C, 2006, WORLD J SURG, V30, P946, DOI 10.1007/s00268-005-0768-4; Mock C, 2012, WORLD J SURG, V36, P959, DOI 10.1007/s00268-012-1459-6; Ozgediz D, 2011, MT SINAI J MED, V78, P327, DOI 10.1002/msj.20253; Quansah R, 2008, CLIN ORTHOP RELAT R, V466, P2403, DOI 10.1007/s11999-008-0401-6; Son NT, 2007, INJURY, V38, P1014, DOI 10.1016/j.injury.2007.04.010; Trauma American College of Surgeons Trauma Committee, 2006, RES OPT CAR INJ PAT; van Olden GDJ, 2004, J TRAUMA, V57, P381, DOI 10.1097/01.TA.0000096645.13484.E6; World Health Organization, 2010, INJ VIOL FACTS	27	26	26	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2014	45	9					1350	1354		10.1016/j.injury.2014.04.037			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AN0NI	WOS:000340280900012	24861416				2021-06-18	
J	Moster, S; Wilson, JA; Galetta, SL; Balcer, LJ				Moster, Stephen; Wilson, James A.; Galetta, Steven L.; Balcer, Laura J.			The King-Devick (K-D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						King-Devick; Quality of life; Visual acuity; Low-contrast letter acuity; Optical coherence tomography; Retinal nerve fiber layer	MULTIPLE-SCLEROSIS; VISION; CONCUSSION	Objective: We investigated the King-Devick (K-D) test of rapid number naming as a visual performance measure in a cohort of patients with multiple sclerosis (MS). Methods: In this cross-sectional study, 81 patients with MS and 20 disease-free controls from an ongoing study of visual outcomes underwent K-D testing. A test of rapid number naming, K-D requires saccadic eye movements as well as intact vision, attention and concentration. To perform the K-D test, participants are asked to read numbers aloud as quickly as possible from three test cards; the sum of the three test card times in seconds constitutes the summary score. High-contrast visual acuity (VA), low-contrast letter acuity (1.25% and 25% levels), retinal nerve fiber layer (RNFL) thickness by optical coherence tomography (OCT), MS Functional Composite (MSFC) and vision-specific quality of life (QOL) measures (25-Item NEI Visual Functioning Questionnaire [NEI-VFQ-25] and 10-Item Neuro-Ophthalmic Supplement) were also assessed. Results: K-D time scores in the MS cohort (total time to read the three test cards) were significantly higher (worse) compared to those for disease-free controls (P = 0.003, linear regression, accounting for age). Within the MS cohort, higher K-D scores were associated with worse scores for the NEI-VFQ-25 composite (P < 0.001), 10-Item Neuro-Ophthalmic Supplement (P < 0.001), binocular low-contrast acuity (25%, 1.25%, P < 0.001, and high-contrast VA (P = 0.003). Monocular low-contrast vision scores (P = 0.001-0.009) and RNFL thickness (P = 0.001) were also reduced in eyes of patients with worse K-D scores (GEE models accounting for age and within-patient, inter-eye correlations). Patients with a history of optic neuritis (ON) had increased (worse) K-D scores. Patients who classified their work disability status as disabled (receiving disability pension) did worse on K-D testing compared to those working full-time (P = 0.001, accounting for age). Conclusions: The K-D test, a <2 minute bedside test of rapid number naming, is associated with visual dysfunction, neurologic impairment, and reduced vision-specific QOL in patients with MS. Scores reflect work disability as well as structural changes as measured by OCT imaging. History of ON and abnormal binocular acuities were associated with worse K-D scores, suggesting that abnormalities detected by K-D may go along with afferent dysfunction in MS patients. A brief test that requires saccadic eye movements, K-D should be considered for future MS trials as a rapid visual performance measure. (C), 2014 Elsevier B.V. All rights reserved.	[Moster, Stephen; Wilson, James A.; Galetta, Steven L.; Balcer, Laura J.] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Balcer, Laura J.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA	Balcer, LJ (corresponding author), NYU, Sch Med, 240 East 38th St,15th Floor, New York, NY 10016 USA.	laura.balcer@nyumc.org					Baumstarck K, 2013, MULT SCLER INT, V2013, P1; BLAKE R, 1973, PERCEPT PSYCHOPHYS, V14, P161, DOI 10.3758/BF03198631; BLAKE R, 1981, PERCEPT PSYCHOPHYS, V30, P266, DOI 10.3758/BF03214282; Cohen JA, 2012, LANCET NEUROL, V11, P467, DOI 10.1016/S1474-4422(12)70059-5; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Kulp MT, 1997, OPTOMETRY VISION SCI, V74, P37, DOI 10.1097/00006324-199701000-00018; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Mowry EM, 2009, J NEUROL NEUROSUR PS, V80, P767, DOI 10.1136/jnnp.2008.165449; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Pineles SL, 2011, AM J OPHTHALMOL, V152, P133, DOI 10.1016/j.ajo.2011.01.023; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; Rudick RA, 2009, MULT SCLER J, V15, P984, DOI 10.1177/1352458509106212; Sakai RE, 2011, J NEURO-OPHTHALMOL, V31, P362, DOI 10.1097/WNO.0b013e318238937f; Talman LS, 2010, ANN NEUROL, V67, P749, DOI 10.1002/ana.22005; Wu GF, 2007, NEUROLOGY, V69, P2128, DOI 10.1212/01.wnl.0000278387.15090.5a	20	26	26	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	AUG 15	2014	343	1-2					105	109		10.1016/j.jns.2014.05.047			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AN0WE	WOS:000340303900021	24954088				2021-06-18	
J	Giacci, MK; Wheeler, L; Lovett, S; Dishington, E; Majda, B; Bartlett, CA; Thornton, E; Harford-Wright, E; Leonard, A; Vink, R; Harvey, AR; Provis, J; Dunlop, SA; Hart, NS; Hodgetts, S; Natoli, R; Van Den Heuvel, C; Fitzgerald, M				Giacci, Marcus K.; Wheeler, Lachlan; Lovett, Sarah; Dishington, Emma; Majda, Bernadette; Bartlett, Carole A.; Thornton, Emma; Harford-Wright, Elizabeth; Leonard, Anna; Vink, Robert; Harvey, Alan R.; Provis, Jan; Dunlop, Sarah A.; Hart, Nathan S.; Hodgetts, Stuart; Natoli, Riccardo; Van Den Heuvel, Corinna; Fitzgerald, Melinda			Differential Effects of 670 and 830 nm Red near Infrared Irradiation Therapy: A Comparative Study of Optic Nerve Injury, Retinal Degeneration, Traumatic Brain and Spinal Cord Injury	PLOS ONE			English	Article							LEVEL LASER THERAPY; CONTROLLED CORTICAL IMPACT; CYTOCHROME-C-OXIDASE; LIGHT THERAPY; SECONDARY DEGENERATION; IN-VIVO; ABSORPTION-MEASUREMENTS; FUNCTIONAL RECOVERY; OXIDATIVE DAMAGE; WHITE-MATTER	Red/near-infrared irradiation therapy (R/NIR-IT) delivered by laser or light-emitting diode (LED) has improved functional outcomes in a range of CNS injuries. However, translation of R/NIR-IT to the clinic for treatment of neurotrauma has been hampered by lack of comparative information regarding the degree of penetration of the delivered irradiation to the injury site and the optimal treatment parameters for different CNS injuries. We compared the treatment efficacy of R/NIR-IT at 670 nm and 830 nm, provided by narrow-band LED arrays adjusted to produce equal irradiance, in four in vivo rat models of CNS injury: partial optic nerve transection, light-induced retinal degeneration, traumatic brain injury (TBI) and spinal cord injury (SCI). The number of photons of 670 nm or 830 nm light reaching the SCI injury site was 6.6% and 11.3% of emitted light respectively. Treatment of rats with 670 nm R/NIR-IT following partial optic nerve transection significantly increased the number of visual responses at 7 days after injury (P <= 0.05); 830 nm R/NIR-IT was partially effective. 670 nm R/NIR-IT also significantly reduced reactive species and both 670 nm and 830 nm R/NIR-IT reduced hydroxynonenal immunoreactivity (P <= 0.05) in this model. Pre-treatment of light-induced retinal degeneration with 670 nm R/NIR-IT significantly reduced the number of Tunel+ cells and 8-hydroxyguanosine immunoreactivity (P <= 0.05); outcomes in 830 nm R/NIR-IT treated animals were not significantly different to controls. Treatment of fluid-percussion TBI with 670 nm or 830 nm R/NIR-IT did not result in improvements in motor or sensory function or lesion size at 7 days (P>0.05). Similarly, treatment of contusive SCI with 670 nm or 830 nm R/NIR-IT did not result in significant improvements in functional recovery or reduced cyst size at 28 days (P>0.05). Outcomes from this comparative study indicate that it will be necessary to optimise delivery devices, wavelength, intensity and duration of R/NIR-IT individually for different CNS injury types.	[Giacci, Marcus K.; Wheeler, Lachlan; Lovett, Sarah; Dishington, Emma; Majda, Bernadette; Bartlett, Carole A.; Harvey, Alan R.; Dunlop, Sarah A.; Hodgetts, Stuart; Fitzgerald, Melinda] Univ Western Australia, Crawley, WA 6009, Australia; [Giacci, Marcus K.; Bartlett, Carole A.; Dunlop, Sarah A.; Hart, Nathan S.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Giacci, Marcus K.; Wheeler, Lachlan; Lovett, Sarah; Dishington, Emma; Majda, Bernadette; Harvey, Alan R.; Hodgetts, Stuart] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA 6009, Australia; [Thornton, Emma; Harford-Wright, Elizabeth; Leonard, Anna; Vink, Robert; Van Den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Adelaide, SA, Australia; [Provis, Jan; Natoli, Riccardo] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia; [Provis, Jan; Natoli, Riccardo] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; [Hart, Nathan S.] Univ Western Australia, Oceans Inst, Neuroecol Grp, Crawley, WA 6009, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Hart, Nathan S/B-8564-2011; Fitzgerald, Melinda/C-4235-2011; AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Provis, Jan/C-9529-2009	Hart, Nathan S/0000-0002-7289-9399; Fitzgerald, Melinda/0000-0002-4823-8179; AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Alan/0000-0002-2590-831X; Provis, Jan/0000-0002-6405-2868; Hodgetts, Stuart/0000-0002-3318-0410; Dunlop, Sarah/0000-0002-1306-3962; , Corinna/0000-0003-0664-8935; Giacci, Marcus/0000-0002-8330-678X; Natoli, Riccardo/0000-0002-9350-0439	Neurotrauma Research Program (Western Australia); Road Trauma Trust Account; University of Western Australia; Western Australian State Government as part of a Western Australian Premiers Fellowship	This work was supported by the Neurotrauma Research Program (Western Australia) (http://www.nrp.org.au/). This project is funded through the Road Trauma Trust Account, but does not reflect views or recommendations of the Road Safety Council. NSH was funded by The University of Western Australia and The Western Australian State Government as part of a Western Australian Premiers Fellowship to Prof. Shaun Collin. No individuals employed or contracted by the funders (other than the named authors) played any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abler AS, 1996, RES COMMUN MOL PATH, V92, P177; Albarracin R, 2012, PHOTOCHEM PHOTOBIOL; Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Albarracin RS, 2012, ADV EXP MED BIOL, V723, P121, DOI 10.1007/978-1-4614-0631-0_17; Ando T, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.9.098002; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Aonuma H, 1999, JPN J OPHTHALMOL, V43, P171, DOI 10.1016/S0021-5155(99)00011-8; Back SA, 2005, ANN NEUROL, V58, P108, DOI 10.1002/ana.20530; Back SA, 1998, J NEUROSCI, V18, P6241; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Cummins N, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-98; Demidova-Rice TN, 2007, LASER SURG MED, V39, P706, DOI 10.1002/lsm.20549; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023; Godinho MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069987; Gupta A, 2014, LASER MED SCI, V29, P257, DOI 10.1007/s10103-013-1319-0; Hacke W, 2013, TRANSCRANIAL LASER T; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEBEDA KM, 1994, NEUROSURGERY, V35, P720, DOI 10.1227/00006123-199410000-00019; Hodgetts SI, 2013, EXP NEUROL, V248, P343, DOI 10.1016/j.expneurol.2013.06.018; Hodgetts SI, 2013, CELL TRANSPLANT, V22, P393, DOI 10.3727/096368912X656081; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2012, EXPERT REV MED DEVIC, V9, P71, DOI 10.1586/ERD.11.64; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lenz P, 1999, APPL OPTICS, V38, P3662, DOI 10.1364/AO.38.003662; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medalha CC, 2010, PHOTOMED LASER SURG, V28, P669, DOI 10.1089/pho.2009.2691; Metz GA, 2009, J VIS EXP; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Moody DJ, 2005, SPECIFIC EXTINCTION; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Natoli R, 2010, MOL VIS, V16, P1801; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Peoples Cassandra, 2012, ISRN Neurol, V2012, P850150, DOI 10.5402/2012/850150; Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; Sykova E, 2008, NEUROCHEM INT, V52, P5, DOI 10.1016/j.neuint.2007.04.007; Szymanski CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066448; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	80	26	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2014	9	8							e104565	10.1371/journal.pone.0104565			15	Multidisciplinary Sciences	Science & Technology - Other Topics	AR0CG	WOS:000343231900072	25105800	DOAJ Gold, Green Published			2021-06-18	
J	Acker, SN; Ross, JT; Partrick, DA; Nadlonek, NA; Bronsert, M; Bensard, DD				Acker, Shannon N.; Ross, James T.; Partrick, David A.; Nadlonek, Nicole A.; Bronsert, Michael; Bensard, Denis D.			Glasgow motor scale alone is equivalent to Glasgow Coma Scale at identifying children at risk for serious traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; children; Glasgow Coma Scale; Glasgow Coma Scale motor score	SCORE; RELIABILITY	BACKGROUND: Glasgow Coma Scale (GCS) is a validated assessment of neurologic state. Assessment of the eye and verbal components is difficult to reliably obtain in children. We hypothesized that an abnormal Glasgow motor scale (GMS) score alone will reliably identify children with serious traumatic brain injury (TBI). METHODS: We reviewed all children with a diagnosis of TBI from 2002 to 2011 at two urban Level I pediatric trauma centers. We used logistic regression to model GCS, GMS, Glasgow verbal scale (GVS), and Glasgow eye scale (GES) for seven outcomes: need for craniotomy, intracranial pressure monitoring, admission to the intensive care unit, hospital stay of 5 days or longer, discharge to rehabilitation, dependence on caretakers at follow-up, and survival to hospital discharge. We then used three measures of fit analysis to determine which scale offered the best fit for each of the outcomes. RESULTS: A total of 2,341 patients (mean [SD] age, 6.9 [5.8] years; 64.7% male) with TBI and GCS data available were identified. The median GCS on presentation was 15 (interquartile range [IQR], 8-15); the median GMS on presentation was 6 (IQR, 4-6). The median GVS was 5 (IQR, 1-5), and the median GES was 4 (IQR, 2-4). GCS as a whole offered the best fit for the data in predicting need for intensive care unit admission, need for intracranial pressure monitoring, prolonged hospital length of stay, and discharge to rehabilitation but was equivalent to GMS in predicting need for craniotomy, survival to hospital discharge, or dependence on a caretaker at follow-up. Further analysis revealed that GMS was more predictive of these outcomes than GVS + GES, indicating that GMS provides the greatest contribution to the predictive ability of the GCS. CONCLUSION: GMS score alone and GCS do not differ in identifying children with serious TBI. Eliminating the eye and verbal components of GCS does not adversely affect the accuracy of this tool to identify children at risk for serious TBI. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Acker, Shannon N.; Ross, James T.; Partrick, David A.; Nadlonek, Nicole A.; Bensard, Denis D.] Univ Colorado, Sch Med, Dept Pediat Surg, Childrens Hosp Colorado, Aurora, CO 80045 USA; [Bronsert, Michael] Univ Colorado, Sch Med, Dept Surg, Aurora, CO 80045 USA; [Bensard, Denis D.] Denver Hlth & Hosp Author, Dept Surg, Denver, CO USA	Acker, SN (corresponding author), Univ Colorado, Sch Med, Dept Pediat Surg, Childrens Hosp Colorado, 12631 E 17th Ave,C302, Aurora, CO 80045 USA.	shannon.acker@ucdenver.edu					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Browne G J, 2001, Emerg Med (Fremantle), V13, P418, DOI 10.1046/j.1035-6851.2001.00255.x; Caterino JM, 2012, EMERG MED J, V29, P492, DOI 10.1136/emj.2010.110437; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fortune PM, 2010, PEDIATR CRIT CARE ME, V11, P339, DOI 10.1097/PCC.0b013e3181c014ab; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Kornbluth J, 2011, NEUROCRIT CARE, V14, P134, DOI 10.1007/s12028-010-9409-3; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SIMPSON D, 1982, LANCET, V2, P450; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J Neurotrauma, V17, P563, DOI 10.1089/neu.2000.17.563; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007	22	26	26	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2014	77	2					304	309		10.1097/TA.0000000000000300			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AN0EJ	WOS:000340255700020	25058258				2021-06-18	
J	Adembri, C; Selmi, V; Vitali, L; Tani, A; Margheri, M; Loriga, B; Carlucci, M; Nosi, D; Formigli, L; De Gaudio, AR				Adembri, Chiara; Selmi, Valentina; Vitali, Luca; Tani, Alessia; Margheri, Martina; Loriga, Beatrice; Carlucci, Martina; Nosi, Daniele; Formigli, Lucia; De Gaudio, Angelo Raffaele			Minocycline But Not Tigecycline Is Neuroprotective and Reduces the Neuroinflammatory Response Induced by the Superimposition of Sepsis Upon Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						cecal ligation and puncture; controlled cortical impact; experimental model; minocycline; sepsis; tigecycline; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; MICROGLIAL ACTIVATION; COGNITIVE FUNCTION; WATER-MAZE; MICE; RAT; INFLAMMATION; MODEL; TETRACYCLINES	Objective: The development of sepsis in patients with traumatic brain injury increases mortality, exacerbates morphological and functional cerebral damage, and causes persistent neuroinflammation, including microglial activation. The administration of antibiotics possessing both antimicrobial and immunomodulatory activity might attenuate both sepsis and posttraumatic cerebral inflammation. We compared the potential therapeutic efficacy of two tetracyclines, minocycline and the newer generation tigecycline, on functional neurobehavioral impairment and regional histopathological damage in an experimental model of combined traumatic brain injury and sepsis. Design: Prospective, experimental animal study. Setting: University Research Laboratory. Subjects: Adult male Sprague-Dawley rats. Interventions: Controlled cortical impact was used to induce traumatic brain injury and cecal ligation and puncture for sepsis. Immediately following injury, animals were treated with minocycline (45 mg/kg intraperitoneal), tigecycline (7.5 mg/kg intraperitoneal), or saline every 12 hours for 3 days. Measurements and Main Results: The development of sepsis and cerebral inflammatory response were evaluated, respectively, by 1) growth of peritoneal microorganisms and clinical variables and 2) tumor necrosis factor-a expression in the perilesional cortex. To assess posttraumatic outcome, vestibulomotor and cognitive function were evaluated at different time points for 14 days post injury whereupon animals were killed and cerebral tissue analyzed for lesion volume, regional hippocampal (CA1/CA3) cell death, and microglial activation in the perilesional cortex, lesion core zone, and choroid plexus. Treatment with both antibiotics reduced microorganism growth, body weight loss, and mortality but had no effect on vestibulomotor or cognitive function. Minocycline alone attenuated postinjury cortical lesion volume, hippocampal CA3 neuronal cell loss, tumor necrosis factor-a expression, and the extent of microglial activation and infiltration. Conclusions: The significantly heightened mortality caused by the superimposition of sepsis upon traumatic brain injury can be reduced by administration of both antibiotics but only minocycline can decrease the extent of cell death in selectively cortical and hippocampal brain regions, via, in part, a reduction in cerebral inflammation.	[Adembri, Chiara] Univ Florence, Dept Hlth Sci, Sect Anesthesiol & Intens Care, Florence, Italy; Univ Florence, Dept Expt & Clin Med, Florence, Italy	Adembri, C (corresponding author), Univ Florence, Dept Hlth Sci, Sect Anesthesiol & Intens Care, Florence, Italy.	chiara.adembri@unifi.it			Cassa Risparmio Firenze, Firenze; Ministero della Ricerca, Italy; Ministero della Ricerca [20087SM5HM_003]	Dr. Adembri received grant support from Cassa Risparmio Firenze, Firenze; served as board member for Merck Sharp & Dohme (MSD); and received support for article research from Ministero della Ricerca, Italy. Drs. Selmi, Vitali, Tani, Margheri, Loriga, Carlucci, Nosi, and Formigli received support for article research from Ministero della Ricerca, Italy. Dr. De Gaudio served as board member for MSD and received support for article research from Ministero della Ricerca (#20087SM5HM_003). His institution received grant support from Ministero della ricerca.	Adembri C, 2011, CRIT CARE, V15, DOI 10.1186/cc10559; Aid S, 2010, NEUROSCI LETT, V478, P113, DOI 10.1016/j.neulet.2010.04.076; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Chen XH, 2011, J NEUROIMMUNOL, V235, P1, DOI 10.1016/j.jneuroim.2011.04.006; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Czlonkowska A, 2011, J NEUROIMMUNOL, V231, P78, DOI 10.1016/j.jneuroim.2010.09.020; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Huang DR, 2005, FASEB J, V19, P761, DOI 10.1096/fj.04-3104com; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kieburtz K, 2008, CLIN NEUROPHARMACOL, V31, P141, DOI 10.1097/WNF.0b013e3181342f32; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murata Y, 2008, STROKE, V39, P3372, DOI 10.1161/STROKEAHA.108.514026; Murphy TM, 2000, ANTIMICROB AGENTS CH, V44, P3022, DOI 10.1128/AAC.44.11.3022-3027.2000; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Patel K, 1998, BRIT DENT J, V185, P560, DOI 10.1038/sj.bdj.4809867; Peeling James, 2006, J Stroke Cerebrovasc Dis, V15, P101, DOI 10.1016/j.jstrokecerebrovasdis.2006.03.001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Schutt AC, 2009, ANN PHARMACOTHER, V43, P2108, DOI 10.1345/aph.1M324; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Seputiene V, 2010, MEDICINA-LITHUANIA, V46, P240, DOI 10.3390/medicina46040033; Shlaes DM, 2006, CURR OPIN INVEST DR, V7, P167; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Wafaisade A, 2011, CRIT CARE MED, V39, P621, DOI 10.1097/CCM.0b013e318206d3df; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zheng WW, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-40; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	53	26	26	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2014	42	8					E570	E582		10.1097/CCM.0000000000000414			13	Critical Care Medicine	General & Internal Medicine	AL7QV	WOS:000339330700003	24810523				2021-06-18	
J	Sun, TY; Chen, XR; Liu, ZL; Zhao, LL; Jiang, YX; Qu, GQ; Wang, RS; Huang, SZ; Liu, L				Sun, Ting-yi; Chen, Xiao-rui; Liu, Zi-long; Zhao, Li-li; Jiang, Yong-xiang; Qu, Guo-qiang; Wang, Rong-shuai; Huang, Si-zhe; Liu, Liang			Expression profiling of MicroRNAs in hippocampus of rats following traumatic brain injury	JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES			English	Article						forensic clinical medicine; traumatic brain injury; microRNA; microarray technique; hippocampus	CELL PROLIFERATION; MIR-222; MIR-142-3P; CARCINOMA; GENES	The changes of microRNA expression in rat hippocampus after traumatic brain injury (TBI) were explored. Adult SD rats received a single controlled cortical impact injury, and the ipsilateral hippocampus was harvested for the subsequent microarray assay at three time points after TBI: 1st day, 3rd day and 5th day, respectively. We characterized the microRNA expression profile in rat hippocampus using the microRNA microarray analysis, and further verified microarray results of miR-142-3p and miR-221 using quantitative real-time PCR. Totally 205 microRNAs were identified and up-/down-regulated more than 1.5 times. There were significant changes in 17 microRNAs at all three time points post-TBI. The quantitative real-time PCR results of miR-142-3p and miR-221 indicated good consistency with the results of the microarray method. MicroRNAs altered at different time points post-TBI. MiR-142-3p and miR-221 may be used as potentially biological markers for TBI assessment in forensic practice.	[Sun, Ting-yi; Chen, Xiao-rui; Liu, Zi-long; Zhao, Li-li; Qu, Guo-qiang; Wang, Rong-shuai; Huang, Si-zhe; Liu, Liang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430030, Peoples R China; [Jiang, Yong-xiang] Xiling Dist Publ Secur Bur, Forens Expertise Ctr, Yichang 443001, Peoples R China	Liu, ZL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430030, Peoples R China.	sty-j211@sohu.com; chenxiaorui@mails.tjmu.edu.cn; lzlongfy@gmail.com; liuliang@mails.tjmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81102304]; Doctoral Fund of Ministry of Education of ChinaMinistry of Education, China [20090142120054]; Foundation of Huazhong University of Science and Technology [20100573]	This project was supported by grants from the National Natural Science Foundation of China (No. 81102304), Doctoral Fund of Ministry of Education of China (No. 20090142120054), and Foundation of Huazhong University of Science and Technology (No. 20100573).	Almog N, 2013, TRANSCR-AUSTIN, V4, P177, DOI 10.4161/trns.25558; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Castagnino P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056140; Chen Y, 2010, MOL CELL BIOL, V30, P3902, DOI 10.1128/MCB.01237-09; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Huang B, 2009, EMBO REP, V10, P180, DOI 10.1038/embor.2008.224; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Kaduthanam S, 2013, LUNG CANCER, V80, P223, DOI 10.1016/j.lungcan.2013.01.013; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu XJ, 2009, CIRC RES, V104, P476, DOI 10.1161/CIRCRESAHA.108.185363; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Smith B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011109; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang F, 2012, MOL BIOL REP, V39, P2713, DOI 10.1007/s11033-011-1026-5; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840	29	26	26	1	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1672-0733	1993-1352		J HUAZHONG U SCI-MED	J. Huazhong Univ. Sci. Tech.-Med.	AUG	2014	34	4					548	553		10.1007/s11596-014-1313-1			6	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AN5DT	WOS:000340610700013	25135725				2021-06-18	
J	Kolar, MK; Kingham, PJ; Novikova, LN; Wiberg, M; Novikov, LN				Kolar, Mallappa K.; Kingham, Paul J.; Novikova, Liudmila N.; Wiberg, Mikael; Novikov, Lev N.			The Therapeutic Effects of Human Adipose-Derived Stem Cells in a Rat Cervical Spinal Cord Injury Model	STEM CELLS AND DEVELOPMENT			English	Article							MARROW STROMAL CELLS; HUMAN BONE-MARROW; FIBROBLAST GROWTH-FACTORS; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; GLIAL SCAR; IN-VITRO; MATRIX METALLOPROTEINASES; CORTICOSPINAL NEURONS; REGENERATIVE MEDICINE	Spinal cord injury triggers a cascade of degenerative changes leading to cell death and cavitation. Severed axons fail to regenerate across the scar tissue and are only capable of limited sprouting. In this study, we investigated the effects of adult human adipose-derived stem cells (ASC) on axonal regeneration following transplantation into the injured rat cervical spinal cord. ASC did not induce activation of astrocytes in culture and supported neurite outgrowth from adult rat sensory dorsal root ganglia neurons. After transplantation into the lateral funiculus 1mm rostral and caudal to the cervical C3-C4 hemisection, ASC continued to express brain-derived neurotrophic factor, vascular endothelial growth factor, and fibroblast growth factor-2 for 3 weeks but only in animals treated with cyclosporine A. Transplanted ASC stimulated extensive ingrowth of 5HT-positive raphaespinal axons into the trauma zone with some terminal arborizations reaching the caudal spinal cord. In addition, ASC induced sprouting of raphaespinal terminals in C2 contralateral ventral horn and C6 ventral horn on both sides. Transplanted cells also changed the structure of the lesion scar with numerous astrocytic processes extended into the middle of the trauma zone in a chain-like pattern and in close association with regenerating axons. The density of the astrocytic network was also significantly decreased. Although the transplanted cells had no effect on the density of capillaries around the lesion site, the activity of OX42-positive microglial cells was markedly reduced. However, ASC did not support recovery of forelimb function. The results suggest that transplanted ASC can modify the structure of the glial scar and stimulate axonal sprouting.	[Kolar, Mallappa K.; Kingham, Paul J.; Novikova, Liudmila N.; Wiberg, Mikael; Novikov, Lev N.] Umea Univ, Sect Anat, Dept Integrat Med Biol, S-90187 Umea, Sweden; [Kolar, Mallappa K.; Wiberg, Mikael] Umea Univ, Sect Hand & Plast Surg, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden	Novikov, LN (corresponding author), Umea Univ, Sect Anat, Dept Integrat Med Biol, S-90187 Umea, Sweden.	lev.novikov@anatomy.umu.se		Kingham, Paul/0000-0003-2596-5936; Novikov, Lev/0000-0001-5520-3890	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European UnionEuropean Commission; Umea University; county of Vasterbotten	We would like to thank Mrs. G. Folkesson and Mrs. G. Hellstrom for their excellent technical assistance. This study was supported by the Swedish Research Council, European Union, Umea University, and county of Vasterbotten.	Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Arboleda D, 2011, CELL MOL NEUROBIOL, V31, P1113, DOI 10.1007/s10571-011-9712-3; Attar A, 2011, CYTOTHERAPY, V13, P54, DOI 10.3109/14653249.2010.510506; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; Banas A, 2008, STEM CELLS, V26, P2705, DOI 10.1634/stemcells.2008-0034; Bradbury EJ, 2011, BRAIN RES BULL, V84, P306, DOI 10.1016/j.brainresbull.2010.06.015; Brohlin M, 2009, NEUROSCI RES, V64, P41, DOI 10.1016/j.neures.2009.01.010; Choi JS, 2012, KOREAN J PHYSIOL PHA, V16, P405, DOI 10.4196/kjpp.2012.16.6.405; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Chung CS, 2013, J VET MED SCI, V75, P879, DOI 10.1292/jvms.12-0470; Cizkova D, 2011, J NEUROTRAUM, V28, P1951, DOI 10.1089/neu.2010.1413; Cizkova D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571-006-9093-1; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Forostyak S, 2013, BIOCHIMIE, V95, P2257, DOI 10.1016/j.biochi.2013.08.004; Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood-2012-02-404475; Garcia-Alias G, 2012, EXP NEUROL, V235, P26, DOI 10.1016/j.expneurol.2011.09.009; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Grimpe B, 2005, MOL CELL NEUROSCI, V28, P18, DOI 10.1016/j.mcn.2004.06.010; Hall ED, 2011, NEUROTHERAPEUTICS, V8, P152, DOI 10.1007/s13311-011-0026-4; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P2222, DOI 10.1089/scd.2011.0596; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P432, DOI 10.1089/scd.2011.0242; Hawthorne AL, 2011, J NEUROSCI, V31, P5605, DOI 10.1523/JNEUROSCI.6663-10.2011; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hollis ER, 2011, NEUROTHERAPEUTICS, V8, P694, DOI 10.1007/s13311-011-0074-9; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kalbermatten DF, 2011, CELL TISSUE RES, V344, P251, DOI 10.1007/s00441-011-1142-5; Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kim HJ, 2009, J ORTHOP RES, V27, P612, DOI 10.1002/jor.20766; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Liu J, 2013, J NEUROL SCI, V325, P127, DOI 10.1016/j.jns.2012.11.022; Lu P, 2007, EXP NEUROL, V203, P8, DOI 10.1016/j.expneurol.2006.07.030; Macaya DJ, 2013, BIOMATERIALS, V34, P3591, DOI 10.1016/j.biomaterials.2012.12.050; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McTigue DM, 1998, J NEUROSCI, V18, P5354; Moskowitz MAE, 1995, CER DIS 19 PRINC STR; Mothe AJ, 2012, J CLIN INVEST, V122, P3824, DOI 10.1172/JCI64124; Muir GD, 2007, EUR J NEUROSCI, V25, P1501, DOI 10.1111/j.1460-9568.2007.05411.x; Nacev BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024793; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Novikova LN, 2008, BIOMATERIALS, V29, P1198, DOI 10.1016/j.biomaterials.2007.11.033; Novikova LN, 2011, CYTOTHERAPY, V13, P873, DOI 10.3109/14653249.2011.574116; Novikova LN, 2011, EXP NEUROL, V229, P132, DOI 10.1016/j.expneurol.2010.09.021; Novikova LN, 2000, J COMP NEUROL, V428, P671, DOI 10.1002/1096-9861(20001225)428:4<671::AID-CNE7>3.0.CO;2-H; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Oh JS, 2012, NEUROREPORT, V23, P277, DOI 10.1097/WNR.0b013e3283505ae2; Pluchino S, 2013, GLIA, V61, P1379, DOI 10.1002/glia.22500; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Ra JC, 2011, STEM CELLS DEV, V20, P1297, DOI 10.1089/scd.2010.0466; Reilly JF, 1998, GLIA, V22, P202, DOI 10.1002/(SICI)1098-1136(199802)22:2<202::AID-GLIA11>3.0.CO;2-1; Roh DH, 2013, CELL TRANSPLANT, V22, P1577, DOI 10.3727/096368912X659907; Ryu HH, 2012, J VET MED SCI, V74, P1617, DOI 10.1292/jvms.12-0065; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Salgado AJ, 2010, CURR STEM CELL RES T, V5, P103; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schira J, 2012, BRAIN, V135, P431, DOI 10.1093/brain/awr222; Shi D, 2011, EXP HEMATOL, V39, P214, DOI 10.1016/j.exphem.2010.10.009; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Strem Brian M., 2005, Keio Journal of Medicine, V54, P132, DOI 10.2302/kjm.54.132; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Uccelli A, 2011, BEST PRACT RES CL HA, V24, P59, DOI 10.1016/j.beha.2011.01.004; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Vawda R, 2013, CURR STEM CELL RES T, V8, P25, DOI 10.2174/1574888X11308010005; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; WALICKE PA, 1988, J NEUROSCI, V8, P2618; Weishaupt N, 2013, EXP NEUROL, V247, P241, DOI 10.1016/j.expneurol.2013.05.003; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205; Yuan YM, 2013, NEUROSCI BULL, V29, P421, DOI 10.1007/s12264-013-1358-3; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhou ZL, 2012, BRAIN RES, V1481, P79, DOI 10.1016/j.brainres.2012.08.051; Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015	92	26	27	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUL 15	2014	23	14					1659	1674		10.1089/scd.2013.0416			16	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	AL7LJ	WOS:000339315000009	24803143				2021-06-18	
J	De Luca, R; Calabro, RS; Gervasi, G; De Salvo, S; Bonanno, L; Corallo, F; De Cola, MC; Bramanti, P				De Luca, Rosaria; Calabro, Rocco Salvatore; Gervasi, Giuseppe; De Salvo, Simona; Bonanno, Lilla; Corallo, Francesco; De Cola, Maria Cristina; Bramanti, Placido			Is computer-assisted training effective in improving rehabilitative outcomes after brain injury? A case-control hospital-based study	DISABILITY AND HEALTH JOURNAL			English	Article						Computerized cognitive training; Recovery; Rehabilitation outcomes; Stroke; TBI	OF-THE-LITERATURE; COGNITIVE REHABILITATION; WORKING-MEMORY; HEAD-INJURY; PEOPLE	Background: Rehabilitation of impaired cognitive functions begins to be considered a standard component of medical care after acquired brain injury. Indeed, many evidences support the effectiveness of the two major categories of techniques, i.e. the traditional and computer-assisted ones, which are widely used in cognitive rehabilitative treatment. Objective: Aim of this study is to evaluate the effects of pc - cognitive training in brain injury patients. Methods: We studied 35 subjects (randomly divided into two groups), affected by traumatic or vascular brain injury, having attended from January 2010 to December 2012 the Laboratory of Robotic and Cognitive Rehabilitation of IRCCS Neurolesi of Messina. Cognitive impairment was investigated through psychometric battery, administered before (T0) and two months (T1) after the cognitive pc-training, which was performed only by the experimental group, in addition to conventional treatment. Statistical analysis was performed using Wilcoxon test with a p < 0.01. Results: At time T0, all patients showed language deficits and cognitive alterations in visual attention and memory abilities. After the rehabilitation program we noted a global improvement in both the groups. However, at T1, the experimental group showed a greater cognitive improvement than the control group, with significant differences in nearly all the neuropsychological tests performed. Conclusions: Our data suggest that cognitive pc-training may be a promising methodology to optimize the rehabilitation outcomes following brain injury. (C) 2014 Elsevier Inc. All rights reserved.	[De Luca, Rosaria; Calabro, Rocco Salvatore; Gervasi, Giuseppe; De Salvo, Simona; Bonanno, Lilla; Corallo, Francesco; De Cola, Maria Cristina; Bramanti, Placido] IRCCS Ctr Neurolesi Bonino Pulejo, I-98124 Messina, Italy	Calabro, RS (corresponding author), IRCCS Ctr Neurolesi Bonino Pulejo, SS 113, I-98124 Messina, Italy.	salbro77@tiscali.it	Calabro, Rocco S/K-7520-2016; Gervasi, Giuseppe/A-7875-2016; Gervasi, Giuseppe/AAE-8044-2019; De Salvo, Simona/K-3180-2016; calabro, rocco salvatore/L-9570-2019; Bramanti, Placido/K-5117-2016; Bonanno, Lilla/K-3937-2016; De Cola, Maria C/B-7714-2017; corallo, francesco/K-5932-2016	Gervasi, Giuseppe/0000-0001-8527-645X; Gervasi, Giuseppe/0000-0001-8527-645X; De Salvo, Simona/0000-0001-9501-3258; calabro, rocco salvatore/0000-0002-8566-3166; Bonanno, Lilla/0000-0002-0282-405X; corallo, francesco/0000-0003-4862-3832; De Cola, Maria Cristina/0000-0002-7509-3833			Adrian JA, 2003, APHASIOLOGY, V17, P981, DOI 10.1080/02687030344000256; Alderson AL, 2002, J HEAD TRAUMA REHAB, V17, P210, DOI 10.1097/00001199-200206000-00003; Alladi S, 2002, NEUROL INDIA, V50, pS102; Ashman TA, 2006, MT SINAI J MED, V73, P999; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; Cappa SF, 2005, EUR J NEUROL, V12, P665; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Fernandez E, 2012, MEDICC REV, V14, P32, DOI 10.1590/S1555-79602012000400007; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Schneider William N, 2011, Continuum (Minneap Minn), V17, P462, DOI 10.1212/01.CON.0000399067.69567.f2; Tam SF, 2004, BRAIN INJURY, V18, P461, DOI 10.1080/02699050310001646099; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; van Heugten C, 2012, NEUROPSYCHOL REHABIL, V22, P653, DOI 10.1080/09602011.2012.680891; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Wilson BA, 2002, NEUROREHAB NEURAL RE, V16, P207, DOI 10.1177/0888439002016002003	24	26	26	0	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1936-6574	1876-7583		DISABIL HEALTH J	Disabil. Health J.	JUL	2014	7	3					356	360		10.1016/j.dhjo.2014.04.003			5	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation	Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation	AJ8UR	WOS:000337983800014	24947578				2021-06-18	
J	Vaughn, MG; Salas-Wright, CP; Delisi, M; Perron, B				Vaughn, Michael G.; Salas-Wright, Christopher P.; Delisi, Matt; Perron, Brian			Correlates of traumatic brain injury among juvenile offenders: A multi-site study	CRIMINAL BEHAVIOUR AND MENTAL HEALTH			English	Article							LIFE-COURSE-PERSISTENT; SELF-CONTROL; CRIME; PREVALENCE; HYPERACTIVITY; DELINQUENCY; GOTTFREDSON; INVENTORY; PATHWAYS; VIOLENCE	Background There is some evidence that antisocial individuals, including young delinquents, are significantly more likely than people in the general population to incur a traumatic brain injury (TBI). Extant studies are hampered by methodological limitations, such as small sample sizes, lack of control for confounding effects, and use of single sites and may lack representativeness. Hypothesis The hypothesis for this study is that young offenders with a history of TBI will not only be at higher risk of impulsivity and negative emotionality than their non-injured peers but also that those with TBI will have had more previous victimisation experiences. Methods Data from two sites (Philadelphia, PA and Phoenix, AZ) in a substantial longitudinal, prospective study - the Pathways to Desistance Study - were used to compare young people (average age 16 years) who reported TBI with those who did not. Independent variables were behavioural, criminogenic and psychosocial measures. Results Male youths were about twice as likely as young females to report TBI. Such injury was associated with higher impulsivity and negative emotion ratings, even after allowing for potentially confounding factors, including sex. In addition, TBI was independently associated with self-reported experience of victimisation. Conclusions/implications This extends the generalisability of earlier suggestions of a relationship between TBI and offending, and various factors thought likely to mediate the relationship. The implications are, thus, that it is likely to be of practical value to screen young people who get into the criminal justice system for a history of TBI, and thus to allow for more specific tailoring of interventions to reduce the range of associated problems, including likely reoffending. Copyright (C) 2014 John Wiley & Sons, Ltd.	[Vaughn, Michael G.] St Louis Univ, Sch Social Work, St Louis, MO 63103 USA; [Salas-Wright, Christopher P.] Univ Texas Austin, Austin, TX 78712 USA; [Delisi, Matt] Iowa State Univ, Ames, IA USA; [Perron, Brian] Univ Michigan, Ann Arbor, MI 48109 USA	Vaughn, MG (corresponding author), St Louis Univ, Sch Social Work, 3550 Lindell BLVD, St Louis, MO 63103 USA.	mvaughn9@slu.edu	Vaughn, Michael/W-2694-2019; Salas-Wright, Christopher/K-5463-2014; DeLisi, Matt/U-9128-2019				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Armstrong TA, 2012, J CRIM JUST, V40, P31, DOI 10.1016/j.jcrimjus.2011.11.001; Bandura A, 1996, J PERS SOC PSYCHOL, V71, P364, DOI 10.1037/0022-3514.80.1.125; Barnes JC, 2010, J CRIM JUST, V38, P1176, DOI 10.1016/j.jcrimjus.2010.09.006; Carswell K, 2004, J ADOLESCENCE, V27, P415, DOI 10.1016/j.adolescence.2004.04.003; Chung HL, 2007, CRIM JUSTICE BEHAV, V34, P1402, DOI 10.1177/0093854807307170; Cohen J, 1988, STAT POWER BEHAV SCI; Cox J, 2013, J CRIM JUST, V41, P125, DOI 10.1016/j.jcrimjus.2012.12.001; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; de Ridder DTD, 2012, PERS SOC PSYCHOL REV, V16, P76, DOI 10.1177/1088868311418749; Defoe IN, 2013, J CRIM JUST, V41, P100, DOI 10.1016/j.jcrimjus.2012.12.002; DeLisi M, 2008, INT J OFFENDER THER, V52, P520, DOI 10.1177/0306624X07308553; DeLisi M, 2011, J CRIM JUST, V39, P103, DOI 10.1016/j.jcrimjus.2011.02.012; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrington DP, 2009, AGGRESSIVE BEHAV, V35, P150, DOI 10.1002/ab.20296; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Forth A.E., 2003, HARE PSYCHOPATHY CHE; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Golden C., 1978, STROOP COLOR WORD TE; Gottfredson M.R., 1990, GEN THEORY CRIME, DOI DOI 10.2307/1964276; Jennings WG, 2012, J CRIM JUST, V40, P472, DOI 10.1016/j.jcrimjus.2012.07.001; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lichtenstein P, 2012, NEW ENGL J MED, V367, P2006, DOI 10.1056/NEJMoa1203241; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Moffitt TE, 2002, DEV PSYCHOPATHOL, V14, P179, DOI 10.1017/S0954579402001104; Moffitt TE, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P49; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Mulvey EP, 2012, VICTIMS OFFENDERS, V7, P407, DOI 10.1080/15564886.2012.713903; Patrick CJ, 2012, DEV PSYCHOPATHOL, V24, P1047, DOI 10.1017/S0954579412000533; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Pratt TC, 2000, CRIMINOLOGY, V38, P931, DOI 10.1111/j.1745-9125.2000.tb00911.x; Raine A, 2005, J ABNORM PSYCHOL, V114, P38, DOI 10.1037/0021-843X.114.1.38; Reynolds C.R., 1985, REVISED CHILDRENS MA; Rocque M, 2012, J CRIM JUST, V40, P306, DOI 10.1016/j.jcrimjus.2012.05.003; Schubert CA, 2004, YOUTH VIOLENCE JUV J, V2, P37; Selner-O'Hagan MB, 1998, J CHILD PSYCHOL PSYC, V39, P215, DOI 10.1111/1469-7610.00315; Shaw DS, 2012, DEV PSYCHOPATHOL, V24, P871, DOI 10.1017/S0954579412000429; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; StataCorp, 2011, STAT STAT SOFTW REL; Thornberry T. P., 2003, GANGS DELINQUENCY DE; Vaughn MG, 2011, J CRIM JUST, V39, P212, DOI 10.1016/j.jcrimjus.2011.02.003; Vaughn MG, 2011, J CRIM JUST, V39, P75, DOI 10.1016/j.jcrimjus.2010.12.001; Vaughn MG, 2009, ADDICT BEHAV, V34, P112, DOI 10.1016/j.addbeh.2008.08.011; Walters GD, 2013, J CRIM JUST, V41, P135, DOI 10.1016/j.jcrimjus.2012.12.004; WEINBERGER DA, 1990, J PERS, V58, P381, DOI 10.1111/j.1467-6494.1990.tb00235.x; Welsh BC, 2012, J CRIM JUST, V40, P128, DOI 10.1016/j.jcrimjus.2012.01.008; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; World Health Organization (WHO), 2008, ICD 10 INT STAT CLAS	51	26	26	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0957-9664	1471-2857		CRIM BEHAV MENT HEAL	Crim. Behav. Ment. Health	JUL	2014	24	3					188	203		10.1002/cbm.1900			16	Criminology & Penology; Psychiatry	Criminology & Penology; Psychiatry	AL5GE	WOS:000339160800005	24425682	Green Published			2021-06-18	
J	Ye, YQ; Xu, HY; Zhang, X; Li, Z; Jia, YF; He, XS; Huang, JH				Ye, Yuqin; Xu, Hongyu; Zhang, Xin; Li, Ze; Jia, Yanfeng; He, Xiaosheng; Huang, Jason H.			Association between Toll-Like Receptor 4 Expression and Neural Stem Cell Proliferation in the Hippocampus Following Traumatic Brain Injury in Mice	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						toll-like receptor 4 (TLR4); neural stem cells (NSCs); hippocampus; traumatic brain injury (TBI); mice	NEUROGENESIS; ADULT; INFLAMMATION; DISEASE	Whether or how neural stem cells (NSCs) respond to toll-like receptor 4 (TLR4) in an inflammatory environment caused by traumatic brain injury (TBI) has not been understood. In the present study, association between TLR4 expression and NSCs proliferation in the hippocampus was investigated in a mouse model of TBI using controlled cortical impact (CCI). Hippocampal proliferating cells were labeled with the thymidine analog 5-bromo-2-deoxyuridine (BrdU). In order to identify NSCs, the proliferating cells were further co-labeled with BrdU/sex determination region of Y chromosome related high mobility group box gene 2 (SOX2). Morphological observation on the expression of BrdU, SOX2, and TLR4 in the hippocampus was performed by inmmunofluorescence (IF). Relative quantification of TLR4 expression at the protein and mRNA level was performed using Western blotting and real-time polymerase chain reaction (PCR). It was observed that BrdU(+)/SOX2(+) cells accounted for 95.80% +/- 7.91% among BrdU(+) cells; several BrdU(+) cells and SOX2(+) cells in the hippocampus were also TLR4-positive post injury, and that BrdU(+) cell numbers, together with TLR4 expression at either protein or mRNA level, increased significantly in TBI mice over 1, 3, 7, 14, and 21 days survivals and changed in a similar temporal pattern with a peak at 3 day post-injury. These results indicate that hippocampal proliferating cells (suggestive of NSCs) expressed TLR4, and that there was a potential association between increased expression of TLR4 and the proliferation of NSCs post TBI. It is concluded that hippocampal TLR4 may play a potential role in endogenous neurogenesis after TBI.	[Ye, Yuqin; Xu, Hongyu; Zhang, Xin; Li, Ze; Jia, Yanfeng; He, Xiaosheng] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China; [Ye, Yuqin] Hunan Normal Univ, Affiliated Hosp 2, Dept Neurosurg, Changsha 410000, Hunan, Peoples R China; [Huang, Jason H.] Baylor Scott & White Hlth, Dept Neurosurg, Temple, TX 76508 USA	He, XS (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Peoples R China.	chinayeyuqin@163.com; xuhy@fmmu.edu.cn; heartychang@163.com; lizewyl@163.com; sjwkjyf@126.com; hexiaos@fmmu.edu.cn; JHUANG@sw.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	NSFCNational Natural Science Foundation of China (NSFC) [81171155]	The present study was supported by funds from the 2012 NSFC proposal (Item No. 81171155). We want to thank Glen Cryer, manager of publications at Bayor Scott & White Healthcare (Temple, TX, USA) for editing and proofreading the manuscript.	Acosta C, 2008, J NEUROSCI RES, V86, P1077, DOI 10.1002/jnr.21565; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Carty M, 2011, BIOCHEM PHARMACOL, V81, P825, DOI 10.1016/j.bcp.2011.01.003; Covacu R, 2009, J IMMUNOL, V182, P6889, DOI 10.4049/jimmunol.0802907; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Kim HJ, 2012, INT NEUROUROL J, V16, P57, DOI 10.5213/inj.2012.16.2.57; Kohman RA, 2013, BRAIN BEHAV IMMUN, V27, P22, DOI 10.1016/j.bbi.2012.09.003; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; Sauerzweig S, 2009, J NEUROSCI METH, V177, P149, DOI 10.1016/j.jneumeth.2008.10.009; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stella N, 2012, SCIENCE, V338, P1303, DOI 10.1126/science.1232331; Trudler D, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/497987	22	26	30	0	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JUL	2014	15	7					12651	12664		10.3390/ijms150712651			14	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	AM7ID	WOS:000340038500089	25036030	DOAJ Gold, Green Published			2021-06-18	
J	Taub, E; Uswatte, G; Mark, VW				Taub, Edward; Uswatte, Gitendra; Mark, Victor W.			The functional significance of cortical reorganization and the parallel development of CI therapy	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						CI therapy; cortical reorganization; neurorehabilitation; neuroplasticity; stroke; traumatic brain injury; cerebral palsy; multiple sclerosis	INDUCED MOVEMENT THERAPY; PHANTOM-LIMB PAIN; PRIMARY SOMATOSENSORY CORTEX; CONSTRAINT-INDUCED APHASIA; REPETITIVE STRAIN INJURY; UPPER EXTREMITY FUNCTION; CROSS-MODAL PLASTICITY; FOCAL HAND DYSTONIA; MOTOR FUNCTION-TEST; FORCED-USE THERAPY	For the nineteenth and the better part of the twentieth centuries two correlative beliefs were strongly held by almost all neuroscientists and practitioners in the field of neurorehabilitation. The first was that after maturity the adult CNS was hardwired and fixed, and second that in the chronic phase after CNS injury no substantial recovery of function could take place no matter what intervention was employed. However, in the last part of the twentieth century evidence began to accumulate that neither belief was correct. First, in the 1960s and 1970s, in research with primates given a surgical abolition of somatic sensation from a single forelimb, which rendered the extremity useless, it was found that behavioral techniques could convert the limb into an extremity that could be used extensively. Beginning in the late 1980s, the techniques employed with deafferented monkeys were translated into a rehabilitation treatment, termed Constraint Induced Movement therapy or CI therapy, for substantially improving the motor deficit in humans of the upper and lower extremities in the chronic phase after stroke. CI therapy has been applied successfully to other types of damage to the CNS such as traumatic brain injury, cerebral palsy, multiple sclerosis, and spinal cord injury, and it has also been used to improve function in focal hand dystonia and for aphasia after stroke. As this work was proceeding, it was being shown during the 1980s and 1990s that sustained modulation of afferent input could alter the structure of the CNS and that this topographic reorganization could have relevance to the function of the individual. The alteration in these once fundamental beliefs has given rise to important recent developments in neuroscience and neurorehabilitation and holds promise for further increasing our understanding of CNS function and extending the boundaries of what is possible in neurorehabilitation.	[Taub, Edward; Uswatte, Gitendra; Mark, Victor W.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Uswatte, Gitendra] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA; [Mark, Victor W.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; [Mark, Victor W.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA	Taub, E (corresponding author), Univ Alabama Birmingham, Ctr Psychiat Med 714, 1720 2nd Ave South, Birmingham, AL 35294 USA.	etaub@uab.edu	Mark, Victor/AAT-3772-2020				ALHO K, 1993, ELECTROEN CLIN NEURO, V86, P418, DOI 10.1016/0013-4694(93)90137-K; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Bach-y-Rita P, 1992, J NEUROL REHABIL, V6, P191, DOI [10.1177/136140969200600404, DOI 10.1177/136140969200600404]; BACHYRITA P, 1990, CAN J PSYCHOL, V44, P148, DOI 10.1037/h0084247; Bara-Jimenez W, 1998, ANN NEUROL, V44, P828, DOI 10.1002/ana.410440520; BARD GREGORY, 1965, ARCH PHYS MED REHABIL, V46, P567; Bauder H, 1999, PSYCHOPHYSIOLOGY, V36, pS31; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Birbaumer N, 1997, J NEUROSCI, V17, P5503; BONDA E, 1995, P NATL ACAD SCI USA, V92, P11180, DOI 10.1073/pnas.92.24.11180; Braun C, 2000, J NEUROSCI, V20, P446, DOI 10.1523/JNEUROSCI.20-01-00446.2000; Briones TL, 2006, EXP NEUROL, V198, P530, DOI 10.1016/j.expneurol.2005.12.032; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Byl NN, 1997, PHYS THER, V77, P269, DOI 10.1093/ptj/77.3.269; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; Candia V, 2002, ARCH PHYS MED REHAB, V83, P1342, DOI 10.1053/apmr.2002.35094; Casey K., 1991, PAIN CENTRAL NERVOUS; CHAMBERS W W, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P721; Charles J, 2001, Pediatr Phys Ther, V13, P68, DOI 10.1097/00001577-200107000-00003; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; COROTTO FS, 1994, NEUROSCIENCE, V61, P739, DOI 10.1016/0306-4522(94)90397-2; Cronholm B., 1951, ACTA PSYCHIAT SCAND, V72, P151; Croteau C, 2006, APHASIOLOGY, V20, P327, DOI 10.1080/02687030500475051; DeBow SB, 2003, STROKE, V34, P1021, DOI 10.1161/01.STR.0000063374.89732.9F; Draganski B, 2006, NEUROIMAGE, V31, P951, DOI 10.1016/j.neuroimage.2006.01.018; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Dromerick AW, 2000, STROKE, V31, P2984, DOI 10.1161/01.STR.31.12.2984; Elbert T, 2002, J NEUROSCI, V22, P9941; Elbert T, 1997, EXP BRAIN RES, V117, P161, DOI 10.1007/s002210050210; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Elbert T, 1998, NEUROREPORT, V9, P3571, DOI 10.1097/00001756-199811160-00006; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Flor H, 2000, NEUROREPORT, V11, P1407, DOI 10.1097/00001756-200005150-00011; Flor H, 2001, LANCET, V357, P1763, DOI 10.1016/S0140-6736(00)04890-X; Flor H, 1998, EXP BRAIN RES, V119, P205, DOI 10.1007/s002210050334; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Foster L., 1996, NEUROLOGY REPORT, V20, P10, DOI [10.1097/01253086-199620040-00030, DOI 10.1097/01253086-199620040-00030]; Franz S. I., 1915, JAMA-J AM MED ASSOC, V65, P2150, DOI [DOI 10.1001/JAMA.1915.02580250022007, 10.1001/jama.1915.02580250022007]; Gauthier LV, 2008, STROKE, V39, P1520, DOI 10.1161/STROKEAHA.107.502229; GOULD E, 1992, J NEUROSCI, V12, P3642; Gritsenko V., 2001, Society for Neuroscience Abstracts, V27, P562; HALBERSTAM J L, 1971, Archives of Physical Medicine and Rehabilitation, V52, P318; HENDERSON WR, 1948, J NEUROL NEUROSUR PS, V11, P88, DOI 10.1136/jnnp.11.2.88; INCE LP, 1969, PSYCHON SCI, V16, P49; James W., 1887, P AM SOC PSYCHIC RES, V1, P249; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82; Johnson ML, 2014, AM J SPEECH-LANG PAT, V23, P60, DOI 10.1044/1058-0360(2013/12-0168); Johnson MJ, 2001, ASSIST TECHN RES SER, V9, P123; KATZ J, 1991, J PAIN SYMPTOM MANAG, V6, P73, DOI 10.1016/0885-3924(91)90521-5; Kedlaya D., 2001, ARCH PHYS MED REHAB, V82, P1340; KEW JJM, 1994, J NEUROPHYSIOL, V72, P2517; Kirmess M, 2010, APHASIOLOGY, V24, P725, DOI 10.1080/02687030903437682; KNAPP H D, 1959, Trans Am Neurol Assoc, V84, P185; KNAPP HD, 1963, EXP NEUROL, V7, P305, DOI 10.1016/0014-4886(63)90077-3; Knecht S, 1996, BRAIN, V119, P1213, DOI 10.1093/brain/119.4.1213; Knecht S, 1998, BRAIN, V121, P717, DOI 10.1093/brain/121.4.717; Kolb B, 2007, J CEREBR BLOOD F MET, V27, P983, DOI 10.1038/sj.jcbfm.9600402; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; KUJALA T, 1992, ELECTROEN CLIN NEURO, V84, P469, DOI 10.1016/0168-5597(92)90034-9; Kujala T, 1997, PSYCHOPHYSIOLOGY, V34, P213, DOI 10.1111/j.1469-8986.1997.tb02134.x; KUJALA T, 1995, EXP BRAIN RES, V104, P519; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Lashley KS, 1924, ARCH NEURO PSYCHIATR, V12, P249, DOI 10.1001/archneurpsyc.1924.02200030002001; LASSEK AM, 1953, J NEUROPATH EXP NEUR, V12, P83, DOI 10.1097/00005072-195301000-00008; Lessard N, 1998, NATURE, V395, P278; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Liepert J, 2001, J NEUROL, V248, P315, DOI 10.1007/s004150170207; LIU CN, 1958, ARCH NEURO PSYCHIATR, V79, P46, DOI 10.1001/archneurpsyc.1958.02340010064005; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lotze M, 1999, NAT NEUROSCI, V2, P501, DOI 10.1038/9145; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Maher LM, 2006, J INT NEUROPSYCH SOC, V12, P843, DOI 10.1017/S1355617706061029; Mall V, 2005, NEUROPEDIATRICS, V36, P373, DOI 10.1055/s-2005-873077; Mark VW, 2008, MULT SCLER J, V14, P992, DOI 10.1177/1352458508090223; Mark V W, 2006, Eura Medicophys, V42, P269; Mark VW, 2013, ARCH PHYS MED REHAB, V94, P753, DOI 10.1016/j.apmr.2012.09.032; Meinzer M, 2007, NEUROREHABILITATION, V22, P311; Meinzer M, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-20; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; Mitchell SW, 1871, LIPPINCOTTS MAGAZINE, V8, P563; Morris D., 2010, IMPROVING FUNCTIONAL, P232; Morris D M, 2006, Eura Medicophys, V42, P257; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; MUCHNIK C, 1991, SCAND AUDIOL, V20, P19, DOI 10.3109/01050399109070785; Muhlnickel W, 1998, P NATL ACAD SCI USA, V95, P10340, DOI 10.1073/pnas.95.17.10340; Nudo RJ, 1996, J NEUROSCI, V16, P785; Ogden R, 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; OSTENDORF CG, 1981, PHYS THER, V61, P1022, DOI 10.1093/ptj/61.7.1022; Parker V M, 1986, Int Rehabil Med, V8, P69; Peter C., 1997, J NEUROGICAL REHABIL, V3, P137; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Ploughman M, 2004, ARCH PHYS MED REHAB, V85, P1417, DOI 10.1016/j.apmr.2004.01.018; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; Ramachandran VS, 2000, ARCH NEUROL-CHICAGO, V57, P317, DOI 10.1001/archneur.57.3.317; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; RAUSELL E, 1992, P NATL ACAD SCI USA, V89, P2571, DOI 10.1073/pnas.89.7.2571; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031; Roder B, 1999, NATURE, V400, P162, DOI 10.1038/22106; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Roder B, 1997, PSYCHOPHYSIOLOGY, V34, P292, DOI 10.1111/j.1469-8986.1997.tb02400.x; ROSLER F, 1993, COGNITIVE BRAIN RES, V1, P145, DOI 10.1016/0926-6410(93)90022-W; Shaw S. E., 2003, J NEUROL PHYS THER, V27, P180, DOI [10.1682/JRRD.2005.06.0094, DOI 10.1682/JRRD.2005.06.0094]; Sherman R. A., 1997, PHANTOM PAIN, DOI [10.1007/978-1-4757-6169-6, DOI 10.1007/978-1-4757-6169-6]; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; Sherrington CS, 1931, BRAIN, V54, P1, DOI 10.1093/brain/54.1.1; Sherrington CS., 1894, P ROY SOC LONDON, V57, P481, DOI DOI 10.1098/RSP1.1894.0179; Skinner B. F., 1968, TECHNOLOGY TEACHING; Skinner BF, 1938, BEHAV ORGANISMS; STEIN JF, 1989, Q J EXP PHYSIOL CMS, V74, P583, DOI 10.1113/expphysiol.1989.sp003314; Sterling C, 2013, PEDIATRICS, V131, pE1664, DOI 10.1542/peds.2012-2051; Sterr A, 2003, NEUROLOGY, V61, P842, DOI 10.1212/WNL.61.6.842; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; Sterr A, 1998, NATURE, V391, P134, DOI 10.1038/34322; Stevenson T, 2012, PHYSIOTHER CAN, V64, P397, DOI 10.3138/ptc.2011-24; TAUB E, 1975, EXP NEUROL, V46, P178, DOI 10.1016/0014-4886(75)90040-0; TAUB E, 1965, J COMP PHYSIOL PSYCH, V59, P275, DOI 10.1037/h0021817; Taub E, 2006, Eura Medicophys, V42, P241; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; TAUB E, 1977, ANN NY ACAD SCI, V290, P348, DOI 10.1111/j.1749-6632.1977.tb39737.x; Taub E, 2004, AM PSYCHOL, V59, P692, DOI 10.1037/0003-066X.59.8.692; Taub E, 2004, PEDIATRICS, V113, P305, DOI 10.1542/peds.113.2.305; TAUB E, 1975, BIOL PSYCHIAT, V10, P609; TAUB E, 1963, J COMP PHYSIOL PSYCH, V56, P1012, DOI 10.1037/h0048315; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Taub E., 1995, J NIH RES, V1, P49; Taub E., 2009, HDB NEUROSCIENCE BEH, P1296; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; Taub E, 1968, NEUROPSYCHOL SPATIAL, P173; Taub Edward, 2007, Dev Neurorehabil, V10, P3, DOI 10.1080/13638490601151836; Taub E, 2006, NEUROREHABILITATION, V21, P93; Taub E, 2013, STROKE, V44, P1383, DOI 10.1161/STROKEAHA.111.000559; Taub E, 2013, ARCH PHYS MED REHAB, V94, P86, DOI 10.1016/j.apmr.2012.07.029; Taub E, 2011, J CHILD NEUROL, V26, P1163, DOI 10.1177/0883073811408423; Tower SS, 1940, BRAIN, V63, P36, DOI 10.1093/brain/63.1.36; TWITCHELL TE, 1954, J NEUROPHYSIOL, V17, P239; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; Uswatte G, 2006, NEUROLOGY, V67, P1189, DOI 10.1212/01.wnl.0000238164.90657.c2; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; Uswatte G, 2006, NEUROREHABILITATION, V21, P147; Uswatte G, 2013, PROG BRAIN RES, V207, P379, DOI 10.1016/B978-0-444-63327-9.00015-1; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; Weeks R, 2000, J NEUROSCI, V20, P2664; Weiss T, 2004, EUR J NEUROSCI, V20, P3413, DOI 10.1111/j.1460-9568.2004.03790.x; Weiss T, 1999, NEUROSCI LETT, V272, P131, DOI 10.1016/S0304-3940(99)00595-9; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; WOLF SL, 1983, PHYS THER, V63, P1393, DOI 10.1093/ptj/63.9.1393; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Wolf SL, 2008, LANCET NEUROL, V7, P33, DOI 10.1016/S1474-4422(07)70294-6; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Woods TM, 2000, J NEUROSCI, V20, P3884; Yamashima T, 2004, HIPPOCAMPUS, V14, P861, DOI 10.1002/hipo.20001; YANG TT, 1994, NATURE, V368, P592, DOI 10.1038/368592b0	172	26	26	1	57	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JUN 27	2014	8								396	10.3389/fnhum.2014.00396			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AM6BK	WOS:000339945600001	25018720	DOAJ Gold, Green Published			2021-06-18	
J	Daoud, H; Alharfi, I; Alhelali, I; Stewart, TC; Qasem, H; Fraser, DD				Daoud, Hani; Alharfi, Ibrahim; Alhelali, Ibrahim; Stewart, Tanya Charyk; Qasem, Hadiah; Fraser, Douglas D.			Brain Injury Biomarkers as Outcome Predictors in Pediatric Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Pediatric; Severe traumatic brain injury; Biomarker; Outcome; Systematic review	NERVE GROWTH-FACTOR; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; HEAD-INJURY; TRANSLATIONAL RESEARCH; FACTOR EXPRESSION; CHILDREN; SERUM; PERFORMANCE; RECLASSIFICATION	To systematically review the literature on brain injury biomarkers, defined as any injury biomarker detected in cerebrospinal fluid (CSF) or blood injury biomarkers primarily expressed in the brain parenchyma, to determine outcome prediction in pediatric severe traumatic brain injury (sTBI). A search of MEDLINEA (R), EMBASE(A (R)), PsycINFO(A (R)), Pubmed(A (R)), and the Cochrane Database, as well as grey literature sources, personal contacts, hand searches, and reference lists. The search terms used were traumatic brain injury, biomarkers, prognosis, and children. No language, publication type, or publication date restrictions were imposed. All articles were critically reviewed by two clinicians independently. A total of 7,150 articles were identified initially with 16 studies identified for review. Eighteen different biomarkers were examined; 11 in CSF and 7 in blood. Outcomes assessed included either in-hospital mortality or functional state (hospital discharge, 3-months or 6-months; Glasgow Outcome Scale or Pediatric Cerebral Performance Category). Significant correlations were established between sTBI outcomes and various biomarkers in CSF (IL-6, IL-8, IL-1 beta, S100 beta, NGF, NSE, DCX, ET-1, HMGB-1, cytochrome C) and blood (GFAP, NF-H, UCH-L1, SBDP-145, leptin). Mixed results were obtained for blood S100 beta. Outcome did not correlate with several biomarkers in either CSF (BDNF, GDNF, alpha-Syn) or blood (NSE, MBP). The Class of Evidence was considered II in 1 study and III in the remaining 15 studies. Based on the status of current sTBI biomarker research, we recommend that future research should be directed at both novel biomarker discovery and validation of biomarker panels in large, well-designed longitudinal studies.	[Daoud, Hani; Alharfi, Ibrahim; Alhelali, Ibrahim; Qasem, Hadiah; Fraser, Douglas D.] Univ Western Ontario, Dept Paediat, London, ON, Canada; [Alharfi, Ibrahim] King Fahad Med City, Dept Pediat Crit Care, Riyadh, Saudi Arabia; [Stewart, Tanya Charyk] Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada; [Stewart, Tanya Charyk; Fraser, Douglas D.] London Hlth Sci Ctr, Trauma Program, London, ON, Canada; [Fraser, Douglas D.] Translat Res Ctr, London, ON, Canada; [Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, London, ON, Canada; [Fraser, Douglas D.] Childrens Hosp, London Hlth Sci Ctr, London N6A 5W9, England	Fraser, DD (corresponding author), Childrens Hosp, London Hlth Sci Ctr, Room C2-C82,800 Commissioners Rd East, London N6A 5W9, England.	douglas.fraser@lhsc.on.ca					Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Brisson AR, 2012, PEDIATRICS, V129, P153, DOI 10.1542/peds.2011-0134; Charyk Stewart T, 2013, J TRAUMA AC IN PRESS; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Gillio-Meina C, 2013, PEDIATRICS, V131, P754, DOI 10.1542/peds.2012-1181; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Houser B, 2012, ARCH PHYSIOL BIOCHEM, V118, P192, DOI 10.3109/13813455.2012.705301; JENNETT B, 1975, LANCET, V1, P480; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kaska M, 2002, Rozhl Chir, V81, P22; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS7, DOI 10.1097/PCC.0b013e31823f43df; Lin C, 2012, PEPTIDES, V35, P166, DOI 10.1016/j.peptides.2012.03.024; Morrison G., 2012, PATHOPHYSIOLOGY, V20, P49; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Sangha GS, 2012, INJURY, V43, P2046, DOI 10.1016/j.injury.2011.10.034; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shaw G, 2004, BIOCHEM BIOPH RES CO, V325, P619, DOI 10.1016/j.bbrc.2004.09.223; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Zurek J, 2011, J TRAUMA, V71, P854, DOI 10.1097/TA.0b013e3182140c8c; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	42	26	26	0	16	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2014	20	3					427	435		10.1007/s12028-013-9879-1			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	AI7RH	WOS:000337092900011	23943317				2021-06-18	
J	George, EO; Roys, S; Sours, C; Rosenberg, J; Zhuo, JC; Shanmuganathan, K; Gullapalli, RP				George, Elijah O.; Roys, Steve; Sours, Chandler; Rosenberg, Joseph; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Longitudinal and Prognostic Evaluation of Mild Traumatic Brain Injury: A 1H-Magnetic Resonance Spectroscopy Study	JOURNAL OF NEUROTRAUMA			English	Article						longitudinal study; magnetic resonance spectroscopy; mTBI; neuropsychological tests	PROTON-MAGNETIC-RESONANCE; DIFFUSE AXONAL INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; POSTTRAUMATIC-STRESS-DISORDER; APPEARING WHITE-MATTER; N-ACETYL-ASPARTATE; MITOCHONDRIAL DYSFUNCTION; MR SPECTROSCOPY; METABOLIC-CHANGES; HEAD-INJURY	In the majority of patients with mild traumatic brain injury (mTBI), brain tissue impairment is undetectable by computed tomography and/or structural magnetic resonance imaging. Even in confirmed cases of head injury, conventional neuroimaging methods lack sensitivity in predicting neuropsychological outcomes of patients. The objectives of this study were to (1) cross-sectionally determine deviations in the neurometabolic profile of patients with mTBI from healthy controls at different stages of mTBI using tightly controlled examination windows, and (2) determine associations between acute neurometabolic markers of mTBI and chronic neurocognitive performance. Patients were examined at the early subacute (n = 43; 5.44 +/- 3.15 days post-injury (DPI)), late subacute (n = 33; 37.00 +/- 12.26 DPI) and chronic (n = 27; 195.30 +/- 19.60 DPI) stages of mTBI. Twenty-one neurologically intact subjects were used as controls. Proton magnetic resonance spectroscopy imaging (H-1-MRSI) was used to obtain metabolic measurements from different brain regions. The Automated Neuropsychological Assessment Metrics (ANAM) was used for cognitive evaluation of patients at the chronic stage of mTBI. Measurements in the thalamus and centrum semiovale (CSV) emerged as the most indicative of injury and were used to predict neurocognitive outcome. The major findings of this study are (1) decreases in Cho/Cre (choline-to-creatine ratio) measured in the thalamus (p = 0.042) and CSV (p = 0.017) at the late subacute stage of mTBI; (2) positive associations of early subacute Cre measurements in the CSV with chronic ANAM scores measuring performance in delayed (r = 0.497, p = 0.019) and immediate (r = 0.391, p = 0.072) code substitution. These findings show that metabolic measurements in the thalamus and CSV can potentially serve as diagnostic and prognostic markers of mTBI.	[George, Elijah O.; Roys, Steve; Sours, Chandler; Rosenberg, Joseph; Zhuo, Jiachen; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [George, Elijah O.; Gullapalli, Rao P.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA	Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu			US ArmyUnited States Department of Defense [W81XWH-08-1-0725, W81XWH-12-1-0098]	The authors would like to thank the Adam Cowley Shock Trauma Core team for their help with patient recruitment, George Makris for help with data acquisition, and Jacqueline Janowich for assistance with neuropsychological assessments. This study was supported by US Army awards W81XWH-08-1-0725 and W81XWH-12-1-0098.	Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bay E, 2012, BRAIN INJURY, V26, P941, DOI 10.3109/02699052.2012.666365; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bendszus M, 2001, AM J NEURORADIOL, V22, P1926; Berman JI, 2004, J NEUROSURG, V101, P66, DOI 10.3171/jns.2004.101.1.0066; Bizzi A, 2001, AM J NEURORADIOL, V22, P1125; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Chang L, 1996, LIFE SCI, V58, P2049, DOI 10.1016/0024-3205(96)00197-X; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; DAVIE CA, 1993, LANCET, V341, P630, DOI 10.1016/0140-6736(93)90390-3; Demougeot C, 2003, J CEREBR BLOOD F MET, V23, P482, DOI 10.1097/01.WCB.0000050066.57184.60; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Durazzo TC, 2004, ALCOHOL CLIN EXP RES, V28, P1849, DOI 10.1097/01.ALC.0000148112.92525.AC; Freeman TW, 1998, MAGNET RESON MED, V40, P66, DOI 10.1002/mrm.1910400110; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRAHAM GD, 1993, STROKE, V24, P1891, DOI 10.1161/01.STR.24.12.1891; Greco T, 2013, J CHILD NEUROL, V28, P983, DOI 10.1177/0883073813487594; Greenfield J., 2008, GREENFIELDS NEUROPAT, V1; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hattingen E, 2009, BRAIN, V132, P3285, DOI 10.1093/brain/awp293; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kamada Kyousuke, 1994, Neurologia Medico-Chirurgica, V34, P676, DOI 10.2176/nmc.34.676; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Ongur D, 2010, MAGN RESON MED, V63, P1, DOI 10.1002/mrm.22148; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Parks MH, 2002, ALCOHOL CLIN EXP RES, V26, P1368, DOI 10.1097/01.ALC.0000029598.07833.2D; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Renshaw PF, 1997, BIOL PSYCHIAT, V41, P837, DOI 10.1016/S0006-3223(96)00256-9; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; SBARRA AJ, 1959, J BIOL CHEM, V234, P1355; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tartaglia MC, 2002, J NEUROL, V249, P1382, DOI 10.1007/s00415-002-0846-6; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toblin RL, 2012, J AFFECT DISORDERS, V136, P469, DOI 10.1016/j.jad.2011.10.048; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	88	26	28	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1018	1028		10.1089/neu.2013.3224			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300004	24467391				2021-06-18	
J	Steppacher, I; Kaps, M; Kissler, J				Steppacher, Inga; Kaps, Michael; Kissler, Johanna			Will time heal? A long-term follow-up of severe disorders of consciousness	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; PROLONGED UNCONSCIOUS STATE; VEGETATIVE STATE; PREDICTS RECOVERY; SEX-DIFFERENCES; YOUNG-ADULTS; OUTCOMES; REHABILITATION; CHILDREN; DISABILITY	Objective: Little is known about the long-term outcome of patients with disorders of consciousness (DOCs) such as unresponsive wakefulness syndrome (UWS) or minimally conscious state (MCS). We describe the disease course of a large group of DOC patients 2-14 years after brain damage. Methods: In 102 patients (59 UWS, 43 MCS), clinical and demographic variables from disorder onset were related to the patients' outcomes 2-14 years after discharge. Etiology, age at event, time since onset, gender, and home care versus institutional care were assessed as predictors and similarities and differences between UWS and MCS determined. Results: Seventy-one percent of the patients had passed away or showed no improvement in condition. Twenty-nine percent regained consciousness and developed some communicative capacities. The time a syndrome persisted did not predict clinical outcome in either condition. Six patients regained consciousness after more than 3 years. Of these, five had been UWS (42% of recovered UWS, three traumatic origins, one tumor, one hypoxia) and one MCS (5% of recovered MCS, traumatic origin). In UWS, younger patients, those cared for at home, and in tendency those with traumatic origins, were more likely to recover. In MCS, no reliable outcome predictors were found. Interpretation: Current predictors are too vague for single patient predictions. This study identifies a subgroup of late-recovering patients, casting doubt on the 12-month boundary, after which UWS is stated to be permanent. Routine reexamination, use of more reliable outcome predictors and research determining optimal care settings are needed to inform the crucial decisions made for these patients.	[Steppacher, Inga; Kissler, Johanna] Univ Bielefeld, Dept Psychol, D-33615 Bielefeld, Germany; [Kaps, Michael] Kliniken Schmieder Allensbach, Lurija Inst, Early Rehabil Unit, D-78476 Allensbach, Germany	Steppacher, I (corresponding author), Univ Bielefeld, Univ Str 25, D-33615 Bielefeld, Germany.	Inga.Steppacher@Uni-Bielefeld.de	Kissler, Johanna/B-7361-2019	Kissler, Johanna/0000-0002-4567-1997			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Cavinato M, 2009, BRAIN INJURY, V23, P973, DOI 10.3109/02699050903373493; Childs NL, 1996, BRIT MED J, V313, P944; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Cranford R, 1996, BRIT MED J, V313, P5, DOI 10.1136/bmj.313.7048.5; Deakin CD, 2010, NOTFALL RETTUNGSMED, V13, P559, DOI 10.1007/s10049-010-1370-3; Eilander HJ, 2007, BRAIN INJURY, V21, P53, DOI 10.1080/02699050601151795; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Glader EL, 2003, STROKE, V34, P1970, DOI 10.1161/01.STR.0000083534.81284.C5; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Martinez-Sanchez P, 2011, CEREBROVASC DIS, V31, P455, DOI 10.1159/000323851; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1861, DOI 10.1016/j.apmr.2013.05.027; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; PAGNI CA, 1977, ACTA NEUROCHIR, V36, P37, DOI 10.1007/BF01405985; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Roquer J, 2003, STROKE, V34, P1581, DOI 10.1161/01.STR.0000078562.82918.F6; Steppacher I, 2013, ANN NEUROL, V73, P594, DOI 10.1002/ana.23835; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strens LHA, 2004, BRAIN INJURY, V18, P213, DOI 10.1080/0269905031000149533; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Voss A, 1993, SPECTRUM NEUROREHABI, P112; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1851, DOI 10.1016/j.apmr.2013.07.003; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1855, DOI 10.1016/j.apmr.2012.10.041; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020	37	26	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	JUN	2014	1	6					401	408		10.1002/acn3.63			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V45KI	WOS:000209815100003	25356410	DOAJ Gold, Green Published			2021-06-18	
J	Huusko, N; Pitkanen, A				Huusko, N.; Pitkanen, A.			PARVALBUMIN IMMUNOREACTIVITY AND EXPRESSION OF GABA(A) RECEPTOR SUBUNITS IN THE THALAMUS AFTER EXPERIMENTAL TBI	NEUROSCIENCE			English	Article						epileptogenesis; lateral fluid-percussion injury; parvalbumin; pentylenetetrazol; reticular nucleus; seizure susceptibility	TRAUMATIC BRAIN-INJURY; RAT HIPPOCAMPUS; POSTTRAUMATIC EPILEPSY; PATHOLOGICAL RESEARCH; SOMATOSENSORY CORTEX; GABAERGIC NEURONS; RETICULAR NEURONS; CARDIAC-ARREST; SELECTIVE LOSS; MESSENGER-RNA	Traumatic brain injury (TBI) causes 10-20% of acquired epilepsy in humans, resulting in an ictogenic region that is often located in the cerebral cortex. The thalamus provides heavy projections to the cortex and the activity of thalamocortical pathways is controlled by GABAergic afferents from the reticular nucleus of the thalamus (RT). As rats with TBI induced by lateral fluid-percussion injury (FPI) undergo epileptogenesis, we hypothesized that damage to the parvalbumin (PARV)-immunoreactive (ir) neurons in the RT is associated with seizure susceptibility after lateral FPI. To address this hypothesis, adult Sprague-Dawley rats (n = 13) were injured with lateral FPI. At 6 months post-TBI, each animal underwent a pentylenetetrazol (PTZ) seizure susceptibility test and 2 weeks of continuous video-electroencephalography (EEG) monitoring for detection of the occurrence of spontaneous seizures. Thereafter, the brain was processed for PARV immunohistochemistry. We (a) estimated the total number of PARV-ir neurons in the RT using unbiased stereology, (b) measured the volume of the ventroposteromedial (VPM) and ventroposterolateral (VPL) nuclei of the thalamus, which receive PARV-ir inputs from the RT and project to the perilesional cortex, (c) quantified the density of PARV-ir terminals in the VPM-VPL, and (d) studied the expression of GABA(A) receptor subunits in a separate group of rats using laser-dissection of the thalamus followed by Real-Time polymerase chain reaction (RTPCR) array studies. At 6 months post-TBI, only 64% of PARV-ir neurons were remaining in the RT ipsilaterally (p < 0.001 as compared to controls) and 84% contralaterally (p < 0.05). Accordingly, the volume of the ipsilateral RT was 58% of that in controls ipsilaterally (p < 0.001) and 90% contralaterally (p > 0.05). Also, the volume of the VPM-VPL was only 51% of that in controls ipsilaterally (p < 0.001) and 91% contralaterally (p < 0.05). The density of PARV-ir axonal labeling was remarkably increased in the lateral aspects of the VPM and VPL (both p < 0.001). Expression of the epsilon- and theta-subunits of the GABAA receptor was down-regulated (0.152, p < 0.01 and 0.302, p < 0.05, respectively), which could relate to the inclusion of the hypothalamus into the tissue analyzed with RT-PCR arrays. In controls, the lower the number of PARV-ir neurons in the RT, the higher the seizure susceptibility in the PTZ test. Rats with TBI showed seizure susceptibility comparable to that in controls with the lowest number of PARV-ir neurons in the RT. Our data show that the RT and VPM-VPL undergo remarkable degeneration after lateral-FPI which results in reorganization of PARV-ir terminals in the VPM-VPL. The contribution of RT damage to seizure susceptibility and post-traumatic epileptogenesis deserves further studies. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Huusko, N.; Pitkanen, A.] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, FI-70211 Kuopio, Finland; [Pitkanen, A.] Kuopio Univ Hosp, Dept Neurol, FI-70211 Kuopio, Finland	Huusko, N (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland.	noora.huusko@uef.fi			FP6European Commission [LSHM-CT-2006-037315]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; COST ActionEuropean Cooperation in Science and Technology (COST) [BM1001]; North-Savo Regional Fund of The Finnish Cultural FoundationFinnish Cultural Foundation; Finnish Epilepsy Foundation	This study was supported by the FP6 Grant LSHM-CT-2006-037315 (A. P.), Academy of Finland (A. P.), The Sigrid Juselius Foundation (A. P.), COST Action BM1001 (A. P.), The North-Savo Regional Fund of The Finnish Cultural Foundation (N.H.), and The Finnish Epilepsy Foundation (N.H.). We thank Mr. Jarmo Hartikainen and Mrs. Merja Lukkari for their excellent technical assistance.	Airaksinen AM, 2012, ISMRM 20 ANN M MELB; Aker RG, 2006, BRAIN RES, V1111, P213, DOI 10.1016/j.brainres.2006.06.118; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ARAI R, 1994, BRAIN RES BULL, V33, P595, DOI 10.1016/0361-9230(94)90086-8; Avoli M, 2011, PROG NEUROBIOL, V95, P104, DOI 10.1016/j.pneurobio.2011.07.003; Bailey MES, 1999, MAMM GENOME, V10, P839, DOI 10.1007/s003359901101; Barba C, 2007, EPILEPSIA, V48, P278, DOI 10.1111/j.1528-1167.2007.00935.x; Barba C, 2012, J NEUROL, V259, P1613, DOI 10.1007/s00415-011-6387-0; BARBARESI P, 1986, BRAIN RES, V382, P305, DOI 10.1016/0006-8993(86)91340-5; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bottiger BW, 1998, J CEREBR BLOOD F MET, V18, P1077; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; BURTON H, 1984, J COMP NEUROL, V224, P173, DOI 10.1002/cne.902240203; CARMAN JB, 1964, J ANAT, V98, P587; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; Fritschy JM, 2003, PHARMACOL THERAPEUT, V98, P299, DOI 10.1016/S0163-7258(03)00037-8; Fritschy JM, 1999, NEUROCHEM INT, V34, P435, DOI 10.1016/S0197-0186(99)00040-6; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; Guillery RW, 1998, TRENDS NEUROSCI, V21, P28, DOI 10.1016/S0166-2236(97)01157-0; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HARRIS RM, 1987, NEUROSCIENCE, V21, P229, DOI 10.1016/0306-4522(87)90335-6; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Henry EC, 2006, ANAT REC PART A, V288A, P626, DOI 10.1002/ar.a.20328; HOUSER CR, 1980, BRAIN RES, V200, P341, DOI 10.1016/0006-8993(80)90925-7; Huusko N., 2013, BRAIN STRUCT FUNCT; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jones EG, 2009, ANN NY ACAD SCI, V1157, P10, DOI 10.1111/j.1749-6632.2009.04534.x; KAWAI K, 1995, ACTA NEUROPATHOL, V89, P262; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; LEE SM, 1994, J NEUROPHYSIOL, V71, P1702; LEE SM, 1994, J NEUROPHYSIOL, V71, P1716; Lehto LJ, 2012, NEUROIMAGE, V61, P761, DOI 10.1016/j.neuroimage.2012.03.002; Liao CC, 2008, ANAT REC, V291, P960, DOI 10.1002/ar.20696; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; LOSCHER W, 1991, EPILEPSY RES, V9, P1, DOI 10.1016/0920-1211(91)90041-D; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; MIRSKI MA, 1986, EPILEPSIA, V27, P194, DOI 10.1111/j.1528-1157.1986.tb03528.x; MIRSKI MA, 1986, BRAIN RES, V399, P212, DOI 10.1016/0006-8993(86)91511-8; MIRSKI MA, 1984, SCIENCE, V226, P72, DOI 10.1126/science.6433485; MIRSKI MA, 1986, BRAIN RES, V397, P377, DOI 10.1016/0006-8993(86)90642-6; Moragues N, 2002, NEUROSCIENCE, V111, P657, DOI 10.1016/S0306-4522(02)00033-7; Niskanen JP, 2013, J NEUROTRAUM, V30, P546, DOI 10.1089/neu.2012.2416; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pierret T, 2000, J NEUROSCI, V20, P7455; Pinault D, 1998, J COMP NEUROL, V391, P180, DOI 10.1002/(SICI)1096-9861(19980209)391:2<180::AID-CNE3>3.0.CO;2-Z; PINAULT D, 1995, EUR J NEUROSCI, V7, P31, DOI 10.1111/j.1460-9568.1995.tb01017.x; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; ROSS DT, 1993, J CEREBR BLOOD F MET, V13, P558, DOI 10.1038/jcbfm.1993.73; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1995, BRAIN RES, V683, P117, DOI 10.1016/0006-8993(95)00344-P; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; SETOOHSHIMA A, 1989, EXP BRAIN RES, V75, P653; Sherman AM, 2006, EXPLORING THALAMUS I; SHOSAKU A, 1989, PROG NEUROBIOL, V32, P77, DOI 10.1016/0301-0082(89)90011-7; Sinkkonen ST, 2000, J NEUROSCI, V20, P3588; Sperk G, 1998, EPILEPSY RES, V32, P129, DOI 10.1016/S0920-1211(98)00046-1; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	74	26	26	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAY 16	2014	267						30	45		10.1016/j.neuroscience.2014.02.026			16	Neurosciences	Neurosciences & Neurology	AF0KM	WOS:000334402700004	24607347				2021-06-18	
J	Montani, V; De Grazia, MD; Zorzi, M				Montani, Veronica; De Grazia, Michele De Filippo; Zorzi, Marco			A new adaptive videogame for training attention and executive functions: design principles and initial validation	FRONTIERS IN PSYCHOLOGY			English	Article						videogames; attention; attention deficits; executive functions; cognitive enhancement	TRAUMATIC BRAIN-INJURY; DUAL-TASK PERFORMANCE; CLOSED-HEAD INJURY; GAME PLAYERS; SPATIAL COGNITION; OLDER-ADULTS; TIME; PLASTICITY; DEFICITS; CORTEX	A growing body of evidence suggests that action videogames could enhance a variety of cognitive skills and more specifically attention skills. The aim of this study was to develop a novel adaptive videogame to support the rehabilitation of the most common consequences of traumatic brain injury (TBI), that is the impairment of attention and executive functions. TBI patients can be affected by psychomotor slowness and by difficulties in dealing with distraction, maintain a cognitive set for a long time, processing different simultaneously presented stimuli, and planning purposeful behavior. Accordingly, we designed a videogame that was specifically conceived to activate those functions. Playing involves visuospatial planning and selective attention, active maintenance of the cognitive set representing the goal, and error monitoring. Moreover, different game trials require to alternate between two tasks (i.e., task switching) or to perform the two tasks simultaneously (i.e., divided attention/dual-tasking). The videogame is controlled by a multidimensional adaptive algorithm that calibrates task difficulty on-line based on a model of user performance that is updated on a trial-by-trial basis. We report simulations of user performance designed to test the adaptive game as well as a validation study with healthy participants engaged in a training protocol. The results confirmed the involvement of the cognitive abilities that the game is supposed to enhance and suggested that training improved attentional control during play.	[Montani, Veronica; De Grazia, Michele De Filippo; Zorzi, Marco] Univ Padua, Dept Gen Psychol, I-35131 Padua, Italy; [Zorzi, Marco] Univ Padua, Ctr Cognit Neurosci, I-35131 Padua, Italy; [Zorzi, Marco] IRCCS San Camillo Neurorehabil Hosp, Venice Lido, Italy	Zorzi, M (corresponding author), Univ Padua, Dept Gen Psychol, Via Venezia 8, I-35131 Padua, Italy.	marco.zorzi@unipd.it	De Filippo De Grazia, Michele/AAA-3054-2021; Zorzi, Marco/B-7863-2008	De Filippo De Grazia, Michele/0000-0003-3682-8582; Zorzi, Marco/0000-0002-4651-6390			Achtman RL, 2008, RESTOR NEUROL NEUROS, V26, P435; Andreadis N, 2010, ATTEN PERCEPT PSYCHO, V72, P1776, DOI 10.3758/APP.72.7.1776; Anguera JA, 2013, NATURE, V501, P97, DOI 10.1038/nature12486; Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; Baayen R. H., 2008, ANAL LINGUISTIC DATA, DOI [10.1017/CBO9780511801686, DOI 10.1017/CBO9780511801686]; Baniqued PL, 2013, ACTA PSYCHOL, V142, P74, DOI 10.1016/j.actpsy.2012.11.009; Basak C, 2008, PSYCHOL AGING, V23, P765, DOI 10.1037/a0013494; Basso D, 2001, BRAIN COGNITION, V46, P38, DOI 10.1016/S0278-2626(01)80029-4; Bates D., 2013, LME4 LINEARMIXED EFF; Bavelier D, 2012, VISION RES, V61, P132, DOI 10.1016/j.visres.2011.08.007; Bherer L, 2005, PSYCHOL AGING, V20, P695, DOI 10.1037/0882-7974.20.4.695; Bonato M, 2013, BEHAV NEUROL, V26, P179, DOI [10.3233/BEN-2012-129005, 10.1155/2013/139812]; Bonato M, 2012, NEUROPSYCHOLOGY, V26, P20, DOI 10.1037/a0025306; Bonato M, 2010, NEUROPSYCHOLOGIA, V48, P3934, DOI 10.1016/j.neuropsychologia.2010.08.022; Boot WR, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00226; Boot WR, 2008, ACTA PSYCHOL, V129, P387, DOI 10.1016/j.actpsy.2008.09.005; Brehmer Y, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00063; Cain MS, 2012, ATTEN PERCEPT PSYCHO, V74, P641, DOI 10.3758/s13414-012-0284-1; Castel AD, 2005, ACTA PSYCHOL, V119, P217, DOI 10.1016/j.actpsy.2005.02.004; Chiappe D, 2013, APPL ERGON, V44, P278, DOI 10.1016/j.apergo.2012.08.002; Chisholm JD, 2010, ATTEN PERCEPT PSYCHO, V72, P667, DOI 10.3758/APP.72.3.667; CLARK JE, 1987, J GERONTOL, V42, P82, DOI 10.1093/geronj/42.1.82; Clark K, 2011, ACTA PSYCHOL, V136, P67, DOI 10.1016/j.actpsy.2010.10.003; Colzato LS, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00008; Cutini S, 2008, COGN NEUROPSYCHOL, V25, P194, DOI 10.1080/02643290701606408; Dell'Acqua R, 2006, PSYCHOL RES-PSYCH FO, V70, P553, DOI 10.1007/s00426-005-0016-4; Donohue SE, 2012, ATTEN PERCEPT PSYCHO, V74, P803, DOI 10.3758/s13414-012-0323-y; Dux PE, 2009, NEURON, V63, P127, DOI 10.1016/j.neuron.2009.06.005; Dye MWG, 2009, NEUROPSYCHOLOGIA, V47, P1780, DOI 10.1016/j.neuropsychologia.2009.02.002; Dye MWG, 2009, CURR DIR PSYCHOL SCI, V18, P321, DOI 10.1111/j.1467-8721.2009.01660.x; Feng J, 2007, PSYCHOL SCI, V18, P850, DOI 10.1111/j.1467-9280.2007.01990.x; Foley JA, 2010, BRAIN INJURY, V24, P851, DOI 10.3109/02699051003789278; Franceschini S, 2013, CURR BIOL, V23, P462, DOI 10.1016/j.cub.2013.01.044; Gehring K, 2008, LANCET NEUROL, V7, P548, DOI 10.1016/S1474-4422(08)70111-X; GIALANELLA B, 1992, NEUROPSYCHOL REHABIL, V2, P169, DOI DOI 10.1080/09602019208401406; GOPHER D, 1994, HUM FACTORS, V36, P387; Green CS, 2006, COGNITION, V101, P217, DOI 10.1016/j.cognition.2005.10.004; Green CS, 2006, J EXP PSYCHOL HUMAN, V32, P1465, DOI 10.1037/0096-1523.32.6.1465; Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647; Holmes J, 2009, DEVELOPMENTAL SCI, V12, pF9, DOI 10.1111/j.1467-7687.2009.00848.x; Hubert-Wallander B, 2011, ATTEN PERCEPT PSYCHO, V73, P2399, DOI 10.3758/s13414-011-0194-7; Hubert-Wallander B, 2011, WIRES COGN SCI, V2, P222, DOI 10.1002/wcs.116; Irons JL, 2011, AUST J PSYCHOL, V63, P224, DOI 10.1111/j.1742-9536.2011.00001.x; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; Kamke MR, 2012, J NEUROSCI, V32, P7001, DOI 10.1523/JNEUROSCI.1028-12.2012; Karle JW, 2010, ACTA PSYCHOL, V134, P70, DOI 10.1016/j.actpsy.2009.12.007; Krainik A, 2004, NEUROLOGY, V62, P1323, DOI 10.1212/01.WNL.0000120547.83482.B1; Kristjansson A, 2013, ATTEN PERCEPT PSYCHO, V75, P667, DOI 10.3758/s13414-013-0427-z; Kuznetsova A., 2013, LMERTEST TESTS RANDO LMERTEST TESTS RANDO LMERTEST TESTS RANDO; Latham AJ, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00629; Lawrence MA, 2012, EZ EASY ANAL VISUALI; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Mathewson KE, 2012, PSYCHOPHYSIOLOGY, V49, P1558, DOI 10.1111/j.1469-8986.2012.01474.x; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Meiran N, 2000, COGNITIVE PSYCHOL, V41, P211, DOI 10.1006/cogp.2000.0736; Mishra J, 2011, J NEUROSCI, V31, P992, DOI 10.1523/JNEUROSCI.4834-10.2011; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Morey RD, 2008, TUTOR QUANT METHODS, V4, P61, DOI 10.20982/tqmp.04.2.p061; Murphy K., 2009, J ARTICLES SUPPORT N, V6, P1; Nelson RA, 2009, PERCEPTION, V38, P1678, DOI 10.1068/p6324; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prigatano G. P., 1991, AWARENESS DEFICIT BR; R Core Team, 2013, R LANG ENV STAT COMP; RECANZONE GH, 1993, J NEUROSCI, V13, P87; Rosenberg BH, 2005, J ENDOUROL, V19, P372, DOI 10.1089/end.2005.19.372; Schumacher EH, 2001, PSYCHOL SCI, V12, P101, DOI 10.1111/1467-9280.00318; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Singmann H, 2013, AFEX ANAL FACTORIAL; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Spence I, 2010, REV GEN PSYCHOL, V14, P92, DOI 10.1037/a0019491; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Strobach T, 2012, ACTA PSYCHOL, V140, P13, DOI 10.1016/j.actpsy.2012.02.001; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tombu M, 2004, J EXP PSYCHOL HUMAN, V30, P795, DOI 10.1037/0096-1523.30.5.795; Van Selst M, 1999, J EXP PSYCHOL HUMAN, V25, P1268, DOI 10.1037/0096-1523.25.5.1268; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; Waters J., 1986, COGNITIVE REHABILITA, V4, P26; West GL, 2008, J VISION, V8, DOI 10.1167/8.16.13; Wilson Anna J, 2006, Behav Brain Funct, V2, P19, DOI 10.1186/1744-9081-2-19; Wu SJ, 2012, J COGNITIVE NEUROSCI, V24, P1286, DOI 10.1162/jocn_a_00192	84	26	28	2	64	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	MAY 13	2014	5								409	10.3389/fpsyg.2014.00409			12	Psychology, Multidisciplinary	Psychology	AH3OG	WOS:000336033000001	24860529	DOAJ Gold, Green Published			2021-06-18	
J	Novgorodov, SA; Riley, CL; Yu, J; Borg, KT; Hannun, YA; Proia, RL; Kindy, MS; Gudz, TI				Novgorodov, Sergei A.; Riley, Christopher L.; Yu, Jin; Borg, Keith T.; Hannun, Yusuf A.; Proia, Richard L.; Kindy, Mark S.; Gudz, Tatyana I.			Essential Roles of Neutral Ceramidase and Sphingosine in Mitochondrial Dysfunction Due to Traumatic Brain Injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Brain; Cell Death; Mitochondria; Respiratory Chain; Sphingolipid	CYTOCHROME-C-OXIDASE; SUBCELLULAR-LOCALIZATION; CHRONIC ACTIVATION; RESPIRATORY-CHAIN; MOLECULAR-CLONING; RAT-BRAIN; IN-VITRO; KINASE; SPHINGOSINE-1-PHOSPHATE; SPHINGOLIPIDS	Background: A cardinal feature of many neurological disorders is mitochondrial dysfunction. Results: Knocking down neutral ceramidase reduces mitochondrial sphingosine, preserves mitochondrial function, and improves brain function recovery after trauma. Conclusion: Activation of the sphingosine-generating pathway plays a significant role in promoting mitochondrial injury. Significance: This is the first direct evidence of endogenous sphingosine involvement in regulation of mitochondrial function. In addition to immediate brain damage, traumatic brain injury (TBI) initiates a cascade of pathophysiological events producing secondary injury. The biochemical and cellular mechanisms that comprise secondary injury are not entirely understood. Herein, we report a substantial deregulation of cerebral sphingolipid metabolism in a mouse model of TBI. Sphingolipid profile analysis demonstrated increases in sphingomyelin species and sphingosine concurrently with up-regulation of intermediates of de novo sphingolipid biosynthesis in the brain. Investigation of intracellular sites of sphingosine accumulation revealed an elevation of sphingosine in mitochondria due to the activation of neutral ceramidase (NCDase) and the reduced activity of sphingosine kinase 2 (SphK2). The lack of change in gene expression suggested that post-translational mechanisms are responsible for the shift in the activities of both enzymes. Immunoprecipitation studies revealed that SphK2 is complexed with NCDase and cytochrome oxidase (COX) subunit 1 in mitochondria and that brain injury hindered SphK2 association with the complex. Functional studies showed that sphingosine accumulation resulted in a decreased activity of COX, a rate-limiting enzyme of the mitochondrial electron transport chain. Knocking down NCDase reduced sphingosine accumulation in mitochondria and preserved COX activity after the brain injury. Also, NCDase knockdown improved brain function recovery and lessened brain contusion volume after trauma. These studies highlight a novel mechanism of secondary TBI involving a disturbance of sphingolipid-metabolizing enzymes in mitochondria and suggest a critical role for mitochondrial sphingosine in promoting brain injury after trauma.	[Riley, Christopher L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA; [Yu, Jin; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA; [Novgorodov, Sergei A.; Kindy, Mark S.; Gudz, Tatyana I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Borg, Keith T.] Med Univ S Carolina, Dept Emergency Med, Charleston, SC 29425 USA; [Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Proia, Richard L.] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Gudz, TI (corresponding author), 114 Doughty St, Charleston, SC 29425 USA.	gudz@musc.edu	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 GM103339]; Veterans Affairs Merit AwardsUS Department of Veterans Affairs [I01RX000206, I01BX001104, I01RX000331]; American Diabetes AssociationAmerican Diabetes Association [7-12-IN-28]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA172517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [ZIADK056016, ZIADK056014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103339, R37GM043825] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001104, I01RX000206, I01RX000331] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant P30 GM103339 (to S. A. N.). This work was also supported by Veterans Affairs Merit Awards I01RX000206 (to T. I. G.), I01BX001104 (to T. I. G.), and I01RX000331 (to M. S. K.). The Lipidomics Core Facility at Medical University of South Carolina is supported in part by National Institutes of Health Grant P30 GM103339.; Supported in part by American Diabetes Association Innovation Grant 7-12-IN-28.	Arnold S, 2012, ADV EXP MED BIOL, V748, P305, DOI 10.1007/978-1-4614-3573-0_13; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Chan HS, 2013, BBA-MOL CELL BIOL L, V1831, P147, DOI 10.1016/j.bbalip.2012.07.005; Chudakova DA, 2008, J BIOL CHEM, V283, P28806, DOI 10.1074/jbc.M803301200; Clarke CJ, 2011, J BIOL CHEM, V286, P21565, DOI 10.1074/jbc.M110.193375; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Galadari S, 2006, BIOCHEM J, V393, P687, DOI 10.1042/BJ20050682; Geoffroy K, 2004, J BIOL CHEM, V279, P34343, DOI 10.1074/jbc.M403273200; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hwang YH, 2005, BIOCHEM BIOPH RES CO, V331, P37, DOI 10.1016/j.bbrc.2005.03.134; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; Kono M, 2006, J BIOL CHEM, V281, P7324, DOI 10.1074/jbc.M508382200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Merrill AH, 2011, CHEM REV, V111, P6387, DOI 10.1021/cr2002917; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Novgorodov AS, 2007, FASEB J, V21, P1503, DOI 10.1096/fj.06-7420com; Novgorodov Sergei A, 2011, Int J Biochem Mol Biol, V2, P347; Novgorodov SA, 2011, J BIOL CHEM, V286, P25352, DOI 10.1074/jbc.M110.214866; Novgorodov SA, 2011, J BIOL CHEM, V286, P4644, DOI 10.1074/jbc.M110.164392; Noygorodov SA, 2009, J CARDIOVASC PHARM, V53, P198, DOI 10.1097/FJC.0b013e31819b52d5; O'Neill SM, 2011, ARCH BIOCHEM BIOPHYS, V511, P31, DOI 10.1016/j.abb.2011.04.009; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rotstein NP, 2010, J LIPID RES, V51, P1247, DOI 10.1194/jlr.R003442; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Stancevic B, 2010, FEBS LETT, V584, P1728, DOI 10.1016/j.febslet.2010.02.026; Strub GM, 2011, FASEB J, V25, P600, DOI 10.1096/fj.10-167502; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tani M, 1999, J BIOCHEM-TOKYO, V125, P746; Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Veenith Tonny, 2009, World J Emerg Surg, V4, P7, DOI 10.1186/1749-7922-4-7; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wong-Riley MTT, 2012, ADV EXP MED BIOL, V748, P283, DOI 10.1007/978-1-4614-3573-0_12; Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118; Wu BX, 2010, J BIOL CHEM, V285, P17993, DOI 10.1074/jbc.M110.102988; Yu J, 2007, J BIOL CHEM, V282, P25940, DOI 10.1074/jbc.M701812200; Zhu Q, 2008, ACTA PHARMACOL SIN, V29, P593, DOI 10.1111/j.1745-7254.2008.00781.x; Zigdon H, 2013, J BIOL CHEM, V288, P4947, DOI 10.1074/jbc.M112.402719	64	26	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2014	289	19					13142	13154		10.1074/jbc.M113.530311			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AG6IR	WOS:000335522800016	24659784	Green Published, Other Gold			2021-06-18	
J	Brisson, CD; Hsieh, YT; Kim, D; Jin, AY; Andrew, RD				Brisson, C. Devin; Hsieh, Yi-Ting; Kim, Danielle; Jin, Albert Y.; Andrew, R. David			Brainstem Neurons Survive the Identical Ischemic Stress That Kills Higher Neurons: Insight to the Persistent Vegetative State	PLOS ONE			English	Article							DORSAL-ROOT GANGLIA; SPREADING DEPRESSION; ANOXIC DEPOLARIZATION; LOCUS-COERULEUS; CARDIAC-ARREST; RAT; NUCLEUS; HYPOXIA; GLUTAMATE; DAMAGE	Global ischemia caused by heart attack, pulmonary failure, near-drowning or traumatic brain injury often damages the higher brain but not the brainstem, leading to a 'persistent vegetative state' where the patient is awake but not aware. Approximately 30,000 U. S. patients are held captive in this condition but not a single research study has addressed how the lower brain is preferentially protected in these people. In the higher brain, ischemia elicits a profound anoxic depolarization (AD) causing neuronal dysfunction and vasoconstriction within minutes. Might brainstem nuclei generate less damaging AD and so be more resilient? Here we compared resistance to acute injury induced from simulated ischemia by 'higher' hippocampal and striatal neurons versus brainstem neurons in live slices from rat and mouse. Light transmittance (LT) imaging in response to 10 minutes of oxygen/glucose deprivation (OGD) revealed immediate and acutely damaging AD propagating through gray matter of neocortex, hippocampus, striatum, thalamus and cerebellar cortex. In adjacent brainstem nuclei, OGD-evoked AD caused little tissue injury. Whole-cell patch recordings from hippocampal and striatal neurons under OGD revealed sudden membrane potential loss that did not recover. In contrast brainstem neurons from locus ceruleus and mesencephalic nucleus as well as from sensory and motor nuclei only slowly depolarized and then repolarized post-OGD. Two-photon microscopy confirmed non-recoverable swelling and dendritic beading of hippocampal neurons during OGD, while mesencephalic neurons in midbrain appeared uninjured. All of the above responses were mimicked by bath exposure to 100 mu M ouabain which inhibits the Na+/K+ pump or to 1-10 nM palytoxin which converts the pump into an open cationic channel. Therefore during ischemia the Na+/K+ pump of higher neurons fails quickly and extensively compared to naturally resilient hypothalamic and brainstem neurons. The selective survival of lower brain regions that maintain vital functions will support the persistent vegetative state.	[Brisson, C. Devin; Hsieh, Yi-Ting; Kim, Danielle; Jin, Albert Y.; Andrew, R. David] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada	Andrew, RD (corresponding author), Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.	andrewd@queensu.ca			Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada [T- 4478]; Faculty of Health Sciences, Queen's University	This work was supported by the Heart and Stroke Foundation of Canada (grant T- 4478) and the Faculty of Health Sciences, Queen's University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Anderson TR, 2005, J NEUROPHYSIOL, V93, P963, DOI 10.1152/jn.00654.2004; Andrew R. D., 2013, Society for Neuroscience Abstract Viewer and Itinerary Planner, V43; Andrew R. D., 2012, Society for Neuroscience Abstract Viewer and Itinerary Planner, V42; Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Andrew RD, 2011, VAS 2011 11 INT C NE, P311; Artigas P, 2004, J GEN PHYSIOL, V123, P357, DOI 10.1085/jgp.200308964; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Bargiotas P, 2011, P NATL ACAD SCI USA, V108, P20772, DOI 10.1073/pnas.1018262108; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Blanco G, 2005, SEMIN NEPHROL, V25, P292, DOI 10.1016/j.semnephrol.2005.03.004; Brisson CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079589; Brisson CD, 2012, J NEUROPHYSIOL, V108, P419, DOI 10.1152/jn.00090.2012; BURCHIEL KJ, 1984, EXP NEUROL, V85, P257, DOI 10.1016/0014-4886(84)90139-0; BURES J, 1981, J NEUROBIOL, V12, P211, DOI 10.1002/neu.480120303; Centonze D, 2001, PROG NEUROBIOL, V63, P687, DOI 10.1016/S0301-0082(00)00037-X; COWAN AI, 1992, J PHYSIOL-LONDON, V455, P89, DOI 10.1113/jphysiol.1992.sp019292; CZEH G, 1992, NEUROREPORT, V3, P197, DOI 10.1097/00001756-199202000-00019; de Oliveira RB, 2011, BRAIN RES, V1425, P27, DOI 10.1016/j.brainres.2011.09.053; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dobretsov M, 2005, FRONT BIOSCI-LANDMRK, V10, P2373, DOI 10.2741/1704; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Falini A, 1998, AM J NEURORADIOL, V19, P648; Farkas E, 2010, NEUROIMAGE, V51, P734, DOI 10.1016/j.neuroimage.2010.02.055; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Funke F, 2009, J NEUROPHYSIOL, V101, P2395, DOI 10.1152/jn.91260.2008; Gadsby DC, 2009, PHILOS T R SOC B, V364, P229, DOI 10.1098/rstb.2008.0243; Gao H, 2009, BRAIN RES, V1291, P40, DOI 10.1016/j.brainres.2009.07.024; Gottron MA, 2009, CONTEMP NEUROSCI, P129, DOI 10.1007/978-1-60761-280-3_8; Hamann M, 2005, BRAIN, V128, P2408, DOI 10.1093/brain/awh619; Hawrylycz MJ, 2012, NATURE, V489, P391, DOI 10.1038/nature11405; HENDERSON G, 1982, EXP BRAIN RES, V45, P29; Higuchi T, 1997, MAGNET RESON MED, V37, P851, DOI 10.1002/mrm.1910370608; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Joshi I, 2001, J NEUROPHYSIOL, V85, P414; Kaminogo M, 1998, NEUROL RES, V20, P343, DOI 10.1080/01616412.1998.11740529; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Karunasinghe RN, 2013, BRAIN RES, V1527, P209, DOI 10.1016/j.brainres.2013.06.016; KAWAI K, 1992, J CEREBR BLOOD F MET, V12, P238, DOI 10.1038/jcbfm.1992.34; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Koroleva VI, 2000, ZH VYSSH NERV DEYAT+, V50, P612; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; LONGSTRETH WT, 2008, NEUROLOGY GEN MED, P163; Luigetti M, 2012, ACTA NEUROL BELG, V112, P105, DOI 10.1007/s13760-012-0007-3; Madry C, 2010, BRAIN, V133, P3755, DOI 10.1093/brain/awq284; Martin RL, 1999, J PHYSIOL-LONDON, V519, P131, DOI 10.1111/j.1469-7793.1999.0131o.x; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Moriguchi S, 2002, EXP BRAIN RES, V144, P238, DOI 10.1007/s00221-002-1039-3; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; Muller M, 2000, J NEUROPHYSIOL, V84, P1869, DOI 10.1152/jn.2000.84.4.1869; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Obeidat AS, 2000, J CEREBR BLOOD F MET, V20, P412, DOI 10.1097/00004647-200002000-00024; PATON JFR, 1993, BRAIN RES, V604, P112, DOI 10.1016/0006-8993(93)90358-T; Richter F, 2012, J CEREBR BLOOD F MET, V32, P1535, DOI 10.1038/jcbfm.2012.40; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rossini GP, 2011, TOXICON, V57, P429, DOI 10.1016/j.toxicon.2010.09.011; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Senatorov VV, 1997, J PHYSIOL-LONDON, V502, P387, DOI 10.1111/j.1469-7793.1997.387bk.x; SIEBER FE, 1995, STROKE, V26, P2091, DOI 10.1161/01.STR.26.11.2091; Tanaka E, 1999, J NEUROPHYSIOL, V81, P1872; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; URBAN L, 1990, BRAIN RES, V520, P36, DOI 10.1016/0006-8993(90)91689-E; UTZSCHNEIDER DA, 1991, BRAIN RES, V551, P136, DOI 10.1016/0006-8993(91)90924-K; Vincent A, 1999, NEUROSCIENCE, V93, P293, DOI 10.1016/S0306-4522(99)00109-8; White SH, 2012, J NEUROPHYSIOL, V107, P2083, DOI 10.1152/jn.00701.2011; WYTRZES LM, 1989, ARCH NEUROL-CHICAGO, V46, P93, DOI 10.1001/archneur.1989.00520370095028; Yang JJ, 1997, LIFE SCI, V61, P1763, DOI 10.1016/S0024-3205(97)00800-X; Yokomizo Y, 2005, NEUROSCI RES, V51, P463, DOI 10.1016/j.neures.2004.12.016; Yoshida S, 1998, NEUROSCI RES, V30, P227, DOI 10.1016/S0168-0102(98)00003-0; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466; Zhang B, 2012, J PHYSIOL-LONDON, V590, P753, DOI 10.1113/jphysiol.2011.221051	75	26	27	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2014	9	5							e96585	10.1371/journal.pone.0096585			16	Multidisciplinary Sciences	Science & Technology - Other Topics	AJ9KS	WOS:000338029800090	24802253	DOAJ Gold, Green Published			2021-06-18	
J	Le, C; Guppy, KH; Axelrod, YV; Hawk, MW; Silverthorn, J; Inacio, MC; Akins, PT				Le, Catherine; Guppy, Kern H.; Axelrod, Yekaterina V.; Hawk, Mark W.; Silverthorn, James; Inacio, Maria C.; Akins, Paul T.			Lower complication rates for cranioplasty with pen-operative bundle	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Craniectomy; Cranioplasty; MRSA infection; Surgical site infection; Care bundles	TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEMICRANIECTOMY; INFECTIONS; MANAGEMENT; SERIES; DEFECT	Background: The overall benefits of craniectomy must include procedural risks from cranioplasty. Cranioplasty carries a high risk of surgical site infections (SSI) particularly with antibiotic resistant bacteria. The goal of this study was to measure the effect of a cranioplasty bundle on pen-operative complications. Methods: The authors queried a prospective, inpatient neurosurgery database at Kaiser Sacramento Medical Center for craniectomy and cranioplasty over a 7 year period. 57 patients who underwent cranioplasties were identified. A retrospective chart review was completed for complications, including surgical complications such as SSI, wound dehiscence, and re-do cranioplasty. We measured cranioplasty complication rates before and after implementation of a pen-operative bundle, which consisted of peri-operative vancomycin (4 doses), a barrier dressing through post-operative day (POD) 3, and de-colonization of the surgical incision using topical chlorhexidine from POD 4 to 7. Results: The rate of MRSA colonization in cranioplasty patients is three times higher than the average seen on ICU admission screening (19% vs. 6%). The cranioplasty surgical complication rate was 22.8% and SSI rate was 10.5%. The concurrent SSI rate for craniectomy was 1.9%. Organisms isolated were methicillin-resistant Staphylococcus aureus (4), methicillin-sensitive S. aureus (1), Propionibacterium acnes (1), and Escherichia coli (1). Factors associated with SSI were pen-operative vancomycin (68.6% vs. 16.7%, p = 0.0217). Complication rates without (n = 21) and with (n = 36) the bundle were: SSI (23.8% vs. 2.8%, p = 0.0217) and redo cranioplasty (19% vs. 0%, p = 0.0152). Bundle use did not affect rates for superficial wound dehiscence, seizures, or hydrocephalus. Conclusions: The cranioplasty bundle was associated with reduced SSI rates and the need for re-do cranioplasties. (C) 2014 Elsevier B.V. All rights reserved.	[Le, Catherine] Univ Calif Los Angeles, Neurocrit Care Dept, Los Angeles, CA USA; [Guppy, Kern H.; Axelrod, Yekaterina V.; Hawk, Mark W.; Silverthorn, James; Akins, Paul T.] Kaiser Sacramento Neurosurg Dept, Sacramento, CA 95825 USA; [Inacio, Maria C.] Kaiser Surg Implant Registry, San Diego, CA 92108 USA	Akins, PT (corresponding author), Kaiser Sacramento Neurosurg Dept, 2025 Morse Ave, Sacramento, CA 95825 USA.	paul.t.akins@kp.org	Axelrod, Katia/AAN-6454-2020; Inacio, Maria/G-9593-2018	Inacio, Maria/0000-0001-8261-2665			Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Akins PT, 2010, J NEUROSURG, V112, P354, DOI 10.3171/2009.5.JNS081589; Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Lavu H, 2012, J SURG RES, V174, P215, DOI 10.1016/j.jss.2011.09.028; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Park JS, 2007, J KOREAN NEUROSURG S, V42, P89; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sughrue ME, 2011, J CLIN NEUROSCI, V18, P1201, DOI 10.1016/j.jocn.2011.01.016; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	23	26	26	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAY	2014	120						41	44		10.1016/j.clineuro.2014.02.009			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AG7UB	WOS:000335623200009	24731574				2021-06-18	
J	Lu, XY; Wang, HD; Xu, JG; Ding, K; Li, T				Lu, Xin-Yu; Wang, Han-dong; Xu, Jian-Guo; Ding, Ke; Li, Tao			Pretreatment with tert-butylhydroquinone attenuates cerebral oxidative stress in mice after traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; tBHQ; Nrf2; Oxidative stress	CLOSED-HEAD INJURY; NEUROLOGICAL DEFICIT; CELL-DEATH; DAMAGE; NRF2; INHIBITION; MODEL; RATS	Background: Traumatic brain injury (TBI) is a worldwide health problem, identified as a major cause of death and disability. Increasing evidence has shown that oxidative stress plays an important role in TBI pathogenesis. The antioxidant transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), is a known mediator in protection against TBI-induced brain damage. The objective of this study was to test whether tert-butylhydroquinone (tBHQ), a novel Nrf2 activator, can protect against TBI-induced oxidative stress. Methods: Adult male imprinting control region mice were randomly divided into three groups: (1) sham + vehicle group; (2) TBI + vehicle group; and (3) TBI + tBHQ group. Closed-head brain injury was applied using the Feeney weight-drop method. We accessed the neurologic outcome of mice at 24 h after TBI, and subsequently measured protein levels of Nrf2 and the NOX2 subunit of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), the concentration of malondialdehyde, superoxide dismutase activity, and brain edema. Result: The NOX2 protein level was increased fivefold in the TBI + vehicle group, whereas pretreatment with tBHQ markedly attenuated the NOX2 protein expression relative to that in the TBI + vehicle group. TBI increased Nrf2 formation by 5% compared with the sham group, whereas treatment with tBHQ further upregulated the Nrf2 protein level by 12% compared with the sham group. The level of the oxidative damage marker malondialdehyde was reduced by 29% in the TBI + tBHQ group compared with the TBI + vehicle group, Moreover, pretreatment with tBHQ significantly increased the antioxidant enzyme superoxide dismutase activity. Administration of tBHQ also significantly decreased TBI-induced brain edema and neurologic deficits. Conclusions: Pretreatment with tBHQ effectively attenuated markers of cerebral oxidative stress after TBI, thus supporting the testing of tBHQ as a potential neuroprotectant and adjunct therapy for TBI patients. (C) 2014 Elsevier Inc. All rights reserved.	[Lu, Xin-Yu; Wang, Han-dong; Xu, Jian-Guo; Ding, Ke; Li, Tao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China; [Lu, Xin-Yu] Jiangsu Univ, Peoples Hosp, Dept Neurosurg, Zhenjiang, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Science and Technology Development Fund of Zhenjiang [SH20130037]	This study was supported by the Science and Technology Development Fund of Zhenjiang (No. SH20130037).	Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Chapple SJ, 2012, INT J BIOCHEM CELL B, V44, P1315, DOI 10.1016/j.biocel.2012.04.021; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Ho WE, 2012, FREE RADICAL BIO MED, V53, P498, DOI 10.1016/j.freeradbiomed.2012.05.021; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Kahles T, 2012, CELL MOL LIFE SCI, V69, P2345, DOI 10.1007/s00018-012-1011-8; Kalayci M, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-75; Kandasamy R, 2013, INT J NEUROSCI, V123, P385, DOI 10.3109/00207454.2012.761983; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Kerman M, 2012, J MOL HISTOL, V43, P49, DOI 10.1007/s10735-011-9376-9; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lee JH, 2013, CANCER RES, V73, P785, DOI 10.1158/0008-5472.CAN-12-1994; Lo W, 2007, NEUROSCI LETT, V414, P228, DOI 10.1016/j.neulet.2006.12.055; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Sitic S, 2008, ACTA CLIN CROAT, V47, P155; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Ye QY, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-156; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	30	26	28	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY	2014	188	1					206	212		10.1016/j.jss.2013.11.1106			7	Surgery	Surgery	AE4RS	WOS:000333971300026	24387843				2021-06-18	
J	Almeida-Suhett, CP; Li, Z; Marini, AM; Braga, MFM; Eiden, LE				Almeida-Suhett, Camila P.; Li, Zheng; Marini, Ann M.; Braga, Maria F. M.; Eiden, Lee E.			Temporal Course of Changes in Gene Expression Suggests a Cytokine-Related Mechanism for Long-Term Hippocampal Alteration after Controlled Cortical Impact	JOURNAL OF NEUROTRAUMA			English	Article						Ccl2; Lcn2; mild traumatic brain injury (mTBI); controlled cortical injury (CCI); Ccl7	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; MOUSE MODEL; HEAD-INJURY; CHEMOKINES; MODULATION; INHIBITOR; RECEPTORS; INDUCTION; IMMUNE	Mild traumatic brain injury (mTBI) often has long-term effects on cognitive function and social behavior. Altered gene expression may be predictive of long-term psychological effects of mTBI, even when acute clinical effects are minimal or transient. Controlled cortical impact (CCI), which causes concussive, but nonpenetrant, trauma to underlying (non-cortical) brain, resulting in persistent changes in hippocampal synaptic function, was used as a model of mTBI. The hippocampal transcriptomes of sham-operated or injured male rats at 1, 7, and 30 days postinjury were examined using microarrays comprising a comprehensive set of expressed genes, subsequently confirmed by quantitative reverse-transcriptase polymerase chain reaction. Transcripts encoding the chemokines, chemokine (C-C motif) ligand (Ccl)2 and Ccl7, inflammatory mediators lipocalin-2 (Lcn2) and tissue inhibitor of metalloproteinase 1 (Timp1), immunocyte activators C-C chemokine receptor type 5 (Ccr5) and Fc fragment of IgG, low affinity IIb, receptor (CD32) (Fcgr2b), the major histocompatibility complex II immune response-related genes, Cd74 and RT1 class II, locus Da (RT1-Da), the complement component, C3, and the transcription factor, Kruppel-like factor 4 (Klf4), were identified as early (Ccl2, Ccl7, Lcn2, and Timp1), intermediate (Ccr5, Fcgr2b, Cd74, RT1-Da, and C3), and late (Klf4) markers for bilateral hippocampal response to CCI. Ccl2 and Ccl7 transcripts were up-regulated within 24 h after CCI, and their elevation subsided within 1 week of injury. Other transcriptional changes occurred later and were more stable, some persisting for at least 1 month, suggesting that short-term inflammatory responses trigger longer-term alteration in the expression of genes previously associated with injury, aging, and neuronal function in the brain. These transcriptional responses to mTBI may underlie long-term changes in excitatory and inhibitory neuronal imbalance in hippocampus, leading to long-term behavioral consequences of mTBI.	[Almeida-Suhett, Camila P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA; [Li, Zheng] Natl Inst Mental Hlth, Unit Synapse Dev & Plast, Bethesda, MD 20892 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Physiol, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Genet, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA; [Eiden, Lee E.] Natl Inst Mental Hlth, Sect Mol Neurosci, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Eiden, LE (corresponding author), Natl Inst Mental Hlth, Sect Mol Neurosci, Lab Cellular & Mol Regulat, 9000 Rockville Pike Bldg 49,Room 5A-38, Bethesda, MD 20892 USA.	eidenl@mail.nih.gov	Li, Zheng/I-8016-2014; Almeida-Suhett, Camila/I-8045-2016	Li, Zheng/0000-0002-2978-2531; Almeida-Suhett, Camila/0000-0002-7588-9487; Eiden, Lee/0000-0001-7524-944X	NIMH Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); Department of DefenseUnited States Department of Defense; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002881, ZIAMH002386] Funding Source: NIH RePORTER	The authors thank Charisse Winston (NIMH-IRP Technical IRTA) and Dr. Babru Samal (NIMH Bioinformatics Core Specialist), for contributions to early phases of this work, and Dr. Abdel Eklahloun (Core Manager, NIHGRI-NIMH-NINCDS Microarray Core Facility) for invaluable assistance and consultation throughout the duration of these experiments. Work reported here was funded, in part, by the NIMH Intramural Research Program and by a grant from the Department of Defense administered through the Center for Neuroscience and Regenerative Medicine. The contributions of Djida Ait-Ali, who participated in the project as a Henry M. Jackson Foundation Research Fellow, are acknowledged here in lieu of co-authorship for which her written permission could not be obtained.	Almeida C. P., 2011, SOC NEUR 2011 2011 N; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Griffin WST, 2013, NEW ENGL J MED, V368, P770, DOI 10.1056/NEJMcibr1214546; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Khandaker GM, 2011, JAMA-J AM MED ASSOC, V305, P673, DOI 10.1001/jama.2011.142; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Naude PJW, 2012, FASEB J, V26, P2811, DOI 10.1096/fj.11-202457; Renner NA, 2011, J NEUROVIROL, V17, P146, DOI 10.1007/s13365-010-0017-y; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Schmitz C, 2000, J CHEM NEUROANAT, V20, P93, DOI 10.1016/S0891-0618(00)00066-1; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; VanGuilder HD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-138; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang XK, 1999, MOL BRAIN RES, V71, P304, DOI 10.1016/S0169-328X(99)00203-X; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang N, 2005, J LEUKOCYTE BIOL, V78, P1210, DOI 10.1189/jlb.0405224; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	26	26	2	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					683	690		10.1089/neu.2013.3029			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000010	24344922	Green Published			2021-06-18	
J	Hart, T; Benn, EKT; Bagiella, E; Arenth, P; Dikmen, S; Hesdorffer, DC; Novack, TA; Ricker, JH; Zafonte, R				Hart, Tessa; Benn, Emma K. T.; Bagiella, Emilia; Arenth, Patricia; Dikmen, Sureyya; Hesdorffer, Dale C.; Novack, Thomas A.; Ricker, Joseph H.; Zafonte, Ross			Early Trajectory of Psychiatric Symptoms after Traumatic Brain Injury: Relationship to Patient and Injury Characteristics	JOURNAL OF NEUROTRAUMA			English	Article						longitudinal studies; neurobehavioral signs and symptoms; psychological outcome; traumatic brain injury	MINOR DEPRESSION; HEALTH OUTCOMES; DISORDERS; PSYCHOPATHOLOGY; FREQUENCY; PATTERNS; VALIDITY; 1-YEAR; RATES	Psychiatric disturbance is common and disabling after traumatic brain injury (TBI). Few studies have investigated the trajectory of psychiatric symptoms in the first 6 months postinjury, when monitoring and early treatment might prevent persistent difficulties. The aim of this study was to examine the trajectory of psychiatric symptoms 1-6 months post-TBI, the patient/injury characteristics associated with changes, and characteristics predictive of persisting symptoms. A secondary analysis was performed on data from a clinical trial with three data collection points. Across eight centers, 872 participants with complicated mild to severe TBI were administered the Brief Symptom Inventory (BSI) at 30, 90, and 180 days postinjury. Mixed-effects models were used to assess longitudinal changes in the BSI Global Severity Index (GSI). Multi-variate logistic regression was used to assess predictors of clinically significant GSI elevations persisting to 6 months post-TBI. In general, GSI scores improved over time. Women improved faster than men; race/ethnicity was also significantly associated with rate of change, with Hispanics showing the most and African Americans the least improvement. Clinically significant psychiatric symptoms (caseness) occurred in 42% of the sample at 6 months, and more than one type of symptom was common. Significant predictors of caseness included African American race, age from 30 to 60 years, longer post-traumatic amnesia (PTA) duration, pre-TBI unemployment, and pre-TBI risky alcohol use. Findings indicate that psychiatric symptoms are common in the first 6 months post-TBI and frequently extend beyond the depression and anxiety symptoms that may be most commonly screened. Patients with longer PTA and preinjury alcohol misuse may need more intensive monitoring for symptom persistence.	[Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Benn, Emma K. T.; Bagiella, Emilia] Icahn Sch Med Mt Sinai, Dept Hlth Evidence & Policy, New York, NY USA; [Benn, Emma K. T.; Bagiella, Emilia] Icahn Sch Med Mt Sinai, Ctr Biostat, New York, NY USA; [Arenth, Patricia; Ricker, Joseph H.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Hesdorffer, Dale C.] Columbia Univ, GH Sergievsky Ctr, New York, NY USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu		Benn, Emma/0000-0001-7051-5841; Ricker, Joseph/0000-0003-3415-991X	NIH (National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD042738]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042738] Funding Source: NIH RePORTER	This work was funded by Cooperative Agreement #U01 HD042738 from the NIH (National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research).	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown S, 2004, ELECTRON WORLD, V110, P54; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eisen SV, 2011, J BEHAV HEALTH SER R, V38, P170, DOI 10.1007/s11414-010-9216-9; Gallo LC, 2009, J PERS, V77, P1707, DOI 10.1111/j.1467-6494.2009.00598.x; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hart T, 2012, J HEAD TRAUMA REHAB, V27, P113, DOI 10.1097/HTR.0b013e31820e686c; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Long JD, 2007, PSYCHOL ASSESSMENT, V19, P298, DOI 10.1037/1040-3590.19.3.298; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Morales LS, 2002, J HEALTH CARE POOR U, V13, P477, DOI 10.1177/104920802237532; National Comorbidity Survey (NCS) and NCS Replication, 2005, NAT COM SURV; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	38	26	26	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					610	617		10.1089/neu.2013.3041			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000002	24237113	Green Published			2021-06-18	
J	Rowe, AS; Goodwin, H; Brophy, GM; Bushwitz, J; Castle, A; Deen, D; Johnson, D; Lesch, C; Liang, N; Potter, E; Roels, C; Samaan, K; Rhoney, DH				Rowe, A. Shaun; Goodwin, Haley; Brophy, Gretchen M.; Bushwitz, Jennifer; Castle, Amber; Deen, David; Johnson, Dachelle; Lesch, Christine; Liang, Norah; Potter, Emily; Roels, Christina; Samaan, Karen; Rhoney, Denise H.		Neurocritical Care Soc Pharm Sect	Seizure Prophylaxis in Neurocritical Care: A Review of Evidence-Based Support	PHARMACOTHERAPY			English	Article						seizure; prophylaxis; phenytoin; levetiracetam; critical care	ANEURYSMAL SUBARACHNOID HEMORRHAGE; QUALITY STANDARDS SUBCOMMITTEE; STEVENS-JOHNSON-SYNDROME; BRAIN-TUMORS; INTRACEREBRAL HEMORRHAGE; ARTERIOVENOUS-MALFORMATIONS; ANTICONVULSANT PROPHYLAXIS; PRACTICE PARAMETER; AMERICAN-ACADEMY; ISCHEMIC-STROKE	Seizures are a well-described complication of acute brain injury and neurosurgery. Antiepileptic drugs (AEDs) are frequently utilized for seizure prophylaxis in neurocritical care patients. In this review, the Neurocritical Care Society Pharmacy Section describes the evidence associated with the use of AEDs for seizure prophylaxis in patients with intracerebral tumors, traumatic brain injury, aneurysmal subarachnoid hemorrhage, craniotomy, ischemic stroke, and intracerebral hemorrhage. Clear evidence indicates that the short-term use of AEDs for seizure prophylaxis in patients with traumatic brain injury and aneurysmal subarachnoid hemorrhage may be beneficial; however, evidence to support the use of AEDs in other disease states is less clear.	[Rowe, A. Shaun] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Dept Clin Pharm, Knoxville, TN USA; [Goodwin, Haley] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA; [Bushwitz, Jennifer] Shands Univ Florida, Dept Pharm, Gainesville, FL USA; [Castle, Amber] Yale New Haven Med Ctr, Dept Pharm, New Haven, CT 06504 USA; [Deen, David] Mem Hlth Univ Med Ctr, Dept Pharm, Savannah, GA 31404 USA; [Johnson, Dachelle] Johns Hopkins Bayview Med Ctr, Dept Pharm, Baltimore, MD USA; [Lesch, Christine] NewYork Presbyterian, Dept Pharm, New York, NY USA; [Liang, Norah] Hartford Hosp, Dept Pharm, Hartford, CT 06115 USA; [Potter, Emily] Dwight D Eisenhower Med Ctr, Dept Vet Affairs, Leavenworth, KS USA; [Roels, Christina] Forsyth Med Ctr, Dept Pharm, Winston Salem, NC USA; [Samaan, Karen] St Vincent Hosp, Dept Pharm, Indianapolis, IN USA; [Rhoney, Denise H.] Univ N Carolina, Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC USA	Goodwin, H (corresponding author), Johns Hopkins Univ Hosp, Dept Pharm, 600 North Wolfe St Carnegie 180, Baltimore, MD 21287 USA.	hgood-wi3@jhmi.edu		Brophy, Gretchen/0000-0002-4749-2693; Rowe, Anthony/0000-0002-2533-9233			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], CENTR NERV SYST CANC; BAKER CJ, 1995, NEUROSURGERY, V37, P863, DOI 10.1227/00006123-199511000-00003; Beghi E, 2011, NEUROLOGY, V77, P1785, DOI 10.1212/WNL.0b013e3182364878; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chumnanvej S, 2007, NEUROSURGERY, V60, P99, DOI 10.1227/01.NEU.0000249207.66225.D9; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; De Herdt V, 2011, NEUROLOGY, V77, P1794, DOI 10.1212/WNL.0b013e31823648a6; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; Forsyth PA, 2003, CAN J NEUROL SCI, V30, P106, DOI 10.1017/S0317167100053361; Gilmore E, 2010, NEUROLOGIST, V16, P165, DOI 10.1097/NRL.0b013e3181c7cd0b; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hanon E, 2001, SEIZURE-EUR J EPILEP, V10, P287, DOI 10.1053/seiz.2000.0511; Hart Y, 2011, J NEUROSURG, V115, P1159, DOI 10.3171/2011.6.JNS101836; Hoh BL, 2011, NEUROSURGERY, V69, P644, DOI 10.1227/NEU.0b013e31821bc46d; HORNER S, 1995, J NEUROL SCI, V132, P57, DOI 10.1016/0022-510X(95)00122-I; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Josephson CB, 2011, NEUROLOGY, V76, P1548, DOI 10.1212/WNL.0b013e3182190f37; Kandil AO, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-49; Kern K, 2012, J CLIN NEUROSCI, V19, P99, DOI 10.1016/j.jocn.2011.07.021; Khafaga YM, 1999, ACTA ONCOL, V38, P111, DOI 10.1080/028418699431898; KILPATRICK CJ, 1992, ARCH NEUROL-CHICAGO, V49, P509, DOI 10.1001/archneur.1992.00530290097017; Komotar RJ, 2011, J NEUROSURG, V115, P483, DOI 10.3171/2011.4.JNS101585; Kruer RM, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.11.020; Kwan J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005398.pub2; Lamy C, 2003, NEUROLOGY, V60, P400, DOI 10.1212/WNL.60.3.400; LANCMAN ME, 1993, EPILEPSIA, V34, P141, DOI 10.1111/j.1528-1157.1993.tb02386.x; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Meador KJ, 2007, NEUROLOGY, V69, P2076, DOI 10.1212/01.wnl.0000281104.55418.60; Messe S, 2009, NEUROCRIT CARE, V11, P38, DOI 10.1007/s12028-009-9207-y; Mikkelsen T, 2010, J NEURO-ONCOL, V96, P97, DOI 10.1007/s11060-009-0056-5; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Murphy-Human T, 2011, WORLD NEUROSURG, V75, P269, DOI 10.1016/j.wneu.2010.09.002; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; Olafsson E, 2000, EPILEPSIA, V41, P1201, DOI 10.1111/j.1528-1157.2000.tb00326.x; Passero S, 2002, EPILEPSIA, V43, P1175, DOI 10.1046/j.1528-1157.2002.00302.x; PECHADRE JC, 1991, PRESSE MED, V20, P841; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Sirven JI, 2004, MAYO CLIN PROC, V79, P1489, DOI 10.4065/79.12.1489; Smith KM, 2006, NEUROSURGERY, V58, P426, DOI 10.1227/01.NEU.000197321.57853.83; Szaflarski JP, 2008, EPILEPSIA, V49, P974, DOI 10.1111/j.1528-1167.2007.01513.x; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TARTARA A, 1991, BRIT J CLIN PHARMACO, V32, P335, DOI 10.1111/j.1365-2125.1991.tb03908.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tremont-Lukats IW, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004424.pub2; UCBI, 2006, KEPPR LEV PACK INS; van Breemen MSM, 2007, LANCET NEUROL, V6, P421, DOI 10.1016/S1474-4422(07)70103-5; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; Wu AS, 2013, J NEUROSURG, V118, P873, DOI 10.3171/2012.12.JNS111970; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x; Zachenhofer I, 2011, J NEURO-ONCOL, V101, P101, DOI 10.1007/s11060-010-0235-4	75	26	26	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-0008	1875-9114		PHARMACOTHERAPY	Pharmacotherapy	APR	2014	34	4					396	409		10.1002/phar.1374			14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AE1RC	WOS:000333746000013	24277723				2021-06-18	
J	Sillesen, M; Johansson, PI; Rasmussen, LS; Jin, G; Jepsen, CH; Imam, A; Hwabejire, JO; Deperalta, D; Duggan, M; deMoya, M; Velmahos, GC; Alam, HB				Sillesen, Martin; Johansson, Paer I.; Rasmussen, Lars S.; Jin, Guang; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; Deperalta, Danielle; Duggan, Michael; deMoya, Marc; Velmahos, George C.; Alam, Hasan B.			Fresh frozen plasma resuscitation attenuates platelet dysfunction compared with normal saline in a large animal model of multisystem trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Trauma; brain; platelets; endothelium; swine	MASSIVE TRANSFUSION; BRAIN-INJURY; ENDOTHELIAL-CELLS; HEMORRHAGIC-SHOCK; IN-VITRO; MORTALITY; THROMBOCYTOPENIA; COAGULOPATHY; COAGULATION; INHIBITION	BACKGROUND Platelet dysfunction following trauma has been identified as an independent predictor of mortality. We hypothesized that fresh frozen plasma (FFP) resuscitation would attenuate platelet dysfunction compared with 0.9% normal saline (NS). METHODS Twelve swine were subjected to multisystem trauma (traumatic brain injury, liver injury, rib fracture, and soft tissue injury) with hemorrhagic shock (40% of estimated blood volume). Animals were left in shock (mean arterial pressure, 30-35 mm Hg) for 2 hours followed by resuscitation with three times shed volume NS (n = 6) or one times volume FFP (n = 6) and monitored for 6 hours. Platelet function was assessed by adenosine diphosphate (ADP)-induced platelet aggregation at baseline, after 2 hours of shock following resuscitation, and 6 hours after resuscitation. Fibrinogen levels and markers of platelet activation (transforming growth factor [TGF-], sP-Selectin, and CD40L) as well as endothelial injury (intercellular adhesion molecule 1 [ICAM-1], vascular cell adhesion molecule 1 [VCAM-1]) were also assayed. Thromboelastography was used to measure clotting activity. RESULTS ADP-induced platelet aggregation was significantly higher in the FFP group (46.3 U vs. 25.5 U, p < 0.01) following resuscitation. This was associated with higher fibrinogen levels (202 mg/dL vs. 80 mg/dL, p < 0.01) but lower endothelial activation (VCAM-1, 1.25 ng/mL vs. 3.87 ng/mL, p = 0.05). Other markers did not differ. After 6 hours of observation, ADP-induced platelet aggregation remained higher in the FFP group (53.8 U vs. 37.0 U, p = 0.03) as was fibrinogen levels (229 mg/dL vs. 153 mg/dL, p < 0.01). Endothelial activation was lower (ICAM-1, 21.0 ng/mL vs. 24.4 ng/mL, p = 0.05), whereas TGF- levels were higher (2,138 pg/mL vs. 1,802 pg/mL, p = 0.03) in the FFP group. Other markers did not differ. Thromboelastography revealed increased clot strength in the FFP group at both postresuscitation time points. CONCLUSION Resuscitation with FFP resulted in an immediate and sustained improvement in platelet function and clot strength compared with high-volume NS resuscitation. This was associated with an increase in fibrinogen levels and an attenuation of endothelial activation.	[Sillesen, Martin; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; Deperalta, Danielle; Duggan, Michael; deMoya, Marc; Velmahos, George C.] Harvard Univ, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg,Med Sch, Boston, MA USA; [Sillesen, Martin; Rasmussen, Lars S.] Rigshosp, Copenhagen Univ Hosp, Dept Anesthesia, Copenhagen, Denmark; [Johansson, Paer I.; Jepsen, Cecilie H.] Rigshosp, Copenhagen Univ Hosp, Ctr Head & Orthoped, Copenhagen, Denmark; [Johansson, Paer I.; Jepsen, Cecilie H.] Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, Copenhagen, Denmark; [Johansson, Paer I.] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX USA; [Jin, Guang; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Johansson, Par I/P-9283-2015	Johansson, Par I/0000-0001-9778-5964; Rasmussen, Lars/0000-0002-7480-3004; Sillesen, Martin/0000-0001-9494-5475	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Copenhagen University Hospital, Rigshospitalet (Denmark); Laerdal Foundation (Norway); Aase and Ejnar Danielsen foundation (Denmark); Olof Norlander foundation (Sweden); Maersk Foundation (Denmark); Tryg Foundation (Denmark); Lundbeck Foundation (Denmark)Lundbeckfonden; Polsky family	The study was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H.B.A. Grants from Copenhagen University Hospital, Rigshospitalet (Denmark), The Laerdal Foundation (Norway), The Aase and Ejnar Danielsen foundation (Denmark), The Olof Norlander foundation (Sweden), and The Maersk Foundation (Denmark) supported the work done by M.S. L.S.R. has received funding from the Tryg Foundation (Denmark). P.I.J. received funding from the Lundbeck Foundation (Denmark). M.De. received funding from the Polsky family. The Multiplate machine was on unconditional loan from US Distributor Diapharma Group, Inc. (West Chester, OH) for the duration of the study, while the TEG-5000 machine was on unconditional loan from Haemonetics Corp. (Braintree, MA). These companies did not participate in study planning, execution, data analysis, or manuscript preparation.	Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P358, DOI 10.1097/TA.0b013e31825889ba; Brown LM, 2011, J TRAUMA, V71, pS358, DOI 10.1097/TA.0b013e318227f152; Caballo C, 2013, BLOOD TRANSFUS-ITALY, V11, P391, DOI 10.2450/2012.0034-12; Duan CJ, 2011, SHOCK, V36, P54, DOI 10.1097/SHK.0b013e318214475e; Ekseth K, 2002, ANAESTHESIA, V57, P1102, DOI 10.1046/j.1365-2044.2002.02782_1.x; Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676; Harr JN, 2012, SURGERY, V152, P270, DOI 10.1016/j.surg.2012.05.002; Inaba K, 2013, J AM COLL SURGEONS, V216, P290, DOI 10.1016/j.jamcollsurg.2012.10.017; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Kozek-Langenecker SA, 1999, KIDNEY INT, V56, P299, DOI 10.1046/j.1523-1755.1999.00518.x; Kozek-Langenecker S, 2011, CRIT CARE, V15, DOI 10.1186/cc10488; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; LANDOLFI R, 1991, BLOOD, V78, P377; Mengistu AM, 2011, ACTA ANAESTH SCAND, V55, P903, DOI 10.1111/j.1399-6576.2011.02496.x; Ostrowski SR, 2011, MED HYPOTHESES, V77, P798, DOI 10.1016/j.mehy.2011.07.040; Pati S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025171; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; Sillesen M, 2013, SURGERY, V154, P197, DOI 10.1016/j.surg.2013.04.002; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Stissing T, 2011, CLIN APPL THROMB-HEM, V17, pE211, DOI 10.1177/1076029610397183; Thekkedath UR, 2006, AM J HEMATOL, V81, P915, DOI 10.1002/ajh.20720; Wataha K, 2013, TRANSFUSION, V53, p80S, DOI 10.1111/trf.12040; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	29	26	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					998	1007		10.1097/TA.0000000000000193			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500021	24662863				2021-06-18	
J	Teel, EF; Ray, WJ; Geronimo, AM; Slobounov, SM				Teel, E. F.; Ray, W. J.; Geronimo, A. M.; Slobounov, S. M.			Residual alterations of brain electrical activity in clinically asymptomatic concussed individuals: An EEG study	CLINICAL NEUROPHYSIOLOGY			English	Article						Concussion; EEG; Power; Coherence; ImPACT; Virtual Reality (VR)	SYMPTOMS; QEEG	Objective: To examine the neural substrates underlying performance on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and HeadRehab Virtual Reality (VR) balance and spatial modules in a concussed and control group. Methods: Thirteen controls and seven concussed participants were fitted with a Geodesic 128-channel EEG cap and completed three assessments: EEG baseline, ImPACT testing, and VR balance and spatial modules. Concussed participants completed were tested within 8 (5 +/- 1) days after injury. Results: EEG power was significantly (p <.05) decreased in the concussed group over all testing modalities. EEG coherence was significantly (p <.05) increased in the concussed group during EEG baseline and ImPACT. For VR testing, two conditions showed significant (p <.05) increases in EEG coherence between ROIs, while two different conditions showed significant (p <.05) decreases in coherence levels. Conclusions: Concussed participants passed all clinical concussion testing tools, but showed pathophysiological dysfunction when evaluating EEG variables. Significance: Concussed participants are able to compensate and achieve normal functioning due to recruiting additional brain networks. This allows concussed participants to pass clinical tests while still displaying electrophysiological deficits and clinicians must consider this information when making return-to-play decisions. (C) 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Teel, E. F.; Slobounov, S. M.] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Teel, E. F.; Slobounov, S. M.] Penn State Ctr Sport Concuss Res & Serv, University Pk, PA 16802 USA; [Ray, W. J.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Geronimo, A. M.] Penn State Univ, Dept Engn Sci & Mech, University Pk, PA 16802 USA	Slobounov, SM (corresponding author), 276 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu		Teel, Elizabeth/0000-0002-2846-5884	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R01 NS056227-06]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	This research was supported by National Institute of Health Grant # 2R01 NS056227-06 "The Effects of Mild Traumatic Brain Injury on Neuropsychological Test Scores, Postural Stability and General Brain Function''. The authors would like to thank Katie Finelli, Jordan Griswold, Chris Ertle, and Phil Derise for their assistance with data collection and signal pre-processing.	Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Cannon RL, 2012, NEUROSCI LETT, V518, P27, DOI 10.1016/j.neulet.2012.04.035; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hillman CH, 2000, BIOL PSYCHOL, V52, P71, DOI 10.1016/S0301-0511(99)00021-6; Knyazev GG, 2007, NEUROSCI BIOBEHAV R, V31, P377, DOI 10.1016/j.neubiorev.2006.10.004; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; *R DEV COR TEAM, 2012, R LANG ENV STAT COMP; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006	12	26	26	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	APR	2014	125	4					703	707		10.1016/j.clinph.2013.08.027			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AC3FH	WOS:000332400300010	24140103				2021-06-18	
J	Awai, L; Curt, A				Awai, Lea; Curt, Armin			Intralimb coordination as a sensitive indicator of motor-control impairment after spinal cord injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						spinal cord injury; human; gait; intralimb; coordination; categorization; cyclogram	GAIT ANALYSIS; TREADMILL; PATTERNS; LOCOMOTION; WALKING; PEOPLE	Background: Recovery of walking function after neurotrauma, e.g., after spinal cord injury, is routinely captured using standardized walking outcome measures of time and distance. However, these measures do not provide information on possible underlying mechanisms of recovery, nor do they tell anything about the quality of gait. Subjects with an incomplete spinal cord injury are a very heterogeneous group of people with a wide range of functional impairments. A stratification of these subjects would allow increasing sensitivity for hypothesis testing and a more targeted treatment strategy. Methods: The gait of incomplete spinal cord injured subjects was compared to healthy control subjects by analyzing kinematic data obtained by a 3-D motion capture system. Hip knee angle-angle plots (cyclograms) informed on the qualitative aspect of gait and the intralimb coordination. Features of the cyclogram, e.g., shape of the cyclogram, cycle-to-cycle consistency and its modulation due to changes in walking speed were discerned and used to stratify spinal cord injured subjects. Results: Spinal cord injured subjects were unable to modulate their cyclogram configuration when increasing speed from slow to preferred. Their gait quality remained clearly aberrant and showed even higher deviations from normal when walking at preferred speed. Qualitative categorization of spinal cord injured subjects based on their intralimb coordination was complemented by quantitative measures of cyclogram shape comparison. Discussion: Spinal cord injured subjects showed distinct distortions of intralimb coordination as well as limited modulation to changes in walking speed. The specific changes of the cyclograms revealed complementary insight in the disturbance of lower-limb control in addition to measures of time and distance and may be a useful tool for patient categorization and stratification prior to clinical trial inclusion.	[Awai, Lea; Curt, Armin] Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, CH-8008 Zurich, Switzerland	Awai, L (corresponding author), Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, Forchstr 340, CH-8008 Zurich, Switzerland.	lawai@paralab.balgrist.ch		Awai, Lea/0000-0002-9542-1152	European Commission's Seventh Framework Program [CP-IP 258654]; Wolf Foundation, Switzerland; Clinical Research Priority Program CRPP Neurorehab UZH; European Commission's Seventh Framework Program [NEUWalk]	We thank B. Huber for assistance with subject recruitment and kinematic data acquisition, funding: this work was supported by the European Commission's Seventh Framework Program [CP-IP 258654, NEUWalk]; the Wolf Foundation, Switzerland; the Clinical Research Priority Program CRPP Neurorehab UZH.	Abel R, 2002, SPINAL CORD, V40, P17, DOI 10.1038/sj.sc.3101239; Bachmann LC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005972; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Borghese NA, 1996, J PHYSIOL-LONDON, V494, P863, DOI 10.1113/jphysiol.1996.sp021539; COTES JE, 1960, ERGONOMICS, V3, P97, DOI 10.1080/00140136008930473; Courtemanche R, 1996, ARCH PHYS MED REHAB, V77, P849, DOI 10.1016/S0003-9993(96)90269-5; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Duysens J, 1998, GAIT POSTURE, V7, P131, DOI 10.1016/S0966-6362(97)00042-8; Field-Fote EC, 2002, PHYS THER, V82, P707, DOI 10.1093/ptj/82.7.707; Field-Fote EC, 2001, J REHABIL MED, V33, P177, DOI 10.1080/165019701750300645; Gil-Agudo A, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-7; Grasso R, 1998, J NEUROPHYSIOL, V80, P1868; Ivanenko YP, 2003, J NEUROPHYSIOL, V90, P3555, DOI 10.1152/jn.00223.2003; Krawetz P, 1996, ARCH PHYS MED REHAB, V77, P635, DOI 10.1016/S0003-9993(96)90000-3; KUHN RA, 1950, BRAIN, V73, P1, DOI 10.1093/brain/73.1.1; Lacquaniti F, 1999, NEWS PHYSIOL SCI, V14, P168, DOI 10.1152/physiologyonline.1999.14.4.168; MacLellan MJ, 2013, EXP BRAIN RES, V225, P217, DOI 10.1007/s00221-012-3364-5; Manor B, 2009, GAIT POSTURE, V30, P253, DOI 10.1016/j.gaitpost.2009.04.011; Morris M, 2005, MOVEMENT DISORD, V20, P40, DOI 10.1002/mds.20278; Morris M, 1998, MOVEMENT DISORD, V13, P61, DOI 10.1002/mds.870130115; Nakajima K, 2000, J NEUROPHYSIOL, V84, P698; Nooijen CFJ, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-36; Pepin A, 2003, SPINAL CORD, V41, P257, DOI 10.1038/sj.sc.3101452; ROBINSON JL, 1981, PHYS THER, V61, P351, DOI 10.1093/ptj/61.3.351; SAINBURG RL, 1993, J NEUROPHYSIOL, V70, P2136; Tamburella F, 2013, EUR J PHYS REHAB MED, V49, P353; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45	27	26	26	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 17	2014	8								148	10.3389/fnhum.2014.00148			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AC9IP	WOS:000332848200001	24672464	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Coronel, MF; Labombarda, F; De Nicola, AF; Gonzalez, SL				Coronel, M. F.; Labombarda, F.; De Nicola, A. F.; Gonzalez, S. L.			Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central neuropathic pain	EUROPEAN JOURNAL OF PAIN			English	Article							TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; GLUCOCORTICOID-MEDIATED REPRESSION; RANDOMIZED CLINICAL-TRIAL; CORD-INJURY; NERVE INJURY; GLIAL-CELLS; ACTIVATION; RECEPTOR; INFLAMMATION	BackgroundSpinal cord injury (SCI) results in the development of chronic pain that is refractory to conventional treatment. Progesterone, a neuroprotective steroid, may offer a promising perspective in pain modulation after central injury. Here, we explore the impact of progesterone administration on the post-injury inflammatory cascade involving the enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) at the spinal cord level. We also analyse pain behaviours, the profile of glial cell activation, and IB- mRNA levels, as an index of NF-B transactivation. MethodsWe used biochemical, immunohistochemical and molecular techniques, as well as behavioural studies, to investigate the effects of progesterone in a well-characterized model of central neuropathic pain. ResultsInjured animals receiving progesterone presented reduced mRNA levels of the proinflammatory enzymes, as well as decreased COX-2 activity and nitrite levels, as compared to vehicle-treated injured rats. Further, animals receiving the steroid exhibited lower levels of IB- mRNA, suggesting decreased NF-B transactivation. Progesterone administration also attenuated the injury-induced increase in the number of glial fibrillary acidic protein and OX-42 positive cells both at early and late time points after injury, and prevented the development of mechanical and thermal allodynia. Further, when injured rats received early progesterone administration for a critical period of time after injury, they did not display allodynic behaviours even after the treatment had stopped. ConclusionsOur results suggest that progesterone, by modulating early neuroinflammatory events triggered after SCI, may represent a useful strategy to prevent the development of central chronic pain.	[Coronel, M. F.; Gonzalez, S. L.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Nocicepc & Dolor Neuropt, RA-1033 Buenos Aires, DF, Argentina; [Labombarda, F.; De Nicola, A. F.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Bioquim Neuroendocrina, RA-1033 Buenos Aires, DF, Argentina; [Labombarda, F.; De Nicola, A. F.; Gonzalez, S. L.] Univ Buenos Aires, Fac Med, Dept Bioquim Humana, RA-1053 Buenos Aires, DF, Argentina	Gonzalez, SL (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Nocicepc & Dolor Neuropt, RA-1033 Buenos Aires, DF, Argentina.	sugnzlz@gmail.com	Labombarda, Fabien/AAE-7747-2020		Universidad de Buenos AiresUniversity of Buenos Aires [20020090200126]; CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 201-101-00576]; Fundacion Alberto J. Roemmers	This work was supported by Universidad de Buenos Aires (Grant no. 20020090200126), CONICET (PIP 201-101-00576) and Fundacion Alberto J. Roemmers.	APPLEBY SB, 1994, BIOCH J, V302; Bottero Virginie, 2003, Mol Diagn, V7, P187, DOI 10.2165/00066982-200307030-00008; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Cady RJ, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-94; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; Coronel MF, 2011, J PAIN, V12, P71, DOI 10.1016/j.jpain.2010.04.013; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dableh Liliane J, 2011, J Pain Res, V4, P91, DOI 10.2147/JPR.S17009; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Finnerup NB, 2012, CURR PAIN HEADACHE R, V16, P207, DOI 10.1007/s11916-012-0259-x; Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x; Fu ES, 2010, PAIN, V148, P509, DOI 10.1016/j.pain.2010.01.001; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Gwak YS, 2012, EXP NEUROL, V234, P362, DOI 10.1016/j.expneurol.2011.10.010; Hardy DB, 2006, MOL ENDOCRINOL, V20, P2724, DOI 10.1210/me.2006-0112; Hervera A, 2010, J PHARMACOL EXP THER, V334, P887, DOI 10.1124/jpet.110.167585; Hewett SJ, 2006, PHARMACOL THERAPEUT, V112, P335, DOI 10.1016/j.pharmthera.2005.04.011; Jiang C, 2011, INT IMMUNOPHARMACOL, V11, P1925, DOI 10.1016/j.intimp.2011.08.001; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kim MJ, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-16; Kuboyama K, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-50; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2008, NEUROSCI LETT, V447, P115, DOI 10.1016/j.neulet.2008.09.062; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Little JW, 2012, AMINO ACIDS, V42, P75, DOI 10.1007/s00726-010-0633-0; Luongo L, 2010, NEUROBIOL DIS, V37, P177, DOI 10.1016/j.nbd.2009.09.021; Ma WY, 2012, EXPERT OPIN THER TAR, V16, P527, DOI 10.1517/14728222.2012.680955; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; Mensah-Nyagan A.G., 2009, PSYCHONEUROENDOCRINO, V34, P169; Menzies FM, 2011, IMMUNOLOGY, V134, P281, DOI 10.1111/j.1365-2567.2011.03488.x; Milani P, 2010, J BRACHIAL PLEX PERI, V5, DOI 10.1186/1749-7221-5-11; Molander Carl, 1995, P39; Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rafati DS, 2008, J NEUROSCI RES, V86, P566, DOI 10.1002/jnr.21508; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Roh DH, 2010, EXP NEUROL, V224, P123, DOI 10.1016/j.expneurol.2010.03.002; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schmidtko A, 2009, TRENDS NEUROSCI, V32, P339, DOI 10.1016/j.tins.2009.01.010; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Seybold V S, 2009, Handb Exp Pharmacol, P451, DOI 10.1007/978-3-540-79090-7_13; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tamura I, 2011, J CLIN ENDOCR METAB, V96, pE1073, DOI 10.1210/jc.2010-2489; Tan AM, 2009, J REHABIL RES DEV, V46, P123, DOI 10.1682/JRRD.2008.03.0048; Tenorio G, 2013, PAIN, V154, P71, DOI 10.1016/j.pain.2012.09.008; Vaisanen-Tommiska M, 2006, HUM REPROD, V21, P2180, DOI 10.1093/humrep/del141; Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0; Wang Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/848309; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yezierski RP, 2009, J REHABIL RES DEV, V46, P95, DOI 10.1682/JRRD.2008.06.0074; Zhang G., 2011, PLOS ONE, V6; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	67	26	30	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAR	2014	18	3					348	359		10.1002/j.1532-2149.2013.00376.x			12	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	304JZ	WOS:000330744200006	23929706				2021-06-18	
J	Graham, JE; Granger, CV; Karmarkar, AM; Deutsch, A; Niewczyk, P; DiVita, MA; Ottenbacher, KJ				Graham, James E.; Granger, Carl V.; Karmarkar, Amol M.; Deutsch, Anne; Niewczyk, Paulette; DiVita, Margaret A.; Ottenbacher, Kenneth J.			The Uniform Data System for Medical Rehabilitation Report of Follow-up Information on Patients Discharged from Inpatient Rehabilitation Programs in 2002-2010	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Benchmark; Evaluation; Quality Improvement	FUNCTIONAL INDEPENDENCE MEASURE; STROKE	Objective The aim of this study was to present yearly aggregated summaries of rehabilitation outcomes at admission, discharge, and follow-up from a national sample of patients receiving inpatient medical rehabilitation for stroke, traumatic brain injury, lower extremity fracture, lower extremity joint replacement, traumatic spinal cord injury, or debility. Design This is an analysis of secondary data from more than 300 inpatient rehabilitation facilities in the United States that contributed inpatient and follow-up data to the Uniform Data System for Medical Rehabilitation during the period January 2002 through December 2010. Aggregate variables reported include demographic information, social situation, and functional status (Functional Independence Measure instrument ratings at admission, discharge, and follow-up). Follow-up data were obtained 80-180 days after discharge through telephone interviews by trained clinical staff. Results The final sample included 287,104 patients with follow-up information. The median time to follow-up was 95 days. Overall, more than 90% of the patients within each impairment group were living in the community at follow-up. Follow-up Functional Independence Measure total ratings were stable to slightly increased over time. Change scores (discharge to follow-up) increased in all six groups. The mean Functional Independence Measure gains from discharge to follow-up, as a percentage of mean gains from admission to discharge, varied by impairment category: 46% for spinal cord injury to 71% for lower extremity fracture. Locomotion yielded the lowest ratings at all three assessments within each of the six impairment groups. Conclusions The follow-up data from the national sample of patients discharged from inpatient rehabilitation indicate that gains in mean functional independence scores from both admission to discharge and discharge to follow-up gradually increased from 2002 to 2010. At follow-up, more than nine of ten patients in all six groups are living in the community.	[Graham, James E.; Karmarkar, Amol M.; Ottenbacher, Kenneth J.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Granger, Carl V.; Niewczyk, Paulette; DiVita, Margaret A.] Uniform Data Syst Med Rehabil, Buffalo, NY USA; [Deutsch, Anne] Rehabil Inst Chicago, Chicago, IL USA; [Deutsch, Anne] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Deutsch, Anne] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Deutsch, Anne] RTI Int, Washington, DC USA	Ottenbacher, KJ (corresponding author), Univ Texas Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.			DiVita, Margaret/0000-0002-4878-2959; Deutsch, Anne/0000-0003-2290-7757; Ottenbacher, Kenneth/0000-0001-5990-3982	Department of EducationUS Department of Education; National Institute on Disability and Rehabilitation Research [H133G080163, H133N060014]; National Institutes of Health, National Center for Medical Rehabilitation ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24 HD065702]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024832] Funding Source: NIH RePORTER	Supported by grants from the Department of Education; the National Institute on Disability and Rehabilitation Research (H133G080163 [to K.J.O.] and H133N060014 [to A. D.]); and the National Institutes of Health, National Center for Medical Rehabilitation Research (R24 HD065702 [to K.J.O., J.E.G., A.M.K.]).	CARTER GM, 2002, EXECUTIVE SUMMARY AN; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1297, DOI 10.1016/j.apmr.2008.12.029; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P184, DOI 10.1097/00002060-200003000-00012; Galloway RV, 2013, AM J PHYS MED REHAB, V92, P14, DOI 10.1097/PHM.0b013e31827441bc; Granger CV, 2012, AM J PHYS MED REHAB, V91, P289, DOI 10.1097/PHM.0b013e31824ad2fd; Granger CV, 2011, AM J PHYS MED REHAB, V90, P177, DOI 10.1097/PHM.0b013e31820b18d7; Granger CV, 2010, AM J PHYS MED REHAB, V89, P781, DOI 10.1097/PHM.0b013e3181f1c83a; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Granger CV, 2009, AM J PHYS MED REHAB, V88, P961, DOI [10.1097/PHM.0b013e3181c1ec38, 10.1097/PHM.0b013e3181clec38]; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Stineman MG, 1997, STROKE, V28, P550, DOI 10.1161/01.STR.28.3.550; US Department of Health and Human Services, 2009, FED REG, VB74, P151; WALKER AJ, 1995, FAM RELAT, V44, P402, DOI 10.2307/584996	14	26	28	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2014	93	3					231	244		10.1097/PHM.0b013e3182a92c58			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AB3RH	WOS:000331707400005	24088780	Green Accepted			2021-06-18	
J	Knutson, KM; Dal Monte, O; Raymont, V; Wassermann, EM; Krueger, F; Grafman, J				Knutson, Kristine M.; Dal Monte, Olga; Raymont, Vanessa; Wassermann, Eric M.; Krueger, Frank; Grafman, Jordan			Neural correlates of apathy revealed by lesion mapping in participants with traumatic brain injuries	HUMAN BRAIN MAPPING			English	Article						voxel-based lesion-symptom mapping; apathy; cingulate cortex; fatigue; traumatic brain injury; insula	PENETRATING HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC INVENTORY; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; COGNITIVE FATIGUE; RATING-SCALE; CORTEX; PERFUSION; SYMPTOMS	Apathy, common in neurological disorders, is defined as disinterest and loss of motivation, with a reduction in self-initiated activity. Research in diseased populations has shown that apathy is associated with variations in the volume of brain regions such as the anterior cingulate and the frontal lobes. The goal of this study was to determine the neural signatures of apathy in people with penetrating traumatic brain injuries (pTBIs), as to our knowledge, these have not been studied in this sample. We studied 176 male Vietnam War veterans with pTBIs using voxel-based lesion-symptom mapping (VLSM) and apathy scores from the UCLA Neuropsychiatric Inventory (NPI), a structured inventory of symptoms completed by a caregiver. Our results revealed that increased apathy symptoms were associated with brain damage in limbic and cortical areas of the left hemisphere including the anterior cingulate, inferior, middle, and superior frontal regions, insula, and supplementary motor area. Our results are consistent with the literature, and extend them to people with focal pTBI. Apathy is a significant symptom since it can reduce participation of the patient in family and other social interactions, and diminish affective decision-making. Hum Brain Mapp 35:943-953, 2014. (c) 2013 Wiley Periodicals, Inc.	[Knutson, Kristine M.; Dal Monte, Olga; Wassermann, Eric M.] NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA; [Dal Monte, Olga] Univ Turin, Dept Neuropsychol, Turin, Italy; [Dal Monte, Olga] Henry M Jackson Fdn, Rockville, MD USA; [Raymont, Vanessa] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England; [Raymont, Vanessa] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Grafman, Jordan] Rehabil Inst Chicago, Brain Injury Res Program, Chicago, IL 60611 USA	Grafman, J (corresponding author), Rehabil Inst Chicago, Brain Injury Res Program, 345 East Super St, Chicago, IL 60611 USA.	fkrueger@gmu.edu; jgrafman@ric.org	Dal Monte, Olga/P-3759-2018; Wassermann, Eric M./AAC-9064-2020	Dal Monte, Olga/0000-0002-7823-4769; Wassermann, Eric M./0000-0003-0628-0210; Knutson, Kristine/0000-0003-4626-4514; Grafman, Jordan H./0000-0001-8645-4457	U.S. National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [DAMD17-01-1-0675]	This work was supported by funding from the U.S. National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the United States Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year post-injury follow-up study, grant number DAMD17-01-1-0675).	Aalten P, 2008, DEMENT GERIATR COGN, V25, P1, DOI 10.1159/000111082; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Apostolova LG, 2007, DEMENT GERIATR COGN, V24, P91, DOI 10.1159/000103914; BECK AT, 1978, BECK DEPRESSION INVE; Benoit M, 2004, INT J GERIATR PSYCH, V19, P864, DOI 10.1002/gps.1163; Benoit M, 2002, PSYCHIAT RES-NEUROIM, V114, P103, DOI 10.1016/S0925-4927(02)00003-3; Benoit M, 1999, DEMENT GERIATR COGN, V10, P511, DOI 10.1159/000017198; Bruen PD, 2008, BRAIN, V131, P2455, DOI 10.1093/brain/awn151; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Craig AH, 1996, ARCH NEUROL-CHICAGO, V53, P1116, DOI 10.1001/archneur.1996.00550110056012; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Damasio A., 1994, DESCARTESERROR EMOTI; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Dujardin K, 2008, MOVEMENT DISORD, V23, P845, DOI 10.1002/mds.21968; First MB., 2002, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Greene J G, 1982, Age Ageing, V11, P121, DOI 10.1093/ageing/11.2.121; Guimaraes HC, 2008, ARQ NEURO-PSIQUIAT, V66, P436, DOI 10.1590/S0004-282X2008000300035; Hoare J, 2010, J NEUROPSYCH CLIN N, V22, P313, DOI 10.1176/appi.neuropsych.22.3.313; Holthoff VA, 2005, BIOL PSYCHIAT, V57, P412, DOI 10.1016/j.biopsych.2004.11.035; JENNETT B, 1975, LANCET, V1, P480; Jouvent E, 2011, NEUROLOGY, V76, P1472, DOI 10.1212/WNL.0b013e31821810a4; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kim JW, 2011, AM J GERIAT PSYCHIAT, V19, P644, DOI 10.1097/JGP.0b013e31820dcc73; Kirsch-Darrow L, 2011, J INT NEUROPSYCH SOC, V17, P1058, DOI 10.1017/S1355617711001068; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kumral E, 2002, EUR J NEUROL, V9, P615, DOI 10.1046/j.1468-1331.2002.00452.x; Lanctot KL, 2007, DEMENT GERIATR COGN, V24, P65, DOI 10.1159/000103633; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; LAPLANE D, 1981, J NEUROL SCI, V51, P289, DOI 10.1016/0022-510X(81)90107-6; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; LUDLOW CL, 1986, BRAIN, V109, P55, DOI 10.1093/brain/109.1.55; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Manes F, 1999, J NERV MENT DIS, V187, P707, DOI 10.1097/00005053-199912000-00001; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; Marshall GA, 2006, DEMENT GERIATR COGN, V21, P144, DOI 10.1159/000090674; Marshall GA, 2007, ARCH NEUROL-CHICAGO, V64, P1015, DOI 10.1001/archneur.64.7.1015; Massimo L, 2009, DEMENT GERIATR COGN, V27, P96, DOI 10.1159/000194658; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; MILLER BL, 1999, SCI PRACT NEUROPSYCH, P557; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mortby Moyra Elizabeth, 2012, Aging Clin Exp Res, V24, P305, DOI 10.3275/8105; Nieuwenhuys R, 2012, PROG BRAIN RES, V195, P123, DOI 10.1016/B978-0-444-53860-4.00007-6; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; Plassmann H, 2007, J NEUROSCI, V27, P9984, DOI 10.1523/JNEUROSCI.2131-07.2007; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Reijnders JSAM, 2010, MOVEMENT DISORD, V25, P2318, DOI 10.1002/mds.23268; Robert PH, 2006, EUR J NEUROL, V13, P729, DOI 10.1111/j.1468-1331.2006.01088.x; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; Rosen HJ, 2005, BRAIN, V128, P2612, DOI 10.1093/brain/awh628; Rudebeck PH, 2006, NAT NEUROSCI, V9, P1161, DOI 10.1038/nn1756; Rushworth MFS, 2007, TRENDS COGN SCI, V11, P168, DOI 10.1016/j.tics.2007.01.004; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Sescousse G, 2010, J NEUROSCI, V30, P13095, DOI 10.1523/JNEUROSCI.3501-10.2010; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.6.872; Starkstein SE, 2009, J NEUROPSYCH CLIN N, V21, P259, DOI 10.1176/appi.neuropsych.21.3.259; Tunnard C, 2011, INT J GERIATR PSYCH, V26, P741, DOI 10.1002/gps.2603; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Woolley SC, 2011, AMYOTROPH LATERAL SC, V12, P52, DOI 10.3109/17482968.2010.521842; Zamboni G, 2008, NEUROLOGY, V71, P736, DOI 10.1212/01.wnl.0000324920.96835.95	75	26	27	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2014	35	3					943	953		10.1002/hbm.22225			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AF0IW	WOS:000334398500016	23404730	Green Published, Green Accepted			2021-06-18	
J	Shafi, S; Barnes, SA; Millar, D; Sobrino, J; Kudyakov, R; Berryman, C; Rayan, N; Dubiel, R; Coimbra, R; Magnotti, LJ; Vercruysse, G; Scherer, LA; Jurkovich, GJ; Nirula, R				Shafi, Shahid; Barnes, Sunni A.; Millar, D.; Sobrino, Justin; Kudyakov, Rustam; Berryman, Candice; Rayan, Nadine; Dubiel, Rosemary; Coimbra, Raul; Magnotti, Louis J.; Vercruysse, Gary; Scherer, Lynette A.; Jurkovich, Gregory J.; Nirula, Raminder			Suboptimal compliance with evidence-based guidelines in patients with traumatic brain injuries	JOURNAL OF NEUROSURGERY			English	Article						evidence-based management; quality of care; traumatic brain injury; quality chasm; variations in care	UNITED-STATES; HEALTH-CARE; QUALITY; MORTALITY; CENTERS	Object. Evidence-based management (EBM) guidelines for severe traumatic brain injuries (TBIs) were promulgated decades ago. However, the extent of their adoption into bedside clinical practices is not known. The purpose of this study was to measure compliance with EBM guidelines for management of severe TBI and its impact on patient outcome. Methods. This was a retrospective study of blunt TBI (11 Level I trauma centers, study period 2008-2009, n = 2056 patients). Inclusion criteria were an admission Glasgow Coma Scale score s 8 and a CT scan showing TBI, excluding patients with nonsurvivable injuries-that is, head Abbreviated Injury Scale score of 6. The authors measured compliance with 6 nonoperative EBM processes (endotracheal intubation, resuscitation, correction of coagulopathy, intracranial pressure monitoring, maintaining cerebral perfusion pressure >= 50 cm H2O, and discharge to rehabilitation). Compliance rates were calculated for each center using multivariate regression to adjust for patient demographics, physiology, injury severity, and TBI severity. Results. The overall compliance rate was 73%, and there was wide variation among centers. Only 3 centers achieved a compliance rate exceeding 80%. Risk-adjusted compliance was worse than average at 2 centers, better than average at 1, and the remainder were average. Multivariate analysis showed that increased adoption of EBM was associated with a reduced mortality rate (OR 0.88; 95% CI 0.81-0.96, p < 0.005). Conclusions. Despite widespread dissemination of EBM guidelines, patients with severe TBI continue to receive inconsistent care. Barriers to adoption of EBM need to be identified and mitigated to improve patient outcomes.	[Shafi, Shahid; Barnes, Sunni A.; Sobrino, Justin; Kudyakov, Rustam; Berryman, Candice; Rayan, Nadine] Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX 75206 USA; [Dubiel, Rosemary] Baylor Hlth Care Syst, Baylor Inst Rehabil, Dallas, TX 75206 USA; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; [Magnotti, Louis J.] Univ Tennessee, Ctr Hlth Sci, Dept Gen Surg, Memphis, TN 38163 USA; [Vercruysse, Gary] Emory Univ, Div Trauma Surg Crit Care, Atlanta, GA 30322 USA; [Scherer, Lynette A.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA; [Jurkovich, Gregory J.] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; [Millar, D.; Nirula, Raminder] Univ Utah, Dept Surg, Salt Lake City, UT USA	Shafi, S (corresponding author), Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, 8080 N Cent Expressway,Ste 500, Dallas, TX 75206 USA.	shahid.shafi@baylorhealth.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851	National Institute on Disability and Rehabilitation Research [H133A070027-11]; American Recovery and Reinvestment Act/National Institute of Neurological Disorders and Stroke [1RC1NS069066-01, 5RC1NS069066-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC1NS069066] Funding Source: NIH RePORTER	Support was provided in part by a grant from the National Institute on Disability and Rehabilitation Research (no. H133A070027-11) and by the American Recovery and Reinvestment Act/National Institute of Neurological Disorders and Stroke (nos. 1RC1NS069066-01 and 5RC1NS069066-02).	Brain Injury Association of America, BRAIN INJ; Brain Trauma Foundation, AB BTF; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Fleming NS, 2009, JT COMM J QUAL PATIE, V35, P414, DOI 10.1016/S1553-7250(09)35058-8; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Rayan N, 2012, J TRAUMA ACUTE CARE, V72, P585, DOI 10.1097/TA.0b013e318243da4d; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Shafi S, 2012, J TRAUMA ACUTE CARE, V72, P870, DOI 10.1097/TA.0b013e3182463e20; Shafi S, 2010, J TRAUMA, V68, P771, DOI 10.1097/TA.0b013e3181d03a20; Sucher JF, 2008, J TRAUMA, V64, P520, DOI 10.1097/TA.0b013e3181601812	12	26	26	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2014	120	3					773	777		10.3171/2013.12.JNS132151			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AB8OB	WOS:000332048800028	24438538				2021-06-18	
J	Shimada, R; Abe, K; Furutani, R; Kibayashi, K				Shimada, Ryo; Abe, Keiichi; Furutani, Rui; Kibayashi, Kazuhiko			Changes in dopamine transporter expression in the midbrain following traumatic brain injury: an immunohistochemical and in situ hybridization study in a mouse model	NEUROLOGICAL RESEARCH			English	Article						Head trauma; Dopamine transporter; Retrorubral field; In situ hybridization	VENTRAL TEGMENTAL AREA; STRIATAL DOPAMINE; RETRORUBRAL FIELD; HIPPOCAMPAL-FORMATION; SUBSTANTIA-NIGRA; RAT; INNERVATION; PROJECTIONS; PROBES; RNA	Objectives: An association has been suggested between trauma and neurological degenerative diseases. Magnetic resonance imaging has revealed that traumatic brain injury (TBI) can cause primary lesions in the midbrain including the substantia nigra (SN). Dopamine transporter (DAT) is mainly expressed in the SN, ventral tegmental area (VTA), and retrorubral field (RRF) of the ventral midbrain. Previous western blot studies have examined DAT levels in the rat frontal cortex and striatum after a controlled cortical impact (CCI); however, no study has comprehensively examined DAT expression in the midbrain following TBI in an animal model. Methods: We used immunohistochemistry and in situ hybridization to examine the time-dependent changes in the expression of DAT in the midbrain during the first 14 days after TBI in a mouse CCI model. Results: The expression of DAT protein in the RRF on the side ipsilateral to the site of injury decreased in 14 days after injury. Dopamine transporter mRNA expression in the RRF on the ipsilateral side decreased in 1, 7, and 14 days and increased in 4 days after injury. Discussion: These findings indicated that TBI induced changes in DAT expression in the RRF. Because the DAT pumps dopamine (DA) out of the synapse back into the cytosol and maintains DA homeostasis, the decreased expression of DAT after TBI may result in decreased DA neurotransmission in the brain.	[Shimada, Ryo; Furutani, Rui; Kibayashi, Kazuhiko] Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Tokyo 1628666, Japan; [Abe, Keiichi] Tokyo Womens Med Univ, Sch Med, Dept Neurosurg, Tokyo 1628666, Japan	Shimada, R (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	shimada@research.twmu.ac.jp	Kazuhiko, Kibayashi/F-5173-2013	Kazuhiko, Kibayashi/0000-0001-6510-5215	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26293164] Funding Source: KAKEN		Backman CM, 2006, GENESIS, V44, P383, DOI 10.1002/dvg.20228; Bisaglia M, 2013, FASEB J, V27, P2101, DOI 10.1096/fj.12-226852; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; Dahlstroem A, 1964, ACTA PHYSIOL SCAND S, V232, P1; Desvignes C, 1999, NEUROSCI LETT, V261, P175, DOI 10.1016/S0304-3940(99)00026-9; Fazeli G, 2011, BRAIN PATHOL, V21, P237, DOI 10.1111/j.1750-3639.2010.00440.x; Fu YH, 2012, BRAIN STRUCT FUNCT, V217, P591, DOI 10.1007/s00429-011-0349-2; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gasbarri A, 1997, PROG NEURO-PSYCHOPH, V21, P1, DOI 10.1016/S0278-5846(96)00157-1; Gasbarri A, 1996, EXP BRAIN RES, V112, P244; Hasue RH, 2002, J COMP NEUROL, V454, P15, DOI 10.1002/cne.10420; Hu ZL, 2004, J COMP NEUROL, V476, P301, DOI 10.1002/cne.20230; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kerner JA, 1998, BRAIN RES PROTOC, V3, P22, DOI 10.1016/S1385-299X(98)00017-8; KOLLER WC, 1989, MOVEMENT DISORD, V4, P20, DOI 10.1002/mds.870040106; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mejias-Aponte CA, 2009, J NEUROSCI, V29, P3613, DOI 10.1523/JNEUROSCI.4632-08.2009; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; Nakao K, 2010, J NEUROTRAUM, V27, P1925, DOI 10.1089/neu.2010.1379; Patel J, 2003, J NEUROCHEM, V85, P898, DOI 10.1046/j.1471-4159.2003.01732.x; Sato H, 1994, PROG COMPUT IMAGING, V16, P187; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shimada R, 2012, J CLIN NEUROSCI, V19, P447, DOI 10.1016/j.jocn.2011.06.033; Tanizaki Y, 2006, PATHOL INT, V56, P510, DOI 10.1111/j.1440-1827.2006.01999.x; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Vikman P, 2007, J NEUROSURG, V107, P1015, DOI 10.3171/JNS-07/11/1015; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013	34	26	29	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2014	36	3					239	246		10.1179/1743132813Y.0000000289			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AI7VL	WOS:000337108800007	24512017				2021-06-18	
J	Vaaramo, K; Puljula, J; Tetri, S; Juvela, S; Hillbom, M				Vaaramo, K.; Puljula, J.; Tetri, S.; Juvela, S.; Hillbom, M.			Head trauma sustained under the influence of alcohol is a predictor for future traumatic brain injury: a long-term follow-up study	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						alcohol; harmful drinking; hazardous drinking; head trauma; traumatic brain injury	DRINKING; INTERVENTIONS; RISK	Background and purposeHazardous drinking may result in recurrent head trauma. It was investigated whether head trauma sustained under the influence of alcohol is a predictor of future traumatic brain injury (TBI). MethodsAll subjects with head trauma (n=827) brought to the emergency room at Oulu University Hospital during 1999 were identified and followed up until death or the end of 2009. The National Hospital Discharge Register and hospital charts were used to identify TBIs during the follow-up and Kaplan-Meier curves and the Cox proportional hazards model were used to characterize predictors of TBI. ResultsDuring the total follow-up of 7386 person-years, 52/827 subjects sustained a new head trauma with TBI and the risk of TBI was significantly (P=0.005) higher amongst subjects who had been under the influence of alcohol at the time of the index trauma in 1999. New TBI occurred under the influence of alcohol in 30/52 cases (57.7%). An alcohol-related index trauma [adjusted hazard ratio (HR) 2.51, 95% confidence interval (CI) 1.38-4.56, P<0.01] and history of TBI (HR 3.39, 95% CI 1.32-8.72, P<0.05) were independent risk factors for subsequent TBI after adjustment for sex and age. A history of harmful drinking was also a significant risk factor (adjusted HR 10.37, 95% CI 5.53-19.43, P<0.001). In the subset of 396 patients having an index head trauma without TBI, this being alcohol related was also a significant risk factor for subsequent TBI after adjustment for sex, age and history of TBI (HR 3.54, 95% CI 1.36-9.18, P=0.009). ConclusionsEven head trauma without TBI under the influence of alcohol implies an elevated risk of subsequent TBI. A brief intervention to reduce hazardous drinking is needed to prevent TBI.	[Vaaramo, K.; Puljula, J.; Hillbom, M.] Univ Oulu, Dept Neurol, Oulu Univ Hosp, Oulu, Finland; [Tetri, S.] Univ Oulu, Dept Neurosurg, Oulu Univ Hosp, Oulu, Finland; [Juvela, S.] Univ Helsinki, Dept Clin Neurosci, Helsinki, Finland	Vaaramo, K (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, Oulu 90029, Finland.	kallevaa@mail.student.oulu.fi			Maire Taponen Foundation	This research was supported in part by a grant to Dr Vaaramo from the Maire Taponen Foundation.	Babor TF, 2005, J TRAUMA, V59, pS80, DOI 10.1097/01.ta.0000174664.88603.21; BABOR TF, 1994, LEXICON ALCOHOL OTHE; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dinh-Zarr T, 1999, ALCOHOL ALCOHOLISM, V34, P609, DOI 10.1093/alcalc/34.4.609; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Paljarvi T, 2005, ADDICTION, V100, P1851, DOI 10.1111/j.1360-0443.2005.01258.x; Paljarvi T, 2012, ADDICTION, V107, P323, DOI 10.1111/j.1360-0443.2011.03596.x; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Puljula J, 2007, ALCOHOL ALCOHOLISM, V42, P474, DOI 10.1093/alcalc/agm003; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Schermer CR, 2003, J TRAUMA, V54, P701, DOI 10.1097/01.TA.0000056158.25478.50; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	18	26	26	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	FEB	2014	21	2					293	298		10.1111/ene.12302			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	287MZ	WOS:000329547200020	24237603				2021-06-18	
J	Shehadah, A; Chen, JL; Pal, A; He, SY; Zeitlin, A; Cui, X; Zacharek, A; Cui, YS; Roberts, C; Lu, M; Hariri, R; Chopp, M				Shehadah, Amjad; Chen, Jieli; Pal, Ajai; He, Shuyang; Zeitlin, Andrew; Cui, Xu; Zacharek, Alex; Cui, Yisheng; Roberts, Cynthia; Lu, Mei; Hariri, Robert; Chopp, Michael			Human Placenta-Derived Adherent Cell Treatment of Experimental Stroke Promotes Functional Recovery after Stroke in Young Adult and Older Rats	PLOS ONE			English	Article							MARROW STROMAL CELLS; SENSORIMOTOR CORTEX LESIONS; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; STEM-CELLS; SYNAPTIC PLASTICITY; EMBOLIC STROKE; GENE-EXPRESSION; INFARCT VOLUME; AGED RATS	Background: Human Placenta-Derived Adherent Cells (PDAC (R)) are a novel mesenchymal-like cell population derived from normal human placental tissue. PDA-001 is a clinical formulation of PDAC (R) developed for intravenous administration. In this study, we investigated the efficacy of PDA-001 treatment in a rat model of transient middle cerebral artery occlusion (MCAo) in young adult (2-3 month old) and older rats (10-12 months old). Methods: To evaluate efficacy and determine the optimal number of transplanted cells, young adult Wistar rats were subjected to MCAo and treated 1 day post MCAo with 1x10(6), 4x10(6) or 8x10(6) PDA-001 cells (i. v.), vehicle or cell control. 4x10(6) or 8x10(6) PDA-001 cells were also tested in older rats after MCAo. Treatment response was evaluated using a battery of functional outcome tests, consisting of adhesive-removal test, modified Neurological Severity Score (mNSS) and foot-fault test. Young adult rats were sacrificed 56 days after MCAo, older rats were sacrificed 29 days after MCAo, and lesion volumes were measured using H& E. Immunohistochemical stainings for bromodeoxyuridine (BrdU) and von Willebrand Factor (vWF), and synaptophysin were performed. Results: In young adult rats, treatment with 4x10(6) PDA-001 cells significantly improved functional outcome after stroke (p<0.05). In older rats, significant functional improvement was observed with PDA-001 cell therapy in both of the 4x10(6) and 8x10(6) treatment groups. Functional benefits in young adult and older rats were associated with significant increases in the number of BrdU immunoreactive endothelial cells, vascular density and perimeter in the ischemic brain, as well as significantly increased synaptophysin expression in the ischemic border zone (p<0.05). Conclusion: PDA-001 treatment significantly improved functional outcome after stroke in both young adult and older rats. The neurorestorative effects induced by PDA-001 treatment may be related to increased vascular density and synaptic plasticity.	[Shehadah, Amjad; Chen, Jieli; Cui, Xu; Zacharek, Alex; Cui, Yisheng; Roberts, Cynthia; Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Pal, Ajai; He, Shuyang; Zeitlin, Andrew; Hariri, Robert] Celgene Cellular Therapeut, Warren, NJ USA; [Lu, Mei] Henry Ford Hosp, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Chen, JL (corresponding author), Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA.	jieli@neuro.hfh.edu		Shehadah, Amjad/0000-0001-8679-3774; Cui, Xu/0000-0002-6937-6191	Celgene Cellular Therapeutics, New Jersey, USA	This work was funded by Celgene Cellular Therapeutics, New Jersey, USA. The funders had no role in study design, data collection, analysis or preparation of the manuscript. Study design and decision to publish were approved by the funders.	Adkins DL, 2008, EXP NEUROL, V212, P14, DOI 10.1016/j.expneurol.2008.01.031; BARTH TM, 1990, STROKE, V21, P153; Bohotin Catalina Roxana, 2004, Rom J Physiol, V41, P99; CHEN H, 1991, NEUROLOGY, V41, P1133, DOI 10.1212/WNL.41.7.1133; Chen J, 2006, NEUROSCIENCE, V141, P737, DOI 10.1016/j.neuroscience.2006.04.042; Chen J, 2012, CELL TRANSPLANT; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; Ding GL, 2011, STROKE, V42, P3537, DOI 10.1161/STROKEAHA.111.622092; FUTRELL N, 1991, STROKE, V22, P1582, DOI 10.1161/01.STR.22.12.1582; GARCIA JH, 1971, ACTA NEUROPATHOL, V18, P273, DOI 10.1007/BF00688441; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; He SY, 2013, BRAIN BEHAV IMMUN, V27, P185, DOI 10.1016/j.bbi.2012.10.015; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kranz A, 2010, BRAIN RES, V1315, P128, DOI 10.1016/j.brainres.2009.12.001; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Li X, 2011, STEM CELLS, V29, P263, DOI 10.1002/stem.572; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mayer L, 2013, INFLAMM BOWEL DIS, V19, P754, DOI 10.1097/MIB.0b013e31827f27df; Mochizuki N, 2008, EXP NEUROL, V211, P194, DOI 10.1016/j.expneurol.2008.01.027; Nichols RC, 2011, CLIN LUNG CANCER, V12, P252, DOI 10.1016/j.cllc.2011.03.027; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pratt Phillip F, 2004, Curr Opin Investig Drugs, V5, P952; Rao MS, 2001, MECH AGEING DEV, V122, P713, DOI 10.1016/S0047-6374(01)00224-X; Rempe DA, 2002, NEUROLOGY, V59, P486, DOI 10.1212/WNL.59.4.486; Risau W, 1998, KIDNEY INT, V54, pS3, DOI 10.1046/j.1523-1755.1998.06701.x; SCHALLERT T, 1984, BEHAV NEUROSCI, V98, P518; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Takahashi K, 2008, BRAIN RES, V1234, P172, DOI 10.1016/j.brainres.2008.07.086; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Yoon YS, 2005, BIOL CELL, V97, P253, DOI 10.1042/BC20040099; Yu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076329; Zacharek A, 2010, STROKE, V41, P524, DOI 10.1161/STROKEAHA.109.568881; Zhang L, 2005, STROKE, V36, P847, DOI 10.1161/01.STR.0000158923.19956.73; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	47	26	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2014	9	1							e86621	10.1371/journal.pone.0086621			9	Multidisciplinary Sciences	Science & Technology - Other Topics	297GT	WOS:000330244500266	24466174	DOAJ Gold, Green Published			2021-06-18	
J	van Klaveren, D; Steyerberg, EW; Perel, P; Vergouwe, Y				van Klaveren, David; Steyerberg, Ewout W.; Perel, Pablo; Vergouwe, Yvonne			Assessing discriminative ability of risk models in clustered data	BMC MEDICAL RESEARCH METHODOLOGY			English	Article						Clustered data; Concordance; Discrimination; Meta-analysis; Prediction; Risk model	TRAUMATIC BRAIN-INJURY; PREDICTION MODELS; HETEROGENEITY; METAANALYSIS; INDEX; AREA	Background: The discriminative ability of a risk model is often measured by Harrell's concordance-index (c-index). The c-index estimates for two randomly chosen subjects the probability that the model predicts a higher risk for the subject with poorer outcome (concordance probability). When data are clustered, as in multicenter data, two types of concordance are distinguished: concordance in subjects from the same cluster (within-cluster concordance probability) and concordance in subjects from different clusters (between-cluster concordance probability). We argue that the within-cluster concordance probability is most relevant when a risk model supports decisions within clusters (e.g. who should be treated in a particular center). We aimed to explore different approaches to estimate the within-cluster concordance probability in clustered data. Methods: We used data of the CRASH trial (2,081 patients clustered in 35 centers) to develop a risk model for mortality after traumatic brain injury. To assess the discriminative ability of the risk model within centers we first calculated cluster-specific c-indexes. We then pooled the cluster-specific c-indexes into a summary estimate with different meta-analytical techniques. We considered fixed effect meta-analysis with different weights (equal; inverse variance; number of subjects, events or pairs) and random effects meta-analysis. We reflected on pooling the estimates on the log-odds scale rather than the probability scale. Results: The cluster-specific c-index varied substantially across centers (IQR = 0.70-0.81; I-2 = 0.76 with 95% confidence interval 0.66 to 0.82). Summary estimates resulting from fixed effect meta-analysis ranged from 0.75 (equal weights) to 0.84 (inverse variance weights). With random effects meta- analysis - accounting for the observed heterogeneity in c-indexes across clusters - we estimated a mean of 0.77, a between-cluster variance of 0.0072 and a 95% prediction interval of 0.60 to 0.95. The normality assumptions for derivation of a prediction interval were better met on the probability than on the log-odds scale. Conclusion: When assessing the discriminative ability of risk models used to support decisions at cluster level we recommend meta- analysis of cluster-specific c-indexes. Particularly, random effects meta- analysis should be considered.	[van Klaveren, David; Steyerberg, Ewout W.; Vergouwe, Yvonne] Erasmus MC, Dept Publ Hlth, NL-3015 GE Rotterdam, Netherlands; [Perel, Pablo] Univ London London Sch Hyg & Trop Med, Dept Populat Hlth, London WC1E 7HT, England	van Klaveren, D (corresponding author), Erasmus MC, Dept Publ Hlth, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	d.vanklaveren.1@erasmusmc.nl		/0000-0002-2342-301X	Netherlands Organisation for Scientific ResearchNetherlands Organization for Scientific Research (NWO) [917.11.383]	This work was supported by the Netherlands Organisation for Scientific Research (grant 917.11.383).	Bouwmeester W, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-19; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Duchateau L, 2008, STAT BIOL HEALTH, P1; Edwards P, 2005, LANCET, V365, P1957; Gelman A., 2007, DATA ANAL USING REGR; Gonen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; JENNETT B, 1975, LANCET, V1, P480; Lumley T, 2009, RMETA METAANALYSIS R; Nam BH, 2002, STAT IND TECHNOL, P267; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Quade D, 1967, NONPARAMETRIC UNPUB, V526; R Development Core Team, 2011, R LANG ENV STAT COMP; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Therneau T, 2011, SURVIVAL SURVIVAL AN; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Uno H, 2011, STAT MED, V30, P1105, DOI 10.1002/sim.4154; Van Oirbeek R, 2012, COMPUT STAT DATA AN, V56, P1966, DOI 10.1016/j.csda.2011.11.023; Van Oirbeek R, 2010, STAT MED, V29, P3160, DOI 10.1002/sim.4058; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223	31	26	26	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2288			BMC MED RES METHODOL	BMC Med. Res. Methodol.	JAN 15	2014	14								5	10.1186/1471-2288-14-5			10	Health Care Sciences & Services	Health Care Sciences & Services	AB5LR	WOS:000331830600001	24423445	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Wisdom, NM; Pastorek, NJ; Miller, BI; Booth, JE; Romesser, JM; Linck, JF; Sim, AH				Wisdom, Nick M.; Pastorek, Nicholas J.; Miller, Brian I.; Booth, Jane E.; Romesser, Jennifer M.; Linck, John F.; Sim, Anita H.			CE PTSD and Cognitive Functioning: Importance of Including Performance Validity Testing	CLINICAL NEUROPSYCHOLOGIST			English	Article						Symptom validity testing; Performance validity testing; Post-traumatic stress disorder; PTSD; Effort; Malingering	POSTTRAUMATIC-STRESS-DISORDER; GULF-WAR VETERANS; FAKE BAD SCALE; COMBAT VETERANS; HIPPOCAMPAL VOLUME; COMPENSATION-SEEKING; BRAIN-INJURY; PSYCHOMETRIC PROPERTIES; VIETNAM VETERANS; REPORT SYMPTOMS	Many studies have observed an association between post-traumatic stress disorder (PTSD) and cognitive deficits across several domains including memory, attention, and executive functioning. The inclusion of response bias measures in these studies, however, remains largely unaddressed. The purpose of this study was to identify possible cognitive impairments correlated with PTSD in returning OEF/OIF/OND veterans after excluding individuals failing a well-validated performance validity test. Participants included 126 men and 8 women with a history of mild traumatic brain injury (TBI) referred for a comprehensive neuropsychological evaluation as part of a consortium of five Veterans Affairs hospitals. The PTSD CheckList (PCL) and Word Memory Test (WMT) were used to establish symptoms of PTSD and invalid performance, respectively. Groups were categorized as follows: Control (PCL < 50, pass WMT), PTSD-pass (PCL 50, pass WMT), and PTSD-fail (PCL 50, fail WMT). As hypothesized, failure on the WMT was associated with significantly poorer performance on almost all cognitive tests administered; however, no significant differences were detected between individuals with and without PTSD symptoms after separating out veterans failing the WMT. These findings highlight the importance of assessing respondent validity in future research examining cognitive functioning in psychiatric illness and warrant further consideration of prior studies reporting PTSD-associated cognitive deficits.	[Wisdom, Nick M.; Pastorek, Nicholas J.; Miller, Brian I.; Booth, Jane E.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Wisdom, Nick M.; Miller, Brian I.; Booth, Jane E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Romesser, Jennifer M.] Mental Hlth, George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA; [Linck, John F.] Mental & Behav Hlth, Oklahoma City Vet Affairs Med Ctr, Oklahoma City, OK USA; [Sim, Anita H.] Mirmeapolis Vet Affairs Hlth Care Syst, Dept Phys Med & Rehabil, Mirmeapolis, MN USA	Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd RCL 117, Houston, TX 77030 USA.	nicholas.pastorek@va.gov			Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs [B6812C]	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; B6812C (PI- Levin HS) VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks; Minnesota Veterans Medical Research & Education Foundation. No pharmaceutical or corporate funding was used in the preparation of this manuscript or collection of data.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boone, 2007, ASSESSMENT FEIGNED C; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brandt J, 2007, CLIN NEUROPSYCHOL, V21, P553, DOI 10.1080/13854040600770800; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Burges C, 2001, BRIT J CLIN PSYCHOL, V40, P209, DOI 10.1348/014466501163544; BURKETT BG, 1998, STOLEN VALOR VIETNAM; BURSTEIN A, 1985, J CLIN PSYCHIAT, V46, P374; Bush S. S., 2012, NEUROPSYCHOLOGICAL P, P27; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Butcher J. N., 2001, MMPI 2 MAN ADM SCORI; Carroll MF, 2003, PSYCHIAT ANN, V33, P732, DOI 10.3928/0048-5713-20031101-09; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Demakis GJ, 2011, PSYCHOL INJ LAW, V4, P24, DOI 10.1007/s12207-011-9099-y; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Frueh BC, 2013, PSYCHIAT SERV, V64, P1, DOI 10.1176/appi.ps.640101; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1002/jts.2490090303; Frueh BC, 1997, J PERS ASSESS, V68, P369, DOI 10.1207/s15327752jpa6802_8; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Gavin H., 1843, BEING PRIZ ESS CLASS, P1835; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Gill T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Golden CJ, 2002, STROOP COLOR WORD TE; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P, 2003, WORD MEMORY TEST WIN; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Guilmette T. J., 2013, MILD TRAUMATIC BRAIN, P31; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Gurvits TV, 2002, PSYCHIAT RES, V112, P263, DOI 10.1016/S0165-1781(02)00234-2; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Howe LLS, 2012, DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION, P301, DOI 10.1007/978-1-4614-0442-2_11; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnsen GE, 2008, J ANXIETY DISORD, V22, P464, DOI 10.1016/j.janxdis.2007.04.007; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Larrabee G. J., 2007, ASSESSMENT MALINGERI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; Llewellyn L. J., 1919, PENSIONS PRINCIPLES; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mol MEM, 2006, INT J GERIATR PSYCH, V21, P432, DOI 10.1002/gps.1487; Morel K. R., 2010, DIFFERENTIAL DIAGNOS; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Office of Inspector General Department of Veterans Affairs, 2010, C APR 1 2010 SEP 30, V64; Office of the Inspector General Department of Veterans Affairs, 2005, REV STAT VAR VA DIS; Peterson DI, 1998, NEUROLOGIST, V4, P131, DOI 10.1097/00127893-199805000-00004; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Reckess G. Z., 2012, NEUROPSYCHOLOGICAL P, P161; Reitan RM., 1985, HALSTEAD REITAN NEUR; Richardson JD, 2006, J CLIN PSYCHIAT, V67, P1240, DOI 10.4088/JCP.v67n0810; Roca V, 2001, AM J PSYCHIAT, V158, P1738, DOI 10.1176/appi.ajp.158.10.1738-a; Rosen G, 2003, COMMENTARY, V115, P17; Rosen GM, 2006, J ANXIETY DISORD, V20, P530, DOI 10.1016/j.janxdis.2005.03.004; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; SLOVENKO R, 1994, PSYCHIAT CLIN N AM, V17, P439; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Stone D. C., 2007, ASSESSMENT FEIGNED C, P3; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Tanielian T, 2008, INVISIBLE WOUNDS WAR; U. S. Government Accountability Office, 2008, VA HEALTHC MIL TRAUM; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wechsler D., 2008, WIAS 4 ADM SCORING M; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Yehuda R, 2000, J CLIN PSYCHIAT, V61, P14; Yehuda R, 2005, J CLIN EXP NEUROPSYC, V27, P504, DOI 10.1080/138033990520223; Young JC, 2011, ARCH CLIN NEUROPSYCH, V26, P194, DOI 10.1093/arclin/acr015	111	26	26	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					128	145		10.1080/13854046.2013.863977			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800009	24354897				2021-06-18	
J	Bashem, JR; Rapport, LJ; Miller, JB; Hanks, RA; Axelrod, BN; Millis, SR				Bashem, Jesse R.; Rapport, Lisa J.; Miller, Justin B.; Hanks, Robin A.; Axelrod, Bradley N.; Millis, Scott R.			Comparisons of Five Performance Validity Indices in Bona Fide and Simulated Traumatic Brain Injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Assessment; Performance validity; Traumatic brain injury; Malingering; Sensitivity; Specificity; Diagnostic classification accuracy; ROC curve; Bayesian information criterion	SYMPTOM VALIDITY; NEUROPSYCHOLOGICAL TESTS; HEAD-INJURY; SCORES; EXAGGERATION; INDICATORS; SEVERITY; FAILURE; NUMBER; INTACT	A number of performance validity tests (PVTs) are used to assess memory complaints associated with traumatic brain injury (TBI); however, few studies examine the concordance and predictive accuracy of multiple PVTs, specifically in the context of combined models in known-group designs. The present study compared five widely used PVTs: the Test of Memory Malingering (TOMM), Medical Symptom Validity Test (MSVT), Reliable Digit Span (RDS), Word Choice Test (WCT), and California Verbal Learning Test - Forced Choice (CVLT-FC). Participants were 51 adults with bona fide moderate to severe TBI and 58 demographically comparable healthy adults coached to simulate memory impairment. Classification accuracy of individual PVTs was evaluated using logistic regression and receiver operating characteristic (ROC) curves, examining both the dichotomous cutting scores as recommended by the test publishers and continuous scores for the measures. Results demonstrated nearly equivalent discrimination ability of the TOMM, MSVT, and CVLT-FC as individual predictors, all of which markedly outperformed the WCT and RDS. Models of combined PVTs were examined using Bayesian information criterion statistics, with results demonstrating that diagnostic accuracy showed only small to modest growth when the number of tests was increased beyond two. Considering the clinical and pragmatic issues in deriving a parsimonious assessment battery, these findings suggest that using the TOMM and CVLT in conjunction or the MSVT and CVLT in conjunction maximized predictive accuracy as compared to a single index or an assortment of these widely used measures.	[Bashem, Jesse R.; Rapport, Lisa J.; Miller, Justin B.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Sch Med, Detroit, MI 48202 USA; [Axelrod, Bradley N.] John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	rapport@wayne.edu		Miller, Justin B./0000-0002-4439-6604	Wayne State University; Del Harder Foundation; National Institute on Disability and Rehabilitation Research [H133A080044]	This study was supported by grants from Wayne State University (Thesis and Dissertation Grants to Bashem and Miller under the direction of Rapport), the Del Harder Foundation (Miller, Rapport & Hanks), and the National Institute on Disability and Rehabilitation Research (H133A080044).	Axelrod BN, 2007, INT J NEUROSCI, V117, P1591, DOI 10.1080/00207450600941189; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; BINDER LM, 1994, ARCH CLIN NEUROPSYCH, V9, P111; Boone, 2007, ASSESSMENT FEIGNED C; Brennan A, 2009, CLIN NEUROPSYCHOL, V23, P314, DOI 10.1080/13854040802054151; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC, 2000, CALIFORNIA VERBAL LE; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Green P., 2005, MED SYMPTOM VALIDITY; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hunsley J, 2003, PSYCHOL ASSESSMENT, V15, P446, DOI 10.1037/1040-3590.15.4.446; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Larrabee G.J., 2007, ASSESSMENT MALINGERE, P334; Larrabee G. J., 2014, ARCH CLIN NEUROPSYCH; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Millis SR, 2009, J NEUROTRAUM, V26, P2409, DOI 10.1089/neu.2008.0530; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pearson Education Inc., 2008, WECHSL MEM SCAL; Psychological Corporation, 2001, WECHSLER TEST ADULT; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; ROGERS R, 1988, CLIN ASSESSMENT MALI; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J.A., 2007, ASSESSMENT MALINGERE, P287; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	63	26	26	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	5					851	875		10.1080/13854046.2014.927927			25	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AP4MM	WOS:000342051100011	24983387				2021-06-18	
J	Di Saverio, S; Gambale, G; Coccolini, F; Catena, F; Giorgini, E; Ansaloni, L; Amadori, N; Coniglio, C; Giugni, A; Biscardi, A; Magnone, S; Filicori, F; Cavallo, P; Villani, S; Cinquantini, F; Annicchiarico, M; Gordini, G; Tugnoli, G				Di Saverio, Salomone; Gambale, Giorgio; Coccolini, Federico; Catena, Fausto; Giorgini, Eleonora; Ansaloni, Luca; Amadori, Niki; Coniglio, Carlo; Giugni, Aimone; Biscardi, Andrea; Magnone, Stefano; Filicori, Filippo; Cavallo, Piergiorgio; Villani, Silvia; Cinquantini, Francesco; Annicchiarico, Massimo; Gordini, Giovanni; Tugnoli, Gregorio			Changes in the outcomes of severe trauma patients from 15-year experience in a Western European trauma ICU of Emilia Romagna region (1996-2010). A population cross-sectional survey study	LANGENBECKS ARCHIVES OF SURGERY			English	Article						Trauma; Trauma outcomes; Epidemiology; Trauma ICU; Morbidity; Mortality; Prognostic factors; Damage control surgery; Trauma center; Safety regulations; Prevention; Traumatic brain injury; Hemorrhage; MOF	DAMAGE CONTROL; MORTALITY; INJURY; CARE; LEVEL; TRANSFUSION; SURVIVAL; CENTERS; SURGERY	Our experience in trauma center management increased over time and improved with development of better logistics, optimization of structural and technical resources. In addition recent Government policy in safety regulations for road traffic accident (RTA) prevention, such compulsory helmet use (2000) and seatbelt restraint (2003) were issued with aim of decreasing mortality rate for trauma. The evaluation of their influence on mortality during the last 15 years can lead to further improvements. In our level I trauma center, 60,247 trauma admissions have been recorded between 1996 and 2010, with 2183 deaths (overall mortality 3.6 %). A total of 2,935 trauma patients with ISS > 16 have been admitted to Trauma ICU and recorded in a prospectively collected database (1996-2010). Blunt trauma occurred in 97.1 % of the cases, whilst only 2.5 % were penetrating. A retrospective review of the outcomes was carried out, including mortality, cause of death, morbidity and length of stay (LOS) in the intensive care unit (ICU), with stratification of the outcome changes through the years. Age, sex, mechanism, glasgow coma scale (GCS), systolic blood pressure (SBP), respiratory rate (RR), revised trauma score (RTS), injury severity score (ISS), pH, base excess (BE), as well as therapeutic interventions (i.e., angioembolization and number of blood units transfused in the first 24 h), were included in univariate and multivariate analyses by logistic regression of mortality predictive value. Overall mortality through the whole period was 17.2 %, and major respiratory morbidity in the ICU was 23.3 %. A significant increase of trauma admissions has been observed (before and after 2001, p < 0.01). Mean GCS (10.2) increased during the period (test trend p < 0.05). Mean age, ISS (24.83) and mechanism did not change significantly, whereas mortality rate decreased showing two marked drops, from 25.8 % in 1996, to 18.3 % in 2000 and again down to 10.3 % in 2004 (test trend p < 0.01). Traumatic brain injury (TBI) accounted for 58.4 % of the causes of death; hemorrhagic shock was the death cause in 28.4 % and multiple organ failure (MOF)/sepsis in 13.2 % of the patients. However, the distribution of causes of death changed during the period showing a reduction of TBI-related and increase of MOF/sepsis (CTR test trend p < 0.05). Significant predictors of mortality in the whole group were year of admission (p < 0.05), age, hemorrhagic shock and SBP at admission, ISS and GCS, pH and BE (all p < 0.01). In the subgroup of patients that underwent emergency surgery, the same factors confirmed their prognostic value and remained significant as well as the adjunctive parameter of total amount of blood units transfused (p < 0.05). Surgical time (mean 71 min) showed a significant trend towards reduction but did not show significant association with mortality (p = 0.06). Mortality of severe trauma decreased significantly during the last 15 years as well as mean GCS improved whereas mean ISS remained stable. The new safety regulations positively influenced incidence and severity of TBI and seemed to improve the outcomes. ISS seems to be a better predictor of outcome than RTS.	[Di Saverio, Salomone; Giorgini, Eleonora; Amadori, Niki; Biscardi, Andrea; Villani, Silvia; Tugnoli, Gregorio] AUSL Bologna Local Hlth Dist, Maggiore Hosp Trauma Ctr, Dept Emergency, Trauma Surg Unit, Bologna, Italy; [Gambale, Giorgio; Coniglio, Carlo; Giugni, Aimone; Cavallo, Piergiorgio; Gordini, Giovanni] Maggiore Hosp, Dept Emergency, Ctr Trauma, Trauma ICU, Bologna, Italy; [Coccolini, Federico; Ansaloni, Luca; Magnone, Stefano] Osped Riuniti Bergamo, Unit 1, I-24100 Bergamo, Italy; [Catena, Fausto] S Orsola Malpighi Univ Hosp, Dept Gen & Transplant Surg, Emergency Surg Unit, Bologna, Italy; [Filicori, Filippo] New York Presbyterian Hosp, Dept Surg, Weill Cornell Med Coll, New York, NY USA; [Cinquantini, Francesco] Maggiore Hosp, Dept Radiol, Intervent Radiol Unit, Bologna, Italy; [Annicchiarico, Massimo] AUSL Bologna, Bologna, Italy	Di Saverio, S (corresponding author), AUSL Bologna Local Hlth Dist, Maggiore Hosp Trauma Ctr, Dept Emergency, Trauma Surg Unit, Bologna, Italy.	salo75@inwind.it	Magnone, Stefano/N-4905-2019; Magnone, Stefano/R-6719-2016; Coccolini, Federico/AAJ-6507-2020; Ansaloni, Luca/AAP-9134-2020; Di Saverio, Salomone/G-1437-2012	Magnone, Stefano/0000-0002-8001-3754; Magnone, Stefano/0000-0002-8001-3754; Coccolini, Federico/0000-0001-6364-4186; Ansaloni, Luca/0000-0001-6427-0307; Di Saverio, Salomone/0000-0001-5685-5022			[Anonymous], 2000, DAMAGE CONTROL SURG, V5, P6; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Baldoni F, 2011, AM J SURG, V201, pE5, DOI 10.1016/j.amjsurg.2010.05.015; Casali M, 2008, ANN ITAL CHIR, V79, P399; Christensen MC, 2010, J TRAUMA, V69, P344, DOI 10.1097/TA.0b013e3181e74c69; Christensen MC, 2008, CRIT CARE, V12, DOI 10.1186/cc6797; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Davenport RA, 2010, BRIT J SURG, V97, P109, DOI 10.1002/bjs.6806; Di Saverio S, MINERVA ANE IN PRESS; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Edwards A, 2007, RESUSCITATION, V75, P286, DOI 10.1016/j.resuscitation.2007.06.023; Filicori F, 2010, WORLD J SURG, V34, P2064, DOI 10.1007/s00268-010-0667-1; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; Hackford SR, 1986, J TRAUMA, V26, P812; Haddon W Jr, 1999, Inj Prev, V5, P231; Hammond J, 2008, SURGERY, VTwo, P403, DOI [10.1007/978-0-387-68113-9_21, DOI 10.1007/978-0-387-68113-9_21]; HIRSHBERG A, 1995, ANN SURG, V222, P3, DOI 10.1097/00000658-199507000-00002; Hosmer D.W., 2000, LEMESHOW S APPL LOGI; Ikegami Keiichi, 2002, Nihon Geka Gakkai Zasshi, V103, P507; Liu B, 2005, COCHRANE DATABASE SY; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Napolitano LM, 2010, J TRAUMA, V69, P1619, DOI 10.1097/TA.0b013e3182011089; Newgard CD, 2007, J TRAUMA, V63, P965, DOI 10.1097/TA.0b013e31803c5665; Peden M, 2004, WORLD REPORT ROAD TR, P12; Poortman P, 2000, Ned Tijdschr Geneeskd, V144, P1337; Racioppi F., 2004, PREVENTING ROAD TRAF; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Rotondo MF, 1997, SURG CLIN N AM, V77, P761, DOI 10.1016/S0039-6109(05)70582-X; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Shafi S, 2010, J TRAUMA, V69, P1367, DOI 10.1097/TA.0b013e3181fb785d; Spiritus E, 2000, AM J MANAG CARE, V6, pS1216; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Tien H, 2007, CAN J SURG, V50, P202; Tugnoli G, 2007, ANN ITAL CHIR, V78, P81; World Health Organization (WHO), 2008, GLOB BURD DIS 2004 U	38	26	26	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1435-2443	1435-2451		LANGENBECK ARCH SURG	Langenbecks Arch. Surg.	JAN	2014	399	1					109	126		10.1007/s00423-013-1143-9			18	Surgery	Surgery	291MW	WOS:000329833800013	24292078				2021-06-18	
J	Diedler, J; Santos, E; Poli, S; Sykora, M				Diedler, Jennifer; Santos, Edgar; Poli, Sven; Sykora, Marek			Optimal cerebral perfusion pressure in patients with intracerebral hemorrhage: an observational case series	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; REACTIVITY; MANAGEMENT	Introduction: Current guidelines for spontaneous intracerebral hemorrhage (ICH) recommend maintaining cerebral perfusion pressure (CPP) between 50 and 70 mmHg, depending on the state of autoregulation. We continuously assessed dynamic cerebral autoregulation and the possibility of determination of an optimal CPP (CPPopt) in ICH patients. Associations between autoregulation, CPPopt and functional outcome were explored. Methods: Intracranial pressure (ICP), mean arterial pressure (MAP) and CPP were continuously recorded in 55 patients, with 38 patients included in the analysis. The pressure reactivity index (PRx) was calculated as moving correlation between MAP and ICP. CPPopt was defined as the CPP associated with the lowest PRx values. CPPopt was calculated using hourly updated of 4 hour windows. The modified Rankin Scale (mRS) was assessed at 3 months and associations between PRx, CPPopt and outcomes were explored using Pearson correlation and Fisher's exact test. Multivariate stepwise logistic regression models were calculated including standard outcome predictors along with percentage of time with PRx > 0.2 and percentage of time within the CPPopt range. Results: An overall PRx indicating impairment of pressure reactivity was found in 47% of patients (n = 18). The mean PRx and the time spent with a PRx > 0.2 significantly correlated with mRS at 3 months (r = 0.50, P = 0.002; r = 0.46, P = 0.004). CPPopt was calculable during 57% of the monitoring time. The median CPP was 78 mmHg, the median CPPopt 83 mmHg. Mortality was lowest in the group of patients with a CPP close to their CPPopt. However, for none of the CPPopt variables a significant association to outcome was found. The percentage of time with impaired autoregulation and hemorrhage volume were independent predictors for acceptable outcome (mRS 1 to 4) at three months. Conclusions: Failure of pressure reactivity seems common following severe ICH and is associated with unfavorable outcome. Real-time assessment of CPPopt is feasible in ICH and might provide a tool for an autoregulation-oriented CPP management. A larger trial is needed to explore if a CPPopt management results in better functional outcomes.	[Diedler, Jennifer; Poli, Sven] Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; [Diedler, Jennifer] Univ Tubingen, Dept Neurosurg, D-72076 Tubingen, Germany; [Diedler, Jennifer; Poli, Sven; Sykora, Marek] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Santos, Edgar] Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany	Diedler, J (corresponding author), Univ Tubingen, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	jennifer.diedler@med.uni-tuebingen.de		Santos, Edgar/0000-0002-8976-5549	Olympia-Morata scholarship of the University of Heidelberg	JD was supported by the Olympia-Morata scholarship of the University of Heidelberg. There was no special funding for the study.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2012, NEUROCRIT CARE, V17, P67, DOI 10.1007/s12028-012-9687-z; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Fernandes HM, 2000, ACT NEUR S, V76, P463; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; Jaeger M, 2012, STROKE, V43, P2097, DOI 10.1161/STROKEAHA.112.659888; Ko SB, 2011, STROKE, V42, P3087, DOI 10.1161/STROKEAHA.111.623165; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Nakagawa K, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-108; Oeinck M, 2013, STROKE, V44, P2722, DOI 10.1161/STROKEAHA.113.001913; Rasulo FA, 2012, J NEUROSURG ANESTH, V24, P3, DOI 10.1097/ANA.0b013e318224030a; Reinhard M, 2012, ACTA NEUROL SCAND, V125, P156, DOI 10.1111/j.1600-0404.2011.01515.x; Reinhard M, 2010, INTENS CARE MED, V36, P264, DOI 10.1007/s00134-009-1698-7; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner T, 2006, CEREBROVASC DIS, V22, P294, DOI 10.1159/000094831; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388	19	26	30	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	2							R51	10.1186/cc13796			8	Critical Care Medicine	General & Internal Medicine	AM1SA	WOS:000339627400069	24666981	DOAJ Gold, Green Published			2021-06-18	
J	Hackenberg, B; Lee, C; Caterson, EJ				Hackenberg, Berit; Lee, Cameron; Caterson, E. J.			Management of Subcondylar Mandible Fractures in the Adult Patient	JOURNAL OF CRANIOFACIAL SURGERY			English	Article						Subcondylar mandible fracture; open reduction; maxillomandibular fixation; endoscopic; treatment algorithm	CONDYLAR PROCESS FRACTURES; CLOSED TREATMENT; TEMPOROMANDIBULAR-JOINT; OPEN REDUCTION; POSTTRAUMATIC ANKYLOSIS; NONSURGICAL TREATMENT; CONCOMITANT INJURIES; ENDOSCOPIC APPROACH; FACIAL FRACTURES; CURRENT THOUGHTS	The treatment of subcondylar mandible fractures is a topic of debate and can be variable even though these fractures are commonly seen. Historically, the treatment algorithm was between open reduction and closed treatment. Now, recent technical advances regarding the use of the endoscope in the field of craniofacial surgery provide additional treatment options. This article aimed to evaluate 3 current management strategies: closed reduction with maxillomandibular fixation, open reduction with internal fixation, and endoscopic-assisted reduction with internal fixation. We present our rationale for surgical decision making and attempt to develop an algorithmic approach to subcondylar fractures. Ankylosis of the temporomandibular joint is a feared complication in these fractures that can lead to the decision to apply maxillomandibular fixation for potentially too short of a period. It is the condylar head fractures within the joint's capsule that contain the hemarthrosis that are often responsible for ankylosis. Subcondylar fractures are, by definition, below the attachment of the joint capsule and in general are devoid of ankylosis. Therefore, maxillomandibular fixation is recommended to be applied for a period of 4 to 6 weeks in most cases. Open reduction with internal fixation can increase the risk for facial nerve damage during the operative approach. However, open reduction is often necessary in fracture patterns with a high degree of displacement. In these cases, facial nerve monitoring can successfully mitigate risks to allow safe exposure for open reduction with internal fixation of subcondylar fractures. Endoscopic-assisted reduction with internal fixation combines the benefits of both techniques while minimizing their associated risks. Nevertheless, reduction can be difficult especially when there is significant medial displacement of the proximal fracture fragment. In our experience, the endoscopic option is optimal for mildly displaced fractures and for the patient with multiple injuries who cannot tolerate closed reduction.	[Hackenberg, Berit; Caterson, E. J.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA; [Hackenberg, Berit] Heidelberg Univ, Sch Med, Heidelberg, Germany; [Lee, Cameron] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; [Caterson, E. J.] Brigham & Womens Hosp, Div Plast Surg, Boston, MA 02115 USA	Caterson, EJ (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	ecaterson@partners.org					Alvi A, 2003, LARYNGOSCOPE, V113, P102, DOI 10.1097/00005537-200301000-00019; AO Foundation, MAND DIAGN AO SURG R; Arakeri G, 2012, BRIT J ORAL MAX SURG, V50, P8, DOI 10.1016/j.bjoms.2010.09.012; Baker AW, 1998, INT J ORAL MAX SURG, V27, P258, DOI 10.1016/S0901-5027(05)80507-7; Brandt MT, 2003, J ORAL MAXIL SURG, V61, P1324, DOI 10.1016/S0278-2391(03)00735-3; Lee GYC, 2008, MED ORAL PATOL ORAL, V13, pE511; Choi BH, 1999, ORAL SURG ORAL MED O, V88, P292, DOI 10.1016/S1079-2104(99)70030-2; Danda AK, 2010, J ORAL MAXIL SURG, V68, P1238, DOI 10.1016/j.joms.2009.09.042; Ebenezer V, 2011, J MAXILLOFAC ORAL SU, V10, P38, DOI 10.1007/s12663-010-0145-1; Ellis E, 2000, J ORAL MAXIL SURG, V58, P950, DOI 10.1053/joms.2000.8734; Ellis E, 2000, J ORAL MAXIL SURG, V58, P719, DOI 10.1053/joms.2000.7253; Ellis E, 2000, J ORAL MAXIL SURG, V58, P260, DOI 10.1016/S0278-2391(00)90047-8; Ellis E, 2000, J ORAL MAXILLOFAC SU, V58, P729; Ellis ED, 2001, J ORAL MAXIL SURG, V59, P389, DOI 10.1053/joms.2001.21873; Farahvash MR, 2013, AESTHET SURG J, V33, P201, DOI 10.1177/1090820X12473104; Ferretti C, 2005, INT J ORAL MAX SURG, V34, P376, DOI 10.1016/j.ijom.2004.09.003; Haug RH, 2001, J ORAL MAXIL SURG, V59, P370, DOI 10.1053/joms.2001.21868; Haug RH, 2007, PLAST RECONSTR SURG, V120, p90S, DOI 10.1097/01.prs.0000260730.43870.1b; Jacobovicz J, 1998, PLAST RECONSTR SURG, V101, P437, DOI 10.1097/00006534-199802000-00030; Kellman Robert M, 2004, Facial Plast Surg, V20, P239, DOI 10.1055/s-2004-861780; Kellman Robert M, 2003, Arch Facial Plast Surg, V5, P244, DOI 10.1001/archfaci.5.3.244; Kellman RM, 2009, FACIAL PLAST SURG, V25, P23, DOI 10.1055/s-0028-1112228; Konstantinovic FX, 1992, J ORAL MAXILLOFAC SU, V50, P352; KONSTANTINOVIC VS, 1992, J ORAL MAXIL SURG, V50, P349, DOI 10.1016/0278-2391(92)90395-G; Kostakis G, 2012, OR SURG OR MED OR PA, V114, pS69, DOI 10.1016/j.tripleo.2011.08.029; Kyrgidis A, 2013, J CRANIO MAXILL SURG, V41, P637, DOI 10.1016/j.jcms.2012.11.046; Lee Jing-Wei, 2010, Plast Reconstr Surg, V125, P609, DOI 10.1097/PRS.0b013e3181c82ff0; Meng FW, 2009, MED HYPOTHESES, V73, P92, DOI 10.1016/j.mehy.2009.01.024; Mueller R, 2008, FACIAL PLAST SURG, V24, P78, DOI 10.1055/s-2008-1037452; Palmieri C, 1999, J ORAL MAXIL SURG, V57, P764, DOI 10.1016/S0278-2391(99)90810-8; Palmieri C, 1999, J ORAL MAXILLOFAC SU, V57, P775; Pham Annette M, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P234, DOI 10.1097/01.moo.0000233593.84175.6e; Santler G, 1999, J ORAL MAXIL SURG, V57, P392, DOI 10.1016/S0278-2391(99)90276-8; Schubert W, 2009, J CRANIOFAC SURG, V20, P154, DOI 10.1097/SCS.0b013e318191cfb8; SILVENNOINEN U, 1992, J ORAL MAXIL SURG, V50, P1032, DOI 10.1016/0278-2391(92)90484-H; Singh V, 2010, J ORAL MAXIL SURG, V68, P1304, DOI 10.1016/j.joms.2010.01.001; Smith Hayden, 2012, J Trauma Nurs, V19, P57, DOI 10.1097/JTN.0b013e31823a4c0e; Troulis Maria J, 2006, Facial Plast Surg Clin North Am, V14, P45, DOI 10.1016/j.fsc.2005.11.003; Troulis MJ, 2004, J ORAL MAXIL SURG, V62, P1269, DOI 10.1016/j.joms.2004.04.016; Villarreal PM, 2004, J ORAL MAXIL SURG, V62, P155, DOI 10.1016/j.joms.2003.08.010; Vural E, 2004, ARCH OTOLARYNGOL, V130, P1228, DOI 10.1001/archotol.130.10.1228; WORSAAE N, 1994, J ORAL MAXIL SURG, V52, P353, DOI 10.1016/0278-2391(94)90436-7; Worsaae N, 1994, J ORAL MAXILLOFAC SU, P360; Yang WG, 2002, J TRAUMA, V52, P498, DOI 10.1097/00005373-200203000-00014; Zachariades N, 2006, J CRANIO MAXILL SURG, V34, P421, DOI 10.1016/j.jcms.2006.07.854; Zide MF, 2001, J ORAL MAXIL SURG, V59, P375, DOI 10.1053/joms.2001.21869	46	26	27	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1049-2275	1536-3732		J CRANIOFAC SURG	J. Craniofac. Surg.	JAN	2014	25	1					166	171		10.1097/SCS.0000000000000498			6	Surgery	Surgery	AH2CP	WOS:000335928600071	24406572				2021-06-18	
J	Joseph, B; Sadoun, M; Aziz, H; Tang, A; Wynne, JL; Pandit, V; Kulvatunyou, N; O'Keeffe, T; Friese, RS; Rhee, P				Joseph, Bellal; Sadoun, Moutamn; Aziz, Hassan; Tang, Andrew; Wynne, Julie L.; Pandit, Viraj; Kulvatunyou, Narong; O'Keeffe, Terence; Friese, Randall S.; Rhee, Peter			Repeat Head Computed Tomography in Anticoagulated Traumatic Brain Injury Patients: Still Warranted	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Scientific Meeting of the Trauma-Association-of-Canada	APR 12-13, 2012	Toronto, CANADA	Trauma Assoc Canada			INTRACRANIAL HEMORRHAGE; PREINJURY WARFARIN; THERAPY; UTILITY	Anticoagulation agents are proven risk factors for intracranial hemorrhage (ICH) in traumatic brain injury (TBI). The aim of our study is to describe the epidemiology of prehospital coumadin, aspirin, and Plavix (CAP) patients with ICH and evaluate the use of repeat head computed tomography (CT) in this group. We performed a retrospective study from our trauma registry. All patients with intracranial hemorrhage on initial CTwith prehospital CAP therapy were included. Demographics, CT scan findings, number of repeat CT scans, progressive findings, and neurosurgical intervention were abstracted. A comparison between prehospital CAP and no-CAP patients was done using chi(2) and Mann-Whitney U test. A total of 1606 patients with blunt TBI charts were reviewed of whom 508 patients had intracranial bleeding on initial CT scan and 72 were on prehospital CAP therapy. CAP patients were older (P < 0.001), had higher Injury Severity Score and head Abbreviated Injury Scores on admission (P < 0.001), were more likely to present with an abnormal neurologic examination (P = 0.004), and had higher hospital and intensive care unit lengths of stay (P < 0.005). Eighty-four per cent of patients were on antiplatelet therapy and 27 per cent were on warfarin. The CAP patients have a threefold increase in the rate of worsening repeat head CT (26 vs 9%, P < 0.05). Prehospital CAP therapy is high risk for progression of bleeding on repeat head CT. Routine repeat head CT remains an important component in this patient population and can provide useful information.	[Joseph, Bellal; Sadoun, Moutamn; Aziz, Hassan; Tang, Andrew; Wynne, Julie L.; Pandit, Viraj; Kulvatunyou, Narong; O'Keeffe, Terence; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Hirsh J, 1995, J TRAUMA, V108, p231S; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Saab M, 1996, J ACCID EMERG MED, V13, P208; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; SREERAMA V, 1973, CAN MED ASSOC J, V108, P305; Wahl WL, 2001, J TRAUMA, V51, P1151; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	16	26	26	0	3	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JAN	2014	80	1					43	47					5	Surgery	Surgery	AJ5PQ	WOS:000337738000023	24401514				2021-06-18	
J	Lang, KP; Veazey-Morris, K; Andrasik, F				Lang, Katie P.; Veazey-Morris, Katherine; Andrasik, Frank			Exploring the Role of Insomnia in the Relation Between PTSD and Pain in Veterans With Polytrauma Injuries	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mediation; insomnia; traumatic brain injury; pain; posttraumatic stress disorder; veteran	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; COMBAT VETERANS; SLEEP; WAR; IRAQ; AFGHANISTAN; PREVALENCE; VALIDATION	Background: Soldiers returning from Operation Enduring Freedom/Operation Iraqi Freedom experience polytrauma injuries including traumatic brain injury. Traumatic brain injury is often complicated by symptoms of insomnia, posttraumatic stress disorder (PTSD), and pain that can impact treatment and rehabilitation. Methods: The medical records of 137 veterans seen at a Veterans Affairs Medical Center Polytrauma clinic who sustained traumatic brain injury in combat were reviewed for this study. Demographic variables include age, sex, ethnicity, military branch, and service connection. Outcome measures include PTSD, pain, and insomnia. Results: Analyses revealed a high prevalence of PTSD, insomnia, and pain co-occurring in 51.8% of veterans. Increased PTSD symptomatology was significantly correlated with reports of more pain severity (r = 0.53), pain interference (r = 0.61), and insomnia (r = 0.67). Further analyses, controlling for service connection, indicated that insomnia partially mediated the relation between PTSD and both pain severity and interference. Conclusions: These results highlight the overlap and complexity of presenting complaints in veterans and help identify the role of sleep disturbances in complicating diagnosis and treatment of veterans. As sleep problems reduce pain tolerance and exacerbate other symptoms, such as cognitive deficits and irritability, failure to address sleep disturbances may compromise rehabilitation efforts, suggesting the importance of a multidisciplinary team approach to assessing and treating these veterans.	[Lang, Katie P.; Veazey-Morris, Katherine; Andrasik, Frank] Univ Memphis, Dept Psychol, Memphis, TN 38152 USA; [Veazey-Morris, Katherine] Memphis VA Med Ctr, Memphis, TN USA	Lang, KP (corresponding author), Univ Memphis, Dept Psychol, 202 Psychol Bldg, Memphis, TN 38152 USA.	klang1@memphis.edu		Andrasik, Frank/0000-0001-6625-479X	Memphis VA Medical Center Office of Research and Development	This work was supported by the Memphis VA Medical Center Office of Research and Development.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ANDRASIK F, 1981, HEADACHE, V21, P218, DOI 10.1111/j.1526-4610.1981.hed2105218.x; Andrasik F., 2009, P 2 DEPL MENT HLTH S; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beecher H, 1959, MEASUREMENT SUBJECTI; Belleville G, 2011, J PSYCHOSOM RES, V70, P318, DOI 10.1016/j.jpsychores.2010.09.022; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bourbonnais Frances Fothergill, 2004, J Nurs Manag, V12, P194; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carskadon MA, 2000, PRINCIPLES PRACTICE, P15; Clark W., 1983, PAIN MEASUREMENT ASS, P15; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Defrin R, 2008, PAIN, V138, P450, DOI 10.1016/j.pain.2008.05.006; Ebben MR, 2009, J BEHAV MED, V32, P244, DOI 10.1007/s10865-008-9198-8; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gellis LA., 2011, J AGGRESS MALTREAT T, V20, P904, DOI DOI 10.1080/10926771.2011.613448; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Inman D. J., 1990, J TRAUMA STRESS, V3, P429, DOI [10.1002/jts.2490030311, DOI 10.1007/BF00974782]; Jackson P, 2013, VISN 09 DATA EXTRACT; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kobayashi I, 2007, PSYCHOPHYSIOLOGY, V44, P660, DOI 10.1111/j.1469-8986.2007.537.x; LAVIE P, 1979, AM J PSYCHIAT, V136, P175; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Litz BT, 1997, AM J PSYCHIAT, V154, P178; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; MacKinnon DP, 2004, MULTIVAR BEHAV RES, V39, P99, DOI 10.1207/s15327906mbr3901_4; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P110; MELZACK R, 1968, P423; MIKULINCER M, 1989, PSYCHOL REP, V65, P567, DOI 10.2466/pr0.1989.65.2.567; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Moore BA, 2010, PSYCHOL TRAUMA-US, V2, P232, DOI 10.1037/a0019895; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nappi CM, 2010, BEHAV THER, V41, P237, DOI 10.1016/j.beth.2009.03.003; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Onen SH, 2001, J SLEEP RES, V10, P35, DOI 10.1046/j.1365-2869.2001.00240.x; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2010, PSYCHOL SERV, V7, P126, DOI 10.1037/a0020512; Ouellet M, 2012, INT ENCY REHABILITAT; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Perlis ML., 2010, BEHAV TREATMENTS SLE, V1; Poundja J, 2007, J PAIN SYMPTOM MANAG, V33, P720, DOI 10.1016/j.jpainsymman.2006.09.031; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schwab KA, 2006, NEUROLOGY, V66, pA235; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Smith M. T., 2003, MEASURES FATIGUE SLE, V49, P184; Smith S, 2001, J SLEEP RES, V10, P229, DOI 10.1046/j.1365-2869.2001.00262.x; Snyder's L.B., 2008, SAGE SOURCEBOOK ADV, P13, DOI [10.4135/9781452272054.n2, DOI 10.4135/9781452272054.N2]; SUTKER PB, 1993, J SOC ISSUES, V49, P33, DOI 10.1111/j.1540-4560.1993.tb01180.x; Swanson LM, 2009, J TRAUMA STRESS, V22, P639, DOI 10.1002/jts.20468; Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005; Terrio HP, 2011, REHABIL PSYCHOL, V56, P26, DOI 10.1037/a0022685; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers FW, 1993, P ANN M INT SOC TRAU; Yetkin S, 2010, PSYCHIAT CLIN NEUROS, V64, P309, DOI 10.1111/j.1440-1819.2010.02084.x; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	69	26	27	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					44	53		10.1097/HTR.0b013e31829c85d0			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400010	23835878				2021-06-18	
J	Wang, XM; Ji, JH; Fen, L; Wang, AZ				Wang, Xuemin; Ji, Junhui; Fen, Liang; Wang, Aizhong			Effects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: A prospective controlled trial	BRAIN INJURY			English	Article						Cerebral blood flow; cerebral metabolic rate; patient; traumatic brain injury	ALPHA(2)-AGONIST DEXMEDETOMIDINE; ALPHA(2A)-ADRENOCEPTOR SUBTYPE; OXYGEN-CONSUMPTION; RATS; ISCHEMIA; SEDATION; ULTRASOUND; VOLUME; DOGS; AUTOREGULATION	Study objective: To examine the effect of dexmedetomidine on CBF in critical ill patients with or without TBI. Research design: Prospective controlled trial (ISRCTN57998533). Methods: Fifteen patients without TBI and 20 patients with TBI with a Glasgow Coma Scale score of 4-14 were assigned to CON or TBI groups, respectively. All patients received 1 mu g kg(-1) dexmedetomidine infused over 10 minutes, followed by a 0.4 mu g kg(-1) h(-1) continuous infusion for 60 minutes. Blood pressure was maintained at the pre-sedation level with dopamine for all patients. The CBF and cerebral metabolic rate equivalent (CMRe) were measured before sedation and 70 minutes after dexmedetomidine administration. Results: Dexmedetomidine administration significantly decreased CBF in patients of the CON group (difference = 3.3 ml s(-1), 95% confidence interval [CI] = 0.92-5.7 ml s(-1), p = 0.008), without altering the CMRe and CMRe/CBF ratio. The dexmedetomidine-induced change of CBF, CMRe and CMRe/CBF was not significant in the TBI group. The percentage of CBF reduction was greater in the CON group than in the TBI group (difference = 13.9%, 95% CI = 5.5-22.2%, p = 0.002). Conclusions: Dexmedetomidine may be used in patients with TBI without risk of affecting brain oxygenation.	[Wang, Xuemin; Wang, Aizhong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Intens Care Unit, Coll Med, Shanghai 200233, Peoples R China; [Ji, Junhui] Soochow Univ, Affiliated Hosp 1, Dept Anesthesiol, Suzhou, Jiangsu, Peoples R China; [Fen, Liang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Ultrasound Med, Coll Med, Shanghai 200233, Peoples R China	Wang, AZ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Intens Care Unit, Coll Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.	think.free@hotmail.com		Wang, Xuemin/0000-0002-7241-868X	Suzhou University	The authors report no conflicts of interest. This work was supported by an Educational Medical Doctor Research Grant from Suzhou University.	Albayrak R, 2006, RESP MED, V100, P1826, DOI 10.1016/j.rmed.2006.01.015; Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; But AK, 2006, ACTA ANAESTH SCAND, V50, P1207, DOI 10.1111/j.1399-6576.2006.01136.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi OZ, 2011, ANESTH ANALG, V113, P349, DOI 10.1213/ANE.0b013e31822071db; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Elvan EG, 2008, EUR J ANAESTH, V25, P357, DOI 10.1017/S0265021507003110; Engelhard K, 2002, ANESTHESIOLOGY, V96, P450, DOI 10.1097/00000542-200202000-00034; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Farag E, 2010, DISCOV MED, V9, P42; GILL RW, 1985, ULTRASOUND MED BIOL, V11, P625, DOI 10.1016/0301-5629(85)90035-3; Grof TM, 2010, NEUROCRIT CARE, V12, P356, DOI 10.1007/s12028-008-9156-x; Ho SSY, 2002, AM J ROENTGENOL, V178, P551, DOI 10.2214/ajr.178.3.1780551; Huang R, 2000, J CEREBR BLOOD F MET, V20, P895, DOI 10.1097/00004647-200006000-00001; Iida H, 1999, ANESTHESIOLOGY, V91, P479, DOI 10.1097/00000542-199908000-00023; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jolkkonen J, 1999, EUR J PHARMACOL, V372, P31, DOI 10.1016/S0014-2999(99)00186-7; KARLSSON BR, 1990, ANESTH ANALG, V71, P125; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; McPherson RW, 1997, ANESTH ANALG, V84, P139, DOI 10.1097/00000539-199701000-00026; Mirski MA, 2010, INTENS CARE MED, V36, P1505, DOI 10.1007/s00134-010-1874-9; Nakano T, 2009, J ANESTH, V23, P378, DOI 10.1007/s00540-009-0777-9; Ogawa Y, 2008, ANESTHESIOLOGY, V109, P642, DOI 10.1097/ALN.0b013e3181862a33; Paris A, 2006, ANESTH ANALG, V102, P456, DOI 10.1213/01.ane.0000194301.79118.e9; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; REIVICH M, 1964, AM J PHYSIOL, V206, P25; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Sanders RD, 2009, ANESTHESIOLOGY, V110, P1077, DOI 10.1097/ALN.0b013e31819daedd; Schebesch KM, 2007, NEUROL RES, V29, P210, DOI 10.1179/016164107X181761; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033; Tang JF, 2011, NEUROCRIT CARE, V15, P175, DOI 10.1007/s12028-009-9315-8	33	26	30	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2013	27	13-14					1617	1622		10.3109/02699052.2013.831130			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	259BW	WOS:000327503400017	24102571				2021-06-18	
J	Zhang, L; Yan, R; Zhang, Q; Wang, HN; Kang, XK; Li, J; Yang, SY; Zhang, JN; Liu, ZL; Yang, XY				Zhang, Lin; Yan, Rong; Zhang, Qi; Wang, Haining; Kang, Xiaokui; Li, Jia; Yang, Shuyuan; Zhang, Jianning; Liu, Zhenlin; Yang, Xinyu			Survivin, a key component of the Wnt/beta-catenin signaling pathway, contributes to traumatic brain injury-induced adult neurogenesis in the mouse dentate gyrus	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						survivin; dentate gyrus; adult neurogenesis; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; CELL-PROLIFERATION; ALZHEIMERS-DISEASE; UP-REGULATION; APOPTOSIS; EXPRESSION; PROTEIN; DIFFERENTIATION; CANCER; RATS	The enhancement of endogenous neurogenesis has been suggested in the treatment of traumatic brain injury (TBI); however, the factors that trigger the process of adult neurogenesis following TBI remain elusive. In the adult mammalian central nervous system, there are 2 neurogenic regions: the subgranular zone (SGZ) of the hippocampus and the subventricular zone (SVZ) of the lateral ventricles, both of which maintain relatively quiescent states in a stable microenvironment. However, once stimulated by intrinsic and extrinsic events, relevant signals are activated in these 2 regions. In this study, in order to explore the mechanisms behind endogenous neurogenesis following TBI, we investigated potential factors regulating this process. We observed that the expression of survivin, an anti-apoptotic protein, increased in a time-dependent manner in the hippocampus in a mouse model of TBI. In addition, the number of survivin (+) cells, as well as that of BrdU (+) cells increased in the SGZ of the dentate gyrus (DG) in the hippocampus following TBI, as shown by immunofluorescence double staining; the co-localization of survivin and BrdU was shown in the merged images. The expression of survivin was also significantly increased in the doublecortin (DCX) (+) immature neurons in the DG of the hippocampus soon after the induction of TBI. Taken together, these data confirm the connection between the expression of survivin and adult neurogenesis following TBI; our data also suggest the therapeutic potential of upregulating survivin expression as a novel strategy for the effective treatment of TBI.	[Zhang, Lin; Yan, Rong; Zhang, Qi; Wang, Haining; Kang, Xiaokui; Li, Jia; Yang, Shuyuan; Zhang, Jianning; Yang, Xinyu] Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China; [Zhang, Lin; Yan, Rong; Liu, Zhenlin] Tianjin 5th Cent Hosp, Dept Neurosurg, Tianjin 300450, Peoples R China	Yang, XY (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.	wjzhenlin817@sina.com; yangxinyu@tijmu.edu.cn			Science and Technology Foundation of Tianjin [10JCYBJC25700]; Health-System Science Foundation of Binhai New Area in Tianjin [2011BHKL002]	We thank Linchun Huan, Wangmiao Zhao and Zhen Zhang for their helpful comments on the manuscript. This study was supported by grants from the Science and Technology Foundation of Tianjin (no. 10JCYBJC25700) and the Health-System Science Foundation of Binhai New Area in Tianjin (no. 2011BHKL002).	Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Baratchi S, 2010, CRIT REV BIOCHEM MOL, V45, P535, DOI 10.3109/10409238.2010.516740; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Coremans V, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-2; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; De Ferrari GV, 2006, ONCOGENE, V25, P7545, DOI 10.1038/sj.onc.1210064; De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Gulacsi AA, 2008, NAT NEUROSCI, V11, P1383, DOI 10.1038/nn.2226; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Inestrosa NC, 2000, ACTA NEUROL SCAND, V102, P53, DOI 10.1034/j.1600-0404.2000.00308.x; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Jiang YY, 2005, J NEUROSCI, V25, P6962, DOI 10.1523/JNEUROSCI.1446-05.2005; Johnson EA, 2005, EXP BRAIN RES, V167, P17, DOI 10.1007/s00221-005-2362-2; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Li FZ, 2006, AM J PATHOL, V169, P1, DOI 10.2353/ajpath.2006.060121; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lovestone S, 2007, TRENDS NEUROSCI, V30, P142, DOI 10.1016/j.tins.2007.02.002; Lu Na, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1856; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Okazaki T, 2008, NEUROSCI LETT, V430, P109, DOI 10.1016/j.neulet.2007.10.046; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tamm I, 1998, CANCER RES, V58, P5315; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4; Zhang L, 2011, EUR J NEUROSCI, V33, P1, DOI 10.1111/j.1460-9568.2010.7483.x; Zhang T, 2001, CANCER RES, V61, P8664; Zhang YH, 2007, AM J PHYSIOL-HEART C, V292, pH2573, DOI 10.1152/ajpheart.01098.2006; Zhao WM, 2010, NEURAL REGEN RES, V5, P645, DOI 10.3969/j.issn.1673-5374.2010.09.001; Zhu HX, 2010, CANCER SCI, V101, P1156, DOI 10.1111/j.1349-7006.2010.01528.x; Zwerts F, 2007, BLOOD, V109, P4742, DOI 10.1182/blood-2006-06-028068	56	26	29	0	17	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	OCT	2013	32	4					867	875		10.3892/ijmm.2013.1456			9	Medicine, Research & Experimental	Research & Experimental Medicine	209AL	WOS:000323725200016	23900556	Bronze			2021-06-18	
J	Karch, D; Albers, L; Renner, G; Lichtenauer, N; von Kries, R				Karch, Dieter; Albers, Lucia; Renner, Gerolf; Lichtenauer, Norbert; von Kries, Ruediger			The Efficacy of Cognitive Training Programs in Children and Adolescents A Meta-analysis	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Article							TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT HYPERACTIVITY DISORDER; RANDOMIZED CLINICAL-TRIAL; MULTIMODAL TREATMENT; EXECUTIVE FUNCTIONS; WORKING-MEMORY; ADHD; REHABILITATION; INTERVENTIONS	Background: Cognitive therapies are intended to improve basic cognitive functions, whatever the cause of the deficiency may be. Children and adolescents with various cognitive deficits are treated with behavioral therapeutic and computer-supported training programs. We here report the first meta-analysis of the efficacy of such programs. Methods: We systematically searched the Medline, Embase, PsycINFO, PSYNDEX, and ERIC databases to find pertinent publications for a meta-analysis of cognitive training programs that are used in children and adolescents to improve attention, memory, and executive performance (primary goals) as well as behavior/psychopathology, intelligence, and school performance (secondary goals). The mean differences between the treatment and control groups are given here as standard deviation (SD) scores. Results: 1661 potentially relevant publications were found, including 22 studies that were considered in the meta-analysis, 17 of which were randomized controlled trials. The target variables were measured with more than 90 different testing techniques. The overall effects of cognitive training on attention (SD 0.18, 95% CI -0.11-0.47) and executive function (SD 0.17, 95% CI -0.12-0.46) were consistently small. A relatively strong effect was found on memory performance (0.65 SD, 95% [-0.12-1.42), albeit with marked heterogeneity (I-2 = 82%) owing to two studies. The largest effect was found in the area of behavior and psychopathology (SD 0.58, 95% CI 0.31-0.85), but this last figure is derived mainly from studies that lacked an active control group. Conclusion: Cognitive therapies for children and adolescents have generally favorable, but probably nonspecific effects on behavior. On the other hand, the specific effects, however, were weak overall. Therapeutic benefit has been demonstrated only for certain individual types of therapy for specific indications.	[Karch, Dieter] Children Ctr Maulbronn, Clin Pediat Neurol & Social Pediat, Maulbronn, Germany; [Albers, Lucia; von Kries, Ruediger] Univ Munich, Inst Sozaile Padiatrie & Jugendmed, D-81377 Munich, Germany; [Renner, Gerolf] Univ Educ Ludwigsburg, Fac Special Pedag, Ludwigsburg, Germany	von Kries, R (corresponding author), Univ Munich, Inst Sozaile Padiatrie & Jugendmed, Heigelhofstr 63, D-81377 Munich, Germany.	ruediger.kries@med.uni-muenchen.de					ABIKOFF H, 1991, J LEARN DISABIL, V24, P205, DOI 10.1177/002221949102400404; BANASCHEWSKI T, 2006, MOTORIK, V29, P57; Bangirana P, 2009, J DEV BEHAV PEDIATR, V30, P310, DOI 10.1097/DBP.0b013e3181b0f01b; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Boivin MJ, 2010, NEUROPSYCHOLOGY, V24, P667, DOI 10.1037/a0019312; Borenstein M., 2009, INTRO METAANALYSIS; Boutron I, 2008, ANN INTERN MED, V148, pW60, DOI 10.7326/0003-4819-148-4-200802190-00008-w1; Braun J, PSYCHOL ERZIEHUNG UN, V47, P10; BROWN RT, 1986, J ABNORM CHILD PSYCH, V14, P481, DOI 10.1007/BF01260518; Buch SR, 2009, KOGNITIVE FORDERUNG; Bundesarztekammer, 2005, DTSCH ARZTEBL, V102, pA; Butler RW, 2008, J CONSULT CLIN PSYCH, V76, P367, DOI 10.1037/0022-006X.76.3.367; Chenault BM, 2004, EFFECTS PRIOR ATTENT; Cohen J., 1969, STAT POWER ANAL BEHA; Conners CK, 2001, J AM ACAD CHILD PSY, V40, P159, DOI 10.1097/00004583-200102000-00010; Crowe LM, 2012, PEDIATRICS, V129, pE262, DOI 10.1542/peds.2011-0438; Domsch H, 2009, PSYCHOL FORDER INTER; Dopfner M, 2004, EUR CHILD ADOLES PSY, V13, P117, DOI 10.1007/s00787-004-1011-9; DOPFNER M, 1998, THERAPIEPROGRAMM KIN; Dreisorner T., 2006, KINDH ENTWICKL, V15, P255; FEHLINGS DL, 1991, J DEV BEHAV PEDIATR, V12, P223; G-BA, 2011, STELL AMB NEUR THER; Galbiati S, 2009, NEUROPSYCHOLOGY, V23, P40, DOI 10.1037/a0013409; Hedges L. V., 1981, J EDUC STAT, V6, P107; Jaeggi SM, 2011, P NATL ACAD SCI USA, V108, P10081, DOI 10.1073/pnas.1103228108; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kausch T, 2002, THESIS U TUBINGEN TU; Kline R.B., 2004, SIGNIFICANCE TESTING; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kozulin A, 2010, RES DEV DISABIL, V31, P551, DOI 10.1016/j.ridd.2009.12.001; Lauth GW, 2006, KINDH ENTWICKL, V15, P229, DOI 10.1026/0942-5403.15.4.229; Lauth GW, 1996, Z KINDER JUG-PSYCH, V24, P164; Lauth GW, 2002, TRAINING AUFMERKSAMK; Lepach AC, 2009, KINDH ENTWICKL, V18, P105, DOI 10.1026/0942-5403.18.2.105; Lomas KM, 2002, THESIS HOWARD U WASH; MEICHENBAUM DH, 1971, J ABNORM PSYCHOL, V77, P115, DOI 10.1037/h0030773; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Sonntag W, 2004, Z PADAGOG PSYCHOL, V18, P101, DOI 10.1024/1010-0652.18.2.101; Sturm W, 2010, NEURO REHABIL, V16, P55; Thorell LB, 2009, DEVELOPMENTAL SCI, V12, P106, DOI 10.1111/j.1467-7687.2008.00745.x; Toplak ME, 2008, CLIN PSYCHOL REV, V28, P801, DOI 10.1016/j.cpr.2007.10.008; Tucha O, 2011, ADHD-ATTEND DEFICIT, V3, P271, DOI 10.1007/s12402-011-0059-x; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	49	26	29	0	45	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	SEP 27	2013	110	39					643	U23		10.3238/arztebl.2013.0643			20	Medicine, General & Internal	General & Internal Medicine	248UQ	WOS:000326730200001	24163706	Green Published			2021-06-18	
J	Tolan, NV; Vidal-Folch, N; Algeciras-Schimnich, A; Singh, RJ; Grebe, SKG				Tolan, Nicole V.; Vidal-Folch, Noemi; Algeciras-Schimnich, Alicia; Singh, Ravinder J.; Grebe, Stefan K. G.			Individualized correction of neuron-specific enolase (NSE) measurement in hemolyzed serum samples	CLINICA CHIMICA ACTA			English	Article						Neuron-specific enolase; Ischemic brain injury; Therapeutic hypothermia; Neurological prognosis; Individualized hemolysis correction	TRAUMATIC BRAIN-INJURY; CREUTZFELDT-JAKOB-DISEASE; MILD THERAPEUTIC HYPOTHERMIA; CELL LUNG-CANCER; CARDIAC-ARREST; PROGNOSTIC VALUE; TUMOR-MARKERS; BIOMARKERS; DIAGNOSIS; CSF	Background: Accuracy of serum neuron-specific enolase (NSE) measurement is paramount, particularly in the context of neurological outcome prognostication. However, NSE measurements are compromised by even slight hemolysis, as it is abundant in red blood cells (RBCs). We derived and validated an individualized hemolysis correction equation in an attempt to reduce the current rejection rate of 14% at our institution. Methods: Intracellular NSE was measured in RBC lysates to determine concentration variability. A correction equation was derived, accounting for both RBC-derived NSE false-elevation and hemoglobin-derived signal quenching. The performance of this individualized correction was evaluated in intentionally hemolyzed samples and accuracy was compared to a generalized correction. Results: Significant inter-individual variability of RBC NSE was observed, with an almost two-fold range (15.7-28.5 ng NSE/mg Hb, p < 0.001); intra-individual variability was insignificant. The individualized hemolysis correction equation derived: NSEcorr = NSEmeas - (Hb(serum))(NSERBCs/Hb) + 0.0844(Hb(serum)) + 1.1 corrected 95% of the intentionally hemolyzed samples to within +/- 5 ng/ml of corresponding baseline NSE concentrations, compared to 74% using a generalized formula. Conclusions: The individualized hemolysis correction provides increased accuracy in the estimation of true serum NSE concentrations for hemolyzed samples, compared to a generalized approach, by accounting for inter-individual RBC NSE variability. Incorporating this correction should reduce sample rejection rates and overall health care costs. (c) 2013 Elsevier B.V. All rights reserved.	[Tolan, Nicole V.; Vidal-Folch, Noemi; Algeciras-Schimnich, Alicia; Singh, Ravinder J.; Grebe, Stefan K. G.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA	Grebe, SKG (corresponding author), Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	grebe.stefan@mayo.edu					Aksamit AJ, 2001, NEUROLOGY, V57, P728, DOI 10.1212/WNL.57.4.728; Auer Johann, 2006, CJEM, V8, P13; Bahl JMC, 2009, NEUROBIOL AGING, V30, P1834, DOI 10.1016/j.neurobiolaging.2008.01.013; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; BURGHUBER OC, 1990, CANCER, V65, P1386, DOI 10.1002/1097-0142(19900315)65:6<1386::AID-CNCR2820650623>3.0.CO;2-9; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Cho WCS, 2007, BIOMED PHARMACOTHER, V61, P515, DOI 10.1016/j.biopha.2007.08.005; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Einav S, 2012, J AM COLL CARDIOL, V60, P304, DOI 10.1016/j.jacc.2012.04.020; FAIRBANKS VF, 1992, CLIN CHEM, V38, P132; Fugate JE, 2010, ANN NEUROL, V68, P907, DOI 10.1002/ana.22133; Gonzalez-Garcia S, 2012, CLIN BIOCHEM, V45, P1302, DOI 10.1016/j.clinbiochem.2012.07.094; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Green AJE, 2001, J NEUROL NEUROSUR PS, V70, P744, DOI 10.1136/jnnp.70.6.744; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Holdenrieder S, 2008, CLIN CANCER RES, V14, P7813, DOI 10.1158/1078-0432.CCR-08-0678; Holzer M, 2002, NEW ENGL J MED, V346, P549; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; NIKLINSKI J, 1995, EUR J CANCER PREV, V4, P129, DOI 10.1097/00008469-199504000-00002; Oddo M, 2011, CURR OPIN CRIT CARE, V17, P254, DOI 10.1097/MCC.0b013e328344f2ae; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Samaniego EA, 2011, CURR NEUROL NEUROSCI, V11, P111, DOI 10.1007/s11910-010-0148-9; Sanchez-Juan P, 2006, NEUROLOGY, V67, P637, DOI 10.1212/01.wnl.0000230159.67128.00; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Steffen IG, 2010, CRIT CARE, V14, DOI 10.1186/cc8975; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Storm C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-6; Tolan NV, 2009, ANAL CHEM, V81, P3102, DOI 10.1021/ac900084g; Verfaillie CJ, 2010, CLIN CHEM LAB MED, V48, P891, DOI 10.1515/CCLM.2010.159; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WOLD F, 1957, J BIOL CHEM, V227, P313; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88	38	26	28	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981	1873-3492		CLIN CHIM ACTA	Clin. Chim. Acta	SEP 23	2013	424						216	221		10.1016/j.cca.2013.06.009			6	Medical Laboratory Technology	Medical Laboratory Technology	226NH	WOS:000325042600041	23778024				2021-06-18	
J	Aslaksen, PM; Orbo, M; Elvestad, R; Schafer, C; Anke, A				Aslaksen, P. M.; Orbo, M.; Elvestad, R.; Schafer, C.; Anke, A.			Prediction of on-road driving ability after traumatic brain injury and stroke	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						driving; neuropsychology; stroke; traumatic brain injury	NEUROPSYCHOLOGICAL ASSESSMENT; MEDICAL CONDITIONS; FITNESS; REHABILITATION; DRIVERS; TRAIL	Background and purpose: The aim of the study was to examine the predictive value of widely used standardized neuropsychological tests in a clinical setting for on-road driving performance in patients with cerebral stroke or traumatic brain injury (TBI), and to provide cut-off values for neuropsychological test results under which driving should not be recommended. Methods: Data from 78 patients who had undergone comprehensive driving assessment after stroke or TBI were retrospectively included in the analysis. Patients underwent medical examination, neuropsychological testing and on-road assessment. Medical data, demographic variables and neuropsychological performance were used as predictors in a stepwise logistic regression analysis with pass/fail after the on-road test as the dependent variable. Receiver operating characteristic curve analysis was employed to select cut-off values for the tests that were significant predictors for on-road performance. Results: Forty-three patients passed and 35 failed the on-road driving task. Logistic regression analysis revealed three significant neuropsychological tests (CalCap simple reaction time, Trail Making Test A, Grooved Pegboard) as predictors for on-road performance explaining 46% of the variance with an overall classification accuracy of 82.1%. Receiver operating characteristic curve analysis showed the following cutoff values: CalCap, 395 ms; Trail Making Test A, 46 s; Grooved Pegboard, 97.5 s. Conclusion: The results suggest that driving ability after brain damage and cerebral disease with no severe neurological deficits can be measured with a few distinctive neuropsychological tests together with medical examination and on-road assessment. Cut-off scores are a useful supplement to normative data/scaled scores.	[Aslaksen, P. M.; Orbo, M.; Elvestad, R.; Schafer, C.; Anke, A.] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Aslaksen, P. M.] Univ Tromso, Dept Psychol, Fac Hlth Sci, N-9037 Tromso, Norway; [Anke, A.] Univ Tromso, Dept Clin Med, Fac Hlth Sci, N-9037 Tromso, Norway	Aslaksen, PM (corresponding author), Univ Tromso, Dept Psychol, Fac Hlth Sci, N-9037 Tromso, Norway.	per.aslaksen@uit.no	Aslaksen, Per/J-6589-2019; Orbo, Marte/AAA-2899-2021	Aslaksen, Per/0000-0002-9299-7260; Anke, Audny/0000-0002-2491-2560; Schafer, Christoph/0000-0002-4740-0429	University Hospital North Norway; University of Tromso, Norway	The authors wish to thank Morten Overvoll, Department of Psychology, University of Tromso, for his valuable assistance regarding ROC curve analyses. The study was funded by the University Hospital North Norway and the University of Tromso, Norway.	Akinwuntan AE, 2006, NEUROREHAB NEURAL RE, V20, P417, DOI 10.1177/1545968306287157; Alexandersen A, 2009, BRAIN INJURY, V23, P313, DOI 10.1080/02699050902788428; Bacon D, 2007, NEUROLOGY, V68, P1174, DOI 10.1212/01.wnl.0000259514.85579.e0; Barrash J, 2010, J INT NEUROPSYCH SOC, V16, P679, DOI 10.1017/S1355617710000470; Bliokas VV, 2011, BRAIN INJURY, V25, P471, DOI 10.3109/02699052.2011.559609; Cernich AN, 2010, CURR TREAT OPTION NE, V12, P412, DOI 10.1007/s11940-010-0085-6; Currie Z, 2000, BRIT MED J, V321, P990, DOI 10.1136/bmj.321.7267.990; Dawson JD, 2010, J AM GERIATR SOC, V58, P1090, DOI 10.1111/j.1532-5415.2010.02872.x; Devos H, 2011, NEUROLOGY, V76, P747, DOI 10.1212/WNL.0b013e31820d6300; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Gottesman RF, 2010, LANCET NEUROL, V9, P895, DOI 10.1016/S1474-4422(10)70164-2; Heaton R., 1980, MANUAL WISCONSIN CAR; Jacobson SC, 2011, BRAIN COGNITION, V77, P60, DOI 10.1016/j.bandc.2011.06.001; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; Miller E. N., 1990, CALIFORNIA COMPUTERI; Ortoleva C, 2012, J HEAD TRAUMA REHAB, V27, P302, DOI 10.1097/HTR.0b013e3182236299; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rizzo M, 2011, JAMA-J AM MED ASSOC, V305, P1018, DOI 10.1001/jama.2011.252; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; Sand KM, 2012, CEREBROVASC DIS EXTR, V2, P17, DOI 10.1159/000337016; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Soderstrom ST, 2006, SCAND J PSYCHOL, V47, P419, DOI 10.1111/j.1467-9450.2006.00550.x; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILSON B, 1987, ARCH PHYS MED REHAB, V68, P98; Withaar FK, 2000, J INT NEUROPSYCH SOC, V6, P480, DOI 10.1017/S1355617700644065	28	26	26	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	SEP	2013	20	9					1227	1233		10.1111/ene.12172			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	190WD	WOS:000322372400007	23560568				2021-06-18	
J	Gorsuch, J; Long, J; Miller, K; Primeau, K; Rutledge, S; Sossong, A; Durocher, JJ				Gorsuch, Joshua; Long, Janey; Miller, Katie; Primeau, Kyle; Rutledge, Sarah; Sossong, Andrew; Durocher, John J.			The Effect of Squat Depth on Multiarticular Muscle Activation in Collegiate Cross-Country Runners	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						concurrent training; EMG; resistance training; running; strength	RUNNING ECONOMY; DISTANCE RUNNERS; LOWER-EXTREMITY; CONCURRENT ENDURANCE; TRAINING EXERCISES; PERFORMANCE; BIOMECHANICS	Gorsuch, J, Long, J, Miller K, Primeau, K, Rutledge, S, Sossong, A, and Durocher, JJ. The effect of squat depth on multiarticular muscle activation in collegiate cross-country runners. J Strength Cond Res 27(9): 2619-2625, 2013The squat is a closed-chain lower body exercise commonly performed by many athletes. Muscle activity has been examined during partial and parallel squats in male weightlifters, but not in male and female runners. Therefore, this study measured muscle activity with surface electromyography (EMG) during partial and parallel squats in 20 Division I collegiate cross-country runners (10 males and 10 females) in a randomized crossover design. We hypothesized the parallel squat would increase extensor muscle activitation (i.e. hamstrings and erector spinae). Furthermore, we sought to determine if changes in muscle activity were different between males and females. Participants performed 6 repetitions using their 10 repetition maximum loads for each condition during EMG testing. EMG was performed on the right rectus femoris, biceps femoris, lumbar erector spinae, and lateral head of the gastrocnemius. Rectus femoris activity (0.18 +/- 0.01 vs. 0.14 +/- 0.01 mV) and erector spinae activity (0.16 +/- 0.01 vs. 0.13 +/- 0.01 mV) were significantly higher (p < 0.05) during the parallel squat than during the partial squat condition. This increase in muscle activity may be attributed to greater ranges of motion at the hip and knee joints. Biceps femoris and gastrocnemius activity were similar between conditions. No significant differences existed between males and females (squat condition x gender; p > 0.05). During preliminary isokinetic testing, both male and female runners demonstrated deficient hamstrings-to-quadriceps ratios, which would not likely improve by performing parallel squats based on our EMG findings. Despite the reduced load of the parallel squat, rectus femoris and erector spinae activity were elevated. Thus, parallel squats may help runners to train muscles vital for uphill running and correct posture, while preventing injury by using lighter weights through a larger range of motion.	[Gorsuch, Joshua; Long, Janey; Miller, Katie; Primeau, Kyle; Rutledge, Sarah; Sossong, Andrew; Durocher, John J.] St Francis Univ, Dept Phys Therapy, DiSepio Inst Human Performance Lab, Loretto, PA USA; [Durocher, John J.] Michigan Technol Univ, Dept Biol Sci, Clin & Appl Human Physiol Lab, Houghton, MI 49931 USA	Durocher, JJ (corresponding author), St Francis Univ, Dept Phys Therapy, DiSepio Inst Human Performance Lab, Loretto, PA USA.	jjduroch@mtu.edu			Saint Francis University Department of Physical Therapy	The authors are grateful to the Saint Francis University cross-country runners who volunteered for testing, and appreciate the assistance of Gordon Thomson, Jesse Webber, and Dr John Miko during data collection and analyses. The authors also thank Dr Kay Malek and the Saint Francis University Department of Physical Therapy for providing funding to support this project. Finally, the authors appreciate the contributions of Freya Moran, Jenna Edwards, and Marie Mets towards revisions of this manuscript.	Behm DG, 2009, APPL PHYSIOL NUTR ME, V34, P1008, DOI 10.1139/H09-102; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Caterisano A, 2002, J STRENGTH COND RES, V16, P428; Ebben WP, 2009, INT J SPORT PHYSIOL, V4, P84, DOI 10.1123/ijspp.4.1.84; Escamilla RF, 2001, MED SCI SPORT EXER, V33, P127; Esteve-Lanao J, 2008, J STRENGTH COND RES, V22, P1176, DOI 10.1519/JSC.0b013e31816a861f; Hamlyn N, 2007, J STRENGTH COND RES, V21, P1108; Hanon C, 2005, EUR J APPL PHYSIOL, V94, P118, DOI 10.1007/s00421-004-1276-1; Hoskins W, 2005, MANUAL THER, V10, P96, DOI 10.1016/j.math.2005.03.006; Isear JA, 1997, MED SCI SPORT EXER, V29, P532, DOI 10.1097/00005768-199704000-00016; Johnston RE, 1997, J STRENGTH COND RES, V11, P224; Kelly CM, 2008, J STRENGTH COND RES, V22, P396, DOI 10.1519/JSC.0b013e318163534a; MANN RA, 1980, AM J SPORT MED, V8, P345, DOI 10.1177/036354658000800510; MANN RA, 1986, AM J SPORT MED, V14, P501, DOI 10.1177/036354658601400614; Mikkola J, 2007, INT J SPORTS MED, V28, P602, DOI 10.1055/s-2007-964849; Millet GP, 2002, MED SCI SPORT EXER, V34, P1351, DOI 10.1097/00005768-200208000-00018; Nummela AT, 2006, EUR J APPL PHYSIOL, V97, P1, DOI 10.1007/s00421-006-0147-3; Nuzzo JL, 2008, J STRENGTH COND RES, V22, P95, DOI 10.1519/JSC.0b013e31815ef8cd; Paavolainen L, 1999, J APPL PHYSIOL, V86, P1527; Sloniger MA, 1997, J APPL PHYSIOL, V83, P2073; Storen O, 2008, MED SCI SPORT EXER, V40, P1087, DOI 10.1249/MSS.0b013e318168da2f; Wright GA, 1999, J STRENGTH COND RES, V13, P168; Yamamoto LM, 2008, J STRENGTH COND RES, V22, P2036, DOI 10.1519/JSC.0b013e318185f2f0	23	26	26	1	37	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1064-8011			J STRENGTH COND RES	J. Strength Cond. Res.	SEP	2013	27	9					2619	2625		10.1519/JSC.0b013e31828055d5			7	Sport Sciences	Sport Sciences	210NB	WOS:000323839400033	23254544				2021-06-18	
J	Max, JE; Pardo, D; Hanten, G; Schachar, RJ; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Wilde, EA; Bigler, ED; Thompson, WK; Yang, TT; Levin, HS				Max, Jeffrey E.; Pardo, David; Hanten, Gerri; Schachar, Russell J.; Saunders, Ann E.; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Wilde, Elisabeth A.; Bigler, Erin D.; Thompson, Wesley K.; Yang, Tony T.; Levin, Harvey S.			Psychiatric Disorders in Children and Adolescents Six-to-Twelve Months After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; POST-CONCUSSIVE SYMPTOMS; 1ST 6 MONTHS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PERSONALITY-CHANGE; COGNITIVE RESERVE; PREDICTORS; RELIABILITY; VALIDITY	The objective of this study was to understand how novel psychiatric disorders (NPD) in children with mild traumatic brain injury (MTBI) are related to pre-injury variables, injury-related variables, and concurrent neurocognitive outcome. A group of 79 children, ages 5 to 14 years, who had experienced MTBI, were studied from consecutive hospital admissions with semistructured psychiatric interviews soon after injury (baseline); 60 children were reassessed 12 months post-injury. Standardized instruments were used to assess injury severity; lesion characteristics; pre-injury variables, including psychiatric disorder, family psychiatric history, family functioning, socioeconomic status, psychosocial adversity, adaptive functioning, and post-injury neurocognitive and adaptive functioning. NPD occurred in 17 of 60 participants (28%) in the 6-12-month interval after injury, with disorders that were significantly associated with socioeconomic status, psychosocial adversity, estimated pre-injury academic functioning, and concurrent deficits in adaptive functioning, academic performance, processing speed, memory, and expressive language. NPD was not significantly associated with pre-injury adaptive functioning, injury severity, family psychiatric history, pre-injury psychiatric disorder, lesion location, gender, or age at injury. These findings suggest that the short-term psychiatric morbidity associated with MTBI in children occurs more commonly than previously reported and is related to both pre-injury social factors and concurrent neurocognitive functioning.	[Max, Jeffrey E.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Rady Childrens Hosp, San Diego, CA USA	Max, JE (corresponding author), Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.	jmax@ucsd.edu		Schachar, Russell/0000-0002-2015-4395	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH085734, K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Boyle MH, 1996, J AM ACAD CHILD PSY, V35, P1440, DOI 10.1097/00004583-199611000-00012; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Delis D.C., 1994, CVLT C CALIFORNIA VE; DENCKLA M B, 1974, Cortex, V10, P186; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 2010, NEUROPSYCHOLOGICAL P; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Semel E. M., 1995, CLIN EVALUATION LANG; Sparrow S., 1984, VINELAND ADAPTIVE BE; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wechsler D., 1991, WECHSLER INTELLIGENC; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	50	26	26	0	12	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2013	25	4					272	282		10.1176/appi.neuropsych.12040078			11	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	286TN	WOS:000329491700035	24247854	Green Accepted			2021-06-18	
J	Nelson, PA; Sage, JR; Wood, SC; Davenport, CM; Anagnostaras, SG; Boulanger, LM				Nelson, P. Austin; Sage, Jennifer R.; Wood, Suzanne C.; Davenport, Christopher M.; Anagnostaras, Stephan G.; Boulanger, Lisa M.			MHC class I immune proteins are critical for hippocampus-dependent memory and gate NMDAR-dependent hippocampal long-term depression	LEARNING & MEMORY			English	Article							LOW-FREQUENCY STIMULATION; BIDIRECTIONAL SYNAPTIC PLASTICITY; NEURODEVELOPMENTAL ANIMAL-MODEL; RAT HIPPOCAMPUS; CA1 REGION; COGNITIVE DYSFUNCTION; DEVELOPMENTAL SWITCH; RECEPTOR ANTAGONIST; PRENATAL INFECTION; BRAIN-DEVELOPMENT	Memory impairment is a common feature of conditions that involve changes in inflammatory signaling in the brain, including traumatic brain injury, infection, neurodegenerative disorders, and normal aging. However, the causal importance of inflammatory mediators in cognitive impairments in these conditions remains unclear. Here we show that specific immune proteins, members of the major histocompatibility complex class I (MHC class I), are essential for normal hippocampus-dependent memory, and are specifically required for NMDAR-dependent forms of long-term depression (LTD) in the healthy adult hippocampus. In beta 2m(-/-)TAP(-/-) mice, which lack stable cell-surface expression of most MHC class I proteins, NMDAR-dependent LTD in area CA1 of adult hippocampus is abolished, while NMDAR-independent forms of potentiation, facilitation, and depression are unaffected. Altered NMDAR-dependent synaptic plasticity in the hippocampus of beta 2m(-/-)TAP(-/-) mice is accompanied by pervasive deficits in hippocampus-dependent memory, including contextual fear memory, object recognition memory, and social recognition memory. Thus normal MHC class I expression is essential for NMDAR-dependent hippocampal synaptic depression and hippocampus-dependent memory. These results suggest that changes in MHC class I expression could be an unexpected cause of disrupted synaptic plasticity and cognitive deficits in the aging, damaged, and diseased brain.	[Nelson, P. Austin; Anagnostaras, Stephan G.; Boulanger, Lisa M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Sage, Jennifer R.; Wood, Suzanne C.; Anagnostaras, Stephan G.] Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA; [Davenport, Christopher M.; Boulanger, Lisa M.] Univ Calif San Diego, Neurobiol Sect, La Jolla, CA 92093 USA	Boulanger, LM (corresponding author), Princeton Univ, 123 Lewis Thomas Labs, Princeton, NJ 08544 USA.	lboulang@princeton.edu		Boulanger, Lisa/0000-0002-6578-7890	Alfred P. Sloan FoundationAlfred P. Sloan Foundation; Silvio Varon Chair in Neuroregeneration; Whitehall Foundation; Cure Autism Now; Autism Speaks; Hellman Fellowship;  [MH071666]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH071666, T32MH018870] Funding Source: NIH RePORTER	We thank P. Riquelme, N. Colaco, J. Kim, S. Carmack, and T. Czech for expert technical assistance, D. Feldman for lending equipment and expertise for the cortical LTD experiments, M. Scanziani for helpful discussions, and D. Raulet for providing TAP<SUP>-/-</SUP> mice. We are grateful for the support and guidance of C. J. Shatz, who was instrumental in initiating these experiments at Harvard Medical School, supported in part by MH071666 (C. J. Shatz). Additional support for these studies was provided by The Alfred P. Sloan Foundation, the Silvio Varon Chair in Neuroregeneration, and grants from the Whitehall Foundation, Cure Autism Now, and Autism Speaks (L. M. B), and a Hellman Fellowship (S.G.A.).	Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ADAMS W, 1993, BRIT J PSYCHIAT, V163, P522, DOI 10.1192/bjp.163.4.522; Allen CB, 2003, NAT NEUROSCI, V6, P291, DOI 10.1038/nn1012; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; Anagnostaras SG, 2003, NAT NEUROSCI, V6, P51, DOI 10.1038/nn992; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Banks WA, 2001, J PHARMACOL EXP THER, V299, P536; Barch DM, 2012, TRENDS COGN SCI, V16, P27, DOI 10.1016/j.tics.2011.11.015; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; Ben Shalom D, 2003, CORTEX, V39, P1129; Bender VA, 2006, J NEUROSCI, V26, P4166, DOI 10.1523/JNEUROSCI.0176-06.2006; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bilousova T, 2012, J NEUROIMMUNOL, V247, P1, DOI 10.1016/j.jneuroim.2012.03.008; Bitanihirwe BKY, 2010, INT J NEUROPSYCHOPH, V13, P981, DOI 10.1017/S1461145710000192; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001; Boulanger LM, 2004, NAT REV NEUROSCI, V5, P521, DOI 10.1038/nrn1428; Boulanger LM, 2001, CURR OPIN NEUROBIOL, V11, P568, DOI 10.1016/S0959-4388(00)00251-8; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Brown AS, 2006, SCHIZOPHRENIA BULL, V32, P200, DOI 10.1093/schbul/sbj052; Chacon MA, 2013, MOL CELL NEUROSCI, V52, P117, DOI 10.1016/j.mcn.2012.11.004; COAN EJ, 1987, NEUROSCI LETT, V80, P111, DOI 10.1016/0304-3940(87)90505-2; Collingridge GL, 2013, NEUROPHARMACOLOGY, V64, P13, DOI 10.1016/j.neuropharm.2012.06.051; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; Datwani A, 2009, NEURON, V64, P463, DOI 10.1016/j.neuron.2009.10.015; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dorfman JR, 1997, J IMMUNOL, V159, P5219; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Elmer BM, 2012, TRENDS NEUROSCI, V35, P660, DOI 10.1016/j.tins.2012.08.001; Feldman DE, 1998, NEURON, V21, P347, DOI 10.1016/S0896-6273(00)80544-9; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Fitzjohn SM, 1999, NEUROPHARMACOLOGY, V38, P1577, DOI 10.1016/S0028-3908(99)00123-9; Fitzjohn SM, 2001, J PHYSIOL-LONDON, V537, P421, DOI 10.1111/j.1469-7793.2001.00421.x; Fitzjohn SM, 1998, NEUROPHARMACOLOGY, V37, P1445, DOI 10.1016/S0028-3908(98)00145-2; Fourgeaud L, 2010, P NATL ACAD SCI USA, V107, P22278, DOI 10.1073/pnas.0914064107; Fourgeaud L, 2010, EUR J NEUROSCI, V32, P207, DOI 10.1111/j.1460-9568.2010.07342.x; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; Gibertini M, 1996, ADV EXP MED BIOL, V402, P207; Glynn MW, 2011, NAT NEUROSCI, V14, P442, DOI 10.1038/nn.2764; Goddard CA, 2007, P NATL ACAD SCI USA, V104, P6828, DOI 10.1073/pnas.0702023104; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; He HY, 2006, J NEUROSCI, V26, P2951, DOI 10.1523/JNEUROSCI.5554-05.2006; Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257; Huang CC, 2001, J BIOL CHEM, V276, P48108, DOI 10.1074/jbc.M106388200; Huber KM, 2001, J NEUROPHYSIOL, V86, P321; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Ibi D, 2009, NEUROSCI RES, V64, P297, DOI 10.1016/j.neures.2009.03.015; Ireland DR, 2009, J NEUROPHYSIOL, V101, P1375, DOI 10.1152/jn.90643.2008; Ito HT, 2010, BRAIN BEHAV IMMUN, V24, P930, DOI 10.1016/j.bbi.2010.03.004; Jo J, 2006, NAT NEUROSCI, V9, P170, DOI 10.1038/nn1637; Kipnis J, 2004, P NATL ACAD SCI USA, V101, P8180, DOI 10.1073/pnas.0402268101; Kipnis J, 2012, NAT REV IMMUNOL, V12, P662, DOI 10.1038/nri3280; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Leinders-Zufall T, 2004, SCIENCE, V306, P1033, DOI 10.1126/science.1102818; Li R, 2004, NEUROSCI LETT, V357, P87, DOI 10.1016/j.neulet.2003.11.004; Lidman O, 1999, EUR J NEUROSCI, V11, P4468, DOI 10.1046/j.1460-9568.1999.00904.x; Lin YX, 2008, NATURE, V455, P1198, DOI 10.1038/nature07319; Linda H, 1999, J NEUROIMMUNOL, V101, P76, DOI 10.1016/S0165-5728(99)00135-6; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Maren S, 1999, TRENDS NEUROSCI, V22, P561, DOI 10.1016/S0166-2236(99)01465-4; Maren S, 1998, TRENDS COGN SCI, V2, P39, DOI 10.1016/S1364-6613(98)01123-1; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; Matynia A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002121; McAllister AK, 2009, NEURON, V64, P9, DOI 10.1016/j.neuron.2009.09.038; McConnell MJ, 2009, P NATL ACAD SCI USA, V106, P6784, DOI 10.1073/pnas.0902018106; MERRILL JE, 1995, FASEB J, V9, P611; Meyer U, 2005, NEUROSCI BIOBEHAV R, V29, P913, DOI 10.1016/j.neubiorev.2004.10.012; Meyer U, 2008, BRAIN BEHAV IMMUN, V22, P469, DOI 10.1016/j.bbi.2007.09.012; Meyer U, 2010, PSYCHOPHARMACOLOGY, V208, P531, DOI 10.1007/s00213-009-1754-6; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Miralves J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001354; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nabavi S, 2013, P NATL ACAD SCI USA, V110, P4027, DOI 10.1073/pnas.1219454110; Needleman LA, 2010, P NATL ACAD SCI USA, V107, P16999, DOI 10.1073/pnas.1006087107; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Nicoll RA, 1998, NEUROBIOL LEARN MEM, V70, P62, DOI 10.1006/nlme.1998.3838; Nosyreva ED, 2005, J NEUROSCI, V25, P2992, DOI 10.1523/JNEUROSCI.3652-04.2005; O'Connor DH, 2005, J NEUROPHYSIOL, V94, P1565, DOI 10.1152/jn.00047.2005; O'Connor DH, 2005, P NATL ACAD SCI USA, V102, P9679, DOI 10.1073/pnas.0502332102; O'Dell T J, 1994, Learn Mem, V1, P129; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Oliet SHR, 1997, NEURON, V18, P969, DOI 10.1016/S0896-6273(00)80336-0; Ozawa K, 2006, BIOL PSYCHIAT, V59, P546, DOI 10.1016/j.biopsych.2005.07.031; Palmer MJ, 1997, NEUROPHARMACOLOGY, V36, P1517, DOI 10.1016/S0028-3908(97)00181-0; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Patterson PH, 2009, BEHAV BRAIN RES, V204, P313, DOI 10.1016/j.bbr.2008.12.016; Peineau S, 2007, NEURON, V53, P703, DOI 10.1016/j.neuron.2007.01.029; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Radjavi A, 2014, MOL PSYCHIATR, V19, P531, DOI 10.1038/mp.2013.79; RALL GF, 1995, J EXP MED, V182, P1201, DOI 10.1084/jem.182.5.1201; Rampon C, 2000, NAT NEUROSCI, V3, P238; Sanchez-Andrade G, 2005, J REPROD DEVELOP, V51, P547, DOI 10.1262/jrd.17031; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Schmidt H, 2006, BRAIN, V129, P333, DOI 10.1093/brain/awh711; Shatz CJ, 2009, NEURON, V64, P40, DOI 10.1016/j.neuron.2009.09.044; Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Torres AR, 2001, FRONT BIOSCI, V6, pD936, DOI 10.2741/Torres; ULLAL GR, 1989, EPILEPSY RES, V3, P232, DOI 10.1016/0920-1211(89)90029-6; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; Vugmeyster Y, 1998, P NATL ACAD SCI USA, V95, P12492, DOI 10.1073/pnas.95.21.12492; Washburn LR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018439; Watabe AM, 2002, J NEUROPHYSIOL, V87, P1395, DOI 10.1152/jn.00723.2001; Wood S, 2009, PSYCHOPHARMACOLOGY, V202, P197, DOI 10.1007/s00213-008-1185-9; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zelcer I, 2006, CEREB CORTEX, V16, P460, DOI 10.1093/cercor/bhi125; Zhang L, 2009, EUR J NEUROSCI, V29, P2137, DOI 10.1111/j.1460-9568.2009.06783.x; Zhong J, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-17; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629; Ziv Y, 2008, BRAIN BEHAV IMMUN, V22, P167, DOI 10.1016/j.bbi.2007.08.006; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	136	26	27	0	18	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	1072-0502	1549-5485		LEARN MEMORY	Learn. Mem.	SEP	2013	20	9					505	517		10.1101/lm.031351.113			13	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	220KC	WOS:000324581100008	23959708	Green Published, Other Gold			2021-06-18	
J	Wright, MJ; McArthur, DL; Alger, JR; Van Horn, J; Irimia, A; Filippou, M; Glenn, TC; Hovda, DA; Vespa, P				Wright, Matthew J.; McArthur, David L.; Alger, Jeffry R.; Van Horn, Jack; Irimia, Andrei; Filippou, Maria; Glenn, Thomas C.; Hovda, David A.; Vespa, Paul			Early metabolic crisis-related brain atrophy and cognition in traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Metabolic crisis; Neuropsychology; Brain atrophy; Neuroimaging	HEAD-INJURY; WHITE-MATTER; MEMORY; MODERATE; DYSFUNCTION; MICRODIALYSIS; GLUCOSE; CONSOLIDATION; RETRIEVAL; IMPACT	Traumatic brain injury often results in acute metabolic crisis. We recently demonstrated that this is associated with chronic brain atrophy, which is most prominent in the frontal and temporal lobes. Interestingly, the neuropsychological profile of traumatic brain injury is often characterized as 'frontal-temporal' in nature, suggesting a possible link between acute metabolic crisis-related brain atrophy and neurocognitive impairment in this population. While focal lesions and diffuse axonal injury have a well-established role in the neuropsychological deficits observed following traumatic brain injury, no studies to date have examined the possible contribution of acute metabolic crisis-related atrophy in the neuropsychological sequelae of traumatic brain injury. In the current study we employed positron emission tomography, magnetic resonance imaging, and neuropsychological assessments to ascertain the relationship between acute metabolic crisis-related brain atrophy and neurocognitive outcome in a sample of 14 right-handed traumatic brain injury survivors. We found that acute metabolic crisisaEurorelated atrophy in the frontal and temporal lobes was associated with poorer attention, executive functioning, and psychomotor abilities at 12 months post-injury. Furthermore, participants with gross frontal and/or temporal lobe atrophy exhibited numerous clinically significant neuropsychological deficits in contrast to participants with other patterns of brain atrophy. Our findings suggest that interventions that reduce acute metabolic crisis may lead to improved functional outcomes for traumatic brain injury survivors.	[Wright, Matthew J.] Harbor Univ Calif, Los Angeles Med Ctr, Los Angeles Biomed Res Inst, Psychol Div, Torrance, CA 90502 USA; [Wright, Matthew J.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [McArthur, David L.; Filippou, Maria; Glenn, Thomas C.; Hovda, David A.; Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Van Horn, Jack; Irimia, Andrei; Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Wright, MJ (corresponding author), Harbor Univ Calif, Los Angeles Med Ctr, Los Angeles Biomed Res Inst, Psychol Div, 1124 W Carson St,B 4 South Box 490, Torrance, CA 90502 USA.	mwright@labiomed.org	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Glenn, Thomas/0000-0003-4273-3408; Filippou-Frye, Maria/0000-0001-5516-0384	California State Neurotrauma Initiative;  [NS049471];  [NS02089];  [P01-NS058489]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002089, P01NS058489, R01NS049471] Funding Source: NIH RePORTER	This research was supported by NS049471, NS02089, P01-NS058489 and the California State Neurotrauma Initiative.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Army Individual Test Battery, 1944, MAN DIR SCOR; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bentourkia M, 2000, J NEUROL SCI, V181, P19, DOI 10.1016/S0022-510X(00)00396-8; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bor D, 2004, EUR J NEUROSCI, V19, P3365, DOI 10.1111/j.1460-9568.2004.03438.x; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Gleissner U, 1997, NEUROREPORT, V8, P2893, DOI 10.1097/00001756-199709080-00018; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Habib R, 2003, TRENDS COGN SCI, V7, P241, DOI 10.1016/S1364-6613(03)00110-4; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hattori N, 2003, J NUCL MED, V44, P1709; Hayman LA, 1992, CLIN BRAIN IMAGING N, P130; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lezak M, 2004, NEUROPSYCHOLOGICAL A, P158; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Matthews C, 1964, INSTRUCTION MANUAL A; Mitrushina M, 2005, HDB NORMATIVE DATA N, P648; NIELSENBOHLMAN L, 1994, NEUROREPORT, V5, P1517, DOI 10.1097/00001756-199407000-00027; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raz N, 2000, HDB AGING COGNITION, P1; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P104, DOI 10.1037/0894-4105.18.1.104; Schmitter-Edgecombe M, 2003, J CLIN EXP NEUROPSYC, V25, P933, DOI 10.1076/jcen.25.7.933.16493; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; Shattuck DW, 2002, MED IMAGE ANAL, V6, P129, DOI 10.1016/S1361-8415(02)00054-3; Smith A., 1991, SYMBOL DIGIT MODALIT; SQUIRE LR, 1994, INT REV NEUROBIOL, V37, P243; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.3.CO;2-8; SQUIRE LR, 1980, NEUROPSYCHOLOGIA, V18, P369, DOI 10.1016/0028-3932(80)90134-7; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2004, BRAIN PATHOL, V14, P210, DOI 10.1111/j.1750-3639.2004.tb00055.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Wright MJ, 2011, J HEAD TRAUMA REHAB, V26, P182, DOI 10.1097/HTR.0b013e318218dcf9; Wright MJ, 2010, J CLIN EXP NEUROPSYC, V32, P728, DOI 10.1080/13803390903512652; Wright MJ, 2009, J CLIN EXP NEUROPSYC, V31, P790, DOI 10.1080/13803390802508918; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	56	26	27	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2013	7	3					307	315		10.1007/s11682-013-9231-6			9	Neuroimaging	Neurosciences & Neurology	253GG	WOS:000327071400009	23636971	Green Accepted			2021-06-18	
J	Cohen-Yeshurun, A; Willner, D; Trembovler, V; Alexandrovich, A; Mechoulam, R; Shohami, E; Leker, RR				Cohen-Yeshurun, Ayelet; Willner, Dafna; Trembovler, Victoria; Alexandrovich, Alexander; Mechoulam, Raphael; Shohami, Esther; Leker, Ronen R.			N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cannabinoids; immunohistochemistry; neural stem cells; neuroregeneration	CLOSED-HEAD-INJURY; GROWTH-FACTOR; SUBVENTRICULAR ZONE; STIMULATES NEUROGENESIS; CELLULAR PROLIFERATION; CELLS; MIGRATION; PATHOPHYSIOLOGY; ENDOTHELIUM; HIPPOCAMPUS	N-arachidonoyl-L-serine (AraS) is a novel neuroprotective endocannabinoid. We aimed to test the effects of exogenous AraS on neurogenesis after traumatic brain injury (TBI). The effects of AraS on neural progenitor cells (NPC) proliferation, survival, and differentiation were examined in vitro. Next, mice underwent TBI and were treated with AraS or vehicle. Lesion volumes and clinical outcome were evaluated and the effects on neurogenesis were tested using immunohistochemistry. Treatment with AraS led to a dose-dependent increase in neurosphere size without affecting cell survival. These effects were partially reversed by CB1, CB2, or TRPV1 antagonists. AraS significantly reduced the differentiation of NPC in vitro to astrocytes or neurons and led to a 2.5-fold increase in expression of the NPC marker nestin. Similar effects were observed in vivo in mice treated with AraS 7 days after TBI. These effects were accompanied by a reduction in lesion volume and an improvement in neurobehavioral function compared with controls. AraS increases proliferation of NPCs in vitro in cannabinoid-receptor-mediated mechanisms and maintains NPC in an undifferentiated state in vitro and in vivo. Moreover, although given at 7 days post injury, these effects are associated with significant neuroprotective effects leading to an improvement in neurobehavioral functions.	[Cohen-Yeshurun, Ayelet; Trembovler, Victoria; Alexandrovich, Alexander; Mechoulam, Raphael; Shohami, Esther] Hebrew Univ Jerusalem, Fac Med, Inst Drug Res, Jerusalem, Israel; [Cohen-Yeshurun, Ayelet; Leker, Ronen R.] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Comprehens Stroke Ctr, IL-91120 Jerusalem, Israel; [Willner, Dafna] Hadassah Hebrew Univ Med Ctr, Dept Anesthesiol, IL-91120 Jerusalem, Israel	Leker, RR (corresponding author), Hadassah Hebrew Univ Med Ctr, Dept Neurol, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Comprehens Stroke Ctr, POB 12000, IL-91120 Jerusalem, Israel.	leker@hadassah.org.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA-9789]; Brettler Center for Research in Molecular Pharmacology and Therapeutics; HU School of Pharmacy; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; Sol Irwin Juni Trust Fund; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER	This study was supported by NIH Grant No. DA-9789, a grant from the Brettler Center for Research in Molecular Pharmacology and Therapeutics, the HU School of Pharmacy, The Peritz and Chantal Scheinberg Cerebrovascular Research Fund and the Sol Irwin Juni Trust Fund. ES is the incumbent of the Dr. Leon and Mina Deutch Chair in Psychopharmacology at the Hebrew University.	Aguado T, 2005, FASEB J, V19, P1704, DOI 10.1096/fj.05-3995fje; Aguado T, 2006, J NEUROSCI, V26, P1551, DOI 10.1523/JNEUROSCI.3101-05.2006; Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lachyankar MB, 1997, EXP NEUROL, V144, P350, DOI 10.1006/exnr.1997.6434; Leker RR, 2009, J NEURAL TRANSM, V116, P1397, DOI 10.1007/s00702-009-0329-3; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Madhavan L, 2008, STEM CELLS, V26, P254, DOI 10.1634/stemcells.2007-0221; McHugh D, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-44; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Merkle FT, 2006, CURR OPIN CELL BIOL, V18, P704, DOI 10.1016/j.ceb.2006.09.008; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Palazuelos J, 2006, FASEB J, V20, P2405, DOI 10.1096/fj.06-6164fje; Palazuelos J, 2012, J BIOL CHEM, V287, P1198, DOI 10.1074/jbc.M111.291294; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shingo T, 2003, SCIENCE, V299, P117, DOI 10.1126/science.1076647; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Su HX, 2009, J NEUROTRAUM, V26, P67, DOI 10.1089/neu.2008.0656; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	42	26	28	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2013	33	8					1242	1250		10.1038/jcbfm.2013.75			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	193OQ	WOS:000322570000014	23695434	Green Published, Bronze			2021-06-18	
J	Kumar, S; Rao, SL; Chandramouli, BA; Pillai, S				Kumar, Sanjay; Rao, Shobini L.; Chandramouli, Bangalore A.; Pillai, Shibu			Reduced contribution of executive functions in impaired working memory performance in mild traumatic brain injury patients	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Brain injury; Working memory; Executive function; Neuropsychology	CLOSED-HEAD-INJURY; DIVIDED ATTENTION; DYSFUNCTION; IMPAIRMENTS; SEQUELAE; DEFICITS; LESIONS	Aim: Mild traumatic brain injury (MTBI) is associated with often selective impairment of both working memory (WM) and the executive functions (EFs). Research indicates that one of the commonest deficits present in MTBI patients falls in the domain of WM. We aimed to investigate the role of EFs in WM impairment following MTBI. Methods: Performance on the tests of EFs and the verbal and visuo-spatial WM of 30 consecutive MTBI patients were compared with age/education/IQ matched 30 normal healthy control participants. Correlation between EFs and WM was studied separately for the MTBI and the control group. Results: The MTBI and control group were tested on a range of EF tests and WM. The MTBI group was demonstrated impairment on verbal and visuo-spatial WM and category fluency tests only. Furthermore, the MTBI group had fewer significant correlations between the WM and EFs (5 out of 54 possible correlations) than in the control group (13 out of 54 possible correlations). Conclusions: We suggest that MTBI may lead to WM deficits as the contribution of executive processes to support the WM is diminished following MTBI. Such an understanding of the poor WM performance in MTBI patients will be helpful when planning appropriate strategies for cognitive rehabilitation. (C) 2013 Elsevier B.V. All rights reserved.	[Kumar, Sanjay] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; [Kumar, Sanjay; Rao, Shobini L.] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Bangalore 560029, Karnataka, India; [Chandramouli, Bangalore A.; Pillai, Shibu] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India	Kumar, S (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	sanjay.kumar@psy.ox.ac.uk		Kumar, Sanjay/0000-0001-5018-4184	NIMHANS fellowship; Department of Biotechnology, Ministry of Science and Technology (Government of India)Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India	This work was supported by an NIMHANS fellowship for Ph.D. to S. Kumar and a Department of Biotechnology, Ministry of Science and Technology (Government of India) grant to S.L. Rao.	ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blanchet S, 2009, BRAIN INJURY, V23, P111, DOI 10.1080/02699050802649688; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; de Oliveira FF, 2011, ARQ NEURO-PSIQUIAT, V69, P790, DOI 10.1590/S0004-282X2011000600013; DeHaan A, 2007, NEUROPSYCHOLOGIA, V45, P406, DOI 10.1016/j.neuropsychologia.2006.06.008; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fossati P, 1999, PSYCHIAT RES, V89, P171, DOI 10.1016/S0165-1781(99)00110-9; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geary E. K., 2011, J INT NEUROPSYCH SOC, P1; Gilhooly K.J., 2002, THINK-PHILOS EVERYON, V8, P165, DOI [10.1080/13546780244000006, DOI 10.1080/13546780244000006]; Goldberg D, 1988, USERS GUIDE GEN HLTH; Hartman M, 2003, SCHIZOPHR RES, V63, P201, DOI 10.1016/S0920-9964(02)00353-5; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mayer A. R., 2011, HUMAN BRAIN MAPPING; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Miotto EC, 2012, CLIN NEUROLOGY NEURO; MORRIS RG, 1990, Q J EXP PSYCHOL-A, V42, P67, DOI 10.1080/14640749008401208; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Proctor A, 2000, BRAIN INJURY, V14, P633; Raven JC, 1939, PROGR MATRICES PERCE; Roca M, 2010, BRAIN, V133, P234, DOI 10.1093/brain/awp269; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Salthouse TA, 2003, J EXP PSYCHOL GEN, V132, P566, DOI 10.1037/0096-3445.132.4.566; Schelstraete MA, 2002, EXP AGING RES, V28, P269, DOI 10.1080/03610730290080326; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Vitali P, 2005, BRAIN LANG, V93, P32, DOI 10.1016/j.bandl.2004.08.005; Was Christopher A, 2008, Adv Cogn Psychol, V3, P399, DOI 10.2478/v10053-008-0004-5; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	49	26	26	1	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	AUG	2013	115	8					1326	1332		10.1016/j.clineuro.2012.12.038			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	198NJ	WOS:000322929300024	23374237				2021-06-18	
J	Sumpter, RE; Dorris, L; Kelly, T; McMillan, TM				Sumpter, Ruth E.; Dorris, Liam; Kelly, Thomas; McMillan, Thomas M.			Pediatric Sleep Difficulties after Moderate-Severe Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; Head injury; Child; Pediatric; Dyssomnias; Actigraphy	SELF-REPORT; CHILDREN; ADOLESCENTS; DISTURBANCES; QUESTIONNAIRE; ACTIGRAPHY; ATTENTION; MILD	The objective of this study is to systematically investigate sleep following moderate-severe pediatric traumatic brain injury (TBI). School-aged children with moderate-severe TBI identified via hospital records were invited to participate, along with a school-age sibling. Subjective reports and objective actigraphy correlates of sleep were recorded: Children's Sleep Habits Questionnaire (CSHQ), Sleep Self-Report questionnaire (SSR), and 5-night actigraphy. TBI participants (n = 15) and their siblings (n = 15) participated. Significantly more sleep problems were parent-reported (CSHQ: p = 0.003; d = 1.57), self-reported (SSR: p = 0.003; d = 1.40), and actigraph-recorded in the TBI group (sleep efficiency: p = 0.003; d = 1.23; sleep latency: p = 0.018; d = 0.94). There was no evidence of circadian rhythm disorders, and daytime napping was not prevalent. Moderate-severe pediatric TBI was associated with sleep inefficiency in the form of sleep onset and maintenance problems. This preliminary study indicates that clinicians should be aware of sleep difficulties following pediatric TBI, and their potential associations with cognitive and behavioral problems in a group already at educational and psychosocial risk.	[Sumpter, Ruth E.; McMillan, Thomas M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Dorris, Liam] Natl Hlth Serv Greater Glasgow & Clyde, Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow, Lanark, Scotland; [Kelly, Thomas] Newcastle & Tyne Natl Hlth Serv Trust, Newcastle Gen Hosp, Reg Neurosci Ctr, Newcastle, England	Dorris, L (corresponding author), Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland.	liam.dorris@ggc.scot.nhs.uk	Dorris, Liam/AAK-2273-2021	Dorris, Liam/0000-0002-9502-3154	NHS Research and Development	This research was completed in part fulfillment of a Masters degree in Clinical Neuropsychology. The authors thank Dr. David Young for consultation on statistical analyses. The research was sponsored by NHS Research and Development, but received no grant from any funding agency. There are no conflicts of interest. The authors thank all the children and young people and families who took part.	Acebo C, 1999, SLEEP, V22, P95, DOI 10.1093/sleep/22.1.95; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beebe DW, 2012, CHILD NEUROPSYCHOL, V18, P313, DOI 10.1080/09297049.2011.602014; Beebe DW, 2010, J ADOLESCENT HEALTH, V47, P523, DOI 10.1016/j.jadohealth.2010.03.005; Blunden SL, 2006, SLEEP MED REV, V10, P109, DOI 10.1016/j.smrv.2005.11.003; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Dorris L, 2008, DEV NEUROREHABIL, V11, P95, DOI 10.1080/17518420701860149; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Lewandowski AS, 2011, J PEDIATR PSYCHOL, V36, P780, DOI 10.1093/jpepsy/jsq119; Meltzer LJ, 2012, SLEEP MED REV, V16, P463, DOI 10.1016/j.smrv.2011.10.002; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2000, ARCH PEDIAT ADOL MED, V154, P549, DOI 10.1001/archpedi.154.6.549; Ponsford J. L., 1999, J HEAD TRAUMA REHAB, V14, P25; Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001; Sambuco M, 2008, BRAIN INJURY, V22, P7, DOI 10.1080/02699050701822022; TEASDALE G, 1974, LANCET, V2, P81; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1	24	26	26	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2013	19	7					829	834		10.1017/S1355617713000465			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	186CI	WOS:000322018900010	23601180	Green Accepted			2021-06-18	
J	Wang, JQ; Fox, MA; Povlishock, JT				Wang, Jiaqiong; Fox, Michael A.; Povlishock, John T.			Diffuse Traumatic Axonal Injury in the Optic Nerve Does Not Elicit Retinal Ganglion Cell Loss	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Microglia/macrophage; Retinal ganglion cell survival; Traumatic axonal injury; Traumatic brain injury; Visual system; YFP-16 transgenic mice	C-JUN EXPRESSION; BRAIN-INJURY; NEURITE TRANSECTION; NEUROTROPHIC FACTOR; NEURONAL SURVIVAL; CALCIUM-CHANNEL; STRETCH-INJURY; MOUSE MODEL; TIME-COURSE; ADULT-RAT	Much of the morbidity after traumatic brain injury (TBI) is associated with traumatic axonal injury (TAI). Although most TAI studies focus on corpus callosum white matter, the visual system has received increased interest. To assess visual system TAI, we developed a mouse model of optic nerve TAI. It is unknown, however, whether this TAI causes retinal ganglion cell (RGC) death. To address this issue, YFP (yellow fluorescent protein)-16 transgenic mice were subjected to mild TBI and followed from 2 to 28 days. Neither TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive or cleaved caspase-3Yimmunoreactive RGCs were observed from 2 to 28 days after TBI. Quantification of immunoreactivity of Brn3a, an RGC marker, demonstrated no RGC loss; parallel electron microscopic analysis confirmed RGC viability. Persistent RGC survival was also consistent with the finding of reorganization in the proximal axonal segments after TAI, wherein microglia/macrophages remained inactive. In contrast, activated microglia/macrophages closely enveloped the distal disconnected, degenerating axonal segments at 7 to 28 days after injury, thereby confirming that this model consistently evoked TAI followed by disconnection. Collectively, these data provide novel insight into the evolving pathobiology associated with TAI that will form a foundation for future studies exploring TAI therapy and its downstream consequences.	[Wang, Jiaqiong; Fox, Michael A.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, 1101 E Marshall St,Sanger Hall,Room 12-048, Richmond, VA 23298 USA.	jtpovlis@vcu.edu		Fox, Michael/0000-0002-1649-7782	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD055813, NS047463]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grants HD055813 and NS047463.	Agudo M, 2008, MOL VIS, V14, P1050; Alarcon-Martinez L, 2010, VISION RES, V50, P2176, DOI 10.1016/j.visres.2010.08.014; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BRUCK W, 1995, ACTA NEUROPATHOL, V89, P363; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Busch SA, 2010, J NEUROSCI, V30, P255, DOI 10.1523/JNEUROSCI.3705-09.2010; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Catrinescu MM, 2012, EXP EYE RES, V97, P31, DOI 10.1016/j.exer.2012.02.006; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Comley LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017639; DALE SM, 1995, EXP NEUROL, V135, P67, DOI 10.1006/exnr.1995.1066; Dibas A, 2010, MOL VIS, V16, P330; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EMERY DG, 1991, EXP BRAIN RES, V86, P60; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Galindo-Romero C, 2011, EXP EYE RES, V92, P377, DOI 10.1016/j.exer.2011.02.008; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; Gown AM, 2002, J HISTOCHEM CYTOCHEM, V50, P449, DOI 10.1177/002215540205000401; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; HERDEGEN T, 1993, J NEUROBIOL, V24, P528, DOI 10.1002/neu.480240410; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hu Y, 2012, NEURON, V73, P445, DOI 10.1016/j.neuron.2011.11.026; HULL M, 1994, NEUROSCI LETT, V178, P39, DOI 10.1016/0304-3940(94)90284-4; HULL M, 1994, J NEUROBIOL, V25, P92, DOI 10.1002/neu.480250109; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kielczewski JL, 2005, INVEST OPHTH VIS SCI, V46, P3188, DOI 10.1167/iovs.05-0321; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lefebvre JL, 2008, DEVELOPMENT, V135, P4141, DOI 10.1242/dev.027912; Leybaert L, 1996, EXP BRAIN RES, V112, P392, DOI 10.1007/BF00227945; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Liu PH, 2004, ANAT EMBRYOL, V207, P439, DOI 10.1007/s00429-003-0361-2; Liu PH, 2003, EXP NEUROL, V179, P111, DOI 10.1006/exnr.2002.8057; Lu Q, 2003, INVEST OPHTH VIS SCI, V44, P5342, DOI 10.1167/iovs.03-0444; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; Lukas TJ, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-5; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; MEIRI H, 1983, BRAIN RES, V263, P1, DOI 10.1016/0006-8993(83)91195-2; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Nehrt A, 2007, NEUROSCIENCE, V146, P1504, DOI 10.1016/j.neuroscience.2007.02.015; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; ROBINSON GA, 1994, MOL BRAIN RES, V24, P43, DOI 10.1016/0169-328X(94)90116-3; ROBINSON GA, 1995, MOL BRAIN RES, V30, P61, DOI 10.1016/0169-328X(94)00277-L; Rosenberg LJ, 2001, J NEUROPATH EXP NEUR, V60, P33, DOI 10.1093/jnen/60.1.33; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith PD, 2013, ANN THORAC SURG, V95, P1647, DOI 10.1016/j.athoracsur.2012.11.075; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Viana LC, 2013, NEUROSCIENCE, V238, P280, DOI 10.1016/j.neuroscience.2013.02.019; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; XIANG MQ, 1995, J NEUROSCI, V15, P4762; XIE XY, 1991, J NEUROSCI, V11, P3257; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	72	26	26	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2013	72	8					768	781		10.1097/NEN.0b013e31829d8d9d			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	299GI	WOS:000330383600006	23860030	Bronze, Green Accepted			2021-06-18	
J	Baykara, B; Aksu, I; Buyuk, E; Kiray, M; Sisman, AR; Baykara, B; Dayi, A; Tas, A; Ozdemir, D; Arda, MN; Uysal, N				Baykara, B.; Aksu, I.; Buyuk, E.; Kiray, M.; Sisman, A. R.; Baykara, B.; Dayi, A.; Tas, A.; Ozdemir, D.; Arda, M. N.; Uysal, N.			Progesterone treatment decreases traumatic brain injury induced anxiety and is correlated with increased serum IGF-1 levels; prefrontal cortex, amygdala, hippocampus neuron density; and reduced serum corticosterone levels in immature rats	BIOTECHNIC & HISTOCHEMISTRY			English	Article						amygdala; anxiety; brain injury; corticosterone; hippocampus; IGF-1; prefrontal cortex	DOPAMINERGIC ACTIVITY; MESSENGER-RNA; BEHAVIOR; MICE; FEAR; DYSFUNCTION; EXPRESSION; MECHANISM; EXERCISE; BDNF	Traumatic brain injury (TBI) may cause neuropsychiatric problems, such as anxiety disorder, that have negative effects on cognitive functions and behavior. We investigated the effects of progesterone on traumatic brain injury induced anxiety in 7-day-old rat pups subjected to contusion injury. Progesterone treatment decreased TBI induced anxiety and serum corticosterone levels, and increased serum IGF-1 levels. Moreover, progesterone treatment increased amygdala, prefrontal cortex and hippocampal neuron density. We found a negative correlation between serum corticosterone levels and anxiety tests, and a positive correlation between serum IGF-1 levels and anxiety tests. In addition, progesterone treatment decreased serum corticosterone compared to the controls and sham. Our results indicate that single dose progesterone may be effective for treating anxiety caused by TBI.	[Baykara, B.] Dokuz Eylul Univ, Fac Med, High Sch Phys Therapy & Rehabil, TR-35340 Izmir, Turkey; [Aksu, I.; Kiray, M.; Sisman, A. R.; Dayi, A.; Tas, A.; Ozdemir, D.; Arda, M. N.; Uysal, N.] Dokuz Eylul Univ, Fac Med, TR-35340 Izmir, Turkey; [Buyuk, E.] Albert Einstein Coll Med, Montefiore Med Ctr, Div Reprod Endocrinol & Infertil, Dept Obstet Gynecol & Womens Hlth, New York, NY USA; [Baykara, B.] Dokuz Eylul Univ, Fac Med, Dept Child & Adolescent Psychiat, TR-35340 Izmir, Turkey	Uysal, N (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Physiol, TR-35340 Izmir, Turkey.	nazan.uysal@deu.edu.tr	Baykara, Basak/AAC-6504-2019; Baykara, Huseyin Burak/AAH-4898-2020; dayi, ayfer/O-9503-2019	Baykara, Basak/0000-0002-4178-2235; Baykara, Huseyin Burak/0000-0002-1530-0159; dayi, ayfer/0000-0002-4102-1399; Uysal, Nazan/0000-0002-2348-7427	Dokuz Eylul University Research FoundationDokuz Eylul University [2012.KB.SAG.070]	This work was supported by Dokuz Eylul University Research Foundation Grant no: 2012.KB.SAG.070.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Aksu I, 2012, NEUROSCI LETT, V531, P176, DOI 10.1016/j.neulet.2012.10.045; Albanidou-Farmaki E, 2008, TOHOKU J EXP MED, V214, P291, DOI 10.1620/tjem.214.291; Baykara B., 2012, TURK NEUROSURG; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Brummelte S, 2010, NEUROSCIENCE, V168, P680, DOI 10.1016/j.neuroscience.2010.04.023; De Bellis MD, 2000, BIOL PSYCHIAT, V48, P51, DOI 10.1016/S0006-3223(00)00835-0; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; El-Bakri NK, 2004, GROWTH HORM IGF RES, V14, P388, DOI 10.1016/j.ghir.2004.04.004; Frye CA, 2004, BRAIN RES, V1004, P116, DOI 10.1016/j.brainres.2004.01.020; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Jahng JW, 2010, NEUROSCIENCE, V171, P144, DOI 10.1016/j.neuroscience.2010.08.063; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Klur S, 2009, HIPPOCAMPUS, V19, P800, DOI 10.1002/hipo.20562; Kroboth PD, 1997, PSYCHOPHARMACOL BULL, V33, P297; LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; LUO JM, 1989, ENDOCRINOLOGY, V125, P165, DOI 10.1210/endo-125-1-165; Luoma JI, 2011, STEROIDS, V76, P845, DOI 10.1016/j.steroids.2011.02.013; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Mitschelen M, 2011, NEUROSCIENCE, V185, P50, DOI 10.1016/j.neuroscience.2011.04.032; Offen D, 2001, NEUROSCI LETT, V316, P129, DOI 10.1016/S0304-3940(01)02344-8; Ozdemir D, 2012, NEUROSCI LETT, V507, P84, DOI 10.1016/j.neulet.2011.11.059; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pezze MA, 2004, PROG NEUROBIOL, V74, P301, DOI 10.1016/j.pneurobio.2004.09.004; Porritt MJ, 2005, EXP NEUROL, V192, P226, DOI 10.1016/j.expneurol.2004.11.030; Rosen JB, 1998, PSYCHOL REV, V105, P325, DOI 10.1037/0033-295X.105.2.325; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SCHMIDT PJ, 1994, J CLIN ENDOCR METAB, V79, P1256, DOI 10.1210/jc.79.5.1256; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Selman PJ, 1997, J REPROD FERTIL, P345; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; Trejo JL, 2008, MOL CELL NEUROSCI, V37, P402, DOI 10.1016/j.mcn.2007.10.016; Uysal N, 2011, NEUROSCI LETT, V505, P273, DOI 10.1016/j.neulet.2011.10.039; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	41	26	27	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1052-0295	1473-7760		BIOTECH HISTOCHEM	Biotech. Histochem.	JUL	2013	88	5					250	257		10.3109/10520295.2013.769630			8	Biotechnology & Applied Microbiology; Cell Biology	Biotechnology & Applied Microbiology; Cell Biology	184PP	WOS:000321904800005	23480228				2021-06-18	
J	Corson, K; Denneson, LM; Bair, MJ; Helmer, DA; Goulet, JL; Dobscha, SK				Corson, Kathryn; Denneson, Lauren M.; Bair, Matthew J.; Helmer, Drew A.; Goulet, Joseph L.; Dobscha, Steven K.			Prevalence and correlates of suicidal ideation among Operation Enduring Freedom and Operation Iraqi Freedom veterans	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Suicidal ideation; Depression; Veterans; Primary health care; Mental health; Screening	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; RISK-FACTORS; COMBAT VETERANS; AFGHANISTAN; CARE; VA; DEPRESSION; VALIDITY	Background: We sought to determine the prevalence and correlates of suicidal ideation (SI) among Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans following the Department of Veterans Affairs' (VA) 2007 implementation of required brief SI assessments for veterans who screen positive for depression and post-traumatic stress disorder. Methods: We retrospectively identified OEF/OIF veterans screened for depression using the Patient Health Questionnaire (PHQ-2) between April 2008 and September 2009 at three geographically-distinct VA Medical Centers' primary care or mental health clinics. Veteran responses to a two-item risk assessment tool (VA Pocket Card) or PHQ-9 9th item, administered following a positive depression screen (PHQ-2 > 3), were determined using manual chart review. Generalized estimating equations were used to calculate adjusted odds ratios for demographic and clinical correlates of positive SI assessments. Results: Of 1340 OEF/OIF veterans with positive depression screens, 32.4% reported SI. In multivariate models, odds of SI were lower for non-Hispanic white veterans (AOR=0.68) and greater for those with PHQ-2 >= 5 (AOR=1.87), depression (AOR=1.45), bipolar disorder/schizophrenia (AOR=2.84), and 2 or >= 3 diagnoses (AORs=1.59 and 2.49, respectively). Limitations: Study findings may not be generalizable to non-veteran patient populations and the study does not address the reliability and validity of tools employed for brief suicidal ideation assessment. Conclusions: SI is common among OEF/OIF veterans who receive VA care, perhaps more so among non-white veterans. Targeting veterans with higher PHQ-2 scores for SI assessment should be considered to reduce patient and administrative burden. Published by Elsevier B.V.	[Corson, Kathryn; Denneson, Lauren M.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Dept Psychiat, Portland, OR 97207 USA; [Bair, Matthew J.] Indiana Univ, Dept Med, Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA; [Helmer, Drew A.] Univ Med & Dent New Jersey, Sch Med, Vet Affairs New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, Newark, NJ USA; [Goulet, Joseph L.] Yale Univ, Sch Med, Dept Psychiat, West Haven Vet Affairs Med Ctr, New Haven, CT USA; [Dobscha, Steven K.] Portland VA Med Ctr, Portland, OR USA	Corson, K (corresponding author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Dept Psychiat, POB 1034 P3 DEP PC, Portland, OR 97207 USA.	kathryn.corson@va.gov		Goulet, Joseph/0000-0002-0842-804X	Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service ProjectUS Department of Veterans Affairs [DHI-08-096]	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Project DHI-08-096. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. The funding source had no role in study design; data collection, analysis, or interpretation; or in writing of the manuscript and submission process.	Basham C, 2011, SUICIDE LIFE-THREAT, V41, P287, DOI 10.1111/j.1943-278X.2011.00028.x; Bauer A. M., JOURNAL OF GENERAL I; Borges G, 2008, J AFFECT DISORDERS, V105, P25, DOI 10.1016/j.jad.2007.01.036; Brenner LA, 2011, SUICIDE LIFE-THREAT, V41, P416, DOI 10.1111/j.1943-278X.2011.00041.x; Britton PC, 2012, PSYCHIAT RES, V200, P395, DOI 10.1016/j.psychres.2012.06.036; Bronisch T, 2008, J AFFECT DISORDERS, V108, P135, DOI 10.1016/j.jad.2007.10.010; Bruce ML, 2010, ANN NY ACAD SCI, V1208, P98, DOI 10.1111/j.1749-6632.2010.05697.x; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Department of Veterans Affairs, 2008, REPORT OF THE BLUE R; Department of Veterans Affairs, 2007, OFFICE OF INSPECTOR; Department of Veterans Affairs, 2007, OFFICE OF INFORMATIO; Department of Veterans Affairs, 2008, SUICIDE RISK ASSESSM; Dobscha S. K., GENERAL HOSPITAL PSY; Epidemiology Program, 2012, EPIDEMIOLOGY PROGRAM; Ganzini L., JOURNAL OF GENERAL I; Gaynes BN, 2004, ANN INTERN MED, V140, P822, DOI 10.7326/0003-4819-140-10-200405180-00015; Gibbons RD, 2012, AM J PUBLIC HEALTH, V102, pS17, DOI 10.2105/AJPH.2011.300491; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Haney E., 2012, VETERANS AFFAIRS EVI; Hawkins EJ, 2010, DRUG ALCOHOL DEPEN, V109, P147, DOI 10.1016/j.drugalcdep.2009.12.025; Hawton K, 2003, AM J PSYCHIAT, V160, P1494, DOI 10.1176/appi.ajp.160.8.1494; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Institute of Medicine, 2010, COMMITTEE ON THE INI; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Kashner TM, 1998, MED CARE, V36, P1324, DOI 10.1097/00005650-199809000-00005; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Kline A, 2011, J NERV MENT DIS, V199, P914, DOI 10.1097/NMD.0b013e3182392917; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; La Bash HAJ, 2009, J INTERPERS VIOLENCE, V24, P231, DOI 10.1177/0886260508317177; Lambert MT, 1997, J MENT HEALTH ADMIN, V24, P350, DOI 10.1007/BF02832668; Lambert MT, 2002, PSYCHIATR SERV, V53, P92, DOI 10.1176/appi.ps.53.1.92; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lowe B, 2005, J PSYCHOSOM RES, V58, P163, DOI 10.1016/j.jpsychores.2004.09.006; Mann JJ, 2008, J CLIN PSYCHIAT, V69, P23, DOI 10.4088/JCP.v69n0104; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Martin J., 2009, J MENT HEALTH, V31, P101, DOI DOI 10.17744/MEHC.31.2.A6338384R2770383; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mills PD, 2011, SUICIDE LIFE-THREAT, V41, P21, DOI 10.1111/j.1943-278X.2010.00012.x; NIELSEN B, 1990, ACTA PSYCHIAT SCAND, V81, P250, DOI 10.1111/j.1600-0447.1990.tb06490.x; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Ramchand R., 2011, THE WAR WITHIN PREVE; Razykov I, 2012, J PSYCHOSOM RES, V73, P163, DOI 10.1016/j.jpsychores.2012.06.001; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schell T. L., 2008, SURVEY OF INDIVIDUAL; Schinka JA, 2012, AM J PUBLIC HEALTH, V102, pS147, DOI 10.2105/AJPH.2011.300436; Schulberg HC, 2005, ANN FAM MED, V3, P523, DOI 10.1370/afm.377; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sher L, 2011, MIL MED, V176, P601, DOI 10.7205/MILMED-D-11-00026; Stroupe KT, 2010, J REHABIL RES DEV, V47, P781, DOI 10.1682/JRRD.2009.08.0122; Sundararaman R., 2008, SUICIDE PREVENTION A; SUTKER PB, 1995, J PERS ASSESS, V64, P415, DOI 10.1207/s15327752jpa6403_2; Szanto K, 2003, ARCH GEN PSYCHIAT, V60, P610, DOI 10.1001/archpsyc.60.6.610; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Uebelacker L.A., 2011, PRIMARY CARE COMPANI, V13; VA/DoD Evidence Based Practice Guideline Work Group, 2011, VA DOD CLINICAL PRAC; West AN, 2010, J RURAL HEALTH, V26, P301, DOI 10.1111/j.1748-0361.2010.00298.x; Wittkampf KA, 2007, GEN HOSP PSYCHIAT, V29, P388, DOI 10.1016/j.genhosppsych.2007.06.004; Zivin K, 2007, AM J PUBLIC HEALTH, V97, P2193, DOI 10.2105/AJPH.2007.115477	71	26	26	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	JUL	2013	149	1-3					291	298		10.1016/j.jad.2013.01.043			8	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	166XJ	WOS:000320593000038	23531358				2021-06-18	
J	Harris, NG; Nogueira, MSM; Verley, DR; Sutton, RL				Harris, Neil G.; Nogueira, Marcia S. M.; Verley, Derek R.; Sutton, Richard L.			Chondroitinase Enhances Cortical Map Plasticity and Increases Functionally Active Sprouting Axons after Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal sprouting; c-Fos; cortex; CSPG; perineuronal net; plasticity	SPINAL-CORD-INJURY; C-FOS EXPRESSION; EXTRACELLULAR-MATRIX; PERINEURONAL NETS; IMPACT INJURY; INHIBITORY PROTEOGLYCANS; SULFATE PROTEOGLYCANS; ADULT RATS; IN-VITRO; ABC	The beneficial effect of interventions with chondroitinase ABC enzyme to reduce axon growth-inhibitory chondroitin sulphate side chains after central nervous system injuries has been mainly attributed to enhanced axonal sprouting. After traumatic brain injury (TBI), it is unknown whether newly sprouting axons that occur as a result of interventional strategies are able to functionally contribute to existing circuitry, and it is uncertain whether maladaptive sprouting occurs to increase the well-known risk for seizure activity after TBI. Here, we show that after a controlled cortical impact injury in rats, chondroitinase infusion into injured cortex at 30 min and 3 days reduced c-Fos(+) cell staining resulting from the injury alone at 1 week postinjury, indicating that at baseline, abnormal spontaneous activity is likely to be reduced, not increased, with this type of intervention. c-Fos(+) cell staining elicited by neural activity from stimulation of the affected forelimb 1 week after injury was significantly enhanced by chondroitinase, indicating a widespread effect on cortical map plasticity. Underlying this map plasticity was a larger contribution of neuronal, rather than glial cells and an absence of c-Fos(+) cells surrounded by perineuronal nets that were normally present in stimulated naive rats. After injury, chondroitin sulfate proteoglycan digestion produced the expected increase in growth-associated protein 43-positive axons and perikarya, of which a significantly greater number were double labeled for c-Fos after intervention with chondroitinase, compared to vehicle. These data indicate that chondroitinase produces significant gains in cortical map plasticity after TBI, and that either axonal sprouting and/or changes in perineuronal nets may underlie this effect. Chondroitinase dampens, rather than increases nonspecific c-Fos activity after brain injury, and induction of axonal sprouting is not maladaptive because greater numbers are functionally active and provide a significant contribution to forelimb circuitry after brain injury.	[Harris, Neil G.; Nogueira, Marcia S. M.; Verley, Derek R.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Harris, NG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu	Verley, Derek/J-4550-2015	Verley, Derek/0000-0002-2670-6568; Harris, Neil/0000-0002-1965-6750	National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS055910]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH NINDS; award no.: NS055910) and the UCLA Brain Injury Research Center.	Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Benali A, 2008, J NEUROSCI, V28, P12284, DOI 10.1523/JNEUROSCI.1952-08.2008; Bowes C, 2012, P NATL ACAD SCI USA, V109, P2595, DOI 10.1073/pnas.1121604109; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BULLITT E, 1992, BRAIN RES, V580, P172, DOI 10.1016/0006-8993(92)90941-2; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Carter LM, 2008, J NEUROSCI, V28, P14107, DOI 10.1523/JNEUROSCI.2217-08.2008; Carulli D, 2010, BRAIN, V133, P2331, DOI 10.1093/brain/awq145; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Dityatev A, 2007, DEV NEUROBIOL, V67, P570, DOI 10.1002/dneu.20361; Frischknecht R, 2009, NAT NEUROSCI, V12, P897, DOI 10.1038/nn.2338; Garcia-Alias G, 2011, J NEUROSCI, V31, P17788, DOI 10.1523/JNEUROSCI.4308-11.2011; Gentet LJ, 2012, NAT NEUROSCI, V15, P607, DOI 10.1038/nn.3051; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Goldenberg-Cohen N, 2005, INVEST OPHTH VIS SCI, V46, P2716, DOI 10.1167/iovs.04-0547; Grimpe B, 2004, J NEUROSCI, V24, P1393, DOI 10.1523/JNEUROSCI.4986-03.2004; Harris N., 2010, J NEUROTRAUM, V27, P1; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Hermann GE, 2009, BRAIN RES, V1273, P72, DOI 10.1016/j.brainres.2009.03.059; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Hrabetov D.A., 2001, J PHYSL, V587, P4029; Ikegami T, 2005, EUR J NEUROSCI, V22, P3036, DOI 10.1111/j.1460-9568.2005.04492.x; Karetko-Sysa M, 2011, EXP NEUROL, V231, P113, DOI 10.1016/j.expneurol.2011.05.022; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lowe AS, 2007, NEUROIMAGE, V35, P719, DOI 10.1016/j.neuroimage.2006.12.014; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; Moon LDF, 2001, NAT NEUROSCI, V4, P465; Nedergaard M, 2012, GLIA, V60, P1013, DOI 10.1002/glia.22288; Papadopoulos CM, 2006, CEREB CORTEX, V16, P529, DOI 10.1093/cercor/bhi132; Pawela CP, 2009, NEUROIMAGE, V46, P1137, DOI 10.1016/j.neuroimage.2009.03.004; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Pyka M, 2011, EUR J NEUROSCI, V33, P2187, DOI 10.1111/j.1460-9568.2011.07690.x; Rolls A, 2006, FASEB J, V20, P547, DOI 10.1096/fj.05-4540fje; Rusakov DA, 2001, BIOPHYS J, V81, P1947, DOI 10.1016/S0006-3495(01)75846-8; Saghatelyan AK, 2001, MOL CELL NEUROSCI, V17, P226, DOI 10.1006/mcne.2000.0922; Soleman S, 2012, BRAIN, V135, P1210, DOI 10.1093/brain/aws027; Steinmetz MP, 2005, J NEUROSCI, V25, P8066, DOI 10.1523/JNEUROSCI.2111-05.2005; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; Su CK, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-44; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Verley D., 2011, J NEUROTRAUM, V28, p[A, P220]; Wang DF, 2011, J NEUROSCI, V31, P9332, DOI 10.1523/JNEUROSCI.0983-11.2011; Wegner F, 2003, EXP NEUROL, V184, P705, DOI 10.1016/S0014-4886(03)00313-3; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3; Zhao RR, 2011, J NEUROSCI METH, V201, P228, DOI 10.1016/j.jneumeth.2011.08.003	57	26	26	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1257	1269		10.1089/neu.2012.2737			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100006	23517225	Green Published			2021-06-18	
J	Liu, HD; Li, W; Chen, ZR; Zhou, ML; Zhuang, Z; Zhang, DD; Zhu, L; Hang, CH				Liu, Huan-Dong; Li, Wei; Chen, Zhen-Rui; Zhou, Meng-Liang; Zhuang, Zong; Zhang, Ding-Ding; Zhu, Lin; Hang, Chun-Hua			Increased expression of ferritin in cerebral cortex after human traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						Ferritin; Iron; Traumatic brain injury; Inflammation	HEME OXYGENASE-1 HO-1; INTRACEREBRAL HEMORRHAGE; OXIDATIVE STRESS; IRON; DEFEROXAMINE; HEMOGLOBIN; CYTOKINES; PROTEINS; EDEMA	Despite numerous researches and improvements in the past few years, the precise mechanisms underlying secondary brain injury after trauma remain obscure. Iron is essential for almost all types of cells, including nerve cells. However, excess of iron has been proved to contribute to the brain injury following trauma in animal models. As a key iron-handling protein in the brain, ferritin might be involved in iron-induced pathophysiological process of various brain disorders. Therefore, the current study was aimed to investigate the expression of ferritin in the human contused brain. Nineteen contused brain samples were obtained from 19 patients undergoing surgery for brain contusions 3 h-17 d after trauma, and three normal temporal pole samples from 3 patients with petroclival meningioma were collected as controls. Expression of ferritin-H-chain was measured by quantitative real-time polymerase chain reaction (PCR), western blot and immunohistochemistry, respectively. Perl's reaction was taken for iron staining. The results showed that human traumatic brain injury (TBI) could up-regulate ferritin-H-chain in pericontusional cortex. A marked increase of ferritin was detected in the early group (a parts per thousand currency sign12 h), and remained elevated for a long time till after 48 h post-injury. The location of ferritin-H-chain was found mainly at the neuron-like cells and seldom at glia-like cells. Perl's reaction showed that most of the iron-positive cells were glia-like cells. These findings suggested that iron and ferritin might be involved in the secondary brain injury and could be therapeutic targets for patients with TBI.	[Liu, Huan-Dong; Chen, Zhen-Rui; Hang, Chun-Hua] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Li, Wei; Zhou, Meng-Liang; Zhuang, Zong; Zhang, Ding-Ding; Zhu, Lin; Hang, Chun-Hua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 8100053, 81271377]; Nature Science Foundation of Jiangsu Province, ChinaNatural Science Foundation of Jiangsu Province [BK2010459]	This study was supported by grants from National Natural Science Foundation, China (No. 81171170 for C.-H. Hang, No. 8100053 for M.-L. Zhou and No. 81271377 for L. Zhu) and Nature Science Foundation of Jiangsu Province, China (BK2010459).	Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Carbonell T, 2007, CURR MED CHEM, V14, P857, DOI 10.2174/092986707780363014; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755; Chiueh CC, 2001, PEDIATR NEUROL, V25, P138, DOI 10.1016/S0887-8994(01)00266-1; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Connor JR, 2001, PEDIATR NEUROL, V25, P118, DOI 10.1016/S0887-8994(01)00303-4; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Khoshyomn Sami, 2004, Semin Pediatr Surg, V13, P80, DOI 10.1053/j.sempedsurg.2004.01.003; Koeppen AH, 1995, J NEUROL SCI, V134, P102, DOI 10.1016/0022-510X(95)00215-N; Lee JY, 2010, J CEREBR BLOOD F MET, V30, P1793, DOI 10.1038/jcbfm.2010.137; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; Li W, 2012, NEUROL SCI; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; Okauchi M, 2009, STROKE, V40, P1858, DOI 10.1161/STROKEAHA.108.535765; Roth P, 2000, Crit Care Nurs Q, V23, P14; Selim M, 2009, STROKE, V40, pS90, DOI 10.1161/STROKEAHA.108.533125; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; YOUDIM MBH, 1991, EUR NEUROL, V31, P34, DOI 10.1159/000116719; Zhang L, 2012, NEUROL SCI; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	33	26	27	0	7	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	JUL	2013	34	7					1173	1180		10.1007/s10072-012-1214-7			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	187SS	WOS:000322140400020	23079850				2021-06-18	
J	Sanganahalli, BG; Herman, P; Hyder, F; Kannurpatti, SS				Sanganahalli, Basavaraju G.; Herman, Peter; Hyder, Fahmeed; Kannurpatti, Sridhar S.			Mitochondrial calcium uptake capacity modulates neocortical excitability	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aging; brain injury; BOLD; calcium uniporter; CBF; mitochondria	RAT SOMATOSENSORY CORTEX; ACTIVITY-DEPENDENT INCREASES; HIPPOCAMPAL SLICE CULTURES; TRAUMATIC BRAIN-INJURY; SPONTANEOUS CA2+ WAVES; NEURONAL-ACTIVITY; BLOOD-FLOW; ALZHEIMERS-DISEASE; INTERSTITIAL-CELLS; ENERGY-METABOLISM	Local calcium (Ca2+) changes regulate central nervous system metabolism and communication integrated by subcellular processes including mitochondrial Ca2+ uptake. Mitochondria take up Ca2+ through the calcium uniporter (mCU) aided by cytoplasmic microdomains of high Ca2+. Known only in vitro, the in vivo impact of mCU activity may reveal Ca2+-mediated roles of mitochondria in brain signaling and metabolism. From in vitro studies of mitochondrial Ca2+ sequestration and cycling in various cell types of the central nervous system, we evaluated ranges of spontaneous and activity-induced Ca2+ distributions in multiple subcellular compartments in vivo. We hypothesized that inhibiting (or enhancing) mCU activity would attenuate (or augment) cortical neuronal activity as well as activity-induced hemodynamic responses in an overall cytoplasmic and mitochondrial Ca2+-dependent manner. Spontaneous and sensory-evoked cortical activities were measured by extracellular electrophysiology complemented with dynamic mapping of blood oxygen level dependence and cerebral blood flow. Calcium uniporter activity was inhibited and enhanced pharmacologically, and its impact on the multimodal measures were analyzed in an integrated manner. Ru360, an mCU inhibitor, reduced all stimulus-evoked responses, whereas Kaempferol, an mCU enhancer, augmented all evoked responses. Collectively, the results confirm aforementioned hypotheses and support the Ca2+ uptake-mediated integrative role of in vivo mitochondria on neocortical activity.	[Sanganahalli, Basavaraju G.; Herman, Peter; Hyder, Fahmeed] Yale Univ, Dept Diagnost Radiol, Sch Med, New Haven, CT 06510 USA; [Sanganahalli, Basavaraju G.; Herman, Peter; Hyder, Fahmeed] Yale Univ, MRRC, Sch Med, New Haven, CT USA; [Sanganahalli, Basavaraju G.; Herman, Peter; Hyder, Fahmeed] Yale Univ, Sch Med, Core Ctr, QNMR, New Haven, CT USA; [Hyder, Fahmeed] Yale Univ, Sch Med, Dept Biomed Engn, New Haven, CT USA; [Kannurpatti, Sridhar S.] UMDNJ New Jersey Med Sch, Dept Radiol, Newark, NJ 07103 USA	Kannurpatti, SS (corresponding author), UMDNJ New Jersey Med Sch, Dept Radiol, ADMC Bldg 5,Suite 575,Bergen St, Newark, NJ 07103 USA.	kannursr@umdnj.edu	Sanganahalli, Basavaraju G/C-3296-2008; Hyder, Fahmeed/A-2644-2015	Sanganahalli, Basavaraju G/0000-0002-0851-6621; Hyder, Fahmeed/0000-0001-7822-4002; Herman, Peter/0000-0003-2218-9652	American Heart AssociationAmerican Heart Association [0930132N]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30NS052519]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH067528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS052519] Funding Source: NIH RePORTER	This work was supported by grants from the American Heart Association 0930132N (SK) and National Institute of Health P30NS052519 (FH).	Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Azarias G, 2011, J NEUROSCI, V31, P3550, DOI 10.1523/JNEUROSCI.4378-10.2011; Barve A, 2009, BIOPHARM DRUG DISPOS, V30, P356, DOI 10.1002/bdd.677; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002; Bindokas VP, 1998, J NEUROSCI, V18, P4570; Boumezbeur F, 2010, J CEREBR BLOOD F MET, V30, P211, DOI 10.1038/jcbfm.2009.197; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Burkeen JF, 2011, J NEUROSCI, V31, P8432, DOI 10.1523/JNEUROSCI.6576-10.2011; Busche MA, 2012, P NATL ACAD SCI USA, V109, P8740, DOI 10.1073/pnas.1206171109; de la Fuente S, 2012, CELL CALCIUM, V51, P65, DOI 10.1016/j.ceca.2011.10.007; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; Fluegge D, 2012, NAT NEUROSCI, V15, P754, DOI 10.1038/nn.3074; Garcia-Rivas GD, 2005, FEBS J, V272, P3477, DOI 10.1111/j.1742-4658.2005.04771.x; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hashiatni H, 2010, BRIT J PHARMACOL, V161, P680, DOI 10.1111/j.1476-5381.2010.00902.x; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Huchzermeyer C, 2008, J NEUROSCI, V28, P1153, DOI 10.1523/JNEUROSCI.4105-07.2008; Huttunen JK, 2008, NEUROIMAGE, V39, P775, DOI 10.1016/j.neuroimage.2007.06.042; HYDER F, 1995, MAGN RESON IMAGING, V13, P97, DOI 10.1016/0730-725X(94)00068-E; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; Hyder F, 2013, P NATL ACAD SCI USA, V110, P3549, DOI 10.1073/pnas.1214912110; Kann O, 2003, NEUROSCIENCE, V119, P87, DOI 10.1016/S0306-4522(03)00026-5; Kannurpatti SS, 2008, J CEREBR BLOOD F MET, V28, P772, DOI 10.1038/sj.jcbfm.9600574; Kannurpatti SS, 2011, BRAIN RES, V1417, P16, DOI 10.1016/j.brainres.2011.08.026; Kannurpatti SS, 2000, NEUROCHEM RES, V25, P1527, DOI 10.1023/A:1026602100160; Kim J, 2010, HUM MOL GENET, V19, P3919, DOI 10.1093/hmg/ddq306; Kovacs R, 2005, J NEUROSCI, V25, P4260, DOI 10.1523/JNEUROSCI.4000-04.2005; Kreiner L, 2006, J BIOL CHEM, V281, P4691, DOI 10.1074/jbc.M511971200; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LINDAUER U, 1993, AM J PHYSIOL, V264, pH1223; Liu RN, 2006, BIOMED CHROMATOGR, V20, P1178, DOI 10.1002/bmc.675; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lopez-Sanchez C, 2007, BRAIN RES, V1182, P123, DOI 10.1016/j.brainres.2007.08.087; Mann ZF, 2009, CELL CALCIUM, V46, P136, DOI 10.1016/j.ceca.2009.06.005; Masamoto K, 2012, J CEREBR BLOOD F MET, V32, P1233, DOI 10.1038/jcbfm.2012.50; Masamoto K, 2009, EUR J NEUROSCI, V30, P242, DOI 10.1111/j.1460-9568.2009.06812.x; Mathiesen C, 2011, J NEUROSCI, V31, P18327, DOI 10.1523/JNEUROSCI.4526-11.2011; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391; Montero M, 2004, BIOCHEM J, V384, P19, DOI 10.1042/BJ20040990; Moreira PI, 2006, J ALZHEIMERS DIS, V9, P101; Nemoto EM, 2005, ADV EXP MED BIOL, V566, P83; Nemoto M, 2012, NEUROIMAGE, V59, P3325, DOI 10.1016/j.neuroimage.2011.11.067; Nicholls DG, 2005, CELL CALCIUM, V38, P311, DOI 10.1016/j.ceca.2005.06.011; Nielsen AN, 2001, J PHYSIOL-LONDON, V533, P773, DOI 10.1111/j.1469-7793.2001.00773.x; Nir Y, 2007, CURR BIOL, V17, P1275, DOI 10.1016/j.cub.2007.06.066; Parekh AB, 2008, J PHYSIOL-LONDON, V586, P3043, DOI 10.1113/jphysiol.2008.153460; Pivovarova NB, 2010, FEBS J, V277, P3622, DOI 10.1111/j.1742-4658.2010.07754.x; Rauch A, 2008, P NATL ACAD SCI USA, V105, P6759, DOI 10.1073/pnas.0800312105; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; Restom K, 2007, NEUROIMAGE, V37, P430, DOI 10.1016/j.neuroimage.2007.05.024; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Sanganahalli BG, 2009, J NEUROSCI, V29, P1707, DOI 10.1523/JNEUROSCI.5549-08.2009; Sanganahalli Basavaraju G., 2009, V489, P213, DOI 10.1007/978-1-59745-543-5_10; Sarnat HB, 2011, CAN J NEUROL SCI, V38, P909, DOI 10.1017/S0317167100012518; Schulz K, 2012, NAT METHODS, V9, P597, DOI [10.1038/NMETH.2013, 10.1038/nmeth.2013]; Sergeant GP, 2008, J PHYSIOL-LONDON, V586, P4631, DOI 10.1113/jphysiol.2008.159194; Simpson PB, 2000, J BIOENERG BIOMEMBR, V32, P5, DOI 10.1023/A:1005552126516; Simpson PB, 1998, BRAIN RES REV, V26, P72, DOI 10.1016/S0165-0173(97)00056-8; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Soane L, 2007, J NEUROSCI RES, V85, P3407, DOI 10.1002/jnr.21498; Tsytsarev V, 2012, J NEUROSCI METH, V203, P136, DOI 10.1016/j.jneumeth.2011.09.005; Ueki M, 1992, ACTA ANAESTH SCAND, V36, P5; Vay L, 2007, J PHYSIOL-LONDON, V580, P39, DOI 10.1113/jphysiol.2006.126391; Verkhratsky A, 2012, MOL CELL ENDOCRINOL, V353, P45, DOI 10.1016/j.mce.2011.08.039; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3; YAMAGUCHI T, 1986, STROKE, V17, P1220, DOI 10.1161/01.STR.17.6.1220; Zazueta C, 1999, J BIOENERG BIOMEMBR, V31, P551, DOI 10.1023/A:1005464927366; Zetterling M, 2010, NEUROSURGERY, V66, P1102, DOI 10.1227/01.NEU.0000370893.04586.73	72	26	26	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2013	33	7					1115	1126		10.1038/jcbfm.2013.61			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	174VW	WOS:000321185800018	23591650	Green Published, Bronze			2021-06-18	
J	Kokjohn, TA; Maarouf, CL; Daugs, ID; Hunter, JM; Whiteside, CM; Malek-Ahmadi, M; Rodriguez, E; Kalback, W; Jacobson, SA; Sabbagh, MN; Beach, TG; Roher, AE				Kokjohn, Tyler A.; Maarouf, Chera L.; Daugs, Ian D.; Hunter, Jesse M.; Whiteside, Charisse M.; Malek-Ahmadi, Michael; Rodriguez, Emma; Kalback, Walter; Jacobson, Sandra A.; Sabbagh, Marwan N.; Beach, Thomas G.; Roher, Alex E.			Neurochemical Profile of Dementia Pugilistica	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; immunoblots; neurodegenerative disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; AMYLOID-BETA-PROTEIN; SPORADIC ALZHEIMERS-DISEASE; REPETITIVE HEAD-INJURY; DIFFUSE AXONAL INJURY; A-BETA; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH; ALPHA-SYNUCLEIN	Dementia pugilistica (DP), a suite of neuropathological and cognitive function declines after chronic traumatic brain injury (TBI), is present in approximately 20% of retired boxers. Epidemiological studies indicate TBI is a risk factor for neuro-degenerative disorders including Alzheimer disease (AD) and Parkinson disease (PD). Some biochemical alterations observed in AD and PD may be recapitulated in DP and other TBI persons. In this report, we investigate long-term biochemical changes in the brains of former boxers with neuropathologically confirmed DP. Our experiments revealed biochemical and cellular alterations in DP that are complementary to and extend information already provided by histological methods. ELISA and one-dimensional and two dimensional Western blot techniques revealed differential expression of select molecules between three patients with DP and three age-matched non-demented control (NDC) persons without a history of TBI. Structural changes such as disturbances in the expression and processing of glial fibrillary acidic protein, tau, and alpha-synuclein were evident. The levels of the A beta-degrading enzyme neprilysin were reduced in the patients with DP. Amyloid-beta levels were elevated in the DP participant with the concomitant diagnosis of AD. In addition, the levels of brain-derived neurotrophic factor and the axonal transport proteins kinesin and dynein were substantially decreased in DP relative to NDC participants. Traumatic brain injury is a risk factor for dementia development, and our findings are consistent with permanent structural and functional damage in the cerebral cortex and white matter of boxers. Understanding the precise threshold of damage needed for the induction of pathology in DP and TBI is vital.	[Kokjohn, Tyler A.; Maarouf, Chera L.; Daugs, Ian D.; Hunter, Jesse M.; Whiteside, Charisse M.; Rodriguez, Emma; Kalback, Walter; Roher, Alex E.] Banner Sun Hlth Res Inst, Longtine Ctr Neurodegenerat Biochem, Sun City, AZ 85351 USA; [Kokjohn, Tyler A.] Midwestern Univ, Sch Med, Dept Microbiol, Glendale, AZ USA; [Malek-Ahmadi, Michael; Jacobson, Sandra A.; Sabbagh, Marwan N.] Banner Sun Hlth Res Inst, Cleo Roberts Ctr Clin Res, Sun City, AZ 85351 USA; [Rodriguez, Emma] Natl Inst Cardiol, Mexico City, DF, Mexico; [Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ 85351 USA	Roher, AE (corresponding author), Banner Sun Hlth Res Inst, Longtine Ctr Neurodegenerat Biochem, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA.	alex.roher@bannerhealth.com	Malek-Ahmadi, Michael/AAT-1052-2020	Malek-Ahmadi, Michael/0000-0001-9901-3650; Rodriguez, Emma/0000-0002-5509-5321	The National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG019795, P30 AG19610]; State of Arizona Alzheimer's Disease Research Consortium; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U24 NS0702026]; Arizona Department of Health Services [211002]; Arizona Biomedical Research Commission [4001, 011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019795, P30AG013846, P30AG019610, P50AG005134] Funding Source: NIH RePORTER	This study was supported by The National Institute on Aging (R01 AG019795), by the State of Arizona Alzheimer's Disease Research Consortium. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS0702026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium), and the Michael J. Fox Foundation for Parkinson's Research. We would like to kindly acknowledge Dr. Ann McKee from the Department of Veterans Affairs and National Institute of Aging Boston University Alzheimer's Disease Center (P30 AG13846) for aid in facilitating the provision of DP brain tissues of cases #1 and #2 and for critical review of the manuscript. We also appreciate the Neuropathology Core of the Massachusetts Alzheimer Disease Research Center (P50 AG005134) and Ms. Karlotta Fitch of the Massachusetts Neuropathology Service, Massachusetts General Hospital, for providing DP brain tissue of case #3. We are in debt to Dr. Dean C. Luehrs for critical review of the manuscript.	AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bartzokis G, 2011, NEUROBIOL AGING, V32, P1341, DOI 10.1016/j.neurobiolaging.2009.08.007; Beach TG, 2008, CELL TISSUE BANK, V9, P229, DOI 10.1007/s10561-008-9067-2; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Bishop GM, 2004, BRAIN PATHOL, V14, P448; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Breydo L, 2012, BBA-MOL BASIS DIS, V1822, P261, DOI 10.1016/j.bbadis.2011.10.002; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P285; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; CASTEJON OJ, 1985, J SUBMICR CYTOL PATH, V17, P703; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chuang JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033120; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Crawford F, 1997, ANN NY ACAD SCI, V826, P35, DOI 10.1111/j.1749-6632.1997.tb48459.x; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; Davidson YS, 2011, ACTA NEUROPATHOL, V122, P703, DOI 10.1007/s00401-011-0879-y; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goux WJ, 2001, J ALZHEIMERS DIS, V3, P455, DOI 10.3233/JAD-2001-3504; GOUX WJ, 1995, FEBS LETT, V366, P81, DOI 10.1016/0014-5793(95)00486-S; GOWING E, 1994, J BIOL CHEM, V269, P10987; Graham DI, 1996, ACT NEUR S, V66, P96; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; GUALTIERI T, 1991, Brain Injury, V5, P219, DOI 10.3109/02699059109008093; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; He XS, 2010, ACTA NEUROL BELG, V110, P49; Hersh LB, 2008, CURR ALZHEIMER RES, V5, P225, DOI 10.2174/156720508783954703; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Hirokawa N, 2010, NEURON, V68, P610, DOI 10.1016/j.neuron.2010.09.039; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hol EM, 2003, MOL PSYCHIATR, V8, P786, DOI 10.1038/sj.mp.4001379; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; INAGAKI M, 1994, BRAIN PATHOL, V4, P239, DOI 10.1111/j.1750-3639.1994.tb00839.x; Iwata N, 2000, NAT MED, V6, P143; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2012, EXP NEUROL; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Johnston H, 2011, BIOCHEM SOC T, V39, P886, DOI 10.1042/BST0390886; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalback W, 2004, NEUROL RES, V26, P525, DOI 10.1179/016164104225017668; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kokjohn TA, 2012, ALZHEIMERS DEMENT, V8, P574, DOI 10.1016/j.jalz.2011.05.2429; Korolainen MA, 2005, NEUROBIOL DIS, V20, P858, DOI 10.1016/j.nbd.2005.05.021; KUCHNA I, 1991, Neuropatologia Polska, V29, P103; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Liao MC, 2010, J BIOL CHEM, V285, P35590, DOI 10.1074/jbc.M110.169599; Liao MC, 2009, J BIOL CHEM, V284, P28917, DOI 10.1074/jbc.M109.050856; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Maarouf CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027291; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Martin L, 2011, NEUROCHEM INT, V58, P458, DOI 10.1016/j.neuint.2010.12.023; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouser PE, 2006, AM J PATHOL, V168, P936, DOI 10.2353/ajpath.2006.050798; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Paris D, 2003, NEUROL RES, V25, P642, DOI 10.1179/016164103101201940; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Porchet R, 2003, PROTEOMICS, V3, P1476, DOI 10.1002/pmic.200300456; Rauramaa T, 2011, J NEURAL TRANSM, V118, P683, DOI 10.1007/s00702-010-0574-5; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Robinson SR, 2002, NEUROBIOL AGING, V23, P1051, DOI 10.1016/S0197-4580(01)00342-6; Roher AE, 2003, ARTERIOSCL THROM VAS, V23, P2055, DOI 10.1161/01.ATV.0000095973.42032.44; Roher AE, 2002, BIOCHEMISTRY-US, V41, P11080, DOI 10.1021/bi026173d; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Sabbagh MN, 2010, CURR ALZHEIMER RES, V7, P280, DOI 10.2174/156720510791162340; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schenker M, 2001, J BONE JOINT SURG BR, V83B, P916, DOI 10.1302/0301-620X.83B6.10725; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SPARKMAN DR, 1991, BIOCHEM BIOPH RES CO, V181, P771, DOI 10.1016/0006-291X(91)91257-D; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thal DR, 2005, ACTA NEUROPATHOL, V110, P459, DOI 10.1007/s00401-005-1053-1; Thomas SN, 2012, ACTA NEUROPATHOL, V123, P105, DOI 10.1007/s00401-011-0893-0; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VanPaesschen W, 1997, J NEUROL NEUROSUR PS, V63, P513, DOI 10.1136/jnnp.63.4.513; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wu CW, 2004, NEUROBIOL DIS, V17, P367, DOI 10.1016/j.nbd.2004.08.014; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Zurek J, 2011, J TRAUMA, V71, P854, DOI 10.1097/TA.0b013e3182140c8c	127	26	26	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					981	997		10.1089/neu.2012.2699			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300009	23268705	Green Published			2021-06-18	
J	Spanevello, MD; Tajouri, SI; Mirciov, C; Kurniawan, N; Pearse, MJ; Fabri, LJ; Owczarek, CM; Hardy, MP; Bradford, RA; Ramunno, ML; Turnley, AM; Ruitenberg, MJ; Boyd, AW; Bartlett, PF				Spanevello, Mark Damien; Tajouri, Sophie Ines; Mirciov, Cornel; Kurniawan, Nyoman; Pearse, Martin John; Fabri, Louis Jerry; Owczarek, Catherine Mary; Hardy, Matthew Philip; Bradford, Rebecca Anne; Ramunno, Melanie Louise; Turnley, Ann Maree; Ruitenberg, Marc Jan; Boyd, Andrew Wallace; Bartlett, Perry Francis			Acute Delivery of EphA4-Fc Improves Functional Recovery after Contusive Spinal Cord Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						EphA4; magnetic resonance imaging; neurotrauma; spinal cord injury	EX-VIVO; AXONAL REGENERATION; UP-REGULATION; EPHRINB3; PATTERNS; LESIONS; GROWTH; BOS	Blocking the action of inhibitory molecules at sites of central nervous system injury has been proposed as a strategy to promote axonal regeneration and functional recovery. We have previously shown that genetic deletion or competitive antagonism of EphA4 receptor activity promotes axonal regeneration and functional recovery in a mouse model of lateral hemisection spinal cord injury. Here we have assessed the effect of blocking EphA4 activation using the competitive antagonist EphA4-Fc in a rat model of thoracic contusive spinal cord injury. Using a ledged tapered balance beam and open-field testing, we observed significant improvements in recovery of locomotor function after EphA4-Fc treatment. Consistent with functional improvement, using high-resolution ex vivo magnetic resonance imaging at 16.4T, we found that rats treated with EphA4-Fc had a significantly increased cross-sectional area of the dorsal funiculus caudal to the injury epicenter compared with controls. Our findings indicate that EphA4-Fc promotes functional recovery following contusive spinal cord injury and provides further support for the therapeutic benefit of treatment with the competitive antagonist in acute cases of spinal cord injury.	[Spanevello, Mark Damien; Tajouri, Sophie Ines; Mirciov, Cornel; Ruitenberg, Marc Jan; Bartlett, Perry Francis] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Kurniawan, Nyoman] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld, Australia; [Ruitenberg, Marc Jan] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Boyd, Andrew Wallace] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Spanevello, Mark Damien; Boyd, Andrew Wallace] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Pearse, Martin John; Fabri, Louis Jerry; Owczarek, Catherine Mary; Hardy, Matthew Philip; Bradford, Rebecca Anne; Ramunno, Melanie Louise] CSL Ltd, Melbourne, Vic, Australia; [Turnley, Ann Maree] Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia	Boyd, AW (corresponding author), Univ Queensland, Royal Brisbane Hosp, Queensland Inst Med Res, Locked Bag 2000, Herston, Qld 4029, Australia.	Andrew.Boyd@qimr.edu.au; p.bartlett@uq.edu.au	Kurniawan, Nyoman/D-9764-2011; Bartlett, Perry/F-3813-2012	Kurniawan, Nyoman/0000-0001-6340-182X; fabri, louis/0000-0003-4033-3304; Ruitenberg, Marc/0000-0002-6917-0708; Mirciov, Cornel/0000-0002-9083-2614	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [511212, APP1017308]; Australian Research CouncilAustralian Research Council [DP110103201]; Lisa Palmer bequest; Spinal Cure Australia	This work was supported by the National Health and Medical Research Council (Grants 511212 and APP1017308 to Prof. Bartlett) and the Australian Research Council (Grant DP110103201 to Prof. Bartlett). This work was also supported by funding from the Lisa Palmer bequest and Spinal Cure Australia. We acknowledge the assistance of Rowan Tweedale and Ashley Cooper (Queensland Brain Institute, The University of Queensland) for their critical review of this manuscript.	Anseloni VCZ, 2003, J NEUROSCI METH, V131, P93, DOI 10.1016/S0165-0270(03)00241-3; Arocho LC, 2011, CELL MOL NEUROBIOL, V31, P1057, DOI 10.1007/s10571-011-9705-2; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bilgen M, 2008, BIOMARK MED, V2, P113, DOI 10.2217/17520363.2.2.113; Blomster LV, 2013, NMR BIOMED, V26, P141, DOI 10.1002/nbm.2829; Bowden TA, 2009, STRUCTURE, V17, P1386, DOI 10.1016/j.str.2009.07.018; Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; Byrnes KR, 2010, J MAGN RESON IMAGING, V32, P836, DOI 10.1002/jmri.22323; Cruz-Orengo L, 2006, EXP NEUROL, V202, P421, DOI 10.1016/j.expneurol.2006.07.005; Day BW, 2006, PROTEIN PEPTIDE LETT, V13, P193, DOI 10.2174/092986606775101625; Dixon KJ, 2012, NEUROSCI LETT, V525, P66, DOI 10.1016/j.neulet.2012.07.023; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; Dries JL, 2011, J PHYSIOL-LONDON, V589, P1725, DOI 10.1113/jphysiol.2010.202366; Duffy P, 2012, P NATL ACAD SCI USA, V109, P5063, DOI 10.1073/pnas.1113953109; Ellingson BM, 2010, J NEUROSURG-SPINE, V13, P181, DOI 10.3171/2010.3.SPINE09523; Ellingson BM, 2008, J MAGN RESON IMAGING, V28, P1068, DOI 10.1002/jmri.21578; Fabes J, 2006, EUR J NEUROSCI, V23, P1721, DOI 10.1111/j.1460-9568.2006.04704.x; Fabes J, 2007, EUR J NEUROSCI, V26, P2496, DOI 10.1111/j.1460-9568.2007.05859.x; Fleming SM, 2009, INT REV NEUROBIOL, V89, P57, DOI 10.1016/S0074-7742(09)89003-X; Gao YJ, 2010, NEUROTHERAPEUTICS, V7, P482, DOI 10.1016/j.nurt.2010.05.016; Ghosh A, 2009, J NEUROSCI, V29, P12210, DOI 10.1523/JNEUROSCI.1828-09.2009; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Ho SKY, 2009, NEUROSCIENCE, V160, P784, DOI 10.1016/j.neuroscience.2009.03.013; Iwasato T, 2007, CELL, V130, P742, DOI 10.1016/j.cell.2007.07.022; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Kullander K, 2003, SCIENCE, V299, P1889, DOI 10.1126/science.1079641; Lau E, 2010, CLIN EXP PHARMACOL P, V37, P417, DOI 10.1111/j.1440-1681.2009.05318.x; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Munro KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037635; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Nielson JL, 2011, J COMP NEUROL, V519, P2852, DOI 10.1002/cne.22661; Nishi RA, 2007, J NEUROTRAUM, V24, P674, DOI 10.1089/neu.2006.0204; Omoto S, 2011, NEUROSCI RES, V69, P187, DOI 10.1016/j.neures.2010.12.004; Qin HN, 2010, J BIOL CHEM, V285, P644, DOI 10.1074/jbc.M109.064824; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Rossi SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011852; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Smith FM, 2004, J BIOL CHEM, V279, P9522, DOI 10.1074/jbc.M309326200; STEEVES JD, 1980, NEUROSCI LETT, V20, P283, DOI 10.1016/0304-3940(80)90161-5; Van Hoecke A, 2012, NAT MED, V18, P1418, DOI 10.1038/nm.2901; Velardo MJ, 2004, J NEUROSCI, V24, P8562, DOI 10.1523/JNEUROSCI.3316-04.2004; Wang R, 2007, P INT SOC MAG RESON, V15, P3720; Wen YR, 2011, J FORMOS MED ASSOC, V110, P487, DOI 10.1016/S0929-6646(11)60074-0	54	26	26	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	12					1023	1034		10.1089/neu.2012.2729			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	168KZ	WOS:000320705900001	23557244	Green Published			2021-06-18	
J	Yeo, SS; Jang, SH				Yeo, Sang Seok; Jang, Sung Ho			NEURAL REORGANIZATION FOLLOWING BILATERAL INJURY OF THE FORNIX CRUS IN A PATIENT WITH TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						head trauma; fornix; memory; diffusion tensor imaging; brain plasticity	DIFFUSE AXONAL INJURY; INFERIOR LONGITUDINAL FASCICULUS; MINI-MENTAL-STATE; TENSOR TRACTOGRAPHY; FIBER TRACTOGRAPHY; MEMORY IMPAIRMENT; STROKE PATIENTS; MOTOR RECOVERY	Objective: We report on a patient who appeared to demonstrate neural reorganization after head trauma resulting in bilateral injury of the fornix emus. Case report: A 58-year-old male patient and 8 control subjects were recruited. The patient had undergone head trauma as the result of a car accident and had lost consciousness for 30 min. Brain magnetic resonance imaging, performed 3 years after the head trauma, showed no evidence of abnormality. Results: Discontinuation of both crus in the proximal region was observed on diffusion tensor tractography of the fornix. In the right fornix, an abnormal neural tract originating from the right crus passed through the splenium of the corpus callosum to connect with the right inferior longitudinal fasciculus. By contrast, in the left fornix, another abnormal neural tract originating from the left column passed through the left inferior longitudinal fasciculus and the splenium of the corpus callosum. None of these abnormal neural tracts was observed in normal subjects. Conclusion: We presume that the abnormal neural tracts of the fornix observed in this patient were the result of neural reorganization triggered by bilateral injury of the fornix crus. The results of this study suggest a mechanism for recovery of the injured fornix following head trauma.	[Yeo, Sang Seok; Jang, Sung Ho] Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			National Research Foundation of Korea (NRF)National Research Foundation of Korea; Ministry of Education, Science and TechnologyMinistry of Education, Science and Technology, Republic of Korea [2012R1A1A4A01001873]	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A4A01001873).	Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Ashtari M, 2012, DEV MED CHILD NEUROL, V54, P6, DOI 10.1111/j.1469-8749.2011.04122.x; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Concha L, 2005, AM J NEURORADIOL, V26, P2267; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Han C, 2008, ARCH GERONTOL GERIAT, V47, P302, DOI 10.1016/j.archger.2007.08.012; Hong JH, 2010, J REHABIL MED, V42, P979, DOI 10.2340/16501977-0603; Hong JH, 2010, EUR NEUROL, V63, P252, DOI 10.1159/000277477; Jang SH, 2011, NEUROREHABILITATION, V28, P345, DOI 10.3233/NRE-2011-0662; Jang SH, 2011, J REHABIL MED, V43, P268, DOI 10.2340/16501977-0654; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Lee SK, 2005, RADIOGRAPHICS, V25, P53, DOI 10.1148/rg.251045085; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parker GJM, 2005, PHILOS T R SOC B, V360, P893, DOI 10.1098/rstb.2005.1639; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; TUCKER DM, 1988, CORTEX, V24, P465, DOI 10.1016/S0010-9452(88)80010-8; TUSA RJ, 1985, ANN NEUROL, V18, P583, DOI 10.1002/ana.410180512; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D., 1981, WAIS R MANUAL WECHSL; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Williams JM, 1991, MAS MEMORY ASSESSMEN; Wolk David A, 2010, Continuum (Minneap Minn), V16, P15, DOI 10.1212/01.CON.0000368257.30791.3a; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165; Yamada K, 2009, P NATL ACAD SCI USA, V106, pE14, DOI 10.1073/pnas.0812352106	28	26	27	0	5	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	JUN	2013	45	6					595	598		10.2340/16501977-1145			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	172UI	WOS:000321030000013	23588891	DOAJ Gold			2021-06-18	
J	Al-Ali, H; Schurer, SC; Lemmon, VP; Bixby, JL				Al-Ali, Hassan; Schuerer, Stephan C.; Lemmon, Vance P.; Bixby, John L.			Chemical Interrogation of the Neuronal Kinome Using a Primary Cell-Based Screening Assay	ACS CHEMICAL BIOLOGY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; NEURITE OUTGROWTH; AXONAL GROWTH; KINASE INHIBITORS; RHOA-KINASE; MYOSIN-II; REGENERATION; RETRACTION; CNS; PHOSPHORYLATION	A fundamental impediment to functional recovery from spinal cord injury (SCI) and traumatic brain injury is the lack of sufficient axonal regeneration in the adult central nervous system. There is thus a need to develop agents that can stimulate axon growth to re-establish severed connections. Given the critical role played by protein kinases in regulating axon growth and the potential for pharmacological intervention, small molecule protein kinase inhibitors present a promising therapeutic strategy. Here, we report a robust cell-based phenotypic assay, utilizing primary rat hippocampal neurons, for identifying small molecule kinase inhibitors that promote neurite growth. The assay is highly reliable and suitable for medium-throughput screening, as indicated by its Z'-factor of 0.73. A focused structurally diverse library of protein kinase inhibitors was screened, revealing several compound groups with the ability to strongly and consistently promote neurite growth. The best performing bioassay hit robustly and consistently promoted axon growth in a postnatal cortical slice culture assay. This study can serve as a jumping-off point for structure activity relationship (SAR) and other drug discovery approaches toward the development of drugs for treating SCI and related neurological pathologies.	[Al-Ali, Hassan; Lemmon, Vance P.; Bixby, John L.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Schuerer, Stephan C.; Lemmon, Vance P.; Bixby, John L.] Univ Miami, Miller Sch Med, Ctr Computat Sci, Miami, FL 33136 USA; [Lemmon, Vance P.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Schuerer, Stephan C.; Bixby, John L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA	Lemmon, VP (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA.	vlemmon@med.miami.edu; jbixby@med.miami.edu	Lemmon, Vance/A-7410-2010	Lemmon, Vance/0000-0003-3550-7576; Bixby, John/0000-0003-1633-5318; Al-Ali, Hassan/0000-0002-8899-3443	James and Esther King Biomedical Research Program [JEK09KW-05]; U.S ArmyUnited States Department of Defense [W81XWH-05-1-0061]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD057521, NS059866]; Buoniconti Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059866] Funding Source: NIH RePORTER	We thank current and former members of the LemBix laboratory for assisting with several steps of this project, especially Y. Shi with the HCA, A. Oliva and T. Slepak with the primary cell culture, and Y. Martinez with the slice cultures. We acknowledge resources from the Center for Computational Science. V.P.L. holds the Walter G Ross Distinguished Chair in Developmental Neuroscience. We thank P. Hong at Brandeis University for providing guidance and executables for the neurite extraction software. This work was supported by grants from the James and Esther King Biomedical Research Program JEK09KW-05 (JLB), the U.S Army W81XWH-05-1-0061 (V.P.L., J.L.B.), the National Institutes of Health [HD057521 (V.P.L.), NS059866 (J.L.B.)], and the Buoniconti Fund.	Abe N, 2010, J BIOL CHEM, V285, P28034, DOI 10.1074/jbc.M110.125336; Alabed YZ, 2010, J NEUROSCI, V30, P5635, DOI 10.1523/JNEUROSCI.6154-09.2010; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; BIXBY JL, 1992, J NEUROBIOL, V23, P468, DOI 10.1002/neu.480230503; BIXBY JL, 1989, NEURON, V3, P287, DOI 10.1016/0896-6273(89)90253-5; Blackmore MG, 2012, P NATL ACAD SCI USA, V109, P7517, DOI 10.1073/pnas.1120684109; Buchser WJ, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.52; Cafferty WBJ, 2008, TRENDS NEUROSCI, V31, P215, DOI 10.1016/j.tins.2008.02.004; Diez H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032715; Dimitropoulou A, 2005, MOL CELL NEUROSCI, V28, P292, DOI 10.1016/j.mcn.2004.09.013; Don ASA, 2012, DRUG DISCOV TODAY, V17, P861, DOI 10.1016/j.drudis.2012.04.010; Duffy P, 2009, J NEUROSCI, V29, P15266, DOI 10.1523/JNEUROSCI.4650-09.2009; Feng YB, 2008, J MED CHEM, V51, P6642, DOI 10.1021/jm800986w; Fischer M, 2009, MOL CELL NEUROSCI, V42, P134, DOI 10.1016/j.mcn.2009.06.006; Furuya H, 2011, CANCER METAST REV, V30, P567, DOI 10.1007/s10555-011-9304-1; Gallo G, 2002, J CELL BIOL, V158, P1219, DOI 10.1083/jcb.200204140; Gallo G, 2006, J CELL SCI, V119, P3413, DOI 10.1242/jcs.03084; Ghoreschi K, 2009, NAT IMMUNOL, V10, P356, DOI 10.1038/ni.1701; Gopalakrishnan SM, 2008, J NEUROSCI RES, V86, P2214, DOI 10.1002/jnr.21671; Gutierrez H, 2011, TRENDS NEUROSCI, V34, P316, DOI 10.1016/j.tins.2011.03.001; Klebl BM, 2005, EXPERT OPIN THER TAR, V9, P975, DOI 10.1517/14728222.9.5.975; Lee Jae-Hyuk, 2011, Chonnam Med J, V47, P27, DOI 10.4068/cmj.2011.47.1.27; Lerch JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030417; Lie M, 2010, NEUROSCIENCE, V169, P855, DOI 10.1016/j.neuroscience.2010.05.020; Lingor P, 2007, J NEUROCHEM, V103, P181, DOI 10.1111/j.1471-4159.2007.04756.x; Loh SHY, 2008, CELL DEATH DIFFER, V15, P283, DOI 10.1038/sj.cdd.4402258; Loudon RR, 2006, J NEUROBIOL, V66, P847, DOI 10.1002/neu.20258; Michaelevski I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000952; Minase T, 2010, EUR J PHARMACOL, V648, P67, DOI 10.1016/j.ejphar.2010.09.007; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Park KK, 2010, EXP NEUROL, V223, P45, DOI 10.1016/j.expneurol.2009.12.032; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pettus LH, 2008, CURR TOP MED CHEM, V8, P1452, DOI 10.2174/156802608786264245; Samara C, 2010, P NATL ACAD SCI USA, V107, P18342, DOI 10.1073/pnas.1005372107; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P329, DOI 10.1006/bbrc.1997.7666; Schmidt JT, 2002, J NEUROBIOL, V52, P175, DOI 10.1002/neu.10083; Schurer SC, 2013, J CHEM INF MODEL, V53, P27, DOI 10.1021/ci300403k; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Swinney DC, 2011, NAT REV DRUG DISCOV, V10, P507, DOI 10.1038/nrd3480; Wang PY, 2001, AM J PHYSIOL-LUNG C, V281, pL1472; Wu CH, 2010, NEUROINFORMATICS, V8, P83, DOI 10.1007/s12021-010-9067-9; Yoshimura K, 2011, NEUROSCI RES, V71, P266, DOI 10.1016/j.neures.2011.07.1830; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	47	26	27	0	14	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1554-8929	1554-8937		ACS CHEM BIOL	ACS Chem. Biol.	MAY	2013	8	5					1027	1036		10.1021/cb300584e			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	155BP	WOS:000319720700022	23480631	Green Published, Green Accepted			2021-06-18	
J	Bennett, RE; Esparza, TJ; Lewis, HA; Kim, E; Mac Donald, CL; Sullivan, PM; Brody, DL				Bennett, Rachel E.; Esparza, Thomas J.; Lewis, Hal A.; Kim, Eddie; Mac Donald, Christine L.; Sullivan, Patrick M.; Brody, David L.			Human Apolipoprotein E4 Worsens Acute Axonal Pathology but Not Amyloid-beta Immunoreactivity After Traumatic Brain Injury in 3xTG-AD Mice	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Apolipoprotein E; Axon injury; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; HEAD-INJURY; MOUSE MODEL; PROTEIN DEPOSITION; TYPE-4 ALLELE; E-GENOTYPE; A-BETA; PRECURSOR; TAU	Apolipoprotein E4 (APOE4) genotype is a risk factor for poor outcome after traumatic brain injury (TBI), particularly in young patients, but the underlying mechanisms are not known. By analogy to effects of APOE4 on the risk of Alzheimer disease (AD), the APOE genotype may influence beta-amyloid (A beta) and tau deposition after TBI. To test this hypothesis, we crossed 3xTG-AD transgenic mice carrying 3 human familial AD mutations (PS1(M146V), tau(P301L), and APP(SWE)) to human ApoE2-, ApoE3-, and ApoE4-targeted replacement mice. Six- to 8-month-old 3xTG-ApoE mice were assayed by quantitative immunohistochemistry for amyloid precursor protein (APP), A beta(1-40) (A beta 40), A beta(1-42) (A beta 42), total human tau, and phosphoserine 199 (pS199) tau at 24 hours after moderate controlled cortical impact. There were increased numbers of APP-immunoreactive axonal varicosities in 3xTG-ApoE4 mice versus the other genotypes. This finding was repeated in a separate cohort of ApoE4-targeted replacement mice without human transgenes compared with ApoE3 and ApoE2 mice. There were no differences between genotypes in the extent of intra-axonal A beta 40 and A beta 42; none of the mice had extracellular A beta deposition. Regardless of injury status, 3xTG-ApoE4 mice had more total human tau accumulation in both somatodendritic and intra-axonal compartments than other genotypes. These results suggest that the APOE4 genotype may have a primary effect on the severity of axonal injury in acute TBI.	[Bennett, Rachel E.; Esparza, Thomas J.; Lewis, Hal A.; Kim, Eddie; Mac Donald, Christine L.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Sullivan, Patrick M.] Duke Univ, Dept Med, Div Geriatr, VAMC,Geriatr Res Educ Clin Ctr, Durham, NC USA; [Kim, Eddie] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Brody, David L.] Hope Ctr Neurol Disorders, St Louis, MO USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS065069, K08-NS049237, F31-NS076047]; Burroughs Wellcome FundBurroughs Wellcome Fund; Thrasher Research Fund; Health South Research Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069, K08NS049237, F31NS076047] Funding Source: NIH RePORTER	This work was funded by NIH NS065069 (David Brody), NIH K08-NS049237 (David Brody), NIH F31-NS076047 (Rachel Bennett), the Burroughs Wellcome Fund (David Brody), the Thrasher Research Fund (David Brody), and a Health South Research Grant (David Brody).	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Bien-Ly N, 2012, J NEUROSCI, V32, P4803, DOI 10.1523/JNEUROSCI.0033-12.2012; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Guo QX, 2012, CELL RES, V22, P78, DOI 10.1038/cr.2011.116; Hartman RE, 2002, J NEUROSCI, V22, P10083; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ohkubo N, 2002, FASEB J, V16, P295, DOI 10.1096/fj.02-0434fje; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102	53	26	27	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2013	72	5					396	403		10.1097/NEN.0b013e31828e24ab			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	133RS	WOS:000318158000003	23584199	Bronze, Green Accepted			2021-06-18	
J	Clavisi, O; Bragge, P; Tavender, E; Turner, T; Gruen, RL				Clavisi, Ornella; Bragge, Peter; Tavender, Emma; Turner, Tari; Gruen, Russell L.			Effective stakeholder participation in setting research priorities using a Global Evidence Mapping approach	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Prioritization; Traumatic brain injury; Research funding; Evidence mapping; Research gaps; Rehabilitation	TRAUMATIC BRAIN-INJURY; HEALTH; REHABILITATION	Objective: We present a multistep process for identifying priority research areas in rehabilitation and long-term care of traumatic brain-injured (TBI) patients. In particular, we aimed to (1) identify which stakeholders should be involved; (2) identify what methods are appropriate; (3) examine different criteria for the generation of research priority areas; and (4) test the feasibility of linkage and exchange among researchers, decision makers, and other potential users of the research. Study Design and Setting: Potential research questions were identified and developed using an initial scoping meeting and preliminary literature search, followed by a facilitated mapping workshop and an online survey. Identified research questions were then prioritized against specific criteria (clinical importance, novelty, and controversy). Existing evidence was then mapped to the high-priority questions using usual processes for search, screening, and selection. A broad range of stakeholders were then brought together at a forum to identify priority research themes for future research investment. Using clinical and research leaders, smaller targeted planning workshops prioritized specific research projects for each of the identified themes. Results: Twenty-six specific questions about TBI rehabilitation were generated, 14 of which were high priority. No one method identified all high-priority questions. Methods that relied solely on the views of clinicians and researchers identified fewer high-priority questions compared with methods that used broader stakeholder engagement. Evidence maps of these high-priority questions yielded a number of evidence gaps. Priority questions and evidence maps were then used to inform a research forum, which identified 12 priority themes for future research. Conclusion: Our research demonstrates the value of a multistep and multimethod process involving many different types of stakeholders for prioritizing research to improve the rehabilitation outcomes of people who have suffered TBI. Enhancing stakeholder representation can be augmented using a combination of methods and a process of linkage and exchange. This process can inform decisions about prioritization of research areas. (C) 2013 Elsevier Inc. All rights reserved.	[Clavisi, Ornella; Bragge, Peter; Tavender, Emma; Gruen, Russell L.] Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Clavisi, Ornella; Bragge, Peter; Tavender, Emma; Gruen, Russell L.] Monash Univ, Melbourne, Vic 3004, Australia; [Turner, Tari] Monash Univ, Australasian Cochrane Ctr, Dept Epidemiol & Preventat Med, Melbourne, Vic 3004, Australia	Gruen, RL (corresponding author), Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Level 4,89 Commercial Rd, Melbourne, Vic 3004, Australia.	russell.gruen@monash.edu		Bragge, Peter/0000-0003-0745-5131; Turner, Tari/0000-0002-7990-1623; Tavender, Emma/0000-0002-7230-712X	Victorian Transport Accident Commission; Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	The Global Evidence Mapping Initiative is supported by the Victorian Transport Accident Commission. The authors thank Jason Wasiak, Loyal Pattuwage, Marisa Chau, Marion Cincotta, Haifa Sekkouah, and Anne Parkhill for their valuable input to this work. R.L.G. is supported by a Practitioner Fellowship from the Australian National Health and Medical Research Council.	Anderson Stuart, 2008, Health Res Policy Syst, V6, P7, DOI 10.1186/1478-4505-6-7; [Anonymous], 2000, Health Policy Plan, V15, P130; Arvidsson E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-71; BATTISTA RN, 1995, CAN MED ASSOC J, V153, P1233; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Doyle J, 2005, J EPIDEMIOL COMMUN H, V59, P193, DOI 10.1136/jech.2003.019547; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Institute of Medicine, 2008, KNOW WHAT WORKS HLTH; Kapiriri Lydia, 2002, Health Expect, V5, P55; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lomas J, 2003, MILBANK Q, V81, P363, DOI 10.1111/1468-0009.t01-1-00060; McKinlay E, 2001, CLIN PRACTICE GUIDEI; Noorani HZ, 2007, INT J TECHNOL ASSESS, V23, P310, DOI 10.1017/S026646230707050X; Oliver S, 2006, EVALUATION PUBLIC IN; Oxman Andrew D, 2006, Health Res Policy Syst, V4, P14, DOI 10.1186/1478-4505-4-14; Sassi F, 2003, HEALTH POLICY, V63, P141, DOI 10.1016/S0168-8510(02)00061-1; Sibbald SL, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-43; SitthiAmorn C, 1995, INT J TECHNOL ASSESS, V11, P663, DOI 10.1017/S0266462300009090; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; VANDEVEN A, 1971, ACAD MANAGE J, V14, P203, DOI 10.2307/255307; World Health Organization, 2008, ICF BROWS; World Health Organization ( WHO ), 2002, COMM LANG FUNCT DIS; YANG J M, 1987, Yonsei Medical Journal, V28, P60	24	26	26	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	MAY	2013	66	5					496	502		10.1016/j.jclinepi.2012.04.002			7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	125QW	WOS:000317557400007	22819249				2021-06-18	
J	Poropatich, R; Lai, E; McVeigh, F; Bashshur, R				Poropatich, Ronald; Lai, Eva; McVeigh, Francis; Bashshur, Rashid			The U.S. Army Telemedicine and m-Health Program: Making a Difference at Home and Abroad	TELEMEDICINE AND E-HEALTH			English	Article						behavioral health; mobile health; cell phone; teleconsultation; synchronous; asynchronous; telemedicine; telehealth; military	TRAUMATIC BRAIN-INJURY; TELEMENTAL HEALTH; SERVICE DELIVERY; MILITARY; TECHNOLOGY	This article highlights the deployment of telemedicine by the U.S. Army through the various echelons of care and in overseas locations, including range and scope of health services provided by telemedicine in a challenging environment. This is followed by a discussion of technological developments advances in mobile communications likely to change the practice of telemedicine in the military from limited fixed-point access to a highly mobile individual with handheld communication devices.	[Poropatich, Ronald; Lai, Eva; McVeigh, Francis] USA, Telemed & Adv Technol Res Ctr, Med Res & Mat Command, Ft Detrick, MD USA; [Poropatich, Ronald] Univ Pittsburgh, Ctr Mil Med Res, Pittsburgh, PA 15219 USA; [Lai, Eva] Johns Hopkins Univ, Baltimore, MD USA; [Bashshur, Rashid] Univ Michigan, Ann Arbor, MI 48109 USA	Poropatich, R (corresponding author), Univ Pittsburgh, Ctr Mil Med Res Hlth Sci, Bridgeside Point 2,Room 410 450 Technol Dr, Pittsburgh, PA 15219 USA.	rkp19@pitt.edu					[Anonymous], 1995, JOINT PUBLICATION, V4-02; [Anonymous], 2010, TELEBEHAVIORAL HLTH; Blank Elizabeth, 2011, J Surg Orthop Adv, V20, P50; Doarn CR, 2012, TELEMED E-HEALTH, V18, P654, DOI 10.1089/tmj.2012.0123; Doarn CR, 2011, TELEMED E-HEALTH, V17, P501, DOI 10.1089/tmj.2011.0088; Doarn Charles R, 2010, Telemed J E Health, V16, P373, DOI 10.1089/tmj.2010.0009; Girard P, 2007, J REHABIL RES DEV, V44, P1017, DOI 10.1682/JRRD.2006.12.0174; Gros DF, 2011, CONTEMP CLIN TRIALS, V32, P122, DOI 10.1016/j.cct.2010.10.003; Hsu J., 2011, 23KM0DPH11 USACHPPM; Jones MD, 2012, PSYCHOL SERV, V9, P132, DOI 10.1037/a0026709; Kosaraju A, 2010, TELEMED J E-HEALTH, V16, P219, DOI 10.1089/tmj.2009.0095; Lam DM, 2008, TELEMED J E-HEALTH, V14, P946, DOI 10.1089/tmj.2008.0018; Mahnke CB, 2011, TELEMED E-HEALTH, V17, P35, DOI 10.1089/tmj.2010.0089; McManus J, 2008, PREHOSP DISASTER MED, V23, P210, DOI 10.1017/S1049023X0006489X; Mines MJ, 2011, AM J OPHTHALMOL, V152, P126, DOI 10.1016/j.ajo.2011.01.028; Morgan AE, 2009, MIL MED, V174, P1055, DOI 10.7205/MILMED-D-04-6308; Morgan Jeffrey, 2012, Stud Health Technol Inform, V173, P294; Nieves JE, 2009, MIL MED, V174, pXXI; Poropatich RK, 2006, TELEMED J E-HEALTH, V12, P396, DOI 10.1089/tmj.2006.12.396; Rand ER, 2009, MIL MED, V174, P1144, DOI 10.7205/MILMED-D-00-2309; Schmidt T, 2011, MIL MED, V176, P1417, DOI 10.7205/MILMED-D-11-00237; Stetz MC, 2011, J CLIN PSYCHOL MED S, V18, P188, DOI 10.1007/s10880-011-9246-3; Yurkiewicz IR, 2012, NEUROLOGY, V79, P1237, DOI 10.1212/WNL.0b013e31826aac33	23	26	26	0	15	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED E-HEALTH	Telemed. e-Health	MAY	2013	19	5					380	386		10.1089/tmj.2012.0297			7	Health Care Sciences & Services	Health Care Sciences & Services	130FR	WOS:000317899200013	23537383				2021-06-18	
J	Bolorunduro, OB; Haider, AH; Oyetunji, TA; Khoury, A; Cubangbang, M; Haut, ER; Greene, WR; Chang, DC; Cornwell, EE; Siram, SM				Bolorunduro, Oluwaseyi B.; Haider, Adil H.; Oyetunji, Tolulope A.; Khoury, Amal; Cubangbang, Maricel; Haut, Elliot R.; Greene, Wendy R.; Chang, David C.; Cornwell, Edward E., III; Siram, Suryanarayana M.			Disparities in trauma care: are fewer diagnostic tests conducted for uninsured patients with pelvic fracture?	AMERICAN JOURNAL OF SURGERY			English	Article						Pelvic fracture; Disparities; Uninsured; Procedures; Trauma; Diagnostic tests	INSURANCE STATUS; MASSACHUSETTS; MORTALITY; ASSOCIATION; OUTCOMES; CHILDREN; ACCESS	BACKGROUND: Research from other medical specialties suggests that uninsured patients experience treatment delays, receive fewer diagnostic tests, and have reduced health literacy when compared with their insured counterparts. We hypothesized that these disparities in interventions would not be present among patients experiencing trauma. Our objective was to examine differences in diagnostic and therapeutic procedures administered to patients undergoing trauma with pelvic fractures using a national database. METHODS: A retrospective analysis was conducted using the National Trauma Data Bank (NTDB), 2002 to 2006. Patients aged 18 to 64 years who experienced blunt injuries with pelvic fractures were analyzed. Patients who were dead on arrival, those with an injury severity score (ISS) less than 9, those with traumatic brain injury, and patients with burns were excluded. The likelihood of the uninsured receiving select diagnostic and therapeutic procedures was compared with the same likelihood in the insured. Multivariate analysis for mortality was conducted, adjusting for age, sex, race, ISS, presence of shock, Glasgow Coma Scale (GCS) motor score, and mechanism of injury. RESULTS: Twenty-one thousand patients met the inclusion criteria: 82% of these patients were insured and 18% were uninsured. There was no clinical difference in ISSs (21 vs 20), but the uninsured were more likely to present in shock (P < .001). The mortality rate in the uninsured was 11.6% vs 5.0% in the insured (P < .001). The uninsured were less likely to receive vascular ultrasonography (P - .01) and computed tomography (CT) of the abdomen (P < .005). There was no difference in the rates of CT of the thorax and abdominal ultrasonography, but the uninsured were more likely to receive radiographs. There was no difference in exploratory laparotomy and fracture reduction, but uninsured patients were less likely to receive transfusions, central venous pressure (CVP) monitoring, or arterial catheterization for embolization. Insurance-based disparities were less evident in level 1 trauma centers. CONCLUSIONS: Uninsured patients with pelvic fractures get fewer diagnostic procedures compared with their insured counterparts; this disparity is much greater for more invasive and resource-intensive tests and is less apparent in level 1 trauma centers. Differences in care that patients receive after trauma may be 1 of the mechanisms that leads to insurance disparities in outcomes after trauma. (C) 2013 Elsevier Inc. All rights reserved.	[Bolorunduro, Oluwaseyi B.; Oyetunji, Tolulope A.; Khoury, Amal; Cubangbang, Maricel; Greene, Wendy R.; Chang, David C.; Cornwell, Edward E., III; Siram, Suryanarayana M.] Howard Univ, Coll Med, Howard Hopkins Ctr Outcomes Res, Dept Surg, Washington, DC 20060 USA; [Haider, Adil H.; Haut, Elliot R.] Johns Hopkins Sch Med, Ctr Surg Trials & Outcomes Res, Baltimore, MD USA	Bolorunduro, OB (corresponding author), Howard Univ, Coll Med, Howard Hopkins Ctr Outcomes Res, Dept Surg, 2041 Georgia Ave Northwest, Washington, DC 20060 USA.	obolorun@gmail.com	Haut, Elliott R./J-3948-2019	Oyetunji, Tolulope/0000-0003-3039-7195			Center for American Progress, MOR AM LOS HLTH INS; DeNavas-Walt Carmen, 2008, INC POV HLTH INS COV; Downing SR, 2011, J TRAUMA, V70, P130, DOI 10.1097/TA.0b013e3182032b34; Fowler RA, 2010, AM J RESP CRIT CARE, V181, P1003, DOI 10.1164/rccm.200902-0281ST; Greene WR, 2010, AM J SURG, V199, P554, DOI 10.1016/j.amjsurg.2009.11.005; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Hadley J, 2007, JAMA-J AM MED ASSOC, V297, P1774; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Halpern MT, 2009, ANN SURG ONCOL, V16, P562, DOI 10.1245/s10434-008-0205-7; *IOM, 2002, CAR COV TOO LITTL TO; Oyetunji TA, 2011, J SURG RES, V165, pE37, DOI 10.1016/j.jss.2010.09.025; Pierce CA, 2008, J TRAUMA, V64, P932, DOI 10.1097/TA.0b013e318166b808; Quintana JM, 1997, INT J QUAL HEALTH C, V9, P419, DOI 10.1093/intqhc/9.6.419; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; Zhu J, 2010, J GEN INTERN MED, V25, P1356, DOI 10.1007/s11606-010-1482-y	17	26	26	0	2	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610			AM J SURG	Am. J. Surg.	APR	2013	205	4					365	370		10.1016/j.amjsurg.2012.10.026			6	Surgery	Surgery	123UV	WOS:000317417600001	23375757				2021-06-18	
J	Huang, L; Coats, JS; Mohd-Yusof, A; Yin, YF; Assaad, S; Muellner, MJ; Kamper, JE; Hartman, RE; Dulcich, M; Donovan, VM; Oyoyo, U; Obenaus, A				Huang, Lei; Coats, Jacqueline S.; Mohd-Yusof, Alena; Yin, Yufang; Assaad, Sarah; Muellner, Michael J.; Kamper, Joel E.; Hartman, Richard E.; Dulcich, Melissa; Donovan, Virginia M.; Oyoyo, Udo; Obenaus, Andre			Tissue vulnerability is increased following repetitive mild traumatic brain injury in the rat	BRAIN RESEARCH			English	Article						Concussion; Magnetic resonance imaging; Behavior; Cumulative injury; Gliosis; Rat	PROFESSIONAL FOOTBALL PLAYERS; CLOSED-HEAD INJURY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; AXONAL INJURY; NEUROLOGICAL IMPAIRMENT; COMPUTED-TOMOGRAPHY; MICE; DEFICITS; SPORTS	Repetitive mild traumatic brain injury (rmTBI) is an important medical concern for active sports and military personnel. Multiple mild injuries may exacerbate tissue damage resulting in cumulative brain injury and poor functional recovery. In the present study, we investigated the time course of brain vulnerability to rmTBI in a rat model of mild cortical controlled impact. An initial mild injury was followed by a second injury unilaterally at an interval of 1, 3, or 7 days. RmTBI animals were compared to single mTBI and sham treated animals. Neuropathology was assessed using multi-modal magnetic resonance imaging (MRI), followed by ex vivo tissue immunohistochemistry. Neurological and behavioral outcomes were evaluated in a subset of animals receiving rmTBI 3 days apart and shams. RmTBI 1 or 3 days apart but not 7 days apart revealed significantly exacerbated MRI-definable lesion volumes compared to single mTBI and shams. Increases in cortical tissue damage, extravascular iron and glial activation assessed by histology/immunohistochemistry correlated with in vivo MRI findings where shorter intervals (1 or 3 days apart) resulted in greater tissue pathology. There were no neurological deficits associated with rmTBI 3 day animals. At 1 mo post-injury, animals with rmTBI 3 days apart showed reduced exploratory behaviors and subtle spatial learning memory impairments were observed. Collectively, our findings suggest that the mildly-impacted brain is more vulnerable to repetitive injury when delivered within 3 days following initial mTBI. (c) 2012 Elsevier B.V. All rights reserved.	[Huang, Lei] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Huang, Lei] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; [Coats, Jacqueline S.; Mohd-Yusof, Alena; Yin, Yufang; Assaad, Sarah; Muellner, Michael J.; Obenaus, Andre] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA; [Kamper, Joel E.; Hartman, Richard E.; Dulcich, Melissa] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Donovan, Virginia M.; Obenaus, Andre] Univ Calif Riverside, Dept Cell Mol & Dev Biol, Riverside, CA 92521 USA; [Oyoyo, Udo] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA; [Obenaus, Andre] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA	Obenaus, A (corresponding author), Loma Linda Univ, Dept Pediat, 1175 Campus St,CSPA1010, Loma Linda, CA 92354 USA.	aobenaus@llu.edu	Hartman, Richard/C-5767-2008; Kamper, Joel/V-2450-2019	Hartman, Richard/0000-0001-9235-3169; Kamper, Joel/0000-0001-5098-5176	Department of Defense (DCMRP) [DR080470]; National Science Foundation (IGERT: Video Bioinformatics Grant) [DGE 0903667]; Walter E. McPherson Scholarship	This study was supported by funding from Department of Defense (DCMRP #DR080470, AO) and in part by a National Science Foundation (IGERT: Video Bioinformatics Grant DGE 0903667; VMD is an IGERT Fellow) as well as a Walter E. McPherson Scholarship (MJM).	Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lee Bruce, 2005, NeuroRx, V2, P372; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; Masdeu J C, 1994, J Neuroimaging, V4, P177; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Recker R, 2009, J CEREBR BLOOD F MET, V29, P1305, DOI 10.1038/jcbfm.2009.56; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Sousa JC, 2004, J NEUROCHEM, V88, P1052, DOI 10.1046/j.1471-4159.2003.02309.x; Theye Fred, 2004, Clin Med Res, V2, P165; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tokutomi T, 1997, ACT NEUR S, V70, P80; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	51	26	26	0	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 7	2013	1499						109	120		10.1016/j.brainres.2012.12.038			12	Neurosciences	Neurosciences & Neurology	113ZX	WOS:000316710300010	23276495				2021-06-18	
J	Evans, CT; St Andre, JR; Pape, TLB; Steiner, ML; Stroupe, KT; Hogan, TP; Weaver, FM; Smith, BM				Evans, Charlesnika T.; St Andre, Justin R.; Pape, Theresa L. -B.; Steiner, Monica L.; Stroupe, Kevin T.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.			An Evaluation of the Veterans Affairs Traumatic Brain Injury Screening Process Among Operation Enduring Freedom and/or Operation Iraqi Freedom Veterans	PM&R			English	Article							POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN; SYMPTOMS; HEALTH; CARE	Objective: To describe the early results of the U.S. Department of Veterans Affairs (VA) screening program for traumatic brain injury (TBI) and to identify patient and facility characteristics associated with receiving a TBI screen and results of the screening. Design: National retrdspective cohort study. Setting: VA Medical facilities. Patients: A total of 170,681 Operation Enduring Freedom and/or Operation Iraqi Freedom (OEF/OIF) Veterans who sought care at VA medical facilities from April 2007 to September 30, 2008. Methods: Data were abstracted from VA administrative and operational databases, including patient demographics, facility characteristics, and outcomes. Main Outcome Measurements: The main outcomes were receipt of and results of the TBI screen. Results: The majority of veterans eligible received the TBI screen (91.6%). Screening rates varied by patient and facility characteristics. In all, 25% of screened veterans had probable TBI exposure, in which the majority. of the exposures were blasts (85.0%). The rate of a positive TBI screen was 20.5% for the screened cohort. Male gender, service in the army, multiple deployments, and mental health diagnoses in the previous year were associated with a positive screen. Conclusions: TBI screening rates are high in VA; concomitant mental health diagnoses were highly prevalent in individuals with positive TBI screens. These data indicate that there will be a significant need for long-term health care services for veterans with TBI symptomatology. PM R 2013;5:210-220	[Evans, Charlesnika T.] Edward Hines Jr Vet Affairs VA Hosp, Dept VA, Ctr Management Complex Chron Care, Hines, IL 60141 USA; [Evans, Charlesnika T.] Spinal Cord Injury Qual Enhancement Res Initiat S, Dept VA, Hines, IL USA; [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA; [St Andre, Justin R.; Pape, Theresa L. -B.; Stroupe, Kevin T.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.] Hines VA Hosp, Ctr Management Complex Chron Care, Dept VA, Hines, IL USA; [St Andre, Justin R.; Hogan, Timothy P.; Weaver, Frances M.; Smith, Bridget M.] SCI QUERI, Dept VA, Hines, IL USA; [St Andre, Justin R.] Hlth Res & Educ Trust, Chicago, IL USA; [Pape, Theresa L. -B.; Steiner, Monica L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept VA, Hines, IL 60141 USA; [Pape, Theresa L. -B.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Stroupe, Kevin T.; Weaver, Frances M.; Smith, Bridget M.] Loyola Univ Chicago, Stritch Sch Med, Program Hlth Serv Res, Maywood, IL USA; [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA; [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, eHlth QUERI, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA; [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA	Evans, CT (corresponding author), Edward Hines Jr Vet Affairs VA Hosp, Dept VA, Ctr Management Complex Chron Care, 5000 S 5th Ave, Hines, IL 60141 USA.	Charlesnika.Evans@va.gov	Weaver, Frances/S-1540-2019	Bender Pape, Theresa/0000-0001-7738-5963			Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Bergquist TF, 2010, TELEMED J E-HEALTH, V16, P417, DOI 10.1089/tmj.2009.0118; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Carey K, 2000, HEALTH ECON, V9, P435, DOI 10.1002/1099-1050(200007)9:5<435::AID-HEC523>3.0.CO;2-Z; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; HINES EJ, 2003, VIREC RES USER GUIDE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Maguen S, 2012, J PSYCHIATR RES, V46, P311, DOI 10.1016/j.jpsychires.2011.11.007; Nemeroff CB, 2006, J PSYCHIATR RES, V40, P1, DOI 10.1016/j.jpsychires.2005.07.005; Sayer NA, 2011, J HEAD TRAUMA REHAB, V26, P454, DOI 10.1097/HTR.0b013e3181ff393c; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Stroupe KT, 2010, J REHABIL RES DEV, V47, P781, DOI 10.1682/JRRD.2009.08.0122; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	21	26	26	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482			PM&R	PM&R	MAR	2013	5	3					210	220		10.1016/j.pmrj.2012.12.004			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	110HN	WOS:000316433300008	23375630				2021-06-18	
J	Matuseviciene, G; Borg, J; Stalnacke, BM; Ulfarsson, T; de Boussard, C				Matuseviciene, Giedre; Borg, Jorgen; Stalnacke, Britt-Marie; Ulfarsson, Trandur; de Boussard, Catharina			Early intervention for patients at risk for persisting disability after mild traumatic brain injury: A randomized, controlled study	BRAIN INJURY			English	Article						Mild brain injury; intervention; traumatic brain injury; concussion	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; ROUTINE FOLLOW-UP; POSTCONCUSSION SYNDROME; CONTROLLED-TRIAL; DEPRESSION; PREDICTION; QUESTIONNAIRE; MODERATE; IMPACT	Study objective: To investigate the effect of an early intervention visit in addition to written information and treatment as usual for patients with an estimated high risk for persisting disability after a mild traumatic brain injury (MTBI). Research design: Randomized controlled trial. Methods: One hundred and seventy-three patients, aged 15-70 years with a Glasgow Coma Scale of 14-15 were included. All received written information about MTBI. Ninety-seven patients who reported three or more symptoms according to the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) at 10 days after the injury were considered as high-risk patients and were randomized to either early visit to a doctor or to treatment as usual (TAU); all patients including the 76 low-risk patients were followed-up at 3 months. Completion rate was 83%. Outcome measures included RPQ and the Hospital Anxiety and Depression Scale. Results: RPQ symptoms decreased significantly in both randomized groups, but were not significantly different in the groups at 3 months. At 3 months, anxiety and depression scores did not differ between groups. Conclusions: An early intervention, offered to patients with an estimated high risk for persisting disability, had no additional effect on symptom level at 3 months after MTBI as compared to TAU.	[Matuseviciene, Giedre; Borg, Jorgen; de Boussard, Catharina] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden; [Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, Umea, Sweden; [Ulfarsson, Trandur] Sahlgrens Univ Hosp, Dept Rehabil Med, Gothenburg, Sweden	Matuseviciene, G (corresponding author), Danderyds Sjukhus AB, Dept Rehabil Med, S-18288 Stockholm, Sweden.	giedre.matuseviciene@ds.se		Borg, Jorgen/0000-0002-2372-7478	AFA insurance [060083]	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was supported by grants from AFA insurance, No 060083. The funders had no input to the study design or analysis.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lannsjo M, 2012, EUROPEAN J NEUROLOGY; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organization, 1992, ICD 10 CLASS MENT BE; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	26	26	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2013	27	3					318	324		10.3109/02699052.2012.750740			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	096OG	WOS:000315413400009	23438351				2021-06-18	
J	Sun, YX; Dai, DK; Liu, R; Wang, T; Luo, CL; Bao, HJ; Yang, R; Feng, XY; Qin, ZH; Chen, XP; Tao, LY				Sun, Yu-Xia; Dai, Ding-Kun; Liu, Ran; Wang, Tao; Luo, Cheng-Liang; Bao, Hai-Jun; Yang, Rui; Feng, Xue-Ying; Qin, Zheng-Hong; Chen, Xi-Ping; Tao, Lu-Yang			Therapeutic effect of SN50, an inhibitor of nuclear factor-kappa B, in treatment of TBI in mice	NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; NF-kappa B; Apoptosis; TNF-alpha; Cathepsin B; Caspase-3	TRAUMATIC BRAIN-INJURY; CELL-DEATH MECHANISMS; INDUCED APOPTOSIS; ACTIVATION; MITOCHONDRIA; NEUROPROTECTION; CONTRIBUTES	NF-kappa B upregulation has been demonstrated in neurons and glial cells in response to experimental injury and neuropathological disorders, where it has been related to both neurodegenerative and neuroprotective activities. It has been generally recognized that NF-kappa B plays important roles in the regulation of apoptosis and inflammation as well as innate and adaptive immunity. However, the regulatory mechanism of NF-kappa B in apoptosis remained to be determined. The present study sought to first investigate the effect of a NF-kappa B inhibitor SN50, which inhibits NF-kappa B nuclear translocation, on cell death and behavioral deficits in our mice traumatic brain injury (TBI) models. Additionally, we tried to elucidate the possible mechanisms of the therapeutic effect of SN50 through NF-kappa B regulating apoptotic and inflammatory pathway in vivo. Encouragingly, the results showed that pretreatment with SN50 remarkably attenuated TBI-induced cell death (detected by PI labeling), cumulative loss of cells (detected by lesion volume), and motor and cognitive dysfunction (detected by motor test and Morris water maze). To analyze the mechanism of SN50 on cell apoptotic and inflammatory signaling pathway, we thus assessed expression levels of TNF-alpha, cathepsin B and caspase-3, Bid cleavage and cytochrome c release in SN50-pretreated groups compared with those in saline vehicle groups. The results imply that through NF-kappa B/TNF-alpha/cathepsin networks SN50 may contribute to TBI-induced extrinsic and intrinsic apoptosis, and inflammatory pathways, which partly determined the fate of injured cells in our TBI model.	[Sun, Yu-Xia; Dai, Ding-Kun; Liu, Ran; Wang, Tao; Luo, Cheng-Liang; Bao, Hai-Jun; Yang, Rui; Feng, Xue-Ying; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Qin, Zheng-Hong] Soochow Univ, Lab Aging & Nerves Dis, Dept Pharmacol, Suzhou 215123, Peoples R China; [Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Lab Aging & Nerves Dis, Suzhou 215123, Peoples R China; [Chen, Xi-Ping; Tao, Lu-Yang] Minist Justice, Inst Forens Sci, Shanghai Key Lab Forens Med, Shanghai, Peoples R China	Chen, XP (corresponding author), Soochow Univ, Dept Forens Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30571909, 30872666, 30870808, 81172911]; Shanghai Forensic Key Lab Foundation [KF0904, KF1005]	The work was supported by the National Science Foundation of China (No. 30571909, 30872666, 30870808, 81172911) and the Shanghai Forensic Key Lab Foundation (No. KF0904, KF1005).	Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ellen Niederberger, 2010, EXPERT REV PROTEOMIC, V7, P189; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferlazzo N, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-62; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Luo CL, 2010, NEURAL REGEN RES, V5, P706, DOI 10.3969/j.issn.1673-5374.2010.09.012; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Olga Sanz, 2002, J NEUROSCI RES, V67, P772; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 1998, MOL PHARMACOL, V53, P33; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Saika S, 2005, AM J PATHOL, V166, P1393, DOI 10.1016/S0002-9440(10)62357-7; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tao LY, 2003, J FORENSIC MED, V19, P4; Tardy C, 2006, BBA-REV CANCER, V1765, P101, DOI 10.1016/j.bbcan.2005.11.003; Uberti D, 2004, BIOCHEM PHARMACOL, V67, P1743, DOI 10.1016/j.bcp.2004.01.012; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Walker PA, 2010, STEM CELLS DEV, V19, P867, DOI 10.1089/scd.2009.0188; Werneburg N, 2004, AM J PHYSIOL-GASTR L, V287, pG436, DOI 10.1152/ajpgi.00019.2004; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	34	26	27	0	9	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAR	2013	34	3					345	355		10.1007/s10072-012-1007-z			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	098RL	WOS:000315566300011	22437493				2021-06-18	
J	Weber, AF; Mihalik, JP; Register-Mihalik, JK; Mays, S; Prentice, WE; Guskiewicz, KM				Weber, Amanda Friedline; Mihalik, Jason P.; Register-Mihalik, Johna K.; Mays, Sally; Prentice, William E.; Guskiewicz, Kevin M.			Dehydration and Performance on Clinical Concussion Measures in Collegiate Wrestlers	JOURNAL OF ATHLETIC TRAINING			English	Article						balance; mild traumatic brain injury; neurocognitive test; SCAT2	POSTURAL STABILITY; HYDRATION STATUS; WEIGHT-LOSS; HIGH-SCHOOL; URINARY INDEXES; INJURIES; EXERCISE; DEPRIVATION; SYMPTOMS; DURATION	Context: The effects of dehydration induced by wrestling-related weight-cutting tactics on clinical concussion outcomes, such as neurocognitive function, balance performance, and symptoms, have not been adequately studied. Objective: To evaluate the effects of dehydration on the outcome of clinical concussion measures in National Collegiate Athletic Association Division I collegiate wrestlers. Design: Repeated-measures design. Setting: Clinical research laboratory. Patients or Other Participants: Thirty-two Division I healthy collegiate male wrestlers (age = 20.0 +/- 1.4 years; height 175.0 +/- 7.5 cm; baseline mass 79.2 +/- 12.6 kg). Intervention(s): Participants completed preseason concussion baseline testing in early September. Weight and urine samples were also collected at this time. All participants reported to prewrestling practice and postwrestling practice for the same test battery and protocol in mid-October. They had begun practicing weight-cutting tactics a day before prepractice and postpractice testing. Differences between these measures permitted us to evaluate how dehydration and weight-cutting tactics affected concussion measures. Main Outcome Measures: Sport Concussion Assessment Tool 2 (SCAT2), Balance Error Scoring System, Graded Symptom Checklist, and Simple Reaction Time scores. The Simple Reaction Time was measured using the Automated Neuropsychological Assessment Metrics. Results: The SCAT2 measurements were lower at prepractice (P = .002) and postpractice (P < .001) when compared with baseline. The BESS error scores were higher at postpractice when compared with baseline (P = .015). The GSC severity scores were higher at prepractice (P = .011) and postpractice (P < .001) than at baseline and at postpractice when than at prepractice (P = .003). The number of Graded Symptom Checklist symptoms reported was also higher at prepractice (P = .036) and postpractice (P < .001) when compared with baseline, and at postpractice when compared with prepractice (P = .003). Conclusions: Our results suggest that it is important for wrestlers to be evaluated in a euhydrated state to ensure that dehydration is not influencing the outcome of the clinical measures.	[Weber, Amanda Friedline; Mihalik, Jason P.; Register-Mihalik, Johna K.; Prentice, William E.; Guskiewicz, Kevin M.] WakeMed Hlth & Hosp, Dept Exercise & Sport Sci, Matthew A Geller Sport Related Traumat Brain Inju, Raleigh, NC USA; [Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Clin Res Unit, Emergency Serv Inst, Raleigh, NC USA; [Mays, Sally] Univ N Carolina, Chapel Hill, NC 27599 USA	Mihalik, JP (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Register-Mihalik, Johna/0000-0002-4229-4743; Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Agel J, 2007, J ATHL TRAINING, V42, P303; Armstrong LE, 1998, INT J SPORT NUTR, V8, P345, DOI 10.1123/ijsn.8.4.345; ARMSTRONG LE, 1994, INT J SPORT NUTR, V4, P265, DOI 10.1123/ijsn.4.3.265; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Choma CW, 1998, MED SCI SPORT EXER, V30, P746, DOI 10.1097/00005768-199805000-00016; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jarrett GJ, 1998, AM J SPORT MED, V26, P674, DOI 10.1177/03635465980260051301; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2001, BRIT J SPORT MED, V35, P209, DOI 10.1136/bjsm.35.4.209-a; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Oppliger RA, 2003, INT J SPORT NUTR EXE, V13, P29, DOI 10.1123/ijsnem.13.1.29; Oppliger RA, 2005, INT J SPORT NUTR EXE, V15, P236, DOI 10.1123/ijsnem.15.3.236; Patel AV, 2007, J ATHL TRAINING, V42, P66; Petri NM, 2006, CROAT MED J, V47, P855; Popowski LA, 2001, MED SCI SPORT EXER, V33, P747; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shirreffs SM, 2004, BRIT J NUTR, V91, P951, DOI 10.1079/BJN20041149; Szinnai G, 2005, AM J PHYSIOL-REG I, V289, pR275, DOI 10.1152/ajpregu.00501.2004; Vicente R., 2004, NCAA SPORTS SPONSORS; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Wroble RR, 1998, MED SCI SPORT EXER, V30, P625, DOI 10.1097/00005768-199804000-00022; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	34	26	27	0	36	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2013	48	2					153	160		10.4085/1062-6050-48.1.07			8	Sport Sciences	Sport Sciences	211GP	WOS:000323894300002	23672379	Green Published, Bronze			2021-06-18	
J	Hennelly, KE; Mannix, R; Nigrovic, LE; Lee, LK; Thompson, KM; Monuteaux, MC; Proctor, M; Schutzman, S				Hennelly, Kara E.; Mannix, Rebekah; Nigrovic, Lise E.; Lee, Lois K.; Thompson, Kimberly M.; Monuteaux, Michael C.; Proctor, Mark; Schutzman, Sara			Pediatric Traumatic Brain Injury and Radiation Risks: A Clinical Decision Analysis	JOURNAL OF PEDIATRICS			English	Article							QUALITY-OF-LIFE; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; INTRACRANIAL INJURY; UNITED-STATES; EMERGENCY-DEPARTMENTS; IDENTIFYING CHILDREN; BREAST-CANCER; HEALTH; CT	Objective To determine the optimal imaging strategy for young children with minor head injury considering health-related quality of life and radiation risk. In children with minor head trauma, the risk of missing a clinically important traumatic brain injury (ciTBI) must be weighed against the risk of radiation-induced malignancy from computed tomography (CT) to assess impact on public health. Study design We included children <2 years old with minor blunt head trauma defined by a Glasgow Coma Scale score of 14-15. We used decision analysis to model a CT-all versus no-CT strategy and assigned values to clinical outcomes based on a validated health-related quality of life scale: (1) baseline health; (2) non-ciTBI; (3) ciTBI without neurosurgery, death, or intubation; and (4) ciTBI with neurosurgery, death, or intubation >24 hours with probabilities from a prospective study of 10 000 children. Sensitivity analysis determined the optimal management strategy over a range of ciTBI risk. Results The no-CT strategy resulted in less risk with the expected probability of a ciTBI of 0.9%. Sensitivity analysis for the probability of ciTBI identified 4.8% as the threshold above which CT all becomes the preferred strategy and shows that the threshold decreases with less radiation. The CT all strategy represents the preferred approach for children identified as high-risk. Conclusion Among children <2 years old with minor head trauma, the no-CT strategy is preferable for those at low risk, reserving CT for children at higher risk. (J Pediatr 2013;162:392-7).	[Hennelly, Kara E.; Mannix, Rebekah; Nigrovic, Lise E.; Lee, Lois K.; Monuteaux, Michael C.; Schutzman, Sara] Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Proctor, Mark] Childrens Hosp Boston, Div Neurosurg, Boston, MA 02115 USA; [Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL USA	Hennelly, KE (corresponding author), Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	kara.hennelly@childrens.harvard.edu	Monuteaux, Michael C/O-5032-2018; Mannix, Rebekah/AAD-8702-2020	Nigrovic, Lise/0000-0002-6369-3997; Thompson, Kimberly/0000-0002-0849-9147			Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Callahan Michael J, 2011, Pediatr Radiol, V41 Suppl 2, P488, DOI 10.1007/s00247-011-2099-y; Calonge N, 2009, ANN INTERN MED, V151, P716, DOI 10.7326/0003-4819-151-10-200911170-00008; Centers for Disease Control National Center for Injury Prevention and Control, 2006, TRAUM BRAIN INJ US A; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Frush Donald P, 2011, Pediatr Radiol, V41 Suppl 2, P483, DOI 10.1007/s00247-011-2098-z; Frush DP, 2003, RADIOLOGY, V229, P289, DOI 10.1148/radiol.2291030373; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Gordon JB, 2010, J AM COLL RADIOL, V7, P243, DOI 10.1016/j.jacr.2010.01.010; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Huda W, 1997, RADIOLOGY, V203, P417, DOI 10.1148/radiology.203.2.9114097; Kanal KM, 2011, J AM COLL RADIOL, V8, P242, DOI 10.1016/j.jacr.2010.11.005; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Korley FK, 2010, JAMA-J AM MED ASSOC, V304, P1465, DOI 10.1001/jama.2010.1408; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Luchette F, 2010, J TRAUMA, V69, P530; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2009, PEDIATR EMERG CARE, V25, P61, DOI 10.1097/PEC.0b013e318196e9c0; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Petersen C, 2008, BUNDESGESUNDHEITSBLA, V51, P629, DOI 10.1007/s00103-008-0536-3; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Seidenwurm D, 2010, J AM COLL RADIOL, V7, P265, DOI 10.1016/j.jacr.2010.01.001; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Stein SC, 2008, PEDIATR NEUROSURG, V44, P448, DOI 10.1159/000172967; Sun BC, 2007, ANN EMERG MED, V49; Woolf SH, 2010, JAMA-J AM MED ASSOC, V303, P162, DOI 10.1001/jama.2009.1989	47	26	27	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	FEB	2013	162	2					392	397		10.1016/j.jpeds.2012.07.018			6	Pediatrics	Pediatrics	071GX	WOS:000313579900034	22921827				2021-06-18	
J	Maerlender, A; Flashman, L; Kessler, A; Kumbhani, S; Greenwald, R; Tosteson, T; McAllister, T				Maerlender, A.; Flashman, L.; Kessler, A.; Kumbhani, S.; Greenwald, R.; Tosteson, T.; McAllister, T.			Discriminant Construct Validity of ImPACT (TM): A Companion Study	CLINICAL NEUROPSYCHOLOGIST			English	Article						Sports concussion; ImPACT; Contruct validity; Discriminant validity; Neuropsychological testing	NEUROPSYCHOLOGICAL MEASURES; CONCUSSION; VALIDATION	In a previous analysis of ImPACT scores relative to traditional neuropsychological tests (NP) and experimental tasks (Maerlender et al., 2010) we demonstrated convergent construct validity for the primary ImPACT test-score composites. A complete analysis of discriminant validity was not undertaken at that time. Here, test scores from the 54 collegiate football and hockey players were re-analyzed to specifically address the discriminant validity of the ImPACT composite scores using a multiply operationalized correlation matrix of multi-trait multi-method data. In the method used here, discriminant validity is determined by obtaining non-significant correlations between a target score when correlated with the average of the other trait measurements (multiply-operationalized multi-trait-mono-method analysis). Results showed that the ImPACT Verbal Memory (p=.044), Visual Memory (p=.006), and Visual Motor Speed (p=.000) scores were highly correlated with composites of the other scores, while the Reaction Time composite demonstrated adequate discriminant validity (p=.145). In comparison all of the NP composites showed good discrimination (all p-values >.05, except for Reaction Time p=.05). Thus the apparent lack of discriminability between three of four composite scores in this sample raises questions about using ImPACT composite scores to support specific construct-oriented interpretations. Taken together, the discriminant and convergent construct validity properties of ImPACT indicate construct sensitivity, but limited construct specificity.	[Maerlender, A.; Flashman, L.; McAllister, T.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Kessler, A.] Univ Wisconsin, Sch Med, Dept Psychiat, Madison, WI 53706 USA; [Greenwald, R.] Simbex LLC, Hanover, NH USA; [Greenwald, R.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Tosteson, T.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Lebanon, NH USA	Maerlender, A (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Art.Maerlender@dartmouth.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [BRP R01HD048638, RO1NS055020]; National Center for Medical Rehabilitation Research; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Health/National Institute of Neurological Disease and Stroke; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported by National Institute of Health BRP R01HD048638 National Center for Medical Rehabilitation Research, National Institute of Child Health and Development, and National Institute of Health RO1NS055020 National Institute of Health/National Institute of Neurological Disease and Stroke.	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Benedict R., 1997, BRIEF VISUOSPATIAL M; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Cole D., 1981, J COUNSELING CLIN PS, V34, P315; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Green P., 1995, MANUAL ORAL WORD MEM; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOWARD GS, 1992, J COUNS PSYCHOL, V39, P398, DOI 10.1037/0022-0167.39.3.398; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson G. L., 2003, NAT AC NEUR ANN M HO; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Smith A., 1991, SYMBOL DIGIT MODALIT; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2	19	26	26	0	24	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB 1	2013	27	2					290	299		10.1080/13854046.2012.744098			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	146MH	WOS:000319094700007	23317033	Green Published, Green Accepted			2021-06-18	
J	Rieger, BP; Lewandowski, LJ; Callahan, JM; Spenceley, L; Truckenmiller, A; Gathje, R; Miller, LA				Rieger, Brian P.; Lewandowski, Lawrence J.; Callahan, James M.; Spenceley, Laura; Truckenmiller, Adrea; Gathje, Rebecca; Miller, Laura A.			A prospective study of symptoms and neurocognitive outcomes in youth with concussion vs orthopaedic injuries	BRAIN INJURY			English	Article						concussion; mild traumatic brain injury; post-concussion; paediatric; outcome	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; POSTCONCUSSIVE SYMPTOMS; STANDARDIZED ASSESSMENT; HEAD-INJURIES; MILD; CHILDREN; MANAGEMENT; VALIDITY; IMPACT	Background: This study examined symptom reports and neurocognitive outcomes in children (8-17 years) with mild traumatic brain injury (mTBI) or orthopaedic injury (OI). Method: Children and parents were initially assessed upon presentation in the Emergency Department of a local hospital and again at 3 months. Children completed the Immediate Post-Concussion Assessment and Cognitive Testing battery (ImPACT) and parents completed the Behavior Rating Inventory of Executive Function (BRIEF). The Peabody Picture Vocabulary Test, 3rd edition (PPVT-III) was completed by the children at the 3-month assessment. Results: Children with mTBI reported more symptoms than the OI group initially, but did not differ from the OI group at 3 months. Both groups reported a higher than expected number of symptoms at 3 months. On the ImPACT, children with mTBI performed significantly worse than the OI on a visual memory test at both assessments. The OI group had higher levels of parent-reported executive dysfunction on the BRIEF at initial and 3-month assessments. Discussion: As expected, more post-concussion symptoms were initially reported by children and adolescents with mTBI vs orthopaedic injury, but there was no difference at 3 months. The BRIEF and ImPACT cognitive measures did not differentiate concussed subjects from controls, with the exception of concussed subjects' lower performance on a visual memory test at both initial assessment and at 3 months.	[Rieger, Brian P.] SUNY Upstate Med Univ, Dept Phys Med & Rehabil, Syracuse, NY 13210 USA; [Lewandowski, Lawrence J.] Syracuse Univ, Dept Psychol, Syracuse, NY USA; [Callahan, James M.] Childrens Hosp Philadelphia, Div Emergency Med, Dept Pediat, Philadelphia, PA USA; [Callahan, James M.] Univ Penn, Perelman Sch Med, Philadelphia, PA USA; [Spenceley, Laura; Truckenmiller, Adrea; Miller, Laura A.] Syracuse Univ, Dept Psychol, Syracuse, NY USA; [Gathje, Rebecca] Univ Nebraska Med Ctr, Omaha, NE USA	Rieger, BP (corresponding author), Univ Hosp Room 2104,750 E Adams St, Syracuse, NY 13210 USA.	riegerb@upstate.edu	Truckenmiller, Adrea/AAM-1840-2021; Meijer, Anna/K-5118-2016	Truckenmiller, Adrea/0000-0002-6101-6175; 	Hendricks Fund for Medical Research, SUNY Upstate Medical University	Dr Rieger is the Director of the Concussion Management Programme and Upstate Sports Concussion Centre at SUNY Upstate Medical University, Syracuse, NY. He earns occasional honoraria for speaking about concussion at medical, sports, and community forums. This study was funded by the Hendricks Fund for Medical Research, SUNY Upstate Medical University.	Alloway TP, 2009, CHILD PSYCHIAT HUM D, V40, P353, DOI 10.1007/s10578-009-0131-3; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gioia G. A., 2005, BRIEF BEHAV RATING I; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Iverson G.L., 2007, BRAIN INJURY MED PRI; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2003, NAT AC NEUR ANN M DA; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR., 2000, IMPACT IMMEDIATE POS; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	44	26	26	0	28	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2013	27	2					169	178		10.3109/02699052.2012.729290			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	083PX	WOS:000314478500005	23384214				2021-06-18	
J	Wang, XY; Tang, SS; Hu, M; Long, Y; Li, YQ; Liao, MX; Ji, H; Hong, H				Wang, Xiao Yun; Tang, Su Su; Hu, Mei; Long, Yan; Li, Yong Qi; Liao, Ming Xing; Ji, Hui; Hong, Hao			Leukotriene D4 induces amyloid-beta generation via CysLT(1)R-mediated NF-kappa B pathways in primary neurons	NEUROCHEMISTRY INTERNATIONAL			English	Article						LTD4; CysLT(1)R; NF-kappa B; BACE1; A beta	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; CYSTEINYL-LEUKOTRIENES; ASTROCYTE PROLIFERATION; MOUSE MODEL; SECRETASE; RECEPTORS; PROTEIN; BACE1; 5-LIPOXYGENASE	Although the pathogenesis of sporadic Alzheimer's disease (AD) is not clearly understood, neuroinflammation has been known to play a role in the pathogenesis of AD. To investigate a functional link between the neuroinflammation and AD, the effect of leukotriene D4 (LTD4), an inflammatory lipid mediator, was studied on amyloid-beta generation in vitro. Application of LTD4 to cell monolayers at concentrations up to 40 nM LTD4 caused increases in the A beta releases. Concentrations >= 40 nM LTD4 decreased neuronal viability. Application of 20 nM LTD4 caused a significant increase in A beta generation, as assessed by ELISA or Western blotting, without significant cytotoxicity. At this concentration, exposure of neurons to LTD4 for 24 h produced maximal effect in the A beta generation, and significant increases in the expressions of cysteinyl leukotriene 1 receptor (CysLT(1)R) and activity of beta- or gamma-secretase with complete abrogation by the selective CysLT(1)R antagonist pranlukast. Exposure of neurons to LTD4 for 1 h showed activation of NF-kappa B pathway, by assessing the levels of p65 or phospho-p65 in the nucleus, and either CysLT(1)R antagonist pranlukast or NF-kappa B inhibitor PDTC prevented the nuclear translocation of p65 and the consequent phosphorylation. PDTC also inhibited LTD4-induced elevations of beta- or gamma-secretase activity and All generation in vitro. Overall, our data show for the first time that LTD4 causes A beta production by enhancement of beta- or gamma-secretase resulting from activation of CysLT(1)R-mediated NF-kappa B signaling pathway. These findings provide a novel pathologic link between neuroinflammation and AD. (C) 2013 Elsevier Ltd. All rights reserved.	[Wang, Xiao Yun; Tang, Su Su; Hu, Mei; Long, Yan; Li, Yong Qi; Liao, Ming Xing; Ji, Hui; Hong, Hao] China Pharmaceut Univ, Dept Pharmacol, Lab Diabet & Brain Dis, Nanjing 210009, Jiangsu, Peoples R China	Hong, H (corresponding author), China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Jiangsu, Peoples R China.	haohongchina@hotmail.com			college graduate research and innovation projects; Jiangsu Province, China	This work was supported by the college graduate research and innovation projects funded by Jiangsu Province, China.	Ait-Ghezala G, 2007, EUR J NEUROSCI, V25, P1685, DOI 10.1111/j.1460-9568.2007.05424.x; Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184; Bisgaard H, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.56.s66.2.x; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Buggia-Prevot V, 2008, J BIOL CHEM, V283, P10037, DOI 10.1074/jbc.M706579200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capra V, 2004, PHARMACOL RES, V50, P1, DOI 10.1016/j.phrs.2003.12.012; Chami L, 2012, J BIOL CHEM, V287, P24573, DOI 10.1074/jbc.M111.333054; Chinnici CM, 2007, NEUROBIOL AGING, V28, P1457, DOI 10.1016/j.neurobiolaging.2006.06.007; Cho HJ, 2009, FASEB J, V23, P2639, DOI 10.1096/fj.08-126383; Choi DY, 2012, NEUROCHEM INT, V60, P68, DOI 10.1016/j.neuint.2011.11.005; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ding Q, 2007, ACTA PHARMACOL SIN, V28, P945, DOI 10.1111/j.1745-7254.2007.00576.x; Firuzi O, 2008, FASEB J, V22, P1169, DOI 10.1096/fj.07-9131.com; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Guglielmotto M., 2010, NEUROBIOL AGING, V196, pe13; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XJ, 2008, GLIA, V56, P27, DOI 10.1002/glia.20588; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2008, J HISTOCHEM CYTOCHEM, V56, P1065, DOI 10.1369/jhc.2008.951855; Jiang LY, 2012, CNS NEUROSCI THER, V18, P659, DOI 10.1111/j.1755-5949.2012.00341.x; Kawano T, 2003, J ALLERGY CLIN IMMUN, V112, P369, DOI 10.1067/mai.2003.1636; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lee JW, 2008, J NEUROINFLAMM, V29, P5; Lynch KR, 1999, NATURE, V399, P789; Morris AAM, 1998, LANCET, V352, P1487, DOI 10.1016/S0140-6736(05)60322-4; ORNING L, 1980, J BIOL CHEM, V255, P8023; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Sala A, 2001, BIOCHEM BIOPH RES CO, V283, P1003, DOI 10.1006/bbrc.2001.4865; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669; Suzuki S, 2008, PHARMACOLOGY, V81, P221, DOI 10.1159/000112866; Thompson C, 2006, AM J RESP CELL MOL, V35, P697, DOI 10.1165/rcmb.2005-0407OC; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; Uz T, 1998, FASEB J, V12, P439; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Walch L, 2000, AM J RESP CRIT CARE, V161, pS107, DOI 10.1164/ajrccm.161.supplement_1.ltta-21; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Zhang J, 2006, ACTA PHARMACOL SIN, V27, P1553, DOI 10.1111/j.1745-7254.2006.00458.x; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	45	26	30	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	FEB	2013	62	3					340	347		10.1016/j.neuint.2013.01.002			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	105BX	WOS:000316041700016	23318673				2021-06-18	
J	Cohen, SI; Suri, P; Amick, MM; Yan, K				Cohen, Sara I.; Suri, Pradeep; Amick, Melissa M.; Yan, Kun			Clinical and demographic factors associated with employment status in US military veterans returning from Iraq and Afghanistan	WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION			English	Article						Depression; OIF/OEF; pain; Polytrauma; posttraumatic stress disorder	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; WORK; DEPRESSION; OUTCOMES; SERVICE; REHABILITATION; INTEGRATION; PREDICTION	OBJECTIVE: To determine the association between clinical and demographic factors with employment status in post-deployment US military veterans returning from Iraq and Afghanistan. PARTICIPANTS: 169 OIF/OEF veterans seen at a post-deployment clinic between December of 2009 and May of 2010. METHODS: Data was collected retrospectively on employment status, age, marital status, gender, pre-deployment education, ratings of sleep disturbance, pain, and depression, and mild traumatic brain injury (mTBI) or PTSD diagnosis. RESULTS: Unemployment was highly prevalent in this sample (45%). Of the demographic and clinical factors examined, only a self-report of global depression severity was significantly associated with a higher prevalence of unemployment in multivariate analysis (odds ratio [OR] 0.21, 95% confidence interval [CI] 0.10-0.47). Age greater than 40 demonstrated a positive association with employment status that was of borderline statistical significance ([OR] 2.8, 95% confidence interval [CI] 1.0-8.1). Prior diagnoses of mTBI or PTSD, and current sleep or pain symptoms, were not associated with employment status. CONCLUSIONS: Individuals with more severe self-reported depression had a higher prevalence of unemployment. Future prospective studies are needed to better understand which factors determine employment status in returning veterans.	[Cohen, Sara I.] Braintree Rehabil Hosp, Braintree, MA USA; [Suri, Pradeep; Amick, Melissa M.; Yan, Kun] VA Boston Healthcare Syst, W Roxbury, MA USA; [Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA; [Amick, Melissa M.; Yan, Kun] Def & Vet Brain Injury Ctr, Boston, MA USA; [Amick, Melissa M.] Boston Univ, Dept Psychiat, Sch Med, Medford, MA USA; [Yan, Kun] Tufts Univ, Medford, MA USA	Suri, P (corresponding author), PMR Serv, 1400 VFW Pkwy,MC 117, W Roxbury, MA 01232 USA.	Pradeep.Suri@va.gov	Suri, Pradeep/AAH-9572-2020				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2010, WASHINGTON POST; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bureau of Labor Statistics, 2010, NEW ENGL STAT UN; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen SP, 2010, LANCET, V375, P301, DOI 10.1016/S0140-6736(09)61797-9; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Economics T., 2011, US UN RAT; Fleming J, 1999, BRAIN INJURY, V13, P417; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Kissinger DB, 2008, WORK, V31, P309; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Latham J, 1994, Disabil Rehabil, V16, P39; Lerner D, 2004, PSYCHIAT SERV, V55, P1371, DOI 10.1176/appi.ps.55.12.1371; Leung K L, 2005, Work, V25, P333; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Patten SB, 2009, CAN J PSYCHIAT, V54, P841, DOI 10.1177/070674370905401207; Prigerson HG, 2002, AM J PUBLIC HEALTH, V92, P59, DOI 10.2105/AJPH.92.1.59; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Semuels Alana, 2011, LOS ANGELES TIMES; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Tanielian T, 2008, INVISIBLE WOUNDS WAR; US Government Accountability Office, 2008, VA HLTH CAR MILD TRA; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8	36	26	26	0	18	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1051-9815			WORK	Work		2013	44	2					213	219		10.3233/WOR-2012-1417			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	087ZC	WOS:000314802300011	22927609				2021-06-18	
J	Demange, L; Abdellah, FN; Lozach, O; Ferandin, Y; Gresh, N; Meijer, L; Galons, H				Demange, Luc; Abdellah, Fatma Nait; Lozach, Olivier; Ferandin, Yoan; Gresh, Nohad; Meijer, Laurent; Galons, Herve			Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						CDK5; Kinase; Roscovitine; Buchwald-Hartwig amination	CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; CELL-CYCLE; PHOSPHORYLATION; DEREGULATION; SPECIFICITY; TOXICITY; PURINES; DYRK1A; FAMILY	Cyclin dependent kinase 5 (CDK5) is a serine/threonine kinase belonging to the cyclin dependent kinase (CDK) family. CDK5 is involved in numerous neuronal diseases (including Alzheimer's or Parkinson's diseases, stroke, traumatic brain injury), pain signaling and cell migration. In the present Letter, we describe syntheses and biological evaluations of new 2,6,9-trisubstituted purines, structurally related to roscovitine, a promising CDK inhibitor currently in clinical trials (CDK1/Cyclin B, IC50 = 350 nM; CDK5/p25, IC50 = 200 nM). These new molecules were synthesized using an original Buchwald-Hartwig catalytic procedure; several compounds (3j, 3k, 3l, 3e, 4k, 6b, 6c) displayed potent kinase inhibitory potencies against CDK5 (IC50 values ranging from 17 to 50 nM) and showed significant cell death inducing activities (IC50 values ranging from 2 to 9 mu M on SH-SY5Y). The docking of the inhibitors into the ATP binding domain of the CDK5 catalytic site highlighted the discriminatory effect of a hydrogen bond involving the CDK5 Lys-89. In addition, the calculated final energy balances for complexation measured for several inhibitors is consistent with the ranking of the IC50 values. Lastly, we observed that several compounds exhibit submicromolar activities against DYRK1A (dual specificity, tyrosine phosphorylation regulated kinase 1A), a kinase involved in Down syndrome and Alzheimer's disease (3g, 3h, 4m; IC50 values ranging from 300 to 400 nM). (C) 2012 Elsevier Ltd. All rights reserved.	[Demange, Luc; Abdellah, Fatma Nait; Gresh, Nohad] Univ Paris 05, UFR Biomed St Peres, CNRS, LCBPT,UMR 8601, F-75270 Paris 06, France; [Lozach, Olivier; Ferandin, Yoan; Meijer, Laurent] CNRS, Biol Stn, USR3151, Prot Phosphorylat & Human Dis Grp, F-29680 Roscoff, Bretagne, France; [Meijer, Laurent; Galons, Herve] Ctr Perharidy, Hotel Rech, ManRos Therapeut, F-29680 Roscoff, France; [Galons, Herve] Univ Paris 05, Lab Pharmacochim, F-75006 Paris, France	Demange, L (corresponding author), Univ Paris 05, UFR Biomed St Peres, CNRS, LCBPT,UMR 8601, 45 Rue St Peres, F-75270 Paris 06, France.	luc.demange@parisdescartes.fr; meijer@manros-therapeutics.com		, laurent/0000-0003-3511-4916; , Demange/0000-0002-2976-8916; Olivier, Lozach/0000-0003-0568-4387	'Canceropole Grand-Ouest' Grant; 'Institut National du Cancer' (INCa "Cancer Detection d'innovations"); 'Association France-Alzheimer Finistere'; 'Ligue Nationale contre le Cancer (Grand-Ouest)'	This research was supported by Grants from the 'Canceropole Grand-Ouest' Grant (L. M.), the 'Institut National du Cancer' (INCa "Cancer Detection d'innovations 2006") (L. M.), the 'Association France-Alzheimer Finistere' (L. M.) and the 'Ligue Nationale contre le Cancer (Grand-Ouest)' (L.M.).	Abbas T, 2006, CELL CYCLE, V5, P1123, DOI 10.4161/cc.5.10.2819; Anne SL, 2007, J NEUROSCI, V27, P7318, DOI 10.1523/JNEUROSCI.1831-07.2007; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Becker W, 2011, FEBS J, V278, P246, DOI 10.1111/j.1742-4658.2010.07956.x; Borgne Annie, 2003, Prog Cell Cycle Res, V5, P453; Brown NR, 1999, NAT CELL BIOL, V1, P438; Carassou P, 2012, B CANCER, V99, P163, DOI 10.1684/bdc.2011.1383; Cheung ZH, 2012, TRENDS CELL BIOL, V22, P169, DOI 10.1016/j.tcb.2011.11.003; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; Cruz JC, 2006, J NEUROSCI, V26, P10536, DOI 10.1523/JNEUROSCI.3133-06.2006; Demange L., 2012, MED CHEM RES; Demange L, 2008, HETEROCYCLES, V75, P1735; Dhariwala FA, 2008, CELL MOL NEUROBIOL, V28, P351, DOI 10.1007/s10571-007-9242-1; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Heathcore D. A., 2010, J MED CHEM, V53, P85082; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Ko J, 2001, J NEUROSCI, V21, P6758; Laha JK, 2011, BIOORG MED CHEM LETT, V21, P2098, DOI 10.1016/j.bmcl.2011.01.140; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee M. H., 1907, CELL MOL LIFE SCI, V2001, P58; Legraverend M, 2006, BIOORGAN MED CHEM, V14, P3987, DOI 10.1016/j.bmc.2005.12.060; LEW J, 1992, J BIOL CHEM, V267, P13383; Lolli G, 2005, CELL CYCLE, V4, P572, DOI 10.4161/cc.4.4.1607; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 2006, MONOGRAPHS ENZYME IN, V2, P187; Meijer L, 2006, B CANCER, V93, P41; Menn B., 2010, PLOS ONE, P5; Neagoie C, 2012, EUR J MED CHEM, V49, P379, DOI 10.1016/j.ejmech.2012.01.040; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Oumata N, 2008, J MED CHEM, V51, P5229, DOI 10.1021/jm800109e; Pareek TK, 2006, CELL CYCLE, V5, P585, DOI 10.4161/cc.5.6.2578; Popowycz F, 2009, J MED CHEM, V52, P655, DOI 10.1021/jm801340z; Sadleir KR, 2012, J BIOL CHEM, V287, P7224, DOI 10.1074/jbc.M111.333914; Shiradkar M, 2011, EUR J MED CHEM, V46, P2066, DOI 10.1016/j.ejmech.2011.02.059; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Utreras E, 2009, J BIOL CHEM, V284, P2275, DOI 10.1074/jbc.M805052200; Wang D, 2012, BIOORG MED CHEM LETT, V22, P168, DOI 10.1016/j.bmcl.2011.11.043; Wegiel J, 2011, FEBS J, V278, P236, DOI 10.1111/j.1742-4658.2010.07955.x; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Wong ASL, 2011, NAT CELL BIOL, V13, P568, DOI 10.1038/ncb2217	44	26	27	1	45	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	JAN 1	2013	23	1					125	131		10.1016/j.bmcl.2012.10.141			7	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	053JO	WOS:000312267700020	23218601				2021-06-18	
J	Ge, YF; Sun, J; Jin, CJ; Cao, BQ; Jiang, ZF; Shao, JF				Ge, Yun-Fei; Sun, Jun; Jin, Chun-Jie; Cao, Bo-Qiang; Jiang, Zhi-Feng; Shao, Jun-Fei			AntagomiR-27a Targets FOXO3a in Glioblastoma and Suppresses U87 Cell Growth in Vitro and in Vivo	ASIAN PACIFIC JOURNAL OF CANCER PREVENTION			English	Article						MiR-27a; antagomiR-27a; glioblastoma; target gene FOXO3a	TUMOR SUPPRESSION; SPROUTY; PROLIFERATION; ACTIVATION; MIGRATION; MICRORNAS; PATHWAYS	Objective: To study the effect of the antagomiR-27a inhibitor on glioblastoma cells. Methods: The miR-27a expression level in specimens of human glioblastoma and normal human brain tissues excised during decompression for traumatic brain injury was assessed using qRT-PCR; The predicted target gene of miR-27a was screened out through bioinformatics databases, and the predicted gene was verified using genetic report assays; the effect of antagomiR-27a on the invasion and proliferation of glioma cells was analyzed using MTT assays and 5-ethynyl-2'-deoxyuridine (EdU) labeling. A xenograft glioblastoma model in BALB-c nude mice was established to detect the effect of antagomiR-27a on tumour growth. Results: qRT-PCR results showed that miR-27a significantly increased in specimens from glioblastoma comparing with normal human brain tissues. Th miR-27a inhibitor significantly suppressed invasion and proliferation of glioblastoma cells. FOXO3a was verified as a new target of miR-27a by Western blotting and reporter analyzes. Tumor growth in vivo was suppressed by administration of the miR-27a inhibitor. Conclusion: MiR-27a may be up-regulated in human glioblastoma, and antagomiR-27a could inhibit the proliferation and invasion ability of glioblastoma cells.	[Ge, Yun-Fei; Sun, Jun; Cao, Bo-Qiang; Shao, Jun-Fei] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Neurosurg, Wuxi, Peoples R China; [Jin, Chun-Jie] Beichen Hosp Tianjin, Dept Neurosurg, Tianjin, Peoples R China; [Jiang, Zhi-Feng] Southeast Univ, Jiangyin Peoples Hosp, Dept Neurosurg, Jiangyin, Peoples R China	Shao, JF (corresponding author), Nanjing Med Univ, Wuxi Peoples Hosp, Dept Neurosurg, Wuxi, Peoples R China.	wxbrain@163.com			National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [812272791]	This study was supported by the grants from the National Natural Science Foundation (812272791).	Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Burgess R, 2008, CANCER BIOL THER, V7, P1326, DOI 10.4161/cbt.7.9.6992; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Li XR, 2010, ENDOCRINOLOGY, V151, P2462, DOI 10.1210/en.2009-1150; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Wang Q, 2011, ONCOGENE, V30, P3875, DOI 10.1038/onc.2011.103; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200	20	26	27	0	2	ASIAN PACIFIC ORGANIZATION CANCER PREVENTION	GYEONGGI-DO	APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA	1513-7368			ASIAN PAC J CANCER P	Asian Pac. J. Cancer Prev.		2013	14	2					963	968		10.7314/APJCP.2013.14.2.963			6	Oncology	Oncology	224VU	WOS:000324920000063	23621269	DOAJ Gold			2021-06-18	
J	Glynn, N; Agha, A				Glynn, Nigel; Agha, Amar			Which patient requires neuroendocrine assessment following traumatic brain injury, when and how?	CLINICAL ENDOCRINOLOGY			English	Article							ANTERIOR-PITUITARY INSUFFICIENCY; HEAD-INJURY; POSTTRAUMATIC HYPOPITUITARISM; ACUTE-PHASE; DYSFUNCTION; HYPONATREMIA; PREVALENCE; SECRETION; HORMONE	Traumatic brain injury (TBI) is an important public health problem, particularly among young adults in industrialized countries. Hypopituitarism is a common occurrence among survivors of TBI and may contribute to the associated morbidity seen in the acute and chronic phases following injury. The available data suggest that survivors of moderate to severe TBI should undergo screening for hypopituitarism particularly in the first year after injury. This requires a close liaison between endocrinologists, neurosurgeons, neuropsychologists, intensive care and rehabilitation physicians. Patients who suffer milder forms of TBI should also be considered for endocrine evaluation if they exhibit any clinical features of pituitary hormone deficiencies.	[Agha, Amar] Beaumont Hosp, Acad Dept Endocrinol, Div Neuroendocrinol, Dublin 9, Ireland; RCSI Med Sch, Dublin, Ireland	Agha, A (corresponding author), Beaumont Hosp, Acad Dept Endocrinol, Div Neuroendocrinol, Beaumont Rd, Dublin 9, Ireland.	amaragha@beaumont.ie		Glynn, Nigel/0000-0002-9248-8191			Agha A, 2006, J CLIN ENDOCR METAB, V91, P43, DOI 10.1210/jc.2005-1131; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Coronado VG, 2011, SURVEILLANCE TRAUMAT; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hannon M. J., 2011, ENDOCR REV, V32; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Moro N, 2007, SURG NEUROL, V68, P387, DOI 10.1016/j.surneu.2006.11.052; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; VINGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50, DOI 10.1007/BF01400528	28	26	27	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664			CLIN ENDOCRINOL	Clin. Endocrinol.	JAN	2013	78	1					17	20		10.1111/cen.12010			4	Endocrinology & Metabolism	Endocrinology & Metabolism	053DF	WOS:000312249800003	22891644				2021-06-18	
J	Maki-Marttunen, V; Diez, I; Cortes, JM; Chialvo, DR; Villarreal, M				Maeki-Marttunen, Veronica; Diez, Ibai; Cortes, Jesus M.; Chialvo, Dante R.; Villarreal, Mirta			Disruption of transfer entropy and inter-hemispheric brain functional connectivity in patients with disorder of consciousness	FRONTIERS IN NEUROINFORMATICS			English	Article						disorder of consciousness; resting state; functional magnetic resonance imaging; BOLD signal; transfer entropy; partial correlation; functional connectivity; brain networks		Severe traumatic brain injury can lead to disorders of consciousness (DOC) characterized by deficit in conscious awareness and cognitive impairment including coma, vegetative state, minimally consciousness, and lock-in syndrome. Of crucial importance is to find objective markers that can account for the large-scale disturbances of brain function to help the diagnosis and prognosis of DOC patients and eventually the prediction of the coma outcome. Following recent studies suggesting that the functional organization of brain networks can be altered in comatose patients, this work analyzes brain functional connectivity (FC) networks obtained from resting-state functional magnetic resonance imaging (rs-fMRI). Two approaches are used to estimate the FC: the Partial Correlation (PC) and the Transfer Entropy (TE). Both the PC and the TE show significant statistical differences between the group of patients and control subjects; in brief, the inter-hemispheric PC and the intra-hemispheric TE account for such differences. Overall, these results suggest two possible rs-fMRI markers useful to design new strategies for the management and neuropsychological rehabilitation of DOC patients.	[Maeki-Marttunen, Veronica; Villarreal, Mirta] FLENI, Neurol Res Inst, Dept Cognit Neurosci, Buenos Aires, DF, Argentina; [Maeki-Marttunen, Veronica; Cortes, Jesus M.; Chialvo, Dante R.] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; [Diez, Ibai; Cortes, Jesus M.] Hosp Univ Cruces, Biocruces Hlth Res Inst, Baracaldo, Spain; [Cortes, Jesus M.] Basque Fdn Sci, Ikerbasque, Bilbao, Spain	Villarreal, M (corresponding author), FLENI, Neurol Res Inst, Dept Cognit Neurosci, Montaneses 2325,C1428AQK, Buenos Aires, DF, Argentina.	mvillarreal@fleni.org.ar	Cortes, Jesus/D-9949-2012; Chialvo, Dante R/A-4658-2009; Chialvo, Dante R./P-5279-2019	Cortes, Jesus/0000-0002-9059-8194; Chialvo, Dante R/0000-0002-1038-3637; Chialvo, Dante R./0000-0002-1038-3637; Diez, Ibai/0000-0001-5769-0178	Ikerbasque: The Basque Foundation for Science; Junta de AndaluciaJunta de Andalucia [P09-FQM-4682]; CONICET (National Council of Scientific and Technological Research) of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Department of Neurology; Department of Teaching and Research of FLENI, Buenos Aires, Argentina	Jesus M. Cortes is supported by Ikerbasque: The Basque Foundation for Science. Jesus M. Cortes acknowledges financial support from Junta de Andalucia, grant P09-FQM-4682. Veronica Maki-Marttunen, Mirta Villarreal, and Dante R. Chialvo are partially supported by CONICET (National Council of Scientific and Technological Research) of Argentina. Additional support was provided by the Department of Neurology, and Department of Teaching and Research of FLENI, Buenos Aires, Argentina.	Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Barnett L, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.238701; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bonachela JA, 2008, J PHYS A-MATH THEOR, V41, DOI 10.1088/1751-8113/41/20/202001; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Cover T., 2006, ELEMENTS INFORM THEO; de Pasquale F, 2012, NEURON, V74, P753, DOI 10.1016/j.neuron.2012.03.031; de Pasquale F, 2010, P NATL ACAD SCI USA, V107, P6040, DOI 10.1073/pnas.0913863107; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gaillard R, 2009, PLOS BIOL, V7, P472, DOI 10.1371/journal.pbio.1000061; Ganzetti M, 2013, NEUROSCIENCE, V240, P297, DOI 10.1016/j.neuroscience.2013.02.032; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; JAYNES ET, 1957, PHYS REV, V106, P620, DOI 10.1103/PhysRev.106.620; Nir Y, 2008, NAT NEUROSCI, V11, P1100, DOI 10.1038/nn.2177; Noirhomme Q, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00160; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ovadia-Caro S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037238; Paninski L, 2003, NEURAL COMPUT, V15, P1191, DOI 10.1162/089976603321780272; Panzeri S, 1996, NETWORK-COMP NEURAL, V7, P87, DOI 10.1080/0954898X.1996.11978656; Peng H., MUTUAL INFORM TOOLBO; Perri C. D., 2013, EPILEPSY BEHAV, DOI [10.1016/j.yebeh.2013.09.014, DOI 10.1016/J.YEBEH.2013.09.014]; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Schreiber T, 2000, PHYS REV LETT, V85, P461, DOI 10.1103/PhysRevLett.85.461; Seth AK, 2006, P NATL ACAD SCI USA, V103, P10799, DOI 10.1073/pnas.0604347103; TEASDALE G, 1974, LANCET, V2, P81; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Vidal JR, 2012, J NEUROSCI, V32, P6421, DOI 10.1523/JNEUROSCI.4363-11.2012	34	26	26	0	11	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5196			FRONT NEUROINFORM	Front. Neuroinformatics		2013	7								UNSP 24	10.3389/fninf.2013.00024			11	Mathematical & Computational Biology; Neurosciences	Mathematical & Computational Biology; Neurosciences & Neurology	V36JA	WOS:000209207300023	24312048	DOAJ Gold, Green Published			2021-06-18	
J	Matsuoka, Y; Nishi, D; Noguchi, H; Kim, Y; Hashimoto, K				Matsuoka, Yutaka; Nishi, Daisuke; Noguchi, Hiroko; Kim, Yoshiharu; Hashimoto, Kenji			Longitudinal Changes in Serum Brain-Derived Neurotrophic Factor in Accident Survivors with Posttraumatic Stress Disorder	NEUROPSYCHOBIOLOGY			English	Article						Brain-derived neurotrophic factor; Posttraumatic stress disorder; Accident survivors	LONG-TERM POTENTIATION; SOCIAL DEFEAT; BDNF; DEPRESSION; INJURY; SCALE; ANTIDEPRESSANTS; EXPRESSION; CLINICIAN; DISTRESS	Background: This prospective cohort study investigated the serum levels of brain-derived neurotrophic factor (BDNF), which mediates synaptic plasticity crucial for fear memory extinction, in patients severely injured in motor vehicle accidents (MVAs). Method: A nested, case-controlled study was conducted with 103 MVA survivors: 8 medication-naive patients who met the criteria for full diagnosis of posttraumatic stress disorder (PTSD) at 6 months after MVA, 10 medication-naive patients with partial PTSD and 85 patients with no PTSD. PTSD was evaluated by the Clinician-Administered PTSD Scale (CAPS). Serum BDNF levels were measured shortly after the MVA (baseline) and at 6-month follow-up. Results: Posttrauma serum BDNF levels differed between the 3 groups after controlling for age and sex (F = 3.41, p = 0.04), with unexpectedly higher serum BDNF levels seen in the full-PTSD group compared with the no-PTSD group. Additional analysis of patients with serum samples taken at baseline and at 6 months revealed the full-PTSD group had significantly higher serum BDNF levels over the 6 months than the no-PTSD group after controlling for age and sex (F = 6.44, p < 0.01). A positive correlation was seen between changes in serum BDNF levels over 6 months and the CAPS score at 6 months (r = 0.26, p = 0.014). Conclusions: The findings of this study, the first to report longitudinal serum BDNF levels in MVA survivors, suggest that elevated serum BDNF levels could be a biomarker of PTSD after a traumatic event. Copyright (c) 2013 S. Karger AG, Basel	[Matsuoka, Yutaka; Noguchi, Hiroko] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Kodaira, Tokyo 1878551, Japan; [Matsuoka, Yutaka; Nishi, Daisuke; Kim, Yoshiharu] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Tokyo, Japan; [Matsuoka, Yutaka; Nishi, Daisuke] Natl Disaster Med Ctr, Dept Psychiat, Tokyo, Japan; [Matsuoka, Yutaka; Nishi, Daisuke; Noguchi, Hiroko; Kim, Yoshiharu; Hashimoto, Kenji] Japan Sci & Technol Agcy, CREST, Tokyo, Japan; [Hashimoto, Kenji] Chiba Univ, Div Clin Neurosci, Ctr Forens Mental Hlth, Chiba, Japan	Matsuoka, Y (corresponding author), Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878551, Japan.	yutaka@ncnp.go.jp	Nishi, Daisuke/AAH-7211-2019; Matsuoka, Yutaka/N-1588-2019; Hashimoto, Kenji/I-5800-2015	Nishi, Daisuke/0000-0001-9349-3294; Matsuoka, Yutaka/0000-0002-8690-8129; Hashimoto, Kenji/0000-0002-8892-0439	Japanese Ministry of Health, Labor and WelfareMinistry of Health, Labour and Welfare, Japan [16190501, 19230701, 2030701]; Intramural Research grant for neurological and psychiatric disorders from NCNP [24-4]; CREST, Japan Science and Technology AgencyJapan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST); Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour and Welfare, Japan; Takeda Pharmaceutical Company LtdTakeda Pharmaceutical Company Ltd; Suntory Wellness Ltd; Eli Lilly Japan KKEli Lilly; Otsuka Pharmaceutical Co., Ltd.Otsuka Pharmaceutical; Toray Industries, Inc.Toray Industries, Inc.; Foundation for Total Health PromotionFoundation for Total Health Promotion; Qol Co., Ltd; NTT DoCoMo, Inc.; Japan Science and Technology AgencyJapan Science & Technology Agency (JST); CRESTCore Research for Evolutional Science and Technology (CREST); GlaxoSmithKline, JapanGlaxoSmithKline; DHA & EPA Association; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24659143] Funding Source: KAKEN	We especially thank Mss. Akutsu and Kamoshida for clinical data management and Ms. T. Ishima for technical assistance with BDNF measurements. This work was supported by grants from the Japanese Ministry of Health, Labor and Welfare (Research on Psychiatric and Neurological Disease and Mental Health: 16190501, 19230701 and 2030701), an Intramural Research grant (24-4) for neurological and psychiatric disorders from NCNP and CREST, Japan Science and Technology Agency.; Y.M. received research support from the Japan Science and Technology Agency, CREST, and the Ministry of Health, Labor and Welfare of Japan, an Intramural Research grant for neurological and psychiatric disorders from NCNP and lecture fees from Takeda Pharmaceutical Company Ltd, Suntory Wellness Ltd, Eli Lilly Japan KK and Otsuka Pharmaceutical Co., Ltd. D.N. received research support from Toray Industries, Inc. and the Foundation for Total Health Promotion and lecture fees from Qol Co., Ltd, the DHA & EPA Association and NTT DoCoMo, Inc.. Y.K. received research support from the Japanese Ministry of Health, Labour and Welfare, Japan Science and Technology Agency and CREST and received a grant from GlaxoSmithKline, Japan. He has been a speaker for GlaxoSmithKline, Pfizer, Meiji Seika Pharma, Yoshitomi Pharmaceutical and Meiji Yasuda Insurance Co.. The other two authors reported no biomedical financial interests or potential conflicts of interest.	Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; Asukai N., 2003, JAP J TRAUM STRESS, V1, P47; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Berger W, 2010, PROG NEURO-PSYCHOPH, V34, P1279, DOI 10.1016/j.pnpbp.2010.07.008; Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Chen LY, 2010, J NEUROSCI, V30, P15097, DOI 10.1523/JNEUROSCI.3549-10.2010; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Eisch AJ, 2003, BIOL PSYCHIAT, V54, P994, DOI 10.1016/j.biopsych.2003.08.003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Hauck S, 2010, PROG NEURO-PSYCHOPH, V34, P459, DOI 10.1016/j.pnpbp.2010.01.010; Hauck S, 2009, REV BRAS PSIQUIATR, V31, P48, DOI 10.1590/S1516-44462009000100012; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Krishnan V, 2007, CELL, V131, P391, DOI 10.1016/j.cell.2007.09.018; Kugaya A, 1998, JPN J CLIN ONCOL, V28, P333, DOI 10.1093/jjco/28.5.333; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Matsuoka Y, 2009, SOC PSYCH PSYCH EPID, V44, P341; Matsuoka Y, 2011, PSYCHOTHER PSYCHOSOM, V80, P310, DOI 10.1159/000322980; Mori E., 1985, JPN J NEUROPSYCHOL, V1, P82; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Peters J, 2010, SCIENCE, V328, P1288, DOI 10.1126/science.1186909; Ressler KJ, 2007, NAT NEUROSCI, V10, P1116, DOI 10.1038/nn1944; Saruta J, 2010, STRESS, V13, P53, DOI 10.3109/10253890902875167; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1; Takei S, 2011, J PSYCHIATR RES, V45, P460, DOI 10.1016/j.jpsychires.2010.08.009; Weiss Daniel S., 1997, P399; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	26	26	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0302-282X			NEUROPSYCHOBIOLOGY	Neuropsychobiology		2013	68	1					44	50		10.1159/000350950			7	Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	178YE	WOS:000321482500005	23774996				2021-06-18	
J	Walker, JJ; Cleveland, LM; Davis, JL; Seales, JS				Walker, Jennifer Junnila; Cleveland, Leanne M.; Davis, Jenny L.; Seales, Jennifer S.			Audiometry Screening and Interpretation	AMERICAN FAMILY PHYSICIAN			English	Article							TRAUMATIC BRAIN-INJURY; HEARING-LOSS; PREVALENCE; HEALTH; CARE	The prevalence of hearing loss varies with age, affecting at least 25 percent of patients older than 50 years and more than 50 percent of those older than 80 years. Adolescents and young adults represent groups in which the prevalence of hearing loss is increasing and may therefore benefit from screening. If offered, screening can be performed periodically by asking the patient or family if there are perceived hearing problems, or by using clinical office tests such as whispered voice, finger rub, or audiometry. Audiometry in the family medicine clinic setting is a relatively simple procedure that can be interpreted by a trained health care professional. Pure-tone testing presents tones across the speech spectrum (500 to 4,000 Hz) to determine if the patient's hearing levels fall within normal limits. A quiet testing environment, calibrated audiometric equipment, and appropriately trained personnel are required for in-office testing. Pure-tone audiometry may help physicians appropriately refer patients to an audiologist or otolaryngologist. Unilateral or asymmetrical hearing loss can be symptomatic of a central nervous system lesion and requires additional evaluation. (Am Fam Physician. 2013;87(1) :41-47. Copyright (C) 2013 American Academy of Family Physicians.)	[Walker, Jennifer Junnila] USA, Hlth Clin, Schofield Barracks, HI 96857 USA; [Cleveland, Leanne M.] Ft Richardson Troop Hlth Clin, Joint Base Elmendorf Ric, AK USA; [Davis, Jenny L.] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Seales, Jennifer S.] Gen Leonard Wood Army Community Hosp, Ft Leonard Wood, MO USA	Walker, JJ (corresponding author), USA, Hlth Clin, Bldg 683, Schofield Barracks, HI 96857 USA.						Abraham M, 2011, CPT 2012 CURRENT PRO; Agrawal Y, 2008, ARCH INTERN MED, V168, P1522, DOI 10.1001/archinte.168.14.1522; American Academy of Audiology, 1997, POS STAT GUID CONS P; American Academy of Otolaryngology-Head and Neck Surgery, FAQS CMS AUD TRANSM; American Academy of Pediatrics Bright Futures Steering Committee, BRIGHT FUT GUID HLTH; American National Standards Institute, 2008, S311999 ANSIASA; American National Standards Institute, S362010 ANSI; American Speech-Language-Hearing Association, 2004, SUPP PERS ISS ETH; [Anonymous], PHYS FEE SCHED SEARC; Army Publishing Directorate, 1998, DEP ARM PAMPHL 40 50, pDecember; Barnett S, 2002, AM FAM PHYSICIAN, V66, P911; Bogardus ST, 2003, JAMA-J AM MED ASSOC, V289, P1986, DOI 10.1001/jama.289.15.1986; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chung JH, 2005, PEDIATRICS, V115, P861, DOI 10.1542/peds.2004-0173; Council for Accreditation in Occupational Hearing Conservation, COURS LEAD CERT REC; Cunningham M, 2003, PEDIATRICS, V111, P436, DOI 10.1542/peds.111.2.436; Durmaz A, 2009, J LARYNGOL OTOL, V123, P840, DOI 10.1017/S0022215109004769; Elsawy B, 2011, AM FAM PHYSICIAN, V83, P48; Fausti SA, 2005, J REHABIL RES DEV, V42, P45, DOI 10.1682/JRRD.2005.02.0039; Forzley GJ, 2003, PFENNINGER FOWLERS P, P409; FRANK T, 1987, EAR HEARING, V8, P180, DOI 10.1097/00003446-198706000-00009; Halloran DR, 2009, ARCH PEDIAT ADOL MED, V163, P158, DOI 10.1001/archpediatrics.2008.526; Harrell R.W., 2002, HDB CLIN AUDIOLOGY, V5th ed., P71; Institute for Clinical Systems Improvement, HLTH CAR GUID PREV S; Jupiter T, 2009, AM J AUDIOL, V18, P99, DOI 10.1044/1059-0889(2009/08-0020); Katz J, 2002, HDB CLIN AUDIOLOGY, P124; KLOCKHOFF I, 1986, SCAND AUDIOL, V15, P217, DOI 10.3109/01050398609042146; Moore KJ, 2003, FAM PRACT MANAG, V10, P17; MULROW CD, 1991, J GEN INTERN MED, V6, P249, DOI 10.1007/BF02598971; Rabinowitz PM, 2000, AM FAM PHYSICIAN, V61, P2749; RAPPO PD, 1995, PEDIATRICS, V96, P373; Saliba I, 2009, OTOL NEUROTOL, V30, P515, DOI 10.1097/MAO.0b013e3181a5297a; Shargorodsky J, 2010, JAMA-J AM MED ASSOC, V304, P772, DOI 10.1001/jama.2010.1124; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Torres-Russotto D, 2009, NEUROLOGY, V72, P1595, DOI 10.1212/WNL.0b013e3181a41280; U. S. Department of Health and Human Services Centers for Disease Control and Prevention Centers for Medicare & Medicaid Services, 2007, ICD 9 CM INT CLASS D; U. S. Preventive Services Task Force, SCREEN HEAR IMP OLD; Vogel I, 2008, J PEDIATR-US, V152, P400, DOI 10.1016/j.jpeds.2007.07.009	39	26	27	0	12	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	JAN 1	2013	87	1					41	47					7	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	068QN	WOS:000313381400007	23317024				2021-06-18	
J	Zhao, W; Ho, L; Varghese, M; Yemul, S; Dams-O'Connor, K; Gordon, W; Knable, L; Freire, D; Haroutunian, V; Pasinetti, GM				Zhao, Wei; Ho, Lap; Varghese, Merina; Yemul, Shrishailam; Dams-O'Connor, Kristen; Gordon, Wayne; Knable, Lindsay; Freire, Daniel; Haroutunian, Vahram; Pasinetti, Giulio Maria			Decreased Level of Olfactory Receptors in Blood Cells Following Traumatic Brain Injury and Potential Association with Tauopathy	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Biomarker; olfactory receptor; peripheral blood mononuclear cell; tauopathy; traumatic brain injury	ALZHEIMERS-DISEASE; MOUSE MODEL; IN-VITRO; EXPRESSION; PROTEIN; TAU; MEMORY; DISCOVERY; DEFICITS; RISK	Traumatic brain injury (TBI) is a leading cause of death and disability among children and young adults in the United States. In this study, we explored whether changes in the gene expression profile of peripheral blood mononuclear cells (PBMC) may provide a clinically assessable "window" into the brain, reflecting molecular alterations following TBI that might contribute to the onset and progression of TBI clinical complications. We identified three olfactory receptor (OR) TBI biomarkers that are aberrantly down-regulated in PBMC specimens from TBI subjects. Down-regulation of these OR biomarkers in PBMC was correlated with the severity of brain injury and TBI-specific symptoms. A two-biomarker panel comprised of OR11H1 and OR4M1 provided the best criterion for segregating the TBI and control cases with 90% accuracy, 83.3% sensitivity, and 100% specificity. We found that the OR biomarkers are ectopically expressed in multiple brain regions, including the entorhinal-hippocampus system known to play an important role in memory formation and consolidation. Activation of OR4M1 led to attenuation of abnormal tau phosphorylation, possibly through JNK signaling pathway. Our results suggested that addition of the two-OR biomarker model to current diagnostic criteria may lead to improved TBI detection for clinical trials, and decreased expression of OR TBI biomarkers might be associated with TBI-induced tauopathy. Future studies exploring the physiological relevance of OR TBI biomarkers in the normal brain and in the brain following TBI will provide a better understanding of the biological mechanisms underlying TBI and insights into novel therapeutic targets for TBI.	[Zhao, Wei; Ho, Lap; Varghese, Merina; Yemul, Shrishailam; Knable, Lindsay; Freire, Daniel; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil, New York, NY 10029 USA; [Haroutunian, Vahram; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Yemul, Shrishailam; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA.	Giulio.Pasinetti@mssm.edu	Varghese, Merina/H-5472-2019; Zhao, Wei/A-2206-2010	Varghese, Merina/0000-0002-1517-3903; Pasinetti, Giulio/0000-0002-1524-5196; Zhao, Wei/0000-0002-3449-2395	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138, P01AG002219] Funding Source: NIH RePORTER	This study was supported in part by discretionary funding to GMP and in part from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (UL1RR029887).	Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008; [Anonymous], 2009, ALL HUM CORT STUD; Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; DeMaria S, 2010, J CELL BIOL, V191, P443, DOI 10.1083/jcb.201008163; Derdikman D, 2010, TRENDS COGN SCI, V14, P561, DOI 10.1016/j.tics.2010.09.004; Eichenbaum H, 2008, HIPPOCAMPUS, V18, P1314, DOI 10.1002/hipo.20500; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Feldmesser E, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-121; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gardiner E, 2012, MOL PSYCHIATR, V17, P827, DOI 10.1038/mp.2011.78; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Haroutunian V, 1999, ARCH NEUROL-CHICAGO, V56, P713, DOI 10.1001/archneur.56.6.713; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lovell M, 2012, NEUROPSYCHIATRY TRAU; Maes OC, 2009, J GERONTOL A-BIOL, V64, P636, DOI 10.1093/gerona/glp045; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Speciale L, 2007, NEUROBIOL AGING, V28, P1163, DOI 10.1016/j.neurobiolaging.2006.05.020; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; van Heerden Johan H, 2009, BMC Res Notes, V2, P195, DOI 10.1186/1756-0500-2-195; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51	50	26	27	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2013	34	2					417	429		10.3233/JAD-121894			13	Neurosciences	Neurosciences & Neurology	095MF	WOS:000315337900008	23241557	Green Accepted			2021-06-18	
J	Hu, R; Sun, HD; Zhang, Q; Chen, JY; Wu, N; Meng, H; Cui, GY; Hu, SL; Li, F; Lin, JK; Wan, Q; Feng, H				Hu, Rong; Sun, Haodong; Zhang, Qian; Chen, Jingyu; Wu, Nan; Meng, Hui; Cui, Gaoyu; Hu, Shengli; Li, Fei; Lin, Jiangkai; Wan, Qi; Feng, Hua			G-protein coupled estrogen receptor 1 mediated estrogenic neuroprotection against spinal cord injury	CRITICAL CARE MEDICINE			English	Article						apoptosis; estrogen; functional recovery; G-protein coupled estrogen receptor 1; neuroprotection	MESSENGER-RNA; IMMUNOREACTIVE NEURONS; BRAIN-STEM; ALPHA; RAT; EXPRESSION; 17-BETA-ESTRADIOL; ACTIVATION; BETA; APOPTOSIS	Objective: What underlies the protection of estrogen against spinal cord injury remains largely unclear. Here, we investigated the expression pattern of a new estrogen receptor, G-protein coupled estrogen receptor 1 in the spinal cord and its role in estrogenic protection against spinal cord injury. Design and Settings: Department of Neurosurgery and Key Laboratory of Neurotrauma, Southwest Hospital. Subjects: Male Sprague-Dawley rats. Interventions: The animals subjected to spinal cord injury were divided into six groups and given vehicle solution, 17 beta-estradiol, or G-protein coupled estrogen receptor 1 agonist G-1 at 15 mins and 24 hrs postinjury, or given nuclear estrogen receptor antagonist ICI 182,780 at 1 hr before spinal cord injury followed by 17 beta-estradiol administration at 15 mins and 24 hrs postinjury, or given G-protein coupled estrogen receptor 1 specific antisense or random control oligonucleotide at 4 days before spinal cord injury followed by 17 beta-estradiol administration at 15 mins and 24 hrs postinjury. Measurements: Male Sprague-Dawley rats were subjected to spinal cord injury using a weight-drop injury approach. Immunohistochemical assays were used to observe the distribution and cell-type expression pattern of G-protein coupled estrogen receptor 1. The terminal deoxynucleotidyl transferase dUTP nickend labeling-staining assay and behavior tests were employed to assess the role of G-protein coupled estrogen receptor 1 in mediating estrogenic protection against spinal cord injury. Main Results: We show that G-protein coupled estrogen receptor 1 is mainly distributed in the ventral horn and white matter of the spinal cord, which is totally different from nuclear estrogen receptors. We also show that G-protein coupled estrogen receptor 1 is specifically expressed by neurons, oligodendrocytes, and microglial cells, but not astrocytes. Furthermore, estrogen treatment prevents spinal cord injury-induced apoptotic cell death and enhances functional recovery after spinal cord injury, which can be mimicked by the specific G-protein coupled estrogen receptor 1 agonist G-1 and inhibited by specific knockdown of G-protein coupled estrogen receptor 1 expression, but not pure nuclear ER antagonist ICI 182,780. Finally, we show that estrogen or G-1 up-regulates the protein expression level of G-protein coupled estrogen receptor 1 to intensify estrogenic effects during spinal cord injury. Conclusions: These results reveal that G-protein coupled estrogen receptor 1 may mediate estrogenic neuroprotection against spinal cord injury, and underline the promising potential of estrogen with its new target G-protein coupled estrogen receptor 1 for the treatment of spinal cord injury patients. (Crit Care Med 2012; 40:3230-3237)	[Hu, Rong; Zhang, Qian; Chen, Jingyu; Wu, Nan; Meng, Hui; Cui, Gaoyu; Hu, Shengli; Li, Fei; Lin, Jiangkai; Wan, Qi; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China; [Hu, Rong; Zhang, Qian; Chen, Jingyu; Wu, Nan; Meng, Hui; Cui, Gaoyu; Hu, Shengli; Li, Fei; Lin, Jiangkai; Wan, Qi; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Key Lab Neurotrauma, Chongqing, Peoples R China; [Sun, Haodong] Gen Hosp Chengdu Mil Command, Dept Neurosurg, Chengdu, Sichuan, Peoples R China	Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.	feng-hua8888@yahoo.com.cn		HU, RONG/0000-0002-3916-186X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872735]; "863 Programs (Chinese National Programs for High Technology Research and Development)"National High Technology Research and Development Program of China [2009AA02Z409]; Natural Science Foundation of ChongqingNatural Science Foundation of Chongqing [CSTC2008BB5125]	Supported by grants from the National Natural Science Foundation of China (No. 30872735), from the "863 Programs (Chinese National Programs for High Technology Research and Development)" (No. 2009AA02Z409), and from the Natural Science Foundation of Chongqing (No. CSTC2008BB5125).	Amandusson A, 1996, EUR J NEUROSCI, V8, P2440, DOI 10.1111/j.1460-9568.1996.tb01207.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Dun SL, 2009, J NEUROSCI RES, V87, P1610, DOI 10.1002/jnr.21980; Fehlings MG, 2010, J NEUROSURG-SPINE, V13, P165, DOI 10.3171/2009.11.SPINE09862; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Fu ES, 2005, CURR OPIN ANESTHESIO, V18, P181, DOI 10.1097/01.aco.0000162838.56344.88; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hebbeler SL, 2001, J NEUROBIOL, V48, P301, DOI 10.1002/neu.1059; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hu R, 2007, NEUROSCIENCE, V144, P1229, DOI 10.1016/j.neuroscience.2006.09.056; Hu R, 2011, ANN SURG, V254, P353, DOI 10.1097/SLA.0b013e31822645b4; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Isensee J, 2009, ENDOCRINOLOGY, V150, P1722, DOI 10.1210/en.2008-1488; Ismailoglu O, 2010, J CLIN NEUROSCI, V17, P1306, DOI 10.1016/j.jocn.2010.01.049; Kan WH, 2008, ANN SURG, V248, P294, DOI 10.1097/SLA.0b013e318180a3db; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lu CL, 2009, GASTROENTEROLOGY, V137, P1040, DOI 10.1053/j.gastro.2009.03.047; Macias CA, 2009, ANN SURG, V249, P10, DOI 10.1097/SLA.0b013e31818a1505; Matsuda KI, 2008, NEUROSCI LETT, V441, P94, DOI 10.1016/j.neulet.2008.05.108; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785; Merchenthaler I, 2004, J COMP NEUROL, V473, P270, DOI 10.1002/cne.20128; Micevych P, 2009, FRONT NEUROENDOCRIN, V30, P315, DOI 10.1016/j.yfrne.2009.04.011; MOGIL JS, 1993, PAIN, V53, P17, DOI 10.1016/0304-3959(93)90050-Y; Nakamizo T, 2000, NEUROREPORT, V11, P3493, DOI 10.1097/00001756-200011090-00019; Nilsson S, 2001, PHYSIOL REV, V81, P1535; Olde B, 2009, TRENDS ENDOCRIN MET, V20, P409, DOI 10.1016/j.tem.2009.04.006; Papka RE, 2001, CELL TISSUE RES, V304, P193, DOI 10.1007/s004410100363; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Sakamoto H, 2007, ENDOCRINOLOGY, V148, P5842, DOI 10.1210/en.2007-0436; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Takanami K, 2010, BRAIN RES, V1310, P17, DOI 10.1016/j.brainres.2009.11.004; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Vanderhorst VGJM, 2009, NEUROSCIENCE, V158, P798, DOI 10.1016/j.neuroscience.2008.10.017; VanderHorst VGJM, 2005, J COMP NEUROL, V488, P152, DOI 10.1002/cne.20569; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; WAKELING AE, 1992, J STEROID BIOCHEM, V43, P173, DOI 10.1016/0960-0760(92)90204-V; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Yu HP, 2007, ANN SURG, V245, P971, DOI 10.1097/01.sla.0000254417.15591.88; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	54	26	28	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2012	40	12					3230	3237		10.1097/CCM.0b013e3182657560			8	Critical Care Medicine	General & Internal Medicine	041UQ	WOS:000311427100016	22975889				2021-06-18	
J	Liao, CC; Chiu, WT; Yeh, CC; Chang, HC; Chen, TL				Liao, Chien-Chang; Chiu, Wen-Ta; Yeh, Chun-Chieh; Chang, Huai-Chia; Chen, Ta-Liang			Risk and outcomes for traumatic brain injury in patients with mental disorders	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURIES; BIRTH COHORT; HIP FRACTURE; OLDER WOMEN; SCHIZOPHRENIA; HEALTH; FALLS; HOSPITALIZATIONS; DEPRESSION; VIOLENCE	Objective To investigate the risk of traumatic brain injury (TBI) and post-injury mortality in patients with mental disorders. Background Patients with mental disorders are at higher risk of injuries. However, the association between mental disorders and TBI is still not understood. We conducted case-control studies to investigate whether people with pre-existing mental disorders are at higher risk of TBI and post-injury mortality. Methods Using reimbursement claims, we analysed 16 635 patients with TBI and 66 540 controls with adjustment of covariates to study the association of mental disorders and TBI. A nested case-control study was also conducted to analyse contributory factors for post-injury mortality. Results People with mental disorders were at increased risk of TBI (odds ratio (OR) 1.94, 95% confidence interval (CI) 1.86 to 2.02). Men, older age, living in highly urbanised areas and patients on low income had a higher risk of TBI and post-injury mortality. Psychiatric medication intensity and frequency of psychiatric visits was significantly correlated with TBI in a severity dependent relationship (p for trend <0.0001). Patients receiving advanced psychiatric healthcare had an increased risk of TBI (OR 2.98, 95% CI 2.67 to 3.33) and post-injury mortality (OR 1.92, 95% CI 1.34 to 2.77). A history of receiving psychiatric related outpatient care (OR 1.77, 95% CI 1.70 to 1.85), hospitalisation (OR 3.21, 95% CI 2.79 to 3.70) or emergency visits (OR 3.53, 95% CI 3.15 to 3.94) were highly associated with subsequent TBI. Conclusions Patients with mental disorders have an increased risk of TBI. Intensity of psychiatric medication is associated with increased post-injury mortality. Special attention to prevent TBI among this disabled population is mandatory.	[Chen, Ta-Liang] Taipei Med Univ, Coll Med, Sch Med, Taipei Med Univ Hosp,Dept Anaesthesiol, Taipei 11031, Taiwan; [Liao, Chien-Chang; Chang, Huai-Chia; Chen, Ta-Liang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei 11031, Taiwan; [Yeh, Chun-Chieh] China Med Univ Hosp, Trauma & Emergency Ctr, Taichung, Taiwan; [Liao, Chien-Chang; Chang, Huai-Chia; Chen, Ta-Liang] Taipei Med Univ, Sch Med, Taipei 11031, Taiwan	Chen, TL (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Taipei Med Univ Hosp,Dept Anaesthesiol, 250 Wuxing St, Taipei 11031, Taiwan.	tlc@tmu.edu.tw	Yeh, Chun Chieh/I-4893-2019; Yeh, Chun Chieh/Y-3304-2019	Yeh, Chun Chieh/0000-0001-6753-7564; 			Arseneault L, 2000, ARCH GEN PSYCHIAT, V57, P979, DOI 10.1001/archpsyc.57.10.979; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Brennan PA, 2000, ARCH GEN PSYCHIAT, V57, P494, DOI 10.1001/archpsyc.57.5.494; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Coben JH, 2009, AM J PREV MED, V36, P49, DOI 10.1016/j.amepre.2008.10.001; Cooke BK, 2007, AM J SURG, V193, P41, DOI 10.1016/j.amjsurg.2006.06.034; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Daumit GL, 2006, ARCH GEN PSYCHIAT, V63, P267, DOI 10.1001/archpsyc.63.3.267; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Howard L, 2007, BRIT J PSYCHIAT, V190, P129, DOI 10.1192/bjp.bp.106.023671; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Joo JH, 2002, J CLIN PSYCHIAT, V63, P936, DOI 10.4088/JCP.v63n1012; Kerse N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002423; Kudoh A, 2005, ANESTH ANALG, V101, P1867, DOI 10.1213/01.ANE.0000184123.67853.86; Lai SW, 2010, MEDICINE, V89, P295, DOI 10.1097/MD.0b013e3181f15efc; Li Y, 2007, MED CARE, V45, P587, DOI 10.1097/MLR.0b013e31803d3b54; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Liperoti R, 2007, J CLIN PSYCHIAT, V68, P929, DOI 10.4088/JCP.v68n0616; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Meaney AM, 2007, SCHIZOPHR RES, V93, P136, DOI 10.1016/j.schres.2007.01.013; Newgard CD, 2011, AM J PUBLIC HEALTH, V101, P669, DOI 10.2105/AJPH.2010.300063; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel V, 2010, JAMA-J AM MED ASSOC, V303, P1976, DOI 10.1001/jama.2010.616; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Thapa PB, 1998, NEW ENGL J MED, V339, P875, DOI 10.1056/NEJM199809243391303; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Whooley MA, 1999, ARCH INTERN MED, V159, P484, DOI 10.1001/archinte.159.5.484; Wu Q, 2010, OSTEOPOROSIS INT, V21, P1627, DOI 10.1007/s00198-010-1181-x; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Yeh CC, 2012, INJURY, V43, P1903, DOI 10.1016/j.injury.2011.03.016	40	26	26	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2012	83	12					1186	1192		10.1136/jnnp-2012-302337			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	037IU	WOS:000311097700015	22773855				2021-06-18	
J	Ruban, A; Berkutzki, T; Cooper, I; Mohar, B; Teichberg, VI				Ruban, Angela; Berkutzki, Tamara; Cooper, Itzik; Mohar, Boaz; Teichberg, Vivian I.			Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas	INVESTIGATIONAL NEW DRUGS			English	Article						Blood glutamate scavengers; Gliomas; Glutamate-oxaloacetate transferase	CLOSED-HEAD INJURY; HUMAN GLIOBLASTOMA; MALIGNANT GLIOMAS; AMINO-ACID; GROWTH; CELLS; NEUROPROTECTION; MICRODIALYSIS; COTRANSPORTER; TRANSPORTERS	L-Glutamate (Glu) plays a crucial role in the growth of malignant gliomas. We have established the feasibility of accelerating a naturally occurring brain to-blood Glu efflux by decreasing blood Glu levels with intravenous oxaloacetate, the respective Glu co-substrate of the blood resident enzyme humane glutamate-oxaloacetate transaminase (hGOT). We wished to demonstrate that blood Glu scavenging provides neuroprotection in the case of glioma. We now describe the neuroprotective effects of blood Glu scavenging in a fatal condition such as brain-implanted C6 glioma in rats and brain-implanted human U87 MG glioma in nude mice. Rat (C-6) or human (U87) glioma cells were grafted stereotactically in the brain of rats or mice. After development of tumors, the animals were drinking oxaloacetate with or without injections of hGOT. In addition, mice were treated with combination treatment, which included drinking oxaloacetate with intracutaneous injections of hGOT and intraperitoneal injection of Temozolomide. Animals drinking oxaloacetate with or without injections of hGOT displayed a smaller tumor volume, reduced invasiveness and prolonged survival than control animals drinking saline. These effects were significantly enhanced by Temozolomide in mice, which increased survival by 237%. This is the first demonstration of blood Glu scavenging in brain cancer, and because of its safety, is likely to be of clinical significance for the future treatment of human gliomas. As we demonstrated, the blood glutamate scavenging treatment in combination with TMZ could be a good candidate or as an alternative treatment to the patients that do not respond to TMZ.	[Ruban, Angela; Cooper, Itzik; Mohar, Boaz; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Berkutzki, Tamara] Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel	Ruban, A (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	Angela.matuzani@weizmann.ac.il	Mohar, Boaz/H-6398-2011	Mohar, Boaz/0000-0002-8613-2869; cooper, itzik/0000-0003-0723-5542; Ruban, Angela/0000-0003-1091-8854	Bio-Med Morasha ISF [1898/08]; NISF-Legacy-Bio-Med [1162]; Nella and Leon Benoziyo Center for Neurological Diseases; Irwin Green Fund for Studying the Development of the Brain; Carl and Micaela Einhorn-Dominic Institute for Brain Research; estate of Lola Asseof	This work was supported by grants to VIT from the Bio-Med Morasha ISF program no. 1898/08, the NISF-Legacy-Bio-Med 1162, the Nella and Leon Benoziyo Center for Neurological Diseases; the Irwin Green Fund for Studying the Development of the Brain, the Carl and Micaela Einhorn-Dominic Institute for Brain Research and the estate of Lola Asseof. VIT is the incumbent of the Louis and Florence Katz-Cohen Chair of Neuropharmacology.	Arcella A, 2005, NEURO-ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961; Augustine CK, 2009, CLIN CANCER RES, V15, P502, DOI 10.1158/1078-0432.CCR-08-1916; Behrens PF, 2000, J NEURO-ONCOL, V47, P11, DOI 10.1023/A:1006426917654; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Burckhardt BC, 2005, AM J PHYSIOL-RENAL, V288, pF792, DOI 10.1152/ajprenal.00360.2004; Campos F, 2011, J CEREB BLOOD FLOW M; Campos F, J CEREB BLOOD FLOW M; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Cohen-Kashi-Malina K, J CEREB BLOOD FLOW M; de Groot J, 2011, GLIA, V59, P1181, DOI 10.1002/glia.21113; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; HAUSSINGER D, 1989, EUR J BIOCHEM, V185, P189, DOI 10.1111/j.1432-1033.1989.tb15101.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Ishiuchi S, 2007, J NEUROSCI, V27, P7987, DOI 10.1523/JNEUROSCI.2180-07.2007; Kollareddy M, 2008, BIOMED PAP, V152, P27, DOI 10.5507/bp.2008.004; Loh JK, BMC CANC, V10, P268; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Ma DQ, 2004, BRIT MED BULL, V71, P77, DOI 10.1093/bmb/ldh036; OKA A, 1993, J NEUROSCI, V13, P1441; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215; Philip M, 2009, STROKE, V40, P577, DOI 10.1161/STROKEAHA.108.524330; Rich JN, 2004, NAT REV DRUG DISCOV, V3, P430, DOI 10.1038/nrd1380; Rijpkema M, 2003, NMR BIOMED, V16, P12, DOI 10.1002/nbm.807; Roslin M, 2003, J NEURO-ONCOL, V61, P151, DOI 10.1023/A:1022106910017; Sontheimer H, 2004, MOL NEUROBIOL, V29, P61, DOI 10.1385/MN:29:1:61; Sontheimer H, 2003, TRENDS NEUROSCI, V26, P543, DOI 10.1016/j.tins.2003.08.007; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Ye ZC, 1999, CANCER RES, V59, P4383; Ye ZC, 1999, J NEUROSCI, V19, P10767; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zlotnik A, 2009, J NEUROSURG ANESTH, V21, P235, DOI 10.1097/ANA.0b013e3181a2bf0b	35	26	26	0	9	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0167-6997			INVEST NEW DRUG	Invest. New Drugs	DEC	2012	30	6					2226	2235		10.1007/s10637-012-9794-x			10	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	029BP	WOS:000310470100015	22392507	Other Gold, Green Published			2021-06-18	
J	Wu, HT; Mahmood, A; Qu, CS; Xiong, Y; Chopp, M				Wu, Hongtao; Mahmood, Asim; Qu, Changsheng; Xiong, Ye; Chopp, Michael			Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons	BRAIN RESEARCH			English	Article						Axonal injury; Glycogen synthase kinase 3 beta; Neurite outgrowth; Simvastatin; Traumatic brain injury	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; REDUCTASE INHIBITORS; ADULT CNS; REGENERATION; LITHIUM; STROKE; DAMAGE; GROWTH; MODEL	The beneficial effects of simvastatin on experimental traumatic brain injury (TBI) have been demonstrated in previous studies. In this study, we investigated the effects of simvastatin on axonal injury and neurite outgrowth after experimental TBI and explored the underlying mechanisms. Wistar rats were subjected to controlled cortical impact or sham surgery. Saline or simvastatin was administered for 14 days. A modified neurological severity score (mNSS) test was performed to evaluate functional recovery. Immunohistochemistry studies using synaptophysin, neurofilament H (NF-H) and amyloid-beta precursor protein (APP) were performed to examine synaptogenesis and axonal injury. Primary cortical neurons (PCNs) were subjected to oxygen glucose deprivation (OGD) followed by various treatments. Western blot analysis was utilized to assess the activation of phosphatidylinositol-3 kinase (PI-3 K)/Akt/mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3 beta (GSK-3 beta)/adenomatous polyposis coli (APC) pathways. Simvastatin decreased the density of APP-positive profiles and increased the density of NF-H-positive profiles. Simvastatin reduced mNSS, which was correlated with the increase of axonal density. Simvastatin treatment stimulated the neurite outgrowth of PCNs after OGD, which was attenuated by LY294002 and enhanced by lithium chloride (LiCl). Simvastatin activated Akt and mTOR, inactivated GSK-3 beta and dephosphorylated APC in the injured PCNs. Our data suggest that simvastatin reduces axonal injury, enhances neurite outgrowth and promotes neurological functional recovery after experimental TBI. The beneficial effects of simvastatin on neurite outgrowth may be mediated through manipulation of the PI-3 K/Akt/mTOR and PI-3 K/GSK-3 beta/APC pathways. (C) 2012 Elsevier B.V. All rights reserved.	[Wu, Hongtao; Mahmood, Asim; Qu, Changsheng; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg 3072,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052280-01A1, R01AG037506]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, R01NS088656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG037506] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grants R01NS052280-01A1 (A.M.), and R01AG037506 (M.C.)	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Barth AIM, 2008, SEMIN CELL DEV BIOL, V19, P245, DOI 10.1016/j.semcdb.2008.02.003; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Chauhan NB, 2010, BRAIN RES, V1360, P177, DOI 10.1016/j.brainres.2010.09.010; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Culmsee C, 2003, J NEUROSCI, V23, P8586; Di Giovanni S, 2009, EXPERT OPIN THER TAR, V13, P1387, DOI 10.1517/14728220903307517; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Goold RG, 2004, BIOCHEM SOC T, V32, P809, DOI 10.1042/BST0320809; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Jope RS, 1999, MOL PSYCHIATR, V4, P117, DOI 10.1038/sj.mp.4000494; Kavanova M, 2005, ANN BOT-LONDON, V95, P457, DOI 10.1093/aob/mci054; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee JK, 2009, J NEUROSCI, V29, P8649, DOI 10.1523/JNEUROSCI.1864-09.2009; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lucas FR, 1998, J CELL SCI, V111, P1351; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Povlishock J T, 2000, Clin Neurosurg, V46, P113; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Read DE, 2009, CELL MOL LIFE SCI, V66, P2975, DOI 10.1007/s00018-009-0057-8; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; SALTHOUSE TN, 1964, STAIN TECHNOL, V39, P123; SatoSuzuki I, 1996, NEUROSCI LETT, V220, P21, DOI 10.1016/S0304-3940(96)13221-3; Shehadah A, 2010, J NEUROL SCI, V294, P107, DOI 10.1016/j.jns.2010.03.020; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Teng FYH, 2006, J NEUROCHEM, V96, P1501, DOI 10.1111/j.1471-4159.2006.03663.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Bohlen und Halbach O, 1998, J NEUROSCI METH, V81, P169, DOI 10.1016/S0165-0270(98)00026-0; Votin V, 2005, J CELL SCI, V118, P5699, DOI 10.1242/jcs.02679; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2011, NEUROSURGERY, V68, P1363, DOI 10.1227/NEU.0b013e31820c06b9; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	58	26	26	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 27	2012	1486						121	130		10.1016/j.brainres.2012.09.039			10	Neurosciences	Neurosciences & Neurology	049KX	WOS:000311983000012	23026078	Green Accepted			2021-06-18	
J	Cuthbert, JP; Corrigan, JD; Whiteneck, GG; Harrison-Felix, C; Graham, JE; Bell, JM; Coronado, VG				Cuthbert, Jeffrey P.; Corrigan, John D.; Whiteneck, Gale G.; Harrison-Felix, Cynthia; Graham, James E.; Bell, Jeneita M.; Coronado, Victor G.			Extension of the Representativeness of the Traumatic Brain Injury Model Systems National Database: 2001 to 2010	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						methodology; rehabilitation; traumatic brain injury		Objective: To extend the representativeness of the Traumatic Brain Injury Model Systems National Database (TBIMS-NDB) for individuals 16 years and older, admitted for acute, inpatient rehabilitation in the United States with a primary diagnosis of traumatic brain injury (TBI) analyses completed by Corrigan and colleagues by comparing this data set to national data for patients admitted to inpatient rehabilitation with identical inclusion criteria that included 3 additional years of data and 2 new demographic variables. Design: Secondary analysis of existing data sets and extension of previously published analyses. Setting: Acute inpatient rehabilitation facilities. Participants: Patients 16 years and older with a primary rehabilitation diagnosis of TBI; the US TBI Rehabilitation population, n = 156 447; and the TBIMS-NDB population, n = 7373. Interventions: None. Main Outcome Measures: Demographics, functional status, and length of stay in hospital. Results: The TBIMS-NDB was largely representative of patients 16 years and older, admitted for rehabilitation in the United States with a primary diagnosis of TBI on or after October 1, 2001, and discharged as of December 31, 2010. The results of the extended analyses were similar to those reported by Corrigan and colleagues. Age accounted for the largest difference between the samples, with the TBIMS-NDB including a smaller proportion of patients 65 years and older than all those admitted for rehabilitation with a primary diagnosis of TBI in the United States. After partitioning each data set at age 65, most distributional differences found between samples were markedly reduced; however, differences in the preinjury vocational status of the employed and rehabilitation lengths of stay between 1 and 9 days remained robust. The subsamples of patients 64 years and younger were found to differ only slightly on all remaining variables, whereas those 65 years and older were found to have meaningful differences in insurance type and age distribution. Conclusions: These results reconfirm that the TBIMS-NDB is largely representative of patients with TBI receiving inpatient rehabilitation in the United States. Differences between the 2 data sets were found to be stable across the 3 additional years of data, and new differences were limited to those involving newly introduced variables. To use these data for population-based research, it is strongly recommended that statistical adjustment be conducted to account for the lower percentage of patients older than 65 years, inpatient rehabilitation stays less than 10 days, and preinjury vocational status in the TBIMS-NDB.	[Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Harrison-Felix, Cynthia] Craig Hosp, Dept Res, Englewood, CO 80113 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA; [Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Cuthbert, JP (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@Craighospital.org	Corrigan, John D./E-2921-2011		US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; National Institute on Disability and Rehabilitation Research (NIDRR) [H133A110006]; US Department of EducationUS Department of Education; Office of Special Education and Rehabilitative Services; TBI Model System Centers grant from NIDRR [H133A070029]; National Institutes of Health National Center for Medical Rehabilitation Research within the National Institute of Child Health and Human Development [R24 HD065702]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065702, P2CHD065702] Funding Source: NIH RePORTER	This research was supported by an intra-agency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and the National Institute on Disability and Rehabilitation Research (NIDRR), US Department of Education, Office of Special Education and Rehabilitative Services, with supplemental funding to the NIDRR-funded Traumatic Brain Injury (TBI) Model Systems National Data and Statistical Center (grant H133A110006). It was also supported by a TBI Model System Centers grant (H133A070029) from the NIDRR to Ohio State University and by a grant (R24 HD065702) from the National Institutes of Health National Center for Medical Rehabilitation Research within the National Institute of Child Health and Human Development. This article does not reflect the official policy or opinions of the CDC or the US Department of HHS and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. The TBI Model Systems National Database is supported by the NIDRR and created and maintained by the TBI Model Systems Centers Program. However, these contents do not necessarily reflect the opinions or views of the TBI Model Systems Centers, the NIDRR, or the US Department of Education.	Centers for Medicare & Medicaid Services, INP REH FAC PAT ASS; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Marr AL., 2004, CENTRAL NERVOUS SYST; Stineman MG, 2002, ARCH PHYS MED REHAB, V83, P1802, DOI 10.1053/apmr.2002.36067; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD	6	26	26	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E15	E27		10.1097/HTR.0b013e31826da983			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200002	23131967	Green Accepted			2021-06-18	
J	Fang, F; Chen, HL; Feldman, AL; Kamel, F; Ye, WM; Wirdefeldt, K				Fang, Fang; Chen, Honglei; Feldman, Adina L.; Kamel, Freya; Ye, Weimin; Wirdefeldt, Karin			Head injury and Parkinson's disease: A population-based study	MOVEMENT DISORDERS			English	Article						Parkinson disease; head injury; nested case-control study; odds ratio	ENVIRONMENTAL RISK-FACTORS; TRAUMATIC BRAIN-INJURY; HISTORY	Background: The epidemiological evidence on head injury and the risk of Parkinson's disease (PD) has been inconsistent. Methods: We examined the relation between previous hospitalization for head injury and PD using a population-based nested case-control design based on the Swedish National Patient Register from 2001 until 2007, including 18,648 PD cases and 93,240 controls, randomly selected from the general population. Exposure was defined as hospitalization for head injury between 1987 and index date. Results: Overall, previous hospitalization resulting from head injury was associated with an increased risk of PD; this association appeared to be largely explained by head injuries experienced recently, especially within 1 year before PD ascertainment. Conclusions: Our results do not provide convincing evidence for a causal relationship between head injury later in life and PD. (C) 2012 Movement Disorder Society	[Fang, Fang; Feldman, Adina L.; Ye, Weimin; Wirdefeldt, Karin] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden; [Chen, Honglei; Kamel, Freya] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; [Wirdefeldt, Karin] Karolinska Inst, Dept Clin Neurosci, SE-17177 Stockholm, Sweden	Wirdefeldt, K (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Box 281, SE-17177 Stockholm, Sweden.	karin.wirdefeldt@ki.se	Feldman, Adina/H-3435-2012	Feldman, Adina/0000-0002-9388-6896; Kamel, Freya/0000-0001-5052-6615; Fang, Fang/0000-0002-3310-6456; Chen, Honglei/0000-0003-3446-7779	Swedish Research Council (SIMSAM)Swedish Research Council [80748301]; Swedish Parkinson Foundation; Swedish Medical Society; Swedish Society for Medical Research; Swedish Brain Foundation; National Institutes of Health, the National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01-ES-101986]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01ES101986, ZIAES101986, ZIAES044007] Funding Source: NIH RePORTER	The study was supported by the Swedish Research Council (SIMSAM grant no. 80748301), the Swedish Parkinson Foundation, the Swedish Medical Society, the Swedish Society for Medical Research, the Swedish Brain Foundation, and the intramural research program of the National Institutes of Health, the National Institute of Environmental Health Sciences (Z01-ES-101986 and unmet need funding). The funding sources had no role in the design of the study or the decision to submit the manuscript for publication.	Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Dahl E, 2006, INJURY, V37, P402, DOI 10.1016/j.injury.2005.09.008; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dong JQ, 2003, BIOMED ENVIRON SCI, V16, P173; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Feldman AL, 2012, NEUROEPIDEMIOLOGY, V38, P186, DOI 10.1159/000336356; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hawkes CH, 2010, PARKINSONISM RELAT D, V16, P79, DOI 10.1016/j.parkreldis.2009.08.007; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; LACAVA G, 1963, J Sports Med Phys Fitness, V3, P87; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Logroscino G, 2005, ENVIRON HEALTH PERSP, V113, P1234, DOI 10.1289/ehp.7573; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Tsai CH, 2002, CLIN NEUROL NEUROSUR, V104, P328, DOI 10.1016/S0303-8467(02)00027-6; Wirdefeldt K, 2008, NEUROBIOL AGING, V29, P1765, DOI 10.1016/j.neurobiolaging.2007.04.009; Wirdefeldt K, 2011, EUR J EPIDEMIOL, V26, pS1, DOI 10.1007/s10654-011-9581-6; Wright JM, 2005, ARCH ENVIRON HEALTH, V60, P32, DOI 10.3200/AEOH.60.1.32-38	22	26	26	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	NOV	2012	27	13					1632	1635		10.1002/mds.25143			4	Clinical Neurology	Neurosciences & Neurology	045KU	WOS:000311695500013	23143933				2021-06-18	
J	Gradisek, P; Osredkar, J; Korsic, M; Kremzar, B				Gradisek, Primoz; Osredkar, Josko; Korsic, Marjan; Kremzar, Boriana			Multiple indicators model of long-term mortality in traumatic brain injury	BRAIN INJURY			English	Article						S100B; NSE; GFAP; Glasgow Coma Scale; CT; prognostic model	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; PROGNOSTIC MODELS; SERUM; S100B; DAMAGE; GFAP; VALIDATION; CLASSIFICATION	Objective: To examine the prognostic ability of protein S100B, neuron-specific enolase (NSE) and glial fibrillary acid protein (GFAP) for prediction of 1-year mortality in patients with traumatic brain injury (TBI) in relation to clinical and radiological characteristics of TBI. Methods: Brain injury was quantified in 84 patients (Glasgow Coma Scale [GCS] <= 12) using clinical (GCS, pupils), radiological (computed tomography [CT] classification and individual CT characteristics) and biochemical (S100B, NSE and GFAP) data at admission and in the acute post-injury period. Results: Initial and peak S100B, NSE and GFAP concentrations were higher in non-survivors (n = 26) than in survivors (p-value range: <0.001-0.018). Cox regression showed that GFAP and S100B concentration and the temporal profile of S100B were more powerful independent predictors of mortality than baseline clinical and radiological characteristics or clinical and radiological indicators of neurological deterioration. The prognostic models containing admission variables and those available during the subsequent clinical course showed the same discrimination ability (area under receiver characteristic curve 0.92), but the model based on variables available in the acute post-injury period calibrated better (p = 0.428). Conclusion: Mortality at 1-year post-TBI is accurately predicted by the combination of GFAP and S100B concentration and clinical and radiological characteristics at admission or in the acute post-injury period.	[Gradisek, Primoz; Kremzar, Boriana] Univ Med Ctr Ljubljana, Ctr Intens Therapy, Clin Dept Anaesthesiol & Intens Therapy, Ljubljana 1000, Slovenia; [Osredkar, Josko] Univ Med Ctr Ljubljana, Clin Inst Clin Chem & Clin Biochem, Ljubljana 1000, Slovenia; [Korsic, Marjan] Univ Med Ctr Ljubljana, Clin Dept Neurosurg, Ljubljana 1000, Slovenia	Gradisek, P (corresponding author), Univ Med Ctr Ljubljana, Ctr Intens Therapy, Clin Dept Anaesthesiol & Intens Therapy, Zaloska 7, Ljubljana 1000, Slovenia.	primoz.gradisek@kclj.si		Gradisek, Primoz/0000-0002-1741-3798			Altman DG, 1990, PRACTICAL STAT MED R, P365; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kochanek PM, 2007, J NEUROTRAUM, V24, P1, DOI 10.1089/neu.2006.0209; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Servadei F, 2000, NEUROSURGERY, V46, P70; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thelin E, 2009, J NEUROTRAUM, V26, pA44; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Xu XY, 2007, BRAIN INJURY, V21, P575, DOI 10.1080/02699050701426881	36	26	26	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2012	26	12					1472	1481		10.3109/02699052.2012.694567			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	022DL	WOS:000309935400008	22721420				2021-06-18	
J	Squarcina, L; Bertoldo, A; Ham, TE; Heckemann, R; Sharp, DJ				Squarcina, Letizia; Bertoldo, Alessandra; Ham, Timothy E.; Heckemann, Rolf; Sharp, David J.			A robust method for investigating thalamic white matter tracts after traumatic brain injury	NEUROIMAGE			English	Article						Diffusion tensor imaging; Tractography; Thalamus; Traumatic axonal injury	DIFFUSE AXONAL INJURY; PROBABILISTIC TRACTOGRAPHY; STRUCTURAL CONNECTIVITY; MULTIPLE-SCLEROSIS; HEAD TRAUMA; TENSOR MRI; MILD; SEGMENTATION; NEUROPATHOLOGY; RECONSTRUCTION	Damage to the structural connections of the thalamus is a frequent feature of traumatic brain injury (TBI) and can be a key factor in determining clinical outcome. Until recently it has been difficult to quantify the extent of this damage in vivo. Diffusion tensor imaging (DTI) provides a validated method to investigate traumatic axonal injury, and can be applied to quantify damage to thalamic connections. DTI can also be used to assess white matter tract structure using tractography, and this technique has been used to study thalamo-cortical connections in the healthy brain. However, the presence of white matter injury can cause failure of tractography algorithms. Here, we report a method for investigating thalamo-cortical connectivity that bypasses the need for individual tractography. We first created a template for a number of thalamo-cortical connections using probabilistic tractography performed in ten healthy subjects. This template for investigating white matter structure was validated by comparison with individual tractography in the same group, as well as in an independent control group (N = 11). We also evaluated two methods of masking tract location using the tract skeleton generated by tract based spatial statistics, and a cerebrospinal fluid mask Voxel-wise estimates of fractional anisotropy derived from the template were more strongly correlated with individual tractography when both types of masking were used. The tract templates were then used to sample DTI measures from a group of TBI patients (N = 22), with direct comparison performed against probabilistic tractography in individual patients. Probabilistic tractography often failed to produce anatomically plausible tracts in TBI patients. Importantly, we show that this problem increases as tracts become more damaged, and leads to underestimation of the amount of traumatic axonal injury. In contrast, the tract template can be used in these cases, allowing a more accurate assessment of white matter damage. In summary, we propose a method suitable for assessing specific thalamo-cortical white matter connections after TBI that is robust to the presence of varying amounts of traumatic axonal injury, as well as highlighting the potential problems of applying tractography algorithms in patient populations. (C) 2012 Elsevier Inc. All rights reserved.	[Squarcina, Letizia; Bertoldo, Alessandra] Univ Padua, Dept Informat Engn, I-35131 Padua, Italy; [Ham, Timothy E.; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England; [Heckemann, Rolf] CERMEP Imagerie Vivant, Neurodis Fdn, F-69003 Lyon, France; [Heckemann, Rolf] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London W12 0NN, England	Sharp, DJ (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Heckemann, Rolf Andreas/H-9022-2019; Sharp, David J/A-2119-2013; Squarcina, Letizia/J-9869-2016	Heckemann, Rolf Andreas/0000-0003-3582-3683; Squarcina, Letizia/0000-0001-6209-4629; Bertoldo, Alessandra/0000-0002-6262-6354	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Imperial College Healthcare Charity; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951] Funding Source: researchfish	This work was supported by grants from The Medical Research Council (UK) to DJS and The Imperial College Healthcare Charity to DJS. We would like to thank all the subjects who took part in this study.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alkonyi B, 2011, AM J NEURORADIOL, V32, P962, DOI 10.3174/ajnr.A2417; Alkonyi B, 2010, EUR J PAEDIATR NEURO, V14, P425, DOI 10.1016/j.ejpn.2010.03.012; Andersson J., 2008, 14 ANN M ORG HUM BRA; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bruns J. Jr., 2003, EPILEPSIA, V10, P2, DOI DOI 10.1046/J.1528-1157.44.S10.3.X; Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Glenn OA, 2003, J MAGN RESON IMAGING, V18, P641, DOI 10.1002/jmri.10420; Gousias IS, 2008, NEUROIMAGE, V40, P672, DOI 10.1016/j.neuroimage.2007.11.034; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; Hashimoto K, 2007, J REHABIL MED, V39, P418, DOI 10.2340/16501977-0065; Heckemann RA, 2006, NEUROIMAGE, V33, P115, DOI 10.1016/j.neuroimage.2006.05.061; Heckemann RA, 2011, NEUROIMAGE, V56, P2024, DOI 10.1016/j.neuroimage.2011.03.014; Heckemann RA, 2010, NEUROIMAGE, V51, P221, DOI 10.1016/j.neuroimage.2010.01.072; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kanaan RA, 2006, PSYCHIAT RES-NEUROIM, V146, P73, DOI 10.1016/j.pscychresns.2005.11.002; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pagani E, 2005, NEUROIMAGE, V26, P258, DOI 10.1016/j.neuroimage.2005.01.008; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reich DS, 2010, NEUROIMAGE, V49, P3047, DOI 10.1016/j.neuroimage.2009.11.043; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tozer DJ, 2012, NEUROIMAGE, V59, P3094, DOI 10.1016/j.neuroimage.2011.10.088; Traynor C, 2010, NEUROIMAGE, V52, P69, DOI 10.1016/j.neuroimage.2010.04.024; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Xue R, 1999, MAGNET RESON MED, V42, P1123, DOI 10.1002/(SICI)1522-2594(199912)42:6<1123::AID-MRM17>3.0.CO;2-H; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	53	26	26	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	NOV 1	2012	63	2					779	788		10.1016/j.neuroimage.2012.07.016			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	013VY	WOS:000309335200015	22813952	Green Published, Other Gold			2021-06-18	
J	Cooper, DB; Chau, PM; Armistead-Jehle, P; Vanderploeg, RD; Bowles, AO				Cooper, Douglas B.; Chau, Phuong M.; Armistead-Jehle, Patrick; Vanderploeg, Rodney D.; Bowles, Amy O.			Relationship Between Mechanism of Injury and Neurocognitive Functioning in OEF/OIF Service Members With Mild Traumatic Brain Injuries	MILITARY MEDICINE			English	Article								Military personnel deployed to combat theaters in Iraq and Afghanistan are at risk of sustaining mild traumatic brain injuries (mTBI) from causes such as improvised explosive devices, motor vehicle accidents, and falls. Despite the high incidence of mTBI in deployed personnel, questions remain about the effects of blast-related vs. non-blast-related mTBI on acute and long-term sequelae. This investigation is a retrospective review of service members who presented for evaluation of suspected mTBI and underwent neurocognitive screening evaluation. mTBI diagnosis was made by semistructured clinical interview. Only individuals in whom mechanism of injury could be determined (blast vs. non-blast) were included. Sixty individuals were included in the final sample: 32 with blast mTBI and 28 with non-blast mTBI. There were no differences between the blast-related and non-blast-related mTBI groups on age, time since injury, combat stress symptoms, or headache. Analysis of variance showed no significant between-group differences on any of the neurocognitive performance domains. Although speculation remains that the effects of primary blast exposure are unique, the results of this study are consistent with prior research suggesting that blast-related mTBI does not differ from other mechanisms of injury with respect to cognitive sequelae in the postacute phase.	[Cooper, Douglas B.; Chau, Phuong M.; Bowles, Amy O.] San Antonio Mil Med Ctr, Dept Orthoped & Rehabil, Traumat Brain Injury Serv, Ft Sam Houston, TX 78234 USA; [Cooper, Douglas B.; Vanderploeg, Rodney D.] San Antonio Mil Med Ctr, DVBIC, Ft Sam Houston, TX 78234 USA; [Armistead-Jehle, Patrick] Munson Army Hlth Ctr, Concuss Clin, Fort Leavenworth, KS 66027 USA; [Vanderploeg, Rodney D.] James A Haley VA Med Ctr, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA	Cooper, DB (corresponding author), San Antonio Mil Med Ctr, Dept Orthoped & Rehabil, Traumat Brain Injury Serv, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.		Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Casscells S., 2007, HLTH AFFAIRS MEMORAN; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cohen J., 1983, APPL MULTIPLE REGRES; Friedl KE, 2009, P INT STAT SCI M NON; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mckay C, 2008, CLIN NEUROPSYCHOL, V22, P228, DOI 10.1080/13854040701260370; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C, 1998, REPEATABLE BATTERY A; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Ware JE, 2000, NEUROLOGY, V54, pA336; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	19	26	26	0	5	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2012	177	10					1157	1160		10.7205/MILMED-D-12-00098			4	Medicine, General & Internal	General & Internal Medicine	V33OE	WOS:000209027300011	23113441	Bronze			2021-06-18	
J	Scalfani, MT; Dhar, R; Zazulia, AR; Videen, TO; Diringer, MN				Scalfani, Michael T.; Dhar, Rajat; Zazulia, Allyson R.; Videen, Tom O.; Diringer, Michael N.			Effect of osmotic agents on regional cerebral blood flow in traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article						Osmotic agents; Cerebral blood flow; Traumatic brain injury; Intracranial hypertension	HYPERTONIC SALINE; INTRACRANIAL HYPERTENSION; MANNITOL; PRESSURE; 7.5-PERCENT; METABOLISM; MANAGEMENT	Purpose: Cerebral blood flow (CBF) is reduced after severe traumatic brain injury (TBI) with considerable regional variation. Osmotic agents are used to reduce elevated intracranial pressure (ICP), improve cerebral perfusion pressure, and presumably improve CBF. Yet, osmotic agents have other physiologic effects that can influence CBF. We sought to determine the regional effect of osmotic agents on CBF when administered to treat intracranial hypertension. Materials and Methods: In 8 patients with acute TBI, we measured regional CBF with positron emission tomography before and 1 hour after administration of equi-osmolar 20% mannitol (1 g/kg) or 23.4% hypertonic saline (0.686 mL/kg) in regions with focal injury and baseline hypoperfusion (CBF <25 mL per 100 g/min). Results: The ICP fell (22.4 +/- 5.1 to 15.7 +/- 7.2 mm Hg, P = .007), and cerebral perfusion pressure rose (75.7 +/- 5.9 to 81.9 +/- 10.3 mm Hg, P = .03). Global CBF tended to rise (30.9 +/- 3.7 to 33.1 +/- 4.2 mL per 100 g/min, P = .07). In regions with focal injury, baseline flow was 25.7 +/- 9.1 mL per 100 g/min and was unchanged; in hypoperfused regions (15% of regions), flow rose from 18.6 +/- 5.0 to 22.4 +/- 6.4 mL per 100 g/min (P < .001). Osmotic therapy reduced the number of hypoperfused brain regions by 40% (P < .001). Conclusion: Osmotic agents, in addition to lowering ICP, improve CBF to hypoperfused brain regions in patients with intracranial hypertension after TBI. (C) 2012 Elsevier Inc. All rights reserved.	[Scalfani, Michael T.; Dhar, Rajat; Zazulia, Allyson R.; Videen, Tom O.; Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Dhar, Rajat; Diringer, Michael N.] Washington Univ, Sch Med, Neurol Neurosurg Intens Care Unit, St Louis, MO 63110 USA; [Zazulia, Allyson R.; Videen, Tom O.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA	Diringer, MN (corresponding author), Washington Univ, Sch Med, Dept Neurol, Campus Box 8111, St Louis, MO 63110 USA.	diringerm@neuro.wustl.edu	Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537; Dhar, Rajat/0000-0002-5167-5097	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS03596610, UL1 RR024992]; NIH National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024992]; NIH National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P01NS035966]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966, P50NS035966] Funding Source: NIH RePORTER	Funded by NIH grant number(s): NS03596610 and UL1 RR024992.; The authors thank Angela Shackelford, RN, John Hood, and the cyclotron and NNICU staff for their assistance in conducting this research and caring for these patients. This work was supported by the NIH National Center for Research Resources (UL1 RR024992) and the NIH National Institutes of Neurological Disorders and Stroke (5P01NS035966).	Allen CH, 1998, CRIT CARE CLIN, V14, P485, DOI 10.1016/S0749-0704(05)70012-9; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; DIRNAGL U, 1990, J CEREBR BLOOD F MET, V10, P327, DOI 10.1038/jcbfm.1990.61; Forsyth LL, 2008, PHARMACOTHERAPY, V28, P469, DOI 10.1592/phco.28.4.469; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; KIESEWETTER H, 1982, BIORHEOLOGY, V19, P737; KLEISER B, 1992, STROKE, V23, P171, DOI 10.1161/01.STR.23.2.171; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Videen TO, 2001, NEUROLOGY, V57, P2120, DOI 10.1212/WNL.57.11.2120; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	30	26	30	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	OCT	2012	27	5							526.e7	10.1016/j.jcrc.2011.10.008			6	Critical Care Medicine	General & Internal Medicine	025PP	WOS:000310204300031	22176808	Green Accepted			2021-06-18	
J	de Jongh, MAC; van Stel, HF; Schrijvers, AJP; Leenen, LPH; Verhofstad, MHJ				de Jongh, Mariska A. C.; van Stel, Henk F.; Schrijvers, Augustinus J. P.; Leenen, Luke P. H.; Verhofstad, Michael H. J.			The effect of Helicopter Emergency Medical Services on trauma patient mortality in the Netherlands	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Trauma; Mortality; Prehospital care; HEMS	INJURY SEVERITY SCORE; ON-SCENE TIMES; BRAIN-INJURY; ENDOTRACHEAL INTUBATION; GOLDEN HOUR; CARE; SURVIVAL; SCALE; IMPACT; COHORT	Introduction: Object of this study was to evaluate the effect of the Helicopter Emergency Medical Services (HEMS) on trauma patient mortality and the effect of prehospital time on the association between HEMS and mortality. Materials and methods: Trauma patients admitted to a level 1 trauma centre and treated on-scene by the HEMS and Emergency Medical Services (EMS) between 2003 and 2008 were included (n = 186). A control group treated by EMS only (n = 186) was created by matching on ISS, age and severe traumatic brain injury (TBI). Mortality was compared by calculating odds ratios (OR) and numbers needed to treat (NNT), with adjustment for prehospital coded Revised Trauma Score. The effect of prehospital time mortality was tested by a logistic regression. Analyses were made for patients with and without TBI. Results: The OR of early trauma fatality for the HEMS/EMS versus EMS-only groups was 0.8 for patients both with TBI (95% CI 0.4-1.7; NNT: 22) and without TBI (95% CI 0.2-3.3; NNT: 273). The risk of in-hospital mortality was non-significantly higher for patients with TBI in the HEMS/EMS group (OR = 1.3; 95% CI 0.6-2.7; NNT: -15) compared to the EMS-only group and non-significantly lower for patients without TBI (OR = 0.9; 95% CI 0.3-2.5; NNT: 129). After adjustment for prehospital time, the risk of early trauma fatality for patients with TBI treated by the HEMS decreased (OR = 0.6; 95% CI 0.3-1.6). The risk of in-hospital mortality for these patients decreased from 1.3 to 0.8 (95% CI 0.4-2.0). The effect of the HEMS on patients without TBI did not change after adjustment for prehospital time. Discussion: HEMS treatment is associated with a non-significantly higher risk of in-hospital mortality for patients with TBI and a non-significantly lower risk for patients without TBI. This increased risk of mortality in TBI patients is attributable to the increased prehospital time. These results indicate that HEMS does not have a positive impact on survival. (C) 2012 Elsevier Ltd. All rights reserved.	[de Jongh, Mariska A. C.; Verhofstad, Michael H. J.] St Elizabeth Hosp, Trauma Ctr Brabant, NL-5000 LC Tilburg, Netherlands; [van Stel, Henk F.; Schrijvers, Augustinus J. P.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Leenen, Luke P. H.] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands; [Verhofstad, Michael H. J.] St Elizabeth Hosp, Dept Surg, NL-5000 LC Tilburg, Netherlands	de Jongh, MAC (corresponding author), St Elizabeth Hosp, Trauma Ctr Brabant, POB 90151, NL-5000 LC Tilburg, Netherlands.	m.d.jongh@elisabeth.nl		van Stel, Henk/0000-0002-3475-9846; Leenen, Luke/0000-0001-8385-1801			[Anonymous], 2011, NUMB NEED TREAT; [Anonymous], 2011, KERNC PROV 2010; Association for the Advancement of Automotive Medicine (AAAM), 1998, COMM INJ SCAL ABBR I; Aydin S, 2010, J TRAUMA, V69, P589, DOI 10.1097/TA.0b013e3181e74858; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Carr BG, 2008, PREHOSP EMERG CARE, V12, P327, DOI 10.1080/10903120802096928; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; de Jongh MAC, 2010, BRIT J SURG, V97, P1805, DOI 10.1002/bjs.7216; de Jongh MAC, 2008, INJURY, V39, P1007, DOI 10.1016/j.injury.2008.03.026; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iirola TT, 2006, EUR J EMERG MED, V13, P335, DOI 10.1097/01.mej.0000224429.51623.fb; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; Lemson J, 2008, Ned Tijdschr Geneeskd, V152, P1106; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Mitchell AD, 2007, CAN J SURG, V50, P129; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Osler T, 2008, ANN SURG, V247, P1041, DOI 10.1097/SLA.0b013e31816ffb3f; Ringburg Akkie N, 2005, Air Med J, V24, P248, DOI 10.1016/j.amj.2005.08.002; Ringburg AN, 2007, J TRAUMA, V63, P258, DOI 10.1097/01.ta.0000240449.23201.57; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Spaite DW, 2003, ANN EMERG MED, V42, P729, DOI 10.1016/S0196-0644(03)00822-9; van der Velden MWA, 2008, EMERG MED J, V25, P444, DOI 10.1136/emj.2007.052662; Zink BJ, 2004, ANN EMERG MED, V44, P451, DOI 10.1016/j.annemergmed.2004.05.001	29	26	26	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1362	1367		10.1016/j.injury.2012.01.009			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100005	22305588				2021-06-18	
J	Edlow, BL; Wu, O				Edlow, Brian L.; Wu, Ona			Advanced Neuroimaging in Traumatic Brain Injury	SEMINARS IN NEUROLOGY			English	Article						traumatic brain injury (TBI); susceptibility-weighted imaging (SWI); diffusion tensor imaging (DTI); high angular resolution diffusion imaging (HARDI); functional MRI (fMRI); traumatic axonal injury (TAI)	DIFFUSE AXONAL INJURY; DEFAULT-MODE NETWORK; AMYLOID PRECURSOR PROTEIN; MINIMALLY CONSCIOUS STATE; WHITE-MATTER INTEGRITY; COMMON DATA ELEMENTS; RESTING-STATE; VEGETATIVE STATE; HEAD-INJURY; FUNCTIONAL CONNECTIVITY	Advances in structural and functional neuroimaging have occurred at a rapid pace over the past two decades. Novel techniques for measuring cerebral blood flow, metabolism, white matter connectivity, and neural network activation have great potential to improve the accuracy of diagnosis and prognosis for patients with traumatic brain injury (TB!), while also providing biomarkers to guide the development of new therapies. Several of these advanced imaging modalities are currently being implemented into clinical practice, whereas others require further development and validation. Ultimately, for advanced neuroimaging techniques to reach their full potential and improve clinical care for the many civilians and military personnel affected by TB!, it is critical for clinicians to understand the applications and methodological limitations of each technique. In this review, we examine recent advances in structural and functional neuroimaging and the potential applications of these techniques to the clinical care of patients with TBI. We also discuss pitfalls and confounders that should be considered when interpreting data from each technique. Finally, given the vast amounts of advanced imaging data that will soon be available to clinicians, we discuss strategies for optimizing data integration, visualization, and interpretation.	[Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Edlow, Brian L.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Edlow, Brian L.; Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Wu, Ona] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA	Edlow, BL (corresponding author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St Lunder 650, Boston, MA 02114 USA.	bedlow@partners.org		Wu, Ona/0000-0002-5509-9461	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, P41RR14075]; Center for Integration of Medicine & Innovative Technology (Boston, MA); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (R25NS065743 and P41RR14075) and the Center for Integration of Medicine & Innovative Technology (Boston, MA).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alexander DC, 2011, DIFFUSION MRI, P451; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, J HEAD TRAUMA REHABI; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Betz J, 2012, J NEUROTRAUM, V29, P1292, DOI 10.1089/neu.2011.2215; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Chen YF, 2011, J MAGN RESON IMAGING, V33, P940, DOI 10.1002/jmri.22345; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Clark CA, 2000, MAGN RESON MED, V44, P852, DOI 10.1002/1522-2594(200012)44:6<852::AID-MRM5>3.0.CO;2-A; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Cordonnier C, 2009, STROKE, V40, P94, DOI 10.1161/STROKEAHA.108.526996; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dai WY, 2008, MAGN RESON MED, V60, P1488, DOI 10.1002/mrm.21790; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Detre JA, 2002, CLIN NEUROPHYSIOL, V113, P621, DOI 10.1016/S1388-2457(02)00038-X; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; Edlow BL, 2010, NEUROLOGY, V75, pE69, DOI 10.1212/WNL.0b013e3181f962d7; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez-Espejo D, 2008, BRAIN INJURY, V22, P882, DOI 10.1080/02699050802403573; Fernandez-Seara MA, 2008, MAGN RESON MED, V59, P1467, DOI 10.1002/mrm.21633; Fins JJ, 2009, PROG BRAIN RES, V177, P371, DOI 10.1016/S0079-6123(09)17726-9; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Frank LR, 2001, MAGN RESON MED, V45, P935, DOI 10.1002/mrm.1125; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Fukunaga M, 2006, MAGN RESON IMAGING, V24, P979, DOI 10.1016/j.mri.2006.04.018; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GREENBERG JH, 1981, SCIENCE, V212, P678, DOI 10.1126/science.6971492; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hagmann P, 2005, THESIS U LAUSANNE LA, P1; Hansen B, 2011, NEUROIMAGE, V57, P1458, DOI 10.1016/j.neuroimage.2011.04.052; Helle M, 2010, MAGN RESON MED, V64, P777, DOI 10.1002/mrm.22451; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hess CP, 2007, NEUROIMAG CLIN N AM, V17, P407, DOI 10.1016/j.nic.2007.07.002; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2011, NEW ENGL J MED, V365, P860, DOI 10.1056/NEJMc1107891; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Janke AL, 2001, MAGNET RESON MED, V46, P661, DOI 10.1002/mrm.1243; Jansons KM, 2003, LECT NOTES COMPUT SC, V2732, P672; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones DK, 1999, MAGN RESON MED, V42, P37, DOI 10.1002/(SICI)1522-2594(199907)42:1<37::AID-MRM7>3.0.CO;2-O; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Kammond ME, 2009, ISMRM 17 SCI M EXH A; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kelly JP, 1997, NEUROLOGY, V48, P581; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kim J, 2012, PSYCHOPHARMACOLOGY, V222, P47, DOI 10.1007/s00213-011-2622-8; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Leergaard TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008595; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu AA, 2011, NEUROLOGY, V77, P1518, DOI 10.1212/WNL.0b013e318233b229; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Melhem ER, 2000, AM J NEURORADIOL, V21, P1813; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Muccio CF, 2009, BRAIN INJURY, V23, P466, DOI 10.1080/02699050902841912; Mulkern RV, 2009, MAGN RESON IMAGING, V27, P1151, DOI 10.1016/j.mri.2009.05.003; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Newsome MR, 2010, NEUROPSYCHOLOGY, V24, P139, DOI 10.1037/a0017432; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Palacios EM, 2012, CORTEX; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pieper S., 2004, IEEE INT S BIOMED IM, P632, DOI [10.1109/ISBI.2004.1398617, DOI 10.1109/ISBI.2004.1398617]; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Reese TG, 2009, J MAGN RESON IMAGING, V29, P517, DOI 10.1002/jmri.21497; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Rizzo J, MILITARY SURG MRIS W; Ropper A, 2011, NEW ENGL J MED, V364, P2156, DOI 10.1056/NEJMe1102187; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ropper AH, 2010, NEW ENGL J MED, V362, P648, DOI 10.1056/NEJMe0909667; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salat D, 1997, NEUROBIOL AGING, V18, P191, DOI 10.1016/S0197-4580(97)00014-6; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Setsompop K, 2012, MAGN RESON MED, V67, P1210, DOI 10.1002/mrm.23097; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Singh KD, 2008, NEUROIMAGE, V41, P100, DOI 10.1016/j.neuroimage.2008.01.051; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith K, 2012, NATURE, V484, P24, DOI 10.1038/484024a; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Sporns O., 2011, NETWORKS BRAIN; STEJSKAL EO, 1965, J CHEM PHYS, V43, P3597, DOI 10.1063/1.1696526; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Talairach J., 1988, COPLANAR STEREOTAXIC; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tanielian TL, 2008, INVISIBLE WOUNDS WAR, pxliii; Tensaouti F, 2011, J MAGN RESON IMAGING, V34, P165, DOI 10.1002/jmri.22584; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tournier JD, 2011, DIFFUSION MRI, P465; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wada T, 2012, AJNR AM J NEURORADIO; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang JY, 2012, NEUROIMAGE, V60, P1127, DOI 10.1016/j.neuroimage.2011.12.062; Wang R, TRACKVIS; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wedeen VJ, 2012, SCIENCE, V335, P1628, DOI 10.1126/science.1215280; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wong EC, 2006, MAGN RESON MED, V55, P1334, DOI 10.1002/mrm.20906; Worsley K.J., 2001, FUNCTIONAL MRI INTRO; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403; Wu WC, 2009, IEEE T MED IMAGING, V28, P703, DOI 10.1109/TMI.2008.2012020; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Xu V, 2008, SEMIN NEUROL, V28, P407, DOI 10.1055/s-0028-1083685; Yan CG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005743; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yoshiura T, 2001, MAGNET RESON MED, V45, P734, DOI 10.1002/mrm.1100; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008; Zaharchuk G, 2007, AM J NEURORADIOL, V28, P1850, DOI 10.3174/ajnr.A0831; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zoroya G, US TODAY	262	26	27	0	33	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	SEP	2012	32	4					374	400		10.1055/s-0032-1331810			27	Clinical Neurology	Neurosciences & Neurology	077AD	WOS:000313999400008	23361483	Green Accepted			2021-06-18	
J	von Holst, H; Li, XG; Kleiven, S				von Holst, Hans; Li, Xiaogai; Kleiven, Svein			Increased strain levels and water content in brain tissue after decompressive craniotomy	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Stroke; Decompressive craniotomy; Strain level; Water content	HOUNSFIELD UNIT; AXONAL DAMAGE; CRANIECTOMY; INJURY; DEFORMATION; EDEMA; GRAVITY; REGISTRATION; MRI; ICP	At present there is a debate on the effectiveness of the decompressive craniotomy (DC). Stretching of axons was speculated to contribute to the unfavourable outcome for the patients. The quantification of strain level could provide more insight into the potential damage to the axons. The aim of the present study was to evaluate the strain level and water content (WC) of the brain tissue for both the pre- and post-craniotomy period. The stretching of brain tissue was quantified retrospectively based on the computerised tomography (CT) images of six patients before and after DC by a non-linear image registration method. WC was related to specific gravity (SG), which in turn was related to the Hounsfield unit (HU) value in the CT images by a photoelectric correction according to the chemical composition of brain tissue. For all the six patients, the strain level showed a substantial increase in the brain tissue close to the treated side of DC compared with that found at the pre-craniotomy period and ranged from 24 to 55 % at the post-craniotomy period. Increase of strain level was also observed at the brain tissue opposite to the treated side, however, to a much lesser extent. The mean area of craniotomy was found to be 91.1 +/- 12.7 cm(2). The brain tissue volume increased from 27 to 127 ml, corresponding to 1.65 % and 8.13 % after DC in all six patients. Also, the increased volume seemed to correlate with increased strain level. Specifically, the overall WC of brain tissue for two patients evaluated presented a significant increase after the treatment compared with the condition seen before the treatment. Furthermore, the Glasgow Coma Scale (GCS) improved in four patients after the craniotomy, while two patients died. The GCS did not seem to correlate with the strain level. We present a new numerical method to quantify the stretching or strain level of brain tissue and WC following DC. The significant increase in strain level and WC in the post-craniotomy period may cause electrophysiological changes in the axons, resulting in loss of neuronal function. Hence, this new numerical method provides more insight of the consequences following DC and may be used to better define the most optimal size and area of the craniotomy in reducing the strain level development.	[von Holst, Hans] Karolinska Univ Hosp, Dept Neurosurg, SE-17176 Stockholm, Sweden; [von Holst, Hans] Karolinska Inst, Div Clin Neurosci, Sect Neurosurg, SE-17176 Stockholm, Sweden; [von Holst, Hans; Li, Xiaogai; Kleiven, Svein] Royal Inst Technol KTH, Div Neuron Engn, Sch Technol & Hlth, Stockholm, Sweden	von Holst, H (corresponding author), Karolinska Univ Hosp, Dept Neurosurg, SE-17176 Stockholm, Sweden.	hans.vonholst@karolinska.se		Li, Xiaogai/0000-0001-8522-4705	Swedish Research CouncilSwedish Research CouncilEuropean Commission [621-2008-3400]; Swedish Governmental Agency for Innovation Systems (VINNOVA)Vinnova; Chinese Council Scholarship (CSC)	We would like to acknowledge financial support provided by the Swedish Research Council D.nr. 621-2008-3400, the Swedish Governmental Agency for Innovation Systems (VINNOVA), and the Chinese Council Scholarship (CSC) for the second author.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BAJCSY R, 1989, COMPUT VISION GRAPH, V46, P1, DOI 10.1016/S0734-189X(89)80014-3; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Berger M, 2010, XCOM PHOTON CROSS SE; Boldea V, 2003, LECT NOTES COMPUT SC, V2878, P770; BORIS P, 1987, CHILD NERV SYST, V3, P175, DOI 10.1007/BF00717896; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; BROOKS RA, 1980, J COMPUT ASSIST TOMO, V4, P489, DOI 10.1097/00004728-198008000-00016; BROOKS RA, 1977, J COMPUT ASSIST TOMO, V1, P487, DOI 10.1097/00004728-197710000-00016; Cabezas M, 2011, COMPUT METH PROG BIO, V104, pE158, DOI 10.1016/j.cmpb.2011.07.015; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Crum WR, 2003, NEUROIMAGE, V20, P1425, DOI 10.1016/j.neuroimage.2003.07.014; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; Feigin V. L., 2007, HDB CLIN NEUROEPIDEM, P197; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fowler SS, 2001, OTOLARYNG HEAD NECK, V124, P641, DOI 10.1067/mhn.2001.115908; GAAB M, 1979, CHILD BRAIN, V5, P484; Gee J, 2003, ACAD RADIOL, V10, P1147, DOI 10.1016/S1076-6332(03)00329-5; Hartkens T, 2003, IEEE T MED IMAGING, V22, P82, DOI 10.1109/TMI.2002.806596; Holzapfel G., 2000, NONLINEAR SOLID MECH; ITO U, 1986, ACTA NEUROCHIR, V81, P53, DOI 10.1007/BF01456265; Johnson H, 2009, BRAINSDEMONWARP APPL; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kruggel F, 2006, NEUROIMAGE, V30, P1, DOI 10.1016/j.neuroimage.2005.09.063; Li X, 2012, THESIS ROYAL I TECHN; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; McCollough C, 2008, 96 AM ASS PHYS MED; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; Phatak NS, 2009, MED IMAGE ANAL, V13, P354, DOI 10.1016/j.media.2008.07.004; Pieper S, 2004, IEEE INT S, P32; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; RIETH KG, 1980, RADIOLOGY, V135, P343, DOI 10.1148/radiology.135.2.6768102; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; ROZSA L, 1989, NEUROSURG REV, V12, P133, DOI 10.1007/BF01741486; Schneider GH, 2002, ACT NEUR S, V81, P77; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Szczygielski J, 2010, ACTA NEUROCHIR SUPPL, V106, P225, DOI 10.1007/978-3-211-98811-4_42; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vashu R, 2011, ACTA NEUROCHIR, V153, P2065, DOI 10.1007/s00701-011-1101-7; Vercauteren T, 2009, NEUROIMAGE, V45, pS61, DOI 10.1016/j.neuroimage.2008.10.040; Veress AI, 2005, J BIOMECH ENG-T ASME, V127, P1195, DOI 10.1115/1.2073677; Wirtz CR, 1997, NEUROSURG FOCUS, V2; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	56	26	26	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2012	154	9					1583	1593		10.1007/s00701-012-1393-2			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	994UF	WOS:000307957500007	22648479				2021-06-18	
J	Alessandri, B; Schwandt, E; Kamada, Y; Nagata, M; Heimann, A; Kempski, O				Alessandri, Beat; Schwandt, Eike; Kamada, Yoshitaka; Nagata, Momoko; Heimann, Axel; Kempski, Oliver			The Neuroprotective Effect of Lactate Is Not Due to Improved Glutamate Uptake after Controlled Cortical Impact in Rats	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; lactic acid; neuroprotection; rat	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HIPPOCAMPAL SLICE PREPARATION; SMALL-VOLUME RESUSCITATION; HUMAN HEAD-INJURY; IN-VITRO; EXTRACELLULAR LACTATE; NEUROLOGICAL STATUS; COGNITIVE DEFICITS; 5-PERCENT DEXTROSE	For many years lactate was considered to be a waste product of glycolysis. Data are accumulating that suggest that lactate is an important energy substrate for neurons during activation. In severe traumatic brain injury (TBI) glutamate release and ischemic cerebral blood flow (CBF) are major factors for a mismatch between energy demand and supply and for neuronal cell death. Although ATP and behavior could be improved by lactate treatment after TBI, no histological correlate nor any linkage to better astrocytic glutamate uptake or CBF as possible mechanisms have been described. We subjected male rats to a controlled cortical impact (CCI; 5 m/sec, 2.5 mm). To study the effects of lactate treatment on lesion volume, glutamate release, and CBF, animals were infused with either NaCl or 100 mM lactate for up to 3 h. The role of endogenous lactate was investigated by inhibiting transport with alpha-cyano-4-hydroxy-cinnamic acid (4-CIN; 90 mg/kg). Lactate treatment 15 min post-CCI reduced lesion volume from 21.1 +/- 2.8 mm(3) to 12.1 +/- 1.9 mm(3) at day 2 after CCI. Contusion produced a significant three- to fourfold increase of glutamate in microdialysates, but there was no significant difference between treatments that began 30 min before CCI. In this experiment lesion volume was significantly reduced by lactate at day 7 post-CCI (23.7 +/- 4 to 9.3 +/- 1-2 mm(3)). CBF increased immediately after CCI and dropped thereafter below baseline in all animals. Lactate infusion 15 min post-CCI elevated CBF for 20 min in 7 of 10 animals, whereas 7 of 8 NaCl-treated animals showed a further CBF decline. Neuroprotection was achieved by lactate treatment following contusion injury, whereas blocking of endogenous lactate transport exerted no adverse effects. Neuroprotection was not achieved by improved glutamate uptake into astrocytes, but was supported by augmented CBF following CCI. Due to its neuroprotective property, lactate might be a beneficial pharmacological treatment for TBI patients.	[Alessandri, Beat; Schwandt, Eike; Kamada, Yoshitaka; Nagata, Momoko; Heimann, Axel; Kempski, Oliver] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neurosurg Pathophysiol, D-55101 Mainz, Germany	Alessandri, B (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Neurosurg Pathophysiol, Langenbeckstr 1, D-55101 Mainz, Germany.	beat.alessandri@unimedizin-mainz.de		Heimann, Axel/0000-0003-2510-3228			Alessandri B, 2006, BRAIN RES, V1111, P196, DOI 10.1016/j.brainres.2006.06.105; Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Alessandri B, 2009, FUTUR NEUROL, V4, P209, DOI 10.2217/14796708.4.2.209; Bermueller C, 2006, J NEUROL SCI, V241, P73, DOI 10.1016/j.jns.2005.10.016; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Erlichman JS, 2008, J NEUROSCI, V28, P4888, DOI 10.1523/JNEUROSCI.5430-07.2008; FELDMAN Z, 1995, J NEUROSURG, V83, P1060, DOI 10.3171/jns.1995.83.6.1060; FELLOWS LK, 1993, J NEUROCHEM, V60, P1258, DOI 10.1111/j.1471-4159.1993.tb03285.x; Fray AE, 1996, J PHYSIOL-LONDON, V496, P49, DOI 10.1113/jphysiol.1996.sp021664; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Groussard C, 2000, J APPL PHYSIOL, V89, P169; Gurevich B, 1997, ANESTH ANALG, V84, P554, DOI 10.1097/00000539-199703000-00016; Hashimoto T, 2008, MED SCI SPORT EXER, V40, P486, DOI [10.1249/mss.0b013e31815fcb04, 10.1249/MSS.0b013e31815fcb04]; Hill J, 2010, J NEUROTRAUM, V27, P1439, DOI 10.1089/neu.2010.1328; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hu YB, 1997, J NEUROCHEM, V69, P1484; Ido Y, 2004, P NATL ACAD SCI USA, V101, P653, DOI 10.1073/pnas.0307458100; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1998, ACT NEUR S, V71, P114; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; Laughton JD, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-35; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Lin JY, 2002, LIFE SCI, V71, P803, DOI 10.1016/S0024-3205(02)01738-1; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Melena J, 2003, BRAIN RES, V989, P128, DOI 10.1016/S0006-8993(03)03375-4; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Mintun MA, 2004, P NATL ACAD SCI USA, V101, P659, DOI 10.1073/pnas.0307457100; O'Brien J, 2007, NEUROCHEM RES, V32, P597, DOI 10.1007/s11064-006-9132-9; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pecha T, 2011, ANESTH ANALG, V113, P336, DOI 10.1213/ANE.0b013e31821d3dde; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; SCHURR A, 1989, J NEUROSCI METH, V28, P7, DOI 10.1016/0165-0270(89)90004-6; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Schurr A, 1997, J NEUROCHEM, V69, P423; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Serres S, 2003, NMR BIOMED, V16, P430, DOI 10.1002/nbm.838; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Soehle M, 2000, ACTA NEUROCHIR SUPPL, V76, P181; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; Thomale UW, 2004, J NEUROTRAUM, V21, P1737; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435	66	26	27	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2181	2191		10.1089/neu.2011.2067			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900006	22888957				2021-06-18	
J	Seo, JW; Kim, JH; Kim, JH; Seo, M; Han, HS; Park, J; Suk, K				Seo, Jung-Wan; Kim, Jong-Heon; Kim, Jae-Hong; Seo, Minchul; Han, Hyung Soo; Park, Jaechan; Suk, Kyoungho			Time-dependent effects of hypothermia on microglial activation and migration	JOURNAL OF NEUROINFLAMMATION			English	Article						Hypothermia; Microglia; Cell migration; Neuroinflammation; Neuroprotection	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA STABILITY; MILD HYPOTHERMIA; GENE-EXPRESSION; POSTISCHEMIC HYPOTHERMIA; INFLAMMATORY RESPONSE; MODERATE HYPOTHERMIA; CELL-DEATH	Background: Therapeutic hypothermia is one of the neuroprotective strategies that improve neurological outcomes after brain damage in ischemic stroke and traumatic brain injury. Microglial cells become activated following brain injury and play an important role in neuroinflammation and subsequent brain damage. The aim of this study was to determine the time-dependent effects of hypothermia on microglial cell activation and migration, which are accompanied by neuroinflammation. Methods: Microglial cells in culture were subjected to mild (33 degrees C) or moderate (29 degrees C) hypothermic conditions before, during, or after lipopolysaccharide (LPS) or hypoxic stimulation, and the production of nitric oxide (NO), proinflammatory cytokines, reactive oxygen species, and neurotoxicity was evaluated. Effects of hypothermia on microglial migration were also determined in in vitro as well as in vivo settings. Results: Early-, co-, and delayed-hypothermic treatments inhibited microglial production of inflammatory mediators to varying degrees: early treatment was the most efficient, and delayed treatment showed time-dependent effects. Delayed hypothermia also suppressed the mRNA levels of proinflammatory cytokines and iNOS, and attenuated microglial neurotoxicity in microglia-neuron co- cultures. Furthermore, delayed hypothermia reduced microglial migration in the Boyden chamber assay and wound healing assay. In a stab injury model, delayed local hypothermia reduced migration of microglia toward the injury site in the rat brain. Conclusion: Taken together, our results indicate that delayed hypothermia is sufficient to attenuate microglial activation and migration, and provide the basis of determining the optimal time window for therapeutic hypothermia. Delayed hypothermia may be neuroprotective by inhibiting microglia-mediated neuroinflammation, indicating the therapeutic potential of post-injury hypothermia for patients with brain damages exhibiting some of the inflammatory components.	[Seo, Jung-Wan; Kim, Jong-Heon; Kim, Jae-Hong; Seo, Minchul; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, CMRI, Brain Sci & Engn Inst,Dept Pharmacol, Taegu 700422, South Korea; [Han, Hyung Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, Brain Sci & Engn Inst, Taegu 700422, South Korea; [Park, Jaechan] Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Brain Sci & Engn Inst, Taegu 700422, South Korea	Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, CMRI, Brain Sci & Engn Inst,Dept Pharmacol, 101 Dong In, Taegu 700422, South Korea.	ksuk@knu.ac.kr		Park, Jaechan/0000-0001-7572-3260	Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A100870]; National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of Korean governmentMinistry of Education, Science and Technology, Republic of Korea [20110028240]	This work was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100870), and by the National Research Foundation (NRF) grants funded by the Ministry of Education, Science and Technology (MEST) of Korean government (20110028240).	Al-Fageeh MB, 2009, RNA, V15, P1164, DOI 10.1261/rna.1179109; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Askalan R, 2011, DEV NEUROSCI-BASEL, V33, P320, DOI 10.1159/000329924; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bassi R, 2008, J NEURO-ONCOL, V87, P23, DOI 10.1007/s11060-007-9488-y; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chang RCC, 2000, BRAIN RES, V853, P236, DOI 10.1016/S0006-8993(99)02255-6; Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83; Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Diestel A, 2010, EUR J NEUROSCI, V31, P779, DOI 10.1111/j.1460-9568.2010.07128.x; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Gundersen Y, 2001, ACTA ANAESTH SCAND, V45, P994, DOI 10.1034/j.1399-6576.2001.450812.x; Hagiwara S, 2007, INFLAMM RES, V56, P297, DOI 10.1007/s00011-007-6161-z; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hinojosa AE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-77; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Hollams EM, 2002, NEUROCHEM RES, V27, P957, DOI 10.1023/A:1020992418511; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; Karabiyikoglu M, 2003, J NEUROSURG, V98, P1271, DOI 10.3171/jns.2003.98.6.1271; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Lee M, 2011, BRAIN RES, V1400, P99, DOI 10.1016/j.brainres.2011.05.021; Lee S, 2012, J BIOL CHEM, V287, P9414, DOI 10.1074/jbc.M111.330662; Lee S, 2011, J BIOL CHEM, V286, P43855, DOI 10.1074/jbc.M111.299248; Lee S, 2009, J NEUROSCI, V29, P234, DOI 10.1523/JNEUROSCI.5273-08.2009; Lee S, 2007, BIOCHEM PHARMACOL, V74, P723, DOI 10.1016/j.bcp.2007.06.016; Lelekov-Boissard T, 2009, PHILOS T R SOC A, V367, P4699, DOI 10.1098/rsta.2009.0184; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Maekawa S, 2002, CRIT CARE MED, V30, P2700, DOI 10.1097/00003246-200212000-00014; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsui T, NEUROCRIT C IN PRESS; Matsui T, 2008, J NEUROTRAUM, V25, P709, DOI 10.1089/neu.2007.0482; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOYER DJ, 1992, STROKE, V23, P1812, DOI 10.1161/01.STR.23.12.1812; Nagel S, 2012, NEUROSCIENCE, V208, P109, DOI 10.1016/j.neuroscience.2012.01.048; Ock J, 2007, J NEUROSCI RES, V85, P1989, DOI 10.1002/jnr.21322; Ock J, 2010, BRIT J PHARMACOL, V159, P1646, DOI 10.1111/j.1476-5381.2010.00659.x; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Salman H, 2000, ACTA PHYSIOL SCAND, V168, P431; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Seko Y, 2006, AUTOIMMUN REV, V5, P299, DOI 10.1016/j.autrev.2005.10.013; Shpargel Karl B, 2008, Cleve Clin J Med, V75 Suppl 2, pS77; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Tang XN, 2010, AGEING RES REV, V9, P61, DOI 10.1016/j.arr.2009.10.002; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tymianski M, 1998, J CEREBR BLOOD F MET, V18, P848, DOI 10.1097/00004647-199808000-00005; Wolff B, 2009, INT J CARDIOL, V133, P223, DOI 10.1016/j.ijcard.2007.12.039; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yuan HB, 2004, ANESTHESIOLOGY, V100, P331, DOI 10.1097/00000542-200402000-00023; Yunoki M, 2003, EXP NEUROL, V181, P291, DOI 10.1016/S0014-4886(03)00056-6; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	79	26	31	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 9	2012	9								164	10.1186/1742-2094-9-164			22	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	021IQ	WOS:000309878900001	22776061	DOAJ Gold, Green Published			2021-06-18	
J	Zhao, S; Yu, ZY; Zhao, G; Xing, CH; Hayakawa, K; Whalen, MJ; Lok, JM; Lo, EH; Wang, XY				Zhao, Song; Yu, Zhanyang; Zhao, Gang; Xing, Changhong; Hayakawa, Kazuhide; Whalen, Michael J.; Lok, Josephine M.; Lo, Eng H.; Wang, Xiaoying			Neuroglobin-overexpression reduces traumatic brain lesion size in mice	BMC NEUROSCIENCE			English	Article						Neuroglobin; Neuroprotection; Controlled cortical impact; Oxidative stress; Traumatic brain injury	OXIDATIVE STRESS; IN-VIVO; INJURY; EXPRESSION; PROTECTS; OUTCOMES; NEUROPROTECTION; MECHANISMS; ISCHEMIA; PROTEINS	Background: Accumulating evidence has demonstrated that over-expression of Neuroglobin (Ngb) is neuroprotective against hypoxic/ischemic brain injuries. In this study we tested the neuroprotective effects of Ngb over-expression against traumatic brain injury (TBI) in mice. Results: Both Ngb over-expression transgenic (Ngb-Tg) and wild-type (WT) control mice were subjected to TBI induced by a controlled cortical impact (CCI) device. TBI significantly increased Ngb expression in the brains of both WT and Ngb-Tg mice, but Ngb-Tg mice had significantly higher Ngb protein levels at the pre-injury baseline and post-TBI. Production of oxidative tissue damage biomarker 3NT in the brain was significantly reduced in Ngb-Tg mice compared to WT controls at 6 hours after TBI. The traumatic brain lesion volume was significantly reduced in Ngb Tg mice compared to WT mice at 3 weeks after TBI; however, there were no significant differences in the recovery of sensorimotor and spatial memory functional deficits between Ngb-Tg and WT control mice for up to 3 weeks after TBI. Conclusion: Ngb over-expression reduced traumatic lesion volume, which might partially be achieved by decreasing oxidative stress.	[Zhao, Song; Yu, Zhanyang; Xing, Changhong; Hayakawa, Kazuhide; Lok, Josephine M.; Lo, Eng H.; Wang, Xiaoying] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, Charlestown, MA 02129 USA; [Zhao, Song; Yu, Zhanyang; Xing, Changhong; Hayakawa, Kazuhide; Lok, Josephine M.; Lo, Eng H.; Wang, Xiaoying] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol, Charlestown, MA 02129 USA; [Zhao, Song; Zhao, Gang] Jilin Univ, Bethune Hosp 1, Dept Orthoped, Changchun 130023, Jilin, Peoples R China; [Zhao, Song; Zhao, Gang] Jilin Univ, Bethune Hosp 1, Dept Neurosurg, Changchun 130023, Jilin, Peoples R China; [Whalen, Michael J.; Lok, Josephine M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA	Wang, XY (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Neurol, 149 13th St,Room 2401, Charlestown, MA 02129 USA.	wangxi@helix.mgh.harvard.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS049476]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049476] Funding Source: NIH RePORTER	This work was supported in part by NIH grant R01-NS049476 (to X.W.). We appreciate Ms. Jessica L. Poppe for language editorial assistance.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, NEWS PHYSIOL SCI, V19, P110, DOI 10.1152/nips.01513.2003; Chuang PY, 2010, J NEUROTRAUM, V27, P999, DOI 10.1089/neu.2009.1129; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Houdebine LM, 2002, J BIOTECHNOL, V98, P145, DOI 10.1016/S0168-1656(02)00129-3; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jin KL, 2008, NEUROSCI LETT, V430, P135, DOI 10.1016/j.neulet.2007.10.031; Jin KL, 2011, PHARMACOLOGY, V87, P81, DOI 10.1159/000322998; Khan AA, 2008, FASEB J, V22, P1737, DOI 10.1096/fj.07-100784; Khan AA, 2007, P NATL ACAD SCI USA, V104, P19114, DOI 10.1073/pnas.0706167104; Khan AA, 2006, P NATL ACAD SCI USA, V103, P17944, DOI 10.1073/pnas.0607497103; Lin Xin, 2010, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V26, P39; Liu JX, 2009, J NEUROSCI RES, V87, P164, DOI 10.1002/jnr.21826; Liu N, 2012, BIOCHEM J, V443, P153, DOI 10.1042/BJ20111856; Lok J, 2011, J NEUROCHEM, V118, P248, DOI 10.1111/j.1471-4159.2011.07294.x; Shang AJ, 2012, NEUROL SCI, V33, P551, DOI 10.1007/s10072-011-0772-4; Sijen T, 2001, CURR BIOL, V11, P436, DOI 10.1016/S0960-9822(01)00116-6; Sultana R, 2008, METHOD ENZYMOL, V440, P309, DOI 10.1016/S0076-6879(07)00820-8; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang XY, 2008, STROKE, V39, P1869, DOI 10.1161/STROKEAHA.107.506022; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wei X, 2011, AM J PATHOL, V179, P2788, DOI 10.1016/j.ajpath.2011.08.015; Yu Z, 2009, NEUROSCIENCE, V162, P396, DOI 10.1016/j.neuroscience.2009.04.055; Yu ZY, 2009, NEUROL RES, V31, P122, DOI 10.1179/174313209X389866	31	26	31	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUN 15	2012	13								67	10.1186/1471-2202-13-67			8	Neurosciences	Neurosciences & Neurology	010PJ	WOS:000309106300001	22703519	DOAJ Gold, Green Published			2021-06-18	
J	Calvete, E; de Arroyabe, EL				Calvete, Esther; Lopez de Arroyabe, Elena			Depression and grief in Spanish family caregivers of people with traumatic brain injury: The roles of social support and coping	BRAIN INJURY			English	Article						Caregiver; coping; depression; distress; family; support system	NEEDS; STRESS; INDIVIDUALS; PREDICTORS; BURDEN; PERSPECTIVES; DISTRESS; OUTCOMES; DISEASE; IMPACT	Purpose: To examine the associations between social support, coping responses and depressive and grief symptoms in caregivers of people with traumatic brain injury (TBI). Methods and procedures: A cross-sectional study of Spanish primary caregivers of individuals with TBI. The study included 223 caregivers (72.2% female and 26.9% male). Main outcomes: Measures administered included the Family Needs Questionnaire, the Texas Revised Inventory of Grief, the Centre for Epidemiological Studies Depression Scale and the Responses to Stress Questionnaire. Results: A structural equation model indicated that secondary control coping (e.g. acceptance and positive thinking) was associated with less grief and depressive symptoms, whereas primary control coping (e.g. problem-solving and emotional expression) and disengagement were associated with more symptoms. Emotional and instrumental supports were directly associated with less depressive symptoms. In addition, emotional and professional supports were associated with symptoms through the use of primary control and disengagement coping. Conclusions: These results indicate that future interventions with families should improve social networks of emotional, instrumental and professional support, as well as help caregivers to develop adaptive coping strategies, such as acceptance and positive thinking.	[Calvete, Esther; Lopez de Arroyabe, Elena] Univ Deusto, Dept Personal Psychol Assessment & Treatment, Bilbao 48080, Spain	Calvete, E (corresponding author), Univ Deusto, Dept Personal Psychol Assessment & Treatment, Apdo 1, Bilbao 48080, Spain.	esther.calvete@deusto.es	Calvete, Esther/B-8418-2011	Calvete, Esther/0000-0002-6928-9557	Mapfre Foundation	This research was supported by a grant of Mapfre Foundation.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; Bishop M, 2006, AUST J REHABIL COUNS, V12, P73, DOI 10.1375/jrc.12.2.73; Blankfeld DF, 1999, PSYCHOL HEALTH, V14, P609, DOI 10.1080/08870449908410753; Boss P., 2006, LOSS TRAUMA RESILIEN; BOYD JH, 1982, ARCH GEN PSYCHIAT, V39, P1195; Calvete E, 2006, ANXIETY STRESS COPIN, V19, P47, DOI 10.1080/10615800500472963; Carde?oso E., 1999, ANALES PSICOLOGIA, V15, P179; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; CEADAC, DAN CER SOBR; Chan J, 2009, ADV MENT HEALTH, V8, P155, DOI 10.5172/jamh.8.2.155; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cole DA, 2003, J ABNORM PSYCHOL, V112, P558, DOI 10.1037/0021-843X.112.4.558; Connor-Smith JK, 2004, ANXIETY STRESS COPIN, V17, P163, DOI 10.1080/10615800410001709412; Connor-Smith JK, 2000, J CONSULT CLIN PSYCH, V68, P976, DOI 10.1037/0022-006X.68.6.976; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Devany CW, 1992, ANN C REH SEV BRAIN; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Faschingbauer TR, 1981, TEXAS REVISED INVENT; Fernandez Guinea S, 1997, FAMILIAS PROCESO REH, V1; Fleishman JA, 2000, AM J COMMUN PSYCHOL, V28, P421, DOI 10.1023/A:1005132430171; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HOLAHAN CJ, 1987, J PERS SOC PSYCHOL, V52, P946, DOI 10.1037/0022-3514.52.5.946; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kendall E, 2008, SOC SCI MED, V67, P1217, DOI 10.1016/j.socscimed.2008.05.033; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; Kreutzer JS, 1997, J HEAD TRAUMA REHAB, V12, P63, DOI 10.1097/00001199-199712000-00006; Lakey B., 2000, SOCIAL SUPPORT MEASU; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI DOI 10.1037/1091-7527.26.1.69; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Little TD, 2006, STRUCT EQU MODELING, V13, P59, DOI 10.1207/s15328007sem1301_3; Lopez de Arroyabe E, ANALES PSIC IN PRESS; Lopez de Arroyabe E, 2005, MAPFRE MED, V16, P266; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Minnes P, 2000, BRAIN INJURY, V14, P737; Oyserman D, 2002, PSYCHOL BULL, V128, P3, DOI 10.1037/0033-2909.128.1.3; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rokach A, 2001, SOC BEHAV PERSONAL, V29, P477, DOI 10.2224/sbp.2001.29.5.477; Sanders S, 2008, DEATH STUD, V32, P495, DOI 10.1080/07481180802138845; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422; Skinner EA, 2003, PSYCHOL BULL, V129, P216, DOI 10.1037/0033-2909.129.2.216; Sohlberg MM, 2001, J HEAD TRAUMA REHAB, V16, P498, DOI 10.1097/00001199-200110000-00008; Triandis H.C., 1995, INDIVIDUALISM COLLEC; Uchino B.N., 2004, SOCIAL SUPPORT PHYS; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; Zinner ES, 1997, ARCH CLIN NEUROPSYCH, V12, P435, DOI 10.1016/S0887-6177(96)00034-0	69	26	27	0	29	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2012	26	6					834	843		10.3109/02699052.2012.655363			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	943EO	WOS:000304103500005	22583174				2021-06-18	
J	Gibson, TJ; Ridler, AL; Lamb, CR; Williams, A; Giles, S; Gregory, NG				Gibson, T. J.; Ridler, A. L.; Lamb, C. R.; Williams, A.; Giles, S.; Gregory, N. G.			Preliminary evaluation of the effectiveness of captive-bolt guns as a killing method without exsanguination for horned and unhorned sheep	ANIMAL WELFARE			English	Article						animal welfare; captive bolt; disease control; ewes; rams; sheep horned and polled	BRAIN-FUNCTION; CONCUSSIVE METHODS; SLAUGHTER; CATTLE; CALVES; RESPONSES; INJURY	The current study aims to make welfare-based recommendations for gun/cartridge combinations and shooting positions that will ensure death of the sheep (horned, unhorned, rams and ewes), without the need for either sticking or pithing. The study examined the pathophysiology of captive-bolt gun (CBG) injuries that result in incomplete concussion leading to death. Behavioural, brainstem and cranial/spinal responses were examined along with gross pathology in 489 animals (116 polled ewes, 134 horned ewes, 117 polled rams and 122 horned rams) following a variety of CBG-cartridge combinations. Shooting horned rams was more challenging than unhorned sheep, partly because minor movements of the head at the time of shooting can result in deflection of the gun by the horns. Marksmanship was the definitive factor: 100% of animals that showed signs of incomplete concussion were found to have been shot incorrectly. The findings will have application when it is necessary to kill sheep on farms for disease control or euthanasia purposes.	[Gibson, T. J.; Lamb, C. R.; Gregory, N. G.] Univ London Royal Vet Coll, Dept Vet Clin Sci, Hatfield AL9 7TA, Herts, England; [Ridler, A. L.] Massey Univ, Inst Vet Anim & Biomed Sci, Pamerston North 4442, New Zealand; [Williams, A.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England; [Giles, S.] Univ Bristol, Sch Clin Vet Sci, Anim Welf & Behav Grp, Bristol BS8 1TH, Avon, England	Gibson, TJ (corresponding author), Univ London Royal Vet Coll, Dept Vet Clin Sci, Hatfield AL9 7TA, Herts, England.	tgibson@rvc.ac.uk	Lamb, Christopher R./G-3963-2014; Gibson, Troy/AAA-8687-2019	Gibson, Troy/0000-0002-1242-2695	Department for Environment Food and Rural Affairs UKDepartment for Environment, Food & Rural Affairs (DEFRA)	The authors thank Accles & Shelvoke and the Humane Slaughter Association for assistance during the study. We also wish to thank Richard Prior, Gwen Fraser, Gilly Ansell, Chris Davies, Karin Klinglmair, Gabriela Olmos Antillon, Mick Kirby and David Manners. This work was funded by a research grant from the Department for Environment Food and Rural Affairs UK.	Aarabi B, 2005, HEAD INJURY PATHOPHY, P384; Adams JH, 1995, MUIRS TXB PATHOLOGY, V12, P2121; ADAS, 2007, MH0133 ADAS DEFR, P1; BLACKMORE DK, 1982, MEAT SCI, V7, P19, DOI 10.1016/0309-1740(82)90094-8; BLACKMORE DK, 1979, VET REC, V105, P372, DOI 10.1136/vr.105.16.372; BLACKMORE DK, 1984, RES VET SCI, V37, P223, DOI 10.1016/S0034-5288(18)31909-X; DALY CC, 1986, RES VET SCI, V41, P349, DOI 10.1016/S0034-5288(18)30628-3; DALY CC, 1986, RES VET SCI, V41, P353, DOI 10.1016/S0034-5288(18)30629-5; DALY CC, 1987, BRIT VET J, V143, P574, DOI 10.1016/0007-1935(87)90049-2; Finnie JW, 1997, AUST VET J, V75, P204, DOI 10.1111/j.1751-0813.1997.tb10067.x; FRICKER C, 1981, FLEISCHWIRTSCHAFT, V61, P124; Gibson TJ, 2009, NEW ZEAL VET J, V57, P96, DOI 10.1080/00480169.2009.36885; Gouveia KG, 2009, ANIM WELFARE, V18, P171; Gregory NG, 2009, MEAT SCI, V81, P178, DOI 10.1016/j.meatsci.2008.07.016; Gregory NG, 2005, MEAT SCI, V70, P481, DOI 10.1016/j.meatsci.2004.06.026; Grosse Perdekamp M, 2010, INT J LEGAL MED, V124, P605, DOI 10.1007/s00414-010-0450-8; Nikolic S, 2011, J FORENSIC SCI, V56, P248, DOI 10.1111/j.1556-4029.2010.01507.x; Owen R, 2005, HEAD INJURY PATHOPHY, V2, P472; Teasdale E, 2005, HEAD INJURY PATHOPHY, V2, P169; Viel G, 2009, FORENSIC SCI INT, V187, pE7, DOI 10.1016/j.forsciint.2009.01.022; Wei G, 2010, J NEUROTRAUM, V27, P1635, DOI 10.1089/neu.2010.1378	21	26	27	0	35	UNIV FEDERATION ANIMAL WELFARE	WHEATHAMPSTEAD	OLD SCHOOL, BREWHOUSE HILL, WHEATHAMPSTEAD AL4 8AN, HERTS, ENGLAND	0962-7286			ANIM WELFARE	Anim. Welf.	JUN	2012	21			2			35	42		10.7120/096272812X13353700593446			8	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	952JA	WOS:000304787600007					2021-06-18	
J	Lopez, NE; Krzyzaniak, MJ; Costantini, TW; Putnam, J; Hageny, AM; Eliceiri, B; Coimbra, R; Bansal, V				Lopez, Nicole E.; Krzyzaniak, Michael J.; Costantini, Todd W.; Putnam, James; Hageny, Ann-Marie; Eliceiri, Brian; Coimbra, Raul; Bansal, Vishal			Vagal nerve stimulation decreases blood-brain barrier disruption after traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						TBI; VNS; BBB; AQP-4	INTESTINAL DYSFUNCTION; RECOVERY; GHRELIN	BACKGROUND: Traumatic brain injury (TBI) may alter sympathetic tone causing autonomic abnormalities and organ dysfunction. Vagal nerve stimulation (VNS) has been shown to decrease inflammation and distant organ injury after TBI. It is unknown whether VNS may reduce blood-brain barrier (BBB) dysfunction after TBI. We hypothesize that VNS prevents TBI-induced breakdown of the BBB, subsequent brain edema, and neuronal injury. METHODS: A weight-drop model was used to create severe TBI in balb/c mice. Animals were divided into three groups: TBI-TBI only; TBI or VNS-animals that were treated with 10 minutes of VNS immediately before TBI; and sham-animals with opening of the skull but no TBI and VNS treatment. Brain vascular permeability to injected (M-r 70,000) FITC-dextran was measured by radiated fluorescence 6 hours after injury. Injured tissue sections were stained for perivascular aquaporin 4 (AQP-4), an important protein causing BBB-mediated brain edema. Fluorescence was quantified under laser scanning by confocal microscopy. RESULTS: Six hours after TBI, cerebral vascular permeability was increased fourfold compared with sham (mean [SD], 6.6(E+08) [5.5(E+07)] arbitrary fluorescence units [afu] vs. 1.5(E+08) [2.9(E+07)] afu; p < 0.001). VNS prevented the increase in permeability when compared with TBI alone (mean [SD], 3.5(E+08) [8.3(E+07)] afu vs. 6.6(E+08) [5.5(E+07)] afu; p < 0.05). Perivascular expression of AQP-4 was increased twofold in TBI animals compared with sham (mean [SD], 0.96 [0.12] afu vs. 1.79 [0.37] afu; p < 0.05). Similarly, VNS decreased post-TBI expression of AQP-4 to levels similar to sham (mean [SD], 1.15 [0.12] afu; p < 0.05). CONCLUSION: VNS attenuates cerebral vascular permeability and decreases the up-regulation of AQP-4 after TBI. Future studies are needed to assess the mechanisms by which VNS maintains the BBB. (J Trauma Acute Care Surg. 2012;72: 1562-1566. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Lopez, Nicole E.; Krzyzaniak, Michael J.; Costantini, Todd W.; Putnam, James; Hageny, Ann-Marie; Eliceiri, Brian; Coimbra, Raul; Bansal, Vishal] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA	Bansal, V (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	v3bansal@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916; Lopez, Nicole/0000-0002-4807-7360	Division of Trauma, University of California, San Diego; American Surgical Association Foundation	Nicole E. Lopez, MD, Michael J. Krzyzaniak, MD, Todd W. Costantini, James Putnam, BS, Ann-Marie Hageny, BS, Brian Eliceiri, PhD, and Raul Coimbra, MD, received funding from the Division of Trauma, University of California, San Diego. Vishal Bansal MD, received funding from the American Surgical Association Foundation.	Bansal V, 2012, INFLAMMATION, V35, P214, DOI 10.1007/s10753-011-9307-7; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Clough RW, 2007, NEUROSCIENCE, V147, P286, DOI 10.1016/j.neuroscience.2007.04.043; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; De Herdt V, 2009, J NEUROIMMUNOL, V214, P104, DOI 10.1016/j.jneuroim.2009.06.008; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; Fazzina G, 2010, J NEUROTRAUM, V27, P453, DOI 10.1089/neu.2008.0782; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Li G, SEIZURE, V20, P249; Li L, FASEB J, V25, P1556; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Pan WH, 2011, CURR PHARM DESIGN, V17, P3729, DOI 10.2174/138161211798220918; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555	24	26	30	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUN	2012	72	6					1562	1566		10.1097/TA.0b013e3182569875			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	960WH	WOS:000305422900025	22695423				2021-06-18	
J	Stein, DM; Lindel, AL; Murdock, KR; Kufera, JA; Menaker, J; Scalea, TM				Stein, Deborah M.; Lindel, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Scalea, Thomas M.			USE OF SERUM BIOMARKERS TO PREDICT SECONDARY INSULTS FOLLOWING SEVERE TRAUMATIC BRAIN INJURY	SHOCK			English	Article; Proceedings Paper	25th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN, 2012	Lake Buena Vista, FL	Eastern Assoc Surg Trauma		Traumatic brain injury; neuroinflammation; biomarker; intracranial hypertension; cerebral hypoperfusion	TUMOR-NECROSIS-FACTOR; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL HYPERTENSION; CEREBROSPINAL-FLUID; INTERLEUKIN-8; CYTOKINES; MORTALITY; HYPOPERFUSION; DYSFUNCTION; PLASMA	The management of severe traumatic brain injury (TBI) focuses on prevention and treatment of intracranial hypertension (ICH) and cerebral hypoperfusion (CH). Predicting which patients will develop these secondary insults is currently not possible. This study investigates the systemic manifestation of neuroinflammation and its role in helping to predict clinical deterioration following severe TBI. Patients with head Abbreviated Injury Severity greater than 3, age older than 14 years, "isolated'' TBI, and placement of intracranial pressure monitor were prospectively enrolled. Serum was collected within 24 h and twice daily for 7 days. Measures of moderate and severe ICH (intracranial pressure >20 and >30 mmHg) and moderate and severe CH (cerebral perfusion pressure <60 and <50 mmHg) were compared with interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-alpha) levels drawn before periods of monitoring. An adjusted mixed-model analysis accounting for longitudinal correlations was applied. Sixty-eight patients were enrolled; 670 12-h periods of monitoring and 845 serum samples were available for analysis. Associations were found between serum levels of IL-8 and moderate and severe CH. Levels of TNF-alpha and severe ICH and CH were also correlated. Specificities of 81% to 95% were found for prediction of ICH and CH for TNF-alpha and CH for IL-8. Interleukin 8 and TNF-alpha demonstrate promise as candidate serum markers of impending ICH and CH. This suggests that we may be able to "predict'' imminent events following TBI before clinical manifestations. Given the morbidity of ICH and CH, minimizing the effects of these secondary insults may have a significant impact on outcome and help guide decisions about timing of interventions.	[Stein, Deborah M.] Univ Maryland, Sch Med, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Stein, Deborah M.; Lindel, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Sch Med, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Bansal V, 2012, INFLAMMATION, V35, P214, DOI 10.1007/s10753-011-9307-7; Bratton S. L., 2007, J NEUROTRAUMA S1, V24, pS37; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Jawa Randeep S, 2006, J Intensive Care Med, V21, P63, DOI 10.1177/0885066605284325; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	34	26	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2012	37	6					563	568		10.1097/SHK.0b013e3182534f93			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	944LD	WOS:000304202200001	22552017				2021-06-18	
J	Ewing-Cobbs, L; Prasad, MR; Swank, P; Kramer, L; Mendez, D; Treble, A; Payne, C; Bachevalier, J				Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul; Kramer, Larry; Mendez, Donna; Treble, Amery; Payne, Christa; Bachevalier, Jocelyne			Social communication in young children with traumatic brain injury: Relations with corpus callosum morphometry	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Brain injury; Young children; Joint attention; Gesture; Corpus callosum; Social communication	CLOSED-HEAD INJURY; SUPERIOR FRONTAL GYRUS; PROBLEM-SOLVING SKILLS; JOINT ATTENTION; SEX-DIFFERENCES; CHILDHOOD; OUTCOMES; CORTEX; TERM; RECOVERY	The purpose of the present investigation was to characterize the relations of specific social communication behaviors, including joint attention, gestures, and verbalization, with surface area of midsagittal corpus callosum (CC) subregions in children who sustained traumatic brain injury (TBI) before 7 years of age. Participants sustained mild (n = 10) or moderate-severe (n = 26) noninflicted TBI. The mean age at injury was 33.6 months; mean age at MRI was 44.4 months. The CC was divided into seven subregions. Relative to young children with mild TBI, those with moderate-severe TBI had smaller surface area of the isthmus. A semi-structured sequence of social interactions between the child and an examiner was videotaped and coded for specific social initiation and response behaviors. Social responses were similar across severity groups. Even though the complexity of their language was similar, children with moderate-severe TBI used more gestures than those with mild TBI to initiate social overtures; this may indicate a developmental lag or deficit as the use of gestural communication typically diminishes after age 2. After controlling for age at scan and for total brain volume, the correlation of social interaction response and initiation scores with the midsagittal surface area of the CC regions was examined. For the total group, responding to a social overture using joint attention was significantly and positively correlated with surface area of all regions, except the rostrum. Initiating joint attention was specifically and negatively correlated with surface area of the anterior midbody. Use of gestures to initiate a social interaction correlated significantly and positively with surface area of the anterior and posterior midbody. Social response and initiation behaviors were selectively related to regional callosal surface areas in young children with TBI. Specific brainbehavior relations indicate early regional specialization of anterior and posterior CC for social communication. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda; Prasad, Mary R.; Swank, Paul] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Kramer, Larry] Univ Texas Hlth Sci Ctr Houston, Dept Intervent Radiol, Houston, TX 77030 USA; [Mendez, Donna] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA; [Treble, Amery] Univ Houston, Dept Psychol, Houston, TX 77004 USA; [Payne, Christa; Bachevalier, Jocelyne] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA	Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat, 7000 Fannin,Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu		Payne, Christa/0000-0002-6281-1269	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2RO1 NS29462]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER	This work was supported in part by NIH 2RO1 NS29462. The authors thank Dr. Giuseppe Colasurdo for facilitating acquisition of the MRI scans. We are grateful to the parents and children who participated in this project.	Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bates E, 1997, DEV NEUROPSYCHOL, V13, P447, DOI 10.1080/87565649709540686; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; Bayley N., 2006, BAYLEY SCALES INFANT; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Carpenter M, 2002, J AUTISM DEV DISORD, V32, P91, DOI 10.1023/A:1014836521114; Casey BJ, 2005, CURR OPIN NEUROBIOL, V15, P239, DOI 10.1016/j.conb.2005.03.012; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; Cutini S, 2008, NEUROIMAGE, V42, P945, DOI 10.1016/j.neuroimage.2008.05.013; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Dennis Maureen, 1988, CLIN NEUROPSYCHOLOGY, P89; du Boisgueheneuc F, 2006, BRAIN, V129, P3315, DOI 10.1093/brain/awl244; Dunham P.J., 1995, JOINT ATTENTION ITS, P29; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L., 2008, HDB DEV COGNITIVE NE, P399; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Frischen A, 2007, PSYCHOL BULL, V133, P694, DOI 10.1037/0033-2909.133.4.694; Ganesalingam K., 2011, NEUROPSYCHOLOGY; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Goldin-Meadow S, 2010, LANG COGN, V2, P1, DOI 10.1515/LANGCOG.2010.001; Goldman PS, 1974, PLASTICITY RECOVERY; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Grossmann T, 2010, BIOL LETTERS, V6, P540, DOI 10.1098/rsbl.2009.1069; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hasan KM, 2008, BRAIN RES, V1227, P52, DOI 10.1016/j.brainres.2008.06.030; Hasan KM, 2009, BRAIN RES, V1249, P91, DOI 10.1016/j.brainres.2008.10.026; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hirotani M, 2009, NEUROREPORT, V20, P600, DOI 10.1097/WNR.0b013e32832a0a7c; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Kolb B, 2010, BEHAV NEUROSCI, V124, P873, DOI 10.1037/a0021822; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Laube I, 2011, NEUROIMAGE, V54, P1643, DOI 10.1016/j.neuroimage.2010.08.074; Lebel C, 2010, NEUROIMAGE, V52, P20, DOI 10.1016/j.neuroimage.2010.03.072; LEUNG EHL, 1981, DEV PSYCHOL, V17, P215, DOI 10.1037/0012-1649.17.2.215; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Lindenberg R, 2012, HUM BRAIN MAPP, V33, P812, DOI 10.1002/hbm.21258; Malkova L, 2010, BEHAV NEUROSCI, V124, P742, DOI 10.1037/a0021622; Materna S, 2008, J COGNITIVE NEUROSCI, V20, P108, DOI 10.1162/jocn.2008.20008; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Mundy P, 2003, J CHILD PSYCHOL PSYC, V44, P793, DOI 10.1111/1469-7610.00165; Mundy P, 2010, NEURAL NETWORKS, V23, P985, DOI 10.1016/j.neunet.2010.08.009; Park HJ, 2008, HUM BRAIN MAPP, V29, P503, DOI 10.1002/hbm.20314; Pelphrey KA, 2003, NEUROPSYCHOLOGIA, V41, P156, DOI 10.1016/S0028-3932(02)00146-X; Posner MI, 2009, PHYS LIFE REV, V6, P103, DOI 10.1016/j.plrev.2009.02.001; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Saito DN, 2010, FRONT INTEGR NEUROSC, V4, DOI 10.3389/fnint.2010.00127; Sauer E, 2010, CHILD DEV, V81, P528, DOI 10.1111/j.1467-8624.2009.01413.x; SCAIFE M, 1975, NATURE, V253, P265, DOI 10.1038/253265a0; SCHALTEN.G, 1972, CONFIN NEUROL, V34, P169; Schilbach L, 2010, J COGNITIVE NEUROSCI, V22, P2702, DOI 10.1162/jocn.2009.21401; Sheehan EA, 2007, BRAIN LANG, V101, P246, DOI 10.1016/j.bandl.2006.11.008; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Thorndike RL., 1986, STANFORD BINET INTEL, V4; Tomasello M, 2005, BEHAV BRAIN SCI, V28, P675, DOI 10.1017/S0140525X05000129; Verger K, 2001, BRAIN INJURY, V15, P211; Vygotsky L.S., 1978, MIND SOC; Walzer N, 2010, J CLIN GASTROENTEROL, V44, P361, DOI 10.1097/MCG.0b013e3181c8a4f8; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2009, P NATL ACAD SCI USA, V106, P20664, DOI 10.1073/pnas.0909197106; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zaidel E., 2003, PARALLEL BRAIN COGNI	94	26	27	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		247	254		10.1016/j.ijdevneu.2011.07.004			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800011	21807088	Green Accepted			2021-06-18	
J	Sun, CY; Ou, XM; Farley, JM; Stockmeier, C; Bigler, S; Brinton, RD; Wang, JM				Sun, Chenyou; Ou, Xiaoming; Farley, Jerry M.; Stockmeier, Craig; Bigler, Steven; Brinton, Roberta Diaz; Wang, Jun Ming			Allopregnanolone Increases the Number of Dopaminergic Neurons in Substantia Nigra of a Triple Transgenic Mouse Model of Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Allopregnanolone; neurogenesis; tyrosine hydroxylase (TH); substantia nigra; dopaminergic neurons	GAMMA-AMINOBUTYRIC-ACID; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; LOCUS-COERULEUS; LEWY BODIES; CELL-DEATH; NEUROSTEROID ALLOPREGNANOLONE; PRESENILIN-1 MUTATION; TYROSINE-HYDROXYLASE; TANGLE FORMATION	More than a third of Alzheimer's disease (AD) patients show nigrostriatal pathway disturbances, resulting in akinesia (inability to initiate movement) and bradykinesia (slowness of movement). The high prevalence of this dysfunction of dopaminergic neuron in the nigrostriatal pathway in AD suggests that the risk factors for AD appear also significant risk factors for substantia nigra pars compacta (SNpc) lesions. Previously, we have demonstrated that allopregnanolone (AP alpha) promotes neurogenesis and improves the cognitive function in a triple transgenic mouse model of AD (3xTgAD). In this study, we sought to exam 1) the SNpc lesions in 3xTgAD mice and 2) the impact of AP alpha on promoting the regeneration of new dopaminergic neurons in SNpc of the 3xTgAD mice. The number of Nissl-stained total neurons, tyrosine hydroxylase (TH) positive neurons, and BrdU/TH double positive newly formed neurons were analyzed with unbiased stereology. In the SNpc of 3xTgAD mice, TH positive neurons was 47 +/- 18 % (p = 0.007), total neurons was 62 +/- 11.6 % (p = 0.016), of those in the SNpc of non-Tg mice, respectively. APa treatment increased the TH positive neurons in the SNpc of 3xTgAD mice to 93.2 +/- 18.5 % (p = 0.021 vs. 3xTgAD vehicle) and the total neurons to 84.9 +/- 6.6 (p = 0.046 vs. 3xTgAD vehicle) of non-Tg mice. These findings indicate that there is a loss of neurons, specifically the TH positive neurons in SNpc of 3xTgAD mice, and that AP alpha reverses the lesion in SNpc of 3xTgAD by increasing the formation of new TH neurons.	[Sun, Chenyou; Bigler, Steven; Wang, Jun Ming] Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA; [Ou, Xiaoming; Stockmeier, Craig; Wang, Jun Ming] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA; [Farley, Jerry M.; Wang, Jun Ming] Univ Mississippi, Med Ctr, Dept Pharmacol & Toxicol, Jackson, MS 39216 USA; [Sun, Chenyou] Wenzhou Medial Coll, Dept Anat, Wenzhou 325035, Zhejiang, Peoples R China; [Brinton, Roberta Diaz] Univ So Calif, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA	Wang, JM (corresponding author), Univ Mississippi, Med Ctr, Dept Pathol, 2500 N State St, Jackson, MS 39208 USA.	jwang@umc.edu		Brinton, Roberta/0000-0001-8450-772X	Michael J FOX RRIA; Carryway foundation; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR17701]; IIRG from the Alzheimer's Association; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017701] Funding Source: NIH RePORTER	The authors thank Dr. Frank LaFerla for his gift of 3xTgAD mice. This study was supported by Michael J FOX RRIA grant, a Carryway foundation grant, a small grant of NCRR RR17701 and a IIRG grant from the Alzheimer's Association. All experiments conformed to the Animal Welfare Act, Guide to Use and Care of Laboratory Animals, and the U. S. Government Principles of the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training guidelines on the ethical use of animals. In addition, the minimal number of required animals was used for these experiments and pain was minimized.	Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Arias-Carrion O, 2009, J NEURAL TRANSM-SUPP, P279, DOI 10.1007/978-3-211-92660-4_23; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Baulieu EE, 2000, STEROIDS, V65, P605, DOI 10.1016/S0039-128X(00)00173-2; Bittner T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015477; Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Burns JM, 2005, NEUROLOGY, V64, P1397, DOI 10.1212/01.WNL.0000158423.05224.7F; Chen S, 2011, PLOS ONE UNPUB; Chen SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024293; CHUI HC, 1986, ARCH NEUROL-CHICAGO, V43, P991, DOI 10.1001/archneur.1986.00520100013007; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; DAHLSTROM A, 1964, EXPERIENTIA, V20, P398, DOI 10.1007/BF02147990; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; German DC, 2005, J COMP NEUROL, V492, P469, DOI 10.1002/cne.20744; Gomez-Tortosa E, 1998, J AM GERIATR SOC, V46, P1449, DOI 10.1111/j.1532-5415.1998.tb06016.x; Gong CX, 2008, CURR MED CHEM, V15, P2321, DOI 10.2174/092986708785909111; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Iqbal K, 2006, J ALZHEIMERS DIS, V9, P219; JELLINGER K, 1987, J NEURAL TRANSM, P109; Jellinger KA, 2003, ACTA NEUROPATHOL, V106, P191, DOI 10.1007/s00401-003-0725-y; Jimenez-Escrig A, 2004, EUR J NEUROL, V11, P663, DOI 10.1111/j.1468-1331.2004.00865.x; KASTNER A, 1993, J NEUROCHEM, V61, P1024, DOI 10.1111/j.1471-4159.1993.tb03616.x; KAZEE AM, 1995, ARCH PATHOL LAB MED, V119, P448; KAZEE AM, 1995, ALZ DIS ASSOC DIS, V9, P61, DOI 10.1097/00002093-199509020-00001; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; MAYEUX R, 1985, NEUROLOGY, V35, P453, DOI 10.1212/WNL.35.4.453; McCormack AL, 2006, NEUROSCIENCE, V141, P929, DOI 10.1016/j.neuroscience.2006.03.069; McMillan PJ, 2011, BRAIN RES, V1373, P240, DOI 10.1016/j.brainres.2010.12.015; Mellon SH, 2002, ENDOCR RES, V28, P463, DOI 10.1081/ERC-120016823; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; MITSUYAMA Y, 1993, DEMENTIA, V4, P137, DOI 10.1159/000107312; MORRIS JC, 1989, ARCH NEUROL-CHICAGO, V46, P651, DOI 10.1001/archneur.1989.00520420071025; Mudher A, 2004, MOL PSYCHIATR, V9, P522, DOI 10.1038/sj.mp.4001483; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Naylor JC, 2010, BBA-MOL CELL BIOL L, V1801, P951, DOI 10.1016/j.bbalip.2010.05.006; Nelson EL, 1996, J COMP NEUROL, V369, P361, DOI 10.1002/(SICI)1096-9861(19960603)369:3<361::AID-CNE3>3.0.CO;2-3; O'Neil JN, 2007, J CHEM NEUROANAT, V34, P102, DOI 10.1016/j.jchemneu.2007.05.008; Oberto A, 2002, J NEUROCHEM, V82, P1272, DOI 10.1046/j.1471-4159.2002.01079.x; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Perez SE, 2005, J NEUROSCI, V25, P10220, DOI 10.1523/JNEUROSCI.2773-05.2005; Ramsden M, 2005, J NEUROSCI, V25, P10637, DOI 10.1523/JNEUROSCI.3279-05.2005; Rey NL, 2012, NEUROBIOL AGING, V33; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schmitz C, 2004, AM J PATHOL, V164, P1495, DOI 10.1016/S0002-9440(10)63235-X; Singh C, 2011, NEUROBIOLOG IN PRESS; Snider BJ, 2005, ARCH NEUROL-CHICAGO, V62, P1821, DOI 10.1001/archneur.62.12.1821; Szot P, 2009, NEUROSCI LETT, V463, P93, DOI 10.1016/j.neulet.2009.07.055; TORACK RM, 1992, J NEURAL TRANSM-PARK, V4, P165, DOI 10.1007/BF02251479; Verny M, 1998, ANN MED INTERNE, V149, P209; Wang Doris D, 2008, Epilepsy Curr, V8, P137, DOI 10.1111/j.1535-7511.2008.00270.x; Wang J, 2010, HIPPOCAMPAL NEURAL P; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Wang JM, 2007, ALLOPREGNANOLONE REV; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Wang JM, 2007, CURR ALZHEIMER RES, V4, P510, DOI 10.2174/156720507783018262; Wang JM, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00194; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wang JM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S11; Yang SY, 2005, TRENDS ENDOCRIN MET, V16, P167, DOI 10.1016/j.tem.2005.03.006; Zarow C, 2003, ARCH NEUROL-CHICAGO, V60, P337, DOI 10.1001/archneur.60.3.337; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	73	26	36	0	6	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	MAY	2012	9	4					473	480		10.2174/156720512800492567			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	944HF	WOS:000304189200009	22272610	Green Accepted			2021-06-18	
J	Baker, KS; Piriyapunyaporn, T; Cunnington, R				Baker, Katharine S. y; Piriyapunyaporn, Teerut; Cunnington, Ross			Neural activity in readiness for incidental and explicitly timed actions	NEUROPSYCHOLOGIA			English	Article						Motor preparation; Time reproduction; Readiness potential; Attention; ERP	MOVEMENT-RELATED POTENTIALS; SUPPLEMENTARY MOTOR AREA; EXTERNALLY TRIGGERED MOVEMENTS; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; VOLUNTARY MOVEMENT; TEMPORAL REPRODUCTION; PARKINSONS-DISEASE; PREFRONTAL CORTEX; TOURETTE-SYNDROME	Voluntary, self-initiated actions are preceded by slowly increasing neural activity in pre-motor regions of the brain, beginning up to 2s before the onset of muscle movement. This activity is commonly seen in the scalp-recorded readiness potential, and is an index of movement preparation involving both motor programming and non-motor or cognitive processes such as attention. The specific contribution of cognitive processes, thought to occur during the earliest stage of planning, remains somewhat unclear. We suggest that attention to the timing of movement is a key voluntary process contributing to early-stage cortical activity. As a novel approach to examining this, we recorded EEG throughout a time reproduction task in which participants replicated the interval between two tones with two button-press actions. The first action, i.e. the beginning of the reproduced interval, was somewhat incidental to the task of time reproduction and required minimal attention to the time of initiation, while the second action required explicit attention to the time of initiation. Pre-movement neural activity preceding the first, relatively unattended movement was greatly reduced in amplitude and almost absent in the early stage, in contrast with readiness potentials typically seen prior to voluntary movement. Neural activity preceding explicitly timed movements was significantly larger, with effects emerging in the early component of pre-movement activity over frontal and right frontal scalp regions. We propose that attention to movement timing, i.e. the process of orienting attention in time towards the moment of movement initiation, is a key component of voluntary action preparation that is reflected in the early-stage neural activity we typically see prior to voluntary movement. (C) 2012 Elsevier Ltd. All rights reserved.	[Baker, Katharine S. y; Piriyapunyaporn, Teerut; Cunnington, Ross] Univ Queensland, Queensland Brain Inst, St Lucia, Qld 4072, Australia; [Baker, Katharine S. y; Cunnington, Ross] Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia	Cunnington, R (corresponding author), Univ Queensland, Queensland Brain Inst, QBI Bldg 79, St Lucia, Qld 4072, Australia.	r.cunnington@uq.edu.au		Cunnington, Ross/0000-0002-7423-4809	Australian Research CouncilAustralian Research Council [FT0991468]; Mahidol University, Thailand	This study was supported by funding from the Australian Research Council (FT0991468) and travel funding to TP from Mahidol University, Thailand.	Baker KS, 2011, NEUROPSYCHOLOGIA, V49, P3303, DOI 10.1016/j.neuropsychologia.2011.08.003; Ball T, 1999, NEUROIMAGE, V10, P682, DOI 10.1006/nimg.1999.0507; Bohlhalter S, 2006, BRAIN, V129, P2029, DOI 10.1093/brain/awl050; Bortoletto M, 2011, BRAIN COGNITION, V75, P196, DOI 10.1016/j.bandc.2010.11.016; Bortoletto M, 2010, NEUROIMAGE, V49, P3338, DOI 10.1016/j.neuroimage.2009.11.048; Coull JT, 2000, NEUROPSYCHOLOGIA, V38, P808, DOI 10.1016/S0028-3932(99)00132-3; Coull JT, 1998, J NEUROSCI, V18, P7426; Coull JT, 2004, SCIENCE, V303, P1506, DOI 10.1126/science.1091573; Cunnington R, 2005, HUM MOVEMENT SCI, V24, P644, DOI 10.1016/j.humov.2005.10.001; Cunnington R, 2003, NEUROIMAGE, V20, P404, DOI 10.1016/S1053-8119(03)00291-X; DEECKE L, 1969, EXP BRAIN RES, V7, P158; Haggard P., 1999, EXPT BRAIN RES, V126; Jahanshahi M, 1998, COGN NEUROPSYCHOL, V15, P483, DOI 10.1080/026432998381005; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; Jenkins IH, 2000, BRAIN, V123, P1216, DOI 10.1093/brain/123.6.1216; Jones CRG, 2004, EXP BRAIN RES, V158, P366, DOI 10.1007/s00221-004-1912-3; Jueptner M, 1997, J NEUROPHYSIOL, V77, P1313; Kagerer FA, 2002, NEUROPSYCHOLOGIA, V40, P357, DOI 10.1016/S0028-3932(01)00111-7; Karp BI, 1996, J NEUROL NEUROSUR PS, V61, P103, DOI 10.1136/jnnp.61.1.103; KELLER I, 1990, ELECTROEN CLIN NEURO, V76, P351, DOI 10.1016/0013-4694(90)90036-J; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; Lau HC, 2004, SCIENCE, V303, P1208, DOI 10.1126/science.1090973; Lee KM, 1999, NEUROIMAGE, V9, P117, DOI 10.1006/nimg.1998.0393; Lewis PA, 2003, CURR OPIN NEUROBIOL, V13, P250, DOI 10.1016/S0959-4388(03)00036-9; LIBET B, 1982, ELECTROEN CLIN NEURO, V54, P322, DOI 10.1016/0013-4694(82)90181-X; Macar F, 2003, PSYCHOPHYSIOLOGY, V40, P950, DOI 10.1111/1469-8986.00113; Malapani C, 1998, J COGNITIVE NEUROSCI, V10, P316, DOI 10.1162/089892998562762; Meck WH, 2002, BRAIN COGNITION, V48, P195, DOI 10.1006/brcg.2001.1313; OBESO JA, 1981, J NEUROL NEUROSUR PS, V44, P735, DOI 10.1136/jnnp.44.8.735; Passingham RE, 1996, PHILOS T ROY SOC B, V351, P1473, DOI 10.1098/rstb.1996.0132; Pfeuty M, 2003, EXP BRAIN RES, V151, P372, DOI 10.1007/s00221-003-1505-6; Praamstra P, 2006, J NEUROSCI, V26, P5448, DOI 10.1523/JNEUROSCI.0440-06.2006; Rammsayer TH, 1999, Q J EXP PSYCHOL-B, V52, P273; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Rowe J, 2002, NEUROIMAGE, V17, P988, DOI 10.1006/nimg.2002.1156; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; Shibasaki H, 2006, CLIN NEUROPHYSIOL, V117, P2341, DOI 10.1016/j.clinph.2006.04.025; SINGH J, 1990, BRAIN RES, V531, P45, DOI 10.1016/0006-8993(90)90756-2; Stephan KM, 2002, NEUROIMAGE, V15, P345, DOI 10.1006/nimg.2001.0929; Stern E, 2000, ARCH GEN PSYCHIAT, V57, P741, DOI 10.1001/archpsyc.57.8.741; Trevena J, 2010, CONSCIOUS COGN, V19, P447, DOI 10.1016/j.concog.2009.08.006; Ulbrich P, 2007, ACTA PSYCHOL, V125, P51, DOI 10.1016/j.actpsy.2006.06.004; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P2677, DOI 10.1016/j.clinph.2004.06.015; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Wildgruber D, 1997, NEUROSCI LETT, V227, P161, DOI 10.1016/S0304-3940(97)00329-7	45	26	26	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	APR	2012	50	5					715	722		10.1016/j.neuropsychologia.2011.12.026			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	941HS	WOS:000303954900017	22245011				2021-06-18	
J	Bornstein, N; Poon, WS				Bornstein, N.; Poon, W. S.			ACCELERATED RECOVERY FROM ACUTE BRAIN INJURIES: CLINICAL EFFICACY OF NEUROTROPHIC TREATMENT IN STROKE AND TRAUMATIC BRAIN INJURIES	DRUGS OF TODAY			English	Article							ACUTE ISCHEMIC-STROKE; ENHANCES FUNCTIONAL RECOVERY; RANDOMIZED CONTROLLED-TRIAL; FOCAL CEREBRAL INFARCTION; DOUBLE-BLIND; CEREBROLYSIN; RATS; MODERATE; IMMUNOREACTIVITY; THROMBOLYSIS	Stroke is one of the most devastating vascular diseases in the world as it is responsible for almost five million deaths per year. Almost 90% of all strokes are ischemic and mainly due to atherosclerosis, cardiac embolism and small-vessel disease. Intracerebral or subarachnoid hemorrhage can lead to hemorrhagic stroke, which usually has the poorest prognosis. Cerebrolysin is a peptide preparation which mimics the action of a neurotrophic factor, protecting stroke-injured neurons and promoting neuroplasticity and neuro genesis. Cerebrolysin has been widely studied as a therapeutic tool for both ischemic and hemorrhagic stroke, as well as traumatic brain injury. In ischemic stroke, Cerebrolysin given as an adjuvant therapy to antiplatelet and rheologically active medication resulted in accelerated improvement in global, neurological and motor functions, cognitive performance and activities of daily living. Cerebrolysin was also safe and well tolerated when administered in patients suffering from hemorrhagic stroke. Traumatic brain injury leads to transient or chronic impairments in physical, cognitive, emotional and behavioral functions. This is associated with deficits in the recognition of basic emotions, the capacity to interpret the mental states of others, and executive functioning. Pilot clinical studies with adjuvant Cerebrolysin in the acute and postacute phases of the injury have shown faster recovery, which translates into an earlier onset of rehabilitation and shortened hospitalization time.	[Bornstein, N.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv Med Sch, IL-64239 Tel Aviv, Israel; [Poon, W. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China	Bornstein, N (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv Med Sch, 6 Weizman St, IL-64239 Tel Aviv, Israel.	natanb@tasmc.health.gov.il	Poon, Wai Sang/F-1558-2011		EVER Neuro Pharma	The production of this supplement of Drugs of Today was sponsored by EVER Neuro Pharma, the manufacturer of Cerebrolysin. The authors have not received any payments for the writing of this article.	Abdelaziz O., 2007, PAN ARAB J NEUROSURG, V11, P51; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; [Anonymous], 1993, INV HLTH; Alvarez XA, 2008, J NEURAL TRANSM, V115, P683, DOI 10.1007/s00702-008-0024-9; Bajenaru O, 2010, J Med Life, V3, P137; Bogousslavsky J, 1999, CEREBROVASC DIS, V9, P1; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Butcher K, 2003, STROKE, V34, P2159, DOI 10.1161/01.STR.0000086529.83878.A2; Clark WM, 2001, NEUROLOGY, V57, P1595, DOI 10.1212/WNL.57.9.1595; Conte V., 2003, EUR J TRAUMA, V29, P335; Daniels J.P., 2006, J FAM PRACTICE, V5, P5; Davis S, 2006, INT J CLIN PRACT, V60, P399, DOI 10.1111/j.1368-5031.2006.00873.x; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Feim Z., 1992, CHINESE J NERVOUS ME, V18, P6; Frey W., 2002, TREATMENT STROKE INT, P1; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hacke W, 1999, NEUROLOGY, V53, pS3; Haffner Z, 2001, CEREBROVASC DIS, V11, P76; Haffner Z., 1999, 31 INT DAN S NEUR SC; Haninec P, 2004, EXP BRAIN RES, V159, P425, DOI 10.1007/s00221-004-1969-z; Hartbauer M, 2001, J NEURAL TRANSM, V108, P581, DOI 10.1007/s007020170058; He J, 2002, CHINESE J CLIN PRACT, V4, P71; Heiss WD, 2012, STROKE, V43, P630, DOI 10.1161/STROKEAHA.111.628537; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Herrschaft H., 1998, WIRKSAMKEIT CEREBROL; Hong Z, 2009, INT J STROKE, V4, P406, DOI 10.1111/j.1747-4949.2009.00340.x; Hong Z, 2005, CHINESE J GERIATRIC, V7, P331; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Konig P, 2006, J NEUROL NEUROCHIR P, V7, P12; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Ladurner G, 2005, J NEURAL TRANSM, V112, P415, DOI 10.1007/s00702-004-0248-2; Lang W., 2009, PROSPECTIVE RANDOMIZ; Lin SZ, 1999, STROKE, V30, P126, DOI 10.1161/01.STR.30.1.126; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Martinez Vila W., 2001, CEREBROVASC DIS, V11, P60; Maximova MY, 2009, ZH NEVROL PSIKHIATR, V109, P20; Muresanu D.F., 1999, CEREBROLYSIN THERAPE; Payne KA, 2002, PHARMACOECONOMICS, V20, P813, DOI 10.2165/00019053-200220120-00002; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Reinprecht I, 1999, HISTOCHEM J, V31, P394; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Shamalov NA, 2010, ZH NEVROL PSIKHIATR, V110, P34; Shi Y-M, 1990, CHINESE J NERVOUS ME, V16, P228; Skvortsova VI, 2004, ZH NEVROPATOL PSIKH, P51; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Windholz E, 2000, HISTOCHEM J, V32, P79, DOI 10.1023/A:1004053809591; Wong GKC, 2005, ACTA NEUROCHIR SUPPL, V95, P59; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495; Zhou D, 1993, ZHONG HUA CHUANG SHA, V9, P289	56	26	27	1	19	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	1699-3993	1699-4019		DRUG TODAY	Drugs Today	APR	2012	48			A			43	61		10.1358/dot.2012.48(Suppl.A).1739723			19	Pharmacology & Pharmacy	Pharmacology & Pharmacy	959GW	WOS:000305301900004	22514794				2021-06-18	
J	Feng, JF; Zhao, XR; Gurkoff, GG; Van, KC; Shahlaie, K; Lyeth, BG				Feng, Jun-feng; Zhao, Xueren; Gurkoff, Gene G.; Van, Ken C.; Shahlaie, Kiarash; Lyeth, Bruce G.			Post-Traumatic Hypoxia Exacerbates Neuronal Cell Death in the Hippocampus	JOURNAL OF NEUROTRAUMA			English	Article						hippocampal fields; hippocampus; hypoxia; neuronal degeneration; neuronal survival; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; LATERAL FLUID-PERCUSSION; FLUORO-JADE-B; HEAD-INJURY; SELECTIVE VULNERABILITY; RAT HIPPOCAMPUS; AMINO-ACIDS; AUTOREGULATION; GLUTAMATE	Hypoxia frequently occurs in patients with traumatic brain injury (TBI) and is associated with increased morbidity and mortality. This study examined the effects of immediate or delayed post-traumatic hypoxia (fraction of inspired oxygen [FiO(2)] 11%) on acute neuronal degeneration and long-term neuronal survival in hippocampal fields after moderate fluid percussion injury in rats. In Experiment 1, hypoxia was induced for 15 or 30 min alone or immediately following TBI. In Experiments 2 and 3, 30 min of hypoxia was induced immediately after TBI or delayed until 60 min after TBI. In Experiment 1, acute neurodegeneration was evaluated in the hippocampal fields 24 h after insults using Fluoro-Jade staining and stereological quantification. During hypoxia alone, or in combination with TBI, mean arterial blood pressure was significantly reduced by approximately 30%, followed by a rapid return to normal values upon return to pre-injury FiO(2). Hypoxia alone failed to cause hippocampal neuronal degeneration when measured at 24 h after insult. TBI alone resulted in neuronal degeneration in each ipsilateral hippocampal field, predominantly in CA2-CA3 and the dentate gyrus. Compared to TBI alone, TBI plus immediate hypoxia for either 15 or 30 min significantly increased neuronal loss in most ipsilateral hippocampal fields and in the contralateral hilus and dentate gyrus. In Experiment 2, TBI plus hypoxia delayed 30 min significantly increased degeneration only in ipsilateral CA2-CA3. In Experiment 3, 30 min of immediate hypoxia significantly reduced the numbers of surviving neurons in the CA3 at 14 days after TBI. The greatly increased vulnerability in all hippocampal fields by immediate 30 min post-traumatic hypoxia provides a relevant model of TBI complicated with hypoxia/hypotension. These data underscore the significance of the secondary insult, the necessity to better characterize the range of injuries experienced by the TBI patient, and the importance of strictly avoiding hypoxia in the early management of TBI patients.	[Feng, Jun-feng; Zhao, Xueren; Gurkoff, Gene G.; Van, Ken C.; Shahlaie, Kiarash; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Feng, Jun-feng] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Renji Hosp, Shanghai 200030, Peoples R China; [Gurkoff, Gene G.] Univ Calif Davis, NSF Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995]; Center for Biophotonics Science and Technology, a designated NSF Science and Technology Center [PHY 0120999]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke grant NS29995, and the Center for Biophotonics Science and Technology, a designated NSF Science and Technology Center, managed by the University of California at Davis, under cooperative agreement number PHY 0120999. Expert technical assistance was provided by Rahil Ghiasvand and Darrin Lee.	Amaral David G., 1995, P443; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Anderson RE, 2003, J TRAUMA, V54, P550, DOI 10.1097/01.TA.0000047049.64695.69; Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Bales JW, 2010, J NEUROTRAUM, V27, P109, DOI 10.1089/neu.2009.1072; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; Bedell EA, 2004, J NEUROTRAUM, V21, P1212; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gilbert PE, 2001, HIPPOCAMPUS, V11, P626, DOI 10.1002/hipo.1077; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman M.D., 2010, J SURG RES; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hellewell S.C., 2010, J NEUROTRAUMA; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kesner RP, 2004, REV NEUROSCIENCE, V15, P333; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McSwain NE, 2004, J TRAUMA, V57, P8; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Okada K, 2009, BEHAV BRAIN RES, V200, P181, DOI 10.1016/j.bbr.2009.01.011; Owens J, 1997, ANN NEUROL, V41, P187, DOI 10.1002/ana.410410210; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266	61	26	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1167	1179		10.1089/neu.2011.1867			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100017	22191636	Green Published			2021-06-18	
J	Gaur, V; Kumar, A				Gaur, Vaibhav; Kumar, Anil			Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury	DRUG AND CHEMICAL TOXICOLOGY			English	Article						Glutathione system; inflammation; memory; mitochondrial dysfunction; stroke	TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; RAT-BRAIN; STROKE; INFLAMMATION; INVOLVEMENT; EXPRESSION; NEURONS; PATHOPHYSIOLOGY; HYPOPERFUSION	Involvement of the glutathione system is well established in stroke-induced memory dysfunction. The aim of the present study was to investigate the effects of celecoxib (a selective cyclooxygenase-2 [COX-2] inhibitor), nimesulide (a preferential COX-2 inhibitor), and ibuprofen (a nonselective COX-2 inhibitor) against bilateral common carotid artery occlusion (BCCAO)-induced memory dysfunction. BCCAO for 30 minutews, followed by 24-hour reperfusion, significantly delayed transfer latency in the plus-maze performance task and shortened fall-off time in the hanging-wire experimental test. Besides significant alterations in glutathione defense (i.e., glutathione S-transferase and redox ratio), increased acetylcholinesterase activity and proinflammatory marker (tumor necrosis factor alpha TNF-alpha) in the hippocampus was seen. Seven days of treatment with celecoxib (3 and 10 mg/kg, p.o.), nimesulide (10 mg/kg, p.o.), and ibuprofen (30 mg/kg, p.o.) significantly improved behavioral alterations and glutathione defense and attenuated acetylcholinesterase activity and TNF-alpha levels, as compared to the control (i.e., ischemic reperfusion) group. The present study highlights the neuroprotective effect of celecoxib and nimesulide against ischemia reperfusion injury-induced memory dysfunction, neuroinflammation, and oxidative damage.	[Gaur, Vaibhav; Kumar, Anil] Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Chandigarh 160014, India	Kumar, A (corresponding author), Panjab Univ, Div Pharmacol, Univ Inst Pharmaceut Sci, UGC Ctr Adv Study, Chandigarh 160014, India.	kumaruips@yahoo.com	KUMAR, ANIL -/D-7471-2011; Gaur, Vaibhav/AAE-1706-2019	KUMAR, ANIL -/0000-0002-9506-6197; 	University Grant Commission (U.G.C.), New DelhiUniversity Grants Commission, India; U.G.C.University Grants Commission, India	The authors gratefully acknowledge the financial support of the University Grant Commission (U.G.C.), New Delhi, for carrying out this work. The Research Fellowship in Science for Meritorious Students (to V. G.) of the U.G.C. is gratefully acknowledged.	Aggarwal A, 2010, LIFE SCI, V86, P928, DOI 10.1016/j.lfs.2010.04.011; Aronowski J, 1999, J CEREBR BLOOD F MET, V19, P652, DOI 10.1097/00004647-199906000-00008; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Candelario-Jalil Eduardo, 2003, BMC Pharmacol, V3, P7, DOI 10.1186/1471-2210-3-7; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Cruz R, 2003, REV NEUROLOGIA, V36, P877, DOI 10.33588/rn.3609.2002395; Cruz-Aguado R, 2001, BRAIN RES BULL, V55, P327, DOI 10.1016/S0361-9230(01)00484-1; Degi R, 1998, Neurobiology (Bp), V6, P467; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Gaur Vaibhav, 2011, Inflammopharmacology, V19, P205, DOI 10.1007/s10787-010-0068-y; Gaur V, 2010, PHARMACOL REP, V62, P635, DOI 10.1016/S1734-1140(10)70321-2; Gaur V, 2010, BRAIN RES, V1353, P204, DOI 10.1016/j.brainres.2010.07.004; Gaur V, 2010, BRAIN RES BULL, V82, P57, DOI 10.1016/j.brainresbull.2010.01.010; Gaur V, 2009, EUR J PHARMACOL, V616, P147, DOI 10.1016/j.ejphar.2009.06.056; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Jingtao Jiang, 1999, Medical Electron Microscopy, V32, P175, DOI 10.1007/s007950050025; Kaufmann AM, 1999, STROKE, V30, P93, DOI 10.1161/01.STR.30.1.93; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; KULKARNI SK, 1999, HDB EXPT PHARM, P117; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Linnik MD, 1993, STROKE, V24, p[2002, 2008], DOI 10.1161/01.STR.24.12.20028248983; Mabuchi N, 2000, J CARDIOVASC PHARM, V36, pS87, DOI 10.1097/00005344-200000006-00019; Maher P, 2005, AGEING RES REV, V4, P288, DOI 10.1016/j.arr.2005.02.005; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Nogawa S, 1997, J NEUROSCI, V17, P2746; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; REITER RJ, 1995, FASEB J, V9, P526; Reyes AE, 1997, BIOCHEM BIOPH RES CO, V232, P652, DOI 10.1006/bbrc.1997.6357; Schmidt-Kastner R, 2001, MOL BRAIN RES, V92, P157, DOI 10.1016/S0169-328X(01)00157-7; Siesjo BK, 2008, J NEUROSURG, V108, P616, DOI 10.3171/JNS/2008/108/3/0616; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Yan B, 2004, PHARMACOL BIOCHEM BE, V78, P319, DOI 10.1016/j.pbb.2004.04.010; Yanpallewar S, 2005, LIFE SCI, V76, P1325, DOI 10.1016/j.lfs.2004.06.029; Yanpallewar SU, 2004, PHARMACOL BIOCHEM BE, V79, P155, DOI 10.1016/j.pbb.2004.07.008; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	50	26	29	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0148-0545			DRUG CHEM TOXICOL	Drug Chem. Toxicol.	APR	2012	35	2					218	224		10.3109/01480545.2011.589850			7	Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology	Chemistry; Pharmacology & Pharmacy; Toxicology	894UG	WOS:000300451900014	21995864				2021-06-18	
J	Glover, LE; Tajiri, N; Lau, T; Kaneko, Y; van Loveren, H; Borlongan, CV				Glover, Loren E.; Tajiri, Naoki; Lau, Tsz; Kaneko, Yuji; van Loveren, Harry; Borlongan, Cesario V.			Immediate, but Not Delayed, Microsurgical Skull Reconstruction Exacerbates Brain Damage in Experimental Traumatic Brain Injury Model	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; DECOMPRESSIVE CRANIECTOMY; EARLY CRANIOPLASTY; MICE; AQUAPORIN-4; COMPLICATIONS; EXPRESSION; MANAGEMENT; EDEMA; DEATH	Moderate to severe traumatic brain injury (TBI) often results in malformations to the skull. Aesthetic surgical maneuvers may offer normalized skull structure, but inconsistent surgical closure of the skull area accompanies TBI. We examined whether wound closure by replacement of skull flap and bone wax would allow aesthetic reconstruction of the TBI-induced skull damage without causing any detrimental effects to the cortical tissue. Adult male Sprague-Dawley rats were subjected to TBI using the controlled cortical impact (CCI) injury model. Immediately after the TBI surgery, animals were randomly assigned to skull flap replacement with or without bone wax or no bone reconstruction, then were euthanized at five days post-TBI for pathological analyses. The skull reconstruction provided normalized gross bone architecture, but 2,3,5-triphenyltetrazolium chloride and hematoxylin and eosin staining results revealed larger cortical damage in these animals compared to those that underwent no surgical maneuver at all. Brain swelling accompanied TBI, especially the severe model, that could have relieved the intracranial pressure in those animals with no skull reconstruction. In contrast, the immediate skull reconstruction produced an upregulation of the edema marker aquaporin-4 staining, which likely prevented the therapeutic benefits of brain swelling and resulted in larger cortical infarcts. Interestingly, TBI animals introduced to a delay in skull reconstruction (i.e., 2 days post-TBI) showed significantly reduced edema and infarcts compared to those exposed to immediate skull reconstruction. That immediate, but not delayed, skull reconstruction may exacerbate TBI-induced cortical tissue damage warrants a careful consideration of aesthetic repair of the skull in TBI.	[Glover, Loren E.; Tajiri, Naoki; Lau, Tsz; Kaneko, Yuji; van Loveren, Harry; Borlongan, Cesario V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA	Glover, LE (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Tajiri, Naoki/K-1230-2012; Borlongan, Cesar/I-5696-2012	Tajiri, Naoki/0000-0003-2189-662X; Borlongan, Cesar/0000-0002-2966-9782	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; James and Esther King Foundation; SanBio Inc.; Celgene Cellular TherapeuticsCelgene Corporation; KM Pharmaceutical Consulting; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	CVB is supported by the National Institutes of Health, the National Institute of Neurological Disorders and Stroke 1R01NS071956-01, the James and Esther King Foundation for Biomedical Research Program, SanBio Inc., Celgene Cellular Therapeutics, KM Pharmaceutical Consulting, and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amorini AM, 2003, ACT NEUR S, V86, P261; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bolkvadze T, 2011, J NEUROTRAUMA; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Dumont TM, 2010, J NEUROTRAUM, V27, P1233, DOI 10.1089/neu.2009.1216; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Ho KM, 2011, CRITICAL CARE MED; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Huang X, 2010, INT J MED SCI, V7, P385; Lethaus B, J NEUROTRAUMA; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Lund-Johansen M, 2011, WORLD NEUROSURG, V75, P454, DOI 10.1016/j.wneu.2011.01.020; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Minardi J, 2009, MT SINAI J MED, V76, P138, DOI 10.1002/msj.20105; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Petersen K, 2011, J TRAUMA, V71, pS264, DOI 10.1097/TA.0b013e318227ad9a; Piero C, 2009, J CRANIOFAC SURG, V20, P498, DOI 10.1097/SCS.0b013e31819b9e14; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; SCHIETROMA M, 1992, Annali Italiani di Chirurgia, V63, P163; Shelton SB, 2008, J NEUROSCI METH, V168, P431, DOI 10.1016/j.jneumeth.2007.11.003; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Thavarajah D, 2011, BRIT J NEUROSURGERY, P1; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Walberer M, 2008, AGGRAVATION INFARCT; Walcott BP, 2011, NEUROTHERAPEUTICS, P1; Wang P, 2011, GENET MOL RES, V10, P2165, DOI 10.4238/vol10-3gmr1212; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025; Xia CF, 2006, HYPERTENSION, V47, P752, DOI 10.1161/01.HYP.0000214867.35632.0e; Yanagawa Y, 2000, NEUROL MED-CHIR, V40, P133, DOI 10.2176/nmc.40.133; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu GL, 2004, BRAIN RES, V1015, P50, DOI 10.1016/j.brainres.2004.04.055; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zador Zsolt, 2009, Handb Exp Pharmacol, P159, DOI 10.1007/978-3-540-79885-9_7; Zweckberger K, 2011, NEUROSCIENCE LETT	53	26	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2012	7	3							e33646	10.1371/journal.pone.0033646			9	Multidisciplinary Sciences	Science & Technology - Other Topics	932RV	WOS:000303309100080	22438975	DOAJ Gold, Green Published			2021-06-18	
J	Callcut, RA; Hanseman, DJ; Solan, PD; Kadon, KS; Ingalls, NK; Fortuna, GR; Tsuei, BJ; Robinson, BRH				Callcut, Rachael A.; Hanseman, Dennis J.; Solan, Patrick D.; Kadon, Kurt S.; Ingalls, Nichole K.; Fortuna, Gerald R.; Tsuei, Betty J.; Robinson, Bryce R. H.			Early treatment of blunt cerebrovascular injury with concomitant hemorrhagic neurologic injury is safe and effective	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Blunt cerebrovascular injury; traumatic brain injury; carotid injury; vertebral injury	VENOUS THROMBOEMBOLISM; PROPHYLAXIS; MANAGEMENT; ANTICOAGULATION; ASSOCIATION; DIAGNOSIS	BACKGROUND: Early pharmacologic treatment for blunt cerebrovascular injury (BCVI) is often withheld when concomitant traumatic brain injury or cervical spinal cord injury occurs. This study examines the safety and efficacy of early treatment for patients with both BCVI and traumatic neurologic injury (TNI). METHODS: Ten-year retrospective review of patients with BCVI and a TNI was performed. Stroke outcomes for those treated with pharmacologic therapy for their BCVI were compared with those not treated. In addition, the likelihood of worsening of TNI was determined for those exposed to pharmacologic therapy compared with those not exposed. Multivariate logistic regression techniques were used to analyze adjusted odds ratio for stroke risk. RESULTS: Seventy-seven patients were identified with BCVI + TNI. Strokes occurred in 27% patients with 3 of 21 (14%) strokes present at arrival. There were no differences in baseline characteristics between groups. Stroke rate was higher in the untreated group compared with treated (57% vs. 4%, p < 0.0001). On multivariate regression, treatment status was the most significant stroke predictor (adjusted odds ratio 4.4, 3.0-6.5, p < 0.0001, c-stat 0.93). There was no difference in risk of hemorrhagic deterioration of traumatic brain injury based on pharmacologic exposure versus no exposure (5% vs. 6%, p = 0.6). Likewise, no patient with spinal cord injury worsened as a result of pharmacologic exposure. Of the potentially preventable strokes, 24% (4 of 17) resulted in a stroke-related death and all four deaths occurred in the untreated group. CONCLUSION: The benefit of early treatment for BCVI markedly outweighs the risk of treatment for patients suffering concomitant BCVI and hemorrhagic neurologic injury. (J Trauma. 2012; 72: 338-346. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Callcut, Rachael A.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA; [Hanseman, Dennis J.; Solan, Patrick D.; Kadon, Kurt S.; Ingalls, Nichole K.; Fortuna, Gerald R.; Tsuei, Betty J.; Robinson, Bryce R. H.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA	Callcut, RA (corresponding author), 300 Pasteur Dr,S-067B, Stanford, CA 94305 USA.	rcallcut@stanford.edu					Barnes Bryan, 2004, Neurosurg Focus, V17, pE5; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Bromberg WJ, 2011, J TRAUMA, V70, P1063; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Cothren C. Clay, 2005, Clinics, V60, P489, DOI 10.1590/S1807-59322005000600011; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Flint L, 2011, J AM COLL SURGEONS, V212, P557; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P612; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Romualdi E, 2009, THROMB HAEMOSTASIS, V101, P290, DOI 10.1160/TH08-07-0474; Scales DC, 2009, J CRIT CARE, V24, P176, DOI 10.1016/j.jcrc.2009.03.010; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Thumbikat P, 2002, SPINAL CORD, V40, P416, DOI 10.1038/sj.sc.3101325; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Vermes E, 2005, ASAIO J, V51, P485, DOI 10.1097/01.mat.0000169141.01817.e0; Wei CW, 2010, CAN J NEUROL SCI, V37, P574, DOI 10.1017/S0317167100010726	29	26	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2012	72	2					338	345		10.1097/TA.0b013e318243d978			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	898ZN	WOS:000300781000022	22327975				2021-06-18	
J	Campbell, JN; Low, B; Kurz, JE; Patel, SS; Young, MT; Churn, SB				Campbell, John N.; Low, Brian; Kurz, Jonathan E.; Patel, Sagar S.; Young, Matt T.; Churn, Severn B.			Mechanisms of Dendritic Spine Remodeling in a Rat Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						calcineurin; cofilin; excitatory post-synaptic protein PSD-95; lateral fluid percussion injury; spine-associated Rap guanosine triphosphatase activating protein	MAXIMAL CALCINEURIN ACTIVITY; LATERAL FLUID PERCUSSION; SUBCELLULAR-DISTRIBUTION; SIGNIFICANT INCREASE; HIPPOCAMPAL-NEURONS; PILOCARPINE MODEL; SYNAPTIC PROTEINS; OXIDATIVE STRESS; PHOSPHORYLATION; ASTROCYTES	Traumatic brain injury (TBI), a leading cause of death and disability in the United States, causes potentially preventable damage in part through the dysregulation of neural calcium levels. Calcium dysregulation could affect the activity of the calcium-sensitive phosphatase calcineurin (CaN), with serious implications for neural function. The present study used both an in vitro enzymatic assay and Western blot analyses to characterize the effects of lateral fluid percussion injury on CaN activity and CaN-dependent signaling in the rat forebrain. TBI resulted in an acute alteration of CaN phosphatase activity and long-lasting alterations of its downstream effector, cofilin, an actin-depolymerizing protein. These changes occurred bilaterally in the neocortex and hippocampus, appeared to persist for hours after injury, and coincided with synapse degeneration, as suggested by a loss of the excitatory post-synaptic protein PSD-95. Interestingly, the effect of TBI on cofilin in some brain regions was blocked by a single bolus of the CaN inhibitor FK506, given 1 h post-TBI. Overall, these findings suggest a loss of synapse stability in both hemispheres of the laterally-injured brain, and offer evidence for region-specific, CaN-dependent mechanisms.	[Campbell, John N.; Churn, Severn B.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Low, Brian; Churn, Severn B.] Virginia Commonwealth Univ, Dept Physiol & Biophys, Richmond, VA 23298 USA; [Kurz, Jonathan E.; Patel, Sagar S.; Young, Matt T.; Churn, Severn B.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; [Churn, Severn B.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Churn, SB (corresponding author), Virginia Commonwealth Univ, Dept Anat, POB 980599, Richmond, VA 23298 USA.	schurn@vcu.edu		Kurz, Jonathan/0000-0002-2259-4263	Commonwealth Neurotrauma Initiative [07-302E]; Alzheimer's and Related Diseases Research Award Fund [11-1]	The authors are grateful to Drs. Bob Hamm and Tom Reeves for use of the fluid percussion injury device, and to Drs. Hamm and Leroy Thacker for guidance with statistics. The authors would also like to acknowledge David Register for his technical assistance with these studies. This work was supported by Commonwealth Neurotrauma Initiative grant 07-302E (to S.B.C.), and an Alzheimer's and Related Diseases Research Award Fund, award number 11-1 (to S.B.C.).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bales JW, 2010, BRAIN RES, V1358, P211, DOI 10.1016/j.brainres.2010.08.029; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell J.N., 2011, J NEUROTRAUMA   0425; Campbell JN, 2009, DENDRITIC SPINES: BIOCHEMISTRY, MODELING AND PROPERTIES, P45; CHURN SB, 1992, J NEUROCHEM, V59, P1221, DOI 10.1111/j.1471-4159.1992.tb08431.x; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Groth RD, 2003, BIOCHEM BIOPH RES CO, V311, P1159, DOI 10.1016/j.bbrc.2003.09.002; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Kato H, 2000, MOL BRAIN RES, V84, P58, DOI 10.1016/S0169-328X(00)00210-2; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Kurz JE, 2003, NEUROBIOL DIS, V14, P483, DOI 10.1016/j.nbd.2003.08.018; Kurz JE, 2001, J NEUROCHEM, V78, P304, DOI 10.1046/j.1471-4159.2001.00426.x; Kurz JE, 2008, EPILEPSIA, V49, P1696, DOI 10.1111/j.1528-1167.2008.01616.x; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Morishita W, 2005, NAT NEUROSCI, V8, P1043, DOI 10.1038/nn1506; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; PALLEN CJ, 1985, ARCH BIOCHEM BIOPHYS, V237, P281, DOI 10.1016/0003-9861(85)90279-6; Park KS, 2006, SCIENCE, V313, P976, DOI 10.1126/science.1124254; Romero-Calvo I, 2010, ANAL BIOCHEM, V401, P318, DOI 10.1016/j.ab.2010.02.036; Seeburg DP, 2008, J NEUROSCI, V28, P6583, DOI 10.1523/JNEUROSCI.1853-08.2008; Seeburg DP, 2008, NEURON, V58, P571, DOI 10.1016/j.neuron.2008.03.021; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Szydlowska K, 2006, J NEUROCHEM, V99, P965, DOI 10.1111/j.1471-4159.2006.04136.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010; Wu LX, 2007, BRAIN RES, V1168, P38, DOI 10.1016/j.brainres.2007.06.082; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011	46	26	27	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					218	234		10.1089/neu.2011.1762			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300003	21838518	Green Published			2021-06-18	
J	Crawford, F; Crynen, G; Reed, J; Mouzon, B; Bishop, A; Katz, B; Ferguson, S; Phillips, J; Ganapathi, V; Mathura, V; Roses, A; Mullan, M				Crawford, Fiona; Crynen, Gogce; Reed, Jon; Mouzon, Benoit; Bishop, Alex; Katz, Benjamin; Ferguson, Scott; Phillips, John; Ganapathi, Vani; Mathura, Venkatarajan; Roses, Allen; Mullan, Michael			Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model	JOURNAL OF NEUROTRAUMA			English	Article						APOE; biomarkers; proteomics; TBI	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; APOLIPOPROTEIN-E; INTRACEREBRAL HEMORRHAGE; ALZHEIMERS-DISEASE; SUBARACHNOID HEMORRHAGE; TRANSGENIC MICE; PROTEINS; EXPRESSION; SERUM	The current lack of diagnostic and prognostic biomarkers for traumatic brain injury (TBI) confounds treatment and management of patients and is of increasing concern as the TBI population grows. We have generated plasma proteomic profiles from mice receiving TBI by controlled cortical impact at either 1.3 mm or 1.8 mm depth, comparing these against those of sham injured-animals to identify plasma biomarkers specific to mild or severe TBI at 24 hours, 1 month, or 3 months post-injury. To identify possible prognostic biomarkers, we used apolipoprotein E (APOE)3 and APOE4 transgenic mice, which demonstrate relatively favorable and unfavorable outcomes respectively, following TBI. Using a quantitative proteomics approach (isobaric tagging for relative and absolute quantitation - iTRAQ) we have identified proteins that are significantly modulated as a function of TBI and also in response to the TBI*APOE genotype interaction, the latter representing potential prognostic biomarkers. These preliminary data clearly demonstrate plasma protein changes that are not only injury dependent but also interaction dependent. Importantly, these results demonstrate the presence of TBI-dependent and interaction-dependent plasma proteins at a 3-month time point, which is a considerable time post-injury in the mouse model, and will potentially be of significance for combat veterans receiving assessment at extended periods post-injury. Furthermore, our identification of clusters of functionally related proteins indicates disturbance of particular biological modules, which potentially increases their value beyond that of solitary biomarkers.	[Crawford, Fiona; Crynen, Gogce; Reed, Jon; Mouzon, Benoit; Bishop, Alex; Katz, Benjamin; Ferguson, Scott; Phillips, John; Ganapathi, Vani; Mathura, Venkatarajan; Mullan, Michael] Roskamp Inst, Sarasota, FL 34243 USA; [Crawford, Fiona; Reed, Jon; Mouzon, Benoit; Ferguson, Scott; Mathura, Venkatarajan; Mullan, Michael] James A Haley Vet Adm, Tampa, FL 33612 USA; [Roses, Allen] Duke Univ, R David Thomas Execut Training Ctr, Durham, NC 27706 USA	Crawford, F (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	fcrawford@rfdn.org		Mullan, Michael/0000-0002-1473-7527; Crynen, Gogce/0000-0001-6066-9900	Department of DefenseUnited States Department of Defense [W81XWH-07-1-0700]; Roskamp Foundation	This research was funded by a Department of Defense award (W81XWH-07-1-0700) to Dr. Fiona Crawford and by the Roskamp Foundation. The authors thank James Evans for his assistance in data review and manuscript preparation.	Abildayeva K, 2008, J LIPID RES, V49, P856, DOI 10.1194/jlr.M700518-JLR200; ABRAHAM CR, 1993, BRAIN RES, V621, P222, DOI 10.1016/0006-8993(93)90110-9; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bantscheff M, 2008, MOL CELL PROTEOMICS, V7, P1702, DOI 10.1074/mcp.M800029-MCP200; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Buttini M, 1999, J NEUROSCI, V19, P4867; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Dzietko M, 2008, ANN NEUROL, V64, P664, DOI 10.1002/ana.21516; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Fu Q, 2005, PROTEOMICS, V5, P2656, DOI 10.1002/pmic.200402048; Gilar M, 2005, ANAL CHEM, V77, P6426, DOI 10.1021/ac050923i; Gros-Louis F, 2007, NAT GENET, V39, P80, DOI 10.1038/ng1927; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Hill EG, 2008, J PROTEOME RES, V7, P3091, DOI 10.1021/pr070520u; Iwata A, 2005, J NEUROSCI RES, V82, P103, DOI 10.1002/jnr.20607; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kato K, 2001, J BIOL CHEM, V276, P14562, DOI 10.1074/jbc.M010725200; Kay A, 2003, STROKE, V34, pE240, DOI 10.1161/01.STR.0000100157.88508.2F; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Keep RF, 2008, ACT NEUR S, V105, P73; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kramer AH, 2009, NEUROCRIT CARE, V10, P157, DOI 10.1007/s12028-008-9171-y; Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Serra-Grabulosa JM, 2003, NEUROGENETICS, V4, P141, DOI 10.1007/s10048-002-0142-8; Shao J, 2006, ACTA NEUROCHIR SUPPL, V96, P183; SLEMMON JR, 1988, J NEUROSCI, V8, P4603; Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78; Urban S, 2006, GENE DEV, V20, P3054, DOI 10.1101/gad.1488606; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Vitek MP, 2009, NEUROBIOL AGING, V30, P1350, DOI 10.1016/j.neurobiolaging.2007.11.014; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; WONG CG, 1983, J LIPID RES, V24, P666; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Yao DL, 1999, BRAIN RES, V818, P140, DOI 10.1016/S0006-8993(98)01118-4	54	26	28	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					246	260		10.1089/neu.2011.1789			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300005	21895520				2021-06-18	
J	Fink, EL; Kochanek, PM; Clark, RSB; Bell, MJ				Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.			Fever control and application of hypothermia using intravenous cold saline	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injury; hypothermia; fever; pediatric; cold saline	TRAUMATIC BRAIN-INJURY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; COMATOSE SURVIVORS; TEMPERATURE; CHILDREN	Objectives: To describe the use and feasibility of cold saline to decrease body temperature in pediatric neurocritical care. Design: Retrospective chart review. Setting: Pediatric tertiary care university hospital. Patients: Children between 1 wk and 17 yrs of age admitted to the pediatric intensive care unit with acute brain injury and having received intravenous cold saline between June and August 2009. Interventions: None. Measurements and Main Results: Eighteen subjects accounted for 20 infusions with mean infusion volume 18 +/- 10 mL/kg. Eight subjects had traumatic brain injury, two had intracranial hemorrhage, six had cardiac arrest, and one each had ischemic stroke and status epilepticus. The mean age was 9.5 +/- 4.8 yrs. Temperature decreased from 38.7 +/- 1.1 degrees C to 37.7 +/- 1.2 degrees C and from 37.0 +/- 2.0 degrees C to 35.3 +/- 1.6 degrees C 1 hr after infusion for fever (n = 14; p < .05) or hypothermia induction (n = 6; p = .05), respectively. Cold saline was not bloused but rather infused over 10-15 mins. Mean arterial blood pressure and oxygenation parameters (PaO(2)/FIO(2) ratio, mean airway pressure) were unchanged, but heart rate decreased in those with hypothermia (121 +/- 4 beats per minute vs. 109 +/- 12 beats per minute; p < .05). Serum sodium concentration and international normalized ratio were significantly increased after cold saline infusion. There were no differences between preinfusion and postinfusion serum glucose and hematocrit, or between cerebral perfusion pressure and intracranial pressure in traumatic brain injury patients. Conclusions: Cold saline was an effective method of reducing temperature in children with acute brain injury. This approach can be considered to treat fever or to induce hypothermia. A prospective study comparing safety and efficacy vs. other cooling measures should be considered. (Pediatr Crit Care Med 2012; 13:80-84)	[Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA	Fink, EL (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	finkel@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23NS065132, 5K12HD047349, NS052478]; Laerdal Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS065132, U01NS052478] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health grants 1K23NS065132, 5K12HD047349, and NS052478; and The Laerdal Foundation.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Atkins DL, 2006, PEDIATRICS, V117, pE1005, DOI 10.1542/peds.2006-0346; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; Crowder CM, 1996, J NEUROSURG, V85, P98, DOI 10.3171/jns.1996.85.1.0098; Fink EL, 2010, NEUROCRIT CARE, V12, P414, DOI 10.1007/s12028-010-9334-5; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Kelly BP, 2010, PEDIATR CARDIOL, V31, P11, DOI 10.1007/s00246-009-9526-y; Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Kim Y, 1996, STROKE, V27, P2281; Kim YM, 2008, RESUSCITATION, V79, P336, DOI 10.1016/j.resuscitation.2008.07.010; Kliegel A, 2005, RESUSCITATION, V64, P347, DOI 10.1016/j.resuscitation.2004.09.002; Kollmar R, 2009, STROKE, V40, P1907, DOI 10.1161/STROKEAHA.108.530410; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Maxton FJC, 2004, J ADV NURS, V45, P214, DOI 10.1046/j.1365-2648.2003.02883.x; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Robinson JL, 1998, J PEDIATR-US, V133, P553, DOI 10.1016/S0022-3476(98)70067-8; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004	31	26	26	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2012	13	1					80	84		10.1097/PCC.0b013e3181fe27c7			5	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	875YT	WOS:000299073000025	21037507	Green Accepted			2021-06-18	
J	Katada, R; Nishitani, Y; Honmou, O; Mizuo, K; Okazaki, S; Tateda, K; Watanabe, S; Matsumoto, H				Katada, Ryuichi; Nishitani, Yoko; Honmou, Osamu; Mizuo, Keisuke; Okazaki, Shunichiro; Tateda, Kenji; Watanabe, Satoshi; Matsumoto, Hiroshi			Expression of Aquaporin-4 Augments Cytotoxic Brain Edema after Traumatic Brain Injury during Acute Ethanol Exposure	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CYTOCHROME-P450 2E1; WATER TRANSPORT; ALCOHOL; RAT; MICE; MORTALITY; INTOXICATION; ASTROCYTES; SEVERITY; LIVER	We previously reported that ethanol consumption affects morbidity and mortality after traumatic brain injury (TBI) by accelerating brain edema via oxidative stress after TBI. Aquaporin-4 (AQP4), a water channel, is involved in brain edema formation. In this study, we found that acute ethanol administration increased AQP4 expression after TBI, leading to severe brain edema in rats. Rats were pretreated with ethanol (3 g/kg) or DL-buthionine-(S, R)-sulfoximine (BSO; 100 mg/kg), an oxidative stressor, before TBI. Acetazolamide, an AQP4 inhibitor, was administered to ethanol-pretreated rats 3 or 12 hours after TBI. Brain edema was increased 24 hours after TBI in both the ethanol- and BSO-pretreated groups. Ethanol pretreatment induced lipid peroxidation 24 hours after TBI. Transcription factors, NE-kappa B and hypoxia-inducible factor-1 alpha, were activated 3 and 24 hours after TBI in the BSO- and ethanol-pretreated groups, respectively. In the ethanol-pretreated group, AQP4 was accumulated, particularly in astrocyte end feet, 24 hours after TBI. Acetazolamide treatment improved the survival rate to 100% and decreased brain edema and AQP4 in ethanol-pretreated rats. These findings suggest that ethanol induces up-regulation of AQP4, leading to brain edema. The accumulation of AQP4 may play an important role in the augmentation of brain edema after TBI under ethanol consumption. (Am J Pathol 2012, 180:17-23; DOL. 10.1016/j.ajpath.2011.09.011)	[Matsumoto, Hiroshi] Sapporo Med Univ, Dept Legal Med & Mol Alcohol, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Honmou, Osamu] Sapporo Med Univ, Dept Neural Repair & Therapeut, Sch Med, Sapporo, Hokkaido 0608556, Japan; [Nishitani, Yoko] Kumamoto Univ, Grad Sch Med Sci, Dept Forens Med, Kumamoto, Japan	Matsumoto, H (corresponding author), Sapporo Med Univ, Dept Legal Med & Mol Alcohol, Sch Med, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	hmatsumo@sapmed.ac.jp		honmou, Osamu/0000-0001-8697-7530	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [22790601, 20390196]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22790601] Funding Source: KAKEN	Supported in part by Grants-in-Aid for Young Scientists (B) (22790601 to R.K.) and for Scientific Research (B) (20390196 to H.M.) and grants from the Japan Society for the Promotion of Science.	Allansson L, 2001, J NEUROCHEM, V76, P472, DOI 10.1046/j.1471-4159.2001.00097.x; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Aschner M, 2001, BRAIN RES, V900, P219, DOI 10.1016/S0006-8993(01)02314-9; Blanco AM, 2004, NEUROREPORT, V15, P681, DOI 10.1097/00001756-200403220-00021; Davis RL, 2004, NEUROSCI LETT, V371, P128, DOI 10.1016/j.neulet.2004.08.051; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Illarionova NB, 2010, NEUROSCIENCE, V168, P915, DOI 10.1016/j.neuroscience.2009.11.062; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; JAMIE YD, 2009, NEUROSCI LETT, V453, P68; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lange RT, 2008, ARCH CLIN NEUROPSYCH, V23, P809, DOI 10.1016/j.acn.2008.07.004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mansouri A, 2001, J PHARMACOL EXP THER, V298, P737; Matsumoto H, 2002, ALCOHOL CLIN EXP RES, V26, p6S, DOI 10.1097/01.ALC.0000026827.79925.C9; Migliati ER, 2010, NEUROCRIT CARE, V13, P123, DOI 10.1007/s12028-010-9376-8; Nielsen S, 1997, J NEUROSCI, V17, P171; Nishitani Y, 2006, FEBS LETT, V580, P9, DOI 10.1016/j.febslet.2005.11.030; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Rabinstein AA, 2010, CURR TREAT OPTION NE, V12, P129, DOI 10.1007/s11940-010-0062-0; Raza H, 2004, DIABETES, V53, P185, DOI 10.2337/diabetes.53.1.185; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Sripathirathan K, 2009, J NEUROTRAUM, V26, P261, DOI 10.1089/neu.2008.0682; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Tindberg N, 1996, MOL PHARMACOL, V50, P1065; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verkman AS, 2009, J EXP BIOL, V212, P1707, DOI 10.1242/jeb.024125; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; YANG B, 2008, J BIOL CHEM, V1229, P224; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yuki T, 1980, Adv Exp Med Biol, V132, P689	40	26	35	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2012	180	1					17	23		10.1016/j.ajpath.2011.09.011			7	Pathology	Pathology	874RO	WOS:000298976000003	22051773	Bronze			2021-06-18	
J	Mellergard, P; Sjogren, F; Hillman, J				Mellergard, Pekka; Sjogren, Florence; Hillman, Jan			The Cerebral Extracellular Release of Glycerol, Glutamate, and FGF2 Is Increased in Older Patients following Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; FGF2; glutamate; glycerol; microdialysis; monitoring; traumatic brain injury	NEUROSURGICAL INTENSIVE-CARE; HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; AGED BRAIN; STROKE; MECHANISMS; MORTALITY; RECOVERY; MODERATE	Old age is associated with a poor recovery from traumatic brain injury (TBI). In a retrospective study we investigated if the biochemical response following TBI is age dependent. Extracellular fluids were continuously sampled by microdialysis in 69 patients admitted to our NSICU following severe TBI. The concentrations of glycerol, glutamate, lactate, pyruvate, and eight different cytokines (IL-1 beta, IL-6, IL-10, IL-8, MIP-1 beta, RANTES, FGF2, and VEGF) were determined by fluorescence multiplex bead technology. Patients in the oldest age group (>= 65 years) had significantly higher microdialysate concentrations of glycerol and glutamate compared to younger patients: the mean microdialysate concentration of glycerol increased from 55.9 mu mol/L (25-44 year) to 252 mu mol/L (>= 65 years; p < 0.0001); similarly glutamate increased from 15.8 mmol/L to 92.2 mmol/L (p < 0.0001). The lactate-pyruvate ratio was also significantly higher in the patients >= 65 years of age (63.9) compared with all the other age groups. The patterns of cytokine responses varied. For some cytokines (IL-1b, IL-10, and IL-8) there were no differences between age groups, while for others (MIP-1b, RANTES, VEGF, and IL-6) some differences were observed, but with no clear correlation with increasing age. For FGF2 the mean microdialysate concentration was 43 pg/mL in patients >= 65 years old, significantly higher compared to all other age groups (p < 0.0001). Increased concentrations of glycerol and glutamate would indicate more extensive damaging processes in the elderly. An increase in concentration of FGF2 could serve a protective function, but could also be related to a dysregulation of the timing in the cellular response in elderly patients.	[Mellergard, Pekka; Hillman, Jan] Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; [Sjogren, Florence] Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden	Mellergard, P (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	pekka.mellergard@efk.se					Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Frykholm P, 2001, J NEUROL NEUROSUR PS, V71, P455, DOI 10.1136/jnnp.71.4.455; Fulwyler M J, 1990, Methods Cell Biol, V33, P613; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KEMENY DM, 1992, J IMMUNOL METHODS, V150, P57, DOI 10.1016/0022-1759(92)90065-2; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Mellergard P, 2010, BRIT J NEUROSURG, V24, P261, DOI 10.3109/02688690903521605; Monfils MH, 2005, NEUROSCIENCE, V134, P1, DOI 10.1016/j.neuroscience.2005.04.006; Mudo G, 2009, J NEURAL TRANSM, V116, P995, DOI 10.1007/s00702-009-0207-z; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Petcu EB, 2008, GERONTOLOGY, V54, P6, DOI 10.1159/000112845; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Sturnegk P, 2007, BRIT J NEUROSURG, V21, P332, DOI 10.1080/02688690701411574; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998	31	26	27	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					112	118		10.1089/neu.2010.1732			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300013	21988111				2021-06-18	
J	Weckbach, S; Perl, M; Heiland, T; Braumuller, S; Stahel, PF; Flierl, MA; Ignatius, A; Gebhard, F; Huber-Lang, M				Weckbach, Sebastian; Perl, Mario; Heiland, Tim; Braumueller, Sonja; Stahel, Philip F.; Flierl, Michael A.; Ignatius, Anita; Gebhard, Florian; Huber-Lang, Markus			A New Experimental Polytrauma Model in Rats: Molecular Characterization of the Early Inflammatory Response	MEDIATORS OF INFLAMMATION			English	Article							INJURY SEVERITY; COMPLEMENT ACTIVATION; TRAUMA; SEPSIS; C5A; CARDIOPULMONARY; INTERLEUKIN-6; APOPTOSIS; FAILURE; BLOOD	Background. The molecular mechanisms of the immune response after polytrauma are highly complex and far from fully understood. In this paper, we characterize a new standardized polytrauma model in rats based on the early molecular inflammatory and apoptotic response. Methods. Male Wistar rats (250 g, 6-10/group) were anesthetized and exposed to chest trauma (ChT), closed head injury (CHI), or Tib/Fib fracture including a soft tissue trauma (Fx + STT) or to the following combination of injuries: (1) ChT; (2) ChT + Fx + STT; (3) ChT + CHI; (4) CHI; (5) polytrauma (PT = ChT + CHI + Fx+ STT). Sham-operated rats served as negative controls. The inflammatory response was quantified at 2 hours and 4 hours after trauma by analysis of "key" inflammatory mediators, including selected cytokines and complement components, in serum and bronchoalveolar (BAL) fluid samples. Results. Polytraumatized (PT) rats showed a significant systemic and intrapulmonary release of cytokines, chemokines, and complement anaphylatoxins, compared to rats with isolated injuries or selected combinations of injuries. Conclusion. This new rat model appears to closely mimic the early immunological response of polytrauma observed in humans and may provide a valid basis for evaluation of the complex pathophysiology and future therapeutic immune modulatory approaches in experimental polytrauma.	[Weckbach, Sebastian; Perl, Mario; Heiland, Tim; Braumueller, Sonja; Gebhard, Florian; Huber-Lang, Markus] Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89075 Ulm, Germany; [Stahel, Philip F.; Flierl, Michael A.] Univ Colorado, Dept Orthopaed Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA; [Ignatius, Anita] Univ Ulm, Ctr Musculoskeletal Res Ulm, Inst Orthopaed Res & Biomech, D-89075 Ulm, Germany	Gebhard, F (corresponding author), Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89075 Ulm, Germany.	florian.gebhard@uniklinik-ulm.de; markus.huber-lang@uniklinik-ulm.de	Heiland, Tim/J-7306-2019; Ignatius, Anita/M-6012-2013; Huber-Lang, Markus/AAJ-2209-2020	Ignatius, Anita/0000-0002-4782-1979; 	German Research Foundation DFGGerman Research Foundation (DFG) [(KFO-200) HU 823/3-1, PE EN 908/2-1]	The authors thank Barbara Acker, Stephanie Denk, Ralf Reuter, and Christoph Hohmann for outstanding technical support. They especially thank Assistant Professor Dr. Lutz Duerselen for his excellent biomechanic assistance. They also want to express our gratitude to Justin Losacco for cross-reading the paper and correcting the language. This study was supported by Grants from the German Research Foundation DFG (KFO-200) HU 823/3-1 and PE EN 908/2-1.	BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Bryan SA, 2002, AM J RESP CRIT CARE, V165, P1602, DOI 10.1164/rccm.200111-059OC; Claes L, 2006, J ORTHOP RES, V24, P1178, DOI 10.1002/jor.20173; Cohen MJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8152; Efstathopoulos N, 2006, CLIN EXP IMMUNOL, V145, P139, DOI 10.1111/j.1365-2249.2006.03112.x; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Flach R, 1999, CYTOKINE, V11, P173, DOI 10.1006/cyto.1998.0412; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fremont RD, 2010, J TRAUMA, V68, P1121, DOI 10.1097/TA.0b013e3181c40728; Ganter MT, 2007, SHOCK, V28, P29, DOI 10.1097/shk.0b013e3180342439; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gebhard F., 2000, UNTERSUCHUNGEN SYSTE; Guo RF, 2006, J LEUKOCYTE BIOL, V80, P1575, DOI 10.1189/jlb.0106065; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang M, 2005, J IMMUNOL, V174, P1104, DOI 10.4049/jimmunol.174.2.1104; Irwin R J, 1998, J Okla State Med Assoc, V91, P387; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Knoferl MW, 2004, SHOCK, V22, P51, DOI 10.1097/01.shk.0000127684.64611.5c; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Liener UC, 2002, SHOCK, V17, P169, DOI 10.1097/00024382-200203000-00002; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MCCABE WR, 1973, NEW ENGL J MED, V288, P21, DOI 10.1056/NEJM197301042880105; Mkhoian G G, 2009, Anesteziol Reanimatol, P60; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Perl M, 2006, CRIT CARE MED, V34, P1152, DOI 10.1097/01.CCM.0000207343.53990.A8; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schreiber H, 2006, ADV EXP MED BIOL, V586, P217; Spolarics Z, 2001, CRIT CARE MED, V29, P728, DOI 10.1097/00003246-200104000-00005; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Stiletto RJ, 2001, CRIT CARE MED, V29, P1690, DOI 10.1097/00003246-200109000-00006; Strecker W, 2002, EUR J TRAUMA, V28, P75; Trupka A, 1998, UNFALLCHIRURG, V101, P244, DOI 10.1007/s001130050265	36	26	26	0	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2012	2012								890816	10.1155/2012/890816			9	Cell Biology; Immunology	Cell Biology; Immunology	923YI	WOS:000302656300001	22481866	DOAJ Gold, Green Published			2021-06-18	
J	Itoh, T; Imano, M; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, A; Satou, T				Itoh, Tatsuki; Imano, Motohiro; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Akihiko; Satou, Takao			(-)-Epigallocatechin-3-gallate Protects Against Neuronal Cell Death and Improves Cerebral Function After Traumatic Brain Injury in Rats	NEUROMOLECULAR MEDICINE			English	Article						Epigallocatechin; Traumatic brain injury; Neuroprotection; Apoptosis; Oxidative stress	CENTRAL-NERVOUS-SYSTEM; GREEN TEA POLYPHENOL; NEURAL STEM-CELLS; OXYGEN RADICALS; ISCHEMIA; DAMAGE; PROLIFERATION; ACTIVATION; RECEPTOR; GERBILS	A major component of green tea, a widely consumed beverage, is (-)-epigallocatechin gallate (EGCG), which has strong antioxidant properties. Our previous study has indicated that free radical production following rat traumatic brain injury (TBI) induces neural degeneration. In this study, we investigated the effects of EGCG on cerebral function and morphology following TBI. Six-week-old male Wistar rats that had access to normal drinking water, or water containing 0.1% (w/v) EGCG ad libitum, received TBI with a pneumatic controlled injury device at 10 weeks of age. Immunohistochemistry and lipid peroxidation studies revealed that at 1, 3 and 7 days post-TBI, the number of 8-hydroxy-2'-deoxyguanosine-, 4-hydroxy-2-nonenal-and single-stranded DNA (ssDNA)-positive cells, and the levels of malondialdehyde (MDA) around the damaged area after TBI, significantly decreased in the EGCG treatment group compared with the water group (P < 0.05). Most ssDNA-positive cells in the water group co-localized with neuronal cells. However, in the EGCG treatment group, few ssDNA-positive cells co-localized with neurons. In addition, there was a significant increase in the number of surviving neuronal cells and an improvement in cerebral dysfunction after TBI in the EGCG treatment group compared with the water group (P < 0.05). These results indicate that consumption of water containing EGCG pre- and post-TBI inhibits free radical-induced neuronal degeneration and apoptotic cell death around the damaged area, resulting in the improvement of cerebral function following TBI. In summary, consumption of green tea may be an effective therapy for TBI patients.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Dept Pathol, Fac Med, Osakasayama City, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Dept Surg, Fac Med, Osaka, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Fac Pharmaceut Sci, Osaka 577, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Div Sports Med, Inst Life Sci, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Div Hosp Pathol, Fac Med, Osaka, Japan	Itoh, T (corresponding author), Kinki Univ, Dept Pathol, Fac Med, 377-2 Ohno Higashi, Osakasayama City, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			 [21500803]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21500803, 23500629] Funding Source: KAKEN	This work was supported by the Grant-in-Aid for Scientific Research (21500803). The authors thank Mari Yachi for technical assistance.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hong JT, 2000, BRAIN RES BULL, V53, P743, DOI 10.1016/S0361-9230(00)00348-8; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; Jang S, 2010, BRAIN RES, V1313, P25, DOI 10.1016/j.brainres.2009.12.012; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lee SY, 2003, BRAIN RES BULL, V61, P399, DOI 10.1016/S0361-9230(03)00139-4; Loren DJ, 2005, PEDIATR RES, V57, P858, DOI 10.1203/01.PDR.0000157722.07810.15; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Park JW, 2009, J NEUROSCI RES, V87, P567, DOI 10.1002/jnr.21847; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sakurai M, 2003, J VASC SURG, V37, P446, DOI 10.1067/mva.2003.100; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Wang XY, 2001, BIOL NEONATE, V79, P172; Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4; Weissman L, 2007, NEUROSCIENCE, V145, P1318, DOI 10.1016/j.neuroscience.2006.08.061; Won MH, 2001, NEUROSCI LETT, V301, P139, DOI 10.1016/S0304-3940(01)01625-1; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Yu JX, 2010, FEBS LETT, V584, P2921, DOI 10.1016/j.febslet.2010.05.011	32	26	30	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1535-1084			NEUROMOL MED	Neuromol. Med.	DEC	2011	13	4					300	309		10.1007/s12017-011-8162-x			10	Neurosciences	Neurosciences & Neurology	893KS	WOS:000300355400007	22038400				2021-06-18	
J	Wood, RL; McCabe, M; Dawkins, J				Wood, Rodger Ll.; McCabe, Michael; Dawkins, Jayne			The role of anxiety sensitivity in symptom perception after minor head injury: An exploratory study	BRAIN INJURY			English	Article						Mild traumatic brain injury; somatization; belief systems; cognition; perception; personality trait	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYMPTOMS; COLLABORATING-CENTER; TASK-FORCE; PAIN; STRESS; ALEXITHYMIA; DISORDER; MODERATE	Primary objective: This exploratory study examined the role of anxiety sensitivity (AS) as a factor contributing to outcome following minor head injury (MHI). Recent research has implicated AS in perception of pain intensity after orthopaedic trauma. AS, therefore, has the potential to mediate perception of and reaction to post-concussion symptoms at an early stage of recovery, increasing the risk of a protracted and incomplete recovery. Research design: A case series analysis. Methods and procedures: Sixty-three head trauma patients referred from an accident and emergency unit to an acute minor head injury service were compared to 58 patients who had suffered recent orthopaedic injury. Participants completed the Rivermead Post-Concussion Questionnaire (RPQ), to determine the number and severity of head injury-related symptoms, and the Anxiety Sensitivity Index (ASI), to measure their emotional reaction to symptoms. Main outcomes and results: Significant between-group differences were found for both RPQ and ASI measures. The MHI group reported more serious symptoms. Both groups also recorded significant positive correlations between the RPQ and ASI measures, with a stronger relationship recorded for the MHI group. Conclusions: The results support the impression that anxiety sensitivity may be an important factor mediating perception of symptoms after injury, potentially influencing speed and quality of recovery.	[Wood, Rodger Ll.] Swansea Univ, Sch Human & Hlth Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales; [Wood, Rodger Ll.] Morriston Hosp Swansea, Dept Accid & Emergency, Swansea, W Glam, Wales	Wood, RL (corresponding author), Swansea Univ, Sch Human & Hlth Sci, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					Asmundson GJG, 2001, EUR J PAIN, V5, P23, DOI 10.1053/eujp.2000.0211; ASMUNDSON GJG, 1995, BEHAV RES THER, V33, P771, DOI 10.1016/0005-7967(95)00012-M; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jenewein J, 2009, J PSYCHOSOM RES, V66, P119, DOI 10.1016/j.jpsychores.2008.07.011; Keogh E, 2001, EUR J PAIN, V5, P11, DOI 10.1053/eujp.2000.0210; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; MALLER RG, 1992, J ANXIETY DISORD, V6, P241, DOI 10.1016/0887-6185(92)90036-7; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2008, MILD TRAUMATIC BRAIN; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Meares S, 2010, J NEUROL NEUROSUR PS, V79, P300; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mueller J, 2006, COMPR PSYCHIAT, V47, P489, DOI 10.1016/j.comppsych.2006.03.001; Muris P, 2001, BEHAV RES THER, V39, P1357, DOI 10.1016/S0005-7967(01)00018-3; Peterson RA, 1999, LEA SER PER CLIN PSY, P61; Peterson RA., 1987, ANXIETY SENSITIVITY; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reiss S., 1985, THEORETICAL ISSUES B, P107; Taylor S., 1999, ANXIETY SENSITIVITY; Thompson T, 2008, PAIN, V134, P187, DOI 10.1016/j.pain.2007.04.018; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wood RLL, 2009, BRAIN INJURY, V23, P649, DOI 10.1080/02699050902970786; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Wood RL, 2011, INJURY, V42, P1214, DOI 10.1016/j.injury.2010.07.245	33	26	26	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2011	25	13-14					1296	1299		10.3109/02699052.2011.624569			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	847MI	WOS:000296976600004	22077534				2021-06-18	
J	Exo, J; Kochanek, PM; Adelson, PD; Greene, S; Clark, RSB; Bayir, H; Wisniewski, SR; Bell, MJ				Exo, Jennifer; Kochanek, Patrick M.; Adelson, P. David; Greene, Stephanie; Clark, Robert S. B.; Bayir, Huelya; Wisniewski, Stephen R.; Bell, Michael J.			Intracranial pressure-monitoring systems in children with traumatic brain injury: Combining therapeutic and diagnostic tools	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cerebrospinal fluid diversion; children; external ventricular drain; intracranial monitoring; pediatric neurotrauma database; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; TISSUE PRESSURE; FIBEROPTIC DEVICE; SURVIVAL; LESIONS	Objective: To compare the correlation of intracranial pressure (ICP) measurement and time to detection of ICP crises (defined as ICP >= 20 mm Hg for >= 5 mins) between an intraparenchymal (IP) monitor and external ventricular drain (EVD) in children for whom continuous cerebrospinal fluid diversion was used as a therapy for severe traumatic brain injury. Setting: Academic, pediatric intensive care unit. Design: Retrospective review of a prospectively collected pediatric neurotrauma database. Patients: Children with severe traumatic brain injury (Glasgow Coma Scale score of <= 8) who underwent ICP monitoring with both IP and EVD techniques were studied. In cohort 1 (n = 58), hourly ICP measurements were extracted from the medical record; in cohort 2 (n = 4), ICP measurements were collected every minute by an automated data-collection system. Measurements and Main Results: The mean absolute difference in ICP (vertical bar ICP vertical bar) and intraclass correlation coefficients were calculated. Timing to detection of ICP crises was analyzed. Data were expressed as mean +/- SEM. For cohort 1, 7,387 hrs of data were analyzed; 399 hrs (23,940 mins) were analyzed for cohort 2. In cohort 1, the. ICP. was 3.10 +/- 0.04 mm Hg (intraclass correlation coefficients = 0.98, p < .001). The. vertical bar ICP vertical bar in cohort 2 was 3.30 +/- 0.05 mm Hg (intraclass correlation coefficients = 0.98, p < .001). In cohort 2, a total of 75 ICP crises were observed. Fifty- five (73%) were detected first by the IP monitor, of which 35 were not identified by the EVD monitor. Time between IP and EVD detection of a crisis was 12.60 +/- 2.34 mins. Conclusion: EVD and IP measurements of ICP were highly correlated, although intermittent EVD ICP measurements may fail to identify ICP events when continuously draining cerebrospinal fluid. In institutions that use continuous cerebrospinal fluid diversion as a therapy, a two-monitor system may be valuable for accomplishing monitoring and therapeutic goals. (Pediatr Crit Care Med 2011; 12:560-565)	[Exo, Jennifer; Kochanek, Patrick M.; Clark, Robert S. B.; Bayir, Huelya; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Greene, Stephanie; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Biostat, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Clark, Robert S. B.; Bayir, Huelya; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA; [Adelson, P. David] Phoenix Childrens Hosp, Dept Neurol Surg, Phoenix, AZ USA	Exo, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	exojl@upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Greene, Stephanie/0000-0002-5858-4032; Wisniewski, Stephen/0000-0002-3877-9860	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD040686, NS30318, HD08003, NS052478]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD008003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS052478, P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER	This work was supported in part by NIH 5T32HD040686 (JLE), NS30318 (PMK), HD08003 (MJB, RSBC), and NS052478 (MJB, PDA).	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Caruselli G, 1992, J Neurosurg Sci, V36, P219; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; GAMBARDELLA G, 1993, CHILD NERV SYST, V9, P470, DOI 10.1007/BF00393552; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kerr M E, 2001, Neurosurg Focus, V11, pE1; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PIEK J, 1987, ACTA NEUROCHIR, V87, P144, DOI 10.1007/BF01476066; PIEK J, 1990, INTENS CARE MED, V16, P184, DOI 10.1007/BF01724800; Qureshi AI, 2002, CRIT CARE MED, V30, P435, DOI 10.1097/00003246-200202000-00028; ROSENWASSER RH, 1989, J NEUROSURG, V71, P503, DOI 10.3171/jns.1989.71.4.0503; Salim A, 2008, AM SURGEON, V74, P1088; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; Shapiro S, 1996, SURG NEUROL, V45, P278, DOI 10.1016/0090-3019(95)00359-2; Shore PM, 2004, J NEUROTRAUM, V21, P1113	25	26	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2011	12	5					560	565		10.1097/PCC.0b013e3181e8b3ee			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	816KP	WOS:000294598400019	20625341	Green Accepted			2021-06-18	
J	Rojo, DR; Prough, DS; Falduto, MT; Boone, DR; Micci, MA; Kahrig, KM; Crookshanks, JM; Jimenez, A; Uchida, T; Cowart, JC; Hawkins, BE; Avila, M; DeWitt, DS; Hellmich, HL				Rojo, Daniel R.; Prough, Donald S.; Falduto, Michael T.; Boone, Deborah R.; Micci, Maria-Adelaide; Kahrig, Kristen M.; Crookshanks, Jeanna M.; Jimenez, Arnaldo; Uchida, Tatsuo; Cowart, Jeremy C.; Hawkins, Bridget E.; Avila, Marcela; DeWitt, Douglas S.; Hellmich, Helen L.			Influence of Stochastic Gene Expression on the Cell Survival Rheostat after Traumatic Brain Injury	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; FLUORO-JADE; HIPPOCAMPAL NEUROGENESIS; SYNAPTIC PLASTICITY; MOLECULAR NETWORKS; MOUSE MODEL; HEAD-INJURY; DISEASE; DEATH; NEURONS	Experimental evidence suggests that random, spontaneous (stochastic) fluctuations in gene expression have important biological consequences, including determination of cell fate and phenotypic variation within isogenic populations. We propose that fluctuations in gene expression represent a valuable tool to explore therapeutic strategies for patients who have suffered traumatic brain injury (TBI), for which there is no effective drug therapy. We have studied the effects of TBI on the hippocampus because TBI survivors commonly suffer cognitive problems that are associated with hippocampal damage. In our previous studies we separated dying and surviving hippocampal neurons by laser capture microdissection and observed unexplainable variations in post-TBI gene expression, even though dying and surviving neurons were adjacent and morphologically identical. We hypothesized that, in hippocampal neurons that subsequently are subjected to TBI, randomly increased pre-TBI expression of genes that are associated with neuroprotection predisposes neurons to survival; conversely, randomly decreased expression of these genes predisposes neurons to death. Thus, to identify genes that are associated with endogenous neuroprotection, we performed a comparative, high-resolution transcriptome analysis of dying and surviving hippocampal neurons in rats subjected to TBI. We found that surviving hippocampal neurons express a distinct molecular signature - increased expression of networks of genes that are associated with regeneration, cellular reprogramming, development, and synaptic plasticity. In dying neurons we found decreased expression of genes in those networks. Based on these data, we propose a hypothetical model in which hippocampal neuronal survival is determined by a rheostat that adds injury-induced genomic signals to expression of pro-survival genes, which pre-TBI varies randomly and spontaneously from neuron to neuron. We suggest that pharmacotherapeutic strategies that co-activate multiple survival signals and enhance self-repair mechanisms have the potential to shift the cell survival rheostat to favor survival and therefore improve functional outcome after TBI.	[Rojo, Daniel R.; Prough, Donald S.; Boone, Deborah R.; Micci, Maria-Adelaide; Kahrig, Kristen M.; Crookshanks, Jeanna M.; Uchida, Tatsuo; Cowart, Jeremy C.; Hawkins, Bridget E.; Avila, Marcela; DeWitt, Douglas S.; Hellmich, Helen L.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Falduto, Michael T.] GenUs BioSyst, Northbrook, IL USA; [Jimenez, Arnaldo] Vel Lab Res, Missouri City, TX USA	Rojo, DR (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013; Hawkins, Bridget/H-4933-2015	Prough, Donald S/0000-0001-7994-532X; Hawkins, Bridget/0000-0002-1887-3657	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS052532]; Moody Foundation; Department of Anesthesiology, University of Texas Medical Branch; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052532] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health, RO1 NS052532 (to H.L.H), by a grant from the Moody Foundation and the Department of Anesthesiology, University of Texas Medical Branch. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alberts P, 2006, MOL BIOL CELL, V17, P1194, DOI 10.1091/mbc.E05-07-0643; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Andrews MR, 2009, J NEUROSCI, V29, P5546, DOI 10.1523/JNEUROSCI.0759-09.2009; Armstrong JS, 2004, BIOESSAYS, V26, P894, DOI 10.1002/bies.20071; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bast T, 2007, REV NEUROSCIENCE, V18, P253; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; Benekareddy M, 2008, SYNAPSE, V62, P590, DOI 10.1002/syn.20529; Bigelow DJ, 2005, BBA-PROTEINS PROTEOM, V1703, P121, DOI 10.1016/j.bbapap.2004.09.012; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fontan- Lozano A, 2008, MOL NEUROBIOL, V27; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Fraser D, 2009, MOL MICROBIOL, V71, P1333, DOI 10.1111/j.1365-2958.2009.06605.x; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; Grimaldi B, 2009, INT J BIOCHEM CELL B, V41, P81, DOI 10.1016/j.biocel.2008.08.035; Grossmann KS, 2009, P NATL ACAD SCI USA, V106, P16704, DOI 10.1073/pnas.0904336106; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Han JH, 2007, SCIENCE, V316, P457, DOI 10.1126/science.1134697; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hebert SS, 2009, TRENDS NEUROSCI, V32, P199, DOI 10.1016/j.tins.2008.12.003; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; HERRUP K, 1995, DEVELOPMENT, V121, P2385; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Josselyn Sheena A., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P481, DOI 10.2174/156800705774322058; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kesavan G, 2009, CELL, V139, P791, DOI 10.1016/j.cell.2009.08.049; Kopp JL, 2008, STEM CELLS, V26, P903, DOI 10.1634/stemcells.2007-0951; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kotani S, 2006, NEUROSCIENCE, V142, P505, DOI 10.1016/j.neuroscience.2006.06.035; Ladurner AG, 2006, MOL CELL, V24, P1, DOI 10.1016/j.molcel.2006.09.002; Lee YS, 2009, NAT REV NEUROSCI, V10, P126, DOI 10.1038/nrn2572; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Lim CM, 2009, J NEUROSCI RES, V87, P1037, DOI 10.1002/jnr.21899; Losick R, 2008, SCIENCE, V320, P65, DOI 10.1126/science.1147888; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Lynch G, 2007, J NEUROSCI, V27, P4424, DOI 10.1523/JNEUROSCI.5113-06.2007; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Nagy Z, 2000, NEUROBIOL AGING, V21, P761, DOI 10.1016/S0197-4580(00)00223-2; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Pagani MR, 2009, CELL, V139, P186, DOI 10.1016/j.cell.2009.08.033; Paizanis E, 2007, NEUROCHEM RES, V32, P1762, DOI 10.1007/s11064-007-9330-0; Palacios-Pelaez R, 2010, MOL NEUROBIOL, V41, P367, DOI 10.1007/s12035-010-8139-z; Papa L, 2009, CRIT CARE MED; Pirity MK, 2005, MOL CELL BIOL, V25, P7193, DOI 10.1128/MCB.25.16.7193-7202.2005; Puzzo D, 2009, J NEUROSCI, V29, P8075, DOI 10.1523/JNEUROSCI.0864-09.2009; Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050; Raj A, 2010, NATURE, V463, P913, DOI 10.1038/nature08781; Ramocki MB, 2008, NATURE, V455, P912, DOI 10.1038/nature07457; Roberge MC, 2008, NEUROSCIENCE, V156, P11, DOI 10.1016/j.neuroscience.2008.05.062; *SAS I INC, 2004, SAS STAT US GUID VER; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weinreb O, 2009, NEUROTHERAPEUTICS, V6, P163, DOI 10.1016/j.nurt.2008.10.030; Winship IR, 2008, J NEUROSCI, V28, P6592, DOI 10.1523/JNEUROSCI.0622-08.2008; Ye XM, 2001, BRAIN RES PROTOC, V8, P104, DOI 10.1016/S1385-299X(01)00086-1; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025	86	26	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2011	6	8							e23111	10.1371/journal.pone.0023111			16	Multidisciplinary Sciences	Science & Technology - Other Topics	808CS	WOS:000293953400028	21853077	DOAJ Gold, Green Published			2021-06-18	
J	Curia, G; Levitt, M; Fender, JS; Miller, JW; Ojemann, J; D'Ambrosio, R				Curia, Giulia; Levitt, Michael; Fender, Jason S.; Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo			Impact of Injury Location and Severity on Posttraumatic Epilepsy in the Rat: Role of Frontal Neocortex	CEREBRAL CORTEX			English	Article						drug screening; electrocorticography; endophenotype; model; partial seizures; syndrome; trauma	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; COMPLEX PARTIAL SEIZURES; HEAD-INJURY; LOBE EPILEPSY; ELECTRICAL-STIMULATION; TEMPORAL-LOBE; CLINICAL CHARACTERISTICS; INTERNATIONAL-BUREAU; GENE POLYMORPHISMS	Human posttraumatic epilepsy (PTE) is highly heterogeneous, ranging from mild remitting to progressive disabling forms. PTE results in simple partial, complex partial, and secondarily generalized seizures with a wide spectrum of durations and semiologies. PTE variability is thought to depend on the heterogeneity of head injury and patient's age, gender, and genetic background. To better understand the role of these factors, we investigated the seizures resulting from calibrated fluid percussion injury (FPI) to adolescent male Sprague-Dawley rats with video electrocorticography. We show that PTE incidence and the frequency and severity of chronic seizures depend on the location and severity of FPI. The frontal neocortex was more prone to epileptogenesis than the parietal and occipital, generating earlier, longer, and more frequent partial seizures. A prominent limbic focus developed in most animals, regardless of parameters of injury. Remarkably, even with carefully controlled injury parameters, including type, severity, and location, the duration of posttraumatic apnea and the age and gender of outbred rats, there was great subject-to-subject variability in frequency, duration, and rate of progression of seizures, indicating that other factors, likely the subjects' genetic background and physiological states, have critical roles in determining the characteristics of PTE.	[Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo] Univ Washington, Harborview Med Ctr, Dept Neurosurg, Seattle, WA 98104 USA; [Curia, Giulia] Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy; [Curia, Giulia; Levitt, Michael; Fender, Jason S.; Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Miller, John W.; Ojemann, Jeffrey; D'Ambrosio, Raimondo] Univ Washington, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA	D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, Box 359915,325 9Th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu	Curia, Giulia/A-8863-2008	Curia, Giulia/0000-0002-8472-350X; Ojemann, Jeffrey/0000-0001-7580-8934	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS053928]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053928] Funding Source: NIH RePORTER	National Institutes of Health (NS053928 to R. D.).	Aarabi B, 2000, NEUROSURG FOCUS, V8, P1, DOI DOI 10.3171/FOC.2000.8.1.155; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Bancaud J, 1992, Adv Neurol, V57, P3; BECKER DP, 1979, ARCH NEUROL-CHICAGO, V36, P750, DOI 10.1001/archneur.1979.00500480024005; Beghi E, 2005, EPILEPSIA, V46, P1698, DOI 10.1111/j.1528-1167.2005.00273_1.x; BEGHI E, 1992, EPILEPSIA, V33, P45; Benbadis SR, 2003, SEIZURE-EUR J EPILEP, V12, P167, DOI 10.1016/S1059-1311(02)00320-5; Berg AT, 2009, ANN NEUROL, V65, P510, DOI 10.1002/ana.21642; Besenski N, 1996, NEURORADIOLOGY, V38, pS36; Binnie CD, 2003, CLINICAL NEUROPHYSIOLOGY, VOL 2, P268; BLACKWOOD DHR, 1982, J NEUROSCI METH, V5, P343, DOI 10.1016/0165-0270(82)90004-8; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Brandt C, 2003, EPILEPSY RES, V55, P83, DOI 10.1016/S0920-1211(03)00114-1; Browning RA, 1987, EPILEPSY RETICULAR F, P137; CAVENESS W F, 1954, Clin Neurosurg, V2, P116; CAVENESS WF, 1961, EPILEPSIA, V2, P123; CAVENESS WF, 1962, J NEUROSURG, V19, P122, DOI 10.3171/jns.1962.19.2.0122; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen J, 2005, EPILEPSIA, V46, P956, DOI 10.1111/j.1528-1167.2005.51204.x; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Costello Daniel J, 2004, Expert Rev Neurother, V4, P541, DOI 10.1586/14737175.4.3.541; Cukiert A, 2001, EPILEPSIA, V42, P889, DOI 10.1046/j.1528-1157.2001.00201.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; DEVINSKY O, 1989, NEUROLOGY, V39, P527; DEVINSKY O, 1988, NEUROLOGY, V38, P1347, DOI 10.1212/WNL.38.9.1347; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Eastman CL, 2010, EXP NEUROL, V224, P369, DOI 10.1016/j.expneurol.2010.04.013; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Epsztein J, 2008, NEUROSCIENTIST, V14, P78, DOI 10.1177/1073858407301681; Fisher RS, 2008, EPILEPSIA, V49, P7, DOI 10.1111/j.1528-1167.2008.01921.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gale K, 1988, MECHANISMS EPILEPTOG, P111; GEIER S, 1977, NEUROLOGY, V27, P951, DOI 10.1212/WNL.27.10.951; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hartzfeld P, 2008, BRIT J NEUROSURG, V22, P224, DOI 10.1080/02688690701818901; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Holguin A, 2007, J NEUROSCI METH, V161, P265, DOI 10.1016/j.jneumeth.2006.11.014; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Ikeda A, 2009, EPILEPSIA, V50, P2072, DOI 10.1111/j.1528-1167.2009.02097.x; INOUE M, 1990, PHYSIOL BEHAV, V48, P199, DOI 10.1016/0031-9384(90)90285-C; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JABBARI B, 1986, ELECTROEN CLIN NEURO, V64, P285, DOI 10.1016/0013-4694(86)90151-3; JENNETT W B, 1961, Ann R Coll Surg Engl, V29, P370; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Jobst BC, 2000, EPILEPSIA, V41, P1139, DOI 10.1111/j.1528-1157.2000.tb00319.x; Jyoti A, 2009, NEUROSCI LETT, V453, P86, DOI 10.1016/j.neulet.2009.01.082; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; Kelly KM, 2010, EPILEPSY CURR, V10, P15, DOI 10.1111/j.1535-7511.2009.01341.x; Kerling F, 2006, EPILEPSY BEHAV, V9, P281, DOI 10.1016/j.yebeh.2006.05.010; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Klein PM, 2009, EPILEPSIA, V50, P385; Langendorf F, EPILEPSY COMPREHENSI, P2469; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Leppik IE, 1997, CONT DIAGNOSIS MANAG, P8; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; LOSCHER W, 1995, BRAIN RES, V697, P197, DOI 10.1016/0006-8993(95)00843-F; Luders H O, 1992, Adv Neurol, V57, P149; LUDERS HO, 1995, ADV NEUROL, V67, P115; LUDWIG B, 1975, EPILEPSIA, V16, P141, DOI 10.1111/j.1528-1157.1975.tb04731.x; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Muller CJ, 2009, GENES BRAIN BEHAV, V8, P481, DOI 10.1111/j.1601-183X.2009.00490.x; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Noebels JL, 2003, ANNU REV NEUROSCI, V26, P599, DOI 10.1146/annurev.neuro.26.010302.081210; OZTAS B, 1990, MECH AGEING DEV, V51, P149, DOI 10.1016/0047-6374(90)90097-Y; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; Penfield W, 1954, EPILEPSY FUNCTIONAL; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RASMUSSEN T, 1983, EPILEPSIA, V24, P482, DOI 10.1111/j.1528-1157.1983.tb04919.x; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; SALANOVA V, 1995, EPILEPSIA, V36, P16, DOI 10.1111/j.1528-1157.1995.tb01659.x; Salanova V, 2002, EPILEPSIA, V43, P170, DOI 10.1046/j.1528-1157.2002.33800.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1995, NEUROSURG CLIN N AM, V6, P715; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Shinomoto S, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000433; So NK, 1998, EPILEPSIA, V39, pS49, DOI 10.1111/j.1528-1157.1998.tb05125.x; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sutula TP, 2004, EPILEPSY RES, V60, P161, DOI 10.1016/j.eplepsyres.2004.07.001; SWARTZ BE, 1992, J EPILEPSY, V5, P80, DOI 10.1016/S0896-6974(05)80055-6; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vezzani A, 2008, BRAIN BEHAV IMMUN, V22, P797, DOI 10.1016/j.bbi.2008.03.009; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Virta N, 2002, PEDIATR NEUROL, V26, P192, DOI 10.1016/S0887-8994(01)00380-0; WALKER A E, 1965, J Med Assoc State Ala, V35, P93; WALKER A. EARL, 1962, WORLD NEUROL, V3, P185; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1972, J NEUROSURG, V37, P164, DOI 10.3171/jns.1972.37.2.0164; Williamson P D, 1992, Adv Neurol, V57, P289; WILLIAMSON PD, 1985, ANN NEUROL, V18, P647, DOI 10.1002/ana.410180604; WILLIAMSON PD, 1986, EPILEPSIA, V27, pS46, DOI 10.1111/j.1528-1157.1986.tb05740.x; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413; WILLIAMSON PD, 1992, ANN NEUROL, V31, P3, DOI 10.1002/ana.410310103; Willmore LJ, 2009, NEUROCHEM RES, V34, P688, DOI 10.1007/s11064-008-9841-3; Winawer MR, 2007, MAMM GENOME, V18, P23, DOI 10.1007/s00335-006-0087-6; Wohlrab G, 1997, EPILEPSIA, V38, P275, DOI 10.1111/j.1528-1157.1997.tb01117.x; Worrell GA, 2008, BRAIN, V131, P928, DOI 10.1093/brain/awn006	132	26	26	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JUL	2011	21	7					1574	1592		10.1093/cercor/bhq218			19	Neurosciences	Neurosciences & Neurology	779AL	WOS:000291750400010	21112931	Green Published, Bronze			2021-06-18	
J	Pandya, JD; Sullivan, PG; Pettigrew, LC				Pandya, Jignesh D.; Sullivan, Patrick G.; Pettigrew, L. Creed			Focal cerebral ischemia and mitochondrial dysfunction in the TNF alpha-transgenic rat	BRAIN RESEARCH			English	Article						Calcium homeostasis; Brain ischemia; Transgenic rat; Tumor necrosis factor alpha; Mitochondrial bioenergetics; Mitochondrial permeability; transition pore; Reactive oxygen species	TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; METHYL-D-ASPARTATE; PERMEABILITY TRANSITION; REACTIVE OXYGEN; CELL-DEATH; SYNAPTIC MITOCHONDRIA; HYPOXIA-ISCHEMIA; FREE-RADICALS; CYTOKINES	Post-ischemic neurodegeneration may be accelerated by a cytokine-receptor mediated apoptotic pathway, as shown in a transgenic rat overexpressing tumor necrosis factor-alpha (TNF alpha) in brain. To further investigate the mechanism of ischemic cellular injury in this animal, we tested the hypothesis that increased synthesis of TNF alpha augments neuronal death by promoting mitochondrial dysfunction, calcium dysregulation, and oxidative stress. Adult male TNF alpha-transgenic (TNF alpha-Tg) and non-transgenic (non-Tg) littermates underwent reversible middle cerebral artery occlusion (MCAO) for 1 hour followed by 1 hour of reperfusion. Cortical mitochondria were isolated from injured (ipsilateral) and uninjured (contralateral) hemispheres of ischemic rats or from pooled hemispheres of control animals. ATP synthesis was attenuated in non-ischemic TNF alpha-Tg rats, demonstrated by reduction of state III and respiratory control ratio, increased production of reactive oxygen species, and earlier formation of the calcium-induced membrane permeability transition pore. After MCAO, mitochondrial dysfunction was augmented more significantly in ischemic TNF alpha-Tg brain mitochondria than in non-Tg rats. These results show that mitochondrial dysfunction may be caused by increased brain levels of TNF alpha without physiological stress but will be exacerbated after MCAO. We conclude that ischemic stress and synthesis of inflammatory cytokines synergistically augment mitochondrial dysfunction to promote neuronal death. Published by Elsevier B.V.	[Pettigrew, L. Creed] Univ Kentucky, Med Ctr, Univ Kentucky Stroke Program, Dept Neurol, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Pettigrew, L. Creed] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Pettigrew, L. Creed] Vet Adm VA Med Ctr, Lexington, KY USA	Pettigrew, LC (corresponding author), Univ Kentucky, Med Ctr, Univ Kentucky Stroke Program, Dept Neurol, 101 Sanders Brown Bldg,800 S Limestone St, Lexington, KY 40536 USA.	cpetti@uky.edu		Pettigrew, Luther Creed/0000-0001-7878-5803	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01s N5048191, NS047375, P30 NS051220]; Medical Research Service, Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS048191] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS grants awarded to the University of Kentucky (R01s N5048191 [PGS] and NS047375 [LCP]; P30 NS051220) and a Merit Review Award from the Medical Research Service, Department of Veterans Affairs (LCP). We thank Susan D. Craddock for her expert technical assistance. Sherry Chandler Williams, ELS, edited the manuscript and prepared the figures.	Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Clarkson AN, 2007, NEUROSCIENCE, V144, P547, DOI 10.1016/j.neuroscience.2006.09.040; Dave KR, 2001, J CEREBR BLOOD F MET, V21, P1401, DOI 10.1097/00004647-200112000-00004; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Ginsburg I, 1998, MED HYPOTHESES, V51, P337, DOI 10.1016/S0306-9877(98)90059-7; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacerda L, 2006, LIFE SCI, V79, P2194, DOI 10.1016/j.lfs.2006.07.020; Lipton P, 1999, PHYSIOL REV, V79, P1431; LIU Y, 1994, J CEREBR BLOOD F MET, V14, P348, DOI 10.1038/jcbfm.1994.43; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Montaner J, 2003, J CEREBR BLOOD F MET, V23, P1403, DOI 10.1097/01.WCB.0000100044.07481.97; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PETITO CK, 1984, J NEUROPATH EXP NEUR, V43, P141, DOI 10.1097/00005072-198403000-00004; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P43, DOI 10.1016/S0165-3806(00)00111-5; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Shakibaei M, 2005, ANTIOXID REDOX SIGN, V7, P482, DOI 10.1089/ars.2005.7.482; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tomimoto H, 1996, ACTA NEUROPATHOL, V92, P281, DOI 10.1007/s004010050519; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Zaremba J, 2001, BIOMED PHARMACOTHER, V55, P258, DOI 10.1016/S0753-3322(01)00058-0	42	26	27	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 12	2011	1384						151	160		10.1016/j.brainres.2011.01.102			10	Neurosciences	Neurosciences & Neurology	750JT	WOS:000289543100017	21300036	Green Accepted			2021-06-18	
J	Gura, M; Elmaci, I; Sari, R; Coskun, N				Gura, Melek; Elmaci, Ilhan; Sari, Ramazan; Coskun, Nilufer			Correlation of Pulsatility Index with Intracranial Pressure in Traumatic Brain Injury	TURKISH NEUROSURGERY			English	Article						Intracranial pressure; Pulsatility index; Transcranial doppler ultrasonography; Traumatic brain injury	TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; CEREBRAL-BLOOD-FLOW; HYPERTENSION; CARE; ICP	AIM: In traumatic brain injury (TBI) patients, it is desired to monitor the intracranial pressure (ICP) to assess the cerebral haemodynamics and guide the therapy. The study was designed to see if the pulsatility index (PI) measured by transcranial Doppler ultrasonography (TCD) predicts information about ICP values. MATERIAL and METHODS: In 52 TBI patients with Glasgow Coma Scale (GCS) score < 9, invasive intracranial monitoring and TCD ultrasonography for PI were performed through five days. ICP, cerebral perfusion pressure (CPP), PI values were recorded and calculated. The correlation and regression analysis between ICP, PI and CPP were investigated in the whole group and in patients with a Glasgow Outcome Score (GOS) of 3-5. RESULTS: The decline in ICP and PI values was significant through five days. The correlation between ICP and PI was strongly significant (p < 0.0001) on days 1, 3 and 5. In patients with a GOS of 3-5, correlation of ICP and PI was also observed. The only significant correlation observed between CPP and PI was on days. CONCLUSION: The strong correlation observed between ICP and PI through the management period of TBI patients can lead us to use TCD ultrasonography-derived PI as a guide if invasive monitoring is not available.	[Gura, Melek; Coskun, Nilufer] Goztepe Training Hosp, Dept Anesthesiol & Reanimatol, Istanbul, Turkey; [Elmaci, Ilhan] Acibadem Univ, Fac Med, Dept Neurosurg, Istanbul, Turkey; [Sari, Ramazan] Goztepe Training Hosp, Dept Neurosurg, Istanbul, Turkey	Gura, M (corresponding author), Goztepe Training Hosp, Dept Anesthesiol & Reanimatol, Istanbul, Turkey.	melekgura@gmail.com	Elmaci, Ilhan/AAF-3459-2021; SARI, Ramazan/AAJ-9244-2020; Soytas, Ugur/A-5498-2010	Elmaci, Ilhan/0000-0001-9433-0307; SARI, Ramazan/0000-0001-7866-8113; 			Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHAN KH, 1992, NEUROSURGERY, V30, P697; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2001, J NEUROSURG, V94, P685; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Kincaid MS, 2006, CRIT CARE NEURO, V12, P93; Klingerhofer J, 1997, J Mol Med, V65, P542; Lescot T, 2008, CURR OPIN CRIT CARE, V14, P129, DOI 10.1097/MCC.0b013e3282f63c51; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin N A, 1993, Neurosurgery, V33, P761; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; MORENO JA, 2000, NEUROSURG FOCUS, V8; Rincon F, 2007, CURR OPIN CRIT CARE, V13, P115, DOI 10.1097/MCC.0b013e32808255c6; Saqqur M, 2007, CRIT CARE MED, V35, pS216, DOI 10.1097/01.CCM.0000260633.66384.FB; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Sorteberg A, 2007, CONT NEUROSURGERY, V29, P1; Splavski B, 2006, BRIT J NEUROSURG, V20, P386, DOI 10.1080/02688690601048104; Splavski B, 2006, BRAIN INJURY, V20, P1265, DOI 10.1080/02699050601082099; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; The Brain Trauma Foundation, 2007, J NEUROTRAUM, pS45; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Umamaheswara R, 2008, SAARC J ANAESTH, P58; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	32	26	28	0	5	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	APR	2011	21	2					210	215					6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	761CC	WOS:000290371700015	21534204	Bronze			2021-06-18	
J	Luostarinen, T; Niiya, T; Schramko, A; Rosenberg, P; Niemi, T				Luostarinen, Teemu; Niiya, Tomohisa; Schramko, Alexey; Rosenberg, Per; Niemi, Tomi			Comparison of Hypertonic Saline and Mannitol on Whole Blood Coagulation In Vitro Assessed by Thromboelastometry	NEUROCRITICAL CARE			English	Article						Hypertonic saline; Mannitol; Coagulation; Traumatic brain injury; Craniotomy; Neurosurgery	INTRACRANIAL HYPERTENSION; 20-PERCENT MANNITOL; 7.5-PERCENT SALINE; BRAIN RELAXATION; RESUSCITATION; PRESSURE	Hypertonic saline (HS) is an alternative to mannitol for decreasing intracranial pressure in traumatic brain injury and before craniotomy. Both HS and mannitol may interfere with blood coagulation but their influence on coagulation has not been compared in controlled situations. Therefore, we evaluated different strengths of HS and 15% mannitol on blood coagulation in vitro. Citrated fresh whole blood, withdrawn from 10 volunteers, was diluted with 0.9%, 2.5%, or 3.5% HS or 15% mannitol to make 10 vol.% and 20 vol.% hemodilution in vitro. The diluted blood and undiluted control samples were analyzed with thromboelastometry (ROTEMA (R)) using two activators, tissue thromboplastin without (ExTEM(A (R))) or with cytochalasin (FibTEM(A (R))). In the FibTEM(A (R)) analysis, maximum clot firmness (MCF) was stronger in the 2.5% HS group than in the mannitol group after both dilutions (P < 0.05). In the ExTEM(A (R)) analysis, clot formation time (CFT) was more delayed in the mannitol group than in the 0.9%, 2.5%, or 3.5% HS groups in 20 vol.% hemodilution (P < 0.05). MCF was weaker in the mannitol group than in the other groups after 20 vol.% dilution (P < 0.05). MCF was also weaker in the 3.5% than in the 0.9% saline group after 20 vol.% dilution (P < 0.05). Blood coagulation is disturbed more by 15% mannitol than by equiosmolar 2.5% saline. This disturbance seems to be attributed to overall clot formation and strength but also to pure fibrin clot firmness. This saline solution might be more favorable than mannitol before craniotomy in patients with a high risk of bleeding.	[Luostarinen, Teemu; Schramko, Alexey; Rosenberg, Per; Niemi, Tomi] Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Toolo Hosp, Helsinki 00029, Finland; [Niiya, Tomohisa] Sapporo Med Univ, Dept Anesthesiol, Sapporo, Hokkaido, Japan	Luostarinen, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Toolo Hosp, POB 266, Helsinki 00029, Finland.	teemu.luostarinen@hus.fi					Bischof D, 2010, MINERVA ANESTESIOL, V76, P131; Brummel-Ziedins K, 2006, J TRAUMA, V61, P1350, DOI 10.1097/01.ta.0000235525.64176.01; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; da Silva JC, 2010, NEUROL RES, V32, P139, DOI 10.1179/174313209X405119; De Vivo P, 2001, Minerva Anestesiol, V67, P603; Erard AC, 2003, ANN FR ANESTH, V22, P18, DOI 10.1016/S0750-7658(02)00004-7; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GRUZ J, 2001, NEUROSURGERY, V49, P864; Keyrouz SG, 2008, NEUROCRIT CARE, V9, P204, DOI 10.1007/s12028-008-9118-3; Krausz Michael M, 2006, World J Emerg Surg, V1, P14, DOI 10.1186/1749-7922-1-14; Lindroos AC, 2010, J NEUROSURG ANESTH, V22, P16, DOI 10.1097/ANA.0b013e3181bd4ede; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Niemi TT, 2005, ACTA ANAESTH SCAND, V49, P373, DOI 10.1111/j.1399-6576.2005.00619.x; Perez-Perez AJ, 2002, AM J NEPHROL, V22, P573, DOI 10.1159/000065279; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Rozet I, 2007, ANESTHESIOLOGY, V107, P697, DOI 10.1097/01.anes.0000286980.92759.94; Tan TS, 2002, ANAESTHESIA, V57, P644, DOI 10.1046/j.1365-2044.2002.02603.x; Tsai SF, 2010, CLIN NEPHROL, V74, P70; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; Wilder DM, 2002, THROMB RES, V107, P255, DOI 10.1016/S0049-3848(02)00335-3; Wu CT, 2010, ANESTH ANALG, V110, P903, DOI 10.1213/ANE.0b013e3181cb3f8b	26	26	27	0	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2011	14	2					238	243		10.1007/s12028-010-9475-6			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	738SY	WOS:000288663800014	21369792				2021-06-18	
J	Fort, E; Bouffard, E; Charnay, P; Bernard, M; Boisson, D; Laumon, B; Hours, M				Fort, Emmanuel; Bouffard, Emilie; Charnay, Pierrette; Bernard, Marlene; Boisson, Dominique; Laumon, Bernard; Hours, Martine			RETURN TO WORK FOLLOWING ROAD ACCIDENTS: FACTORS ASSOCIATED WITH LATE WORK RESUMPTION	JOURNAL OF REHABILITATION MEDICINE			English	Article						return to work; road traffic accident; cohort; injury	TRAUMATIC BRAIN-INJURY; VOCATIONAL-REHABILITATION; WHIPLASH INJURY; MAJOR TRAUMA; RISK-FACTORS; DISABILITY; COMPENSATION; DETERMINANTS; RECOVERY; CHALLENGES	Objective: To analyse factors associated with late return to work in road accident victims. Materials and methods: The ESPARR cohort comprises road accident victims monitored over time from initiation of hospital care. A total of 608 ESPARR cohort subjects were working at the time of their accident and answered questionnaires at 6 months and/or 1 year. For each level of overall severity of injury (Maximum - Abbreviated Injury Scale (M-AIS) 1, 2,3 and 4-5), a time-off-work threshold was defined, beyond which the subject was deemed to be a late returner; 179 subjects were considered to be late in returning to work, while 402 showed a normal pattern of return. Logistic regression identified factors associated with late return. Results: Type of journey, overall injury severity and intention to press charges emerged as factors predictive of late return to work on the basis of the data collected at inclusion alone. After adjustment, pain (odds ratio (OR): 2.6; 95% confidence interval (95% CI) 1.0-6.7) and physical sequelae (OR: 3.8; 95% CI 1.7-8.3) at 6 months and the fact of pressing charges (OR: 2.6; 95% CI 1.2-5.5) remained significantly linked with late return to work. Conclusion: Impaired health status at 6 months after the initial accident (in the form of persistent pain and physical sequelae) is a determining factor delaying return to work following a road traffic accident.	[Fort, Emmanuel; Bouffard, Emilie; Hours, Martine] Univ Lyon 1, INRETS, UMRESTTE, Univ Lyon, FR-69500 Bron, France; [Charnay, Pierrette; Bernard, Marlene; Laumon, Bernard; Hours, Martine] Univ Lyon 1, INRETS Domaine Rockefeller, Univ Lyon, UMRESTTE, F-69365 Lyon, France; [Boisson, Dominique] Hosp Civils Lyon, Hop Henry Gabrielle, Serv Med Phys & Readaptat, St Genis Laval, France	Hours, M (corresponding author), Univ Lyon 1, INRETS, UMRESTTE, Univ Lyon, 25 Ave Francois Mitterrand, FR-69500 Bron, France.	martine.hours@inrets.fr	Fort, Emmanuel/Q-4570-2019	Fort, Emmanuel/0000-0003-1419-9914	French Ministry of Equipment, Transport, Housing, Tourism and Sea [SU0400066]; French Ministry or Health [PHRC2003, PHRC-N03, PHRC2005, PHRC-N051]	We acknowledge funding from the French Ministry of Equipment, Transport, Housing, Tourism and Sea (Predit 3 Program "New Knowledge in the Field of Road Safety": Number SU0400066) and from the French Ministry or Health (Program PHRC2003: PHRC-N03; and PHRC2005: PHRC-N051).	*AAAM, 1990, ABBR INJ SCAL 1990 R; Adams H, 2007, J OCCUP REHABIL, V17, P305, DOI 10.1007/s10926-007-9082-3; BALLABENI P, 2010, J OCCUP REHABIL 0710; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Bruyns CNP, 2003, J HAND SURG-AM, V28A, P28, DOI 10.1053/jhsu.2003.50026; Burnham RS, 1996, SPINE, V21, P1066, DOI 10.1097/00007632-199605010-00015; Chamberlain MA, 2009, J REHABIL MED, V41, P856, DOI 10.2340/16501977-0457; CHEADLE A, 1994, AM J PUBLIC HEALTH, V84, P190, DOI 10.2105/AJPH.84.2.190; Clay FJ, 2010, INJURY, V41, P787, DOI 10.1016/j.injury.2010.04.005; Clay FJ, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-6; *CPAM, CIR772004 CPAM, P15; Crook J, 1998, J RHEUMATOL, V25, P1570; Ferrari R, 2001, MED HYPOTHESES, V56, P372, DOI 10.1054/mehy.2000.1215; Galizzi M, 2003, LABOUR ECON, V10, P311, DOI 10.1016/S0927-5371(03)00014-9; Gun RT, 2005, SPINE, V30, P386, DOI 10.1097/01.brs.0000153399.24457.ee; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Hours M, 2008, ACCIDENT ANAL PREV, V40, P1789, DOI 10.1016/j.aap.2008.06.017; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; JAMES SKP, 2003, ARCH PHYS MED REHAB, V84, P1282; Krause N, 2001, AM J IND MED, V40, P464, DOI 10.1002/ajim.1116; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lenne-Aurier K., 1998, Annales de Readaptation et de Medecine Physique, V41, P5, DOI 10.1016/S0168-6054(97)83589-1; Lidal IB, 2007, DISABIL REHABIL, V29, P1341, DOI 10.1080/09638280701320839; MacEachen E, 2010, J OCCUP REHABIL, V20, P349, DOI 10.1007/s10926-010-9229-5; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Oyeflaten I, 2008, J REHABIL MED, V40, P548, DOI 10.2340/16501977-0202; Ozegovic D, 2009, EUR SPINE J, V18, P893, DOI 10.1007/s00586-009-0954-4; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rusch MD, 2003, J HAND SURG-AM, V28A, P673, DOI 10.1016/S0363-5023(03)00178-3; Selander J, 2002, DISABIL REHABIL, V24, P704, DOI 10.1080/09638280210124284; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Ventureyra VAG, 2002, PSYCHOTHER PSYCHOSOM, V71, P47, DOI 10.1159/000049343; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wasiak R, 2007, J OCCUP REHABIL, V17, P766, DOI 10.1007/s10926-007-9101-4; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	40	26	27	0	12	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAR	2011	43	4					283	291		10.2340/16501977-0670			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	743ID	WOS:000289011000002	21347505	DOAJ Gold			2021-06-18	
J	Jin, X; Yang, KH; King, AI				Jin, Xin; Yang, King H.; King, Albert I.			Mechanical properties of bovine pia-arachnoid complex in shear	JOURNAL OF BIOMECHANICS			English	Article						Pia-arachnoid complex (PAC); Mechanical properties; Shear loading; CSF layer; Dynamic loading	HUMAN BRAIN-TISSUE; SUBDURAL SPACE; HUMAN HEAD; BEHAVIOR; ELASTICITY; IMPACT; MATER; MODEL	Traumatic brain injury (TBI) has become a major public health and socioeconomic problem that affects 1.5 million Americans annually. Finite element methods have been widely used to investigate TBI mechanisms. The pia-arachnoid complex (PAC) covering the brain plays an important role in the mechanical response of the brain during impact or inertial loading. Existing finite element brain models have tended to oversimplify the response of the PAC due to a lack of accurately defined material properties of this structure, possibly resulting in a loss of accuracy in the model predictions. The objectives of this study were to experimentally determine the material properties of the PAC under shear loading. Bovine PAC was selected in the current study in view of its availability and comparability with previous studies. Tangential shear tests were conducted at 0.8, 7.3, and 72 s(-1). The mean shear moduli were 11.73, 20.04, and 22.37 kPa at the three strain rates tested. The ultimate stress, at the three strain rates, was 9.21, 17.01, and 22.26 kPa, while the ultimate strain was 1.52, 1.58, and 1.81. Results from the current study provide essential information to properly model the PAC membrane, an important component in the skull/brain interface, in a computational model of the human/animal head. Such an improved representation of the in vivo skull/brain interface will enhance future studies investigating brain injury mechanisms under various loading conditions. (C) 2010 Elsevier Ltd. All rights reserved.	[Jin, Xin; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA	Jin, X (corresponding author), Wayne State Univ, Ctr Bioengn, 818 W Hancock, Detroit, MI 48201 USA.	mail.jinxin@gmail.com	Jin, Xin/J-6476-2015				Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; Arbogast K., 1997, P 41 STAPP CAR CRASH; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; BANDAK FA, 1994, P 37 STAPP CAR CRASG, V37; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Brands D W, 2000, Stapp Car Crash J, V44, P249; Claessens M., 1997, P 41 STAPP CAR CRASH; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; ESTES MS, 1970, P 4 ASME BIOM C; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; FREDERICKSON RG, 1991, ANAT RECORD, V230, P38, DOI 10.1002/ar.1092300105; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HARRIGAN TP, 1988, J BIOMECH, V21, P269, DOI 10.1016/0021-9290(88)90257-6; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Jin X, 2007, STAPP CAR CRASH JO, V51, P115; KANG HS, 1997, P P 41 STAPP CAR CRA; Killer HE, 2003, BRIT J OPHTHALMOL, V87, P777, DOI 10.1136/bjo.87.6.777; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King A I, 2003, P INT IRCOBI C BIOM; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MAO H, 2010, J NEUROTRAUMA; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller RT, 1998, P 42 STAPP CAR CRASH; Ozawa H, 2004, J NEUROSURG-SPINE, V1, P122, DOI 10.3171/spi.2004.1.1.0122; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Shreiber D. I., 1997, P 41 STAPP CAR CRASH; Takhounts EG, 2008, STAPP CAR C, V52, P1; THURMAN DL, 2000, TRAUMATIC BRAIN INJU; TROSEILLE X, 1992, P 36 STAPP CAR CRASH; TUNTURI AR, 1978, J NEUROSURG, V48, P975, DOI 10.3171/jns.1978.48.6.0975; TURQUIER F, 1996, P 40 STAPP CAR CRASH; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Zhang L, 2001, Stapp Car Crash J, V45, P369; ZHANG L, 2003, P ASME BIOENG C, P37; ZHOU C, 1994, P 38 STAPP CAR CRASH	47	26	26	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	FEB 3	2011	44	3					467	474		10.1016/j.jbiomech.2010.09.035			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	724BL	WOS:000287551000018	21087768				2021-06-18	
J	O'Reilly, RC; Greywoode, J; Morlet, T; Miller, F; Henley, J; Church, C; Campbell, J; Beaman, J; Cox, AM; Zwicky, E; Bean, C; Falcheck, S				O'Reilly, Robert C.; Greywoode, Jewell; Morlet, Thierry; Miller, Freeman; Henley, John; Church, Chris; Campbell, Jeffrey; Beaman, Jason; Cox, Anne Marie; Zwicky, Emily; Bean, Charles; Falcheck, Stephen			Comprehensive Vestibular and Balance Testing in the Dizzy Pediatric Population	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article; Proceedings Paper	23rd Annual Meeting of the American-Society-of-Pediatric-Otolaryngology	MAY 02-04, 2008	Orlando, FL	Amer Soc Pediat Otolaryngol		balance; pediatric; vertigo; vestibular disorders	BENIGN PAROXYSMAL VERTIGO; EVOKED MYOGENIC POTENTIALS; CHILDREN; CHILDHOOD; MIGRAINE; DIZZINESS; INFANTS	Objective. To describe the spectrum of balance disease in a large population of children presenting to a tertiary care vestibular and balance laboratory. Study Design. Case series with chart review. Setting. Tertiary care pediatric hospital. Main Outcome Measures. Results of audiometric, vestibular, and balance tests and final diagnosis. Subjects and Methods. Retrospective review of audiometric, vestibular, balance testing, and final diagnosis from a patient database. Results. Between September 2003 and September 2007, 132 children were evaluated at the Alfred I. duPont Hospital for Children Vestibular Disorders Program. Sixty-nine of the patients were boys and 63 were girls. The average age was 9.7 +/- 5.0 years (range, 1-17 years). Although not all were able to complete the entire test battery (99 children completed at least 50% of the tests in the protocol), a diagnosis was achieved in most cases. The most common diagnoses were peripheral vestibulopathy (29.5%), migraine/benign recurrent vertigo of childhood (24.2%), motor/developmental delay (10.6%), traumatic brain injury (9.8%), and central nervous system structural lesion (9.1%). Conclusions. Peripheral vestibular deficits and migraine disease account for most of the pathology in the pediatric population. With a multidisciplinary approach, diagnosis of the source of vertigo and imbalance is possible in most children.	[O'Reilly, Robert C.] Alfred I duPont Hosp Children, Div Pediat Otolaryngol, Wilmington, DE 19899 USA; [Greywoode, Jewell] Thomas Jefferson Univ Hosp, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA; [Morlet, Thierry] Alfred I duPont Hosp Children, Ctr Pediat Auditory & Speech Sci, Wilmington, DE 19899 USA; [Miller, Freeman; Henley, John; Church, Chris] Alfred I duPont Hosp Children, Gait Lab, Wilmington, DE 19899 USA; [Campbell, Jeffrey] Alfred I duPont Hosp Children, Div Pediat Neurosurg, Wilmington, DE 19899 USA; [Beaman, Jason] Alfred I duPont Hosp Children, Dept Phys Therapy, Wilmington, DE 19899 USA; [Cox, Anne Marie; Zwicky, Emily] Alfred I duPont Hosp Children, Dept Audiol, Wilmington, DE 19899 USA; [Bean, Charles] Neurol Associates PA, Newark, DE USA; [Falcheck, Stephen] Alfred I duPont Hosp Children, Dept Neurol, Wilmington, DE 19899 USA	O'Reilly, RC (corresponding author), Alfred I duPont Hosp Children, Div Pediat Otolaryngol, POB 269, Wilmington, DE 19899 USA.	roreilly@nemours.org	Morlet, Thierry/AAL-8442-2021				Al-Twaijri WA, 2002, PEDIATR NEUROL, V26, P365, DOI 10.1016/S0887-8994(01)00416-7; ANDRIEUGUITRANCOURT J, 1981, INT J PEDIATR OTORHI, V3, P245, DOI 10.1016/0165-5876(81)90007-0; Bachor E, 2002, LARYNGOSCOPE, V112, P147, DOI 10.1097/00005537-200201000-00026; Balatsouras DG, 2007, INT J PEDIATR OTORHI, V71, P487, DOI 10.1016/j.ijporl.2006.11.024; BASSER LS, 1964, BRAIN, V87, P141, DOI 10.1093/brain/87.1.141; BOWER CM, 1995, ARCH OTOLARYNGOL, V121, P911; Choung YH, 2003, INT J PEDIATR OTORHI, V67, P889, DOI 10.1016/S0165-5876(03)00136-8; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Drigo P, 2001, BRAIN DEV-JPN, V23, P38, DOI 10.1016/S0387-7604(01)00175-9; EEGOLOFSSON O, 1982, ACTA OTO-LARYNGOL, V93, P283, DOI 10.3109/00016488209130884; Erbek SH, 2006, INT J PEDIATR OTORHI, V70, P1547, DOI 10.1016/j.ijporl.2006.04.001; Eviatar L, 1978, Adv Otorhinolaryngol, V23, P169; EVIATAR L, 1979, LARYNGOSCOPE, V89, P1036; FILIPO R, 1985, J LARYNGOL OTOL, V99, P193, DOI 10.1017/S0022215100096523; Horlings CGC, 2008, NAT CLIN PRACT NEURO, V4, P504, DOI 10.1038/ncpneuro0886; Katz-Leurer M, 2008, BRAIN INJURY, V22, P153, DOI 10.1080/02699050801895399; Kelsch TA, 2006, LARYNGOSCOPE, V116, P895, DOI 10.1097/01.mlg.0000214664.97049.3e; KENYON GS, 1988, J ROY SOC MED, V81, P644; Kumar A, 2002, OTOL NEUROTOL, V23, P727, DOI 10.1097/00129492-200209000-00021; Lindskog U, 1999, HEADACHE, V39, P33, DOI 10.1046/j.1526-4610.1999.3901033.x; MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P181, DOI 10.1016/S0194-5998(95)70102-8; MULCH G, 1979, ANN OTO RHINOL LARYN, V88, P1; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; Neuhauser HK, 2007, CURR OPIN NEUROL, V20, P40, DOI 10.1097/WCO.0b013e328013f432; Oh AK, 2001, J NEUROL, V248, P971, DOI 10.1007/s004150170050; Pakalnis A, 2001, FAM PRACT, V18, P101, DOI 10.1093/fampra/18.1.101; Purdy RA, 2008, NEUROL SCI, V29, pS44, DOI 10.1007/s10072-008-0885-6; Ravid S, 2003, PEDIATR NEUROL, V29, P317, DOI 10.1016/S0887-8994(03)00278-9; Riina N, 2005, ARCH OTOLARYNGOL, V131, P996, DOI 10.1001/archotol.131.11.996; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; TELISCHI FF, 2005, NEUROTOLOGY, P553; Valente M, 2007, J AM ACAD AUDIOL, V18, P461	32	26	29	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	FEB	2011	144	2					142	148		10.1177/0194599810393679			7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	808RV	WOS:000293997000002	21493408				2021-06-18	
J	Perkes, I; Schofield, PW; Butler, T; Hollis, SJ				Perkes, Iain; Schofield, Peter W.; Butler, Tony; Hollis, Stephanie J.			Traumatic brain injury rates and sequelae: A comparison of prisoners with a matched community sample in Australia	BRAIN INJURY			English	Article						Prisoners; traumatic brain injury; community comparison; Australia	HEAD-INJURY; PSYCHIATRIC-DISORDERS; SUBSTANCE-ABUSE; UNITED-STATES; POPULATION; PREVALENCE; BEHAVIOR; ILLNESS; COHORT; CRIME	Aim: To compare rates of past reported traumatic brain injury (TBI) in a prisoner sample with those in a control group drawn from the same location of usual residence. Method: The prisoner group comprised a consecutive sample of men (n=200) received into custody and screened by face-to-face interview. The control group comprised men (n=200) matched for location of usual residence screened by telephone interview. Participants were asked about past TBIs and screened for drug and alcohol abuse, impulsivity and dissocial personality disorder. Results: Eighty-two per cent of prisoners and 71.5% of community participants reported at least one past TBI of any severity (i.e. with or without a loss of consciousness (LOG)) and 64.5% of prisoners and 32.2% of community participants reported at least one TBI associated with a LOC. Prisoners were more likely to report persisting side-effects of TBI and were much more likely to screen positive for impulsivity and dissocial personality disorder. Multivariate analyses found no significant association between TBI frequency or severity and custody/community group membership. Conclusions: High reported rates of TBI in prisoner populations may reflect the excess of socio-demographic risk factors for TBI. Results of the current study do not support a role for TBI as causally related to criminal conduct.	[Schofield, Peter W.] Univ Newcastle, Neuropsychiat Serv, Hunter New England Area Hlth, Ctr Brain & Mental Hlth Res, Newcastle, NSW 2300, Australia; [Perkes, Iain] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Butler, Tony] Curtin Univ Technol, Natl Drug Res Inst, Perth, WA, Australia; [Hollis, Stephanie J.] Univ Sydney, Sch Publ Hlth, Sydney Med Sch, Sydney, NSW 2006, Australia	Schofield, PW (corresponding author), Univ Newcastle, Neuropsychiat Serv, Hunter New England Area Hlth, Ctr Brain & Mental Hlth Res, POB 833, Newcastle, NSW 2300, Australia.	peter.schofield@hnehealth.nsw.gov.au	Butler, Tony/F-4614-2012; Perkes, Iain/J-7001-2017; Schofield, Peter/J-7133-2013; Hollis, Stephanie J/B-5977-2011	Butler, Tony/0000-0002-2679-2769; Perkes, Iain/0000-0001-8028-9032; Schofield, Peter/0000-0001-8298-8590	NHMRCNational Health and Medical Research Council of Australia [533554]; NSW Justice Health; Ian Potter Foundation (Melbourne)	Margot Eyeson-Annan and Matt Gorringe from the NSW Health Department's Health Survey Team assisted with developing the community survey component. Dr Nadine Smith provided advice on the statistical analysis. Tony Butler is supported by an NHMRC Career development Award (No 533554). NSW Justice Health and the Ian Potter Foundation (Melbourne) provided financial assistance for this project.	Allnutt S, 2008, AUST NZ J PSYCHIAT, V42, P969, DOI 10.1080/00048670802415350; *AUSTR BUR STAT, 2004, PRIS AUSTR; *AUSTR I HLTH WELF, 2008, SER AUSTR I HLTH WEL, V31; Australian Bureau of Statistics, 2001, CENS POP HOUS SOC IN; Australian Bureau of Statistics (ABS), 2001, CENS POP HOUS; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bell N, 2009, CAN J PUBLIC HEALTH, V100, P73, DOI 10.1007/BF03405498; Butler T, 2006, AUST NZ J PSYCHIAT, V40, P272, DOI 10.1111/j.1440-1614.2006.01785.x; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; DIRKMEN SS, 1989, NEUROPSYCHOLOGICAL R; EYSENCK SBG, 1980, PSYCHOL REP, V47, P1299, DOI 10.2466/pr0.1980.47.3f.1299; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; GRONWALL D, 1975, LANCET, V2, P995; HORVATH P, 1993, PERS INDIV DIFFER, V14, P41, DOI 10.1016/0191-8869(93)90173-Z; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3; KRUEGER RF, 1994, J ABNORM PSYCHOL, V103, P328, DOI 10.1037/0021-843X.103.2.328; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LORANGER AW, 1997, ICD 10 INT PERSONALI; Lynam DR, 2000, J ABNORM PSYCHOL, V109, P563, DOI 10.1037//0021-843X.109.4.563; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SAMPSON RJ, 1997, SCIENCE, V277, P5328; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Silver JM, 2005, TXB TRAUMATIC BRAIN; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; *SPSS INC, 2009, SPSS VERS 17 COMP PR; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Winkleby MA, 2003, J EPIDEMIOL COMMUN H, V57, P444, DOI 10.1136/jech.57.6.444	39	26	26	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2011	25	2					131	141		10.3109/02699052.2010.536193			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800001	21117917				2021-06-18	
J	Qu, CS; Mahmood, A; Liu, XS; Xiong, Y; Wang, L; Wu, HT; Li, B; Zhang, ZG; Kaplan, DL; Chopp, M				Qu, Changsheng; Mahmood, Asim; Liu, Xian Shuang; Xiong, Ye; Wang, Lei; Wu, Hongtao; Li, Bo; Zhang, Zheng Gang; Kaplan, David L.; Chopp, Michael			The treatment of TBI with human marrow stromal cells impregnated into collagen scaffold: Functional outcome and gene expression profile	BRAIN RESEARCH			English	Article						Endothelial vascular growth factor (VEGF); Traumatic brain injury (TBI); Marrow stromal cell; Collagen scaffold; Restorative therapy	TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; UP-REGULATION; ADULT RATS; NEUROGENESIS; ANGIOGENESIS; TRANSPLANTATION; NEUROPROTECTION; INCREASES; SURVIVIN	We have previously demonstrated that human marrow stromal cells (hMSCs) embedded in collagen I scaffolds significantly enhance the restorative therapeutic effect of hMSCs after traumatic brain injury (TBI). In this study, we test the hypothesis that the collagen scaffold alters gene expression in hMSCs and that hMSCs impregnated into scaffolds increase the astrocytic expression of vascular endothelial growth factor (VEGF) in the injured brain. Following TBI induced by controlled cortical impact injury, scaffold with hMSCs (3.0 x 10(6)), hMSCs-only and saline were implanted into the lesion cavity one week after brain injury (n = 8/each group). Morris water maze and modified neurological severity scores were performed to evaluate the spatial learning and sensorimotor functions, respectively. Lesion volume and expression of VEGF were measured one week after different treatments. In vitro, total RNA from hMSCs was extracted one week after culture with or without collagen I scaffold for evaluation of gene microarrays. Furthermore, an RT-PCR study on a select subgroup of genes was performed to identify the changes of expression between the culturing hMSCs with collagen scaffolds and hMSCs only. The treatment of TBI with collagen scaffold impregnated with hMSCs significantly decreases the functional deficits from TB! within 7 days after treatment, and significantly enhances the VEGF expression of astrocytes in the injured brain compared to the hMSCs-only group. In vitro data indicate that collagen scaffolds stimulate hMSCs to express multiple factors which may contribute to hMSC survival, tissue repair and functional recovery after TBI. (C) 2010 Elsevier B.V. All rights reserved.	[Qu, Changsheng; Mahmood, Asim; Xiong, Ye; Wu, Hongtao; Li, Bo] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Liu, Xian Shuang; Wang, Lei; Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [PO1 NS42345, RO1 NS042259, P41 EB002520]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259, P01NS042345] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health grants PO1 NS42345, RO1 NS042259 and P41 EB002520.	Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIXON CE, 1991, J NEUROSCI METH, V39, P253; During Matthew J., 2006, Current Alzheimer Research, V3, P29, DOI 10.2174/156720506775697133; Gao F, 2007, CAN J CARDIOL, V23, P891; Horiba M, 2006, CIRCULATION, V114, P1713, DOI 10.1161/CIRCULATIONAHA.106.632273; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kawamura K, 2005, BIOL REPROD, V73, P1094, DOI 10.1095/biolreprod.105.042754; Krieglstein K, 2002, J PHYSIOLOGY-PARIS, V96, P25, DOI 10.1016/S0928-4257(01)00077-8; Lee E, 2009, BMB REP, V42, P239, DOI 10.5483/BMBRep.2009.42.5.239; Li CM, 2006, BIOMATERIALS, V27, P3115, DOI 10.1016/j.biomaterials.2006.01.022; Li WZ, 2007, STEM CELLS, V25, P2118, DOI 10.1634/stemcells.2006-0771; Liu XS, 2007, J CEREBR BLOOD F MET, V27, P564, DOI 10.1038/sj.jcbfm.9600371; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; MacKenzie F, 2004, J BIOL CHEM, V279, P11657, DOI 10.1074/jbc.M312102200; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010; Meinel L, 2004, BIOTECHNOL BIOENG, V88, P379, DOI 10.1002/bit.20252; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pati S, 2009, BRAIN RES, V1256, P85, DOI 10.1016/j.brainres.2008.11.086; Polazzi E, 2009, J NEUROCHEM, V110, P545, DOI 10.1111/j.1471-4159.2009.06117.x; Qu CS, 2009, J NEUROSURG, V111, P658, DOI 10.3171/2009.4.JNS081681; REH T, 1982, J COMP NEUROL, V211, P276, DOI 10.1002/cne.902110306; Salerno A, 2009, J MATER SCI-MATER M, V20, P2043, DOI 10.1007/s10856-009-3767-4; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun FY, 2005, J NEUROSCI RES, V79, P180, DOI 10.1002/jnr.20321; Sun JQ, 2010, BIOCHEM BIOPH RES CO, V394, P146, DOI 10.1016/j.bbrc.2010.02.132; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Wang L, 2004, NEUROREPORT, V15, P1225, DOI 10.1097/01.wnr.0000127636.15181.c1; Xiong Y, 2009, BRAIN RES, V1263, P183, DOI 10.1016/j.brainres.2009.01.032; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Zen AA, 2010, CIRC RES, V107, P283, DOI 10.1161/CIRCRESAHA.110.221663; Zwerts F, 2007, BLOOD, V109, P4742, DOI 10.1182/blood-2006-06-028068	56	26	28	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 31	2011	1371						129	139		10.1016/j.brainres.2010.10.088			11	Neurosciences	Neurosciences & Neurology	720JV	WOS:000287277900014	21062621	Green Accepted			2021-06-18	
J	Attar, A; Ayten, M; Ozdemir, M; Ozgencil, E; Bozkurt, M; Kaptanoglu, E; Beksac, M; Kanpolat, Y				Attar, Ayhan; Ayten, Murat; Ozdemir, Mevci; Ozgencil, Enver; Bozkurt, Melih; Kaptanoglu, Erkan; Beksac, Meral; Kanpolat, Yucel			An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells	CYTOTHERAPY			English	Article						mononuclear cell; regeneration; spinal cord; trauma	MESENCHYMAL STEM-CELLS; REGENERATION; RECOVERY; BRAIN; STRATEGIES; ETIOLOGY	Background aims. Spinal cord injury is common among young subjects involved in motor vehicle accidents. Mechanisms and attempts to reverse post-traumatic pathophysiologic consequences are still being investigated. Unfortunately no effective and well-established treatment modality has been developed so far. The regeneration capability of the human nervous system following an injury is highly limited. Methods. The study involved four patients (two male, two female) who had suffered spinal cord injury as a result of various types of trauma. On neurologic examination, all the patients were determined to be in American Spinal Injury Association (ASIA) grade A. All patients were treated with decompression, stabilization and fusion for vertebral trauma anteriorly, as well as intralesional implantation of cellular bone marrow concentrates using a posterior approach 1 month after the first operation. The patients were then treated and followed-up in the physical rehabilitation clinic. Results. At the end of the post-operative 1-year follow-up, two of the patients were classified as ASIA C while one was classified as ASIA B. One patient showed no neurologic change; none of the patients suffered from any complications or adverse effects as a result of intralesional application of bone marrow cells. Conclusions. The results of this experimental study show the potential contribution of intralesional implantation of bone marrow to neuronal regeneration in the injured spinal cord, with neuronal changes. In light of the results of this experimental study, the potential for regenerative treatment in injuries of the human spinal cord is no longer a speculation but an observation.	[Ozdemir, Mevci] Ergani Publ Hosp, Dept Neurosurg, TR-21950 Diyarbakir, Turkey; [Attar, Ayhan] Ankara Univ, Dept Neurosurg, Sch Med, TR-06100 Ankara, Turkey; [Ayten, Murat] Trabzon Publ Hosp, Dept Neurosurg, Trabzon, Turkey; [Ozgencil, Enver] Ankara Univ, Sch Med, Dept Anesthesiol, TR-06100 Ankara, Turkey; [Bozkurt, Melih; Kaptanoglu, Erkan] Ankara Numune Hosp, Dept Neurosurg, Ankara, Turkey; [Beksac, Meral] Ankara Univ, Sch Med, Dept Hematol, TR-06100 Ankara, Turkey; [Kanpolat, Yucel] Turkish Acad Sci, Ankara, Turkey	Ozdemir, M (corresponding author), Ergani Publ Hosp, Dept Neurosurg, TR-21950 Diyarbakir, Turkey.	drmevci@hotmail.com	Ozdemir, Mevci/Y-8197-2019; Ozgencil, Enver Gungor/L-7819-2018; bozkurt, melih/D-2848-2009; Beksac, Meral/D-6411-2013	Beksac, Meral/0000-0003-1797-8657; bozkurt, melih/0000-0001-7433-081X			Ahn H, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E15; Attar A, 2005, SURG NEUROL, V64, P28, DOI 10.1016/j.surneu.2005.07.057; Bergmark BA, 2008, SPINAL CORD, V46, P684, DOI 10.1038/sc.2008.15; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; CARTER RE, 1977, TEX MED, V73, P61; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chu K, 2003, NEUROSCI LETT, V343, P129, DOI 10.1016/S0304-3940(03)00174-5; Copray JCVM, 2003, ACTA NEUROCHIR, V145, P425, DOI 10.1007/s00701-003-0062-x; Coskun K, 2000, ACTA NEUROCHIR, V142, P1143, DOI 10.1007/s007010070043; Furlan JC, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E13; Kaptanoglu E, 2005, ACTA NEUROCHIR, V147, P405, DOI 10.1007/s00701-004-0447-5; Lima C, 2006, J SPINAL CORD MED, V29, P191, DOI 10.1080/10790268.2006.11753874; Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495; Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a; Schultz SS, 2005, CURR DRUG TARGETS, V6, P63, DOI 10.2174/1389450053345046; Tator CH, 2005, J NEUROSURG-SPINE, V2, P1, DOI 10.3171/spi.2005.2.1.0001; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Tsai EC, 2005, CURR PHARM DESIGN, V11, P1211, DOI 10.2174/1381612053507404; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yuceer N, 2002, NEUROSURG REV, V25, P184, DOI 10.1007/s10143-001-0193-6; Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103	23	26	26	1	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	JAN	2011	13	1					54	60		10.3109/14653249.2010.510506			7	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	693SX	WOS:000285246800006	20735163				2021-06-18	
J	Hansson, MJ; Morota, S; Chen, L; Matsuyama, N; Suzuki, Y; Nakajima, S; Tanoue, T; Omi, A; Shibasaki, F; Shimazu, M; Ikeda, Y; Uchino, H; Elmer, E				Hansson, Magnus J.; Morota, Saori; Chen, Li; Matsuyama, Nagahisa; Suzuki, Yoshiaki; Nakajima, Satoshi; Tanoue, Tadashi; Omi, Akibumi; Shibasaki, Futoshi; Shimazu, Motohide; Ikeda, Yukio; Uchino, Hiroyuki; Elmer, Eskil			Cyclophilin D-Sensitive Mitochondrial Permeability Transition in Adult Human Brain and Liver Mitochondria	JOURNAL OF NEUROTRAUMA			English	Article						ischemia; oxidative stress; mitochondria; traumatic brain injury; traumatic spinal cord injury	CA-2&-INDUCED MEMBRANE TRANSITION; CYCLOSPORINE-A; CYTOCHROME-C; HEART-MITOCHONDRIA; FOREBRAIN ISCHEMIA; PHOSPHATE CARRIER; NEURONAL DEATH; MOUSE MODEL; CELL-DEATH; PORE	The mitochondrial permeability transition (mPT) is considered to be a major cause of cell death under a variety of pathophysiological conditions of the central nervous system (CNS) and other organs. Pharmacological inhibition or genetic knockout of the matrix protein cyclophilin D (CypD) prevents mPT and cell degeneration in several models of brain injury. If these findings in animal models are translatable to human disease, pharmacological inhibition of mPT offers a promising therapeutic target. The objective of this study was to validate the presence of a CypD-sensitive mPT in adult human brain and liver mitochondria. In order to perform functional characterization of human mitochondria, fresh tissue samples were obtained during hemorrhage or tumor surgery and mitochondria were rapidly isolated. Mitochondrial calcium retention capacity, a quantitative assay for mPT, was significantly increased by the CypD inhibitor cyclosporin A in both human brain and liver mitochondria, whereas thiol-reactive compounds and oxidants sensitized mitochondria to calcium-induced mPT. Brain mitochondria underwent swelling upon calcium overload, which was reversible upon calcium removal. To further explore mPT of human mitochondria, liver mitochondria were demonstrated to exhibit several classical features of the mPT phenomenon, such as calcium-induced loss of membrane potential and respiratory coupling, as well as release of the pro-apoptotic protein cytochrome c. We concluded that adult viable human brain and liver mitochondria possess an active CypD-sensitive mPT. Our findings support the rationale of CypD and mPT inhibition as pharmacological targets in acute and chronic neurodegeneration.	[Hansson, Magnus J.; Morota, Saori; Elmer, Eskil] Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Mitochondrial Pathophysiol Unit, SE-22184 Lund, Sweden; [Hansson, Magnus J.] Skane Univ Hosp, Dept Clin Physiol, Lund, Sweden; [Elmer, Eskil] Skane Univ Hosp, Dept Clin Neurophysiol, Lund, Sweden; [Chen, Li; Shibasaki, Futoshi] Tokyo Metropolitan Inst Med Sci, Dept Mol Cell Physiol, Tokyo 113, Japan; [Matsuyama, Nagahisa] Tokyo Med Univ, Dept Pathol, Tokyo, Japan; [Suzuki, Yoshiaki; Shimazu, Motohide] Tokyo Med Univ, Dept Surg, Tokyo, Japan; [Uchino, Hiroyuki] Tokyo Med Univ, Dept Anesthesiol, Tokyo, Japan; [Nakajima, Satoshi; Ikeda, Yukio] Tokyo Med Univ, Hachioji Med Ctr, Dept Neurosurg, Tokyo, Japan; [Tanoue, Tadashi] Kumamoto Reg Med Ctr, Dept Anesthesiol, Kumamoto, Japan; [Omi, Akibumi] Kosei Chuoh Hosp, Dept Anesthesiol, Tokyo, Japan	Hansson, MJ (corresponding author), Lund Univ, Dept Clin Sci, Expt Brain Res Lab, Mitochondrial Pathophysiol Unit, SE-22184 Lund, Sweden.	magnus.hansson@med.lu.se	Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2008-2634]; Japanese Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [18591724]; Foundation of the Swedish National Board of Health and Welfare; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22249016] Funding Source: KAKEN	This study was supported by the Swedish Research Council (reference no. 2008-2634), by the Japanese Ministry of Health, Labour and Welfare grant no. 18591724, and the Foundation of the Swedish National Board of Health and Welfare. The authors are grateful to Hitoshi Miura, Takashi Ogata, Hiroshi Nishioka, Tetsuo Ishizaki, Tomohiro Nomura, Mamoru Murakami, Shingo Ohno, Hiroyuki Jinbo, and Hitoshi Izawa for support in obtaining tissue samples. D-MeAla<SUP>3</SUP>EtVal<SUP>4</SUP>-cyclosporin (Debio-025) was kindly provided by Debiophami S.A.	Alcala S, 2008, ONCOGENE, V27, P44, DOI 10.1038/sj.onc.1210600; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Baines CP, 2010, ANNU REV PHYSIOL, V72, P61, DOI 10.1146/annurev-physiol-021909-135929; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; CROMPTON M, 1988, BIOCHEM J, V255, P357; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Eliseev RA, 2007, NEUROBIOL AGING, V28, P1532, DOI 10.1016/j.neurobiolaging.2006.06.022; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Friberg H, 1998, J NEUROSCI, V18, P5151; Halestrap AP, 2009, BBA-BIOENERGETICS, V1787, P1402, DOI 10.1016/j.bbabio.2008.12.017; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Hansson MJ, 2010, J BIOL CHEM, V285, P741, DOI 10.1074/jbc.M109.017731; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Karlsson J, 2004, J NEUROSURG, V101, P128, DOI 10.3171/jns.2004.101.1.0128; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Kirkinezos IG, 2004, J NEUROCHEM, V88, P821, DOI 10.1046/j.1471-4159.2003.02181.x; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuznetsov AV, 2004, AM J PHYSIOL-HEART C, V286, pH1633, DOI 10.1152/ajpheart.00701.2003; Leung AWC, 2008, J BIOL CHEM, V283, P26312, DOI 10.1074/jbc.M805235200; Liu RR, 2009, J BIOL CHEM, V284, P36109, DOI 10.1074/jbc.M109.055301; Mansson R, 2010, HEPATOLOGY, V51, P347, DOI 10.1002/hep.23465; Martin LJ, 2009, EXP NEUROL, V218, P333, DOI 10.1016/j.expneurol.2009.02.015; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Mewton N, 2010, J AM COLL CARDIOL, V55, P1200, DOI 10.1016/j.jacc.2009.10.052; Millay DP, 2008, NAT MED, V14, P442, DOI 10.1038/nm1736; Morota S, 2009, EXP NEUROL, V218, P353, DOI 10.1016/j.expneurol.2009.03.036; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholls DG, 2009, BBA-BIOENERGETICS, V1787, P1416, DOI 10.1016/j.bbabio.2009.03.010; PETITO CK, 1984, J CEREBR BLOOD F MET, V4, P194, DOI 10.1038/jcbfm.1984.28; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; Russmann S, 2009, CURR MED CHEM, V16, P3041, DOI 10.2174/092986709788803097; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; Sims NR, 2008, NAT PROTOC, V3, P1228, DOI 10.1038/nprot.2008.105; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	66	26	27	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					143	153		10.1089/neu.2010.1613			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800014	21121808	Bronze, Green Published			2021-06-18	
J	Kamps, M; Bisschops, LA; van der Hoeven, JG; Hoedemaekers, CWE				Kamps, Marlijn; Bisschops, Laurens A.; van der Hoeven, Johannes G.; Hoedemaekers, Cornelia W. E.			Hypothermia does not increase the risk of infection: a case control study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; VENTILATOR-ASSOCIATED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; TERM MILD HYPOTHERMIA; C-REACTIVE PROTEIN; DIGESTIVE-TRACT; SELECTIVE DECONTAMINATION; INTENSIVE-CARE; DOUBLE-BLIND; SERUM PROCALCITONIN	Introduction: Hypothermia may improve outcome in patients after traumatic brain injury, especially when hypothermia is maintained for more than 48 hours. In the acute phase, patients with severe brain injury are more vulnerable to infections. Prolonged hypothermic treatment may further enhance the risk of infection. Selective decontamination of the digestive tract (SDD) reduces the risk of respiratory tract infections. The aim of this study was to investigate the incidence of infections in patients treated with hypothermia and normothermia while receiving SDD. Methods: In this retrospective case control study 35 patients treated with prolonged hypothermia (cases) were identified and 169 patients with severe brain injury were included (controls). Propensity score matching was performed to correct for differences in baseline characteristics and clinical parameters. Primary outcome was the incidence of infection. The secondary endpoints were the micro-organisms found in the surveillance cultures and infection. In addition, a number of clinical characteristics were assessed. Results: The demographic and clinical data indicated that the cases and controls were well matched. The overall risk of infection during ICU stay was 20% in the hypothermia groups versus 34.4% in the normothermia group (P = 0.388). Pneumonia was diagnosed in 11.4% of patients in both groups (P = 1.000). The incidence of meningitis, wound infection, bacteremia, and urinary tract infection was low and comparable between the groups. SDD surveillance cultures indicated a higher colonization with gram-negative bacteria in the rectal samples of the hypothermia patients. Conclusions: Hypothermia does not increase the risk of infection in patients treated with SDD.	[Kamps, Marlijn; Bisschops, Laurens A.; van der Hoeven, Johannes G.; Hoedemaekers, Cornelia W. E.] Radboud Univ Nijmegen, Dept Intens Care, Med Ctr, NL-6500 HB Nijmegen, Netherlands	Hoedemaekers, CWE (corresponding author), Radboud Univ Nijmegen, Dept Intens Care, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	C.Hoedemaekers@ic.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015; van der Hoeven, J.G./H-8048-2014				Bergmans DCJJ, 2001, AM J RESP CRIT CARE, V164, P382, DOI 10.1164/ajrccm.164.3.2005003; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; Chan EY, 2007, BMJ-BRIT MED J, V334, P889, DOI 10.1136/bmj.39136.528160.BE; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Fagerli J, 1996, W V Med J, V92, P265; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kox M, 2008, NEUROLOGY, V70, P480, DOI 10.1212/01.wnl.0000279479.69502.3e; Lingnau W, 1998, J HOSP INFECT, V39, P195, DOI 10.1016/S0195-6701(98)90258-4; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Schuetz P, 2010, EUR J CLIN INVEST, V40, P376, DOI 10.1111/j.1365-2362.2010.02259.x; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014	26	26	29	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	1							R48	10.1186/cc10012			8	Critical Care Medicine	General & Internal Medicine	742RJ	WOS:000288961900048	21291523	DOAJ Gold, Green Published			2021-06-18	
J	Morin, A				Morin, Alain			Self-recognition, theory-of-mind, and self-awareness: What side are you on?	LATERALITY			English	Article						Self-awareness; Self-recognition; Theory-of-mind; Right hemisphere; Inner speech	CORTICAL MIDLINE STRUCTURES; TRAUMATIC BRAIN-INJURY; LEFT-HAND ADVANTAGE; INNER SPEECH; SOCIAL COGNITION; PREFRONTAL CORTEX; FACE RECOGNITION; RIGHT-HEMISPHERE; DEFAULT MODE; CONSCIOUSNESS	A fashionable view in comparative psychology states that primates possess self-awareness because they exhibit mirror self-recognition (MSR), which in turn makes it possible to infer mental states in others (otheory-of-mindo; ToM). In cognitive neuroscience, an increasingly popular position holds that the right hemisphere represents the centre of self-awareness because MSR and ToM tasks presumably increase activity in that hemisphere. These two claims are critically assessed here as follows: (1) MSR should not be equated with full-blown self-awareness, as it most probably only requires kinaesthetic self-knowledge and does not involve access to one's mental events; (2) ToM and self-awareness are fairly independent and should also not be taken as equivalent notions; (3) MSR and ToM tasks engage medial and left brain areas; (4) other self-awareness tasks besides MSR and ToM tasks (e.g., self-description, autobiography) mostly recruit medial and left brain areas; (5) and recent neuropsychological evidence implies that inner speech (produced by the left hemisphere) plays a significant role in self-referential activity. The main conclusions reached based on this analysis are that (a) organisms that display MSR most probably do not possess introspective self-awareness, and (b) self-related processes most likely engage a distributed network of brain regions situated in both hemispheres.	Mt Royal Univ, Dept Psychol, Calgary, AB T3E 6K6, Canada	Morin, A (corresponding author), Mt Royal Univ, Dept Psychol, 4825 Mt Royal Gate SW, Calgary, AB T3E 6K6, Canada.	amorin@mtroyal.ca					Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; AMSTERDAM B, 1972, DEV PSYCHOBIOL, V5, P297, DOI 10.1002/dev.420050403; Bard KA, 2006, INFANCY, V9, P191, DOI 10.1207/s15327078in0902_6; Barnacz AL, 2004, SCHIZOPHR RES, V70, P115, DOI 10.1016/j.schres.2003.12.006; Baron-Cohen S., 2001, PRISME, V34, P174; Birch SAJ, 2004, TRENDS COGN SCI, V8, P255, DOI 10.1016/j.tics.2004.04.011; BIRINGER F, 1992, J GERONTOL, V47, pP385, DOI 10.1093/geronj/47.6.P385; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Calarge C, 2003, AM J PSYCHIAT, V160, P1954, DOI 10.1176/appi.ajp.160.11.1954; CAMERON PA, 1988, INFANT BEHAV DEV, V11, P465, DOI 10.1016/0163-6383(88)90006-9; Carpendale JIM, 2004, BEHAV BRAIN SCI, V27, P79; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Cocchini G, 2009, NEUROPSYCHOLOGY, V23, P223, DOI 10.1037/a0014266; Cunningham C., 2004, INT J DISABIL DEV ED, V51, P335, DOI [10.1080/1034912042000295017., DOI 10.1080/1034912042000295017]; D'Argembeau A, 2008, SOC COGN AFFECT NEUR, V3, P244, DOI 10.1093/scan/nsn020; DAWSON G, 1984, J AUTISM DEV DISORD, V14, P383, DOI 10.1007/BF02409829; de Veer MW, 1999, ANIM BEHAV, V58, P459, DOI 10.1006/anbe.1999.1166; Dimaggio G, 2008, CONSCIOUS COGN, V17, P778, DOI 10.1016/j.concog.2008.02.005; Dimaggio G, 2009, CONSCIOUS COGN, V18, P653, DOI 10.1016/j.concog.2009.06.003; EPSTEIN R, 1981, SCIENCE, V212, P695, DOI 10.1126/science.212.4495.695; Feinberg TE, 2005, CONSCIOUS COGN, V14, P661, DOI 10.1016/j.concog.2005.01.002; FENIGSTEIN A, 1975, J CONSULT CLIN PSYCH, V43, P522, DOI 10.1037/h0076760; FENIGSTEIN A, 1986, J PERS, V55, P543; Fink GR, 1996, J NEUROSCI, V16, P4275; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallagher HL, 2003, TRENDS COGN SCI, V7, P77, DOI 10.1016/S1364-6613(02)00025-6; Gallup G.G. Jr., 1975, P309; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GALLUP GG, 1982, AM J PRIMATOL, V2, P237, DOI 10.1002/ajp.1350020302; GALLUP GG, 1985, NEUROSCI BIOBEHAV R, V9, P631, DOI 10.1016/0149-7634(85)90010-7; Gallup GG, 2002, COGNITIVE ANIMAL, P325; GALLUP GG, 1979, AM SCI, V67, P417; Gallup GG, 1997, ANN NY ACAD SCI, V818, P73, DOI 10.1111/j.1749-6632.1997.tb48247.x; GALLUP GG, 1977, AM PSYCHOL, V32, P329, DOI 10.1037/0003-066X.32.5.329; GALLUP GG, 1968, PSYCHOL BULL, V70, P782, DOI 10.1037/h0026777; GALLUP GG, 1998, SCI AM           NOV; Garfield JL, 2001, MIND LANG, V16, P494, DOI 10.1111/1468-0017.00180; Gillihan SJ, 2005, PSYCHOL BULL, V131, P76, DOI 10.1037/0033-2909.131.1.76; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Guise K, 2007, HUM NATURE-INT BIOS, V18, P132, DOI 10.1007/s12110-007-9009-x; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gutchess AH, 2007, SOC NEUROSCI-UK, V2, P117, DOI 10.1080/17470910701399029; Heyes CM, 1998, BEHAV BRAIN SCI, V21, P101, DOI 10.1017/S0140525X98000703; Joireman J, 2004, SELF IDENTITY, V3, P225, DOI 10.1080/13576500444000038; Joireman JA, 2002, SELF IDENTITY, V1, P53, DOI 10.1080/152988602317232803; Kaplan JT, 2008, SOC COGN AFFECT NEUR, V3, P218, DOI 10.1093/scan/nsn014; Keenan J.P., 2003, FACE MIRROR SEARCH O; Keenan JP, 1999, NEUROPSYCHOLOGIA, V37, P1421, DOI 10.1016/S0028-3932(99)00025-1; Keenan JP, 2000, TRENDS COGN SCI, V4, P338, DOI 10.1016/S1364-6613(00)01521-7; Keenan JP, 2005, CORTEX, V41, P695, DOI 10.1016/S0010-9452(08)70286-7; Keenan JP, 2001, NATURE, V409, P305, DOI 10.1038/35053167; Keenan JP, 2001, BRAIN COGNITION, V47, P87; Keenan JP, 2007, CORTEX, V43, P1074, DOI 10.1016/S0010-9452(08)70705-6; Kelley WM, 2002, J COGNITIVE NEUROSCI, V14, P785, DOI 10.1162/08989290260138672; Kircher T., 2003, SELF NEUROSCIENCE PS; Klein SB, 2008, SOC COGNITION, V26, P766, DOI 10.1521/soco.2008.26.6.766; Langdon R, 2009, PSYCHOL MED, V39, P655, DOI 10.1017/S0033291708003978; Leary M. R., 2004, CURSE SELF SELF AWAR; Lee J, 2007, SCHIZOPHR RES, V94, P215, DOI 10.1016/j.schres.2007.03.032; McGuire PK, 1996, PSYCHOL MED, V26, P29, DOI 10.1017/S0033291700033699; Mead George Herbert, 1934, MIND SELF SOC STANDP; Milligan K, 2007, CHILD DEV, V78, P622, DOI 10.1111/j.1467-8624.2007.01018.x; MITCHELL RW, 1993, NEW IDEAS PSYCHOL, V11, P295, DOI 10.1016/0732-118X(93)90002-U; Mitchell RW, 1997, J THEOR SOC BEHAV, V27, P17, DOI 10.1111/1468-5914.00024; Mitchell RW, 2002, COGNITIVE ANIMAL, P345; Mitchell RW, 1997, ANN NY ACAD SCI, V818, P39, DOI 10.1111/j.1749-6632.1997.tb48245.x; MITCHELL RW, 2002, HDB SELF IDENTITY, P3; Morin A, 2005, J CONSCIOUSNESS STUD, V12, P115; Morin A, 2004, GENET SOC GEN PSYCH, V130, P197, DOI 10.3200/MONO.130.3.197-224; Morin A, 2002, CONSCIOUS COGN, V11, P396, DOI 10.1016/S1053-8100(02)00009-0; MORIN A, 1990, NEW IDEAS PSYCHOL, V8, P337, DOI 10.1016/0732-118X(94)90020-5; MORIN A, 1993, J MIND BEHAV, V14, P223; Morin A., 1993, REV QUEBECOISE PSYCH, V14, P3; Morin A., 2003, EVOL PSYCHOL-US, V1, P161, DOI DOI 10.1177/147470490300100113; Morin A, 2007, BRAIN RES BULL, V74, P387, DOI 10.1016/j.brainresbull.2007.06.013; Morin A, 2007, CORTEX, V43, P1068, DOI 10.1016/S0010-9452(08)70704-4; Morin A, 2006, CONSCIOUS COGN, V15, P358, DOI 10.1016/j.concog.2005.09.006; Morin A, 2009, CONSCIOUS COGN, V18, P524, DOI 10.1016/j.concog.2008.09.008; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; OJEMANN G, 1986, CAN PSYCHOL, V27, P158; Paulus MP, 2003, NEUROREPORT, V14, P1311, DOI 10.1097/01.wnr.0000078543.07662.02; Phan KL, 2004, CNS SPECTRUMS, V9, P258, DOI 10.1017/S1092852900009196; Platek SM, 2003, SCHIZOPHR RES, V65, P147, DOI 10.1016/S0920-9964(02)00494-2; Platek SM, 2004, COGNITIVE BRAIN RES, V19, P114, DOI 10.1016/j.cogbrainres.2003.11.014; Platek SM, 2004, CONSCIOUS COGN, V13, P197, DOI 10.1016/j.concog.2003.10.001; Platek SM, 2008, BRAIN RES, V1232, P173, DOI 10.1016/j.brainres.2008.07.010; Plotnik JM, 2006, P NATL ACAD SCI USA, V103, P17053, DOI 10.1073/pnas.0608062103; Povinelli DJ, 1996, CHILD DEV, V67, P1540, DOI 10.1111/j.1467-8624.1996.tb01813.x; Povinelli DJ, 1995, SELF INFANCY THEORY, P161, DOI DOI 10.1016/S0166-4115(05)80011-1; Preilowski B, 1977, Act Nerv Super (Praha), V19 Suppl 2, P343; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prior H, 2008, PLOS BIOL, V6, P1642, DOI 10.1371/journal.pbio.0060202; RAMACHANDRAN VS, 2007, EDGE 3 CULTURE  0108; Reiss D, 2001, P NATL ACAD SCI USA, V98, P5937, DOI 10.1073/pnas.101086398; Rosa C, 2008, BRAIN COGNITION, V68, P204, DOI 10.1016/j.bandc.2008.04.007; Rusalova M N, 2005, Neurosci Behav Physiol, V35, P821, DOI 10.1007/s11055-005-0131-0; Salzen EA, 1998, APPL ANIM BEHAV SCI, V57, P299, DOI 10.1016/S0168-1591(98)00104-X; Schilbach L, 2008, CONSCIOUS COGN, V17, P457, DOI 10.1016/j.concog.2008.03.013; Schilhab TSS, 2004, BIOL PHILOS, V19, P111, DOI 10.1023/B:BIPH.0000013249.23475.1f; Schneider JF, 2005, PSYCHOL REP, V96, P387; Seger CA, 2004, NEUROPSYCHOLOGIA, V42, P1168, DOI 10.1016/j.neuropsychologia.2004.02.003; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; SIEGRIST M, 1995, PSYCHOL REP, V76, P259, DOI 10.2466/pr0.1995.76.1.259; Silani G, 2008, SOC NEUROSCI-UK, V3, P97, DOI 10.1080/17470910701577020; SPERRY RW, 1979, NEUROPSYCHOLOGIA, V17, P153, DOI 10.1016/0028-3932(79)90006-X; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; SUAREZ SD, 1981, J HUM EVOL, V10, P175, DOI 10.1016/S0047-2484(81)80016-4; Sugiura M, 2006, NEUROIMAGE, V32, P1905, DOI 10.1016/j.neuroimage.2006.05.026; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; Taylor J. B., 2006, MY STROKE INSIGHT BR; Trapnell PD, 1999, J PERS SOC PSYCHOL, V76, P284, DOI 10.1037/0022-3514.76.2.284; Turk DJ, 2002, NAT NEUROSCI, V5, P841, DOI 10.1038/nn907; Uddin LQ, 2005, CONSCIOUS COGN, V14, P633, DOI 10.1016/j.concog.2005.01.008; Uddin LQ, 2007, TRENDS COGN SCI, V11, P153, DOI 10.1016/j.tics.2007.01.001; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Wicker B, 2003, BRAIN RES REV, V43, P224, DOI 10.1016/j.brainresrev.2003.08.003; Wicklund, 1972, THEORY OBJECTIVE SEL; Zhu Y, 2007, NEUROIMAGE, V34, P1310, DOI 10.1016/j.neuroimage.2006.08.047	118	26	27	2	65	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1357-650X	1464-0678		LATERALITY	Laterality		2011	16	3					367	383	PII 929082268	10.1080/13576501003702648			17	Psychology, Multidisciplinary; Psychology, Experimental	Psychology	753PL	WOS:000289791900008	21049317				2021-06-18	
J	Wallace, SE; Hux, K; Beukelman, DR				Wallace, Sarah E.; Hux, Karen; Beukelman, David R.			Navigation of a Dynamic Screen AAC Interface by Survivors of Severe Traumatic Brain Injury	AUGMENTATIVE AND ALTERNATIVE COMMUNICATION			English	Article							SYSTEMS; SYMBOLS; ADULTS; DISCOURSE; APHASIA	The researchers examined the effect of cognitive flexibility, image contextualization, and prompt type on accuracy and speed when adults with severe traumatic brain injury (TBI) navigated dynamic screen augmentative and alternative communication (AAC) interfaces. Eighteen participants formed two groups based on cognitive flexibility status. Given matching informative versus uninformative prompts and three image contextualization conditions, participants located words on 3-level AAC systems. ANOVA computations revealed differences between groups and between prompt types for navigation accuracy; differences occurred among image conditions and between prompt types for navigation speed. Analyses using responses from participants with cognitive flexibility challenges revealed inter-subject variability regarding error types. Overall, findings suggest cognitive flexibility may predict who may and may not need explicit training to master AAC device navigation.</.	[Wallace, Sarah E.] Duquesne Univ, Dept Speech Language Pathol, Pittsburgh, PA 15282 USA; [Hux, Karen; Beukelman, David R.] Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, Lincoln, NE USA	Wallace, SE (corresponding author), Duquesne Univ, Dept Speech Language Pathol, 410 Fisher Hall,600 Forbes Ave, Pittsburgh, PA 15282 USA.	wallaces@duq.edu	Hux, Karen/AAQ-2078-2020	Wallace, Sarah E./0000-0003-4085-9250			American Speech-Language-Hearing Association (ASHA), 2005, ASHA S, V25, P1; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BLOOMBERG K, 1990, J SPEECH HEAR RES, V33, P717, DOI 10.1044/jshr.3304.717; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Burke R, 2004, BRAIN INJURY, V18, P497, DOI 10.1080/02699050310001645784; Callaghan TC, 1999, CHILD DEV, V70, P1314, DOI 10.1111/1467-8624.00096; Campbell L, 2002, ADV SPEECH LANG PATH, V4, P89; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Demasco P, 1994, Assist Technol, V6, P10; Dietz A., 2006, PERSPECTIVES AUGMENT, V15, P13, DOI [10.1044/aac15.1.13, DOI 10.1044/AAC15.1.13]; Doyle M, 2000, AUG ALTER COMMUN SER, P271; Fager S, 2006, AUGMENT ALTERN COMM, V22, P37, DOI 10.1080/07434610500243990; FAGER S, 2007, AUGMENTATIVE COMMUNI, P317; Fried-Oken M, 1992, J HEAD TRAUMA REHAB, V7, P59, DOI DOI 10.1097/00001199-199209000-00008; Hagen C, 2000, TBI REH MAN CAR ENV; HELMESTABROOKS N, 2001, CLQT COGNITIVE LINGU; Heuer S, 2007, APHASIOLOGY, V21, P883, DOI 10.1080/02687030600695194; Hux K, 2003, ASSISTING SURVIVORS OF TRAUMATIC BRAIN INJURY, P93; HUX K, 1993, J MED SPEECH-LANG PA, V1, P121; Hux K, 2008, J MED SPEECH-LANG PA, V16, P83; Kertesz A., 2007, W APHASIA BATTERY RE; Lacy S, 1996, JOURNALISM MASS COMM, V73, P963, DOI 10.1177/107769909607300414; Ladtkow Margaret, 1993, Seminars in Speech and Language, V14, P61, DOI 10.1055/s-2008-1064159; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; Light J., 1991, AUGMENTATIVE ALTERNA, V7, DOI [10.1080/07434619112331275893, DOI 10.1080/07434619112331275893]; Light J, 2007, AUGMENT ALTERN COMM, V23, P204, DOI 10.1080/07434610701553635; LLOYD LL, 1984, J MENT DEFIC RES, V28, P3; LOFTUS GR, 1982, ESSENCE STAT; McKelvey ML, 2010, AM J SPEECH-LANG PAT, V19, P22, DOI 10.1044/1058-0360(2009/08-0021); MCNAUGHTON S, 1993, TOP LANG DISORD, V13, P58, DOI 10.1097/00011363-199302000-00007; MIRENDA P, 1989, AUGMENTATIVE ALTERNA, V5, P3, DOI DOI 10.1080/07434618912331274916; MIZUKO M, 1989, J SPEECH HEAR DISORD, V54, P627, DOI 10.1044/jshd.5404.627; Rowland C., 2003, COMMUNICATIVE COMPET, P241; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sohlberg M. M., 2001, COGNITIVE REHABILITA; THOMAS K, 2007, TEX SPEECH LANG HEAR; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th	40	26	26	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0743-4618	1477-3848		AUGMENT ALTERN COMM	Augment. Altern. Commun.	DEC	2010	26	4					242	254		10.3109/07434618.2010.521895			13	Audiology & Speech-Language Pathology; Rehabilitation	Audiology & Speech-Language Pathology; Rehabilitation	684GO	WOS:000284538600004	20979429				2021-06-18	
J	Kang, CE; Clarkson, R; Tator, CH; Yeung, IWT; Shoichet, MS				Kang, Catherine E.; Clarkson, Richard; Tator, Charles H.; Yeung, Ivan W. T.; Shoichet, Molly S.			Spinal Cord Blood Flow and Blood Vessel Permeability Measured by Dynamic Computed Tomography Imaging in Rats after Localized Delivery of Fibroblast Growth Factor	JOURNAL OF NEUROTRAUMA			English	Article						blood flow; growth factors; computed tomography scanning; traumatic spinal cord injury	BRAIN-BARRIER; NONINVASIVE MEASUREMENT; ENDOTHELIAL-CELLS; CONTUSION INJURY; PERFUSION CT; ANGIOGENESIS; HYALURONAN; NEOVASCULARIZATION; OLIGOSACCHARIDES; RECOMMENDATIONS	Following spinal cord injury, profound vascular changes lead to ischemia and hypoxia of spinal cord tissue. Since fibroblast growth factor 2 (FGF2) has angiogenic effects, its delivery to the injured spinal cord may attenuate the tissue damage associated with ischemia. To limit systemic mitogenic effects, FGF2 was delivered to the spinal cord via a gel of hyaluronan and methylcellulose (HAMC) injected into the intrathecal space, and compared to controls receiving HAMC alone and artificial cerebrospinal fluid (aCSF) alone. Dynamic perfusion computed tomography (CT) was employed for the first time in small animals to serially measure blood flow and permeability in the injured and uninjured spinal cord. Spinal cord blood flow (SCBF) and permeability-surface area (PS) measurements were obtained near the injury epicenter, and at two regions rostral to the epicenter in animals that received a 26-g clip compression injury. As predicted, SCBF measurements decreased and PS increased after injury. FGF2 delivered via HAMC after injury restored SCBF towards pre-injury values in all regions, and increased blood flow rates at 7 days post-injury compared to pre-injury measurements. PS was stabilized at regions rostral to the epicenter of injury when FGF2 was delivered with HAMC, with significantly lower values than aCSF controls at 7 days in the region farthest from the epicenter. Laminin staining for blood vessels showed a qualitative increase in vessel density after 7 days when FGF2 was locally delivered. Additionally, permeability stains showed that FGF2 moderately decreased permeability at 7 days post-injury. These data demonstrate that localized delivery of FGF2 improves spinal cord hemodynamics following injury, and that perfusion CT is an important technique to serially measure these parameters in small animal models of spinal cord injury.	[Kang, Catherine E.; Shoichet, Molly S.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada; [Yeung, Ivan W. T.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada; [Shoichet, Molly S.] Univ Toronto, Dept Chem, Toronto, ON M5S 1A1, Canada; [Kang, Catherine E.; Shoichet, Molly S.] Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Clarkson, Richard; Yeung, Ivan W. T.] Princess Margaret Hosp, Univ Hlth Network, Dept Radiat Phys, Toronto, ON M4X 1K9, Canada; [Tator, Charles H.] Univ Toronto, Krembil Neurosci Ctr, Toronto Western Res Inst, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Dept Surg, Toronto, ON, Canada	Shoichet, MS (corresponding author), Donnelly Ctr, 160 Coll St,Room 514, Toronto, ON M5S 3E1, Canada.	molly.shoichet@utoronto.ca			Canadian Institute for Health ResearchCanadian Institutes of Health Research (CIHR)	The authors are indebted to Peter Poon for all of his surgical and technical assistance with these studies. The authors would also like to thank Sunmo Kim and Nicolas Gonzalez for fruitful discussions regarding perfusion CT modeling and measurements. We acknowledge funding from the Canadian Institute for Health Research (to M.S.S. and C.H.T.).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; BECK DW, 1984, J NEUROPATH EXP NEUR, V43, P219, DOI 10.1097/00005072-198405000-00001; Bendfeldt K, 2007, J NEUROSCI, V27, P3260, DOI 10.1523/JNEUROSCI.4033-06.2007; Bisdas S, 2008, EUR RADIOL, V18, P2321, DOI 10.1007/s00330-008-0973-2; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; Fehlings MG, 2001, SPINE, V26, pS56, DOI 10.1097/00007632-200112151-00012; GUHA A, 1989, STROKE, V20, P372, DOI 10.1161/01.STR.20.3.372; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hamann MCJ, 2003, EXP NEUROL, V182, P300, DOI 10.1016/S0014-4886(03)00040-2; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; Hayashi Y, 1997, GLIA, V19, P13, DOI 10.1002/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B; Hebel R., 1986, ANATOMY EMBRYOLOGY L; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Kang CE, 2009, TISSUE ENG PT A, V15, P595, DOI 10.1089/ten.tea.2007.0349; KANG CE, 2009, J CONTROLLE IN PRESS; KETY SS, 1951, PHARMACOL REV, V3, P1; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Lee TT, 1999, J NEUROTRAUM, V16, P347, DOI 10.1089/neu.1999.16.347; LEES VC, 1995, LAB INVEST, V73, P259; Leggett D A, 1998, Australas Radiol, V42, P335, DOI 10.1111/j.1440-1673.1998.tb00533.x; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Miles KA, 2000, ACAD RADIOL, V7, P840, DOI 10.1016/S1076-6332(00)80632-7; Miles KA, 1998, BRIT J RADIOL, V71, P276, DOI 10.1259/bjr.71.843.9616236; MILES KA, 1991, BRIT J RADIOL, V64, P409, DOI 10.1259/0007-1285-64-761-409; MILES KA, 1993, RADIOLOGY, V188, P405, DOI 10.1148/radiology.188.2.8327686; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; Murakami M, 2008, CURR OPIN HEMATOL, V15, P215, DOI 10.1097/MOH.0b013e3282f97d98; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PETERS AM, 1987, CARDIOVASC RES, V21, P830, DOI 10.1093/cvr/21.11.830; PETERS AM, 1987, NUCL MED COMMUN, V8, P823, DOI 10.1097/00006231-198710000-00009; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; PRESTI D, 1994, CELL BIOCHEM FUNCT, V12, P281, DOI 10.1002/cbf.290120409; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; *REEV FDN CD, 2009, ON DEGR SEP PAR SPIN; Relf M, 1997, CANCER RES, V57, P963; Reuss B, 2003, J NEUROSCI, V23, P6404; Rivlin A S, 1978, Surg Neurol, V10, P38; SANDLER AN, 1976, BRAIN RES, V118, P181, DOI 10.1016/0006-8993(76)90707-1; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; Tateishi U, 2001, J COMPUT ASSIST TOMO, V25, P23, DOI 10.1097/00004728-200101000-00004; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Toda H, 2008, J PHYSIOL SCI, V58, P263, DOI 10.2170/physiolsci.RP005008; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; Wu XH, 2007, J NEUROTRAUM, V24, P1502, DOI 10.1089/neu.2006.0228; YEUNG WTI, 1994, J NEURO-ONCOL, V18, P53, DOI 10.1007/BF01324604; Yi CA, 2004, RADIOLOGY, V233, P191, DOI 10.1148/radiol.2331031535; Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841	52	26	27	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2041	2053		10.1089/neu.2010.1345			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500011	20799884				2021-06-18	
J	Norwood, KW; DeBoer, MD; Gurka, MJ; Kuperminc, MN; Rogol, AD; Blackman, JA; Wamstad, JB; Buck, ML; Patrick, PD				Norwood, Kenneth W.; DeBoer, Mark D.; Gurka, Matthew J.; Kuperminc, Michelle N.; Rogol, Alan D.; Blackman, James A.; Wamstad, Julia B.; Buck, Marcia L.; Patrick, Peter D.			Traumatic Brain Injury in Children and Adolescents: Surveillance for Pituitary Dysfunction	CLINICAL PEDIATRICS			English	Article						Growth hormone; traumatic brain injury; pituitary; pediatric	GROWTH-HORMONE; BODY-COMPOSITION; GH REPLACEMENT; LONG-TERM; HIGH-RISK; HYPOPITUITARISM; DEFICIENCY; SURVIVORS; MASS	Background. Children who sustain traumatic brain injury (TBI) are at risk for developing hypopituitarism, of which growth hormone deficiency (GHD) is the most common manifestation. Objective. To determine the prevalence of GHD and associated features following TBI among children and adolescents. Study design. A total of 32 children and adolescents were recruited from a pediatric TBI clinic. Participants were diagnosed with GHD based on insufficient growth hormone release during both spontaneous overnight testing and following arginine/glucagon administration. Results. GHD was diagnosed in 5/32 participants (16%). Those with GHD exhibited more rapid weight gain following injury than those without GHD and had lower levels of free thyroxine and follicle-stimulating hormone. Males with GHD had lower testosterone levels. Conclusions. GHD following TBI is common in children and adolescents, underscoring the importance of assessing for GHD, including evaluating height and weight velocities after TBI. Children and adolescents with GHD may further exhibit absence or intermediate function for other pituitary hormones.	[Norwood, Kenneth W.; DeBoer, Mark D.; Gurka, Matthew J.; Kuperminc, Michelle N.; Rogol, Alan D.; Blackman, James A.; Wamstad, Julia B.; Buck, Marcia L.; Patrick, Peter D.] Univ Virginia, Charlottesville, VA USA; [Rogol, Alan D.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA	Patrick, PD (corresponding author), POB 800386, Charlottesville, VA 22908 USA.	pdp2n@virginia.edu	Rogol, A.D./H-5871-2019	Rogol, A.D./0000-0002-7526-3142	Commonwealth Neurotrauma Initiative Trust [07-302]; General Clinical Research Center, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00847, HD060739-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD060739] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000847] Funding Source: NIH RePORTER	This study was funded by Commonwealth Neurotrauma Initiative Trust Fund, administered by VA Dept. of Rehabilitative Services, Grant #07-302; General Clinical Research Center Grant M01 RR00847 (to UVA) NIH HD060739-01 (MDD).	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; [Anonymous], 2000, J CLIN ENDOCR METAB, V85, P3990, DOI [https://doi.org/10.1210/jcem.85.11.6984, DOI 10.1210/jcem.85.11.6984]; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Boot AM, 1997, J CLIN ENDOCR METAB, V82, P2423, DOI 10.1210/jc.82.8.2423; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Gleeson H, 2007, CLIN ENDOCRINOL, V66, P466, DOI 10.1111/j.1365-2265.2007.02753.x; Hulthen L, 2001, J CLIN ENDOCR METAB, V86, P4765, DOI 10.1210/jc.86.10.4765; Juul A, 2002, HORM RES, V58, P233, DOI 10.1159/000066265; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE YJ, 1994, RAPID COMMUN MASS SP, V8, P571, DOI 10.1002/rcm.1290080714; Lustig Robert H, 2008, Pediatr Endocrinol Rev, V6, P220; Monson JP, 2003, EUR J ENDOCRINOL, V148, pS9, DOI 10.1530/eje.0.148S009; Moon RJ, 2009, ARCH DIS CHILD, V94, P699, DOI 10.1136/adc.2008.145235; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Roemmich JN, 2005, METABOLISM, V54, P1374, DOI 10.1016/j.metabol.2005.04.029; Roemmich JN, 2001, METABOLISM, V50, P537, DOI 10.1053/meta.2001.22510; Rose SR, 1996, J CLIN ENDOCR METAB, V81, P1063, DOI 10.1210/jc.81.3.1063; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476	30	26	26	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	NOV	2010	49	11					1044	1049		10.1177/0009922810376234			6	Pediatrics	Pediatrics	662OA	WOS:000282815700006	20724335	Green Accepted			2021-06-18	
J	Cook, NL; Vink, R; Helps, SC; Manavis, J; van den Heuvel, C				Cook, Naomi L.; Vink, Robert; Helps, Stephen C.; Manavis, Jim; van den Heuvel, Corinna			Transient Receptor Potential Melastatin 2 Expression is Increased Following Experimental Traumatic Brain Injury in Rats	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Real-time PCR; Reference genes; Transient receptor potential melastatin 2; mRNA quantification; Immunohistochemistry	HYDROGEN-PEROXIDE; CALCIUM INFLUX; OXIDATIVE STRESS; CATION CURRENTS; TRPM2 CHANNELS; PCR DATA; LTRPC2; MODEL; SUSCEPTIBILITY; VARIANT	Traumatic brain injury (TBI) elicits a sequence of complex biochemical changes including oxidative stress, oedema, inflammation and excitotoxicity. These factors contribute to the high morbidity and mortality following TBI, although their underlying molecular mechanisms remain poorly understood. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel, highly expressed in the brain and immune cells. Recent studies have implicated TRPM2 channels in processes involving oxidative stress, inflammation and cell death. However, no studies have investigated the role of TRPM2 in TBI pathophysiology. In the present study, we have characterised TRPM2 mRNA and protein expression following experimental TBI. Adult male Sprague Dawley rats were injured using the impact-acceleration model of diffuse TBI with survival times between 5 and 5 days. Real-time RT-PCR (including reference gene validation studies) and semi-quantitative immunohistochemistry were used to quantify TRPM2 mRNA and protein levels, respectively, following TBI. Significant increases in TRPM2 mRNA and protein expression were observed in the cerebral cortex and hippocampus of injured animals, suggesting that TRPM2 may contribute to TBI injury processes such as oxidative stress, inflammation and neuronal death. Further characterisation of how TRPM2 may contribute to TBI pathophysiology is warranted.	[van den Heuvel, Corinna] Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia; [Cook, Naomi L.; Vink, Robert; Helps, Stephen C.; Manavis, Jim; van den Heuvel, Corinna] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia	van den Heuvel, C (corresponding author), Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019; Cook, Naomi L/P-1223-2019; Cook, Naomi L/B-2536-2012	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Cook, Naomi L/0000-0002-1830-2432; Cook, Naomi L/0000-0002-1830-2432; , Corinna/0000-0003-0664-8935	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	Naomi Cook is a grateful recipient of a postgraduate scholarship from the National Health and Medical Research Council of Australia.	Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cappelli K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-49; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; DONKIN JJ, 2009, J CEREB BLOOD F 0513, P1; Fleig A, 2004, TRENDS PHARMACOL SCI, V25, P633, DOI 10.1016/j.tips.2004.10.004; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fonfria E, 2006, J RECEPT SIG TRANSD, V26, P179, DOI 10.1080/10799890600637522; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2006, BIOCHEM J, V398, P225, DOI 10.1042/BJ20060183; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Hermosura MC, 2008, P NATL ACAD SCI USA, V105, P18029, DOI 10.1073/pnas.0808218105; Kaneko S, 2006, J PHARMACOL SCI, V101, P66, DOI 10.1254/jphs.FP0060128; Kraft R, 2004, AM J PHYSIOL-CELL PH, V286, pC129, DOI 10.1152/ajpcell.00331.2003; Kuhn FJP, 2005, PFLUG ARCH EUR J PHY, V451, P212, DOI 10.1007/s00424-005-1446-y; Lange I, 2008, CELL CALCIUM, V44, P604, DOI 10.1016/j.ceca.2008.05.001; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Olah ME, 2009, J PHYSIOL-LONDON, V587, P965, DOI 10.1113/jphysiol.2008.162289; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Perez R, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-79; Perraud AL, 2004, MOL IMMUNOL, V41, P657, DOI 10.1016/j.molimm.2004.04.013; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Roth P, 2000, Crit Care Nurs Q, V23, P14; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Starkus J, 2007, J GEN PHYSIOL, V130, P427, DOI 10.1085/jgp.200709836; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Xu C, 2009, BIPOLAR DISORD, V11, P1, DOI 10.1111/j.1399-5618.2008.00655.x; Yamamoto S, 2008, NAT MED, V14, P738, DOI 10.1038/nm1758; Yang XR, 2006, AM J PHYSIOL-LUNG C, V290, pL1267, DOI 10.1152/ajplung.00515.2005; Zhang W, 2003, J BIOL CHEM, V278, P16222, DOI 10.1074/jbc.M300298200	48	26	26	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	OCT	2010	42	2					192	199		10.1007/s12031-010-9347-8			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	636BL	WOS:000280702700009	20309649				2021-06-18	
J	Akyuz, M; Ucar, T; Acikbas, C; Kazan, S; Yilmaz, M; Tuncer, R				Akyuz, Mahmut; Ucar, Tanju; Acikbas, Cem; Kazan, Saim; Yilmaz, Murat; Tuncer, Recai			Effect of Early Bilateral Decompressive Craniectomy on Outcome for Severe Traumatic Brain Injury	TURKISH NEUROSURGERY			English	Article						Severe traumatic brain injury; Decompressive craniectomy; Intracranial pressure	CEREBRAL HEMISPHERIC STROKE; SEVERE HEAD-INJURY; SURGICAL DECOMPRESSION; MASS LESION; BLOOD-FLOW; MANAGEMENT; PRESSURE; INFARCTION; EDEMA; HEMORRHAGE	AIM: Debate continues as to whether decompressive craniectomy (DC) is an effective treatment for severe traumatic brain injury (STBI). DC is mostly used as a second tier treatment option. The aim of this study was determined whether early bilateral DC is effective as a first tier treatment option in patients with STBI. MATERIAL and METHODS: The study compared two groups. Group 1 comprised 36 STBI patients for whom control of intracranial pressure (ICP) was not achieved with conservative treatment methods according to radiological and neurological findings. These patients underwent bilateral or unilateral DC as a second tier treatment. Group 2 comprised 40 STBI patients who underwent early bilateral DC as a first tier treatment. RESULTS: Group 2 patients had a mean better outcome than Group 1patients, especially for patients with a GCS 6-8. Postoperative ICP was lower in Group 2 patients than Group 1 patients. CONCLUSION: This study indicates that early bilateral DC can be effective for controlling ICP in STBI patients. It is likely the favorable outcome results for Group 2 patients reflects the relatively short time between trauma and surgery. Therefore, these data indicate early bilateral DC can be considered as a first tier treatment in STBI patients.	[Akyuz, Mahmut; Ucar, Tanju; Acikbas, Cem; Kazan, Saim; Tuncer, Recai] Akdeniz Univ, Fac Med, Dept Neurosurg, TR-07058 Antalya, Turkey; [Yilmaz, Murat] Akdeniz Univ, Fac Med, Anesthesiol & Intens Care Unit, TR-07058 Antalya, Turkey	Akyuz, M (corresponding author), Akdeniz Univ, Fac Med, Dept Neurosurg, TR-07058 Antalya, Turkey.	mahmutakyuz@akdeniz.edu.tr	tuncer, mehmet recai/C-6969-2016; Kazan, Saim/G-1782-2016; Yilmaz, Murat/I-6629-2017		Akdeniz University Research FoundationAkdeniz University	This study was supported by the Akdeniz University Research Foundation.	Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; Engelhorn T, 1999, STROKE, V30, P1456, DOI 10.1161/01.STR.30.7.1456; GAAB MR, 1990, ACT NEUR S, V51, P326; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; IVAMOTO HS, 1974, STROKE, V5, P365, DOI 10.1161/01.STR.5.3.365; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; KONDZIOLKA D, 1988, NEUROSURGERY, V23, P143, DOI 10.1227/00006123-198808000-00002; Kunze E, 1998, ACT NEUR S, V71, P16; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Wolfla CE, 1997, J NEUROSURG, V86, P505, DOI 10.3171/jns.1997.86.3.0505; Wolfla CE, 1996, J NEUROSURG, V84, P642, DOI 10.3171/jns.1996.84.4.0642; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YONAS H, 1990, J NEUROSURG, V73, P266, DOI 10.3171/jns.1990.73.2.0266; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	32	26	31	3	12	TURKISH NEUROSURGICAL SOC	BAHCELIEVLER	TASKENT CADDESI 13-4, BAHCELIEVLER, ANKARA 06500, TURKEY	1019-5149			TURK NEUROSURG	Turk. Neurosurg.	JUL	2010	20	3					382	389					8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	634DC	WOS:000280558700015	20669113	Bronze			2021-06-18	
J	Bombardier, CH; Ehde, DM; Stoelb, B; Molton, IR				Bombardier, Charles H.; Ehde, Dawn M.; Stoelb, Brenda; Molton, Ivan R.			The Relationship of Age-Related Factors to Psychological Functioning Among People With Disabilities	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Multiple sclerosis; Growth; Aging; Depression	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; SELF-RATED HEALTH; MULTIPLE-SCLEROSIS; POSTTRAUMATIC GROWTH; MAJOR DEPRESSION; PERCEIVED BENEFIT; POSITIVE CHANGE; BREAST-CANCER; LIFE	The potential influence of age and aging on the psychological functioning of people with disabilities is surprisingly complex. In people with spinal cord injury or multiple sclerosis, depression is highly prevalent. The limited research in this area indicates that older age and greater time span since disability onset may be associated with less self-reported depressive symptoms. Posttraumatic growth (PTG) and benefit finding (BF) are also common in people with disabilities. Older age tends to be associated with less BF and PTG. Studies that use longitudinal designs and examine multiple age-related factors simultaneously are needed. Potential mediators of age-related effects, such as historical trends, life-cycle events, maturity, and declining health, also need to be examined. There are many interesting theoretic and empiric concepts from aging research that can inform future research on the psychological aspects of aging with disability.	[Bombardier, Charles H.; Ehde, Dawn M.; Molton, Ivan R.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; [Stoelb, Brenda] Talaria Inc, Seattle, WA 98122 USA; [Molton, Ivan R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, 325 9th Ave,Box 359612, Seattle, WA 98104 USA.	chb@uw.edu	Ehde, Dawn/K-1883-2016	Ehde, Dawn/0000-0002-9555-2347	Department of Education, National Institute on Disability and Rehabilitation Research [H133B080024]	This research was supported, in part, by a grant from the Department of Education, National Institute on Disability and Rehabilitation Research (H133B080024). The contents of this article do not necessarily represent the policy of the Department of Education and the reader should not assume endorsement by the Federal Government.	Albright KJ, 2008, REHABIL PSYCHOL, V53, P400, DOI 10.1037/a0013040; Alexopoulos GS, 2008, INT J GERIATR PSYCH, V23, P782, DOI 10.1002/gps.1988; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arnett P, 2005, MULT SCLER J, V11, P328, DOI 10.1191/1352458505ms1162oa; Arnett PA, 2006, J NEUROL NEUROSUR PS, V77, P606, DOI 10.1136/jnnp.2004.047712; Bamer AM, 2008, GEN HOSP PSYCHIAT, V30, P311, DOI 10.1016/j.genhosppsych.2008.04.006; Beal CC, 2007, ARCH PSYCHIAT NURS, V21, P181, DOI 10.1016/j.apnu.2007.02.008; Beiske AG, 2008, EUR J NEUROL, V15, P239, DOI 10.1111/j.1468-1331.2007.02041.x; Bellizzi KM, 2004, INT J AGING HUM DEV, V58, P267, DOI 10.2190/DC07-CPVW-4UVE-5GK0; Benyamini Y, 1999, RES AGING, V21, P392, DOI 10.1177/0164027599213002; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P33, DOI 10.1111/j.1600-0447.1988.tb08545.x; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Caine ED, 1994, DIAGNOSIS TREATMENT, P21; Calhoun L. G., 1998, POSTTRAUMATIC GROWTH; Carstensen LL, 1999, AM PSYCHOL, V54, P165, DOI 10.1037/0003-066X.54.3.165; Cetin K, 2007, MULT SCLER, V13, P1046, DOI 10.1177/1352458507077864; Charlifue S, 2004, ARCH PHYS MED REHAB, V85, P1848, DOI 10.1016/j.apmr.2004.03.017; Charlifue S, 2004, NEUROREHABILITATION, V19, P15; Charlifue SW, 1999, ARCH PHYS MED REHAB, V80, P1429, DOI 10.1016/S0003-9993(99)90254-X; Chwalisz K, 2008, REHABIL PSYCHOL, V53, P387, DOI 10.1037/a0012998; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; Chwastiak LA, 2007, PSYCHIAT CLIN N AM, V30, P803, DOI 10.1016/j.psc.2007.07.003; Cole MG, 1996, INT J GERIATR PSYCH, V11, P157, DOI 10.1002/(SICI)1099-1166(199602)11:2<157::AID-GPS304>3.0.CO;2-S; Cole MG, 1999, AM J PSYCHIAT, V156, P1182; Cordova MJ, 2001, HEALTH PSYCHOL, V20, P176, DOI 10.1037//0278-6133.20.3.176; Dalton EJ, 2005, NEUROPSYCHOLOGY, V19, P152, DOI 10.1037/0894-4105.19.2.152; Davis CG, 1998, J PERS SOC PSYCHOL, V75, P561, DOI 10.1037/0022-3514.75.2.561; Diener E, 1997, ANN REV GERONTOLOGY; Ehde DM, 2006, TRAUMA REHABILITATION, P245; Ehde Dawn M, 2005, Phys Med Rehabil Clin N Am, V16, P437, DOI 10.1016/j.pmr.2005.01.010; Ehde DM., 2009, HDB REHABILITATION P, P417; Elliott T. R., 2002, HDB POSITIVE PSYCHOL, P687; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Evers AWM, 2001, J CONSULT CLIN PSYCH, V69, P1026, DOI 10.1037//0022-006X.69.6.1026; First M.B., 1996, STRUCTURED CLIN INTE; FISKE A, 1998, COMPREHENSIVE CLIN P, V7, P193; Frazier P, 2001, J CONSULT CLIN PSYCH, V69, P1048, DOI 10.1037//0022-006X.69.6.1048; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; Galeazzi GM, 2005, NEUROL SCI, V26, P255, DOI 10.1007/s10072-005-0468-8; Glass CA, 1997, SPINAL CORD, V35, P349, DOI 10.1038/sj.sc.3100448; Hawley CA, 2008, BRAIN INJURY, V22, P427, DOI 10.1080/02699050802064607; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; Hitzig SL, 2008, AM J PHYS MED REHAB, V87, P545, DOI 10.1097/PHM.0b013e31817c16d6; Holicky R, 1999, DISABIL REHABIL, V21, P250; Idler EL, 2003, GERONTOLOGIST, V43, P372, DOI 10.1093/geront/43.3.372; Joseph S, 2006, CLIN PSYCHOL REV, V26, P1041, DOI 10.1016/j.cpr.2005.12.006; Kalpakjian CZ, 2009, J SPINAL CORD MED, V32, P6, DOI 10.1080/10790268.2009.11760748; Kasl-Godley JE, 1998, CLINICAL GEROPSYCHOLOGY, P211, DOI 10.1037/10295-019; Kemp BJ, 1999, DISABIL REHABIL, V21, P241; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Krause JS, 2008, ARCH PHYS MED REHAB, V89, P1482, DOI 10.1016/j.apmr.2007.11.062; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Laidlaw K, 2008, INT J GERIATR PSYCH, V23, P843, DOI 10.1002/gps.1993; Lechner SC, 2008, TRAUMA RECOVERY GROW, P207; Lenze Eric J, 2008, Dialogues Clin Neurosci, V10, P419; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; LYONS JA, 2008, TRAUMA RECOVERY GROW, P233; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; MCMILLEN C, 1995, J CONSULT CLIN PSYCH, V63, P1037, DOI 10.1037/0022-006X.63.6.1037; McMillen JC, 1997, J CONSULT CLIN PSYCH, V65, P733, DOI 10.1037/0022-006X.65.5.733; McMillen JC, 2003, REHABIL PSYCHOL, V48, P77, DOI 10.1037/0090-5550.48.2.77; Milam J, 2005, TRAUMATOLOGY, V11, P233, DOI DOI 10.1177/153476560501100404; Milam JE, 2004, J ADOLESCENT RES, V19, P192, DOI 10.1177/0743558403258273; Mohr DC, 2007, MULT SCLER J, V13, P215, DOI 10.1177/1352458506070926; NEWMANN JP, 1991, PSYCHOL AGING, V6, P212, DOI 10.1037/0882-7974.6.2.212; Oaksford K, 2005, REHABIL PSYCHOL, V50, P266, DOI 10.1037/0090-5550.50.3.266; Pakenham KI, 2005, HEALTH PSYCHOL, V24, P123, DOI 10.1037/0278-6133.24.2.123; Pargament KI, 1998, J SCI STUD RELIG, V37, P710, DOI 10.2307/1388152; Park C. L., 2005, TRAUMATOLOGY, V11, P297, DOI [10.1177/153476560501100408, DOI 10.1177/153476560501100408]; Park CL, 1996, J PERS, V64, P71, DOI 10.1111/j.1467-6494.1996.tb00815.x; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; Patten SB, 2000, MULT SCLER, V6, P115, DOI 10.1177/135245850000600210; Phillips LJ, 2008, J HOLIST NURS, V26, P41, DOI 10.1177/0898010107301870; Pollard C, 2007, BRIT J HEALTH PSYCH, V12, P347, DOI 10.1348/135910707X197046; Powell S, 2003, J CLIN PSYCHOL, V59, P71, DOI 10.1002/jclp.10117; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; PROHASKA TR, 1987, HEALTH PSYCHOL, V6, P495, DOI 10.1037/0278-6133.6.6.495; Richardson EJ, 2008, REHABIL PSYCHOL, V53, P243, DOI 10.1037/0090-5550.53.2.243; Rosenbach C, 2008, J BURN CARE RES, V29, P638, DOI 10.1097/BCR.0b013e31817de275; Saikkonen J, 2004, SPINAL CORD, V42, P459, DOI 10.1038/sj.sc.3101618; Schroots JJF, 1996, GERONTOLOGIST, V36, P742, DOI 10.1093/geront/36.6.742; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; Siegel K, 2000, SOC SCI MED, V51, P1543, DOI 10.1016/S0277-9536(00)00144-1; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; Teddlie C., 2009, FDN MIXED METHODS RE; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tennen H., 2002, HDB POSITIVE PSYCHOL, P584; Tsivgoulis G, 2007, ACTA NEUROL SCAND, V115, P67, DOI 10.1111/j.1600-0404.2006.00736.x; VANMARWIJK H, 1994, FAM PRACT, V11, P80; Weiss T, 2002, J PSYCHOSOC ONCOL, V20, P65, DOI 10.1300/J077v20n02_04; Wells K B, 1991, Psychiatr Med, V9, P503; Weston R, 2008, REHABIL PSYCHOL, V53, P340, DOI 10.1037/a0013039; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Wilhelm K, 2003, J AFFECT DISORDERS, V75, P155, DOI 10.1016/S0165-0327(02)00040-X; Williams RM, 2005, NEUROLOGY, V64, P75, DOI 10.1212/01.WNL.0000148480.31424.2A; WILLIAMSON GM, 1995, PSYCHOL AGING, V10, P369, DOI 10.1037/0882-7974.10.3.369; Yang Y, 2007, J HEALTH SOC BEHAV, V48, P16, DOI 10.1177/002214650704800102	98	26	27	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2010	21	2					281	+		10.1016/j.pmr.2009.12.005			19	Rehabilitation	Rehabilitation	613GC	WOS:000278966400005	20494277				2021-06-18	
J	Costa, T; Constantino, LC; Mendonca, BP; Pereira, JG; Herculano, B; Tasca, CI; Boeck, CR				Costa, Tayana; Constantino, Leandra C.; Mendonca, Bruna P.; Pereira, Josimar G.; Herculano, Bruno; Tasca, Carla I.; Boeck, Carina R.			N-Methyl-D-Aspartate Preconditioning Improves Short-Term Motor Deficits Outcome After Mild Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						NMDA preconditioning; neuroprotection; trauma brain injury; motor behavior	CEREBELLAR GRANULE CELLS; ISCHEMIC TOLERANCE; QUINOLINIC ACID; COGNITIVE DEFICITS; NMDA RECEPTORS; GLUTAMATE; MODEL; NEUROPROTECTION; TOXICITY; SEIZURES	Traumatic brain injury (TBI) causes impairment of fine motor functions in humans and nonhuman mammals that often persists for months after the injury occurs. Neuroprotective strategies for prevention of the seguelae of TBI and understanding the molecular mechanisms and cellular pathways are related to the glutamatergic system. It has been suggested that cellular damage subsequent to TBI is mediated by the excitatory neurotransmitters, glutamate and aspartate, through the excessive activation of the N-methyl-D-aspartate (NMDA) receptors. Thus, preconditioning with a low dose of NMDA was used as a strategy for protection against locomotor deficits observed after TBI in mice. Male adult mice CF-1 were preconditioned with NMDA (75 mg/kg) 24 hr before the TBI induction. Under anesthesia with O-2/N2O (33%: 66%) inhalation, the animals were subjected to the experimental model of trauma that occurs by the impact of a 25 g weight on the skull. Sensorimotor gating was evaluated at 1.5, 6, or 24 hr after TBI induction by using footprint and rotarod tests. Cellular damage also was assessed 24 hr after occurrence of cortical trauma. Mice preconditioned with NMDA were protected against all motor deficits revealed by footprint tests, but not those observed in rotarod tasks. Although mice showed motor deficits after TBI, no cellular damage was observed. These data corroborate the hypothesis that glutamatergic excitotoxicity, especially via NMDA receptors, contributes to severity of trauma. They also point to a putative neuroprotective mechanism induced by a sublethal dose of NMDA to improve motor behavioral deficits after TBI. (C) 2009 Wiley-Liss, Inc.	[Costa, Tayana; Constantino, Leandra C.; Mendonca, Bruna P.; Pereira, Josimar G.; Boeck, Carina R.] Univ Extremo Catarinense, Lab Neurociencias, PPGCS, Unidad Acad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil; [Herculano, Bruno; Tasca, Carla I.] Univ Fed Santa Catarina, Dept Bioquim, Ctr Ciencias Biol, Florianopolis, SC, Brazil	Boeck, CR (corresponding author), Univ Extremo Catarinense, Lab Neurociencias, PPGCS, Unidad Acad Ciencias Saude, BR-88806000 Criciuma, SC, Brazil.	cariboeck@hotmail.com	Boeck, Carina Rodrigues/E-9472-2011; Constantino, Leandra/H-8505-2018; Tasca, Carla Ines/AAB-8287-2019; Herculano, Bruno/N-4587-2019; Herculano, Bruno/F-8917-2018	Boeck, Carina Rodrigues/0000-0002-6828-5634; Constantino, Leandra/0000-0003-0523-4351; Tasca, Carla Ines/0000-0002-3414-6150; Herculano, Bruno/0000-0003-0095-3381; Herculano, Bruno/0000-0003-0095-3381	Brazilian National Council Research [478249/200C-3]; FAPESCFundacao de Amparo a Pesquisa e Inovacoo Estado de Santa Catarina (FAPESC) [12348/2007-0]; UNESC	Contract grant sponsor: Brazilian National Council Research (CNN): Contract grant number: 478249/200C-3; Contract grant sponsor: FAPESC; Contract grant number: 12348/2007-0 (to CRIB): Contract grant sponsor: UNESC.	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Billinger M, 1999, J AM COLL CARDIOL, V33, P1027, DOI 10.1016/S0735-1097(98)00674-3; Boeck CR, 2005, NEUROPHARMACOLOGY, V49, P17, DOI 10.1016/j.neuropharm.2005.01.024; Boeck CR, 2004, EPILEPSIA, V45, P745, DOI 10.1111/j.0013-9580.2004.65203.x; Bristow LJ, 1996, J PHARMACOL EXP THER, V277, P578; Carter RJ, 1999, J NEUROSCI, V19, P3248; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHUANG DM, 1992, MOL PHARMACOL, V42, P210; DAMSCHRODERWILLIAMS P, 1995, J NEUROCHEM, V65, P1069; Dietrich MO, 2005, ENVIRON TOXICOL PHAR, V19, P169, DOI 10.1016/j.etap.2004.07.004; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farlow MR, 2008, DRUG SAFETY, V31, P577, DOI 10.2165/00002018-200831070-00003; Ferguson AL, 2008, EUR J NEUROSCI, V28, P2084, DOI 10.1111/j.1460-9568.2008.06490.x; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GimenezLlort L, 1997, PHARMACOL BIOCHEM BE, V56, P549, DOI 10.1016/S0091-3057(96)00295-X; Grabb MC, 1999, J NEUROSCI, V19, P1657; Grusser-Cornehls U, 2001, PROG NEUROBIOL, V63, P489, DOI 10.1016/S0301-0082(00)00024-1; Jadhav V, 2007, SURG NEUROL, V67, P15, DOI 10.1016/j.surneu.2006.07.014; Jiang XY, 2003, ANN NY ACAD SCI, V993, P134, DOI 10.1111/j.1749-6632.2003.tb07522.x; Jonas W, 2001, NEUROREPORT, V12, P335, DOI 10.1097/00001756-200102120-00031; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Lin CH, 2008, EUR J PHARMACOL, V589, P85, DOI 10.1016/j.ejphar.2008.05.047; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MARINI AM, 1992, P NATL ACAD SCI USA, V89, P6555, DOI 10.1073/pnas.89.14.6555; Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Ogita K, 2003, J NEUROCHEM, V85, P1336, DOI 10.1046/j.1471-4159.2003.01778.x; Pagliaro P, 2001, LIFE SCI, V69, P1, DOI 10.1016/S0024-3205(01)01113-4; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rejdak R, 2001, POL J PHARMACOL, V53, P73; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rybnikova E, 2005, BEHAV BRAIN RES, V160, P107, DOI 10.1016/j.bbr.2004.11.023; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saleh MC, 2009, BRAIN RES, V1247, P212, DOI 10.1016/j.brainres.2008.10.014; SASAHIRA M, 1995, NEUROSCI LETT, V185, P95, DOI 10.1016/0304-3940(94)11233-9; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Sei Y, 1998, NEUROSCI LETT, V241, P180, DOI 10.1016/S0304-3940(97)00980-4; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Tauskela JS, 2003, AM J PHYSIOL-CELL PH, V285, pC899, DOI 10.1152/ajpcell.00110.2003; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Vandresen S, 2007, BRAIN RES, V1184, P38, DOI 10.1016/j.brainres.2007.09.091; Vohra HA, 2006, J SURG RES, V134, P138, DOI 10.1016/j.jss.2005.12.009; Willis C., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003986.PUB2; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; YANG GM, 1997, NEUROMETHODS, P47	59	26	26	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2010	88	6					1329	1337		10.1002/jnr.22300			9	Neurosciences	Neurosciences & Neurology	575ZK	WOS:000276112600017	19998488				2021-06-18	
J	Lange, RT; Sullivan, KA; Scott, C				Lange, Rae T.; Sullivan, Karen A.; Scott, Clinton			Comparison of MMPI-2 and PAI validity indicators to detect feigned depression and PTSD symptom reporting	PSYCHIATRY RESEARCH			English	Article						MMPI-2; PAI; Symptom exaggeration; PTSD; Depression; Malingering	POSTTRAUMATIC-STRESS-DISORDER; PERSONALITY-ASSESSMENT INVENTORY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; MENTAL-DISORDERS; TEST USAGE; SCALE; VALIDATION; SPECIFICITY; SENSITIVITY	The purpose of this study was to compare the clinical utility of PAI and MMPI-2 validity indicators to detect exaggeration of psychological symptoms. Participants were 49 (75.5% female) Australian university students who completed the MMPI-2 and PAI under one of three conditions: Control [i.e., honest responding (n = 20)], Feign Post Traumatic Stress Disorder [PTSD (n 15)], or Feign Depression (n = 14). Participants instructed to feign depression or feign PTSD had significantly higher scores on the majority of MMPI-2 and PAI validity indicators compared with controls. The Meyers Validity Index, the Obvious-Subtle index, and the Response Bias Scale were the most accurate MMPI-2 validity indicators. Diagnostic-specific MMPI-2 validity indicators, such as the Infrequency-PSTD scales and Malingered Depression scale, were not effective at detecting participants instructed to feign those conditions. For the PAI, the most accurate validity indicator was the MAL index: however, the detection rate using this validity indicator was modest at best. The MMPI-2 validity indicators were clearly superior to those on the PAI at identifying feigned versus honest responding in this sample. Crown Copyright (C) 2009 Published by Elsevier Ireland Ltd. All rights reserved.	[Lange, Rae T.] BC Mental Hlth & Addict Serv, PHSA Res & Networks, Dept Res, Vancouver, BC V5Z 4C2, Canada; [Lange, Rae T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Sullivan, Karen A.] Queensland Univ Technol, Sch Psychol & Counseling, Brisbane, Qld 4001, Australia; [Scott, Clinton] Queensland Univ Technol, Dept Psychol, Brisbane, Qld 4001, Australia; [Sullivan, Karen A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia	Lange, RT (corresponding author), BC Mental Hlth & Addict Serv, PHSA Res & Networks, Dept Res, Suite 201,601 W Broadway, Vancouver, BC V5Z 4C2, Canada.	rlange@bcmhs.bc.ca			Queensland University of Technology (QUT), Brisbane, Australia	This study was supported in part by a research grant from the Queensland University of Technology (QUT), Brisbane, Australia.	Allen L.M., 1997, CARB 97 MANUAL COMPU; Arbisi PA, 1997, PSYCHOL ASSESSMENT, V9, P102, DOI 10.1037/1040-3590.9.2.102; Bagby RM, 2002, J PERS ASSESS, V78, P69, DOI 10.1207/S15327752JPA7801_05; Bagby RM, 1997, J PERS ASSESS, V68, P650, DOI 10.1207/s15327752jpa6803_11; BARRON F, 1956, J CONSULT PSYCHOL, V19, P239; Blanchard DD, 2003, J PERS ASSESS, V80, P197, DOI 10.1207/S15327752JPA8002_08; Butcher, 1989, MINNESOTA MULTIPHASI; Calhoun PS, 2000, J PERS ASSESS, V75, P338, DOI 10.1207/S15327752JPA7502_11; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; CASHEL ML, 1995, ASSESSMENT, V2, P333, DOI DOI 10.1177/1073191195002004004; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Eakin DE, 2006, J PSYCHOPATHOL BEHAV, V28, P145, DOI 10.1007/s10862-005-9006-5; Elhai JD, 2004, ASSESSMENT, V11, P139, DOI 10.1177/1073191104264965; Elhai JD, 2002, J PERS ASSESS, V79, P531, DOI 10.1207/S15327752JPA7903_08; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; GOUGH H, 1957, CALIFORNIA PSYCHOL I; GOUGH HG, 1947, J ABNORM SOC PSYCH, V42, P215, DOI 10.1037/h0063295; GOUGH HG, 1950, J CONSULT PSYCHOL, V14, P408; GREENE RL, 1999, MMPI 2 INTERPRETIVE; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Hathaway S. R., 1989, MINNESOTA MULTIPHASI; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson G., 2006, PSYCHOL INJURIES FOR, P76; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Liljequist L, 1998, J PERS ASSESS, V71, P322, DOI 10.1207/s15327752jpa7103_3; Marshall MB, 2006, ASSESSMENT, V13, P417, DOI 10.1177/1073191106290842; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Morey L, 1996, INTERPRETIVE GUIDE P; Morey L. C., 1991, PERSONALITY ASSESSME; Morey LC, 1998, ASSESSMENT, V5, P203, DOI 10.1177/107319119800500301; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; ROGERS R, 1993, J PERS ASSESS, V60, P554, DOI 10.1207/s15327752jpa6003_12; Rogers R, 1996, J PERS ASSESS, V67, P629, DOI 10.1207/s15327752jpa6703_15; SILVERTON L, 1998, MALINGERING PROBABIL; Smith GP, 1997, J AM ACAD PSYCHIATRY, V25, P183; Steffan JS, 2003, ASSESSMENT, V10, P382, DOI 10.1177/1073191103259548; Strauss E, 2006, COMPENDIUM NEUROPSYC, P3; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P541, DOI 10.1080/13854040590967135; Tombaugh TN, 1996, TEST MEMORY MALINGER; WIENER D, 1946, SUBTLE OBVIOUS KEYS; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594	45	26	26	2	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	APR 30	2010	176	2-3					229	235		10.1016/j.psychres.2009.03.004			7	Psychiatry	Psychiatry	585MP	WOS:000276830000024	20207423	Green Published			2021-06-18	
J	O'Brien, NF; Reuter-Rice, KE; Khanna, S; Peterson, BM; Quinto, KB				O'Brien, Nicole Fortier; Reuter-Rice, Karin E.; Khanna, Sandeep; Peterson, Bradley M.; Quinto, Kenneth B.			Vasospasm in children with traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Vasospasm; Transcranial doppler ultrasound; Traumatic brain injury; Pediatric	CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; AGE-DEPENDENCE; VELOCITY; SONOGRAPHY; ARTERIES; ULTRASONOGRAPHY; DIAGNOSIS; PERFUSION	To determine the incidence of vasospasm in children who have suffered moderate to severe traumatic brain injury. A prospective observational pilot study in a 24-bed pediatric intensive care unit was performed. Twenty-two children aged 7 months to 14 years with moderate to severe traumatic brain injury as indicated by Glasgow Coma Score a parts per thousand currency sign12 and abnormal head imaging were enrolled. Transcranial Doppler ultrasound was performed to identify and follow vasospasm. Patients with a flow velocity in the middle cerebral artery (MCA) > 120 cm/s were considered to have vasospasm by criterion A. If flow velocity in the MCA was > 120 cm/s and the Lindegaard ratio was > 3, vasospasm was considered to be present by criterion B. Patients with basilar artery (BA) flow velocity > 90 cm/s met criteria for vasospasm in the posterior circulation (criterion C). In the MCA, 45.5% of patients developed vasospasm based on criterion A and 36.3% developed vasospasm based on criterion B. A total of 18.2% of patients developed vasospasm in the BA by criterion C. Typical day of onset of vasospasm was hospital day 2-3. Duration of vasospasm in the anterior circulation was 4 +/- A 2 days based on criteria A and 3 +/- A 1 days based on criteria B. Vasospasm in the posterior circulation persisted for 2 +/- A 1 days. Using the adult criteria outlined above to diagnose vasospasm, a significant proportion of pediatric patients who have suffered moderate to severe traumatic brain injury develop vasospasm during the course of their treatment.	[O'Brien, Nicole Fortier] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Reuter-Rice, Karin E.; Khanna, Sandeep; Peterson, Bradley M.] Univ Calif San Diego, Rady Childrens Hosp, Dept Pediat Crit Care, San Diego, CA 92103 USA; [Quinto, Kenneth B.] Univ Calif San Diego, Rady Childrens Hosp, Dept Allergy & Immunol, San Diego, CA 92103 USA	O'Brien, NF (corresponding author), Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.	Nicole.Obrien@nationwidechildrens.org; skhanna@rchsd.org; bpeterson@rchsd.org; kbquinto@ucsd.edu	O'brien, Nicole/E-3776-2011	Reuter-Rice, Karin/0000-0003-1501-8994			AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BODE H, 1989, EUR J PEDIATR, V148, P406, DOI 10.1007/BF00595898; BODE H, 1988, ARCH DIS CHILD, V63, P606, DOI 10.1136/adc.63.6.606; BODE H, 1989, J CHILD NEUROL, V4, pS68, DOI 10.1177/0883073889004001S11; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Pietrini D, 2004, Minerva Anestesiol, V70, P549; SCHONING M, 1993, STROKE, V24, P1305, DOI 10.1161/01.STR.24.9.1305; Society of Critical Care Medicine, 2003, Crit Care Med, V31, pS407; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; Wintermark M, 2004, PEDIATRICS, V113, P1642, DOI 10.1542/peds.113.6.1642	21	26	28	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2010	36	4					680	687		10.1007/s00134-009-1747-2			8	Critical Care Medicine	General & Internal Medicine	568UK	WOS:000275548400014	20091024	Green Published, Other Gold			2021-06-18	
J	Rohlwink, UK; Figaji, AA				Rohlwink, Ursula K.; Figaji, Anthony A.			Methods of monitoring brain oxygenation	CHILDS NERVOUS SYSTEM			English	Article						Brain oxygen; Jugular venous saturation; Near-infrared spectroscopy; Brain tissue oxygen tension; Children; Traumatic brain injury	NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; TISSUE OXYGEN; BLOOD-FLOW; INTRACRANIAL-PRESSURE; ANEURYSM SURGERY; SUBARACHNOID HEMORRHAGE; REGIONAL OXYGENATION; CARBON-DIOXIDE	Posttraumatic brain ischemia or hypoxia is a major potential cause of secondary injury that may lead to poor outcome. Avoidance, or amelioration, of this secondary injury depends on early diagnosis and intervention before permanent injury occurs. However, tools to monitor brain oxygenation continuously in the neuro-intensive care unit have been lacking. In recent times, methods of monitoring aspects of brain oxygenation continuously by the bedside have been evaluated in several experimental and clinical series and are potentially changing the way we manage head-injured patients. These monitors have the potential to alert the clinician to possible secondary injury and enable intervention, help interpret pathophysiological changes (e.g., hyperemia causing raised intracranial pressure), monitor interventions (e.g., hyperventilation for increased intracranial pressure), and prognosticate. This review focuses on jugular venous saturation, brain tissue oxygen tension, and near-infrared spectroscopy as practical methods that may have an important role in managing patients with brain injury, with a particular focus on the available evidence in children. However, to use these monitors effectively and to understand the studies in which these monitors are employed, it is important for the clinician to appreciate the technical characteristics of each monitor, as well as respective strengths and limitations of each. It is equally important that the clinician understands relevant aspects of brain oxygen physiology and head trauma pathophysiology to enable correct interpretation of the monitored data and therefore to direct an appropriate therapeutic response that is likely to benefit, not harm, the patient.	[Figaji, Anthony A.] Red Cross Childrens Hosp, ZA-7700 Cape Town, South Africa; [Rohlwink, Ursula K.; Figaji, Anthony A.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa	Figaji, AA (corresponding author), Red Cross Childrens Hosp, 617 ICH Bldg,Klipfontein Rd, ZA-7700 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Rohlwink, Ursula Karin/U-8917-2019; Viani, Rafael/V-1196-2018; Rohlwink, Ursula/AAE-2513-2020	Figaji, Anthony/0000-0002-3357-6490	National Research Foundation [GUN 2072790]; Integra Foundation	This work was supported in part by a grant from the South Africa-Swedish Links Program/National Research Foundation (GUN 2072790). Dr. Figaji also received a grant from the Integra Foundation for the study of cerebral perfusion pressure thresholds in children.	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 1998, ACT NEUR S, V71, P250; Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; Alten Jeffrey, 2005, Pediatr Crit Care Med, V6, P480, DOI 10.1097/01.PCC.0000162450.62812.AE; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bruzzone P, 1998, ACT NEUR S, V71, P111; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Chieregato A, 2003, J NEUROL NEUROSUR PS, V74, P784, DOI 10.1136/jnnp.74.6.784; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; Gatto R, 2006, J NEUROSCI METH, V157, P274, DOI 10.1016/j.jneumeth.2006.04.013; Gelabert-Gonzalez M, 2002, ACTA NEUROCHIR, V144, P863, DOI 10.1007/s00701-002-0975-9; Gomersall CD, 1997, CRIT CARE MED, V25, P1252, DOI 10.1097/00003246-199707000-00031; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Holzschuh M, 1997, NEUROL RES, V19, P246, DOI 10.1080/01616412.1997.11740807; Huchzermeyer C, 2008, J NEUROSCI, V28, P1153, DOI 10.1523/JNEUROSCI.4105-07.2008; Hull Rachel, 2009, Open Neuroimag J, V3, P26; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Jodicke A, 2003, J NEUROSURG, V98, P515, DOI 10.3171/jns.2003.98.3.0515; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kakihana Y, 2002, EUR J CARDIO-THORAC, V21, P434, DOI 10.1016/S1010-7940(01)01139-3; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Knirsch W, 2008, ACTA ANAESTH SCAND, V52, P1370, DOI 10.1111/j.1399-6576.2008.01703.x; Kurth CD, 2009, ANESTH ANALG, V108, P1268, DOI 10.1213/ane.0b013e318196ac8e; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Latronico N, 2000, NEUROSURGERY, V46, P1131, DOI 10.1097/00006123-200005000-00021; LENIGERFOLLERT E, 1975, PFLUG ARCH EUR J PHY, V359, P81, DOI 10.1007/BF00581279; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Marion DW, 2000, J TRAUMA, V48, P1032; Marshall RS, 2004, CURR OPIN NEUROL, V17, P705, DOI 10.1097/00019052-200412000-00010; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nemoto EM, 2000, ANESTHESIOLOGY, V92, P1847, DOI 10.1097/00000542-200006000-00057; Nemoto EM, 2000, CRIT CARE MED, V28, P1052, DOI 10.1097/00003246-200004000-00023; Nievas MCY, 2005, SURG NEUROL, V64, P362, DOI 10.1016/j.surneu.2005.02.008; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Perez Augusto, 2003, Pediatr Crit Care Med, V4, P33; Poca MA, 2007, J NEUROSURG, V106, P530, DOI 10.3171/jns.2007.106.4.530; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rolfe P, 2000, ANNU REV BIOMED ENG, V2, P715, DOI 10.1146/annurev.bioeng.2.1.715; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Salim A, 2008, AM SURGEON, V74, P1088; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Schneider GH, 1998, ACT NEUR S, V71, P62; Schwarz G, 1996, J NEUROSURG ANESTH, V8, P189, DOI 10.1097/00008506-199607000-00001; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Siesjo BK, 2008, J NEUROSURG, V108, P616, DOI 10.3171/JNS/2008/108/3/0616; Smith M, 2009, ANESTH ANALG, V108, P1055, DOI 10.1213/ane.0b013e31819a0301; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stocchetti N, 2004, ANESTH ANALG, V99, P230, DOI 10.1213/01.ane.0000130393.08355.d4; Stocchetti N, 1998, ACT NEUR S, V71, P162; Subbaswamy A, 2009, NEUROCRIT CARE, V10, P129, DOI 10.1007/s12028-008-9122-7; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vavilala MS, 2007, PEDIATR CRIT CARE ME, V8, P192, DOI 10.1097/01.PCC.0000257105.56861.7A; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017	85	26	26	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	APR	2010	26	4					453	464		10.1007/s00381-009-1033-1			12	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	568QI	WOS:000275537100007	19937250				2021-06-18	
J	Wang, HC; Duan, ZX; Wu, FF; Xie, L; Zhang, H; Ma, YB				Wang, Hong-Cai; Duan, Zhi-Xin; Wu, Fang-Fang; Xie, Le; Zhang, Hong; Ma, Yan-Bin			A New Rat Model for Diffuse Axonal Injury Using a Combination of Linear Acceleration and Angular Acceleration	JOURNAL OF NEUROTRAUMA			English	Article						animal model; beta-amyloid precursor protein; diffuse axonal injury; injury mechanism; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; COLLEGIATE FOOTBALL PLAYERS; HEAD IMPACT; WHITE-MATTER; BIOMECHANICS; HIPPOCAMPUS; CONCUSSION; PATHOBIOLOGY; AXOTOMY	Diffuse axonal injury (DAI) is a frequent form of traumatic brain injury, and is usually associated with long-lasting neurological impairments. A new experimental model was developed in the present study to induce DAI in rats by combining low linear and angular accelerations. In most clinical scenarios, DAI is caused by these two forms of acceleration in combination. In the injury-producing facility described here, the rat rotated instantly after it had sustained the impact that produced linear acceleration. Rats rotated rapidly 90 degrees in the coronal plane at a peak angular acceleration of 137 +/- 12 krad/sec(2) with a duration of 33.7 +/- 1.2 msec. The linear acceleration was applied to the rat's head by dropping a 450 g weight from a height of 0.9 m. Rats exposed to the combined accelerations took significantly longer to regain consciousness (11.9 +/- 3.6 min) than control rats (p < 0.01) or rats subjected to purely angular or linear acceleration (p < 0.01). Although macroscopic damage was observed in all brain-injured animals, axonal damage and hemorrhagic tissue tears were only noted in the animals sustaining the combined accelerations. All rats survived the purely linear or angular acceleration, whereas the mortality rate reached 21.7% following the combined accelerations. These results show that this model is capable of reproducing the major histological and neurological changes that are associated with DAI, and that the combination of low linear and angular accelerations can produce non-linear and synergistic effects to induce moderate/severe DAI.	[Wang, Hong-Cai; Duan, Zhi-Xin; Wu, Fang-Fang; Zhang, Hong; Ma, Yan-Bin] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp Affiliated 3, Dept Neurosurg, Shanghai 201900, Peoples R China; [Xie, Le] Shanghai Jiao Tong Univ, Natl & Mould Engn Res Ctr, Shanghai 201900, Peoples R China	Ma, YB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp Affiliated 3, Dept Neurosurg, Shanghai 201900, Peoples R China.	mybxj@yahoo.com.cn			Shanghai Education Committee [06BZ042]; Shanghai Municipal Health Bureau [2008115]; Shanghai Jiao Tong University [YG2009MS14]	We acknowledge Yuying Chen, Zhuying Guo, and Dong Yang for excellent technical support. This work is supported by grants from Shanghai Education Committee (no. 06BZ042), Shanghai Municipal Health Bureau (no. 2008115), and Shanghai Jiao Tong University Medicine and Engineering Cross Fund (no. YG2009MS14).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Clark RSB, 1997, J NEUROSCI, V17, P9172; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dusart I, 2005, BRAIN RES REV, V49, P300, DOI 10.1016/j.brainresrev.2004.11.007; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; KILBOURNE M, 2009, J NEUROTRAUM, V26, P1; King A.I., 2003, IRCOBI C LISB PORT, P1; Liu PH, 2006, J NEUROTRAUM, V23, P1857, DOI 10.1089/neu.2006.23.1857; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH M, 2003, TRAUMA, V5, P227; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; UENO K, 1995, J BIOMECH ENG-T ASME, V117, P319, DOI 10.1115/1.2794187; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Vorst MV, 2007, J TRAUMA, V62, P199, DOI 10.1097/01.ta.0000238665.09611.4b; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Yoganandan N, 2009, J TRAUMA, V66, P309, DOI 10.1097/TA.0b013e3181692104; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	60	26	29	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2010	27	4					707	719		10.1089/neu.2009.1071			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	584CG	WOS:000276727000005	20039778				2021-06-18	
J	Tait, RJ; Anstey, KJ; Butterworth, P				Tait, Robert J.; Anstey, Kaarin J.; Butterworth, Peter			Incidence of self-reported brain injury and the relationship with substance abuse: findings from a longitudinal community survey	BMC PUBLIC HEALTH			English	Article							CLINICALLY IMPORTANT DIFFERENCES; BLOOD-ALCOHOL LEVEL; UNITED-STATES; HEALTH SURVEY; HEAD-INJURY; PREVALENCE; EPIDEMIOLOGY; AUSTRALIA; CANNABIS; OUTCOMES	Background: Traumatic or serious brain injury (BI) has persistent and well documented adverse outcomes, yet 'mild' or 'moderate' BI, which often does not result in hospital treatment, accounts for half the total days of disability attributed to BI. There are currently few data available from community samples on the incidence and correlates of these injuries. Therefore, the study aimed to assess the 1) incidence of self-reported mild (not requiring hospital admission) and moderate (admitted to hospital)) brain injury (BI), 2) causes of injury 3) physical health scores and 4) relationship between BI and problematic alcohol or marijuana use. Methods: An Australian community sequential-cohort study (cohorts aged 20-24, 40-44 and 60-64 years at wave one) used a survey methodology to assess BI and substance use at baseline and four years later. Results: Of the 7485 wave one participants, 89.7% were re-interviewed at wave two. There were 56 mild (230.8/100000 person-years) and 44 moderate BI (180.5/100000 person-years) reported between waves one and two. Males and those in the 20-24 year cohort had increased risk of BI. Sports injury was the most frequent cause of BI (40/100) with traffic accidents being a greater proportion of moderate (27%) than mild (7%) BI. Neither alcohol nor marijuana problems at wave one were predictors of BI. BI was not a predictor of developing substance use problems by wave two. Conclusions: BI were prevalent in this community sample, though the incidence declined with age. Factors associated with BI in community samples differ from those reported in clinical samples (e. g. typically traumatic brain injury with traffic accidents the predominate cause). Further, detailed evaluation of the health consequences of these injuries is warranted.	[Tait, Robert J.; Anstey, Kaarin J.; Butterworth, Peter] Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia	Tait, RJ (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, GPO Box 4, Canberra, ACT 0200, Australia.	Robert.Tait@anu.edu.au	Anstey, Kaarin J/A-3852-2008; Anstey, Kaarin/AAB-4870-2020; Tait, Robert/B-8693-2009	Anstey, Kaarin/0000-0002-9706-9316; Butterworth, Peter/0000-0002-1531-3881; Tait, Robert/0000-0003-0648-3093	NHMRCNational Health and Medical Research Council of Australia [179805, 157125, 366756, 366781]	This study was supported by NHMRC Program Grant 179805 and NHMRC Project Grant 157125. The sponsors had no role in the design, conduct or reporting of the research. Anstey and Butterworth are funded by NHMRC Fellowships #366756, #366781.	Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; *CDC, 2002, MMWR-MORBID MORTAL W, V55, P201; *CDC, 2003, MMWR-MORBID MORTAL W, V56, P167; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; English D., 1995, QUANTIFICATION DRUG; Fairweather AK, 2007, J NERV MENT DIS, V195, P130, DOI 10.1097/01.nmd.0000254746.15325.fa; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fisk JE, 2008, J PSYCHOPHARMACOL, V22, P727, DOI 10.1177/0269881107084000; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; JENNETT B, 1975, LANCET, V1, P480; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MILLER LL, 1983, PSYCHOL BULL, V93, P441, DOI 10.1037/0033-2909.93.3.441; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; OCONNOR P, 1999, HOSPITALISATION DUE; ORANCE L, 2007, B AUSTR I HLTH WELFA, V55, P1; Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; Schootman M, 2000, BRAIN INJURY, V14, P373; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tate PS, 1999, BRAIN INJURY, V13, P767; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organisation, 2004, GLOB STAT REP ALC 20; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Wyrwich KW, 2005, HEALTH SERV RES, V40, P577, DOI 10.1111/j.1475-6773.2005.0l374.x	45	26	26	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	MAR 29	2010	10								171	10.1186/1471-2458-10-171			11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	588ZY	WOS:000277114700001	20350327	DOAJ Gold, Green Published			2021-06-18	
J	Scheid, R; von Cramon, DY				Scheid, Rainer; von Cramon, D. Yves			Clinical Findings in the Chronic Phase of Traumatic Brain Injury	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Article							DIFFUSE AXONAL INJURY; BLUNT HEAD-INJURY; FOCAL LESIONS; POSTTRAUMATIC SEIZURES; RISK-FACTORS; EPILEPSY; SEQUELAE; ADULTS; MRI; REHABILITATION	Background: There are many unresolved issues in the diagnosis and treatment of persons with traumatic brain injury (TBI) in its post-acute and chronic phases. This article deals with two problems of clinical importance: (i) the interrelationships between structural brain damage, brain function, and clinical outcome, and (ii) post-traumatic epilepsy. Methods: Exploratory, retrospective analysis of clinical, neuroradiological (MRI), and neuropsychological data of all patients with TBI who were treated in a cognitive neurology outpatient clinic of a German university hospital over a period of 12 years (n=320). Results: 156 patients (48.8%) had brain contusions, 83 of them (25.9%) as the sole neuroradiological abnormality. Traumatic micro-hemorrhages were seen in 148 patients (46.2%) and were the sole neuroradiological abnormality in 79 of them (24.7%). 49 patients (15.3%) had no structural brain lesion. There was no obvious correlation between the neuroradiological findings and the clinical outcome, as measured either by a general outcome parameter such as the extended Glasgow Outcome Scale (GOSE) or by neuropsychological testing. 47 patients (14.7%) had post-traumatic epilepsy; its occurrence was positively correlated with the presence of brain contusions, but not with an isolated diagnosis of diffuse axonal injury (DAI). Conclusion: A comparison of the findings of neuroradiological studies and neuropsychological tests among patients in the chronic phase of traumatic brain injury does not reveal any simple relationship between structural and functional brain abnormalities. Diffuse axonal injury is often present in combination with other findings, and it may well be the only structural abnormality in many cases; therefore, all symptomatic patients should undergo MRI of the brain. Patients with isolated DAI seem to be less prone to post-traumatic epilepsy than those with brain contusions.	[Scheid, Rainer; von Cramon, D. Yves] Max Planck Inst Kognit & Neurowissensch, D-04103 Leipzig, Germany; [Scheid, Rainer; von Cramon, D. Yves] Univ Klinikum, Tagesklin Kognit Neurol, Leipzig, Germany; [von Cramon, D. Yves] Max Planck Inst Neurol Res, D-50931 Cologne, Germany	Scheid, R (corresponding author), Max Planck Inst Kognit & Neurowissensch, Stephanstr 1A, D-04103 Leipzig, Germany.	scheid@cbs.mpg.de					Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bigler ED, 2007, BRAIN INJURY MED PRI, P201; Brodie MJ, 2000, LANCET, V356, P323, DOI 10.1016/S0140-6736(00)02515-0; BROWN AW, 2008, ARCH PHYS MED REH S1, V89; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Delis DC, 1987, CALIFORNIA VERBAL LE; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Harting C, 2000, WECHSLER GEDACHTNIS; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Jennett B, 1975, EPILEPSY NONMISSILE; Kamikubo Takeshi, 2003, No To Shinkei, V55, P669; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KIRALY M, 2007, THESCIENTIFICWORLDJO, V12, P1768; Koponen S, 2006, PSYCHIAT RES-NEUROIM, V146, P263, DOI 10.1016/j.pscychresns.2005.05.015; Kothari S, 2008, ARCH PHYS MED REHAB, V89, pS27, DOI 10.1016/j.apmr.2007.12.014; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lehrl S, 1991, MEHRFACHWAHL WORTSCH; MCALLISTER TW, 2007, BRAIN INJURY MED PRI, P835; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; RICKELS E, 2006, SCHADEL HIM VERLET Z; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Scheid R, 2006, NEUROLOGIST, V12, P255, DOI 10.1097/01.nrl.0000243977.17242.ab; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Werhahn KJ, 2009, DTSCH ARZTEBL INT, V106, P135, DOI 10.3238/arztebl.2009.0135; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WOLFRAM H, 1986, PSYCHOL LEISTUNGSTES; YABLON SA, 2007, BRAIN INJURY MED PRI, P835; Zimmermann P, 1993, TESTBATTERIE AUFMERK; 2006, GESUNDHEITSBERICHT D	49	26	26	0	1	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	MAR 26	2010	107	12					199	U9		10.3238/arztebl.2010.0199			8	Medicine, General & Internal	General & Internal Medicine	575ZJ	WOS:000276112500001	20386669	Green Published			2021-06-18	
J	Umschwief, G; Shein, NA; Alexandrovich, AG; Trembovler, V; Horowitz, M; Shohami, E				Umschwief, Gali; Shein, Na'ama A.; Alexandrovich, Alexander G.; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther			Heat acclimation provides sustained improvement in functional recovery and attenuates apoptosis after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Bad; Bcl-xL; caspase-3; cytochrome c; neuroprotection	MIDDLE CEREBRAL-ARTERY; CENTRAL-NERVOUS-SYSTEM; NEURONAL CELL-DEATH; TRANSGENIC MICE; CHANNEL ACTIVITY; CROSS-TOLERANCE; CNS INJURY; BCL-X; ISCHEMIA; BAD	Heat acclimation (HA) offers functional neuroprotection in mice after traumatic brain injury (TBI). This study further characterizes endogenous neuroprotection acquired by HA (34 +/- 1 degrees C, 30 d) after TBI. We establish here the ability of HA to induce sustained functional benefits and to reduce activation of apoptotic pathways. Neurobehavioral recovery, assessed by the Neurological Severity Score, was greater in HA mice up to 8 days after injury as compared with normothermic controls (P < 0.05) and lesion volume was also smaller in the HA group (P < 0.05). Reduced apoptotic cell death in HA mice was confirmed using caspase-3 activity measurements and immunohistochemistry. To investigate the underlying molecular pathways, expression levels of intrinsic apoptotic pathway-related proteins were examined. HA mice displayed higher mitochondrial levels of antiapoptotic Bcl-xL, accompanied by lower proapoptotic Bad levels and decreased cytochrome c release, suggesting a higher apoptotic threshold. Taken together with our previous reports, indicating increased Akt phosphorylation and antioxidative capacity, alongside with reduced tumor necrosis alpha levels after TBI in HA animals, the current results support the involvement of an antiapoptotic effect in HA-induced neuroprotection. Current results warrant further study as TBI-induced apoptosis may persist over weeks after injury, possibly providing a target for belated therapeutic intervention. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 616-627; doi: 10.1038/jcbfm.2009.234; published online 11 November 2009	[Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Umschwief, Gali; Shein, Na'ama A.; Horowitz, Michal] Hebrew Univ Jerusalem, Dept Physiol, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	horowitz@cc.huji.ac.il; esty@cc.huji.ac.il			ISFIsrael Science Foundation [241/04]	This work was supported in part by a grant (# 241/04) from the ISF. ES is a member in the Brettler Center for Research in Molecular Pharmacology and Therapeutics, and the incumbent of the Dr Leon and Mina Deutch Chair in psychopharmacology at the Hebrew University.	Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; ASSAYAG MG, 2007, 15 EUR AP 4 TRAIN CO; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bonanni L, 2006, J NEUROSCI, V26, P6851, DOI 10.1523/JNEUROSCI.5444-05.2006; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chong ZZ, 2004, ANTIOXID REDOX SIGN, V6, P277, DOI 10.1089/152308604322899341; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Fukunaga K, 2003, J PHARMACOL SCI, V92, P317; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Horowitz M, 2007, PROG BRAIN RES, V162, P373, DOI 10.1016/S0079-6123(06)62018-9; Kamada H, 2007, J CEREBR BLOOD F MET, V27, P521, DOI 10.1038/sj.jcbfm.9600367; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LEVI E, 1993, J APPL PHYSIOL, V75, P833; Miyawaki T, 2008, P NATL ACAD SCI USA, V105, P4892, DOI 10.1073/pnas.0800628105; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; SCHMIDTNIELSEN K, 1964, ANIMAL PHYSL, P13; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sugawara T, 2003, ANTIOXID REDOX SIGN, V5, P597, DOI 10.1089/152308603770310266; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Tetievsky A, 2008, PHYSIOL GENOMICS, V34, P78, DOI 10.1152/physiolgenomics.00215.2007; Wang FR, 2008, J HUAZHONG U SCI-MED, V28, P56, DOI 10.1007/s11596-008-0114-9; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	41	26	29	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2010	30	3					616	627		10.1038/jcbfm.2009.234			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	563DV	WOS:000275108900016	19904288	Green Published, Bronze			2021-06-18	
J	Covey, MV; Jiang, YH; Alli, VV; Yang, ZG; Levison, SW				Covey, Matthew V.; Jiang, Yuhui; Alli, Vamsi V.; Yang, Zhengang; Levison, Steven W.			Defining the Critical Period for Neocortical Neurogenesis after Pediatric Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Subventricular zone; Stem cells; Neurons; Regenerative medicine; Traumatic brain injury; Brain damage	NEURAL STEM-CELLS; SUBVENTRICULAR ZONE; FRONTAL LESIONS; CEREBRAL-CORTEX; ADULT RATS; PERSISTENT PRODUCTION; MIGRATORY PATHWAY; CORTICAL-LESIONS; NERVOUS-SYSTEM; COLD-INJURY	Pediatric traumatic brain injury (TBI) is a significant and underappreciated societal problem. Whereas many TBI studies have evaluated the mechanisms of cell death after TBI, fewer studies have evaluated the extent to which regeneration is occurring. Here we used a cryoinjury model to damage the somatosensory cortex of rats at postnatal day 6 (P6), P10 and P21. We evaluated the production of new neocortical neurons using a combination of 5-bromo-2-deoxyuridine (BrdU) labeling combined with staining for doublecortin (DCX). BrdU+/DCX+ bipolar cells were observed adjacent to the neocortical lesion, with their processes oriented perpendicular to the pial surface. As the animals aged, both the overall proliferative response as well as the production of neocortical neuroblasts diminished, with P6 animals responding most robustly, P10 animals less strongly, and P21 animals showing a very modest proliferative response and virtually no evidence of neocortical neurogenesis. When BrdU was administered at increasingly delayed intervals after the injury at P6, there was a clear difference in the number of new neuroblasts produced as a function of age, with the greatest number of new neocortical neurons produced between 4 and 7 days after the injury. These studies demonstrate that the immature brain has the capacity to produce neocortical neurons after traumatic injury, but this capacity diminishes as the brain continues to develop. Furthermore, in contrast to moderate hypoxic/ischemic brain damage in the P6 rat, where neurogenesis persists for at least 2 months, the response to cryoinjury is quite different as the neurogenic response diminishes over time. Copyright (C) 2010 S. Karger AG, Basel	[Levison, Steven W.] Univ Med & Dent New Jersey, New Jersey Med Sch, Lab Regenerat Neurobiol, Dept Neurol & Neurosci, Newark, NJ 07103 USA; [Covey, Matthew V.; Jiang, Yuhui; Alli, Vamsi V.; Yang, Zhengang; Levison, Steven W.] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp Canc Ctr, Newark, NJ 07103 USA	Levison, SW (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Lab Regenerat Neurobiol, Dept Neurol & Neurosci, 205 S Orange Ave,H-1226, Newark, NJ 07103 USA.	steve.levison@umdnj.edu	Levison, Steven W./Q-6903-2019	Levison, Steven W./0000-0002-1264-7309; Covey, Matthew/0000-0002-0160-6712; Alli, Vamsi/0000-0002-6569-4272	New Jersey Commission on Brain Injury Research [08.001.BIR2]	These studies were supported by a grant from the New Jersey Commission on Brain Injury Research awarded to S.W.L. (No. 08.001.BIR2).	Alagappan D, 2009, ASN NEURO, V1, DOI 10.1042/AN20090002; Alonso G, 1999, J COMP NEUROL, V405, P508, DOI 10.1002/(SICI)1096-9861(19990322)405:4<508::AID-CNE5>3.0.CO;2-5; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Felling RJ, 2006, J NEUROSCI, V26, P4359, DOI 10.1523/JNEUROSCI.1898-05.2006; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jankovski A, 1996, J COMP NEUROL, V371, P376; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Miller JT, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-63; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P880, DOI 10.1097/00005072-199608000-00003; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Romanko MJ, 2004, J CEREBR BLOOD F MET, V24, P814, DOI 10.1097/01.WCB.0000123906.17746.00; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Smith KS, 2007, BEHAV NEUROSCI, V121, P449, DOI 10.1037/0735-7044.121.3.449; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; WILLIS P, 1976, NEUROPATH APPL NEURO, V2, P377, DOI 10.1111/j.1365-2990.1976.tb00511.x; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Yang ZG, 2007, DEV NEUROSCI-BASEL, V29, P331, DOI 10.1159/000105474; Yang ZG, 2007, ANN NEUROL, V61, P199, DOI 10.1002/ana.21068; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	33	26	26	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					488	498		10.1159/000321607			11	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900017	21160158				2021-06-18	
J	Erickson, SJ; Montague, EQ; Gerstle, MA				Erickson, Sarah J.; Montague, Erica Q.; Gerstle, Melissa A.			Health-related quality of life in children with moderate-to-severe traumatic brain injury	DEVELOPMENTAL NEUROREHABILITATION			English	Article						children; adolescents; traumatic brain injury; health-related quality of life	GENERIC CORE SCALES; BASIC ISSUES; ADOLESCENTS; RELIABILITY; VALIDITY; RECOMMENDATIONS; PEDSQL(TM); CANCER; MODULE	Objective: To investigate health-related quality of life (HRQOL) in a sample of ethnically diverse children with traumatic brain injury (TBI). Methods: Twenty children with moderate-severe TBI and their parents were recruited from a TBI clinic at a paediatric rehabilitation hospital. Children's self-reported HRQOL was assessed with the Pediatric Quality of Life Inventory. Parents completed a parallel proxy measure. Results: Children reported significantly lower Psychosocial HRQOL compared to their Total HRQOL, driven largely by low School HRQOL scores. Compared to other paediatric populations, children with TBI reported lower or equivalent HRQOL. Compared with children's self-reports, parents reported even lower HRQOL for their children across primary domains, with fair-to-moderate convergence between informants. Conclusions: Results provide preliminary evidence that children who have suffered moderate-severe TBI experience relatively poor HRQOL, particularly in the School domain. Limited convergence between informants suggests that children and parents perceive HRQOL differently, with parents reporting lower HRQOL.	[Erickson, Sarah J.; Montague, Erica Q.; Gerstle, Melissa A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Erickson, SJ (corresponding author), Univ New Mexico, Dept Psychol, 1 UNM,MSC03 2220, Albuquerque, NM 87131 USA.	erickson@unm.edu	Erickson, Sarah/AAH-1620-2020	Erickson, Sarah/0000-0002-4863-0074			Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Eiser C, 2003, CHILD CARE HLTH DEV, V29, P95, DOI 10.1046/j.1365-2214.2003.00318.x; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fennell EB, 2001, J CHILD NEUROL, V16, P58, DOI 10.1177/088307380101600110; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Ocampo S, 1997, OCCUP THER INT, V4, P161; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; Souza Ligia Maria Do N, 2007, Dev Neurorehabil, V10, P35, DOI 10.1080/13638490600822239; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; TEASDALE G, 1974, LANCET, V2, P81; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2002, ARTHRITIS RHEUM, V46, P714, DOI 10.1002/art.10095; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2005, DEV MED CHILD NEUROL, V47, P592, DOI 10.1017/S0012162205001179; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109	21	26	27	0	8	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1751-8423			DEV NEUROREHABIL	Dev. Neurorehabil.		2010	13	3					175	181		10.3109/17518420903479867			7	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	686LM	WOS:000284697800005	20450467				2021-06-18	
J	Jersey, SL; Baril, RT; McCarty, RD; Millhouse, CM				Jersey, Sean L.; Baril, Robert T.; McCarty, Richmond D.; Millhouse, Christina M.			Severe Neurological Decompression Sickness in a U-2 Pilot	AVIATION SPACE AND ENVIRONMENTAL MEDICINE			English	Article						U-2; case report; altitude; decompression sickness; neurological symptoms; traumatic brain injury; magnetic resonance imaging	PREVALENCE; LESIONS	Severe neurological decompression sickness (DCS) has been a rare entity in the U.S. Air Force, including the U-2 community. In over 50 yr of operation, few U-2 pilots reported severe neurological DCS in flight despite the extreme altitudes at which they operate. This article describes a near-fatal case of neurological DCS that occurred during a combat mission. The injury left the pilot with permanent cognitive deficits that correlated with focal lesions present on magnetic resonance imaging of his brain. To our knowledge, the images presented herein are the first to show radiological evidence of brain injury induced by altitude DCS. Though only a single case, the objective and clinical findings in the case pilot are similar to results documented in divers suffering DCS with central nervous system injury and victims of traumatic brain injury. DCS will remain a potentially serious threat to current and future air and space operations.	[Jersey, Sean L.; Millhouse, Christina M.] 99th Reconnaissance Squadron, Beale AFB, CA USA; [Baril, Robert T.] USAF, David Grant Med Ctr, Radiol Residence Program, Travis AFB, CA USA; [McCarty, Richmond D.] N Mississippi Med Ctr, Family Med Residency Program, Tupelo, MS USA	Jersey, SL (corresponding author), 9th AMDS SGOAF, 15301 Warren Shingle Rd, Beale AFB, CA 95903 USA.	sean.jersey@beale.af.mil					Balldin UI, 2004, AVIAT SPACE ENVIR MD, V75, P969; Bendrick GA, 1996, AVIAT SPACE ENVIR MD, V67, P199; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Erdem I, 2009, AVIAT SPACE ENVIR MD, V80, P2, DOI 10.3357/ASEM.2234.2009; Gronning M, 2005, UNDERSEA HYPERBAR M, V32, P397; Koch AE, 2008, UNDERSEA HYPERBAR M, V35, P197; Krause KM, 2000, AVIAT SPACE ENVIR MD, V71, P115; Moon RE, 1997, AVIAT SPACE ENVIR MD, V68, P234; Pickard BJ, 2003, AVIAT SPACE ENVIR MD, V74, P357; Pilmanis AA, 2004, AVIAT SPACE ENVIR MD, V75, P749; Ryles MT, 1996, AVIAT SPACE ENVIR MD, V67, P983; Webb JT, 2005, AVIAT SPACE ENVIR MD, V76, P547; WEIEN RW, 1990, AVIAT SPACE ENVIR MD, V61, P833; WIRJOSEMITO SA, 1989, AVIAT SPACE ENVIR MD, V60, P256	14	26	29	0	2	AEROSPACE MEDICAL ASSOC	ALEXANDRIA	320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA	0095-6562			AVIAT SPACE ENVIR MD	Aviat. Space Environ. Med.	JAN	2010	81	1					64	68		10.3357/ASEM.2303.2010			5	Public, Environmental & Occupational Health; Medicine, General & Internal; Sport Sciences	Public, Environmental & Occupational Health; General & Internal Medicine; Sport Sciences	539QB	WOS:000273270900011	20058739				2021-06-18	
J	Lew, HL; Amick, MM; Kraft, M; Stein, MB; Cifu, DX				Lew, Henry L.; Amick, Melissa M.; Kraft, Malissa; Stein, Murray B.; Cifu, David X.			Potential driving issues in combat returnees	NEUROREHABILITATION			English	Article						Traumatic brain injury; post traumatic stress disorder; motor vehicle crashes; deployment; evasive driving skills; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSIAN-GULF-WAR; NEUROCOGNITIVE PERFORMANCE; POSTCONCUSSIVE SYMPTOMS; US VETERANS; CONCUSSION; IRAQ; MORTALITY; SOLDIERS	The driving abilities of service members returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) have not been well reported and are an important aspect of their return to normal life. This article reviews the unique risk factors for unsafe driving in this cohort. In particular, the cognitive and psychological symptoms of mild traumatic brain injury and postraumatic stress disorder, two of the most common diagnoses affecting these returning warriors, are specified, and their possible association with impaired driving is examined. The potential negative impact of the "battlemind driving tactics" (i.e., evasive driving skills) acquired by these service members as part of their military tours is also highlighted. The article concludes with comments about the functional consequences of impaired driving in this population, including limits to participation in rehabilitation and community reintegration, as well as recognition of the need for further research in this area.	[Lew, Henry L.] VA Boston Hlth Care Syst, PM& R Serv, Polytrauma & TBI Res Ctr, Boston, MA 02130 USA; [Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Cifu, David X.] Hunter Holmes McGuire VA Healthcare Syst, PM&R Serv, Richmond, VA USA	Lew, HL (corresponding author), VA Boston Hlth Care Syst, PM& R Serv, Polytrauma & TBI Res Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.	Henry.Lew@VA.gov		Cifu, David/0000-0003-1600-9387			*AM PSYCH ASS, 2000, DIAGN MAN PSYCH DIS; Amick MM, 2007, ARCH CLIN NEUROPSYCH, V22, P957, DOI 10.1016/j.acn.2007.07.004; [Anonymous], 1987, JAMA, V257, P790; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bell NS, 2000, MIL MED, V165, P762; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; *DEP VET AFF, 2008, DEADL TOLL POSTD CAR; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hooper TI, 2005, AM J IND MED, V48, P118, DOI 10.1002/ajim.20190; JONES BH, 1999, MILITARY MED S, V164; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; Kang HK, 2001, AM J EPIDEMIOL, V154, P399, DOI 10.1093/aje/154.5.399; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Krull MAR, 2004, MIL MED, V169, P926, DOI 10.7205/MILMED.169.11.926; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P963, DOI 10.1682/JRRD.2006.12.0169; Lew HL, 2009, J HEAD TRAUMA REHAB, V24, P51, DOI 10.1097/HTR.0b013e3181956fe3; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lincoln Andrew E, 2006, Traffic Inj Prev, V7, P31, DOI 10.1080/15389580500412028; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ott BR, 2008, NEUROLOGY, V70, P1171, DOI 10.1212/01.wnl.0000294469.27156.30; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; *PDHRA, 2006, BATTL TRAIN CONT TRA; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; Sivak M, 1996, J SAFETY RES, V27, P225, DOI 10.1016/S0022-4375(96)00027-8; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tavris DR, 2001, ACCIDENT ANAL PREV, V33, P167, DOI 10.1016/S0001-4575(00)00027-0; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Uc EY, 2008, CURR NEUROL NEUROSCI, V8, P377, DOI 10.1007/s11910-008-0059-1; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	50	26	26	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					271	278		10.3233/NRE-2010-0562			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300010	20448316				2021-06-18	
J	Makri, G; Lavdas, AA; Katsimpardi, L; Charneau, P; Thomaidou, D; Matsas, R				Makri, Georgia; Lavdas, Alexandros A.; Katsimpardi, Lida; Charneau, Pierre; Thomaidou, Dimitra; Matsas, Rebecca			Transplantation of Embryonic Neural Stem/Precursor Cells Overexpressing BM88/Cend1 Enhances the Generation of Neuronal Cells in the Injured Mouse Cortex	STEM CELLS			English	Article						Neuronal differentiation; Traumatic brain injury; Motor cortex; Neurosphere cultures; Lentiviral vectors; Brain repair	ADULT-RAT BRAIN; SPINAL-CORD-INJURY; EPIDERMAL-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; IN-VITRO MODEL; STEM-CELLS; REACTIVE ASTROCYTES; PRECURSOR CELLS; PROGENITOR CELLS; GLIAL SCAR	The intrinsic inability of the central nervous system to efficiently repair traumatic injuries renders transplantation of neural stem/precursor cells (NPCs) a promising approach towards repair of brain lesions. In this study, NPCs derived from embryonic day 14.5 mouse cortex were genetically modified via transduction with a lentiviral vector to overexpress the neuronal lineage-specific regulator BM88/Cend1 that coordinates cell cycle exit and differentiation of neuronal precursors. BM88/Cend1-overexpressing NPCs exhibiting enhanced differentiation into neurons in vitro were transplanted in a mouse model of acute cortical injury and analyzed in comparison with control NPCs. Immunohistochemical analysis revealed that a smaller proportion of BM88/Cend1-overexpressing NPCs, as compared with control NPCs, expressed the neural stem cell marker nestin 1 day after transplantation, while the percentage of nestin-positive cells was significantly reduced thereafter in both types of cells, being almost extinct 1 week post-grafting. Both types of cells did not proliferate up to 4 weeks in vivo, thus minimizing the risk of tumorigenesis. In comparison with control NPCs, Cend1-overexpressing NPCs generated more neurons and less glial cells 1 month after transplantation in the lesioned cortex whereas the majority of graft-derived neurons were identified as GABAergic interneurons. Furthermore, transplantation of Cend1-overexpressing NPCs resulted in a marked reduction of astrogliosis around the lesioned area as compared to grafts of control NPCs. Our results suggest that transplantation of Cend1-overexpressing NPCs exerts beneficial effects on tissue regeneration by enhancing the number of generated neurons and restricting the formation of astroglial scar, in a mouse model of cortical brain injury. STEM CELLS 2010; 28: 127	[Makri, Georgia; Lavdas, Alexandros A.; Katsimpardi, Lida; Thomaidou, Dimitra; Matsas, Rebecca] Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, Athens 11521, Greece; [Charneau, Pierre] Inst Pasteur, Grp Mol Virol & Vectorol, F-75724 Paris 15, France	Thomaidou, D (corresponding author), Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vassilissis Sofias Ave, Athens 11521, Greece.	thomaidou@pasteur.gr; rmatsa@pasteur.gr	Lavdas, Alexandros Alpha./H-3353-2019; CHARNEAU, Pierre/M-1565-2017	Lavdas, Alexandros Alpha./0000-0002-4206-6724; CHARNEAU, Pierre/0000-0003-1184-5773	Hellenic General Secretariat for Research and TechnologyGreek Ministry of Development-GSRT [YB-11, YB26]; Institut Pasteur Paris Grand Programme Horizontal on Stem Cells	This work was supported by the Hellenic General Secretariat for Research and Technology EPAN Grants YB-11 and YB26 and the Institut Pasteur Paris Grand Programme Horizontal on Stem Cells. We thank Dr. M. Gaitanou for providing af. nity purified anti-BM88/Cend1 antibody, Dr. E. Siapati for help with qPCR, and Drs F. Stylianopoulou and I. Kazanis for introducing us to the methodology of brain trauma. L. K. is currently affiliated with Harvard Stem Cell Institute, Harvard University, 7 Divinity Avenue, Sherman Fairchild B-09, Cambridge, MA 02138, USA.	AGULLO L, 1995, BRAIN RES, V686, P160, DOI 10.1016/0006-8993(95)00486-A; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Antony JM, 2004, NAT NEUROSCI, V7, P1088, DOI 10.1038/nn1319; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200; Einstein O, 2006, EXP NEUROL, V198, P275, DOI 10.1016/j.expneurol.2005.11.007; Fricker RA, 1999, J NEUROSCI, V19, P5990, DOI 10.1523/JNEUROSCI.19-14-05990.1999; Fricker-Gates RA, 2002, J NEUROSCI, V22, P4045, DOI 10.1523/JNEUROSCI.22-10-04045.2002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gaillard A, 2007, NAT NEUROSCI, V10, P1294, DOI 10.1038/nn1970; Georgopoulou N, 2006, J BIOL CHEM, V281, P33606, DOI 10.1074/jbc.M602689200; Glaser T, 2007, STEM CELLS, V25, P3016, DOI 10.1634/stemcells.2007-0218; Gritti A, 1999, J NEUROSCI, V19, P3287; Hargus G, 2008, STEM CELLS, V26, P1973, DOI 10.1634/stemcells.2007-0929; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kirik D, 2003, TRENDS NEUROSCI, V26, P386, DOI 10.1016/S0166-2236(03)00164-4; Koutmani Y, 2004, EUR J NEUROSCI, V20, P2509, DOI 10.1111/j.1460-9568.2004.03724.x; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Magavi Sanjay S P, 2002, Methods Mol Biol, V198, P283; Magavi SS, 2000, NATURE, V405, P951; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Masgrau R, 2009, NEUROPHARMACOLOGY, V56, P598, DOI 10.1016/j.neuropharm.2008.10.015; McKay R, 2000, NAT MED, V6, P747, DOI 10.1038/77468; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Neufeld AH, 2003, NEUROSCIENTIST, V9, P485, DOI 10.1177/1073858403253460; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Parmar M, 2002, MOL CELL NEUROSCI, V21, P645, DOI 10.1006/mcne.2002.1204; PATSAVOUDI E, 1995, J NEUROSCI RES, V40, P506, DOI 10.1002/jnr.490400410; Pluchino S, 2008, J NEUROL SCI, V265, P105, DOI 10.1016/j.jns.2007.07.020; Politis PK, 2007, P NATL ACAD SCI USA, V104, P17861, DOI 10.1073/pnas.0610973104; Politis PK, 2007, GENE EXPR PATTERNS, V7, P165, DOI 10.1016/j.modgep.2006.06.007; Salmon P, 2007, CURR PROTOC HUM GENE, DOI DOI 10.1002/0471142905.HG0808S52; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Tang BL, 2007, CELL MOL NEUROBIOL, V27, P75, DOI 10.1007/s10571-006-9119-8; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Tuszynski MH, 2007, NAT NEUROSCI, V10, P1229, DOI 10.1038/nn1007-1229; Vitry S, 2001, MOL CELL NEUROSCI, V17, P983, DOI 10.1006/mcne.2001.0987; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	56	26	30	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	JAN	2010	28	1					127	139		10.1002/stem.258			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	555GJ	WOS:000274496600017	19911428	Bronze			2021-06-18	
J	Naunheim, RS; Treaster, M; English, J; Casner, T; Chabot, R				Naunheim, Rosanne S.; Treaster, Matthew; English, Joy; Casner, Teya; Chabot, Robert			Use of brain electrical activity to quantify traumatic brain injury in the emergency department	BRAIN INJURY			English	Article						Electroencephalogram; traumatic brain injury	HEAD-INJURY; EEG; CONCUSSION; MILD; CANCER; QEEG	Primary objective: To validate a QEEG algorithm on traumatic brain injury in an Emergency Department (ED) setting. Methods and procedures: EEG data were collected from 105 patients with head injury (53 CT+ and 52 CT-) and 50 ED controls. Ten minutes of eyes closed resting EEG was collected from five frontal locations. A discriminant index of the probability of belonging to the TBI CT+ group was computed. Analysis of variance was computed comparing this index across the three patient groups. Using ROC curves, the p<0.05 confidence level was determined to compute sensitivity and specificity for the TBI CT+ population. Results: CT+ patients had a mean TBI discriminant index of 80.4, CT- patients 38.9 and controls 24.5; F = 70.2, p<0.0001. Sensitivity was 92.45% for the CT+ group and specificity was 90.00% for the control group. Conclusions: The TBI discriminant index appears to be a sensitive index of brain function. It may be used to suggest whether or not a patient presenting with altered mental status requires a CT scan. This index may aid in the triage of such patients in the ED. Such an easy to use, automated system may greatly enhance the clinical utility of EEG in the ED.	[Naunheim, Rosanne S.; Treaster, Matthew; English, Joy; Casner, Teya] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Chabot, Robert] NYU, Sch Med, Brain Res Labs, New York, NY USA	Naunheim, RS (corresponding author), Washington Univ, Sch Med, 660 So Euclid Box 8072, St Louis, MO 63110 USA.	naunheir@wusm.wustl.edu			BrainScope	Teya Casner, MPH, is funded by BrainScope and responsible for collection of data and data transfer to New York University. Robert Chabot is a scientific consultant to BrainScope, Co. However, BrainScope did not participate in the data analysis or writing of the manuscript.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Brewer TL, 2002, RES NURS HEALTH, V25, P269, DOI 10.1002/nur.10045; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Chen Xi-Ping, 2006, Neurosci Bull, V22, P165; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Gurdjian ES, 1975, IMPACT HEAD INJURY; JACQUIN A, 2010, IEEE T BIOM IN PRESS; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kondacs A, 1999, CLIN NEUROPHYSIOL, V110, P1708, DOI 10.1016/S1388-2457(99)00122-4; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Malloy P.F., 1998, SEMIN CLIN NEUROPSYC, V3, P186; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Redberg RF, 2009, ARCH INTERN MED, V169, P2049, DOI 10.1001/archinternmed.2009.453; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; THIRUPPATHY SP, 2004, ACTA NEUOCHIRURGICA, V146, P1083; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	25	26	27	0	4	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	11					1324	1329		10.3109/02699052.2010.506862			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800006	20722504				2021-06-18	
J	Park, KD; Kim, DY; Lee, JK; Nam, HS; Park, YG				Park, Ki Deok; Kim, Deog Young; Lee, Ju Kang; Nam, Hee-Seung; Park, Yoon-Ghil			Anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury patients and the influence on functional outcome	BRAIN INJURY			English	Article						Traumatic brain injury; pituitary dysfunction; BMI; functional outcome	GROWTH-HORMONE DEFICIENCY; GH	Objective: The objective of this study is to determine the prevalence of anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury (TBI) patients. The investigation of a relationship between pituitary hormonal status and body mass index (BMI) in TBI patients by observing changes in BMI was conducted as well as an assessment of whether there is a difference in functional outcome related to anterior pituitary dysfunction in TBI patients. Methods: Forty-five TBI patients and 30 normal controls underwent a series of standard endocrine tests for anterior pituitary hormone function. It was studied whether changes in BMI correlated with anterior pituitary hormone levels. This study also compared changes in mini-mental state examination (K-MMSE) and functional independence measure (FIM) scores between patients in the hormone-sufficient and -deficient groups. Results: Anterior pituitary dysfunction was found in 31.1% of TBI patients. Changes in BMI statistically correlated with IGF-1 and basal cortisol levels. A meaningful difference was found between the hormone-sufficient and -deficient groups in light of the K-MMSE and FIM score gains. Conclusions: These findings strongly suggest that patients who suffer head trauma should be routinely tested for anterior pituitary hormone deficiency.	[Park, Ki Deok; Lee, Ju Kang] Gachon Univ Med & Sci, Gil Med Ctr, Dept Rehabil Med, Inchon, South Korea; [Kim, Deog Young] Yonsei Univ, Coll Med, Dept & Res Inst Rehabil Med, Seoul, South Korea; [Nam, Hee-Seung] Hallym Univ, Dept Rehabil Med, Coll Med, Seoul, South Korea; [Park, Yoon-Ghil] Yonsei Univ, Coll Med, Dept Rehabil Med & Rehabil, Inst Muscular Dis, Seoul, South Korea	Park, YG (corresponding author), 146-92 Dogok Dong, Seoul 135270, South Korea.	drtlc@yuhs.ac	kim, deog young/Q-8498-2019	Park, Yoon Ghil/0000-0001-9054-5300; kim, deog young/0000-0001-7622-6311			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha Amar, 2005, Am J Med, V118, P1416; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Elovic EP, 2004, J HEAD TRAUMA REHAB, V19, P184, DOI 10.1097/00001199-200403000-00010; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P541, DOI 10.1097/00001199-200311000-00008; FISHER DA, 1998, QUEST DIAGNOSTIC MAN, P312; GUNN IR, 1991, ANN CLIN BIOCHEM, V28, P327, DOI 10.1177/000456329102800402; HO KKY, 1995, METABOLISM, V44, P91, DOI 10.1016/0026-0495(95)90227-9; Kang Y., 1997, J KOREAN NEUROL ASS, V15, P300; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Toogood AA, 1998, CLIN ENDOCRINOL, V48, P569, DOI 10.1046/j.1365-2265.1998.00440.x; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51	17	26	27	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	11					1330	1335		10.3109/02699052.2010.506863			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MY	WOS:000283198800007	20828231				2021-06-18	
J	Snell, DL; Siegert, RJ; Hay-Smith, EJC; Surgenor, LJ				Snell, Deborah L.; Siegert, Richard J.; Hay-Smith, E. Jean C.; Surgenor, Lois J.			An examination of the factor structure of the Revised Illness Perception Questionnaire modified for adults with mild traumatic brain injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; Revised Illness Perception Questionnaire; factor analysis; illness beliefs	CONFIRMATORY FACTOR-ANALYSIS; PAIN PATIENTS; PRIMARY-CARE; IPQ-R; HEAD; OUTCOMES; BELIEFS; DEPRESSION; RECOVERY; VERSION	Objective: Factors influencing outcome after mild traumatic brain injury (MTBI) remain poorly understood. In other health conditions patient illness perceptions have been associated with outcome and have provided targets for effective interventions. These have not been systematically explored in MTBI and identifying reliable and valid measures of illness perceptions in MTBI is a first step before such concepts can be explored in clinical and research settings. Method: This study investigated the factor structure and internal consistency reliability of the Illness Perceptions Questionnaire-Revised (IPQ-R) modified for MTBI in a sample of 147 adults recruited within 3 months of injury. Results: The results demonstrated a close replication of the original factor structure although there were notable exceptions likely to be specific to MTBI and potentially other acutely injured populations. Final scales showed good internal consistency although factors relating to causal attribution were less so. Conclusion: The IPQ-R (MTBI) provides an acceptable measure of key components of injury perceptions after MTBI. Minor refinements appear required if this measure is to make a contribution to research and clinical practice in injury-based populations such as MTBI.	[Snell, Deborah L.] Burwood Hosp, Brain Injury Rehabil Serv, Concuss Clin, Canterbury Dist Hlth Board, Christchurch, New Zealand; [Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago Wellington, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, Sch Med, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, London WC2R 2LS, England; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand	Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Concuss Clin, Canterbury Dist Hlth Board, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929	Neurological Foundation of New Zealand [0728-SPG]	This research has been support by a Small Project Grant from the Neurological Foundation of New Zealand (Grant no: 0728-SPG).	Alexander Hamish, 2007, N Z Med J, V120, pU2420; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg Jorgen, 2004, Journal of Rehabilitation Medicine Supplement, P76; Cabassa LJ, 2008, CULT DIVERS ETHN MIN, V14, P377, DOI 10.1037/a0012820; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen SL, 2008, J ADV NURS, V64, P524, DOI 10.1111/j.1365-2648.2008.04808.x; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Figueiras MJ, 2007, PSYCHOL HEALTH, V22, P143, DOI 10.1080/14768320600774462; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; French DP, 2008, PSYCHOL HEALTH, V23, P5, DOI 10.1080/08870440701616714; French DP, 2006, J PSYCHOSOM RES, V61, P757, DOI 10.1016/j.jpsychores.2006.07.029; Frostholm L, 2007, J PSYCHOSOM RES, V62, P129, DOI 10.1016/j.jpsychores.2006.09.003; Hagger MS, 2005, PSYCHOL HEALTH, V20, P161, DOI 10.1080/0887044042000334724; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hobro N, 2004, PAIN, V108, P276, DOI 10.1016/j.pain.2003.12.027; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Llewellyn CD, 2007, J PSYCHOSOM RES, V63, P17, DOI 10.1016/j.jpsychores.2007.01.013; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Saltapidas H, 2008, BRAIN IMPAIR, V9, P1, DOI 10.1375/brim.9.1.1; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Skinner EA, 1996, J PERS SOC PSYCHOL, V71, P549, DOI 10.1037/0022-3514.71.3.549; Snell Deborah, 2006, N Z Med J, V119, pU1902; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Stuifbergen AK, 2006, WOMEN HEALTH ISS, V16, P353, DOI 10.1016/j.whi.2006.05.003; Surgenor LJ, 2003, EUR EAT DISORD REV, V11, P291, DOI 10.1002/erv.499; TEASDALE G, 1974, LANCET, V2, P81; Van Ittersum MW, 2009, PATIENT EDUC COUNS, V74, P53, DOI 10.1016/j.pec.2008.07.041; Watson R, 2006, J ADV NURS, V55, P330, DOI 10.1111/j.1365-2648.2006.03915.x; Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wittkowski Anja, 2008, Psychol Health Med, V13, P346, DOI 10.1080/13548500701487697	44	26	26	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1595	1605		10.3109/02699052.2010.523048			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800009	20973627				2021-06-18	
J	Svoboda, E; Richards, B; Polsinelli, A; Guger, S				Svoboda, Eva; Richards, Brian; Polsinelli, Angelina; Guger, Sharon			A theory-driven training programme in the use of emerging commercial technology: Application to an adolescent with severe memory impairment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Cognitive rehabilitation; Memory intervention; Technology; Adolescent; Amnesia; Suprasellar germinoma	TRAUMATIC BRAIN-INJURY; PAGING SYSTEM; DEVELOPMENTAL AMNESIA; REHABILITATION; AID; CHILDREN; NEUROPAGE; PEOPLE; INDIVIDUALS; PATIENT	We describe a theory-driven memory intervention programme for training individuals with moderate to severe memory impairment in the use of emerging commercial technology. Here we demonstrate the application of the programme to training MK, an 18-year-old woman with severe memory impairment following treatment for a suprasellar germinoma, to autonomously use a smartphone to support her day-to-day memory. A within-subject A1B1A2B2 single-case experimental design was used to evaluate the impact of smartphone use on MK's real-life functioning. Following intervention MK showed increased confidence in dealing with memory-demanding situations and generalised smartphone use across all aspects of her life as quantified by several and varied ecologically valid measures including a phone call schedule, behaviour memory observations and questionnaires. Moreover the intervention also benefited her family as indicated by a sustained reduction in caregiver strain and an increase in reported quality of life. These findings suggest that individuals with severe memory impairment, particularly young adults with potentially life-long dependence on their families, are able to capitalise on emerging commercial technology to function more autonomously. The findings also suggest that the gap between individuals with severe memory impairment and potent emerging technology can be closed by provision of a theory-driven structured training programme.	[Svoboda, Eva; Richards, Brian; Polsinelli, Angelina] Baycrest, Cognit & Behav Hlth Program, Toronto, ON M6A 2E1, Canada; [Guger, Sharon] Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Svoboda, E (corresponding author), Baycrest, Cognit & Behav Hlth Program, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	esvoboda@baycrest.org					BATT RC, 1990, AM J OCCUP THER, V44, P364, DOI 10.5014/ajot.44.4.364; Brizzolara D, 2003, CORTEX, V39, P605, DOI 10.1016/S0010-9452(08)70856-6; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Cullen C. N., 1976, NURS TIMES, V72, P45; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DePompei R, 2008, NEUROREHABILITATION, V23, P487; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gadian DG, 2000, BRAIN, V123, P499, DOI 10.1093/brain/123.3.499; Gentry T., 2008, AM J OCCUPATIONAL TH, V62, P8, DOI DOI 10.5014/AJOT.62.1.18; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; GREENE J, 1999, LEARNING USE STAT TE; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; JOHNSON R, 1990, BRIT J CLIN PSYCHOL, V29, P437, DOI 10.1111/j.2044-8260.1990.tb00909.x; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; MCGUIRE BE, 1990, CLIN REHABIL, V4, P319, DOI DOI 10.1177/026921559000400412; Oddy M, 2004, NEUROPSYCHOL REHABIL, V14, P481, DOI 10.1080/09602010343000309; RICHARDS B, 1990, J CLIN EXPT NEUROPSY, V12, P395; Roth R.M., 2005, BEHAV RATING INVENTO; Schacter DL, 1995, MEMORY DISTORTION, P1; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 2001, COGNITIVE REHABILITA, P194; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Stull D, 1996, J CLIN GEROPSYCHOL, V2, P175; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Teasdale TW, 2009, J NEUROL NEUROSUR PS, V80, P781, DOI 10.1136/jnnp.2008.162966; Troyer AK, 2002, J GERONTOL B-PSYCHOL, V57, pP19, DOI 10.1093/geronb/57.1.P19; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Tulving E, 1972, ORG MEMORY, P382; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Vargha-Khadem F, 2003, P NATL ACAD SCI USA, V100, P10055, DOI 10.1073/pnas.1233756100; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 2009, DEV NEUROREHABIL, V12, P421, DOI 10.3109/17518420903200573; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	55	26	26	0	15	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	4					562	586	PII 921646372	10.1080/09602011003669918			25	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	622BT	WOS:000279634300005	20425664				2021-06-18	
J	Curtis, KL; Greve, KW; Bianchini, KJ				Curtis, Kelly L.; Greve, Kevin W.; Bianchini, Kevin J.			The Wechsler Adult Intelligence Scale-III and Malingering in Traumatic Brain Injury Classification Accuracy in Known Groups	ASSESSMENT			English	Article						Wechsler Adult Intelligence Scale; malingering; traumatic brain injury; effort; classification accuracy; known groups	CARD SORTING TEST; HEAD-INJURY; WAIS-III; NEUROCOGNITIVE DYSFUNCTION; PERFORMANCE PATTERNS; LIKELIHOOD RATIOS; INCOMPLETE EFFORT; DIGIT SPAN; INDICATORS; SEVERITY	A known-groups design was used to determine the classification accuracy of Wechsler Adult Intelligence Scale-III (WAIS-III) variables in detecting malingered neurocognitive dysfunction (MND) in traumatic brain injury (TBI). TBI patients were classified into the following groups: (a) mild TBI not-MND (n = 26), (b) mild TBI MND (n = 31), and (c) moderate/severe (M/S) TBI not-MND (n = 26). A sample of 80 general clinical patients was used for comparison. Verbal IQ, Verbal Comprehension Index, and Working Memory Index detected approximately 25% of malingerers with a false positive (FP) error rate of approximately 5% in the mild TBI group. Comparable FP rates were obtained in M/S TBI. FP rates for Performance IQ, Perceptual Organization Index, and Processing Speed Index were acceptable in mild TBI but too high in M/S TBI. Previously studied specialized indicators (Vocabulary minus Digit Span and the Mittenberg formula) failed to differentiate malingerers from nonmalingerers. The clinical application of these findings is discussed.	[Greve, Kevin W.] Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Jefferson, AR USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Demakis GJ, 2004, APPL NEUROPSYCHOL, V11, P222; Demakis GJ, 2001, PSYCHOL ASSESSMENT, V13, P240, DOI 10.1037//1040-3590.13.2.240; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 1998, ARCH CLIN NEUROPSYCH, V13, P138; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, APPL NEUROPSYCHOL, V15, P161, DOI 10.1080/09084280802324085; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Johnstone L, 2003, BRIT J CLIN PSYCHOL, V42, P303, DOI 10.1348/01446650360703401; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Larrabee G. J., 2007, ASSESSMENT MALINGERE, P14; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LARRABEE GJ, 2007, EVALUATION MALINGERI, P334; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Miller LJ, 2004, CLIN NEUROPSYCHOL, V18, P327, DOI 10.1080/13854040490501592; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Wechsler D, 1997, WAIS 3 ADM SCORING M; WECHSLER D, 1997, WAIS III SCORING ASS; WILLIAMS RW, 1999, AM J FORENSIC PSYCH, V17, P35	64	26	26	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2009	16	4					401	414		10.1177/1073191109338161			14	Psychology, Clinical	Psychology	519QC	WOS:000271781100008	19797328				2021-06-18	
J	Liossi, C; Wood, RL				Liossi, Christina; Wood, Rodger Ll			Gender as a Moderator of Cognitive and Affective Outcome After Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MINOR HEAD-INJURY; SEX-DIFFERENCES; EXECUTIVE TESTS; DEPRESSION; SAMPLE; MILD; HIPPOCAMPUS; IMPAIRMENT; PREDICTORS; ADJUSTMENT	The aim of this investigation was to compare cognitive and affective functions in men and women who had suffered comparable brain injuries. In a prospective matched cohort design, 150 community-dwelling patients were individually matched on the basis of age, severity of injury, premorbid IQ, and time since injury. Women were significantly more impaired in verbal and visual memory compared with men. The degree of cognitive decline was significantly positively correlated with age in women, but not in men. Women had marginally higher scores compared with men on measures of anxiety and depression. It is concluded that gender is a moderator of cognitive and affective outcome after brain injury.	[Liossi, Christina] Univ Southampton, Sch Psychol, Southampton SO17 1BJ, Hants, England; [Wood, Rodger Ll] Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Swansea, W Glam, Wales	Liossi, C (corresponding author), Univ Southampton, Sch Psychol, Southampton SO17 1BJ, Hants, England.	cliossi@soton.ac.uk		Liossi, Christina/0000-0003-0627-6377			Baddeley A.D., 1992, SPEED CAPACITY LANGU; Barnes EF, 2005, J MED SPEECH-LANG PA, V13, P69; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cummings P, 2003, EPIDEMIOL REV, V25, P43, DOI 10.1093/epirev/mxg002; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farace E., 1996, NEUROIMAGING HDB BRA, P127; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Halstead WC, 1985, HALSTEAD REITAN NEUR; HART RP, 1987, PSYCHOL AGING, V2, P111, DOI 10.1037/0882-7974.2.2.111; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; HORTNAGL H, 1993, BRAIN RES BULL, V31, P129, DOI 10.1016/0361-9230(93)90019-8; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOZNIEWSKA E, 1995, CIRC RES, V76, P551, DOI 10.1161/01.RES.76.4.551; Kraus J F, 2000, Neurosurg Focus, V8, pe5; KRAUS JF, 1998, REHABILITATION ADULT, P3; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Little R.J.A., 1995, HDB STAT MODELING SO, P39, DOI [10.1007/978-1-4899-1292-3_2, DOI 10.1007/978-1-4899-1292-3_2]; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; NELSON H, 1991, NATL ADULT READING R; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Ritchie K, 2000, LANCET, V355, P225, DOI 10.1016/S0140-6736(99)06155-3; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; RUTHERFORD WH, 1978, BRAIN INJURY, V10, P225; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Shallice, 1997, HAYLING BRIXTON TEST; Shors TJ, 2001, J NEUROSCI, V21, P6292; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1997, WECHSLER ADULT MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; WHWLAN EA, 1990, AM J EPIDEMIOL, V131, P625; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P90, DOI 10.1017/S1355617707070129	59	26	27	0	5	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2009	21	1					43	51		10.1176/appi.neuropsych.21.1.43			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	431ES	WOS:000265044700007	19359451				2021-06-18	
J	Schuster, KM; Lofthouse, R; Moore, C; Lui, F; Kaplan, LJ; Davis, KA				Schuster, Kevin M.; Lofthouse, Rebecca; Moore, Christopher; Lui, Felix; Kaplan, Lewis J.; Davis, Kimberly A.			Pulseless Electrical Activity, Focused Abdominal Sonography for Trauma, and Cardiac Contractile Activity as Predictors of Survival After Trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	39th Annual Meeting of the Western-Trauma-Association	FEB 22-28, 2009	Crested Butte, CO	Western Trauma Assoc		Ultrasound; Echocardiography; Trauma; Pulseless electrical activity	PREHOSPITAL PULSELESS; ULTRASOUND; RESUSCITATION; EMERGENCY	Background: Pulseless electrical activity (PEA) secondary to both blunt and penetrating trauma is associated with minimal survival. The pericardial view of the focused abdominal sonography for trauma (p-FAST) can differentiate between patients with and without organized cardiac activity and may assist in the decision to terminate ongoing resuscitation. Methods: A retrospective review was performed for all patients presenting to a level I trauma center from January 2006 through January/2009 who had PEA on arrival or developed PEA in the emergency department. Additional data abstracted included outcome, the p-FAST findings, and mechanism of injury. Recorded FAST examinations were reviewed by a blinded ultrasound trained physician. Results: During the study period 25 patients presented with PEA and three developed PEA during initial resuscitation. Contractile cardiac activity was present in nine patients with PEA on presentation and immediately after deterioration to PEA in the three patients developing PEA. Four patients had a penetrating mechanism and 24 were blunt. Two pericardial effusions were present on examination, both after blunt trauma. Three patients survived beyond the emergency department (89% early mortality). The survivors had presented in PEA with organized cardiac contractile activity on ultrasound and had tension pneumothorax, tension hemothorax, and hypovolemia treated. Two patients died in the operating room of uncontrolled hemorrhage and one patient died 6 days after admission because of closed head injury. Conclusions: The presence of PEA at any time during initial resuscitation is a grave prognostic indicator. p-FAST is a useful test to identify contractile cardiac activity. p-FAST may identify those patients with potential for survival.	[Schuster, Kevin M.; Moore, Christopher] Yale Univ, Sch Med, Dept Surg, Sect Emergency Med, New Haven, CT 06520 USA; [Lofthouse, Rebecca] Yale New Haven Med Ctr, Ctr Trauma, New Haven, CT 06504 USA	Schuster, KM (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Emergency Med, 330 Cedar St,BB310, New Haven, CT 06520 USA.	kevin.schuster@yale.edu					*AM COLL SURG, 2008, AM COLL SURG COMM TR; Antonenko DR, 1999, ARCH SURG-CHICAGO, V134, P745; Battistella FD, 1999, ARCH SURG-CHICAGO, V134, P742, DOI 10.1001/archsurg.134.7.742; Blaivas M, 2001, ACAD EMERG MED, V8, P616, DOI 10.1111/j.1553-2712.2001.tb00174.x; Boulanger BR, 2001, J TRAUMA, V51, P320, DOI 10.1097/00005373-200108000-00015; Chang MC, 1998, J TRAUMA, V44, P296; Dyer D, 2008, J TRAUMA, V65, P1209, DOI 10.1097/TA.0b013e3181878052; Falcone R E, 1995, Air Med J, V14, P197, DOI 10.1016/1067-991X(95)90002-0; Falcone RE, 1995, AIR MED J, V14, P204; FRESHMAN SP, 1991, J TRAUMA, V31, P902, DOI 10.1097/00005373-199107000-00004; Martin SK, 2002, J TRAUMA, V53, P876, DOI 10.1097/00005373-200211000-00011; Rozycki GS, 1999, J TRAUMA, V46, P543, DOI 10.1097/00005373-199904000-00002; ROZYCKI GS, 1993, J TRAUMA, V34, P516, DOI 10.1097/00005373-199304000-00008; Salen P, 2001, ACAD EMERG MED, V8, P610, DOI 10.1111/j.1553-2712.2001.tb00172.x; Sisley AC, 1998, J TRAUMA, V44, P291, DOI 10.1097/00005373-199802000-00009; Stratton SJ, 1998, J TRAUMA, V45, P96, DOI 10.1097/00005373-199807000-00021; Su MJ, 2008, TELEMED J E-HEALTH, V14, P816, DOI 10.1089/tmj.2008.0076; Wherrett LJ, 1996, J TRAUMA, V41, P815, DOI 10.1097/00005373-199611000-00008; Wisner DH, 1999, J TRAUMA, V46, P551	19	26	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2009	67	6					1154	1157		10.1097/TA.0b013e3181c303e8			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	531IL	WOS:000272658100005	20009660				2021-06-18	
J	Markianos, M; Tripodianakis, J; Istikoglou, C; Rouvali, O; Christopoulos, M; Papageorgopoulos, P; Seretis, A				Markianos, Manolis; Tripodianakis, John; Istikoglou, Christos; Rouvali, Olga; Christopoulos, Markos; Papageorgopoulos, Pavlos; Seretis, Andreas			Suicide attempt by jumping: A study of gonadal axis hormones in male suicide attempters versus men who fell by accident	PSYCHIATRY RESEARCH			English	Article						Suicide attempt; Jumping; Accident; Fall from heights; Testosterone; LH; FSH; Cortisol; Prolactin	TRAUMATIC BRAIN-INJURY; TESTOSTERONE; STRESS; PROLACTIN; PLASMA; SUPPRESSION; DYSFUNCTION; DEPRESSION; SEVERITY; DOPAMINE	Low plasma total testosterone (T) levels may influence the sense of well-being and produce depressive symptomatology, increasing the risk of suicide. In a previous study, we reported reduced serum T levels in male psychiatric patients after a suicide attempt. The reduction was more pronounced in subjects who used violent attempt methods, and we discussed the possible influence of stress of hospitalization, serious medical condition and treatment In order to minimize the influence of such factors, we compared in this study the levels of plasma sex hormones of 15 psychiatric patients (10 suffering from schizophrenia and 5 from depression) who had attempted suicide by jumping with those of a group of 18 male subjects who were hospitalized after accidentally falling from a high height. Compared with a healthy control group of 40 males, both accident and attempt groups had lower T levels. The attempt group showed a trend toward lower T levels compared with levels in the accident group. In the accident group, luteinizing hormone (LH) levels were elevated compared with levels in healthy controls, indicating a normal function of the hypothalamic-pituitary-gonadal (HPG) axis. This was not the case for the attempt group, where low T levels were not accompanied by increases in LH. Cortisol and prolactin were similarly elevated in both patient groups, but were not related to the low T levels. The results indicate that male psychiatric patients who attempt suicide by violent methods may have low total plasma T levels, possibly due to a dysfunction of the HPG axis at the hypothalamic-pituitary level. Monitoring HPG axis function in future studies could prove to be a predictor of suicide at least for male psychiatric attempters, and could lead to preventive strategies. (c) 2008 Elsevier Ireland Ltd. All rights reserved.	[Markianos, Manolis] Univ Athens, Eginit Hosp, Sch Med, Lab Clin Neurochem, GR-11528 Athens, Greece; [Tripodianakis, John; Rouvali, Olga] Evangelismos Gen Hosp, Dept Psychiat, Athens 10676, Greece; [Istikoglou, Christos] Asclepe Hosp, Dept Psychiat, Voula Athens, Greece; [Christopoulos, Markos; Papageorgopoulos, Pavlos; Seretis, Andreas] Thriass Gen Hosp, Dept Neurosurg, Eleusis, Greece	Markianos, M (corresponding author), Univ Athens, Eginit Hosp, Sch Med, Lab Clin Neurochem, Vas Sophias 74, GR-11528 Athens, Greece.	markian@otenet.gr		Markianos, Manolis/0000-0002-4751-1014			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ARCHER J, 1991, BRIT J PSYCHOL, V82, P1, DOI 10.1111/j.2044-8295.1991.tb02379.x; BECK AT, 1975, AM J PSYCHIAT, V132, P182; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; Elman I, 1997, LIFE SCI, V61, P1705, DOI 10.1016/S0024-3205(97)00776-5; Gustavsson G, 2003, EUR NEUROPSYCHOPHARM, V13, P105, DOI 10.1016/S0924-977X(02)00131-1; HANDA RJ, 1994, PHYSIOL BEHAV, V55, P117, DOI 10.1016/0031-9384(94)90018-3; HASKINS JT, 1981, ENDOCRINOLOGY, V108, P767, DOI 10.1210/endo-108-3-767; Jokinen J, 2007, PSYCHIAT RES, V150, P297, DOI 10.1016/j.psychres.2006.12.001; JURCOVICOVA J, 1990, ENDOCRINOLOGY, V126, P2527, DOI 10.1210/endo-126-5-2527; LEE SC, 1994, BRAIN INJURY, V8, P571; Pope HG, 2003, AM J PSYCHIAT, V160, P105, DOI 10.1176/appi.ajp.160.1.105; REYMOND MJ, 1983, BRAIN RES, V262, P253, DOI 10.1016/0006-8993(83)91015-6; RIVIER C, 1991, BIOL REPROD, V45, P523, DOI 10.1095/biolreprod45.4.523; ROY A, 1992, BIOL PSYCHIAT, V32, P812, DOI 10.1016/0006-3223(92)90084-D; Shores MM, 2004, ARCH GEN PSYCHIAT, V61, P162, DOI 10.1001/archpsyc.61.2.162; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1548, DOI 10.1210/jc.76.6.1548; TRIPODIANAKIS J, 2007, EUROPEAN ARCH PSYCHI, V101, P255; van Heeringen K, 2000, J AFFECT DISORDERS, V60, P181, DOI 10.1016/S0165-0327(99)00180-9; Viau V, 2002, J NEUROENDOCRINOL, V14, P506, DOI 10.1046/j.1365-2826.2002.00798.x; Viau V, 1996, J NEUROSCI, V16, P1866; Zitzmann M, 2001, EUR J ENDOCRINOL, V144, P183, DOI 10.1530/eje.0.1440183	22	26	27	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	NOV 30	2009	170	1					82	85		10.1016/j.psychres.2008.08.001			4	Psychiatry	Psychiatry	522TY	WOS:000272023000013	19781790				2021-06-18	
J	Chen, ZY; Tortella, FC; Dave, JR; Marshall, VS; Clarke, DL; Sing, G; Du, F; Lu, XCM				Chen, Zhiyong; Tortella, Frank C.; Dave, Jitendra R.; Marshall, Vivienne S.; Clarke, Diana L.; Sing, George; Du, Fu; Lu, X. -C. May			Human Amnion-Derived Multipotent Progenitor Cell Treatment Alleviates Traumatic Brain Injury-Induced Axonal Degeneration	JOURNAL OF NEUROTRAUMA			English	Article						axon degeneration; human amnion; penetrating ballistic-like brain injury; progenitor cells; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MARROW STROMAL CELLS; EMBRYONIC STEM-CELLS; EPITHELIAL-CELLS; RAT MODEL; PRECURSOR CELLS; SPINAL-CORD; TRANSPLANTATION; NEURONS; NEUROGENESIS	To identify a viable cell source with potential neuroprotective effects, we studied amnion-derived multipotent progenitor (AMP) cells in a rat model of penetrating ballistic-like brain injury (PBBI). AMP cells were labeled with fluorescent dye PKH26 and injected in rats immediately following right hemispheric PBBI or sham PBBI surgery by ipsilateral i.c.v. administration. At 2 weeks post-injury, severe necrosis developed along the PBBI tract and axonal degeneration was prominent along the corpus callosum (cc) and in the ipsilateral thalamus. Injected AMP cells first entered the subventricular zone (SVZ) in both sham and PBBI rats. Further AMP cell migration along the cc only occurred in PBBI animals. No significant difference in injury volume was observed across all treatment groups. In contrast, treatment with AMP cells significantly attenuated axonal degeneration in both the thalamus and the cc. Interestingly, PKH26-labeled AMP cells were detected only in the SVZ and the cc (in parallel with the axonal degeneration), but not in the thalamus. None of the labeled AMP cells appeared to express neural differentiation, as evidenced by the lack of double labeling with nestin, S-100, GFAP, and MAP-2 immunostaining. In conclusion, AMP cell migration was specifically induced by PBBI and requires SVZ homing, yet the neuroprotective effect of intracerebral ventrical treatment using AMP cells was not limited to the area where the cells were present. This suggests that the attenuation of the secondary brain injury following PBBI was likely to be mediated by mechanisms other than cell replacement, possibly through delivery or sustained secretion of neurotrophic factors.	[Chen, Zhiyong; Tortella, Frank C.; Dave, Jitendra R.; Lu, X. -C. May] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Marshall, Vivienne S.; Clarke, Diana L.; Sing, George] Stemnion Inc, Pittsburgh, PA USA; [Du, Fu] FD NeuroTechnol Inc, Ellicott City, MD USA	Chen, ZY (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Zhiyong.chen@amedd.army.mil	Dave, Jitendra R/A-8940-2011				Bantubungi K, 2008, MOL CELL NEUROSCI, V37, P454, DOI 10.1016/j.mcn.2007.11.001; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Ben Menachem-Zidon O, 2008, NEUROPSYCHOPHARMACOL, V33, P2251, DOI 10.1038/sj.npp.1301606; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; CDC, 1999, TRAUM BRAIN INJ US R; DUNNETT SB, 1994, J NEUROL, V242, pS43, DOI 10.1007/BF00939242; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010; HernitGrant CS, 1996, EXP NEUROL, V139, P131, DOI 10.1006/exnr.1996.0088; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Janardhan Vallabh, 2004, Curr Cardiol Rep, V6, P117, DOI 10.1007/s11886-004-0009-8; Kakishita K, 2000, EXP NEUROL, V165, P27, DOI 10.1006/exnr.2000.7449; Kakishita K, 2003, BRAIN RES, V980, P48, DOI 10.1016/S0006-8993(03)02875-0; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kong XY, 2008, BRAIN RES, V1205, P108, DOI 10.1016/j.brainres.2008.02.040; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood U, 2004, RADIOLOGY, V233, P625, DOI 10.1148/radiol.2333041190; McDonald JW, 2004, J NEUROTRAUM, V21, P383, DOI 10.1089/089771504323004539; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Pierret C, 2007, STEM CELLS DEV, V16, P1017, DOI 10.1089/scd.2007.0012; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sakuragawa N, 1996, NEUROSCI LETT, V209, P9, DOI 10.1016/0304-3940(96)12599-4; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schuldiner M, 2001, BRAIN RES, V913, P201, DOI 10.1016/S0006-8993(01)02776-7; Snyder E Y, 1997, Adv Neurol, V72, P121; SOTELO C, 1991, TRENDS NEUROSCI, V14, P350, DOI 10.1016/0166-2236(91)90161-M; Steed David L, 2008, Eplasty, V8, pe18; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAKAHASHI K, 1970, Development Growth and Differentiation, V12, P65; Uchida S, 2000, J NEUROSCI RES, V62, P585, DOI 10.1002/1097-4547(20001115)62:4<585::AID-JNR13>3.0.CO;2-U; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	38	26	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1987	1997		10.1089/neu.2008.0863			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600014	19886807				2021-06-18	
J	Li, H; Lu, GP; Shi, W; Zheng, S				Li, Hao; Lu, Guoping; Shi, Wei; Zheng, Shan			Protective Effect of Moderate Hypothermia on Severe Traumatic Brain Injury in Children	JOURNAL OF NEUROTRAUMA			English	Article						children; moderate hypothermia; traumatic brain injury	PERINATAL ASPHYXIA; MILD HYPOTHERMIA; NEWBORN-INFANTS; INTRACRANIAL HYPERTENSION; CEREBRAL HYPOTHERMIA; HEAD-INJURY; PHASE-II; DAMAGE; THERAPY; PIGLETS	This study investigated the safety and neuroprotective effect of moderate hypothermia in children with severe traumatic brain injury (TBI). Twenty-two children suffering from TBI were randomly divided into groups treated with moderate hypothermia (intracranial temperature of 34.5 +/- 0.2 degrees C, maintained for 72 h, n = 12) or normothermia (intracranial temperature of 38.0 +/- 0.5, n =10). The cerebrospinal fluid levels of neuron-specific enolase (NSE), S-100, brain-specific creatine kinase (CK-BB), and intracranial pressure (ICP) levels were used to assess the protective effects. The variations in pH and electrolyte balance were also examined. The results indicated that the peak ICP level in the normothermia group (26.30 +/- 1.08 mm Hg) was reached 48 h after TBI. The ICP level in the moderate hypothermia group was lower than in the control group at every time point examined (p < 0.01). Furthermore, at 24, 48, and 72 h, the NSE, S-100, and CK-BB levels in the moderate hypothermia group were also lower than that of the normothermia group (p < 0.01). In the moderate hypothermia group, the pH and electrolyte balance at the end of the monitoring period were normal, but the heart rates were lower (p < 0.05). There were a total of three deaths (13.6%) in this study: one in the moderate hypothermia group (8.3%) and two in the normothermia group (20%). In conclusion, moderate hypothermia provided neuronal protection for children with severe TBI, and maintaining the intracranial temperature at 34.5 degrees C for 72 h was safe in this clinical setting.	[Li, Hao; Shi, Wei; Zheng, Shan] Fudan Univ, Childrens Hosp, Dept Pediat Surg, Shanghai 200032, Peoples R China; [Lu, Guoping] Fudan Univ, Childrens Hosp, PICU, Shanghai 200032, Peoples R China; [Lu, Guoping] Neurochirurg Univ Klinikum Schleswig Holstein, Campus Kiel, Germany	Zheng, S (corresponding author), Fudan Univ, Childrens Hosp, Dept Pediat Surg, Shanghai 200032, Peoples R China.	lihao7272@163.com					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; ADELSON PD, 2003, PEDIATR CRIT CARE ME, V2, pS75; Amess PN, 1998, BIOL NEONATE, V73, P40, DOI 10.1159/000013958; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Compagnoni G, 2002, BIOL NEONATE, V82, P222, DOI 10.1159/000065890; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1998, EARLY HUM DEV, V53, P19, DOI 10.1016/S0378-3782(98)00033-4; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Haaland K, 1997, PEDIATR RES, V41, P505, DOI 10.1203/00006450-199704000-00009; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; HEISTAD DD, 1973, J APPL PHYSIOL, V35, P581; HENDRICK E, 1963, CLIN NEUROSURG, V11, P46; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jia Jun, 2005, Chin J Traumatol, V8, P138; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Liu XM, 2006, AM J RESP CELL MOL, V34, P56, DOI 10.1165/rcmb.2005-0189OC; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Simbruner G, 1999, INTENS CARE MED, V25, P1111, DOI 10.1007/s001340051020; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Thoresen M, 1996, PEDIATR RES, V40, P738, DOI 10.1203/00006450-199611000-00014; WANG X, 1999, CHIN J PEDIAT, V37, P670; Williams GD, 1997, PEDIATR RES, V42, P700, DOI 10.1203/00006450-199711000-00024; ZHOU W, 2001, CHIN J PEDIAT, V39, P198	29	26	28	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1905	1909		10.1089/neu.2008.0828			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600005	19469686				2021-06-18	
J	McCarthy, MC; Moncrief, H; Sands, JM; Markert, RJ; Hall, LC; Wenker, IC; Anderson, HL; Ekeh, AP; Walusimbi, MS; Woods, RJ; Saxe, JM; Tchorz, KM				McCarthy, Mary C.; Moncrief, Hugh; Sands, Jean M.; Markert, Ronald J.; Hall, Lawrence C.; Wenker, Ian C.; Anderson, Harry L., III; Ekeh, A. Peter; Walusimbi, Mbaga S.; Woods, Randy J.; Saxe, Jonathan M.; Tchorz, Kathryn M.			Neurologic outcomes with cerebral oxygen monitoring in traumatic brain injury	SURGERY			English	Article							TISSUE OXYGENATION; HEAD-INJURY	Background. Optimizing cerebral oxygenation is advocated to Improve outcome in head-injured patients. The purpose of this study was to compare outcomes in brain-injured patients treated with 2 types of monitors. Methods. Patients with traumatic brain injury and a Glasgow Coma Scale score<8 were identified 071 admission. A polarographic cerebral oxygen/pressure monitor (Licox) or fiberoptic intracranial pressure monitor (Camino) was inserted tin. evidence-based algorithm treatment was Implemented Elements from the prehospital and emergency department records and the first 10 days of intensive care unit (ICU) care were collected Glasgow Outcome Scores (GOS) were determined every 3 months after discharge. Results. Over a 3-year period, 145 patient, were entered into the study; 81 patients In. the Lucox group and 64 patients in the Camino group. Mortality, hospital length of stay, and ICU length of stay were equivalent In the 2 groups. More patients In the Lucox group achieved a moderate/recovered GOS at 3 months than in the Camino Group (79% vs 61%, P = 09) Conclusion.. Three-month GOS revealed a clinically meaningful 18% benefit in patients undergoing cerebial oxygen monitoring and optimization. Six-month outcomes were also better Unfortunately, these important differences did-not reach significance Continued study of the benefits of cerebral oxygen. monitoring is warranted. (Surgery 2009:146:585-91)	[Sands, Jean M.] Miami Valley Hosp, Clin Res Ctr, Dayton, OH 45409 USA; [Moncrief, Hugh] Neurosurg Inst Inc, Dayton, OH USA; [Hall, Lawrence C.] Radiol Phys Inc, Dayton, OH USA; [McCarthy, Mary C.; Anderson, Harry L., III; Ekeh, A. Peter; Walusimbi, Mbaga S.; Woods, Randy J.; Saxe, Jonathan M.; Tchorz, Kathryn M.] Wright State Univ, Sch Med, Div Trauma Crit Care & Emergency Gen Surg, Dept Surg, Dayton, OH USA; [Markert, Ronald J.] Wright State Univ, Sch Med, Dept Internal Med & Orthoped, Dayton, OH USA; Wright State Univ, Sch Med, Dept Emergency Med, Dayton, OH USA	McCarthy, MC (corresponding author), Miami Valley Hosp, Clin Res Ctr, 1 Wyoming St,Suite 7000, Dayton, OH 45409 USA.			Wenker, Ian/0000-0002-0744-6510			DONG HK, 2006, NEUROCRIT CARE, V4, P83; Haitsma IK, 2007, PROG BRAIN RES, V161, P207, DOI 10.1016/S0079-6123(06)61014-5; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; SLICFEL MF, 2006, J NEUROSURG, V105, P568; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815	10	26	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2009	146	4					585	591		10.1016/j.surg.2009.06.059			7	Surgery	Surgery	507OD	WOS:000270863100007	19789016				2021-06-18	
J	Englander, J; Bushnik, T; Wright, JM; Jamison, L; Duong, TT				Englander, Jeffrey; Bushnik, Tamara; Wright, Jerry M.; Jamison, Laura; Duong, Thao T.			Mortality in Late Post-Traumatic Seizures	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; EPILEPSY; POPULATION; COHORT; RISK; PREVALENCE; DEATH; LIFE	The objective of this study was to examine the mortality rates in individuals with traumatic brain injury (TBI) who were classified as having experienced late post-traumatic seizures (LPTS) in the first 2 years post-TBI compared to those who were seizure-free (non-LPTS). Participants were a pooled sample (n = 508) from two studies which enrolled individuals with TBI who were injured between March 31, 1992 and December 20, 1999. The first sample was made up of individuals enrolled in a study of risk factors for LPTS development; the second sample was composed of individuals enrolled in the TBI National Database from a single rehabilitation center. Seventy-one (14%) participants had LPTS, of which 27% had died at 8-15 years post-injury, as compared to 10% of non-LPTS participants. Individuals with LPTS died at a younger age (54.1 versus 67.7 years; p = 0.01), but there were no statistically significant differences in either time from date of injury to death or highest GCS score in the first 24 h. Causes of death were variable and not specifically related to epilepsy. Of those with LPTS, risk factors for death include advanced age at time of injury and presence of subdural hematoma. The higher mortality rate and death at younger age with variable causes in TBI individuals with LPTS warrant close medical evaluation and monitoring of these individuals, particularly accessibility and compliance with ongoing general medical care, and education of primary care colleagues of the unique needs of this at-risk population.	[Bushnik, Tamara; Wright, Jerry M.; Jamison, Laura] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; [Englander, Jeffrey; Duong, Thao T.] Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA	Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	tamara@tbi-sci.org		Bushnik, Tamara/0000-0003-3328-257X	This work was supported by the U. S. Department of Education, Office of Special Education and Rehabilitative Services; National Institute on Disability and Rehabilitation Research [H133A020524]	This work was supported by the U. S. Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability and Rehabilitation Research ( grant no. H133A020524).	AISKAINEN I, 1999, EPILEPSIA, V40, P584; Annegers JF, 1999, SEIZURE-EUR J EPILEP, V8, P347, DOI 10.1053/seiz.1999.0306; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baguley I, 2000, BRAIN INJURY, V14, P505; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; COURJON J, 1970, EPILEPSIA, V11, P29, DOI 10.1111/j.1528-1157.1970.tb03863.x; DASILVA AM, 1990, ACT NEUR S, V50, P48; De Santis A, 1979, J Neurosurg Sci, V23, P207; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; JENNETT WB, 1975, EPILEPSY NONMISSILE; Kobau R, 2007, EPILEPSIA, V48, P1904, DOI 10.1111/j.1528-1167.2007.01161.x; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Langan Y, 2002, J NEUROL NEUROSUR PS, V73, P751, DOI 10.1136/jnnp.73.6.751; Lhatoo SD, 2005, EPILEPSIA, V46, P36, DOI 10.1111/j.1528-1167.2005.00406.x; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Nilsson L, 2003, EPILEPSIA, V44, P575, DOI 10.1046/j.1528-1157.2003.03302.x; Roberts A.V., 1979, SEVERE ACCIDENTAL HE, P140; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1987, ADV EPILEPTOL, V16, P627; Shackleton DP, 1999, J NEUROL NEUROSUR PS, V66, P636, DOI 10.1136/jnnp.66.5.636; Shackleton DP, 2002, EPILEPSIA, V43, P445, DOI 10.1046/j.1528-1157.2002.10301.x; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Strauss D, 1999, J INSUR MED, V31, P104; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; Wiebe S, 1999, CAN J NEUROL SCI, V26, P263, DOI 10.1017/S0317167100000354; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594	37	26	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1471	1477		10.1089/neu.2008.0729			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200004	19508123	Green Published			2021-06-18	
J	Kendall, E; Terry, D				Kendall, Elizabeth; Terry, Deborah			Predicting emotional well-being following traumatic brain injury: A test of mediated and moderated models	SOCIAL SCIENCE & MEDICINE			English	Article						Traumatic brain injury; Moderating role of appraisal; Mediating role of appraisal; Emotional well-being; Adjustment outcomes; Australia	SOCIAL SUPPORT; COPING STRATEGIES; STRESS; ADJUSTMENT; INDIVIDUALS; EXAMPLES; HEALTH; SAMPLE; BUFFER	This study examined two models for predicting emotional well-being following traumatic brain injury (TBI), namely the Lazarus and Folkman (1984) mediated model of stress and coping and the stress-buffer hypothesis (Cohen & Edwards, 1988). The mediated model suggests that antecedent variables (i.e., personal and environmental resources) will predict emotional well-being, but their effect will be mediated through cognitive variables, such as appraisal and coping. In contrast, the moderated (buffer) hypothesis suggests that resources will protect individuals from the effects of stress, so will have different relationships with outcome at different levels of perceived stress. Ninety individuals with TBI were recruited from a major hospital in Brisbane, Australia. They and their relatives completed questionnaires at three time intervals: discharge, one month and nine months post-discharge, discharge being in 1998. Hierarchical regression was used to examine the relationships among the proposed predictors, mediators and outcomes. Support was found for some aspects of both models in the short-term. In the long-term, stress-buffer effects were no longer apparent. However, with the exception of family support, the predictors all influenced long-term adjustment through their impact on short-term adjustment. The role of family support as a direct predictor of emotional well-being in the long-term is highlighted. The findings have the potential to enable the identification of "at risk" individuals prior to discharge and can highlight important foci for rehabilitation. Specifically, the study has identified the importance of early psychological intervention to address appraisal and the need to engage families in rehabilitation. (C) 2009 Elsevier Ltd. All rights reserved.	[Kendall, Elizabeth] Griffith Univ, Ctr Natl Res Disabil & Rehabil Med, Logan, Qld 4131, Australia; [Terry, Deborah] Univ Queensland, Brisbane, Qld 4072, Australia	Kendall, E (corresponding author), Griffith Univ, Ctr Natl Res Disabil & Rehabil Med, Logan Campus,Univ Dr Meadowbrook, Logan, Qld 4131, Australia.	e.kendall@griffith.edu.au	kendall, elizabeth/F-5065-2013	Kendall, Elizabeth/0000-0003-2399-1460			Aiken L.S., 1991, MULTIPLE REGRESSION; ALDWIN CM, 1987, J PERS SOC PSYCHOL, V53, P337, DOI 10.1037/0022-3514.53.2.337; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beck A., 1979, COGNITIVE THERAPY EM; Bedford A, 1997, PERS INDIV DIFFER, V22, P493, DOI 10.1016/S0191-8869(96)00242-5; BEDFORD A, 1976, BRIT J SOC CLIN PSYC, V15, P387, DOI 10.1111/j.2044-8260.1976.tb00050.x; Carte TA, 2003, MIS QUART, V27, P479; Cast AD, 2002, SOC FORCES, V80, P1041, DOI 10.1353/sof.2002.0003; CHAN F, 2008, REHABILITATION COUNS, V2009, P114; Chin W. W., 1998, MIS Q, V22, P7, DOI DOI 10.2307/249674; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cohen J., 1983, APPL MULTIPLE REGRES; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; Cohen S., 1988, ADV INVESTIGATION PS, P235; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Ellis A., 1987, J COGNITIVE PSYCHOTH, V1, P73; ELLSWORTH E, 1995, J INSTRUCTIONAL PSYC, V22, P19; FELTON BJ, 1984, J CONSULT CLIN PSYCH, V52, P343, DOI 10.1037/0022-006X.52.3.343; FINNEY JW, 1984, J HEALTH SOC BEHAV, V25, P85, DOI 10.2307/2136706; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Gignac MAM, 1996, PSYCHOL AGING, V11, P214, DOI 10.1037//0882-7974.11.2.214; GUO B, 2008, BRIT J SOCIAL WO JUL, P1; HOLAHAN CJ, 1985, J PERS SOC PSYCHOL, V49, P739, DOI 10.1037/0022-3514.49.3.739; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Jennett B, 1981, MANAGEMENT HEAD INJU; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KENDALL E, 2003, J VOCAT REHABIL, V19, P31; Kendall E, 2007, SOC SCI MED, V64, P735, DOI 10.1016/j.socscimed.2006.09.012; KESSLER RC, 1985, ANNU REV PSYCHOL, V36, P531, DOI 10.1146/annurev.ps.36.020185.002531; Krause N, 1995, PSYCHOL AGING, V10, P518, DOI 10.1037/0882-7974.10.4.518; Larson R, 1996, J SOC PSYCHOL, V136, P5, DOI 10.1080/00224545.1996.9923024; Lazarus R. S., 1990, PSYCHOL INQUIRY, V1, P3, DOI DOI 10.1207/S15327965PLI0101_1; Lazarus R.S., 1984, STRESS APPRAISAL COP; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; MacKinnon DP, 2007, ANNU REV PSYCHOL, V58, P593, DOI 10.1146/annurev.psych.58.110405.085542; Marshall Stephen W, 2007, Epidemiol Perspect Innov, V4, P4, DOI 10.1186/1742-5573-4-4; MCCOLL MA, 1995, SOC SCI MED, V41, P395, DOI 10.1016/0277-9536(94)00338-T; MENAGHAN EG, 1983, INDIVIDUAL COPING EF, P157; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; MOORE AD, 1994, CANADIAN J REHABILIT, V7, P193; Muller D, 2005, J PERS SOC PSYCHOL, V89, P852, DOI 10.1037/0022-3514.89.6.852; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; Penninx BWJH, 1997, SOC SCI MED, V44, P393, DOI 10.1016/S0277-9536(96)00156-6; Prawitz A., 2006, FINANCIAL COUNSELING, V17, P34, DOI 10.1037/t60365-000; Rahim MA, 1996, J SOC PSYCHOL, V136, P69, DOI 10.1080/00224545.1996.9923030; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932; Stroebe W, 1996, J PERS SOC PSYCHOL, V70, P1241, DOI 10.1037/0022-3514.70.6.1241; TERRY DJ, 1991, AUST J PSYCHOL, V43, P29, DOI 10.1080/00049539108259093	56	26	28	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	SEP	2009	69	6					947	954		10.1016/j.socscimed.2009.06.021			8	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	504UJ	WOS:000270642900019	19616354				2021-06-18	
J	Lee, SW; Hong, YS; Han, C; Kin, SJ; Moon, SW; Shin, JH; Baek, KJ				Lee, Sung-Woo; Hong, Yun-Sik; Han, Chul; Kin, Su-Jin; Moon, Sung-Woo; Shin, Jung-Ho; Baek, Kwang-Je			Concordance of End-Tidal Carbon Dioxide and Arterial Carbon Dioxide in Severe Traumatic Brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						End-tidal carbon dioxide; Arterial carbon dioxide; Tratumatic brain injury	RAPID-SEQUENCE INTUBATION; HEAD-INJURY; HYPERVENTILATION; VENTILATION; CO2	Objective: It is important for preventing hyperventilation so as to improve the outcomes of patients with severe traumatic brain injuries. End-tidal CO, (PetCO(2)) reflects arterial CO2 (PaCO2), noninvasively and continuously. The aim of this study is to examine the concordance between PaCO2 and PetCO(2) among adults presenting to the emergency department with severe traumatic brain injury and to elucidate the patient groups who had discordance. Methods: From July 1, 2006 to December 31, 2007, 77 patients who presented in the emergency department of the hospital after severe brain injury were enrolled. Glasgow Coma Scale, blood pressure, heart rate, respiration rate, body temperature, arterial blood gas variables, and serum lactate levels were measured under the mechanical ventilation support. Finally, Injury Severity Score and Abbreviated Injury Scale of head and chest were recorded. The concordance between PetCO(2) and PaCO2 analyzed using Bland-Altinan plot. We defined that normal gap of PaCO2 and PetCO(2) [p(a-et)CO2] is -5 mm Hg to 5 mm Hg, and compared the normal and high P(a-et)CO2 groups to find the factors affecting the P(a-et)CO2. Results: Sixty-six patients after exception of 11 patients with nontraumatic brain injury were analyzed. Ten patients (15.2%) were below 30 mm Hg of PaCO2. Pearson's correlation coefficient between PaCO2 and PetCO(2) was 0.666 (p < 0.001) and the concordance between PaCO2 and PetCO(2) was 77.3%. The patients with high P(a-et)CO2 showed significantly higher Injury Severity Score, lower systolic blood pressure, lower arterial pH, lower base deficit, and higher serum lactate levels than patients with normal P(a-et)CO2. Patients with severe chest trauma, hypotension, and metabolic acidosis increased the risk of the discordance between PaCO2 and PetCO(2). Twenty-eight patients who had no hypotension, no metabolic acidosis, and no severe chest trauma showed concordance rate of 100.0% between PaCO2 and PetCO(2). Conclusions: Severe chest trauma and hemodynamic and tissue perfusion state should be considered when attempting to monitor the hyperventilation in severe brain injury patients using PetCO(2)	[Baek, Kwang-Je] Konkuk Univ, Sch Med, Dept Emergency Med, Seoul, South Korea; [Lee, Sung-Woo; Hong, Yun-Sik; Han, Chul; Kin, Su-Jin; Moon, Sung-Woo; Shin, Jung-Ho] Korea Univ, Sch Med, Dept Emergency Med, Ansan 425707, South Korea	Lee, SW (corresponding author), Korea Univ, Ansan Hosp, Emergency Dept, 516 Gojan Dong, Ansan 425707, South Korea.	kuedlee@korea.ac.kr		shin, jungho/0000-0002-5388-2655			Benallal H, 2000, EUR J APPL PHYSIOL, V83, P402, DOI 10.1007/s004210000260; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BULLOCK MR, 2000, J NEUROTRAUM, V17, P513; Corbo J, 2005, ANN EMERG MED, V46, P323, DOI 10.1016/j.annemergmed.2004.12.005; Davis DP, 2007, RESUSCITATION, V73, P354, DOI 10.1016/j.resuscitation.2006.09.015; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Fall Pamela J, 2005, J Intensive Care Med, V20, P255, DOI 10.1177/0885066605278644; Kim Sunghan, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P9; KIRSCH TD, 2006, EMERGENCY MED COMPRE, P1557; Levine RL, 2000, INTENS CARE MED, V26, P1595, DOI 10.1007/s001340000699; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Nuckton TJ, 2002, NEW ENGL J MED, V346, P1281, DOI 10.1056/NEJMoa012835; NUNN JF, 1960, J APPL PHYSIOL, V15, P383; Seguin P, 2001, CAN J ANAESTH, V48, P396, DOI 10.1007/BF03014971; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Ward KR, 1998, ACAD EMERG MED, V5, P628, DOI 10.1111/j.1553-2712.1998.tb02473.x; Warner KJ, 2008, J TRAUMA, V64, P341, DOI 10.1097/TA.0b013e318160dfb3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	20	26	30	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2009	67	3					526	530		10.1097/TA.0b013e3181866432			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	493IL	WOS:000269729900019	19741395				2021-06-18	
J	Nagy, D; Marosi, M; Kis, Z; Farkas, T; Rakos, G; Vecsei, L; Teichberg, VI; Toldi, J				Nagy, David; Marosi, Mate; Kis, Zsolt; Farkas, Tamas; Rakos, Gabriella; Vecsei, Laszlo; Teichberg, Vivian I.; Toldi, Jozsef			Oxaloacetate Decreases the Infarct Size and Attenuates the Reduction in Evoked Responses after Photothrombotic Focal Ischemia in the Rat Cortex	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Glutamate excitotoxicity; Evoked potentials; Photothrombotic lesion; Neuroprotection	GLUTAMATE NEUROTOXICITY; CEREBROSPINAL-FLUID; HEME DEGRADATION; MOTOR CORTEX; BRAIN-INJURY; AMINO-ACIDS; IN-VITRO; MODEL; POTENTIALS; NEUROPROTECTION	A traumatic brain injury or a focal brain lesion is followed by acute excitotoxicity caused by the presence of abnormally high glutamate (Glu) levels in the cerebrospinal and interstitial fluids. It has recently been demonstrated that this excess Glu in the brain can be eliminated into the blood following the intravenous administration of oxaloacetate (OxAc), which, by scavenging the blood Glu, induces an enhanced and neuroprotective brain-to-blood Glu efflux. In this study, we subjected rats to a photothrombotic lesion and treated them after the illumination with a single 30-min-long administration of OxAc (1.2 mg/100 g, i.v.). Following induction of the lesion, we measured the infarct size and the amplitudes of the somatosensory evoked potentials (SEPs) as recorded from the skull surface. The photothrombotic lesion resulted in appreciably decreased amplitudes of the evoked potentials, but OxAc administration significantly attenuated this reduction, and also the infarct size assessed histologically. We suggest that the neuroprotective effects of OxAc are due to its blood Glu-scavenging activity, which, by increasing the brain-to-blood Glu efflux, reduces the excess Glu responsible for the anatomical and functional correlates of the ischemia, as evaluated by electrophysiological evoked potential (EP) measurements.	[Nagy, David; Marosi, Mate; Kis, Zsolt; Farkas, Tamas; Rakos, Gabriella; Toldi, Jozsef] Univ Szeged, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary; [Vecsei, Laszlo] Univ Szeged, Dept Neurol, H-6701 Szeged, Hungary; [Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Toldi, J (corresponding author), Univ Szeged, Dept Physiol Anat & Neurosci, Kozep Fasor 52, H-6726 Szeged, Hungary.	david.nagy01@gmail.com; marosi.mate@gmail.com; zskis@bio.u-szeged.hu; tfarkas@bio.u-szeged.hu; rakosgabi@gmail.com; vecsei@nepsy.szote.u-szeged.hu; vivian.teichberg@weizmann.ac.il; toldi@bio.u-szeged.hu	Vecsei, Laszlo/B-2066-2010; Nagy, David/C-7775-2011; Farkas, Tamas/B-7193-2008; Toldi, Jozsef/M-4858-2018; Kis, Zsolt/A-4583-2009	Vecsei, Laszlo/0000-0001-8037-3672; Toldi, Jozsef/0000-0001-7355-0503; Kis, Zsolt/0000-0002-6896-5883	National Bureau of Research and DevelopmentNational Office for Research and Technology [NKTH RET 08/2004]; OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [K75628]; TeT [SK-26/200]; Weizmann Institute Nella; Leon Benoziyo Center for Neurological Diseases;  [GVOP-3.2.1-2004-04-0357/3.0]	This work was supported by the National Bureau of Research and Development (NKTH RET 08/2004), OTKA K75628, TeT SK-26/200, and GVOP-3.2.1-2004-04-0357/3.0. T. F. is a Bolyai Fellow of the Hungarian Academy of Sciences. V. I. T has received support from the Weizmann Institute Nella and Leon Benoziyo Center for Neurological Diseases.	Back T, 2004, J NEUROL, V251, P388, DOI 10.1007/s00415-004-0399-y; BAIK MW, 1990, ELECTROEN CLIN NEURO, V75, P433, DOI 10.1016/0013-4694(90)90088-2; Bordi F, 1997, EXP NEUROL, V145, P425, DOI 10.1006/exnr.1997.6442; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Damjanac M, 2007, BRAIN RES, V1128, P40, DOI 10.1016/j.brainres.2006.05.050; Ebisu T, 2001, MAGN RESON IMAGING, V19, P153, DOI 10.1016/S0730-725X(01)00233-8; Farkas T, 2000, EUR J NEUROSCI, V12, P2190, DOI 10.1046/j.1460-9568.2000.00096.x; Farkas T, 2003, NEUROSCI LETT, V342, P49, DOI 10.1016/S0304-3940(03)00230-1; GIROTTI A W, 1985, Journal of Free Radicals in Biology and Medicine, V1, P395, DOI 10.1016/0748-5514(85)90152-7; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; HAMMOUDA AERMA, 1995, CYTOMETRY, V20, P19, DOI 10.1002/cyto.990200105; Hodgkins PS, 1999, J NEUROCHEM, V72, P643, DOI 10.1046/j.1471-4159.1999.0720643.x; Kharlamov A, 1996, BRAIN RES, V734, P1; LADDS A, 1988, ELECTROEN CLIN NEURO, V71, P233, DOI 10.1016/0168-5597(88)90008-1; LIU XG, 1992, ELECTROEN CLIN NEURO, V85, P209, DOI 10.1016/0168-5597(92)90134-W; LYE RH, 1987, J NEUROSCI METH, V22, P133, DOI 10.1016/0165-0270(87)90007-0; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MINAMIDE H, 1994, SURG NEUROL, V42, P138, DOI 10.1016/0090-3019(94)90375-1; Molchanova S, 2004, NEUROCHEM RES, V29, P1519, DOI 10.1023/B:NERE.0000029564.98905.5c; MULLER TB, 1995, STROKE, V26, P1453, DOI 10.1161/01.STR.26.8.1453; Nagababu E, 2004, ANTIOXID REDOX SIGN, V6, P967, DOI 10.1089/1523086042259823; Nagababu E, 1998, BIOCHEM BIOPH RES CO, V247, P592, DOI 10.1006/bbrc.1998.8846; Nistico R, 2008, BRIT J PHARMACOL, V153, P1022, DOI 10.1038/sj.bjp.0707587; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2; Scheller D, 2000, AMINO ACIDS, V19, P571, DOI 10.1007/s007260070007; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; Spreux-Varoquaux O, 2002, J NEUROL SCI, V193, P73, DOI 10.1016/S0022-510X(01)00661-X; Stieg PE, 1999, EUR J PHARMACOL, V375, P115, DOI 10.1016/S0014-2999(99)00214-9; STONE TW, 1993, PHARMACOL REV, V45, P309; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Toldi J, 1999, NEUROREPORT, V10, P2143, DOI 10.1097/00001756-199907130-00027; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; Umemura K, 1997, BRAIN RES, V773, P61, DOI 10.1016/S0006-8993(97)00894-9; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Wright A, 2003, FREE RADICAL BIO MED, V34, P637, DOI 10.1016/S0891-5849(02)01361-8; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	43	26	26	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	SEP	2009	29	6-7					827	835		10.1007/s10571-009-9364-8			9	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	476YI	WOS:000268482300008	19259807				2021-06-18	
J	Stein, SC; Ganguly, K; Belfield, CM; Xu, XS; Swanson, EW; Chen, XH; Browne, KD; Johnson, VE; Smith, DH; LeBold, DG; Cines, DB; Muzykhantov, VR				Stein, Sherman C.; Ganguly, Kumkum; Belfield, Caitlin M.; Xu, Xiangsheng; Swanson, Edward W.; Chen, Xiao-Han; Browne, Kevin D.; Johnson, Victoria E.; Smith, Douglas H.; LeBold, David G.; Cines, Douglas B.; Muzykhantov, Vladimir R.			Erythrocyte-Bound Tissue Plasminogen Activator is Neuroprotective in Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Conference of the International-Neurotrauma-Society	2006	Rotterdam, NETHERLANDS	Int Neurotrauma Soc		blood-brain barrier; microclots; tissue plasminogen activator; traumatic brain injury	FIBRINOLYSIS; CLEARANCE; AFFINITY; DAMAGE; RAT	The purpose of this study was to test the effects of exogenous tissue plasminogen activator (tPA) in traumatic brain injury (TBI). We tested two different tPA formulations, free tPA and tPA bound to erythrocytes (RBC/tPA). Vehicle and each of the tPA treatments were injected intravenously into anesthetized rats 15 min after moderate lateral fluid percussion injury. The animals were sacrificed at 2 days for calculating microclot burden (n = 13) and IgG staining area (n = 13) in the brain sections as indicators of post-traumatic thrombosis and blood-brain barrier (BBB) breakdown, respectively. Another set of injured animals treated in the same way were sacrificed at 7 days to compare cortical lesion volumes (n = 28) and CA3 hippocampal cell loss (n = 24). All evaluations were done blinded with respect to treatment. No significant differences were found with respect to microclot burden or IgG staining volume. Injection of wild-type tPA caused significantly (p < 0.05) larger cortical injuries and greater cerebral hemorrhage. In contrast, there was significantly less cortical injury (p < 0.01) and hippocampal cell loss (p < 0.01) in the RBC/tPA group than in all other groups. These results reveal that RBC/tPA is more neuroprotective in experimental TBI than is unbound tPA.	[Stein, Sherman C.; Belfield, Caitlin M.; Xu, Xiangsheng; Swanson, Edward W.; Chen, Xiao-Han; Browne, Kevin D.; Johnson, Victoria E.; Smith, Douglas H.; LeBold, David G.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19106 USA; [Cines, Douglas B.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19106 USA; [Muzykhantov, Vladimir R.] Univ Penn, Sch Med, Inst Environm Med, Inst Translat Med, Philadelphia, PA 19106 USA; [Muzykhantov, Vladimir R.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19106 USA; [Ganguly, Kumkum] Los Alamos Natl Lab, Div B, Los Alamos, NM USA	Stein, SC (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 310 Spruce St, Philadelphia, PA 19106 USA.	sherman.stein@uphs.upenn.edu	smith, douglas/A-1321-2007	Ganguly, Kumkum/0000-0002-2255-8940	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL076206, R01HL090697, R01HL077760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053410] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA83121] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL077760-01A2, R01 HL76206, R01 HL07971, R01 HL090697, R01 HL090697-01A1, R01 HL81864, R01 HL76406] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS053410] Funding Source: Medline		Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; ARMSTEAD WM, 2008, STOKE, V30, P165; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; Danielyan K, 2008, CIRCULATION, V118, P1442, DOI 10.1161/CIRCULATIONAHA.107.750257; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Ganguly K, 2006, J PHARMACOL EXP THER, V316, P1130, DOI 10.1124/jpet.105.093450; Ganguly K, 2005, J PHARMACOL EXP THER, V312, P1106, DOI 10.1124/jpet.104.075770; Ganguly K, 2007, J PHARMACOL EXP THER, V321, P158, DOI 10.1124/jpet.106.114405; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846; Muzykantov VR, 1996, BIOTECHNOL APPL BIOC, V24, P41; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Yepes M, 2004, EXP BIOL MED, V229, P1097; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Zaitsev S, 2006, BLOOD, V108, P1895, DOI 10.1182/blood-2005-11-012336	27	26	28	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1585	1592		10.1089/neu.2008.0720			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200015	19331516	Green Published, Green Accepted			2021-06-18	
J	Gordan, W; Spivak-David, D; Adornato, V; Dale, B; Brougham, R; Georgeadis, AC; Gassaway, J				Gordan, Wendy; Spivak-David, Dana; Adornato, Viki; Dale, Beverly; Brougham, Rebecca; Georgeadis, Amy C.; Gassaway, Julie			SCIRehab Project Series: The Speech Language Pathology Taxonomy	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries, Rehabilitation, physical; Speech language pathology, Taxonomy; Practice-based evidence; Tracheostomy; Ventilator; Dysphagia; Apraxia; Dysarthria	SPINAL-CORD-INJURY; CLOSED HEAD-INJURY; COGNITIVE REHABILITATION; DYSFUNCTION; STROKE; RISK	Introduction: Outcomes research for speech language pathology (SLP) interventions for acute traumatic spinal cord injury (SCI) rehabilitation in the US is difficult because of the lack of a treatment classification system (taxonomy). Objective: To describe a taxonomy developed by speech language pathologists (SLPs) to examine the effects of SLP interventions on SCI rehabilitation outcomes. Methods: The SCIRehab study uses practice-based evidence, a rigorous observational methodology that examines treatment processes without specifying or requiring specific therapeutic interventions. Speech language pathology lead clinicians and researchers at 6 US SCI centers developed a detailed SLP taxonomy documentation process that is comprehensive of SLP interventions for patients with SCI. Results: The SLP taxonomy consists of 7 intervention categories that address deficits (speech production for patients with artificial airway, motor speech and voice, swallowing, cognitive-communication, and communication) and the associated exercises and tasks that patients perform. Time is recorded for each category, and supplementary information focuses on cueing needs and family involvement that helps to describe and guide intervention selection. The SCIRehab project is enrolling 1,500 patients with acute traumatic SCI at 6 inpatient rehabilitation facilities. Conclusions: Speech language pathology taxonomy information is being captured for the SCIRehab patients who are referred for SLP services; this may be the first attempt to document the many details of the SLP rehabilitation process for patients with SCI in the US.	[Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Gordan, Wendy] Craig Hosp, Englewood, CO USA; [Spivak-David, Dana] Mt Sinai Med Ctr, New York, NY 10029 USA; [Adornato, Viki] Carolinas Rehabil, Charlotte, NC USA; [Dale, Beverly] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Brougham, Rebecca] Shepherd Ctr, Atlanta, GA USA; [Georgeadis, Amy C.] Natl Rehabil Hosp, Washington, DC USA	Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E S Temple, Salt Lake City, UT 84102 USA.	jgassaway@isisicor.com			National Institute on Disability and Rehabilitation Research (NIDRR); US Department of EducationUS Department of Education [H133A060103, H133N060005, H133N060027, H133N060028, H133A21943-16, H133N060009, H133N060014]	This work was supported in part by grants from the National Institute on Disability and Rehabilitation Research (NIDRR), Office of Special Education Services, US Department of Education to Craig Hospital (grants #H133A060103 and #H133N060005), Mount Sinai School of Medicine (grant #H133N060027), National Rehabilitation Hospital (grant #H133N060028), Carolinas Rehabilitation (grant #H133A21943-16), Shepherd Center (#grant H133N060009), and Rehabilitation Institute of Chicago (grant #H133N060014).	Abel R, 2004, DYSPHAGIA, V19, P87, DOI 10.1007/s00455-003-0511-y; Ashley MJ, 1995, TRAUMATIC BRAIN INJU; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DAHLBERG C, 1997, TOP SPINAL CORD INJ, V2, P41; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; FOLKINS JW, 1990, J SPEECH HEAR DISORD, V55, P596, DOI 10.1044/jshd.5504.596; Frempong-Boadu A, 2002, J SPINAL DISORD TECH, V15, P362, DOI 10.1097/00024720-200210000-00004; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; Hatfield B, 2005, ARCH PHYS MED REHAB, V86, pS61, DOI 10.1016/j.apmr.2005.08.111; HOIT JD, 1990, J SPEECH HEAR RES, V33, P798, DOI 10.1044/jshr.3304.798; Holland A., 1984, LANGUAGE DISORDERS A; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Logemann J. A., 1998, EVALUATION TREATMENT; MacBean N, 2006, J MED SPEECH-LANG PA, V14, P167; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; MARTYNOV AI, 1997, KLIN MED MOSCOW, V12, P8; *NAT SPIN CORD INJ, 2008, SPIN CORD INJ FACTS; *NAT SPIN CORD INJ, 1999, ANN REP MOD SPIN COR; Parente R., 1996, RETRAINING COGNITION; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; UB Foundation Activities Inc., 2004, IRF PAI TRAIN MAN; Wenke RJ, 2008, BRAIN INJURY, V22, P339, DOI 10.1080/02699050801960987; Whitford DL, 2009, DIABETES CARE, V32, P251, DOI 10.2337/dc08-1200; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; Winslow CP, 1999, AM J OTOLARYNG, V20, P16, DOI 10.1016/S0196-0709(99)90046-7; Wolfe DL, 2004, TOP SPINAL CORD INJ, V10, P41	31	26	26	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUN	2009	32	3					307	318		10.1080/10790268.2009.11760784			12	Clinical Neurology	Neurosciences & Neurology	474NF	WOS:000268290100011	19810632	Green Published			2021-06-18	
J	Ernst, WJ; Trice, AD; Gilbert, JL; Potts, H				Ernst, William J.; Trice, Ashton D.; Gilbert, Jennifer L.; Potts, Heather			Misconceptions About Traumatic Brain Injury and Recovery Among Nursing Students	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						healthcare; misconceptions; recovery; traumatic brain injury		Objective: To identify potential misconceptions that nursing students have regarding traumatic brain injury (TBI) and recovery, Design: Descriptive questionnaire. Setting: University. Main Measure: Thirty-item questionnaire addressing knowledge about TBI and recovery. Participants: One hundred eight undergraduate students, 65 in the prenursing program and 43 nursing majors. Results: In general, nursing students had a lower frequency of misconceptions than did university students in a prior study, and the more advanced nursing majors had a lower frequency of misconceptions than did the prenursing students. Substantial misconceptions did exist, though, especially concerning unconsciousness, amnesia, and recovery. Conclusions: Nursing students possess several misconceptions pertaining to TBI and recovery that have the potential to adversely affect assessment, treatment, and education of patients and family members. Education focusing on TBI and recovery should be included in the nursing curriculum and be a part of continuing education at the professional level.	[Ernst, William J.; Trice, Ashton D.] James Madison Univ, Dept Grad Psychol, Harrisonburg, VA 22807 USA; [Gilbert, Jennifer L.] Childrens Natl Med Ctr, Dept Psychiat Psychol, Washington, DC 20010 USA; [Potts, Heather] George Washington Univ, Grad Sch Educ & Human Dev, Washington, DC USA	Ernst, WJ (corresponding author), Neuropsychol Evaluat Serv, 495 Iron Bridge Rd,Ste 8, Freehold, NJ 07728 USA.	william-e@earthlink.net					Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lucas JA, 2006, CLIN NEUROPSYCHOLOGY, P351; O'Jile J. R., 1997, INT J REHABILITATION, V3, P61, DOI DOI 10.1007/BF02766798; Semrud-Clikeman M, 2005, HDB SCH NEUROPSYCHOL; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	13	26	26	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					213	220		10.1097/HTR.0b013e3181a7ecd8			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800007	19461368				2021-06-18	
J	Zweckberger, K; Plesnila, N				Zweckberger, Klaus; Plesnila, Nikolaus			Anatibant (R), a selective non-peptide bradykinin B-2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Bradykinin; Bradykinin B-2 receptor antagonist; Contusion volume; Intracranial pressure	CONTROLLED CORTICAL IMPACT; CLOSED-HEAD TRAUMA; CEREBRAL BLOOD-VOLUME; LF 16-0687 MS; KININ RECEPTORS; RAT MODEL; EDEMA; KALLIKREIN; NEURONS; SYSTEM	Bradykinin, the main metabolite of the kallikrein-kinin system and one of the first mediators released during inflammation, is well known to increase the permeability of the blood brain barrier (BBB) by activation of kinin B-2 receptors and hence promote brain edema formation following traumatic brain injury (TBI). Anatibant (R) (LF 16-0687), a selective non-peptide bradykinin B-2 receptor antagonist, reduces brain edema after experimental TBI, however, so far no data are available if Anatibant (R) reduces also the sequels of brain edema formation, i.e. morphological brain damage. Therefore, we investigated the effect of Anatibant (3.0 mg/kg b.w.) on intracranial pressure (ICP) and contusion volume after experimental TBI. Male C57/BI6 mice (25-28 g) were subjected to Controlled Cortical Impact trauma (CCI). Anatibant (R) was administrated as a subcutaneous bolus 15 min and 8 h after TBI. ICP was measured 3, 6, and 10 h after injury and contusion volume was quantified 24 h after trauma. Our data demonstrate a significant reduction of ICP (16.6 +/- 1.67 mmHg vs. 24.40 +/- 3.58 mmHg; n=6; p=0.002) and of contusion volume 24 h after trauma (28.28 +/- 5.18 mm(3) vs. 35.0 +/- 3.32 mm(3) n=7; p=0.003) in treated mice. Therefore we conclude, that inhibition of bradykinin B-2 receptors seems to be a promising treatment option, and might therefore be investigated in clinical trails for the treatment of TBI. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Zweckberger, Klaus; Plesnila, Nikolaus] Univ Munich, Inst Surg Res, Med Ctr Grosshadern, D-8000 Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Munich, Germany	Plesnila, N (corresponding author), Royal Coll Surgeons Ireland, 123 St,Stephens Green, Dublin 2, Ireland.	klaus.zweckberger@med.uni-heidelberg.de; nikolausplesnila@rcsi.ie	Plesnila, Nikolaus/T-7522-2019				BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BAETHMANN A, 1982, MUNCHEN MED WOCHEN, V124, P941; Bouma GJ, 1998, ACT NEUR S, V71, P272; BULLOCK R, 1990, BRIT MED J, V300, P1515, DOI 10.1136/bmj.300.6738.1515; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lee YJ, 2002, MOL CELL NEUROSCI, V19, P186, DOI 10.1006/mcne.2001.1073; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Mahabeer R, 2000, METAB BRAIN DIS, V15, P325, DOI 10.1023/A:1011131510491; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Mayhan WG, 1996, BRAIN RES, V738, P337, DOI 10.1016/S0006-8993(96)01000-1; Murone C, 1997, J COMP NEUROL, V381, P203, DOI 10.1002/(SICI)1096-9861(19970505)381:2<203::AID-CNE7>3.0.CO;2-7; Pela IR, 1996, BRIT J PHARMACOL, V118, P1488, DOI 10.1111/j.1476-5381.1996.tb15564.x; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Rachinsky M, 2001, J TRAUMA, V51, P944, DOI 10.1097/00005373-200111000-00020; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; REGOLI D, 1984, J CARDIOVASC PHARM, V6, pS401, DOI 10.1097/00005344-198406002-00015; REILLY PL, 1975, LANCET, V2, P375; Schulz J, 2000, ACT NEUR S, V76, P137; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; Wahl M., 1999, Acta Physiologica Hungarica, V86, P155; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Zausinger S, 2002, BRAIN RES, V950, P268, DOI 10.1016/S0006-8993(02)03053-6; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	33	26	28	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 24	2009	454	2					115	117		10.1016/j.neulet.2009.02.014			3	Neurosciences	Neurosciences & Neurology	435MH	WOS:000265347500002	19429066				2021-06-18	
J	Bonatti, E; Kuchukhidze, G; Zamarian, L; Trinka, E; Bodner, T; Benke, T; Delazer, M				Bonatti, Elisabeth; Kuchukhidze, Giorgi; Zamarian, Laura; Trinka, Eugen; Bodner, Thomas; Benke, Thomas; Delazer, Margarete			Decision making in ambiguous and risky situations after unilateral temporal lobe epilepsy surgery	EPILEPSY & BEHAVIOR			English	Article						Decision making; Ambiguity; Risk; Executive functions; Mesial temporal lobe epilepsy; Epilepsy surgery	VENTROMEDIAL PREFRONTAL CORTEX; MILD ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; GAMBLING TASK; PARKINSONS-DISEASE; HUMAN AMYGDALA; EMOTION; DAMAGE; IMPAIRMENT; RESECTION	Decision making is essential in everyday life. Though the importance of the mesial temporal structures in emotional processing and feedback learning is well established, decision making in patients after mesial temporal lobe surgery has rarely been studied. We studied 23 patients with mesial temporal lobe epilepsy after unilateral temporal lobe surgery and 26 healthy controls using two different gambling tasks. the Iowa Gambling Task (IGT) and the Probability-Associated Gambling (PAG) task. In the IGT, rules for gains and losses are implicit; in the PAG task, winning probabilities are well defined. Compared with healthy controls, patients performed poorly on the IGT (decisions under ambiguity). No group difference was found in the PAG task (decisions under risk. Results of the present investigation indicate that after mesial temporal lobe surgery, patients have difficulties in making decisions under ambiguity, whereas they decide advantageously when information about the decision situation is explicitly given. (C) 2009 Elsevier Inc. All rights reserved.	[Bonatti, Elisabeth; Kuchukhidze, Giorgi; Zamarian, Laura; Trinka, Eugen; Bodner, Thomas; Benke, Thomas; Delazer, Margarete] Innsbruck Med Univ, Dept Clin Neurol, A-6020 Innsbruck, Austria	Bonatti, E (corresponding author), Innsbruck Med Univ, Dept Clin Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	Elisabeth.Bonatti@i-med.ac.at	Zamarian, Laura/J-9575-2018	Zamarian, Laura/0000-0002-1640-4179; Kuchukhidze, Giorgi/0000-0001-6899-8506; Delazer, Margarete/0000-0001-6482-4445; Trinka, Eugen/0000-0002-5950-2692	Austrian Science FundAustrian Science Fund (FWF) [P18896-1305]; Tiroler Wissenschaftsfonds; Medical University Innsbruck; Medizinische Forschungsforderung Innsbruck [PDO-Nr. 12880 (2007-419)]	The present research was supported by Austrian Science Fund (FWF) Grant P18896-1305, by Tiroler Wissenschaftsfonds (TWF), by a predoctoral grant from the Medical University Innsbruck, and by Medizinische Forschungsforderung Innsbruck Grant PDO-Nr. 12880 (2007-419).	Andresen B, 2002, HPI HAMBURGER PERSON; Aschenbrenner S, 2002, REGENSBURGER WORTFLU; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1999, J NEUROSCI, V19, P5473; Bolla KI, 2004, CEREB CORTEX, V14, P1226, DOI 10.1093/cercor/bhh083; Bonatti E, 2008, COGN BEHAV NEUROL, V21, P164, DOI 10.1097/WNN.0b013e318184e688; Brand M, 2004, BEHAV NEUROL, V15, P77, DOI 10.1155/2004/578354; Brand M, 2005, NEUROPSYCHOLOGY, V19, P267, DOI 10.1037/0894-4105.19.3.267; Brand M., 2002, TEST ZUM KOGNITIVEN; Brand M, 2007, NEUROPSYCHOLOGIA, V45, P1305, DOI 10.1016/j.neuropsychologia.2006.09.021; Brand M, 2006, NEURAL NETWORKS, V19, P1266, DOI 10.1016/j.neunet.2006.03.001; Brand M, 2008, J NEUROPSYCHOL, V2, P431, DOI 10.1348/174866407X220607; Buss U., 1995, HOSP ANXIETY DEPRESS; Butman J, 2007, ACTAS ESP PSIQUIATRI, V35, P8; Cavedini P, 2002, NEUROPSYCHOLOGIA, V40, P205, DOI 10.1016/S0028-3932(01)00077-X; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Cohen MX, 2008, NEUROIMAGE, V39, P1396, DOI 10.1016/j.neuroimage.2007.10.004; Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9; Delazer M, 2007, NEUROPSYCHOLOGIA, V45, P1632, DOI 10.1016/j.neuropsychologia.2007.01.006; Denburg NL, 2007, ANN NY ACAD SCI, V1121, P480, DOI 10.1196/annals.1401.031; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Denburg NL, 2001, BRAIN COGNITION, V47, P156; Dunn BD, 2006, NEUROSCI BIOBEHAV R, V30, P239, DOI 10.1016/j.neubiorev.2005.07.001; Fein G, 2007, J INT NEUROPSYCH SOC, V13, P480, DOI 10.1017/S135561770707052X; Fox AM, 2000, CLIN NEUROPHYSIOL, V111, P1045, DOI 10.1016/S1388-2457(00)00257-1; Frank MJ, 2004, SCIENCE, V306, P1940, DOI 10.1126/science.1102941; Harting C., 2000, WMS R WECHSLER GEDAC; Heaton R., 1993, WISCONSIN CARD SORTI; Helmstaedter C, 2008, EPILEPSIA, V49, P88, DOI 10.1111/j.1528-1167.2007.01386.x; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Huettel SA, 2006, NEURON, V49, P765, DOI 10.1016/j.neuron.2006.01.024; ILMBERGER J, 1988, 30 ANN M TEAP MARB; JACKSON M, 1986, CORTEX, V22, P611, DOI 10.1016/S0010-9452(86)80020-X; KOHLER J, 2000, PLANUNGSTEST KONSTAN; Labudda K, 2009, NEUROPSYCHOLOGIA, V47, P50, DOI 10.1016/j.neuropsychologia.2008.08.014; LEHRL S, 1991, MANUAL ZUM MWT B BAL; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEZAK MD, 1998, NEUROPSYCHOLOGICAL A; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Overman WH, 2004, BRAIN COGNITION, V55, P134, DOI 10.1016/s0278-2626(03)00279-3; Phelps EA, 2006, ANNU REV PSYCHOL, V57, P27, DOI 10.1146/annurev.psych.56.091103.070234; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Phelps EA, 1997, CURR BIOL, V7, pR311, DOI 10.1016/S0960-9822(06)00146-1; Roth M., 2003, Z DIFFERENTIELLE DIA, V24, P65; Shaw P, 2007, NEUROPSYCHOLOGIA, V45, P2783, DOI 10.1016/j.neuropsychologia.2007.04.020; Sinz H, 2008, NEUROPSYCHOLOGIA, V46, P2043, DOI 10.1016/j.neuropsychologia.2008.02.002; Stout JC, 2001, J INT NEUROPSYCH SOC, V7, P92, DOI 10.1017/S1355617701711095; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Wieser HG, 2001, EPILEPSIA, V42, P282, DOI 10.1046/j.1528-1157.2001.4220282.x; WYNNE HJ, 2002, MEASURING GAMBLING P; Zamarian L, 2008, NEUROPSYCHOLOGY, V22, P645, DOI 10.1037/0894-4105.22.5.645	54	26	27	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	APR	2009	14	4					665	673		10.1016/j.yebeh.2009.02.015			9	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	435JR	WOS:000265340700017	19233314				2021-06-18	
J	Tan, AA; Quigley, A; Smith, DC; Hoane, MR				Tan, Arlene A.; Quigley, Andrea; Smith, Douglas C.; Hoane, Michael R.			Strain Differences in Response to Traumatic Brain Injury in Long-Evans Compared to Sprague-Dawley Rats	JOURNAL OF NEUROTRAUMA			English	Article						beam walk; fluid percussion injury; loss of consciousness; Morris water maze; recovery of function; strain differences; traumatic brain injury	FLUID PERCUSSION INJURY; MORRIS WATER MAZE; GENETIC-DIFFERENCES; SPATIAL NAVIGATION; MOTOR CORTEX; DARK-AGOUTI; ALBINO-RATS; RECOVERY; WISTAR; PERFORMANCE	The selected strain of rodent used in experimental models of traumatic brain injury is typically dependent upon the experimental questions asked and the familiarity of the investigator with a specific rodent strain. This archival study compares the injury responsiveness and recovery profiles of two popular outbred strains, the Long-Evans (LE) and the Sprague-Dawley (SD), after brain injury induced by lateral fluid percussion injury (LFPI). General findings include a significantly longer duration of unconsciousness in LE rats, but similar durations of apnea. Both strains displayed the same level of initial FPI-induced behavioral deficits, followed by a more rapid rate of functional recovery in SD rats. Cortical volume loss was not significantly different, but close inspection of the data suggests the possibility that LE rats may be more susceptible to damage in the hemisphere contralateral to the injury site than are SD rats. It is hoped that the information provided here encourages greater attention to the subtle differences and similarities between strains in future pre-clinical efficacy studies of traumatic brain injury.	[Tan, Arlene A.; Quigley, Andrea; Smith, Douglas C.; Hoane, Michael R.] So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Brain & Cognit Sci Program, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	The authors would like to thank Bryan McConomy, Keith Gregory, Mustafa Aladin, and Nicholas Kuypers for their assistance in data collection. Thanks also to Jason Beare and Nicholas Kaufmann for their assistance in lesion analysis. Special thanks to Dr. Douglas C. Smith for the use of laboratory facilities. Funding for this project was provided by National Institute of Neurological Disorders and Stroke grant NS045647 to M. R. H.	ANDREWS JS, 1995, PHYSIOL BEHAV, V57, P785, DOI 10.1016/0031-9384(94)00336-X; Bardutzky J, 2005, STROKE, V36, P2000, DOI 10.1161/01.STR.0000177486.85508.4d; CARR MM, 1992, ANN PLAS SURG, V28, P538; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; de Bruin NMWJ, 2000, NEUROSCI RES, V38, P165, DOI 10.1016/S0168-0102(00)00154-1; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; DIANA G, 1994, NEUROSCI LETT, V171, P113, DOI 10.1016/0304-3940(94)90618-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAGER UC, 1985, P NATL ACAD SCI USA, V82, P6716, DOI 10.1073/pnas.82.19.6716; Faraday MM, 2002, PHYSIOL BEHAV, V75, P507, DOI 10.1016/S0031-9384(02)00645-5; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Ferguson SA, 2004, PHARMACOL BIOCHEM BE, V77, P583, DOI 10.1016/j.pbb.2003.12.014; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Gleason TC, 1999, NEUROPEPTIDES, V33, P265, DOI 10.1054/npep.1999.0044; Grant S, 2001, VISUAL NEUROSCI, V18, P245, DOI 10.1017/S095252380118209X; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Harker KT, 2004, NEUROSCI BIOBEHAV R, V28, P485, DOI 10.1016/j.neubiorev.2004.06.005; Harker KT, 2002, BEHAV BRAIN RES, V134, P467; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; INOUE M, 1990, PHYSIOL BEHAV, V48, P199, DOI 10.1016/0031-9384(90)90285-C; Kearns DN, 2006, BEHAV BRAIN RES, V169, P193, DOI 10.1016/j.bbr.2006.01.005; Kosten TA, 2002, PSYCHONEUROENDOCRINO, V27, P35, DOI 10.1016/S0306-4530(01)00035-X; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; LINDNER MD, 1988, BEHAV NEUROSCI, V102, P621, DOI 10.1037/0735-7044.102.5.621; LUND RD, 1965, SCIENCE, V149, P1506, DOI 10.1126/science.149.3691.1506; Ma S, 2004, NEUROSCIENCE, V124, P963, DOI 10.1016/j.neuroscience.2003.12.028; MAYOMICHELSON L, 1993, BRAIN RES BULL, V31, P345, DOI 10.1016/0361-9230(93)90226-2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meyerson BJ, 2006, BEHAV BRAIN RES, V168, P100, DOI 10.1016/j.bbr.2005.10.020; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nikkhah G, 1998, BEHAV BRAIN RES, V92, P85, DOI 10.1016/S0166-4328(97)00128-9; Oliff HS, 1996, BRAIN RES, V731, P208, DOI 10.1016/S0006-8993(96)00582-3; Pardon MC, 2002, NEUROSCIENCE, V115, P229, DOI 10.1016/S0306-4522(02)00364-0; Paulson PE, 2005, EXP NEUROL, V196, P413, DOI 10.1016/j.expneurol.2005.08.015; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Prusky GT, 2002, BEHAV BRAIN RES, V136, P339, DOI 10.1016/S0166-4328(02)00126-2; SHERIDAN CL, 1965, J COMP PHYSIOL PSYCH, V59, P292, DOI 10.1037/h0021816; SISSON DF, 1991, PHARMACOL BIOCHEM BE, V39, P665, DOI 10.1016/0091-3057(91)90144-Q; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Takaba H, 2004, CELL MOL NEUROBIOL, V24, P589, DOI 10.1023/B:CEMN.0000036400.55503.5e; TONKISS J, 1992, DEV PSYCHOBIOL, V25, P567, DOI 10.1002/dev.420250804; Toth E, 1996, NEUROBIOL LEARN MEM, V66, P230, DOI 10.1006/nlme.1996.0063; Vales K, 2006, NEUROSCI RES, V55, P383, DOI 10.1016/j.neures.2006.04.007; van Lier H, 2003, PHYSIOL BEHAV, V78, P91, DOI 10.1016/S0031-9384(02)00893-4; vanderStaay FJ, 1996, PHYSIOL BEHAV, V60, P97; Vorhees CV, 1999, PHARMACOGENETICS, V9, P171; Walberer M, 2006, LAB ANIM-UK, V40, P1, DOI 10.1258/002367706775404426; Whishaw IQ, 2003, BEHAV BRAIN RES, V145, P221, DOI 10.1016/S0166-4328(03)00143-8; Woodlee M.T., 2005, BEHAV LAB RAT HDB TE, P129; Wyss JM, 2000, NEUROBIOL AGING, V21, P671, DOI 10.1016/S0197-4580(00)00132-9; Xu XJ, 2001, PAIN, V89, P135, DOI 10.1016/S0304-3959(00)00356-0; Zamudio S, 2005, BRAIN RES BULL, V65, P339, DOI 10.1016/j.brainresbull.2005.01.009	59	26	26	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					539	548		10.1089/neu.2008.0611			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300006	19216636	Green Accepted, Green Published			2021-06-18	
J	Wei, EP; Hamm, RJ; Baranova, AI; Povlishock, JT				Wei, Enoch P.; Hamm, Robert J.; Baranova, Anna I.; Povlishock, John T.			The Long-Term Microvascular and Behavioral Consequences of Experimental Traumatic Brain Injury after Hypothermic Intervention	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; behavioral assessment; hypothermia; TBI; vascular reactivity	FLUID-PERCUSSION MODEL; CEREBRAL-BLOOD-FLOW; POSTTRAUMATIC HYPOTHERMIA; POTASSIUM CHANNELS; RELAXING FACTOR; SMOOTH-MUSCLE; NITRIC-OXIDE; ENDOTHELIUM; RATS; CATS	Traumatic brain injury (TBI) has been demonstrated to induce cerebral vascular dysfunction that is reflected in altered responses to various vasodilators. While previous reports have focused primarily on the short-term vascular alterations, few have examined these vascular changes for more than 7 days, or have attempted to correlate these alterations with any persisting behavioral changes or potential therapeutic modulation. Accordingly, we evaluated the long-term microvascular and behavioral consequences of experimental TBI and their therapeutic modulation via hypothermia. In this study, one group was injured with no treatment, another group was injured and 1 h later was treated with 120 min of hypothermia followed by slow rewarming, and a third group was non-injured. Animals equipped with cranial windows for visualization of the pial microvasculature were challenged with various vasodilators, including acetylcholine, hypercapnia, adenosine, pinacidil, and sodium nitroprusside, at either 1 or 3 weeks post-TBI. In addition, all animals were tested for vestibulomotor tasks at 1 week post-TBI, and animals surviving for 3 weeks post-TBI were tested in a Morris water maze (MWM). The results of this investigation demonstrated that TBI resulted in long-term vascular dysfunction in terms of altered vascular reactivity to various vasodilators, which was significantly improved with the use of a delayed 120-min hypothermic treatment. In contrast, data from the MWM task indicated that injured animals revealed persistent deficits in the spatial memory test performance, with hypothermia exerting no protective effects. Collectively, these data illustrate that TBI can evoke long-standing brain vascular and spatial memory dysfunction that manifest different responses to hypothermic intervention. These findings further illustrate the complexity of TBI and highlight the fact that the chosen hypothermic intervention may not necessarily exert a global protective response.	[Wei, Enoch P.; Baranova, Anna I.; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Ctr, Richmond, VA 23298 USA; [Wei, Enoch P.] Virginia Commonwealth Univ, Dept Med, Med Ctr, Richmond, VA 23298 USA; [Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Med Ctr, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Ctr, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD055813, NS057175]; Commonwealth Neurotrauma Trust Fund [NCI 04-095]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS057175] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants HD055813 and NS057175 and the Commonwealth Neurotrauma Trust Fund Grant NCI 04-095.	BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Faraci FM, 1998, PHYSIOL REV, V78, P53; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kontos H A, 1980, Adv Exp Med Biol, V131, P243; Kontos H A, 1981, Trans Am Clin Climatol Assoc, V92, P111; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259; Kontos HA, 1998, AM J PHYSIOL-HEART C, V274, pH974; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Povlishock JT, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P19; Quayle JM, 1997, PHYSIOL REV, V77, P1165; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Ueda Y, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P141; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; WEI EP, 1992, STROKE, V23, P1623, DOI 10.1161/01.STR.23.11.1623; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	42	26	27	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					527	537		10.1089/neu.2008.0797			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300005	19245307	Green Published			2021-06-18	
J	Gerlach, R; Dittrich, S; Schneider, W; Ackermann, H; Seifert, V; Kieslich, M				Gerlach, Ruediger; Dittrich, Simone; Schneider, Wilfried; Ackermann, Hanns; Seifert, Volker; Kieslich, Matthias			Traumatic Epidural Hematomas in Children and Adolescents Outcome Analysis in 39 Consecutive Unselected Cases	PEDIATRIC EMERGENCY CARE			English	Article						epidural hematoma; head injury; skull fracture; surgery; outcome	EXTRADURAL HEMATOMAS; HEAD-INJURY; INTRACRANIAL INJURY; MANAGEMENT; EXPERIENCE; EMERGENCY	Objective: Despite early diagnosis of traumatic epidural hematomas (EDHs) in children, mortality remained quite high in recent series. The aims of this analysis were to review the cause and outcome of pediatric EDH nowadays and to discuss outcome-related variables in a large consecutive series of surgically treated EDH in children. Methods: This is a retrospective case series of 39 patients (27 males, 69%)with surgically treated EDH between June 1997 and February 2007. Patients' medical records, computed tomographic scans, and, if performed, magnetic resonance unagings were reviewed to define variables associated with outcome. Variables included in the analysis were age, associated severe extracranial injury, abnormal pupillary response, hematoma thickness, severity of head injury (Glasgow Coma Scale score <= 8), parenchymal brain injury, and diffuse axonal injury. Long-term follow-up (mean [SD], 51.3 [27] months) was available in 38 patients, and outcomes were classified as excellent (modified Rankin Scale score [mRS], 0; Glasgow Outcome Scale score, 5) and good (mRS scores, I and 2; Glasgow Outcome Scale score, 4). Results: The mean (SD) age of the patients was 83.1 (59.9) months (range, 1-191 months). The mortality was zero, and the outcomes were excellent in 34 and good in 4 patients (one was lost to follow-up). Most of the injuries with EDH occurred in familial settings (23 cases), with falls being the most common mechanism of injury in 20 patients. Trauma was caused by traffic accidents in 14 cases (pedestrians hit by a motor vehicle, 7 cases; bicycle accidents, 5 cases; and motorbike and car accidents, 1 case each). One EDH occurred during delivery. The mean size of the EDH was 18.5 (12) mm (range, 5-40 mm). Three patients were referred with unilateral or bilateral dilated pupil(s). Except in 4 patients, all EDHs were associated with skull fracture(s) (90%). Computed tomography or magnetic resonance imaging revealed brain contusion in 13 patients, and 1 had diffuse axonal injury. None of the tested variables were found to have a prognostic relevance as tested by multivariate analysis (backward exclusion, Wald method). Conclusions: Regardless of the EDH size, the clinical status of the patients, the abnormal pupillary findings, or the cause of injury, the outcome and prognosis of the patients with EDH are excellent.	[Gerlach, Ruediger; Seifert, Volker] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany; [Dittrich, Simone; Schneider, Wilfried; Kieslich, Matthias] Goethe Univ Frankfurt, Dept Pediat, D-60528 Frankfurt, Germany; [Ackermann, Hanns] Goethe Univ Frankfurt, Inst Biostat, D-60528 Frankfurt, Germany	Gerlach, R (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	r.gerlach@em.uni-frankfurt.de					Balmer B, 2006, CHILD NERV SYST, V22, P363, DOI 10.1007/s00381-005-1254-x; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; Ben Abraham R, 2000, PEDIATR NEUROSURG, V33, P70, DOI 10.1159/000028990; Beni-Adani L, 1999, J TRAUMA, V46, P306, DOI 10.1097/00005373-199902000-00018; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Browne GJ, 2002, PEDIATR EMERG CARE, V18, P86, DOI 10.1097/00006565-200204000-00006; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; CHOUX M, 1975, CHILD BRAIN, V1, P337; Ciurea AV, 2007, CHILD NERV SYST, V23, P335, DOI 10.1007/s00381-006-0230-4; DAVID PA, 1990, POP STUD-J DEMOG, V44, P421, DOI 10.1080/0032472031000144836; DE SM, 2007, J TRAUMA, V63, P370; DHELLEMMES P, 1985, J NEUROSURG, V62, P861, DOI 10.3171/jns.1985.62.6.0861; DOSSANTOS ALM, 1994, PEDIATR NEUROSURG, V21, P50; Erdogan B, 2003, PEDIATR NEUROSURG, V39, P208, DOI 10.1159/000072473; ERSAHIN Y, 1993, CHILD NERV SYST, V9, P96, DOI 10.1007/BF00305316; ERSAHIN Y, 1993, PEDIATR NEUROSURG, V19, P31, DOI 10.1159/000120697; HELFER RE, 1977, PEDIATRICS, V60, P533; Lee ACW, 1997, J PAEDIATR CHILD H, V33, P446; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; Maggi G, 1998, J Neurosurg Sci, V42, P95; Marion DW, 2006, NEUROSURGERY, V58, P655; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PASAOGLU A, 1990, ACTA NEUROCHIR, V106, P136, DOI 10.1007/BF01809456; PILLAY R, 1995, S AFR MED J, V85, P672; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Rocchi G, 2005, J CHILD NEUROL, V20, P569, DOI 10.1177/08830738050200070501; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Stieg PE, 1998, NEUROL CLIN, V16, P373, DOI 10.1016/S0733-8619(05)70069-4; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Zuccarello M, 1983, Zentralbl Neurochir, V44, P11	36	26	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAR	2009	25	3					164	169		10.1097/PEC.0b013e31819a8966			6	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	419VX	WOS:000264248900007	19262419				2021-06-18	
J	Mello, MJ; Myers, R; Christian, JB; Palmisciano, L; Linakis, JG				Mello, Michael J.; Myers, Richard; Christian, Jennifer B.; Palmisciano, Lynne; Linakis, James G.			Injuries in Youth Football: National Emergency Department Visits during 2001-2005 for Young and Adolescent Players	ACADEMIC EMERGENCY MEDICINE			English	Article						American football; pediatrics; injury	HIGH-SCHOOL FOOTBALL; TRAUMATIC BRAIN-INJURY; UNITED-STATES; RISK-FACTORS; SPORTS; EPIDEMIOLOGY; ATHLETE	Limited research exists describing youth football injuries, and many of these are confined to specific regions or communities. The authors describe U.S. pediatric football injury patterns receiving emergency department (ED) evaluation and compare injury patterns between the younger and older youth football participants. A retrospective analysis of ED data on football injuries was performed using the National Electronic Injury Surveillance System-All Injury Program. Injury risk estimates were calculated over a 5-year period (2001-2005) using participation data from the National Sporting Goods Association. Injury types are described for young (7-11 years) and adolescent (12-17 years) male football participants. There were an estimated total of 1,060,823 visits to U.S. EDs for males with football-related injuries. The most common diagnoses in the younger group (7-11 years) were fracture/dislocation (29%), sprain/strain (27%), and contusion (27%). In the older group (ages 12-17 years), diagnoses included sprain/strain (31%), fracture/dislocation (29%), and contusion (23%). Older participants had a significantly higher injury risk of injury over the 5-year study period: 11.0 (95% confidence interval [CI] = 9.2 to 12.8) versus 6.1 (95% CI = 4.8 to 7.3) per 1,000 participants/year. Older participants had a higher injury risk across all categories, with the greatest disparity being with traumatic brain injury (TBI), 0.8 (95% CI = 0.6 to 1.0) versus 0.3 (95% CI = 0.2 to 0.4) per 1,000 participants/year. National youth football injury patterns are similar to those previously reported in community and cohort studies. Older participants have a significantly higher injury risk, especially with TBI.	[Mello, Michael J.; Myers, Richard; Palmisciano, Lynne; Linakis, James G.] Injury Prevent Ctr Rhode Isl Hosp, Providence, RI USA; [Mello, Michael J.; Palmisciano, Lynne; Linakis, James G.] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA; [Mello, Michael J.; Christian, Jennifer B.] Brown Univ, Alpert Med Sch, Dept Community Hlth, Providence, RI 02912 USA; [Palmisciano, Lynne; Linakis, James G.] Brown Univ, Alpert Med Sch, Dept Pediat, Providence, RI 02912 USA	Mello, MJ (corresponding author), Injury Prevent Ctr Rhode Isl Hosp, Providence, RI USA.	mjmello@lifespan.org					Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; [Anonymous], 2004, NAT EL INJ SURV SYST; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; Dick R, 2007, J ATHL TRAINING, V42, P221; Dompier TP, 2007, J ATHL TRAINING, V42, P395; GOLDBERG B, 1988, PEDIATRICS, V81, P255; Hergenroeder AC, 1998, PEDIATRICS, V101, P1057, DOI 10.1542/peds.101.6.1057; LINDER MM, 1995, CLIN J SPORT MED, V5, P167, DOI 10.1097/00042752-199507000-00006; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; Marshall Stephen W, 2007, N C Med J, V68, P430; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; ROSER LA, 1970, CLIN ORTHOP RELAT R, P219; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; *SPORTS BUS RES NE, 2007, FOOTB TACKL MARK RES; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; Turbeville SD, 2003, AM J SPORT MED, V31, P276, DOI 10.1177/03635465030310022001; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; United States Department of Health and Human Services Centers for Disease Control and Prevention National Center for Injury Prevention and Control United States Consumer Product Safety Commission, 2007, NAT EL INJ SURV SYST; *US DEP HHS, 2006, NAT EL INJ SURV SYST; *US DEP HHS, 2005, NAT EL INJ SURV SYST; *US DEP HHS, 2003, NAT EL INJ SURV SYST; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034	28	26	26	0	10	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	MAR	2009	16	3					243	248		10.1111/j.1553-2712.2009.00357.x			6	Emergency Medicine	Emergency Medicine	414HZ	WOS:000263855800008	19210487	Bronze			2021-06-18	
J	Tukhovskaya, EA; Yukin, AY; Khokhlova, ON; Murashev, AN; Vitek, MP				Tukhovskaya, Elena A.; Yukin, Alexey Yu.; Khokhlova, Oksana N.; Murashev, Arkady N.; Vitek, Michael P.			COG1410, a Novel Apolipoprotein-E Mimetic, Improves Functional and Morphological Recovery in a Rat Model of Focal Brain Ischemia	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						apolipoprotein E; MCAO; neuroprotection	SYSTEM INFLAMMATORY RESPONSE; CEREBRAL-ARTERY OCCLUSION; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; TRANSGENIC MICE; APOE; PEPTIDES; ALLELE; STROKE; ONSET	Apolipoprotein E (apoE) is the primary apolipoprotein synthesized in the brain in response to injury with known neuroprotective effects exerted through antioxidant, anti inflammatory, antiexcitotoxic, and neurotrophic mechanisms. We have previously demonstrated that COG1410, an apoE mimetic peptide, exerts neuroprotective and anti inflammatory effects in a murine model of traumatic brain injury (TBI). As in TBI, ischemia-reperfusion injury is a component of acute stroke, which displays a pharmacogenetic association with the APOE4 gene. Using an intraluminal middle cerebral occlusion (MCAO) model in rats, we found that a single intravenous injection of COG1410 at 120 min post-MCAO significantly improved vestibulomotor function, decreased poststroke locomotor asymmetry, and decreased infarct volume of the ipsilateral hemisphere. These results support further exploration of a novel apoE-mimetic peptide, COG1410, as a therapeutic treatment for stroke. (C) 2008 Wiley-Liss, Inc.	[Tukhovskaya, Elena A.; Yukin, Alexey Yu.; Khokhlova, Oksana N.; Murashev, Arkady N.] Russian Acad Sci, Inst Bioorgan Chem, Branch Shemyakin & Ovchinnikov, Moscow, Russia; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; [Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC USA	Tukhovskaya, EA (corresponding author), Prospect Nauki 6, Pushchino 142290, Moscow Region, Russia.	lenoktuk@rambler.ru	Khokhlova, Oksana/D-2319-2015	Khokhlova, Oksana/0000-0003-3613-7693; Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R43AG020473, R44AG020473] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 020473, R43 AG020473, R44 AG020473, R44 AG020473-05] Funding Source: Medline		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Arendt T, 1997, J NEUROSCI, V17, P516; ASPLUND K, 1985, STROKE, V16, P885; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Ferro MM, 2007, BRAZ J MED BIOL RES, V40, P89, DOI 10.1590/S0100-879X2006005000053; FUJIKAWA DG, 1995, EPILEPSIA, V36, P186, DOI 10.1111/j.1528-1157.1995.tb00979.x; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lebedev SV, 2003, B EXP BIOL MED+, V135, P424, DOI 10.1023/A:1024946821482; LINTON M, 1991, J CLIN INVEST, V81, P270; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lopez-Martin E, 1998, EXP BRAIN RES, V120, P153, DOI 10.1007/s002210050389; Lyden PD, 2001, STROKE, V32, P1310, DOI 10.1161/01.STR.32.6.1310; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Spilker J, 1997, J Neurosci Nurs, V29, P384; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; WHO, 1999, WORLD HLTH REP; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006	42	26	28	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 15	2009	87	3					677	682		10.1002/jnr.21874			6	Neurosciences	Neurosciences & Neurology	404YX	WOS:000263190100010	18803296	Green Accepted			2021-06-18	
J	Cyr, AA; Stinchcombe, A; Gagnon, S; Marshall, S; Hing, MMS; Finestone, H				Cyr, Andree-Ann; Stinchcombe, Arne; Gagnon, Sylvain; Marshall, Shawn; Hing, Malcolm Man-Son; Finestone, Hillel			Driving difficulties of brain-injured drivers in reaction to high-crash-risk simulated road events: A question of impaired divided attention?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Brain injury; Driving; Simulation; Cognitive load; Unexpected driving events	CLOSED-HEAD-INJURY; OF-THE-LITERATURE; OLDER DRIVERS; PERFORMANCE; DEFICITS; PREDICTORS; DEMENTIA; METAANALYSIS; DISEASE; FITNESS	This study examined the role of impaired divided attention and speed of processing in traumatic brain injury (TBI) drivers in high-crash-risk simulated road events. A total of 17 TBI drivers and 16 healthy participants were exposed to four challenging simulated roadway events to which behavioral reactions were recorded. Participants were also asked to perform a dual task during portions of the driving task, and TBI individuals were administered standard measures of divided attention and reaction time. Results indicated that the TBI group crashed significantly more than controls (p <.05) and that dual-task performance correlated significantly with crash rate (r = .58, p = .05).	[Gagnon, Sylvain] Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada; [Gagnon, Sylvain; Marshall, Shawn; Hing, Malcolm Man-Son; Finestone, Hillel] Elisabeth Bruyere Res Inst, Ottawa, ON, Canada; [Marshall, Shawn] Ottawa Gen Hosp, Rehabil Ctr, Ottawa, ON K1H 8L6, Canada	Gagnon, S (corresponding author), Univ Ottawa, Sch Psychol, Pavillon Montpetit 410A,CP 450,Succ A, Ottawa, ON K1N 6N5, Canada.	sgagnon@uottawa.ca		Cyr, Andree-Ann/0000-0001-9036-2889			Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; Ball K., 1992, J AM OPTOM ASSOC, V64, P71; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROUWER WH, 1991, HUM FACTORS, V33, P573; Brown LB, 2004, J GERIATR PSYCH NEUR, V17, P232, DOI 10.1177/0891988704269825; CANTAGALLO A, 1995, J INT NEUROPSYCH SOC, V1, P198; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CYR AA, 2006, ADV TRANSPORTATION S, P31; Dobbs AR, 1998, ACCIDENT ANAL PREV, V30, P363, DOI 10.1016/S0001-4575(97)00110-3; FINKELMAN JM, 1977, J APPL PSYCHOL, V62, P713, DOI 10.1037/0021-9010.62.6.713; Fisk GD, 1998, BRAIN INJURY, V12, P683; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Grace J, 2005, J INT NEUROPSYCH SOC, V11, P766, DOI 10.1017/S135561770505848; HILL SG, 1992, HUM FACTORS, V34, P429; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Hunt LA, 1997, ARCH NEUROL-CHICAGO, V54, P707, DOI 10.1001/archneur.1997.00550180029008; Kennedy R. S., 1993, Int'l. J. Aviat. Psychol., V3, P203, DOI [DOI 10.1207/S15327108IJAP0303_3, 10.1207/s15327108ijap0303_3]; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Mital, 1989, ADV IND ERGONOMICS S, P481; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; OTT BR, 2003, J GERIATR PSYCHIAT, V18, P85; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Trick LM, 2004, THEOR ISSUES ERGON, V5, P385, DOI DOI 10.1080/14639220412331298938; VANZOMEREN AH, 1994, NEUROPSYCHOLOGY ATTE; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; WITHAAR FK, 2000, THESIS RIJSKUNIVERSI	43	26	27	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	4					472	482	PII 901408923	10.1080/13803390802255627			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	435HH	WOS:000265334200010	18686115				2021-06-18	
J	Evans, B; Gervais, JT; Heard, K; Valley, M; Lowenstein, SR				Evans, Bruce; Gervais, Jack T.; Heard, Kennon; Valley, Morgan; Lowenstein, Steven R.			Ski patrollers: Reluctant role models for helmet use	INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION			English	Article						traumatic brain injury; helmets; ski patrollers; skiing; snowboarding	RISK COMPENSATION; HEAD-INJURIES; SNOWBOARDERS	Ski helmets reduce the risk of traumatic brain injury (TBI), but usage rates are low. Ski patrollers could serve as role models for helmet use, but little is known about their practices and beliefs. A written survey was distributed to ski patrollers attending continuing education conferences. The questions addressed included helmet use rates, prior TBI experiences, perceptions of helmet risks and benefits and willingness to serve as safety role models for the public. To assess predictors of helmet use, odds ratios (OR) were calculated, after adjusting for skiing experience. Ninety-three ski patrollers participated and the main outcome was self-reported helmet use of 100% while patrolling. Helmet use was 23% (95% CI 15-32%). Common reasons for non-use included impaired hearing (35%) and discomfort (29%). Most patrollers believed helmets prevent injuries (90%; 95% CI 84-96%) and that they are safety role models (92%; 95% CI 86-98%). However, many believed helmets encourage recklessness (39%; 95% CI 29-49%) and increase injury risks (16%; 95% CI 7-25%). Three factors predicted 100% helmet use: perceived protection from exposure (OR = 9.68; 95% CI 3.14-29.82) or cold (OR = 5.68; 95% CI 1.27-25.42); and belief that role modelling is an advantage of helmets (OR = 4.06; 95% CI 1.29-12.83). Patrollers who believed helmets encourage recklessness were eight times less likely to wear helmets (OR = 0.13; 95% CI 0.03-0.58). Ski patrollers know helmets reduce serious injury and believe they are role models for the public, but most do not wear helmets regularly. To increase helmet use, manufacturers should address hearing-and comfort-related factors. Education programmes should address the belief that helmets encourage recklessness and stress role modelling as a professional responsibility.	[Evans, Bruce; Heard, Kennon; Valley, Morgan; Lowenstein, Steven R.] Univ Colorado Denver, Dept Surg, Sch Med, Div Emergency Med, Aurora, CO 80045 USA; [Lowenstein, Steven R.] Univ Colorado Denver, Dept Med, Sch Med, Aurora, CO 80045 USA; [Lowenstein, Steven R.] Univ Colorado Denver, Dept Prevent Med Biometr, Sch Med, Aurora, CO 80045 USA; [Evans, Bruce; Heard, Kennon; Valley, Morgan] Univ Colorado Denver, Colorado Emergency Med Res Ctr, Sch Med, Aurora, CO 80045 USA	Lowenstein, SR (corresponding author), Univ Colorado Denver, Dept Surg, Sch Med, Div Emergency Med, Leprino Off Bldg,7th Floor 12401 E 17th Ave,B215, Aurora, CO 80045 USA.	Steven.Lowenstein@ucdenver.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K08 DA020573-03, K08 DA020573, DA 020573] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 811509] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K08DA020573] Funding Source: NIH RePORTER		BROOKE J, 1998, NY TIMES        0107; Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; Hagel B, 2005, ACCIDENT ANAL PREV, V37, P103, DOI 10.1016/j.aap.2004.04.003; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hedlund J, 2000, Inj Prev, V6, P82, DOI 10.1136/ip.6.2.82; Henrich J, 2001, EVOL HUM BEHAV, V22, P165, DOI 10.1016/S1090-5138(00)00071-4; JANOFSKY M, 2002, NY TIMES        0331; KENWORTHY T, 1998, WASHINGTON POST 0101; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; MCCLELLAN D, 2002, COLORADO SKI AREAS C; *NAT SKI AR ASS, 2007, NAT DEM SURV; *NAT SKI AR ASS, 2008, EV NAT SAF AW WEEK; *NAT SKI AR ASS, 2007, FACTS SKIING SNOWB S; PENNINGTON B, 2007, NY TIMES        0126; Richerson PJ, 2005, NOT GENES ALONE CULT; Scott MD, 2007, INJURY PREV, V13, P173, DOI 10.1136/ip.2006.014142; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; *UT DEP HLTH, 2004, UT DEP HLTH OFF FREE; *VT SNOW SPORTS RE, 2007, PHAT PROT YOUR HEAD; Xiang H, 2004, INJURY PREV, V10, P99, DOI 10.1136/ip.2003.004655; Xiang HY, 2003, INJURY, V34, P892, DOI 10.1016/S0020-1383(03)00055-X	23	26	26	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1745-7300	1745-7319		INT J INJ CONTROL SA	Int. J. Inj. Control Saf. Promot.		2009	16	1					9	14		10.1080/17457300902732045			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	618ZB	WOS:000279394500002	19225971	Green Accepted			2021-06-18	
J	Jaffee, MS; Helmick, KM; Girard, PD; Meyer, KS; Dinegar, K; George, K				Jaffee, Michael S.; Helmick, Kathy M.; Girard, Philip D.; Meyer, Kim S.; Dinegar, Kathy; George, Karyn			Acute clinical care and care coordination for traumatic brain injury within Department of Defense	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive assessment; community reentry; loss of consciousness; medical evacuation; polytrauma; posttraumatic amnesia; rehabilitation; TBI; TBI screening; traumatic brain injury	NEUROPSYCHOLOGICAL STATUS RBANS; REPEATABLE BATTERY; MILITARY; REHABILITATION; RELIABILITY; IMPAIRMENT; VALIDITY	The nature of current combat situations that U.S. military forces encounter and the use of unconventional weaponry have dramatically increased service personnel's risks of sustaining a traumatic brain injury (TBI). Although the true incidence and prevalence of combat-related TBI are unknown, service personnel returning from deployment have reported rates of concussion between 10% and 20%. The Department of Defense has recently released statistics on TBI dating back to before the wars in Iraq and Afghanistan to better elucidate the impact and burden of TBI on America's warriors and veterans. Patients with severe TBI move through a well-established trauma system of care, beginning with triage of initial injury by first-responders in the war zone to acute care to rehabilitation and then returning home and to the community. Mild and moderate TBIs may pose different clinical challenges, especially when initially undetected or if treatment is delayed because more serious injuries are present. To ensure identification and prompt treatment of mild and moderate TBI, the U.S. Congress has mandated that military and Department of Veterans Affairs hospitals screen all service personnel returning from combat. Military health professionals must evaluate them for concussion and then treat the physical, emotional, and cognitive problems that may surface. A new approach to health management and care coordination is needed that will allow medical transitions between networks of care to become more centralized and allow for optimal recovery at all severity levels. This article summarizes the care systems available for the acute management of TBI from point of injury to stateside military treatment facilities. We describe TBI assessment, treatment, and overall coordination of care, including innovative clinical initiatives now used.	[Jaffee, Michael S.; Helmick, Kathy M.; Girard, Philip D.; Meyer, Kim S.; George, Karyn] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Girard, Philip D.] Manchester Dept Vet Affairs Med Ctr, Manchester, NH USA	Girard, PD (corresponding author), Manchester VA Med Ctr, Off Telemed, 718 Smyth Rd, Manchester, NH 03104 USA.	Philip.girard@va.gov					Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COOPER GJ, 1983, J TRAUMA, V23, P955, DOI 10.1097/00005373-198311000-00001; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; *DEF VET BRAIN INJ, 2009, OCT 2009 ARM FORC SU; Girard P, 2007, J REHABIL RES DEV, V44, P1017, DOI 10.1682/JRRD.2006.12.0174; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Institute of Medicine, 2008, GULF WAR HLTH, V7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Johnson DR, 2008, ARCH CLIN NEUROPSYCH, V23, P73, DOI 10.1016/j.acn.2007.10.001; Knuth T., 2005, GUIDELINES FIELD MAN; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McCrea M., 1997, STANDARDIZED ASSESSM; Mckay C, 2008, CLIN NEUROPSYCHOL, V22, P228, DOI 10.1080/13854040701260370; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Tanielian T., 2008, RAND CORPORATION INV; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tsokos M, 2003, AM J RESP CRIT CARE, V168, P549, DOI 10.1164/rccm.200304-528OC; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015	31	26	26	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					655	665		10.1682/JRRD.2008.09.0114			11	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100003	20104395	Bronze			2021-06-18	
J	Levin, HS; Hanten, G; Li, XQ				Levin, Harvey S.; Hanten, Gerri; Li, Xiaoqi			The relation of cognitive control to social outcome after paediatric TBI: Implications for intervention	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Paediatric TBI; rehabilitation; intervention; cognition; cognitive control; social outcome; social cognition	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; WORKING-MEMORY; SHORT-TERM; CHILDREN; CHILDHOOD; ADJUSTMENT; SKILLS; CONSEQUENCES; ADOLESCENTS	Hypothesis: This study postulated cognitive control is related to social outcome in children with traumatic brain injury (TBI) and orthopaedic injury (OI). Procedure and design: This study analysed 12-month, post-injury, cross-sectional data from 52 children (7-17 years) with moderate-to-severe TBI and 41 children with OI. Cognitive control was measured with the Sternberg Task (memory) and the Flanker Task (resistance to interference). Relations to social outcome (Vineland Adaptive Behavioural Scales-Socialization and Communications domains) were measured. Results: Reaction time (RT) on the Sternberg task was related to social outcome, with stronger relations in children of lower SES. Flanker baseline and interference RTs were related to social outcome, with the relation for interference RT more robust in children with lower SES. Conclusions: Cognitive control is related to social outcome. Further, it is suggested that cognitive training may have positive effects on social function through improved efficiency of social information processing.	[Levin, Harvey S.; Hanten, Gerri; Li, Xiaoqi] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin 1144, Houston, TX 77030 USA.	hlevin@bcm.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by Grant Number R01NS021889 from the National Institute of Neurological Disorders and Stroke. The authors wish to acknowledge the contributions of Kimberly Orsten and Stacey Martin for editing, proof-reading and all-around helpfulness during the preparation of this manuscript.	Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BERNDT TJ, 1982, CHILD DEV, V53, P1447, DOI 10.1111/j.1467-8624.1982.tb03466.x; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Borkowski J. G., 1996, ATTENTION MEMORY EXE, P235; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Burnett S, 2009, J COGNITIVE NEUROSCI, V21, P1736, DOI 10.1162/jocn.2009.21121; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Cheeran B, 2009, NEUROREHAB NEURAL RE, V23, P97, DOI 10.1177/1545968308326636; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Csikszentmihalyi M., 1984, BEING ADOLESCENT CON; Damon W., 1983, SOCIAL PERSONALITY D; Deaton A, 1994, ED DIMENSIONS ACQUIR, P257; Denckla M.B., 1996, ATTENTION MEMORY EXE, P263; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Gioia G.A., 2000, BEHAV RATING INVENTO; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Graham S., 1996, ATTENTION MEMORY EXE, P349; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; HANTEN G, 2008, COGNITIVE NEUROREHAB, P487; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Happaney K, 2004, BRAIN COGNITION, V55, P1, DOI 10.1016/j.bandc.2004.01.001; KELLY JA, 1987, HDB ADOLESCENT PSYCH, P131; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; March JS, 1997, J AM ACAD CHILD PSY, V36, P554, DOI 10.1097/00004583-199704000-00019; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MUSCARA F, 2009, NEUROPSYCHOL REHABIL, V33, P623; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Oswald H., 1994, SOCIAL NETWORKS SOCI, P171; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; PETERSEN AC, 1986, BEHAV THER, V17, P480, DOI 10.1016/S0005-7894(86)80090-9; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rosso IM, 2004, ANN NY ACAD SCI, V1021, P355, DOI 10.1196/annals.1308.045; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sparrow S., 1984, VINELAND ADAPTIVE BE; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; WALKER HM, 1994, TOP LANG DISORD, V14, P70, DOI 10.1097/00011363-199405000-00007; Wechsler D., 1991, WECHSLER INTELLIGENC; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369	69	26	26	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	5					320	329		10.3109/17518420903087673			10	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FS	WOS:000207788500007	20477561				2021-06-18	
J	Lew, HL; Rosen, PN; Thomander, D; Poole, JH				Lew, Henry L.; Rosen, Peter N.; Thomander, Darryl; Poole, John H.			The Potential Utility of Driving Simulators in the Cognitive Rehabilitation of Combat-Returnees With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive assessment; cognitive rehabilitation; cognitive training; driving simulator; transfer of training	VIRTUAL-REALITY; PERFORMANCE; IMPAIRMENT; OUTCOMES; DRIVERS; DAMAGE; RISK	A large number of Operation Enduring Freedom/Operation Iraqi Freedom returnees are seeking DOD and VA rehabilitative care for war-related traumatic brain injury (TBI). This article reviews evidence on the utility of driving simulators as tools for assessment and training in TBI rehabilitation. Traditionally, cognitive rehabilitation has been shown to improve specific cognitive skills. However, there are few studies and only weak evidence to show that these gains transfer to everyday activities. Theoretically, modern driving simulators may be useful in cognitive rehabilitation because they can systematically present realistic and interesting tasks that approximate driving activities, while automatically monitoring performance. The use of simulation technology for patients with TBI provides cognitive stimulation in an ecologically compatible setting, without the risks associated with a corresponding real-world experience. The utility, limitations, and future directions for the use of driving simulator in the rehabilitation of patients with war-related TBI are discussed.	[Lew, Henry L.] Vet Affairs Boston Hlth Care Syst, PM&R Serv, Boston, MA 02130 USA; [Rosen, Peter N.] Univ Calif San Diego, Sharp Mem Hosp, Rehabil Ctr, Driving Performance Lab,Sharp Rees Stealy Med Grp, San Diego, CA 92103 USA; [Rosen, Peter N.] Univ Calif San Diego, Dept Family & Prevent Med, Div Hlth Care Sci, San Diego, CA 92103 USA; [Thomander, Darryl] Vet Affairs Palo Alto Hlth Care Syst, Polytrauma Transit Rehabil Program, Palo Alto, CA USA; [Poole, John H.] Vet Affairs Palo Alto Hlth Care Syst, Def & Vet Brain Injury Ctr, Polytrauma Network Site, Palo Alto, CA USA	Lew, HL (corresponding author), Vet Affairs Boston Hlth Care Syst, PM&R Serv, 150 S Huntington Ave, Boston, MA 02130 USA.	henry.lew@va.gov					Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; ALLEN RW, 1999, 34 ANN M HUM FACT SO; Ball K, 1997, ALZ DIS ASSOC DIS, V11, P42, DOI 10.1097/00002093-199706001-00010; Bieliauskas LA, 2005, BRAIN INJURY, V19, P221, DOI 10.1080/02699050400017213; Brookhuis KA, 2003, ERGONOMICS, V46, P433, DOI 10.1080/001401302/1000039556; Brooks N, 2005, BRAIN INJURY, V19, P165, DOI 10.1080/02699050410001720004; Cappa SF, 2005, EUR J NEUROL, V12, P665; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coleman BR., 2005, DRIVER REHABILITATIO, P165; Freund B, 2002, J AM GERIATR SOC, V50, P1309, DOI 10.1046/j.1532-5415.2002.50325.x; Freund B, 2006, J AM GERIATR SOC, V54, P1943, DOI 10.1111/j.1532-5415.2006.00966.x; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Geusgens CAV, 2007, J REHABIL MED, V39, P425, DOI 10.2340/16501977-0092; Johansson BB, 2003, J REHABIL MED, V35, P11, DOI 10.1080/16501960310010089; Kerkhoff G, 2000, J NEUROL NEUROSUR PS, V68, P691, DOI 10.1136/jnnp.68.6.691; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; LEW HL, 2003, DRIVING ISSUES TRAUM; Lynch B, 2002, J HEAD TRAUMA REHAB, V17, P446, DOI 10.1097/00001199-200210000-00006; MALIA K, 2004, RECOMMENDATIONS PRAC; Marcotte TD, 2004, NEUROLOGY, V63, P1417, DOI 10.1212/01.WNL.0000141920.33580.5D; MARCOTTE TD, 2004, ADV TANSP STUD   NOV; Michel J A, 2006, Eura Medicophys, V42, P59; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; Rizzo M, 2001, ALZ DIS ASSOC DIS, V15, P10, DOI 10.1097/00002093-200101000-00002; Rizzo M, 2004, ARCH OPHTHALMOL-CHIC, V122, P641, DOI 10.1001/archopht.122.4.641; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; ROSEN PN, 2004, ADV TANSP STUD   NOV; ROSEN PN, 2005, DRIV SIM US GROUPS 3; STEIN AC, 1992, ERG SOC AUSTR 28 ANN; STERN EB, 2004, ADV TRANSPORTATION S, P67; Stern EB, 2006, DRIVER REHABILITATIO, P26; WACHTEL J, 1995, TR NEWS, V179, P26; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X; Zoltan B, 2007, VISION PERCEPTION CO, P1	49	26	26	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					51	56		10.1097/HTR.0b013e3181956fe3			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500008	19158596				2021-06-18	
J	Chaumet, G; Quera-Salva, MA; MacLeod, A; Hartley, S; Taillard, J; Sagaspe, P; Mazaux, JM; Azouvi, P; Joseph, PA; Guilleminault, C; Bioulac, B; Leger, D; Philip, P				Chaumet, G.; Quera-Salva, M. -A.; MacLeod, A.; Hartley, S.; Taillard, J.; Sagaspe, P.; Mazaux, J. -M.; Azouvi, P.; Joseph, P. -A.; Guilleminault, C.; Bioulac, B.; Leger, D.; Philip, P.			Is there a link between alertness and fatigue in patients with traumatic brain injury?	NEUROLOGY			English	Article							HEAD-INJURY; DAYTIME SLEEPINESS; ATTENTION; ADULTS; PERFORMANCE; PREVALENCE; OUTCOMES; RETURN; SCALE; TIME	Objectives: Many patients with traumatic brain injury (TBI) report chronic fatigue, and previous studies showed a potential relationship between sleepiness and fatigue in these patients. Our study first looked at the impact of objective and subjective sleepiness on fatigue in patients with TBI. We then investigated how fatigue could affect driving performance in these patients. Methods: Nocturnal polysomnography, the Fatigue Severity Scale (FSS), the Epworth Sleepiness Scale (ESS), and five 40-minute maintenance of wakefulness tests (MWT) were collected in 36 patients with TBI. Fitness to drive was assessed in a subsample of 22 patients compared to 22 matched controls during an hour simulated driving session. Results: In patients with TBI, FSS, ESS, and mean MWT scores (+/- SD) were 27 +/- 10, 8 +/- 4, and 35 +/- 7 minutes vs 15 +/- 2.5, 5 +/- 3, and 37 +/- 5 minutes in controls. Patients with TBI reported more chronic fatigue (W = 99, p < 0.001) than controls, and, unlike in controls, the level of chronic fatigue was correlated to their MWT scores. Patients' driving performances were worse than the controls' (W = 79, p < 0.001). The best predictive factors of driving performance were fatigue scores and body mass index (multiple R = 0.458, 41.8% of explained variance). Conclusion: In patients with TBI, chronic fatigue is significantly related to subjective and objective levels of alertness, even though these levels are not highly pathologic. This might suggest that a small level of sleepiness (i.e., MWT scores between 33 and 39 minutes) worsens fatigue in these patients. Chronic fatigue and body mass index could predict driving simulator performance in patients with TBI. Neurology (R) 2008; 71: 1609-1613	[Chaumet, G.] Univ Bordeaux 2, Dept Psychol, F-33076 Bordeaux, France; [Chaumet, G.; Taillard, J.; Sagaspe, P.; Bioulac, B.; Philip, P.] CNRS, GENPPHASS, UMR 5227, Bordeaux, France; [Quera-Salva, M. -A.; Hartley, S.] Garches Univ, Sch Med, Neurol Rehabil Dept, Garches, France; [MacLeod, A.; Taillard, J.; Philip, P.] Univ Hosp Pellegrin, Sleep Clin, Bordeaux, France; [Sagaspe, P.] INRETS, Arcueil, France; [Mazaux, J. -M.; Joseph, P. -A.] Univ Bordeaux, Sch Med, Ctr Neurol Rehabil Dept, Bordeaux, France; [Azouvi, P.; Leger, D.] Univ Hosp Hotel Dieu, Sleep Clin, Paris, France; [Guilleminault, C.] Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA	Philip, P (corresponding author), Univ Bordeaux 2, CHU Pellegrin GENPPHASS, CNRS, UMR 5227, Pl Amelie Raba Leon, F-33076 Bordeaux, France.	pr.philip@free.fr	PHILIP, Pierre/AAS-8889-2020; Taillard, Jacques/H-5063-2018	PHILIP, Pierre/0000-0003-3267-634X; Taillard, Jacques/0000-0001-9067-8189; Hartley, Sarah/0000-0003-3028-4430; SAGASPE, Patricia/0000-0003-2845-1199	French Ministry of Health; Conseil Regional d'AquitaineRegion Nouvelle-Aquitaine	Supported by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC). G. C. was funded by a grant of Conseil Regional d'Aquitaine.	Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barkley RA, 2007, J SAFETY RES, V38, P113, DOI 10.1016/j.jsr.2006.09.004; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Doghramji K, 1997, ELECTROEN CLIN NEURO, V103, P554, DOI 10.1016/S0013-4694(97)00010-2; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; Fisk GD, 1998, BRAIN INJURY, V12, P683; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hillier SL, 1997, BRAIN INJURY, V11, P661; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; MARSHALL LF, 1991, J NEUROSURG, P75; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Newby G, 1999, BRIT J GEN PRACT, V49, P301; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; STOOHS RA, 1994, SLEEP, V17, P619; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Young T, 2004, JAMA-J AM MED ASSOC, V291, P2013, DOI 10.1001/jama.291.16.2013; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	36	26	27	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 11	2008	71	20					1609	1613		10.1212/01.wnl.0000334753.49193.48			5	Clinical Neurology	Neurosciences & Neurology	370XF	WOS:000260795700009	19001250				2021-06-18	
J	Benton, RL; Maddie, MA; Worth, CA; Mahoney, ET; Hagg, T; Whittemore, SR				Benton, Richard L.; Maddie, Melissa A.; Worth, Christopher A.; Mahoney, Edward T.; Hagg, Theo; Whittemore, Scott R.			Transcriptomic screening of microvascular endothelial cells implicates novel molecular regulators of vascular dysfunction after spinal cord injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						flow cytometry; PAI-1; spinal cord injury; TSP-1; uPA	PLASMINOGEN-ACTIVATOR RECEPTOR; CONTUSION INJURY; UP-REGULATION; HUMAN BRAIN; RAT; BARRIER; VESSELS; GROWTH; MOUSE; PAI-1	Microvascular dysfunction is a critical pathology that underlies the evolution of secondary injury mechanisms after traumatic spinal cord injury (SCI). However, little is known of the molecular regulation of endothelial cell (EC) plasticity observed acutely after injury. One reason for this is the relative lack of methods to quickly and efficiently obtain highly enriched spinal microvascular ECs for high-throughput molecular and biochemical analyses. Adult C57Bl/6 mice received an intravenous injection of fluorescein isothiocyanate ( FITC)-conjugated Lycopersicon esculentum lectin, and FITC-lectin-bound spinal microvessels were greatly enriched by fluorescence-activated cell sorter (FACS) purification. This technique allows for rapid (< 1.5 h postmortem) isolation of spinal cord microvascular ECs (smvECs). The results from cell counting, reverse-transcription polymerase chain reaction (RT-PCR), and western blot analyses show a high degree of EC enrichment at mRNA and protein levels. Furthermore, a focused EC biology microarray analysis identified multiple mRNAs dramatically increased in the EC compartment 24 h after SCI, which is a time point associated with the pathologic loss of spinal vasculature. These included thrombospondin-1, CCL5/RANTES, and urokinase plasminogen activator, suggesting they may represent targets for therapeutic intervention. Furthermore, these novel methodologic approaches will likely facilitate the discovery of molecular regulators of endothelial dysfunction in a variety of central nervous system (CNS) disorders including stroke and other neurodegenerative diseases having a vascular component.	[Benton, Richard L.; Maddie, Melissa A.; Mahoney, Edward T.; Hagg, Theo; Whittemore, Scott R.] Univ Louisville, Sch Med, Kentucky Spinal Cord Res Ctr, Louisville, KY 40292 USA; [Benton, Richard L.; Maddie, Melissa A.; Mahoney, Edward T.; Hagg, Theo; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; [Benton, Richard L.; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Worth, Christopher A.] Univ Louisville, Sch Med, Brown Canc Ctr, Louisville, KY 40292 USA; [Hagg, Theo] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA	Benton, RL (corresponding author), Univ Louisville, Sch Med, Kentucky Spinal Cord Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	rlbent01@louisville.edu			Norton Healthcare [NS045734, RR15576]; Commonwealth of Kentucky Challenge for Excellence; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045734] Funding Source: NIH RePORTER	This research was supported by NS045734, RR15576, Norton Healthcare, and by the Commonwealth of Kentucky Challenge for Excellence (SRW and TH).	Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Albo D, 1999, J SURG RES, V82, P331, DOI 10.1006/jsre.1998.5578; Arai Y, 1998, ACTA NEUROCHIR, V140, P377, DOI 10.1007/s007010050112; Benton RL, 2008, J COMP NEUROL, V507, P1031, DOI 10.1002/cne.21570; Beschorner R, 2000, NEUROPATH APPL NEURO, V26, P522, DOI 10.1046/j.0305-1846.2000.287.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Casella GTB, 2006, EXP NEUROL, V202, P8, DOI 10.1016/j.expneurol.2006.05.028; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; DIGLIO CA, 1982, LAB INVEST, V46, P554; DUCKER T B, 1969, Surgical Forum (Chicago), V20, P428; Enerson BE, 2006, J CEREBR BLOOD F MET, V26, P959, DOI 10.1038/sj.jcbfm.9600249; Ge SJ, 2006, J NEUROIMMUNOL, V177, P209, DOI 10.1016/j.jneuroim.2006.05.012; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Hemmings SJ, 1999, MOL CELL BIOCHEM, V202, P119, DOI 10.1023/A:1007069431615; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; JOO F, 1982, J NEUROCHEM, V39, P263, DOI 10.1111/j.1471-4159.1982.tb04731.x; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Lin Y, 2007, J CEREBR BLOOD F MET, V27, P1010, DOI 10.1038/sj.jcbfm.9600412; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Minor KH, 2008, MOL CELL NEUROSCI, V37, P143, DOI 10.1016/j.mcn.2007.09.005; Nagai N, 2008, NEUROSCI LETT, V432, P46, DOI 10.1016/j.neulet.2007.12.004; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Prager GW, 2004, CIRC RES, V94, P1562, DOI 10.1161/01.RES.0000131498.36194.6b; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Shusta EV, 2002, J CEREBR BLOOD F MET, V22, P245, DOI 10.1097/00004647-200203000-00001; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Wu ZH, 2003, J NEUROSCI METH, V130, P53, DOI 10.1016/S0165-0270(03)00206-1; YANG GY, 1994, J NEUROSURG, V81, P82; Yousif S, 2007, BRAIN RES, V1134, P1, DOI 10.1016/j.brainres.2006.11.089; Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007; Zhang ZG, 1999, J NEUROSCI, V19, P10898	38	26	27	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2008	28	11					1771	1785		10.1038/jcbfm.2008.76			15	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	366IB	WOS:000260472900002	18612314	Green Accepted			2021-06-18	
J	Zetterberg, H; Jacobsson, J; Rosengren, L; Blennow, K; Andersen, PM				Zetterberg, Henrik; Jacobsson, Johan; Rosengren, Lars; Blennow, Kaj; Andersen, Peter M.			Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						amyotrophic lateral sclerosis; SOD1; apolipoprotein E; age at onset	CUZN-SUPEROXIDE-DISMUTASE; TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; EPSILON-4 ALLELE; GENOTYPE; MUTATIONS; DEMENTIA; FAMILIES; GENE	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative syndrome with familial and sporadic forms. We conducted a study including 60 sporadic and 19 familial ALS patients, 206 reference patients with other neurological disorders and 1265 neurologically healthy controls to assess the Alzheimer-associated apolipoprotein E (APOE) epsilon 4 gene variant as a possible risk factor for ALS. While no major influence of APOE FA on disease risk was detected, a gene dose-dependent effect with lower age at onset of sporadic ALS in epsilon 4 carriers was found (p=0.027). These data support APOE M as a subordinate contributing factor in ALS. (c) 2008 Elsevier B.V. All rights reserved.	[Zetterberg, Henrik] Univ Gothenburg, Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, SE-43180 Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, SE-43180 Molndal, Sweden; [Jacobsson, Johan; Andersen, Peter M.] Umea Univ Hosp, Dept Neurol, S-90185 Umea, Sweden; [Rosengren, Lars] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Neurol, SE-43180 Molndal, Sweden	Zetterberg, H (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, SE-43180 Molndal, Sweden.	henrik.zetterberg@clinchem.gu.se		Rosengren, Lars/0000-0003-0505-8896	Kempe Foundation; Swedish Brain Research Foundation; Hallstens Research Foundation; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Council for Working Life and Social researchSwedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte); Swedish Medical Society; Bjorklund Foundation for ALS Research; Alzheimer Foundation; Swedish Association for the Neurologically Disabled	We are indebted to the patients for their participation in this project. We thank Mona Seibt Palmer for the excellent technical assistance. This study was funded by grants from the Kempe Foundation, the Swedish Brain Research Foundation, the Hallstens Research Foundation, the Swedish Research Council, the Swedish Council for Working Life and Social research, the Swedish Medical Society and the Bjorklund Foundation for ALS Research, the Alzheimer Foundation, and the Swedish Association for the Neurologically Disabled.	Altman D, 1991, PRACTICAL STAT MED R; Andersen PM, 2006, CURR NEUROL NEUROSCI, V6, P37, DOI 10.1007/s11910-996-0008-9; Andersen PM, 2005, EUR J NEUROL, V12, P921, DOI 10.1111/j.1468-1331.2005.01351.x; ANDERSEN PM, 1995, NAT GENET, V10, P61, DOI 10.1038/ng0595-61; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; FARRER LA, 1995, EXP NEUROL, V136, P162, DOI 10.1006/exnr.1995.1093; Greenway MJ, 2006, NAT GENET, V38, P411, DOI 10.1038/ng1742; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Moulard B, 1996, J NEUROL SCI, V139, P34, DOI 10.1016/0022-510X(96)00085-8; MUI S, 1995, ANN NEUROL, V38, P460, DOI 10.1002/ana.410380318; PERICAKVANCE MA, 1993, GENET EPIDEMIOL, V10, P361, DOI 10.1002/gepi.1370100605; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Prince JA, 2004, NEUROLOGY, V62, P2116, DOI 10.1212/01.WNL.0000128088.08695.05; Siddique T, 1998, NEUROGENETICS, V1, P213, DOI 10.1007/s100480050031; VAN BROECKHOVEN C, 1994, NEUROSCI LETT, V169, P179, DOI 10.1016/0304-3940(94)90385-9; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111; Zetterberg H, 2007, EUR J NEUROL, V14, P1329, DOI 10.1111/j.1468-1331.2007.01972.x; ZETTERBERG M, 2007, AM J MED GENE B 1228	25	26	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	OCT 15	2008	273	1-2					67	69		10.1016/j.jns.2008.06.025			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	356CL	WOS:000259756200013	18656208				2021-06-18	
J	Hartley, CE; Varma, M; Fischer, JP; Riccardi, R; Strauss, JA; Shah, S; Zhang, S; Yang, ZJ				Hartley, Chad E.; Varma, Madhu; Fischer, John P.; Riccardi, Richard; Strauss, Judith A.; Shah, Sejal; Zhang, Shengle; Yang, Zhong-Jin			Neuroprotective effects of erythropoietin on acute metabolic and pathological changes in experimentally induced neurotrauma	JOURNAL OF NEUROSURGERY			English	Article						erythropoietin; microdialysis; neuroprotection; rat; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; IN-VIVO EVIDENCE; CEREBRAL-ISCHEMIA; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; ENDOTHELIAL-CELLS; PROTECTS NEURONS; BRAIN-INJURY; RECEPTOR; LACTATE	Object. Head trauma is a dynamic process characterized by a cascade of metabolic and molecular events. Erythropoietin (EPO) has been shown to have neuroprotective effects in animal models Of traumatic brain injury (TBI). Acute in vivo mechanisms and pathological changes associated with EPO following TBI are unknown. In this study the authors compare acute metabolic and pathological changes following TBI with and without systemically administered EPO. Methods. Right frontal lobe microdialysis cannulae and right parietal lobe percussion hubs were inserted into 16 Sprague-Dawley rats. After a 4- to 5-day recovery. TBI was induced via a DragonFly fluid-percussion device at 2.5-2.8 atm. Rats were randomized into 2 groups. which received 5000 U/kg EPO or normal saline intraperitoneally 30 minutes after TBI. Microdialysis samples for glucose, lactate, pyruvate. and glutamate were obtained every 25 minutes for 10 hours. Rats were killed, their brains processed for light microscopy, and sections stained with H & E. Results. Erythropoietin administered 30 Minutes after TBI directly affects acute brain metabolism. Brains treated with EPO maintain hi-her levels Of glucose 4-10 hours after TBI (p < 0.01). lower levels of lactate 6-10 hours after TBI (p < 0.01). and lower levels of pyruvate 7.5-10 hours after TBI (1) < 0.01) compared with saline-treated controls. Erythropoietin maintains aerobic metabolism after TBI. Systemic EPO administration reduces acute TBI-induced lesion volume (1) < 0.05). Conclusions. Following TBI, neuron use initially increases, with subsequent depletion of extracellular glucose, resulting in increased levels of extracellular lactate and pyruvate. This energy requirement can result in cell death due to increased metabolic demands. These data Suggest that the neuroprotective effect of EPO may be partially due to improved energy metabolism in the acute phase in this rat model of TBI.	[Hartley, Chad E.; Fischer, John P.] SUNY, Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA; [Varma, Madhu; Riccardi, Richard; Yang, Zhong-Jin] SUNY, Upstate Med Univ, Dept Anesthesiol, Syracuse, NY 13210 USA; [Strauss, Judith A.] SUNY, Upstate Med Univ, Dept Orthoped, Syracuse, NY 13210 USA; [Shah, Sejal; Zhang, Shengle] SUNY, Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	Hartley, CE (corresponding author), SUNY, Upstate Med Univ, Dept Neurosurg, 750 E Adams St, Syracuse, NY 13210 USA.	chadhartley@centura.org			Departments of Anesthesiology and Neurosurgery, Upstate Medical University, State University of New York	Support was provided for Dr. Hartley by the Departments of Anesthesiology and Neurosurgery, Upstate Medical University, State University of New York.	Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Banerjee D, 2000, KIDNEY INT, V57, P1895, DOI 10.1046/j.1523-1755.2000.00039.x; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; BUEMI M, 1993, NEPHRON, V65, P440, DOI 10.1159/000187526; Buemi M, 2000, EUR J PHARMACOL, V392, P31, DOI 10.1016/S0014-2999(00)00081-9; Buemi M, 2000, NEPHROL DIAL TRANSPL, V15, P422, DOI 10.1093/ndt/15.3.422; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cheetham JC, 1998, NAT STRUCT BIOL, V5, P861, DOI 10.1038/2302; Chin K, 2000, MOL BRAIN RES, V81, P29, DOI 10.1016/S0169-328X(00)00157-1; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; Grasso G, 2001, J Neurosurg Sci, V45, P7; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; HOWARD CV, 1998, UNBIASED STEREOLOGY; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Reeker W, 2000, CAN J ANAESTH, V47, P572, DOI 10.1007/BF03018950; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	26	27	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					708	714		10.3171/JNS/2008/109/10/0708			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100017	18826359				2021-06-18	
J	Sharp, HM; Hillenbrand, K				Sharp, Helen M.; Hillenbrand, Kathryn			Speech and Language Development and Disorders in Children	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article						Child language; Developmental disabilities; Articulation; Apraxia; Cleft palate; Autism; Speech-languate evaluation; Speech therapy	AUTISM SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; PALATE; IDENTIFICATION; VOCALIZATIONS; DISABILITIES; IMPAIRMENT; MANAGEMENT; CHILDHOOD	Language disorders are identified when a person has difficulty with expressive language, receptive language, or pragmatic language. Speech disorders are identified when a person's voice, fluency, or articulation call attention to the speaker because his or her speech is sufficiently different from the norm. Speech and language development should be consistent with a child's overall development and can be tracked using typical milestone markers. Differential diagnosis is critical to designing appropriate intervention, which should be tailored to the parents' goals along with the child's clinical and educational needs. Early identification and intervention assist in educational planning and are often associated with better long-term outcomes. Any speech-language therapy plan should be designed with measurable goals and consistent monitoring of progress toward those goals.	[Sharp, Helen M.; Hillenbrand, Kathryn] Western Michigan Univ, Dept Speech Pathol & Audiol, Kalamazoo, MI 49008 USA	Sharp, HM (corresponding author), Western Michigan Univ, Dept Speech Pathol & Audiol, 1903 W Michigan Ave,MS 5355, Kalamazoo, MI 49008 USA.	helen.sharp@wmich.edu					*AM AC PED, 2007, AUT ALARM; *AM SPEECH LANG HE, WHAT IS LANG WHAT IS; *AM SPEECH LANG HE, 2008, PRINC SPEECH LANG PA; American Speech-Language-Hearing Association, 2008, ROL RESP SPEECH LANG; American Speech-Language-Hearing Association, NAT OUTC MEAS SYST N; American Speech-Language-Hearing Association, 2007, CHILDH APR SPEECH; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Arvedson Joan C, 2000, Lang Speech Hear Serv Sch, V31, P28, DOI 10.1044/0161-1461.3101.28; BAUMANWAENGLER J, 2003, ARTICULATORY PHONOLO; BERNTHAL JE, 2004, ARTICULATION PHONOLO; CATTS HW, 1993, J SPEECH HEAR RES, V36, P948, DOI 10.1044/jshr.3605.948; Clark HM, 2003, AM J SPEECH-LANG PAT, V12, P400, DOI 10.1044/1058-0360(2003/086); Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Frederickson MS, 2006, CLEFT PALATE-CRAN J, V43, P179, DOI 10.1597/04-086.1; Geren Joy, 2005, Seminars in Speech and Language, V26, P44, DOI 10.1055/s-2005-864215; GLENNEN S, 2002, LANGUAGE DEV INT ADO; Greenspan SI, 2008, PEDIATRICS, V121, P828, DOI 10.1542/peds.2007-3833; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Hall PK, 2000, LANG SPEECH HEAR SER, V31, P179, DOI 10.1044/0161-1461.3102.179; Henry J, 2007, LANG SPEECH HEAR SER, V38, P99, DOI 10.1044/0161-1461(2007/010); HODSON B, 1992, LANG SPEECH HEAR SER, V23, P247; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Jones KL, 1997, SMITHS RECOGNIZABLE, V5th; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Krakow Rena A., 2005, Seminars in Speech and Language, V26, P33, DOI 10.1055/s-2005-864214; Kuhl PK, 1996, J ACOUST SOC AM, V100, P2425, DOI 10.1121/1.417951; Light J, 2007, AUGMENT ALTERN COMM, V23, P204, DOI 10.1080/07434610701553635; Luinge MR, 2006, J SPEECH LANG HEAR R, V49, P923, DOI 10.1044/1092-4388(2006/067); MCWILLIAMS BJ, 1991, CLEFT PALATE-CRAN J, V28, P247, DOI 10.1597/1545-1569(1991)028<0247:SCOTPH>2.3.CO;2; Millar DC, 2006, J SPEECH LANG HEAR R, V49, P248, DOI 10.1044/1092-4388(2006/021); Morris H, 2003, CLEFT PALATE-CRAN J, V40, P460, DOI 10.1597/1545-1569(2003)040<0460:PPALSO>2.0.CO;2; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Nelson N. W., 2004, WRITING LAB APPROACH; OLLER DK, 1985, J SPEECH HEAR RES, V28, P47, DOI 10.1044/jshr.2801.47; OWENS RE, 2006, HUMAN COMMUNICATION; PRATHER EM, 1975, J SPEECH HEAR DISORD, V40, P179, DOI 10.1044/jshd.4002.179; RAMIG PR, 2006, HUMAN COMMUNICATION; RICHMAN LC, 1988, CLEFT PALATE J, V25, P21; SCHIFFMYERS NB, 1992, LANG SPEECH HEAR SER, V23, P28; Sebastian-Galles N, 2007, DEVELOPMENTAL SCI, V10, P713, DOI 10.1111/j.1467-7687.2007.00649.x; SMITH BL, 1983, J SPEECH HEAR DISORD, V48, P114, DOI 10.1044/jshd.4802.114; Stoel-Gammon C., 1987, LANG SPEECH HEAR SER, V18, P323, DOI DOI 10.1044/0161-1461.1804.323; SWANSON LA, 1992, J SPEECH HEAR RES, V35, P617, DOI 10.1044/jshr.3503.617; Szatmari P, 2003, J CHILD PSYCHOL PSYC, V44, P520, DOI 10.1111/1469-7610.00141; Thomas JA, 1997, CLIN PEDIATR, V36, P253, DOI 10.1177/000992289703600502; TOMBLIN JB, 1989, J SPEECH HEAR DISORD, V54, P287, DOI 10.1044/jshd.5402.287; Tomblin JB, 1998, J SPEECH LANG HEAR R, V41, P188, DOI 10.1044/jslhr.4101.188; Tomblin JB, 1997, J SPEECH LANG HEAR R, V40, P1245, DOI 10.1044/jslhr.4006.1245; Yairi E, 1996, J SPEECH HEAR RES, V39, P771, DOI 10.1044/jshr.3904.771; Yairi E., 1997, NATURE TREATMENT STU	50	26	27	0	41	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	OCT	2008	55	5					1159	+		10.1016/j.pcl.2008.07.007			16	Pediatrics	Pediatrics	368WY	WOS:000260654800008	18929058				2021-06-18	
J	Oehmichen, M; Schleiss, D; Pedal, I; Saternus, KS; Gerling, I; Meissner, C				Oehmichen, Manfred; Schleiss, Daniela; Pedal, Ingo; Saternus, Klaus-Steffen; Gerling, Ivana; Meissner, Christoph			Shaken baby syndrome: re-examination of diffuse axonal injury as cause of death	ACTA NEUROPATHOLOGICA			English	Article						shaken baby syndrome; subdural hemorrhage; encephalopathy; retinal bleeding; diffuse axonal injury; cervical cord; global brain hypoxia/ischemia	TRAUMATIC BRAIN-INJURY; INFLICTED HEAD-INJURY; RETINAL HEMORRHAGE; INFANT DEATHS; NEUROPATHOLOGY; CHILDREN; BIOMECHANICS; MECHANISMS; DIAGNOSIS; FALLS	The discussion surrounding shaken baby syndrome (SBS) arose from the lack of evidence implicating diffuse axonal injury (DAI) as a cause of death. It was assumed instead that injury to the cervical cord, medulla, and nerve roots played a causal role. The present pathomorphological study examines 18 selected infants (< 1-year-old) whose deaths were highly suspicious for SBS, exhibiting the classical SBS triad of acute subdural hemorrhage (SDH), retinal bleeding, and encephalopathy. Gross autopsy and microscopic findings of these infants were compared with those of 19 victims of sudden infant death syndrome (SIDS; control group 1) and of 14 infants who died of disease or injuries/violence not involving the head, neck or eyes (control group 2). Symptoms of mechanical impact to the head were evident in seven of the SBS infants, but in none of the control infants. DAI was not detected in either the SBS or control cases. Localized axonal injury (AI) was regularly present in the brains of the SBS infants surviving longer than 1.5-3.0 h, but only occasionally in the craniocervical junction and within the nerve roots of the upper cervical cord; it was never present in the medulla. Epidural hemorrhage of the cervical cord was seen in four of the ten examined SBS cases, but in none of the control cases. Based on the absence of DAI in the brain and of signs of generalized cervical cord or nerve root injuries, we conclude that the cause of death in the SBS victims was a global cerebral ischemia secondary to SDH, focal vasospasm, trauma-induced transitory respiratory and/or circulatory failure.	[Oehmichen, Manfred; Schleiss, Daniela; Gerling, Ivana; Meissner, Christoph] Univ Hosp Schleswig Holstein, Inst Legal Med, Lubeck, Germany; [Pedal, Ingo] Heidelberg Univ, Inst Legal Med, Heidelberg, Germany; [Saternus, Klaus-Steffen] Univ Gottingen, Inst Legal Med, Gottingen, Germany	Oehmichen, M (corresponding author), Im Brandenbaumer Feld 39, D-23564 Lubeck, Germany.						ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; Alva NS, 2000, PEDIATR NEUROL, V23, P88, DOI 10.1016/S0887-8994(00)00151-X; ANNABLE WL, 1994, CHILD ABUSE MED DIAG, P138; Bell JE, 2005, CLIN DEV MED, P345; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Dyer C, 2005, BRIT MED J, V331, P253, DOI 10.1136/bmj.331.7511.253; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Forbes BJ, 2004, J PEDIAT OPHTH STRAB, V41, P80, DOI 10.3928/0191-3913-20040301-07; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Gleckman AM, 2000, J FORENSIC SCI, V45, P1151; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; JAYAWANT S, 1998, BMJ-BRIT MED J, V317, P1538; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Koch LE, 1998, FORENSIC SCI INT, V97, P1, DOI 10.1016/S0379-0738(98)00124-8; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; Kuhn J, 2005, ACTA NEUROPATHOL, V110, P579, DOI 10.1007/s00401-005-1090-9; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEDER LD, 1964, KLIN WOCHENSCHR, V42, P553, DOI 10.1007/BF01486688; Leestma J. E., 1997, NEUROPATHOLOGY DIAGN, P518; May K, 2005, CLIN DEV MED, P185; Minns RA, 2005, CLIN DEV MED, P1; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; Oehmichen M, 2005, NEUROPEDIATRICS, V36, P240, DOI 10.1055/s-2005-872812; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Oehmichen M, 2006, FORENSIC NEUROPATHOL; Pai SB, 2005, CHILD NERV SYST, V17, P1; PIATT JH, 1995, PEDIATRICS, V96, P780; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Reece RM, 2004, BMJ-BRIT MED J, V328, P1316, DOI 10.1136/bmj.328.7451.1316; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Saternus KS, 2000, FORENSIC SCI INT, V109, P203, DOI 10.1016/S0379-0738(00)00144-4; Shannon P, 2001, LANCET, V358, P686, DOI 10.1016/S0140-6736(01)05849-4; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849	49	26	26	2	7	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2008	116	3					317	329		10.1007/s00401-008-0356-4			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	334QB	WOS:000258235200009	18365221				2021-06-18	
J	Jennische, E; Bergstrom, T; Johanssona, M; Nystrom, K; Tarkowski, A; Hansson, HA; Lange, S				Jennische, Eva; Bergstrom, Tomas; Johanssona, Maria; Nystrom, Kristina; Tarkowski, Andrej; Hansson, Hans-Arne; Lange, Stefan			The peptide AF-16 abolishes sickness and death at experimental encephalitis by reducing increase of intracranial pressure	BRAIN RESEARCH			English	Article						antisecretory factor; herpes simplex virus type 1; brain inflammation; neuroprotection	HERPES-SIMPLEX ENCEPHALITIS; TRAUMATIC BRAIN-INJURY; ANTISECRETORY FACTOR; PATTERNS; DISEASE	Elevated intracranial pressure (ICP) is strongly aggravating the injury at brain inflammation, resulting in persistent neurological and psychiatric malfunctions. There is no efficient pharmacological treatment to achieve beneficial ICP reduction. Here, the peptide AF-16, comprising the amino terminal part of the endogenous protein Antisecretory Factor (AF), was used to suppress the raised ICP in experimental herpes simplex encephalitis (HSE) in rats. Intranasal instillation of the peptide AF-16 counteracted the ICP elevation and the prevalence of ICP spikes, abrogated the neurological morbidity, and abolished the mortality in a dose-dependent manner. AF-16, 2S mu g twice daily intranasally, rescued all animals with HSE and abrogated neurological malfunction. In contrast, only 10% of the rats survived if treated with the vehicle. A single intranasal dose of 25 mu g AF-16 to a rat displaying overt HSE symptoms reduced the ICP to normal levels within an hour. No effects on viral replication or antigen distribution were demonstrable. Thus, AF-16 abolished the prevalence of sickness signs, ICP elevation, neurological malfunctions and completely prevented deaths. We advocate use of AF-16 for suppression of elevated ICP. (C) 2008 Elsevier B.V. All rights reserved.	[Lange, Stefan] Gothenburg Univ, Dept Clin Bacteriol, Inst Biomed, SE-41346 Gothenburg, Sweden; [Tarkowski, Andrej] Univ Gothenburg, Dept Rheumatol & Inflammat Res, SE-41346 Gothenburg, Sweden	Lange, S (corresponding author), Gothenburg Univ, Dept Clin Bacteriol, Inst Biomed, Guldhedsgatan 10, SE-41346 Gothenburg, Sweden.	stefan.lange@microbio.gu.se	Nystrom, Kristina/N-3125-2014	Bergstrom, Tomas/0000-0002-9257-6757	Goteborg Medical Society [7157]; Sahlgrenska University Hospital [8303]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [11255]	Financial support was provided by the Goteborg Medical Society, Lantmannen AS-Faktor AB, Nectin AB, W and M Lundgren's Stiftelse, the Swedish State under the LUA agreement (grant # 7157), the Sahlgrenska University Hospital (grant # 8303), and the Swedish Research Council (grant # 11255). We thank E. Lycke for the critical comments to the manuscript, I. Bosaeus for the helpful statistical analyses and S. Hojer, Samba Sensors AB, V. Frolunda, Sweden, for the technical support.	BARNETT GH, 1988, J NEUROSURG, V68, P585, DOI 10.3171/jns.1988.68.4.0585; Bjorck S, 2000, GUT, V46, P824, DOI 10.1136/gut.46.6.824; Brodbelt A, 2007, BRIT J NEUROSURG, V21, P510, DOI 10.1080/02688690701447420; Davidson TS, 2004, J LEUKOCYTE BIOL, V76, P835, DOI 10.1189/jlb.0204085; Davson H, 1996, PHYSL CSF BLOOD BRAI; Ebel H, 1999, CHILD NERV SYST, V15, P84, DOI 10.1007/s003810050337; ESIRI MM, 1982, J NEUROL SCI, V54, P209, DOI 10.1016/0022-510X(82)90183-6; Hanner P, 2004, HEARING RES, V190, P31, DOI 10.1016/S0378-5955(03)00368-X; Jennische E, 2006, APMIS, V114, P529, DOI 10.1111/j.1600-0463.2006.apm_464.x; JOHANSSON E, 1995, J BIOL CHEM, V270, P20615, DOI 10.1074/jbc.270.35.20615; Johansson E, 1997, BBA-MOL BASIS DIS, V1362, P177, DOI 10.1016/S0925-4439(97)00066-5; JOHNSON RT, 1998, VIRAL INFECTIONS NER; Kennedy, 2000, INFECT DIS NERVOUS S, P139; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Lange S, 2001, INT REV CYTOL, V210, P39; LOVE S, 2002, GREENFIELDS NEUROPAT, V2, P1; Lundberg N, 1960, ACTA PSYCHIAT NEUR S, V36, P149; Namvar L, 2005, J CLIN MICROBIOL, V43, P2058, DOI 10.1128/JCM.43.5.2058-2064.2005; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; Raschilas F, 2002, CLIN INFECT DIS, V35, P254, DOI 10.1086/341405; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; Steiner I, 2005, EUR J NEUROL, V12, P331, DOI 10.1111/j.1468-1331.2005.01126.x; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Tyler Kenneth L, 2004, Herpes, V11 Suppl 2, p57A; Whitley RJ, 2006, ANTIVIR RES, V71, P141, DOI 10.1016/j.antiviral.2006.04.002; Yan HJ, 2002, SURG NEUROL, V57, P20, DOI 10.1016/S0090-3019(01)00688-7	27	26	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 28	2008	1227						189	197		10.1016/j.brainres.2008.05.083			9	Neurosciences	Neurosciences & Neurology	352PY	WOS:000259510700019	18586012				2021-06-18	
J	Principi, T; Morrison, GC; Matsui, DM; Speechley, KN; Seabrook, JA; Singh, RN; Kornecki, A				Principi, Tania; Morrison, Gavin C.; Matsui, Doreen M.; Speechley, Kathy N.; Seabrook, Jamie A.; Singh, Ram N.; Kornecki, Alik			Elective tracheostomy in mechanically ventilated children in Canada	INTENSIVE CARE MEDICINE			English	Article						tracheostomy; survey; practice; mechanical ventilation; acute respiratory distress syndrome; Acute lung injury	INTENSIVE-CARE-UNIT; CRITICALLY-ILL; SURGICAL TRACHEOSTOMY	Objective: To determine the current practice and opinions of paediatric intensivists in Canada regarding tracheostomy in children with potentially reversible conditions which are anticipated to require prolonged mechanical ventilation. Design and setting: Self-administered survey among paediatric intensivists within paediatrics critical care units (PCCU) across Canada. Measurements and results: All 16 PCCUs participated in the survey with a response rate of 81% (63 physicians). In 14 of 16 centres one to five tracheostomies were performed during 2006. Two centres did not perform any tracheostomies. The overall rate of tracheostomy is less than 1.5%. Percutaneous technique is used in 3/16 (19%) of centres. Readiness to undertake tracheostomy during the first 21 days of illness is influenced by patient diagnosis; severe traumatic brain injury 66% vs. 42% in a 2-year-old with Guillain-Barre syndrome, 48% in a 9- year-old with Guillain-Barre syndrome, and 12% in a child with isolated ARDS. In a child with ARDS 25% of respondents would never consider tracheostomy. Age does not affect timing nor keenness for tracheostomy. The majority, 81%, believe that the risks associated with the procedure do not outweigh the potential benefits. Finally, 51% believe that tracheostomy is underutilized in children. Conclusions: Elective tracheostomy is rarely performed among ventilated children in Canada. However, 51% of physicians believe it is underutilized. The role of elective tracheostomy and the percutaneous technique in children requires further investigation.	[Principi, Tania; Morrison, Gavin C.; Singh, Ram N.; Kornecki, Alik] Childrens Hosp, London Hlth Sci Ctr, Crit Care Unit, London, ON N6A 5W9, Canada; [Principi, Tania; Morrison, Gavin C.; Matsui, Doreen M.; Speechley, Kathy N.; Seabrook, Jamie A.; Singh, Ram N.; Kornecki, Alik] Childrens Hosp, London Hlth Sci Ctr, Dept Paediat, London, ON N6A 5W9, Canada; [Speechley, Kathy N.] Childrens Hosp, London Hlth Sci Ctr, Dept Epidemiol & Biostat, London, ON N6A 5W9, Canada; [Matsui, Doreen M.; Speechley, Kathy N.; Seabrook, Jamie A.; Kornecki, Alik] Univ Western Ontario, London Hlth Sci Ctr, Childrens Hlth Res Inst, London, ON, Canada	Kornecki, A (corresponding author), Childrens Hosp, London Hlth Sci Ctr, Crit Care Unit, 800 Commissioners Rd E, London, ON N6A 5W9, Canada.	Alik.kornecki@lhsc.on.ca	Principi, Tania/AAI-3644-2021				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Albuali WH, 2007, PEDIATR CRIT CARE ME, V8, P324, DOI 10.1097/01.PCC.0000269390.48450.AF; Chastre J, 1998, REAN URG, V7, P435; CIAGLIA P, 1985, CHEST, V87, P715, DOI 10.1378/chest.87.6.715; Combes A, 2007, CRIT CARE MED, V35, P802, DOI 10.1097/01.CCM.0000256721.60517.B1; Corbett HJ, 2007, J PEDIATR SURG, V42, P1251, DOI 10.1016/j.jpedsurg.2007.02.017; Dillman D.A., 1978, MAIL TELEPHONE SURVE; Dulguerov P, 1999, CRIT CARE MED, V27, P1617, DOI 10.1097/00003246-199908000-00041; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Fantoni A, 2002, Minerva Anestesiol, V68, P433; Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44; Freeman BD, 2000, CHEST, V118, P1412, DOI 10.1378/chest.118.5.1412; Frutos-Vivar F, 2005, CRIT CARE MED, V33, P290, DOI 10.1097/01.CCM.0000150026.85210.13; Groves DS, 2007, CURR OPIN CRIT CARE, V13, P90, DOI 10.1097/MCC.0b013e328011721e; Lawn ND, 1999, MUSCLE NERVE, V22, P1058; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Palmieri TL, 2002, CRIT CARE MED, V30, P922, DOI 10.1097/00003246-200204000-00036; Pierson David J, 2005, Respir Care, V50, P526; PUHAKKA HJ, 1992, ACTA PAEDIATR, V81, P231, DOI 10.1111/j.1651-2227.1992.tb12210.x; Simpson TP, 1999, ANAESTHESIA, V54, P186, DOI 10.1046/j.1365-2044.1999.00667.x; TOURSARKISSIAN B, 1994, J PEDIATR SURG, V29, P1421, DOI 10.1016/0022-3468(94)90135-X	21	26	26	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2008	34	8					1498	1502		10.1007/s00134-008-1104-x			5	Critical Care Medicine	General & Internal Medicine	330IH	WOS:000257933700021	18418569				2021-06-18	
J	Jetter, GM; Cavazos, JE				Jetter, Gina Mapes; Cavazos, Jose E.			Epilepsy in the elderly	SEMINARS IN NEUROLOGY			English	Article						epilepsy; geriatrics; antiepileptic drugs	NONCONVULSIVE STATUS EPILEPTICUS; NURSING-HOME RESIDENTS; ANTIEPILEPTIC DRUG-USE; TONIC CLONIC SEIZURES; VITAMIN-D LEVELS; SERUM CONCENTRATIONS; BONE TURNOVER; CARBAMAZEPINE; PHENYTOIN; AGE	There are many unique characteristics in elderly patients with epilepsy. The incidence of seizures in this age group is the highest of any age group and continues to increase as people live longer. Etiology of seizures is different than for adults and includes cerebrovascular disease, dementia, closed head injury, and metabolic encephalopathies. The elderly patient with epilepsy most often presents with complex partial seizures that have a higher recurrence rate than the younger population. The seizures are often difficult to diagnose since they present with atypical symptoms, particularly prolonged postictal symptoms, including memory lapses, confusion, altered mental status, and inattention. There are also therapeutic challenges due to age-related changes in pharmacokinetics, including variations in absorption, distribution, metabolism, and excretion. These must be considered when selecting antiepileptic drug (AED) therapy to avoid harmful side effects. In addition, several of the AEDs have drug-drug interactions, a problem potentially exacerbated in this population of patients due to the use of medications for comorbid conditions.	[Jetter, Gina Mapes; Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Comprehens Epilepsy Ctr, San Antonio, TX 78229 USA; [Cavazos, Jose E.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA	Cavazos, JE (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 7703 Floyd Curl Dr,MC7883, San Antonio, TX 78229 USA.	cavazosj@uthscsa.edu	Cavazos, Jose/J-4122-2016	Cavazos, Jose/0000-0001-5777-2608			BAUER LA, 1982, CLIN PHARMACOL THER, V31, P301, DOI 10.1038/clpt.1982.37; Bergey GK, 2004, NEUROLOGY, V63, pS40, DOI 10.1212/WNL.63.10_suppl_4.S40; Birnbaum A, 2003, NEUROLOGY, V60, P555, DOI 10.1212/01.WNL.0000052997.43492.E0; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 2005, BMJ-BRIT MED J, V331, P1317, DOI 10.1136/bmj.331.7528.1317; Cloyd J, 2006, EPILEPSY RES, V68, pS39, DOI 10.1016/j.eplepsyres.2005.07.016; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/s0140-6736(02)09327-3; DeLorenzo RJ, 1996, NEUROLOGY, V46, P1029, DOI 10.1212/WNL.46.4.1029; Farhat G, 2002, NEUROLOGY, V58, P1348, DOI 10.1212/WNL.58.9.1348; Firth M, 2002, GASTROENTEROLOGY, V122, P1688, DOI 10.1053/gast.2002.33566; Garnett Linda K., 2002, Epilepsia, V43, P282; Garrard J, 2000, J GERONTOL A-BIOL, V55, pM384, DOI 10.1093/gerona/55.7.M384; Gidal BE, 2006, EPILEPSY RES, V68, pS65, DOI 10.1016/j.eplepsyres.2005.07.018; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HOIKKA V, 1984, ACTA NEUROL SCAND, V70, P77; HUDSON SA, 1990, J CLIN PHARM THER, V15, P25, DOI 10.1111/j.1365-2710.1990.tb00352.x; Jetter GM, 2006, EPILEPSIA, V47, P8; Le Couteur DG, 1998, CLIN PHARMACOKINET, V34, P359, DOI 10.2165/00003088-199834050-00003; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Mintzer S, 2006, EPILEPSIA, V47, P510, DOI 10.1111/j.1528-1167.2006.00460.x; Muhlberg W, 1999, GERONTOLOGY, V45, P243, DOI 10.1159/000022097; Pack AM, 2005, ANN NEUROL, V57, P252, DOI 10.1002/ana.20378; Perucca E, 2006, EPILEPSY RES, V68, pS49, DOI 10.1016/j.eplepsyres.2005.07.017; Ramsay RE, 2004, NEUROLOGY, V62, pS24, DOI 10.1212/WNL.62.5_suppl_2.S24; RAMSAY RE, 2001, CLIN GERIATR MED, V9, P47; Rowan AJ, 2005, NEUROLOGY, V64, P1868, DOI 10.1212/01.WNL.0000167384.68207.3E; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; Treiman DM, 2006, EPILEPSY RES, V68, pS77, DOI 10.1016/j.eplepsyres.2005.07.020; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Ucar M, 2004, EUR J CLIN PHARMACOL, V59, P879, DOI 10.1007/s00228-003-0700-5; Walker MC, 2001, CNS DRUGS, V15, P931, DOI 10.2165/00023210-200115120-00003; Wallace H, 1998, LANCET, V352, P1970, DOI 10.1016/S0140-6736(98)04512-7; WalterSack I, 1996, CLIN PHARMACOKINET, V31, P47, DOI 10.2165/00003088-199631010-00004; WILLMORE LJ, 1995, EPILEPSIA, V36, pS14, DOI 10.1111/j.1528-1157.1995.tb06005.x	41	26	27	0	1	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235			SEMIN NEUROL	Semin. Neurol.	JUL	2008	28	3					336	341		10.1055/s-2008-1079338			6	Clinical Neurology	Neurosciences & Neurology	336OL	WOS:000258374400008	18777480				2021-06-18	
J	Mossberg, KA; Masel, BE; Gilkison, CR; Urban, RJ				Mossberg, Kurt A.; Masel, Brent E.; Gilkison, Charles R.; Urban, Randall J.			Aerobic capacity and growth hormone deficiency after traumatic brain injury	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							QUALITY-OF-LIFE; CONSENSUS GUIDELINES; PITUITARY-FUNCTION; MAXIMAL TREADMILL; CHRONIC FATIGUE; GH TREATMENT; ADULTS; HYPOPITUITARISM; EXERCISE; REHABILITATION	Context: GH deficiency occurs in approximately 20% of all individuals who suffer from a moderate to severe traumatic brain injury. Objective: This study determined whether GH deficiency secondary to traumatic brain injury had an effect on aerobic capacity. Design: Subjects were screened for GH deficiency by the glucagon stimulation test and performed a maximal treadmill exercise test. Setting: Patients were studied in the postacute recovery phase after traumatic brain injury. Participants: Thirty-five individuals were studied. Groups were formed as follows: normal GH axis, greater than 8 ng/ml response (n = 12); insufficient, GH 3-8 ng/ml response (n = 11); and deficient, less than 3 ng/ml response (n = 12). Intervention: There was no intervention. Main Outcome Measure: Aerobic capacity was assessed by measuring expired gases during a graded treadmill exercise test. One-way and two-way ANOVAs were carried out on all peak and submaximal cardiorespiratory variables, respectively. Appropriate post hoc comparisons followed as necessary. Results: Significantly higher peak oxygen consumption was found in traumatic brain injury subjects with GH normal vs. GH insufficient and deficient [26.4 +/- 6.9, 20.8 +/- 4.6, and 19.7 +/- 5.0, respectively (P < 0.05)]. Submaximal oxygen consumption was significantly higher in the GH normal group. All other variables were statistically similar. Conclusions: This study shows that individuals with traumatic brain injury with normal GH secretion have below normal aerobic capacity and those patients who have GH insufficiency/deficiency are further deconditioned. Studies of GH replacement in these subjects should be conducted to assess whether GH therapy can improve cardiorespiratory fitness and prevent secondary disability.	[Mossberg, Kurt A.] Univ Texas Galveston, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX 77550 USA	Mossberg, KA (corresponding author), Univ Texas Galveston, Med Branch, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00073, M01 RR000073] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000073] Funding Source: NIH RePORTER		Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Astrand PO., 2003, TXB WORK PHYSL PHYSL, V4; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Colao A, 2001, CLIN ENDOCRINOL, V54, P137, DOI 10.1046/j.1365-2265.2001.01218.x; Conceicao FL, 2003, J ENDOCRINOL INVEST, V26, P1065, DOI 10.1007/BF03345251; Cummings DE, 2003, ANNU REV MED, V54, P513, DOI 10.1146/annurev.med.54.101601.152147; DANIEL PM, 1961, MOD TRENDS ENDOCRINO, V2, P55; Fellus J, 2007, BRAIN INJURY MED, P545; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grohar-Murray M E, 1998, J Neurosci Nurs, V30, P191; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31; Hillier SL, 1997, BRAIN INJURY, V11, P661; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Katz DI, 2007, BRAIN INJURY MED PRI, P3; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LANGLOIS JA, 2004, TRAUMATIC BRAIN INJU, P7; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LUKASKI HC, 1989, J SPORT MED PHYS FIT, V29, P223; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Merola B, 1995, EUR J ENDOCRINOL, V133, P680, DOI 10.1530/eje.0.1330680; MOSSBERG K, 2005, ARCH PHYS MED REHAB, V86, pE12; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; TAYLOR HL, 1955, J APPL PHYSIOL, V8, P73; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; Thomas SG, 2003, J CLIN ENDOCR METAB, V88, P5734, DOI 10.1210/jc.2003-030632; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Whaley MH, 2006, ACSMS GUIDELINES EXE; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022; Woodhouse LJ, 1999, J CLIN ENDOCR METAB, V84, P4570, DOI 10.1210/jc.84.12.4570	43	26	26	0	6	ENDOCRINE SOC	CHEVY CHASE	8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA	0021-972X			J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	JUL 1	2008	93	7					2581	2587		10.1210/jc.2008-0368			7	Endocrinology & Metabolism	Endocrinology & Metabolism	324JA	WOS:000257513700027	18413421	Green Published, Bronze			2021-06-18	
J	Schubert, GA; Poli, S; Schilling, L; Heiland, S; Thome, C				Schubert, Gerrit Alexander; Poli, Sven; Schilling, Lothar; Heiland, Sabine; Thome, Claudius			Hypothermia reduces cytotoxic edema and metabolic alterations during the acute phase of massive SAH: A diffusion-weighted imaging and spectroscopy study in rats	JOURNAL OF NEUROTRAUMA			English	Article						acute; cytotoxic edema; DWI; hypothermia; metabolism; MR spectroscopy; subarachnoid hemorrhage	ANEURYSMAL SUBARACHNOID HEMORRHAGE; MAGNETIC-RESONANCE SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; ACETYL-L-ASPARTATE; TRAUMATIC BRAIN-INJURY; PROLONGED HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; BEDSIDE MICRODIALYSIS; N-ACETYLASPARTATE; MILD HYPOTHERMIA	Acute changes in cerebral perfusion and metabolism after subarachnoid hemorrhage (SAH) have been shown to contribute significantly to acute brain injury. The purpose of this study was to examine the effects of moderate hypothermia on the acute changes after massive experimental SAH as evaluated by diffusion-weighted imaging (DWI) and magnetic resonance spectroscopy (MRS). SAH in rats was induced by injection of 0.5 mL of arterial blood. Normothermic animals (NT, n = 10) were kept at 37.0 +/- 0.2 degrees C, while temperature was lowered to 32.0 +/- 0.2 degrees C in the primary hypothermia group (pHT, n = 10) prior to SAH and in the secondary hypothermia group (sHT, n = 10) immediately after SAH. DWI and MRS were performed from 30 min prior up to 3 h after injury. The apparent diffusion coefficient (ADC) was measured in cortical and hippocampal regions of interest (ROIs). MRS included lactate, N-acetyl aspartate (NAA), and creatine in a central voxel. DWI showed a generalized, significant decline in ADC after SAH in NT. Significant change in ADC in pHT was absent, and accelerated recovery for animals in sHT was noted. MRS analysis revealed significant lactate accumulation to 204 +/- 40% from baseline only in NT, while sHT was characterized by a transient, less pronounced increase of lactate (159 +/- 11%) and lactate in pHT did not change significantly (117 +/- 11%). NAA did not change significantly when compared to baseline or between groups for NT, pHT, or sHT. Creatine rose significantly to 166 +/- 27% in NT after the insult, indicating increased metabolic stress which was absent in pHT (106 +/- 8%) and sHT (124 +/- 18%). Hypothermia can ameliorate early development of cytotoxic edema, lactate accumulation, and a general metabolic stress response after SAH, even when started after the insult. Our study indicates that a potentially beneficial influence on metabolism and cerebral perfusion in this crucial phase is practicable and might hold the key to further improve outcome in SAH.	[Schubert, Gerrit Alexander; Poli, Sven; Thome, Claudius] Heidelberg Univ, Dept Neurosurg, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Schilling, Lothar] Heidelberg Univ, Dept Neurosurg Res, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Heiland, Sabine] Heidelberg Univ, Dept Neuroradiol Res, D-6800 Mannheim, Germany	Schubert, GA (corresponding author), Heidelberg Univ, Dept Neurosurg, Univ Hosp Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	gerrit.schubert@nch.ma.uni-heidelberg.de	Schubert, Gerrit Alexander/Q-9192-2017	Schubert, Gerrit Alexander/0000-0001-9135-6042			Back T, 2004, J NEUROL, V251, P388, DOI 10.1007/s00415-004-0399-y; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf; Barber PA, 1999, STROKE, V30, P2059, DOI 10.1161/01.STR.30.10.2059; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Busch E, 1998, STROKE, V29, P2155, DOI 10.1161/01.STR.29.10.2155; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Condette-Auliac S, 2001, STROKE, V32, P1818, DOI 10.1161/01.STR.32.8.1818; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Ebisu T, 1997, RADIOLOGY, V203, P823, DOI 10.1148/radiology.203.3.9169711; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Gabikian P, 2002, STROKE, V33, P2681, DOI 10.1161/01.STR.0000033931.62992.B1; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gee CE, 2006, EUR J NEUROSCI, V23, P2595, DOI 10.1111/j.1460-9568.2006.04786.x; GIDEON P, 1992, STROKE, V23, P1566, DOI 10.1161/01.STR.23.11.1566; Harris NG, 2000, J CEREBR BLOOD F MET, V20, P28, DOI 10.1097/00004647-200001000-00006; HASEGAWA Y, 1994, NEUROLOGY, V44, P1484, DOI 10.1212/WNL.44.8.1484; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; Hoehn-Berlage M, 1999, NMR BIOMED, V12, P45, DOI 10.1002/(SICI)1099-1492(199902)12:1<45::AID-NBM545>3.0.CO;2-6; Iseda K, 2007, J NEUROSURG, V107, P128, DOI 10.3171/JNS-07/07/0128; JAKOBSEN J, 1992, ACTA NEUROL SCAND, V86, P1, DOI 10.1111/j.1600-0404.1992.tb08044.x; Karibe H, 2000, NEUROSURGERY, V47, P594, DOI 10.1097/00006123-200009000-00012; Kawamura Y, 2000, J NEUROTRAUM, V17, P243, DOI 10.1089/neu.2000.17.243; KNIGHT RA, 1994, STROKE, V25, P1252, DOI 10.1161/01.STR.25.6.1252; Kobayashi M, 2001, STROKE, V32, P2237, DOI 10.1161/hs1001.096621; Kollmar R, 2002, ANESTHESIOLOGY, V97, P868, DOI 10.1097/00000542-200210000-00018; Kuroiwa T, 1998, STROKE, V29, P859, DOI 10.1161/01.STR.29.4.859; Leibovici A, 2007, DEV NEUROSCI-BASEL, V29, P268, DOI 10.1159/000097410; MacLellan C, 2002, BRAIN RES, V958, P192, DOI 10.1016/S0006-8993(02)03702-2; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Nicoli F, 2003, STROKE, V34, pE82, DOI 10.1161/01.STR.0000078659.43423.0A; Parsons MW, 2000, NEUROLOGY, V55, P498, DOI 10.1212/WNL.55.4.498; PEREZTREPICHIO AD, 1995, STROKE, V26, P667, DOI 10.1161/01.STR.26.4.667; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; PRICHARD JW, 1993, RES P ARNMD, V71, P153; ROSENSTEIN J, 1984, NEUROSURGERY, V15, P519, DOI 10.1227/00006123-198410000-00008; Rowe J, 1998, J NEUROL NEUROSUR PS, V64, P98, DOI 10.1136/jnnp.64.1.98; Ryba MS, 1999, BRAIN RES, V850, P225, DOI 10.1016/S0006-8993(99)02161-7; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schubert GA, 2008, J NEUROTRAUM, V25, P539, DOI 10.1089/neu.2007.0500; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Thome C, 2001, ACTA NEUROCHIR SUPPL, V77, P255; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; Valenzuela MJ, 2001, NEUROLOGY, V56, P592, DOI 10.1212/WNL.56.5.592; van Walsum AMV, 1999, AM J OBSTET GYNECOL, V181, P1537, DOI 10.1016/S0002-9378(99)70401-1; VANDERGROND J, 1995, STROKE, V26, P822, DOI 10.1161/01.STR.26.5.822; VANDERSPRENKEL JWB, 1988, STROKE, V19, P1556, DOI 10.1161/01.STR.19.12.1556	59	26	26	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					841	852		10.1089/neu.2007.0443			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000010	18627260				2021-06-18	
J	von Elm, E; Osterwalder, JJ; Graber, C; Schoettker, P; Stocker, R; Zangger, P; Vuadens, P; Egger, M; Walder, B				von Elm, Erik; Osterwalder, Joseph J.; Graber, Claire; Schoettker, Patrick; Stocker, Reto; Zangger, Peter; Vuadens, Phillipe; Egger, Matthias; Walder, Bernhard			Severe traumatic brain injury in Switzerland - feasibility and first results of a cohort study	SWISS MEDICAL WEEKLY			English	Article						cohort study; traumatic brain injury; case fatalit; morbidity; functional outcome; healthrelated quality-of-life	ACUTE SUBDURAL-HEMATOMA; GLASGOW COMA SCALE; HEAD-INJURY; HEALTH SURVEY; CARE; MORTALITY; SCORE; EPIDEMIOLOGY; MULTICENTER; VALIDATION	Background: We aimed to study the incidence and outcome of severe traumatic brain injury (TBI) in Switzerland and to test the feasibility of a large cohort study with case identification in the first 24 hours and 6-month follow-up. Methods: From January to June 2005, we consecutively enrolled and followed up all persons with severe TBI (Abbreviated Injury Score of the head region > 3 and Glasgow Coma Scale < 9) in the catchment areas of 3 Swiss medical centres with neurosurgical facilities. The primary outcome was the Extended Glasgow Outcome Scale (GOSE) after 6 months. Secondary outcomes included survival, Functional Independence Measure (FIM), and health-related quality of life (SF-12) at defined time-points up to 6 months after injury. Results: We recruited 101 participants from a source population of about 2.47 million (ie, about 3 3 % of Swiss population). The incidence of severe TBI was 8.2 per 100,000 person-years. The overall case fatality was 70%: 41 of 101 persons (41%) died at the scene of the accident. 23 of 60 hospitalised participants (38%) died within 48 hours, and 31 (53%) within 6 months. In all hospitalised patients, the median GOSE was I (range 1-8) after 6 months, and was 6 (2-8) in 6-month survivors. The median total FIM score was 125 (range 18-126); median-SF-12 component measures were 44 (25-55) for the physical scale and 52 (32-65) for the mental scale. Conclusions: Severe TBI was associated with high case fatality and considerable morbidity in survivors. We demonstrated the feasibility of a multicentre cohort study in Switzerland with the aim of identifying modifiable determinants of outcome and improving current trauma care.	[Osterwalder, Joseph J.] Univ Geneva, Kantonsspital, Privatdozent Med Sch, Emergency Dept,Zentrale Notfallaufnahme, CH-9007 St Gallen, Switzerland; [von Elm, Erik; Graber, Claire] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Stocker, Reto] Univ Zurich Hosp, Div Surg Intens Care, Zurich, Switzerland; [von Elm, Erik] Univ Med Ctr, Dept Med Biometry & Stat, Freiburg, Germany; [Walder, Bernhard] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland	Osterwalder, JJ (corresponding author), Univ Geneva, Kantonsspital, Privatdozent Med Sch, Emergency Dept,Zentrale Notfallaufnahme, CH-9007 St Gallen, Switzerland.	joseph.osterwalder@kssg.ch	Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; Egger, Matthias/0000-0001-7462-5132; von Elm, Erik/0000-0002-7412-0406			*AM ASS ADV AUT ME, 1990, ABBR INJ SCAL; Baethmann A, 2002, EUR SURG RES, V34, P42, DOI 10.1159/000048886; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Black KL, 2002, J HEAD TRAUMA REHAB, V17, P489, DOI 10.1097/00001199-200212000-00001; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; *BUND STAT, 2 1 6 VERL POT LEB J; *BUND STAT, STAND WOHNB STAATS G; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Dent DL, 1995, J TRAUMA, V39, P42; Dick WF, 1999, RESUSCITATION, V42, P81, DOI 10.1016/S0300-9572(99)00102-1; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Heim C, 2004, ANAESTHESIST, V53, P1245, DOI 10.1007/s00101-004-0777-y; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; KOZLOWSKI P, 2002, ANN READAPT MED PHYS, V45, P466; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mazaux JM, 2002, ACT NEUR S, V79, P49; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Niemcryk SJ, 1998, AM J PREV MED, V14, P43, DOI 10.1016/S0749-3797(97)00013-5; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perneger TV, 2005, J CLIN EPIDEMIOL, V58, P142, DOI 10.1016/j.jclinepi.2004.06.005; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Sergides IG, 2006, BRIT J NEUROSURG, V20, P301, DOI 10.1080/02688690600999976; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	45	26	26	0	1	E M H SWISS MEDICAL PUBLISHERS LTD	MUTTENZ	FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	JUN 14	2008	138	23-24					327	334					8	Medicine, General & Internal	General & Internal Medicine	316FC	WOS:000256933500001	18561037	DOAJ Gold			2021-06-18	
J	Loder, RT				Loder, Randall T.			The demographics of playground equipment injuries in children	JOURNAL OF PEDIATRIC SURGERY			English	Article						playground equipment; injuries; children	SEVERITY; SURFACES; SAFETY	Background/Purpose: There have been many different studies of injuries owing to playground equipment but none that have looked in detail using large nationwide databases. It was the purpose of this Study to investigate injuries owing to playground equipment using the National Electronic Injury Surveillance System (NEISS) database and further understand their demographics. Methods: Detailed NEISS injury data from 2002 through 2004 for slides, monkey bars, and swings were analyzed. Appropriate statistical analyses were performed; because of the many analyses on this large data set, P < .01 was considered statistically significant. Results: There were 22728 emergency department visits owing to playground equipment injuries recorded by NEISS between 2002 and 2004; 83.9% were owing to monkey bars, swings, and slides, and the 5 most common diagnoses were fractures (39.3%), contusions/abrasions (20.6%), lacerations (16.6%), strains/sprains (9.9%), and traumatic brain injuries (TBI) (8.5%). There were 9487 boys (54.3%) and 7995 girls (45.7%). The average age was 6.5 +/- 3.0 years. The injuries occurred at school in 38.9%; at a recreation/sporting facility, in 35.5%; and at home, in 25.6%. Most were treated and released (94.4%). Amerindian children were 2 times more likely than blacks to be admitted; compared to contusions, fractures were 9.8 times, and TBIs, 4.7 times more likely to be admitted. Injuries on monkey bars were 1.2 times more likely to be admitted than those on swings or slides. Fractures were 1.9 times more likely to occur on a monkey bar compared with swings or slides. Traumatic brain injuries were 1.4 times more likely to occur on a swing compared to slides or monkey bars. Conclusion: Swings at school are the most common mechanism of injury for TBIs, and the seasonal data would suggest that increased supervision of children using swings during school hours might reduce the occurrence of TBIs. Monkey bars are the most common cause of fracture, and fracture is the most common cause of admission. Prevention strategies to reduce the number of fractures should be directed at monkey bar equipment and landing surfaces. The trend in playground equipment injury also indicates that monkey bars are problematic because the number of injuries per year per capita owing to monkey bars is stable, whereas those from swings and slides is decreasing. (c) 2008 Elsevier Inc. All rights reserved.	[Loder, Randall T.] James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA; [Loder, Randall T.] Indiana Univ, Dept Orthopaed Surg, Indiana Sch Med, Indianapolis, IN 46202 USA	Loder, RT (corresponding author), James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA.	rloder@iupui.edu					BINGHAM C, 1982, CHRONOBIOLOGIA, V9, P397; BOND MT, 1993, AM J PUBLIC HEALTH, V83, P731, DOI 10.2105/AJPH.83.5.731; Fiissel D, 2005, INJURY PREV, V11, P337, DOI 10.1136/ip.2005.009167; Gunatilaka AH, 2004, INJURY PREV, V10, P174, DOI 10.1136/ip.2003.004010; Howard AW, 2005, CAN MED ASSOC J, V24, P11; ILLINGWORTH C, 1975, BRIT MED J, V4, P332, DOI 10.1136/bmj.4.5992.332; Laforest S, 2001, Inj Prev, V7, P35, DOI 10.1136/ip.7.1.35; Laforest S, 2000, J EPIDEMIOL COMMUN H, V54, P475, DOI 10.1136/jech.54.6.475; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; Mace SE, 2001, ANN EMERG MED, V38, P405, DOI 10.1067/mem.2001.115882; Mack M G, 1997, Inj Prev, V3, P100, DOI 10.1136/ip.3.2.100; Mack M G, 2000, Inj Prev, V6, P141, DOI 10.1136/ip.6.2.141; MAYR J, 1995, ACTA PAEDIATR, V84, P573, DOI 10.1111/j.1651-2227.1995.tb13698.x; Mott A, 1997, LANCET, V349, P1874, DOI 10.1016/S0140-6736(96)10343-3; Norton C, 2004, ARCH DIS CHILD, V89, P103, DOI 10.1136/adc.2002.013045; Petridou E, 2002, ACTA PAEDIATR, V91, P691, DOI 10.1080/080352502760069133; Phelan KJ, 2001, AMBUL PEDIATR, V1, P227, DOI 10.1367/1539-4409(2001)001<0227:TAPOPI>2.0.CO;2; Rivara F P, 1998, Adv Pediatr, V45, P37; Roseveare C A, 1999, Inj Prev, V5, P124; SACKS JJ, 1992, AM J PUBLIC HEALTH, V82, P429, DOI 10.2105/AJPH.82.3.429; Sherker Shauna, 2005, Int J Inj Contr Saf Promot, V12, P63, DOI 10.1080/17457300512331339184; SOSIN DM, 1993, AM J PUBLIC HEALTH, V83, P733, DOI 10.2105/AJPH.83.5.733; Tanner JM, 1990, WORLDWIDE VARIATION; Waltzman ML, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.5.e58; Witheaneachi D, 1997, AUST NZ J PUBL HEAL, V21, P577, DOI 10.1111/j.1467-842X.1997.tb01758.x	25	26	26	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	APR	2008	43	4					691	699		10.1016/j.jpedsurg.2007.12.061			9	Pediatrics; Surgery	Pediatrics; Surgery	291FY	WOS:000255180500017	18405717				2021-06-18	
J	Saganova, K; Orendacova, J; Cizkova, D; Vanicky, I				Saganova, Kamila; Orendacova, Judita; Cizkova, Dasa; Vanicky, Ivo			Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat	NEUROSCIENCE LETTERS			English	Article						secondary injury; neurological outcome; spinal cord white/gray matter	TRAUMATIC BRAIN-INJURY; MOUSE MODEL; ACTIVATION; MICROGLIA; RECOVERY; DEATH; PROLIFERATION; NEUROTOXICITY; REGENERATION; EXPRESSION	Minocycline (MC), a second-generation tetracycline and anti- inflammatory agent reportedly provides neuroprotection following CNS injury. The objective of this study was to examine the neuroprotective effects of short and long-term MC treatment using balloon -compres si on spinal cord injury (SCI) in the rat. Rats subjected to SCI were treated with MC for 1 day (IDMC group; total dose 180 mg/kg) or 5 days (5DMC group; total dose 450 mg/kg) or placebo. The effects of MC treatment on locomotor recovery (BBB scale) and spinal cord white and gray matter sparing were evaluated for up to 28 days. Morphometric analysis showed that while MC treatment spared spinal cord white and gray matter rostral to the lesion epicenter in both, 1DMC and 5DMC groups, sparing of white and gray matter areas was not observed caudal to the traumatic lesion. In addition, MC treatment had no effect on final locomotor recovery. Limited improvement of spinal cord post-compression consequences raises questions about the neuroprotection efficiency of MC treatment following compression SO in the rat. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Saganova, Kamila; Orendacova, Judita; Cizkova, Dasa; Vanicky, Ivo] Slovak Acad Sci, Inst Neurobiol, Ctr Excellence, Kosice 04001, Slovakia	Saganova, K (corresponding author), Slovak Acad Sci, Inst Neurobiol, Ctr Excellence, Soltesovej 6, Kosice 04001, Slovakia.	sagan@saske.sk	Cizkova, Dasa/AAF-8976-2019	cizkova, dasa/0000-0002-2504-3993			Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cho KO, 2007, LIFE SCI, V80, P2030, DOI 10.1016/j.lfs.2007.03.005; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Fendrick SE, 2005, NEUROSCI LETT, V385, P220, DOI 10.1016/j.neulet.2005.05.047; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lin SZ, 2003, LIFE SCI, V72, P1635, DOI 10.1016/S0024-3205(02)02442-6; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Sedy J, 2007, NEUROSCI LETT, V423, P167, DOI 10.1016/j.neulet.2007.06.053; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Szymanska A, 2006, EXP NEUROL, V197, P189, DOI 10.1016/j.expneurol.2005.09.011; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Weng YC, 2007, EXP NEUROL, V204, P433, DOI 10.1016/j.expneurol.2006.12.003; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007	31	26	26	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 15	2008	433	3					246	249		10.1016/j.neulet.2008.01.041			4	Neurosciences	Neurosciences & Neurology	284DR	WOS:000254686500017	18280653				2021-06-18	
J	Quintana, A; Molinero, A; Borup, R; Nielsen, FC; Campbell, IL; Penkowa, M; Hidalgo, J				Quintana, Albert; Molinero, Amalia; Borup, Rehannah; Nielsen, Finn Cilius; Campbell, Iain L.; Penkowa, Milena; Hidalgo, Juan			Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome	DEVELOPMENTAL NEUROBIOLOGY			English	Article						cryolesion; cytokines; gene expression; micro-array; mouse; neuroinflammation	CENTRAL-NERVOUS-SYSTEM; MICE EXPRESSING INTERLEUKIN-6; DEPENDENT PROTEIN-KINASE; MURINE LEUKEMIA-VIRUS; TUMOR-NECROSIS-FACTOR; I PLUS II; TRANSGENIC MICE; GENE-EXPRESSION; METALLOTHIONEIN-I; CEREBRAL OVEREXPRESSION	Interleukin-6 (IL-6) is one of the key players in the response of the brain cortex to injury. We have described previously that astrocyte-driven production of IL-6 (GFAP-IL6) in transgenic mice, although causing spontaneous neuroinflammation and long term damage, is beneficial after an acute (freeze) injury in the cortex, increasing healing and decreasing oxidative stress and apoptosis. To determine the transcriptional basis for these responses here we analyzed the global gene expression profile of the cortex, at 0 (unlesioned), I or 4 days post lesion (dpl), in both GFAP-IL6 mice and their control littermates. GFAP-IL6 mice showed an increase in genes associated with the inflammatory response both at 1 dpl (Iftm1, Endod1) and 4 dpl (Gfap, C4b), decreased expression of proapoptotic genes (i.e. Gadd45b, Clic4, p21) as well as reduced expression of genes involved in the control of oxidative stress (Atf4). Furthermore, the presence of IL-6 altered the expression of genes involved in hemostasis (Vwt), cell migration and proliferation (Cap2), and synaptic activity (Vamp2). All these changes in gene expression could underlie the phenotype of the GFAP-IL6 mice after injury, but many other possible factors were also identified in this study, highlighting the utility of this approach for deciphering new pathways orchestrated by IL-6. (c) 2007 Wiley Periodicals, Inc.	[Quintana, Albert; Molinero, Amalia; Hidalgo, Juan] Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Inst Neurosci, Barcelona, Spain; [Quintana, Albert; Molinero, Amalia; Hidalgo, Juan] Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Dept Cellular Biol Physiol & Immunol, Barcelona, Spain; [Borup, Rehannah; Nielsen, Finn Cilius] Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; [Campbell, Iain L.] Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; [Penkowa, Milena] Univ Copenhagen, Fac Hlth Sci, Sect Neuroprotect, Ctr Inflammat & Metab, Copenhagen, Denmark	Hidalgo, J (corresponding author), Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, Inst Neurosci, Barcelona, Spain.	juan.hidalgo@uab.es	Hidalgo, Juan/C-9082-2011; molinero, amalia/K-2147-2014; Nielsen, Finn Cilius/AAA-4926-2020; Quintana, Albert/N-5544-2015	Hidalgo, Juan/0000-0003-0921-1122; molinero, amalia/0000-0001-8661-8570; Quintana, Albert/0000-0003-1674-7160; Nielsen, Finn Cilius/0000-0002-9829-1031			Abe M, 2003, BIOCHEM BIOPH RES CO, V306, P10, DOI 10.1016/S0006-291X(03)00903-3; Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Arce I, 2004, EUR J IMMUNOL, V34, P210, DOI 10.1002/eji.200324230; Armario A, 1998, J NEUROIMMUNOL, V92, P160, DOI 10.1016/S0165-5728(98)00199-4; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Banett S., 1996, HUM RESOUR MANAG J, V6, P18; Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Bertling E, 2004, MOL BIOL CELL, V15, P2324, DOI 10.1091/mbc.E04-01-0048; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Blagoveshchenskaya AD, 2002, MOL BIOL CELL, V13, P1582, DOI 10.1091/mbc.01-09-0462; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; CHURN SB, 1993, STROKE, V24, P271, DOI 10.1161/01.STR.24.2.271; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; Cooper BJ, 2006, J BIOL CHEM, V281, P22471, DOI 10.1074/jbc.M602520200; Cottrell JR, 2004, NEURON, V44, P677, DOI 10.1016/S0896-6273(04)00688-9; Coutts AS, 2007, EMBO REP, V8, P84, DOI 10.1038/sj.embor.7400855; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Deak F, 2006, J NEUROSCI, V26, P6668, DOI 10.1523/JNEUROSCI.5272-05.2006; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Gebicke-Haerter PJ, 2005, J NEUROSCI RES, V81, P327, DOI 10.1002/jnr.20479; Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480; Gros-Louis F, 2007, NAT GENET, V39, P80, DOI 10.1038/ng1927; Guo L, 2006, NAT BIOTECHNOL, V24, P1162, DOI 10.1038/nbt1238; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harvey J, 2007, J NEUROCHEM, V100, P307, DOI 10.1111/j.1471-4159.2006.04205.x; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Johnson MC, 2006, VET IMMUNOL IMMUNOP, V110, P357, DOI 10.1016/j.vetimm.2005.12.007; Kassouf W, 2006, CANCER RES, V66, P412, DOI 10.1158/0008-5472.CAN-05-2755; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kurnellas MP, 2004, FASEB J, V18, P298, DOI 10.1096/fj.04-2549fje; Ladenheim B, 2000, MOL PHARMACOL, V58, P1247; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liang FY, 1997, J NEUROSCI, V17, P2168; Lu XCM, 2004, J NEUROSCI RES, V77, P843, DOI 10.1002/jnr.20218; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marx CE, 2001, BIOL PSYCHIAT, V50, P743, DOI 10.1016/S0006-3223(01)01209-4; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Murphy PG, 2000, EUR J NEUROSCI, V12, P1891, DOI 10.1046/j.1460-9568.2000.00074.x; Nelson TE, 2004, EUR J NEUROSCI, V20, P2387, DOI 10.1111/j.1460-9568.2004.03706.x; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; O'Neill EE, 2002, PROTEOMICS, V2, P288, DOI 10.1002/1615-9861(200203)2:3<288::AID-PROT288>3.0.CO;2-0; Otero M, 2005, FEBS LETT, V579, P295, DOI 10.1016/j.febslet.2004.11.024; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; PEREZ RP, 1993, CANCER RES, V53, P3771; Peters M, 2003, J NEUROSCI, V23, P9752; PETERSEN R, 1988, GENE, V72, P161, DOI 10.1016/0378-1119(88)90138-2; Pottorf WJ, 2006, J NEUROCHEM, V98, P1646, DOI 10.1111/j.1471-4159.2006.04063.x; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Quintana A, 2007, J NEUROSCI RES, V85, P2668, DOI 10.1002/jnr.21126; Radeke HH, 2002, J BIOL CHEM, V277, P27535, DOI 10.1074/jbc.M200419200; Raivich G, 2003, J NEUROSCI RES, V72, P726, DOI 10.1002/jnr.10621; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sato S, 1997, J IMMUNOL, V159, P3278; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; SHALABY F, 1994, ONCOGENE, V9, P2579; Shibata R, 2006, CLIN CANCER RES, V12, P5363, DOI 10.1158/1078-0432.CCR-05-2245; Shimada A, 1998, J VET MED SCI, V60, P351, DOI 10.1292/jvms.60.351; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; Stein Deborah M, 2004, Curr Opin Crit Care, V10, P520, DOI 10.1097/01.ccx.0000144770.96342.65; Stigliani S, 2006, J NEUROCHEM, V96, P656, DOI 10.1111/j.1471-4159.2005.03631.x; STOYE JP, 1987, J VIROL, V61, P2659, DOI 10.1128/JVI.61.9.2659-2669.1987; Strestik BD, 2001, J GEN VIROL, V82, P1349, DOI 10.1099/0022-1317-82-6-1349; Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200; Svechnikova I, 2007, BIOCHEM BIOPH RES CO, V354, P466, DOI 10.1016/j.bbrc.2006.12.222; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Ur E, 2002, NEUROENDOCRINOLOGY, V75, P264, DOI 10.1159/000054718; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Westberg JA, 2007, STROKE, V38, P1025, DOI 10.1161/01.STR.0000258113.67252.fa; Won SJ, 2002, J BIOCHEM MOL BIOL, V35, P67, DOI 10.5483/BMBRep.2002.35.1.067; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yun SJ, 2002, MOL BRAIN RES, V107, P57, DOI 10.1016/S0169-328X(02)00447-3	95	26	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8451	1932-846X		DEV NEUROBIOL	Dev. Neurobiol.	FEB 1	2008	68	2					195	208		10.1002/dneu.20584			14	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	259OL	WOS:000252948500005	18000830				2021-06-18	
J	Williams, BL; Hornig, M; Yaddanapudi, K; Lipkin, WI				Williams, Bredt L.; Hornig, Mady; Yaddanapudi, Kavitha; Lipkin, W. Ian			Hippocampal poly(ADP-ribose) polymerase 1 and caspase 3 activation in neonatal Bornavirus infection	JOURNAL OF VIROLOGY			English	Article							APOPTOSIS-INDUCING FACTOR; TRAUMATIC BRAIN-INJURY; CELL-DEATH; DISEASE VIRUS; CEREBRAL-ISCHEMIA; NEURONAL DEATH; MICROGLIAL ACTIVATION; DNA FRAGMENTATION; CORTICAL CULTURE; GLUTAMATE UPTAKE	Infection of neonatal rats with Borna disease virus results in a characteristic behavioral syndrome and apoptosis of subsets of neurons in the hippocampus, cerebellum, and cortex (neonatal Borna disease [NBD]). In the NBD rat hippocampus, dentate gyrus granule cells progressively degenerate. Apoptotic loss of granule cells in NBD is associated with accumulation of zinc in degenerating neurons and reduced zinc in granule cell mossy fibers. Excess zinc can trigger poly (ADP-ribose) polymerase 1 (PARP-1) activation, and PARP-1 activation can mediate neuronal death. Here, we evaluate hippocampal PARP-1 mRNA and protein expression levels, activation, and cleavage, as well as apoptosis-inducing factor (AIF) nuclear translocation and executioner caspase 3 activation, in NBD rats. PARP-1 mRNA and protein levels were increased in NBD hippocampi. PARP-1 expression and activity were increased in granule cell neurons and glia with enhanced ribosylation of proteins, including PAR-P-1 itself. In contrast, levels of poly (ADP-ribose) glycohydrolase mRNA were decreased in NBD hippocampi. PARP-1 cleavage and AIF expression were also increased in astrocytes in NBD hippocampi. Levels of activated caspase 3 protein were increased in NBD hippocampi and localized to nuclei, mossy fibers, and dendrites of granule cell neurons. These results implicate aberrant zinc homeostasis, PARP-1, and caspase 3 activation as contributing factors in hippocampal neurodegeneration in NBD.	[Williams, Bredt L.; Hornig, Mady; Yaddanapudi, Kavitha; Lipkin, W. Ian] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10032 USA	Lipkin, WI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, 722 W 168th St,Romm 1801, New York, NY 10032 USA.	wil2001@columbia.edu	Lipkin, W. Ian/ABE-6216-2020; Hornig, Mady/AAE-8431-2020	Lipkin, W. Ian/0000-0002-8768-9386; Hornig, Mady/0000-0001-7572-3092	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD037546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029425] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD037546, HD37546] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29425] Funding Source: Medline		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Armstrong RC, 1997, J NEUROSCI, V17, P553; BAKSI K, 1987, EXP CELL RES, V172, P110, DOI 10.1016/0014-4827(87)90098-X; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Billaud JN, 2000, J VIROL, V74, P10438, DOI 10.1128/JVI.74.22.10438-10446.2000; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; CARBONE KM, 1991, J NEUROPATH EXP NEUR, V50, P205, DOI 10.1097/00005072-199105000-00003; Carbone KM, 2001, CURR OPIN MICROBIOL, V4, P467, DOI 10.1016/S1369-5274(00)00237-X; Carbone M, 2006, J MOL BIOL, V363, P773, DOI 10.1016/j.jmb.2006.05.077; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; Chu CT, 2005, J NEUROCHEM, V94, P1685, DOI 10.1111/j.1471-4159.2005.03329.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; DERY CV, 1986, VIRUS RES, V4, P313, DOI 10.1016/0168-1702(86)90078-X; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; Gaken JA, 1996, J VIROL, V70, P3992; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gordon-Shaag A, 2003, J VIROL, V77, P4273, DOI 10.1128/JVI.77.7.4273-4282.2003; GOSZTONYI G, 1995, CURR TOP MICROBIOL, V190, P39; Griffin DE, 2005, CURR TOP MICROBIOL, V289, P57; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Hatalski CG, 1998, J NEUROIMMUNOL, V90, P137, DOI 10.1016/S0165-5728(98)00076-9; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hornig M, 1999, P NATL ACAD SCI USA, V96, P12102, DOI 10.1073/pnas.96.21.12102; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; NARAYAN O, 1983, SCIENCE, V220, P1401, DOI 10.1126/science.6602380; Nargi-Aizenman JL, 2002, VIROLOGY, V293, P164, DOI 10.1006/viro.2001.1253; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oh YK, 2006, NEUROSCI LETT, V406, P205, DOI 10.1016/j.neulet.2006.07.044; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Park JA, 2000, J NEUROSCI, V20, P9096; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Pletnikov MV, 2000, DEV BRAIN RES, V119, P179, DOI 10.1016/S0165-3806(99)00168-6; Rami A, 2003, NEUROCHEM INT, V43, P211, DOI 10.1016/S0197-0186(03)00002-0; Samuel MA, 2007, J VIROL, V81, P2614, DOI 10.1128/JVI.02311-06; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sheline CT, 2003, EUR J NEUROSCI, V18, P1402, DOI 10.1046/j.1460-9568.2003.02865.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Solbrig MV, 1996, VIROLOGY, V222, P332, DOI 10.1006/viro.1996.0430; Suh SW, 2007, MOL MED, V13, P344, DOI 10.2119/2007-00043.Suh; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2001, NEUROREPORT, V12, P1523, DOI 10.1097/00001756-200105250-00044; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Truong-Tran AQ, 2001, BIOMETALS, V14, P315, DOI 10.1023/A:1012993017026; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x; Willcocks L, 2001, J INFORM TECHNOL, V16, P1, DOI 10.1080/026839601750173660; Williams BL, 2007, J VIROL, V81, P2675, DOI 10.1128/JVI.02245-06; Williams DF, 2001, QUATERN INT, V80-1, P3, DOI 10.1016/S1040-6182(01)00015-5; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zocher M, 2000, J NEUROVIROL, V6, P462, DOI 10.3109/13550280009091947	67	26	29	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	FEB	2008	82	4					1748	1758		10.1128/JVI.02014-07			11	Virology	Virology	258ZQ	WOS:000252909300012	18057239	Bronze, Green Published			2021-06-18	
J	Johnson, DR; Vincent, AS; Johnson, AE; Gilliland, K; Schlegel, RE				Johnson, Dan R.; Vincent, Andrea S.; Johnson, Ashley E.; Gilliland, Kirby; Schlegel, Robert E.			Reliability and construct validity of the Automated Neuropsychological Assessment Metrics (ANAM) mood scale	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mood; construct validity; neuropsychological assessment; traumatic brain injury	TRAUMATIC BRAIN-INJURY; GULF-WAR; DEPRESSION; VALIDATION; VETERANS; FATIGUE	The reliability and construct validity of the Automated Neuropsychological Assessment Metrics (ANAM) mood scale (AMS) were examined using concurrent, well-validated measures of mood and confirmatory factor analysis (CFA) with a sample of 210 volunteer college students. The AMS was given in computerized format with multiple adjectives using a visual analog Likert scale yielding seven dimensions of mood including vigor, restlessness, depression, anger, fatigue, anxiety, and happiness. All seven mood dimensions of the AMS demonstrated excellent test-retest reliability and internal consistency. Also, the AMS anxiety dimension correlated strongly with the Spielberger's State Anxiety Inventory (r=0.67) and the AMS depression dimension correlated strongly with the Beck Depression Inventory-II (r=0.71). CFA revealed that the AMS 7-factor mood model fit the data well and significantly better than an alternative, theoretically plausible model. When concurrent measures of mood were incorporated in the CFA model, the AMS demonstrated both convergent and discriminant validity. The AMS 7-factor model explained 55.12% of the total variance in the items. It was concluded that the AMS provides a brief yet reasonably complete and valid assessment of mood. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Johnson, Dan R.; Vincent, Andrea S.; Johnson, Ashley E.; Gilliland, Kirby; Schlegel, Robert E.] Univ Oklahoma, Ctr Study Human Operator Performance, Norman, OK 73019 USA	Johnson, DR (corresponding author), Univ Oklahoma, Ctr Study Human Operator Performance, 455 W Lindsey,DAHT Room 740, Norman, OK 73019 USA.	johnsoda@ou.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anger WK, 2003, OCCUP ENVIRON MED, V60, P531; Anger WK, 1996, NEUROTOXICOL TERATOL, V18, P347, DOI 10.1016/0892-0362(96)00079-7; Beck A.T., 1996, MANUAL BECK DEPRESSI; BIERSNER RJ, 1984, J HUM STRESS, V10, P43, DOI 10.1080/0097840X.1984.9934958; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Browne M. W., 1982, TOPICS APPL MULTIVAR, P72, DOI [DOI 10.1017/CB09780511897375.003, 10.1017/CBO9780511897375.003]; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Chou C.-P., 1995, STRUCTURAL EQUATION; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Clauw D, 2003, BMJ-BRIT MED J, V327, P1357, DOI 10.1136/bmj.327.7428.1357; David AS, 2002, PSYCHOL MED, V32, P1357, DOI 10.1017/S0033291702006359; ECKERT LH, 1997, P HUMAN FACTORS ERGO, V2, P1408; Frier BM, 2001, INT J CLIN PRACT, P30; GAULTIERI C, 1991, BRAIN INJURY, V5, P219; Glass JM, 2004, J PSYCHOSOM RES, V57, P391, DOI 10.1016/j.jpsychores.2004.04.002; JOHNSON E, 1967, 671 NAV MED RES I; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; LOEHLIN JC, 2004, LETENT VARIABLE MODE; Maruyama Geoffrey, 1998, BASICS STRUCTURAL EQ; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Matthews G., 1999, PERSONALITY PSYCHOL, V7, P335, DOI DOI 10.1177/154193120404801107; Matthews RG, 2002, CHEM REC, V2, P4, DOI 10.1002/tcr.10006; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; McNair D, 1971, MANUAL PROFILE MOOD; Montgomery EB, 2000, MOVEMENT DISORD, V15, P467, DOI 10.1002/1531-8257(200005)15:3<467::AID-MDS1007>3.0.CO;2-#; REEVES D, 2001, NCRFSR200201 ARM MED; Roebuck-Spencer TM, 2006, ARTHRIT RHEUM-ARTHR, V55, P434, DOI 10.1002/art.21992; RYMAN DH, 1974, PSYCHOL REP, V35, P479, DOI 10.2466/pr0.1974.35.1.479; Shackman AJ, 2006, EMOTION, V6, P40, DOI 10.1037/1528-3542.6.1.40; Short P, 2007, ARCH CLIN NEUROPSYCH, V22, pS63, DOI 10.1016/j.acn.2006.10.012; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Storzbach D, 2000, PSYCHOSOM MED, V62, P726, DOI 10.1097/00006842-200009000-00017; Tabachnick B., 2001, USING MULTIVARIATE S; Tanaka J.S., 1993, TESTING STRUCTURAL E, P10; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; West S.G., 1995, STRUCTURAL EQUATION	41	26	27	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2008	23	1					73	85		10.1016/j.acn.2007.10.001			13	Psychology, Clinical; Psychology	Psychology	259ET	WOS:000252922600006	18031982	Bronze			2021-06-18	
J	Nott, MT; Chapparo, C; Heard, R				Nott, Melissa T.; Chapparo, Christine; Heard, Robert			Effective occupational therapy intervention with adults demonstrating agitation during post-traumatic amnesia	BRAIN INJURY			English	Article						agitation information processing; occupational therapy; post-traumatic amnesia	SINGLE-SUBJECT RESEARCH; BRAIN-INJURY; REHABILITATION; DESIGNS; MEMORY; RELIABILITY; PATIENT; STAGE	Objective: To investigate the effectiveness of occupational therapy (OT) with adults demonstrating agitation and post-traumatic amnesia (PTA) following brain injury. Design: Single-system experimental design (ABAB) across subjects. Methods: Eight subjects were recruited during acute rehabilitation. Current OT intervention was alternated with the experimental Perceive, Recall, Plan and Perform (PRPP) System approach over 4-weeks. Therapy was conducted daily. Information processing capacity during occupational tasks was measured using the PRPP System of Task Analysis. PTA status was monitored with the Westmead PTA Scale. Experimental intervention: The PRPP System is a dynamic assessment and intervention approach that directly links results of cognitive task analysis with strategies for intervention. PRPP Intervention adopts an information processing approach that simultaneously focuses on task training, strategy training and strategy application within occupational performance. Results: Seven subjects significantly improved in their application of processing strategies during the PRPP Intervention in comparison to current OT Intervention phases. Large treatment effects favoured the PRPP Intervention. Subjects demonstrated improved information processing strategy use both prior to and following emergence from PTA. Conclusions: Occupational therapy intervention based upon the PRPP System of Task Analysis and Intervention improved subjects' ability to apply information processing strategies during occupational performance when compared to current intervention approaches.	[Nott, Melissa T.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; [Nott, Melissa T.; Chapparo, Christine; Heard, Robert] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia	Nott, MT (corresponding author), Westmead Hosp, Brain Injury Rehabil Unit, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2415, Australia.	melissan@biru.wsahs.nsw.gov.au	Nott, Melissa T/M-6778-2018	Nott, Melissa T/0000-0001-7088-5826			ADAMOVICH BB, 1985, COGNITIVE REHABILITA; ALDERMAN N, 2002, EVIDENCE MENTAL HLTH, P142; Backman CL, 1997, ARCH PHYS MED REHAB, V78, P1145, DOI 10.1016/S0003-9993(97)90142-8; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; BARLOW DH, 1984, SINGLE CASE EXPT DES; BECK J, 1992, STUDENT BEHAV PROBLE; CHAPPARO C, 1997, MONOGRAPH OCCUPATION, V1, P189; Chapparo C., 2007, PRPP SYSTEM INTERVEN; CHAPPARO C, 1997, MONOGRAPH TOTAL PRIN, V1; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fry K, 2002, AUSTR OCCUPATIONAL T, V49, P182, DOI 10.1046/j.1440-1630.2002.00337.x; GASQUOINE P G, 1991, Brain Injury, V5, P169, DOI 10.3109/02699059109008087; GILES GM, 1999, REHABILITATION SEVER, P97; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; HAGEN C, 2001, RELEARNING TIMES, V8, P1; Kazdin A. E., 2003, RES DESIGN CLIN PSYC, V4; KIELHOFNER G, 2004, CONCEPTUAL FDN OCCUP; Kinney A., 2001, J CONTEMP PSYCHOTHER, V31, P89, DOI DOI 10.1023/A:1010261422373; Lee S S, 2001, Can J Occup Ther, V68, P41; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; MURPHY DP, 1999, COMMUNITY PRACTITION, V72, P322; Nott MT, 2006, BRAIN INJURY, V20, P1175, DOI 10.1080/02699050601049114; NOTT MT, 2007, AUSTR OCCUPATIONAL T, V54; Olive ML., 2005, EDUC PSYCHOL-UK, V25, P313, DOI [DOI 10.1080/0144341042000301238, 10.1080/0144341042000301238]; Ottenbacher KJ, 2001, AM J PHYS MED REHAB, V80, P786, DOI 10.1097/00002060-200110000-00014; Ottenbacher KJ, 1986, EVALUATING CLIN CHAN; Parker RI, 2003, BEHAV THER, V34, P189, DOI 10.1016/S0005-7894(03)80013-8; Polatajko Helene J., 2001, Physical and Occupational Therapy in Pediatrics, V20, P83, DOI 10.1300/J006v20n02_06; RADOMSKI MV, 2008, OCCUPATIONAL THERAPY, P748; Rankin G, 1998, CLIN REHABIL, V12, P187, DOI 10.1191/026921598672178340; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Tabachnick BG, 2007, USING MULTIVARIATE S; Thompson CK, 2006, J COMMUN DISORD, V39, P266, DOI 10.1016/j.jcomdis.2006.02.003; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Zhan S, 2001, DISABIL REHABIL, V23, P1, DOI 10.1080/09638280150211202	41	26	27	0	11	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	9					669	683		10.1080/02699050802227170			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600004	18698517				2021-06-18	
J	Rosenthal, G; Hemphill, JC; Sorani, M; Martin, C; Morabito, D; Meeker, M; Wang, V; Manley, GT				Rosenthal, Guy; Hemphill, J. Claude, III; Sorani, Marco; Martin, Christine; Morabito, Diane; Meeker, Michele; Wang, Vincent; Manley, Geoffrey T.			The role of lung function in brain tissue oxygenation following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain tissue oxygenation; PF ratio; pulmonary function; traumatic brain injury	SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBRAL OXYGENATION; HYPEROXIA; TENSION; METABOLISM	Object. Previous studies have demonstrated that periods of low brain tissue oxygen tension (PbtO(2)) are associated with poor outcome after head trauma but have primarily focused on cerebral and hemodynamic factors as causes of low PbtO(2). The purpose of this study was to investigate the influence of lung function on PbtO(2) with an oxygen challenge (increase in fraction of inspired oxygen [FiO(2)] concentration to 1.0). Methods. This prospective observational cohort study was performed in the neurointensive care unit of the Level I trauma center at San Francisco General Hospital. Thirty-seven patients with severe traumatic brain injury (TBI) undergoing brain tissue oxygen monitoring as part of regular care underwent an oxygen challenge, consisting of an increase in FiO(2) concentration from baseline to 1.0 for 20 minutes. Partial pressure of arterial oxygen (PaO2), PbtO(2), and the ratio of PaO2 to FiO(2) (the PF ratio) were determined before and after oxygen challenge. Results. Patients with higher PF ratios achieved greater PbtO(2) during oxygen challenge than those with a low PF ratio because they achieved a higher PaO2 after an oxygen challenge. Lung function, specifically the PF ratio, is a major determinant of the maximal PbtO(2) attained during an oxygen challenge. Conclusions. Given that patients with TBI are at risk for pulmonary complications such as pneumonia, severe atelectasis, and adult respiratory distress syndrome, lung function must be considered when interpreting brain tissue oxygenation.	[Rosenthal, Guy; Martin, Christine; Morabito, Diane; Meeker, Michele; Wang, Vincent; Manley, Geoffrey T.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, San Francisco, CA 94117 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94117 USA; [Sorani, Marco] Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94117 USA	Manley, GT (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Neurosurg, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94117 USA.	manley@neurosurg.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR903697] Funding Source: Medline		*BRAIN TRAUM FDN, 1996, J NEUROTRAUM, V17, P451; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Longhi L, 2002, ACT NEUR S, V81, P315; Meixensberger J, 2004, NEUROL RES, V26, P414, DOI 10.1179/016164104225014094; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Menzel M, 1998, J NEUROTRAUM, V15, P265, DOI 10.1089/neu.1998.15.265; Miller PR, 2006, J TRAUMA, V60, P98, DOI 10.1097/01.ta.0000196379.74305.e4; Porzecanski I, 2006, CHEST, V130, P597, DOI 10.1378/chest.130.2.597; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P243; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	19	26	27	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					59	65		10.3171/JNS/2008/108/01/0059			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300008	18173311				2021-06-18	
J	Sherer, M; Yablon, SA; Nakase-Richardson, R; Nick, TG				Sherer, Mark; Yablon, Stuart A.; Nakase-Richardson, Risa; Nick, Todd G.			Effect of severity of post-traumatic confusion and its constituent symptoms on outcome after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amnesia; brain injuries; confusion; delirium; psychotic disorders; rehabilitation; treatment outcome	CLOSED-HEAD-INJURY; COGNITIVE TEST; RATING-SCALE; AMNESIA; RECOVERY; ORIENTATION; VALIDATION; PSYCHOSIS; DELIRIUM	Objective: To investigate the prognostic significance of severity of post-traumatic confusion (PTC) and its constituent symptoms for early and late outcome after traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Inpatient brain injury rehabilitation program. Participants: A total of 168 patients meeting study criteria from 195 consecutive Traumatic Brain Injury Model Systems neurorehabilitation admissions. Interventions: Not applicable. Main Outcome Measures: Employability at neurorehabilitation discharge and productivity status at 1 year postinjury. Results: More severely confused patients had poorer outcomes for both employability and productivity. Multivariable logistic regression revealed that after adjustment for all other predictors, time to follow commands, and confusion severity predicted employability at discharge and age and confusion severity predicted productivity status at 1 year. Each symptom showed an unadjusted effect on discharge employability. All symptoms except nighttime sleep disturbance or daytime decreased arousal had effects on productivity at 1 year. Presence of psychotic-type symptoms was associated with especially poor productivity outcomes. Conclusions: PTC constituent symptoms and severity predict outcome after TBI. Presence or absence of psychotic-type symptoms on a single evaluation at approximately 21 days postinjury may have particular prognostic significance for productivity outcome.	[Sherer, Mark] Mem Hermann TIRR, Dept Res, Houston, TX 77030 USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, Stuart A.; Nakase-Richardson, Risa] Methodist Rehabil Ctr, Jackson, MS USA; [Yablon, Stuart A.; Nakase-Richardson, Risa] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Nick, Todd G.] Cincinnati Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH USA; [Nick, Todd G.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Sherer, M (corresponding author), Mem Hermann TIRR, Dept Res, 1333 Moursund, Houston, TX 77030 USA.	Mark.Sherer@memorialhermann.org					CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1994, HEAD INJURY, P525; McAllister TW, 2002, NEUROREHABILITATION, V17, P357; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; National Data and Statistical Center, TRAUM BRAIN INJ MOD; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sachdev P, 2001, J NEUROPSYCH CLIN N, V13, P533, DOI 10.1176/appi.neuropsych.13.4.533; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Trzepacz Paula T., 1994, P189; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0	23	26	27	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					42	47		10.1016/j.apmr.2007.08.128			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	249LB	WOS:000252228600008	18164329				2021-06-18	
J	Kuo, JR; Lo, CJ; Chio, CC; Chang, CP; Lin, MT				Kuo, Jinn-Rung; Lo, Chong-Jeh; Chio, Chung-Ching; Chang, Ching-Ping; Lin, Mao-Tsun			Resuscitation from experimental traumatic brain injury by agmatine therapy	RESUSCITATION			English	Article						traumatic brain injury; agmatine; intracranial hypertension; glutamate; nitric oxide; cerebral infarction	LATERAL FLUID-PERCUSSION; NITRIC-OXIDE PRODUCTION; EXCITATORY AMINO-ACIDS; SPINAL-CORD-INJURY; CEREBRAL-ISCHEMIA; RAT; RECEPTOR; SYNTHASE; BLOCKADE; PROTECTS	Both nitric oxide and glutamate contribute to ischaemic brain injury. Agmatine inhibits all isoforms of nitric oxide synthase and blocks N-methyl-D-aspartate receptors. In this study, we gave agmatine intraperitoneally and assessed its effect on fluid percussion brain injury in rats. Anaesthetised rats, immediately after the onset of fluid percussion traumatic brain injury (TBI), were divided into two major groups and given the vehicle solution (1 mL/kg) or agmatine (50mg/kg) intraperitoneally. Mean arterial pressure, intracranial pressure, cerebral perfusion pressure, and levels of glutamate, nitric oxide, lactate/pyruvate ratio, and glycerol in hippocampus were monitored continuously within 120 min after TBI. The weight loss was determined by the difference between the first and third day of body weight after TBI. The maximal grip angle in an inclined plane was measured to determine motor performance whereas the percent of maximal possible effect was used to measure blockade of proprioception. The triphenyltetrazolium chloride staining procedures were used for cerebral infarction assay. Compared to those of the sham-operated controls, the animals with TBI had higher values of extracellular levels of glutamate, nitric oxide, lactate-to-pyruvate ratio, and glycerol in hippocampus and intracranial pressure, but tower values of cerebral perfusion pressure. Agmatine administered immediately after TBI significantly attenuated the TBI-induced increased hippocampal levels of glutamate, nitric oxide, lactate-to-pyruvate ratio, and glycerol, intracranial hypertension, and cerebral hypoperfusion. In addition, the TBI-induced cerebral infarction, motor and proprioception deficits, and body weight toss evaluated 3 days after TBI were significantly attenuated by agmatine therapy. The present data indicate that agmatine may attenuate TBI by reducing the excessive accumulation of both glutamate and nitric oxide in the brain. (C) 2007 Etsevier Ireland Ltd. AR rights reserved.	[Lin, Mao-Tsun] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Kuo, Jinn-Rung; Lo, Chong-Jeh] Natl Cheng Kung Univ, Sch Med, Inst Clin Med, Tainan 70101, Taiwan; [Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Chang, Ching-Ping] So Taiwan Univ Technol, Dept Biotechnol, Tainan, Taiwan	Lin, MT (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.	891201@mait.chimei.org.tw					Abe K, 2000, BRAIN RES, V872, P141, DOI 10.1016/S0006-8993(00)02517-8; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CHIO CC, 2007, IN PRESS SHOCK; Demady DR, 2001, MOL PHARMACOL, V59, P24; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; Gerner P, 2003, ANESTHESIOLOGY, V98, P1484, DOI 10.1097/00000542-200306000-00028; GILAD GM, 1995, LIFE SCI, V58, pPL41, DOI 10.1016/0024-3205(95)02274-0; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Huang Z., 1996, STROKE, V27, P273; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kim JH, 2004, EXP NEUROL, V189, P122, DOI 10.1016/j.expneurol.2004.05.029; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mukhin A, 1996, J NEUROSCI, V16, P6012; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Regunathan S, 2000, J NEUROCHEM, V74, P2201, DOI 10.1046/j.1471-4159.2000.0742201.x; REGUNATHAN S, 2000, SOC NEUR ABSTR, V26, P2171; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Sudoh Y, 2003, PAIN, V103, P49, DOI 10.1016/S0304-3959(02)00375-5; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; THALHAMMER JG, 1995, ANESTHESIOLOGY, V82, P1013, DOI 10.1097/00000542-199504000-00026; Togashi H, 1998, NEUROSCI LETT, V240, P53, DOI 10.1016/S0304-3940(97)00918-X; Tsuji M, 2000, PEDIATR RES, V47, P79, DOI 10.1203/00006450-200001000-00015; Wang Y, 1997, J NEUROSCI, V17, P4341; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	39	26	29	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	DEC	2007	75	3					506	514		10.1016/j.resuscitation.2007.05.011			9	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	242QZ	WOS:000251741900015	17629391				2021-06-18	
J	Chan, L				Chan, Leighton			The state-of-the-science: Challenges in designing postacute care payment policy	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						health policy; outcome and process assessment (health care); outcomes research; rehabilitation	TRAUMATIC BRAIN-INJURY; INPATIENT REHABILITATION; CASE-MIX; SYSTEM; IMPACT; OUTCOMES; FACILITIES; HOSPITALS; PROVIDERS	Chan L. The state-of-the-science: challenges in designing postacute care payment policy, Arch Phys Med Rehabil 2007;88:1522-5. This report describes Medicare's postacute care (PAC) payment systems and their incentives, as well as global changes in capacity, quality, and utilization over time. It assesses the payment systems' impact on PAC services, referencing relevant works in progress. Suggestions are made for future research.	NIH, Dept Rehabil Med, Bethesda, MD 20892 USA	Chan, L (corresponding author), Bldg 10,CRC,Room 1-1469,10 Ctr Dr,MSC 1604, Bethesda, MD 20892 USA.	chanle@cc.nih.gov					BROWN D, 2000, FIM STUDY STANDARDIZ; Chan L, 2000, ARCH PHYS MED REHAB, V81, P715, DOI 10.1016/S0003-9993(00)90098-4; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS93, DOI 10.1016/j.apmr.2005.07.313; Dobrez DG, 2004, ARCH PHYS MED REHAB, V85, P1909, DOI 10.1016/j.apmr.2004.06.064; Frymark TB, 2005, AM J PHYS MED REHAB, V84, P12, DOI 10.1097/01.PHM.0000146501.71140.67; Gage B, 1999, HEALTH CARE FINANC R, V20, P103; HOENIG H, 2007, STAT SCI S POSTAC RE; HOFFMAN J, 2007, STAT SCI S POSTAC RE; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; JOHNSTON MV, 1986, ARCH PHYS MED REHAB, V67, P581; Kaplan SJ, 2007, ARCH PHYS MED REHAB, V88, P1494, DOI 10.1016/j.apmr.2007.08.112; Liu K, 2003, HEALTH CARE FINANC R, V25, P81; McCue MJ, 2006, ARCH PHYS MED REHAB, V87, P198, DOI 10.1016/j.apmr.2005.10.029; McNaughton H, 2005, ARCH PHYS MED REHAB, V86, pS115, DOI 10.1016/j.apmr.2005.08.115; *MED PAYM ADV COMM, 2006, DAT BOOK HEALTHC SPE; Newhouse JP, 2005, HEALTH CARE FINANC R, V27, P35; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Saitto C, 2005, MED CARE, V43, P844, DOI 10.1097/01.mlr.0000173567.80190.32; Saitto C, 2005, MED CARE, V43, P856, DOI 10.1097/01.mlr.0000173568.67805.70; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SANDEL ME, 2007, STAT SCI S POSTAC RE; Schlenker RE, 2005, HEALTH SERV RES, V40, P177, DOI 10.1111/j.1475-6773.2005.00348.x; Schoenman JA, 2005, J RURAL HEALTH, V21, P122, DOI 10.1111/j.1748-0361.2005.tb00072.x; SIDNEY S, 2000, COST STROKE CARE PRE; Thompson J M, 2004, Health Serv Manage Res, V17, P13, DOI 10.1258/095148404322772697; Weinrich M, 2005, NEUROREHAB NEURAL RE, V19, P72, DOI 10.1177/1545968305275718; Yip JY, 2002, GERONTOLOGIST, V42, P653, DOI 10.1093/geront/42.5.653	28	26	26	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2007	88	11					1522	1525		10.1016/j.apmr.2007.05.032			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	229AT	WOS:000250774400025	17964899				2021-06-18	
J	Lewis, SB; Velat, GJ; Miralia, L; Papa, L; Aikman, JM; Wolper, RA; Firment, CS; Liu, MC; Pineda, JA; Wang, KKW; Hayes, RL				Lewis, Stephen B.; Velat, Gregory J.; Miralia, Lynn; Papa, Linda; Aikman, Jada M.; Wolper, Regina A.; Firment, Chris S.; Liu, Ming Chen; Pineda, Jose A.; Wang, Kevin K. W.; Hayes, Ronald L.			Alpha-II spectrin breakdown products in aneurysmal subarachnoid hemorrhage: a novel biomarker of proteolytic injury	JOURNAL OF NEUROSURGERY			English	Article						alpha II spectrin; biomarker; cell death; subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; CEREBROSPINAL-FLUID; PERIMESENCEPHALIC HEMORRHAGE; COMPUTED-TOMOGRAPHY; CALPAIN; RAT; ACCUMULATION; ACTIVATION; DEFICITS	Object. Aneurysmal subarachnoid hemorrhage (ASAH) is a serious event with grave consequences. Delayed ischemic neurological deficits caused by cerebral arterial vasospasm contribute significantly to death and disability. Biomarkers may reflect brain injury and provide an early warning of impending neurological decline and stroke from ASAH-induced vasospasm. Alpha-II spectrin is a cytoskeletal protein whose breakdown products are candidate surrogate markers of injury magnitude, treatment efficacy, and outcome. In addition, alpha II spectrin breakdown products (SBDPs) can provide information on the proteolytic mechanisms of injury. Methods. Twenty patients who received a diagnosis of Fisher Grade 3 ASAH were enrolled in this study to examine the clinical utility of SBDPs in the detection of cerebral vasospasm in patients with ASAH. All patients underwent placement of a ventriculostomy for continual cerebrospinal fluid drainage within 72 hours of ASAH onset. Cerebrospinal fluid samples were collected every 6 hours and analyzed using Western Blotting for SBDPs. Onset of vasospasm was defined as an acute onset of a focal neurological deficit or a change in Glasgow Coma Scale score of two or more points. All suspected cases of vasospasm were confirmed on imaging studies. Results. Both calpain- and caspase-mediated SBDP levels are significantly increased in patients suffering ASAH. The concentration of SBDPs was found to increase significantly over baseline level up to 12 hours before the onset of cerebral arterial vasospasm. Conclusions. Differential expression of SBDPs suggests oncotic necrotic proteolysis may be predominant in acute brain injury after ASAH and cerebral arterial vasospasm.	Univ Florida, Dept Neurol Surg, Gainesville, FL 32610 USA; Univ Florida, Dept Emergency Med, Gainesville, FL USA; Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, Dept Radiol, Gainesville, FL 32610 USA; Florida State Univ, Coll Med, Tallahassee, FL 32306 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Lewis, SB (corresponding author), Univ Florida, Dept Neurol Surg, 100 S Newell Dr,L2-100,POB 100265, Gainesville, FL 32610 USA.	lewis@neurosurgery.ufl.edu	Pineda, Jose/W-2806-2019	Wang, Kevin/0000-0002-9343-6473	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000082] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR00082] Funding Source: Medline		Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Bavbek M, 1998, STROKE, V29, P1930, DOI 10.1161/01.STR.29.9.1930; Brilstra EH, 1997, J NEUROL NEUROSUR PS, V63, P382, DOI 10.1136/jnnp.63.3.382; BROUWERS PJAM, 1993, STROKE, V24, P809, DOI 10.1161/01.STR.24.6.809; DAVELLA D, 2004, ACAD EMERG MED, V11, P515; Frijns CJM, 2006, J NEUROL NEUROSUR PS, V77, P77, DOI 10.1136/jnnp.2005.064956; Germano A, 2002, J NEUROTRAUM, V19, P887, DOI 10.1089/08977150260190474; Hop JW, 1998, STROKE, V29, P798, DOI 10.1161/01.STR.29.4.798; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Petzold A, 2006, J NEUROTRAUM, V23, P1179, DOI 10.1089/neu.2006.23.1179; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Polin RS, 1998, J NEUROSURG, V89, P559, DOI 10.3171/jns.1998.89.4.0559; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Sudlow CLM, 1997, STROKE, V28, P491, DOI 10.1161/01.STR.28.3.491; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; VANGIJN J, 1985, NEUROLOGY, V35, P493, DOI 10.1212/WNL.35.4.493; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	23	26	26	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2007	107	4					792	796		10.3171/JNS-07/10/0792			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	214NY	WOS:000249746500013	17937225				2021-06-18	
J	Huh, JW; Raghupathi, R				Huh, Jimmy W.; Raghupathi, Ramesh			Chronic cognitive deficits and long-term histopathological alterations following contusive brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; children; contusion; head injury; infants; pediatric; traumatic brain injury	TRAUMATIC BRAIN; HEAD-INJURY; FRONTAL LESIONS; CORTICAL IMPACT; AGE; CHILDREN; DAMAGE; VULNERABILITY; MATURATION; RECOVERY	Although diffuse axonal injury is the primary pathology in pediatric brain trauma, the additional presence of focal contusions may contribute to the poor prognosis in brain-injured children younger than 4 years of age. Because existing models of pediatric brain trauma focus on diffuse brain injury, a model of contusive brain trauma was developed using postnatal day (PND) 11 and 17 rats, ages that are neurologically equivalent to a human infant and toddler, respectively. Closed head injury was modeled by subjecting the intact skull over the left parietal cortex of the immature rat to an impact with a metal-tipped indenter. Brain trauma on PND11 or PND17 led to significant spatial learning deficits at 28 days post-injury, compared to age-matched control rats (p < 0.05). Although both groups of rats sustained skull fractures on impact, the histopathologic response of the brain was distinctly age-dependent. At 3 days post-injury in PND11 rats, the cortex below the impact site was contused and hemorrhagic, and contained reactive astrocytes, while the subcortical white matter and thalamus contained injured (swollen) axons. At 14 and 28 days post-injury, the cortex, white matter, and hippocampus were substantially atrophied, and the lateral ventricle was enlarged. In contrast, in PND17 rats, the contused cortex observed at 3 days post-injury matured into a pronounced cavity lined with a glia limitans at 14 days; reactive astrocytes were present in both the hippocampus and thalamus up to 28 days post-injury. No evidence of traumatic axonal injury was observed in any region of the brain-injured PND17 rat. These data suggest that contusive brain trauma in the immature rat is associated with chronic cognitive deficits, but underscore the effect of the age-at-injury on behavioral and histopathologic outcomes.	Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA USA	Raghupathi, R (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA.	rramesh@drexelmed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, K08NS053651] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS053651, R0-NS41561] Funding Source: Medline		Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1978, CURRENT CONCEPTS, P1; CAFFEY J, 1974, PEDIATRICS, V54, P396; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chopp M, 1999, BRAIN RES, V828, P197, DOI 10.1016/S0006-8993(99)01354-2; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CROWNE DP, 1989, NEUROPSYCHOLOGIA, V27, P1119, DOI 10.1016/0028-3932(89)90095-X; DIMATTIA BV, 1988, BEHAV NEUROSCI, V102, P397, DOI 10.1037/0735-7044.102.3.397; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1999, EXP TOXICOL PATHOL, V51, P172, DOI 10.1016/S0940-2993(99)80091-8; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; DUHAIME AC, 1996, NEUROLOGICAL SURG, P1777; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Langfitt T W, 1969, Clin Neurosurg, V16, P436; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POLITIS MJ, 1988, EXP NEUROL, V100, P288, DOI 10.1016/0014-4886(88)90108-2; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Salvati S, 2000, DEV NEUROSCI-BASEL, V22, P481, DOI 10.1159/000017479; SHAPIRA Y, 1989, Neurological Research, V11, P169; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257	51	26	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2007	24	9					1460	1474		10.1089/neu.2006.3787			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	214ZT	WOS:000249777600005	17892408				2021-06-18	
J	Strobel, K; Skalsky, J; Kalff, V; Baumann, K; Seifert, B; Joller-Jemelka, H; Dummer, R; Steinert, HC				Strobel, Klaus; Skalsky, Jeannine; Kalff, Victor; Baumann, Katrin; Seifert, Burkhardt; Joller-Jemelka, Helen; Dummer, Reinhard; Steinert, Hans C.			Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING			English	Article						melanoma; PET; CT; S-100B; metastases	POSITRON-EMISSION-TOMOGRAPHY; SENTINEL NODE BIOPSY; CUTANEOUS MALIGNANT-MELANOMA; TRAUMATIC BRAIN-INJURY; CONSECUTIVE PATIENTS; S-100-BETA PROTEIN; PROGNOSTIC MARKER; PROSTATE-CANCER; F-18-FDG PET; FOLLOW-UP	Purpose To evaluate the usefulness of PET/CT in melanoma patients with an elevated serum S-100B tumour marker level. Methods Out of 165 consecutive high-risk melanoma patients referred for PET/CT imaging, 47 had elevated (> 0.2 mu g/l) S-100B serum levels and a contemporaneous F-18-FDG PET/CT scan. PET/CT scans were evaluated for the presence of metastases. To produce a composite reference standard, we used cytological, histological, MRI and PET/CT follow-up findings as well as clinical and S-100B follow-up. Results Among the 47 patients with increased S-100B levels, PET/CT correctly identified metastases in 38 (30 distant metastases and eight lymph node metastases). In one patient with cervical lymph node metastases, PET/CT was negative. Eight patients had no metastases and PET/CT correctly excluded metastases in all of them. Overall sensitivity for metastases was 97% (38/39), specificity 100% (8/8) and accuracy 98% (46/47). S-100B was significantly higher in patients with distant metastases (mean 1.93 mu g/l, range 0.3-14.3 mu g/l) than in patients with lymph node metastases (mean 0.49 mu g/l, range 0.3-1.6 mu g/l, p = 0.003) or patients without metastases (mean 0.625 mu g/l, range 0.3-2.6 mu g/l, p = 0.007). However, 6 of 14 patients with a tumour marker level of 0.3 mu g/l had no metastases. Conclusion In melanoma patients with elevated S-100B tumour marker levels, FDG-PET/CT accurately identifies lymph node or distant metastases and reliably excludes metastases. Because of the significant number of false positive S-100B tumour marker determinations (17%), we recommend repetition of tumour marker measurements if elevated S-100B levels occur before extensive imaging is used.	Univ Zurich Hosp, Dept Med Radiol, Div Nucl Med, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Alfred Hosp, Dept Nucl Med, Melbourne, Vic, Australia; Univ Zurich, Inst Biostat, Zurich, Switzerland	Strobel, K (corresponding author), Univ Zurich Hosp, Dept Med Radiol, Div Nucl Med, Raemistr 100, CH-8091 Zurich, Switzerland.	klaus.strobel@usz.ch		Seifert, Burkhardt/0000-0002-5829-2478			Abraha HD, 1997, BRIT J DERMATOL, V137, P381, DOI 10.1046/j.1365-2133.1997.18531946.x; Acland KM, 2001, J CLIN ONCOL, V19, P2674, DOI 10.1200/JCO.2001.19.10.2674; Andres R, 2004, TUMORI J, V90, P607; Banfalvi Teodora, 2004, Magy Onkol, V48, P71; Buer J, 1997, BRIT J CANCER, V75, P1373, DOI 10.1038/bjc.1997.232; Cimitan M, 2006, EUR J NUCL MED MOL I, V33, P1387, DOI 10.1007/s00259-006-0150-2; de Jong IJ, 2003, EUR UROL, V44, P32, DOI 10.1016/S0302-2838(03)00207-0; Delbeke D, 2006, J NUCL MED, V47, P885; Domingo-Domenech J, 2005, ONCOLOGY-BASEL, V68, P341, DOI 10.1159/000086973; Dummer R, 1997, DERMATOLOGY, V194, P208, DOI 10.1159/000246103; Dummer R, 2005, DERMATOLOGY, V210, P39, DOI 10.1159/000081482; Eigentler TK, 2003, LANCET ONCOL, V4, P748, DOI 10.1016/S1470-2045(03)01280-4; Fuster D, 2004, J NUCL MED, V45, P1323; Hansson LO, 1997, ANTICANCER RES, V17, P3071; Hauschild A, 1999, BRIT J DERMATOL, V140, P1065; Jury CS, 2000, BRIT J DERMATOL, V143, P269, DOI 10.1046/j.1365-2133.2000.03650.x; Lens MB, 2004, BRIT J DERMATOL, V150, P179, DOI 10.1111/j.1365-2133.2004.05708.x; Libutti SK, 2001, ANN SURG ONCOL, V8, P779, DOI 10.1007/s10434-001-0779-9; Martenson ED, 2001, J CLIN ONCOL, V19, P824, DOI 10.1200/JCO.2001.19.3.824; Molina R, 2002, TUMOR BIOL, V23, P39, DOI 10.1159/000048687; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Morton DL, 2005, ANN SURG, V242, P302, DOI 10.1097/01.sla.0000181092.50141.fa; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Reinhardt MJ, 2006, J CLIN ONCOL, V24, P1178, DOI 10.1200/JCO.2005.03.5634; Reinhardt MJ, 2002, NUKLEARMED-NUCL MED, V41, P143; Rinne D, 1998, CANCER, V82, P1664, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2; Rohren EM, 2003, RADIOLOGY, V226, P181, DOI 10.1148/radiol.2261010920; Schultz ES, 1998, BRIT J DERMATOL, V138, P426; Schwimmer J, 2000, Q J NUCL MED, V44, P153; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; SZE G, 1988, RADIOLOGY, V168, P187, DOI 10.1148/radiology.168.1.3380956; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Wagner JD, 2001, J SURG ONCOL, V77, P237, DOI 10.1002/jso.1102; Wagner JD, 1999, J CLIN ONCOL, V17, P1508, DOI 10.1200/JCO.1999.17.5.1508	36	26	28	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1619-7070	1619-7089		EUR J NUCL MED MOL I	Eur. J. Nucl. Med. Mol. Imaging	SEP	2007	34	9					1366	1375		10.1007/s00259-007-0403-8			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	203LG	WOS:000248975500007	17390135	Green Accepted			2021-06-18	
J	Thickpenny-Davis, KL; Barker-Collo, SL				Thickpenny-Davis, Kirsten L.; Barker-Collo, Suzanne L.			Evaluation of a structured group format memory rehabilitation program for adults following brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						group; memory rehabilitation; traumatic brain injury	CLOSED-HEAD-INJURY; PEOPLE; RELATIVES; DEFICIT; IMAGERY; TRAUMA; STROKE; TRIAL; AIDS	Objective: To evaluate the impact of an 8-session structured group format memory rehabilitation program on impaired memory functioning. Participants: Adults with traumatic brain injury (N = 10) or cerebral vascular accidents (N = 2). Design: A waitlist control study with pregroup, postgroup, and 1-month follow-up assessments. Wechsler Memory Scale-Revised: Neuropsychological assessments of memory (California Verbal Learning Test, Wechsler Memory Scale-Revised logical memory, visual-paired associates, and Rey Complex Figure) and both self-report and significant other report of behaviors indicative of memory difficulties and the use of memory strategies. Results: Participation in the memory group increased participants' knowledge of memory and memory strategies as well as use of memory aids and strategies; reduced behaviors indicative of memory impairment; and had a positive effect on neuropsychological assessments of memory (eg, delayed recall for words and figures). All significant improvements exceeded change experienced by waiting-list controls and were maintained at 1-month follow-up assessment. Conclusions: While extension of the findings is needed, the memory group has a positive impact on both neuropsychological measures of memory and everyday memory functioning.	Univ Auckland, Dept Psychol, Auckland 1142, New Zealand	Barker-Collo, SL (corresponding author), Univ Auckland, Dept Psychol, Private Bag 92019, Auckland 1142, New Zealand.	s.barker-collo@auckland.ac.nz					ASHCRAFT HM, 1989, HUMAN MEMORY COGNITI; BADDELEY AD, 1992, CLIN MANAGEMENT MEMO, P1; Barker-Collo S, 2000, J COGN REHABIL, V18, P16; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CARMIEN S, 2003, 2 INT WORKSH WU COMP; *COMM REH SERV, 1990, CRS MEM GROUP PROGR; DELIS D, 1987, CALIFORNIA VERBAL LE; DEPOMPEI R, 2006, 2 FED TBI INT C MARC; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; FRANZEN M D, 1991, Neuropsychology Review, V2, P29, DOI 10.1007/BF01108846; FRIEDMAN M, 2005, MAKING INFORM TECHNO; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Goldfield GS, 2001, INT J OBESITY, V25, P1843, DOI 10.1038/sj.ijo.0801838; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; Harris J E, 1981, Int Rehabil Med, V3, P206; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Jennett S M, 1991, Int Disabil Stud, V13, P83; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mittenberg W, 1992, PSYCHOL ASSESSMENT, V4, P363; ODDEY M, 1985, J NEUROL NEUROSUR PS, V48, P564; REEVES DW, 1994, CLIN ASSESSMENT MEMO; RICHARDSON JTE, 1985, COGNITIVE NEUROPSYCH, V2, P149, DOI 10.1080/02643298508252864; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Sandford J.A., 2000, INTEGRATED VISUAL AU; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SECKLER P, 1995, CHADD C OCT; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O., COMPENDIUM NEUROPSYC; Stewart FM, 1996, BRIT J CLIN PSYCHOL, V35, P369, DOI 10.1111/j.2044-8260.1996.tb01191.x; Sunderland A, 1996, BRIT J CLIN PSYCHOL, V35, P463, DOI 10.1111/j.2044-8260.1996.tb01200.x; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANDERLINDEN M, 1989, COGNITIVE APPROACHES, P105; Wechsler D., 1987, WECHSLER MEMORY SCAL; WHYTE J, 1999, REPORT NIH CONSENSUS; Wilson B.A., 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI [https://doi.org/10.1080/09602019108401386, DOI 10.1080/09602019108401386]; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 1996, ACTA NEUROL BELG, V96, P51; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; WILSON BA, 1995, HDB MEMORY DISORDERS, P683; WILSON BA, 1992, CLIN MANAGEMENT MEMO, P240; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	52	26	26	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					303	313		10.1097/01.HTR.0000290975.09496.93			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500006	17878772				2021-06-18	
J	Drobin, D; Gryth, D; Persson, JKE; Rocksen, D; Arborelius, UP; Olsson, LG; Bursell, J; Kjellstrom, BT				Drobin, Dan; Gryth, Dan; Persson, Jonas K. E.; Rocksen, David; Arborelius, Ulf P.; Olsson, Lars-Gunnar; Bursell, Jenny; Kjellstroem, B. Thomas			Electroencephalogram, circulation, and lung function after high-velocily behind armor blunt trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						behind armor blunt trauma; BABT; EEG; blunt trauma; pulmonary contusion	NERVOUS-SYSTEM; CONCUSSION; INJURY; IMPACT; DAMAGE	Background: Behind armor blunt trauma (BABT) is defined as the nonpenetrating injury resulting from a ballistic impact on personal body armor. The protective vest may impede the projectile, but some of the kinetic energy is transferred to the body, causing internal injuries and occasionally death. The aim in this study was to investigate changes in electroencephalogram (EEG) and physiologic parameters after high-velocity BABT. Methods: Eight anesthetized pigs, wearing body armor (including a ceramic plate) on the right side of their thorax, were shot with a 7.62-mm assault rifle (velocity approximately 800 m/s). The shots did not penetrate the armor and these animals were compared with control animals (n = 4), shot with blank ammunition. EEG and several physiologic parameters were thereafter monitored during a 2-hour period after the shot. Results: All animals survived during the experimental period. Five of the exposed animals showed a temporary effect on EEG. Furthermore, exposed animals displayed decreased cardiac capacity and an impaired oxygenation of the blood. Postmortem examination revealed subcutaneous hematomas and crush injuries to the right lung. Conclusions: The results in our animal model indicate that high-velocity BABT induce circulatory and respiratory dysfunction, and in some cases even transient cerebral functional disturbances.	Swedish Def Res Agcy FOI, Dept Def Med, Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Clin Neurophysiol, Stockholm, Sweden; Soder Hosp, Karolinska Inst, Dept Anaesthesiol & Intens Care, Stockholm, Sweden; Swedish Def Res Agcy FOI, Dept Armor & Survivabil, Tumba, Sweden; Stockholm Soder Hosp, Karolinska Inst, Stockholm, Sweden; FOI, Karolinska Inst, Dept Def Med, SE-17177 Stockholm, Sweden	Gryth, D (corresponding author), FOI, Karolinska Inst, Dept Def Med, Retzius Vag 8,B 1 5, SE-17177 Stockholm, Sweden.	dangryth@hotmail.com					AKESON J, 1993, ACTA ANAESTH SCAND, V37, P211, DOI 10.1111/j.1399-6576.1993.tb03703.x; BASS CR, 2004, PASS SY, P115; BLACK S, 1990, NEUROLOGIC MONITORIN, P1188; BROWN H, 1996, APPL MIXED MODEL MED; Butler F, 2003, J TRAUMA, V54, pS2; Cannon L, 2001, J R Army Med Corps, V147, P87; CARROLL AW, 1978, ANN SURG, V188, P753, DOI 10.1097/00000658-197812000-00007; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Cooper G J, 1989, J R Army Med Corps, V135, P58; COOPER GJ, 1982, J TRAUMA, V22, P994, DOI 10.1097/00005373-198212000-00004; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; GOLDFARB MA, 1975, EBTR74073; GORANSSON AM, 1988, J TRAUMA, V28, pS204; HINSLEY DE, 2002, PASS S, P103; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; KNUDSEN PT, 1996, PASS S, P213; KNUDSEN PT, 2000, PASS S, P417; LIDEN E, 1988, J TRAUMA, V28, pS145, DOI 10.1097/00005373-198801001-00029; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; MARINO PL, 1998, ICU BOOK, P339; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MAUNDER RJ, 1991, ADULT RESPIRATORY DI, P1; Melton SM, 1999, SHOCK, V11, P396; MISSLIWETZ J, 1995, J FORENSIC SCI, V40, P582; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; Risling M, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P119; SARRON JC, 2000, PASS S, P381; SARRON JC, 2003, RTO SPEC M; SODERSTROM CA, 1978, ARCSLTR77057; STUHMILLER JH, 2003, MODELING MILITARY OP; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; van Belzen J A, 1998, Passau Schr Psychologiegesch, P433; vanBree J, 2000, PASS S, P371; WEST M, 1982, ELECTROEN CLIN NEURO, V53, P192, DOI 10.1016/0013-4694(82)90023-2; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; 1996, NIH PUBLICATION, V8623	38	26	29	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2007	63	2					405	413		10.1097/01.ta.0000236015.68105.48			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	200AC	WOS:000248735300029	17693844				2021-06-18	
J	Redell, JB; Zhao, J; Dash, PK				Redell, John B.; Zhao, Jing; Dash, Pramod K.			Acutely increased cyclophilin A expression after brain injury: A role in blood-brain barrier function and tissue preservation	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						biomarkers; cyclophilin A; cyclosporine A; proteomics; blood-brain barrier	MITOCHONDRIAL PERMEABILITY TRANSITION; CONTROLLED CORTICAL IMPACT; SMOOTH-MUSCLE-CELLS; CYCLOSPORINE-A; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; RAT; DAMAGE; DEATH; IDENTIFICATION	Blood-brain barrier (BBB) compromise is a significant pathologic event that manifests early following traumatic brain injury (TBI). Because many signaling cascades are initiated immediately after the traumatic event, we were interested in examining acute differential protein expression that may be involved in BBB function. At acute time points postinjury, altered protein expression may result from altered translation efficiency or turnover rate rather than from a genomic response. The application of tandem 2-D gel electrophoresis and mass spectrometry analysis is a powerful approach for directly screening differential protein expression following TBI. Using comparative 2-D gel analysis, we selected candidate protein spots with apparent altered expression and identified them by mass spectrometry. Cyclophilin A was selected for further analysis because it has been implicated in endothelial cell activation and inflammation, and studies have suggested cyclosporine A, an inhibitor of all cyclophilin isoforms, might be beneficial after TBI. We examined if altered expression of cyclophilin A in the brain vasculature might play a role in BBB function. We found significantly increased cyclophilin A levels in isolated brain microvessels 30 min following injury. Postinjury administration of cyclosporine A significantly attenuated BBB permeability measured 24 hr postinjury, suggesting cyclophilin activity after TBI may be detrimental. However, direct injection of purified recombinant cyclophilin A attenuated both BBB permeability and tissue damage in a stab wound model of injury. These findings suggest that increased expression of cyclophilin A may play a protective role after TBI, whereas other cyclophilin isoforms may be detrimental. (c) 2007 Wiley-Liss, Inc.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Neurosurg & Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Neurosurg & Vivian L Smith Ctr Neurol Res, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049160, NS35457] Funding Source: Medline		Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Adelson PD, 1998, ACT NEUR S, V71, P104; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; BOULOS S, 2006, NEUROBIOL DIS; CHEN S, 2006, J CEREB BLOOD FLOW M; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; Glod J, 2006, BLOOD, V107, P940, DOI 10.1182/blood-2004-11-4403; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021-8782.2001.00008.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Jin ZG, 2004, ARTERIOSCL THROM VAS, V24, P1186, DOI 10.1161/01.ATV.0000130664.51010.28; Kim SH, 2004, AM J PATHOL, V164, P1567, DOI 10.1016/S0002-9440(10)63715-7; Krizbai IA, 2005, CELL MOL NEUROBIOL, V25, P129, DOI 10.1007/s10571-004-1378-7; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Meloni BP, 2005, PROTEOMICS, V5, P4743, DOI 10.1002/pmic.200500107; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; PLATEEL M, 1995, J NEUROCHEM, V65, P2138; ROOTS BI, 1981, J EXP BIOL, V95, P167; Seko Y, 2004, BIOCHEM BIOPH RES CO, V317, P162, DOI 10.1016/j.bbrc.2004.03.021; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Simpson RJ, 2003, PROTEINS PROTEOMICS; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Wagnerova J, 2002, J NEUROL SCI, V195, P51, DOI 10.1016/S0022-510X(01)00685-2; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Yang H, 2005, J SURG RES, V123, P312, DOI 10.1016/j.jss.2004.08.026; Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200	47	26	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2007	85	9					1980	1988		10.1002/jnr.21324			9	Neurosciences	Neurosciences & Neurology	196EE	WOS:000248463700015	17461417				2021-06-18	
J	Rafols, JA; Morgan, R; Kallakuri, S; Kreipke, CW				Rafols, Jose A.; Morgan, Randy; Kallakuri, Srinivas; Kreipke, Christian W.			Extent of nerve cell injury in Marmarou's model compared to other brain trauma models	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; cell death; diffuse axonal injury; diffuse brain injury	AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; CLOSED-HEAD TRAUMA; NEURONAL DEGENERATION; STRETCH-INJURY; FLUORO-JADE; RATS; MARKER; LOCALIZATION; EXPRESSION	Objectives: We sought to determine the extent of nerve cell injury in the Marmarou's acceleration impact model of diffuse brain injury. Methods: Sensitive markers for cell injury including immunostaining for b-amyloid precursor protein (b-APP, a marker for diffuse axonal injury, DAI), Fluoro-Jade (FJ) histochemistry and electron microscopy (EM) were used in sham- operated and traumatized brains. Results: APP immunostaining confirmed and extended previous findings of DAI in association and subcortical fiber systems in the white matter after injury. Increasing FJ labeling of neurons in layers II-III of sensorimotor cortex (smCx) from 4 to 48 hours after trauma and scattered labeled cells were found in the lower cortical layers. EM confirmed the presence of dystrophic pyramidal neurons in layers II-III of smCx 24 and 48 hours post-trauma. Discussion: Taken together, the data revealed significant nerve cell injury without apparent cell death in this model.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS039860] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Gurevich B, 1998, J NEUROSURG, V88, P1066, DOI 10.3171/jns.1998.88.6.1066; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; *I LAB AN RES COMM, 1996, NIH PUBL; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5	29	26	28	0	9	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUN	2007	29	4					348	355		10.1179/016164107X204657			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	192PM	WOS:000248214200003	17626729				2021-06-18	
J	Shi, J; Miles, DK; Orr, BA; Massa, SM; Kernie, SG				Shi, Jian; Miles, Darryl K.; Orr, Benjamin A.; Massa, Stephen M.; Kernie, Steven G.			Injury-induced neurogenesis in Bax-deficient mice: evidence for regulation by voltage-gated potassium channels	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; calcium; caspase; dentate gyrus; neural stem cell	TRAUMATIC BRAIN-INJURY; ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; APOPTOTIC CELL-DEATH; BCL-2 FAMILY-MEMBERS; NEURAL STEM-CELLS; SPREADING DEPRESSION; K+ CHANNELS; EXTRACELLULAR POTASSIUM	Adult neural stem and progenitor cells may help remodel the brain in response to injury. The pro-apoptotic molecule Bax has recently been identified as a key player in adult neural stem cell survival. In Bax-deficient mice that have undergone traumatic brain injury, we find increased numbers of neural progenitor cells in the dentate gyrus and improved remodeling of the hippocampus. Exogenous potassium chloride mimics spreading depression (SD)-like events in vitro, and Bax-deficient neural stem cells proliferate in response to these events more robustly than wild-type neural stem cells. Selective potassium channel blockers interrupt SD-mediated stimulation of stem cells. In addition, the potassium channel Kv4.1 is expressed within neural stem and progenitor cells in the dentate gyrus and is increased in Bax-deficiency. These data suggest that the neuroprotection observed after injury in Bax-deficiency may be due to increased neurogenesis via activation of the Kv4 family of potassium channels.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Dev Biol, Dallas, TX 75390 USA; VA Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA	Kernie, SG (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS048192] Funding Source: Medline		Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Arkhammar P, 2004, J BIOMOL SCREEN, V9, P382, DOI 10.1177/1087057104263911; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Birnbaum SG, 2004, PHYSIOL REV, V84, P803, DOI 10.1152/physrev.00039.2003; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Conti AC, 1998, J NEUROSCI, V18, P5663; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Ekhterae D, 2001, AM J PHYSIOL-CELL PH, V281, pC157; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hansen DV, 2006, P NATL ACAD SCI USA, V103, P608, DOI 10.1073/pnas.0509549102; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hebert SC, 2005, PHYSIOL REV, V85, P319, DOI 10.1152/physrev.00051.2003; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kolch Walter, 2002, Expert Opin Pharmacother, V3, P709, DOI 10.1517/14656566.3.6.709; Lang F, 2005, J MEMBRANE BIOL, V205, P147, DOI 10.1007/s00232-005-0780-5; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lee YJ, 2006, AM J PHYSIOL-RENAL, V291, pF98, DOI 10.1152/ajprenal.00486.2005; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li Z, 2004, BRAIN RES, V1021, P8, DOI 10.1016/j.brainres.2004.05.115; Lindsten T, 2003, J NEUROSCI, V23, P11112; Liu JJ, 2005, CURR BIOL, V15, P1458, DOI 10.1016/j.cub.2005.07.030; Liu P, 1998, BEHAV NEUROSCI, V112, P512, DOI 10.1037/0735-7044.112.3.512; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nilius B, 1998, J PHYSIOL-LONDON, V506, P353, DOI 10.1111/j.1469-7793.1998.353bw.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OBRENOVITCH TP, 1995, J NEUROPHYSIOL, V73, P2107; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Parent JM, 1997, J NEUROSCI, V17, P3727; Petzold GC, 2005, STROKE, V36, P1270, DOI 10.1161/01.STR.0000166023.51307.e0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SEGER R, 1995, FASEB J, V9, P726; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; Shi J, 2005, CELL DEATH DIFFER, V12, P1601, DOI 10.1038/sj.cdd.4401676; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Sun W, 2003, MOL CELL NEUROSCI, V24, P875, DOI 10.1016/S1044-7431(03)00219-7; Tamura Y, 2004, NEUROSCI RES, V50, P129, DOI 10.1016/j.neures.2004.06.011; Thomas W, 2006, STEROIDS, V71, P256, DOI 10.1016/j.steroids.2005.10.010; Valjent E, 2001, MOL NEUROBIOL, V23, P83; Wang YG, 2006, J CARDIOVASC ELECTR, V17, P298, DOI 10.1111/j.1540-8167.2006.00362.x; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x; Yanamoto H, 2005, STROKE, V36, P1544, DOI 10.1161/01.STR.0000169903.09253.c7; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0; Yu TS, 2005, GENESIS, V41, P147, DOI 10.1002/gene.20110; Yuan LL, 2002, J NEUROSCI, V22, P4860, DOI 10.1523/JNEUROSCI.22-12-04860.2002; Zarayskiy VV, 2005, TOXICON, V45, P431, DOI 10.1016/j.toxicon.2004.11.015; Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675	75	26	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	2007	25	12					3499	3512		10.1111/j.1460-9568.2007.05624.x			14	Neurosciences	Neurosciences & Neurology	184SK	WOS:000247662100002	17610570				2021-06-18	
J	Affonseca, CA; Carvalho, LFA; Guerra, SD; Ferreira, AR; Goulart, EMA				Affonseca, Carolina A.; Carvalho, Luis Fernando A.; Guerra, Sergio D.; Ferreira, Alexandre R.; Goulart, Eugenio M. A.			Coagulation disorder in children and adolescents with moderate to severe traumatic brain injury	JORNAL DE PEDIATRIA			English	Article							SEVERE HEAD-INJURY; COAGULOPATHY; MANAGEMENT; ACTIVATION	Objectives: To describe the epidemiological profile of children and adolescents with moderate to severe traumatic brain injury admitted to an intensive care unit; to describe the frequency of coagulation disorders in these patients; to determine the relationship between coagulopathy and trauma severity; to assess the factors associated with coagulopathy; and to assess the effect of coagulopathy on the mortality of these patients. Methods: Cross-sectional study with 301 patients aged up to 16 years admitted to an intensive care unit due to moderate to severe traumatic brain injury, carried out over a 5-year period. The coagulation profile was associated with clinical, epidemiological and CT findings. Univariate and multivariate analyses were used to check the association between coagulopathy and mortality. Results: Minimum age was 23 days, and maximum age was 16 years (mean of 7.9 years). About 77% of patients had coagulopathy, whose occurrence was directly associated with the severity of the trauma, but not with the rise in mortality. The factors associated with the presence of coagulopathy were the following: severity of the traumatic brain injury (OR = 2.83; 95%CI 1.58-5.07), diagnosis of brain swelling on cranial computed tomography (OR = 2.11; 95%CI 1.13-4.07) and occurrence of chest and/or abdominal injury (OR = 2.07; 95%CI 1.11-4.00). Appi oximately 35% of patients died. The multivariate analysis showed that the factors associated with an increased risk of death were presence of sodium disorders (OR = 5.56; 95%CI 2.90-10.65), hypotension in the intensive care unit (OR = 12.58; 95%CI 4.40-35.00) and acute respiratory distress syndrome (OR = 13.57; 95%CI 1.51-121.66). Conclusion: The development of coagulopathy is a frequent complication in patients with moderate to severe traumatic brain injury. Even though it is not closely associated with death in this study, it may be regarded as a marker of injury severity.	[Affonseca, Carolina A.; Carvalho, Luis Fernando A.; Guerra, Sergio D.; Ferreira, Alexandre R.; Goulart, Eugenio M. A.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil; [Carvalho, Luis Fernando A.; Guerra, Sergio D.] Hosp Joao XXIII, UTI Pediat, Belo Horizonte, MG, Brazil; [Ferreira, Alexandre R.; Goulart, Eugenio M. A.] Univ Fed Minas Gerais, Fac Med, Dept Pediat, Belo Horizonte, MG, Brazil	Affonseca, CA (corresponding author), Rua Heitor Socrates Cardoso,630 Santa Amelia, BR-31560320 Belo Horizonte, MG, Brazil.	luiscarol@uol.com.br	Ferreira, Alexandre Rodrigues/AAK-2601-2021	Ferreira, Alexandre Rodrigues/0000-0001-6749-8980			*AM COLL SURG, 1999, BAS ADV PREH LIF SUP; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; *COL AM CIR, 1997, SUP AV VID TRAUM PRO; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Guerra S D, 1999, J Pediatr (Rio J), V75 Suppl 2, pS279; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; May AK, 1997, AM SURGEON, V63, P233; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; SORENSEN JV, 1993, SCAND J CLIN LAB INV, V53, P659, DOI 10.3109/00365519309092568; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	24	26	27	0	0	SOC BRASIL PEDIATRIA	RIO DE JANEIRO, RJ	RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL	0021-7557	1678-4782		J PEDIAT-BRAZIL	J. Pediatr.	MAY-JUN	2007	83	3					274	282		10.2223/JPED.1639			9	Pediatrics	Pediatrics	281OE	WOS:000254506400014	17551658	Bronze			2021-06-18	
J	Greve, KW; Springer, S; Bianchini, KJ; Black, FW; Heinly, MT; Love, JM; Swift, DA; Ciota, MA				Greve, Kevin W.; Springer, Steven; Bianchini, Kevin J.; Black, F. William; Heinly, Matthew T.; Love, Jeffrey M.; Swift, Douglas A.; Ciota, Megan A.			Malingering in toxic exposure - Classification accuracy of reliable digit span and WAIS-III Digit Span scaled scores	ASSESSMENT			English	Article						digit span; reliable digit span; malingering; response bias; toxic exposure; neuropsychological assessment; traumatic brain injury; chronic pain	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; NEUROCOGNITIVE DYSFUNCTION; HEAD-INJURY; NEUROPSYCHOLOGICAL TESTS; PERFORMANCE PATTERNS; RESPONSE BIAS; MONEY MATTERS; INDICATORS; PAIN	This study examined the sensitivity and false-positive error rate of reliable digit Span (RDS) and the WAIS-III Digit Span (DS) scaled score in persons alleging toxic exposure and determined whether error rates differed from published rates in traumatic brain injury (TBI) and chronic pain (CP). Data were obtained from the files of 123 persons referred for neuropsychological evaluation related to alleged exposure to environmental and industrial substances. Malingering status was determined using the criteria of Slick, Sherman, and Iverson (1999). The sensitivity and specificity of RDS and DS in toxic exposure are consistent with those observed in TBI and CP These findings support the use of these malingering indicators in cases of alleged toxic exposure and suggest that the classification accuracy data of indicators derived from studies of TBI patients may also be validly applied to cases of alleged toxic exposure.	Univ New Orleans, Dept Psychol, Jefferson Neurobehav Grp, New Orleans, LA 70148 USA; Tulane Univ, Sch Med, Hlth Sci Ctr, New Orleans, LA 70118 USA; Tulane Univ, Neuropsychol Lab, New Orleans, LA 70118 USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, Jefferson Neurobehav Grp, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BERGER MA, 2000, REFERENCE MANUAL SCI, P9; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, PORTLAND DIGIT RECOG; BOLLA KI, 2005, FORENSIC NEUROPSYCHO, P271; Butters N, 1980, ALCOHOLIC KORSAKOFFS; CONDER R, 1992, MANUAL COMPUTERIZED; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Duncan SA, 2002, ASSESSMENT, V9, P56, DOI 10.1177/1073191102009001007; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 1996, WORLD MEMORY TEST US; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2006, LEGAL CRIMINOL PSYCH, V11, P131, DOI 10.1348/135532505X49828; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; GREVE KW, IN PRESS CLIN NEUROP; Harris I, 2005, JAMA-J AM MED ASSOC, V293, P1644, DOI 10.1001/jama.293.13.1644; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; HILSABECK RC, 2001, ARCH CLIN NEUROPSYCH, V18, P71; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; MAPOU RL, 1995, CLIN NEUROPSYCHOL, P295; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Tombaugh TN, 1996, TEST MEMORY MALINGER; van Hout MSE, 2006, J NEUROL NEUROSUR PS, V77, P296, DOI 10.1136/jnnp.2004.047167; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1997, WAIS 3 ADM SCORING M	53	26	26	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	MAR	2007	14	1					12	21		10.1177/1073191106295095			10	Psychology, Clinical	Psychology	139EO	WOS:000244415300002	17314176				2021-06-18	
J	Dunn, IF; Woodworth, GF; Siddiqui, AH; Smith, ER; Vates, GE; Day, AL; Goumnerova, LC				Dunn, Ian F.; Woodworth, Graeme F.; Siddiqui, Adnan H.; Smith, Edivvard R.; Vates, G. Edward; Day, Arthur L.; Goumnerova, Liliana C.			Traumatic pericallosal artery aneurysm: a rare complication of transcallosal surgery - Case report	JOURNAL OF NEUROSURGERY			English	Article						pericallosal artery aneurysm; traumatic aneurysm; anterior cerebral artery aneurysm; transcallosal approach; pediatric neurosurgery	ANTERIOR CEREBRAL-ARTERY; INTRACRANIAL ANEURYSMS; SUBARACHNOID HEMORRHAGE; NATURAL-HISTORY; CHILDHOOD; PSEUDOANEURYSM; ADOLESCENCE; CHILDREN	Traumatic intracranial aneurysms are rare in adults but account for up to 33% of all aneurysms encountered in a pediatric population. The most common location of such lesions in children is the pericallosal or adjacent branch of the anterior cerebral artery, where a head impact exerts sudden decelerating shearing forces on the arteries tethered on the brain surface against an immobile falx cerebri, weakening the arterial wall. This action can lead to dissection of the damaged vascular layers, with resultant expansion of the affected site into a fusiform aneurysm. Pericallosal aneurysms following a penetrating intracranial injury have also been described, and the resultant lesion in some cases can be a pseudoaneurysm. The incidence of iatrogenic pericallosal artery aneurysms, however, is extremely rare. The authors describe the first reported case of a traumatic pericallosal artery aneurysm following transcallosal surgery. This 6-year-old boy underwent resection of a hypothalamic pilocytic astrocytoma, which was approached via the transcallosal corridor. A follow-up magnetic resonance image obtained within 1 year of surgery disclosed a small flow void off the fight pericallosal artery, which was initially interpreted as residual tumor. Serial investigations showed the lesion enlarging over time, and subsequent angiography revealed a round 7-mm pericallosal artery aneurysm with an irregularly shaped 2- to 3-mm lumen. The aneurysm was difficult to treat with clip reconstruction or suturing of the affected segment, and an excellent outcome was ultimately achieved with resection of the lesion and autogenous arterial graft interposition. The authors also discuss the likely pathophysiology of the aneurysm and the surgical procedures undertaken to treat it.	Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA	Goumnerova, LC (corresponding author), Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Neurosurg, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	liliana.goumnerova@childrens.harvard.edu	Siddiqui, Adnan H./AAG-9781-2019				Alvarez J A, 1999, J Craniomaxillofac Trauma, V5, P39; APUZZO MLJ, 1982, NEUROSURGERY, V10, P547, DOI 10.1227/00006123-198205000-00001; Becker D H, 1978, Neurosurgery, V2, P1; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; de Sousa AA, 1999, SURG NEUROL, V52, P128, DOI 10.1016/S0090-3019(99)00066-X; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FRANK E, 1991, PEDIATR NEUROSURG, V16, P179, DOI 10.1159/000120521; HAYASHI A, 1986, Neurological Surgery, V14, P881; HOURIHAN MD, 1984, J NEUROSURG, V60, P1163, DOI 10.3171/jns.1984.60.6.1163; Inci S, 1998, SURG NEUROL, V50, P130, DOI 10.1016/S0090-3019(97)00344-3; LAKHANPAL SK, 1995, PEDIATR RADIOL, V25, P249, DOI 10.1007/BF02011088; LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219; McLaughlin MR, 1997, NEUROSURGERY, V41, P1400, DOI 10.1097/00006123-199712000-00034; NAKSTAD P, 1986, NEURORADIOLOGY, V28, P335, DOI 10.1007/BF00333440; OPESKIN K, 1995, AM J FOREN MED PATH, V16, P11, DOI 10.1097/00000433-199503000-00002; PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571; Raju BSV, 2001, NEUROL INDIA, V49, P295; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; Shih TY, 2002, PEDIATR NEUROSURG, V37, P35, DOI 10.1159/000065100; Shirane R, 1999, J NEUROSURG, V91, P1031, DOI 10.3171/jns.1999.91.6.1031; SORIA ED, 1988, ANGIOLOGY, V39, P609, DOI 10.1177/000331978803900708; SUTTON LN, 1991, J NEUROSURG, V74, P695, DOI 10.3171/jns.1991.74.5.0695; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; Weir B, 2002, J NEUROSURG, V96, P64, DOI 10.3171/jns.2002.96.1.0064	25	26	27	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2007	106	2		S			153	157		10.3171/ped.2007.106.2.153			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	140QH	WOS:000244520100018	17330545				2021-06-18	
J	Leitgeb, J; Erb, K; Mauritz, W; Janciak, I; Wilbacher, I; Rusnak, M				Leitgeb, Johannes; Erb, Katharina; Mauritz, Walter; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria V: CT findings and surgical management	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; hematoma; epidural; subdural; intracerebral; hemorrhage; subarachnoid; surgery; osteoplastic; osteclastic; decompressive; outcome	ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; PROGNOSTIC-FACTORS; ADULT PATIENTS; LESION	OBJECTIVES: The aim of this paper is to describe CT findings and surgical management of patients with severe traumatic brain injury (TBI) in Austria. PATIENTS AND METHODS: Data sets from 415 patients treated by 5 Austrian hospitals were available. The analysis focused on incidence, surgical management, and outcome of different types of intracranial lesions, and outcome of surgical interventions with and without monitoring of intracranial pressure (ICP). For the first analysis we assigned the patients to 16 groups based on the type of lesion as evaluated by CT scan. For the second analysis we created 4 groups based on surgical treatment (yes/no) and ICP monitoring (yes/no). RESULTS: The mean age was 48.9 years with a male to female ratio of 299:116. The most frequent single lesions were contusions (CONT) and diffuse brain edema. Combined lesions were far more common than single lesions; the most frequently observed combinations included CONT and subarachnoid hemorrhage (SAH) with or without subdural hematoma (SDH). Surgery was done in 276 (66.5%) patients. Osteoplastic surgery (OPS; n = 221) was the most common method followed by osteoclastic surgery (OCS; n = 91) and decompressive craniectomy (DEC; n = 15). ICU mortality was 29.7% for all patients who had any kind of surgery, which was lower than that of patients who were treated non-operatively (33.1%). The ICU mortality of patients with SDH was lower with OCS (18.8%) than with OPS (36.0%). Patients who received ICP monitoring but did not require surgery had the lowest 90 day mortality (17.5%). CONCLUSIONS: ICP monitoring seems to be beneficial in both operatively and non-operatively treated patients with severe TBI. Patients with SDH who were operated on had significantly better outcomes. In patients with SDH, their outcome after osteoclastic surgery was significantly better than after osteoplastic procedures.	INRO Advisory Board, A-1080 Vienna, Austria; Univ Vienna, Gen Hosp, Dept Trauma Surg, Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Vienna, Austria	Mauritz, W (corresponding author), INRO Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016	Rusnak, Martin/0000-0003-3321-1042; Mauritz, Walter/0000-0001-9043-3712			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P457; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Koumtchev Y, 1993, Folia Med (Plovdiv), V35, P55; Koumtchev Y, 1994, Folia Med (Plovdiv), V36, P49; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Munch E, 2000, NEUROSURGERY, V47, P315; PARZHUBER A, 1994, UNFALLCHIRURG, V97, P615; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Regel JP, 2005, UNFALLCHIRURG, V108, P246, DOI 10.1007/s00113-004-0865-0; Ruchholtz S, 2003, UNFALLCHIRURG, V106, P839; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1997, ACTA NEUROCHIR, V139, P273, DOI 10.1007/BF01808821; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944	23	26	26	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					56	63		10.1007/s00508-006-0764-1			8	Medicine, General & Internal	General & Internal Medicine	142GQ	WOS:000244637800011	17318751				2021-06-18	
J	Teasell, R; Bayona, N; Lippert, C; Villamere, J; Hellings, C				Teasell, Robert; Bayona, Nestor; Lippert, Corbin; Villamere, James; Hellings, Chelsea			Post-traumatic seizure disorder following acquired brain injury	BRAIN INJURY			English	Article						anticonvulsants; brain; brain injuries; craniocerebral trauma; epilepsy; epilepsy post-traumatic; post-traumatic seizure disorder; prophylaxis; seizure	POST-TRAUMATIC EPILEPSY; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; HEAD-INJURY; CRANIOCEREBRAL TRAUMA; PRACTICE PARAMETER; RANDOMIZED-TRIAL; PROPHYLAXIS; PREVENTION; CHILDREN; REHABILITATION	Objective: The present study aimed to evaluate the effectiveness of prophylactic anticonvulsant pharmacological strategies for the prevention of seizure disorders following acquired brain injury (ABI) to provide guidance for clinical practice based on the best available evidence. Methods and main outcomes: A systematic review of the literature from 1980-2005 was conducted focusing on treatment interventions available for post-traumatic seizures following ABI. The evidence for the efficacy of a given intervention was ranked as strong (supported by at least two randomized controlled trials (RCTs), moderate (supported by a single RCT), or limited (supported by other types of studies in the absence of RCTs). Results: Based on a previous meta-analysis and the findings of this review, there is strong evidence that prophylactic anticonvulsant therapy decreases the occurrence of early seizures but only within the first week post-injury. Moreover, the evidence indicates that prophylactic anticonvulsant therapy does not decrease the incidence of seizure onset more than one week post-injury. In children, there is moderate evidence that prophylactic phenytoin does not reduce the incidence of early or late seizures. The efficacy of anticonvulsants after the development of seizures has not been specifically studied in ABI. Conclusions: Prophylactic anti-convulsants are effective in reducing seizures in the first week post-injury in adults. However, they do not reduce the occurrence of seizures after the first week.	St Josephs Hlth Care London, Dept Phys Med & Rehabil, London, ON, Canada; Lawson Hlth Resort Inst, London, ON, Canada; Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada	Teasell, R (corresponding author), St Josephs Hlth Care London, Dept Phys Med & Rehabil, London, ON, Canada.	robert.teasell@sjhc.london.on.ca					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ARMSTRONG KK, 1990, ARCH PHYS MED REHAB, V71, P156; Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; CAVENESS WF, 1961, EPILEPSIA, V2, P123; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cohen M, 1991, EPILEPSIA S1, V32, pS55; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; Jennett B, 1975, EPILEPSY NONMISSILE; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Kollevold T, 1978, J OSLO CITY HOSP, V28, P78; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; MURRI L, 1992, ITAL J NEUROL SCI, V13, P755, DOI 10.1007/BF02229161; MURRI L, 1980, ITAL J NEUROL SCI, V1, P225; Ng WK, 2000, ARCH PHYS MED REHAB, V81, P1266; PECHADRE JC, 1991, PRESSE MED, V20, P841; PRICE DJ, 1980, PLACE SODIUM VALPROA, P23; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Schierhout G, 2001, COCHRANE DB SYST REV, V4; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; SMITH KR, 1994, ARCH NEUROL-CHICAGO, V51, P653, DOI 10.1001/archneur.1994.00540190029012; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; Wroblewski B A, 1989, Brain Inj, V3, P149, DOI 10.3109/02699058909004546; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86; WROBLEWSKI BA, 1992, CLIN NEUROPHARMACOL, V15, P44, DOI 10.1097/00002826-199202000-00006; Yablon S. A., 2001, PHYS MED REHABIL STA, V15, P301; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1983, CHILD BRAIN, V10, P185; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	59	26	26	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2007	21	2					201	214		10.1080/02699050701201854			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	162SQ	WOS:000246110200006	17364531				2021-06-18	
J	Donders, J; Boonstra, T				Donders, Jacobus; Boonstra, Tyler			Correlates of invalid neuropsychological test performance after traumatic brain injury	BRAIN INJURY			English	Article							WORD MEMORY TEST; LEARNING TEST-II; HEAD-INJURY; RANDOMIZED-TRIAL; DIAGNOSIS; EXAGGERATION; CLAIMANTS; UTILITY; RATES	Primary objective: To investigate external correlates of invalid test performance after traumatic brain injury, as assessed by the California Verbal Learning Test - Second Edition ( CVLT - II) and Word Memory Test ( WMT). Research design: Consecutive 2- year series of rehabilitation referrals with a diagnosis of traumatic brain injury ( n 87). Methods and procedures: Logistic regression analysis was used to determine which demographic and neurological variables best differentiated those with vs. without actuarial CVLT - II or WMT evidence for invalid responding. Main outcomes and results: Twenty- one participants ( about 24%) performed in the invalid range. The combination of a premorbid psychiatric history with minimal or no coma was associated with an approximately four- fold increase in the likelihood of invalid performance. Conclusions: Premorbid psychosocial complicating factors constitute a significant threat to validity of neuropsychological test results after ( especially mild) traumatic brain injury. At the same time, care should be taken to not routinely assume that all persons with mild traumatic brain injury and premorbid psychiatric histories are simply malingering. The WMT appears to be a promising instrument for the purpose of identifying those cases where neuropsychological test results are confounded by factors not directly related to acquired cerebral impairment.	Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49603 USA; Hope Coll, Dept Psychol, Holland, MI USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 234 Wealthy SE, Grand Rapids, MI 49603 USA.	jacobus.donders@maryfreebed.com					Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; *CTR DIS CONTR PRE, 2006, MORBIDITY MORTALITY, V55, P201; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; DELIS DC, 2000, CALIFORNIA VERBAL LE; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gervais R.O., 2001, J FORENSIC NEUROPSYC, V2, DOI [DOI 10.1300/J151V02N02_01, https://doi.org/10.1300/J151v02n02_01]; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Hanks RA, 2004, DIFFERENTIAL DIAGNOSIS IN ADULT NEUROPSYCHOLOGICAL ASSESSMENT, P218; Heaton RK, 2004, REVISED COMPREHENSIV; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; IVERSON GL, 2005, CURRENT OPINIONS PSY, V18, P310; Larrabee G, 2005, FORENSIC NEUROPSYCHO, P209; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LEESHALEY PR, 1991, PSYCHOL REP, V68, P208; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; REITAN RM, 1993, HALSTEAD REITAN NEUR, P423; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherman EMS, 2000, BRAIN INJURY, V14, P621; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M	44	26	26	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	3					319	326		10.1080/02699050701253129			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400007	17453760				2021-06-18	
J	O'Brien, A; Chiaravalloti, N; Arango-Lasprilla, JC; Lengenfelder, J; DeLuca, J				O'Brien, Amanda; Chiaravalloti, Nancy; Arango-Lasprilla, Juan Carlos; Lengenfelder, Jeannie; DeLuca, John			An investigation of the differential effect of self-generation to improve learning and memory in multiple sclerosis and traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEMANTIC-MEMORY; ALZHEIMER-TYPE; RETRIEVAL DEFICIT; EPISODIC MEMORY; FREE-RECALL; WORDS; DEMENTIA; DEPTH; ORGANIZATION; ACQUISITION	The generation effect (GE) is a phenomenon in which material that is produced by an individual is learned and remembered better than information that is provided to that individual. The current study examined the potential benefits of self-generation on learning and memory in individuals with traumatic brain injury (TBI) and multiple sclerosis (MS). The impact of cognitive impairment on the benefits of self-generation was also examined. Subjects consisted of 18 individuals with TBI and 31 individuals with clinically definite MS. Both the TBI and MS groups recalled significantly more words in the selfgenerated condition versus the provided condition. Those impaired in the domains of working memory, episodic memory, or executive functioning demonstrated a significant benefit from self-generation (all ps < .05). Furthermore, although individuals with impairments in multiple cognitive domains recalled fewer words overall compared to those with no or one impaired cognitive domain, this group demonstrated a large effect size in the difference in recall for generated versus provided words. Results demonstrate that people with cognitive impairments can benefit from self-generation to improve learning and memory. Future research should focus on how to amplify the benefit of the GE for impaired groups, apply it to everyday functional tasks, and sustain its effect over time.	KMRREC, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA	DeLuca, J (corresponding author), KMRREC, Neuropsychol & Neurosci Lab, 300 Execut Dr,Suite 10, W Orange, NJ 07052 USA.	jdeluca@kmrrec.org					Andrade VM, 2003, J CLIN EXP NEUROPSYC, V25, P1070, DOI 10.1076/jcen.25.8.1070.16730; Arnett PA, 1997, NEUROPSYCHOLOGY, V11, P535, DOI 10.1037/0894-4105.11.4.535; Barrett AM, 2000, NEUROLOGY, V54, P1258, DOI 10.1212/WNL.54.6.1258; BEGG I, 1989, J EXP PSYCHOL LEARN, V15, P977, DOI 10.1037/0278-7393.15.5.977; BEGG I, 1991, MEM COGNITION, V19, P487, DOI 10.3758/BF03199571; BOWER GH, 1979, J RES PERS, V13, P420, DOI 10.1016/0092-6566(79)90005-9; BRAINERD CJ, 1995, J MEM LANG, V34, P157, DOI 10.1006/jmla.1995.1008; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Challis BH, 1996, CONSCIOUS COGN, V5, P142, DOI 10.1006/ccog.1996.0009; Chiaravalloti ND, 2005, MULT SCLER, V11, P58, DOI 10.1191/1352458505ms1118oa; Chiaravalloti ND, 2002, ARCH PHYS MED REHAB, V83, P1070, DOI 10.1053/apmr.2002.33729; Chobor KL, 1998, J NEUROLINGUIST, V11, P119, DOI 10.1016/S0911-6044(98)00009-8; CLARK SE, 1995, MEM COGNITION, V23, P442, DOI 10.3758/BF03197245; CRAIK FIM, 1975, J EXP PSYCHOL GEN, V104, P268, DOI 10.1037/0096-3445.104.3.268; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DICK MB, 1989, BRAIN COGNITION, V9, P88, DOI 10.1016/0278-2626(89)90046-8; Duchnick JJ, 2002, J CLIN EXP NEUROPSYC, V24, P840, DOI 10.1076/jcen.24.6.840.8405; Eustache F, 1999, J NEUROL NEUROSUR PS, V66, P148, DOI 10.1136/jnnp.66.2.148; GARDINER JM, 1984, MEM COGNITION, V12, P443, DOI 10.3758/BF03198305; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; Golden C., 1978, STROOP COLOR WORD TE; Goverover Y., 2005, J INT NEUROPSYCHO S1, V11, P49; HODGES JR, 1994, EXPLORING DISORDERS, P77; Hough MS, 1997, BRAIN INJURY, V11, P801; Howe ML, 1998, J EXP CHILD PSYCHOL, V71, P170, DOI 10.1006/jecp.1998.2469; HUNT RR, 1993, J MEM LANG, V32, P421, DOI 10.1006/jmla.1993.1023; Hunt RR, 2003, J MEM LANG, V48, P811, DOI 10.1016/S0749-596X(03)00018-4; Kenealy PM, 2002, J INT NEUROPSYCH SOC, V8, P855, DOI 10.1017/S1355617702860143; KLEIN SB, 1988, J PERS SOC PSYCHOL, V55, P5, DOI 10.1037/0022-3514.55.1.5; KLEIN SB, 1986, J EXP PSYCHOL GEN, V115, P26, DOI 10.1037/0096-3445.115.1.26; Lengenfelder J., 2002, J INT NEUROPSYCH SOC, V8, P173; LENGENFELDER J, 2003, J INT NEUROPSYCH SOC, V9, P320; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LIPINSKA B, 1994, J CLIN EXP NEUROPSYC, V16, P809, DOI 10.1080/01688639408402695; Lokken K, 1999, Appl Neuropsychol, V6, P147, DOI 10.1207/s15324826an0603_2; MCELROY LA, 1982, J VERB LEARN VERB BE, V21, P249, DOI 10.1016/S0022-5371(82)90593-X; McKinlay W, 1999, COGNITIVE BEHAV EFFE, P74; MCMURRAY DW, 1981, AUST J PSYCHOL, V33, P197, DOI 10.1080/00049538108258736; MITCHELL DB, 1986, J GERONTOL, V41, P79, DOI 10.1093/geronj/41.1.79; Multhaup KS, 1997, NEUROPSYCHOLOGY, V11, P382, DOI 10.1037/0894-4105.11.3.382; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PAYNE DG, 1986, MEM COGNITION, V14, P246, DOI 10.3758/BF03197700; Pesta BJ, 1999, MEM COGNITION, V27, P106, DOI 10.3758/BF03201217; POLLMANN S, 1993, DEMENTIA, V4, P102, DOI 10.1159/000107304; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; Ricker, 1994, Assessment, V1, P47, DOI 10.1177/1073191194001001007; Ricker JH, 1996, NEUROPSY NEUROPSY BE, V9, P50; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Salkind n, 2003, USING SPSS WINDOWS M; SCHALLERT DL, 1976, J VERB LEARN VERB BE, V15, P621, DOI 10.1016/0022-5371(76)90055-4; SEAMON JG, 1976, J EXP PSYCHOL-HUM L, V2, P680; SLAMECKA NJ, 1978, J EXP PSYCHOL-HUM L, V4, P592, DOI 10.1037/0278-7393.4.6.592; Souliez L, 1996, CORTEX, V32, P347, DOI 10.1016/S0010-9452(96)80056-6; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O., 1991, COMPENDIUM NEUROPSYC; Steffens MC, 1998, Q J EXP PSYCHOL-A, V51, P705, DOI 10.1080/027249898391350; Symons CS, 1997, PSYCHOL BULL, V121, P371, DOI 10.1037/0033-2909.121.3.371; Taconnat L, 2004, J EXP PSYCHOL LEARN, V30, P827, DOI 10.1037/0278-7393.30.4.827; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037/0894-4105.11.3.357; Thornton AE, 2002, J INT NEUROPSYCH SOC, V8, P395, DOI 10.1017/S1355617702813200; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Westmacott R, 2003, MEM COGNITION, V31, P761, DOI 10.3758/BF03196114; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME, V3	71	26	27	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	3					273	292		10.1080/09602010600751160			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	165IQ	WOS:000246298500001	17474057				2021-06-18	
J	Sabsovich, I; Rehman, Z; Yunen, J; Coritsidis, G				Sabsovich, Ilya; Rehman, Zia; Yunen, Jose; Coritsidis, George			Propofol infusion syndrome: A case of increasing morbidity with traumatic brain injury	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							ACIDOSIS; SEDATION; RHABDOMYOLYSIS; FAILURE	A previously healthy 16-year-old boy with a closed, severe traumatic brain injury was admitted to a surgical and trauma intensive care unit. He was given a continuous infusion of propofol for sedation and to control intracranial pressure. About 3 days after the propofol infusion was started, metabolic acidosis and rhabdomyolysis developed Acute renal failure ensued as a result of the rhabdomyolysis. Tachycardia with wide QRS complexes developed without hyperkalemia. The patient died of refractory cardiac dysrhythmia and circulatory collapse approximately 36 hours after the first signs of propofol infusion syndrome appeared. Propofol infusion syndrome is a rare but frequently fatal complication in critically ill children who are given prolonged high-dose infusions of the drug. The syndrome is characterized by severe metabolic acidosis, rhabdomyolysis, acute renal failure, refractory myocardial failure, and hyperlipidemia. Despite several publications on the subject in the past decade, most cases still seem to remain undetectable.	[Sabsovich, Ilya; Rehman, Zia; Yunen, Jose; Coritsidis, George] Elmhurst Hosp Ctr, Surg & Trauma Intens Care Unit, New York, NY USA; [Sabsovich, Ilya; Rehman, Zia; Yunen, Jose; Coritsidis, George] Mt Sinai Sch Med, Dept Surg, New York, NY USA	Yunen, J (corresponding author), Montefiore Med Ctr, Albert Einstein Sch Med, 111 E 210th St, Bronx, NY 10467 USA.	jyunen@montefiore.org					AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BENNETT SN, 1995, NEW ENGL J MED, V333, P147, DOI 10.1056/NEJM199507203330303; BRANCA D, 1991, ARCH BIOCHEM BIOPHYS, V290, P517, DOI 10.1016/0003-9861(91)90575-4; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Eriksen J, 2006, ACTA ANAESTH SCAND, V50, P117, DOI 10.1111/j.1399-6576.2006.00904.x; Friedman JA, 2002, J NEUROSURG, V96, P1161; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; Haase R, 2005, J NEUROSURG ANESTH, V17, P122, DOI 10.1097/01.ana.0000161267.63160.13; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; Leisure GS, 1996, ANESTHESIOLOGY, V84, P224, DOI 10.1097/00000542-199601000-00027; Marinella MA, 1996, CHEST, V109, P292, DOI 10.1378/chest.109.1.292; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McKeage K, 2003, CNS DRUGS, V17, P235, DOI 10.2165/00023210-200317040-00003; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; Nathwani RA, 2005, HEPATOLOGY, V41, P380, DOI 10.1002/hep.20548; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Stelow EB, 2000, CLIN CHEM, V46, P577; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; *ZEN PHARM INC, DIPR PROP PROD MON; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	25	26	26	0	0	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264	1937-710X		AM J CRIT CARE	Am. J. Crit. Care	JAN	2007	16	1					82	85		10.4037/ajcc2007.16.1.82			4	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	271SQ	WOS:000253809400015	17192529				2021-06-18	
J	Vavilala, MS; Muangman, S; Waitayawinyu, P; Roscigno, C; Jaffe, K; Mitchell, P; Kirkness, C; Zimmerman, JJ; Ellenbogen, R; Lam, AM				Vavilala, Monica S.; Muangman, Saipin; Waitayawinyu, Pichaya; Roscigno, Cecelia; Jaffe, Kenneth; Mitchell, Pamela; Kirkness, Catherine; Zimmerman, Jerry J.; Ellenbogen, Richard; Lam, Arthur M.			Impaired cerebral autoregulation in infants and young children early after inflicted traumatic brain injury: A preliminary report	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; children; head injury	BLOOD-FLOW; INTRACRANIAL-PRESSURE; SUFENTANIL; SEVOFLURANE; METABOLISM; HYPERCAPNIA; DESFLURANE; FENTANYL	The objective of this report is to describe cerebral autoregulation after severe inflicted pediatric traumatic brain injury (iTBI). We examined cerebral autoregulation of both cerebral hemispheres (mean autoregulatory index; ARI) in children < 5 years with Glasgow Coma Scale (GCS) score of < 9 and no evidence of brain death within the first 48 h of pediatric intensive care unit (PICU) admission. Discharge and 6-month Glasgow Outcome Scale (GOS) scores were collected. GOS of < 4 reflected poor outcome. All three iTBI and all seven noninflicted TBI (nTBI) patients had admission GCS score of < 9. Eight of 10 patients had Autoregulatory Index (ARI) of < 0.4 (impaired cerebral autoregulation) of at least one hemisphere. All children with iTBI had poor outcome, and none had intact cerebral autoregulation in both hemispheres. Children with nTBI had better overall outcome than those with iTBL Two of the children with nTBI had intact autoregulation in both hemispheres and good outcome. Two of the three children with iTBI had differential effects on autoregulation between hemispheres despite bilateral injury. These are, to our knowledge, the first data on cerebral blood flow autoregulation in the unique setting of iTBI and provide a rationale for further study of their relationship to outcome and effects of therapy.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Behav Nursing, Seattle, WA 98195 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004501] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K23 HD 0044632-03] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [2R01 NR 004501-04] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bedforth NM, 2001, BRIT J ANAESTH, V87, P193, DOI 10.1093/bja/87.2.193; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; BODE H, 1988, APPL PEDIAT TRANSCRA; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; COTEV S, 1975, ANESTHESIOLOGY, V43, P117, DOI 10.1097/00000542-197507000-00029; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Hanel F, 1997, J NEUROSURG ANESTH, V9, P223; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kaiser JR, 2005, PEDIATR RES, V58, P931, DOI 10.1203/01.pdr.0000182180.80645.0c; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; McCulloch TJ, 2000, ANESTHESIOLOGY, V93, P1205, DOI 10.1097/00000542-200011000-00012; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; ODDEN JP, 1994, BIOL NEONATE, V65, P367; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Shah M, 2005, CHILD ABUSE NEGLECT, V29, P953, DOI 10.1016/j.chiabu.2004.08.011; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	38	26	26	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					87	96		10.1089/neu.2006.0058			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100008	17263672				2021-06-18	
J	Zhou, ML; Zhu, L; Wang, J; Hang, CH; Shi, JX				Zhou, Meng-liang; Zhu, Lin; Wang, Jian; Hang, Chun-hua; Shi, Ji-xin			The inflammation in the gut after experimental subarachnoid hemorrhage	JOURNAL OF SURGICAL RESEARCH			English	Article						subarachnoid hemorrhage; intestine; inflammation; nuclear factor-kappa B	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; CARDIAC-ARRHYTHMIAS; COMPLICATIONS; LEUKOCYTOSIS; ANEURYSM; STROKE; FAMILY; IMMUNE; HEART	Background. Gastrointestinal dysfunction could be frequently observed in the patients suffering from SAH. This study test the hypothesis that experimental SAH could induce histopathological changes an inflammatory response associating with NF-kappa B activation pathway in the gut. Materials and methods. A total of 17 rabbits were randomly divided into two groups: control group (n = 8) and SAH group (n = 9). In the SAH group, the animals were subjected to experimental SAH according to the "two-hemorrhage" method. The histopathological study was performed to detect the intestinal mucosal morphological changes and immunohistochemical study was used to detect the TNF-alpha and ICAM-1 expressions. NF-kappa B binding activity was measured using the electrophoretic mobility shift assay. Results. It was demonstrated that some damage changes and leukocytes infiltration occurred in the intestinal mucosa after SAH. More positive cells for TNF-a and ICAM-1 were observed in the SAH group. The NF-kappa B binding activity in the intestines was significantly increased in the SAH group (P < 0.01). Conclusions. The results of the present study suggest that SAH in the rabbits could induce NF-kappa B and proinflammatory cytokines activation in the intestine, which is associated with morphological changes. (c) 2007 Elsevier Inc. All rights reserved.	Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing 210002, Peoples R China; Nanjing Univ, Dept Gen Surg, Sch Med, Jinling Hosp, Nanjing 210002, Peoples R China	Shi, JX (corresponding author), Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	shijx52@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489			ASPLIN BR, 1994, AM J EMERG MED, V12, P370, DOI 10.1016/0735-6757(94)90163-5; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; D'Ancona G, 2003, TEX HEART I J, V30, P280; Davenport RJ, 1996, STROKE, V27, P421, DOI 10.1161/01.STR.27.3.421; DIPASQUALE G, 1987, AM J CARDIOL, V59, P596, DOI 10.1016/0002-9149(87)91176-3; Dooling Ellen, 2004, J Neurosci Nurs, V36, P130; ESTANOLVIDAL B, 1979, NEUROSURGERY, V5, P675; FRICK TW, 1992, J TRAUMA, V33, P870, DOI 10.1097/00005373-199212000-00013; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; Liang Y, 2004, CELL MOL IMMUNOL, V1, P343; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; MARION DW, 1986, NEUROSURGERY, V18, P101, DOI 10.1227/00006123-198601000-00019; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; PARKINSON D, 1984, SURG NEUROL, V21, P132, DOI 10.1016/0090-3019(84)90330-6; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHELL AR, 1987, ARCH INTERN MED, V147, P591, DOI 10.1001/archinte.147.3.591; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Souza DG, 2005, BRIT J PHARMACOL, V145, P246, DOI 10.1038/sj.bjp.0706190; SPALLONE A, 1987, SURG NEUROL, V27, P253, DOI 10.1016/0090-3019(87)90038-3; Svigelj V, 1996, ACTA NEUROL SCAND, V94, P120, DOI 10.1111/j.1600-0404.1996.tb07041.x; TANAKA S, 1979, ACTA NEUROCHIR, V48, P223, DOI 10.1007/BF02056970; Tegos TJ, 2000, ANGIOLOGY, V51, P793, DOI 10.1177/000331970005101001; WEIR BK, 1978, J NEUROSURG, V49, P502, DOI 10.3171/jns.1978.49.4.0502; Zingarelli B, 2005, CRIT CARE MED, V33, pS414, DOI 10.1097/01.CCM.0000186079.88909.94	32	26	28	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JAN	2007	137	1					103	108		10.1016/j.jss.2006.06.023			6	Surgery	Surgery	125NS	WOS:000243449400015	17069855				2021-06-18	
J	Borman, JB; Aharonson-Daniel, L; Savitsky, B; Peleg, K				Borman, J. B.; Aharonson-Daniel, L.; Savitsky, B.; Peleg, K.		Israeli Trauma Grp	Unilateral flail chest is seldom a lethal injury	EMERGENCY MEDICINE JOURNAL			English	Article							MANAGEMENT; STABILIZATION; OUTCOMES; TRAUMA	Background: The chest cage is a common target for traumatic damage. Although relatively rare, it is considered to be a serious condition with significant reported mortalities. As most flail injuries are accompanied by severe extrathoracic injuries, it is often difficult to pinpoint a single injury responsible for the patient's death. Aim: To investigate the factors related to mortality when flail injury is diagnosed. Methods: Data from the Israel National Trauma Registry between 1998 and 2003 included 11 966 chest injuries ( 262 flail chest injuries) out of a total of 118 211 trauma hospitalisations. Mortality figures were analysed to determine which factors, singly or in combination, influenced flail chest mortality. Results: Road crashes accounted for most flail injuries (76%). The total mortality was 54 (20.6%) of 262 patients with flail chest injuries. 13 (20.4%) of the deaths occurred soon after admission to the emergency room and 37 (68.5%) within the first 24 h. Mortality in moderate to severe injuries ( injury severity score (ISS) 9 - 24) was 3.6% and that in critical injuries 28.5% (ISS >24). Mortality increased with age: 17% in those aged <45 years, 22.1% in those between 45 and 64 years and 28.8% in those >65 years. Age remained a risk for inpatient death when adjusted for severity. Mortality in isolated unilateral flail injury was not more than 6%. Total mortality for traumatic brain injury (TBI) and flail was 34%. Flail, TBI and other major injuries increased the mortality to 61.1%. Conclusions: Advanced age is associated with higher mortality. Isolated unilateral bony cage instability infrequently leads to death in patients who make it to the emergency department but rather its combination with additional extrathoracic trauma.	Chaim Sheba Med Ctr, Israel Natl Ctr Trauma & Emergency Med Res, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Israel	Aharonson-Daniel, L (corresponding author), Chaim Sheba Med Ctr, Israel Natl Ctr Trauma & Emergency Med Res, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Israel.	limorad@gertner.health.gov.il	Aharonson-Daniel, Limor/F-1998-2012	Aharonson-Daniel, Limor/0000-0003-4585-6892; Savitsky, Bella/0000-0001-8917-8419			Adegboye V O, 2002, Afr J Med Med Sci, V31, P315; Albaugh G, 2000, AM SURGEON, V66, P978; Athanassiadi K, 2004, EUR J CARDIO-THORAC, V26, P373, DOI 10.1016/j.ejcts.2004.04.011; Balci Akin Eraslan, 2004, Asian Cardiovasc Thorac Ann, V12, P11; Leo Francesco, 2003, Asian Cardiovasc Thorac Ann, V11, P188; Liman ST, 2003, EUR J CARDIO-THORAC, V23, P374, DOI 10.1016/S1010-7940(02)00813-8; Tanaka H, 2002, J TRAUMA, V52, P727, DOI 10.1097/00005373-200204000-00020; TRINKLE JK, 1975, ANN THORAC SURG, V19, P355, DOI 10.1016/S0003-4975(10)64034-9; Velmahos GC, 2002, INT SURG, V87, P240; Voggenreiter G, 1998, J AM COLL SURGEONS, V187, P130, DOI 10.1016/S1072-7515(98)00142-2; Yalcinkaya I, 2000, Ulus Travma Derg, V6, P288	11	26	34	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	DEC	2006	23	12					903	905		10.1136/emj.2006.037945			3	Emergency Medicine	Emergency Medicine	109WE	WOS:000242339500005	17130594	Green Published, Bronze			2021-06-18	
J	Levasseur, JE; Alessandri, B; Reinert, M; Clausen, T; Zhou, ZW; Altemeni, N; Bullock, MR				Levasseur, Joseph E.; Alessandri, Beat; Reinert, Michael; Clausen, Tobias; Zhou, Zhengwen; Altemeni, Nabil; Bullock, M. Ross			Lactate not glucose, up-regulates mitochondrial oxygen consumption both in sham and lateral fluid percussed rat brains	NEUROSURGERY			English	Article						brain injury; glucose; lactate; oxygen; oxygen consumption	SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; CEREBRAL-BLOOD-FLOW; CYCLOSPORINE-A; EXTRACELLULAR POTASSIUM; INTRACRANIAL-PRESSURE; COGNITIVE DEFICITS; N-ACETYLASPARTATE; ENERGY-METABOLISM; NEURONAL-ACTIVITY	OBJECTIVE: Failure of energy metabolism after traumatic brain injury may be a major factor limiting outcome. Although glucose is the primary metabolic substrate in the healthy brain, the well documented surge in tissue lactate after traumatic brain injury suggests that lactate may provide an energy need that cannot be met by glucose. We hypothesized, therefore, that administration of lactate or the combination of lactate and supraphysiological oxygen may improve mitochondrial oxidative respiration in the brain after rat fluid percussion injury. We measured oxygen consumption (VO2) to determine what effects glucose, lactate, oxygen, and the combination of lactate and oxygen have on mitochondrial respiration in both injured and uninjured rat brain tissue. METHODS: Anesthetized Sprague-Dawley rats were intubated and ventilated with either 0.21 or 1.0 fraction of inspired oxygen (FIO2). Brain tissue from acute sham animals was subjected in vitro to 1.1 mM, 12 mM and 100 mM concentrations of glucose and L-lactate. In another group, injury (fluid percussion injury of 2.5 +/- 0.02 atmospheres) was induced over the left hemisphere. The VO2 of mu g amounts of brain tissues were measured in a microrespirometry system (Cartesian diver). RESULTS: The VO2 was found to be independent of glucose concentrations, but dose-dependent for lactate. Moreover, the lactate dependent VO(2)s were all significantly higher than those generated by glucose. Injured rats on FIO2 0.21 had brain tissueVO(2) rates that were significantly lower than those of shams or preinjury levels. In injured rats treated with FIO2 1.0, the reduction in VO2 levels was prevented. Injured rats that received an intravenous infusion of.100 mM lactate had VO2 rates that were significantly higher than those obtained with FIO2 1.0. Combined treatment further boosted the lactate generated VO2 rates by approximately 15%. CONCLUSION: Glucose sustains mitochondrial respiration at a low level "fixed" rate because, despite increasing its concentration nearly 100-fold, it cannot up-regulate VO2 after fluid percussion injury. Lactate produces a dose-dependent VO2 response, possibly enabling mitochondria to meet the increased energy needs of the injured brain.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Med Ctr, Richmond, VA 23298 USA; Univ Halle Wittenberg, Dept Anesthesiol, Halle, Saale, Germany; Univ Halle Wittenberg, Dept Intens Care Med, Halle, Saale, Germany; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Mainz, Inst Neurosurg Pathophysiol, D-6500 Mainz, Germany	Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Med Ctr, POB 980631,1200 E Broad St, Richmond, VA 23298 USA.	robulloc@mail2.vcu.edu	Reinert, Michael/AAA-3929-2019; Reinert, Michael/E-4964-2011	Reinert, Michael/0000-0002-0971-9543; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R01NS019316] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 19316-16] Funding Source: Medline		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Aubert A, 2005, J CEREBR BLOOD F MET, V25, P1476, DOI 10.1038/sj.jcbfm.9600144; Aubert A, 2002, NEUROIMAGE, V17, P1162, DOI 10.1006/nimg.2002.1224; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, ACT NEUR S, V76, P359; Cherian L, 1998, J NEUROTRAUM, V15, P1059, DOI 10.1089/neu.1998.15.1059; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DAUGHERTY WP, 2003, J NEUROTRAUM, V20, P1162; Doppenberg EMR, 1999, J NEUROTRAUM, V16, P123, DOI 10.1089/neu.1999.16.123; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; FELLOWS LK, 1993, J NEUROCHEM, V60, P1258, DOI 10.1111/j.1471-4159.1993.tb03285.x; Friedemann TE, 1941, J BIOL CHEM, V141, P993; FUJISAWA H, 1994, ACT NEUR S, V60, P193; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Haljamae H, 1987, INTENSIVE CARE WORLD, V4, P118; HARPER HA, 1959, REV PHYSL CHEM, P179; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; HAWK PB, 1954, PRACTICAL PHYSIOLOGI, P622; Holloway R, 2003, J NEUROTRAUM, V20, P1127; Holter H., 1943, COMPT REND TRAV LAB CARLSBERG [COPENHAGEN] SER CHIM, V24, P399; Hu YB, 1997, J NEUROCHEM, V69, P1484; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KORF J, 1990, INT J BIOCHEM, V22, P1371, DOI 10.1016/0020-711X(90)90225-R; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P848, DOI 10.1038/jcbfm.1988.142; LARABEE MG, 1996, J NEUROCHEM, V67, P1726; LARABEE MJ, 1995, J NEUROCHEM, V64, P1734; Leegsma-Vogt G, 2004, J CEREBR BLOOD F MET, V24, P1071, DOI 10.1097/01.WCB.0000129417.80261.A6; LEVASSEUR J, 1999, J NEUROTRAUM, V16, P991; LEVASSEUR JE, 1985, AM J PHYSIOL, V248, pH534; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Linderstrom-Lang K., 1943, COMPT REND TRAV LAB CARLSBERG [COPENHAGEN] SER CHIM, V24, P333; MAGISTRETTI PJ, 1993, DEV NEUROSCI-BASEL, V15, P306, DOI 10.1159/000111349; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCILWAIN H, 1953, BIOCHEM J, V55, P618, DOI 10.1042/bj0550618; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2002, NEUROL RES, V24, P601, DOI 10.1179/016164102101200438; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Schwandt ES, 2003, J NEUROTRAUM, V20, P1096; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; TSCAOPOULOS M, 1996, J NEUROSCI, V16, P877; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	70	26	27	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2006	59	5					1122	1130		10.1227/01.NEU.0000245581.00908.AF			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	128GI	WOS:000243645800035	17143246				2021-06-18	
J	Shah, SA; Prough, DS; Garcia, JM; DeWitt, DS; Hellmich, HL				Shah, Syed A.; Prough, Donald S.; Garcia, Jeanna M.; DeWitt, Douglas S.; Hellmich, Helen L.			Molecular correlates of age-specific responses to traumatic brain injury in mice	EXPERIMENTAL GERONTOLOGY			English	Article						ribonuclease protection assay; interleukin-1 beta; brain-derived neurotrophic factor; caspase-3; fluid percussion TBI	HIPPOCAMPUS; EXPRESSION; DEFICITS; BDNF	Aged traumatic brain injury (TBI) patients suffer higher rates of mortality and disability than younger patients. Cognitive problems common to TBI patients are associated with damage to the hippocampus, a central locus of learning and memory. To investigate the molecular mechanisms of age-related vulnerability to brain injury in a mouse model of TBI, we studied the effects of TBI on hippocampal gene expression in young and aged mice. Young and aged male C57B1/6 mice were subjected to sham injury or TBI and sacrificed 24 h post-injury. We used laser capture microdissection to obtain pure populations of neurons from the CA1, CA3, and dentate gyrus subfields of the hippocampus. We compared injury-induced gene expression in hippocampal neurons of young and aged mice using quantitative ribonuclease protection assay analysis of linearly amplified mRNA from laser captured neurons. Both increased age and TBI were associated with increased expression of neuroprotective (brain-derived neurotrophic factor), pro-inflammatory (interleukin-1 beta), and proapoptotic (caspase-3) genes in mouse hippocampal neurons. Our data support previous reports that suggested the CA3 subregion is highly susceptible to fluid percussion TBI and that age-related changes in gene expression are one potential mechanism of increased vulnerability of the aged brain to TBI. (c) 2006 Elsevier Inc. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042849-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER		Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; Murray CA, 1998, J NEUROSCI, V18, P2974; Neatherlin J S, 2000, Crit Care Nurs Q, V23, P49; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Schaaf MJM, 2001, BRAIN RES, V915, P227, DOI 10.1016/S0006-8993(01)02855-4; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Ward MT, 1999, NEUROBIOL AGING, V20, P363, DOI 10.1016/S0197-4580(99)00045-7; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; Zhao XY, 2001, J COMP NEUROL, V441, P187, DOI 10.1002/cne.1406	21	26	27	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	NOV	2006	41	11					1201	1205		10.1016/j.exger.2006.07.006			5	Geriatrics & Gerontology	Geriatrics & Gerontology	122IN	WOS:000243219500014	16978820				2021-06-18	
J	Smith, DC; Tan, AA; Duke, A; Neese, SL; Clough, RW; Browning, RA; Jensen, RA				Smith, Douglas C.; Tan, Arlene A.; Duke, Andrea; Neese, Steven L.; Clough, Richard W.; Browning, Ronald A.; Jensen, Robert A.			Recovery of function after vagus nerve stimulation initiated 24 hours after fluid percussion brain injury	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; norepinephrine; recovery of function; traumatic brain injury; vagus nerve stimulation	SENSORIMOTOR CORTEX INJURY; LOCUS-COERULEUS; AMPHETAMINE; MOTOR; RAT; NOREPINEPHRINE; NORADRENALINE; VAGAL; DEFICITS; RELEASE	Recent evidence from our laboratory demonstrated in laboratory rats that stimulation of the vagus nerve (VNS) initiated 2 h after lateral fluid percussion brain injury (FPI) accelerates the rate of recovery on a variety of behavioral and cognitive tests. VNS animals exhibited a level of performance comparable to :that of sham-operated uninjured animals :by the end of a 2-week testing period. The effectiveness of VNS was further evaluated in the present study in which initiation of stimulation was delayed until 24 h post-injury. Rats were subjected to a moderate FPI and tested. on the beam walk, skilled forelimb reaching, locomotor placing, forelimb flexion and Morris water maze tasks for 2 weeks following injury. VNS (30 sec trains of 0:5 mA, 20.0-Hz biphasic pulses) was initiated 24 h post-injury and continued at 30-min intervals for the duration of the study, except for brief periods when the animals were. detached for behavioral assessments. Consistent with our previous findings when stimulation was initiated 2 h post-injury, VNS animals showed significantly faster rates. of recovery compared to controls. By the last day of testing (day 14: post-injury), the FPI-VNS animals were performing significantly better than the FPI-no-VNS animals and were not significantly different from shams in all motor and sensorimotor tasks. Performance in the Morris water maze indicated that the VNS animals acquired the task more rapidly on days 11-13 post-injury. On day 14, the FPI-VNS animals did not differ in the latency to find the platform from sham controls, whereas the injured controls did; however, the FPI-VNS animals and injured controls were not significantly different. Despite the lack of significant histological differences between the FPI groups, VNS, when initiated 24 h following injury, clearly attenuated the ensuing behavioral deficits and enhanced acquisition of the cognitive task. The results are discussed with respect to the norepinephrine hypothesis.	So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA; So Illinois Univ, Dept Psychol, Brain & Cognit Sci Programs, Carbondale, IL USA; So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; So Illinois Univ, Ctr Intergrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Smith, DC (corresponding author), So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA.	dcsmith@siu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER		Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Aston-Jones Gary, 1995, P183; ASTONJONES G, 2002, NEUROPSYCHOPHARMACOL, P47; Ben-Menachem E, 2005, EPILEPTIC DISORD, V7, pS22; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; DeGiorgio CM, 2000, EPILEPSIA, V41, P1195, DOI 10.1111/j.1528-1157.2000.tb00325.x; Dose JM, 1997, J NEUROTRAUM, V14, P327, DOI 10.1089/neu.1997.14.327; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; Fai AHC, 2004, CHINESE MED J-PEKING, V117, P58; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; George MS, 2005, BIOL PSYCHIAT, V58, P364, DOI 10.1016/j.biopsych.2005.07.028; Goldstein LB, 2000, NEUROPHARMACOLOGY, V39, P852, DOI 10.1016/S0028-3908(99)00249-X; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; Goldstein LB, 1998, RESTORATIVE NEUROLOGY, P241; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; HALLMAN H, 1984, EUR J PHARMACOL, V103, P269, DOI 10.1016/0014-2999(84)90487-4; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; HERMANN GE, 1985, J AUTONOM NERV SYST, V13, P1, DOI 10.1016/0165-1838(85)90002-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; Krahl S. E., 1994, Society for Neuroscience Abstracts, V20, P1453; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; Krahl SE, 2004, J PSYCHIATR RES, V38, P237, DOI 10.1016/j.jpsychires.2003.11.005; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LHEUREUX R, 1986, J NEUROCHEM, V46, P1794; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prasad RM, 1995, RESTOR NEUROL NEUROS, V9, P65, DOI 10.3233/RNN-1995-9201; ROOSEVELT RW, IN PRESS BRAIN RES; Rush AJ, 2005, BIOL PSYCHIAT, V58, P355, DOI 10.1016/j.biopsych.2005.05.024; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TAKIGAWA M, 1977, BRAIN RES, V135, P217, DOI 10.1016/0006-8993(77)91027-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	53	26	29	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1549	1560		10.1089/neu.2006.23.1549			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500014	17020489				2021-06-18	
J	Bangirana, P; Idro, R; John, CC; Boivin, MJ				Bangirana, Paul; Idro, Richard; John, Chandy C.; Boivin, Michael J.			Rehabilitation for cognitive impairments after cerebral malaria in African children: strategies and limitations	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						cerebral malaria; cognitive impairment; Africa; children; rehabilitation	PLASMODIUM-FALCIPARUM MALARIA; TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL ENRICHMENT; ATTENTION; SEQUELAE; PERFORMANCE; THERAPY; SCHOOLCHILDREN; INTERVENTION; DISORDERS	Cerebral malaria results in short- to long-term cognitive impairments in many of its child survivors. Although some of the risk factors for impairments have been identified, no attempts have been made to address the plight of those who develop cognitive impairments. This paper discusses the burden of cognitive impairment caused by cerebral malaria and suggests some rehabilitation strategies based on brain injury and cognitive rehabilitation studies. Potential cognitive rehabilitation solutions such as cognitive exercises, environmental enrichment, nutritional supplementation, physical therapy and speech therapy are highlighted. The limitations of implementing these interventions and solutions are discussed in light of the limited human resources and infrastructure of the developing countries that are malaria endemic.	Makerere Univ, Inst Psychol, Dept Mental Hlth & Community Psychol, Kampala, Uganda; Makerere Univ, Mulago Hosp, Med Sch, Dept Paediat & Child Hlth, Kampala, Uganda; Univ Minnesota, Global Pediat Program, Minneapolis, MN USA; Univ Minnesota, Div Pediat Infect Dis, Minneapolis, MN USA; Michigan State Univ, INPEP, E Lansing, MI USA; Univ Michigan, Dept Psychiat, Neuropsychol Program, Ann Arbor, MI USA	Bangirana, P (corresponding author), Makerere Univ, Inst Psychol, Dept Mental Hlth & Community Psychol, POB 7062, Kampala, Uganda.	pbangirana@yahoo.com	, Ridro/ABD-3556-2020; John, Chandy C/B-4164-2008	Bangirana, Paul/0000-0002-7136-0594; Idro, Richard/0000-0003-4728-4605			Anderson V A, 1999, Pediatr Rehabil, V3, P159; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Blundell SW, 2003, CLIN REHABIL, V17, P48, DOI 10.1191/0269215503cr584oa; BOIVIN MJ, 1993, J PEDIATR PSYCHOL, V18, P249, DOI 10.1093/jpepsy/18.2.249; Boivin MJ, 2002, J DEV BEHAV PEDIATR, V23, P353, DOI 10.1097/00004703-200210000-00010; Boivin MJ, 1996, J PSYCHOL, V130, P95, DOI 10.1080/00223980.1996.9914992; BOIVIN MJ, 1993, HEALTH PSYCHOL, V12, P220, DOI 10.1037/0278-6133.12.3.220; Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893; Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x; Carter JA, 2003, BRAIN INJURY, V17, P217, DOI 10.1080/0269905021000038447; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Dickson R, 2000, BRIT MED J, V320, P1697, DOI 10.1136/bmj.320.7251.1697; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Dugbartey AT, 1998, AM J TROP MED HYG, V59, P393, DOI 10.4269/ajtmh.1998.59.393; DUGBARTEY AT, 1995, THESIS U VICTORIA CA; Fernandez-Teruel A, 2002, PHARMACOL BIOCHEM BE, V73, P233, DOI 10.1016/S0091-3057(02)00787-6; Genton B, 1997, INT J EPIDEMIOL, V26, P670, DOI 10.1093/ije/26.3.670; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Goorhuis-Brouwer SM, 2002, INT J PEDIATR OTORHI, V63, P129, DOI 10.1016/S0165-5876(02)00004-6; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; GREALY MA, 2001, PEDIAT REHABILITATIO, V4, P41; Holding PA, 1999, T ROY SOC TROP MED H, V93, P529, DOI 10.1016/S0035-9203(99)90368-1; Holding PA, 2004, J INT NEUROPSYCH SOC, V10, P246, DOI 10.1017/S1355617704102166; Holding PA, 2001, AM J TROP MED HYG, V64, P68, DOI 10.4269/ajtmh.2001.64.68; Klein PS, 2004, INFANT YOUNG CHILD, V17, P340, DOI 10.1097/00001163-200410000-00007; KLEIN PS, 1991, INF MENTAL HLTH J, V12, P321, DOI 10.1002/1097-0355(199124)12:4<321::AID-IMHJ2280120406>3.0.CO;2-Z; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Laatsch L, 1997, BRAIN INJURY, V11, P851; Laatsch L, 2000, NEUROREHABILITATION, V15, P189; Lozoff, 2004, PEDIATRICS, V113, P1853; LOZOFF B, 1995, INT J BEHAV DEV, V18, P277, DOI 10.1177/016502549501800206; Lozoff B, 2003, PEDIATRICS, V112, P846; Marlowe WB, 2000, DEV NEUROPSYCHOL, V18, P445, DOI 10.1207/S1532694209Marlowe; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Mohammed AH, 2002, PROG BRAIN RES, V138, P109, DOI 10.1016/S0079-6123(02)38074-9; Mung'Ala-Odera V, 2004, AM J TROP MED HYG, V71, P64, DOI 10.4269/ajtmh.2004.71.64; Muntendam AH, 1996, T ROY SOC TROP MED H, V90, P391, DOI 10.1016/S0035-9203(96)90518-0; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Newton CRJC, 2000, J NEUROL NEUROSUR PS, V69, P433, DOI 10.1136/jnnp.69.4.433; Nordholm LA, 1999, DISABIL REHABIL, V21, P515; Olness K, 2003, J DEV BEHAV PEDIATR, V24, P120, DOI 10.1097/00004703-200304000-00009; Olumese PE, 1997, J TROP PEDIATRICS, V43, P217, DOI 10.1093/tropej/43.4.217; Palmese CA, 2000, BRAIN INJURY, V14, P535; Raine A, 2001, PSYCHOPHYSIOLOGY, V38, P254, DOI 10.1111/1469-8986.3820254; RICHTER LM, 1991, INF MENTAL HLTH J, V12, P88, DOI 10.1002/1097-0355(199122)12:2<88::AID-IMHJ2280120202>3.0.CO;2-Q; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stoltzfus RJ, 2001, BRIT MED J, V323, P1389, DOI 10.1136/bmj.323.7326.1389; van't Hooft I, 2003, ACTA PAEDIATR, V92, P935, DOI 10.1080/08035250310004586; Zillmer E. A., 2001, PRINCIPLES NEUROPSYC	53	26	26	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2006	11	9					1341	1349		10.1111/j.1365-3156.2006.01685.x			9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	077DF	WOS:000240007200003	16930255				2021-06-18	
J	Grinsell, MM; Showalter, S; Gordon, KA; Norwood, VF				Grinsell, Matthew M.; Showalter, Sharon; Gordon, Katherine A.; Norwood, Victoria F.			Single kidney and sports participation: Perception versus reality	PEDIATRICS			English	Article						kidney; sports; wounds and injuries	BLUNT RENAL TRAUMA; AMERICAN FOOTBALL; ABDOMINAL-TRAUMA; INJURIES; CHILDREN; SECONDARY; GENITOURINARY; FATALITIES; LACERATION; RUPTURE	OBJECTIVES. Physician opinions and practice patterns regarding the participation of children and adolescents with single, normal kidneys in contact/collision sports are widely varied. We hypothesize that limitation of participation from play based only on the presence of a single kidney is not supported by available data. We sought to determine recommendations of pediatric nephrologists regarding the participation of patients with single, normal kidneys in contact/collision sports and review the literature to determine the rate of sports-related kidney injury compared with other organs. METHODS. Members of the American Society of Pediatric Nephrology were surveyed regarding their recommendations for participation of patients with single, normal kidneys in contact/collision sports. Medical and sports literature databases were searched to determine sports-related kidney, brain, spinal cord, and cardiac injury rates and the sports associated with kidney injury. RESULTS. Sixty-two percent of respondents would not allow contact/collision sports participation. Eighty-six percent of respondents barred participation in American football, whereas only 5% barred cycling. Most cited traumatic loss of function as the reason for discouraging participation. The literature search found an incidence of catastrophic sports-related kidney injury of 0.4 per 1 million children per year from all sports. Cycling was the most common cause of sports- related kidney injury causing > 3 times the kidney injuries as football. American football alone accounted for 0.9 to 5.3 fatal brain injuries and 4.9 to 7.3 irreversible spinal cord injuries per 1 million players per year. Commotio cordis causes 2.1 to 9.2 deaths per year. CONCLUSIONS. Most pediatric nephrologists prohibit contact/collision sports participation by athletes with a single kidney, particularly football. The available evidence suggests that cycling is far more likely to cause kidney injury. In addition, kidney injury from sports is much less common than catastrophic brain, spinal cord, or cardiac injury. Restricting participation of patients with a single, normal kidney from contact/collision sports is unwarranted.	Univ Virginia, Dept Pediat, Div Nephrol, Charlottesville, VA 22903 USA; Univ Virginia, Curry Sch Educ, Charlottesville, VA 22903 USA	Grinsell, MM (corresponding author), Univ Virginia, Dept Pediat, Div Nephrol, 1224 Jefferson Pk Ave,Suite 701, Charlottesville, VA 22903 USA.	mmg4x@virginia.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5T32HL07956-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007956] Funding Source: NIH RePORTER		ACTON CHC, 1994, MED J AUSTRALIA, V160, P344, DOI 10.5694/j.1326-5377.1994.tb138235.x; AHMED S, 1982, BRIT J UROL, V54, P470, DOI 10.1111/j.1464-410X.1982.tb13567.x; Anderson C R, 1995, Arch Fam Med, V4, P885, DOI 10.1001/archfami.4.10.885; BASS DH, 1991, J PEDIATR SURG, V26, P196, DOI 10.1016/0022-3468(91)90909-D; Bergqvist D, 1982, Br J Sports Med, V16, P76; Boggi U, 1998, SCAND J UROL NEPHROL, V32, P64; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Carmody DJ, 2005, MED J AUSTRALIA, V182, P561, DOI 10.5694/j.1326-5377.2005.tb06814.x; CASS AS, 1983, J TRAUMA, V23, P123, DOI 10.1097/00005373-198302000-00009; *COMM MED ASP SPOR, 1976, MED EV ATH GUID; DORSEN PJ, 1986, PHYSICIAN SPORTSMED, V14, P130, DOI 10.1080/00913847.1986.11709129; EMANUEL B, 1977, J TRAUMA, V17, P275, DOI 10.1097/00005373-197704000-00003; Geoghegan T, 2003, AM J ROENTGENOL, V181, P886, DOI 10.2214/ajr.181.3.1810886a; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; HILDRETH TA, 1979, MINN MED, V62, P155; Itagaki MW, 2004, AM J SPORT MED, V32, P522, DOI 10.1177/0363546503258879; Johnson B, 2005, J UROLOGY, V174, P686, DOI 10.1097/01.ju.0000164719.91332.42; KRASNOW S, 1990, SPORTS ILLUSTRATED, V72, P14; KUZMAROV IW, 1981, J UROLOGY, V126, P648, DOI 10.1016/S0022-5347(17)54673-X; Lavard P., 1993, Scandinavian Journal of Medicine and Science in Sports, V3, P292; Lee S, 2004, ANZ J SURG, V74, P766, DOI 10.1111/j.1445-1433.2004.03137.x; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; LINKE CA, 1972, NEW YORK STATE J MED, V72, P2414; Machida T, 1999, INJURY, V30, P47, DOI 10.1016/S0020-1383(98)00210-1; Mador J A, 1996, J Emerg Nurs, V22, P358, DOI 10.1016/S0099-1767(96)80042-0; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1142, DOI 10.1001/jama.287.9.1142; Matlaga BR, 2002, J UROLOGY, V168, P672, DOI 10.1016/S0022-5347(05)64719-2; MCALEER IM, 1993, UROLOGY, V42, P563, DOI 10.1016/0090-4295(93)90274-E; McAleer IM, 2002, J UROLOGY, V168, P1805, DOI 10.1016/S0022-5347(05)64418-7; *NAT KIDN FDN, Q A LIV DON; Oliveria GHM, 2003, NEW ENGL J MED, V348, P129, DOI 10.1056/NEJMicm020037; PLISKIN M, 1988, J TRAUMA, V28, P520, DOI 10.1097/00005373-198804000-00018; Radmayr C, 2002, EUR UROL, V42, P297, DOI 10.1016/S0302-2838(02)00317-2; Richter E R, 2001, Urology, V58, P607, DOI 10.1016/S0090-4295(01)01314-0; RISSER WL, 1994, PEDIATRICS, V94, P757; SERUCA H, 1979, CAN J SURG, V22, P24; Sharp DS, 2002, J UROLOGY, V168, P1811, DOI 10.1016/S0022-5347(05)64420-5; Smith M, 2003, AM J ROENTGENOL, V180, P504, DOI 10.2214/ajr.180.2.1800504; SPARNON AL, 1986, J PEDIATR SURG, V21, P118, DOI 10.1016/S0022-3468(86)80061-6; Tator CH, 2004, CAN J NEUROL SCI, V31, P460, DOI 10.1017/S0317167100003632; Terrell T, 1997, PHYSICIAN SPORTSMED, V25, P75, DOI 10.3810/psm.1997.11.1442; Vincent GM, 2000, PHYSICIAN SPORTSMED, V28, P31, DOI 10.3810/psm.2000.11.1285; Waicus KM, 1999, CLIN J SPORT MED, V9, P236, DOI 10.1097/00042752-199910000-00011; Wan J, 2003, J UROLOGY, V170, P1525, DOI 10.1097/01.ju.0000084430.96658.05; Wan J, 2003, J UROLOGY, V170, P1528, DOI 10.1097/01.ju.0000083999.16060.ff; Wexler RK, 2003, PHYSICIAN SPORTSMED, V31, P43, DOI 10.3810/psm.2003.02.198; WICHMANN S, 1992, PHYSICIAN SPORTSMED, V20, P176, DOI 10.1080/00913847.1992.11947420; WOODWARD A, 1982, AUST NZ J SURG, V52, P66, DOI 10.1111/j.1445-2197.1982.tb05290.x; Xiang H, 2004, INJURY PREV, V10, P99, DOI 10.1136/ip.2003.004655	50	26	26	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2006	118	3					1019	1027		10.1542/peds.2006-0663			9	Pediatrics	Pediatrics	090NX	WOS:000240959100020	16950993				2021-06-18	
J	Pitel, AL; Beaunieux, H; Lebaron, N; Joyeux, F; Desgranges, B; Eustache, F				Pitel, Anne Lise; Beaunieux, Helene; Lebaron, Nathalie; Joyeux, Francoise; Desgranges, Beatrice; Eustache, Francis			Two case studies in the application of errorless learning techniques in memory impaired patients with additional executive deficits	BRAIN INJURY			English	Article						errorless learning; semantic learning; cognitive procedural learning; executive functions; episodic memory	HERPES-SIMPLEX ENCEPHALITIS; VANISHING CUES; AMNESIC PATIENT; IMPLICIT MEMORY; BRAIN INJURY; REHABILITATION; ACQUISITION; PEOPLE; ASSOCIATIONS; INDIVIDUALS	Primary objective: The purpose of the present study was to examine in what extent errorless learning can be applied to amnesic patients with additional executive dysfunction. Research design: Two case studies were used in which two patients with severe closed head-injury were compared according to their different neuropsychological profiles. Methods and procedures: Patients were taught complex semantic information about their therapists and cognitive procedures needed to programme an electronic organizer. Main outcomes and results: Both semantic and procedural results suggest that the errorless method can be very helpful for teaching complex new knowledge to amnesic patients with mild executive impairment, whereas the presence of a dysexecutive syndrome may hamper the success of this form of memory rehabilitation. Conclusions: The present study puts forward that executive deficits should be taken into account when neuropsychologists are planning to use errorless techniques.	Univ Caen, Unite EO219, INSERM, EPHE, F-14033 Caen, France; Ctr Hosp, Serv Reeducat & Readaptat Neurol, Aunay Sur Odon, France	Eustache, F (corresponding author), Univ Caen, E0218, INSERM, EPHE,Lab Neuropsychol,CHU Cote Nacre, F-14033 Caen, France.	neuropsycho@chu-caen.fr	Helene, Beaunieux/G-3751-2010; Eustache, Francis/J-9465-2015; Desgranges, Beatrice/L-7739-2015; DESGRANGES, BEATRICE/AAK-4756-2021; Pitel, Anne Lise/L-9693-2015	Eustache, Francis/0000-0003-4460-8686; DESGRANGES, BEATRICE/0000-0002-3657-9996; BEAUNIEUX, HELENE/0000-0003-1354-6558; PITEL, Anne Lise/0000-0001-8573-9506			Andrewes D, 1999, NEUROPSYCHOL REHABIL, V9, P77, DOI 10.1080/713755591; BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; BUTTERS N, 1985, NEUROPSYCHOLOGIA, V23, P729, DOI 10.1016/0028-3932(85)90080-6; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; DAMASIO AR, 1995, ANN NY ACAD SCI, V15, P251; Deltour J. J., 1998, ECHELLE VOCABULAIRE; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Guillery-Girard B, 2004, NEUROREPORT, V15, P377, DOI 10.1097/00001756-200402090-00033; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P1255, DOI 10.1016/0028-3932(95)00061-7; Intons-Peterson MJ, 1992, MEMORY IMPROVEMENT I, P101; Kallosh R, 2000, J HIGH ENERGY PHYS; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Komatsu S, 2000, NEUROPSYCHOL REHABIL, V10, P113, DOI 10.1080/096020100389200; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; McKenna P, 2002, CORTEX, V38, P37, DOI 10.1016/S0010-9452(08)70637-3; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Parkin AJ, 1998, COGNITIVE NEUROPSYCH, V15, P361, DOI 10.1080/026432998381131; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; THOENE AIT, 1995, J INT NEUROPSYCH SOC, V1, P20; TULVING E, 1991, J EXP PSYCHOL LEARN, V17, P595, DOI 10.1037/0278-7393.17.4.595; VANDERLINDEN M, 1994, CORTEX, V30, P305, DOI 10.1016/S0010-9452(13)80201-8; VANDERLINDEN M, 1995, BROKEN MEMORIES NEUR, P54; Verfaellie M, 1995, NEUROCASE, V1, P291; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winter WE, 2001, BRAIN COGNITION, V45, P79, DOI 10.1006/brcg.2000.1257; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	41	26	26	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1099	1110		10.1080/02699050600909961			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100013	17060144				2021-06-18	
J	Ito, Y; Oh-Hashi, K; Kiuchi, K; Hirata, Y				Ito, Yoshimasa; Oh-hashi, Kentaro; Kiuchi, Kazutoshi; Hirata, Yoko			p44/42 MAP kinase and c-Jun N-terminal kinase contribute to the up-regulation of caspase-3 in manganese-induced apoptosis in PC12 cells	BRAIN RESEARCH			English	Article						caspase-3; JNK; MAPK; manganese; rotenone	PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; JNK PATHWAY; HL-60 CELLS; INDUCTION; ACTIVATION; DEATH; INHIBITION; METABOLISM; PROTEASES	Caspase-3 (32 kDa) is one of the primary protease executioners of apoptosis and is activated by intra-chain proteolytic cleavage, which generates a large subunit (17 kDa) and a small subunit (12 kDa). Typically, after apoptotic stimuli, the level of cleaved caspase-3 increases while that of caspase-3 decreases. It has been shown that caspase-3 mRNA levels increase in cortex following traumatic brain injury or focal ischemia. In the present study, we demonstrate that both caspase-3 mRNA and protein increase in apoptotic PC12 cells following exposure to manganese which strongly induces caspase-3 cleavage. Up-regulation of caspase-3 protein was evident in manganese-treated PC12 cells and was moderate in cisplatin-, rotenone- and A23187-treated cells but was not observed in serum deprivation-, anisomycin-, camptothecin-, cycloheximide- or staurosporine-treated cells in which all treatments induced extensive DNA fragmentation. Manganese-induced up-regulation of caspase-3 mRNA was partially attenuated by the pretreatment with the MEK inhibitor U0126, but not with the c-Jun N-terminal kinase (INK) inhibitor SP600125. In contrast, the increase in caspase-3 protein was suppressed by both U0126 and SP600125. These results suggest that p44/42 MAPK contributes to the up-regulation of caspase-3 mRNA and the JNK pathway regulates caspase-3 protein levels posttranslationally in manganese-induced apoptosis in PC12 cells. (c) 2006 Elsevier B.V. All rights reserved.	Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan	Hirata, Y (corresponding author), Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan.	yoko@biomol.gifu-u.ac.jp	Hirata, Yoko/AAG-6798-2020; Hirata, Yoko/L-3142-2019	Hirata, Yoko/0000-0002-7081-4937	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16500240] Funding Source: KAKEN		BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BROUILLET EP, 1993, EXP NEUROL, V120, P89, DOI 10.1006/exnr.1993.1042; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chen J, 1998, J NEUROSCI, V18, P4914; COOK DG, 1974, ARCH NEUROL-CHICAGO, V30, P59, DOI 10.1001/archneur.1974.00490310061010; Cotter T G, 1992, Semin Immunol, V4, P399; COTZIAS GC, 1971, ANNU REV MED, V22, P305, DOI 10.1146/annurev.me.22.020171.001513; Desole MS, 1996, NEUROSCI LETT, V209, P193, DOI 10.1016/0304-3940(96)12645-8; Dodel RC, 1998, NEUROSCIENCE, V86, P701, DOI 10.1016/S0306-4522(98)00154-7; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; HART J, 1994, MICROCONTAMINATION, V12, P63; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hirata Y, 2004, BRAIN RES, V1021, P241, DOI 10.1016/j.brainres.2004.06.064; Hirata Y, 2002, NEUROTOXICOL TERATOL, V24, P639, DOI 10.1016/S0892-0362(02)00215-5; Hirata Y, 1998, J NEUROCHEM, V71, P1607; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; NEFF NH, 1969, EXPERIENTIA, V25, P1140, DOI 10.1007/BF01900234; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; PROHASKA JR, 1987, PHYSIOL REV, V67, P858; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Scheid MP, 1999, BLOOD, V93, P217, DOI 10.1182/blood.V93.1.217.401k16_217_225; Spooren WPJM, 1998, NEUROSCIENCE, V85, P649; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tatton NA, 1997, NEUROSCIENCE, V77, P1037, DOI 10.1016/S0306-4522(96)00545-3; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	31	26	27	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 12	2006	1099						1	7		10.1016/j.brainres.2006.03.126			7	Neurosciences	Neurosciences & Neurology	073HI	WOS:000239733200001	16787641				2021-06-18	
J	Zhang, XP; Chen, YM; Ikonomovic, MD; Nathaniel, PD; Kochanek, PM; Marion, DW; DeKosky, ST; Jenkins, LW; Clark, RSB				Zhang, Xiaopeng; Chen, Yaming; Ikonomovic, Milos D.; Nathaniel, Paula D.; Kochanek, Patrick M.; Marion, Donald W.; DeKosky, Steven T.; Jenkins, Larry W.; Clark, Robert S. B.			Increased phosphorylation of protein kinase B and related substrates after traumatic brain injury in humans and rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Akt; apoptosis; Bad; cyclic AMP responsive element binding protein; FKHR; head injury	CONTROLLED CORTICAL IMPACT; ELEMENT-BINDING PROTEIN; GROWTH FACTOR-1-INDUCED PHOSPHORYLATION; TRANSCRIPTION FACTOR FKHRL1; AKT PHOSPHORYLATION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CELL-DEATH; MOLECULAR-CLONING; IN-VIVO	Activation of protein kinase B (PKB, also known as Akt) by phosphorylation at serine-473 and threonine-308 promotes cell survival in multiple in vitro and in vivo models where neuronal death is seen, including traumatic brain injury (TBI); however, whether PKB is activated in humans after TBI was heretofore unknown. Activated PKB inhibits apoptogenic factors and is involved in the regulation of several transcription factors. Accordingly, we examined phosphorylation of the PKB signaling pathway in humans as well as rats after TBI using phosphospecific antibodies. Increased phosphorylation of PKB and PKB substrates was detected in injured brain from both humans and rats. In humans, increased phosphorylation of the PKB signaling pathway-related proteins Bad and forkhead transcription factor (FKHR) was detected in patients with TBI versus controls. In rats, increased phosphorylation of FKHR, inhibitor of kB alpha, and cyclic adenosine monophosphate responsive element binding protein (CREB) was detected after TBI versus controls. The deoxyribonucleic acid-binding activity of CREB was also enhanced after TBI in rats. Increased phosphorylation of PKB and PKB substrates was identified in neurons and other cell types by immunohistochemistry in both humans and rats. These data show increased phosphorylation of PKB, PKB substrates, and related proteins after both experimental and clinical TBI, suggesting either activation of the PKB signaling pathway or reduced phosphatase activity in both species.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Armstead WM, 2003, BRAIN RES, V971, P153, DOI 10.1016/S0006-8993(03)02287-X; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911; Cancedda L, 2003, J NEUROSCI, V23, P7012, DOI 10.1523/JNEUROSCI.23-18-07012.2003; Cardona E, 1998, NEUROCIRUGIA, V9, P21; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Henshall DC, 2002, J NEUROSCI, V22, P8458; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jin G, 2003, NEUROL RES, V25, P249, DOI 10.1179/016164103101201454; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kasahara J, 2001, J BIOL CHEM, V276, P24044, DOI 10.1074/jbc.M100247200; Lenhard T, 2002, MOL CELL NEUROSCI, V20, P181, DOI 10.1006/mcne.2002.1134; Linseman DA, 2002, J NEUROSCI, V22, P9287; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Omori N, 2002, BRAIN RES, V954, P317, DOI 10.1016/S0006-8993(02)03366-8; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; Perazzona B, 2004, J NEUROSCI, V24, P8823, DOI 10.1523/JNEUROSCI.4542-03.2004; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; RINK A, 1995, AM J PATHOL, V147, P1575; Shibata M, 2002, BRAIN RES, V942, P1, DOI 10.1016/S0006-8993(02)02474-5; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	58	26	26	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2006	26	7					915	926		10.1038/sj.jcbfm.9600238			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	057IO	WOS:000238589700007	16234845	Bronze			2021-06-18	
J	McDermott, S; Moran, R; Platt, T; Dasari, S				McDermott, Suzanne; Moran, Robert; Platt, Tan; Dasari, Srikanth			Variation in health conditions among groups of adults with disabilities in primary care	JOURNAL OF COMMUNITY HEALTH			English	Article						sensory; developmental; traumatic; psychiatric disability	TRAUMATIC BRAIN-INJURY; INTELLECTUAL DISABILITY; SECONDARY CONDITIONS; MENTAL-RETARDATION; PREVALENCE; MODERATE; OUTCOMES; EPILEPSY; PEOPLE	The literature on the health of adults with disabilities focuses on one disability compared to a comparison group. This study allows cross disability comparisons with the hypothesis. Adults with disabilities had higher odds of having common health conditions, compared to adults without disability in the same practice. A retrospective record review of 1449 patients with disability and 2084 patients without disability included individuals with sensory impairments (n=117), developmental disabilities (n=692), trauma-related impairments (n=155) and psychiatric impairments (n=485). The only two health conditions with statistically significantly increased odds for all groups with disabilities were dementia and epilepsy. Patients with developmental disabilities were less likely to have coronary artery disease, cancer, and obesity. Those with sensory impairments had increased odds for congestive heart failure, diabetes, transient ischemic attacks and death. Patients with trauma disabilities had increased odds for chronic obstructive pulmonary disease, and depression. Finally, psychiatric patients had increased odds for most of the investigated condition. In conclusion, there were many similarities in the risk for common health conditions such as asthma, cancer, coronary artery disease, depression, hypertension, and obesity, among patients with and without disability. Some of the conditions with increased odds ratios, including depression, seizures, and dementia are secondary to the primary disability.	Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA	McDermott, S (corresponding author), Family Practice Ctr, 3209 Colonial Dr, Columbia, SC 29208 USA.	suzanne.mcdermott@palmettohealth.org			ODCDC CDC HHS [R01/CCR418776] Funding Source: Medline		Albrecht GL, 2001, HDB DISABILITY STUDI, P585; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Bowley C, 2000, J INTELL DISABIL RES, V44, P529, DOI 10.1046/j.1365-2788.2000.00270.x; Charlifue SW, 1999, ARCH PHYS MED REHAB, V80, P1429, DOI 10.1016/S0003-9993(99)90254-X; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; DAY K, 1994, J INTELL DISABIL RES, V38, P241, DOI 10.1111/j.1365-2788.1994.tb00392.x; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eastgate Gillian, 2003, Aust Fam Physician, V32, P330; Fedeyko HJ, 2003, RES SOC SCI DISABIL, V3, P55, DOI 10.1016/S1479-3547(03)03004-5; Goldzweig CL, 2004, JAMA-J AM MED ASSOC, V291, P1497, DOI 10.1001/jama.291.12.1497; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Jansen DEMC, 2004, J INTELL DISABIL RES, V48, P93, DOI 10.1111/j.1365-2788.2004.00483.x; Kapell D, 1998, MENT RETARD, V36, P269, DOI 10.1352/0047-6765(1998)036<0269:POCMCI>2.0.CO;2; KAYE HS, 1996, TRENDS DISABILITY RA; Kinne S, 2004, AM J PUBLIC HEALTH, V94, P443, DOI 10.2105/AJPH.94.3.443; Kroll Thilo, 2003, Manag Care Q, V11, P11; LARSON CP, 1986, J MENT DEFIC RES, V30, P121; Lollar DJ, 2002, PUBLIC HEALTH REP, V117, P131, DOI 10.1093/phr/117.2.131; McDermott S, 2005, AM J MENT RETARD, V110, P48, DOI 10.1352/0895-8017(2005)110<48:POEIAW>2.0.CO;2; McDermott S, 1997, Fam Med, V29, P429; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; MORGAN C, 2003, AM J MENT DEFIC, V108, P239; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; Phillips A, 2004, J INTELL DISABIL RES, V48, P142, DOI 10.1111/j.1365-2788.2004.00503.x; RUBIN IL, 1987, MENT RETARD, V25, P201; The SAS Institute, 1999, SAS STAT US GUID VER; *WHO, 2000, INT STAT CLASS DIS; World Health Organization, 2001, INT CLASS FUNCT DIS; ZIRING PR, 1988, JAMA-J AM MED ASSOC, V260, P1439, DOI 10.1001/jama.260.10.1439	30	26	26	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0094-5145	1573-3610		J COMMUN HEALTH	J. Community Health	JUN	2006	31	3					147	159		10.1007/s10900-005-9008-y			13	Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	044KO	WOS:000237671400001	16830504				2021-06-18	
J	Barbre, AB; Hoane, MR				Barbre, Adrianne B.; Hoane, Michael R.			Magnesium and riboflavin combination therapy following cortical contusion injury in the rat	BRAIN RESEARCH BULLETIN			English	Article						behavior; B-2; MgCl2; treatment; neuroprotection; sensorimotor; TBI	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; MILD HYPOTHERMIA; DRUG THERAPY; FACILITATE RECOVERY; SENSORIMOTOR CORTEX; OXIDATIVE INJURY; NMDA ANTAGONISTS; PROTECT TISSUES; REDUCES EDEMA	Previous research has shown that magnesium chloride (MgCl2) and riboflavin (B-2) both significantly improve functional recovery when administered shortly after frontal cortical contusion injury (M). The purpose of the present study was to examine the ability of combination treatments of MgCl2 and B-2 to improve functional outcome following unilateral CCI. One hour post-injury, rats were administered MgCl2 (1.0 mmol/kg), B-2 (7.5 mg/kg), MgCl2 + B-2 (1 mmol/kg + 7.5 mg/kg), 1/2 MgCl2 + 1/2 B-2 (0.5 mmol/kg and 3.75 mg/kg), or saline. Two days following CCI rats were tested on a battery of sensorimotor (vibrissae -> forelimb placing and tactile removal test) and motor (staircase test). A regimen of MgCl2 + B-2 significantly reduced the initial impairment and facilitated the rate of recovery on the tactile removal test and facilitated the rate of recovery on the forelimb placing test. The half-dose combination did not significantly improve functional recovery on the tactile removal test compared to the individual treatments: however, it did improve performance on the forelimb placing test compared to saline treatment. Administration of MgCl2 improved performance on the placing and tactile removal tests on 2 post-operative days, as did treatment with B-2 on the tactile removal test. The results indicate that the full combination of MgCl2 + B-2 significantly improved functional recovery to a greater extent than the individual treatments or the low dose combination group on forelimb placing but not on tactile removal. These findings suggest that administration of M-Cl-2 + B-2 may provide better therapeutic action than individual treatments. (c) 2006 Elsevier Inc. All rights reserved.	So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2 MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 045647] Funding Source: Medline		Aikawa J., 1981, MAGNESIUM ITS BIOL S; Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; Bara M, 1984, MAGNESIUM, V3, P212; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BARTH TM, 1990, STROKE, V21, P153; BETZ AL, 1994, ACTA NEUROCHIR, P314; CHRISTENSEN HN, 1993, NUTR REV, V51, P149; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; CROMBLEHOLME W, 1998, CURRENT MED TREATMEN, P731; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; GARFINKEL L, 1985, Magnesium, V4, P60; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HALL ED, 1993, MOL CELLULAR APPROAC; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; HOANE MR, 2005, RESTOR NEUROL NEUROS, P1; HULTQUIST DE, 1993, AM J HEMATOL, V42, P13, DOI 10.1002/ajh.2830420105; Koroshetz WJ, 1996, TRENDS PHARMACOL SCI, V17, P227, DOI 10.1016/0165-6147(96)10020-1; Ksendzova GA, 2004, FREE RADICAL RES, V38, P1183, DOI 10.1080/10715760400016162; Lin YP, 2004, NEUROREPORT, V15, P2241, DOI 10.1097/00001756-200410050-00020; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; MCDONALD JW, 1990, NEUROSCIENCE, V36, P589, DOI 10.1016/0306-4522(90)90002-L; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Napolitano A, 2000, NEUROL SCI, V21, pS981, DOI 10.1007/s100720070015; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147; Rivlin R. S., 1996, PRESENT KNOWLEDGE NU, P167; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; Schmid-Elsaesser R, 1999, NEUROSURGERY, V44, P163, DOI 10.1097/00006123-199901000-00100; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Schmid-Elsaesser R, 1998, EXP BRAIN RES, V122, P121, DOI 10.1007/s002210050498; Schoenen J, 1998, NEUROLOGY, V50, P466, DOI 10.1212/WNL.50.2.466; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van den Heuvel Corinna, 2004, Clin Calcium, V14, P9; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Zausinger S, 2003, STROKE, V34, P1526, DOI 10.1161/01.STR.0000070841.31224.29	54	26	26	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230	1873-2747		BRAIN RES BULL	Brain Res. Bull.	MAY 31	2006	69	6					639	646		10.1016/j.brainresbull.2006.03.009			8	Neurosciences	Neurosciences & Neurology	051SF	WOS:000238180400007	16716831				2021-06-18	
J	Kotil, K; Kuscuoglu, U; Kirali, M; Uzun, H; Akcetin, M; Bilge, T				Kotil, K; Kuscuoglu, U; Kirali, M; Uzun, H; Akcetin, M; Bilge, T			Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; agmatine; neuroprotection; rat	NITRIC-OXIDE SYNTHASE; CLONIDINE-DISPLACING SUBSTANCE; BRAIN-INJURY; RAT-BRAIN; LIPID-PEROXIDATION; TRAUMATIC INJURY; ARGININE; NEURONS; PATHOPHYSIOLOGY; GLUTAMATE	Object. No definitive treatment for spinal cord injuries (SCIs) exists, and more research is required. The use of agmatine [4-(aminobutyl)-guanidine-NH2-CH2-CH2-CH2-CH2-NH-C(-NH2)(=NH)], a guanidinium Compound formed by decarboxylation Of L-arginine by arginine decarboxylase, is a neurotransmitter-neuromodulator with both N-methyl-D-aspartate receptor (NMDAR)-antagonizing and nitric oxide synthase (NOS)-inhibiting activities. The purpose of this study was to demonstrate the dose-dependent activity of agmatine, an inducible NOS (iNOS) inhibitor and selective NMDAR antagonist, on biochemical and functional recovery in an experimental rat SCI model. Methods. This Study involved 40 Wistar albino male rats. The rats were subjected to sleep-awake cycles for 7 days before surgery. In each group, general anesthesia was induced by a 60-mg/kg ketamine injection. For the surgical SCI model, a Yasargil aneurysm clip was placed in the spinal cord. The study was conducted in the following four main groups: Group I (control group) laminectomy only Group II, trauma-only group and SCI; Group III, laminectomy, SCI and agmatine 50 mg/kg for 10 days; and Group IV, laminectomy, SCI, and agmatine 100 mg/kg, for 10 clays. On Day 1, no statistical difference was observed in any group (p < 0.005, analysis of variance [ANOVA] and the Fisher protected least significant difference [PLSD]). On Day 2, no statistical difference was noted among Groups II, III, and IV (p = 0.27, p = 0.42, and p = 0.76, respectively; ANOVA and Fisher PLSD). Beginning on Day 3, recovery in Groups III and IV differed significantly from that in Group 11 (p < 0.005, ANOVA and Fisher PLSD), and a statistically significant difference between Groups III and IV was observed, which also was present on Days 5, 7, and 10 (p = 0.003 p = 0.0024, and p = 0.0036, respectively; ANOVA and Fisher PLSD). Several observations were noteworthy: motor function scores were reduced significantly in the spinal cord-injured rats compared with the controls (p < 0.005); on Day 1, the agreement of motor function scores in rats in each SCI group indicated that the traumatic event had been replicated equally across all groups (p = 0.59, p = 0.59, and p = 0.28); a statistically significant difference in motor function scores developed on Day 3 between the rats subjected to trauma alone (Group II) and those treated with agmatine (Groups III and TV) (p < 0.005) and no statistically significant intergroup difference in motor function existed at any postinjury interval between the 50- and 100-mg/kg/day agmatine-treated rats (p > 0.005). Conclusions. Agmatine administration following SCI was shown to reduce NO levels significantly. No statistically significant intergroup difference in the reduction of NO levels was found between rats treated with 50- and 100-mg/kg/day doses of agmatine. Administration of a 100-mg/kg/day dose of agmatine reduced the NO levels to those measured in controls. The authors conclude that with additional studies into the role of agmatine, this drug may be helpful in the treatment of patients with SCIs.	Haseki Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey; Univ Istanbul, Dept Biochem, Istanbul, Turkey	Kotil, K (corresponding author), Hasan Ali Yucel Sok Senile, Apt 34-14 Ciftehavuzlar, TR-34728 Istanbul, Turkey.	kadirkotil@superonline.com	Uzun, Hafize/D-4811-2019	Uzun, Hafize/0000-0002-1347-8498			Abe K, 2000, BRAIN RES, V872, P141, DOI 10.1016/S0006-8993(00)02517-8; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON DK, 1992, J NEUROTRAUM, V9, P143, DOI 10.1089/neu.1992.9.143; Ascenzi P, 2002, EUR J BIOCHEM, V269, P884, DOI 10.1046/j.0014-2956.2002.02718.x; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Blantz RC, 2000, ACTA PHYSIOL SCAND, V168, P21; Bradley KJ, 1997, EUR J PHARMACOL, V331, P133, DOI 10.1016/S0014-2999(97)01043-1; Buege J A, 1978, Methods Enzymol, V52, P302; Chabrier PE, 1999, CELL MOL LIFE SCI, V55, P1029, DOI 10.1007/s000180050353; COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34; Diaz-Ruiz A, 2002, NEUROSCI LETT, V319, P129, DOI 10.1016/S0304-3940(01)02540-X; Dumont AS, 2002, CURR OPIN NEUROL, V15, P713, DOI 10.1097/00019052-200212000-00009; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P265, DOI 10.1097/00002826-200109000-00003; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; Fairbanks CA, 2000, P NATL ACAD SCI USA, V97, P10584, DOI 10.1073/pnas.97.19.10584; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; FEHLINGS MG, 2001, SPINE, V26, P52; Feng YZ, 2002, PEDIATR RES, V52, P606, DOI 10.1203/01.PDR.0000028057.79132.1F; Festoff BW, 2004, J NEUROTRAUM, V21, P907, DOI 10.1089/0897715041526168; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; GILAD GM, 1995, LIFE SCI, V58, pPL41, DOI 10.1016/0024-3205(95)02274-0; Gilad GM, 2000, NEUROSCI LETT, V296, P97, DOI 10.1016/S0304-3940(00)01625-6; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grillo MA, 2004, AMINO ACIDS, V26, P3, DOI 10.1007/s00726-003-0030-z; GUTIERREZ PA, 1993, UROL CLIN N AM, V20, P373; Horvath G, 1999, EUR J PHARMACOL, V368, P197, DOI 10.1016/S0014-2999(99)00060-6; IADECOLA C, 1992, AM J PHYSIOL, V263, pR1156; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; KALRA SP, 1995, NEUROSCI LETT, V194, P165, DOI 10.1016/0304-3940(95)11750-Q; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632-200207150-00005; Legos JJ, 2002, EXPERT OPIN INV DRUG, V11, P469; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LIAU LM, 1996, NEUROLOGICAL SURG, P1549; Lortie MJ, 1996, J CLIN INVEST, V97, P413, DOI 10.1172/JCI118430; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Morrissey JJ, 1997, P ASSOC AM PHYSICIAN, V109, P51; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Otake K, 1998, BRAIN RES, V787, P1, DOI 10.1016/S0006-8993(97)01200-6; PILETZ JE, 1995, J PHARMACOL EXP THER, V272, P581; Pineda J, 1996, NEUROSCI LETT, V219, P103, DOI 10.1016/S0304-3940(96)13180-3; Raasch W, 1995, Ann N Y Acad Sci, V763, P330, DOI 10.1111/j.1749-6632.1995.tb32419.x; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Ruiz-Durantez E, 2002, BRIT J PHARMACOL, V135, P1152, DOI 10.1038/sj.bjp.0704556; SAKAMOTO A, 1991, BRAIN RES, V554, P186, DOI 10.1016/0006-8993(91)90187-Z; Sastre M, 1997, J NEUROCHEM, V69, P2421; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; TARLOV IM, 1957, SPINAL CORD COMPRESS; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yu CG, 2000, NEUROREPORT, V11, P3203, DOI 10.1097/00001756-200009280-00031; Zhu MY, 2003, CELL MOL NEUROBIOL, V23, P865, DOI 10.1023/A:1025069407173	60	26	28	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	1547-5654			J NEUROSURG-SPINE	J. Neurosurg.-Spine	MAY	2006	4	5					392	399		10.3171/spi.2006.4.5.392			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	041CG	WOS:000237430100007	16703907				2021-06-18	
J	Salehi-Had, H; Brandt, JD; Rosas, AJ; Rogers, KK				Salehi-Had, H; Brandt, JD; Rosas, AJ; Rogers, KK			Findings in older children with abusive head injury: Does shaken-child syndrome exist?	PEDIATRICS			English	Article						shaken-baby syndrome; child abuse; retinal hemorrhages	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; RETINAL HEMORRHAGE; OPHTHALMOLOGIC FINDINGS; SUBDURAL HEMATOMAS; ADULT SYNDROME; BABY SYNDROME; INFANTS	Shaken-baby syndrome (SBS) has been hypothesized to occur after shaking by an adult during the first 2 years of life. We wondered whether it is possible to achieve rotational forces sufficient to cause SBS-like injuries in children > 2 years of age. The present study describes cases of child abuse in older children who presented with the classic ophthalmologic and intracranial findings of SBS. In this case series, 4 cases of older children (2.5-7 years old; 11.8-22 kg) who died from abusive head injuries and who had diffuse retinal hemorrhages identified antemortem were selected for review. The cases were abstracted from hospital charts, records from autopsies, coroners' and district attorneys' offices, and court transcripts. In all 4 cases the history provided by the primary caregiver did not match the severity of the injuries. Three case subjects presented with patterned bruises. Multilayered retinal hemorrhages and acute subdural hematoma were observed in all 4 cases. At autopsy, diffuse axonal injury was evident in 3 of the 4 cases; all 4 cases had optic nerve sheath hemorrhages. None of the victims had skeletal fractures on radiologic examination or at autopsy. This case series demonstrates that it is possible to observe SBS-like retinal and central nervous system findings in the older and heavier child. Our findings underscore the need for providers to consider intentional shaking as a mechanism of injury in the evaluation of abusive head injury in older children.	Univ Calif Davis, Med Ctr, Dept Ophthalmol, Sacramento, CA 95817 USA; Univ Calif Davis, Childrens Hosp, Dept Pediat, Child & Adolescent Resource & Evaluat Diagnost &, Sacramento, CA 95817 USA	Rogers, KK (corresponding author), Univ Calif Davis, Dept Pediat, CAARE Diagnost & Treatment Ctr, 3300 Stockton Blvd, Sacramento, CA 95820 USA.	kristen.rogers@ucdmc.ucdavis.edu	Brandt, James D/H-8249-2016	Brandt, James D/0000-0003-4509-615X			Alexander RC, 2001, CHILD ABUSE MED DIAG, P47; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CAFFEY J, 1974, PEDIATRICS, V54, P396; Carrigan TD, 2000, J ACCID EMERG MED, V17, P138; Case ME, 2001, AM J FOREN MED PATH, V22, P112, DOI 10.1097/00000433-200106000-00002; *CDCP, 2005, WISQARS; Christian CW, 1999, J PEDIATR-US, V135, P125, DOI 10.1016/S0022-3476(99)70343-4; CONRADI S, 1986, FORENSIC SCI INT, V30, P195, DOI 10.1016/0379-0738(86)90014-9; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DIMAUIO V, 2001, FORENSIC PATHOLOGY, V27, P592; DUHAIME AC, 1992, PEDIATRICS, V90, P179; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HOSOKAWA T, 1986, OPHTHALMOLOGICA, V192, P17, DOI 10.1159/000309606; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kivlin J D, 1999, Trans Am Ophthalmol Soc, V97, P545; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LEVIN, 1998, AM ACAD OPHTHALMOL, V16, P1; Levin AV, 2002, NEUROSURG CLIN N AM, V13, P201, DOI 10.1016/S1042-3680(02)00004-9; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; Mierisch RF, 2004, PEDIATR EMERG CARE, V20, P118, DOI 10.1097/01.pec.0000113883.10140.c2; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; Pounder DJ, 1997, AM J FOREN MED PATH, V18, P321, DOI 10.1097/00000433-199712000-00001; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; *US DEP HHS, 2004, CHILD MALTR 2002	28	26	26	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2006	117	5					E1039	E1044		10.1542/peds.2005-0811			6	Pediatrics	Pediatrics	038GO	WOS:000237207300025	16651283				2021-06-18	
J	Belli, A; Sen, J; Petzold, A; Russo, S; Kitchen, N; Smith, M; Tavazzi, B; Vagnozzi, R; Signoretti, S; Amorini, AM; Bellia, F; Lazzarino, G				Belli, A; Sen, J; Petzold, A; Russo, S; Kitchen, N; Smith, M; Tavazzi, B; Vagnozzi, R; Signoretti, S; Amorini, AM; Bellia, F; Lazzarino, G			Extracellular N-acetylaspartate depletion in traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						microdialysis; mitochondria; N-acetylaspartate; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; PROTON MR SPECTROSCOPY; L-ASPARTIC ACID; TEMPORAL-LOBE EPILEPSY; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; ACETYL-L-ASPARTATE; MITOCHONDRIAL DYSFUNCTION; RAT-BRAIN; AXONAL INJURY	N-Acetylaspartate (NAA) is almost exclusively localized in neurons in the adult brain and is present in high concentration in the CNS. It can be measured by proton magnetic resonance spectroscopy and is seen as a marker of neuronal damage and death. NMR spectroscopy and animal models have shown NAA depletion to occur in various types of chronic and acute brain injury. We investigated 19 patients with traumatic brain injury (TBI). Microdialysis was utilized to recover NAA, lactate, pyruvate, glycerol and glutamate, at 12-h intervals. These markers were correlated with survival and a 6-month Glasgow Outcome Score. Eleven patients died and eight survived. A linear mixed model analysis showed a significant effect of outcome and of the interaction between time of injury and outcome on NAA levels (p = 0.009 and p = 0.004, respectively). Overall, extracellular NAA was 34% lower in non-survivors. A significant non-recoverable fall was observed in this group from day 4 onwards, with a concomitant rise in lactate-pyruvate ratio and glycerol. These results suggest that mitochondrial dysfunction is a significant contributor to poor outcome following TBI and propose extracellular NAA as a potential marker for monitoring interventions aimed at preserving mitochondrial function.	UCL Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, London WC1N 3BG, England; Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, London WC1N 3BG, England; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, I-00168 Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; San Camillo Hosp, Div Neurosurg, Rome, Italy; Univ Catania, Dipartimento Sci Chim, Biochem Lab, I-95125 Catania, Italy	Belli, A (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurosurg, Queen Sq,Box 31, London WC1N 3BG, England.	a.belli@ion.ucl.ac.uk	Smith, Martin/B-2616-2009; Signoretti, stefano/AAL-5631-2020; Petzold, Axel/C-1090-2009; Belli, Antonio/I-3799-2015; TAVAZZI, BARBARA/AAB-9830-2019; Bellia, Francesco/H-2812-2013; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; Petzold, Axel/0000-0002-0344-9749; Belli, Antonio/0000-0002-3211-9933; TAVAZZI, BARBARA/0000-0001-8743-0895; Bellia, Francesco/0000-0002-9273-5949; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279			Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Alessandri B, 2000, NEUROL RES, V22, P705; Barkovich AJ, 1999, AM J NEURORADIOL, V20, P1399; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Bhakoo KK, 2001, J NEUROCHEM, V79, P211, DOI 10.1046/j.1471-4159.2001.00561.x; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; BRENNER RE, 1993, MAGNET RESON MED, V29, P737, DOI 10.1002/mrm.1910290605; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brooks WM, 1999, J RHEUMATOL, V26, P81; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CENDES F, 1994, ANN NEUROL, V35, P211, DOI 10.1002/ana.410350213; Cendes F, 1997, NEUROLOGY, V49, P1525, DOI 10.1212/WNL.49.6.1525; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GIDEON P, 1992, STROKE, V23, P1566, DOI 10.1161/01.STR.23.11.1566; Giroud M, 1996, NEUROL RES, V18, P241; GOLDSTEIN FB, 1969, J BIOL CHEM, V244, P4257; Gotoh M, 1997, J NEUROCHEM, V69, P655; Harms L, 1997, J NEUROL NEUROSUR PS, V62, P27, DOI 10.1136/jnnp.62.1.27; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HOLSHOUSER BA, 1997, RADIOLOGY, V202, P187; Hutchinson PJA, 2000, ZBL NEUROCHIR, V61, P88, DOI 10.1055/s-2000-8265; Kalra S, 1998, NEUROREPORT, V9, P1757, DOI 10.1097/00001756-199806010-00016; KNIZLEY H, 1967, J BIOL CHEM, V242, P4619; Koura SS, 1998, ACT NEUR S, V71, P244; Lu ZH, 2004, MOL BRAIN RES, V122, P71, DOI 10.1016/j.molbrainres.2003.12.002; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OBRENOVITCH TP, 1993, J NEUROSCI METH, V47, P139, DOI 10.1016/0165-0270(93)90030-U; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; PEDEN CJ, 1993, DEV MED CHILD NEUROL, V35, P502; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Sager TN, 1997, J NEUROCHEM, V68, P675; SARAGEA M, 1965, MED PHARMACOL EXP, V13, P74; SHIINO A, 1993, SURG NEUROL, V39, P143, DOI 10.1016/0090-3019(93)90093-G; SHONK TK, 1995, RADIOLOGY, V195, P65, DOI 10.1148/radiology.195.1.7892497; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; TAYLOR DL, 1994, J NEUROCHEM, V62, P2349; TAYLOR DL, 1995, J NEUROCHEM, V65, P275; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Uno Masaaki, 1996, Neurologia Medico-Chirurgica, V36, P560, DOI 10.2176/nmc.36.560; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1999, ACT NEUR S, V75, P17	71	26	27	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2006	96	3					861	869		10.1111/j.1471-4159.2005.03602.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	003GV	WOS:000234670700023	16371008				2021-06-18	
J	Juhasz-Vedres, G; Rozsa, E; Rakos, G; Dobszay, MB; Kis, Z; Wolfling, J; Toldi, J; Parducz, A; Farkas, T				Juhasz-Vedres, G; Rozsa, E; Rakos, G; Dobszay, MB; Kis, Z; Wolfling, J; Toldi, J; Parducz, A; Farkas, T			Dehydroepiandrosterone sulfate is neuroprotective when administered either before or after injury in a focal cortical cold lesion model	ENDOCRINOLOGY			English	Article							SPINE SYNAPSE DENSITY; HIPPOCAMPAL-NEURONS; BRAIN-DEVELOPMENT; BCL-2 EXPRESSION; IN-VIVO; KAPPA-B; ESTRADIOL; ESTROGEN; MEMORY; NEUROSTEROIDS	Dehydroepiandrosterone and its sulfate (DHEAS) are sex hormone precursors that exert marked neurotrophic and/or neuroprotective activity in the central nervous system. The present study evaluated the effects of DHEAS and 17 beta-estradiol (E2) in a focal cortical cold lesion model, in which DHEAS (50 mg/kg, sc) and E2 (35 mg/kg, sc) were administered either as pretreatment (two subsequent injections 1 d and 1 h before lesion induction) or posttreatment (immediately after lesion induction). The focal cortical cold lesion was induced in the primary motor cortex by means of a cooled copper cylinder placed directly onto the cortical surface. One hour later, the animals were killed, the brains cut into 0.4-mm-thick slices, and the sections stained with 1% triphenyltetrazolium chloride. The volume of the hemispheric lesion was calculated for each animal. The results demonstrated that the lesion area was significantly attenuated in both the DHEAS- and E2-pre- and posttreated groups and that in the presence of letrozole, a nonsteroidal aromatase inhibitor, no neuroprotection was observed, suggesting that the beneficial effect of DHEAS on the cold injury might depend on the conversion of DHEAS to E2 within the brain. It is concluded that even a single post-traumatic administration of DHEAS may be of substantial therapeutic benefit in the treatment of focal brain injury with vasogenic edema.	Univ Szeged, Dept Comparat Physiol, H-6726 Szeged, Hungary; Univ Szeged, Dept Organ Chem, H-6726 Szeged, Hungary; Biol Res Ctr, Inst Biophys, H-6701 Szeged, Hungary	Farkas, T (corresponding author), Univ Szeged, Dept Comparat Physiol, Kozep Fasor 52, H-6726 Szeged, Hungary.	tfarkas@bio.u-szeged.hu	Kis, Zsolt/A-4583-2009; Toldi, Jozsef/M-4858-2018; Farkas, Tamas/B-7193-2008; Wolfling, Janos/A-3922-2008	Kis, Zsolt/0000-0002-6896-5883; Toldi, Jozsef/0000-0001-7355-0503; Wolfling, Janos/0000-0002-3037-309X			Banks E, 2003, LANCET, V362, P419, DOI 10.1016/s0140-6736(03)14065-2; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; Cordey M, 2005, BRAIN RES, V1045, P217, DOI 10.1016/j.brainres.2005.03.032; Debonnel G, 1996, J ENDOCRINOL, V150, pS33; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Hajszan T, 2004, ENDOCRINOLOGY, V145, P1042, DOI 10.1210/en.2003-1252; HARRISON NL, 1984, BRAIN RES, V323, P287, DOI 10.1016/0006-8993(84)90299-3; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; Labrie F, 2003, ENDOCR REV, V24, P152, DOI 10.1210/er.2001-0031; Lapchak PA, 2000, STROKE, V31, P1953, DOI 10.1161/01.STR.31.8.1953; Lapchak PA, 2001, INT REV NEUROBIOL, V46, P379; Losem-Heinrichs E, 2004, J STEROID BIOCHEM, V89-90, P371, DOI 10.1016/j.jsbmb.2004.03.001; MacLusky NJ, 2004, ENDOCRINOLOGY, V145, P4154, DOI 10.1210/en.2004-0477; Majewska MD, 1995, ANN NY ACAD SCI, V774, P111, DOI 10.1111/j.1749-6632.1995.tb17375.x; Mao XR, 1998, NEUROREPORT, V9, P759, DOI 10.1097/00001756-199803090-00036; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Racchi M, 2001, BRAIN RES REV, V37, P287, DOI 10.1016/S0165-0173(01)00132-1; Rao ML, 2003, PSYCHONEUROENDOCRINO, V28, P83, DOI 10.1016/S0306-4530(02)00126-9; ROBERTS E, 1987, BRAIN RES, V406, P357, DOI 10.1016/0006-8993(87)90807-9; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Stutzmann GE, 2005, NEUROSCIENTIST, V11, P110, DOI 10.1177/1073858404270899; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yen SSC, 1995, ANN NY ACAD SCI, V774, P128, DOI 10.1111/j.1749-6632.1995.tb17377.x	35	26	29	0	1	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0013-7227	1945-7170		ENDOCRINOLOGY	Endocrinology	FEB	2006	147	2					683	686		10.1210/en.2005-0693			4	Endocrinology & Metabolism	Endocrinology & Metabolism	005NN	WOS:000234831200007	16293666	Bronze			2021-06-18	
J	Waschbisch, A; Fiebich, BL; Akundi, RS; Schmitz, ML; Hoozemans, JJM; Candelario-Jalil, E; Virtainen, N; Veerhuis, R; Slawik, H; Yrjanheikki, J; Hull, M				Waschbisch, A; Fiebich, BL; Akundi, RS; Schmitz, ML; Hoozemans, JJM; Candelario-Jalil, E; Virtainen, N; Veerhuis, R; Slawik, H; Yrjanheikki, J; Hull, M			Interleukin-1 beta-induced expression of the prostaglandin E-2-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's desease; cyclooxygenase; cytokines; gene expression; neuroimmunology; signal transduction	RECEPTOR SUBTYPE; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; RAT-BRAIN; ACTIVATION; LIPOPOLYSACCHARIDE; CYCLOOXYGENASE-2; LOCALIZATION; INHIBITION; CULTURES	Both interleukin-1 beta (IL-1 beta) and prostaglandins (PGs) are important mediators of physiological and pathophysiological processes in the brain. PGE(2) exerts its effects by binding to four different types of PGE(2) receptors named EP1-EP4. EP3 has found to be expressed in neurons, whereas expression of EP3 in glial cells has not been reported in the brain yet. Here we describe IL-1 beta-induced EP3 receptor expression in human astrocytoma cells, primary astrocytes of rat and human origin and in rat brain. Using western blot, we found a marked up-regulation of EP3 receptor synthesis in human and rat primary glial cells. Intracerebroventricular administration of IL-1 beta stimulated EP3 receptor synthesis in rat hippocampus. The analysis of involved signal transduction pathways by pathway-specific inhibitors revealed an essential role of protein kinase C and nuclear factor-kappa B in astrocytic IL-1 beta-induced EP3 synthesis. Our data suggest that PGE(2) signaling in the brain may be altered after IL-1 beta release due to up-regulation of EP3 receptors. This might play an important role in acute and chronic conditions such as cerebral ischemia, traumatic brain injury, HIV-encephalitis, Alzheimer's disease and prion diseases in which a marked up-regulation of IL-1 beta is followed by a prolonged increase of PGE(2) levels in the brain.	Univ Freiburg, Sch Med, Dept Psychiat, Freiburg, Germany; Univ Bern, Dept Biochem, Bern, Switzerland; Vrije Univ Amsterdam, Inst Neurosci, Dept Psychiat, VU Univ Med Ctr, Amsterdam, Netherlands; Cerebricon Ltd, Kuopio, Finland	Fiebich, BL (corresponding author), Univ Freiburg, Sch Med, Dept Psychiat, Hugstetter Str 55, Freiburg, Germany.	bernd.fiebich@klinikum.uni-freiburg.de	Hull, Michael/F-2618-2012; Candelario-Jalil, Eduardo/I-1139-2019; Schmitz, M. Lienhard/D-9328-2017; Akundi, Ravi Shankar/J-2673-2019; Candelario-Jalil, Eduardo/A-3528-2008	Candelario-Jalil, Eduardo/0000-0003-3631-1989; Schmitz, M. Lienhard/0000-0002-6984-7192; Akundi, Ravi Shankar/0000-0003-3782-5965; Hoozemans, Jeroen/0000-0002-2888-8967			AKAIKE A, 1994, BRAIN RES, V663, P237, DOI 10.1016/0006-8993(94)91268-8; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Blatteis CM, 2000, CLIN INFECT DIS, V31, pS168, DOI 10.1086/317522; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Candelario-Jalil E, 2004, BRAIN RES, V1007, P98, DOI 10.1016/j.brainres.2004.01.078; CANDELARIOJALIL E, 2005, IN PRESS J MOL NEURO; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeGroot CJA, 1997, J NEUROSCI RES, V49, P342, DOI 10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C; Ek M, 2000, J COMP NEUROL, V428, P5, DOI 10.1002/1096-9861(20001204)428:1<5::AID-CNE2>3.0.CO;2-M; Fiebich BL, 1999, NEUROPHARMACOLOGY, V38, P1325, DOI 10.1016/S0028-3908(99)00055-6; Fiebich BL, 1997, J NEUROCHEM, V68, P704; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; HAYAISHI O, 1991, FASEB J, V5, P2575; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; HORIGUCHI S, 1986, EUR J PHARMACOL, V122, P173, DOI 10.1016/0014-2999(86)90100-7; Hull M, 2002, CURR MED CHEM, V9, P83, DOI 10.2174/0929867023371292; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Iwasaki K, 2003, ORAL MICROBIOL IMMUN, V18, P150, DOI 10.1034/j.1399-302X.2003.00046.x; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Kitanaka J, 1996, BRAIN RES, V707, P282, DOI 10.1016/0006-8993(95)01256-7; Kotani M, 1997, GENOMICS, V40, P425, DOI 10.1006/geno.1996.4585; KOTANI M, 2000, J CLIN ENDOCR METAB, V5, P4315; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AS, 1981, PHARMACOL BIOCHEM BE, V15, P735, DOI 10.1016/0091-3057(81)90014-9; Lieb K, 2005, J NEUROCHEM, V93, P549, DOI 10.1111/j.1471-4159.2005.03079.x; Lieb K, 2003, J NEUROCHEM, V86, P69, DOI 10.1046/j.1471-4159.2003.01802.x; Lieb K, 1996, J NEUROCHEM, V67, P2039; Lieb K, 1996, J NEUROCHEM, V66, P1496; Lim GP, 2000, J NEUROSCI, V20, P5709; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsuoka Y, 2003, P NATL ACAD SCI USA, V100, P4132, DOI 10.1073/pnas.0633341100; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Minghetti L, 2000, J NEUROPATH EXP NEUR, V59, P866, DOI 10.1093/jnen/59.10.866; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; Nakamura K, 2000, J COMP NEUROL, V421, P543, DOI 10.1002/(SICI)1096-9861(20000612)421:4<543::AID-CNE6>3.0.CO;2-3; Nakamura K, 2001, NEUROSCIENCE, V103, P763, DOI 10.1016/S0306-4522(01)00027-6; Nakamura K, 1999, NEUROSCI LETT, V260, P117, DOI 10.1016/S0304-3940(98)00962-8; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650; Othman T, 2003, GLIA, V44, P166, DOI 10.1002/glia.10281; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Parker LC, 2002, BRIT J PHARMACOL, V136, P312, DOI 10.1038/sj.bjp.0704715; Pinteaux E, 2002, J NEUROCHEM, V83, P754, DOI 10.1046/j.1471-4159.2002.01184.x; Prasad KN, 1998, IN VITRO CELL DEV-AN, V34, P265, DOI 10.1007/s11626-998-0133-7; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schlotzer-Schrehardt U, 2002, INVEST OPHTH VIS SCI, V43, P1475; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Slawik H, 2004, NEUROCHEM INT, V45, P653, DOI 10.1016/j.neuint.2004.04.007; Tojima Y, 2000, NATURE, V404, P778; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ushikubi F, 1998, NATURE, V395, P281; Vela JM, 2002, MOL CELL NEUROSCI, V20, P489, DOI 10.1006/mcne.2002.1127; Wang KQ, 2003, J IMMUNOL, V171, P1035, DOI 10.4049/jimmunol.171.2.1035; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wing DA, 2003, J SOC GYNECOL INVEST, V10, P124, DOI 10.1016/S1071-5576(03)00007-8; Zhang J, 1999, EUR J NEUROSCI, V11, P2651, DOI 10.1046/j.1460-9568.1999.00682.x; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5	71	26	27	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2006	96	3					680	693		10.1111/j.1471-4159.2005.03599.x			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	003GV	WOS:000234670700007	16405508	Bronze			2021-06-18	
J	Natale, JE				Natale, JoAnne E.			Clinical trials in pediatric traumatic brain injury: Unique challenges and potential responses	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; translational research; patient recruitment	SEVERE HEAD-INJURY; RESEARCH INVOLVING CHILDREN; LACTATED RINGERS SOLUTION; PLACEBO-CONTROLLED TRIAL; HOSPITAL CARDIAC-ARREST; CONFLICTS-OF-INTEREST; INFORMED-CONSENT; THERAPEUTIC MISCONCEPTION; HYPERTONIC SALINE; INTRACRANIAL-PRESSURE	In order to optimize pediatric traumatic brain injury translational and clinical research, scientific and ethical challenges need to be recognized and addressed. Having recently conducted a multisite phase II safety/feasibility trial of magnesium sulfate as a neuroprotective agent, we supplement our own experience by a mini review of similar studies, identifying challenges and possible responses from the perspective of families, investigators, funding agencies and society. Copyright (c) 2006 S. Karger AG, Basel.	Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Off Dean, Sacramento, CA 95817 USA; Childrens Natl Med Ctr, Gen Clin Res Ctr, Washington, DC 20010 USA; Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada	Natale, JE (corresponding author), Univ Calif Davis, Med Ctr, Dept Pediat, Crit Care Sect, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	joanne.natale@ucdmc.ucdavis.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5-M01-RR-020359-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS43146] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS043146] Funding Source: NIH RePORTER		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Anderson BD, 2004, J CLIN ONCOL, V22, P4846, DOI 10.1200/JCO.2004.02.138; [Anonymous], 2000, J Neurotrauma, V17, P537; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; ARTRU F, 1976, EUR NEUROL, V14, P310, DOI 10.1159/000114753; Bartel DA, 2000, ARCH PEDIAT ADOL MED, V154, P1127, DOI 10.1001/archpedi.154.11.1127; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Boholm A., 1996, ETHNOS, V61, P64, DOI DOI 10.1080/00141844.1996.9981528; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Burns JP, 2003, CRIT CARE MED, V31, pS131, DOI 10.1097/01.CCM.0000054905.39382.58; Cabana MD, 2000, ARCH PEDIAT ADOL MED, V154, P685, DOI 10.1001/archpedi.154.7.685; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Conwit RA, 2005, ANN EMERG MED, V45, P388, DOI 10.1016/j.annemergmed.2004.08.006; Davis DP, 2005, J EMERG MED, V28, P89, DOI 10.1016/j.jemermed.2004.07.012; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Dresser R, 2002, SOC PHILOS POLICY, V19, P271, DOI 10.1017/S0265052502192119; Eagle KA, 2005, J AM COLL CARDIOL, V46, P1242, DOI 10.1016/j.jacc.2004.12.083; Edwards P, 2005, LANCET, V365, P1957; Ette EI, 2004, ANN PHARMACOTHER, V38, P1907, DOI 10.1345/aph.1E259; Ette EI, 2004, ANN PHARMACOTHER, V38, P1702, DOI 10.1345/aph.1D374; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Field MJ, 2004, ETHICAL CONDUCT CLIN; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fisher CB, 2004, J CLIN CHILD ADOLESC, V33, P832, DOI 10.1207/s15374424jccp3304_18; Flores G, 2000, PEDIATRICS, V105, P496, DOI 10.1542/peds.105.3.496; Fogas BS, 2001, J DEV BEHAV PEDIATR, V22, P211, DOI 10.1097/00004703-200108000-00001; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gill D, 2003, EUR J PEDIATR, V162, P455, DOI 10.1007/s00431-003-1192-0; Groeger JS, 2003, CRIT CARE MED, V31, pS137, DOI 10.1097/01.CCM.0000054904.87847.08; Guerguerian AM, 2005, J NEUROTRAUM, V22, P1247; HEINEN M, 2005, NATL TRENDS INJURY H, P12; Holland NT, 2005, TOXICOL APPL PHARM, V206, P261, DOI 10.1016/j.taap.2004.10.024; Isa Ruwaida, 2003, Neurosurg Focus, V15, pE1; Katz Russell, 2004, NeuroRx, V1, P307, DOI 10.1602/neurorx.1.3.307; KAUFFMAN RE, 1995, PEDIATRICS, V95, P286; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kipnis K, 2003, THEOR MED BIOETH, V24, P107, DOI 10.1023/A:1024646912928; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; KOHRMAN A, 1995, PEDIATRICS, V95, P314; LANGLOIS JA, 2000, TRAUMATIC BRAIN INJU, P7; Lidz CW, 2004, SOC SCI MED, V58, P1689, DOI 10.1016/S0277-9536(03)00338-1; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McIntosh N, 2000, Arch Dis Child, V82, P177; Micieli G, 2002, STROKE, V33, P1341, DOI 10.1161/01.STR.0000013663.27776.DB; Miller FG, 2003, NEW ENGL J MED, V348, P1383, DOI 10.1056/NEJMsb030228; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Morin K, 2002, JAMA-J AM MED ASSOC, V287, P78, DOI 10.1001/jama.287.1.78; Morris MC, 2004, PEDIATRICS, V114, P776, DOI 10.1542/peds.2004-0482; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Muszynski CA, 2005, J NEUROSURG, V102, P374, DOI 10.3171/ped.2005.102.4.0374; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor AM, 2003, BMJ-BRIT MED J, V327, P736, DOI 10.1136/bmj.327.7417.736; O'Lonergan Theresa, 2003, Prot Hum Subj, P10; Paling J, 2003, BRIT MED J, V327, P745, DOI 10.1136/bmj.327.7417.745; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PARKS MR, 2004, J TRANSL MED, V2, P28; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Piantadosi S, 2005, WILEY SER PROBAB ST, P1, DOI 10.1002/0471740136; Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Pretzlaff RK, 2005, HEALTH CARE ANAL, V13, P119, DOI 10.1007/s10728-005-4475-y; Puttagunta P Saradhi, 2002, Health Law Rev, V10, P30; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Schaeffer MH, 1996, AM J MED, V100, P261, DOI 10.1016/S0002-9343(97)89483-1; Schmidt TA, 2005, ACAD EMERG MED, V12, P1022, DOI 10.1197/j.aem.2005.06.012; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Simma B, 2001, ANESTH ANALG, V92, P641; Singhal Nalini, 2002, J Perinatol, V22, P57, DOI 10.1038/sj.jp.7210608; SLOVIC P, 1999, RISK DECIS POLICY, V3, P165; Sollitto S, 2003, KENNEDY INST ETHIC J, V13, P83, DOI 10.1353/ken.2003.0015; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; STOLBERG SG, 1999, NY TIMES       1118, P137; Stroup TS, 2006, SCHIZOPHRENIA BULL, V32, P147, DOI 10.1093/schbul/sbj026; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Wendler D, 2006, PLOS MED, V3, P201, DOI 10.1371/journal.pmed.0030019; Wendler D, 2005, JAMA-J AM MED ASSOC, V294, P826, DOI 10.1001/jama.294.7.826; Wilhelmsen L, 2002, STAT MED, V21, P2823, DOI 10.1002/sim.1286; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Youngblut JoAnne M, 2005, Pediatr Crit Care Med, V6, P550, DOI 10.1097/01.PCC.0000163283.27419.E9; Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723; Zerhouni EA, 2005, JAMA-J AM MED ASSOC, V294, P1352, DOI 10.1001/jama.294.11.1352	92	26	26	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					276	290		10.1159/000094154			15	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600005	16943651				2021-06-18	
J	Campbell, M; Parry, A				Campbell, M; Parry, A			Balance disorder and traumatic brain injury: Preliminary findings of a multi-factorial observational study	BRAIN INJURY			English	Article						TBI; brain injury; balance disorder; postural control; clinical assessment	REHABILITATION; AWARENESS; OUTCOMES	The pathophysiology of TBI suggests that balance disorder in this population may be associated with multi-system dysfunction, but this has not been widely explored in the literature. This study was undertaken to begin to describe the nature of balance disorder across the TBI population. A clinically-based observational design was employed and data gathered by a standardized process of structured observation. Twenty-seven subjects were recruited across a range of injury severities. The sample was skewed towards mild/moderate injury with a mean summated GCS score of 9.6. Deficits were observed across a wide range of domains at both individual and group level and the overall level of balance dysfunction was high. Summary results are reported here and a more detailed analysis of individual cases is underway. Additional cross-disciplinary research is required to further develop understanding of the nature of balance disorder in this population and to develop appropriate methods of clinical assessment.	Sheffield W Primary Care Trust, Sheffield S10 3TG, S Yorkshire, England; Sheffield Hallam Univ, Sheffield S1 1WB, S Yorkshire, England	Campbell, M (corresponding author), Sheffield W Primary Care Trust, Fulwood House,Old Fulwood Rd, Sheffield S10 3TG, S Yorkshire, England.	Maggie.campbell@sheffieldw-pct.nhs.uk					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BELL F, 1998, PRINCIPLES MECH BIOM, P26; Beynon GJ, 1998, CLIN OTOLARYNGOL, V23, P117; BRONSTEIN AM, 1995, J NEUROL NEUROSUR PS, V59, P472, DOI 10.1136/jnnp.59.5.472; Campbell M., 2000, REHABILITATION TRAUM, P17; CARR J, 1998, NEUROLOGICAL REHABIL, P47; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; Di Fabio RP, 1998, ACTA OTO-LARYNGOL, V118, P449, DOI 10.1080/00016489850154540; DIFABIO RP, 1990, PHYS THER, V70, P542, DOI 10.1093/ptj/70.9.542; FLEMING JM, 1996, INT PERSPECTIVES TRA, P438; FUKUDA T, 1959, Acta Otolaryngol, V50, P95, DOI 10.3109/00016485909129172; GENTLEMAN D, 1986, BRIT MED J, V292, P449, DOI 10.1136/bmj.292.6518.449; GillBody KM, 1997, PHYS THER, V77, P534, DOI 10.1093/ptj/77.5.534; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Hillier SL, 1997, BRAIN INJURY, V11, P661; HONRUBIA V, 1994, VESTIBULAR REHABILIT, P113; HORAK FB, 1990, EXP BRAIN RES, V82, P167; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; JENNETT B, 1975, LANCET, V1, P480; KARLBERG M, 1995, NECK HUMAN BALANCE C; MANN NR, 1996, MED REHABILITATION T, P479; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; Nashner LM, 1993, HDB BALANCE FUNCTION, P308; Newman AC, 2000, BRAIN INJURY, V14, P333; NEWTON RA, 1995, BRAIN INJURY, V9, P445, DOI 10.3109/02699059509008204; NOLTE J, 1999, HUMAN BRAIN, P325; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Roberts TDM, 1995, UNDERSTANDING BALANC; Schumway-Cook A, 2000, VESTIBULAR REHABILIT, P476; Shepard N.T., 1996, PRACTICAL MANAGEMENT, P33; Shepard NT, 1996, PRACTICAL MANAGEMENT; Shumway-Cook A, 2001, MOTOR CONTROL THEORY, P163; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; WING AM, 1993, REHABILITATION MOTOR, P87; Winter D.A., 1990, BIOMECHANICS MOTOR C, V2nd; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOOLLACOTT MH, 1990, PHYS THER, V70, P799, DOI 10.1093/ptj/70.12.799; YARDLEY L, 1994, VERTIGO DIZZINESS	41	26	27	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1095	1104		10.1080/02699050500188898			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000004	16286323				2021-06-18	
J	Carne, W; Cifu, DX; Marcinko, P; Baron, M; Pickett, T; Qutubuddin, A; Calabrese, V; Roberge, P; Holloway, K; Mutchler, B				Carne, William; Cifu, David X.; Marcinko, Paul; Baron, Mark; Pickett, Treven; Qutubuddin, Abu; Calabrese, Vincent; Roberge, Peggy; Holloway, Kathryn; Mutchler, Brian			Efficacy of multidisciplinary treatment program on long-term outcomes of individuals with Parkinson's disease	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						disease progression; intervention; levodopa; Movement disorder; multidisciplinary team; neurology; outcomes; Parkinson's disease; rehabilitation; Unified Parkinson's Disease Rating Scale	TRAUMATIC BRAIN-INJURY; CONTROLLED-TRIAL; RANDOMIZED-TRIAL; RATING-SCALE; REHABILITATION; PROGRESSION; LEVODOPA; MANAGEMENT; DISABILITY; PEOPLE	We examined the impact of multidisciplinary clinical management of the Parkinson's Disease Research, Education, and Clinical Center program on Parkinson's disease progression. Initial and follow-up scores on the Part III Motor Examination subscale of the Unified Parkinson's Disease Rating Scale (UPDRS) were examined. Overall, 37 (75.5%) of the 49 patients demonstrated stable or improved UPDRS motor scores at 1- to 3-year follow-up; in the 1-year group (n = 28), 22 patients (78.6%) improved, while 6 (21.4%) worsened. In the 2-year group (n = 15). 10 (66.7%) improved, while 5 (33.3%) worsened. In the 3-year group (n = 6), 5 (83.3%) improved, while 1 (16.7%) worsened. Multidisciplinary interventions included neurology (95.9% of patients), physiatry (93.9%). nursing (87.8%), psychology (42.9%), medication changes (59.2% increases, 18.4% decreases), rehabilitation therapies (physical, occupational, speech-language, 67.3%), functional diagnostic testing (18.4%), support group (16.3%), home exercise instruction (85.7%), and disease and wellness education (81.6%). Improved and worsened patients did not significantly differ on the individual program components. Clinical implications and study limitations are discussed.	PADRECC, Dept Rehabil Med, Hunter Holmes McGuire VAMC, Richmond, VA 23249 USA; VAMC, Hunter Holmes McGuire Dept, SE Parkinsons Dis Res Educ & Clin Ctr, Richmond, VA USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23284 USA	Carne, W (corresponding author), PADRECC, Dept Rehabil Med, Hunter Holmes McGuire VAMC, 1201 Broad Rock Blvd,Room 2C-144, Richmond, VA 23249 USA.	william.carne@med.va.gov		Cifu, David/0000-0003-1600-9387; Holloway, Kathryn/0000-0003-3777-0060			Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; Ahlskog JE, 2003, NEUROLOGY, V60, P381, DOI 10.1212/01.WNL.0000044047.58984.2F; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; Cameron IT, 2005, COMPUT-AIDED CHEM EN, V20a-20b, P3; Chan PLS, 2001, ANNU REV PHARMACOL, V41, P625, DOI 10.1146/annurev.pharmtox.41.1.625; Choudhury SR, 2001, J REHABIL RES DEV, V38, P293; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Fahn S, 1999, ARCH NEUROL-CHICAGO, V56, P529, DOI 10.1001/archneur.56.5.529; FAHN S, 1978, NEUROLOGY, V28, P5, DOI 10.1212/WNL.28.1.5; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fahn S, 1992, SCI BASIS TREATMENT, P89; Growdon JH, 1998, NEUROLOGY, V50, P1327, DOI 10.1212/WNL.50.5.1327; Holloway RG, 2005, ARCH NEUROL-CHICAGO, V62, P430; Holloway RG, 2004, ARCH NEUROL-CHICAGO, V61, P1044; Horn S, 2004, NEUROLOGY, V63, pS7, DOI 10.1212/WNL.63.7_suppl_2.S7; JANKOVIC J, 1990, NEUROLOGY, V40, P1529, DOI 10.1212/WNL.40.10.1529; Jankovic J, 2001, ARCH NEUROL-CHICAGO, V58, P1611, DOI 10.1001/archneur.58.10.1611; Kerr EA, 2004, ANN INTERN MED, V141, P272, DOI 10.7326/0003-4819-141-4-200408170-00007; Kieburtz K, 1996, ANN NEUROL, V40, P99; KORCZYN AD, 1998, STUDY GROUP MOV DISO, V13, P46; MacMahon DG, 1999, NEUROLOGY, V52, pS21; Miszko TA, 2003, J GERONTOL A-BIOL, V58, P171; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; Playfer JR, 2002, EUR J NEUROL, V9, P55, DOI 10.1046/j.1468-1331.9.s3.7.x; Poewe WH, 1996, NEUROLOGY, V47, pS146, DOI 10.1212/WNL.47.6_Suppl_3.146S; Reimer J, 2004, J NEUROL NEUROSUR PS, V75, P396, DOI 10.1136/jnnp.2003.022780; RICHARDS M, 1994, MOVEMENT DISORD, V9, P89, DOI 10.1002/mds.870090114; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561; Stocchi F, 2002, BRAIN, V125, P2058, DOI 10.1093/brain/awf214; Trend P, 2002, CLIN REHABIL, V16, P717, DOI 10.1191/0269215502cr545oa; VANHILTEN JJ, 1994, MOVEMENT DISORD, V9, P84, DOI 10.1002/mds.870090113; Wade DT, 2003, J NEUROL NEUROSUR PS, V74, P158, DOI 10.1136/jnnp.74.2.158; 2000, HOSP PHARM, V7, P143	37	26	26	0	17	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	NOV-DEC	2005	42	6					779	786		10.1682/JRRD.2005.03.0054			8	Rehabilitation	Rehabilitation	047MQ	WOS:000237883800008	16680615	Bronze			2021-06-18	
J	Johnson, EA; Svetlov, SI; Wang, KKW; Hayes, RL; Pineda, JA				Johnson, EA; Svetlov, SI; Wang, KKW; Hayes, RL; Pineda, JA			Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats	EXPERIMENTAL BRAIN RESEARCH			English	Article						astrocyte; neuron; caspase-3; survivin; traumatic brain injury; inhibitor of apoptosis protein	APOPTOSIS INHIBITORY PROTEIN; CASPASE-ACTIVATED DNASE; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE; EXPRESSION; DEATH; PROLIFERATION; ASTROCYTES; IDENTIFICATION	Survivin attenuates apoptosis by inhibiting cleavage of some cell proteins by activated caspase-3. We recently discovered strong up-regulation of survivin, primarily in astrocytes and a sub-set of neurons, after traumatic brain injury (TBI) in rats. In this study we characterized co-expression of survivin with activated caspase-3 and downstream DNA fragmentation (TUNEL) in astrocytes and neurons after TBI. Western blot analysis revealed significant time-dependent increases in active caspase-3 between 5 and 14 days post-injury. No difference was observed between the proportion of survivin-positive and survivin-negative cells labeled with active caspase-3 at 5 or 7 days post-injury, as indicated by dual fluorescent immunostaining. Labeling of survivin-negative cells with TUNEL was, however, significantly greater than for survivin-positive cells, suggesting that expression of survivin may attenuate DNA cleavage and progression of apoptosis. A higher proportion of astrocytes than neurons accumulated active caspase-3. In contrast, co-localization with TUNEL was significantly higher for neurons than for astrocytes. These data suggest that survivin expression may attenuate DNA cleavage and cell death, and that this mechanism operates in a cell type-specific manner after TBI.	Univ Florida, Dept Pediat, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, CTBIS, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Univ Florida, Dept Anat & Cell Biol, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, EF & WL McKnight Brain Inst, Gainesville, FL 32610 USA	Pineda, JA (corresponding author), Univ Florida, Dept Pediat, EF & WL McKnight Brain Inst, 100 S Newell Dr Bldg 59,L1-118, Gainesville, FL 32610 USA.	svetlov@mbi.ufl.edu; kwang@psychiatry.ufl.edu; hayes@ufbi.ufl.edu; pineda_J@kids.wustl.edu	Pineda, Jose/W-2806-2019	Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40182, R01 NS39091] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER		Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belluardo N, 2002, EUR J NEUROSCI, V15, P87, DOI 10.1046/j.0953-816x.2001.01847.x; Buki A, 2000, J NEUROSCI, V20, P2825; Chiou Shiun-Kwei, 2003, Med Sci Monit, V9, pPI25; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EBEL RL, 1951, PSYCHOMETRIKA, V16, P407; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Enari M, 1998, NATURE, V391, P43; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim S, 2004, J PEDIATR SURG, V39, P516, DOI 10.1016/j.jpedsurg.2003.12.008; Kitagawa H, 1999, NEUROSCI LETT, V274, P45, DOI 10.1016/S0304-3940(99)00676-X; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Lei B, 2004, NEUROSCIENCE, V125, P691, DOI 10.1016/j.neuroscience.2004.02.034; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Lu CD, 1998, CANCER RES, V58, P1808; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Nakase T, 2004, AM J PATHOL, V164, P2067, DOI 10.1016/S0002-9440(10)63765-0; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Noyan-Ashraf MH, 2005, GLIA, V49, P588, DOI 10.1002/glia.20140; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Van Haren K, 2004, J NEUROPATH EXP NEUR, V63, P618, DOI 10.1093/jnen/63.6.618; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Xia XG, 2002, MOL CELL NEUROSCI, V21, P379, DOI 10.1006/mcne.2002.1180; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997	54	26	30	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	NOV	2005	167	1					17	26		10.1007/s00221-005-2362-2			10	Neurosciences	Neurosciences & Neurology	980NA	WOS:000233024000002	16193270				2021-06-18	
J	Kinoshita, T; Moritani, T; Hiwatashi, A; Wang, HZ; Shrier, DA; Numaguchi, Y; Westesson, PLA				Kinoshita, T; Moritani, T; Hiwatashi, A; Wang, HZ; Shrier, DA; Numaguchi, Y; Westesson, PLA			Conspicuity of diffuse axonal injury lesions on. diffusion-weighted MR imaging	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						diffuse axonal injury; magnetic resonance imaging; diffusion	HEAD-INJURY; BRAIN; CHILDREN; TRAUMA	Objective: (1) To detect diffuse axonal injury (DAI) lesions by diffusion-weighted imaging (DWI), as compared with fluid-attenuated inversion recovery (FLAIR) imaging and (2) to evaluate hemorrhagic DAI lesions by b(o) images obtained from DWI, as compared with gradient-echo (GRE) imaging. Methods: We reviewed MR images of 36 patients with a diagnosis of DAI. MR imaging was performed 20 h to 14 days (mean, 3.7 days) after traumatic brain injury. We evaluated: (1) conspicuity of lesions on DWI and FLAIR and (2) conspicuity of hemorrhage in DAI lesions on bo images and GRE imaging. Results: DWI clearly depicted high-signal DAI lesions. The sensitivity of DWI to lesional conspicuity in DAI lesions was almost equal to that of FLAIR. The sensitivity of bo images to identification of hemorrhagic DAI lesions was inferior to that of GRE. Conclusion: DWI is as useful as FLAIR in detecting DAI lesions. GRE imaging is still the superior tool for the evaluation of hemorrhagic DAL (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Univ Rochester, Med Ctr, Dept Radiol, Div Neuroradiol, Rochester, NY 14642 USA	Kinoshita, T (corresponding author), Tottori Univ, Fac Med, Dept Pathophysiol & Therapeut Sci, Div Radiol, Tottori 6838504, Japan.	kino@grape.med.tottori-u.ac.jp					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hiwatashi A, 2003, AM J ROENTGENOL, V181, P1705, DOI 10.2214/ajr.181.6.1811705; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Lin DDM, 2001, AM J NEURORADIOL, V22, P1275; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maldjian JA, 2001, AM J NEURORADIOL, V22, P112; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; Povlishock JT, 2001, HEAD TRAUMA, P281; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	19	26	27	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	OCT	2005	56	1					5	11		10.1016/j.ejrad.2005.04.001			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	974HL	WOS:000232582000002	16168258				2021-06-18	
J	Howard, I; Joseph, JG; Natale, JE				Howard, I; Joseph, JG; Natale, JE			Pediatric traumatic brain injury: Do racial/ethnic disparities exist in brain injury severity, mortality, or medical disposition?	ETHNICITY & DISEASE			English	Article; Proceedings Paper	9th RCMI International Symposium on Health Disparities	DEC 08-11, 2004	Baltimore, MD	Res Ctr Minor Inst		children; racial/ethnic disparities; traumatic brain injury	HEALTH-CARE; EMERGENCY-DEPARTMENT; CULTURAL COMPETENCE; UNITED-STATES; QUALITY; RACE	Introduction: Little is known regarding pediatric racial/ethnic disparities. We sought to determine if racial/ethnic disparities exist in the severity, mortality, or medical disposition of pediatric traumatic brain injury (TBI). Methods: We analyzed data from a comprehensive trauma database assembled at a large independent children's hospital. Among all patients evaluated by the trauma service in the emergency department (ED), cases of TBI were identified (N= 1035). Analyses contrasted non-Hispanic White children with all others (minority children). The relationship of race to patient characteristics, brain injury severity, mortality, and medical disposition (hospital admission, intensive care unit admission) was analyzed by using bivariable approaches and multivariate logistic regression. The latter controlled for age, overall injury severity, and insurance status. Results: Although sociodemographic characteristics did not differ, the mechanism of injury was significantly different (P<.001); minority children were more likely to have been a pedestrian or cyclist struck by a vehicle. Minority children were less likely to require transfer to the ED for treatment and were more likely to be publicly insured (P<.001). No differences in brain injury severity, mortality, or medical disposition were observed with both bivariable and multivariable approaches. Conclusions: This study is one of the first to examine potential disparities in trauma and contributes to the small but growing literature in pediatric health disparities. Multiple explanations are explored, several with potential implications for reducing disparities in other health conditions. Identifying conditions in which evaluation and treatment appears to be free of disparities may provide insights for subsequent investigations and interventions.	Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; Childrens Natl Med Ctr, Ctr Res Neurosci, Washington, DC 20010 USA; George Washington Univ, Sch Med, Washington, DC 20052 USA; Childrens Natl Med Ctr, Ctr Hlth Serv & Clin Res, Washington, DC 20010 USA	Natale, JE (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave NW, Washington, DC 20010 USA.	jnatale@cnmcresearch.org					Aaron KF, 2003, JAMA-J AM MED ASSOC, V289, P1033, DOI 10.1001/jama.289.8.1033; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; *CDC NAT CTR INJ P, 2002, TRAUM BRAIN INJ INJ; Flores G, 2005, PEDIATRICS, V115, pE183, DOI 10.1542/peds.2004-1474; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnson RL, 2004, J GEN INTERN MED, V19, P101, DOI 10.1111/j.1525-1497.2004.30262.x; Kawachi I, 2005, HEALTH AFFAIR, V24, P343, DOI 10.1377/hlthaff.24.2.343; KRIEGER N, 1987, INT J HEALTH SERV, V17, P259, DOI 10.2190/DBY6-VDQ8-HME8-ME3R; LANGLIOS JA, 2004, TRAUMATIC BRAIN INJU; LaVeist TA, 2002, RACE ETHNICITY HLTH; Lyons RA, 2000, BRIT MED J, V320, P149, DOI 10.1136/bmj.320.7228.149; Sehgal AR, 2003, JAMA-J AM MED ASSOC, V289, P996, DOI 10.1001/jama.289.8.996; Shenassa ED, 2004, AM J PUBLIC HEALTH, V94, P633, DOI 10.2105/AJPH.94.4.633; SMEDLEY BD, 2003, UNEQUAL TREATMENT CO; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	20	26	26	0	7	INT SOC HYPERTENSION BLACKS-ISHIB	ATLANTA	100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA	1049-510X	1945-0826		ETHNIC DIS	Ethn. Dis.	FAL	2005	15	4		5			S51	S56					6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	988PW	WOS:000233614100011					2021-06-18	
J	Seignourel, PJ; Robins, DL; Larson, MJ; Demery, JA; Cole, M; Perlstein, WM				Seignourel, PJ; Robins, DL; Larson, MJ; Demery, JA; Cole, M; Perlstein, WM			Cognitive control in closed head injury: Context maintenance dysfunction or prepotent response inhibition deficit?	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		traumatic brain injury/TBI; cognitive control; Stroop; context maintenance	TRAUMATIC BRAIN-INJURY; COLOR-WORD TEST; WORKING-MEMORY LOAD; PREFRONTAL CORTEX; POSTTRAUMATIC AMNESIA; ATTENTION DEFICITS; TASK-PERFORMANCE; STROOP TASK; SCHIZOPHRENIA; INTERFERENCE	The authors contrasted 2 potential explanations for the cognitive control deficits observed in closed head injury (CHI): a prepotent response inhibition deficit or a deficit in context maintenance, defined as the guidance of appropriate responding by task-relevant information. Healthy and CHI participants performed the traditional card Stroop task and a single-trial Stroop task sensitive to context maintenance deficits. As predicted by a context maintenance deficit, moderate to severe CHI participants showed higher error rates in the single-trial Stroop task only, and only when task instructions had to be maintained over a long delay. Moreover, context maintenance impairment and generalized slowing were both related to reports of daily functioning in CHI participants. Thus, context maintenance could be a useful framework for characterizing cognitive control deficits in CHI.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA	Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@grove.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Burgess P. W., 1997, METHODOLOGY FRONTAL, P81, DOI DOI 10.1024//1016-264X.10.2.123; Chapman LJ, 2001, J ABNORM PSYCHOL, V110, P31, DOI 10.1037/0021-843X.110.1.31; CHAPMAN LJ, 1994, DEV REV, V14, P159, DOI 10.1006/drev.1994.1007; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; COHEN JD, 1993, SCHIZOPHRENIA BULL, V19, P85, DOI 10.1093/schbul/19.1.85; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; GOLDEN CJ, 1978, UNPUB STROOP COLOR W; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HOLZMAN PS, 1994, ARCH GEN PSYCHIAT, V51, P952; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; LARSON MJ, 2004, 32 ANN M INT NEUR SO; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, 2002, PRINCIPLES FRONTAL L, P504; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Logan GD, 2003, CURR DIR PSYCHOL SCI, V12, P45, DOI 10.1111/1467-8721.01223; MacDonald AW, 2003, J ABNORM PSYCHOL, V112, P689, DOI 10.1037/0021-843X.112.4.689; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MacDonald AW, 2002, J CLIN EXP NEUROPSYC, V24, P873, DOI 10.1076/jcen.24.7.873.8386; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Neter J., 1985, APPL LINEAR STAT MOD; *NIH, 1998, NIH CONS STAT REH PE; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 1998, NEUROPSYCHOLOGY, V12, P414, DOI 10.1037/0894-4105.12.3.414; Perlstein WM, 2003, NEUROSCI LETT, V342, P191, DOI 10.1016/S0304-3940(03)00226-X; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PERLSTEIN WM, IN PRESS NEUROSPCYHO; PHILLIPS LJ, 1997, METHODOLOGY FRONTAL, P81; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; RABBITT PM, 1997, METHODOLOGY FRONTAL, P81; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; ROJAS DC, 1995, ARCH CLIN NEUROPSYCH, V10, P101, DOI 10.1016/0887-6177(94)E0038-Q; Rosnow RL, 1996, PSYCHOL METHODS, V1, P331, DOI 10.1037/1082-989X.1.4.331; Salo R, 2001, NEUROPSYCHOLOGY, V15, P462, DOI 10.1037/0894-4105.15.4.462; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P6, DOI 10.1037//0021-843X.110.1.6; Strauss ME, 2001, J ABNORM PSYCHOL, V110, P4, DOI 10.1037//0021-843X.110.1.4; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TRENNERY MR, 1989, STROOP NEURUPSYCHOLO; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Wechsler D, 1985, WECHSLER ADULT INTEL; Weiskrantz L., 1992, NEUROPSYCHOLOGY CONS, P1; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X	96	26	26	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2005	19	5					578	590		10.1037/0894-4105.19.5.578			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	970HU	WOS:000232296700003	16187876				2021-06-18	
J	Kwak, EK; Kim, JW; Kang, KS; Lee, YH; Hua, QH; Park, TI; Park, JY; Sohn, YK				Kwak, EK; Kim, JW; Kang, KS; Lee, YH; Hua, QH; Park, TI; Park, JY; Sohn, YK			The role of inducible nitric oxide synthase following spinal cord injury in rat	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						inducible nitric oxide synthase; spinal cord injuries; apoptosis; rats	TRAUMATIC BRAIN-INJURY; APOPTOSIS; PATHOPHYSIOLOGY; EXPRESSION	Acute spinal cord injury (SCl) is two-step process that first involves the primary mechanical injury and then the secondary injury is induced by various biochemical reactions. Apoptosis is one of secondary SCl mechanisms and it is thought to play an important role for the delayed neuronal injury. The enhanced formation of nitric oxide (NO) via inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesis of apoptosis in SCl. The level of iNOS mRNA peaked at 6 hr after SCI and it declined until 72 hr after SCl in a rat model. Double-immunofluorescence staining revealed that iNOS positive cells were stained for ED-1, synaptophysin, GFAP, and oligodendrocyte marker. The terminal deoxynucleotidyl-transferase-mediated dUDP-biotin nick end-labeling (TUNEL) positive cell count was higher for the 72 hr post-SCl group than for the 24 hr post-SCl group. This cell count was also higher going in the caudal direction than in the rostral direction from the epicenter, and especially for the 72 hr group. Treatment with a selective iNOS inhibitor resulted in the reduction of TUNEL-positive cells at the lesion site. These findings suggest that nitric oxide generated by the iNOS of macrophages, neurons, oligodentrocytes, and astrocytes plays an important role for the acute secondary SCI that results from apoptotic cell death.	Kyungpook Natl Univ, Dept Pathol, Sch Med, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Oral Microbiol, Taegu 700422, South Korea; Sungkyunkwan Univ, Dept Pathol, Sch Med, Samsung Cheil Hosp, Seoul, South Korea	Sohn, YK (corresponding author), Kyungpook Natl Univ, Dept Pathol, Sch Med, 101 2 Ga, Taegu 700422, South Korea.	yksohn@knu.ac.kr					Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEMOPOULOS HB, 1979, MEMBRANE PERTURBATIO, P63; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; ROTELLO RJ, 1994, DEVELOPMENT, V120, P1421; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WOLMAN L, 1965, PARAPLEGIA, V59, P213	20	26	30	0	6	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	AUG	2005	20	4					663	669		10.3346/jkms.2005.20.4.663			7	Medicine, General & Internal	General & Internal Medicine	961AE	WOS:000231633500024	16100462	Green Published			2021-06-18	
J	Baker, F; Kennelly, J; Tamplin, J				Baker, F; Kennelly, J; Tamplin, J			Themes within songs written by people with traumatic brain injury: Gender differences	JOURNAL OF MUSIC THERAPY			English	Article							IDENTITY	The study aimed to identify gender differences in the themes of songs written by patients with traumatic brain injury. Lyrics (1, 834) from 82 songs written by 11 female and 21 male patients were categorized into 8 main themes and 24 subcategories. Incidence of subcategories and themes were calculated and compared across gender Results showed that songs written by patients from both genders were predominantly focused on sending messages to significant others and on self-reflection. Males however tended to focus more on the concern for the future and expressing adversity in their lyrics when compared with females, and the lyrics of females more often reflected upon their relationships with others when compared with males.	Univ Queensland, Brisbane, Qld 4067, Australia; Royal Childrens Hosp, Queensland Pediat Rehabil Serv, Brisbane, Qld, Australia; Royal Talbot Rehabil Ctr, Melbourne, Vic, Australia	Baker, F (corresponding author), Univ Queensland, Brisbane, Qld 4067, Australia.		Tamplin, Jeanette/AAR-2855-2021	Tamplin, Jeanette/0000-0002-3623-033X			BAKER F, UNPUB AUSTR J MUSIC; Barnett R.C., 1987, GENDER STRESS; Charmaz K, 1995, SOCIOL QUART, V36, P657, DOI 10.1111/j.1533-8525.1995.tb00459.x; deRidder D., 2000, WOMEN HLTH MIND, P115; Edgerton C. D., 1990, MUSIC THERAPY PERSPE, V8, P15; ENDLER NS, 1990, J PERS SOC PSYCHOL, V58, P844, DOI 10.1037/0022-3514.58.5.844; FICKEN T, 1976, J MUSIC THER, V13, P163, DOI 10.1093/jmt/13.4.163; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Folkman S., 1992, PERSONAL COPING THEO, P31, DOI DOI 10.1037/0022-3514.50.5.992; Fortune N, 1999, DEFINITION INCIDENCE; Freed B. S., 1987, MUSIC THERAPY PERSPE, V4, P13, DOI [10.1093/mtp/4.1.13, DOI 10.1093/MTP/4.1.13]; GLASSMAN LR, 1991, ART PSYCHOTHER, V18, P149, DOI 10.1016/0197-4556(91)90022-3; GRAY J, 1993, MEN ARE MARS WOMEN A; HOVANITZ CA, 1990, J CLIN PSYCHOL, V45, P766; Kennelly J., 2001, MUSIC THERAPY PERSPE, V4, P137; Lindberg K. A., 1995, MUSIC THERAPY, V13, P93; NAUGLE RI, 1991, PSYCHOL SOCIAL IMPAC; O'Callaghan C, 1999, MUSIC THERAPY PALLIA, P43; OCallaghan CC, 1996, J MUSIC THER, V33, P74, DOI 10.1093/jmt/33.2.74; Olney MF, 2001, DISABIL SOC, V16, P563, DOI 10.1080/09687590120059540; PTACEK JT, 1992, J PERS, V60, P747, DOI 10.1111/j.1467-6494.1992.tb00272.x; Robb Sheri L, 2003, J Pediatr Oncol Nurs, V20, P16, DOI 10.1053/jpon.2003.4; Shontz F. C., 1991, PSYCHOL SOCIAL IMPAC; Silber F., 1995, MUSIC THER PERSPECT, V13, P31, DOI [10.1093/mtp/13.1.31, DOI 10.1093/MTP/13.1.31]; Simpson G., 2002, AUSTR SOCIAL WORK, V55, P24, DOI DOI 10.1080/03124070208411669; TAMPLIN J, 2001, 27 NAT C AUSTR MUS T; TURRY A, 1999, CLIN APPL MUSIC THER, P13; VINGERHOETS AJJM, 1990, PSYCHOL MED, V20, P125, DOI 10.1017/S0033291700013301; WALKER M, 1985, SURVIVING SECRETS; Weidner G, 1993, ATTENTION AVOIDANCE, P241	30	26	27	0	3	NATL ASSOC MUSIC THERAPY INC	SILVER SPRING	8455 COLESVILLE RD, STE 1000, SILVER SPRING, MD 20910 USA	0022-2917			J MUSIC THER	J. Music Ther.	SUM	2005	42	2					111	122		10.1093/jmt/42.2.111			12	Music; Rehabilitation	Music; Rehabilitation	929GY	WOS:000229331300002	15913389				2021-06-18	
J	Armstrong, E				Armstrong, E			Language disorder: A functional linguistic perspective	CLINICAL LINGUISTICS & PHONETICS			English	Article						sociolinguistics; semantics; speech pathology; aphasia	TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; COHESION ANALYSIS; FLUENT; COHERENCE; DEMENTIA; PATTERNS; CHILDREN; PEOPLE; USAGE	This paper explores the issues involved in the linguistic characterisation of disordered discourse and the ways in which a Systemic Functional Linguistic framework addresses these issues. For many years, language disorders were described in terms of formal grammars, with "breakdown'' discussed in terms of one or more of the traditional levels of language, i.e., phonology, syntax, and semantics. While it was acknowledged that an individual could have difficulty at one or more of these levels, each was viewed quite separately, with semantics viewed largely from a referential perspective. More recent approaches using functional grammar have broadened this view of language and have provided a model of language that re-conceptualises the notion of meaning and embraces context as integral to its organisation. Such a model has introduced a different perspective on language into clinical fields, and has enabled researchers and clinicians to explore the skills of speakers with language disorders across a variety of situations and contextual variables, examining the linguistic resources still available to them. This paper introduces principles involved in a functional framework and provides an overview of how these principles have been applied to language disorders to date. In addition, the notion of "disorder'' itself is discussed as it is situated in this alternative model.	Macquarie Univ, Dept Linguist, Sydney, NSW 2109, Australia	Armstrong, E (corresponding author), Macquarie Univ, Dept Linguist, N Ryde, NSW 2010, Australia.	barmstrong@ling.mq.edu.au		Armstrong, Elizabeth/0000-0003-4469-1117			Armstrong E, 2001, APHASIOLOGY, V15, P1029, DOI 10.1080/02687040143000375; ARMSTRONG E, 1995, TREATMENT APHASIA TH, P70; Armstrong E., 1993, APHASIA TREATMENT WO, P263; ARMSTRONG EM, 1991, CLIN LINGUIST PHONET, V5, P39, DOI 10.3109/02699209108985501; ARMSTRONG EM, 1997, THESIS MACQUARIE U S; ARMSTRONG EM, 1987, CLIN APHASIOLOGY, P210; Bird H, 1996, J NEUROLINGUIST, V9, P187, DOI 10.1016/0911-6044(96)00006-1; Bower AR, 1997, J NARRAT LIFE HIST, V7, P265, DOI 10.1075/jnlh.7.1-4.33the; BUTT D, 1995, USING FUNCTIONAL GRA; CHENERY HJ, 1994, APHASIOLOGY, V8, P159, DOI 10.1080/02687039408248648; CHRISTIANSEN JA, 1995, BRAIN LANG, V51, P291, DOI 10.1006/brln.1995.1062; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Cutler A., 1982, SLIPS TONGUE LANGUAG; DUCHAN J, 2001, ADV SPEECH LANGUAGE, V3, P37, DOI DOI 10.3109/14417040109003707; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; HALLIDAY MAK, 1985, LANGUAGE CONTEXT TEX, P3; Halliday Michael A. K., 1976, COHESION ENGLISH; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hasan R., 1985, LANGUAGE CONTEXT TEX, P52; Hasan R., 1994, PERSPECTIVES PEDAGOG, P179, DOI [10.1017/cbo9781139524605.010, DOI 10.1017/CBO9781139524605.010]; HOLLAND A, 1979, RATIONALE ADULT APHA; Labov W, 1993, DISCOURSE NEUROLOGIC, P115; Lemme M.L., 1984, P CLIN APH C SEABR I, P215; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; LILES BZ, 1995, J SPEECH HEAR RES, V38, P415, DOI 10.1044/jshr.3802.415; Lock S, 1997, CLIN LINGUIST PHONET, V11, P299, DOI 10.3109/02699209708985197; Mackenzie C, 2000, INT J LANG COMM DIS, V35, P269, DOI 10.1080/136828200247188; MANOCHIOPINIG S, 1992, APHASIOLOGY, V6, P519, DOI 10.1080/02687039208249489; Martin J. R., 2003, WORKING DISCOURSE ME; Martin J. R., 1992, ENGLISH TEXT SYSTEM; Martin James R., 1997, WORKING FUNCTIONAL G; Matthiessen C.M.I.M., 1995, LEXICOGRAMMATICAL CA; Matthiessen C. M. I. M., 1997, SYSTEMIC FUNCTIONAL; McKeough A, 1995, J NARRAT LIFE HIST, V5, P21, DOI 10.1075/jnlh.5.1.02con; MORTENSEN L, 1992, J NEUROLINGUIST, V7, P309, DOI 10.1016/0911-6044(92)90021-N; MORTENSEN L, 2003, THESIS MACQUARIE U S; NICHOLAS M, 1985, J SPEECH HEAR RES, V28, P405, DOI 10.1044/jshr.2803.405; NORRIS JA, 1988, J SPEECH HEAR DISORD, V53, P416, DOI 10.1044/jshd.5304.416; Penn C, 1985, S Afr J Commun Disord, V32, P18; PIEHLER MF, 1984, CLIN APHASIOLOGY, P208; RIPICH DN, 1988, J SPEECH HEAR DISORD, V53, P8, DOI 10.1044/jshd.5301.08; SAFFRAN EM, 1989, BRAIN LANG, V37, P440, DOI 10.1016/0093-934X(89)90030-8; Schneider P., 1997, J SPEECH LANGUAGE PA, V21, P8; STUARTSMITH VG, 2003, AUSTR J LANGUAGE LIT, V26, P69; Tannen D., 1994, GENDER DISCOURSE; Thoma GJ, 2003, INT J PHYTOREMEDIAT, V5, P41, DOI 10.1080/16226510390856466; THOMSON J, 2000, THESIS U NEWCASTLE A; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L., 2000, BRAIN DAM B, P1; Ulatowska H.K., 1990, DISCOURSE ABILITY BR, P180, DOI [10.1007/978-1-4612-3262-9_8, DOI 10.1007/978-1-4612-3262-9_8]; Ulatowska HK, 2000, BRAIN LANG, V71, P249, DOI 10.1006/brln.1999.2261; Ventola E., 1987, STRUCTURE SOCIAL INT; Wilcox MJ, 1983, TOP LANG DISORD, V3, P35; Williams, 1996, WAYS SAYING WAYS MEA, P51; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205; Young D. J., 1987, NEW DEV SYSTEMIC LIN, P184	63	26	26	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9206	1464-5076		CLIN LINGUIST PHONET	Clin. Linguist. Phon.	APR-MAY	2005	19	3					137	153		10.1080/02699200410001698599			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	913VC	WOS:000228182300002	15823952				2021-06-18	
J	Slemmer, JE; Weber, JT				Slemmer, JE; Weber, JT			The extent of damage following repeated injury to cultured hippocampal cells is dependent on the severity of insult and inter-injury interval	NEUROBIOLOGY OF DISEASE			English	Article						glia; in vitro injury; NSE; repetitive injury; S-100 beta; traumatic brain injury	TRAUMATIC BRAIN-INJURY; STRETCH-INDUCED INJURY; COGNITIVE IMPAIRMENT; PROTEIN; MODEL; S100B; VULNERABILITY; DEATH; S100-BETA; RELEASE	Recent evidence suggests repeated mild brain trauma may result in cumulative damage. We investigated cell damage and death in hippocampal cultures following repeated mechanical trauma in vitro by measuring propidium iodide (PrI) uptake, release of neuron-specific enolase (NSE) and glial S-100 beta protein, and performing neuronal counts. Cultures receiving two mild injuries (31% stretch) 1 or 24 h apart displayed different profiles of PrI uptake and S-100 beta release, although neuronal loss and NSE release was similar in both paradigms. Cells receiving a subthreshold, low-level stretch (10%) repeated several times eventually stained with PrI. Cultures administered 10% stretch before mild injury released less S-100 beta than mild injury alone, suggesting a preconditioning effect. Lastly, exogenous S-100 beta applied to injured cultures decreased PrI uptake, implying a protective role. These results suggest cumulative damage is dependent on injury severity and inter-injury interval, and that neurons and glia react differently to various injury paradigms. (c) 2004 Elsevier Inc. All rights reserved.	Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands	Weber, JT (corresponding author), Erasmus MC, Dept Neurosci, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.weber@erasmusmc.nl					Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; BARGER SW, 1992, J BIOL CHEM, V267, P9689; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GERLAI R, 1995, LEARN MEMORY, V2, P26, DOI 10.1101/lm.2.1.26; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; OLSSON Y, 1971, ACTA NEUROPATHOL, V19, P225, DOI 10.1007/BF00684599; Pike BR, 2001, HEAD TRAUMA, P37; Pinto SS, 2000, FEBS LETT, V486, P203, DOI 10.1016/S0014-5793(00)02301-2; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Schaller B, 2002, J NEUROL, V249, P1503, DOI 10.1007/s00415-002-0933-8; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	42	26	26	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	APR	2005	18	3					421	431		10.1016/j.nbd.2004.09.022			11	Neurosciences	Neurosciences & Neurology	908WI	WOS:000227820500001	15755668				2021-06-18	
J	Moinard, C; Neveux, N; Royo, N; Genthon, C; Marchand-Verrecchia, C; Plotkine, M; Cynober, L				Moinard, C; Neveux, N; Royo, N; Genthon, C; Marchand-Verrecchia, C; Plotkine, M; Cynober, L			Characterization of the alteration of nutritional state in brain injury induced by fluid percussion in rats	INTENSIVE CARE MEDICINE			English	Article						trauma; hypercatabolism; amino acids; muscles; intestine and renal failure	MUSCLE GLUTAMINE-METABOLISM; SKELETAL-MUSCLE; URINARY-EXCRETION; PROTEIN-TURNOVER; CATABOLIC STATE; AMINO-ACIDS; 3-METHYLHISTIDINE; SEPSIS; RILUZOLE; RELEASE	Objective: Patients suffering from traumatic brain injury (TBI) undergo rapid weight loss with negative nitrogen balance and enhanced whole-body protein breakdown, with protein wasting causing morbidity and increased mortality. Many experimental models of TBI have been used to evaluate strategies to improve the outcome of these patients, but nutritional status has not been considered in experiments published to date, although this may have great importance and influence the results obtained with TBI models. This study characterized the hypercatabolism level and nutritional status of TBI rats. Design: Twenty-four male Wistar rats were randomized into three groups. Rats from the TBI group were anesthetized and fluid percussion was applied. The pair-fed (PF) group was healthy but was pair-fed to the TBI group. The ad libitum (AL) group was healthy and fed ad libitum. The study was performed over 10 days post-TBI. Measurements and results: TBI in rats was characterized by remarkable long-lasting anorexia, renal failure (creatinine clearance: AL 1.8+/-0.2 and PF 1.5+/-0.1 vs. TBI 0.9+/-0.1 l/24 hour), anorexia (appetite depressed throughout the study), increased myofibrillar proteolysis (3-methylhistidine/creatinine ratio (day 2: AL 36+/-1 and PF 38+/-2 vs. TBI 54+/-5 mumol/mmol), and intestinal atrophy (ileum: AL 29.3+/-2.5 and PF 28.7+/-1.1 vs. TBI 22.5+/-1.4 mg/cm). In addition, anorexia led to muscular atrophy and decreased nitrogen balance. The metabolic alterations described above can increase morbidity and mortality. Conclusions: TBI by fluid percussion in rats is a model reproducing the metabolic and nutritional alterations observed in clinical practice and is suitable for further studies exploring the efficacy of optimized nutritional support.	Fac Pharm, Lab Biol Nutr, F-75270 Paris 06, France; Assist Publ Hop Paris, Hotel Dieu, Lab Biochim A, Paris, France; Fac Pharm, Lab Pharmacol Circulat Cerebrale EA 2510, Paris 5, France	Moinard, C (corresponding author), Fac Pharm, Lab Biol Nutr, EA 2498,4 Ave Observat, F-75270 Paris 06, France.	christophe.moinard@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; Cynober, Luc/ABB-2368-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; 			ALEXANDER JW, 1995, NUTRITION, V11, P229; AUSTGEN TR, 1992, J TRAUMA, V32, P600, DOI 10.1097/00005373-199205000-00011; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Blanc MC, 2000, CLIN CHEM LAB MED, V38, P465, DOI 10.1515/CCLM.2000.067; Breuille D, 1999, INFECT IMMUN, V67, P1079, DOI 10.1128/IAI.67.3.1079-1085.1999; CANO N, 1990, NUTR CLIN METAB, V4, P151; Chambon-Savanovitch C, 1999, EUR J CLIN INVEST, V29, P504, DOI 10.1046/j.1365-2362.1999.00469.x; Cooney RN, 1997, SHOCK, V7, P1, DOI 10.1097/00024382-199701000-00001; CYNOBER L, 1989, JPEN-PARENTER ENTER, V13, P196, DOI 10.1177/0148607189013002196; DRUML W, 1994, AM J CLIN NUTR, V60, P418; Felgines C, 1999, JPEN-PARENTER ENTER, V23, P32, DOI 10.1177/014860719902300132; FISCHER CP, 1995, SHOCK, V3, P315; FLEURY P, 1951, Ann Biol Clin (Paris), V9, P453; HASSELGREN PO, 1990, BIOCHEM J, V267, P37, DOI 10.1042/bj2670037; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; HOLT PR, 1986, AM J PHYSIOL, V251, pG124; Jeevanandam M., 1995, Amino acid metabolism and therapy in health and nutritional disease., P245; KAIYALA KJ, 1995, AM J CLIN NUTR, V62, P1123; LeBoucher J, 1997, CLIN CHEM, V43, P1421; LEBOUCHER J, 1997, AM J PHYSIOL, V273, P557; Levillain O, 1997, METABOLISM, V46, P611, DOI 10.1016/S0026-0495(97)90002-0; LONG CL, 1981, METABOLISM, V30, P765, DOI 10.1016/0026-0495(81)90022-6; MALTIN CA, 1989, AM J PHYSIOL, V257, pE823; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; Martindale RG, 2001, JPEN-PARENTER ENTER, V25, pS27, DOI 10.1177/014860710102500207; Mendez C, 1996, SHOCK, V6, P7, DOI 10.1097/00024382-199607000-00003; Minet-Quinard R, 2000, JPEN-PARENTER ENTER, V24, P30, DOI 10.1177/014860710002400130; PARRYBILLINGS M, 1989, INT J BIOCHEM, V21, P419, DOI 10.1016/0020-711X(89)90366-2; PARRYBILLINGS M, 1990, LANCET, V336, P523, DOI 10.1016/0140-6736(90)92083-T; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Schlegel L, 1999, CRIT CARE MED, V27, P1511, DOI 10.1097/00003246-199908000-00019; SJOLIN J, 1989, METABOLISM, V38, P23, DOI 10.1016/0026-0495(89)90175-3; SOUBA WW, 1990, JPEN-PARENTER ENTER, V14, pS90, DOI 10.1177/014860719001400411; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VARY TC, 1992, AM J PHYSIOL, V262, pC445; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wischmeyer PE, 2001, SHOCK, V16, P398, DOI 10.1097/00024382-200116050-00014; YOUNG VR, 1978, FED PROC, V37, P2291	38	26	26	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	FEB	2005	31	2					281	288		10.1007/s00134-004-2489-9			8	Critical Care Medicine	General & Internal Medicine	896ZN	WOS:000226973400017	15703899				2021-06-18	
J	Newburn, G; Newburn, D				Newburn, G; Newburn, D			Selegiline in the management of apathy following traumatic brain injury	BRAIN INJURY			English	Article							METHYLPHENIDATE TREATMENT; HEAD-INJURY; AMANTADINE; DEPRESSION; REHABILITATION; DYSFUNCTION; PREVALENCE; PATIENT	Primary objective: To provide a brief review of apathy following traumatic brain injury (TBI) and describe the use of selegiline in a group of patients with this symptom. Main outcome: Four patients are described who showed improvement in Apathy Evaluation Scale scores and functional improvement, following the use of selegiline. In each case, selegiline was well tolerated whereas methylphenidate was not. Conclusions: Selegiline shows potential for the management of apathy following TBI. This provides further evidence that impaired dopaminergic processes are prominent in the genesis of these symptoms. However, these findings require confirmation in controlled studies.	Rotorua Rehabil Clin, Rotorua, New Zealand	Newburn, G (corresponding author), Rotorua Rehabil Clin, POB 920, Rotorua, New Zealand.	dengil@xtra.co.nz					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Galynker I, 1997, J NEUROPSYCH CLIN N, V9, P231; Glenn MB, 1998, J HEAD TRAUMA REHAB, V13, P87, DOI 10.1097/00001199-199810000-00010; GUALTIERI CT, 2002, BRAIN INJURY MENTAL, P301; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Plutchik L, 1998, PSYCHOSOMATICS, V39, P118, DOI 10.1016/S0033-3182(98)71358-1; Schaller JL, 1997, J NEUROPSYCH CLIN N, V9, P301; Shiller AD, 1999, BRAIN INJURY, V13, P715; Stuss DT., 2000, DIFFERENTIATION STAT, P340; TEASDALE G, 1984, CLOSED HEAD INJURY P, P5; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	32	26	27	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2005	19	2					149	154		10.1080/02699050410001719989			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	990JR	WOS:000233739600008	15841758				2021-06-18	
J	Gramsbergen, JB; Skjoth-Rasmussen, J; Rasmussen, C; Lambertsen, KL				Gramsbergen, JB; Skjoth-Rasmussen, J; Rasmussen, C; Lambertsen, KL			On-line monitoring of striatum glucose and lactate in the endothelin-1 rat model of transient focal cerebral ischemia using microdialysis and flow-injection analysis with biosensors	JOURNAL OF NEUROSCIENCE METHODS			English	Article; Proceedings Paper	10th International Conference on In Vivo Methods	JUN 24-27, 2003	Karolinska Inst, Stockholm, SWEDEN		Karolinska Inst	biosensor; cerebral ischemia; endothelin-1; glucose; lactate; microdialysis	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; SUBARACHNOID HEMORRHAGE; ARTERY OCCLUSION; CONSCIOUS RATS; ENERGY; METABOLISM; GLUTAMATE; NEURONS; OXYGEN	In vivo studies on cerebral glucose and lactate metabolism following a brain insult require fast and sensitive monitoring techniques. Here we report on-line monitoring of ischemic events and metabolic changes following reperfusion in striatum of freely moving rats subjected to endothelin-1 (60-240 pmol) induced. transient focal cerebral ischemia using slow microdialysis (0.5 mul/min). fast sampling (every minute) and flow-injection analysis with biosensors for glucose and lactate. The high-time resolution provides detailed information on lactate rise times and duration of low glucose. In rats, developing large striatal lesions, lactate increased from 1.0 +/- 0.1 to 4.2 +/- 0.7 mM within 37 +/- 1 min, whereas glucose dropped from 0.3 +/- 0.1 mM to below detection levels (<0.05 mM) for a period of 80 +/- 18 min. The lactate increase measured over a 2-h period after endothelin-1 infusion was highly correlated with striatal infarct size. In some rats oscillatory, changes are observed which cannot be detected in traditional assays. The here-described monitoring technique applied in a clinically relevant rat model is a sensitive tool to study post-ischemic energy metabolism, effects of therapeutic interventions and its relationship with histological outcome. (C) 2004 Elsevier B.V. All rights reserved.	Univ So Denmark, Med Biol Inst, Odense, Denmark; Univ So Denmark, Dept Neurosurg, Inst Clin, Odense, Denmark; Univ So Denmark, Biomed Lab, Odense, Denmark	Gramsbergen, JB (corresponding author), Univ So Denmark, Med Biol Inst, Odense, Denmark.	jbgramsbergcn@health.sdu.dk	Lambertsen, Kate L./I-8676-2014	Lambertsen, Kate L./0000-0001-9276-4902			Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Bogaert L, 2000, BRAIN RES, V887, P266, DOI 10.1016/S0006-8993(00)02959-0; Callaway JK, 1999, STROKE, V30, P2704, DOI 10.1161/01.STR.30.12.2704; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gramsbergen JB, 2003, J NEUROCHEM, V85, P399, DOI 10.1046/j.1471-4159.2003.01673.x; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Jones DA, 2002, J ELECTROANAL CHEM, V538, P243, DOI 10.1016/S0022-0728(02)00839-2; Jones DA, 2000, J NEUROCHEM, V75, P1703, DOI 10.1046/j.1471-4159.2000.0751703.x; Kaptein WA, 1998, ANAL CHEM, V70, P4696, DOI 10.1021/ac980137w; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Leegsma-Vogt G, 2003, J CEREBR BLOOD F MET, V23, P933, DOI 10.1097/01.WCB.0000080650.64357.8F; Leegsma-Vogt G, 2001, J NEUROSCI RES, V66, P795, DOI 10.1002/jnr.10046; LEEGSMAVOGT G, 2004, IN PRESS ANAL CHEM; Leth H, 1996, ACTA PAEDIATR, V85, P859, DOI 10.1111/j.1651-2227.1996.tb14168.x; Madsen PL, 1998, J CEREBR BLOOD F MET, V18, P742, DOI 10.1097/00004647-199807000-00005; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MARAN A, 1994, LANCET, V343, P16, DOI 10.1016/S0140-6736(94)90876-1; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; MOLLER A, 1995, NEUROL RES, V17, P353; Moyanova S, 2003, J NEUROL SCI, V212, P59, DOI 10.1016/S0022-510X(03)00102-3; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Petzold GC, 2003, ANN NEUROL, V54, P591, DOI 10.1002/ana.10723; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Ros J, 2002, J NEUROSCI METH, V119, P129, DOI 10.1016/S0165-0270(02)00174-7; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Schurr A, 1997, J NEUROCHEM, V69, P423; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Van Hemelrijck A, 2003, J NEUROCHEM, V87, P66, DOI 10.1046/j.1471-4159.2003.01977.x; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	42	26	27	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	DEC 30	2004	140	1-2					93	101		10.1016/j.jneumeth.2004.03.027			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	885TO	WOS:000226180100014	15589339				2021-06-18	
J	Hanten, G; Chapman, SB; Gamino, JF; Zhang, LF; Benton, SB; Stallings-Roberson, G; Hunter, JV; Levin, HS				Hanten, G; Chapman, SB; Gamino, JF; Zhang, LF; Benton, SB; Stallings-Roberson, G; Hunter, JV; Levin, HS			Verbal selective learning after traumatic brain injury in children	ANNALS OF NEUROLOGY			English	Article							ORBITOFRONTAL CORTEX; MEMORY	Selective learning (SL), the ability to select items to learn from among other items, engages cognitive control, which is purportedly mediated by the frontal cortex and its circuitry. Using incentive-based auditory word recall and expository discourse tasks, we studied the efficiency of SL in children ages, 6 to 16 years who had sustained severe traumatic brain injury (TBI) at least 1 year earlier. We hypothesized that SL would be compromised by severe TBI. Results indicated that children with severe TBI performed significantly worse than age-matched typically developing children on word- and discourse-level measures of SL efficiency with no significant group differences in number of items recalled from auditory word lists or declarative facts. We conclude that severe TBI disrupts incentive-based cognitive control processes, possibly due to involvement of frontal neural networks.	Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Ctr Brain Hlth, Dallas, TX 75230 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 6560 Fannin St,Suite 1144, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson VA, 2000, BRAIN INJURY, V14, P679; BAUER RH, 1990, J GEN PSYCHOL, V117, P447, DOI 10.1080/00221309.1990.9921150; BAYLIS LL, 1991, EXP BRAIN RES, V86, P617; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; CHAPMAN SB, 1999, BRAIN DAM B, P235; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Drummey AB, 2002, DEVELOPMENTAL SCI, V5, P502, DOI 10.1111/1467-7687.00243; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Francis S, 1999, NEUROREPORT, V10, P453, DOI 10.1097/00001756-199902250-00003; HAMM VP, 1992, PSYCHOL AGING, V7, P56, DOI 10.1037/0882-7974.7.1.56; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; HANTEN G, 2000, 3 INT C MEM VAL SPAI; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; OSULLIVAN JT, 1993, J EXP CHILD PSYCHOL, V55, P396, DOI 10.1006/jecp.1993.1022; Pennington B. F., 1997, DEV PREFRONTAL CORTE, P265; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; WardLonergan JM, 1998, J COMMUN DISORD, V31, P1, DOI 10.1016/S0021-9924(97)00048-8; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203	35	26	26	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	DEC	2004	56	6					847	853		10.1002/ana.20298			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	876NV	WOS:000225504700012	15562406				2021-06-18	
J	Whishaw, IQ; Piecharka, DM; Zeeb, F; Stein, DG				Whishaw, IQ; Piecharka, DM; Zeeb, F; Stein, DG			Unilateral frontal lobe contusion and forelimb function: Chronic quantitative and qualitative impairments in reflexive and skilled forelimb movements in rats	JOURNAL OF NEUROTRAUMA			English	Article						bilateral skilled limb use impairments; concussion; concussion and skilled movement impairment; contusion; skilled forelimb use; skilled forelimb use and recovery; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MOTOR CORTEX; PYRAMIDAL TRACT; RECOVERY; DOPAMINE; DEFICITS; LESIONS; LOCOMOTION; GENDER; IMPACT	Traumatic brain injury induced by mechanical impacts of the head can be modeled in rats in order to investigate acute and chronic therapy. Because frontal lobe contusion affects the neural representation of the forelimb in both the neocortex and basal ganglia, the purpose of the present experiments was to examine the chronic changes in reflexive and skilled forelimb induced by the injury. Contusions produced a cavity in the sensorimotor cortex, accompanied by shrinkage of the pyramidal tract, loss of cells in the dorsolateral striatum, and enlargement of the lateral ventricle. There were substantial individual differences in lesion size despite use of two different contusion forces, but all rats receiving contusions displayed chronic forelimb deficits. Reflexive tests of forelimb use (limb posture, placing, and support) indicated that impairments were most pronounced in the forelimb contralateral to the lesion. Tests of limb preference indicated that the contusion rats displayed a forelimb asymmetry: they were more likely to lean on their ipsilateral-to-lesion forelimb for support when rearing in a test cylinder, and this impairment was amplified in a home cage test. They also displayed a preference for the forelimb ipsilateral to the lesion when reaching for food, although both forelimbs were equally impaired on measures of success when reaching for food from a tray and reaching for a single food pellet on a shelf. A qualitative analysis from frame-by-frame video records indicated that when reaching for single pellets, impairments in forelimb use primarily affected the contralateral-to-lesion limb, especially limb aiming, supination, and food pellet release. Impairments in the ipsilateral-to-lesion forelimb were generally, but not exclusively, secondary to postural abnormalities. The wide range of chronic impairments in forelimb use following contusion injuries are discussed in relation to the anatomical and behavioral origins of the impairments and the potential use of forelimb tests in the assessment of therapy for traumatic brain injury to the frontal cortex.	Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA	Whishaw, IQ (corresponding author), Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada.	whishaw@uleth.ca	Stein, Donald/AAJ-5139-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [5R01 38664-3] Funding Source: Medline		Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BORLONGAN CV, 1995, BRAIN RES, V676, P231, DOI 10.1016/0006-8993(95)00150-O; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; De Mulder G, 2000, ACT NEUR S, V76, P409; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Feeney DM, 1997, ADV NEUROL, V73, P383; Gharbawie OA, 2004, BEHAV BRAIN RES, V151, P125, DOI 10.1016/j.bbr.2003.08.009; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Halliday A, 1999, TRAUMATIC BRAIN INJU, P29; HICKS SP, 1975, AM J ANAT, V143, P1, DOI 10.1002/aja.1001430102; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; ISACSON O, 1986, P NATL ACAD SCI USA, V83, P2728, DOI 10.1073/pnas.83.8.2728; Johnston RE, 1999, BEHAV BRAIN RES, V104, P189, DOI 10.1016/S0166-4328(99)00068-6; Ke C, 2000, ACT NEUR S, V76, P405; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LEVERE TE, 1998, BRAIN INJURY RECOVER, P15; MCINTOSH T, 1999, TRAUMATIC BRAIN INJU; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Metz GAS, 1998, BEHAV BRAIN RES, V96, P37, DOI 10.1016/S0166-4328(97)00195-2; MIKLYAEVA EI, 1994, J NEUROSCI, V14, P7148; MIKLYAEVA EI, 1995, BRAIN RES, V681, P23, DOI 10.1016/0006-8993(95)00277-W; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PELLIS SM, 1987, PHYSIOL BEHAV, V39, P127, DOI 10.1016/0031-9384(87)90409-4; PISA M, 1990, BEHAV BRAIN RES, V37, P281, DOI 10.1016/0166-4328(90)90140-A; ROBINSON TE, 1974, J COMP PHYSIOL PSYCH, V86, P768, DOI 10.1037/h0036397; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SCHALLERT T, 1979, EXP NEUROL, V64, P33, DOI 10.1016/0014-4886(79)90003-7; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Vergara-Aragon P, 2003, J NEUROSCI, V23, P579; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1992, BEHAV BRAIN RES, V48, P113, DOI 10.1016/S0166-4328(05)80147-0; WHISHAW IQ, 1990, BEHAV BRAIN RES, V41, P49, DOI 10.1016/0166-4328(90)90053-H; WHISHAW IQ, 1992, BEHAV BRAIN RES, V47, P59, DOI 10.1016/S0166-4328(05)80252-9; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WHISHAW IQ, 1993, BEHAV BRAIN RES, V56, P59, DOI 10.1016/0166-4328(93)90022-I; Whishaw IQ, 2002, BEHAV BRAIN RES, V134, P323, DOI 10.1016/S0166-4328(02)00051-7; WHISHAW IQ, 1981, J COMP PHYSIOL PSYCH, V95, P85, DOI 10.1037/h0077760; WHISHAW IQ, 1996, INVERTEBRATES HUMANS, P130; Winer B.J., 1962, STAT PRINCIPLES EXPT; WINSLADE WJ, 1998, CONFRONTING BRAIN TR	56	26	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1584	1600		10.1089/neu.2004.21.1584			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800006	15684651				2021-06-18	
J	Ebel, BE; Mack, C; Diehr, P; Rivara, FP				Ebel, BE; Mack, C; Diehr, P; Rivara, FP			Lost working days, productivity, and restraint use among occupants of motor vehicles that crashed in the United States	INJURY PREVENTION			English	Article							TRAUMATIC BRAIN-INJURY; SEAT-BELTS; RETURN; CONSEQUENCES; DISABILITY; SEVERITY; OUTCOMES; HANDICAP	Background: In 2001, 6.3 million passengers were involved in motor vehicle crashes. This study aimed to determine the number of work days lost as a result of motor vehicle crashes and factors that influenced people's return to work. Methods: This was a retrospective, population based cohort study of occupants in motor vehicles involved in crashes from the 1993-2001 Crashworthiness Data System produced by the National Highway Traffic Safety Administration. The sample population of people aged 18-65 years included two groups: occupants who survived and were working before the crash and occupants who were injured fatally and were estimated to have been working before the crash. Multivariate linear regression was used to analyze the impact of restraint use and injury type on return to work. Results: Overall, 30.1% of occupants of vehicles that crashed missed one or more days of work. A crash resulted in a mean 28.0 (95% confidence interval 15.8 to 40.1) days lost from work, including losses associated with fatalities. The 2.1 million working occupants of vehicles that crashed in 2001 lost a total of 60 million days of work, resulting in annual productivity losses of over $7.5 billion ( 2964 to 12 075). Unrestrained vehicle occupants accounted for $5.6 billion in lost productivity. Conclusions: Motor vehicle crashes result in large and potentially preventable productive losses that are mostly attributable to fatal injuries.	Univ Washington, Dept Pediat, Seattle, WA 98104 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98104 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Div Gen Res, Seattle, WA 98104 USA	Ebel, BE (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Div Gen Res, 325 9th Ave,Box 359960, Seattle, WA 98104 USA.	bebel@u.washington.edu	Ebel, Beth/F-4544-2014	Ebel, Beth/0000-0001-9310-8325			*ASS ADV AUT MED, 1990, ABBR INJ SCAL; *BUR LAB STAT, 2003, HISPANIC LATINO ETHN; CAMPBELL BJ, 1987, J TRAUMA, V27, P733, DOI 10.1097/00005373-198707000-00007; *CDCP, 2003, WISQARS WEB BAS INJ; COOPER PJ, 1994, ACCIDENT ANAL PREV, V26, P263, DOI 10.1016/0001-4575(94)90096-5; Cummings P, 2003, ACCIDENT ANAL PREV, V35, P143, DOI 10.1016/S0001-4575(01)00087-2; Currens JAB, 2000, INJURY, V31, P99, DOI 10.1016/S0020-1383(99)00246-6; Engels JM, 2003, J CLIN EPIDEMIOL, V56, P968, DOI 10.1016/S0895-4356(03)00170-7; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MARINE WM, 1994, J TRAUMA, V36, P96, DOI 10.1097/00005373-199401000-00015; Mason S, 2002, J TRAUMA, V53, P98, DOI 10.1097/00005373-200207000-00019; MCGEE DL, 1989, STAT MED, V8, P379, DOI 10.1002/sim.4780080319; MILLER TR, 1993, ACCIDENT ANAL PREV, V25, P593, DOI 10.1016/0001-4575(93)90011-K; Mock C, 2000, J TRAUMA, V49, P1002, DOI 10.1097/00005373-200012000-00005; *NAT CTR STAT AN, 2003, CRASHW DAT SYST; NEWMAN RJ, 1986, J TRAUMA, V26, P561, DOI 10.1097/00005373-198606000-00014; ORSAY EM, 1990, ANN EMERG MED, V19, P258; Rivara FP, 2000, JAMA-J AM MED ASSOC, V283, P2826, DOI 10.1001/jama.283.21.2826; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; van der Sluis CK, 1998, INJURY, V29, P281, DOI 10.1016/S0020-1383(97)00199-X; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470	26	26	27	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047			INJURY PREV	Inj. Prev.	OCT	2004	10	5					314	319		10.1136/ip.2004.005850			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	869MT	WOS:000224989300012	15470014	Green Published, Bronze			2021-06-18	
J	Zausinger, S; Thal, SC; Kreimeier, U; Messmer, K; Schmid-Elsaesser, R				Zausinger, S; Thal, SC; Kreimeier, U; Messmer, K; Schmid-Elsaesser, R			Hypertonic fluid resuscitation from subarachnoid hemorrhage in rats	NEUROSURGERY			English	Article						cerebral blood flow; global cerebral ischemia; hypertonic solutions; small-volume resuscitation; subarachnoid hemorrhage	CEREBRAL-BLOOD-FLOW; SMALL-VOLUME RESUSCITATION; BRAIN-BARRIER DAMAGE; SALINE DEXTRAN; INTRACRANIAL-PRESSURE; HYDROXYETHYL STARCH; PERFUSION-PRESSURE; ISCHEMIA; MODEL; DEATH	OBJECTIVE: Increased intracranial pressure (ICP) and decreased cerebral blood flow leading to global cerebral ischemia are the primary causes of death after severe subarachnoid hemorrhage (SAH). Hypertonic saline has been demonstrated to exert neuroprotective properties after traumatic brain injury by osmotic mobilization of parenchymal water and improvement of microcirculation. We used a rat model to investigate the effects of hypertonic fluid resuscitation after SAH on ICP, cerebral blood flow, body weight, neurological recovery, and morphological damage. METHODS: Sixty rats were subjected to SAH induced by an endovascular filament. ICP and local cerebral blood flow were recorded continuously. Animals were assigned to three groups: 1) NaCl 0.9%; 2) NaCl 7.5% (4 ml/kg); and 3) NaCl 7.5% plus 6% dextran 70 (4 ml/kg) given 30 minutes after SAH. Body weight and neurological deficits were assessed daily. Morphological damage was evaluated on Day 7. RESULTS: SAH resulted in an immediate increase of ICP to approximately 60 mm Hg initially, and then to approximately 30 mm Hg for the next 90 minutes. Although NaCl 7.5% alone and in combination with dextran led to an immediate, significant, and lasting decrease of ICP to 15 to 20 mm Hg, only the combined therapy significantly increased body weight and improved neurological recovery. Furthermore, the group that received combined therapy exhibited significantly more surviving neurons in hippocampus, cortex, caudoputamen, and cerebellum. Mortality was reduced nonsignificantly, from approximately 65% in groups I and II to 35% in Group III. CONCLUSION: Treatment with NaCl 7.5% plus 6% dextran 70 is significantly effective for reducing the initial harmful sequelae of SAH. The regimen resulted in lowered ICP, improved neurological recovery, and less morphological damage after SAH in the rat.	Univ Munich, Klinikum Grosshadern, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Anesthesiol, D-81377 Munich, Germany	Zausinger, S (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.	Stefan.Zausinger@med.uni-muenchen.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Akopov S, 1996, CEREBROVAS BRAIN MET, V8, P11; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; CROMPTON MR, 1964, BRAIN, V87, P263, DOI 10.1093/brain/87.2.263; DAVIS SM, 1992, STROKE, V23, P492, DOI 10.1161/01.STR.23.4.492; de Jonge E, 2001, CRIT CARE MED, V29, P1261, DOI 10.1097/00003246-200106000-00038; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; GROTE E, 1988, NEUROSURGERY, V22, P654, DOI 10.1227/00006123-198804000-00006; HESS JR, 1992, J TRAUMA, V32, P40, DOI 10.1097/00005373-199201000-00009; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JAKUBOWSKI J, 1982, STROKE, V13, P601, DOI 10.1161/01.STR.13.5.601; JOHSHITA H, 1990, J NEUROSURG, V73, P410, DOI 10.3171/jns.1990.73.3.0410; Jones SB, 2003, ANESTH ANALG, V96, P363, DOI 10.1097/00000539-200302000-00012; JUVELA S, 1991, J NEUROSURG, V74, P386, DOI 10.3171/jns.1991.74.3.0386; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; Kempski O, 1996, ACT NEUR S, V66, P114; Kramer GC, 1998, ACTA ANAESTH SCAND, V42, P141, DOI 10.1111/j.1399-6576.1998.tb05099.x; KRAUS GE, 1991, SURG NEUROL, V35, P20, DOI 10.1016/0090-3019(91)90197-H; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Laubenthal H, 1998, ANASTH INTENSIV NOTF, V33, P251, DOI 10.1055/s-2007-994241; LAUBENTHAL H, 1986, ANASTH INTENSIVMED, V169, P1; Lipton P, 1999, PHYSIOL REV, V79, P1431; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MATSUDA M, 1990, ACTA NEUROCHIR, V105, P98, DOI 10.1007/BF01669990; MEYER CHA, 1983, NEUROSURGERY, V12, P58, DOI 10.1227/00006123-198301000-00010; MICKEY B, 1984, J NEUROSURG, V60, P916, DOI 10.3171/jns.1984.60.5.0916; NEILDWYER G, 1994, ACTA NEUROCHIR, V131, P137, DOI 10.1007/BF01401464; NOLTE D, 1992, AM J PHYSIOL, V263, pH1411; NORNES H, 1973, J NEUROSURG, V39, P226, DOI 10.3171/jns.1973.39.2.0226; Pellegrino L.J., 1979, STEREOTAXIC ATLAS RA; Petroianu GA, 2000, ANESTH ANALG, V90, P795; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Schwartz AY, 2000, J NEUROSCI METH, V96, P161, DOI 10.1016/S0165-0270(00)00156-4; Sehba FA, 2000, J CEREBR BLOOD F MET, V20, P604, DOI 10.1097/00004647-200003000-00018; Smith SL, 1996, J NEUROSURG, V84, P229, DOI 10.3171/jns.1996.84.2.0229; Steinbauer M, 1996, PROG APPL MICROCIR, V22, P114; STUMMER W, 1994, STROKE, V25, P1862, DOI 10.1161/01.STR.25.9.1862; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WEST GB, 1985, INT ARCH ALLER A IMM, V78, P221, DOI 10.1159/000233888; Widenka DC, 1999, J NEUROSURG, V90, P1098, DOI 10.3171/jns.1999.90.6.1098; WILLIAMS RW, 1998, J COMP NEUROL, V15, P344; Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1	49	26	27	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2004	55	3					679	686		10.1227/01.NEU.0000134558.28977.EE			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	860AH	WOS:000224309000047	15335436				2021-06-18	
J	McPherson, KM; Brander, P; Taylor, WJ; McNaughton, HK				McPherson, KM; Brander, P; Taylor, WJ; McNaughton, HK			Consequences of stroke, arthritis and chronic pain - are there important similarities?	DISABILITY AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; RHEUMATOID-ARTHRITIS; HEALTH-CARE; REHABILITATION; DISABLEMENT; OUTCOMES; MODELS; CLASSIFICATION; EXPERIENCE; MEDICINE	Purpose: This study aimed to explore the applicability of a previously derived model of what mattered most to people with arthritis across a number of different disabling conditions. Method: A qualitative study using interviews with 30 participants from three out-patient groups (rheumatoid arthritis, stroke and chronic pain) was conducted. Participants were asked to identify and discuss the most important consequences of living with their condition. Narratives were explored for similarities and differences within and across conditions. Results: While diagnostically related differences were clearly evident, particularly in categories within the Intrinsic, Extrinsic and Future Issues themes, a marked level of similarity in view was apparent in two themes, Taking Charge and Perceptions of Normality. Conclusions: The study identified a shared perspective about a number of issues, but also detailed where there were differences. We suggest explicit consideration of the themes highlighted in this research, and a deeper understanding of the inter-relatedness of seemingly separate issues will help health professionals and researchers re-think ways of working with people who have disabling conditions, and identify different factors to address in measuring the success of rehabilitation.	Univ Southampton, Sch Hlth Profess, Southampton SO17 1BJ, Hants, England; Univ Otago, Wellington Sch Med & Hlth Sci, Dunedin, New Zealand; Med Res Inst New Zealand, Wellington, New Zealand	McPherson, KM (corresponding author), Univ Southampton, Sch Hlth Profess, Bldg 45,Highfield Campus, Southampton SO17 1BJ, Hants, England.	K.McPherson@soton.ac.uk	McNaughton, Harry/AAC-6556-2020	McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; BECKER G, 1995, MED ANTHROPOL Q, V9, P165, DOI 10.1525/maq.1995.9.2.02a00040; Bickenbach JE, 1999, SOC SCI MED, V48, P1173, DOI 10.1016/S0277-9536(98)00441-9; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Coughlin AM, 2000, ARCH PHYS MED REHAB, V81, P739, DOI 10.1016/S0003-9993(00)90103-5; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Gustafsson M, 1996, PATIENT EDUC COUNS, V29, P179, DOI 10.1016/0738-3991(96)00864-6; HAAS J, 1993, AM J PHYS MED REHAB, V72, P228, DOI 10.1097/00002060-199308000-00011; Haigh R, 2001, J REHABIL MED, V33, P273; HALL RW, 1995, TRANSPORT PLAN TECHN, V19, P1, DOI 10.1080/03081069508717554; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; Maclean N, 2000, SOC SCI MED, V50, P495; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; McPherson KM, 2001, DISABIL REHABIL, V23, P706; MCPHERSON KM, 2000, NZ J PHYSIOTHERAPY, V28, P1; Oliver M, 1998, BRIT MED J, V317, P1446, DOI 10.1136/bmj.317.7170.1446; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Persson LO, 1999, SCAND J RHEUMATOL, V28, P137; PETERS DJ, 1995, DISABIL REHABIL, V17, P135, DOI 10.3109/09638289509166708; Peters DJ, 1996, DISABIL REHABIL, V18, P593, DOI 10.3109/09638289609166320; Pound P, 1998, CLIN REHABIL, V12, P338, DOI 10.1191/026921598677661555; *QSR, 1997, NUDIST 4 0; Ray L, 1999, J ADV NURS, V30, P1017, DOI 10.1046/j.1365-2648.1999.01207.x; Strauss A., 1998, BASICS QUALITATIVE R; Wade DT, 2000, BMJ-BRIT MED J, V320, P1385, DOI 10.1136/bmj.320.7246.1385; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 1993, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS; World Health Organization, 1999, INT CLASS IMP DIS HA	34	26	26	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	AUG 19	2004	26	16					988	999		10.1080/09638280410001702414			12	Rehabilitation	Rehabilitation	846OJ	WOS:000223324800005	15371047				2021-06-18	
J	Grellner, W; Buhmann, D; Giese, A; Gehrke, G; Koops, E; Puschel, K				Grellner, W; Buhmann, D; Giese, A; Gehrke, G; Koops, E; Puschel, K			Fatal and non-fatal injuries caused by crossbows	FORENSIC SCIENCE INTERNATIONAL			English	Article						crossbow; bow and arrow; morphology; homicide; suicide; accident	ARROW WOUNDS; BOLT; SUICIDE; BRAIN	Today in modem times, traumatic injuries caused by crossbows are a rarity. The largest collection of cases so far is presented in this study, consisting of four fatalities (two homicides and two suicides) and two non-fatal injuries (grievous bodily harm and an accident). All the victims were male having an age between 31 and 54. The weapons, which were used, were mainly high-performance precision crossbows with telescopic sights and hunting bolts. The parts of the body involved were the facial/head area in three of the cases and the thorax in three of them. There were either deep or total penetration injuries to the cranium and thorax with the bolt remaining in the wound in four out of six cases. The persons with non-fatal crossbow injuries exhibited comparatively few symptoms, despite the sometimes extensive involvement of the interior of the cranium (cerebrocranial penetration, in one instance). The two cases of suicide favoured the body areas often found with gun-users. The aetiological classification of crossbow injuries may be difficult after the removal of the bolt. The external morphology is strongly dependent on the type of tip used. Multiple-bladed hunting broadheads produce radiating incised wounds, whereas conical field tips produce circular to slitlike defects. Correspondingly, the external injuries can be reminiscent of the effects of a violent attack by sharp force or of a gunshot wound. The possibility, supported by clinical data, that the victim might have the ability to act or even to survive for a period of time, even with penetration of the brain, should be taken into account when the cause of death is being investigated. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Univ Mainz, Inst Forens Med, DE-55131 Mainz, Germany; Univ Saarland, Inst Forens Med, DE-66421 Homburg, Germany; Univ Hamburg, Dept Neurosurg, DE-20246 Hamburg, Germany; Henriettenstift Hannover, Dept Oral & Maxillofacial Surg, DE-30171 Hannover, Germany; Univ Hamburg, Inst Forens Med, DE-22529 Hamburg, Germany	Grellner, W (corresponding author), Univ Mainz, Inst Forens Med, Pulverturm 3, DE-55131 Mainz, Germany.	grellner@uni-mainz.de					Alessi F J, 1976, J La State Med Soc, V128, P231; Besler K, 1998, INT J LEGAL MED, V111, P88, DOI 10.1007/s004140050121; Byard RW, 1999, AM J FOREN MED PATH, V20, P347, DOI 10.1097/00000433-199912000-00007; Cina SJ, 1998, AM J FOREN MED PATH, V19, P102, DOI 10.1097/00000433-199803000-00020; CLAYDON SM, 1993, MED SCI LAW, V33, P349, DOI 10.1177/002580249303300414; DOWNS JCU, 1994, J FORENSIC SCI, V39, P428; Eriksson A, 2000, J FORENSIC SCI, V45, P911; FRADET G, 1988, ANN THORAC SURG, V45, P680, DOI 10.1016/S0003-4975(10)64779-0; GRESHAM GA, 1977, MED SCI LAW, V17, P239, DOI 10.1177/002580247701700403; HAIN JR, 1989, J FORENSIC SCI, V34, P691; Karger B, 1998, J TRAUMA, V45, P495, DOI 10.1097/00005373-199809000-00011; Karger B, 1998, INT J LEGAL MED, V111, P314, DOI 10.1007/s004140050178; MISLIWETZ J, 1985, BEITR GERICHTL MED, V43, P437; MULLAN FJ, 1991, BRIT J SURG, V78, P972, DOI 10.1002/bjs.1800780825; OPESKIN K, 1994, AM J FOREN MED PATH, V15, P14, DOI 10.1097/00000433-199403000-00004; RANDALL B, 1989, J FORENSIC SCI, V34, P579; ROGERS C, 1990, J FORENSIC SCI, V35, P886; SALAM AA, 1990, ARCH EMERG MED, V7, P224; SALVINO CK, 1991, NEUROSURGERY, V28, P904, DOI 10.1227/00006123-199106000-00023; SAW EC, 1973, ARCH SURG-CHICAGO, V106, P721; SIVALOGANATHAN D, 1979, POLICE J, V52, P42; Taupin JM, 1998, J FORENSIC SCI, V43, P205	22	26	28	1	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAY 28	2004	142	1					17	23		10.1016/j.forsciint.2003.12.021			7	Medicine, Legal	Legal Medicine	820GN	WOS:000221375600003	15110069				2021-06-18	
J	Atchison, TB; Sander, AM; Struchen, MA; High, WM; Roebuck, TM; Contant, CF; Wefel, JS; Novack, TA; Sherer, M				Atchison, TB; Sander, AM; Struchen, MA; High, WM; Roebuck, TM; Contant, CF; Wefel, JS; Novack, TA; Sherer, M			Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							COMMUNITY INTEGRATION QUESTIONNAIRE; CLOSED-HEAD-INJURY; COMA-DATA-BANK; SUPPORTED EMPLOYMENT; WORK; RETURN; REHABILITATION; PREDICTORS; ABILITY; EMPLOYABILITY	While there has been strong evidence for the ability of neuropsychological performance at resolution of posttraumatic amnesia to predict later productivity, there has been less conclusive evidence for the relationship of neuropsychological test scores to concurrent productivity status. The purpose of the current study was to evaluate the relationship of neuropsychological test performance at 1 year post-injury to productivity assessed at the same time point. Participants were 518 persons with medically documented TBI who were enrolled in the TBI Model Systems Research and Demonstration Project. Stepwise logistic regression was utilized to determine the contributions of neuropsychological test scores to productivity after accounting for demographic characteristics, injury severity, and pre-injury productivity. Missing neuropsychological test scores were accounted for in the model. Variables that remained in the model and accounted for a significant proportion of the variance included age, duration of impaired consciousness, pre-injury productivity, and scores on measures of GOAT, Logical Memory II, and Trail Making Test, part B. The results indicate that neuropsychological test performance provides important information regarding the ability of persons with injury to return to productive activities. The results also indicate that inability to complete neuropsychological tests at 1 year post-injury is associated with non-productive activity.	W Texas A&M Univ, Dept Behav Sci, Canyon, TX 79016 USA; Univ Houston, Dept Psychol, Houston, TX USA; Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Natl Rehabil Hosp, Dept Neurosurg, Washington, DC USA; Natl Rehabil Hosp, Dept Phys Med & Rehabil, Washington, DC USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Alabama Birmingham, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA; Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA	Atchison, TB (corresponding author), W Texas A&M Univ, Dept Behav Sci, Box 60296, Canyon, TX 79016 USA.	tatchison@mail.wtamu.edu					BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Benton A, 1989, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Goran DA, 1997, ARCH CLIN NEUROPSYCH, V12, P691, DOI 10.1016/S0887-6177(97)00004-8; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; Isaki E, 2000, BRAIN INJURY, V14, P441; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KlOve H, 1963, MED CLIN N AM; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Matthews C, 1964, INSTRUCTION MANUAL A; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MELAMED S, 1985, SCAND J REHABIL MED, P21; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Putnam S, 1999, REHABILITATION ADULT, P147; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sbordone R. J., 1998, ECOLOGICAL VALIDITY; Schneider JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P658; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TAYLOR JM, 1959, PSYCHOL APPRAISAL CH; WEBER NC, 1984, STAT PROBABIL LETT, V2, P275, DOI 10.1016/0167-7152(84)90064-6; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	60	26	26	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	2004	18	2					249	265		10.1080/13854040490501475			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	850HU	WOS:000223602600005	15587672				2021-06-18	
J	Formisano, R; Carlesimo, GA; Sabbadini, M; Loasses, A; Penta, F; Vinicola, V; Caltagirone, C				Formisano, R; Carlesimo, GA; Sabbadini, M; Loasses, A; Penta, F; Vinicola, V; Caltagirone, C			Clinical predictors and neuropsychological outcome in severe traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; prolonged coma; neuropsychological outcome; predictive factors	CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; NEUROGENIC DYSPHAGIA; COMA; MEMORY; REHABILITATION; DAMAGE	Background. The aim of the study was to evaluate the possible significant role of some clinical factors in predicting cognitive outcome in a group of severe traumatic brain injury (TBI) patients, with Glasgow Coma Scale (GCS) lower than 8 and duration of unconsciousness for at least 15 days (prolonged coma). Method. A consecutive sample of 25 survivors of severe TBI attending the Physical and Cognitive Rehabilitation program participated in this study. The neuropsychological test battery included: Word-list Learning, Prose recall, Rey Figure Delayed recall, Word fluency, Raven's Progressive Matrices' 47. The clinical variables evaluated in correlation with the neuropsychological outcome were the following: age, duration of unconsciousness, duration of post-traumatic amnesia, interval from head trauma to neuropsychological evaluation, interval from head trauma to recovery of oral feeding, and finally interval from head trauma to first verbal communication. Findings. The clinical variable with a significant predictive value on most neuropsychological scores was the interval from head trauma to the recovery of oral feeding. Conclusions. If this result is confirmed in larger samples, time interval of oral feeding recovery from head trauma should be considered as a possible predictor of neuropsychological outcome in TBI patients with prolonged coma.	Santa Lucia Fdn, IRCCS, Rehabil Hosp, I-00179 Rome, Italy; Pediat Hosp Bambino Gesu, Rome, Italy	Formisano, R (corresponding author), Santa Lucia Fdn, IRCCS, Rehabil Hosp, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	Caltagirone, Carlo/B-4930-2013				ALBERICO A, 1987, J NEUROSURG, V67, P649; ARNOLD K, 1969, CHIRURG, V40, P263; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BROOKS D N, 1975, Cortex, V11, P329; Brooks D N, 1979, Int Rehabil Med, V1, P160; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CARLSSON GS, 1986, THESIS GOTEMBURG U; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; FORMISANO R, 1996, EUR J NEUROL S2, V3, P58; FORMISANO R, 1996, 5 C INT ASS STUD TTR; FROWEIN RA, 1989, ADV NEUROSURG, V17, P36; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauri M, 1997, ARCH PSICOL NEUROL P, V58, P621; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MILLER JD, 1986, ADV NEUROTRAUMATOLOG, V1; NEUMANN S, 1995, DYSPHAGIA, V10, P7; OVERGAARD J, 1973, LANCET, V2, P631; PHILIPPON M, 1973, NEUROCHIRURG PARIS, V19, P581; Prosiegel M, 2000, DYSPHAGIA, V15, P173, DOI 10.1007/s004550000024; RAVEN JC, 1947, PROGR MATRICS SET A, P1949; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; SPINNLER H, 1987, ITALIAN J NEUROLOG S, V6, P44; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VAKIL E, 1992, J CONSULTANT CLIN PS, V5, P802; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WILSON BA, 1999, BRAIN INJ       0713, P502; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992	41	26	29	0	7	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAY	2004	146	5					457	462		10.1007/s00701-004-0225-4			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	816MU	WOS:000221114800008	15118882				2021-06-18	
J	Cantor, JB; Gordon, WA; Schwartz, ME; Charatz, HJ; Ashman, TA; Abramowitz, S				Cantor, JB; Gordon, WA; Schwartz, ME; Charatz, HJ; Ashman, TA; Abramowitz, S			Child and parent responses to a brain injury screening questionnaire	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; disabled children; questionnaires; rehabilitation; signs and symptoms; schools	LEARNING-DISABILITIES; HEAD-INJURY; SELF-REPORT; INTERVENTION; SENSITIVITY; STUDENTS	Objectives: To determine, by using a Brain Injury Screening Questionnaire (BISQ), in a sample of urban public school students, what proportion of children are at risk for having sustained a brain injury, to measure the incidence of blows to the head and alterations in mental status, and to determine whether children and parents report differently on the BISQ. Design: Survey. Setting: Research facility and community. Participants: A total of 137 urban students (age range, 12-19y) of varied ethnicity, who were recruited in 2 public schools, and their parents. Interventions: Not applicable. Main Outcome Measure: The BISQ as completed by children and parents. Results: Fourteen children (10%) were at risk for having sustained a brain injury because they or their parents reported an alteration in mental status and 5 or more symptoms sensitive and specific to traumatic brain injury. Most children were reported to have experienced blows to the head, and 50% were reported to have experienced an alteration in mental status. In all areas, no significant differences were found between parent and child reports. Conclusions: There may be significant numbers of children with undetected brain injury in schools. The BISQ is a useful tool to identify children at risk for having sustained a brain injury. Histories should be obtained from parents and children who are older than 11 years when screening children for brain injury.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.	joshua.cantor@mssm.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192			ADELMAN HS, 1989, J LEARN DISABIL, V22, P608, DOI 10.1177/002221948902201004; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; BLASKEY J, 1999, DECISION MAKING PEDI, P84; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; Cronin AF, 2001, AM J OCCUP THER, V55, P377, DOI 10.5014/ajot.55.4.377; DAmato RC, 1996, J LEARN DISABIL, V29, P670, DOI 10.1177/002221949602900611; *DEP PHYS MED REH, REH NEUR SERV; DePompei R, 1997, J HEAD TRAUMA REHAB, V12, pR6, DOI 10.1097/00001199-199704000-00001; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1990, TRAUMATIC BRAIN INJU, P107; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gowers S, 2002, BRIT J PSYCHIAT, V180, P266, DOI 10.1192/bjp.180.3.266; Grimmer K, 2000, J ADOLESCENT HEALTH, V27, P273, DOI 10.1016/S1054-139X(00)00119-1; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keogh E, 2001, EUR J PAIN, V5, P11, DOI 10.1053/eujp.2000.0210; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LAZAR MF, 1995, J HEAD TRAUMA REHAB, V10, P55, DOI 10.1097/00001199-199510000-00007; le Coq EM, 2000, QUAL LIFE RES, V9, P625, DOI 10.1023/A:1008977200176; LEHMKUHL D, 1988, TIRR SYMPTOM CHECKL; MASTROPIERI MA, 1988, LEARNING DISABILITIE, P161; *NY CIT DEP ED, LEARN DIS FACTS; Picard M, 1991, HELPS BRIEF SCREENIN; *RES TRAIN CTR COM, 1997, BRAIN INJ SCREEN QUE; ROSENBAUM P, 1990, QUALITY LIFE ASSESSM, P205; RUTTER M, 1977, J CHILD PSYCHOL PSYC, V18, P1, DOI 10.1111/j.1469-7610.1977.tb00413.x; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; Scruggs TE, 2002, LEARN DISABILITY Q, V25, P155, DOI 10.2307/1511299; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; *US DEP ED, 2001, 33 US DEP ED	38	26	26	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S54	S60		10.1016/j.apmr.2003.08.113			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	812FL	WOS:000220825300007	15083422				2021-06-18	
J	Shi, RY				Shi, RY			The dynamics of axolemmal disruption in guinea pig spinal cord following compression	JOURNAL OF NEUROCYTOLOGY			English	Article							POLYETHYLENE-GLYCOL; ULTRASTRUCTURAL-CHANGES; CYTOCHEMICAL EVIDENCE; NERVE MEMBRANES; STRETCH INJURY; AXONAL INJURY; WHITE-MATTER; OPTIC-NERVE; CALCIUM; PERMEABILITY	Membrane damage has been postulated as a critical factor in mediating axonal degeneration in brain and spinal cord trauma. Despite compelling evidence of membrane disruption as a result of physical insults in both in vivo and in vitro studies, the dynamics of such damage over the time post injury in in vivo studies has not been well documented. Using a well-characterized in vivo guinea pig spinal cord compression model and horseradish peroxidase exclusion assay, we have documented significant membrane disruption at 1 hr, 3 days, and 7 days following injury. Furthermore, the membrane damage was found to spread laterally 10 mm beyond the center of original compression site in both rostral and caudal directions. A second-degree polynomial fit of the measured data predicts a bilateral spread of approximately 20-21 mm of membrane disruption from the epicenter of injury over a period of about 20 days. Thus, this study shows that membrane damage exists days, and possibly weeks, after spinal cord trauma in live guinea pigs. This provides the evidence necessary to investigate the role of membrane damage in triggering axonal deterioration in the future. Furthermore, this study has also revealed a long therapeutical window for membrane repair and functional enhancement following traumatic injury in the central nervous system.	Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Inst Appl Neurol, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@purdue.edu	duan, hf/F-9166-2011				ASANO T, 1995, J NEUROTRAUM, V12, P993; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2002, J EXP BIOL, V205, P1; Duerstock BS, 2002, J EXP BIOL, V205, P13; EMERY DG, 1987, EXP BRAIN RES, V67, P41, DOI 10.1007/BF00269451; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; HUANG PP, 1994, J NEUROTRAUM, V11, P547, DOI 10.1089/neu.1994.11.547; Kim H, 1996, STROKE, V27, P114, DOI 10.1161/01.STR.27.1.114; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; Lucas JH, 1997, NEUROSCIENTIST, V3, P89; LUO J, 2003, NEUROBIOLOGY LIPIDS, V2, P3; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; MEIRI H, 1981, SCIENCE, V211, P709, DOI 10.1126/science.7455707; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; RANSOM BR, 1990, STROKE, V21, P52; ROEDERER E, 1983, J NEUROSCI, V3, P153; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; SHI R, 2002, J NEUROTRAUM, V19, P1394; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	40	26	27	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	MAR	2004	33	2					203	211		10.1023/B:NEUR.0000030695.76840.19			9	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	827DO	WOS:000221879200003	15322378				2021-06-18	
J	Ashman, TA; Schwartz, ME; Cantor, JB; Hibbard, MR; Gordon, WA				Ashman, TA; Schwartz, ME; Cantor, JB; Hibbard, MR; Gordon, WA			Screening for substance abuse in individuals with traumatic brain injury	BRAIN INJURY			English	Article							ALCOHOL-USE; PSYCHIATRIC-DISORDERS; AXIS-I; CAGE; INVENTORY-3; CONCORDANCE; PREVALENCE; DEPENDENCE; VALIDITY; RATINGS	Primary objective: To determine the utility of the CAGE, the Brief Michigan Alcohol Screening Test (BMAST) and the Substance Abuse Subtle Screening Inventory (SASSI-3) with individuals with traumatic brain injury (TBI), two studies were conducted examining the accuracy, sensitivity and specificity of these instruments. Research design: Data from self-report instruments were compared to a clinical interview, Structured Clinical Interview for DSM-IV ( SCID), to determine the accuracy, sensitivity and specificity. Methods and procedures: Two studies were conducted. In study I, 100 individuals with TBI were screened for alcohol abuse using the CAGE and the resulting classifications were compared with those derived from the SCID. In study II, 223 individuals were screened for alcohol abuse and drug abuse using the BMAST and SASSI-3 and the results of these screenings were compared with diagnoses obtained by the SCID. Main outcomes and results: The specificity of the self-report instruments was moderately high, ranging between 81 - 83%. The specificity of the CAGE for alcohol abuse both pre- and post-TBI was high, 96% and 86%, respectively. The sensitivity of the self-report instruments was most variable, ranging from 32 - 95%, with the SASSI face valid drug scale and the CAGE alcohol post-TBI indicating the most sensitivity, 95 and 91%, respectively. Conclusions: The findings suggest that the CAGE may be useful in screening for alcohol abuse and the face valid drug sub-scale of the SASSI-3 may be useful in screening for drug abuse in individuals with TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10021 USA	Ashman, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10021 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013	Ashman, Teresa/0000-0003-2401-7192			ALLEN JP, 1995, ARCH INTERN MED, V155, P1726, DOI 10.1001/archinte.155.16.1726; Arenth PM, 2001, BRAIN INJURY, V15, P499, DOI 10.1080/02699050010006002; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; Conigliaro J, 2000, J GERIATR PSYCH NEUR, V13, P106, DOI 10.1177/089198870001300303; Cooney N, 1995, HDB ALCOHOLISM TREAT, P45; CORNEL M, 1994, J STUD ALCOHOL, V55, P466, DOI 10.15288/jsa.1994.55.466; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DAVIS C, 2001, ANN M AM PSYCH ASS S; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M., 1997, USERS GUIDE STRUCTUR; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Hearne R, 2002, J ROY SOC MED, V95, P84, DOI 10.1258/jrsm.95.2.84; Hibbert L, 1998, PROF ENG, V11, P24; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kranzler HR, 1996, ADDICTION, V91, P859, DOI 10.1046/j.1360-0443.1996.91685911.x; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Lazowski LE, 1998, J PERS ASSESS, V71, P114, DOI 10.1207/s15327752jpa7101_8; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LISKOW B, 1995, J STUD ALCOHOL, V56, P277, DOI 10.15288/jsa.1995.56.277; Maisto SA, 1995, ALCOHOL CLIN EXP RES, V19, P1510, DOI 10.1111/j.1530-0277.1995.tb01015.x; MILLER F, 1997, USERS GUIDE SASSI 3; MILLER FG, 1908, USERS GUIDE SASSI QU; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; Reid MC, 1999, ARCH INTERN MED, V159, P1681, DOI 10.1001/archinte.159.15.1681; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; RYDON P, 1992, J STUD ALCOHOL, V53, P197, DOI 10.15288/jsa.1992.53.197; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Zanarini MC, 2000, J PERS DISORD, V14, P291, DOI 10.1521/pedi.2000.14.4.291	37	26	26	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2004	18	2					191	202		10.1080/0269905031000149506			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000007	14660230				2021-06-18	
J	Tsai, WC; Chiu, WT; Chiou, HY; Choy, CS; Hung, CC; Tsai, SH				Tsai, WC; Chiu, WT; Chiou, HY; Choy, CS; Hung, CC; Tsai, SH			Pediatric traumatic brain injuries in Taiwan: an 8-year study	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						pediatric; traumatic brain injury; severity; GOS	SEVERE HEAD-INJURY; RISK-FACTORS; CHILDREN; CHILDHOOD; TRENDS; COMA	Background. This study is intended to determine the causes of pediatric traumatic brain injuries (PTBI) in children aged 14 years or less, and to identify various types of craniocerebral damage resulting from different mechanisms of injury. Methods. From July 1, 1993 to June 30, 2001, a survey on PTBI was conducted in Taiwan. The data of patients used in this study were collected from 56 major hospitals among the age group of 0-14 years. The items in the traumatic brain injury survey included sex, age, causes of injuries, severity, and the eventual outcome. Results. A total of 5349 cases were identified. The male-to-female ratio was 1.69:1. The incidence rate was higher in the age groups of 4-9 years and 10-14 years. The main cause of PTBI was traffic injury, which accounted for 2537 of the cases (47.3%), followed by falls, 2160 (40.3%). Of all traffic injuries, motorcycle-related injury had the highest incidence, followed by the pedestrian and bicycle-related injury. This study also showed that 83.2% of the patients had mild injury, 9.8% had moderate injury, and 7.0%, severe injury. Conclusions. The results of this study suggest that it is important to decrease all the risk factors in the environment of homes and public areas as much as possible. Helmet wearing and the development of public transportation are essential for the prevention of head injury. (C) 2003 Elsevier Ltd. All rights reserved.	Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei Municipal Wan Fang Hosp, Taipei 110, Taiwan; Taipei Med Univ, Inst Publ Hlth, Taipei, Taiwan; Taipei Med Univ Hosp, Dept Emergency, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan	Chiu, WT (corresponding author), Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei Municipal Wan Fang Hosp, 250 Wu Hsing St, Taipei 110, Taiwan.	wtchiu@tmu.edu.tw		Chiou, Hung Yi/0000-0002-4545-9697			Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; CHIU WT, 1992, B T MED COLL, P105; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; Henry P C, 1992, J Neurosci Nurs, V24, P311; HOYERT DL, 1991, MON VITAL STAT REP, V42; JAMISON DL, 1974, ARCH DIS CHILD, V49, P376, DOI 10.1136/adc.49.5.376; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1980, J NEUROSURG, V53, P803; LESCOHIER I, 1993, PEDIATRICS, V91, P721; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; *MED RES COUNC, 1990, INJ REL DEATHS S AFR, P1; *OKL STAT DEP HLTH, 1991, TRAUM BRAIN INJ; PATTINGTON MW, 1960, ARCH DIS CHILD, P215; Runge J W, 1993, Emerg Med Clin North Am, V11, P241; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; WASTON GS, 1981, AM J PUBLIC HEALTH, V71, P297; *WHO, 1997, MAN INT CLASS DIS IN; 1993, HLTH VITAL STAT; 1989, WORLD HLTH STAT ANN	31	26	27	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	FEB	2004	11	2					126	129		10.1016/S0967-5868(03)00156-5			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	779DM	WOS:000189280200003	14732368				2021-06-18	
J	Crutcher, KA				Crutcher, KA			Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						ApoE; degeneration; toxicity; amyloid; hypothesis; pathology; Alzheimer's disease	AMYLOID-BETA-PEPTIDE; TRAUMATIC BRAIN-INJURY; RECEPTOR-RELATED PROTEIN; LONG-TERM PROGRESSION; TRANSGENIC MICE; APOE GENOTYPE; E GENE; NERVE REGENERATION; MOUSE MODEL; TRANSCRIPTIONAL ACTIVITY	There is now a large body of evidence suggesting that apolipoprotein E (apoE) genotype is the single most important genetic risk factor for the most common (sporadic) form of Alzheimer's disease. Yet in proportion to the total number of investigations in this field, relatively few groups are studying the contribution of this cholesterol-binding protein to disease risk and severity. Of those that are, a major focus is on the impact of apoE on amyloid-related mechanisms of disease. I argue here that apoE should be considered a major culprit in its own right, not simply in a supporting role. The argument is based on several lines of evidence, including the fact that apoE is associated with both plaques and tangles, the overwhelming evidence for genetic risk of the disease attributed to apoE, increasing evidence that apoE might also modify risk of other nonamyloidogenic neurological diseases, neurotoxicity attributed to apoE and/or proteolytic fragments of apoE, negative consequences of transgenic expression of apoE4 in mice, and genetic evidence for polymorphisms that increase both apoE expression and disease risk, regardless of isoform.	Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; ApoLog Inc, Cincinnati, OH 45219 USA	Crutcher, KA (corresponding author), Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.	crutchka@email.uc.edu	Crutcher, Keith/B-5435-2019	Crutcher, Keith/0000-0002-9176-5759	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG20249] Funding Source: Medline		Aizawa Y, 1997, BRAIN RES, V768, P208, DOI 10.1016/S0006-8993(97)00640-9; Artiga MJ, 1998, HUM MOL GENET, V7, P1887, DOI 10.1093/hmg/7.12.1887; Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Becker KG, 2001, NEUROLOGY, V57, P2148, DOI 10.1212/WNL.57.11.2148; Bedlack RS, 2003, NEUROLOGY, V60, P1022, DOI 10.1212/01.WNL.0000056689.50682.94; Bedlack RS, 2000, ARCH NEUROL-CHICAGO, V57, P1561, DOI 10.1001/archneur.57.11.1561; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Cambon K, 2000, NEUROSCIENCE, V97, P685, DOI 10.1016/S0306-4522(00)00065-8; Cedazo-Minguez A, 2001, NEUROREPORT, V12, P201, DOI 10.1097/00001756-200102120-00006; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Cho HS, 2001, J NEUROPATH EXP NEUR, V60, P342, DOI 10.1093/jnen/60.4.342; Citron M, 2000, MOL MED TODAY, V6, P392, DOI 10.1016/S1357-4310(00)01759-7; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CRUTCHER KA, 1994, EXP NEUROL, V130, P120, DOI 10.1006/exnr.1994.1191; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; DeMattos RB, 1999, J NEUROSCI, V19, P2464; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Genden EM, 2002, J RECONSTR MICROSURG, V18, P495, DOI 10.1055/s-2002-33321; GOODRUM JF, 1995, J NEUROCHEM, V64, P408; HAN SH, 1994, EXP NEUROL, V128, P13, DOI 10.1006/exnr.1994.1108; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hartman RE, 2001, EXP NEUROL, V170, P326, DOI 10.1006/exnr.2001.7715; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Hogh P, 2000, MULT SCLER J, V6, P226, DOI 10.1191/135245800678827851; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan J, 1998, J NEUROSCI, V18, P195; Kokubo Y, 2000, STROKE, V31, P1299, DOI 10.1161/01.STR.31.6.1299; Lacomblez L, 2002, NEUROLOGY, V58, P1112, DOI 10.1212/WNL.58.7.1112; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Laffont I, 2002, BIOCHEM BIOPH RES CO, V292, P83, DOI 10.1006/bbrc.2002.6586; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Liu YW, 2002, J CEREBR BLOOD F MET, V22, P1336, DOI 10.1097/01.WCB.0000033200.58646.B3; Luthra K, 2002, CLIN GENET, V62, P39, DOI 10.1034/j.1399-0004.2002.620105.x; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Marques M, 1997, ALZHEIMER RES, V3, P1; Marques MA, 1996, NEUROREPORT, V7, P2529, DOI 10.1097/00001756-199611040-00025; Michikawa M, 1998, J NEUROSCI RES, V54, P58, DOI 10.1002/(SICI)1097-4547(19981001)54:1<58::AID-JNR7>3.0.CO;2-G; Nadig Prathibha, 1996, Society for Neuroscience Abstracts, V22, P1696; Naidu A, 2001, NEUROREPORT, V12, P1265, DOI 10.1097/00001756-200105080-00042; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; Nathan BP, 2002, BRAIN RES, V928, P96, DOI 10.1016/S0006-8993(01)03367-4; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; POPKO B, 1993, J NEUROCHEM, V60, P1155, DOI 10.1111/j.1471-4159.1993.tb03268.x; Roks G, 1998, NEUROSCI LETT, V258, P65, DOI 10.1016/S0304-3940(98)00857-X; Roks G, 2002, AM J MED GENET, V114, P570, DOI 10.1002/ajmg.10407; Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Smith G, 2002, DRUG DEV IND PHARM, V28, P151, DOI 10.1081/DDC-120002448; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Szolnoki Z, 2002, J NEUROL, V249, P1391, DOI 10.1007/s00415-002-0848-4; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Tsuzuki S, 1998, Rinsho Byori, V46, P829; UCHIHARA T, 1995, NEUROSCI LETT, V195, P5, DOI 10.1016/0304-3940(95)11763-M; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138; Weir CJ, 2001, NEUROLOGY, V57, P1097, DOI 10.1212/WNL.57.6.1097; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; Woo D, 2002, STROKE, V33, P1190, DOI 10.1161/01.STR.0000014774.88027.22; Zhang D., 2001, ALZHEIMERS REP, V4, P67	85	26	26	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.		2004	23	3					181	188		10.1385/JMN:23:3:181			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	829ZS	WOS:000222092000005	15181246				2021-06-18	
J	Schmidt, OI; Morganti-Kossmann, MC; Heyde, CE; Perez, D; Yatsiv, I; Shohami, E; Ertel, W; Stahel, PF				Schmidt, Oliver I.; Morganti-Kossmann, Maria Cristina; Heyde, Christoph E.; Perez, Daniel; Yatsiv, Ido; Shohami, Esther; Ertel, Wolfgang; Stahel, Philip F.			Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury	JOURNAL OF NEUROINFLAMMATION			English	Article								Tumor necrosis factor (TNF) and interleukin-(IL)-18 are important mediators of neuroinflammation after closed head injury (CHI). Both mediators have been previously found to be significantly elevated in the intracranial compartment after brain injury, both in patients as well as in experimental model systems. However, the interrelation and regulation of these crucial cytokines within the injured brain has not yet been investigated. The present study was designed to assess a potential regulation of intracranial IL-18 levels by TNF based on a clinical study in head-injured patients and an experimental model in mice. In the first part, we investigated the interrelationship between the daily TNF and IL-18 cerebrospinal fluid levels in 10 patients with severe CHI for up to 14 days after trauma. In the second part of the study, the potential TNF-dependent regulation of intracerebral IL-18 levels was further characterized in an experimental set-up in mice: (1) in a standardized model of CHI in TNF/lymphotoxin-alpha gene-deficient mice and wild-type (WT) littermates, and (2) by intracerebro-ventricular injection of mouse recombinant TNF in WT C57BL/6 mice. The results demonstrate an inverse correlation of intrathecal TNF and IL-18 levels in head-injured patients and a TNF-dependent inhibition of IL-18 after intracerebral injection in mice. These findings imply a potential new anti-inflammatory mechanism of TNF by attenuation of IL-18, thus confirming the proposed "dual" function of this cytokine in the pathophysiology of traumatic brain injury.	[Schmidt, Oliver I.; Heyde, Christoph E.; Ertel, Wolfgang; Stahel, Philip F.] Charite, Sch Med, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany; [Morganti-Kossmann, Maria Cristina] Monash Univ, Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3181, Australia; [Perez, Daniel] Univ Zurich Hosp, Dept Surg, CH-8091 Zurich, Switzerland; [Yatsiv, Ido; Shohami, Esther] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Stahel, PF (corresponding author), Charite, Sch Med, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin, D-13353 Berlin, Germany.	olischmidt@web.de; cristina.morganti-kossmann@med.monash.edu.au; ceheyde@aol.com; danielperezch@yahoo.com; idoyat@yahoo.com; esty@huji.ac.il; wolfgang.ertel@charite.de; pfstahel@aol.com					Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Culhane AC, 1998, MOL PSYCHIATR, V3, P362, DOI 10.1038/sj.mp.4000389; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; JENNETT B, 1975, LANCET, V1, P480; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Seabrook TJ, 2001, J NEUROIMMUNOL, V113, P81, DOI 10.1016/S0165-5728(00)00429-X; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	33	26	28	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.		2004	1								13	10.1186/1742-2094-1-13			6	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	V29PB	WOS:000208759200013		DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Ueda, Y; Wei, EP; Kontos, HA; Suehiro, E; Povlishock, JT				Ueda, Y; Wei, EP; Kontos, HA; Suehiro, E; Povlishock, JT			Effects of delayed, prolonged hypothermia on the pial vascular response after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypothermia; cerebrovascular reactivity; cranial window; rat	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; CO2 REACTIVITY; RELAXING FACTOR; CARDIAC-ARREST; ENDOTHELIUM	Object. In the experimental setting, hypothermia has been demonstrated to attenuate the damaging consequences of stroke and traumatic brain injury (TBI). Laboratory studies of TBI have focused primarily on the use of early hypothermic intervention, with little consideration of the potential efficacy of more delayed but prolonged hypothermia, which would constitute a more clinically relevant approach. In this investigation, the authors evaluated whether delayed, prolonged hypothermia after TBI protected the cerebral microcirculation. Methods. Male Sprague-Dawley rats were equipped with cranial windows for direct visualization of the pial arterial circulation and then subjected to impact-acceleration brain injury. The rats were randomly divided into four experimental groups: Group I consisted of normothermic animals; in Group 2 the rats received a I-hour period of hypothermia (32degreesC) 30 minutes posttrauma, followed by slow rewarming (32-37degreesC/90 minutes); and in Groups 3 and 4 the rats received a more delayed induction (at I hour postinjury) of either I hour (Group 3) or 2 hours (Group 4) of hypothermia, followed by the slow rewarming. The pial arteriolar responses to acetylcholine (ACh) or hypercapnia were measured until up to 6 hours postinjury. With this approach the authors found that the normothermic group demonstrated severely impaired vasoreactivity in terms of ACh-dependent dilation and CO2 reactivity in comparison to baseline values (p < 0.001). In contrast, hypothermia of short duration that was initiated early (30 minutes postinjury) conferred significant cerebrovascular protection (p < 0.001), yet this protection was reduced when the onset of this I-hour hypothermic period was postponed to I hour postinjury. Nevertheless, reduced protection could be significantly improved (p < 0.001) with prolongation of the hypothermic period to 2 hours. Conclusions. The results of this study show that early as well as delayed but prolonged hypothermia attenuate the impaired vascular responsiveness seen after TBI, indicating the potential clinical usefulness of this treatment.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 755, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.		Suehiro, Eiichi/I-5852-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS7288, NS 20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, T32NS007288] Funding Source: NIH RePORTER		Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Nakamura Michio, 1995, Brain and Nerve (Tokyo), V47, P484; RERING EA, 1961, AM J PHYSIOL, V200, P417; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; WEI EP, 1992, STROKE, V23, P1623, DOI 10.1161/01.STR.23.11.1623; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	40	26	26	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2003	99	5					899	906		10.3171/jns.2003.99.5.0899			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	737MY	WOS:000186237400018	14609171				2021-06-18	
J	Carhuaporna, JR; Gupta, K; Coplin, WM; Muddassir, SM; Meratee, MM				Carhuaporna, JR; Gupta, K; Coplin, WM; Muddassir, SM; Meratee, MM			Treatment of refractory fever in the neurosciences critical care unit using a novel, water-circulating cooling device - A single-center pilot experience	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						fever; acute brain injury	ACUTE ISCHEMIC STROKE; BODY-TEMPERATURE; ACETAMINOPHEN; HYPOTHERMIA; INDUCTION; MORTALITY; SEVERITY; EFFICACY; SAFETY	Fever after acute brain injury affects neuronal function and recovery. Standard therapies have proven to be inadequate in treating hyperthermia in this patient population. We report on safety/efficacy pilot data collected using a noninvasive, novel, water-circulating cooling device in febrile acute brain injury patients. We enrolled patients who developed fever (rectal temperature greater than or equal to38.0degreesC) refractory to pharmacological therapy. The treatment device uses an ice water circulating system embedded in hydrogel-coated, energy transfer pads. Its thermoregulatory feedback control uses cold water (4.0degreesC-42.0degreesC) and was set at 36.5degreesC for this study. We analyzed the temperature response during 600 consecutive minutes of treatment. Six consecutive patients were enrolled and seven episodes of fever were recorded; the mean age of the patients was 59.7 years (range 46-71 years; five male, one female). Diagnoses were as follows: subarachnoid hemorrhage (two), severe traumatic brain injury (two), status epilepticus following massive cerebral infarction (one), and intracerebral/intraventricular hemorrhage (one). Hand warming was applied at treatment onset on all patients; shivering only responsive to meperidine occurred in five of them. Fever of 38.4degreesC (range 38.0degreesC-38.9degreesC) was reduced to 36.9degreesC (range 36.0degreesC-38.0degreesC) after 120 minutes (P < 0.001). Core temperature remained "locked" during the remainder of the treatment (36.6degreesC, P = 0.5; 36.6degreesC P = 0.9; and 36.5degreesC, P = 0.9 at 180, 300, and 600 minutes, respectively). Skin integrity under the pads was preserved in all study subjects. Our results indicate that use of this novel technique is safe, rapidly effective, and able to maintain sustained normothermia following fever in a cohort of critically ill neurologic/neurosurgical patients.	Wayne State Univ, Sch Med, Neurosci Crit Care Program, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI USA	Carhuaporna, JR (corresponding author), Univ Hlth Ctr, Dept Neurol, 8C 4201 St,Antoine Blvd, Detroit, MI 48201 USA.	jcarhuap@med.wayne.edu	Carhuapoma, Juan/X-9195-2018; Carhuapoma, Juan/AAC-5279-2019	Carhuapoma, Juan/0000-0002-5868-7701			AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Badjatia N, 2003, CRIT CARE MED, V31, pA20; Boysen G, 2001, STROKE, V32, P413, DOI 10.1161/01.STR.32.2.413; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; Dippel DWJ, 2001, STROKE, V32, P1607, DOI 10.1161/01.STR.32.7.1607; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Henker R, 2001, Am J Crit Care, V10, P276; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; Inderbitzen B, 2002, NEUROSURGERY, V50, P364, DOI 10.1097/00006123-200202000-00023; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; Koennecke HC, 2002, STROKE, V33, P134; Koennecke HC, 2001, NEUROLOGY, V57, P2301, DOI 10.1212/WNL.57.12.2301; Mateescu R, 1977, Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir, V26, P397; Mayer SA, 2002, CRIT CARE MED, V30, pA5, DOI 10.1097/00003246-200212001-00016; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; ODonnell J, 1997, CLIN INFECT DIS, V24, P1208, DOI 10.1086/513660; Plattner O, 1997, ANESTHESIOLOGY, V87, P1089, DOI 10.1097/00000542-199711000-00013; Powell RM, 2000, ANESTH ANALG, V90, P1423, DOI 10.1097/00000539-200006000-00032; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; Takagi K, 2002, STROKE, V33, P2154, DOI 10.1161/01.STR.0000028803.70874.AA	25	26	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2003	15	4					313	318		10.1097/00008506-200310000-00004			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	728HF	WOS:000185711200004	14508172				2021-06-18	
J	Aquilani, R; Iadarola, P; Boschi, F; Pistarini, C; Arcidiaco, P; Contardi, A				Aquilani, R; Iadarola, P; Boschi, F; Pistarini, C; Arcidiaco, P; Contardi, A			Reduced plasma levels of tyrosine, precursor of brain catecholamines, and of essential amino acids in patients with severe traumatic brain injury after rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amino acids; head injuries; neurotransmitters; plasmas; rehabilitation	ENERGY-METABOLISM; FATTY-ACIDS; MEMORY; TRYPTOPHAN; PROTEIN; OXIDATION; STRESS; AVAILABILITY; STIMULATION; DEPRESSION	Objective: To investigate whether levels of plasma tyrosine and tryptophan, precursors of brain catecholamine and serotonin neurotransmitters, respectively, and other essential amino acids (EAA) may return to normal in patients with severe traumatic brain injury (TBI) after 2 months in a hospital rehabilitation center. Design: Peripheral plasma concentrations of tyrosine, tryptophan, and other EAAs in subjects with severe TBI, both at admission (44+/-11d postinjury) and at discharge from the center (110+/-15d after acute event) were compared with concentrations in control subjects. Setting: Tertiary care rehabilitation setting in Italy. Participants: Ten men (26.6+/-12.6y) with TBI and 6 healthy subjects (controls) matched for age, sex, voluntary loss of body weight, and sedentary lifestyle. Interventions: Not applicable. Main Outcome Measures: Concentrations of brain neurotransmitter precursor amino acids and of EAA. Results: On admission, patients had lower plasma tyrosine, leucine, valine, methionine, and phenylalanine concentrations than did control subjects. The plasma concentrations of tryptophan were similar in the 2 groups. These amino acid abnormalities were still present at discharge. Conclusion: The levels of plasma tyrosine and many EAA in patients with TBI did not recover by discharge (110+/-15d) from rehabilitation. Plasma tryptophan concentrations were similar in patients and controls.	Fdn S Maugeri, Ist Sci Montescano, Serv Fisiopatol Metab Nutriz & Nutriz Clin, Pavia, Italy; Univ Pavia, Dipartimento Biochim A Castellani, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Sci Fisiofarmacol, Sez Farmacol, I-27100 Pavia, Italy; Univ Pavia, Ctr Grandi Strumenti, I-27100 Pavia, Italy	Boschi, F (corresponding author), Univ Pavia, Fac Sci MM FF NN, Sez Farmacol & Biotecnol Farmacol, Dipartimento Sci Fisiol Farmacol Cellulari Mol, Piazza Botta 11, I-27100 Pavia, Italy.	labmio@unipv.it	Pistarini, CATERINA/K-5234-2018	Pistarini, CATERINA/0000-0001-8925-0484			ALBERS RW, 1998, BASIC NEUROCHEMISTRY, P96; ALLAIN H, 1995, BIOMED PHARMACOTHER, V49, P179, DOI 10.1016/0753-3322(96)82618-7; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1016/S0003-9993(00)90137-0; ARMSTRONG MD, 1973, METABOLISM, V22, P561, DOI 10.1016/0026-0495(73)90069-3; ASHLEY DVM, 1985, J NEURAL TRANSM, V63, P271, DOI 10.1007/BF01252031; Avraham Y, 1996, BRAIN RES, V732, P133, DOI 10.1016/0006-8993(96)00514-8; BANDERET LE, 1989, BRAIN RES BULL, V22, P759, DOI 10.1016/0361-9230(89)90096-8; BISTRIAN BR, 1975, SURG GYNECOL OBSTET, V141, P512; BOADLEBIBER MC, 1993, PROG BIOPHYS MOL BIO, V60, P1, DOI 10.1016/0079-6107(93)90009-9; CHAPLIN ER, 1976, J NEUROCHEM, V26, P701, DOI 10.1111/j.1471-4159.1976.tb04440.x; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; COOPER JR, 1986, BIOCH BASIS NEUROPHA; COPPEN A, 1967, LANCET, V2, P1178; CURCIO CA, 1984, J NEUROPATH EXP NEUR, V43, P359, DOI 10.1097/00005072-198407000-00001; CURZON G, 1973, NATURE, V242, P198, DOI 10.1038/242198a0; CURZON G, 1984, PROGR TRYPTOPHAN SER, P145; DEIJEN JB, 1994, BRAIN RES BULL, V33, P319, DOI 10.1016/0361-9230(94)90200-3; DOLLINS AB, 1995, PHYSIOL BEHAV, V57, P223, DOI 10.1016/0031-9384(94)00278-D; Dolp R, 1975, Infusionsther Klin Ernahr, V2, P321; Fernstrom J. D., 1994, FOOD COMPONENTS ENHA, P161; FERNSTROM JD, 1983, PHYSIOL REV, V63, P484; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; FERNSTROM JD, 1971, SCIENCE, V174, P1023, DOI 10.1126/science.174.4013.1023; FERNSTROM JD, 1972, SCIENCE, V178, P414, DOI 10.1126/science.178.4059.414; FERNSTROM MH, 1995, LIFE SCI, V57, pPL97, DOI 10.1016/0024-3205(95)02026-F; Ferry B, 1999, BIOL PSYCHIAT, V46, P1140, DOI 10.1016/S0006-3223(99)00157-2; FRAZER A, 1988, BASIC NEUROCHEMISTRY, P264; GERMAN DC, 1987, NEUROSCIENCE, V21, P305, DOI 10.1016/0306-4522(87)90123-0; GERNER RH, 1984, AM J PSYCHIAT, V141, P1441; GLAESER BS, 1983, J NEUROCHEM, V41, P1016, DOI 10.1111/j.1471-4159.1983.tb09045.x; GOLDBERG AL, 1978, FED PROC, V37, P2301; GOLDBERG AL, 1983, AMINO ACIDS METABOLI, P201; Grace A A, 1998, Adv Pharmacol, V42, P655; GROWDON JH, 1982, LIFE SCI, V30, P827, DOI 10.1016/0024-3205(82)90596-3; HARTMANN E, 1977, WAKING SLEEPING, V1, P155; HASSMEN P, 1994, NUTRITION, V10, P405; Heninger GR, 1996, PHARMACOPSYCHIATRY, V29, P2, DOI 10.1055/s-2007-979535; HORST D, 1984, HEPATOLOGY, V4, P279, DOI 10.1002/hep.1840040218; IKEDA M, 1965, BIOCHEM BIOPH RES CO, V18, P482, DOI 10.1016/0006-291X(65)90778-3; KIRKPATRICK LL, 1998, BASIC NEUROCHEMISTRY, P156; KOLPEK JH, 1989, JPEN-PARENTER ENTER, V13, P277, DOI 10.1177/0148607189013003277; LALONDE R, 1985, PHARMACOL BIOCHEM BE, V22, P377, DOI 10.1016/0091-3057(85)90035-8; LANCE JW, 1963, BRAIN, V86, P111, DOI 10.1093/brain/86.1.111; LONG CL, 1981, METABOLISM, V30, P765, DOI 10.1016/0026-0495(81)90022-6; Mann JJ, 1996, NEUROPSYCHOPHARMACOL, V15, P576, DOI 10.1016/S0893-133X(96)00102-9; Matsumoto N, 1999, J NEUROPHYSIOL, V82, P978; MEYER RA, 1984, AM J PHYSIOL, V246, pC365; NESTLER EJ, 1998, BASIC NEUROCHEMISTRY, P405; Nielsen DH, 1981, CARDIAC REHABILITATI, P11; O'Carroll RE, 1999, PSYCHOL MED, V29, P1083, DOI 10.1017/S0033291799008703; ODESSEY R, 1972, AM J PHYSIOL, V223, P1376; OGREN SO, 1986, BRAIN RES BULL, V16, P645; OWASOYO JO, 1992, AVIAT SPACE ENVIR MD, V63, P364; Pastoris O, 1997, SCAND J UROL NEPHROL, V31, P281, DOI 10.3109/00365599709070349; PIEK J, 1985, INTENS CARE MED, V11, P192, DOI 10.1007/BF00272402; PRANGE AJ, 1974, ARCH GEN PSYCHIAT, V30, P56; REINSTEIN DK, 1984, LIFE SCI, V34, P2225, DOI 10.1016/0024-3205(84)90209-1; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; SCHONHEYDER F, 1954, SCAND J CLIN LAB INV, V6, P178, DOI 10.3109/00365515409136355; SCHROT J, 1996, 9611 NMRI US DEP NAV; SHAW DM, 1967, BRIT J PSYCHIAT, V113, P1407, DOI 10.1192/bjp.113.505.1407; Shimizu I, 1999, BRAIN RES, V830, P94, DOI 10.1016/S0006-8993(99)01396-7; ShukittHale B, 1996, PHYSIOL BEHAV, V59, P867, DOI 10.1016/0031-9384(95)02107-8; SILIPRAN.N, 1965, BIOCHEM J, V96, P777, DOI 10.1042/bj0960777; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; Sokoloff L, 1969, PSYCHOCHEMICAL RES M, P237; SOLIVERI P, 1992, EUR J COGN PSYCHOL, V4, P161, DOI 10.1080/09541449208406181; STONE EA, 1975, CATECHOLAMINES BEHAV, V2, P31; SUDHOF TC, 1998, BASIC NEUROCHEMISTRY, P176; Tam SY, 1997, BIOCHEM PHARMACOL, V53, P441; Thomas JR, 1999, PHARMACOL BIOCHEM BE, V64, P495, DOI 10.1016/S0091-3057(99)00094-5; THOMAS JR, 1989, AVIAT SPACE ENVIR MD, V60, P1063; THOMAS JR, 1990, J APPL PHYSIOL, V68, P962; TUCKER KR, 1981, J APPL PHYSIOL, V51, P73; VANPRAAG HM, 1974, INT PHARMACOPSYCHIAT, V9, P35, DOI 10.1159/000468114; WURTMAN RJ, 1974, SCIENCE, V185, P183, DOI 10.1126/science.185.4146.183; WURTMAN RJ, 1980, PHARMACOL REV, V32, P315; WURTMAN RJ, 1975, AM J CLIN NUTR, V28, P638	79	26	26	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2003	84	9					1258	1265		10.1016/S0003-9993(03)00148-5			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	718WT	WOS:000185170000001	13680559				2021-06-18	
J	Hoffman, JM; Doctor, JN; Chan, L; Whyte, J; Jha, A; Dikmen, S				Hoffman, JM; Doctor, JN; Chan, L; Whyte, J; Jha, A; Dikmen, S			Potential impact of the new Medicare prospective payment system on reimbursement for traumatic brain injury inpatient rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; health care economics and organizations; Medicare; prospective payment system; rehabilitation		Objective: To evaluate the potential impact of the new Medicare prospective payment system (PPS) on traumatic brain injury (TBI) rehabilitation. Design: Retrospective cohort study of patients with TBI. Patients were assigned to their appropriate case-mix group (CMG) based on Medicare criteria. Setting: Fourteen urban rehabilitation facilities throughout the United States. Participants: Patients with TBI admitted to inpatient rehabilitation and enrolled in the Traumatic Brain Injury Model Systems from 1998 to 2001 (N=1807). Interventions: Not applicable. Main Outcome Measures: Cost of inpatient rehabilitation admission, length of stay (LOS), and functional outcomes. Results: The median cost of inpatient rehabilitation or patients with TBI exceeded median PPS payments for all TBI CMGs by 16%. Only 3 of the 14 hospitals received reimbursement under PPS that exceeded costs for their TBI patients. Conclusions: Compared with current costs, the new Medicare payment system may reimburse facilities significantly less than their costs for the treatment of TBI. To maintain their current financial status, facilities may have to reduce LOS and/or reduce resource use. With a decreased LOS, inpatient rehabilitation services will have to improve FIM efficiency or discharge patients with lower discharge FIM scores. (C) 2003 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA; Univ Washington, Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Neurosurg, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Thomas Jefferson Univ, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA; Craig Hosp, Englewood, CO USA; Univ Colorado, Denver, CO 80202 USA	Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.			Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007424] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07424] Funding Source: Medline		CARTER GM, 2001, ANAL INITIAL IMPLEME; Chan L, 1997, NEW ENGL J MED, V337, P978, DOI 10.1056/NEJM199710023371406; CMS, 2001, FED REGISTER, V66, P41316; Dada M, 1999, MANAGE SCI, V45, P316, DOI 10.1287/mnsc.45.3.316; FRUMMOND M, 1997, METHOD EC EVALUATION; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Grimaldi Paul L, 2002, J Health Care Finance, V28, P32; Reynolds M, 2001, Healthc Financ Manage, V55, P68; Rosenberg M. A., 2001, N AM ACTUARIAL J, V5, P84, DOI DOI 10.1080/10920277.2001.10596020; SCHEFFLER RM, 1994, MED CARE, V32, P471, DOI 10.1097/00005650-199405000-00006; Taheri PA, 2001, J AM COLL SURGEONS, V193, P1, DOI 10.1016/S1072-7515(01)00870-5; 1999, J HEAD TRAUMA REHABI, V14, P189	12	26	27	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2003	84	8					1165	1172		10.1016/S0003-9993(03)00232-6			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	709LQ	WOS:000184627000012	12917856				2021-06-18	
J	Rath, JF; Hennessy, JJ; Diller, L				Rath, JF; Hennessy, JJ; Diller, L			Social problem solving and community integration in postacute rehabilitation outpatients with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	108th Annual Convention of the American-Psychological-Association	AUG 04-08, 2000	WASHINGTON, DC	Amer Psychol Assoc			SELF-AWARENESS; TAT RESPONSES; ABILITIES; ADJUSTMENT; QUESTIONNAIRE; APPRAISAL; VALIDITY; SCORES; ADULTS; POWER	To enhance understanding of the role that social problem solving (SPS) plays in community integration following traumatic brain injury (TBI). Study Design: Regression analysis. Participants: Forty-five adults with TBI participating in higher level outpatient cognitive rehabilitation and 15 uninjured adults. Main Outcome Measures: Measures of community integration, problem-solving ability, and SPS self-appraisal and performance. Results: Individuals with TBI demonstrated poorer problem-solving as measured by both neuropsychological and SPS methods; however, the largest effect size was observed for SPS self-appraisal. Only SPS self-appraisal predicted a significant proportion of the variance in community integration. Conclusions: It is important to assess brain-injured persons' confidence in their ability to cope with problems. A focus on objective test scores alone may lead to underdetection of disabling problem-solving deficits.	NYU, Med Ctr, Rusk Inst Rehabil Med, Dept Rehabil Med, New York, NY 10016 USA; Fordham Univ, Div Psychol & Educ Serv, Grad Sch Educ, Bronx, NY 10458 USA	Rath, JF (corresponding author), NYU, Med Ctr, Rusk Inst Rehabil Med, Dept Rehabil Med, RR 515,400 E 34th St, New York, NY 10016 USA.	joseph.rath@med.nyu.edu	Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299; Diller, Leonard/0000-0001-7295-7846			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; Adamovich BL, 1991, COGNITIVE REHABILITA, P75; Beck A.T., 1987, BECK DEPRESSION INVE; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BENTON AL, 1994, ANNU REV PSYCHOL, V45, P1, DOI 10.1146/annurev.ps.45.020194.000245; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; D'Zurilla TJ, 2001, HANDBOOK OF COGNITIVE-BEHAVIORAL THERAPIES, SECOND EDITION, P211; DANIEL M, 1986, BEHAV THERAPIST, V4, P71; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DZurilla T. J., 1982, ADV COGNITIVE BEHAV, V1, P201, DOI DOI 10.1016/B978-0-12-010601-1.50010-3; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; DZURILLA TJ, 1995, BEHAV THER, V26, P409, DOI 10.1016/S0005-7894(05)80091-7; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; ELLIOTT TR, 1991, COGNITIVE THER RES, V15, P387, DOI 10.1007/BF01173033; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 1999, REHABIL PSYCHOL, V44, P315, DOI 10.1037/0090-5550.44.4.315; ELLIOTT TR, 1994, J COUNS DEV, V72, P531, DOI 10.1002/j.1556-6676.1994.tb00987.x; Foxx R. M., 2000, BEHAV SOCIAL ISSUES, V10, P71, DOI DOI 10.5210/BSI.V10I0.129; Geffen L., 1998, OXFORD HDB SPORTS ME, P152; GOLDSTEIN FC, 1987, NEUROPSYCHOL REHABIL, P327; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HART T, 1986, CLIN NUEROPSYCHOLOGY; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R. K, 1981, WISCONSIN CARD SORTI; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Heppner PP, 1997, MEAS EVAL COUNS DEV, V29, P229, DOI 10.1080/07481756.1997.12068907; Heppner PP., 1988, PROBLEM SOLVING INVE; Herrick SM, 2001, J CLIN PSYCHOL, V57, P75, DOI 10.1002/1097-4679(200101)57:1<75::AID-JCLP9>3.0.CO;2-6; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; KING MC, 1981, J CLIN PSYCHOL, V37, P400, DOI 10.1002/1097-4679(198104)37:2<400::AID-JCLP2270370233>3.0.CO;2-B; Langenbahn DM, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P167; Luria A. R., 1966, HIGHER CORTICAL FUNC; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; MEYER GJ, 1998, BENEFITS COSTS PSYCH; Millis S R, 1994, Int J Neurosci, V79, P165; Montgomery GK, 1999, ARCH CLIN NEUROPSYCH, V14, P794, DOI 10.1016/S0887-6177(99)80337-0; Murray HAMD., 1943, THEMATIC APPERCEPTIO; OVERALL JE, 1995, PSYCHOL REP, V77, P155, DOI 10.2466/pr0.1995.77.1.155; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Paniak C, 2000, BRAIN INJURY, V14, P219; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RABIN LA, 2001, THESIS FORDHAM U; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; RATH JF, 2003, UNPUB CONSTRUCT PROB; RATH JF, IN PRESS NEUROPSYCHO; ROMAN GF, 1990, UNPUB PERSONAL PROBL; RONAN GF, 1995, J PERS ASSESS, V64, P119, DOI 10.1207/s15327752jpa6401_8; Ronan GF, 1996, J PERS ASSESS, V67, P641, DOI 10.1207/s15327752jpa6703_16; RONAN GF, 1993, J PERS ASSESS, V61, P28, DOI 10.1207/s15327752jpa6101_3; RONAN GF, 1997, UNPUB PERSONAL PROBL; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Tabachnick BG, 2013, USING MULTIVARIATE S; TOOBERT DJ, 1991, J BEHAV MED, V14, P71, DOI 10.1007/BF00844769; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; VONCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	77	26	27	1	20	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2003	48	3					137	144		10.1037/0090-5550.48.3.137			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	717FY	WOS:000185077900002					2021-06-18	
